PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Scott, EE; Gibson, QH; Olson, JS				Scott, EE; Gibson, QH; Olson, JS			Mapping the pathways for O-2 entry into and exit from myoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM-WHALE MYOGLOBIN; SITE-DIRECTED MUTAGENESIS; LIGAND-BINDING; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURES; CARBON-MONOXIDE; DISTAL HISTIDINE; PROTEIN DYNAMICS; X-RAY; PICOSECOND	The effects of mutagenesis on geminate and bimolecular O-2 rebinding to 90 mutants at 27 different positions were used to map pathways for ligand movement into and out of sperm whale myoglobin. By analogy to a baseball glove, the protein "catches" and then "holds" incoming ligand molecules long enough to allow bond formation with the iron atom. Opening of the glove occurs by outward movements of the distal histidine (His(64)), and the ligands are trapped in the interior "webbing" of the distal pocket, in the space surrounded by Ile(28), Leu(29), Leu(32), Val(68), and Ile(107). The size of this pocket is a major determinant of the rate of ligand entry into the protein. Immediately after photo- or thermal dissociation, O-2 moves away from the iron into this interior pocket. The majority of the dissociated ligands return to the active site and either rebind to the iron atom or escape through the His(64) gate. A fraction of the ligands migrate further away from the heme group into cavities that have been defined as Xe binding sites 4 and 1; however, most of these ligands also return to the distal pocket, and net escape through the interior of wildtype myoglobin is <20-25%.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, WM Keck Ctr Computat Biol, Houston, TX 77005 USA	Rice University; Rice University	Olson, JS (corresponding author), Rice Univ, Dept Biochem & Cell Biol, MS 140,6100 Main St, Houston, TX 77005 USA.	olson@rice.edu		Olson, John/0000-0002-0760-5403	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035649] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47020] Funding Source: Medline; NIGMS NIH HHS [GM 35649, GM 08280, GM 14276] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BARRICK D, 1993, BIOCHEMISTRY-US, V32, P3790, DOI 10.1021/bi00065a035; BEECE D, 1980, BIOCHEMISTRY-US, V19, P5147, DOI 10.1021/bi00564a001; BOLOGNESI M, 1982, J MOL BIOL, V158, P305, DOI 10.1016/0022-2836(82)90435-1; Brunori M, 1999, BIOPHYS J, V76, P1259, DOI 10.1016/S0006-3495(99)77289-9; Brunori M, 2000, P NATL ACAD SCI USA, V97, P2058, DOI 10.1073/pnas.040459697; Brunori M, 1999, TRENDS BIOCHEM SCI, V24, P253, DOI 10.1016/S0968-0004(99)01421-8; Carlson ML, 1996, BIOCHEMISTRY-US, V35, P1125, DOI 10.1021/bi951767k; CARLSON ML, 1994, BIOCHEMISTRY-US, V33, P10597, DOI 10.1021/bi00201a005; CARVER TE, 1992, J BIOL CHEM, V267, P14443; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CHATFIELD MD, 1990, J AM CHEM SOC, V112, P4680, DOI 10.1021/ja00168a009; Chu K, 2000, NATURE, V403, P921, DOI 10.1038/35002641; EGEBERG KD, 1990, J BIOL CHEM, V265, P11788; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; EICH RF, 1997, THESIS RICE U HOUSTO; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; Eliezer D, 1998, NAT STRUCT BIOL, V5, P148; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; GIBSON QH, 1986, J BIOL CHEM, V261, P228; GIBSON QH, 1993, J BIOL CHEM, V268, P16993; Gryczynski Z, 1998, BIOPHYS CHEM, V74, P187, DOI 10.1016/S0301-4622(98)00181-1; HARGROVE MS, 1994, BIOCHEMISTRY-US, V33, P11767, DOI 10.1021/bi00205a012; Hirota S, 1996, J AM CHEM SOC, V118, P7845, DOI 10.1021/ja9608297; HUANG XH, 1994, NAT STRUCT BIOL, V1, P226, DOI 10.1038/nsb0494-226; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; JOHNSON KA, 1989, J MOL BIOL, V207, P459, DOI 10.1016/0022-2836(89)90269-6; JONGEWARD KA, 1988, J AM CHEM SOC, V110, P380, DOI 10.1021/ja00210a011; LAI HH, 1995, PROTEINS, V22, P322, DOI 10.1002/prot.340220404; LI HY, 1993, J BIOL CHEM, V268, P17908; LIONG EC, 1999, THESIS RICE U HOUSTO; LIONG EC, 2000, IN PRESS J BIOL CHEM; Luo YZ, 1997, NAT STRUCT BIOL, V4, P925, DOI 10.1038/nsb1197-925; Meller J, 1998, BIOPHYS J, V74, P789, DOI 10.1016/S0006-3495(98)74004-4; Olson JS, 1997, J BIOL INORG CHEM, V2, P544, DOI 10.1007/s007750050169; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; Ostermann A, 2000, NATURE, V404, P205, DOI 10.1038/35004622; PERUTZ MF, 1966, J MOL BIOL, V21, P199, DOI 10.1016/0022-2836(66)90088-X; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; QUILLIN ML, 1995, J MOL BIOL, V245, P416, DOI 10.1006/jmbi.1994.0034; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RINGE D, 1984, BIOCHEMISTRY-US, V23, P2, DOI 10.1021/bi00296a001; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; ROMO TD, 1995, PROTEINS, V22, P311, DOI 10.1002/prot.340220403; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; Scott EE, 1997, BIOCHEMISTRY-US, V36, P11909, DOI 10.1021/bi970719s; Scott EE, 1998, THESIS RICE U HOUSTO; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; Teng TY, 1997, BIOCHEMISTRY-US, V36, P12087, DOI 10.1021/bi971140x; TIAN WD, 1993, J MOL BIOL, V233, P155, DOI 10.1006/jmbi.1993.1491; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; TILTON RF, 1988, J MOL BIOL, V199, P195, DOI 10.1016/0022-2836(88)90389-0; Vojtechovsky J, 1999, BIOPHYS J, V77, P2153, DOI 10.1016/S0006-3495(99)77056-6; WHITAKER TL, 1996, THESIS RICE U HOUSTO; Yang F, 1996, J MOL BIOL, V256, P762, DOI 10.1006/jmbi.1996.0123	58	328	331	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5177	5188		10.1074/jbc.M008282200	http://dx.doi.org/10.1074/jbc.M008282200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11018046	hybrid			2022-12-25	WOS:000168484300087
J	Bash, RC; Vargason, JM; Cornejo, S; Ho, PS; Lohr, D				Bash, RC; Vargason, JM; Cornejo, S; Ho, PS; Lohr, D			Intrinsically bent DNA in the promoter regions of the yeast GAL1-10 and GAL80 genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN-STRUCTURE; PROTEINS NHP6A/B; TRANSCRIPTION; BINDING; CONSEQUENCES; ACTIVATION; CURVATURE; REPEAT; SITES	Circular permutation analysis has detected fairly strong sites of intrinsic DNA bending on the promoter regions of the yeast GAL1-10 and GAL80 genes. These bends lie in functionally suggestive locations. On the promoter of the GAL1-10 structural genes, strong bends bracket nucleosome B, which lies between the UAS(G) and the GAL1 TATA, These intrinsic bends could help position nucleosome B, Nucleosome B plus two other promoter nucleosomes protect the TATA and start site elements in the inactive state of expression but are completely disrupted (removed) when GAL1-10 expression is induced. The strongest intrinsic bend (similar to 70 degrees) lies at the downstream edge of nucleosome B; this places it approximately 30 base pairs upstream of the GAL1 TATA a position that could allow it to be involved in GAL1 activation in several ways, including the recruitment of a yeast HMG protein that is required for the normally robust level of GAL1 expression in the induced state (Paull, T,, Carey, M,, and Johnson, R, (1996) Genes Dev, 10, 2769-2781), On the regulatory gene GAL80, the single bend lies in the non-nucleosomal hypersensitive region, between a GAL80-specific far upstream promoter element and the more gene-proximal promoter elements. GAL80 promoter region nucleosomes contain no intrinsically bent DNA.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Arizona State Univ, Dept Biochem & Chem, Tempe, AZ 85287 USA	Oregon State University; Arizona State University; Arizona State University-Tempe	Lohr, D (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.	dlohr@asu.edu	Ho, Pui/AAF-8838-2020; Ho, Pui S/F-6186-2014	Ho, Pui/0000-0002-8082-4311; Ho, Pui S/0000-0002-8082-4311	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bash R, 2001, PROG NUCLEIC ACID RE, V65, P197; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312; BRUKNER I, 1995, EMBO J, V14, P1812, DOI 10.1002/j.1460-2075.1995.tb07169.x; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Cress WD, 1996, MOL CELL BIOL, V16, P2119; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DIECKMANN S, 1987, NUCL ACIDS MOL BIOL, V1, P138; DIEKMANN S, 1987, NUCLEIC ACIDS RES, V15, P5765, DOI 10.1093/nar/15.14.5765; DIEKMANN S, 1989, ELECTROPHORESIS, V10, P354, DOI 10.1002/elps.1150100513; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FISHERADAMS G, 1995, EMBO J, V14, P1468, DOI 10.1002/j.1460-2075.1995.tb07133.x; FITZGERALD DJ, 1994, J BIOL CHEM, V269, P21303; GOODSELL DS, 1994, NUCLEIC ACIDS RES, V22, P5497, DOI 10.1093/nar/22.24.5497; HAGERMAN PJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P125, DOI 10.1016/0167-4781(92)90066-9; HAGERMAN PJ, 1990, ANNU REV BIOCHEM, V59, P755, DOI 10.1146/annurev.biochem.59.1.755; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; Johnston M., 1992, MOL CELLULAR BIOL YE, P193; KAWAMOTO T, 1989, NUCLEIC ACIDS RES, V17, P523, DOI 10.1093/nar/17.2.523; KIM J, 1995, J BIOL CHEM, V270, P1282, DOI 10.1074/jbc.270.3.1282; Kim J, 1996, BIOCHEM BIOPH RES CO, V226, P638, DOI 10.1006/bbrc.1996.1408; LOHR D, 1993, P NATL ACAD SCI USA, V90, P10628, DOI 10.1073/pnas.90.22.10628; LOHR D, 1995, J BIOL CHEM, V270, P27671, DOI 10.1074/jbc.270.46.27671; Lohr D, 1997, J BIOL CHEM, V272, P26795, DOI 10.1074/jbc.272.43.26795; LOHR D, 1984, NUCLEIC ACIDS RES, V12, P8457, DOI 10.1093/nar/12.22.8457; LOHR D, 1985, NUCLEIC ACIDS RES, V13, P8409, DOI 10.1093/nar/13.23.8409; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Maxam A M, 1980, Methods Enzymol, V65, P499; Nair TM, 1998, FEBS LETT, V422, P94, DOI 10.1016/S0014-5793(97)01607-4; NARDULLI AM, 1992, MOL CELL BIOL, V12, P2037, DOI 10.1128/MCB.12.5.2037; PARVIN JD, 1995, NATURE, V373, P724, DOI 10.1038/373724a0; Paull TT, 1996, GENE DEV, V10, P2769, DOI 10.1101/gad.10.21.2769; PAULL TT, 1995, J BIOL CHEM, V270, P8744, DOI 10.1074/jbc.270.15.8744; PECK LJ, 1981, NATURE, V292, P375, DOI 10.1038/292375a0; PEREZMARTIN J, 1994, MICROBIOL REV, V58, P268; PerezMartin J, 1997, ANNU REV MICROBIOL, V51, P593, DOI 10.1146/annurev.micro.51.1.593; RAINBOW M, 1989, BIOCHEMISTRY-US, V28, P7486, DOI 10.1021/bi00444a048; Reece RJ, 1997, BIOESSAYS, V19, P1001, DOI 10.1002/bies.950191110; SAKURAI H, 1994, MOL CELL BIOL, V14, P6819, DOI 10.1128/MCB.14.10.6819; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHROTH GP, 1992, J BIOL CHEM, V267, P9958; SHIMADA H, 1985, GENE, V39, P1; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; Ulyanov NB, 1995, METHOD ENZYMOL, V261, P90; VANHOLDE K, 1988, CHROMATIN, P247; WADAKIYAMA Y, 1994, J BIOL CHEM, V269, P22238; Widlund HR, 1999, J BIOL CHEM, V274, P31847, DOI 10.1074/jbc.274.45.31847; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; Yen YM, 1998, J BIOL CHEM, V273, P4424, DOI 10.1074/jbc.273.8.4424	51	13	13	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					861	866		10.1074/jbc.M007070200	http://dx.doi.org/10.1074/jbc.M007070200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11013248	Green Submitted, hybrid			2022-12-25	WOS:000166430900002
J	Fonteh, AN; LaPorte, T; Swan, D; McAlexander, MA				Fonteh, AN; LaPorte, T; Swan, D; McAlexander, MA			A decrease in remodeling accounts for the accumulation of arachidonic acid in murine mast cells undergoing apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); PROSTAGLANDIN D-2 GENERATION; POLYUNSATURATED FATTY-ACIDS; A-INDEPENDENT TRANSACYLASE; ACYL-COA SYNTHETASE; C-KIT LIGAND; INDUCE APOPTOSIS; LIPID-PEROXIDATION; RELEASE; EXPRESSION	The goal of this study was to examine arachidonic acid (AA) metabolism by murine bone marrow-derived mast cells (BMMC) during apoptosis induced by cytokine depletion. BMMC deprived of cytokines for 12-48 h displayed apoptotic characteristics. During apoptosis, levels of AA, but not other unsaturated fatty acids, correlated with the percentage of apoptotic cells. A decrease in both cytosolic phospholipase A, expression and activity indicated that cytosolic phospholipase A, did not account for AA mobilization during apoptosis, Free AA accumulation is also unlikely to be due to decreases In 5-lipoxygenase and/or cyclooxygenase activities, since BMMC undergoing apoptosis produced similar amounts of leukotriene B-4 and significantly greater amounts of PGD(2) than control cells. Arachidonoyl-CoA synthetase and CoA-dependent transferase activities responsible for incorporating AA into phospholipids were not altered during apoptosis. However, there was an increase in arachidonate in phosphatidylcholine (PC) and neutral lipids concomitant with a 40.7 +/- 8.1% decrease in arachidonate content in phosphatidylethanolamine (PE), suggesting a diminished capacity of mast cells to remodel arachidonate from PC to PE pools. Further evidence of a decrease in AA remodeling was shown by a significant decrease in microsomal CoA-independent transacylase activity. Levels of lyse-PC and lyso-PE were not altered in cells undergoing apoptosis, suggesting that the accumulation of lysophospholipids did not account for the decrease in CoA-independent transacylase activity or the induction of apoptosis, Together, these data suggest that the mole quantities of free AA closely correlated with apoptosis and that the accumulation of AA in BMMC during apoptosis was mediated by a decreased capacity of these cells to remodel AA from PC to PE.	Wake Forest Univ, Sch Med, Dept Internal Med Pulm & Crit Care Med, Winston Salem, NC 27154 USA	Wake Forest University	Fonteh, AN (corresponding author), Wake Forest Univ, Sch Med, Dept Internal Med Pulm & Crit Care Med, Winston Salem, NC 27154 USA.	afonteh@wfubmc.edu			NIAID NIH HHS [AI 24985] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024985, R29AI024985] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adam-Klages S, 1998, J IMMUNOL, V161, P5687; Anderson KM, 1997, J BIOL CHEM, V272, P30504, DOI 10.1074/jbc.272.48.30504; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; CHILTON FH, 1990, METHOD ENZYMOL, V187, P157; CHILTON FH, 1990, CHEM IMMUNOL, V49, P173; CHILTON FH, 1986, J BIOL CHEM, V261, P7771; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; CHILTON FH, 1987, BIOCHEM BIOPH RES CO, V145, P1126, DOI 10.1016/0006-291X(87)91554-3; Costa JJ, 1997, JAMA-J AM MED ASSOC, V278, P1815, DOI 10.1001/jama.278.22.1815; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; Das UN, 1999, PROSTAG LEUKOTR ESS, V61, P157, DOI 10.1054/plef.1999.0085; DAS UN, 1987, BIOCHEM BIOPH RES CO, V145, P15, DOI 10.1016/0006-291X(87)91281-2; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DVORAK AM, 1994, AM J PATHOL, V144, P160; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Elder DJE, 1998, NAT MED, V4, P392, DOI 10.1038/nm0498-392; Enari M, 1996, EUR J BIOCHEM, V236, P533, DOI 10.1111/j.1432-1033.1996.t01-1-00533.x; Fabisiak JP, 2000, BIOCHEMISTRY-US, V39, P127, DOI 10.1021/bi9912544; FONTEH AN, 1995, J CLIN INVEST, V96, P1432, DOI 10.1172/JCI118179; FONTEH AN, 1992, J IMMUNOL, V148, P1784; FONTEH AN, 1994, J IMMUNOL, V152, P5438; Fonteh AN, 2000, J IMMUNOL, V165, P2773, DOI 10.4049/jimmunol.165.5.2773; Fonteh AN, 1999, METH MOL B, V120, P77; FONTEH AN, 1993, J IMMUNOL, V150, P563; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; Gerard-Monnier D, 1998, CHEM RES TOXICOL, V11, P1176, DOI 10.1021/tx9701790; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; Hara A, 1997, JPN J CANCER RES, V88, P600; Hundley TR, 1998, J PHARMACOL EXP THER, V284, P847; JAATTELA M, 1995, ONCOGENE, V10, P2297; Johnson MM, 1999, AM J RESP CELL MOL, V21, P253, DOI 10.1165/ajrcmb.21.2.3489; Kamitani H, 1998, J BIOL CHEM, V273, P21569, DOI 10.1074/jbc.273.34.21569; KRAMER RM, 1984, J BIOL CHEM, V259, P2403; KRAMER RM, 1983, J BIOL CHEM, V258, P3806; LANDS WEM, 1982, J BIOL CHEM, V257, P4968; Lim JTE, 1999, BIOCHEM PHARMACOL, V58, P1097, DOI 10.1016/S0006-2952(99)00200-2; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; MACDONALD JIS, 1989, BIOCHIM BIOPHYS ACTA, V1004, P151, DOI 10.1016/0005-2760(89)90263-4; MEKORI YA, 1993, J IMMUNOL, V151, P3775; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; MORISAKI N, 1982, LIPIDS, V17, P893, DOI 10.1007/BF02534584; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; NAKAGAWA Y, 1983, J LIPID RES, V24, P1268; NAKAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1085, P191, DOI 10.1016/0005-2760(91)90094-X; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; OHISHI S, 1992, JPN J PHARMACOL, V59, P417, DOI 10.1254/jjp.59.417; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; Sawaoka H, 1998, J CLIN GASTROENTEROL, V27, pS47, DOI 10.1097/00004836-199800001-00009; Schor NF, 1999, BRAIN RES, V831, P125, DOI 10.1016/S0006-8993(99)01414-6; Sheng HM, 1998, CANCER RES, V58, P362; Subbaramaiah K, 1997, P SOC EXP BIOL MED, V216, P201; SUGIURA T, 1984, FEBS LETT, V165, P273, DOI 10.1016/0014-5793(84)80184-2; Surette ME, 1996, BIOCHEMISTRY-US, V35, P9187, DOI 10.1021/bi9530245; Surette ME, 1999, CARCINOGENESIS, V20, P757, DOI 10.1093/carcin/20.5.757; TOMODA H, 1991, J BIOL CHEM, V266, P4214; TRIGGIANI M, 1995, J EXP MED, V182, P1181, DOI 10.1084/jem.182.5.1181; Trimboli AJ, 1999, CANCER RES, V59, P6171; TSAI M, 1993, EUR J IMMUNOL, V23, P867, DOI 10.1002/eji.1830230415; Tsujimura T, 1997, AM J PATHOL, V151, P1043; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 2000, J BIOL CHEM, V275, P7492, DOI 10.1074/jbc.275.11.7492; WASSERMAN SI, 1994, AM J RESP CRIT CARE, V150, pS39, DOI 10.1164/ajrccm/150.5_Pt_2.S39; WILSON DB, 1982, J BIOL CHEM, V257, P3510; WINKLER JD, 1994, BBA-LIPID LIPID MET, V1215, P133, DOI 10.1016/0005-2760(94)90102-3; WINKLER JD, 1995, ADV PROSTAG THROMB L, V23, P89; Winkler JD, 1996, J PHARMACOL EXP THER, V279, P956; WINKLER JD, 1994, J LIPID MEDIAT CELL, V10, P315; Yamashita A, 1997, J BIOCHEM-TOKYO, V122, P1	77	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1439	1449		10.1074/jbc.M006551200	http://dx.doi.org/10.1074/jbc.M006551200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11022038	hybrid			2022-12-25	WOS:000166430900078
J	Wielowieyski, PA; Wigle, JT; Salih, M; Hum, P; Tuana, BS				Wielowieyski, PA; Wigle, JT; Salih, M; Hum, P; Tuana, BS			Alternative splicing in intracellular loop connecting domains II and III of the alpha(1) subunit of Ca(v)1.2 Ca2+ channels predicts two-domain polypeptides with unique C-terminal tails	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE DIHYDROPYRIDINE RECEPTOR; PRESYNAPTIC CALCIUM-CHANNELS; PROTEIN-INTERACTION SITE; SKELETAL-MUSCLE; T-TYPE; IMMUNOCHEMICAL IDENTIFICATION; DIFFERENTIAL PHOSPHORYLATION; MOLECULAR CHARACTERIZATION; RELEASE CHANNEL; EXONS 40-42	Novel splice variants of the Lu, subunit of the Ca(v)1.2 voltage-gated Ca2+ channel were identified that predicted two truncated forms of the or, subunit comprising domains I and II generated by alternative splicing in the intracellular loop region linking domains II and III. In rabbit heart splice variant 1 (RH-1), exon 19 was deleted, which resulted in a reading frameshift of exon 20 with a premature termination codon and a novel 19-amino acid carboxyl-terminal tail. In the RH-2 variant, exons 17 and 18 were deleted, leading to a reading frameshift of exons 19 and 20 with a premature stop codon and a novel 62-amino acid carboxyl-terminal tail. RNase protection assays with RH-1 and RH-2 cRNA probes confirmed the expression in cardiac and neuronal tissue but not skeletal muscle. The deduced amino acid sequence from full-length cDNAs encoding the two variants predicted polypeptides of 99.0 and 99.2 kDa, which constituted domains I and II of the alpha (1), subunit of the Ca(v)1.2 channel. Antipeptide antibodies directed to sequences in the second intracellular loop between domains II and III identified the 240-kDa Ca(v)1.2 subunit in sarcolemmal and heavy sarcoplasmic reticulum (HSR) membranes and a 99-kDa polypeptide in the HSR, An antipeptide antibody raised against unique sequences in the RH-2 variant also identified a 99-kDa polypeptide in the HSR. These data reveal the expression of additional Ca2+ channel structural units generated by alternative splicing of the Ca(v)1.2 gene.	Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Tuana, BS (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8H5, Canada.		Wigle, J.t./G-2005-2014	Wigle, J.t./0000-0002-4985-7684				Bahls FH, 1998, J NEUROBIOL, V35, P198, DOI 10.1002/(SICI)1097-4695(199805)35:2<198::AID-NEU6>3.0.CO;2-#; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; Blaine JT, 1998, J NEUROSCI, V18, P9585; Bulman DE, 1997, HUM MOL GENET, V6, P1679, DOI 10.1093/hmg/6.10.1679; Castellano A, 1997, J NEUROSCI, V17, P4652; Catterall WA, 1996, J BIOENERG BIOMEMBR, V28, P219, DOI 10.1007/BF02110697; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; De Waard M, 1996, Ion Channels, V4, P41; DIEBOLD RJ, 1992, P NATL ACAD SCI USA, V89, P1497, DOI 10.1073/pnas.89.4.1497; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FEHER JJ, 1991, J MOL CELL CARDIOL, V23, P249, DOI 10.1016/0022-2828(91)90061-P; FERRIER GR, 1995, J PHYSIOL-LONDON, V484, P107, DOI 10.1113/jphysiol.1995.sp020651; Fisher SE, 1997, GENOMICS, V45, P340, DOI 10.1006/geno.1997.4941; Gurnett CA, 1996, J BIOL CHEM, V271, P27975, DOI 10.1074/jbc.271.45.27975; HELL JW, 1994, ANN NY ACAD SCI, V747, P282; HOFMANN F, 1984, ANNU REV NEUROSCI, V17, P399; Ishibashi K, 2000, BIOCHEM BIOPH RES CO, V270, P370, DOI 10.1006/bbrc.2000.2435; Jones SW, 1998, J BIOENERG BIOMEMBR, V30, P299, DOI 10.1023/A:1021977304001; Klockner U, 1997, AM J PHYSIOL-HEART C, V272, pH1372, DOI 10.1152/ajpheart.1997.272.3.H1372; Lee JH, 1999, J NEUROSCI, V19, P1912; Leong P, 1998, J BIOL CHEM, V273, P29958, DOI 10.1074/jbc.273.45.29958; Lory P, 1997, HUM GENET, V100, P149, DOI 10.1007/s004390050481; LU XY, 1995, J BIOL CHEM, V270, P18459, DOI 10.1074/jbc.270.31.18459; LU XY, 1994, J BIOL CHEM, V269, P6511; MALOUF NN, 1992, NEURON, V8, P899, DOI 10.1016/0896-6273(92)90204-Q; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Mochida S, 1998, P NATL ACAD SCI USA, V95, P14523, DOI 10.1073/pnas.95.24.14523; Mori Y, 1996, JPN J PHARMACOL, V72, P83, DOI 10.1254/jjp.72.83; Nakai J, 1998, J BIOL CHEM, V273, P24983, DOI 10.1074/jbc.273.39.24983; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; Ophoff RA, 1998, TRENDS PHARMACOL SCI, V19, P121, DOI 10.1016/S0165-6147(98)01182-1; Pereon Y, 1998, PFLUG ARCH EUR J PHY, V436, P309, DOI 10.1007/s004240050637; Perez-Reyes E, 1998, J BIOENERG BIOMEMBR, V30, P313, DOI 10.1023/A:1021981420839; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Plummer NW, 1997, J BIOL CHEM, V272, P24008, DOI 10.1074/jbc.272.38.24008; Puri TS, 1997, BIOCHEMISTRY-US, V36, P9605, DOI 10.1021/bi970500d; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; Reuter H, 1996, CURR OPIN NEUROBIOL, V6, P331, DOI 10.1016/S0959-4388(96)80116-4; SAKURAI T, 1995, J BIOL CHEM, V270, P21234, DOI 10.1074/jbc.270.36.21234; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sather William A., 1994, Current Opinion in Neurobiology, V4, P313, DOI 10.1016/0959-4388(94)90091-4; Scott VES, 1998, J NEUROSCI, V18, P641; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; Sheng ZH, 1997, P NATL ACAD SCI USA, V94, P5405, DOI 10.1073/pnas.94.10.5405; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; Sheng ZH, 1998, J BIOENERG BIOMEMBR, V30, P335, DOI 10.1023/A:1021985521748; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; Sobko A, 1998, J NEUROSCI, V18, P10398; SOLDATOV NM, 1992, P NATL ACAD SCI USA, V89, P4628, DOI 10.1073/pnas.89.10.4628; Soldatov NM, 1998, HUM HERED, V48, P241, DOI 10.1159/000022810; SOLDATOV NM, 1995, J BIOL CHEM, V270, P10540, DOI 10.1074/jbc.270.18.10540; SOLDATOV NM, 1994, GENOMICS, V22, P77, DOI 10.1006/geno.1994.1347; Soldatov NM, 1998, J BIOL CHEM, V273, P957, DOI 10.1074/jbc.273.2.957; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; Talley EM, 1999, J NEUROSCI, V19, P1895; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TSIEN RW, 1995, TRENDS NEUROSCI, V18, P52; Vajna R, 1998, EUR J BIOCHEM, V257, P274, DOI 10.1046/j.1432-1327.1998.2570274.x; VARADI G, 1995, TRENDS PHARMACOL SCI, V16, P43, DOI 10.1016/S0165-6147(00)88977-4; Welling A, 1997, CIRC RES, V81, P526, DOI 10.1161/01.RES.81.4.526; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; Yokoyama CT, 1997, J NEUROSCI, V17, P6929; Zhou ZF, 1998, BIOPHYS J, V74, P1830, DOI 10.1016/S0006-3495(98)77893-2	70	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1398	1406		10.1074/jbc.M006868200	http://dx.doi.org/10.1074/jbc.M006868200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11010971	hybrid			2022-12-25	WOS:000166430900073
J	Hu, JB; Roy, SK; Shapiro, PS; Rodig, SR; Reddy, SPM; Platanias, LC; Schreiber, RD; Kalvakolanu, DV				Hu, JB; Roy, SK; Shapiro, PS; Rodig, SR; Reddy, SPM; Platanias, LC; Schreiber, RD; Kalvakolanu, DV			ERK1 and ERK2 activate CCAAAT/enhancer-binding protein-dependent gene transcription in response to interferon-gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; MAP KINASE; TARGETED DISRUPTION; REGULATORY FACTOR; DNA-BINDING; TYROSINE-PHOSPHATASE; FEEDBACK-REGULATION; ALPHA-INTERFERON; CELLS; EXPRESSION	Interferons (IFNs) regulate the expression of a number of cellular genes by activating the JAK-STAT pathway, We have recently discovered that CCAAAT/enhancer-binding protein-beta (C/EBP-beta) induces gene transcription through a novel IFN response element called the gamma -IFN-activated transcriptional element (Roy, S. K., Wachira, S. J., Weihua, X., Hu, J., and Kalvakolanu, D. V, (2000) J. Biol. Chem. 275, 12626-12632, Here, we describe a new IFN-gamma -stimulated pathway that operates C/EBP-beta -regulated gene expression independent of JAK1, We show that ERKs are activated by IFN-gamma to stimulate C/EBP-beta -dependent expression. Sustained ERK activation directly correlated with C/EBP-beta dependent gene expression in response to IFN-gamma. Mutant MKK1, its inhibitors, and mutant ERK suppressed IFN-gamma -stimulated gene induction through the gamma -IFN-activated transcriptional element. Ras and Raf activation was not required for this process. Furthermore, Raf-1 phosphorylation negatively correlated with its activity. Interestingly, C/EBP-beta -induced gene expression required STAT1, but not JAK1. A C/EBP-beta mutant lacking the ERK phosphorylation site failed to promote IFN-gamma stimulated gene expression. Thus, our data link C/EBP-beta to IFN-gamma signaling through ERKs.	Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Microbiol & Immunol,Mol & Cellular Biol Prog, Baltimore, MD 21201 USA; Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA; Johns Hopkins Univ, Dept Environm Hlth Sci, Sch Publ Hlth, Baltimore, MD 21205 USA; Univ Illinois, Sect Hematol & Oncol, Chicago, IL 60607 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Washington University (WUSTL)	Kalvakolanu, DV (corresponding author), Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Microbiol & Immunol,Mol & Cellular Biol Prog, Baltimore, MD 21201 USA.	dkalvako@umaryland.edu	Schreiber, Robert/Q-7550-2019; Schreiber, Robert D/A-1276-2013	Schreiber, Robert D/0000-0001-6311-0432; Schreiber, Robert/0000-0003-1590-2341	NCI NIH HHS [CA 41401, CA 78282, CA77816] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077816, R01CA078282] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bach EA, 1996, MOL CELL BIOL, V16, P3214; BANDYOPADHYAY SK, 1990, MOL CELL BIOL, V10, P5055, DOI 10.1128/MCB.10.10.5055; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Brickey WJ, 1999, J IMMUNOL, V163, P6622; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUCHMEIER NA, 1985, P NATL ACAD SCI USA, V82, P7404, DOI 10.1073/pnas.82.21.7404; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Contursi C, 2000, P NATL ACAD SCI USA, V97, P91, DOI 10.1073/pnas.97.1.91; CRESPO P, 1994, J BIOL CHEM, V269, P21103; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Kalvakolanu DV, 1999, TRENDS MICROBIOL, V7, P166, DOI 10.1016/S0966-842X(99)01476-6; Kaplan DH, 1996, J BIOL CHEM, V271, P9, DOI 10.1074/jbc.271.1.9; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KIMCHI A, 1992, J CELL BIOCHEM, V50, P1, DOI 10.1002/jcb.240500102; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; PETRICOIN E, 1994, MOL CELL BIOL, V14, P1477, DOI 10.1128/MCB.14.2.1477; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Roy SK, 2000, J BIOL CHEM, V275, P12626, DOI 10.1074/jbc.275.17.12626; Sakatsume M, 1998, J BIOL CHEM, V273, P3021, DOI 10.1074/jbc.273.5.3021; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; Shapiro PS, 1998, J BIOL CHEM, V273, P1788, DOI 10.1074/jbc.273.3.1788; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Tolwinski NS, 1999, J BIOL CHEM, V274, P6168, DOI 10.1074/jbc.274.10.6168; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UEKI K, 1994, J BIOL CHEM, V269, P15756; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; Vuong H, 2000, J BIOL CHEM, V275, P32250, DOI 10.1074/jbc.M005227200; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Weihua Xiao, 1997, Journal of Biological Chemistry, V272, P9742; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Xiao WH, 2000, BBA-GENE STRUCT EXPR, V1492, P163, DOI 10.1016/S0167-4781(00)00111-1; Xiao WH, 1997, P NATL ACAD SCI USA, V94, P103, DOI 10.1073/pnas.94.1.103	62	132	133	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					287	297		10.1074/jbc.M004885200	http://dx.doi.org/10.1074/jbc.M004885200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	10995751	hybrid			2022-12-25	WOS:000166280700040
J	Jiang, Z; Guo, Z; Saad, FA; Ellis, J; Zacksenhaus, E				Jiang, Z; Guo, Z; Saad, FA; Ellis, J; Zacksenhaus, E			Retinoblastoma gene promoter directs transgene expression exclusively to the nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RB1 PROMOTER; DIFFERENTIATION; PROTEIN; SKELETAL; ELEMENTS; MOUSE; EMBRYOGENESIS; PROLIFERATION; MUTATIONS; REGION	In human, germ line mutations in the tumor suppressor retinoblastoma (Rb) predispose individuals to retinoblastoma, whereas somatic inactivation of Rb contributes to the progression of a large spectrum of cancers. In mice, Rb is highly expressed in restricted cell lineages including the neurogenic, myogenic, and hematopoietic systems, and disruption of the gene leads to specific embryonic defects in these tissues. The symmetry between Rb expression and the defects in mutant mice suggest that transcriptional control of Rb during embryogenesis is pivotal for normal development. We have initiated studies to dissect the mechanisms of transcriptional regulation of Rb during development by promoter lacZ transgenic analysis. DNA sequences up to 6 kilobase pairs upstream of the mouse Rb promoter, isolated from two different genomic libraries, directed transgene expression exclusively to the developing nervous system, excluding skeletal muscles and liver. Expression of the transgene in the central and peripheral nervous systems, including the retina, recapitulated the expression of endogenous Rb during embryogenesis, A promoter region spanning similar to 250 base pairs upstream of the transcriptional starting site was sufficient to confer expression in the central and peripheral nervous systems. To determine whether this expression pattern was conserved, we isolated the human Rb 5' genomic region and generated transgenic mice expressing lacZ under control of a 1.6-kilobase pair human Rb promoter. The human Rb promoter lacZ mice also expressed the transgene primarily in the nervous system in several independent lines. Thus, transgene expression directed by both the human and mouse Rb promoters is restricted to a subset of tissues in which Rb is normally expressed during embryogenesis. Our findings demonstrate that regulatory elements directing Bb expression to the nervous system are delineated within a well defined core promoter and are regionally separated from elements, yet to be identified, that are required for expression of Rb in the developing hematopoietic and skeletal muscle systems.	Univ Toronto, Univ Hlth Network, Toronto Gen Res Inst, Dept Med, Toronto, ON M5G 2M1, Canada; Univ Toronto, Univ Hlth Network, Toronto Gen Res Inst, Dept Med Biophys, Toronto, ON M5G 2M1, Canada; Univ Toronto, Hosp Sick Children, Dev Biol Program, Toronto, ON M5G, Canada; Univ Toronto, Hosp Sick Children, Canc & Blood Program, Toronto, ON M5G, Canada; Univ Toronto, Dept Med Genet, Toronto, ON M5G, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Zacksenhaus, E (corresponding author), Univ Toronto, Univ Hlth Network, Toronto Gen Res Inst, Dept Med, 67 Coll St,Rm 407, Toronto, ON M5G 2M1, Canada.		Saad, Fawzy A/HHC-9993-2022; Ellis, James/F-4789-2011; Zacksenhaus, Eldad/AAD-3584-2020	Ellis, James/0000-0002-4400-0091; 				BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; Biben C, 1996, DEV BIOL, V173, P200, DOI 10.1006/dbio.1996.0017; BIGNON YJ, 1993, GENE DEV, V7, P1654, DOI 10.1101/gad.7.9.1654; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COPPOLA JA, 1990, ONCOGENE, V5, P1731; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; Ellis J, 1996, EMBO J, V15, P562, DOI 10.1002/j.1460-2075.1996.tb00388.x; GILL RM, 1994, CELL GROWTH DIFFER, V5, P467; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jiang Z, 1997, ONCOGENE, V14, P1789, DOI 10.1038/sj.onc.1201014; JIANG Z, 2000, IN PRESS DEV BIOL; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lehman DA, 1999, DEVELOPMENT, V126, P1793; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Riley DJ, 1997, MOL CELL BIOL, V17, P7342, DOI 10.1128/MCB.17.12.7342; SAKAI T, 1991, AM J HUM GENET, V48, P880; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SLACK RS, 1993, ONCOGENE, V8, P1585; Sowa Y, 1997, CANCER RES, V57, P3145; Tamir A, 1999, MOL CELL BIOL, V19, P4452; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YULE L, 2000, IN PRESS ONCOGENE; ZACKSENHAUS E, 1993, ONCOGENE, V8, P2343; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zacksenhaus E, 1999, BBA-MOL CELL RES, V1451, P288, DOI 10.1016/S0167-4889(99)00103-2; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4	33	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					593	600		10.1074/jbc.M005474200	http://dx.doi.org/10.1074/jbc.M005474200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11016928	hybrid			2022-12-25	WOS:000166280700080
J	Prowse, CN; Lew, J				Prowse, CN; Lew, J			Mechanism of activation of ERK2 by dual phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CATALYTIC SUBUNIT; MAP; DIFFUSION; LIMITS	The mitogen-activated protein (MAP) kinases ape characterized by their requirement for dual phosphorylation at a conserved threonine and tyrosine residue for catalytic activation. The structural consequences of dual-phosphorylation in the MAP kinase ERK2 (extracellular signal-regulated kinase 2) include active site closure, alignment of key catalytic residues that interact with ATP, and remodeling of the activation loop. in this study, we report the specific effects of dual phosphorylation on the individual catalytic reaction steps in ERK2, Dual phosphorylation leads to an increase in overall catalytic efficiency and turnover rate of approximately 600,000- and 50,000-fold, respectively. Solvent viscosometric studies reveal moderate decreases in the equilibrium dissociation constants (K-d) for both ATP and myelin basic protein. However, the majority of the overall rate enhancement is due to an increase in the rate of the phosphoryl group transfer step by approximately 60,000-fold. By comparison, the rate of the same step in the ATPase reaction is enhanced only 2000-fold. This suggests that optimizing the position of the invariant residues Lys(52) and Glu(69), which stabilize the phosphates of ATP, accounts for only part of the enhanced rate of phosphoryl group transfer in the kinase reaction. Thus, significant stabilization of the protein phosphoacceptor group must also occur. Our results demonstrate similarities between the activation mechanisms of ERK2 and the cell cycle control enzyme, Cdk2 (cyclin-dependent kinase 2), Rather than dual phosphorylation, however, activation of the latter is controlled by cyclin binding followed by phosphorylation at Thr(160).	Univ Calif Santa Barbara, Interdepartmental Program Biochem & Mol Biol, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif San Diego, Grad Program Biomed Sci, La Jolla, CA 92093 USA	University of California System; University of California Santa Barbara; University of California System; University of California San Diego	Lew, J (corresponding author), Univ Calif Santa Barbara, Interdepartmental Program Biochem & Mol Biol, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.							ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; BROUWER AC, 1982, BIOCHEMISTRY-US, V21, P1302, DOI 10.1021/bi00535a030; CALDWELL SR, 1991, BIOCHEMISTRY-US, V30, P7438, DOI 10.1021/bi00244a010; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CLELAND WW, 1975, BIOCHEMISTRY-US, V14, P3220, DOI 10.1021/bi00685a029; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hagopian JC, 2001, J BIOL CHEM, V276, P275, DOI 10.1074/jbc.M007337200; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKATANI H, 1979, J PHYS CHEM-US, V83, P2662, DOI 10.1021/j100483a023; Prowse CN, 2000, BIOCHEMISTRY-US, V39, P6258, DOI 10.1021/bi000277b; ZHANG FM, 1993, J MOL BIOL, V233, P550, DOI 10.1006/jmbi.1993.1532; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	18	63	63	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					99	103		10.1074/jbc.M008137200	http://dx.doi.org/10.1074/jbc.M008137200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11016942	hybrid			2022-12-25	WOS:000166280700015
J	Raza, SL; Nehring, LC; Shapiro, SD; Cornelius, LA				Raza, SL; Nehring, LC; Shapiro, SD; Cornelius, LA			Proteinase-activated receptor-1 regulation of macrophage elastase (MMP-12) secretion by serine proteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALVEOLAR MACROPHAGES; NECROSIS-FACTOR-ALPHA; THROMBIN RECEPTOR; MATRIX METALLOPROTEINASES; ANGIOGENESIS INHIBITOR; PLASMINOGEN-ACTIVATOR; ENDOTHELIAL-CELLS; ANGIOSTATIN; EXPRESSION; METALLOELASTASE	The serine proteinases plasmin and thrombin convert proenzyme matrix metalloproteinases (MMPs) into catalytically active forms. In addition, we demonstrate that plasmin(ogen) and thrombin induce a significant increase in secretion of activated murine macrophage elastase (MMP-12) protein. Active serine protease is responsible for induction, as demonstrated by the absence of MMP-12 induction in plasminogen(Plg)-treated urokinase-type plasminogen activator-deficient macrophages, Since increased MMP-12 protein secretion was not accompanied by an increase in MMP-12 mRNA, we examined post-translational mechanisms. Protein synthesis was not required for early release of MMP-12 but was required for later secretion of activated enzyme. Immunofluorescent microscopy demonstrated basal expression in macrophages that increased following serine proteinase exposure. Inhibition of MMP-12 secretion by hirudin and pertussis toxin demonstrated a role for the thrombin G protein-coupled receptor (protease-activated receptor 1 (PAR-1)). PAR-1-activating peptides were able to induce MMP-12 release. Investigation of signal transduction pathways involved in this response demonstrate the requirement for protein kinase C, but not tyrosine kinase, activity. These data demonstrate that plasmin and thrombin regulate MMP-12 activity through distinct mechanisms: post-translational secretion of preformed MMP-12 protein, induction of protein secretion that is protein kinase C-mediated, and extracellular enzyme activation. Most importantly, we show that serine proteinase MMP-12 regulation in macrophages occurs via the protein kinase C-activating G protein-coupled receptor PAR-1.	Washington Univ, Sch Med, Barnes Jewish Hosp, Div Dermatol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Div Resp & Crit Care,Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Div Allergy & Pulm Med,Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)	Cornelius, LA (corresponding author), Div Dermatol, 216 S Kingshighway, St Louis, MO 63110 USA.			Cornelius, Lynn A/0000-0002-6329-2819	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001938] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01HL29594] Funding Source: Medline; NIAMS NIH HHS [K08AR01938] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abraham LA, 1998, J BONE MINER RES, V13, P818, DOI 10.1359/jbmr.1998.13.5.818; Bernatowicz MS, 1996, J MED CHEM, V39, P4879, DOI 10.1021/jm960455s; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu TM, 1998, BIOCHEM BIOPH RES CO, V253, P128, DOI 10.1006/bbrc.1998.9760; Cornelius LA, 1998, J IMMUNOL, V161, P6845; Damiano BP, 1999, J PHARMACOL EXP THER, V288, P671; DeClerck YA, 1997, ADV EXP MED BIOL, V425, P89; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; DUHAMELCLERIN E, 1997, ATHEROSCLER THROMB V, V17, P1555; Ellis CA, 1999, J BIOL CHEM, V274, P13718, DOI 10.1074/jbc.274.19.13718; Falcone DJ, 1998, J BIOL CHEM, V273, P31480, DOI 10.1074/jbc.273.47.31480; Gately S, 1996, CANCER RES, V56, P4887; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; Hollenberg MD, 1997, CAN J PHYSIOL PHARM, V75, P832, DOI 10.1139/cjpp-75-7-832; Kumar R, 1996, J IMMUNOL, V157, P5104; Lijnen HR, 1999, THROMB HAEMOSTASIS, V81, P799; MAZZIERI R, 1997, EMBO J, V9, P2319; MOLINO M, 1995, J BIOL CHEM, V270, P11168, DOI 10.1074/jbc.270.19.11168; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; SAARIALHOKERE UK, 1993, J BIOL CHEM, V268, P17354; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SHAPIRO SD, 1992, J BIOL CHEM, V267, P13890; Shen GX, 1998, SEMIN THROMB HEMOST, V24, P151, DOI 10.1055/s-2007-995834; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; Solomon KR, 1998, J CLIN INVEST, V102, P2019, DOI 10.1172/JCI4317; St-Denis A, 1998, J BIOL CHEM, V273, P32787, DOI 10.1074/jbc.273.49.32787; Stathakis P, 1997, J BIOL CHEM, V272, P20641, DOI 10.1074/jbc.272.33.20641; Sudbeck BD, 1997, J BIOL CHEM, V272, P22103, DOI 10.1074/jbc.272.35.22103; Xie B, 1998, J BIOL CHEM, V273, P11583, DOI 10.1074/jbc.273.19.11583; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730	36	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41243	41250		10.1074/jbc.M005788200	http://dx.doi.org/10.1074/jbc.M005788200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10993890	hybrid			2022-12-25	WOS:000166114600078
J	Toth, M; Bernardo, MM; Gervasi, DC; Soloway, PD; Wang, ZP; Bigg, HF; Overall, CM; DeClerck, YA; Tschesche, H; Cher, ML; Brown, S; Mobashery, S; Fridman, R				Toth, M; Bernardo, MM; Gervasi, DC; Soloway, PD; Wang, ZP; Bigg, HF; Overall, CM; DeClerck, YA; Tschesche, H; Cher, ML; Brown, S; Mobashery, S; Fridman, R			Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (membrane type 1)-MMP-dependent activation of pro-MMP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUAMOUS-CELL CARCINOMA; MEMBRANE-TYPES 1; GELATINASE-A; 1-MATRIX METALLOPROTEINASE; 72-KDA GELATINASE; CATALYTIC DOMAIN; EFFICIENT ACTIVATION; BREAST CARCINOMAS; HUMAN FIBROBLASTS; TERMINAL DOMAIN	The membrane-type 1 matrix metalloproteinase (MT1-MMP) has been shown to be a key enzyme in tumor angiogenesis and metastasis. MT1-MMP hydrolyzes a variety of extracellular matrix components and is a physiological activator of pro-MMP-2, another MMP involved in malignancy. Pro-MMP-2 activation by MT1-MMP involves the formation of an MT1-MMP tissue inhibitors of metalloproteinases 2 (TIMP-2) pro-MMP-2 complex on the cell surface that promotes the hydrolysis of pro-MMP-2 by a neighboring TIMP-2-free MT1-MMP. The MT1-MMP TIMP-2 complex also serves to reduce the intermolecular autocatalytic turnover of MT1-MMP, resulting in accumulation of active MT1-MMP (57 kDa) on the cell surface. Evidence shown here in Timp2-null cells demonstrates that pro-MMP-2 activation by MT1-MMP requires TIMP-2. In contrast, a C-terminally deleted TIMP-2 (Delta -TIMP-2), unable to form ternary complex, had no effect, However, Delta -TIMP-2 and certain synthetic MMP inhibitors, which inhibit MT1-MMP autocatalysis, can act synergistically with TIMP-2 in the promotion of pro-MMP-2 activation by MT1-MMP. In contrast, TIMP-4, an efficient MT1-MMP inhibitor, had no synergistic effect, These studies suggest that under certain conditions the pericellular activity of MT1-MMP in the presence of TIMP-2 can be modulated by synthetic and natural (TIMP-4) MMP inhibitors.	Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Dept Urol, Detroit, MI 48201 USA; Wayne State Univ, Dept Chem, Detroit, MI 48201 USA; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ So Calif, Childrens Hosp Los Angeles, Div Hematol Oncol, Los Angeles, CA 90027 USA; Univ So Calif, Childrens Hosp Los Angeles, Dept Pediat, Los Angeles, CA 90027 USA; Univ Bielefeld, Dept Biochem, Fac Chem, W-4800 Bielefeld 1, Germany	Wayne State University; Wayne State University; Wayne State University; Roswell Park Cancer Institute; University of British Columbia; Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California; University of Bielefeld	Fridman, R (corresponding author), Wayne State Univ, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.	fridman@med.wayne.edu	Soloway, Paul/T-8243-2019	Soloway, Paul/0000-0003-1967-0437; DeClerck, Yves/0000-0002-3688-0113	NCI NIH HHS [CA61986-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061986] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belotti D, 1999, INT J BIOL MARKER, V14, P232, DOI 10.1177/172460089901400406; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brown PD, 1997, MED ONCOL, V14, P1, DOI 10.1007/BF02990939; Brown PD, 1999, APMIS, V107, P174, DOI 10.1111/j.1699-0463.1999.tb01541.x; Brown S, 2000, J AM CHEM SOC, V122, P6799, DOI 10.1021/ja001461n; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Caterina JJ, 2000, J BIOL CHEM, V275, P26416, DOI 10.1074/jbc.M001271200; d'Ortho MP, 1998, FEBS LETT, V421, P159, DOI 10.1016/S0014-5793(97)01555-X; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Davidson B, 1999, GYNECOL ONCOL, V73, P372, DOI 10.1006/gyno.1999.5381; De B, 1999, ANN NY ACAD SCI, V878, P40, DOI 10.1111/j.1749-6632.1999.tb07673.x; Della Porta P, 1999, ANTICANCER RES, V19, P3809; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; FRIDMAN R, 1993, BIOCHEM J, V289, P411, DOI 10.1042/bj2890411; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; Gervasi DC, 1996, BIOCHEM BIOPH RES CO, V228, P530, DOI 10.1006/bbrc.1996.1694; Harada T, 1998, J HEPATOL, V28, P231, DOI 10.1016/0168-8278(88)80010-2; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; HOYHTYA M, 1994, INT J CANCER, V56, P500, DOI 10.1002/ijc.2910560408; Jo Y, 2000, BIOCHEM J, V345, P511, DOI 10.1042/bj3450511; Jones JL, 1999, J PATHOL, V189, P161, DOI 10.1002/(SICI)1096-9896(199910)189:2<161::AID-PATH406>3.0.CO;2-2; Kadono Y, 1998, CANCER RES, V58, P2240; Kanayama H, 1998, CANCER, V82, P1359, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1359::AID-CNCR20>3.0.CO;2-4; Kitagawa Y, 1998, J UROLOGY, V160, P1540, DOI 10.1016/S0022-5347(01)62609-0; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P18; Ko YC, 1997, BIOCHEM BIOPH RES CO, V236, P100, DOI 10.1006/bbrc.1997.6859; Kurahara S, 1999, HEAD NECK-J SCI SPEC, V21, P627, DOI 10.1002/(SICI)1097-0347(199910)21:7<627::AID-HED7>3.3.CO;2-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li H, 1998, MOL CARCINOGEN, V22, P84; Lichte A, 1996, FEBS LETT, V397, P277, DOI 10.1016/S0014-5793(96)01206-9; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MULLERSTEFFNER HM, 1992, J BIOL CHEM, V267, P9606; Murashige M, 1996, JPN J CLIN ONCOL, V26, P303, DOI 10.1093/oxfordjournals.jjco.a023237; Nabeshima K, 2000, CANCER RES, V60, P3364; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Olson MW, 2000, J BIOL CHEM, V275, P2661, DOI 10.1074/jbc.275.4.2661; Overall CM, 1999, ANN NY ACAD SCI, V878, P747, DOI 10.1111/j.1749-6632.1999.tb07780.x; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Puente XS, 1996, CANCER RES, V56, P944; Rasmussen HS, 1997, PHARMACOL THERAPEUT, V75, P69, DOI 10.1016/S0163-7258(97)00023-5; Ree AH, 1997, CLIN CANCER RES, V3, P1623; Rosenthal EL, 1999, OTOLARYNG HEAD NECK, V121, P337, DOI 10.1016/S0194-5998(99)70217-2; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Segel I. H., 1993, ENZYME KINETICS BEHA, P100; Soloway PD, 1996, ONCOGENE, V13, P2307; Stanton H, 1998, J CELL SCI, V111, P2789; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Steward WP, 1999, CANCER CHEMOTH PHARM, V43, pS56, DOI 10.1007/s002800051099; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Toth M, 1997, CANCER RES, V57, P3159; Tsunezuka Y, 1996, CANCER RES, V56, P5678; Ueno H, 1997, CANCER RES, V57, P2055; Velasco G, 2000, CANCER RES, V60, P877; VISSCHER DW, 1994, INT J CANCER, V59, P339, DOI 10.1002/ijc.2910590308; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Wingfield PT, 1999, J BIOL CHEM, V274, P21362, DOI 10.1074/jbc.274.30.21362; Wojtowicz-Praga S, 1999, Drugs R D, V1, P117, DOI 10.2165/00126839-199901020-00001; Yamamoto M, 1998, J MED CHEM, V41, P1209, DOI 10.1021/jm970404a; Yoshizaki T, 1997, CANCER, V79, P139, DOI 10.1002/(SICI)1097-0142(19970101)79:1<139::AID-CNCR20>3.0.CO;2-4; Yu AE, 1997, DRUG AGING, V11, P229, DOI 10.2165/00002512-199711030-00006; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	80	109	114	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41415	41423		10.1074/jbc.M006871200	http://dx.doi.org/10.1074/jbc.M006871200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10998420	hybrid			2022-12-25	WOS:000166114600099
J	Wei, M; Li, Z; Ye, DM; Herzberg, O; Dunaway-Mariano, D				Wei, M; Li, Z; Ye, DM; Herzberg, O; Dunaway-Mariano, D			Identification of domain-domain docking sites within Clostridium symbiosum pyruvate phosphate dikinase by amino acid replacement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MUTAGENESIS; PHOSPHOENOLPYRUVATE FORMATION; PROTEIN-STRUCTURE; CATALYTIC SITE; BINDING SITE; LOCATION	Potential domain-domain docking residues, identified from the x-ray structure of the Clostridium symbiosum apoPPDK, were replaced by site-directed mutagenesis, The steady-state and transient kinetic properties of the mutant enzymes were determined as a way of evaluating docking efficiency. PPDK mutants, in which one of two stringently conserved docking residues located on the N-terminal domain (Arg(219) and Glu(271)) was substituted, displayed largely unimpeded catalysis of the phosphoenolpyruvate partial reaction at the C-terminal domain, but significantly impaired catalysis (>10(4)) of the ATP pyrophosphorylation of His(455) at the N-terminal domain: In contrast, alanine mutants of two potential docking residues located on the N-terminal domain (Ser(262) and Lys(149)), which are not conserved among the PPDKs, exhibited essentially normal catalytic turnover. Arg(219) and Glu(271) were thus proposed to play an important role in guiding the central domain and, hence, the catalytic His(455) into position for catalysis, Substitution of central domain residues Glu(434)/Glu(437) and Thr(453), th, respective docking partners of Arg(219) and Glu(271) resulted in mutants impaired in catalysis at the ATP active site. The x-ray crystal structure of the apo-T453A PPDK mutant was determined to test for possible misalignment of residues at the N-terminal domain-central domain interface that might result from loss of the Thr(453)-Glu(271) binding interaction. With the exception of the mutation site, the structure of T453A PPDK was found to be identical to that of the wild-type enzyme. It is hypothesized that the two Glu(271) interfacial binding sites that remain in the T453A PPDK mutant, Thr(453) backbone NH and Met(452) backbone NH, are sufficient to stabilize the native conformation as observed in the crystalline state but may be less effective in populating the reactive conformation in solution.	Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA	University of New Mexico	Herzberg, O (corresponding author), Ctr Adv Res Biotechnol, Rockville, MD 20850 USA.	dd39@unm.edu		Herzberg, Osnat/0000-0003-2823-7627; Li, Zhong/0000-0002-1039-7000	NIGMS NIH HHS [GM36260] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036260] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CARROLL LJ, 1989, J AM CHEM SOC, V111, P5965, DOI 10.1021/ja00197a081; Cleland W W, 1979, Methods Enzymol, V63, P500; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Herzberg O, 1996, P NATL ACAD SCI USA, V93, P2652, DOI 10.1073/pnas.93.7.2652; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; McGuire M, 1998, BIOCHEMISTRY-US, V37, P13463, DOI 10.1021/bi980920i; McGuire M, 1996, BIOCHEMISTRY-US, V35, P8544, DOI 10.1021/bi960275k; MEHL A, 1994, BIOCHEMISTRY-US, V33, P1093, DOI 10.1021/bi00171a007; POCALYKO DJ, 1990, BIOCHEMISTRY-US, V29, P10757, DOI 10.1021/bi00500a006; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; ROUSSEL A, 1989, TURBO FRODO SILICON; SPOLAR RS, 1989, P NATL ACAD SCI USA, V86, P8382, DOI 10.1073/pnas.86.21.8382; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; WANG HC, 1988, BIOCHEMISTRY-US, V27, P625, DOI 10.1021/bi00402a020; Wood H G, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P85; XU Y, 1995, BIOCHEMISTRY-US, V34, P2181, DOI 10.1021/bi00007a011; YANKIE L, 1995, BIOCHEMISTRY-US, V34, P2188, DOI 10.1021/bi00007a012	18	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41156	41165		10.1074/jbc.M006149200	http://dx.doi.org/10.1074/jbc.M006149200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10995759	hybrid			2022-12-25	WOS:000166114600068
J	Gerelsaikhan, T; Turner, RJ				Gerelsaikhan, T; Turner, RJ			Transmembrane topology of the secretory Na+-K+-2Cl(-) cotransporter NKCC1 studied by in vitro translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORTER; SHARK RECTAL GLAND; MOLECULAR-CLONING; MEMBRANE-PROTEINS; NA-K-2CL COTRANSPORTER; FUNCTIONAL EXPRESSION; HYPOKALEMIC ALKALOSIS; BARTTERS-SYNDROME; PREDICTION; TRANSPORT	The secretory Na+-K+-2Cl(-) cotransporter NKCC1 is a member of a small gene family of electroneutral salt transporters. Hydropathy analyses indicate that all of these transporters have a similar general structure consisting of large hydrophilic N and C termini on either side of a central, relatively well conserved, hydrophobic domain. Programs that predict the transmembrane topology of polytopic membrane proteins identify 10-12 putative membrane-spanning segments (MSSs) in this hydrophobic domain; but to date, there is little experimental data on the structure of this region for any of these transporters. In this report, we have studied the transmembrane topology of NKCC1 using an in vitro translation system designed to test the membrane insertion properties of putative MSSs (Bamberg, K., and Sachs, G. (1994) J. Biol. Chem. 269, 16909-16919). Fusion proteins consisting of putative NKCC1 MSSs inserted either (i) between an N-terminal cytosolic anchor sequence and a C-terminal reporter sequence containing multiple N-linked glycosidation sites or (ii) between an N-terminal signal anchor sequence and the same glycosidation flag were expressed in the presence of canine pancreatic microsomes. The glycosidation status of the reporter sequence, which indicated its luminal or extraluminal location in the microsomes, was then used to characterize the signal anchor or stop transfer activity of the inserted MSSs. The results of this experimental analysis yielded a topology scheme consisting of 12 membrane-spanning segments, two pairs of which apparently form rather tight hairpin-like structures within the membrane.	NIDCR, Membrane Biol Sect, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Turner, RJ (corresponding author), NIDCR, Membrane Biol Sect, Gene Therapy & Therapeut Branch, NIH, Rm 1A01,Bldg 10, Bethesda, MD 20892 USA.	rjturner@nih.gov			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [ZIADE000415, Z01DE000415] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; Bayle D, 1997, J BIOL CHEM, V272, P19697, DOI 10.1074/jbc.272.32.19697; Behnke RD, 1998, FASEB J, V12, pA1013; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; Bowie JU, 1997, J MOL BIOL, V272, P780, DOI 10.1006/jmbi.1997.1279; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; DELPIRE E, 1994, J BIOL CHEM, V269, P25677; Delpire E, 1999, NAT GENET, V22, P192, DOI 10.1038/9713; Evans RL, 1998, BIOCHEM BIOPH RES CO, V245, P301, DOI 10.1006/bbrc.1998.8428; Flagella M, 1999, J BIOL CHEM, V274, P26946, DOI 10.1074/jbc.274.38.26946; FORBUSH B, 1995, INT SOC NEPHR; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; Hegde RS, 1997, CELL, V91, P575, DOI 10.1016/S0092-8674(00)80445-6; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Isenring P, 1998, J GEN PHYSIOL, V112, P549, DOI 10.1085/jgp.112.5.549; Isenring P, 1998, P NATL ACAD SCI USA, V95, P7179, DOI 10.1073/pnas.95.12.7179; Isenring P, 1997, J BIOL CHEM, V272, P24556, DOI 10.1074/jbc.272.39.24556; Kaplan MR, 1996, ANNU REV PHYSIOL, V58, P649, DOI 10.1146/annurev.ph.58.030196.003245; Kurihara K, 1999, AM J PHYSIOL-CELL PH, V277, pC1184, DOI 10.1152/ajpcell.1999.277.6.C1184; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LYTLE C, 1992, J BIOL CHEM, V267, P25428; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Monne M, 1999, J MOL BIOL, V288, P141, DOI 10.1006/jmbi.1999.2657; Moore-Hoon ML, 1998, BBA-BIOMEMBRANES, V1373, P261, DOI 10.1016/S0005-2736(98)00112-6; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; REAGAN JD, 1995, INSECT BIOCHEM MOLEC, V25, P875, DOI 10.1016/0965-1748(95)00049-2; ROST B, 1995, PROTEIN SCI, V4, P521; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201	37	54	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40471	40477		10.1074/jbc.M007751200	http://dx.doi.org/10.1074/jbc.M007751200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11013260	hybrid			2022-12-25	WOS:000166039500090
J	Gorzalczany, Y; Sigal, N; Itan, M; Lotan, O; Pick, E				Gorzalczany, Y; Sigal, N; Itan, M; Lotan, O; Pick, E			Targeting of Rac1 to the phagocyte membrane is sufficient for the induction of NADPH oxidase assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; GTP-BINDING PROTEINS; RESPIRATORY BURST OXIDASE; GDP/GTP EXCHANGE PROTEIN; SUPEROXIDE PRODUCTION; PLASMA-MEMBRANE; IN-VITRO; ACTIVATION; MACROPHAGES; P47(PHOX)	The superoxide (O-2(.-))-generating NADPH oxidase complex of phagocytes consists of a membrane-associated flavocytochrome (cytochrome b559) and four cytosolic proteins, p47(phox) p67(phox), p40(phox), and the small GTPase Rac (Rac1 or -2). NADPH oxidase activation (O-2 production) is elicited as the consequence of assembly of some or all cytosolic components with cytochrome b(559). This process can be reproduced in an in vitro system consisting of phagocyte membranes, p47(phox) p67(phox), and Rac1 activated by an anionic amphiphile. We now show that posttranslationally processed (prenylated) Rad initiates NADPH oxidase assembly, expressed in O-2, production, in a cell-free system containing phagocyte membrane vesicles and p67(phox), in the absence of an activating amphiphile and of p47(phox). Prenylated Cdc42Hs, a GTPase closely related to Rac, is inactive under the same conditions. Results obtained with phagocyte membrane vesicles can be reproduced fully by replacing these with partially purified cytochrome b(559), incorporated in phosphatidylcholine vesicles. Prenylated, but not nonprenylated, Rac1 binds spontaneously to phagocyte membrane vesicles and also to artificial, protein-free, phosphatidylcholine vesicles, a process counteracted by GDP dissociation inhibitor for Rho. Binding of prenylated Rac1 to membrane vesicles is accompanied by the recruitment of p67(phox) to the same location and the formation of an assembled NADPH oxidase complex, producing O-2 upon the addition of NADPH. Amphiphile and p47(phox)-independent NADPH oxidase activation by prenylated Rad is inhibited by Rho GDP dissociation inhibitor and by phosphatidylcholine vesicles, both competing with membrane for prenylated Rac1. We conclude that, in vitro, targeting of Rac to the phagocyte membrane is sufficient for the induction of NADPH oxidase assembly, suggesting that the principal or, possibly, the only role of Rac is to recruit cytosolic p67(phox) to the membrane environment, to be followed by the interaction of p67(phox) with cytochrome b(559).	Tel Aviv Univ, Sackler Sch Med, Julius Friedrich Cohnheim Minerva Ctr Phagocyte R, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Pick, E (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel.		Pick, Edgar/B-1795-2008	Pick, Edgar/0000-0003-4625-3233				ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; Ambruso DR, 2000, P NATL ACAD SCI USA, V97, P4654, DOI 10.1073/pnas.080074897; ANDO S, 1992, J BIOL CHEM, V267, P25709; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1994, J BIOL CHEM, V269, P7055; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; Cross AR, 1999, J BIOL CHEM, V274, P15519, DOI 10.1074/jbc.274.22.15519; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; FUCHS A, 1994, EUR J BIOCHEM, V226, P587, DOI 10.1111/j.1432-1033.1994.tb20084.x; Hata K, 1998, J BIOL CHEM, V273, P4232, DOI 10.1074/jbc.273.7.4232; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Illenberger D, 1998, EMBO J, V17, P6241, DOI 10.1093/emboj/17.21.6241; JOSEPH G, 1995, J BIOL CHEM, V270, P29079, DOI 10.1074/jbc.270.49.29079; JOSEPH G, 1994, J BIOL CHEM, V269, P29024; JOUAN A, 1993, ANAL BIOCHEM, V214, P251; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; Koshkin V, 1997, BBA-BIOENERGETICS, V1319, P139, DOI 10.1016/S0005-2728(96)00154-5; KRECK ML, 1994, J BIOL CHEM, V269, P4161; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; LECABEC V, 1994, BIOCHEM BIOPH RES CO, V198, P1216, DOI 10.1006/bbrc.1994.1172; Leto TL., 1999, INFLAMMATION BASIC P, P769; Lopes LR, 1999, J BIOL CHEM, V274, P15533, DOI 10.1074/jbc.274.22.15533; PHILIPS MR, 1995, J BIOL CHEM, V270, P11514, DOI 10.1074/jbc.270.19.11514; PICK E, 1993, EUR J BIOCHEM, V217, P441, DOI 10.1111/j.1432-1033.1993.tb18264.x; Pugach N., 1998, European Journal of Haematology, V60, P343; QUINN MT, 1993, J BIOL CHEM, V268, P20983; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Toporik A, 1998, BIOCHEMISTRY-US, V37, P7147, DOI 10.1021/bi9800404	40	115	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40073	40081		10.1074/jbc.M006013200	http://dx.doi.org/10.1074/jbc.M006013200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007780	hybrid			2022-12-25	WOS:000166039500039
J	Sakamoto, H; Imai, H; Nakagawa, Y				Sakamoto, H; Imai, H; Nakagawa, Y			Involvement of phospholipid hydroperoxide glutathione peroxidase in the modulation of prostaglandin D-2 synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID METABOLISM; BASOPHILIC LEUKEMIA-CELLS; ENDOPEROXIDE-H SYNTHASE-1; MAST-CELLS; RBL-2H3 CELLS; HYDROGEN-PEROXIDE; OXYGEN RADICALS; RAT; 5-LIPOXYGENASE; TRANSLOCATION	Antigenic cross-linking of the high affinity IgE receptors on mast cells induced the synthesis of prostaglandin D-2 (PGD(2)). The production of PGD(2) in L9 cells, which overexpressed non-mitochondrial phospholipid glutathione peroxidase (PHGPx), was only one-third that in the control line of cells (S1 cells). The reduction in the formation of PGD, in L9 cells was reversed upon inhibition of PHGPx activity by buthionine sulfoximine. Experiments with inhibitors demonstrated that prostaglandin H synthase-a (PGHS-2) was the isozyme responsible for the production of PGD, upon cross-linking of IgE receptors. The conversion of radiolabeled arachidonic acid to prostaglandin H, (PGH,) was strongly inhibited in L9 cells, whereas the rate of conversion of PGH, to PGD, was the same in L9 cells and S1 cells, indicating that PGHS was inactivated in L9 cells. The PGHS activity in L9 cells was about half that in S1 cells. However, PGHS activity in L9 cells increased to the level in S1 cells upon the addition of the hydroperoxide 15-hydroperoxyeicosatetraenoic acid or of 3-chloroperoxy-benzoic acid. These results suggest that non-mitochondrial PHGPx might be involved in the inactivation of PGHS-2 in nucleus and endoplasmic reticulum via reductions in levels of the hydroperoxides that are required for full activation of PGHS. Therefore, it appears that PHGPx might function as a modulator of the production of prostanoids, in addition to its role as an antioxidant enzyme.	Kitasato Univ, Sch Pharmaceut Sci, Minato Ku, Tokyo 1088641, Japan	Kitasato University	Nakagawa, Y (corresponding author), Kitasato Univ, Sch Pharmaceut Sci, Minato Ku, 5-9-1 Shirokane, Tokyo 1088641, Japan.							Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Chen W, 1999, J BIOL CHEM, V274, P20301, DOI 10.1074/jbc.274.29.20301; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Godeas C, 1996, BIOCHEM MOL MED, V59, P118, DOI 10.1006/bmme.1996.0076; GREEN K, 1964, J LIPID RES, V5, P117; GUARNIERI C, 1992, FREE RADICALS AGING, P73; HARLAN JM, 1984, J CLIN INVEST, V74, P442, DOI 10.1172/JCI111440; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HOLGATE ST, 1984, J IMMUNOL, V133, P2138; Imai H, 1996, BIOCHEM BIOPH RES CO, V222, P432, DOI 10.1006/bbrc.1996.0762; Imai H, 1998, J BIOL CHEM, V273, P1990, DOI 10.1074/jbc.273.4.1990; JOLLY SR, 1984, CIRC RES, V54, P277, DOI 10.1161/01.RES.54.3.277; KAWATA R, 1995, J IMMUNOL, V155, P818; Keelan JA, 1999, BIOCHEM BIOPH RES CO, V262, P579, DOI 10.1006/bbrc.1999.1257; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; LEWIS RA, 1982, J IMMUNOL, V129, P1627; Lu GQ, 1999, J BIOL CHEM, V274, P16162, DOI 10.1074/jbc.274.23.16162; MALAVIYA R, 1993, J BIOL CHEM, V268, P4939; Margalit A, 1998, AM J PHYSIOL-REG I, V274, pR294, DOI 10.1152/ajpregu.1998.274.2.R294; MARSHALL PJ, 1986, J LAB CLIN MED, V108, P525; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; PEDEN DB, 1995, AM J PHYSIOL-LUNG C, V268, pL902, DOI 10.1152/ajplung.1995.268.6.L902; PETERS SP, 1984, J IMMUNOL, V132, P1972; ROVERI A, 1994, METHOD ENZYMOL, V143, P307; Sakamoto H, 1999, J BIOCHEM-TOKYO, V125, P90, DOI 10.1093/oxfordjournals.jbchem.a022274; Schnurr K, 1996, J BIOL CHEM, V271, P4653; Shitashige M, 1998, BBA-LIPID LIPID MET, V1389, P57, DOI 10.1016/S0005-2760(97)00129-X; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; SPORN PHS, 1988, AM REV RESPIR DIS, V137, P49, DOI 10.1164/ajrccm/137.1.49; TAYLOR L, 1983, J BIOL CHEM, V258, P6855; THOMAS JP, 1990, J BIOL CHEM, V265, P454; Tsai AL, 1999, J BIOL CHEM, V274, P21695, DOI 10.1074/jbc.274.31.21695; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; WEI CH, 1995, BIOCHEMISTRY-US, V34, P8499, DOI 10.1021/bi00026a034; WENNOGLE LP, 1995, FEBS LETT, V371, P315, DOI 10.1016/0014-5793(95)00930-8; Westcott JY, 1996, BBA-LIPID LIPID MET, V1303, P74, DOI 10.1016/0005-2760(96)00074-4; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u	48	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40028	40035		10.1074/jbc.M003191200	http://dx.doi.org/10.1074/jbc.M003191200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11010961	hybrid			2022-12-25	WOS:000166039500033
J	Carson, JA; Fillmore, RA; Schwartz, RJ; Zimmer, WE				Carson, JA; Fillmore, RA; Schwartz, RJ; Zimmer, WE			The smooth muscle gamma-actin gene promoter is a molecular target for the mouse bagpipe homologue, mNkx3-1, and serum response factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; BOX TRANSCRIPTION FACTORS; DNA-BINDING SPECIFICITY; GROWTH-FACTOR-BETA; HOMEODOMAIN PROTEINS; TINMAN HOMOLOG; HOMEOBOX GENES; CARDIAC TRANSCRIPTION; TRANSGENIC MICE; SONIC HEDGEHOG	An evolutionarily conserved vertebrate homologue of the Drosophila NK-3 homeodomain gene bagpipe, Nkx3-1, is expressed in vascular and visceral mesoderm-derived muscle tissues and may influence smooth muscle cell differentiation. Nkx3-1 was evaluated for mediating smooth muscle gamma -actin (SMGA) gene activity, a specific marker of smooth muscle differentiation. Expression of mNkx3-1 in heterologous CV-1 fibroblasts was unable to elicit SMGA promoter activity but required the coexpression of serum response factor (SRF) to activate robust SMGA transcription. A novel complex element containing a juxtaposed Nkx-binding site (NKE) and an SRF-binding element (SRE) in the proximal promoter region was found to be necessary for the Nkx3-1/SRF coactivation of SMGA transcription. Furthermore, Nkx3-1 and SRF associate through protein-protein interactions and the homeodomain region of Nkx3-1 facilitated SRF binding to the complex NKE SRE. Mutagenesis of Nkx3-1 revealed an inhibitory domain within its C-terminal segment. In addition, mNkx3-1/SRF cooperative activity required an intact Nkx3-1 homeodomain along with the MADS box of SRF, which contains DNA binding and dimerization structural domains, and the contiguous C-terminal SRF activation domain. Thus, SMGA is a novel target for Nkx3-1, and the activity of Nkx3-1 on the SMGA promoter is dependent upon SRF.	Baylor Coll Med, Dept Cellular & Mol Biol, Houston, TX 77030 USA; Univ S Alabama, Dept Struct & Cellular Biol, Mobile, AL 36688 USA	Baylor College of Medicine; University of South Alabama	Schwartz, RJ (corresponding author), Baylor Coll Med, Dept Cellular & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Carson, James/Q-5693-2019	Carson, James/0000-0003-3733-8796; Zimmer, Warren/0000-0002-0668-6096	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038639, P01HL049953] Funding Source: NIH RePORTER; NHLBI NIH HHS [5P60HL38639, R01HL50422, P01HL49953] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BABIJ P, 1989, J MOL BIOL, V210, P673, DOI 10.1016/0022-2836(89)90142-3; BECKER JC, 1995, P NATL ACAD SCI USA, V92, P9727, DOI 10.1073/pnas.92.21.9727; Belaguli NS, 1999, MOL CELL BIOL, V19, P4582; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; BODMER R, 1993, DEVELOPMENT, V118, P719; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; Browning CL, 1998, DEV BIOL, V194, P18, DOI 10.1006/dbio.1997.8808; CARROLL SL, 1986, J BIOL CHEM, V261, P8965; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Chen CY, 1997, MOL ENDOCRINOL, V11, P812, DOI 10.1210/me.11.6.812; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; Chen CY, 1996, MOL CELL BIOL, V16, P6372; COLLINGE M, 1992, MOL CELL BIOL, V12, P2359, DOI 10.1128/MCB.12.5.2359; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Doevendans PA, 1996, INT J BIOCHEM CELL B, V28, P387, DOI 10.1016/1357-2725(95)00145-X; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Durocher D, 1998, DEV GENET, V22, P250, DOI 10.1002/(SICI)1520-6408(1998)22:3<250::AID-DVG7>3.0.CO;2-5; GABBIANI G, 1984, J CLIN INVEST, V73, P148, DOI 10.1172/JCI111185; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; Galvagni F, 1997, MOL CELL BIOL, V17, P1731, DOI 10.1128/MCB.17.3.1731; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Groisman R, 1996, J BIOL CHEM, V271, P5258; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Herring BP, 1996, AM J PHYSIOL-CELL PH, V270, pC1656, DOI 10.1152/ajpcell.1996.270.6.C1656; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034; Kallmeier RC, 1995, J BIOL CHEM, V270, P30949, DOI 10.1074/jbc.270.52.30949; Kerppola TK, 1998, STRUCT FOLD DES, V6, P549, DOI 10.1016/S0969-2126(98)00057-4; Khorasanizadeh S, 1999, CURR BIOL, V9, pR456, DOI 10.1016/S0960-9822(99)80281-4; KIM E, 1989, MOL CELL BIOL, V9, P1875, DOI 10.1128/MCB.9.5.1875; KIM JH, 1994, J BIOL CHEM, V269, P13740; KIM YS, 1989, P NATL ACAD SCI USA, V86, P7716, DOI 10.1073/pnas.86.20.7716; Knezevic V, 1997, DEVELOPMENT, V124, P4523; Kos L, 1998, MECH DEVELOP, V70, P25, DOI 10.1016/S0925-4773(97)00168-8; Kovacs AM, 1998, GENE EXPRESSION, V7, P115; KOVACS AM, 1993, CELL MOTIL CYTOSKEL, V24, P67, DOI 10.1002/cm.970240108; Landerholm TE, 1999, DEVELOPMENT, V126, P2053; LEESMILLER JP, 1987, J BIOL CHEM, V262, P2988; Li L, 1997, DEV BIOL, V187, P311, DOI 10.1006/dbio.1997.8621; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; MACDERMOTT RP, 1988, INFLAMM BOWEL DIS, P21; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; Mannervik M, 1999, BIOESSAYS, V21, P267, DOI 10.1002/(SICI)1521-1878(199904)21:4<267::AID-BIES1>3.3.CO;2-3; MCHUGH KM, 1991, DEV BIOL, V148, P442, DOI 10.1016/0012-1606(91)90263-3; MCHUGH KM, 1995, DEV DYNAM, V204, P278, DOI 10.1002/aja.1002040306; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; MIWA T, 1991, MOL CELL BIOL, V11, P3296, DOI 10.1128/MCB.11.6.3296; MOSSE PRL, 1986, ARTERIOSCLEROSIS, V6, P664, DOI 10.1161/01.ATV.6.6.664; NELSON H B, 1990, New Biologist, V2, P171; NURRISH SJ, 1995, MOL CELL BIOL, V15, P4076; OWENS GK, 1995, PHYSIOL REV, V75, P487; PEREZMARTIN J, 1993, SCIENCE, V260, P805, DOI 10.1126/science.8387228; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; Qian J, 1996, DEV DYNAM, V207, P135; Ray MK, 1996, MOL CELL BIOL, V16, P2056; Reecy JM, 1999, DEVELOPMENT, V126, P839; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Samaha FF, 1996, J BIOL CHEM, V271, P395, DOI 10.1074/jbc.271.1.395; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; Sciavolino PJ, 1997, DEV DYNAM, V209, P127, DOI 10.1002/(SICI)1097-0177(199705)209:1<127::AID-AJA12>3.0.CO;2-Z; SZUCSIK JC, 1995, GENOMICS, V28, P154, DOI 10.1006/geno.1995.1126; Tanaka M, 1998, DEV GENET, V22, P239, DOI 10.1002/(SICI)1520-6408(1998)22:3<239::AID-DVG6>3.3.CO;2-G; Topouzis S, 1996, DEV BIOL, V178, P430, DOI 10.1006/dbio.1996.0229; Tribioli C, 1997, MECH DEVELOP, V65, P145, DOI 10.1016/S0925-4773(97)00067-1; VANDERVLIET PC, 1993, BIOESSAYS, V15, P25, DOI 10.1002/bies.950150105; West AG, 1997, MOL CELL BIOL, V17, P2876, DOI 10.1128/MCB.17.5.2876; Wolberger C, 1999, ANNU REV BIOPH BIOM, V28, P29, DOI 10.1146/annurev.biophys.28.1.29; Yoshiura KI, 1997, GENOMICS, V45, P425, DOI 10.1006/geno.1997.4926; ZIMMER WE, 1996, DEV BIOL, V175, P399	76	72	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39061	39072		10.1074/jbc.M006532200	http://dx.doi.org/10.1074/jbc.M006532200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993896	hybrid			2022-12-25	WOS:000165953100018
J	Gonzalez, A; Schulz, I; Schmid, A				Gonzalez, A; Schulz, I; Schmid, A			Agonist-evoked mitochondrial Ca2+ signals in mouse pancreatic acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; INOSITOL TRISPHOSPHATE; EXOCRINE PANCREAS; CARDIAC MYOCYTES; CALCIUM SIGNALS; SMOOTH-MUSCLE; OSCILLATIONS; RELEASE; WAVES; CONDUCTANCE	In the present study we have investigated cytosolic and mitochondrial Ca2+ signals in isolated mouse pancreatic acinar cells double-loaded with the fluorescent probes fluo-3 and rhod-2. Stimulation of pancreatic acinar cells with 500 nM acetylcholine caused release of Ca2+ from intracellular stores and produced cytosolic Ca2+ signals in form of Ca2+ waves propagating from the luminal to the basal cell pole. The increase in the cytosolic Ca2+ concentration was followed by Ca2+ uptake into mitochondria. Between onset of cytosolic and mitochondriaI Ca2+ signals there was a delay of 10.7 +/- 0.4 s. Ca2+ uptake into mitochondria could be inhibited with Ruthenium Red and carbonyl cyanide m-chlorophenylhydrazone, whereas 2,5-di-tert-butylhydroquinone, which inhibits sarco(endo)plasmic reticulum Ca2+ ATPases, did not prevent Ca2+ accumulation in mitochondria. Carbonyl cyanide m-chlorophenylhydrazone-induced Ca2+ release from mitochondria could only be observed after a preceding stimulation of the cell with a physiological agonist or by treatment with 2,5 di-tertbutylhydroquinone, indicating that under resting conditions mitochondria do not contain releasable Ca2+ ions. Analysis of the propagation rate of acetylcholine-induced Ca2+ waves revealed that inhibition of mitochondrial Ca2+ uptake did not accelerate spreading of cytosolic Ca2+ signals. Our experiments indicate that in the early phase of secretagogue-induced Ca2+ signals, mitochondria behave as passive Ca2+-buffering elements and do not actively suppress spreading of Ca2+ signals in pancreatic acinar cells.	Univ Saarland, Dept Physiol, D-66421 Homburg, Germany	Saarland University	Schmid, A (corresponding author), Univ Saarland, Dept Physiol, D-66421 Homburg, Germany.	andreas.schmid@med-rz.uni-saarland.de	Gonzalez, Antonio/C-5428-2018	Gonzalez, Antonio/0000-0001-8380-0270				Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Belan PV, 1996, J BIOL CHEM, V271, P7615, DOI 10.1074/jbc.271.13.7615; Boitier E, 1999, J CELL BIOL, V145, P795, DOI 10.1083/jcb.145.4.795; Brandenburger Y, 1996, ENDOCRINOLOGY, V137, P5544, DOI 10.1210/en.137.12.5544; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; David G, 1998, J PHYSIOL-LONDON, V509, P59, DOI 10.1111/j.1469-7793.1998.059bo.x; DENTON RM, 1980, FEBS LETT, V119, P1, DOI 10.1016/0014-5793(80)80986-0; Drummond RM, 1999, J PHYSIOL-LONDON, V516, P139, DOI 10.1111/j.1469-7793.1999.139aa.x; Gonzalez A, 1999, BIOCHEM BIOPH RES CO, V261, P726, DOI 10.1006/bbrc.1999.1106; Gonzalez A, 1997, PFLUG ARCH EUR J PHY, V434, P609, DOI 10.1007/s004240050443; Gonzalez A, 1998, AM J PHYSIOL-CELL PH, V275, pC810, DOI 10.1152/ajpcell.1998.275.3.C810; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Hajnoczky G, 1999, J BIOL CHEM, V274, P14157, DOI 10.1074/jbc.274.20.14157; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Haugland RP, 1996, HDB FLUORESCENT PROB, P266; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Jou MJ, 1996, J PHYSIOL-LONDON, V497, P299, DOI 10.1113/jphysiol.1996.sp021769; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; Krause E, 1996, J BIOL CHEM, V271, P32523, DOI 10.1074/jbc.271.51.32523; Lawrie AM, 1996, J BIOL CHEM, V271, P10753, DOI 10.1074/jbc.271.18.10753; McCarron JG, 1999, J PHYSIOL-LONDON, V516, P149, DOI 10.1111/j.1469-7793.1999.149aa.x; MINTA A, 1989, J BIOL CHEM, V264, P8171; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; Monteith GR, 1999, AM J PHYSIOL-CELL PH, V276, pC1193, DOI 10.1152/ajpcell.1999.276.5.C1193; Nitschke R, 1997, PFLUG ARCH EUR J PHY, V433, P653, DOI 10.1007/s004240050327; Pfeiffer F, 1998, AM J PHYSIOL-CELL PH, V274, pC663; Ricken S, 1998, J BIOL CHEM, V273, P34961, DOI 10.1074/jbc.273.52.34961; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; ROHLICEK V, 1994, PFLUG ARCH EUR J PHY, V428, P30, DOI 10.1007/BF00374749; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Schmid A, 1996, PFLUG ARCH EUR J PHY, V432, P876, DOI 10.1007/s004240050211; Schulz I, 1999, BIOL CHEM, V380, P903, DOI 10.1515/BC.1999.111; Simpson PB, 1998, J PHYSIOL-LONDON, V508, P413, DOI 10.1111/j.1469-7793.1998.413bq.x; SMITH JS, 1986, BIOPHYS J, V50, P921, DOI 10.1016/S0006-3495(86)83533-0; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; THEVENOD F, 1989, J MEMBRANE BIOL, V109, P173, DOI 10.1007/BF01870856; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; Tinel H, 1999, EMBO J, V18, P4999, DOI 10.1093/emboj/18.18.4999; TOESCU EC, 1993, BIOCHEM BIOPH RES CO, V192, P854, DOI 10.1006/bbrc.1993.1493; Trollinger DR, 1997, BIOCHEM BIOPH RES CO, V236, P738, DOI 10.1006/bbrc.1997.7042; YULE DI, 1994, PHYSL GASTROINTESTIN	43	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38680	38686		10.1074/jbc.M005667200	http://dx.doi.org/10.1074/jbc.M005667200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10995756	hybrid			2022-12-25	WOS:000165739800074
J	Zheng, YH; Voice, JK; Kong, Y; Goetzl, EJ				Zheng, YH; Voice, JK; Kong, Y; Goetzl, EJ			Altered expression and functional profile of lysophosphatidic acid receptors in mitogen-activated human blood T lymphocytes	FASEB JOURNAL			English	Article									Univ Calif San Francisco, Med Ctr, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Med Ctr, Dept Immunol Microbiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Med Ctr, Dept Med, UB8B,Box 0711,533 Parnassus & 4th, San Francisco, CA 94143 USA.								0	63	66	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2387	2389						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11024010				2022-12-25	WOS:000165723400006
J	Ratcliffe, MJ; Itoh, K; Sokol, SY				Ratcliffe, MJ; Itoh, K; Sokol, SY			A positive role for the PP2A catalytic subunit in Wnt signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; GLYCOGEN-SYNTHASE KINASE-3; TUMOR-SUPPRESSOR PROTEIN; BETA-CATENIN; XENOPUS-EMBRYOS; AXIS FORMATION; NEGATIVE REGULATOR; PATHWAY; TRANSCRIPTION; SIAMOIS	Protein phosphatase-2A (PP2A) is a multisubunit serine/threonine phosphatase involved in intracellular signaling, gene regulation, and cell cycle progression. Different, subunits of PP2A bind to Axin and Adenomatous Polyposis Coli, components of the Wnt signal transduction pathway. Using early Xenopus embryos, we studied how PP2A functions in Wnt signal transduction. The catalytic subunit of PP2A (PP2A-C) potentiated secondary axis induction and Siamois reporter gene activation by Dishevelled, a component of the Wnt pathway, indicating a: positive regulatory role of this enzyme in Wnt signaling. in contrast, small t antigen, an antagonist of PP2A-C, inhibited Dishevelled-mediated signal transduction, as did the regulatory PP2A-B'epsilon subunit, consistent with the requirement of PP2A function in this pathway. Although Wnt signaling is thought to occur via regulation of beta -catenin degradation, PP2A-C did not significantly affect beta -catenin stability. Moreover, the pathway activated by a stabilized form of beta -catenin was sensitive to PP2A-C and its inhibitors, suggesting that PP2A-C acts downstream of beta -catenin. Because previous work has suggested that PP2A can act upstream of beta -catenin, we propose that PP2A regulates the Wnt pathway at multiple levels.	Harvard Univ, Sch Med,Beth Israel Deaconess Med Ctr, Dept Microbiol & Mol Genet, Mol Med Unit, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Ratcliffe, MJ (corresponding author), Harvard Univ, Sch Med,Beth Israel Deaconess Med Ctr, Dept Microbiol & Mol Genet, Mol Med Unit, RW 663,East Campus,330 Brookline Ave, Boston, MA 02215 USA.	mratclif@caregroup.harvard.edu		Sokol, Sergei/0000-0002-3963-9202				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brannon M, 1999, DEVELOPMENT, V126, P3159; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fan MJ, 1998, P NATL ACAD SCI USA, V95, P5626, DOI 10.1073/pnas.95.10.5626; Fan MJ, 1997, DEVELOPMENT, V124, P2581; Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Itoh K, 2000, MOL CELL BIOL, V20, P2228, DOI 10.1128/MCB.20.6.2228-2238.2000; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; Kishida S, 1999, MOL CELL BIOL, V19, P4414; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; LILY W, 1987, NATURE, V326, P512, DOI 10.1038/326512a0; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; ROTHBACHER U, 1995, DEV BIOL, V170, P717, DOI 10.1006/dbio.1995.1249; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SOKOL SY, 1995, DEVELOPMENT, V121, P1637; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Vleminckx K, 1997, J CELL BIOL, V136, P411, DOI 10.1083/jcb.136.2.411; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	50	86	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35680	35683		10.1074/jbc.C000639200	http://dx.doi.org/10.1074/jbc.C000639200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	11007767	hybrid			2022-12-25	WOS:000165382000007
J	Lock, H; Valverde, MA				Lock, H; Valverde, MA			Contribution of the IsK (MinK) potassium channel subunit to regulatory volume decrease in murine tracheal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE P-GLYCOPROTEIN; SMALL-INTESTINAL CRYPTS; AIRWAY SURFACE LIQUID; VESTIBULAR DARK CELLS; CHLORIDE CHANNELS; CYSTIC-FIBROSIS; K+ CONDUCTANCE; SECRETION; CURRENTS; PROTEIN	The cell volume regulatory response following hypotonic shocks is often achieved by the coordinated activation of K+ and Cl- channels. In this study, we investigate the identity of the K+ and Cl- channels that mediate the regulatory volume decrease (RVD) in ciliated epithelial cells from murine trachea. RVD was inhibited by tamoxifen and 1,9-dideoxyforskolin, two agents that block swelling-activated Cl- channels. These data suggest that swelling-activated Cl- channels play an important role in cell volume regulation in murine tracheal epithelial cells. Ba2+ and apamin, inhibitors of K+ channels, were without effect on RVD, while tetraethylammoniun had little effect on RVD. In contrast, clofilium, an inhibitor of the KvLQT/IsK potassium channel complex potently inhibited RVD, suggesting a role for the KvLQT/IsK channel complex in cell volume regulation by tracheal epithelial cells. To investigate further the role of KvLQT/IsK channels in RVD, we used IsK knock-out mice. When exposed to hypotonic solutions, tracheal cells from IsK(+/+) mice underwent RVD, whereas cells from IsK(-/-) failed to recover their normal size. These data suggest that the IsK potassium subunit plays an important role in RVD in murine tracheal epithelial cells.	Univ Pompeu Fabra, Dept Expt Sci, Cell Signalling Unit, Barcelona 08003, Spain	Pompeu Fabra University	Valverde, MA (corresponding author), Univ Pompeu Fabra, Dept Expt Sci, Cell Signalling Unit, C Dr Aiguader 80, Barcelona 08003, Spain.			Valverde, Miguel A./0000-0002-6961-3361				Bleich M, 2000, PFLUG ARCH EUR J PHY, V440, P202, DOI 10.1007/s004240000257; Bond TD, 1998, J PHYSIOL-LONDON, V511, P45, DOI 10.1111/j.1469-7793.1998.045bi.x; Boucher RC, 1999, J PHYSIOL-LONDON, V516, P631, DOI 10.1111/j.1469-7793.1999.0631u.x; BOUCHER RC, 1981, J APPL PHYSIOL, V50, P613, DOI 10.1152/jappl.1981.50.3.613; Busch AE, 1997, TRENDS PHARMACOL SCI, V18, P26, DOI 10.1016/S0165-6147(96)01016-4; BUSCH AE, 1992, BIOCHEM BIOPH RES CO, V184, P804, DOI 10.1016/0006-291X(92)90661-4; CASTLE NA, 1989, TRENDS NEUROSCI, V12, P59, DOI 10.1016/0166-2236(89)90137-9; DIAZ M, 1993, PFLUG ARCH EUR J PHY, V422, P347, DOI 10.1007/BF00374290; Guggino WB, 1999, CELL, V96, P607, DOI 10.1016/S0092-8674(00)80570-X; HOFFMANN EK, 1993, ADV COMP ENV PHYSL, V14, P187; Hwang TH, 1996, J MEMBRANE BIOL, V154, P251, DOI 10.1007/s002329900149; KIM YK, 1993, AM J PHYSIOL, V265, pC1306, DOI 10.1152/ajpcell.1993.265.5.C1306; KROUSE ME, 1994, AM J PHYSIOL, V267, pC642, DOI 10.1152/ajpcell.1994.267.2.C642; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; MacVinish LJ, 1998, J PHYSIOL-LONDON, V510, P237, DOI 10.1111/j.1469-7793.1998.237bz.x; MALAYEV AA, 1995, MOL PHARMACOL, V47, P198; MAN SFP, 1979, J APPL PHYSIOL, V46, P205, DOI 10.1152/jappl.1979.46.2.205; MARCUS DC, 1994, AM J PHYSIOL, V267, pC857, DOI 10.1152/ajpcell.1994.267.3.C857; MCCANN JD, 1989, J GEN PHYSIOL, V94, P1015, DOI 10.1085/jgp.94.6.1015; Niemeyer MI, 2000, J PHYSIOL-LONDON, V524, P757, DOI 10.1111/j.1469-7793.2000.00757.x; OBRIEN JA, 1993, PFLUG ARCH EUR J PHY, V423, P67, DOI 10.1007/BF00374962; Okada Y, 1997, AM J PHYSIOL-CELL PH, V273, pC755, DOI 10.1152/ajpcell.1997.273.3.C755; PRICE AM, 1993, J APPL PHYSIOL, V74, P2788, DOI 10.1152/jappl.1993.74.6.2788; SCHOPPA N, 1989, J MEMBRANE BIOL, V108, P73, DOI 10.1007/BF01870427; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; STRANGE K, 1996, AM J PHYSIOL, V270, P711; Suessbrich H, 1997, FEBS LETT, V414, P435, DOI 10.1016/S0014-5793(97)01030-2; TAKUMI T, 1993, NEWS PHYSIOL SCI, V8, P175; Valverde MA, 1996, EMBO J, V15, P4460, DOI 10.1002/j.1460-2075.1996.tb00823.x; VALVERDE MA, 1993, PFLUG ARCH EUR J PHY, V425, P552, DOI 10.1007/BF00374885; Valverde MA, 1999, CURR OPIN CELL BIOL, V11, P509, DOI 10.1016/S0955-0674(99)80074-X; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WALTERS RJ, 1992, PFLUG ARCH EUR J PHY, V421, P598, DOI 10.1007/BF00375057; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WANGEMANN P, 1995, J MEMBRANE BIOL, V147, P263; WELLS UM, 1994, J APPL PHYSIOL, V77, P2400, DOI 10.1152/jappl.1994.77.5.2400; WILLUMSEN NJ, 1994, J CLIN INVEST, V94, P779, DOI 10.1172/JCI117397; Zabner J, 1998, MOL CELL, V2, P397, DOI 10.1016/S1097-2765(00)80284-1; ZHANG JJ, 1994, J CLIN INVEST, V94, P1690, DOI 10.1172/JCI117514	42	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34849	34852		10.1074/jbc.C000633200	http://dx.doi.org/10.1074/jbc.C000633200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10995738	hybrid			2022-12-25	WOS:000165422800005
J	Silvany, RE; Eliazer, S; Wolff, NC; Ilaria, RL				Silvany, RE; Eliazer, S; Wolff, NC; Ilaria, RL			Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation	ONCOGENE			English	Article						Ewing's sarcoma; ERK; MAPK; ras; EWS/FLI-1	EWINGS-SARCOMA TRANSLOCATION; EWS/FLI-1 FUSION GENE; PROTEIN-KINASE; DNA-BINDING; EWS GENE; TRANSCRIPTIONAL ACTIVATOR; CHROMOSOME-TRANSLOCATION; HUMAN TUMORS; FAMILY; GROWTH	The chimeric gene EWS/FLI-1, the hallmark of the Ewing's sarcoma and primitive neuroectodermal tumor family, encodes a fusion protein with enhanced transcriptional activation properties and preserved recognition of canonical ETS binding sites. Although EWS/FLI-1 alters the expression of various genes, the precise mechanism by which EWS/FLI-1 acts as an oncogene remains to be defined, In this study we report that members of the mitogen-activated protein kinase (MAPK) signaling pathway, ERK1 and ERK2, are constitutively activated in NTH 3T3 cells expressing EWS/FLI-1, Interference with ERK activation by either highly specific inhibitors of MEK1 or a dominant negative ras mutant profoundly impaired the ability of EWS/FLI-1 to transform NIH3T3 cells to growth in semi-solid medium. An EWS/FLI-1 mutant defective in DNA-binding and transcriptional activation failed to activate ERK ana was also defective in 3T3 cell transformation, Constitutive ERK activation was also evident in several human Ewing's sarcoma tumor-derived cell lines, Interestingly, cells expressing the type II EWS/FLI-1 fusion, recently demonstrated more potent in transcriptional activation, showed even greater MAPK activation than cells expressing the more common type I fusion, These results implicate ERK activation in EWS/ FLI-1 transformation and suggest that this signaling pathway may be important in the pathogenesis of Ewing's sarcoma.	UT, SW Med Ctr, Simmons Canc Ctr, Dept Med,Div Hematol Oncol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ilaria, RL (corresponding author), UT, SW Med Ctr, Simmons Canc Ctr, Dept Med,Div Hematol Oncol, 5323 Harry Hines Blvd,MC 8593, Dallas, TX 75390 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003310] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03310] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; CHEN SY, 1994, ONCOGENE, V9, P2691; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; de Alava E, 2000, J CLIN ONCOL, V18, P204, DOI 10.1200/JCO.2000.18.1.204; de Alava E, 1998, J CLIN ONCOL, V16, P1248, DOI 10.1200/JCO.1998.16.4.1248; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FINER MH, 1994, BLOOD, V83, P43; Gioeli D, 1999, CANCER RES, V59, P279; Hahn RG, 1999, SCAND J UROL NEPHROL, V33, P222; HAWLEY RG, 1994, GENE THER, V1, P136; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; LESSNICK SL, 1995, ONCOGENE, V10, P423; Lin PP, 1999, CANCER RES, V59, P1428; Mandell JW, 1998, AM J PATHOL, V153, P1411, DOI 10.1016/S0002-9440(10)65728-8; MAO XH, 1994, J BIOL CHEM, V269, P18216; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; Patton SE, 1998, CANCER RES, V58, P2253; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Porras A, 1998, MOL ENDOCRINOL, V12, P825, DOI 10.1210/me.12.6.825; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Ries L. A. G., 1999, SEER CANC STAT REV 1; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Swantek JL, 1999, ENDOCRINOLOGY, V140, P3163, DOI 10.1210/en.140.7.3163; Thompson AD, 1996, ONCOGENE, V13, P2649; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu X, 1996, ONCOGENE, V13, P135; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	46	37	38	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4523	4530		10.1038/sj.onc.1203811	http://dx.doi.org/10.1038/sj.onc.1203811			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002425				2022-12-25	WOS:000089236800009
J	Solano, RM; Langer, I; Perret, J; Vertongen, P; Juarranz, MG; Robberecht, P; Waelbroeck, M				Solano, RM; Langer, I; Perret, J; Vertongen, P; Juarranz, MG; Robberecht, P; Waelbroeck, M			Two basic residues of the h-VPAC(1) receptor second transmembrane helix are essential for ligand binding and signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; CYCLASE-ACTIVATING POLYPEPTIDE; RAT SECRETIN RECEPTOR; AMINO-TERMINAL TAIL; VIP RECEPTOR; AGONIST BINDING; CHO CELLS; PACAP-I; DOMAINS; PEPTIDE	We mutated the vasoactive intestinal peptide (VIP) Asp(3) residue and two VPAC(1) receptor second transmembrane helix basic residues (Arg(188) and Lys(195)). VIP had a lower affinity for R188Q, R188L, K195Q, and R195I VPAC(1), receptors than for VPAC, receptors, [Asn(3)] VIP and [Gln(3)] VIP had lower affinities than VIP for VPAC, receptors but higher affinities for the mutant receptors; the two basic amino acids facilitated the introduction of the negatively charged aspartate inside the transmembrane domain. The resulting interaction was necessary for receptor activation. 1/[Asn(3)] VIP and [Gln(3)] VIP were partial agonists at VPAC, receptors; 21VIP did not fully activate the K195Q, K195I, R188Q, and R188L VPAC, receptors; a VIP analogue ([Arg(16)] VIP) was more efficient than VIP at the four mutated receptors; and [Asn3] VIP and [Gln(3)] VIP were more efficient than VIP at the R188Q and R188L VPAC, receptors; the [Asp(3)] negative charge did not contribute to the recognition of the VIP1 antagonist, [AcHis(1),D-Phe(2),Lys(15),Arg(16),Leu(27)] VIP (1-7)/growth hormone releasing factor (8-27). This is the first demonstration that, to activate the VPAC, receptor, the Asp(3) side chain of VIP must penetrate within the transmembrane domain, in close proximity to two highly conserved basic amino acids from transmembrane 2.	Free Univ Brussels, Fac Med, Lab Chim Biol & Nutr, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Waelbroeck, M (corresponding author), Free Univ Brussels, Fac Med, Lab Chim Biol & Nutr, 808 Route Lennik,Bldg G-E,CP 611, B-1070 Brussels, Belgium.		Juarranz, Yasmina/H-5545-2019; Juarranz, Yasmina/H-7942-2016	Juarranz, Yasmina/0000-0001-5886-8273; Juarranz, Yasmina/0000-0001-5886-8273				ANDREWS P, 1986, TRENDS PHARMACOL SCI, V7, P148, DOI 10.1016/0165-6147(86)90292-0; CHRISTOPHE J, 1993, BIOCHIM BIOPHYS ACTA, V1154, P183, DOI 10.1016/0304-4157(93)90011-C; CICCARELLI E, 1994, REGUL PEPTIDES, V54, P397, DOI 10.1016/0167-0115(94)90537-1; COUVINEAU A, 1994, BIOCHEM BIOPH RES CO, V200, P769, DOI 10.1006/bbrc.1994.1517; Di Paolo E, 1999, PEPTIDES, V20, P1187, DOI 10.1016/S0196-9781(99)00122-9; DONG M, 2000, J BIOL CHEM; Dong MQ, 1999, J BIOL CHEM, V274, P19161, DOI 10.1074/jbc.274.27.19161; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; Du K, 1997, BIOCHEM BIOPH RES CO, V230, P289, DOI 10.1006/bbrc.1996.5949; Gaudin P, 1999, BIOCHEM BIOPH RES CO, V254, P15, DOI 10.1006/bbrc.1998.9883; Gourlet P, 1996, EUR J BIOCHEM, V239, P349, DOI 10.1111/j.1432-1033.1996.0349u.x; Gourlet P, 1996, BBA-MOL CELL RES, V1314, P267, DOI 10.1016/S0167-4889(96)00106-1; Gourlet P, 1997, PEPTIDES, V18, P1539, DOI 10.1016/S0196-9781(97)00228-3; Gourlet P, 1996, REGUL PEPTIDES, V62, P125, DOI 10.1016/0167-0115(96)00010-9; Gourlet P, 1997, PEPTIDES, V18, P1555, DOI 10.1016/S0196-9781(97)00230-1; Gourlet P, 1996, PEPTIDES, V17, P825, DOI 10.1016/0196-9781(96)00107-6; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Hashimoto H, 1997, MOL PHARMACOL, V52, P128, DOI 10.1124/mol.52.1.128; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; Juarranz MG, 1999, MOL PHARMACOL, V56, P1280, DOI 10.1124/mol.56.6.1280; Juarranz MG, 1999, EUR J BIOCHEM, V265, P449, DOI 10.1046/j.1432-1327.1999.00769.x; Knudsen SM, 1997, FEBS LETT, V412, P141, DOI 10.1016/S0014-5793(97)00714-X; PANDOL SJ, 1986, AM J PHYSIOL, V250, pG553, DOI 10.1152/ajpgi.1986.250.4.G553; Rawlings SR, 1996, ENDOCR REV, V17, P4, DOI 10.1210/er.17.1.4; RAWLINGS SR, 1994, MOL CELL ENDOCRINOL, V101, pC5, DOI 10.1016/0303-7207(94)90212-7; Rekasi Z, 2000, P NATL ACAD SCI USA, V97, P1218, DOI 10.1073/pnas.97.3.1218; Rolz C, 1999, BIOCHEMISTRY-US, V38, P6397, DOI 10.1021/bi9829276; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sambrook J., 2002, MOL CLONING LAB MANU; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; USDIN TB, 1994, ENDOCRINOLOGY, V135, P2662, DOI 10.1210/en.135.6.2662; Van Rampelbergh J, 2000, BRIT J PHARMACOL, V130, P819, DOI 10.1038/sj.bjp.0703384; VanRampelbergh J, 1997, BBA-MOL CELL RES, V1357, P249, DOI 10.1016/S0167-4889(97)00028-1; Vertongen P, 1998, ANN NY ACAD SCI, V865, P412, DOI 10.1111/j.1749-6632.1998.tb11206.x; Vilardaga JP, 1997, EUR J BIOCHEM, V246, P173, DOI 10.1111/j.1432-1033.1997.00173.x; Vilardaga JP, 1996, BIOCHEM BIOPH RES CO, V218, P842, DOI 10.1006/bbrc.1996.0150; VILARDAGA JP, 1995, BIOCHEM BIOPH RES CO, V211, P885, DOI 10.1006/bbrc.1995.1895	39	80	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1084	1088		10.1074/jbc.M007686200	http://dx.doi.org/10.1074/jbc.M007686200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11013258	hybrid			2022-12-25	WOS:000166430900032
J	Kruk, J; Strzalka, K				Kruk, J; Strzalka, K			Redox changes of cytochrome b(559) in the presence of plastoquinones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II REACTION CENTER; ALPHA-TOCOPHEROL QUINONE; ELECTRON-TRANSPORT PROPERTIES; CHARGE-TRANSFER COMPLEXES; PHOTOSYSTEM-II; OXYGEN EVOLUTION; PHOTOINHIBITION; PARTICLES; PLANTS	We have found that short chain plastoquinones effectively stimulated photoreduction of the low potential form of cytochrome b(559) and were also active in dark oxidation of this cytochrome under anaerobic conditions in Triton X-100-solubilized photosystem II (PSII) particles. It is also shown that molecular oxygen competes considerably with the prenylquinones in cytochrome b(559) oxidation under aerobic conditions, indicating that both molecular oxygen and plastoquinones could be electron accepters from cytochrome b(559) in PSII preparations. alpha -Tocopherol quinone was not active in the stimulation of cytochrome photoreduction but efficiently oxidized it in the dark. Both the observed photoreduction and dark oxidation of the cytochrome were not sensitive to 3-(3,4-dichlorophenyl)-1,1-dimethylurea. It was concluded that both quinone-binding sites responsible for the redox changes of cytochrome b(559) are different from either the Q(A) or Q(B) site in PSII and represent new quinone-binding sites in PSII.	Jagiellonian Univ, Jan Zurzycki Inst Mol Biol, Dept Plant Physiol & Biochem, PL-31120 Krakow, Poland	Jagiellonian University	Strzalka, K (corresponding author), Jagiellonian Univ, Jan Zurzycki Inst Mol Biol, Dept Plant Physiol & Biochem, Aleja Mickiewicza 3, PL-31120 Krakow, Poland.	strzalka@mol.uj.edu.pl						BARBER J, 1993, P NATL ACAD SCI USA, V90, P10942, DOI 10.1073/pnas.90.23.10942; Bendall DS, 1971, METHOD ENZYMOL, V23A, P327, DOI DOI 10.1016/S0076-6879(71)23109-8; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; CHAPMAN DJ, 1988, BIOCHIM BIOPHYS ACTA, V933, P423, DOI 10.1016/0005-2728(88)90077-1; GOUNARIS K, 1988, FEBS LETT, V240, P143, DOI 10.1016/0014-5793(88)80356-9; GRUSZECKI WI, 1995, Z NATURFORSCH C, V50, P61; Hanley J, 1999, BIOCHEMISTRY-US, V38, P8189, DOI 10.1021/bi990633u; KRISHTALIK LI, 1993, BIOPHYS J, V65, P184, DOI 10.1016/S0006-3495(93)81050-6; KRUK J, 1992, BIOCHIM BIOPHYS ACTA, V1112, P19, DOI 10.1016/0005-2736(92)90248-K; KRUK J, 1988, BIOPHYS CHEM, V30, P143, DOI 10.1016/0301-4622(88)85011-7; KRUK J, 1995, J PLANT PHYSIOL, V145, P405, DOI 10.1016/S0176-1617(11)81762-1; Kruk J, 1997, Z NATURFORSCH C, V52, P766; Kruk J, 2000, PLANT PHYSIOL BIOCH, V38, P271, DOI 10.1016/S0981-9428(00)00747-6; Kruk J, 1999, PHOTOSYNTH RES, V62, P273, DOI 10.1023/A:1006374319191; MESSINGER J, 1993, BIOCHEMISTRY-US, V32, P7658, DOI 10.1021/bi00081a009; NAKANE H, 1991, PLANT CELL PHYSIOL, V32, P1165; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; NEDBAL L, 1992, P NATL ACAD SCI USA, V89, P7929, DOI 10.1073/pnas.89.17.7929; OMATA T, 1984, BIOCHIM BIOPHYS ACTA, V765, P403, DOI 10.1016/0005-2728(84)90182-8; ORTEGA JM, 1988, EUR J BIOCHEM, V171, P449, DOI 10.1111/j.1432-1033.1988.tb13810.x; Ozawa S, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL I, P535; Patzlaff JS, 1996, BIOCHEMISTRY-US, V35, P7802, DOI 10.1021/bi960056z; POULSON M, 1995, BIOCHEMISTRY-US, V34, P10932, DOI 10.1021/bi00034a027; SATOH K, 1990, BIOCHIM BIOPHYS ACTA, V1016, P121, DOI 10.1016/0005-2728(90)90014-U; Stewart DH, 1998, BBA-BIOENERGETICS, V1367, P63, DOI 10.1016/S0005-2728(98)00139-X; Stewart DH, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1113; TABATA K, 1985, PLANT CELL PHYSIOL, V26, P855; TANG XS, 1994, BIOCHEMISTRY-US, V33, P4594, DOI 10.1021/bi00181a021; TELFER A, 1994, PHOTOINHIBITION PHOT, P25; Whitmarsh J., 1994, PHOTOINHIBITION PHOT, P75; Whitmarsh J., 1996, OXYGENIC PHOTOSYNTHE, P249, DOI 10.1007/0-306-48127-8_13	31	71	72	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					86	91		10.1074/jbc.M003602200	http://dx.doi.org/10.1074/jbc.M003602200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11022032	hybrid			2022-12-25	WOS:000166280700013
J	Solle, M; Labasi, J; Perregaux, DG; Stam, E; Petrushova, N; Koller, BH; Griffiths, RJ; Gabel, CA				Solle, M; Labasi, J; Perregaux, DG; Stam, E; Petrushova, N; Koller, BH; Griffiths, RJ; Gabel, CA			Altered cytokine production in mice lacking P2X(7) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR ATP; IL-1-BETA PRODUCTION; PURINERGIC RECEPTOR; NUCLEOTIDE RECEPTOR; P2Z PURINORECEPTOR; HUMAN MONOCYTES; INTERLEUKIN-1; MACROPHAGES; EXPRESSION; CELLS	The P2X(7) receptor (P2X(7)R) is an ATP-gated ion channel expressed by monocytes and macrophages, To directly address the role of this receptor in interleukin (IL)-1 beta post-translational processing, we have generated a P2X(7)R-deficient mouse line. P2X(7)R(-/-) macrophages respond to lipopolysaccharide and produce levels of cyclooxygenase-2 and pro-IL-1 beta comparable with those generated by wild-type cells. In response to ATP, however, pro-IL-1 beta produced by the P2X(7)R(-/-) cells is not externalized or activated by caspase-1, Nigericin, an alternate secretion stimulus, promotes release of 17-kDa IL-1 beta from P2X(7)R(-/-) macrophages. In response to in vivo lipopolysaccharide injection, both wild-type and P2X(7)R(-/-) animals display increases in peritoneal lavage IL-6 levels but no detectable IL-1. Subsequent ATP injection to wild-type animals promotes an increase in IL-1, which in turn leads to additional IL-6 production; similar increases did not occur in ATP-treated, LPS-primed P2X(7)R(-/-) animals. Absence of the P2X(7)R thus leads to an inability of peritoneal macrophages to release IL-1 in response to ATP. As a result of the IL-1 deficiency, in vivo cytokine signaling cascades are impaired in P2X(7)R-deficient animals. Together these results demonstrate that P2X(7)R activation can provide a signal that leads to maturation and release of IL-1 beta and initiation of a cytokine cascade.	Pfizer Inc, Dept Resp Allergy Immunol Inflammat & Infect Dis, Groton, CT 06340 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA	Pfizer; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Gabel, CA (corresponding author), Pfizer Inc, Dept Resp Allergy Immunol Inflammat & Infect Dis, Groton, CT 06340 USA.	christopher_a_gabel@groton.pfizer.com						Allen M, 2000, J EXP MED, V191, P859, DOI 10.1084/jem.191.5.859; Arend WP, 1998, ANNU REV IMMUNOL, V16, P27, DOI 10.1146/annurev.immunol.16.1.27; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; AYALA JM, 1994, J IMMUNOL, V153, P2592; Balboa MA, 1999, J BIOL CHEM, V274, P36764, DOI 10.1074/jbc.274.51.36764; Baricordi OR, 1999, J BIOL CHEM, V274, P33206, DOI 10.1074/jbc.274.47.33206; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BHAKDI S, 1990, J CLIN INVEST, V85, P1746, DOI 10.1172/JCI114631; Buell G, 1998, BLOOD, V92, P3521, DOI 10.1182/blood.V92.10.3521.422k50_3521_3528; BUISMAN HP, 1988, P NATL ACAD SCI USA, V85, P7988, DOI 10.1073/pnas.85.21.7988; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chessell IP, 1998, FEBS LETT, V439, P26, DOI 10.1016/S0014-5793(98)01332-5; Chiozzi P, 1997, J CELL BIOL, V138, P697, DOI 10.1083/jcb.138.3.697; Collo G, 1997, NEUROPHARMACOLOGY, V36, P1277, DOI 10.1016/S0028-3908(97)00140-8; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Ferrari D, 1999, J BIOL CHEM, V274, P13205, DOI 10.1074/jbc.274.19.13205; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; Flannery CR, 1999, MATRIX BIOL, V18, P225, DOI 10.1016/S0945-053X(99)00024-4; Foresta C, 1996, AM J PHYSIOL-CELL PH, V270, pC1709, DOI 10.1152/ajpcell.1996.270.6.C1709; GRAY PW, 1986, J IMMUNOL, V137, P3644; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; GRIFFITHS RJ, 1995, J IMMUNOL, V154, P2821; GUZN Z, 1998, J BIOL CHEM, V273, P28670; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; HICKMAN SE, 1994, BLOOD, V84, P2452; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Humphreys BD, 1998, MOL PHARMACOL, V54, P22, DOI 10.1124/mol.54.1.22; Humphreys BD, 1996, J IMMUNOL, V157, P5627; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALIBERTE R, 1994, J IMMUNOL, V153, P2168; Laliberte RE, 1999, J BIOL CHEM, V274, P36944, DOI 10.1074/jbc.274.52.36944; Lammas DA, 1997, IMMUNITY, V7, P433, DOI 10.1016/S1074-7613(00)80364-7; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; Michel AD, 1998, BRIT J PHARMACOL, V125, P1194, DOI 10.1038/sj.bjp.0702205; MILLER BE, 1995, J IMMUNOL, V154, P1331; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MOHN A, 1995, DNA CLONING 4; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; MURGIA M, 1992, BIOCHEM J, V288, P897, DOI 10.1042/bj2880897; Mutini C, 1999, J IMMUNOL, V163, P1958; North RA, 1996, CURR OPIN CELL BIOL, V8, P474, DOI 10.1016/S0955-0674(96)80023-8; PERREGAUX D, 1992, J IMMUNOL, V149, P1294; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; Perregaux DG, 1996, J IMMUNOL, V157, P57; PERREGAUX DG, 1999, AM J PHYSIOL, V275, pC1538; PETTIPHER ER, 1986, P NATL ACAD SCI USA, V83, P8749, DOI 10.1073/pnas.83.22.8749; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; Rocca B, 1999, J IMMUNOL, V162, P4589; Sanz JM, 2000, J IMMUNOL, V164, P4893, DOI 10.4049/jimmunol.164.9.4893; Schilling WP, 1999, AM J PHYSIOL-CELL PH, V277, pC766, DOI 10.1152/ajpcell.1999.277.4.C766; SINGER II, 1988, J EXP MED, V167, P389, DOI 10.1084/jem.167.2.389; SLACK J, 1993, J BIOL CHEM, V268, P2513; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WEISMAN GA, 1984, J CELL PHYSIOL, V119, P211, DOI 10.1002/jcp.1041190211; WILEY JS, 1989, BLOOD, V73, P1316	64	744	772	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					125	132		10.1074/jbc.M006781200	http://dx.doi.org/10.1074/jbc.M006781200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11016935	Green Published, hybrid			2022-12-25	WOS:000166280700018
J	Bourke, E; Kennedy, EJ; Moynagh, PN				Bourke, E; Kennedy, EJ; Moynagh, PN			Loss of I kappa B-beta is associated with prolonged NF-kappa B activity in human glial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; ACTIVATES TRANSCRIPTION; ENDOTHELIAL-CELLS; VIRUS TYPE-1; PEST DOMAIN; ALPHA; PHOSPHORYLATION; KINASE; PROTEIN; SIGNAL	Nuclear factor-kappaB (NF-kappaB) is an inducible transcription factor central in the regulation of expression of a wide variety of genes and synthesis of several proteins involved in the generation of the immune response and inflammatory processes. In resting cells, NF-kappaB is maintained in an inactive state through cytoplasmic retention by I kappaB inhibitors. Stimulation of cells with a wide variety of inducers results in proteolytic degradation of these I kappaB proteins, leading to activation of NF-kappaB. The present study shows that interleukin-1 (IL-1) causes persistent activation of NF-kappaB in glial cells. Stimulation with IL-1 also causes rapid but transient degradation of I kappaB-alpha and I kappaB-epsilon. However, NF-kappaB remains active even after these I kappaB isoforms have returned to control levels. In contrast, the I kappaB-beta isoform fails to reappear following its initial degradation by IL-1, coincident with sustained activation of NF-kappaB. In addition, in vivo overexpression of the various I kappaB isoforms revealed that I kappaB-beta is the only isoform that has the ability to inhibit IL-1-induced NF-kappaB-driven transcription. The findings also suggest that the inability of I kappaB-alpha and I kappaB-epsilon to modulate NF-kappaB activity is due to their modification in viuo. These findings indicate that I kappaB-beta is the key regulator of the activity of NF-kappaB in human glial cells.	Univ Coll Dublin, Dept Pharmacol, Conway Inst Biomol & Biomed Res, Dublin 2, Ireland	University College Dublin	Moynagh, PN (corresponding author), Univ Coll Dublin, Dept Pharmacol, Conway Inst Biomol & Biomed Res, Fosters Ave, Dublin 2, Ireland.			Bourke, Emer/0000-0002-2218-3114; Moynagh, Paul/0000-0002-4139-3061				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Heilker R, 1999, BIOCHEMISTRY-US, V38, P6231, DOI 10.1021/bi990220t; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Li Z, 1997, MOL CELL BIOL, V17, P6184, DOI 10.1128/MCB.17.10.6184; Lin RT, 1996, MOL CELL BIOL, V16, P1401; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; McKinsey TA, 1997, J BIOL CHEM, V272, P22377, DOI 10.1074/jbc.272.36.22377; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MOYNAGH PN, 1994, J IMMUNOL, V153, P2681; MOYNAGH PN, 1993, BIOCHEM J, V294, P343, DOI 10.1042/bj2940343; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Sambrook J., 2002, MOL CLONING LAB MANU; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Suyang H, 1996, MOL CELL BIOL, V16, P5444; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRIENZENBERG SJ, 1987, CURRENT PROTOCOLS MO; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	37	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39996	40002		10.1074/jbc.M007693200	http://dx.doi.org/10.1074/jbc.M007693200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10998424	hybrid, Green Accepted			2022-12-25	WOS:000166039500029
J	Komori, K; Sakae, S; Daiyasu, H; Toh, H; Morikawa, K; Shinagawa, H; Ishino, Y				Komori, K; Sakae, S; Daiyasu, H; Toh, H; Morikawa, K; Shinagawa, H; Ishino, Y			Mutational analysis of the Pyrococcus furiosus Holliday junction resolvase Hjc revealed functionally important residues for dimer formation, junction DNA binding, and cleavage activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; AMINO-ACID-RESIDUES; ESCHERICHIA-COLI; HOMOLOGOUS RECOMBINATION; CRYSTAL-STRUCTURE; RIBONUCLEASE-H; ACTIVE-SITE; ENDONUCLEASE; RECOGNITION; PROTEIN	The Holliday junction cleavage protein, Hjc resolvase of Pyrococcus furiosus, is the first Holliday junction resolvase to be discovered in Archaea. Although the archaeal resolvase shares certain biochemical properties with other non-archaeal junction resolvases, no amino acid sequence similarity has been identified. To investigate the structure-function relationship of this new Holliday junction resolvase, we constructed a series of mutant hjc genes using site-directed mutagenesis targeted at the residues conserved among the archaeal orthologs. The products of these mutant genes were purified to homogeneity. With analysis of the activity of the mutant proteins to bind and cleave synthetic Holliday junctions, one acidic residue, Glu-9, and two basic residues, Arg-10 and Arg-25, were found to play critical roles in enzyme action. This is in addition to the three conserved residues, Asp-33, Glu-46, and Lys-48, which are also conserved in the motif found in the type II restriction endonuclease family proteins. Two aromatic residues, Phe-68 and Phe-72, are important for the formation of the homodimer probably through hydrophobic interactions. The results of these studies have provided insights into the structure-function relationships of the archaeal Holliday junction resolvase as well as the universality and diversity of the Holliday junction cleavage reaction.	Biomol Engn Res Inst, Dept Mol Biol, Suita, Osaka 5650874, Japan; Biomol Engn Res Inst, Dept Bioinformat, Suita, Osaka 5650874, Japan; Biomol Engn Res Inst, Dept Biol Struct, Suita, Osaka 5650874, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Mol Microbiol, Osaka 5650874, Japan	Osaka University	Ishino, Y (corresponding author), Biomol Engn Res Inst, Dept Mol Biol, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.	ishino@beri.co.jp		Ishino, Yoshizumi/0000-0001-9419-0826				ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; Bianco P R, 1998, Front Biosci, V3, pD570; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; Daiyasu H, 2000, NUCLEIC ACIDS RES, V28, P4540, DOI 10.1093/nar/28.22.4540; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; Giraud-Panis MJE, 1998, J MOL BIOL, V278, P117, DOI 10.1006/jmbi.1998.1681; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KATAYANAGI K, 1993, J BIOL CHEM, V268, P22092; Kawarabayasi Y, 1999, DNA Res, V6, P83, DOI 10.1093/dnares/6.2.83; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Komori K, 1999, P NATL ACAD SCI USA, V96, P8873, DOI 10.1073/pnas.96.16.8873; Komori K, 2000, NUCLEIC ACIDS RES, V28, P4544, DOI 10.1093/nar/28.22.4544; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kvaratskhelia M, 2000, J BIOL CHEM, V275, P25540, DOI 10.1074/jbc.M003420200; Kvaratskhelia M, 2000, J MOL BIOL, V297, P923, DOI 10.1006/jmbi.2000.3624; LILLEY DM, 1995, DNA PROTEIN STRUCTUR, P114; Lilley DMJ, 2000, P NATL ACAD SCI USA, V97, P9351, DOI 10.1073/pnas.97.17.9351; MIZRAHI V, 1990, NUCLEIC ACIDS RES, V18, P5359, DOI 10.1093/nar/18.18.5359; MORIKAWA K, 1998, NUCL ACID M, V12, P275; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; Raaijmakers H, 1999, EMBO J, V18, P1447, DOI 10.1093/emboj/18.6.1447; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SAITO A, 1995, P NATL ACAD SCI USA, V92, P7470, DOI 10.1073/pnas.92.16.7470; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; Shinagawa H, 1996, TRENDS BIOCHEM SCI, V21, P107, DOI 10.1016/0968-0004(96)10014-1; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsutakawa SE, 1999, MOL CELL, V3, P621, DOI 10.1016/S1097-2765(00)80355-X; Tsutakawa SE, 1999, CELL, V99, P615, DOI 10.1016/S0092-8674(00)81550-0; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; White MF, 1997, J MOL BIOL, V269, P647, DOI 10.1006/jmbi.1997.1097	42	27	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40385	40391		10.1074/jbc.M006294200	http://dx.doi.org/10.1074/jbc.M006294200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11005813	hybrid			2022-12-25	WOS:000166039500080
J	Allen, MP; Xu, M; Zeng, C; Tobet, SA; Wierman, ME				Allen, MP; Xu, M; Zeng, C; Tobet, SA; Wierman, ME			Myocyte enhancer factors-2B and-2C are required for adhesion related kinase repression of neuronal gonadotropin releasing hormone gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; CENTRAL-NERVOUS-SYSTEM; TRANSCRIPTION FACTOR; PROMOTER ACTIVITY; SURVIVAL ACTIVITIES; FUNCTIONAL-ANALYSIS; MEF2 GENES; PROTEIN-S; FACTOR 2C; GROWTH	Synthesis of the hypothalamic peptide, gonadotropin releasing hormone (GnRH), is paramount for reproductive function. GnRH neurons originate in the olfactory region and migrate into the forebrain during development. We recently implicated adhesion related kinase (Ark) in GnRH neuron development based on its differential expression in two GnRH producing cell lines, GT1-7 and Gn10. The Ark membrane receptor encodes an extracellular domain resembling cell adhesion molecules and an intracellular tyrosine kinase. Ark is expressed in Gn10 cells derived from migrating GnRH neurons but not GT1-7 cells of the post-migratory phenotype. Here, we show that Ark and GnRH transcripts are colocalized in the cribriform plate at midgestation, suggesting that Ark is expressed in migrating GnRH neurons in vivo. Furthermore, we have identified the GnRH gene as a downstream target of Ark signaling. Ark inhibits GnRH gene expression in GnRH neuronal cells via the coordinated binding of myocyte enhancer factor-2B and -2C (MEF-2B and -2C) and a putative homeoprotein within the proximal rat GnRH: promoter. Given that MEF-2 proteins are widely expressed in the brain, these studies provide further evidence for MEF-2 action during neuronal development. Moreover, our studies elucidate a potential role for Ark in regulating GnRH gene expression during GnRH neuronal migration.	Vet Affairs Med Ctr, Res Serv, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Physiol & Biophys, Denver, CO 80262 USA; Harvard Univ, Sch Med, Shriver Ctr, Program Neurosci, Waltham, MA 02452 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Harvard University	Wierman, ME (corresponding author), Vet Affairs Med Ctr, Res Serv, Box 111H,1055 Clermont St, Denver, CO 80220 USA.	margaret.wierman@uchsc.edu		Tobet, Stuart/0000-0002-1615-7331	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033441] Funding Source: NIH RePORTER; NICHD NIH HHS [HD33441] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Allen MP, 1999, MOL ENDOCRINOL, V13, P191, DOI 10.1210/me.13.2.191; ALLEN MP, 2000, SOC NEUR ABST, V26, P1352; ASTRUC ME, 1995, ENDOCRINOLOGY, V136, P824, DOI 10.1210/en.136.3.824; Bellosta P, 1997, ONCOGENE, V15, P2387, DOI 10.1038/sj.onc.1201419; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; Belsham DD, 2000, MOL ENDOCRINOL, V14, P212, DOI 10.1210/me.14.2.212; Biscardi JS, 1996, J BIOL CHEM, V271, P29049, DOI 10.1074/jbc.271.46.29049; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Black BL, 1996, J BIOL CHEM, V271, P26659, DOI 10.1074/jbc.271.43.26659; Bless EP, 2000, ENDOCRINOLOGY, V141, P1254, DOI 10.1210/en.141.3.1254; Bruder JM, 1996, MOL ENDOCRINOL, V10, P35, DOI 10.1210/me.10.1.35; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; Chen J, 1997, ONCOGENE, V14, P2033, DOI 10.1038/sj.onc.1201039; CLARK ME, 1995, MOL CELL BIOL, V15, P6169; Crosier KE, 1997, PATHOLOGY, V29, P131, DOI 10.1080/00313029700169744; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fang ZQ, 1998, ENDOCRINOLOGY, V139, P3654, DOI 10.1210/en.139.8.3654; Firulli AB, 1996, CIRC RES, V78, P196, DOI 10.1161/01.RES.78.2.196; Fridell YWC, 1998, J BIOL CHEM, V273, P7123, DOI 10.1074/jbc.273.12.7123; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; FUJIMOTO J, 1994, ONCOGENE, V9, P693; Goruppi S, 1999, ONCOGENE, V18, P4224, DOI 10.1038/sj.onc.1202788; Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442; Goruppi S, 1996, ONCOGENE, V12, P471; Grayson J, 1998, J CELL BIOCHEM, V70, P366, DOI 10.1002/(SICI)1097-4644(19980901)70:3<366::AID-JCB10>3.3.CO;2-T; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HIATT ES, 1992, ENDOCRINOLOGY, V130, P1030, DOI 10.1210/en.130.2.1030; IKESHIMA H, 1995, NEUROSCI LETT, V200, P117, DOI 10.1016/0304-3940(95)12092-I; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; Kelley CG, 2000, MOL ENDOCRINOL, V14, P1246, DOI 10.1210/me.14.8.1246; KEPA JK, 1992, NUCLEIC ACIDS RES, V20, P1393, DOI 10.1093/nar/20.6.1393; Kepa JK, 1996, NUCLEIC ACIDS RES, V24, P3614, DOI 10.1093/nar/24.18.3614; KEPA JK, 1994, ENDOCRINE, V2, P947; KING JC, 1995, CELL MOL NEUROBIOL, V15, P89, DOI 10.1007/BF02069560; Krainc D, 1998, J BIOL CHEM, V273, P26218, DOI 10.1074/jbc.273.40.26218; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; Lakich MM, 1998, J BIOL CHEM, V273, P15217, DOI 10.1074/jbc.273.24.15217; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; LEIFER D, 1994, NEUROSCIENCE, V63, P1067, DOI 10.1016/0306-4522(94)90573-8; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; Lin X, 1996, MOL BRAIN RES, V42, P307, DOI 10.1016/S0169-328X(96)00135-0; Loeser RF, 1997, ARTHRITIS RHEUM, V40, P1455, DOI 10.1002/art.1780400814; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Lu QX, 1999, NATURE, V398, P723, DOI 10.1038/19554; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Mao ZX, 1999, J BIOL CHEM, V274, P31102, DOI 10.1074/jbc.274.43.31102; Mao ZX, 1996, J BIOL CHEM, V271, P14371, DOI 10.1074/jbc.271.24.14371; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; MARK MR, 1994, J BIOL CHEM, V269, P10720; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; McCloskey P, 1997, J BIOL CHEM, V272, P23285, DOI 10.1074/jbc.272.37.23285; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; Melaragno MG, 1998, CIRC RES, V83, P697, DOI 10.1161/01.RES.83.7.697; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; Naya FJ, 1999, DEVELOPMENT, V126, P2045; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; Osborn MT, 1999, BIOTECHNIQUES, V27, P887, DOI 10.2144/99275bm02; RADOVICK S, 1991, P NATL ACAD SCI USA, V88, P3402, DOI 10.1073/pnas.88.8.3402; RESCIGNO J, 1991, ONCOGENE, V6, P1909; SCHUG J, 1997, CBILTR19971001V0 U P; SCHULZ NT, 1995, MOL BRAIN RES, V28, P273, DOI 10.1016/0169-328X(94)00216-2; SCHWANZELFUKUDA M, 1989, NATURE, V338, P161, DOI 10.1038/338161a0; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Tobet SA, 1996, DEV BRAIN RES, V97, P287, DOI 10.1016/S0165-3806(96)00151-4; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Wierman ME, 1997, MOL CELL BIOL, V17, P1652, DOI 10.1128/MCB.17.3.1652; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790	76	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39662	39670		10.1074/jbc.M007097200	http://dx.doi.org/10.1074/jbc.M007097200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995769	hybrid			2022-12-25	WOS:000165953100094
J	Lee, YS; Kim, HW; Park, SS				Lee, YS; Kim, HW; Park, SS			The role of alpha-amino group of the N-terminal serine of beta subunit for enzyme catalysis and autoproteolytic activation of glutaryl 7-aminocephalosporanic acid acylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LYSOSOMAL ASPARTYLGLUCOSAMINIDASE; 20S PROTEASOME; PENICILLIN ACYLASE; MECHANISM; ACIDOPHILUM; STRAIN	Glutaryl 7-aminocephalosporanic acid (GL-7-ACA) acylase of Pseudomonas sp. strain GK16 catalyzes the cleavage of the amide bond in the GL-7-ACA side chain to produce glutaric acid and 7-aminocephalosporanic acid (7-ACA). The active enzyme is an (alpha beta)(2) heterotetramer of two non-identical subunits that are cleaved autoproteolytically from an enzymatically inactive precursor polypeptide. In this study, we prepared and characterized a chemically modified enzyme, and also examined an effect of the modification on enzyme catalysis and autocatalytic processing of the enzyme precursor. We found that treatment of the enzyme with cyanate ion led to a significant loss of the enzyme activity. Structural and functional analyses of the modified enzyme showed that carbamylation of the free alpha -amino group of the N-terminal Ser-199 of the beta subunit resulted in the loss of the enzyme activity. The pH dependence of the kinetic parameters indicates that a single ionizing group is involved in enzyme catalysis with pK(a) = 6.0, which could be attributed to the cu-amino group of the N-terminal Ser-199. The carbamylation also inhibited the secondary processing of the enzyme precursor, suggesting a possible role of the ar-amino group for the reaction. Mutagenesis of the invariant N-terminal residue Ser-199 confirmed the key function of its side chain hydroxyl group in both enzyme catalysis and autoproteolytic activation. Partial activity and correct processing of a mutant S199T were in agreement with the general mechanism of N-terminal nucleophile hydrolases. Our results indicate that GL-7-ACA acylase utilizes as a nucleophile Ser-199 in both enzyme activity and autocatalytic processing and most importantly its own alpha -amino group of the Ser-199 as a general base catalyst for the activation of the hydroxyl group both in enzyme catalysis and in the secondary cleavage of the enzyme precursor. All of the data also imply that GL-7-ACA acylase is a member of a novel class of N-terminal nucleophile hydrolases that have a single catalytic center for enzyme catalysis.	Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea	Korea University	Park, SS (corresponding author), Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea.							BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; CLELAND WW, 1982, METHOD ENZYMOL, V87, P309; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; Guan C, 1998, J BIOL CHEM, V273, P9695, DOI 10.1074/jbc.273.16.9695; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; HAYASHI N, 1994, BIOTECHNIQUES, V17, P314; ICHIKAWA S, 1981, AGR BIOL CHEM TOKYO, V45, P2225, DOI 10.1080/00021369.1981.10864877; ICHIKAWA S, 1981, AGR BIOL CHEM TOKYO, V45, P2281; Kwon TH, 2000, J STRUCT BIOL, V131, P79, DOI 10.1006/jsbi.2000.4256; Lee YS, 1998, J BACTERIOL, V180, P4576, DOI 10.1128/JB.180.17.4576-4582.1998; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MATSUDA A, 1985, J BACTERIOL, V163, P1222, DOI 10.1128/JB.163.3.1222-1228.1985; Morillas M, 1999, BIOCHEM J, V338, P235, DOI 10.1042/0264-6021:3380235; OINONEN C, 1995, NAT STRUCT BIOL, V2, P1102, DOI 10.1038/nsb1295-1102; Saarela J, 1998, J BIOL CHEM, V273, P25320, DOI 10.1074/jbc.273.39.25320; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; TANFORD C, 1962, ADV PROTEIN CHEM, V17, P69; Tikkanen R, 1996, EMBO J, V15, P2954, DOI 10.1002/j.1460-2075.1996.tb00658.x; Xu QA, 1999, CELL, V98, P651, DOI 10.1016/S0092-8674(00)80052-5	22	24	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39200	39206		10.1074/jbc.M002504200	http://dx.doi.org/10.1074/jbc.M002504200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10991936	hybrid			2022-12-25	WOS:000165953100036
J	Muller, L; Cameron, A; Fortenberry, Y; Apletalina, EV; Lindberg, I				Muller, L; Cameron, A; Fortenberry, Y; Apletalina, EV; Lindberg, I			Processing and sorting of the prohormone convertase 2 propeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPROTEIN CONVERTASE; POSTTRANSLATIONAL MODIFICATIONS; ENZYMATIC CHARACTERIZATION; INTRAMOLECULAR CHAPERONES; ENDOPLASMIC-RETICULUM; NEUROENDOCRINE CELLS; STRUCTURAL ELEMENTS; TERMINAL SEQUENCES; PROCATHEPSIN-L; PROTEIN 7B2	The prohormone convertases (PCs) are synthesized as zymogens whose propeptides contain several multibasic sites. In this study, we investigated the processing of the PC2 propeptide and its function in the regulation of PC2 activity. By using purified pro-PC2 and directed mutagenesis, we found that the propeptide is first cleaved at the multibasic site separating it from the catalytic domain (primary cleavage site); the intact propeptide thus generated is then sequentially processed at two internal sites. Unlike the mechanism described for furin, our mutagenesis studies show that internal cleavage of the propeptide is not required for activation of pro-PCS, In addition, we identified a point mutation in the primary cleavage site that does not prevent the folding nor the processing of the zymogen but nevertheless results in the generation of an inactive PC2 species. These data suggest that the propeptide cleavage site is directly involved in the folding of the catalytic site. By using synthetic peptides, we found that a PC2 propeptide fragment inhibits PC2 activity, and we identified the inhibitory site as the peptide sequence containing basic residues at the extreme carboxyl terminus of the primary cleavage site. Finally, our study supplies information concerning the intracellular fate of a convertase propeptide by providing evidence that the PC2 propeptide is generated and is internally processed within the secretory granules, In agreement with this localization, an internally cleaved propeptide fragment could be released by stimulated secretion.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Lindberg, I (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1901 Perdido St, New Orleans, LA 70112 USA.		muller, laurent/S-1990-2016; Lindberg, Iris/Q-3825-2019	muller, laurent/0000-0001-9634-4323; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R56DA005084, R01DA005084] Funding Source: NIH RePORTER; NIDA NIH HHS [R56 DA005084, DA05084] Funding Source: Medline; NIDDK NIH HHS [R01 DK049703, DK49703, DK49703S2] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; Bhattacharjya S, 2000, BIOCHEMISTRY-US, V39, P2868, DOI 10.1021/bi9923961; Boudreault A, 1998, J BIOL CHEM, V273, P31574, DOI 10.1074/jbc.273.47.31574; Carmona E, 1996, BIOCHEMISTRY-US, V35, P8149, DOI 10.1021/bi952736s; COLL M, 1991, EMBO J, V10, P1; Creemers JWM, 1998, SEMIN CELL DEV BIOL, V9, P3, DOI 10.1006/scdb.1997.0195; Creemers JWM, 1996, J BIOL CHEM, V271, P25284, DOI 10.1074/jbc.271.41.25284; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; Cygler M, 1996, STRUCTURE, V4, P405, DOI 10.1016/S0969-2126(96)00046-9; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; Elias CF, 1998, J COMP NEUROL, V402, P442, DOI 10.1002/(SICI)1096-9861(19981228)402:4<442::AID-CNE2>3.0.CO;2-R; FRICKER LD, 1986, NATURE, V323, P461, DOI 10.1038/323461a0; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; GALLAGHER T, 1995, STRUCTURE, V3, P907, DOI 10.1016/S0969-2126(01)00225-8; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; GUEST PC, 1992, J BIOL CHEM, V267, P22401; Hu ZX, 1996, J BIOL CHEM, V271, P3375; INOUYE M, 1991, ENZYME, V45, P314, DOI 10.1159/000468904; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; Johanning K, 1998, J BIOL CHEM, V273, P22672, DOI 10.1074/jbc.273.35.22672; Khan AR, 1998, PROTEIN SCI, V7, P815; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; Lamango NS, 1996, ARCH BIOCHEM BIOPHYS, V330, P238, DOI 10.1006/abbi.1996.0249; Lamango NS, 1999, ARCH BIOCHEM BIOPHYS, V362, P275, DOI 10.1006/abbi.1998.1033; LEDUC R, 1992, J BIOL CHEM, V267, P14304; Lesage G, 2000, MOL BIOL CELL, V11, P1947, DOI 10.1091/mbc.11.6.1947; LI YY, 1994, J BIOL CHEM, V269, P4169; Li YY, 1996, J MOL BIOL, V262, P591, DOI 10.1006/jmbi.1996.0537; LINDBERG I, 1995, BIOCHEMISTRY-US, V34, P5486, DOI 10.1021/bi00016a020; LINDBERG I, 1986, J BIOL CHEM, V261, P6317; MACH L, 1994, J BIOL CHEM, V269, P13036; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; MATTHEWS G, 1994, J BIOL CHEM, V269, P588; MCINTYRE GF, 1994, J BIOL CHEM, V269, P567; Menard R, 1998, J BIOL CHEM, V273, P4478, DOI 10.1074/jbc.273.8.4478; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Muller L, 1997, J CELL BIOL, V139, P625, DOI 10.1083/jcb.139.3.625; Muller L, 2000, PROG NUCLEIC ACID RE, V63, P69, DOI 10.1016/S0079-6603(08)60720-5; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V89, P8235, DOI 10.1073/pnas.89.17.8235; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; SEVARINO KA, 1989, CELL, V57, P11, DOI 10.1016/0092-8674(89)90167-0; SHEN FS, 1993, J BIOL CHEM, V268, P24910; Shinde U, 1999, J BIOL CHEM, V274, P15615, DOI 10.1074/jbc.274.22.15615; SHINDE U, 1995, J MOL BIOL, V247, P390, DOI 10.1006/jmbi.1994.0147; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; SIEZEN RJ, INTRAMOLECULAR CHAPE, P233; Stack MS, 1996, ARCH BIOCHEM BIOPHYS, V333, P163, DOI 10.1006/abbi.1996.0377; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; SUTER U, 1991, EMBO J, V10, P2395, DOI 10.1002/j.1460-2075.1991.tb07778.x; Taylor NA, 1997, BIOCHEM J, V321, P367, DOI 10.1042/bj3210367; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; vandeLoo JWHP, 1997, J BIOL CHEM, V272, P27116, DOI 10.1074/jbc.272.43.27116; Volkov A, 1996, J MOL BIOL, V262, P595, DOI 10.1006/jmbi.1996.0538; Wagner I, 1997, EMBO J, V16, P7317, DOI 10.1093/emboj/16.24.7317; Westphal CH, 1999, CELL, V96, P689, DOI 10.1016/S0092-8674(00)80579-6; Williams J W, 1979, Methods Enzymol, V63, P437; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745; ZHOU A, 1994, J BIOL CHEM, V269, P17440; Zhou A, 1998, J BIOL CHEM, V273, P11107, DOI 10.1074/jbc.273.18.11107; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509; Zhu X, 1996, P NATL ACAD SCI USA, V93, P4919, DOI 10.1073/pnas.93.10.4919; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641; Zhu XR, 1998, J BIOL CHEM, V273, P1158, DOI 10.1074/jbc.273.2.1158	69	41	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39213	39222		10.1074/jbc.M003547200	http://dx.doi.org/10.1074/jbc.M003547200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995742	hybrid			2022-12-25	WOS:000165953100038
J	Aris, L; Gilchrist, A; Rens-Domiano, S; Meyer, C; Schatz, PJ; Dratz, EA; Hamm, HE				Aris, L; Gilchrist, A; Rens-Domiano, S; Meyer, C; Schatz, PJ; Dratz, EA; Hamm, HE			Structural Requirements for the Stabilization of metarhodopsin II by the C terminus of the alpha subunit of transducin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEIN; 4TH CYTOPLASMIC LOOP; CRYSTAL-STRUCTURE; ADENYLYL-CYCLASE; RHODOPSIN MUTANTS; LIGHT-SCATTERING; RECEPTOR-BINDING; AMINO-ACIDS; ACTIVATION; GTP	The retinal receptor rhodopsin undergoes a conformational change upon light excitation to form metarhodopsin II (Meta II), which allows interaction and activation of its cognate G protein, transducin (G(t)). A C-terminal Il-amino acid peptide from transducin, G(t alpha)-(340-350), has been shown to both bind and stabilize the Meta II conformation, mimicking heterotrimeric G,. Using a combinatorial library we identified analogs of G(t alpha)-(340-350) that bound light-activated rhodopsin with high affinity (Martin, E. L., Rens-Domiano, S., Schatz, P. J,, and Hamm, H. E. (1996) J. Biol. Chem. 271, 361-366). We have made peptides with key substitutions either on the background of the native G(t alpha)-(340-350) sequence or on the high affinity sequences and used the stabilization of Meta II as a tool to determine which amino acids are critical in G protein-rhodopsin interaction. Removal of the positive charge at the N termini by acylation or delocalization of the charge by K to R substitution enhances the affinity of the G(t alpha)-(340-350) peptides for Meta II, whereas a decrease was observed following C-terminal amidation. Cys-347, a residue conserved in pertussis toxin-sensitive G proteins, was shown to interact with a hydrophobic site in Meta II. These studies provide further insight into the mechanism of interaction between the G(t alpha) C terminus and light-activated rhodopsin.	Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA; Affymax Res Inst, Palo Alto, CA 94304 USA; Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA	Northwestern University; Montana State University System; Montana State University Bozeman	Aris, L (corresponding author), Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA.	heidi.hamm@mcmail.vanderbilt.edu	Gilchrist, Annette/I-4465-2014; Hamm, Heidi E/G-2374-2014	Gilchrist, Annette/0000-0003-2386-7646; 	NATIONAL EYE INSTITUTE [R01EY010291, R01EY006062] Funding Source: NIH RePORTER; NEI NIH HHS [EY10291, EY06062, EY06913] Funding Source: Medline; NHLBI NIH HHS [HL07829] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Arimoto R, 2000, BIOPHYS J, V78, p42A; Bae H, 1999, J BIOL CHEM, V274, P14963, DOI 10.1074/jbc.274.21.14963; Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; BORNANCIN F, 1989, EUR J BIOCHEM, V184, P687, DOI 10.1111/j.1432-1033.1989.tb15068.x; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CULL MG, 1992, P NATL ACAD SCI USA, V89, P1865, DOI 10.1073/pnas.89.5.1865; DRATZ E, 1996, BIOPHYS J, V70, P16; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; Ellis CA, 1999, J BIOL CHEM, V274, P13718, DOI 10.1074/jbc.274.19.13718; ERNST OP, 1995, J BIOL CHEM, V270, P10580, DOI 10.1074/jbc.270.18.10580; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Gilchrist A, 1999, J BIOL CHEM, V274, P6610, DOI 10.1074/jbc.274.10.6610; Gilchrist A, 1998, J BIOL CHEM, V273, P14912, DOI 10.1074/jbc.273.24.14912; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; HAMM HE, 1989, J BIOL CHEM, V264, P11475; HAMM HE, 1987, J BIOL CHEM, V262, P10831; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; HOFMANN KP, 1985, J BIOL CHEM, V260, P7990; IYENGAR R, 1980, J BIOL CHEM, V255, P312; KAHLERT M, 1990, J BIOL CHEM, V265, P18928; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; Kisselev OG, 1998, P NATL ACAD SCI USA, V95, P4270, DOI 10.1073/pnas.95.8.4270; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE CH, 1995, MOL PHARMACOL, V47, P218; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; Marsh SR, 1998, MOL PHARMACOL, V53, P981; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; Mazzoni MR, 1996, J BIOL CHEM, V271, P30034, DOI 10.1074/jbc.271.47.30034; MIN KC, 1993, J BIOL CHEM, V268, P9400; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Natochin M, 1999, J BIOL CHEM, V274, P7865, DOI 10.1074/jbc.274.12.7865; Natochin M, 2000, J BIOL CHEM, V275, P2669, DOI 10.1074/jbc.275.4.2669; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; PANICO J, 1990, J BIOL CHEM, V265, P18922; PFISTER C, 1983, EUR J BIOCHEM, V136, P489, DOI 10.1111/j.1432-1033.1983.tb07767.x; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17040; PHILLIPS WJ, 1994, BIOCHEM J, V299, P351, DOI 10.1042/bj2990351; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; ROJAS FJ, 1985, J BIOL CHEM, V260, P7829; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STRYER L, 1983, METHOD ENZYMOL, V96, P617; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEST RE, 1985, J BIOL CHEM, V260, P4428; YAMAZAKI A, 1982, METHOD ENZYMOL, V81, P526	65	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2333	2339		10.1074/jbc.M002533200	http://dx.doi.org/10.1074/jbc.M002533200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11018024	hybrid			2022-12-25	WOS:000166784800007
J	Chen, VC; Chao, L; Pimenta, DC; Bledsoe, G; Juliano, L; Chao, J				Chen, VC; Chao, L; Pimenta, DC; Bledsoe, G; Juliano, L; Chao, J			Identification of a major heparin-binding site in kallistatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-C INHIBITOR; ANTITHROMBIN-III-HEPARIN; COFACTOR-II; TISSUE KALLIKREIN; ACTIVATION; THROMBIN; GLYCOSAMINOGLYCANS; LOCALIZATION; SULFATE	Kallistatin is a heparin-binding serine proteinase inhibitor (serpin), which specifically inhibits human tissue kallikrein by forming a covalent complex. The inhibitory activity of kallistatin is blocked upon its binding to heparin, In this study we attempted to locate the heparin-binding site of kallistatin using synthetic peptides derived from its surface regions and by site-directed mutagenesis of basic residues in these surface regions. Two synthetic peptides, containing clusters of positive-charged residues, one derived from the F helix and the other from the region encompassing the H helix and C2 sheet of kallistatin, were used to assess their heparin binding activity. Competition assay analysis showed that the peptide derived from the Il helix and C2 sheet displayed higher and specific heparin binding activity. The basic residues in both regions were substituted to generate three kallistatin double mutants K187A/K188A (mutations in the F helix) and K307A/R308A and K312A/ K313A (mutations in the region between the H helix and Ca sheet), using a kallistatin P1Arg variant as a scaffold. Analysis of these mutants by heparin-affinity chromatography showed that the heparin binding capacity of the variant K187A/K188A was not altered, whereas the binding capacity of K307A/308A and K312A/K313A mutants was markedly reduced. Titration analysis with heparin showed that the K312A/K313A mutant has the highest dissociation constant. Like kallistatin, the binding activity of K187A/K188A to tissue kallikrein was blocked by heparin, whereas K307A/R308A and K312A/ K313A retained significant binding and inhibitory activities in the presence of heparin, These results indicate that the basic residues, particularly Lys(312)-Lys(313) in the region between the H helix and C2 sheet of kallistatin, comprise a major heparin-binding site responsible for its heparin-suppressed tissue kallikrein binding.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Escola Paulista Med, Dept Biofis, BR-04044020 Sao Paulo, Brazil	Medical University of South Carolina; Universidade Federal de Sao Paulo (UNIFESP)	Chao, J (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 171 Ashley Ave, Charleston, SC 29425 USA.		Pimenta, Daniel C/B-4361-2008; Juliano, Luiz/D-7204-2012	Pimenta, Daniel C/0000-0003-2406-0860; Juliano, Luiz/0000-0002-5589-2822	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044083] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44083] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adler A J, 1973, Methods Enzymol, V27, P675; Belzar KJ, 2000, J BIOL CHEM, V275, P8733, DOI 10.1074/jbc.275.12.8733; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Chao JL, 1997, J CLIN INVEST, V100, P11, DOI 10.1172/JCI119502; Chen LM, 1997, HUM GENE THER, V8, P341, DOI 10.1089/hum.1997.8.3-341; CHEN VC, 2001, IN PRESS J BIOL CHEM, V276; CHEN VC, 2000, BIOCHIM BIOPHYS ACTA, V147, P237; Cooper ST, 1996, CLIN APPL THROMB-HEM, V2, P185, DOI 10.1177/107602969600200307; ECKE S, 1992, J BIOL CHEM, V267, P7048; EHRLICH HJ, 1992, J BIOL CHEM, V267, P11606; ErsdalBadju E, 1997, J BIOL CHEM, V272, P19393, DOI 10.1074/jbc.272.31.19393; EVANS DL, 1992, BIOCHEMISTRY-US, V31, P12629, DOI 10.1021/bi00165a013; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OWEN BA, 1990, BIOCHEMISTRY-US, V29, P9412, DOI 10.1021/bi00492a015; PRATT CW, 1992, J BIOL CHEM, V267, P8795; PRATT CW, 1992, J BIOL CHEM, V267, P8789; PRIGLINGER U, 1994, J BIOL CHEM, V269, P14705; SHIMAMOTO K, 1980, J CLIN ENDOCR METAB, V51, P840, DOI 10.1210/jcem-51-4-840; Shirk RA, 1996, ARTERIOSCL THROM VAS, V16, P1138, DOI 10.1161/01.ATV.16.9.1138; SHIRK RA, 1994, J BIOL CHEM, V269, P28690; SONJA E, 1997, EUR J BIOCHEM, V248, P475; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; WHINNA HC, 1991, J BIOL CHEM, V266, P8129; ZHOU GX, 1992, J BIOL CHEM, V267, P25873	30	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1276	1284		10.1074/jbc.M005791200	http://dx.doi.org/10.1074/jbc.M005791200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11016932	hybrid			2022-12-25	WOS:000166430900057
J	Grun, F; Hirose, Y; Kawauchi, S; Ogura, T; Umesono, K				Grun, F; Hirose, Y; Kawauchi, S; Ogura, T; Umesono, K			Aldehyde dehydrogenase 6, a cytosolic retinaldehyde dehydrogenase prominently expressed in sensory neuroepithelia during development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID SYNTHESIS; ABNORMAL-DEVELOPMENT; SYNTHESIZING ENZYME; GENE-EXPRESSION; CHICKEN-EMBRYO; RECEPTORS RARS; VENTRAL RETINA; CLONING; HINDBRAIN; HORMONE	We have isolated the chick and mouse homologs of human aldehyde dehydrogenase 6 (ALDH6) that encode a third cytosolic retinaldehyde-specific aldehyde dehydrogenase, In both chick and mouse embryos, strong expression is observed in the sensory neuroepithelia of the head. In situ hybridization analysis in chick, shows compartmentalized expression primarily in the ventral retina, olfactory epithelium, and otic vesicle; additional sites of expression include the isthmus, Rathke's pouch, posterior spinal cord interneurons, and developing limbs. Recombinant chick ALDH6 has a K-0.5 = 0.26 muM, V-max = 48.4 nmol/min/mg and exhibits strong positive cooperativity (H = 1.9) toward all-trans-retinaldehyde; mouse ALDH6 has similar kinetic parameters. Expression constructs can confer 1000-fold increased sensitivity to retinoic acid receptor-dependent signaling from retinol in transient transfections experiments. The localization of ALDH6 to the developing sensory neuroepithelia of the eye, nose, and ear and discreet sites within the CNS suggests a role for RA signaling during primary neurogenesis at these sites.	Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan; Nara Inst Sci & Technol, Ikoma 6300101, Japan	Kyoto University; University of Tsukuba; Nara Institute of Science & Technology	Grun, F (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, 5207 Biosci 2, Irvine, CA 92697 USA.	fgrun@uci.edu	Grun, Felix/C-8271-2011					Anchan RM, 1997, J COMP NEUROL, V379, P171; BALKAN W, 1992, P NATL ACAD SCI USA, V89, P3347, DOI 10.1073/pnas.89.8.3347; Berggren K, 1999, DEV BIOL, V210, P288, DOI 10.1006/dbio.1999.9286; BLATTER EE, 1992, BIOCHEM J, V282, P353, DOI 10.1042/bj2820353; Blumberg B, 1997, DEVELOPMENT, V124, P373; Burrill JD, 1997, DEVELOPMENT, V124, P4493; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COLBERT MC, 1993, P NATL ACAD SCI USA, V90, P6572, DOI 10.1073/pnas.90.14.6572; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; Dickman ED, 1997, DEVELOPMENT, V124, P3111; Duester G, 1999, ADV EXP MED BIOL, V463, P311; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Frenz DA, 1996, TERATOLOGY, V53, P292; GODBOUT R, 1992, EXP EYE RES, V54, P297, DOI 10.1016/S0014-4835(05)80219-2; Haselbeck RJ, 1999, DEV GENET, V25, P353, DOI 10.1002/(SICI)1520-6408(1999)25:4<353::AID-DVG9>3.0.CO;2-G; HSU LC, 1994, GENOMICS, V24, P333, DOI 10.1006/geno.1994.1624; Hyatt GA, 1996, DEVELOPMENT, V122, P195; Ishii Y, 1997, DEV GROWTH DIFFER, V39, P643; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; Kikonyogo A, 1999, EUR J BIOCHEM, V262, P704, DOI 10.1046/j.1432-1327.1999.00415.x; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; Li HX, 2000, MECH DEVELOP, V95, P283, DOI 10.1016/S0925-4773(00)00352-X; LIRA SA, 1993, MOL ENDOCRINOL, V7, P694, DOI 10.1210/me.7.5.694; LOHNES D, 1994, DEVELOPMENT, V120, P2723; Maden M, 1996, CURR BIOL, V6, P417, DOI 10.1016/S0960-9822(02)00509-2; Maden M, 1998, DEVELOPMENT, V125, P4133; MARSHARMSTRONG N, 1994, P NATL ACAD SCI USA, V91, P7286, DOI 10.1073/pnas.91.15.7286; MCCAFFERY P, 1992, DEVELOPMENT, V115, P371; McCaffery Peter, 1999, Mechanisms of Development, V85, P203; MCCLEAN SW, 1982, CLIN CHEM, V28, P693; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; Mey J, 1997, J NEUROSCI, V17, P7441; Milam AH, 1997, VISUAL NEUROSCI, V14, P601, DOI 10.1017/S0952523800012256; MorrissKay GM, 1996, FASEB J, V10, P961, DOI 10.1096/fasebj.10.9.8801178; Moss JB, 1998, DEV BIOL, V199, P55, DOI 10.1006/dbio.1998.8911; Napoli JL, 2000, PROG NUCLEIC ACID RE, V63, P139, DOI 10.1016/S0079-6603(08)60722-9; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; Niederreither K, 1997, MECH DEVELOP, V62, P67, DOI 10.1016/S0925-4773(96)00653-3; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PAPALOPULU N, 1991, DEVELOPMENT, V113, P1145; Penzes P, 1997, GENE, V191, P167, DOI 10.1016/S0378-1119(97)00054-1; Penzes P, 1997, BBA-PROTEIN STRUCT M, V1342, P175, DOI 10.1016/S0167-4838(97)00102-7; Perozich J, 1999, PROTEIN SCI, V8, P137, DOI 10.1110/ps.8.1.137; Pierani A, 1999, CELL, V97, P903, DOI 10.1016/S0092-8674(00)80802-8; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; Sharpe C, 2000, MECH DEVELOP, V91, P69, DOI 10.1016/S0925-4773(99)00273-7; Swindell EC, 1999, DEV BIOL, V216, P282, DOI 10.1006/dbio.1999.9487; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Wagner E, 2000, DEV BIOL, V222, P460, DOI 10.1006/dbio.2000.9719; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; White JC, 2000, DEV BIOL, V220, P263, DOI 10.1006/dbio.2000.9635; WHITESIDES J, 1996, J COMP NEUROL, V53, P292; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202; YOSHIDA A, 1992, ENZYME, V46, P239, DOI 10.1159/000468794; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x	58	104	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41210	41218		10.1074/jbc.M007376200	http://dx.doi.org/10.1074/jbc.M007376200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11013254	hybrid			2022-12-25	WOS:000166114600074
J	Liu, HL; Lo, CR; Jones, BE; Pradhan, Z; Srinivasan, A; Valentino, KL; Stocker, RJ; Czaja, MJ				Liu, HL; Lo, CR; Jones, BE; Pradhan, Z; Srinivasan, A; Valentino, KL; Stocker, RJ; Czaja, MJ			Inhibition of c-Myc expression sensitizes hepatocytes to tumor necrosis factor-induced apoptosis and necrosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LIVER-REGENERATION; FACTOR-ALPHA; GENE-EXPRESSION; RAT HEPATOCYTES; FACTOR RECEPTOR; CELL-DEATH; TNF-ALPHA; ACTIVATION; DIFFERENTIATION	The typical proliferative response of hepatocytes to tumor necrosis factor (TNF) can be converted to a cytotoxic one by transcriptional arrest. Although NF-kappaB activation is critical for hepatocyte resistance to TNF toxicity, the contribution of other TNF-inducible transcription factors remains unknown. To determine the function of c-Myc in hepatocyte sensitivity to TNF, stable transfectants of the rat hepatocyte cell. line RALA255-10G containing sense and antisense c-myc expression vectors were isolated with increased (S-Myc cells) and decreased (AN-Myc cells) c-Myc transcriptional activity. While S-Myc cells proliferated in response to TNF treatment, AN-Myc cells underwent 32% cell death within 6 h. Fluorescent microscopic studies indicated that TNF induced apoptosis and necrosis in AN-Myc cells. Cell death was associated with DNA hypoploidy and poly(ADP-ribose) polymerase cleavage but occurred in the absence of detectable caspase-3, -7, or -8 activation. TNF-induced, AN-Myc cell death was dependent on Fas-associated protein with death domain and partially blocked by caspase inhibitors. AN-Myc cells had decreased levels of NF-kappaB transcriptional activity, but S-Myc cells maintained resistance to TNF despite NF-kappaB inactivation, suggesting that c-Myc and NF-kappaB independently mediate TNF resistance. Thus, in the absence of sufficient c-Myc expression, hepatocytes are sensitized to TNF-induced apoptosis and necrosis, These findings demonstrate that hepatocyte resistance to TNF is regulated by multiple transcriptional activators.	Yeshiva Univ Albert Einstein Coll Med, Liver Res Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; IDUN Pharmaceut Inc, La Jolla, CA 92037 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Czaja, MJ (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Liver Res Ctr, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Stocker, Roland/AAV-4489-2021		NCI NIH HHS [5P30CA13330] Funding Source: Medline; NIDDK NIH HHS [DK44234, DK32972, R01 DK044234] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032972, R01DK044234] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERMAN P, 1992, AM J PHYSIOL, V263, P579; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BLAZKA ME, 1995, TOXICOL APPL PHARM, V133, P43, DOI 10.1006/taap.1995.1125; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Bradham CA, 1998, AM J PHYSIOL-GASTR L, V275, pG387, DOI 10.1152/ajpgi.1998.275.3.G387; CHOU JY, 1983, MOL CELL BIOL, V3, P1013, DOI 10.1128/MCB.3.6.1013; CZAJA MJ, 1991, J CELL PHYSIOL, V147, P434, DOI 10.1002/jcp.1041470308; CZAJA MJ, 1995, GASTROENTEROLOGY, V108, P1849, DOI 10.1016/0016-5085(95)90149-3; Dang CV, 1999, MOL CELL BIOL, V19, P1; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GALANG CK, 1994, ONCOGENE, V9, P2913; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HISHINUMA I, 1990, HEPATOLOGY, V12, P1187, DOI 10.1002/hep.1840120518; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Jones BE, 1999, HEPATOLOGY, V30, P215, DOI 10.1002/hep.510300146; Jones BE, 2000, J BIOL CHEM, V275, P705, DOI 10.1074/jbc.275.1.705; Jones BE, 2000, AM J PHYSIOL-GASTR L, V278, pG693, DOI 10.1152/ajpgi.2000.278.5.G693; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; KULL FC, 1981, CANCER RES, V41, P4885; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MANCHESTER KM, 1993, BIOCHEM J, V290, P185, DOI 10.1042/bj2900185; NINOMIYATSUJI J, 1993, P NATL ACAD SCI USA, V90, P9611, DOI 10.1073/pnas.90.20.9611; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; SCHMIEDEBERG P, 1993, J CELL PHYSIOL, V154, P294, DOI 10.1002/jcp.1041540212; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Soares MP, 1998, J IMMUNOL, V161, P4572; TERADA K, 1995, J BIOL CHEM, V270, P20410, DOI 10.1074/jbc.270.35.20410; Tracey KJ, 1997, CYTOKINES HLTH DIS, P223; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang W, 1999, J IMMUNOL, V162, P314; Wu M, 1996, MOL CELL BIOL, V16, P5015; Xu J, 1996, AM J PHYSIOL-GASTR L, V270, pG60, DOI 10.1152/ajpgi.1996.270.1.G60; Xu Y, 1997, AM J PHYSIOL-GASTR L, V273, pG795, DOI 10.1152/ajpgi.1997.273.4.G795; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058, DOI 10.1152/ajpcell.1998.275.4.C1058; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441	49	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40155	40162		10.1074/jbc.M001565200	http://dx.doi.org/10.1074/jbc.M001565200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11016920	hybrid			2022-12-25	WOS:000166039500050
J	Pandey, A; Fernandez, MM; Steen, H; Blagoev, B; Nielsen, MM; Roche, S; Mann, M; Lodish, HF				Pandey, A; Fernandez, MM; Steen, H; Blagoev, B; Nielsen, MM; Roche, S; Mann, M; Lodish, HF			Identification of a novel immunoreceptor tyrosine-based activation motif-containing molecule, STAM2, by mass spectrometry and its involvement in growth factor and cytokine receptor signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSDUCING ADAPTER MOLECULE; POLYACRYLAMIDE GELS; PROTEINS; KINASE; PEPTIDE; CANCER; DOMAIN; GENE	In an effort to clone novel tyrosine-phosphorylated substrates of the epidermal growth factor receptor, we have initiated an approach coupling affinity purification using anti-phosphotyrosine antibodies to mass spectrometry-based identification, Here, we report the identification of a signaling molecule containing a Src homology 3 domain as well as an immunoreceptor tyrosine-based activation motif (ITAM). This molecule is 55% identical to a previously isolated molecule designated signal transducing adaptor molecule (STAM) that was identified as an interleukin (IL)-2-induced phosphoprotein and is therefore designated STAM2, Tyrosine phosphorylation of STAM2 is induced by growth factors such as epidermal growth factor and platelet-derived growth factor as well as by cytokines like IL-3. Several of the deletion mutants tested except the one containing only the amino-terminal region underwent tyrosine phosphorylation upon growth factor stimulation, implying that STAM2 is phosphorylated on several tyrosine residues, STAM2 is downstream of the Jak family of kinases since coexpression of STAM2 with Jak1 or Jak2 but not an unrelated Tec family kinase, Etk, resulted in its tyrosine phosphorylation, In contrast to epidermal growth factor receptor-induced phosphorylation, this required the ITAM domain since mutants lacking this region did not undergo tyrosine phosphorylation, Finally, overexpression of wild type STAM2 led to an increase in IL-8-mediated induction of c-Myc promoter activation indicating that it potentiates cytokine receptor signaling.	Univ So Denmark, Ctr Expt Bioinformat, Prot Interact Lab, DK-5230 Odense M, Denmark; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Ctr Rech Biochim & Macromol, CNRS UPR 1086, F-34293 Montpellier, France	University of Southern Denmark; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Brigham & Women's Hospital; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Mann, M (corresponding author), Univ So Denmark, Ctr Expt Bioinformat, Prot Interact Lab, DK-5230 Odense M, Denmark.		Pandey, Akhilesh/B-4127-2009; Mann, Matthias/A-3454-2013	Pandey, Akhilesh/0000-0001-9943-6127; Mann, Matthias/0000-0003-1292-4799; Steen, Hanno/0000-0003-0179-6648; roche, serge/0000-0003-3413-3859; Blagoev, Blagoy/0000-0002-3596-0066	NCI NIH HHS [KO1CA75447] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA075447] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; Dong ZG, 1999, ANTICANCER RES, V19, P3743; Endo K, 2000, FEBS LETT, V477, P55, DOI 10.1016/S0014-5793(00)01760-9; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; Leonard W.J., 1999, FUNDAMENTAL IMMUNOLO, Vfourth, P741; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Mesilaty-Gross S, 1999, GENE, V231, P173, DOI 10.1016/S0378-1119(99)00053-0; Neubauer G, 1999, ANAL CHEM, V71, P235, DOI 10.1021/ac9804902; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; PANDEY A, 2000, SCI STKE; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; Takeshita T, 1996, BIOCHEM BIOPH RES CO, V225, P1035, DOI 10.1006/bbrc.1996.1290; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vente A, 1999, NAT GENET, V22, P22, DOI 10.1038/8734; Watowich SS, 1996, ANNU REV CELL DEV BI, V12, P91, DOI 10.1146/annurev.cellbio.12.1.91; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Yang WC, 2000, IMMUNITY, V12, P373, DOI 10.1016/S1074-7613(00)80189-2	30	99	108	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38633	38639		10.1074/jbc.M007849200	http://dx.doi.org/10.1074/jbc.M007849200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10993906	hybrid			2022-12-25	WOS:000165739800067
J	Rangasamy, D; Woytek, K; Khan, SA; Wilson, VG				Rangasamy, D; Woytek, K; Khan, SA; Wilson, VG			SUMO-1 modification of bovine papillomavirus E1 protein is required for intranuclear accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; DNA-POLYMERASE-ALPHA; REPLICATION PROTEIN; E2 PROTEINS; PML; IDENTIFICATION; ACTIVATION; ORIGIN; LOCALIZATION; CONJUGATION	The El protein is a multifunctional, origin-binding helicase that is essential for replication of papillomaviruses. Recently, bovine papillomavirus El was shown to be post-translationally modified by the addition of the SUMO-1 polypeptide, Here we show that the site of sumoylation maps to lysine residue 514. This lysine and the flanking sequences are well conserved in human papillomavirus (HPV) El proteins. Both HPV1a and HPV18 El proteins are substrates for sumoylation in vitro, which is consistent with this modification being a general property of El proteins. Mutations, which impair the sumoylation of bovine papillomavirus El, prevent normal nuclear accumulation of El with a concomitant loss of replication capacity. These results suggest that sumoylation plays a role in nuclear transport and could regulate the El replication function by controlling access to the nuclear replication domains.	Texas A&M Univ, Coll Med, Dept Med Microbiol, Syst Hlth Sci Ctr, College Stn, TX 77843 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wilson, VG (corresponding author), Texas A&M Univ, Coll Med, Dept Med Microbiol, Syst Hlth Sci Ctr, College Stn, TX 77843 USA.	v-wilson@tamu.edu	, Van G Wilson/B-1868-2009					Boddy MN, 1996, ONCOGENE, V13, P971; BONNEANDREA C, 1995, J VIROL, V69, P2341, DOI 10.1128/JVI.69.4.2341-2350.1995; BONNEANDREA C, 1995, J VIROL, V69, P3201, DOI 10.1128/JVI.69.5.3201-3205.1995; Day PM, 1998, J VIROL, V72, P142, DOI 10.1128/JVI.72.1.142-150.1998; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Gonzalez A, 2000, J VIROL, V74, P245, DOI 10.1128/JVI.74.1.245-253.2000; GOPALAKRISHNAN V, 1994, P NATL ACAD SCI USA, V91, P9597, DOI 10.1073/pnas.91.20.9597; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Han YF, 1999, J VIROL, V73, P4899, DOI 10.1128/JVI.73.6.4899-4907.1999; HOLT SE, 1995, J VIROL, V69, P6525, DOI 10.1128/JVI.69.10.6525-6532.1995; Howley Peter M., 1996, P947; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Kawabe Y, 2000, J BIOL CHEM, V275, P20963, DOI 10.1074/jbc.C000273200; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; LENTZ MR, 1993, J VIROL, V67, P1414, DOI 10.1128/JVI.67.3.1414-1423.1993; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELENDY T, 1995, J VIROL, V69, P7857, DOI 10.1128/JVI.69.12.7857-7867.1995; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; PARK P, 1994, P NATL ACAD SCI USA, V91, P8700, DOI 10.1073/pnas.91.18.8700; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sanders CM, 1998, EMBO J, V17, P7044, DOI 10.1093/emboj/17.23.7044; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; SVERDRUP F, 1994, J VIROL, V68, P505, DOI 10.1128/JVI.68.1.505-509.1994; Swindle CS, 1998, J VIROL, V72, P1994, DOI 10.1128/JVI.72.3.1994-2001.1998; Swindle CS, 1999, J VIROL, V73, P1001, DOI 10.1128/JVI.73.2.1001-1009.1999; USTAV M, 1991, EMBO J, V10, P4321, DOI 10.1002/j.1460-2075.1991.tb05010.x; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; WILSON VG, 1992, BIOCHIM BIOPHYS ACTA, V1129, P215, DOI 10.1016/0167-4781(92)90490-Q; WILSON VG, 1991, J VIROL, V65, P5314, DOI 10.1128/JVI.65.10.5314-5322.1991; XIAO XL, 1994, J GEN VIROL, V75, P2463, DOI 10.1099/0022-1317-75-9-2463; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; Yasugi T, 1997, J VIROL, V71, P891, DOI 10.1128/JVI.71.2.891-899.1997; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	39	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37999	38004		10.1074/jbc.M007777200	http://dx.doi.org/10.1074/jbc.M007777200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	11005821	hybrid			2022-12-25	WOS:000165618700093
J	Maemura, K; de la Monte, SM; Chin, MT; Layne, MD; Hsieh, CM; Yet, SF; Perrella, MA; Lee, ME				Maemura, K; de la Monte, SM; Chin, MT; Layne, MD; Hsieh, CM; Yet, SF; Perrella, MA; Lee, ME			CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAS DOMAIN PROTEIN-1; RPER2 MESSENGER-RNA; SUPRACHIASMATIC NUCLEUS; MYOCARDIAL-INFARCTION; PERIPHERAL-TISSUES; DROSOPHILA PERIOD; ENDOTHELIAL-CELLS; CLOCK PROTEIN; TRANSCRIPTION; LOOP	The onset of myocardial infarction occurs frequently in the early morning, and it may partly result from circadian variation of fibrinolytic activity. Plasminogen activator inhibitor-1 activity shows a circadian oscillation and may account for the morning onset of myocardial infarction, However, the molecular mechanisms regulating this circadian oscillation remain unknown. Recent evidence indicates that basic helix-loop-helix (bHLH)/PAS domain transcription factors play a crucial role in controlling the biological clock that controls circadian rhythm. We isolated a novel bHLH/PAS protein, cycle-like factor (CLIF) rom human umbilical vein endothelial cells. CLIF shares high homology with Drosophila CYCLE, one of the essential transcriptional regulators of circadian rhythm. CLIF is expressed in endothelial cells and neurons in the brain, including the suprachiasmatic nucleus, the center of the circadian clock, In endothelial cells, CLIF forms a heterodimer with CLOCK and up-regulates the PAI-1 gene through E-box sites. Furthermore, Period2 and Cryptochrome1, whose expression show a circadian oscillation in peripheral tissues, inhibit the PAI-1 promoter activation by the CLOCK:CLIF heterodimer. These results suggest that CLIF regulates the circadian oscillation of PAI-1 gene expression in endothelial cells. In addition, the results potentially provide a molecular basis for the morning onset of myocardial infarction,	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pulm & Crit Care, Boston, MA 02115 USA; Brown Univ, Rhode Isl Hosp, Sch Med, Dept Pathol & Med, Providence, RI 02903 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	Maemura, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo 1138655, Japan.		Yet, Shaw-Fang/B-1067-2010; Yet, Shaw-Fang/O-8583-2019; de la monte, suzanne/L-7670-2019	de la monte, suzanne/0000-0001-5886-2306; Layne, Matthew/0000-0003-0007-4870; Yet, Shaw-Fang/0000-0001-9097-3962	NHLBI NIH HHS [HL 60788, HL 10113, HL 03745] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060788, F32HL010113] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADREOTTI F, 1991, CHRONOBIOL INT, V8, P336; ANGLETON P, 1989, CIRCULATION, V79, P101, DOI 10.1161/01.CIR.79.1.101; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; BRAUNWALD E, 1995, CIRCULATION, V91, P1604, DOI 10.1161/01.CIR.91.5.1604; Brown SA, 1999, CURR OPIN GENET DEV, V9, P588, DOI 10.1016/S0959-437X(99)00009-X; Chin MT, 2000, J BIOL CHEM, V275, P6381, DOI 10.1074/jbc.275.9.6381; DelAMonte SM, 1997, MOL CHEM NEUROPATHOL, V30, P139, DOI 10.1007/BF02815155; DELAMONTE SM, 1995, AM J PATHOL, V147, P934; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; ERIKSSON P, 1995, P NATL ACAD SCI USA, V92, P1851, DOI 10.1073/pnas.92.6.1851; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Guney HZ, 1999, CHRONOBIOL INT, V16, P779, DOI 10.3109/07420529909016945; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Kurnik Peter B., 1996, Cardiology Clinics, V14, P251; Maemura K, 1999, J BIOL CHEM, V274, P31565, DOI 10.1074/jbc.274.44.31565; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; Oishi K, 1998, NEUROSCI LETT, V256, P117, DOI 10.1016/S0304-3940(98)00765-4; Oishi K, 1998, BIOCHEM BIOPH RES CO, V253, P199, DOI 10.1006/bbrc.1998.9779; Roest M, 2000, CIRCULATION, V101, P67, DOI 10.1161/01.CIR.101.1.67; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Sakamoto K, 1998, J BIOL CHEM, V273, P27039, DOI 10.1074/jbc.273.42.27039; Sassone-Corsi P, 1998, NATURE, V392, P871, DOI 10.1038/31821; Schibler U, 2000, NATURE, V404, P25, DOI 10.1038/35003674; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266	35	165	172	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36847	36851		10.1074/jbc.C000629200	http://dx.doi.org/10.1074/jbc.C000629200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	11018023	hybrid			2022-12-25	WOS:000165577700058
J	Flores, I; Jones, DR; Merida, I				Flores, I; Jones, DR; Merida, I			Changes in the balance between mitogenic and antimitogenic lipid second messengers during proliferation, cell arrest, and apoptosis in T lymphocytes	FASEB JOURNAL			English	Article									CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Madrid 28049, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Merida, I (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Univ Autonoma, Madrid 28049, Spain.		Merida, Isabel/A-9713-2014; Flores, Ignacio/E-8304-2016	Merida, Isabel/0000-0003-2762-6241; Flores, Ignacio/0000-0001-8789-6396					0	20	21	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					1873	1875						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023971				2022-12-25	WOS:000089634400006
J	Rippo, MR; Malisan, F; Ravagnan, L; Tomassini, B; Condo, I; Costantini, P; Susin, SA; Rufini, A; Todaro, M; Kroemer, G; Testi, R				Rippo, MR; Malisan, F; Ravagnan, L; Tomassini, B; Condo, I; Costantini, P; Susin, SA; Rufini, A; Todaro, M; Kroemer, G; Testi, R			GD3 ganglioside directly targets mitochondria in a bcl-2-controlled fashion	FASEB JOURNAL			English	Article						apoptosis; permeability transition; AIF; cytochrome c; caspase 9	PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; CERAMIDE-INDUCED APOPTOSIS; ACIDIC SPHINGOMYELINASE; EXPRESSION CLONING; G(D3) SYNTHASE; IN-VIVO; BAX; ACTIVATION; NECROSIS	Lipid and glycolipid diffusible mediators are involved in the intracellular progression and amplification of apoptotic signals. GD3 ganglioside is rapidly synthesized from accumulated ceramide after the clustering of death-inducing receptors and triggers apoptosis. Here we show that GD3 induces dissipation of Delta psi(m), and swelling of isolated mitochondria, which results in the mitochondrial release of cytochrome c, apoptosis inducing factor, and caspase 9. Soluble factors released from GD3-treated mitochondria are sufficient to trigger DNA fragmentation in isolated nuclei. All these effects can be blocked by cyclosporin A, suggesting that GD3 is acting at the level of the permeability transition pore complex. We found that endogenous GD3 accumulates within mitochondria of cells undergoing apoptosis after ceramide exposure. Accordingly, suppression of GD3 synthase (ST8) expression in intact cells substantially prevents ceramide-induced Delta psi(m) dissipation, indicating that endogenously synthesized GD3 induces mitochondrial changes in vivo. Finally, enforced expression of bcl-2 significantly prevents GD3-induced mitochondrial changes, caspase 9 activation, and apoptosis. These results show that mitochondria are a key destination for apoptogenic GD3 ganglioside along the lipid pathway to programmed cell death and indicate that relevant GD3 targets are under bcl-2 control.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Lab Signal Transduct, I-00133 Rome, Italy; Inst Gustave Roussy, CNRS, UMR 1599, F-94805 Villejuif, France; Univ Palermo, Sect Anat Sci, I-90133 Palermo, Italy	University of Rome Tor Vergata; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; University of Palermo	Testi, R (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Lab Signal Transduct, Via Tor Vergata 135, I-00133 Rome, Italy.		Rufini, Alessandra/Q-9256-2019; KROEMER, Guido/B-4263-2013; Susin, Santos A/Q-6754-2017; Kroemer, Guido/AAY-9859-2020; Rufini, Alessandra/J-2995-2012; Condò, Ivano/B-4783-2010	Rufini, Alessandra/0000-0001-5654-9615; KROEMER, Guido/0000-0002-9334-4405; Susin, Santos A/0000-0002-3366-1628; Condò, Ivano/0000-0001-5421-4846; RIPPO, Maria Rita/0000-0003-3024-3495; MALISAN, FLORENCE/0000-0002-0213-9407				Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; Basu S, 1998, ONCOGENE, V17, P3277, DOI 10.1038/sj.onc.1202570; Brenner B, 1998, CELL DEATH DIFFER, V5, P29, DOI 10.1038/sj.cdd.4400307; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; DeMaria R, 1996, J CLIN INVEST, V97, P316, DOI 10.1172/JCI118418; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Fraser A, 1998, TRENDS CELL BIOL, V8, P219, DOI 10.1016/S0962-8924(98)01275-6; Geley S, 1997, FEBS LETT, V400, P15, DOI 10.1016/S0014-5793(96)01284-7; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Nakayama J, 1996, J BIOL CHEM, V271, P3684; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; SASAKI K, 1994, J BIOL CHEM, V269, P15950; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; Wiegmann K, 1999, J BIOL CHEM, V274, P5267, DOI 10.1074/jbc.274.9.5267; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; ZENG GC, 1995, P NATL ACAD SCI USA, V92, P8670, DOI 10.1073/pnas.92.19.8670; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	53	154	157	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					2047	2054		10.1096/fj.99-1028com	http://dx.doi.org/10.1096/fj.99-1028com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023989				2022-12-25	WOS:000089634400024
J	Hyun, JW; Choi, JY; Zeng, HH; Lee, YS; Kim, HS; Yoon, SH; Chung, MH				Hyun, JW; Choi, JY; Zeng, HH; Lee, YS; Kim, HS; Yoon, SH; Chung, MH			Leukemic cell line, KG-1 has a functional loss of hOGG1 enzyme due to a point mutation and 8-hydroxydeoxyguanosine can kill KG-1	ONCOGENE			English	Article						KG-1; 8-hydroxyguanine; hOGG1; mutation; cytotoxicity	REMOVES 8-HYDROXYGUANINE RESIDUES; OXIDATIVE DNA-DAMAGE; ESCHERICHIA-COLI; ENDONUCLEASE ACTIVITY; OGG1 GENE; GLYCOSYLASE; CLONING; REPAIR; EXCISION; PROTEIN	We tested the cytotoxic action of 8-hydroxyguanine (8ohG) by observing the viability of several leukemic cell lines (KG-1, U937, Jurkat and K 562) in the presence of 8-hydroxydeoxyguanosine (8ohdG), a nucleoside of 8ohG, It was found that 8ohdG showed cytotoxic action only to KG-1 and that only KG-1 showed a homozygous arginine 209 to glutamine mutation in the hOGG1 gene with an almost negligible hOGG1 enzyme activity, Possibly, the selective cytotoxicity in 8ohdG to KG-1 may be due to its low capacity to cope with an increase in the 8ohG level in DNA resulting from the incorporation of 8ohdG present in the culture media. The mutational impairment of hOGG1 in KG-1 is the first report in leukemic cell lines. Using KG-1 with impaired hOGG1, we demonstrated cytotoxicity of 8ohdG probably due to its incorporation into cellular DNA. This new property of KG-1 may allow it to serve as an useful tool for studies of OGG1, oxidative DNA damage and the cytotoxic action of 8ohG.	Seoul Natl Univ, Coll Med, Dept Pharmacol, Chongno Gu, Seoul 110744, South Korea; Beijing Med Univ, Sch Pharmaceut Sci, Beijing 100083, Peoples R China; Korea Canc Ctr Hosp, Lab Radiat Effect, Nowon Gu, Seoul 139706, South Korea	Seoul National University (SNU); Peking University; National Cancer Center - Korea (NCC)	Chung, MH (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol, Chongno Gu, 28 Yongon Dong, Seoul 110744, South Korea.							Aburatani H, 1997, CANCER RES, V57, P2151; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; CALABRESI P, 1991, GOODMAN GILMANS PHAR, P1227; CARMICHAEL J, 1987, CANCER RES, V47, P936; Chevillard S, 1998, ONCOGENE, V16, P3083, DOI 10.1038/sj.onc.1202096; Choi JY, 1999, FREE RADICAL BIO MED, V27, P848, DOI 10.1016/S0891-5849(99)00141-0; CHUNG MH, 1991, BIOCHEM BIOPH RES CO, V178, P1472, DOI 10.1016/0006-291X(91)91059-L; CHUNG MH, 1991, MUTAT RES, V254, P1, DOI 10.1016/0921-8777(91)90035-N; Dherin C, 1999, NUCLEIC ACIDS RES, V27, P4001, DOI 10.1093/nar/27.20.4001; HAYAKAWA H, 1995, BIOCHEMISTRY-US, V34, P89, DOI 10.1021/bi00001a011; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; Kim HS, 1996, MUTAT RES-DNA REPAIR, V363, P115, DOI 10.1016/0921-8777(96)00006-7; Kohno T, 1998, ONCOGENE, V16, P3219, DOI 10.1038/sj.onc.1201872; LEE YS, 1993, BIOCHEM BIOPH RES CO, V196, P1545, DOI 10.1006/bbrc.1993.2427; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Shinmura K, 1998, JPN J CANCER RES, V89, P825, DOI 10.1111/j.1349-7006.1998.tb00635.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TU CPD, 1980, GENE, V10, P177, DOI 10.1016/0378-1119(80)90135-3; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; YAMAMOTO F, 1992, JPN J CANCER RES, V83, P351, DOI 10.1111/j.1349-7006.1992.tb00114.x	25	50	52	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4476	4479		10.1038/sj.onc.1203787	http://dx.doi.org/10.1038/sj.onc.1203787			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002420	Green Published			2022-12-25	WOS:000089236800004
J	Quick, M; Loo, DDF; Wright, EM				Quick, M; Loo, DDF; Wright, EM			Neutralization of a conserved amino acid residue in the human Na+/glucose transporter (hSGLT1) generates a glucose-gated H+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; COTRANSPORTER SGLT1; NA+/PROLINE TRANSPORTER; ELECTROGENIC PROPERTIES; MEMBRANE TOPOLOGY; LACTOSE PERMEASE; PLASMA-MEMBRANE; SUGAR-TRANSPORT; NA+; BINDING	The role of conserved Asp(204) in the human high affinity Na+/glucose cotransporter (hSGLT1) was investigated by site-directed mutagenesis combined with functional assays exploiting the Xenopus oocyte expression system. Substitution of H+ for Na+ reduces the apparent affinity of hSGLT1 for glucose from 0.3 to 6 mM. The apparent affinity for H+ (7 muM) is about three orders of magnitude higher than for Na+ (6 mM). Cation/glucose cotransport exhibits a coupling ratio of 2 Na+ (or 2 H+):1. Pre-steady-state kinetics indicate that similar Na+- or H+-induced conformational changes are the basis for coupled transport. Replacing Asp204 with Glu increases the apparent affinity for H+ by >20-fold with little impact on the apparent Na+ affinity. This implies that the length of the carboxylate side chain is critical for cation selectivity. Neutralization of (Asp204 Asp --> Asn or Cys) reveals glucose evoked H+ currents that were one order of magnitude greater than Na+ currents. These phlorizin-sensitive H+ currents reverse and are enhanced by internal acidification of oocytes. Together with a H+ to sugar stoichiometry as high as 145:1, these results favor a glucose-gated H+ channel activity of the mutant. Our observations support the idea that cotransporters and channels share common features.	Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Quick, M (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.				NIDDK NIH HHS [DK19567] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019567] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ambroise Y, 2000, BIOCHEMISTRY-US, V39, P1338, DOI 10.1021/bi9916224; Chen XZ, 1997, BIOPHYS J, V73, P2503, DOI 10.1016/S0006-3495(97)78278-X; Chen XZ, 1995, BIOPHYS J, V69, P2405, DOI 10.1016/S0006-3495(95)80110-4; Cordat E, 2000, BIOCHEMISTRY-US, V39, P4493, DOI 10.1021/bi991852i; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P3139, DOI 10.1021/bi00063a028; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; Hazama A, 1997, J MEMBRANE BIOL, V155, P175, DOI 10.1007/s002329900169; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; Hirayama BA, 1996, AM J PHYSIOL-GASTR L, V270, pG919, DOI 10.1152/ajpgi.1996.270.6.G919; Hirayama BA, 1997, J BIOL CHEM, V272, P2110; HIRAYAMA BA, 1994, J BIOL CHEM, V269, P21407; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IKEDA TS, 1989, J MEMBRANE BIOL, V110, P87, DOI 10.1007/BF01870995; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; Lam JT, 1999, BBA-MOL BASIS DIS, V1453, P297, DOI 10.1016/S0925-4439(98)00109-4; LEE JI, 1992, J BIOL CHEM, V267, P20758; Loo DDF, 1998, P NATL ACAD SCI USA, V95, P7789, DOI 10.1073/pnas.95.13.7789; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Loo DDF, 1999, J PHYSIOL-LONDON, V518, P195, DOI 10.1111/j.1469-7793.1999.0195r.x; Lostao MP, 1995, FEBS LETT, V377, P181, DOI 10.1016/0014-5793(95)01339-3; Mackenzie B, 1998, J MEMBRANE BIOL, V162, P101, DOI 10.1007/s002329900347; PanayotovaHeiermann M, 1997, J BIOL CHEM, V272, P20324, DOI 10.1074/jbc.272.33.20324; PanayotovaHeiermann M, 1996, J BIOL CHEM, V271, P10029, DOI 10.1074/jbc.271.17.10029; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; Quick M, 1998, BIOCHEMISTRY-US, V37, P13800, DOI 10.1021/bi980562j; Quick M, 1999, BIOCHEMISTRY-US, V38, P13523, DOI 10.1021/bi991256o; Quick M, 1997, BIOCHEMISTRY-US, V36, P4631, DOI 10.1021/bi963063w; REIZER J, 1994, BBA-REV BIOMEMBRANES, V1197, P133, DOI 10.1016/0304-4157(94)90003-5; SAHINTOTH M, 1993, BIOCHEMISTRY-US, V32, P10027, DOI 10.1021/bi00089a019; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Wright EM, 1996, CURR OPIN CELL BIOL, V8, P468, DOI 10.1016/S0955-0674(96)80022-6; WRIGHT EM, 1994, J EXP BIOL, V196, P197; Zampighi GA, 1999, J GEN PHYSIOL, V113, P507, DOI 10.1085/jgp.113.4.507	40	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1728	1734		10.1074/jbc.M005521200	http://dx.doi.org/10.1074/jbc.M005521200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11024018	hybrid			2022-12-25	WOS:000166528000012
J	Giannoni, F; Muller, HM; Vizioli, J; Catteruccia, F; Kafatos, FC; Crisanti, A				Giannoni, F; Muller, HM; Vizioli, J; Catteruccia, F; Kafatos, FC; Crisanti, A			Nuclear factors bind to a conserved DNA element that modulates transcription of Anopheles gambiae trypsin genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER; BLOOD MEAL; PROTEIN; GUT; EXPRESSION; GATA-1; CELLS; CLONING; FAMILY; HEART	The Anopheles gambiae trypsin family consists of seven genes that are transcribed in the gut of female mosquitoes in a temporal coordinated and mutually exclusive manner, suggesting the involvement of a complex transcription regulatory mechanism. We identified a highly conserved 12-nucleotide motif present in all A. gambiae and Anopheles stephensi trypsin promoters. We investigated the role of this putative trypsin regulatory element (PTRE) in controlling the transcription of the trypsin genes. Gel shift experiments demonstrated that nuclear proteins of A. gambiae cell lines formed two distinct complexes with probes encompassing the PTRE sequence. Mapping of the binding sites revealed that one of the complex has the specificity of a GATA transcription factor. Promoter constructs containing mutations in the PTRE sequence that selectively abolished the binding of either one or both complexes exerted opposite effects on the transcriptional activity of trypsin promoters in A. gambiae and Aedes aegypti cell lines. In addition, the expression of a novel GATA gene was highly enriched in A. gambiae guts. Taken together our data prove that factors binding to the PTRE region are key regulatory elements possibly involved in the blood meal-induced repression and activation of transcription in early and late trypsin genes.	Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 9AX, England; Univ Rome La Sapienza, Ist Parassitol, I-00185 Rome, Italy; European Mol Biol Lab, D-69117 Heidelberg, Germany	Imperial College London; Sapienza University Rome; European Molecular Biology Laboratory (EMBL)	Crisanti, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol, Imperial Coll Rd, London SW7 9AX, England.		Giannoni, Federico/A-6577-2013	Giannoni, Federico/0000-0001-5521-512X; Muller, Hans-Michael/0000-0002-2384-7285; Crisanti, Andrea/0000-0002-2406-4426; vizioli, jacopo/0000-0002-4310-8033; Catteruccia, Flaminia/0000-0003-3295-6683				AUSUBEL FM, 1992, SHORT MOL BIOL; BARILLASMURY C, 1994, INSECT BIOCHEM MOLEC, V25, P241; BILLINGSLEY PF, 1991, J MED ENTOMOL, V28, P865, DOI 10.1093/jmedent/28.6.865; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Catteruccia F, 2000, NATURE, V405, P959, DOI 10.1038/35016096; DREVET JR, 1994, J BIOL CHEM, V269, P10660; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; HOLMES DS, 1973, BIOCHEMISTRY-US, V12, P2330, DOI 10.1021/bi00736a023; Huggon IC, 1997, BBA-GENE STRUCT EXPR, V1353, P98, DOI 10.1016/S0167-4781(97)00049-3; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; Muller H.M., 1993, Parassitologia (Rome), V35, P73; Muller HM, 1995, EXP PARASITOL, V81, P371, DOI 10.1006/expr.1995.1128; Muller HM, 1999, J BIOL CHEM, V274, P11727, DOI 10.1074/jbc.274.17.11727; MULLER HM, 1993, EMBO J, V12, P2891, DOI 10.1002/j.1460-2075.1993.tb05951.x; ORKIN SH, 1992, BLOOD, V80, P575; RAICH N, 1995, EMBO J, V14, P801, DOI 10.1002/j.1460-2075.1995.tb07058.x; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; REITMAN M, 1988, P NATL ACAD SCI USA, V85, P6267, DOI 10.1073/pnas.85.17.6267; Seshasayee D, 1998, MOL CELL BIOL, V18, P3278, DOI 10.1128/MCB.18.6.3278; Shen ZC, 1998, INSECT BIOCHEM MOLEC, V28, P1007, DOI 10.1016/S0965-1748(98)00089-7; SKAVDIS G, 1996, EMBO J, V15, P334; SPIETH J, 1991, MOL CELL BIOL, V11, P4651, DOI 10.1128/MCB.11.9.4651; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089	27	25	25	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					700	707		10.1074/jbc.M005540200	http://dx.doi.org/10.1074/jbc.M005540200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11016929	hybrid			2022-12-25	WOS:000166280700094
J	Chen, Z; Otto, JC; Bergo, MO; Young, SG; Casey, PJ				Chen, Z; Otto, JC; Bergo, MO; Young, SG; Casey, PJ			The C-terminal polylysine region and methylation of K-Ras are critical for the interaction between K-Ras and microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL METHYLTRANSFERASE; ACTIVATE RAF-1; GAMMA-SUBUNIT; CAAX MOTIF; A-FACTOR; PROTEIN; GENE; APOPTOSIS; FARNESYL; P21RAS	After synthesis in the cytosol, Res proteins must be targeted to the inner leaflet of the plasma membrane for biological activity. This targeting requires a series of C-terminal posttranslational modifications initiated by the addition of an isoprenoid lipid in a process termed prenylation. A search for factors involved in the intracellular trafficking of Res has identified a specific and prenylation-dependent interaction between tubulin/microtubules and K-Ras, In this study, we examined the structural requirements for this interaction between K-Ras and microtubules. By using a series of chimeras in which regions of the C terminus of K-Ras were replaced with those of Ha-Ras and vice versa, we found that the polylysine region of K-Ras located immediately upstream of the prenylation site is required for binding of K-Ras to microtubules. Studies in intact cells confirmed the importance of the K-Ras polylysine region for microtubule binding, as deletion or replacement of this region resulted in loss of paclitaxel-induced mislocalization of a fluorescent K-Ras fusion protein. The additional modifications in the prenyl protein processing pathway also affected the interaction of K-Ras with microtubules. Removal of the three C-terminal amino acids of farnesylated K-Ras with the specific endoprotease Rce1p abolished its binding to microtubules. Interestingly, however, methylation of the C-terminal prenylcysteine restored binding. Consistent with these results, localization of the fluorescent K-Ras fusion protein remained paclitaxel-sensitive in cells lacking Reel, whereas no paclitaxel effect was observed in cells lacking the methyltransferase, These studies show that the polylysine region of K-Ras is critical for its interaction with microtubules and provide the first evidence for a functional consequence of Ras C-terminal proteolysis and methylation.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA	Duke University; Duke University; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Casey, PJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	casey006@mc.duke.edu		Casey, Patrick/0000-0002-7366-9309; Young, Stephen/0000-0001-7270-3176	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015451] Funding Source: NIH RePORTER; NIA NIH HHS [AG15451] Funding Source: Medline; NIGMS NIH HHS [GM46372] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Ashby MN, 1998, CURR OPIN LIPIDOL, V9, P99, DOI 10.1097/00041433-199804000-00004; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; Blagosklonny MV, 1996, CANCER RES, V56, P1851; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; FISCHER TH, 1994, J BIOL CHEM, V269, P17257; FUKADA Y, 1994, J BIOL CHEM, V269, P5163; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; Moasser MM, 1998, P NATL ACAD SCI USA, V95, P1369, DOI 10.1073/pnas.95.4.1369; Otto JC, 1999, J BIOL CHEM, V274, P8379, DOI 10.1074/jbc.274.13.8379; PARISH CA, 1995, BIOCHEMISTRY-US, V34, P7722, DOI 10.1021/bi00023a019; Rando RR, 1996, BBA-LIPID LIPID MET, V1300, P5, DOI 10.1016/0005-2760(95)00233-2; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; Thissen JA, 1996, ANAL BIOCHEM, V243, P80, DOI 10.1006/abio.1996.0484; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; THISSEN JA, 1993, J BIOL CHEM, V268, P13780; TORTI M, 1993, P NATL ACAD SCI USA, V90, P7553, DOI 10.1073/pnas.90.16.7553; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Yu DH, 1996, ONCOGENE, V13, P1359; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	41	73	75	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41251	41257		10.1074/jbc.M006687200	http://dx.doi.org/10.1074/jbc.M006687200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007785	hybrid			2022-12-25	WOS:000166114600079
J	Grimm, C; Maser, E; Mobus, E; Klebe, G; Reuter, K; Ficner, R				Grimm, C; Maser, E; Mobus, E; Klebe, G; Reuter, K; Ficner, R			The crystal structure of 3 alpha-hydroxysteroid dehydrogenase/carbonyl reductase from Comamonas testosteroni shows a novel oligomerization pattern within the short chain dehydrogenase/reductase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA ALCOHOL-DEHYDROGENASE; PROTEIN-STRUCTURE COMPARISONS; LUNG CARBONYL REDUCTASE; 3-ALPHA,20-BETA-HYDROXYSTEROID DEHYDROGENASE; 3-DIMENSIONAL STRUCTURE; COENZYME SPECIFICITY; ANGSTROM RESOLUTION; GENETIC ALGORITHM; CDNA CLONING; MEMBER	The crystal structure of 3 alpha -hydroxysteroid dehydrogenase/carbonyl reductase from Comamonas testosteroni (3 alpha -HSDH) as well as the structure of its binary complex with NAD(+) have been solved at 1.68-Angstrom and com 1.95-Angstrom resolution, respectively. The enzyme is a member of the short chain dehydrogenase/reductase (SDR) family. Accordingly, the active center and the conformation of the bound nucleotide cofactor closely resemble those of other SDRs. The crystal structure reveals one homodimer per asymmetric unit representing the physiologically active unity. Dimerization takes place via an interface essentially built-up by helix alphaG and strand betaG of each subunit. So far this type of intermolecular contact has exclusively been observed in homotetrameric SDRs but never in the structure of a homodimeric SDR. The formation of a tetramer is blocked in 3 alpha -HSDH by the presence of a predominantly alpha -helical subdomain which is missing in all other SDRs of known structure.	Univ Marburg, Inst Molekularbiol & Tumorforsch, D-35037 Marburg, Germany; Univ Marburg, Inst Pharmazeut Chem, D-35032 Marburg, Germany; Univ Marburg, Inst Pharmakol & Toxikol, D-35032 Marburg, Germany	Philipps University Marburg; Philipps University Marburg; Philipps University Marburg	Reuter, K (corresponding author), Univ Marburg, Inst Molekularbiol & Tumorforsch, D-35037 Marburg, Germany.		Maser, Edmund/B-1728-2010	Reuter, Klaus/0000-0003-3673-7971				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Auerbach G, 1997, EMBO J, V16, P7219, DOI 10.1093/emboj/16.24.7219; Benach J, 1998, J MOL BIOL, V282, P383, DOI 10.1006/jmbi.1998.2015; Benach J, 1999, J MOL BIOL, V289, P335, DOI 10.1006/jmbi.1999.2765; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chai XY, 1997, J BIOL CHEM, V272, P33125, DOI 10.1074/jbc.272.52.33125; GHOSH D, 1994, STRUCTURE, V2, P973, DOI 10.1016/S0969-2126(94)00099-9; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; GHOSH D, 1994, STRUCTURE, V2, P629, DOI 10.1016/S0969-2126(00)00064-2; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KROOK M, 1993, FEBS LETT, V322, P139, DOI 10.1016/0014-5793(93)81554-D; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Maser E, 2000, BIOCHEM BIOPH RES CO, V272, P622, DOI 10.1006/bbrc.2000.2813; MAY ACW, 1994, PROTEIN ENG, V7, P475, DOI 10.1093/protein/7.4.475; May ACW, 1995, PROTEIN ENG, V8, P873, DOI 10.1093/protein/8.9.873; Mobus E, 1998, J BIOL CHEM, V273, P30888, DOI 10.1074/jbc.273.47.30888; Mobus E, 1997, J BACTERIOL, V179, P5951; Nakajima K, 1998, P NATL ACAD SCI USA, V95, P4876, DOI 10.1073/pnas.95.9.4876; Nakanishi M, 1997, J BIOL CHEM, V272, P2218, DOI 10.1074/jbc.272.4.2218; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Oppermann UCT, 1996, J STEROID BIOCHEM, V58, P217, DOI 10.1016/0960-0760(96)00021-0; Oppermann UCT, 1996, EUR J BIOCHEM, V241, P744, DOI 10.1111/j.1432-1033.1996.00744.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; Somers WS, 1998, STRUCTURE, V6, P1601, DOI 10.1016/S0969-2126(98)00157-9; Su J, 1998, J BIOL CHEM, V273, P17910, DOI 10.1074/jbc.273.28.17910; TALALAY P, 1952, NATURE, V170, P620, DOI 10.1038/170620a0; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; VARUGHESE KI, 1992, P NATL ACAD SCI USA, V89, P6080, DOI 10.1073/pnas.89.13.6080; WILLEMS A, 1992, PROCARYOTES HDB BIOL, P2583; Winberg JO, 1999, J MOL BIOL, V294, P601, DOI 10.1006/jmbi.1999.3235	35	81	83	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41333	41339		10.1074/jbc.M007559200	http://dx.doi.org/10.1074/jbc.M007559200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007791	hybrid			2022-12-25	WOS:000166114600089
J	Ha, NC; Kim, MS; Lee, WT; Choi, KY; Oh, BH				Ha, NC; Kim, MS; Lee, WT; Choi, KY; Oh, BH			Detection of large pK(alpha) perturbations of an inhibitor and a catalytic group at an enzyme active site, a mechanistic basis for catalytic power of many enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARRIER HYDROGEN-BONDS; DELTA(5)-3-KETOSTEROID ISOMERASE; DELTA-5-3-KETOSTEROID ISOMERASE; CARBON ACIDS; 3-OXO-DELTA(5)-STEROID ISOMERASE; PSEUDOMONAS-TESTOSTERONI; ELECTROPHILIC CATALYSIS; SPECTROSCOPIC EVIDENCE; FRACTIONATION FACTORS; DIRECTED MUTAGENESIS	Delta (5)-3-Ketosteroid isomerase catalyzes cleavage and formation of a C-H bond at a diffusion-controlled limit. By determining the crystal structures of the enzyme in complex with each of three different inhibitors and by nuclear magnetic resonance (NMR) spectroscopic investigation, we evidenced the ionization of a hydroxyl group (pK(a) similar to 16.5) of an inhibitor, which forms a low barrier hydrogen bond (LBHB) with a catalytic residue Tyr(14) (pK(a) similar to 11.5), and the protonation of the catalytic residue Asp(38) With pK(a) of similar to4.5 at pH 6.7 in the interaction with a carboxylate group of an inhibitor. The perturbation of the pK(a) values in both cases arises from the formation of favorable interactions between inhibitors and catalytic residues. The results indicate that the pK(a) difference between catalytic residue and substrate can be significantly:reduced in the active site environment as:a result of the formation of energetically favorable interactions during the course of enzyme reactions. The reduction in the pK(a) difference should facilitate the abstraction of a proton and thereby eliminate a large fraction of activation energy in general acid/base enzyme reactions. The pK(a) perturbation provides a mechanistic ground for the fast reactivity of many enzymes and for the understanding of how some enzymes are able to extract a proton from a C-H group with a pK(a) value as high as similar to 30.	Pohang Univ Sci & Technol, Natl Creat Res Iniat Ctr Biomol Recognit, Dept Life Sci, Pohang 790784, Kyungbuk, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, Kyungbuk, South Korea; Yonsei Univ, Dept Biochem, Coll Sci, Seoul 120749, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Yonsei University	Oh, BH (corresponding author), Pohang Univ Sci & Technol, Natl Creat Res Iniat Ctr Biomol Recognit, Dept Life Sci, Pohang 790784, Kyungbuk, South Korea.		Oh, Byung-Ha/C-2061-2011; LEE, WEON TAE/AAQ-9088-2021					Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Cannon WR, 1998, J BIOL CHEM, V273, P26257, DOI 10.1074/jbc.273.41.26257; Cho HS, 1998, BIOCHEMISTRY-US, V37, P8325, DOI 10.1021/bi9801614; Cho HS, 1999, J BIOL CHEM, V274, P32863, DOI 10.1074/jbc.274.46.32863; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; Cleland WW, 1998, J BIOL CHEM, V273, P25529, DOI 10.1074/jbc.273.40.25529; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; GALLO KA, 1993, BIOCHEMISTRY-US, V32, P3991, DOI 10.1021/bi00066a020; GERLT JA, 1991, J AM CHEM SOC, V113, P9667, DOI 10.1021/ja00025a039; GERLT JA, 1993, J AM CHEM SOC, V115, P11552, DOI 10.1021/ja00077a062; GERLT JA, 1992, J AM CHEM SOC, V114, P5928, DOI 10.1021/ja00041a004; HAWKINSON DC, 1994, BIOCHEMISTRY-US, V33, P12172, DOI 10.1021/bi00206a021; HOLMAN CM, 1995, BIOCHEMISTRY-US, V34, P14245, DOI 10.1021/bi00043a032; Hwang KY, 1999, NAT STRUCT BIOL, V6, P422; Kim DH, 2000, BIOCHEMISTRY-US, V39, P4581, DOI 10.1021/bi992119u; KIM SW, 1995, J BACTERIOL, V177, P2602, DOI 10.1128/jb.177.9.2602-2605.1995; Kim SW, 1997, BIOCHEMISTRY-US, V36, P14030, DOI 10.1021/bi971546+; KINTANAR A, 1991, J BIOL CHEM, V266, P17222; LI YK, 1993, BIOCHEMISTRY-US, V32, P1816, DOI 10.1021/bi00058a016; Lin J, 1998, P NATL ACAD SCI USA, V95, P14664, DOI 10.1073/pnas.95.25.14664; LOH SN, 1994, BIOCHEMISTRY-US, V33, P1029, DOI 10.1021/bi00170a023; MAITLAND JJ, 1997, ORGANIC CHEM, P824; MITRA B, 1995, BIOCHEMISTRY-US, V34, P2777, DOI 10.1021/bi00009a006; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; Schiott B, 1998, P NATL ACAD SCI USA, V95, P12799, DOI 10.1073/pnas.95.22.12799; TALALAY P, 1955, BIOCHIM BIOPHYS ACTA, V18, P300, DOI 10.1016/0006-3002(55)90079-2; WALSH C, 1984, ENZYMATIC REACTION M; Wu ZR, 1997, SCIENCE, V276, P415, DOI 10.1126/science.276.5311.415; XUE L, 1991, BIOCHEMISTRY-US, V30, P10858, DOI 10.1021/bi00109a008; XUE L, 1991, BIOCHEMISTRY-US, V30, P4991, DOI 10.1021/bi00234a022; ZHAO QJ, 1995, BIOCHEMISTRY-US, V34, P426, DOI 10.1021/bi00002a006; Zhao QJ, 1996, P NATL ACAD SCI USA, V93, P8220, DOI 10.1073/pnas.93.16.8220; ZHAO QJ, 1995, BIOCHEMISTRY-US, V34, P6562, DOI 10.1021/bi00019a038	34	50	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41100	41106		10.1074/jbc.M007561200	http://dx.doi.org/10.1074/jbc.M007561200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007792	hybrid			2022-12-25	WOS:000166114600060
J	Negulyaev, YA; Khaitlina, SY; Hinssen, H; Shumilina, EV; Vedernikova, EA				Negulyaev, YA; Khaitlina, SY; Hinssen, H; Shumilina, EV; Vedernikova, EA			Sodium channel activity in leukemia cells is directly controlled by actin polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND DIVALENT-CATION; COLI A2 STRAIN; SELECTIVE CHANNELS; MEMBRANE PATCHES; NA+ CHANNELS; CYTOSKELETON; FILAMENTS; MUSCLE; LINE	The actin cytoskeleton has been shown to be involved in the regulation of sodium-selective channels in nonexcitable cells. However, the molecular mechanisms underlying the changes in channel function remain to be defined. In the present work, inside-out patch experiments were employed to elucidate the role of submembranous actin dynamics in the control of sodium channels in human myeloid leukemia K562 cells. We found that the application of cytochalasin D to the cytoplasmic surface of membrane fragments resulted in activation of non-voltage-gated sodium channels of 12 picosiemens conductance. Similar effects could be evoked by addition of the actin-severing protein gelsolin to the bath cytosol-like solution containing 1 muM [Ca2+](i). The sodium channel activity induced by disassembly of submembranous microfilaments with cytochalasin D or gelsolin could be abolished by intact actin added to the bath cytosol-like solution in the presence of 1 mM MgCl2, to induce actin polymerization, In the absence of MgCl2, addition of intact actin did not abolish the channel activity. Moreover, the sodium currents were unaffected by heat-inactivated actin or by actin whose polymerizability was strongly reduced by cleavage with specific Escherichia coli A2 protease ECP32, Thus, the inhibitory effect of actin on channel activity was observed only under conditions promoting rapid polymerization. Taken together, our data show that sodium channels are directly controlled by dynamic assembly and disassembly of submembranous F-actin.	Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia; Univ Bielefeld, Dept Biochem Cell Biol, D-33501 Bielefeld, Germany	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS; University of Bielefeld	Vedernikova, EA (corresponding author), Russian Acad Sci, Inst Cytol, 4 Tikhoretsky Ave, St Petersburg 194064, Russia.		Negulyaev, Yuri/N-6531-2015	Negulyaev, Yuri/0000-0002-1773-9798				BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; Berdiev BK, 1996, J BIOL CHEM, V271, P17704, DOI 10.1074/jbc.271.30.17704; CANTIELLO HF, 1991, AM J PHYSIOL, V261, P882; ESTES JE, 1992, J MUSCLE RES CELL M, V13, P272, DOI 10.1007/BF01766455; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B., 1992, IONIC CHANNELS EXCIT; HINSSEN H, 1984, FEBS LETT, V166, P90, DOI 10.1016/0014-5793(84)80051-4; HORBER JKH, 1995, BIOPHYS J, V68, P1687, DOI 10.1016/S0006-3495(95)80346-2; HUCKRIEDE A, 1988, EUR J CELL BIOL, V46, P506; HUCKRIEDE A, 1990, CELL MOTIL CYTOSKEL, V16, P229, DOI 10.1002/cm.970160403; Jovov B, 1999, J BIOL CHEM, V274, P37845, DOI 10.1074/jbc.274.53.37845; KHAITLINA SY, 1993, EUR J BIOCHEM, V218, P911, DOI 10.1111/j.1432-1033.1993.tb18447.x; KHAITLINA SY, 1991, FEBS LETT, V279, P49, DOI 10.1016/0014-5793(91)80247-Z; Littlefield R, 1998, ANNU REV CELL DEV BI, V14, P487, DOI 10.1146/annurev.cellbio.14.1.487; Matveyev VV, 1996, BBA-PROTEIN STRUCT M, V1296, P55, DOI 10.1016/0167-4838(96)00053-2; Maximov AV, 1997, FEBS LETT, V412, P94, DOI 10.1016/S0014-5793(97)00754-0; Negulyaev YA, 1996, MOL BIOL CELL, V7, P1857, DOI 10.1091/mbc.7.12.1857; NEGULYAEV YA, 1994, BBA-BIOMEMBRANES, V1194, P171, DOI 10.1016/0005-2736(94)90217-8; Negulyaev YA, 1997, GEN PHYSIOL BIOPHYS, V16, P163; NEGULYAEV YA, 1994, J MEMBRANE BIOL, V138, P37; Parekh AB, 1996, J BIOL CHEM, V271, P23161, DOI 10.1074/jbc.271.38.23161; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; RUKNUDIN A, 1991, J CELL BIOL, V112, P125, DOI 10.1083/jcb.112.1.125; SCHWIEBERT EM, 1994, J BIOL CHEM, V269, P7081; SELDEN LA, 1983, BIOCHEM BIOPH RES CO, V116, P478, DOI 10.1016/0006-291X(83)90548-X; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TUROVEROV KK, 1976, FEBS LETT, V62, P4, DOI 10.1016/0014-5793(76)80003-8; VANRENTERGHEM C, 1991, PFLUG ARCH EUR J PHY, V419, P401, DOI 10.1007/BF00371123	30	29	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40933	40937		10.1074/jbc.M008219200	http://dx.doi.org/10.1074/jbc.M008219200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11016945	hybrid			2022-12-25	WOS:000166114600037
J	Abdian, PL; Lellouch, AC; Gautier, C; Ielpi, L; Geremia, RA				Abdian, PL; Lellouch, AC; Gautier, C; Ielpi, L; Geremia, RA			Identification of essential amino acids in the bacterial alpha-mannosyltransferase AceA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; XANTHOMONAS-CAMPESTRIS; BETA-GLUCOSYLTRANSFERASE; SEQUENCE SIMILARITIES; SUBSTRATE-BINDING; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; GLYCOSYLTRANSFERASES; BIOSYNTHESIS; MECHANISM	The alpha -mannosyltransferase AceA from Acetobacter xylinum belongs to the CaZY family 4 of retaining glycosyltransferases. We have identified a series of either highly conserved or invariant residues that are found in all family 4 enzymes as well as other retaining glycosyltransferases. These residues included Glu-287 and Glu-295, which comprise an EX7E motif and have been proposed to be involved in catalysis. Alanine replacements of each conserved residue were constructed by site-directed mutagenesis, The mannosyltransferase activity of each mutant was examined by both an in vitro transferase assay using recombinant mutant AceA expressed in Escherichia coli and by an in vivo rescue assay by expressing the mutant AceA in a Xanthomonas campestris gumH(-) strain. We found that only mutants K211A and E287A lost all detectable activity both in vitro and in vivo, whereas E295A retained residual activity in the more sensitive in vivo assay. H127A and S162A each retained reduced but significant activities both in vitro and in vivo. Secondary structure predictions of AceA and subsequent comparison with the crystal structures of the T4 beta -glucosyltransferase and MurG suggest that AceA Lys-211 and Glu-295 are involved in nucleotide sugar donor binding, leaving Glu-287 of the EX7E as a potential catalytic residue.	Univ Grenoble 1, CNRS, CERMA, Ctr Rech Macromol Vegetales, F-38041 Grenoble 9, France; Fdn Campomar, Inst Invest Bioquim, Fac Ciencias Exactas & Nat, RA-1045 Buenos Aires, DF, Argentina; Consejo Nacl Invest Cient & Tecn, RA-1045 Buenos Aires, DF, Argentina	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Leloir Institute; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Geremia, RA (corresponding author), Univ Grenoble 1, CNRS, CERMA, Ctr Rech Macromol Vegetales, BP 53, F-38041 Grenoble 9, France.	roberto.geremia@cermav.cnrs.fr	Abdian, Patricia/AAW-2420-2020; Geremia, Roberto A/A-7972-2010; Lellouch, Annemarie/E-9905-2014	Abdian, Patricia/0000-0002-8366-8115; 				AMEMURA A, 1986, J GEN MICROBIOL, V132, P2443; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Campbell JA, 1998, BIOCHEM J, V329, P719, DOI 10.1042/bj3290719; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; CAPAGE MA, 1987, Patent No. 8705938; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; Cid E, 2000, J BIOL CHEM, V275, P33614, DOI 10.1074/jbc.M005358200; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; FILISETTICOZZI TMCC, 1991, ANAL BIOCHEM, V197, P157, DOI 10.1016/0003-2697(91)90372-Z; Garinot-Schneider C, 2000, J BIOL CHEM, V275, P31407, DOI 10.1074/jbc.M004524200; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Geremia RA, 1999, MOL GEN GENET, V261, P933, DOI 10.1007/s004380051040; Geremia RA, 1996, BIOCHEM J, V318, P133, DOI 10.1042/bj3180133; Green JA, 1998, METH MOL B, V80, P1; Ha S, 2000, PROTEIN SCI, V9, P1045, DOI 10.1110/ps.9.6.1045; HARDING NE, 1993, J GEN MICROBIOL, V139, P447, DOI 10.1099/00221287-139-3-447; IELPI L, 1993, J BACTERIOL, V175, P2490, DOI 10.1128/JB.175.9.2490-2500.1993; Kapitonov D, 1999, GLYCOBIOLOGY, V9, P961, DOI 10.1093/glycob/9.10.961; Katzen F, 1998, J BACTERIOL, V180, P1607, DOI 10.1128/JB.180.7.1607-1617.1998; LEIGH JA, 1994, TRENDS GENET, V10, P63, DOI 10.1016/0168-9525(94)90151-1; Markwell M A, 1981, Methods Enzymol, V72, P296; Morera S, 1999, J MOL BIOL, V292, P717, DOI 10.1006/jmbi.1999.3094; Nichols DJ, 2000, BIOCHEMISTRY-US, V39, P7820, DOI 10.1021/bi000407g; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Petroni EA, 1996, J BACTERIOL, V178, P4814, DOI 10.1128/jb.178.16.4814-4821.1996; Sambrook J., 2002, MOL CLONING LAB MANU; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; Sippl MJ, 1996, FOLD DES, V1, P289, DOI 10.1016/S1359-0278(96)00042-9; TSENG YH, 1992, LETT APPL MICROBIOL, V14, P43, DOI 10.1111/j.1472-765X.1992.tb00643.x; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; WHITFIELD C, 1993, ADV MICROB PHYSIOL, V35, P135, DOI 10.1016/S0065-2911(08)60099-5; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945	33	48	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40568	40575		10.1074/jbc.M007496200	http://dx.doi.org/10.1074/jbc.M007496200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11001941	Green Published, hybrid			2022-12-25	WOS:000166039500103
J	Bonini, JA; Jones, LK; Adham, N; Forray, C; Artymyshyn, R; Durkin, MM; Smith, KE; Tamm, JA; Boteju, LW; Lakhlani, PP; Raddatz, R; Yao, WJ; Ogozalek, KL; Boyle, N; Kouranova, EV; Quan, Y; Vaysse, PJ; Wetzel, JM; Branchek, TA; Gerald, C; Borowsky, B				Bonini, JA; Jones, LK; Adham, N; Forray, C; Artymyshyn, R; Durkin, MM; Smith, KE; Tamm, JA; Boteju, LW; Lakhlani, PP; Raddatz, R; Yao, WJ; Ogozalek, KL; Boyle, N; Kouranova, EV; Quan, Y; Vaysse, PJ; Wetzel, JM; Branchek, TA; Gerald, C; Borowsky, B			Identification and characterization of two G protein-coupled receptors for neuropeptide FF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SPINAL-CORD; MORPHINE-MODULATING PEPTIDE; PANCREATIC-POLYPEPTIDE; OPIOID RECEPTORS; ANALOGS; IMMUNOREACTIVITY; FLFQPQRFAMIDE; INHIBITION; BINDING; CLONING	The central nervous system octapeptide, neuropeptide FF (NPFF), is believed to play a role in pain modulation and opiate tolerance. Two G protein-coupled receptors, NPFF1 and NPFF2, were isolated from human and rat central nervous system tissues. NPFF specifically bound to NPFF1 (K-d = 1.13 nm) and NPFF2 (K-d = 0.37 nm), and both receptors were activated by NPFF in a variety of heterologous expression systems. The localization of mRNA and binding sites of these receptors in the dorsal horn of the spinal cord, the lateral hypothalamus, the spinal trigeminal nuclei, and the thalamic nuclei supports a role for NPFF in pain modulation. Among the receptors with the highest amino acid sequence homology to NPFF1 and NPFF2 are members of the orexin, NPY, and cholecystokinin families, which have been implicated in feeding. These similarities together with the finding that BIBP3226, an anorexigenic Y1 receptor ligand, also binds to NPFF1 suggest a potential role for NPFF1 in feeding. The identification of NPFF1 and NPFF2 will help delineate their roles in these and other physiological functions.	Synapt Pharmaceut Corp, Paramus, NJ 07652 USA		Bonini, JA (corresponding author), Synapt Pharmaceut Corp, 215 Coll Rd, Paramus, NJ 07652 USA.		Adham, Nika/N-4376-2017	Adham, Nika/0000-0002-2773-2522				ALLARD M, 1992, NEUROSCIENCE, V49, P101, DOI 10.1016/0306-4522(92)90078-G; ALLARD M, 1989, BRAIN RES, V500, P169, DOI 10.1016/0006-8993(89)90311-9; Askwith CC, 2000, NEURON, V26, P133, DOI 10.1016/S0896-6273(00)81144-7; BOEL E, 1984, EMBO J, V3, P909, DOI 10.1002/j.1460-2075.1984.tb01904.x; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cikos S, 1999, BIOCHEM BIOPH RES CO, V256, P352, DOI 10.1006/bbrc.1999.0332; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Doods HN, 1996, REGUL PEPTIDES, V65, P71, DOI 10.1016/0167-0115(96)00074-2; DUPUY V, 1996, PEPTIDES, V17, P399; DUPUY V, 1996, SYNAPSE, V24, P282; Elshourbagy NA, 2000, J BIOL CHEM, V275, P25965, DOI 10.1074/jbc.M004515200; Gherardi N, 1997, PEPTIDES, V18, P577, DOI 10.1016/S0196-9781(97)00071-5; Gouarderes C, 1998, PEPTIDES, V19, P727, DOI 10.1016/S0196-9781(98)00015-1; Gouarderes C, 1997, BRAIN RES BULL, V42, P231, DOI 10.1016/S0361-9230(96)00261-4; Gouarderes C, 1996, BRIT J PHARMACOL, V117, P493, DOI 10.1111/j.1476-5381.1996.tb15217.x; Hoyle CHV, 1999, BRAIN RES, V848, P1, DOI 10.1016/S0006-8993(99)01975-7; Iyengar S, 1999, J PHARMACOL EXP THER, V289, P1031; KIVIPELTO L, 1991, J COMP NEUROL, V307, P107, DOI 10.1002/cne.903070110; KIVIPELTO L, 1989, J COMP NEUROL, V286, P269, DOI 10.1002/cne.902860211; KOHRI K, 1993, BIOCHIM BIOPHYS ACTA, V1173, P345, DOI 10.1016/0167-4781(93)90136-2; Kontinen VK, 1997, PEPTIDES, V18, P287, DOI 10.1016/S0196-9781(96)00287-2; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; MARCO N, 1995, NEUROSCIENCE, V64, P1035, DOI 10.1016/0306-4522(94)00383-G; Morgan DGA, 1998, REGUL PEPTIDES, V75-6, P377, DOI 10.1016/S0167-0115(98)00091-3; Murase T, 1996, PEPTIDES, V17, P353, DOI 10.1016/0196-9781(95)02137-X; Panula P, 1999, BRAIN RES, V848, P191, DOI 10.1016/S0006-8993(99)02044-2; Panula P, 1996, PROG NEUROBIOL, V48, P461, DOI 10.1016/0301-0082(96)00001-9; PAYZA K, 1993, J NEUROCHEM, V60, P1894, DOI 10.1111/j.1471-4159.1993.tb13417.x; PAYZA K, 1993, J PHARMACOL EXP THER, V267, P88; QUICK MW, 1994, J BIOL CHEM, V269, P30164; Roumy M, 1999, BRAIN RES, V845, P208, DOI 10.1016/S0006-8993(99)01965-4; Roumy M, 1998, EUR J PHARMACOL, V345, P1, DOI 10.1016/S0014-2999(97)01604-X; Smith KE, 1998, J BIOL CHEM, V273, P23321, DOI 10.1074/jbc.273.36.23321; TAKEUCHI T, 1986, J CLIN INVEST, V77, P1038, DOI 10.1172/JCI112357; Tan PPC, 1999, PEPTIDES, V20, P1211, DOI 10.1016/S0196-9781(99)00125-4; TANG J, 1984, P NATL ACAD SCI-BIOL, V81, P5002, DOI 10.1073/pnas.81.15.5002; VILIM ES, 1995, SOC NEUR ABSTR, V21, P760; Vilim FS, 1999, MOL PHARMACOL, V55, P804; Wraith A, 2000, GENOME RES, V10, P302, DOI 10.1101/gr.10.3.302; YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757	40	344	361	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39324	39331		10.1074/jbc.M004385200	http://dx.doi.org/10.1074/jbc.M004385200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11024015	hybrid			2022-12-25	WOS:000165953100054
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			Identification of residues within the drug-binding domain of the human multidrug resistance P-glycoprotein by cysteine-scanning mutagenesis and reaction with dibromobimane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREDICTED TRANSMEMBRANE DOMAIN; STIMULATED ATPASE ACTIVITY; HIV-1 PROTEASE INHIBITORS; BLOOD-BRAIN-BARRIER; FUNCTIONAL CONSEQUENCES; SUBSTRATE-SPECIFICITY; MUTATIONAL ANALYSIS; EXPRESSION SYSTEM; LABELING SITES; TRANSPORTER	P-glycoprotein (P-gp) can transport a wide variety of cytotoxic compounds that have diverse structures. Therefore, the drug-binding domain of the human multidrug resistance P-gp likely consists of residues from multiple transmembrane (TM) segments. In this study, we completed cysteine-scanning mutagenesis of all the predicted TRI segments of P-gp (TMs 1-5 and 7-10) and tested for inhibition by a thiol-reactive substrate (dibromobimane) to identify residues within the drug-binding domain. The activities of 189 mutants were analyzed. Verapamil-stimulated ATPase activities of seven mutants (Y118C and V125C (TM2), S222C (TM4), I306C (TM5), S766C (TM9), and I868C and G872C (TM10)) were inhibited by more than 50% by dibromobimane. The activities of mutants S222C (TM4), I306C (TM5), I868C (TM10), and G872C (TM10), but not that of mutants Y118C (TM2), V125C (TM2), and S776C (TM9), were protected from inhibition by dibromobimane by pretreatment with verapamil, vinblastine, or colchicine. These results and those from previous studies (Loo, T. W, and Clarke, D. M. (1997) J. BioL Chem 272, 31945-31948; Loo, T. W. and Clarke, D. M. (1999) J. Biol Chem 274, 35388-35392) indicate that the drug-binding domain of P-gp consists of residues in TMs 4 5, 6, 10, 11, and 12.	Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Canadian Inst Hlth Res Grp Membrane Biol, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA80900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambudkar SV, 1997, J BIOL CHEM, V272, P21160, DOI 10.1074/jbc.272.34.21160; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BALZI E, 1994, J BIOL CHEM, V269, P2206; BEAUDET L, 1995, J BIOL CHEM, V270, P17159, DOI 10.1074/jbc.270.29.17159; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Chen G, 1997, J BIOL CHEM, V272, P5974, DOI 10.1074/jbc.272.9.5974; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; Demmer A, 1997, J BIOL CHEM, V272, P20913, DOI 10.1074/jbc.272.33.20913; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; Egner R, 1998, MOL BIOL CELL, V9, P523, DOI 10.1091/mbc.9.2.523; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; Hanna M, 1996, BIOCHEMISTRY-US, V35, P3625, DOI 10.1021/bi951333p; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; Kwan T, 1998, BIOCHEMISTRY-US, V37, P3337, DOI 10.1021/bi972680x; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, J BIOL CHEM, V269, P7243; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; Loo TW, 1998, J BIOL CHEM, V273, P32373, DOI 10.1074/jbc.273.49.32373; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1993, J BIOL CHEM, V268, P19965; Loo TW, 1998, METHOD ENZYMOL, V292, P480; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; Pascaud C, 1998, BIOCHEM J, V333, P351, DOI 10.1042/bj3330351; Ramachandra M, 1996, MOL BIOL CELL, V7, P1485, DOI 10.1091/mbc.7.10.1485; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; Robert J, 1999, EUR J CLIN INVEST, V29, P536, DOI 10.1046/j.1365-2362.1999.00495.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schinkel AH, 1997, SEMIN CANCER BIOL, V8, P161, DOI 10.1006/scbi.1997.0068; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Shapiro AB, 1999, EUR J BIOCHEM, V259, P841, DOI 10.1046/j.1432-1327.1999.00098.x; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; Shoshani T, 1998, MOL PHARMACOL, V54, P623; Subramaniam S, 1999, CURR OPIN STRUC BIOL, V9, P462, DOI 10.1016/S0959-440X(99)80065-7; Taguchi Y, 1997, FEBS LETT, V413, P142, DOI 10.1016/S0014-5793(97)00899-5; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6	58	123	124	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39272	39278		10.1074/jbc.M007741200	http://dx.doi.org/10.1074/jbc.M007741200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11013259	hybrid			2022-12-25	WOS:000165953100046
J	Patil, S; Wildey, GM; Brown, TL; Choy, L; Derynck, R; Howe, PH				Patil, S; Wildey, GM; Brown, TL; Choy, L; Derynck, R; Howe, PH			Smad7 is induced by CD40 and protects WEHI 231 B-lymphocytes from transforming growth factor-beta-induced growth inhibition and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TGF-BETA; TRANSCRIPTIONAL ACTIVATION; LYMPHOMA MODELS; CELL ACTIVATION; RECEPTOR; EXPRESSION; ARREST; INDUCTION; TOLERANCE	Transforming growth factor-beta (TGF-beta) is a potent inducer of apoptosis in B-lymphocytes and is essential for immune regulation and maintenance of self-tolerance, Here we show that concomitant signaling through CD40 sustains proliferation and rescues the premature B cell line WEHI 231 from both TGF-beta -induced and anti-IgM-induced apoptosis. The anti-apoptotic effect of CD40 is associated with the transcriptional activation of the inhibitory Smad7 protein. The transactivation of Smad7 by CD40 is NF kappaB-dependent in that pharmacological inhibitors of this pathway, N-tosyl-L-phenylalanine chloromethyl ketone and pyrrolidine dithiocarbamate, abrogate CD40-induced Smad7 expression. Ectopic overexpression of Smad7 inhibited Smad2 activation, TGF-beta -mediated growth inhibition, and apoptosis in WEHI 231 cells. Consistent with this result, dominant negative interference with Smad2 and Smad3 function also inhibited TGF-beta -induced apoptosis. The inhibitory effects of Smad7 overexpression were specific to TGF-beta -induced apoptosis and were without effect on anti-IgM-induced cell death. These results suggest a mechanism of suppression of TGF-beta -induced apoptosis by CD40, mediated through activation of NF-kappaB and, consequently, induction of Smad7 expression.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Univ Calif San Francisco, Dept Growth Dev, Cell Biol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Growth Dev, Program Dev Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Program Dev Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Cell Biol Program, San Francisco, CA 94143 USA	Cleveland Clinic Foundation; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Howe, PH (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	howep@ccf.org		Wildey, Gary/0000-0001-7105-1313	NATIONAL CANCER INSTITUTE [R01CA080095] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060231] Funding Source: NIH RePORTER; NCI NIH HHS [CA80095] Funding Source: Medline; NHLBI NIH HHS [P01HL60231] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; An SK, 1996, FEBS LETT, V386, P115, DOI 10.1016/0014-5793(96)00427-9; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; Bitzer M, 2000, GENE DEV, V14, P187; Brodin G, 1999, CANCER RES, V59, P2731; Brown TL, 1999, J BIOL CHEM, V274, P23256, DOI 10.1074/jbc.274.33.23256; Brown TL, 1998, CELL GROWTH DIFFER, V9, P869; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; Coffer PJ, 1998, BIOCHEM J, V335, P1; Craxton A, 2000, CELL IMMUNOL, V200, P56, DOI 10.1006/cimm.2000.1616; Curnock AP, 1998, CELL IMMUNOL, V187, P77, DOI 10.1006/cimm.1998.1335; FRANCIS DA, 1995, INT IMMUNOL, V7, P151, DOI 10.1093/intimm/7.2.151; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; GOTTSCHALK AR, 1995, IMMUNOL CELL BIOL, V73, P8, DOI 10.1038/icb.1995.2; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Ishisaki A, 1998, J BIOL CHEM, V273, P24293, DOI 10.1074/jbc.273.38.24293; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; JOSEPH LF, 1995, CELL GROWTH DIFFER, V6, P51; Kashiwada M, 1996, EUR J IMMUNOL, V26, P1451, DOI 10.1002/eji.1830260708; Kawabata M, 1999, J BIOCHEM, V125, P9, DOI 10.1093/oxfordjournals.jbchem.a022273; Kehry MR, 1996, J IMMUNOL, V156, P2345; Kuss AW, 1999, EUR J IMMUNOL, V29, P3077, DOI 10.1002/(SICI)1521-4141(199910)29:10<3077::AID-IMMU3077>3.0.CO;2-R; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; Lebman DA, 1999, MICROBES INFECT, V1, P1297, DOI 10.1016/S1286-4579(99)00254-3; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MERINO R, 1995, J IMMUNOL, V155, P3830; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Ozes ON, 1999, NATURE, V401, P82; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; Schauer SL, 1998, J IMMUNOL, V160, P4398; SCOTT DW, 1993, ADV IMMUNOL, V54, P393, DOI 10.1016/S0065-2776(08)60539-8; SCOTT DW, 1986, J EXP MED, V164, P156, DOI 10.1084/jem.164.1.156; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; Sutherland CL, 1996, J IMMUNOL, V157, P3381; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Uzzo RG, 1999, J CLIN INVEST, V104, P769, DOI 10.1172/JCI6775; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; WARNER GL, 1992, CELL GROWTH DIFFER, V3, P175; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wu M, 1998, J EXP MED, V187, P1671, DOI 10.1084/jem.187.10.1671; Wu M, 1996, MOL CELL BIOL, V16, P5015; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	59	72	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38363	38370		10.1074/jbc.M004861200	http://dx.doi.org/10.1074/jbc.M004861200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10995749	hybrid			2022-12-25	WOS:000165739800032
J	Saemann, MD; Bohmig, GA; Osterreicher, CH; Burtscher, H; Parolini, O; Diakos, C; Stockl, J; Horl, WH; Zlabinger, GJ				Saemann, MD; Bohmig, GA; Osterreicher, CH; Burtscher, H; Parolini, O; Diakos, C; Stockl, J; Horl, WH; Zlabinger, GJ			Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production	FASEB JOURNAL			English	Article									Univ Vienna, Inst Immunol, A-1090 Vienna, Austria; Univ Vienna, Dept Internal Med 3, A-1090 Vienna, Austria	University of Vienna; University of Vienna	Zlabinger, GJ (corresponding author), Univ Vienna, Inst Immunol, Borschkegasse 8A, A-1090 Vienna, Austria.		PAROLINI, ORNELLA/C-7946-2013; PAROLINI, ORNELLA/ABI-7862-2020	PAROLINI, ORNELLA/0000-0002-5211-6430; PAROLINI, ORNELLA/0000-0002-5211-6430; Stockl, Johannes/0000-0002-3304-6975; Zlabinger, Gerhard/0000-0002-7478-4173					0	287	303	1	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2380	2382						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11024006				2022-12-25	WOS:000165723400004
J	Kim, JW; Choi, EJ; Joe, CO				Kim, JW; Choi, EJ; Joe, CO			Activation of death-inducing signaling complex (DISC) by pro-apoptotic C-terminal fragment of RIP	ONCOGENE			English	Article						RIP; caspase-8; apoptosis; NF-kappa B activation; I-kappa B kinase	NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; INDUCED CELL-DEATH; DOMAIN KINASE RIP; CONTAINS 2; IKK-ALPHA; PROTEIN; CLEAVAGE; CD95; PHOSPHORYLATION	The two opposite signaling pathways that stimulate NF-kappa B activation and apoptosis are both mediated by tumor necrosis factor receptor 1 (TNFR1) and its cytosolic associated proteins. In this study, we demonstrate that the proteolytic cleavage of receptor interacting protein (RIP) by caspase-8 during TNF-induced apoptosis abrogates the stimulatory role of RIP on TNF-induced NF-kappa B activation. The uncleavable RIPD324A mutant was less apoptotic, but its ability to activate NF-kappa B activation was greater than the wild type counterpart, Ectopic expression of the pro-apoptotic C-terminal fragment of RIP inhibited TNF-induced NF-kappa B activation by suppressing the activity of I-kappa B kinase beta (IKK beta) which phosphorylates I-kappa B, an inhibitor of NF-kappa B, and triggers its ubiquitin-mediated degradation, The C-terminal fragment of RIP also enhanced the association between TNFR1 and death domain proteins including TNFR1 associated death domain (TRADD) and Fas associated death domain (FADD), resulting in the activation of caspase-8 and stimulation of apoptosis, The present study suggest that the C-terminal fragment of RIP produced by caspase-8 activates death-inducing signaling complex (DISC), attenuates NF-kappa B activation, and thereby amplifies the activation of caspase-8 which initiates the downstream apoptotic events.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Korea Univ, Grad Sch Biotechnol, Natl Creat Res Initiat Cell Death, Seoul 156701, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea University	Joe, CO (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.		Joe, Cheol O/C-1917-2011; KIM, JIN WOO/C-1655-2011	KIM, JIN WOO/0000-0003-0767-1918				Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Komoriya A, 2000, J EXP MED, V191, P1819, DOI 10.1084/jem.191.11.1819; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Sun XQ, 1999, J BIOL CHEM, V274, P16871, DOI 10.1074/jbc.274.24.16871; Tamm I, 1998, CANCER RES, V58, P5315; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	39	83	86	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4491	4499		10.1038/sj.onc.1203796	http://dx.doi.org/10.1038/sj.onc.1203796			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002422				2022-12-25	WOS:000089236800006
J	Rytomaa, M; Lehmann, K; Downward, J				Rytomaa, M; Lehmann, K; Downward, J			Matrix detachment induces caspase-dependent cytochrome c release from mitochondria: inhibition by PKB/Akt but not Raf signalling	ONCOGENE			English	Article						anoikis; apoptosis; Ras; Akt; PKB; Raf	PROTEIN-KINASE B/AKT; CELL-DEATH; EXTRACELLULAR-MATRIX; APOPTOSIS; SURVIVAL; BAX; PHOSPHORYLATION; ADHESION; PATHWAY; TRANSFORMATION	Detachment of epithelial cells from extracellular matrix results in induction of apoptosis ('anoikis') which can be blocked by expression of activated Pas or PKB/Akt. Here we show that detachment causes release of cytochrome c from mitochondria in MDCK cells, This is blocked by caspase inhibitors, suggesting a role for caspases upstream of mitochondria in the initiation of anoikis, in accord with the ability of dominant negative FADD to inhibit this form of cell death, Bulk activation of caspase-8 following detachment lags behind cytochrome c release, and is likely the result of a mitochondrial positive feed back loop. Matrix detachment also induces Bax translocation to mitochondria in a caspase-dependent manner. Expression of activated Ras or PKB/Akt blocks all the detectable events on the detachment-induced apoptosis signalling pathway, suggesting that PKB/Akt acts at an early point in the pathway, providing the signal normally generated by matrix attachment. Strong activation of Raf can also protect MDCK cells from detachment induced apoptosis, but this occurs at a point downstream of cytochrome c release from mitochondria, and is clearly distinct from the effect of PKB/Akt.	Imperial Canc Res Fund, Signal Transduct Lab, London WC2A 3PX, England	Cancer Research UK	Downward, J (corresponding author), Imperial Canc Res Fund, Signal Transduct Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598	32	121	124	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4461	4468		10.1038/sj.onc.1203805	http://dx.doi.org/10.1038/sj.onc.1203805			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002418				2022-12-25	WOS:000089236800002
J	Gotz, J; Chen, F; Barmettler, R; Nitsch, RM				Gotz, J; Chen, F; Barmettler, R; Nitsch, RM			Tau filament formation in transgenic mice expressing P301L tau	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENT; NEUROFIBRILLARY DEGENERATION; ALZHEIMERS-DISEASE; PROTEIN; BRAIN; MUTATIONS; ISOFORMS; PHOSPHORYLATION; POLYMERIZATION; DEMENTIA	Mutations in the microtubule-associated protein tau, including P301L, are genetically coupled to hereditary frontotemporal dementia with parkinsonism linked to chromosome 17, To determine whether P301L is associated with fibril formation in mice, we expressed the longest human tau isoform, human tau40, with this mutation in transgenic mice by using the neuron-specific mouse Thy1.2 promoter. We obtained mice with high expression of human P301L tau in cortical and hippocampal neurons. Accumulated tau was hyperphosphorylated and translocated from axonal to somatodendritic compartments and was accompanied by astrocytosis and neuronal apoptosis indicated by terminal deoxynucleotidyl transferase-mediated biotinylated dUTP nick end-labeling staining. Moreover, P301L tau formed abnormal filaments. Electron microscopy of sarcosyl-insoluble protein extracts established that the filaments had a straight or twisted structure of variable length and were similar to 15 nm wide. Immunoelcecton microscopy showed that the tau filaments were phosphorylated at the TG3, AT100, AT8, and AD199 epitopes in vivo. In cortex, brain stem, and spinal cord, neurofibrillary tangles were also identified by thioflavin-S fluorescent microscopy and Gallyas silver stains. Together, our results show that expression of the P301L mutation in mice causes neuronal lesions that are similar to those seen in human tauopathies.	Univ Zurich, Div Psychiat Res, CH-8008 Zurich, Switzerland	University of Zurich	Gotz, J (corresponding author), Univ Zurich, Div Psychiat Res, August Forel Str 1, CH-8008 Zurich, Switzerland.		Götz, Jürgen/C-2448-2014	Götz, Jürgen/0000-0001-8501-7896				BRANDT R, 1994, CELL MOTIL CYTOSKEL, V28, P143, DOI 10.1002/cm.970280206; Brion JP, 1999, AM J PATHOL, V154, P255, DOI 10.1016/S0002-9440(10)65272-8; Delacourte A, 1999, NEUROLOGY, V52, P1158, DOI 10.1212/WNL.52.6.1158; Duff K, 2000, NEUROBIOL DIS, V7, P87, DOI 10.1006/nbdi.1999.0279; GALLYAS F, 1971, ACTA MORPHOL HUNG, V19, P1; Goedert M, 1999, AM J PATHOL, V154, P1, DOI 10.1016/S0002-9440(10)65242-X; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1995, NEUROBIOL AGING, V16, P325, DOI 10.1016/0197-4580(95)00017-9; GOTZ J, 1995, EMBO J, V14, P1304, DOI 10.1002/j.1460-2075.1995.tb07116.x; Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; HEINS S, 1993, J CELL BIOL, V123, P1517, DOI 10.1083/jcb.123.6.1517; Iqbal K, 1998, J NEURAL TRANSM-SUPP, P169; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Perez M, 1996, J NEUROCHEM, V67, P1183; Probst A, 1996, ACTA NEUROPATHOL, V92, P588, DOI 10.1007/s004010050565; Probst A, 2000, ACTA NEUROPATHOL, V99, P469, DOI 10.1007/s004010051148; Sergeant N, 1999, J NEUROCHEM, V72, P1243, DOI 10.1046/j.1471-4159.1999.0721243.x; Spillantini MG, 1998, AM J PATHOL, V153, P1359, DOI 10.1016/S0002-9440(10)65721-5; Spittaels K, 1999, AM J PATHOL, V155, P2153, DOI 10.1016/S0002-9440(10)65533-2; Trinczek B, 1999, J CELL SCI, V112, P2355; Varani L, 1999, P NATL ACAD SCI USA, V96, P8229, DOI 10.1073/pnas.96.14.8229; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4884, DOI 10.1073/pnas.85.13.4884; YAMAMOTO T, 1986, NEUROPATH APPL NEURO, V12, P3, DOI 10.1111/j.1365-2990.1986.tb00677.x	26	364	386	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					529	534		10.1074/jbc.M006531200	http://dx.doi.org/10.1074/jbc.M006531200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11013246	hybrid			2022-12-25	WOS:000166280700071
J	Maiti, D; Bhattacharyya, A; Basu, J				Maiti, D; Bhattacharyya, A; Basu, J			Lipoarabinomannan from Mycobacterium tuberculosis promotes macrophage survival by phosphorylating Bad through a phosphatidylinositol 3-kinase/Akt pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE B; FORKHEAD TRANSCRIPTION FACTOR; NF-KAPPA-B; CELL-DEATH; GROWTH-FACTOR; ALVEOLAR MACROPHAGES; BH3 DOMAIN; AKT; ACTIVATION; APOPTOSIS	Efforts in prevention and control of tuberculosis suffer from the lack of detailed knowledge of the mechanisms used by pathogenic mycobacteria for survival within host cell macrophages, The exploitation of host cell signaling pathways to the benefit of the pathogen is a phenomenon that deserves to be looked into in detail, We have tested the hypothesis that lipoarabinomannan (LAM) from the virulent species of Mycobacterium tuberculosis possesses the ability to modulate signaling pathways linked to cell survival. The Bcl-2 family member Bad is a proapoptotic protein, Phosphorylation of Bad promotes cell survival in many cell types. We demonstrate that man-LAM stimulates Bad phosphorylation in a phosphatidylinositol 3-kinase (PI-3K)-dependent pathway in THP-1 cells. Man-LAM activated PI-BK, LAM-stimulated phosphorylation of Bad was abrogated in cells transfected with a dominant-negative mutant of PI-SK (Delta p85), indicating that activation of PI-3K is sufficient to trigger phosphorylation of Bad by LAM. Since phosphorylation of Bad occurred at serine 136, the target of the serine/threonine kinase Akt, the effect of LAM on Akt kinase activity was tested. Man-LAM could activate Akt as evidenced from phosphorylation of Akt at Thr(308) and by the phosphorylation of the exogenous substrate histone 2B, Akt activation was abrogated in cells transfected with Delta p85. The phosphorylation of Bad by man-LAM was abrogated in cells transfected with a kinase-dead mutant of Akt. These results establish that LAM-mediated Bad phosphorylation occurs in a PI-3K/ Akt-dependent manner. It is therefore the first demonstration of the ability of a mycobacterial virulence factor to up-regulate a signaling pathway involved in cell survival. This is likely to be one of a number of virulence-associated mechanisms by which bacilli control host cell apoptosis.	Bose Inst, Dept Chem, Kolkata 700009, W Bengal, India	Department of Science & Technology (India); Bose Institute	Basu, J (corresponding author), Bose Inst, Dept Chem, 93-1 Acharya Prafulla Chandra Rd, Kolkata 700009, W Bengal, India.	joyoti@boseinst.ernet.in	Bhattacharyya, Asima/J-7423-2012	Bhattacharyya, Asima/0000-0001-7292-6644				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; BARNES PF, 1992, INFECT IMMUN, V60, P1441, DOI 10.1128/IAI.60.4.1441-1446.1992; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHAN AWE, 1992, LANGMUIR, V8, P1111, DOI 10.1021/la00040a017; CHAN J, 1991, INFECT IMMUN, V59, P1755, DOI 10.1128/IAI.59.5.1755-1761.1991; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; Fenton MJ, 1996, INFECT IMMUN, V64, P683, DOI 10.1128/IAI.64.3.683-690.1996; Fratazzi C, 1997, J IMMUNOL, V158, P4320; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; Galetic I, 1999, PHARMACOL THERAPEUT, V82, P409, DOI 10.1016/S0163-7258(98)00071-0; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; HUNTER SW, 1986, J BIOL CHEM, V261, P2345; JACKETT PS, 1982, ADV EXP MED BIOL, V155, P687; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Keane J, 1997, INFECT IMMUN, V65, P298, DOI 10.1128/IAI.65.1.298-304.1997; Keane J, 2000, J IMMUNOL, V164, P2016, DOI 10.4049/jimmunol.164.4.2016; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; Knutson KL, 1998, J BIOL CHEM, V273, P645, DOI 10.1074/jbc.273.1.645; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; Meresse S, 1999, NAT CELL BIOL, V1, pE183, DOI 10.1038/15620; Ozes ON, 1999, NATURE, V401, P82; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; ROACH TIA, 1993, J IMMUNOL, V150, P1886; SIBLEY LD, 1988, INFECT IMMUN, V56, P1232, DOI 10.1128/IAI.56.5.1232-1236.1988; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YAO R, 1996, J IMMUNOL, V156, P939; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	54	117	122	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					329	333		10.1074/jbc.M002650200	http://dx.doi.org/10.1074/jbc.M002650200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11020382	hybrid			2022-12-25	WOS:000166280700045
J	Racke, FK; Wang, DY; Zaidi, Z; Kelley, J; Visvader, J; Soh, JW; Goldfarb, AN				Racke, FK; Wang, DY; Zaidi, Z; Kelley, J; Visvader, J; Soh, JW; Goldfarb, AN			A potential role for protein kinase C-epsilon in regulating megakaryocytic lineage commitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; GENE-EXPRESSION; PROGENITOR CELLS; DIFFERENTIATION; ACTIVATION; SIGNAL; ALPHA; PATHWAY; APOPTOSIS; GROWTH	Multiple studies have shown that intracellular signal transduction by the protein kinase C (PKC) family participates in the initiation of megakaryocyte differentiation. In this study, multiple approaches addressed the functional contributions by specific PKC isozymes to megakaryocytic lineage commitment of two independent cell lines, K562 and human erythroleukemia (HEL). Pharmacologic profiles of induction and inhibition of megakaryocytic differentiation in both cell lines suggested a role for the calcium-independent novel PKCs, in particular PKC-epsilon. In transfection studies, the isolated variable domain of PKC-epsilon selectively blocked exogenous activation of the megakaryocyte-specific alpha IIb promoter. Constitutively active mutants of PKC-epsilon, but not of other PKC isozymes, cooperated with the transcription factor GATA-1 in the activation of the alpha IIb promoter. The functional cooperation between GATA-1 and PKC-epsilon displayed dependence on cellular milieu, as well as on the promoter context of GATA binding sites. In aggregate, the data suggest that PKC-epsilon specifically participates in megakaryocytic lineage commitment through functional cooperation with GATA-1 in the activation of megakaryocytic promoters.	Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21287 USA; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Columbia Univ, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10027 USA	University of Virginia; Johns Hopkins University; Johns Hopkins Medicine; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Columbia University	Goldfarb, AN (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pathol, HSC Box 800214, Charlottesville, VA 22908 USA.	ang3x@virginia.edu			NCI NIH HHS [CA-72704] Funding Source: Medline; NHLBI NIH HHS [HL-04017] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA072704] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; Asada A, 1998, J BIOL CHEM, V273, P28392, DOI 10.1074/jbc.273.43.28392; Bassini A, 1999, BLOOD, V93, P1178, DOI 10.1182/blood.V93.4.1178.404k28_1178_1188; Debili N, 1996, BLOOD, V88, P1284, DOI 10.1182/blood.V88.4.1284.bloodjournal8841284; Era T, 2000, BLOOD, V95, P870, DOI 10.1182/blood.V95.3.870.003k44_870_878; Fichelson S, 1999, BLOOD, V94, P1601, DOI 10.1182/blood.V94.5.1601.417k19_1601_1613; FONG AM, 1994, J BIOL CHEM, V269, P18441; GOLDFARB AN, 1992, BLOOD, V80, P2858; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Hundle B, 1997, J BIOL CHEM, V272, P15028, DOI 10.1074/jbc.272.23.15028; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LONG MW, 1990, J CLIN INVEST, V85, P1072, DOI 10.1172/JCI114538; LONG MW, 1984, J CLIN INVEST, V74, P1686, DOI 10.1172/JCI111585; Lumelsky NL, 1997, BBA-MOL CELL RES, V1358, P79, DOI 10.1016/S0167-4889(97)00051-7; MARTIN F, 1993, J BIOL CHEM, V268, P21606; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Myklebust JH, 2000, BLOOD, V95, P510, DOI 10.1182/blood.V95.2.510; Ohoka Y, 1997, J IMMUNOL, V158, P5707; Parissenti AM, 1998, J BIOL CHEM, V273, P8940, DOI 10.1074/jbc.273.15.8940; Pierce A, 1998, J CELL BIOL, V140, P1511, DOI 10.1083/jcb.140.6.1511; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Rossi F, 1996, EMBO J, V15, P1894, DOI 10.1002/j.1460-2075.1996.tb00540.x; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Swanson KD, 1999, J BIOL CHEM, V274, P3385, DOI 10.1074/jbc.274.6.3385; Tang SQ, 1997, J BIOL CHEM, V272, P28704, DOI 10.1074/jbc.272.45.28704; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; Uberall F, 1997, J BIOL CHEM, V272, P4072, DOI 10.1074/jbc.272.7.4072; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VISVADER JE, 1995, MOL CELL BIOL, V15, P634; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9156, DOI 10.1073/pnas.92.20.9156; Weller SG, 1999, GASTROENTEROLOGY, V117, P848, DOI 10.1016/S0016-5085(99)70343-4; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947	36	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					522	528		10.1074/jbc.M005236200	http://dx.doi.org/10.1074/jbc.M005236200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11016926	hybrid			2022-12-25	WOS:000166280700070
J	Skinner, LM; Sudol, M; Harper, AL; Katzman, M				Skinner, LM; Sudol, M; Harper, AL; Katzman, M			Nucleophile selection for the endonuclease activities of human, ovine, and avian retroviral integrases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; SITE-SPECIFIC HYDROLYSIS; VIRAL-DNA SPECIFICITY; STABLE COMPLEX; IN-VITRO; INTEGRATION; PROTEIN; SUBSTRATE; ALCOHOLYSIS; RECOGNITION	Retroviral integrases catalyze four endonuclease reactions (processing, joining, disintegration, and nonspecific alcoholysis) that differ in specificity for the attacking nucleophile and target DNA sites. To assess how the two substrates of this enzyme affect each other, we per formed quantitative analyses, in three retroviral systems, of the two reactions that use a variety of nucleophiles. The integrase proteins of human immunodeficiency virus type 1, visna virus, and Rous sarcoma virus exhibited distinct preferences for water or other nucleophiles during site-specific processing of viral DNA and during nonspecific alcoholysis of nonviral DNA. Although exogenous alcohols competed with water as the nucleophile for processing, the alcohols stimulated nicking of nonviral DNA Moreover, different nucleophiles were preferred when the various integrases acted on different DNA targets. In contrast, the nicking patterns were independent of whether integrase was catalyzing hydrolysis or alcoholysis and were not influenced by the particular exogenous alcohol. Thus, although the target DNA influenced the choice of nucleophile, the nucleophile did not affect the choice of target sites. These results indicate that interaction with target DNA is the critical step before catalysis and suggest that integrase does not reach an active conformation until target DNA has bound to the enzyme.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med,Dept Med, Div Infect Dis, Hershey, PA 17033 USA; Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Katzman, M (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med,Dept Med, Div Infect Dis, POB 850,Mail Code H036, Hershey, PA 17033 USA.	mkatzman@psu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI047216] Funding Source: NIH RePORTER; NIAID NIH HHS [R21-AI47216] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andrake MD, 1996, J BIOL CHEM, V271, P19633, DOI 10.1074/jbc.271.33.19633; Asante-Appiah E, 1998, J BIOL CHEM, V273, P35078, DOI 10.1074/jbc.273.52.35078; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; BUSHMAN FD, 1994, J VIROL, V68, P2215, DOI 10.1128/JVI.68.4.2215-2223.1994; Chen ZG, 2000, J MOL BIOL, V296, P521, DOI 10.1006/jmbi.1999.3451; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DONG JY, 1992, J VIROL, V66, P865, DOI 10.1128/JVI.66.2.865-874.1992; DOTAN I, 1995, J VIROL, V69, P456, DOI 10.1128/JVI.69.1.456-468.1995; ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; Esposito D, 1999, ADV VIRUS RES, V52, P319, DOI 10.1016/S0065-3527(08)60304-8; HAWKINS ME, 1995, NUCLEIC ACIDS RES, V23, P2872, DOI 10.1093/nar/23.15.2872; JONES KS, 1992, J BIOL CHEM, V267, P16037; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZMAN M, 1991, P NATL ACAD SCI USA, V88, P4695, DOI 10.1073/pnas.88.11.4695; Katzman M, 1996, J VIROL, V70, P2598, DOI 10.1128/JVI.70.4.2598-2604.1996; Katzman M, 2000, VIRUS RES, V66, P87, DOI 10.1016/S0168-1702(99)00126-4; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; Katzman M, 1999, ADV VIRUS RES, V52, P371, DOI 10.1016/S0065-3527(08)60307-3; KATZMAN M, 1995, J VIROL, V69, P5687, DOI 10.1128/JVI.69.9.5687-5696.1995; KATZMAN M, 1994, J VIROL, V68, P3558, DOI 10.1128/JVI.68.6.3558-3569.1994; Katzman M, 1998, J VIROL, V72, P1744, DOI 10.1128/JVI.72.3.1744-1753.1998; LAFEMINA RL, 1995, ANTIMICROB AGENTS CH, V39, P320, DOI 10.1128/AAC.39.2.320; LEE SP, 1995, BIOCHEMISTRY-US, V34, P10205, DOI 10.1021/bi00032a014; Maignan S, 1998, J MOL BIOL, V282, P359, DOI 10.1006/jmbi.1998.2002; MAZUMDER A, 1994, NUCLEIC ACIDS RES, V22, P4441, DOI 10.1093/nar/22.21.4441; MILLER MD, 1995, CURR BIOL, V5, P1047, DOI 10.1016/S0960-9822(95)00209-0; Morgan AL, 2000, J GEN VIROL, V81, P839, DOI 10.1099/0022-1317-81-3-839; MULLER B, 1993, P NATL ACAD SCI USA, V90, P11633, DOI 10.1073/pnas.90.24.11633; Pommier Y, 1999, ADV VIRUS RES, V52, P427, DOI 10.1016/S0065-3527(08)60310-3; TERRY R, 1988, J VIROL, V62, P2358, DOI 10.1128/JVI.62.7.2358-2365.1988; Tramontano E, 1998, BIOCHEMISTRY-US, V37, P7237, DOI 10.1021/bi972792o; VANGENT DC, 1993, NUCLEIC ACIDS RES, V21, P3373, DOI 10.1093/nar/21.15.3373; VINK C, 1994, NUCLEIC ACIDS RES, V22, P4103, DOI 10.1093/nar/22.20.4103; VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691; VINK C, 1994, J VIROL, V68, P1468, DOI 10.1128/JVI.68.3.1468-1474.1994; VORA AC, 1990, J VIROL, V64, P5656, DOI 10.1128/JVI.64.11.5656-5659.1990; Yang ZN, 2000, J MOL BIOL, V296, P535, DOI 10.1006/jmbi.1999.3463; Yi JZ, 1999, BIOCHEMISTRY-US, V38, P8458, DOI 10.1021/bi982870n; YOSHINAGA T, 1994, J VIROL, V68, P5690, DOI 10.1128/JVI.68.9.5690-5697.1994	42	24	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					114	124		10.1074/jbc.M007032200	http://dx.doi.org/10.1074/jbc.M007032200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024025	hybrid			2022-12-25	WOS:000166280700017
J	Grover, J; Liu, CY; Kao, WWY; Roughley, PJ				Grover, J; Liu, CY; Kao, WWY; Roughley, PJ			Analysis of the human lumican gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATAN SULFATE PROTEOGLYCAN; HUMAN ARTICULAR-CARTILAGE; RNA-POLYMERASE-II; TRANSCRIPTION FACTORS; CHICK LUMICAN; MOUSE LUMICAN; PROTEIN PRELP; EXPRESSION; COLLAGEN; BINDING	The human lumican gene was shown to possess one major transcription start site, resulting in exon 1 of the gene giving rise to the first 74 base pairs (bp) of the 5'-untranslated region. About 1.6 kilobase pairs of up. stream promoter sequence were sequenced and analyzed to identify elements responsible for gene expression. No typical TATAA sequence was identified in the vacinity of the transcription start site, but an atypical TATCA sequence residing 41 bp upstream was shown to be necessary for transcription, although it was incapable of supporting transcription by itself. A GC box residing 74 bp upstream of the transcription start site also was essential for the initiation of transcription. Sp3 was identified as the transcriptional activator binding to the GC box. No additional elements that significantly modulated transcription were noted in the promoter sequence analyzed, when using human adult chondrocytes as the cell source for transfection in reporter assays. In contrast, reporter assays carried out in human fetal lung fibroblasts, where lumican expression is deplete, revealed the presence of a repressor element located between 384 and 598 bp upstream of the transcription start site. A GATA-binding site located between bp -386 and -391 was identified as being necessary for repression of transcription. The mouse lumican promoter does not possess an equivalent site, and this may explain why the lumican gene is expressed in fetal murine cartilage but not in fetal human cartilage.	Shriners Hosp Children, Genet Unit, Montreal, PQ H3G 1A6, Canada; McGill Univ, Dept Surg, Montreal, PQ H3G 1A6, Canada; Univ Cincinnati, Dept Ophthalmol, Cincinnati, OH 45267 USA	McGill University; McGill University; University System of Ohio; University of Cincinnati	Roughley, PJ (corresponding author), Shriners Hosp Children, Genet Unit, 1529 Cedar Ave, Montreal, PQ H3G 1A6, Canada.			Liu, Chia-yang/0000-0002-8398-5516	NATIONAL EYE INSTITUTE [R01EY011845] Funding Source: NIH RePORTER; NEI NIH HHS [EY11845] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; CHAKRAVARTI S, 1995, GENOMICS, V27, P481, DOI 10.1006/geno.1995.1080; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORNUET PK, 1994, INVEST OPHTH VIS SCI, V35, P870; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dolhnikoff M, 1998, AM J RESP CELL MOL, V19, P582, DOI 10.1165/ajrcmb.19.4.2979; Dunlevy JR, 1998, J BIOL CHEM, V273, P9615, DOI 10.1074/jbc.273.16.9615; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P24773; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; FUNDERBURGH JL, 1995, INVEST OPHTH VIS SCI, V36, P2296; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; Grover J, 1998, BIOCHEM J, V336, P77, DOI 10.1042/bj3360077; Grover J, 1996, GENOMICS, V38, P109, DOI 10.1006/geno.1996.0605; GROVER J, 1995, J BIOL CHEM, V270, P21942, DOI 10.1074/jbc.270.37.21942; Haenlin M, 1997, GENE DEV, V11, P3096, DOI 10.1101/gad.11.22.3096; Hassell JR, 1998, BBA-GENE STRUCT EXPR, V1397, P119, DOI 10.1016/S0167-4781(98)00022-0; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; Hocking AM, 1998, MATRIX BIOL, V17, P1; Holmes M, 1999, J BIOL CHEM, V274, P23491, DOI 10.1074/jbc.274.33.23491; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Melching LI, 1997, MATRIX BIOL, V16, P1, DOI 10.1016/S0945-053X(97)90111-6; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; Saika S, 2000, J BIOL CHEM, V275, P2607, DOI 10.1074/jbc.275.4.2607; Sambrook J., 2002, MOL CLONING LAB MANU; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; TAKAHASHI T, 1993, J HISTOCHEM CYTOCHEM, V41, P1447, DOI 10.1177/41.10.8245404; Weis L, 1997, MOL CELL BIOL, V17, P2973, DOI 10.1128/MCB.17.6.2973; WHYATT DJ, 1993, EMBO J, V12, P4993, DOI 10.1002/j.1460-2075.1993.tb06193.x; Ying SX, 1997, J BIOL CHEM, V272, P30306, DOI 10.1074/jbc.272.48.30306	33	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40967	40973		10.1074/jbc.M004134200	http://dx.doi.org/10.1074/jbc.M004134200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11016924	hybrid			2022-12-25	WOS:000166114600042
J	Kazlauskas, A; Poellinger, L; Pongratz, I				Kazlauskas, A; Poellinger, L; Pongratz, I			The immunophilin-like protein XAP2 regulates ubiquitination and subcellular localization of the dioxin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ARYL-HYDROCARBON RECEPTOR; DNA-BINDING ACTIVITY; HELIX-LOOP-HELIX; AH RECEPTOR; LIGAND-BINDING; GLUCOCORTICOID RECEPTOR; PROGESTERONE-RECEPTOR; NUCLEAR-LOCALIZATION; CORE COMPLEX	The dioxin (aryl hydrocarbon) receptor is a ligand dependent transcription factor that induces expression of a number of genes encoding drug metabolizing enzymes. The nonactivated form of the dioxin receptor is associated with heat shock protein (hsp) 90, the co-chaperone p23, and the immunophilin-like protein XAP2. Whereas hsp90 has a role in maintenance of the high-affinity ligand binding conformation of the dioxin receptor complex, and p23 stabilizes receptor-hsp99 interaction, the exact role of XAP2 is largely unknown. Here we show that XAP2 protected the ligand-free form of receptor against ubiquitination, resulting in increased dioxin receptor protein levels, Upon exposure to ligand, nuclear translocation of the dioxin receptor was markedly delayed by XAP2, indicating an additional role of XAP2 in regulation of the subcellular localization of the receptor by a mechanism of cytoplasmic retention. In order to mediate these effects, XAP2 required stable association with the hsp90-p23 molecular chaperone complex. The association of XAP2 as well as p23 with the dioxin receptor was determined by the functional state of hsp90. These data indicate a novel mode of regulation of dioxin receptor signaling by the hsp90-dependent molecular chaperone machinery.	Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Poellinger, L (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden.							ANTONSSON C, 1995, MOL CELL BIOL, V15, P756; CARVER LA, 1994, J BIOL CHEM, V269, P30109; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Chen HS, 1997, ARCH BIOCHEM BIOPHYS, V348, P190, DOI 10.1006/abbi.1997.0398; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; Davarinos NA, 1999, J BIOL CHEM, V274, P28708, DOI 10.1074/jbc.274.40.28708; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Heid SE, 2000, MOL PHARMACOL, V57, P82; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519; Kuzhandaivelu N, 1996, NUCLEIC ACIDS RES, V24, P4741, DOI 10.1093/nar/24.23.4741; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LaPres JJ, 2000, J BIOL CHEM, V275, P6153, DOI 10.1074/jbc.275.9.6153; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; Ma Q, 2000, J BIOL CHEM, V275, P8432, DOI 10.1074/jbc.275.12.8432; Ma Q, 1997, J BIOL CHEM, V272, P8878; MASON GGF, 1994, J BIOL CHEM, V269, P4438; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; Pongratz I, 1998, MOL CELL BIOL, V18, P4079, DOI 10.1128/MCB.18.7.4079; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; Roberts BJ, 1999, J BIOL CHEM, V274, P36351, DOI 10.1074/jbc.274.51.36351; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WHITELAW ML, 1995, P NATL ACAD SCI USA, V92, P4437, DOI 10.1073/pnas.92.10.4437; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x	40	130	133	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41317	41324		10.1074/jbc.M007765200	http://dx.doi.org/10.1074/jbc.M007765200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11013261	hybrid			2022-12-25	WOS:000166114600087
J	Novitskaya, V; Grigorian, M; Kriajevska, M; Tarabykina, S; Bronstein, I; Berezin, V; Bock, E; Lukanidin, E				Novitskaya, V; Grigorian, M; Kriajevska, M; Tarabykina, S; Bronstein, I; Berezin, V; Bock, E; Lukanidin, E			Oligomeric forms of the metastasis-related Mts1 (S100A4) protein stimulate neuronal differentiation in cultures of rat hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; NEURITE OUTGROWTH; KINASE-C; NEUROTROPHIC FACTORS; IN-VITRO; ACTIVATION; CELLS; EXPRESSION; INHIBITOR; RECEPTOR	Neuronal differentiation and axonal growth are controlled by a variety of factors including neurotrophic factors; extracellular matrix components, and cell adhesion molecules. Here we describe a novel and very efficient neuritogenic factor, the metastasis-related Mts1 protein, belonging to the S100 protein family. The oligomeric but not the dimeric form of Mts1 strongly induces differentiation of cultured hippocampal neurons. A mutant with a single Y75F amino acid substitution, which stabilizes the dimeric form of Mts1, is unable to promote neurite extension. Disulfide bonds do not play an essential role in the Mts1 neuritogenic activity. Mts1-stimulated neurite outgrowth involves activation of phospholipase C and protein kinase C, depends on the intracellular level of Ca2+, and requires activation of the extracellular signal-regulated kinases (ERKs) 1 and 2.	Danish Canc Soc, Inst Mol Canc Biol, Dept Mol Canc Biol, DK-2100 Copenhagen O, Denmark; Univ Copenhagen, Inst Mol Pathol, Prot Lab, DK-2200 Copenhagen N, Denmark; Univ York, Dept Chem, Struct Biol Ctr, York YO1 5DD, N Yorkshire, England	Danish Cancer Society; University of Copenhagen; University of York - UK	Lukanidin, E (corresponding author), Danish Canc Soc, Inst Mol Canc Biol, Dept Mol Canc Biol, DK-2100 Copenhagen O, Denmark.	el@cancer.dk						Ambartsumian N, 1999, INVAS METAST, V18, P96; Ambartsumian NS, 1996, ONCOGENE, V13, P1621; Brewer GJ, 1999, EXP NEUROL, V159, P237, DOI 10.1006/exnr.1999.7123; Davies MPA, 1996, ONCOGENE, V13, P1631; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Duarte WR, 1999, BIOCHEM BIOPH RES CO, V255, P416, DOI 10.1006/bbrc.1999.0214; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GIBBS FEM, 1994, J BIOL CHEM, V269, P18992; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; JARVIS WD, 1994, CANCER RES, V54, P1707; KAJI H, 1992, BIOCHEM BIOPH RES CO, V182, P1356, DOI 10.1016/0006-291X(92)91882-Q; Klingelhofer J, 1997, DEV DYNAM, V210, P87, DOI 10.1002/(SICI)1097-0177(199710)210:2<87::AID-AJA2>3.0.CO;2-5; Kolkova K, 2000, J NEUROSCI, V20, P2238; Kozlova EN, 1999, GLIA, V27, P249, DOI 10.1002/(SICI)1098-1136(199909)27:3<249::AID-GLIA6>3.3.CO;2-5; Kriajevska M, 1998, J BIOL CHEM, V273, P9852, DOI 10.1074/jbc.273.16.9852; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Landar A, 1997, BBA-PROTEIN STRUCT M, V1343, P117, DOI 10.1016/S0167-4838(97)00126-X; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lukanidin EM, 1996, CURR TOP MICROBIOL, V213, P171; Malcolm CS, 1996, J NEUROCHEM, V66, P2350; Matsumura H, 1998, STRUCTURE, V6, P233, DOI 10.1016/S0969-2126(98)00024-0; Mitsumoto H, 1999, MUSCLE NERVE, V22, P983, DOI 10.1002/(SICI)1097-4598(199908)22:8<983::AID-MUS1>3.0.CO;2-V; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Muthalif MM, 1996, J BIOL CHEM, V271, P30149, DOI 10.1074/jbc.271.47.30149; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Pataky DM, 2000, EXP NEUROL, V163, P357, DOI 10.1006/exnr.2000.7365; PRONCE RJ, 1996, BIOCHEM PHARMACOL, V52, P613; *PROT SOL, 1998, SOFT MAN DYN VERS 4; Rammes A, 1997, J BIOL CHEM, V272, P9496; Ronn LCB, 1999, NAT BIOTECHNOL, V17, P1000, DOI 10.1038/13697; Ronn LCB, 2000, J NEUROSCI METH, V100, P25, DOI 10.1016/S0165-0270(00)00228-4; SACHS CW, 1995, J BIOL CHEM, V270, P26639, DOI 10.1074/jbc.270.44.26639; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; Smith SP, 1998, STRUCTURE, V6, P211, DOI 10.1016/S0969-2126(98)00022-7; Tarabykina S, 2000, FEBS LETT, V475, P187, DOI 10.1016/S0014-5793(00)01652-5; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TRIGGLE DJ, 1991, AM J HYPERTENS, V4, pS422, DOI 10.1093/ajh/4.7.422S; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VANELDIK LJ, 1988, CALCIUM CALCIUM BIND, P114; WALICKE PA, 1989, ANNU REV NEUROSCI, V12, P103, DOI 10.1146/annurev.neuro.12.1.103; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063	48	134	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41278	41286		10.1074/jbc.M007058200	http://dx.doi.org/10.1074/jbc.M007058200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018041	hybrid			2022-12-25	WOS:000166114600083
J	Yamaguchi, S; Okamura, Y; Nagao, T; Adachi-Akahane, S				Yamaguchi, S; Okamura, Y; Nagao, T; Adachi-Akahane, S			Serine residue in the IIIS5-S6 linker of the L-type Ca2+ channel alpha(1C) subunit is the critical determinant of the action of dihydropyridine Ca2+ channel agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC CALCIUM CHANNELS; AMINO-ACID-RESIDUES; ALPHA-1 SUBUNIT; 1,4-DIHYDROPYRIDINE SENSITIVITY; MOLECULAR DETERMINANTS; FUNCTIONAL EXPRESSION; RADIOLIGAND BINDING; RECEPTOR-SITE; IDENTIFICATION; ANTAGONISTS	The dihydropyridine (DHP)-binding site has been identified within L-type Ca2+ channel alpha (1C) subunit. However, the molecular mechanism underlying modulation of Ca2+ channel gating by DHPs has not been clarified. To search for novel determinants of high affinity DHP binding, we introduced point mutations in the rat brain Ca2+ channel alpha (1C) subunit (rbCII or Ca(v)1.2c) based on the comparison of amino acid sequences between rbCII and the ascidian L-type Ca2+ channel alpha (1) subunit, which is insensitive to DHPs. The alpha (1C) mutants (S1115A, S1146A, and A1420S) and rbCII were transiently expressed in BHK6 cells with beta (1a) and alpha (2)/delta subunits. The mutation did not affect the electrophysiological properties of the Ca2+ channel, or the voltage- and concentration-dependent block of Ca2+ channel currents produced by diltiazem and verapamil. However, the S1115A channel was significantly less sensitive to DHP antagonists. Interestingly, in the S1115A channel, DHP agonists failed to enhance whole-cell Ca2+ channel currents and the prolongation of mean open time, as well as the increment of NPo. Responsiveness to the non-DHP agonist FPL-64176 was also markedly reduced in the S1115A channel. When S1115 was replaced by other amino acids (S1115D, S1115T, or S1115V), only S1115T was slightly sensitive to S-(-)-Bay K 8644. These results indicate that the hydroxyl group of Ser(1115) in IIIS5-S6 linker of the L-type Ca2+ channel alpha (1C) subunit plays a critical role in DHP binding and in the action of DHP Ca2+ channel agonists.	Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Pharmacaol & Toxicol, Bunkyo Ku, Tokyo 1130033, Japan; Natl Inst Biosci & Human Technol, Dept Biomol Engn, Tsukuba, Ibaraki 3058566, Japan	University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST)	Adachi-Akahane, S (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Pharmacaol & Toxicol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	satomiaa@mol.f.u-tokyo.ac.jp						AdachiAkahane S, 1996, J GEN PHYSIOL, V108, P435, DOI 10.1085/jgp.108.5.435; BANGALORE R, 1994, MOL PHARMACOL, V46, P660; BEAN BP, 1984, P NATL ACAD SCI-BIOL, V81, P6388, DOI 10.1073/pnas.81.20.6388; BECHEM M, 1988, TRENDS PHARMACOL SCI, V9, P257, DOI 10.1016/0165-6147(88)90156-3; Bechem M, 1996, LIFE SCI, V60, P107, DOI 10.1016/S0024-3205(96)00600-5; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; GLOSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; He M, 1997, J BIOL CHEM, V272, P2629, DOI 10.1074/jbc.272.5.2629; HESS P, 1984, NATURE, V311, P538, DOI 10.1038/311538a0; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; Jeziorski MC, 1998, J BIOL CHEM, V273, P22792, DOI 10.1074/jbc.273.35.22792; KALASZ H, 1993, FEBS LETT, V331, P177, DOI 10.1016/0014-5793(93)80321-K; KASS RS, 1989, J GEN PHYSIOL, V93, P1109, DOI 10.1085/jgp.93.6.1109; KASS RS, 1991, J GEN PHYSIOL, V98, P63, DOI 10.1085/jgp.98.1.63; Mitterdorfer J, 1996, J BIOL CHEM, V271, P30330, DOI 10.1074/jbc.271.48.30330; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; Okamura Y, 1999, BIOPHYS J, V76, pA340; Peterson BZ, 1997, J BIOL CHEM, V272, P18752, DOI 10.1074/jbc.272.30.18752; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; RAMPE D, 1991, J PHARMACOL EXP THER, V259, P982; REGULLA S, 1991, EMBO J, V10, P45, DOI 10.1002/j.1460-2075.1991.tb07919.x; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; Sinnegger MJ, 1997, J BIOL CHEM, V272, P27686, DOI 10.1074/jbc.272.44.27686; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; Striessnig J, 1998, TRENDS PHARMACOL SCI, V19, P108, DOI 10.1016/S0165-6147(98)01171-7; STRUBING C, 1993, BRIT J PHARMACOL, V108, P884, DOI 10.1111/j.1476-5381.1993.tb13482.x; TANABE T, 1991, NATURE, V352, P800, DOI 10.1038/352800a0; TRIGGLE DJ, 1989, TRENDS PHARMACOL SCI, V10, P507, DOI 10.1016/0165-6147(89)90051-5; Wakamori M, 1998, J BIOL CHEM, V273, P34857, DOI 10.1074/jbc.273.52.34857; WANG ZY, 1995, J PHYSIOL-LONDON, V486, P131, DOI 10.1113/jphysiol.1995.sp020797; WEI XY, 1994, J BIOL CHEM, V269, P1635; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; ZHANG JF, 1994, NATURE, V372, P97, DOI 10.1038/372097a0; ZHENG W, 1991, MOL PHARMACOL, V40, P734	38	58	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41504	41511		10.1074/jbc.M007165200	http://dx.doi.org/10.1074/jbc.M007165200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11022040	hybrid			2022-12-25	WOS:000166114600109
J	Achur, RN; Valiyaveettil, M; Alkhalil, A; Ockenhouse, CF; Gowda, DC				Achur, RN; Valiyaveettil, M; Alkhalil, A; Ockenhouse, CF; Gowda, DC			Characterization of proteoglycans of human placenta and identification of unique chondroitin sulfate proteoglycans of the intervillous spaces that mediate the adherence of Plasmodium falciparum-infected erythrocytes to the placenta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; MICROVASCULAR ENDOTHELIAL-CELLS; RED-BLOOD-CELLS; ANTIGENIC VARIATION; CARTILAGE PROTEOGLYCAN; MEMBRANE GLYCOPROTEIN; FLOW CONDITIONS; CHICK-EMBRYO; VAR GENES; MALARIA	In pregnant women infected with Plasmodium falciparum, the infected red blood cells (IRBCs) selectively accumulate in the intervillous spaces of placenta, leading to poor fetal outcome and severe health complications in the mother. Although chondroitin 4-sulfate is known to mediate IRBC adherence to placenta, the natural receptor has not been identified. In the present study, the chondroitin sulfate proteoglycans (CSPGs) of human placenta were purified and structurally characterized, and adherence of IRBCs to these CSPGs investigated. The data indicate that the placenta contains three distinct types of CSPGs: significant quantities of uniquely low sulfated, extracellular CSPGs localized in the intervillous spaces, minor amounts of two cell-associated CSPGs, and major amounts of dermatan sulfate-like CSPGs of the fibrous tissue. Of the various CSPGs isolated from the placenta, the low sulfated CSPGs of the intervillous spaces most efficiently bind IRBCs. Based on IRBC adherence capacities and localization patterns of various CSPGs, we conclude that the CSPGs of the intervillous spaces are the receptors for placental IRBC adherence. The identification and characterization of these CSPGs provide a valuable tool for understanding the precise molecular interactions involved in placental IRBC adherence and for the development of therapeutic strategies for maternal malaria. In the accompanying paper we report the structural requirements for the IRBC adherence.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Walter Reed Army Inst Res, Dept Immunol, Silver Spring, MD 20910 USA	Georgetown University; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Gowda, DC (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	gowda@bc.georgetown.edu		Achur, Rajeshwara/0000-0001-9867-8917; Gowda, Channe/0000-0002-6860-5108	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI045086, R01AI045086] Funding Source: NIH RePORTER; NIAID NIH HHS [AI45086] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhalil A, 2000, J BIOL CHEM, V275, P40357, DOI 10.1074/jbc.M006399200; BARNWELL JW, 1989, J CLIN INVEST, V84, P765, DOI 10.1172/JCI114234; Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; Beeson JG, 2000, NAT MED, V6, P86, DOI 10.1038/71582; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BORST P, 1995, CELL, V82, P1, DOI 10.1016/0092-8674(95)90044-6; BRADBURY S., 1965, J ROY MICROSCOP SOC, V84, P199; BRENNAN MJ, 1984, J BIOL CHEM, V259, P3742; Buffet PA, 1999, P NATL ACAD SCI USA, V96, P12743, DOI 10.1073/pnas.96.22.12743; CALATRONI A, 1969, CARBOHYD RES, V10, P535, DOI 10.1016/S0008-6215(00)80122-6; CARLSON DM, 1968, J BIOL CHEM, V243, P616; CARRINO DA, 1984, J BIOL CHEM, V259, P2419; Chaiyaroj SC, 1996, AM J TROP MED HYG, V55, P76, DOI 10.4269/ajtmh.1996.55.76; CHOI HU, 1989, J BIOL CHEM, V264, P2876; Cooke BM, 1996, BLOOD, V88, P4040, DOI 10.1182/blood.V88.10.4040.bloodjournal88104040; CURRIE GA, 1967, LANCET, V1, P708; DAVIDSON EA, 1954, J BIOL CHEM, V211, P605; DISCHE Z, 1947, J BIOL CHEM, V167, P189; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FISHER LW, 1983, J BIOL CHEM, V258, P6588; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Fried M, 1998, J MOL MED-JMM, V76, P162, DOI 10.1007/s001090050205; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Gardner JP, 1996, P NATL ACAD SCI USA, V93, P3503, DOI 10.1073/pnas.93.8.3503; GILLES HM, 1993, BRUCECHWATTS ESSENTI, P1; Gysin J, 1997, MOL BIOCHEM PARASIT, V88, P267, DOI 10.1016/S0166-6851(97)00082-0; HARDY MR, 1989, METHOD ENZYMOL, V179, P76; Hascall V. C., 1981, BIOL CARBOHYDRATES, V1, P1; HATAE Y, 1975, ANAL BIOCHEM, V64, P30, DOI 10.1016/0003-2697(75)90400-5; HOMMEL M, 1993, ANN TROP MED PARASIT, V87, P627, DOI 10.1080/00034983.1993.11812821; HOVINGH P, 1974, CARBOHYD RES, V37, P181, DOI 10.1016/S0008-6215(00)87073-1; Kaul DK, 1998, AM J TROP MED HYG, V58, P240, DOI 10.4269/ajtmh.1998.58.240; KIMATA K, 1986, J BIOL CHEM, V261, P3517; KRUEGER RC, 1987, ANAL BIOCHEM, V167, P295, DOI 10.1016/0003-2697(87)90167-9; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TY, 1973, PEDIATR RES, V7, P965, DOI 10.1203/00006450-197312000-00005; LIN JH, 1994, J BIOL CHEM, V269, P25021; Lovell D, 1967, J Obstet Gynaecol Br Commonw, V74, P568; MARSH K, 1992, PARASITOLOGY, V104, pS53, DOI 10.1017/S0031182000075247; MARTIN BJ, 1974, ANAT REC, V178, P769, DOI 10.1002/ar.1091780408; MARUYAMA I, 1985, J CELL BIOL, V101, P363, DOI 10.1083/jcb.101.2.363; Maubert B, 1997, INFECT IMMUN, V65, P1251, DOI 10.1128/IAI.65.4.1251-1257.1997; Maubert B, 2000, PARASITE IMMUNOL, V22, P191, DOI 10.1046/j.1365-3024.2000.00292.x; McCormick CJ, 1997, J CLIN INVEST, V100, P2521, DOI 10.1172/JCI119794; MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0; MENENDEZ C, 1995, PARASITOL TODAY, V11, P178, DOI 10.1016/0169-4758(95)80151-0; Miller LH, 1998, NAT MED, V4, P1244, DOI 10.1038/3223; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; OCKENHOUSE CF, 1991, J INFECT DIS, V164, P163, DOI 10.1093/infdis/164.1.163; OCKENHOUSE CF, 1992, J EXP MED, V176, P1183, DOI 10.1084/jem.176.4.1183; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; OTOTANI N, 1979, CARBOHYD RES, V70, P295, DOI 10.1016/S0008-6215(00)87109-8; PASLOSKE BL, 1994, ANNU REV MED, V45, P283; PONTING JM, 1995, J ANAT, V186, P131; POOLE AR, 1986, BIOCHEM J, V236, P1; Pouvelle B, 1997, MOL MED, V3, P508, DOI 10.1007/BF03401697; REDINBAUGH MG, 1986, ANAL BIOCHEM, V153, P267, DOI 10.1016/0003-2697(86)90091-6; Reeder JC, 1999, P NATL ACAD SCI USA, V96, P5198, DOI 10.1073/pnas.96.9.5198; Robert C, 1995, RES IMMUNOL, V146, P383, DOI 10.1016/0923-2494(96)81042-X; Rogerson SJ, 1997, EXP PARASITOL, V86, P8, DOI 10.1006/expr.1996.4142; ROGERSON SJ, 1995, J EXP MED, V182, P15, DOI 10.1084/jem.182.1.15; SAITO H, 1968, J BIOL CHEM, V243, P1536; SALEM HH, 1984, J BIOL CHEM, V259, P2246; Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; Steketee RW, 1996, AM J TROP MED HYG, V55, P2, DOI 10.4269/ajtmh.1996.55.2; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; SUNDERLAND CA, 1985, J REPROD IMMUNOL, V8, P197, DOI 10.1016/0165-0378(85)90041-5; SVEJCAR J, 1968, BIOCHIM BIOPHYS ACTA, V165, P84, DOI 10.1016/0304-4165(68)90191-8; Treutiger CJ, 1997, NAT MED, V3, P1405, DOI 10.1038/nm1297-1405; Udomsangpetch R, 1997, J IMMUNOL, V158, P4358; VOGEL KG, 1987, J BIOL CHEM, V262, P13607; WALTER PR, 1982, AM J PATHOL, V109, P330; WARRELL DA, 1987, PARASITOLOGY, V94, pS53, DOI 10.1017/S0031182000085826; WASSERMAN L, 1983, PLACENTA, V4, P101, DOI 10.1016/S0143-4004(83)80021-6; Xiao LH, 1996, EXP PARASITOL, V84, P42, DOI 10.1006/expr.1996.0088; YAMADA M, 1989, AM J TROP MED HYG, V41, P161, DOI 10.4269/ajtmh.1989.41.161; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	84	141	146	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40344	40356		10.1074/jbc.M006398200	http://dx.doi.org/10.1074/jbc.M006398200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11005814	hybrid			2022-12-25	WOS:000166039500075
J	Fagan, KA; Graf, RA; Tolman, S; Schaack, J; Cooper, DMF				Fagan, KA; Graf, RA; Tolman, S; Schaack, J; Cooper, DMF			Regulation of a Ca2+-sensitive adenylyl cyclase in an excitable cell - Role of voltage-gated versus capacitative Ca2+ entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C6-2B GLIOMA-CELLS; CALCIUM-ENTRY; ADENOVIRUS TYPE-5; PITUITARY-CELLS; CYCLIC-AMP; RESPONSE ELEMENT; MESSENGER-RNA; E1A PROTEIN; PC12 CELLS; RAT-BRAIN	In nonexcitable cells, we had previously established that Ca2+-sensitive adenylyl cyclases, whether expressed endogenously or heterologously, were regulated exclusively by capacitative Ca2+ entry (Fagan, K, A, Mahey, R, and Cooper, D, M, F, (1996) J, Biol. Chem. 271, 12438-12444; Fagan, K, A., Mons, N., and Cooper, D. M. F, (1998) J. Biol. Chem, 273, 9297-9305), Relatively little is known about how these enzymes are regulated by Ca2+ in excitable cells, where they predominate. Furthermore, no effort has been made to determine whether the prominent voltage-gated Ca2+ entry, which typifies excitable cells, overwhelms the effect of any capacitative Ca2+ entry that may occur. In the present study, we placed the Ca2+-stimulable, adenylyl cyclase type VIII in an adenovirus vector to optimize its expression in the pituitary-derived GH(4)C(1) cell line. In these cells, a modest degree of capacitative Ca2+ entry could be discerned in the face of a dramatic voltage-gated Ca2+ entry. Nevertheless, both modes of Ca2+ entry were equally efficacious at stimulating adenylyl cyclase, A striking release of Ca2+ from intracellular stores, triggered either by ionophore or thyrotrophin-releasing hormone, was incapable of stimulating the adenylyl cyclase. It thus appears as though the intimate colocalization of adenylyl cyclase with capacitative Ca2+ entry channels is an intrinsic property of these molecules, regardless of whether they are expressed in excitable or nonexcitable cells.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cooper, DMF (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Box C-236,4200 E 9th Ave, Denver, CO 80262 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028389] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28389] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Burnay MM, 1998, BIOCHEM J, V330, P21, DOI 10.1042/bj3300021; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; CHINNADURAI G, 1979, J VIROL, V32, P623, DOI 10.1128/JVI.32.2.623-628.1979; CHINNADURAI G, 1978, J VIROL, V26, P195, DOI 10.1128/JVI.26.1.195-199.1978; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Cooper DMF, 1998, J BIOL CHEM, V273, P27703, DOI 10.1074/jbc.273.42.27703; ENGEL DA, 1991, P NATL ACAD SCI USA, V88, P3957, DOI 10.1073/pnas.88.9.3957; EVANS T, 1984, MOL PHARMACOL, V26, P395; Fagan KA, 1999, J BIOL CHEM, V274, P12445, DOI 10.1074/jbc.274.18.12445; Fagan KA, 2000, J BIOL CHEM, V275, P26530, DOI 10.1074/jbc.M001369200; Fagan KA, 1998, J BIOL CHEM, V273, P9297, DOI 10.1074/jbc.273.15.9297; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; Fomina AF, 1999, J NEUROSCI, V19, P3711; Furukawa T, 1999, J PHARMACOL EXP THER, V291, P464; GEDRICH RW, 1995, J VIROL, V69, P2333, DOI 10.1128/JVI.69.4.2333-2340.1995; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JONES N, 1978, CELL, V13, P181, DOI 10.1016/0092-8674(78)90148-4; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Koizumi S, 1998, BIOCHEM BIOPH RES CO, V244, P293, DOI 10.1006/bbrc.1998.8251; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; Lee BH, 1997, P NATL ACAD SCI USA, V94, P4481, DOI 10.1073/pnas.94.9.4481; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; MOLLARD P, 1990, BIOCHEM J, V268, P345, DOI 10.1042/bj2680345; MOLLARD P, 1994, J BIOL CHEM, V269, P25158; MONS N, 1995, TRENDS NEUROSCI, V18, P536, DOI 10.1016/0166-2236(95)98375-9; Nakahashi Y, 1997, J BIOL CHEM, V272, P18093, DOI 10.1074/jbc.272.29.18093; Naraghi M, 1997, J NEUROSCI, V17, P6961; Otsuka Y, 1998, TOHOKU J EXP MED, V185, P139, DOI 10.1620/tjem.185.139; PASTAN I, 1971, NATURE-NEW BIOL, V229, P5, DOI 10.1038/newbio229005a0; PAULSSEN RH, 1994, EUR J BIOCHEM, V222, P97, DOI 10.1111/j.1432-1033.1994.tb18846.x; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1999, BIOESSAYS, V21, P38; Rossie S, 1999, ADV SEC MESS PHOSPH, V33, P23; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHAACK J, 1995, J VIROL, V69, P3920, DOI 10.1128/JVI.69.6.3920-3923.1995; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; Shuttleworth TJ, 1999, J BIOL CHEM, V274, P31174, DOI 10.1074/jbc.274.44.31174; SMITH DH, 1985, MOL CELL BIOL, V5, P2684, DOI 10.1128/MCB.5.10.2684; Taylor SC, 1999, J NEUROCHEM, V73, P874, DOI 10.1046/j.1471-4159.1999.0730874.x; Watson EL, 1998, AM J PHYSIOL-CELL PH, V274, pC557, DOI 10.1152/ajpcell.1998.274.3.C557; Whalen SG, 1997, J VIROL, V71, P3545, DOI 10.1128/JVI.71.5.3545-3553.1997; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; YU HJ, 1993, MOL PHARMACOL, V44, P689; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209	53	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40187	40194		10.1074/jbc.M006606200	http://dx.doi.org/10.1074/jbc.M006606200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11010970	hybrid			2022-12-25	WOS:000166039500055
J	Farhang-Fallah, J; Yin, XH; Trentin, G; Cheng, AM; Rozakis-Adcock, M				Farhang-Fallah, J; Yin, XH; Trentin, G; Cheng, AM; Rozakis-Adcock, M			Cloning and characterization of PHIP, a novel insulin receptor substrate-1 pleckstrin homology domain interacting protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAYS; IRS-1; RAS; PHOSPHORYLATION; SHC; ASSOCIATION; COMPLEXES; REGION; SYSTEM; CELLS	Insulin receptor substrate-1 (IRS-1) protein is a major substrate of the insulin receptor tyrosine kinase and is essential for transducing many of the biological effects of insulin including mitogenesis, gene expression, and glucose transport. The N terminus of IRS-1 contains a pleckstrin homology (PH) domain that is critical for recognition and subsequent phosphorylation of IRS-1 by the activated insulin receptor. Here we report the isolation of a novel protein, PHIP (PH-interacting protein), which selectively binds to the PH domain of IRS-1 in vitro and stably associates with IRS-1 in vivo, Importantly, mutants of the IRS-1 PH domain that disrupt the PH fold fail to bind to PHIP. Anti-phosphotyrosine immunoblots of PHIP revealed no discernible insulin receptor-regulated phosphorylation, suggesting that PHIP is not itself a substrate of the insulin receptor. In contrast to full-length PHIP, overexpression of the PH-binding region of PHIP has a pronounced inhibitory effect on insulin-induced IRS-1 tyrosine phosphorylation levels. Furthermore, expression of this dominant-negative PHIP mutant leads to a marked attenuation of insulin-stimulated mitogen-activated protein kinase activity. We conclude that PHIP represents a novel protein ligand of the IRS-1 PH domain that may serve to link IRS-1 to the insulin receptor.	Hamilton Reg Canc Ctr, Hamilton, ON L8V 5C2, Canada; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8S 4K1, Canada; Washington Univ, Sch Med, Dept Med & Pathol, St Louis, MO 63110 USA	McMaster University; McMaster University; McMaster University; Washington University (WUSTL)	Rozakis-Adcock, M (corresponding author), Hamilton Reg Canc Ctr, 699 Concess St, Hamilton, ON L8V 5C2, Canada.							Artalejo CR, 1997, EMBO J, V16, P1565, DOI 10.1093/emboj/16.7.1565; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; Burks DJ, 1998, J BIOL CHEM, V273, P31061, DOI 10.1074/jbc.273.47.31061; Burks DJ, 1997, J BIOL CHEM, V272, P27716, DOI 10.1074/jbc.272.44.27716; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; Ma AD, 1997, J CELL BIOL, V136, P1071, DOI 10.1083/jcb.136.5.1071; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; White MF, 1998, CURR TOP MICROBIOL, V228, P179; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Yenush L, 1996, MOL CELL BIOL, V16, P2509	27	40	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40492	40497		10.1074/jbc.C000611200	http://dx.doi.org/10.1074/jbc.C000611200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11018022	hybrid			2022-12-25	WOS:000166039500093
J	Heath, RJ; Su, N; Murphy, CK; Rock, CO				Heath, RJ; Su, N; Murphy, CK; Rock, CO			The enoyl-[acyl-carrier-protein] reductases FabI and FabL from Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-CARRIER-PROTEIN; FATTY-ACID ELONGATION; ENOYL-ACP REDUCTASE; ESCHERICHIA-COLI; MYCOBACTERIUM-TUBERCULOSIS; TRICLOSAN; GENE; TARGET; INHA; INHIBITION	Enoyl-[acyl-carrier-protein] (ACP) reductase is a key enzyme in type II fatty-acid synthases that catalyzes the last step in each elongation cycle. The FabI component of Bacillus subtilis (bsFabI) was identified in the genomic data base by homology to the Escherichia coli protein, bsFabI was cloned and purified and exhibited properties similar to those of E. coli FabI, including a marked preference for NADH over NADPH as a cofactor. Overexpression of the B. subtilis fabI gene complemented the temperature-sensitive growth phenotype of an E. coli fabI mutant. Triclosan was a slow-binding inhibitor of bsFabI and formed a stable bsFabI NAD(+.) triclosan ternary complex. Analysis of the B. subtilis genomic data base revealed a second open reading frame (ygaA) that was predicted to encode a protein with a relatively low overall similarity to FabI, but contained the Tyr-Xaa(6)-Lys enoyl-ACP reductase catalytic architecture. The purified YgaA protein catalyzed the NADPH-dependent reduction of trans-2-enoyl thioesters of both N-acetylcysteamine and ACP. YgaA was reversibly inhibited by triclosan, but did not form the stable ternary complex characteristic of the FabI proteins. Expression of YgaA complemented the fabI(ts) defect in E. coli and conferred complete triclosan resistance. Single knockouts of the ygaA or fabI gene in B. subtilis were viable, but double knockouts were not obtained. The fabI knockout was as sensitive as the wild-type strain to triclosan, whereas the ygaA knockout was 250-fold more sensitive to the drug. YgaA was renamed FabL to denote the discovery of a new family of proteins that carry out the enoyl-ACP reductase step in type II fatty-acid synthases.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38105 USA; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Rock, CO (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.			Heath, Richard/0000-0002-1795-1254	NCI NIH HHS [CA21765] Funding Source: Medline; NIGMS NIH HHS [GM34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034496, R37GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAKER ME, 1995, BIOCHEM J, V309, P1029, DOI 10.1042/bj3091029; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BERGLER H, 1992, J GEN MICROBIOL, V138, P2093, DOI 10.1099/00221287-138-10-2093; BERGLER H, 1994, J BIOL CHEM, V269, P5493; CUTTING SM, 1990, MOL BIOL METHODS BAC, P67; de Boer GJ, 1999, MOL MICROBIOL, V31, P443, DOI 10.1046/j.1365-2958.1999.01182.x; Duax WL, 1996, CURR OPIN STRUC BIOL, V6, P813, DOI 10.1016/S0959-440X(96)80012-1; EGAN AF, 1973, GENET RES, V21, P3603; Heath RJ, 2000, NATURE, V406, P145, DOI 10.1038/35018162; Heath RJ, 1996, J BIOL CHEM, V271, P1833, DOI 10.1074/jbc.271.4.1833; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; HEATH RJ, 1995, J BIOL CHEM, V270, P15531, DOI 10.1074/jbc.270.26.15531; Heath RJ, 1998, J BIOL CHEM, V273, P30316, DOI 10.1074/jbc.273.46.30316; Heath RJ, 2000, J BIOL CHEM, V275, P4654, DOI 10.1074/jbc.275.7.4654; Heath RJ, 1999, J BIOL CHEM, V274, P11110, DOI 10.1074/jbc.274.16.11110; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Levy CW, 1999, NATURE, V398, P383, DOI 10.1038/18803; McMurry LM, 1998, NATURE, V394, P531, DOI 10.1038/28970; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Parikh S, 1999, BIOCHEMISTRY-US, V38, P13623, DOI 10.1021/bi990529c; PETTY KJ, 1994, CURRENT PROTOCOLS MO; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; Rock C. O., 1996, NEW COMPREHENSIVE BI, V31, P35; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; Roujeinikova A, 1999, J MOL BIOL, V294, P527, DOI 10.1006/jmbi.1999.3240; Roujeinikova A, 1999, J BIOL CHEM, V274, P30811, DOI 10.1074/jbc.274.43.30811; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; Wang P, 1996, J BACTERIOL, V178, P6873, DOI 10.1128/jb.178.23.6873-6881.1996; Ward WHJ, 1999, BIOCHEMISTRY-US, V38, P12514, DOI 10.1021/bi9907779; WEEKS G, 1968, J BIOL CHEM, V243, P1180; YOUNGMAN P, 1984, PLASMID, V12, P1, DOI 10.1016/0147-619X(84)90061-1	34	156	175	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40128	40133		10.1074/jbc.M005611200	http://dx.doi.org/10.1074/jbc.M005611200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007778	hybrid			2022-12-25	WOS:000166039500046
J	Mohamed, AJ; Vargas, L; Nore, BF; Backesjo, CM; Christenssonn, B; Smith, CIE				Mohamed, AJ; Vargas, L; Nore, BF; Backesjo, CM; Christenssonn, B; Smith, CIE			Nucleocytoplasmic shuttling of Bruton's tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; X-LINKED AGAMMAGLOBULINEMIA; NUCLEAR EXPORT SIGNALS; SRC FAMILY; TEC FAMILY; ACTIVATION; CELLS; BTK; ASSOCIATION; EXPRESSION	Bruton's tyrosine kinase (Btk), a nonreceptor cytoplasmic tyrosine kinase belonging to the Tec family of kinases, has been shown to be critical for B cell proliferation, differentiation, and signaling. Loss-of-function mutations in the Btk gene lead to X-linked agammaglobulinemia (XLA), a primary immunodeficiency in humans, and the less severe condition xid in mice. Although Btk is mainly localized in the cytoplasm under steady state conditions, it translocates to the plasma membrane upon growth factor stimulation and crosslinking of the B cell receptor. Nevertheless, in ectopically as well as endogenously Btk-expressing cells, it can also translocate to the nucleus. Deletion of the pleckstrin homology (PH) domain (Delta PH1) leads, however, to an even redistribution of Btk within the nucleus and cytoplasm in the majority of transfected cells. In contrast, an SH3-deleted (Delta SH3) mutant of Btk has been found to be predominantly nuclear. We also demonstrate that the nuclear accumulation of Delta PH1 is dependent on Src expression. This nucleocytoplasmic shuttling is sensitive to the exportin 1/CRM1-inactivating drug, leptomycin B, indicating that Btk utilizes functional nuclear export signals. In addition, while the Delta PH1 mutant of Btk was found to be active and tyrosine-phosphorylated in vivo, Delta SH3 displayed decreased autokinase activity and was not phosphorylated. Our findings indicate that the nucleocytoplasmic shuttling of Btk has implications regarding potential targets inside the nucleus, which may be critical in gene regulation during B cell development and differentiation.	Karolinska Inst, Novum, Dept Biosci, Clin Res Ctr, S-14157 Huddinge, Sweden; Huddinge Univ Hosp, Karolinska Inst, Dept Immunol Microbiol Pathol & Infect Dis, SE-14186 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet	Mohamed, AJ (corresponding author), Karolinska Inst, Novum, Dept Biosci, Clin Res Ctr, S-14157 Huddinge, Sweden.		Nore, Beston F./N-9288-2016	Nore, Beston F./0000-0003-3865-2920; SMITH, C. I. Edvard/0000-0003-1907-3392				Afar DEH, 1996, MOL CELL BIOL, V16, P3465; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Ching KA, 1999, J IMMUNOL, V163, P6006; Conley ME, 1998, CURR OPIN IMMUNOL, V10, P399, DOI 10.1016/S0952-7915(98)80112-X; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fridell RA, 1996, P NATL ACAD SCI USA, V93, P4421, DOI 10.1073/pnas.93.9.4421; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Hata D, 1998, J BIOL CHEM, V273, P10979, DOI 10.1074/jbc.273.18.10979; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Kashiwakura J, 1999, J EXP MED, V190, P1147, DOI 10.1084/jem.190.8.1147; Kitanaka A, 1998, BLOOD, V91, P940, DOI 10.1182/blood.V91.3.940.940_940_948; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kurosaki T, 2000, CURR OPIN IMMUNOL, V12, P276, DOI 10.1016/S0952-7915(00)00087-X; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Li TJ, 1997, ONCOGENE, V15, P1375, DOI 10.1038/sj.onc.1201308; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; Mano H, 1999, CYTOKINE GROWTH F R, V10, P267, DOI 10.1016/S1359-6101(99)00019-2; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Mohamed AJ, 1999, SCAND J IMMUNOL, V49, P113; Nore BF, 2000, EUR J IMMUNOL, V30, P145, DOI 10.1002/1521-4141(200001)30:1<145::AID-IMMU145>3.0.CO;2-0; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Sable CL, 1998, J BIOL CHEM, V273, P29600, DOI 10.1074/jbc.273.45.29600; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SMITH CIE, 2001, IN PRESS BIOESSAYS; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Vihinen M, 2001, ADV GENET, V43, P103, DOI 10.1016/S0065-2660(01)43005-7; Yamashita Y, 1998, BLOOD, V91, P1496, DOI 10.1182/blood.V91.5.1496.1496_1496_1507; Yamashita Y, 1996, JPN J CANCER RES, V87, P1106, DOI 10.1111/j.1349-7006.1996.tb03118.x; Yang WC, 2000, IMMUNITY, V12, P373, DOI 10.1016/S1074-7613(00)80189-2; YANG WY, 1995, J BIOL CHEM, V270, P20832, DOI 10.1074/jbc.270.35.20832	38	63	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40614	40619		10.1074/jbc.M006952200	http://dx.doi.org/10.1074/jbc.M006952200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11016936	hybrid			2022-12-25	WOS:000166039500109
J	Pomerance, M; Abdullah, HB; Kamerji, S; Correze, C; Blondeau, JP				Pomerance, M; Abdullah, HB; Kamerji, S; Correze, C; Blondeau, JP			Thyroid-stimulating hormone and cyclic AMP activate p38 mitogen-activated protein kinase cascade - Involvement of protein kinase A, Rac1, and reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; BETA-GAMMA-SUBUNITS; GROWTH FACTOR-I; MAP KINASE; JUN-KINASE; COUPLED RECEPTORS; SUBSTRATE-SPECIFICITY; TRANSCRIPTION FACTORS; DEPENDENT ACTIVATION; ACTIN REORGANIZATION	p38 mitogen-activated protein kinases (p38-MAPKs) are activated by cytokines, cellular stresses, growth factors, and hormones. We show here that p38-MAPKs are activated upon stimulation by thyroid-stimulating hormone (TSH) or cAMP. TSH caused the phosphorylation of p38-MAPK in Chinese hamster ovary cells stably transfected with the human TSH receptor but not in wild-type Chinese hamster ovary cells. The effect of TSH was fully mimicked by the adenylyl cyclase activator, forskolin, and by a permeant analog of cAMP. The effect of forskolin was reproduced in FRTL5 rat thyroid cells. TSH also stimulated the phosphorylation of MAPK kinase 3 or 6, over the same time scale as that of p38-MAPKs. TSH and forskolin stimulated the activity of the cy-isoform of p38-MAPK assayed by phosphorylation of the transcription factor ATF2. The activity of MAPK-activated protein kinase-2 was stimulated by TSH and forskolin. This stimulation was abolished by SB203580, a specific inhibitor of p38-MAPKs. The protein kinase A inhibitor H89 inhibited the stimulation of phosphorylation of p38-MAPKs by forskolin, whereas inhibitors of protein kinase C, p70(S6k), and phosphatidylinositol 3-kinase were ineffective. Expression of the dominant negative form of Rad, but not that of Ras, blocked forskolin-induced p38-MAPK activation. Diphenylene iodonium, a potent inhibitor of NADPH oxidase(s), and ascorbic acid, an effective free radical scavenger, suppressed TSH- or forskolin-stimulated p38-MAPK phosphorylation, indicating that the generation of reactive oxygen species plays a key role in signaling from cAMP to p38-MAPKs. Inhibition of the p38-MAPK pathway with SB203580 partially but significantly, attenuates cAMP- and TSH-induced expression of the sodium iodide symporter in FRTL-5 cells. These results point to a new signaling pathway for the G(s)-coupled TSH receptor, involving cAMP, protein kinase A, Rad, and reactive oxygen species and resulting in the activation of a signaling kinase cascade that includes MAPK kinase 3 or 6, p38-MAPK, and MAPK-activated protein kinase-2.	Fac Pharm Chatenay Malabry, INSERM U486, F-92296 Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Pomerance, M (corresponding author), Fac Pharm Chatenay Malabry, INSERM U486, Tour D1,5 Rue Jean Baptiste Clement, F-92296 Chatenay Malabry, France.		Blondeau, Jean-Paul/AAH-6395-2019	Blondeau, Jean-Paul/0000-0003-4520-6822				ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BJORKMAN U, 1992, ENDOCRINOLOGY, V130, P393, DOI 10.1210/en.130.1.393; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; Browning DD, 1999, J BIOL CHEM, V274, P537, DOI 10.1074/jbc.274.1.537; Cass LA, 1999, MOL CELL BIOL, V19, P5882; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Correze C, 2000, THYROID, V10, P747, DOI 10.1089/thy.2000.10.747; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEME D, 1994, BIOCHEM J, V301, P75, DOI 10.1042/bj3010075; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dremier S, 1997, MOL CELL BIOL, V17, P6717, DOI 10.1128/MCB.17.11.6717; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; EVANS T, 1984, MOL PHARMACOL, V26, P395; FAURE M, 1994, J BIOL CHEM, V269, P7851; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Guay J, 1997, J CELL SCI, V110, P357; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Kogai T, 1997, ENDOCRINOLOGY, V138, P2227, DOI 10.1210/en.138.6.2227; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lopez-Ilasaca M, 1998, BIOCHEM PHARMACOL, V56, P269, DOI 10.1016/S0006-2952(98)00059-8; Maizels ET, 1998, ENDOCRINOLOGY, V139, P3353, DOI 10.1210/en.139.7.3353; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; PERRET J, 1990, BIOCHEM BIOPH RES CO, V171, P1044, DOI 10.1016/0006-291X(90)90789-P; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Pomerance M, 1996, MOL CELL BIOL, V16, P3179; Pomerance M, 1998, J BIOL CHEM, V273, P24301, DOI 10.1074/jbc.273.38.24301; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Rachdaoui N, 1999, MOL CELL ENDOCRINOL, V156, P35, DOI 10.1016/S0303-7207(99)00147-1; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROGER PP, 1982, MOL CELL ENDOCRINOL, V26, P165, DOI 10.1016/0303-7207(82)90014-4; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Spitzweg C, 2000, THYROID, V10, P321, DOI 10.1089/thy.2000.10.321; TAHARA K, 1991, J BIOL CHEM, V266, P440; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P127, DOI 10.1210/endo-122-1-127; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WOLOSHIN PI, 1992, MOL ENDOCRINOL, V6, P1725, DOI 10.1210/me.6.10.1725; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhao M, 1999, MOL CELL BIOL, V19, P21; Zhen XC, 1998, MOL PHARMACOL, V54, P453, DOI 10.1124/mol.54.3.453; Zhou TH, 2000, J BIOL CHEM, V275, P2513, DOI 10.1074/jbc.275.4.2513	66	79	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40539	40546		10.1074/jbc.M002097200	http://dx.doi.org/10.1074/jbc.M002097200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11006268	hybrid			2022-12-25	WOS:000166039500099
J	Pykari, M; Toivonen, S; Natunen, J; Niemela, R; Salminen, H; Aitio, O; Ekstrom, M; Parmanne, P; Valimaki, M; Alais, J; Auge, C; Lowe, JB; Renkonen, O; Renkonen, R				Pykari, M; Toivonen, S; Natunen, J; Niemela, R; Salminen, H; Aitio, O; Ekstrom, M; Parmanne, P; Valimaki, M; Alais, J; Auge, C; Lowe, JB; Renkonen, O; Renkonen, R			The acceptor and site specificity of alpha 3-fucosyltransferase V - High reactivity of the proximal and low of the distal, Gal beta 1-4GlcNAc unit in i-type polylactosamines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; BLOOD-GROUP-I; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; LYMPHOCYTE-ENDOTHELIUM ADHESION; LINKED CARBOHYDRATE CHAINS; WGA-AGAROSE CHROMATOGRAPHY; ENDO-BETA-GALACTOSIDASE; MEDIATED CELL-ADHESION; WHEAT-GERM-AGGLUTININ; LACTO-N-NEOHEXAOSE	We report here on in vitro acceptor and site specificity of recombinant alpha3-fucosyltransferase V (Fuc-TV) with 40 oligosaccharide accepters. Gal beta1-4GlcNAc (LN) and GalNAc beta1-4GlcNAc (LDN) reacted rapidly; Gal beta1-3Glc-NAc (LNB) reacted moderately, and GlcNAc beta1-4GlcNAc (N,N'-diacetyl-chitobiose) reacted slowly yet distinctly. In neutral and terminally alpha3-sialylated polylactosamines of i-type, the reducing end LN unit reacted rapidly and the distal (sialyl)LN group very slowly; the midchain LNs revealed intermediate reactivities. The data suggest that a distal LN neighbor enhances but a proximal LN neighbor reduces the reactivity of the midchain LNs. This implies that Fuc-TV may bind preferably the tetrasaccharide sequence Gal beta1-4GlcNAc beta1-3Gal beta1-4GlcNAc for transfer at the underlined monosaccharide. Terminal alpha3-sialylation of i-type polylactosamines almost doubled the reactivities of the LN units at all positions of the chains. We conclude that, in comparison with human Fuc-TIV and Fuc-TIX, Fuc-TV reacted with a highly distinct site specificity with i-type polylactosamines. The Fuc-TV reactivity of free LNB resembled that of LNB beta1-3'R of a polylactosamine, contrasting strongly with the dissimilarity of the reactivities of the analogous pair of LN and LN beta1-3'R. This observation supports the notion that LN and LNB may be functionally bound at distinct sites on Fuc-TV surface. Our data show that Fuc-TV worked well with a very wide range of LN-glycans, showing weak reactivity only with distal (sialyl)LN units of i-type polylactosamines, biantennary N-glycans, and I branches of polylactosamines.	Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Paris 11, Lab Chim Organ Multifonctionelle, F-91405 Orsay, France; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst, FIN-00014 Helsinki, Finland; HUCH Lab Diagnost, FIN-00014 Helsinki, Finland	University of Helsinki; UDICE-French Research Universities; Universite Paris Saclay; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Helsinki	Renkonen, R (corresponding author), Univ Helsinki, Inst Biotechnol, POB 56, FIN-00014 Helsinki, Finland.	risto.renkonen@helsinki.fi		Valimaki, Mika/0000-0002-9687-8197; Parmanne, Pinja/0000-0002-4691-2107	NATIONAL CANCER INSTITUTE [P01CA071932] Funding Source: NIH RePORTER; NCI NIH HHS [1PO1CA71932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALAIS J, 1990, CARBOHYD RES, V207, P11, DOI 10.1016/0008-6215(90)80002-K; BERGWERFF AA, 1992, FEBS LETT, V314, P389, DOI 10.1016/0014-5793(92)81512-K; Boubelik M, 1998, GLYCOBIOLOGY, V8, P139, DOI 10.1093/glycob/8.2.139; BREW K, 1968, P NATL ACAD SCI USA, V59, P491, DOI 10.1073/pnas.59.2.491; Chandrasekaran EV, 1996, BIOCHEMISTRY-US, V35, P8925, DOI 10.1021/bi952194e; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; DEVRIES T, 1993, EUR J BIOCHEM, V216, P769, DOI 10.1111/j.1432-1033.1993.tb18197.x; DeVries T, 1997, GLYCOBIOLOGY, V7, P921, DOI 10.1093/glycob/7.7.921; Dupuy F, 1999, J BIOL CHEM, V274, P12257, DOI 10.1074/jbc.274.18.12257; EGGENS I, 1989, J BIOL CHEM, V264, P9476; Geyer A, 1999, ANGEW CHEM INT EDIT, V38, P1466, DOI 10.1002/(SICI)1521-3773(19990517)38:10<1466::AID-ANIE1466>3.0.CO;2-#; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; Goodman JL, 1999, J CLIN INVEST, V103, P407, DOI 10.1172/JCI4230; Grabenhorst E, 1998, J BIOL CHEM, V273, P30985, DOI 10.1074/jbc.273.47.30985; GRINNELL BW, 1994, GLYCOBIOLOGY, V4, P221, DOI 10.1093/glycob/4.2.221; GU J, 1992, J BIOL CHEM, V267, P2994; Hakamori S, 1998, ACTA ANAT, V161, P79; HAKOMORI SI, 1992, HISTOCHEM J, V24, P771, DOI 10.1007/BF01046348; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; Kaneko M, 1999, FEBS LETT, V452, P237, DOI 10.1016/S0014-5793(99)00640-7; Kannagi R, 1997, GLYCOCONJUGATE J, V14, P577, DOI 10.1023/A:1018532409041; KOBATA A, 1979, ANAL BIOCHEM, V100, P1, DOI 10.1016/0003-2697(79)90102-7; Koeller KM, 2000, CHEM-EUR J, V6, P1243, DOI 10.1002/(SICI)1521-3765(20000403)6:7<1243::AID-CHEM1243>3.3.CO;2-A; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; Leppanen A, 1997, BIOCHEMISTRY-US, V36, P7026, DOI 10.1021/bi9627673; LEPPANEN A, 1991, BIOCHEMISTRY-US, V30, P9287, DOI 10.1021/bi00102a022; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MAAHEIMO H, 1994, FEBS LETT, V349, P55, DOI 10.1016/0014-5793(94)00638-5; MAAHEIMO H, 1995, EUR J BIOCHEM, V234, P616, DOI 10.1111/j.1432-1033.1995.616_b.x; MACHYTKA D, 1994, CARBOHYD RES, V254, P289, DOI 10.1016/0008-6215(94)84262-0; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; Murray BW, 1996, BIOCHEMISTRY-US, V35, P11183, DOI 10.1021/bi961065a; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NATUNEN J, 1994, GLYCOBIOLOGY, V4, P577, DOI 10.1093/glycob/4.5.577; NATUNEN J, 1997, GLYCOCONJUGATE J, V14, pS114; Nguyen AT, 1998, J BIOL CHEM, V273, P25244, DOI 10.1074/jbc.273.39.25244; NIEMELA R, 1995, GLYCOCONJUGATE J, V12, P36, DOI 10.1007/BF00731866; Niemela R, 1999, GLYCOBIOLOGY, V9, P517, DOI 10.1093/glycob/9.5.517; Niemela R, 1995, CARBOHYD RES, V279, P331, DOI 10.1016/0008-6215(95)00299-5; Niemela R, 1998, J BIOL CHEM, V273, P4021, DOI 10.1074/jbc.273.7.4021; Nishihara S, 1999, FEBS LETT, V462, P289, DOI 10.1016/S0014-5793(99)01549-5; PALCIC M M, 1991, Glycobiology, V1, P205, DOI 10.1093/glycob/1.2.205; PATEL TP, 1994, BIOCHEMISTRY-US, V33, P14815, DOI 10.1021/bi00253a021; Rabina J, 1997, CARBOHYD RES, V305, P491, DOI 10.1016/S0008-6215(97)00260-7; RENKONEN O, 1989, GLYCOCONJUGATE J, V6, P129, DOI 10.1007/BF01047895; RENKONEN O, 1991, GLYCOCONJUGATE J, V8, P361, DOI 10.1007/BF00731349; Renkonen O, 1997, GLYCOBIOLOGY, V7, P453, DOI 10.1093/glycob/7.4.453-c; RENKONEN O, 1990, BIOCHEM CELL BIOL, V68, P1032, DOI 10.1139/o90-152; Rosen SD, 1999, AM J PATHOL, V155, P1013, DOI 10.1016/S0002-9440(10)65201-7; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SEPPO A, 1995, BIOCHEMISTRY-US, V34, P4655, DOI 10.1021/bi00014a019; Seppo A, 1996, GLYCOBIOLOGY, V6, P65, DOI 10.1093/glycob/6.1.65; SIUZDAK G, 1993, J AM CHEM SOC, V115, P2877, DOI 10.1021/ja00060a040; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; Toppila S, 1999, EUR J BIOCHEM, V261, P208, DOI 10.1046/j.1432-1327.1999.00257.x; TOWNSEND RR, 1986, BIOCHEMISTRY-US, V25, P5716, DOI 10.1021/bi00367a055; TURUNEN JP, 1995, J EXP MED, V182, P1133, DOI 10.1084/jem.182.4.1133; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; WONG CH, 1992, J AM CHEM SOC, V114, P7321, DOI 10.1021/ja00044a068; YAMASHITA K, 1977, J BIOL CHEM, V252, P5408; Zollner O, 1996, J BIOL CHEM, V271, P33002, DOI 10.1074/jbc.271.51.33002	65	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40057	40063		10.1074/jbc.M007922200	http://dx.doi.org/10.1074/jbc.M007922200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007797	hybrid			2022-12-25	WOS:000166039500037
J	Viswanath, RL; Rose, SD; Swift, GH; MacDonald, RJ				Viswanath, RL; Rose, SD; Swift, GH; MacDonald, RJ			A binary mechanism for the selective action of a pancreatic beta-cell transcriptional silencer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; ELASTASE-I ENHANCER; SV40 ENHANCER; NEGATIVE REGULATION; REGULATORY ELEMENT; GENE-EXPRESSION; ACINAR-CELLS; INSULIN GENE; REPRESSION; EXOCRINE	The pancreatic elastase I gene (ELA1) is selectively transcribed to high levels in pancreatic acinar cells. Pancreatic specificity is imparted by a 100-base pair enhancer that activates transcription in beta -cells of the islets of Langerhans as well as in acinar cells. Adjacent to the enhancer is a silencer that renders transcription specific to acinar cells by selectively suppressing the inherent beta -cell activity of the enhancer. We show that the selective repression of beta -cell. transcription is due neither to a beta -cell specific activity of the silencer nor to selective interference with beta -cell-specific transcriptional activators acting on the enhancer. Rather, the silencer is effective in both pancreatic endocrine and acinar cell types against all low and moderate strength enhancers and promoters tested. The silencer appears to act in a binary manner by reducing the probability that a promoter will be active without affecting the rate of transcription from active promoters. We propose that the ELA1 silencer is a weak off switch capable of inactivating enhancer/promoter combinations whose strength is below a threshold level but ineffective against stronger enhancer/promoters. The apparent cell-specific effects on the ELA1 enhancer appear due to the ability of the silencer to inactivate the weak beta -cell activity of the enhancer but not the stronger acinar cell activity.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Integrated DNA Technol, Coralville, IA 52241 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	MacDonald, RJ (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	raymond.macdonald@UTSouthwestern.edu	MacDonald, Ray/AAA-1290-2022		NIDDK NIH HHS [DK27430, DK55266] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055266, R01DK027430] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BOAM DSW, 1990, J BIOL CHEM, V265, P8285; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CLARK SA, 1990, ENDOCRINOLOGY, V127, P2779, DOI 10.1210/endo-127-6-2779; Fiering S, 2000, BIOESSAYS, V22, P381, DOI 10.1002/(SICI)1521-1878(200004)22:4<381::AID-BIES8>3.0.CO;2-E; Goodman PA, 1996, MOL CELL ENDOCRINOL, V120, P139, DOI 10.1016/0303-7207(96)03830-0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUERIN SL, 1993, EUR J BIOCHEM, V213, P399, DOI 10.1111/j.1432-1033.1993.tb17774.x; GUZ Y, 1995, DEVELOPMENT, V121, P11; HAMMER RE, 1987, MOL CELL BIOL, V7, P2956, DOI 10.1128/MCB.7.8.2956; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; JACKSON ME, 1991, J CELL SCI, V100, P1; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KRUSE F, 1993, GENE DEV, V7, P774, DOI 10.1101/gad.7.5.774; KRUSE F, 1995, MOL CELL BIOL, V15, P4385; KRUSE F, 1988, MOL CELL BIOL, V8, P893, DOI 10.1128/MCB.8.2.893; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MOREAU P, 1981, NUCLEIC ACIDS RES, V9, P6047, DOI 10.1093/nar/9.22.6047; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; NIR U, 1986, P NATL ACAD SCI USA, V83, P3180, DOI 10.1073/pnas.83.10.3180; Ogbourne S, 1998, BIOCHEM J, V331, P1; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; ORNITZ DM, 1985, COLD SPRING HARB SYM, V50, P399, DOI 10.1101/SQB.1985.050.01.050; ORNITZ DM, 1985, NATURE, V313, P600, DOI 10.1038/313600a0; PHILIPPE J, 1987, J CLIN INVEST, V79, P351, DOI 10.1172/JCI112819; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; ROSE SD, 1994, MOL CELL BIOL, V14, P2048, DOI 10.1128/MCB.14.3.2048; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIRM S, 1987, GENE DEV, V1, P65, DOI 10.1101/gad.1.1.65; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SWIFT GH, 1989, GENE DEV, V3, P687, DOI 10.1101/gad.3.5.687; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; WASYLYK B, 1984, NUCLEIC ACIDS RES, V12, P5589, DOI 10.1093/nar/12.14.5589; WEINTRAUB H, 1988, P NATL ACAD SCI USA, V85, P5819, DOI 10.1073/pnas.85.16.5819; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x	50	2	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40273	40281		10.1074/jbc.M007021200	http://dx.doi.org/10.1074/jbc.M007021200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10995768	hybrid			2022-12-25	WOS:000166039500066
J	Weiss, JL; Archer, DA; Burgoyne, RD				Weiss, JL; Archer, DA; Burgoyne, RD			Neuronal Ca2+ sensor-1/frequenin autocrine pathway regulating Ca2+ bovine adrenal chromaffin cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; CA2+-BINDING PROTEIN; SENSOR 1; MODULATION; CHANNELS; FREQUENIN; CURRENTS; FACILITATION; CALMODULIN; NEUROCALCIN	NCS-1/frequenin belongs to a family of EF-hand-containing Ca2+ sensors expressed mainly in neurons. Overexpression of NCS-1/frequenin has been shown to stimulate neurotransmitter release but little else is known of its cellular roles. We have constructed an EF-hand mutant, NCS-1(E120Q), as a likely dominant inhibitor of cellular NCS-1 function. Recombinant NCS-1(E120Q) showed an impaired Ca2+-dependent conformational change but could still bind to cellular proteins. Transient expression of this mutant, but not NCS-1, in bovine adrenal chromaffin cells increased non-L-type Ca2+ channel currents. Cells expressing NCS-1(E120Q) no longer responded effectively to the removal of autocrine purinergic/opioid inhibition of Ca2+ currents but still showed voltage-dependent facilitation. These data are consistent with the existence of both voltage-dependent and voltage-independent pathways for Ca2+ channel inhibition in chromaffin cells. Our results suggest a novel function for NCS-1 specific for the voltage-independent autocrine pathway that negatively regulates non-L-type Ca2+ channels in chromaffin cells.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Burgoyne, RD (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	burgoyne@liverpool.ac.uk	Burgoyne, Robert D/P-6641-2019; Burgoyne, Robert/C-6706-2008	Burgoyne, Robert D/0000-0002-9219-0387; Burgoyne, Robert/0000-0002-9219-0387; Weiss, Jamie L/0000-0001-6784-5831				ALBILLOS A, 1993, FEBS LETT, V336, P259, DOI 10.1016/0014-5793(93)80815-C; Albillos A, 1996, J PHYSIOL-LONDON, V494, P687, DOI 10.1113/jphysiol.1996.sp021524; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Arnot MI, 2000, J PHYSIOL-LONDON, V527, P203, DOI 10.1111/j.1469-7793.2000.00203.x; ARTALEJO CR, 1990, NATURE, V348, P239, DOI 10.1038/348239a0; ARTALEJO CR, 1994, NATURE, V367, P72, DOI 10.1038/367072a0; Braunewell KH, 1999, CELL TISSUE RES, V295, P1, DOI 10.1007/s004410051207; BURGOYNE RD, 1992, NEUROMETHODS, V20, P433; Burley JR, 2000, BIOPHYS J, V78, p104A; Carabelli V, 1998, NEURON, V20, P1255, DOI 10.1016/S0896-6273(00)80505-X; CENA V, 1989, J MEMBRANE BIOL, V112, P255, DOI 10.1007/BF01870956; COX JA, 1994, J BIOL CHEM, V269, P32807; Currie KPM, 1996, NEURON, V16, P1027, DOI 10.1016/S0896-6273(00)80126-9; Delmas P, 1998, EUR J NEUROSCI, V10, P1654, DOI 10.1046/j.1460-9568.1998.00170.x; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; DIVERSEPIERLUISSI M, 1991, P NATL ACAD SCI USA, V88, P1261, DOI 10.1073/pnas.88.4.1261; Dolphin AC, 1998, J PHYSIOL-LONDON, V506, P3, DOI 10.1111/j.1469-7793.1998.003bx.x; DOUPNIK CA, 1992, PFLUG ARCH EUR J PHY, V420, P61, DOI 10.1007/BF00378642; Dunlap KL, 1998, SEMIN NEUROSCI, V9, P198, DOI 10.1006/smns.1997.0119; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Faurobert E, 1996, J BIOL CHEM, V271, P10256, DOI 10.1074/jbc.271.17.10256; FORMENTI A, 2000, J PHYSL, V509, P395; Graham ME, 2000, J NEUROSCI, V20, P1281; Graham ME, 2000, BIOCHIMIE, V82, P469, DOI 10.1016/S0300-9084(00)00196-6; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; LADANT D, 1995, J BIOL CHEM, V270, P3179; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; McFerran BW, 1999, J BIOL CHEM, V274, P30258, DOI 10.1074/jbc.274.42.30258; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; NEF S, 1995, J RECEPT SIGNAL TR R, V15, P365, DOI 10.3109/10799899509045227; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; Olafsson P, 1997, MOL BRAIN RES, V44, P73, DOI 10.1016/S0169-328X(96)00188-X; OLAFSSON P, 1995, P NATL ACAD SCI USA, V92, P8001, DOI 10.1073/pnas.92.17.8001; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; Powell AD, 2000, J NEUROSCI, V20, P606, DOI 10.1523/JNEUROSCI.20-02-00606.2000; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; RIVOSECCHI R, 1994, J PHYSIOL-LONDON, V474, P223, DOI 10.1113/jphysiol.1994.sp020015; Schaad NC, 1996, P NATL ACAD SCI USA, V93, P9253, DOI 10.1073/pnas.93.17.9253; TANOUYE MA, 1981, P NATL ACAD SCI-BIOL, V78, P6548, DOI 10.1073/pnas.78.10.6548; TWITCHELL WA, 1993, NEURON, V10, P701, DOI 10.1016/0896-6273(93)90171-M; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	44	85	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40082	40087		10.1074/jbc.M008603200	http://dx.doi.org/10.1074/jbc.M008603200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11006299	hybrid			2022-12-25	WOS:000166039500040
J	Elizondo, G; Corchero, J; Sterneck, E; Gonzalez, FJ				Elizondo, G; Corchero, J; Sterneck, E; Gonzalez, FJ			Feedback inhibition of the retinaldehyde dehydrogenase gene ALDH1 by retinoic acid through retinoic acid receptor A and CCAAT/enhancer-binding protein beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDEHYDE DEHYDROGENASE; C/EBP-BETA; RESPONSE ELEMENT; TRANSCRIPTIONAL REGULATION; MAMMALIAN-CELLS; PROMOTER; IDENTIFICATION; ALPHA; EXTRACTION; ACTIVATION	Aldehyde dehydrogenase 1 (ALDH1) plays a major role in the biosynthesis of retinoic acid (RA), a hormone required for several essential life processes. Recent evidence, using the aryl hydrocarbon receptor-null mouse, suggests that elevated hepatic RA down-regulates ALDH1 in a unique feedback pathway to control RA biosynthesis. To determine the mechanism of suppression of the ALDH1 gene by RA, transactivation studies were carried out in Hepa-1 mouse hepatoma cells. RA decreased expression of an ALDH1-CAT construct containing -2536 base pairs of DNA upstream of the transcription start site. Retinoic acid receptor alpha (RAR alpha) transactivates the ALDH1 gene promoter through a complex with an RA response-like element (RARE) located at -91/-75 bp, which bound to the RAR alpha /retinoid X receptor beta heterodimer. CCAAT/enhancer-binding protein (C/EBP beta) also transactivates the ALDH1 gene promoter through a CCAAT box located 3' and directly adjacent to the RARE, and the ALDH1 gene is downregulated in C/EBP beta -null mouse liver. Exposure of Hepa-1 cells to RA results in a decrease in C/EBP beta mRNA levels; however, there was no difference in mRNA and protein levels between wild-type and AHR-null mouse liver. These data support a model in which the RAR alpha and C/EBP beta activate the ALDH1 gene promoter through the RARE and C/EBP response elements, and in Hepa-1 cells, high levels of RA inhibit this activation by decreasing cellular levels of C/EBP beta.	NCI, NIH, Lab Metab, Bethesda, MD 20892 USA; NCI, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Gonzalez, FJ (corresponding author), NCI, NIH, Lab Metab, Bldg 37,Rm 3E-24, Bethesda, MD 20892 USA.			Sterneck, Esta/0000-0001-7716-8766	NATIONAL CANCER INSTITUTE [Z01BC005708, ZIABC005708] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreola F, 1997, CANCER RES, V57, P2835; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Ausubel F., 1999, CURRENT PROTOCOLS MO; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Crowe DL, 1998, MOL CARCINOGEN, V22, P26; de The H, 1990, Nouv Rev Fr Hematol, V32, P30; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DiSepio D, 1997, J BIOL CHEM, V272, P25555, DOI 10.1074/jbc.272.41.25555; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; HAN A, 1983, J BIOL CHEM, V258, P3703; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; HARRINGTON MC, 1988, BIOCHEM SOC T, V16, P239, DOI 10.1042/bst0160239; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; Hsu LC, 1999, BIOCHEM J, V339, P387, DOI 10.1042/0264-6021:3390387; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; MACKERELL AD, 1986, BIOCHEMISTRY-US, V25, P5182, DOI 10.1021/bi00366a030; MCCAFFERY P, 1991, DEVELOPMENT, V112, P693; MenendezHurtado A, 1997, BIOCHEM BIOPH RES CO, V234, P605, DOI 10.1006/bbrc.1997.6635; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; OGATA A, 1994, BLOOD, V84, P3040; RICHARD S, 1991, J BIOL CHEM, V266, P21428; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Sporn M.B., 1994, RETINOIDS BIOL CHEM; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Stewart MJ, 1996, GENE, V173, P155, DOI 10.1016/0378-1119(96)00068-6; Wan YJY, 1998, EXP CELL RES, V238, P241, DOI 10.1006/excr.1997.3851; Welm AL, 1999, MOL CELL BIOL, V19, P1695; YANAGAWA Y, 1995, J BIOL CHEM, V270, P17521, DOI 10.1074/jbc.270.29.17521	35	70	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39747	39753		10.1074/jbc.M004987200	http://dx.doi.org/10.1074/jbc.M004987200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995752	hybrid			2022-12-25	WOS:000165953100105
J	Iwanishi, M; Czech, MP; Cherniack, AD				Iwanishi, M; Czech, MP; Cherniack, AD			The protein-tyrosine kinase Fer associates with signaling complexes containing insulin receptor substrate-1 and phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-L1 ADIPOCYTES; BINDING-PROTEIN; PHOSPHORYLATION; IDENTIFICATION; ACTIVATION; EXPRESSION; TRANSPORT; DOMAIN; CELLS	In a screen for 3T3-F442A adipocyte proteins that bind SH2 domains, we isolated a cDNA encoding Per, a nonreceptor protein-tyrosine kinase of the Fes/Fps family that contains a functional SH2 domain. A truncated splicing variant, iFer, was also cloned, iFer is devoid of both the tyrosine kinase domain and a functional SH2 domain but displays a unique 42-residue C terminus and retains the ability to form oligomers with Per. Expression of both Per and iFer proteins are strikingly increased upon differentiation of 3T3-L1 fibroblasts to adipocytes. Platelet-derived growth factor treatment of the cultured adipocytes caused rapid tyrosine phosphorylation of Per and its recruitment to complexes containing platelet-derived growth factor receptor and the p85 regulatory subunit of phosphatidylinositol (PI) 3-kinase. Insulin treatment of 3T3-L1 adipocytes stimulated association of Per with complexes containing tyrosine phosphorylated IRS-1 and PI 3-kinase but did not stimulate tyrosine phosphorylation of Per, PI 3-kinase activity in anti-Per immunoprecipitates was also acutely activated by insulin treatment of cultured adipocytes. These data demonstrate the presence of Per tyrosine kinase in insulin signaling complexes, suggesting a role of Per in insulin action.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem & Pharmacol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Cherniack, AD (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.		Cherniack, Andrew D./AAY-8132-2020	Cherniack, Andrew D./0000-0003-0470-0111	NIDDK NIH HHS [DK30648] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allard P, 2000, MOL CELL ENDOCRINOL, V159, P63, DOI 10.1016/S0303-7207(99)00205-1; Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; Craig AWB, 1999, J BIOL CHEM, V274, P19934, DOI 10.1074/jbc.274.28.19934; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Dastot F, 1996, P NATL ACAD SCI USA, V93, P10723, DOI 10.1073/pnas.93.20.10723; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELDMAN RA, 1986, MOL CELL BIOL, V6, P1065, DOI 10.1128/MCB.6.4.1065; Halachmy S, 1997, ONCOGENE, V14, P2871, DOI 10.1038/sj.onc.1201145; HAO QL, 1991, MOL CELL BIOL, V11, P1180, DOI 10.1128/MCB.11.2.1180; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; Kanzaki M, 2000, J BIOL CHEM, V275, P7167, DOI 10.1074/jbc.275.10.7167; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; KIM L, 1995, MOL CELL BIOL, V15, P4553; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; Read RD, 1997, J BIOL CHEM, V272, P18498, DOI 10.1074/jbc.272.29.18498; REED BC, 1977, P NATL ACAD SCI USA, V74, P4876, DOI 10.1073/pnas.74.11.4876; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; Salvatore P, 1998, J BIOL CHEM, V273, P6989, DOI 10.1074/jbc.273.12.6989; SINGH H, 1989, BIOTECHNIQUES, V7, P252; Smithgall TE, 1998, CRIT REV ONCOGENESIS, V9, P43, DOI 10.1615/CritRevOncog.v9.i1.40; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; Tian L, 2000, J BIOL CHEM, V275, P7854, DOI 10.1074/jbc.275.11.7854; Ueyama T, 2000, BIOCHEM BIOPH RES CO, V269, P557, DOI 10.1006/bbrc.2000.2331	27	17	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					38995	39000		10.1074/jbc.M006665200	http://dx.doi.org/10.1074/jbc.M006665200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11006284	hybrid			2022-12-25	WOS:000165953100009
J	Jez, JM; Noel, JP				Jez, JM; Noel, JP			Mechanism of chalcone synthase - pK(a) of the catalytic cysteine and the role of the conserved histidine in a plant polyketide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHETASE; ACTIVE-SITE; COMBINATORIAL BIOSYNTHESIS; HETEROLOGOUS EXPRESSION; PAPAIN; RESIDUES; PATHWAY; FAMILY; THIOREDOXIN; MUTAGENESIS	Polyketide synthases (PHS) assemble structurally diverse natural products using a common mechanistic strategy that relies on a cysteine residue to anchor the polyketide during a series of decarboxylative condensation reactions that build the final reaction product. Crystallographic and functional studies of chalcone synthase (CHS), a plant-specific PKS, indicate that a cysteine-histidine pair (Cys(164)His(303)) forms part of the catalytic machinery. Thiol-specific inactivation and the pH dependence of the malonyl-CoA decarboxylation reaction were used to evaluate the potential interaction between these two residues. Inactivation of CHS by iodoacetamide and iodoacetic acid targets Cys(164) in a pH-dependent manner (pK(a) = 5.50). The acidic pK(a) of Cys(164) suggests that an ionic interaction with His(303) stabilizes the thiolate anion. Consistent with this assertion, substitution of a glutamine for His(303) maintains catalytic activity but shifts the pK(a) of the thiol to 6.61. Although the H303A mutant was catalytically inactive, the pH-dependent incorporation of [C-14]iodoacetamide into this mutant exhibits a pK(a) = 7.62. Subsequent analysis of the pH dependence of the malonyl-CoA decarboxylation reaction catalyzed by wild-type CHS and the H303Q and C164A. mutants also supports the presence of an ion pair at the CHS active site. Structural and sequence conservation of a cysteine-histidine pair in the active sites of other PKS implies that a thiolate-imidazolium ion pair plays a central role in polyketide biosynthesis.	Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA	Salk Institute	Noel, JP (corresponding author), Salk Inst Biol Studies, Struct Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Noel, Joseph P/A-9459-2009		NATIONAL CANCER INSTITUTE [F32CA080396] Funding Source: NIH RePORTER; NCI NIH HHS [CA80396] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbadi A, 2000, BIOCHEM J, V345, P153, DOI 10.1042/0264-6021:3450153; Bentley R, 1999, ANNU REV MICROBIOL, V53, P411, DOI 10.1146/annurev.micro.53.1.411; Birt DF, 1996, PROG CLIN BIOL RES, V395, P223; Cleland W W, 1979, Methods Enzymol, V63, P103; Davies C, 2000, STRUCTURE, V8, P185, DOI 10.1016/S0969-2126(00)00094-0; Dillet V, 1998, BIOCHEMISTRY-US, V37, P10298, DOI 10.1021/bi980333x; DIXON RA, 1995, PLANT CELL, V7, P1085, DOI 10.1105/tpc.7.7.1085; Dreier J, 2000, BIOCHEMISTRY-US, V39, P2088, DOI 10.1021/bi992121l; EDWARDS ML, 1990, J MED CHEM, V33, P1948, DOI 10.1021/jm00169a021; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; Ferrer JL, 1999, NAT STRUCT BIOL, V6, P775, DOI 10.1038/11553; Funa N, 1999, NATURE, V400, P897, DOI 10.1038/23748; He M, 2000, J BACTERIOL, V182, P2619, DOI 10.1128/JB.182.9.2619-2623.2000; Helariutta Y, 1996, P NATL ACAD SCI USA, V93, P9033, DOI 10.1073/pnas.93.17.9033; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HOPWOOD DA, 1997, CHEM REV, V97, P2365; Hutchinson CR, 1998, CURR OPIN MICROBIOL, V1, P319, DOI 10.1016/S1369-5274(98)80036-2; Jez JM, 2000, BIOCHEMISTRY-US, V39, P890, DOI 10.1021/bi991489f; JUNGHANNS KT, 1995, PLANT MOL BIOL, V27, P681, DOI 10.1007/BF00020222; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; Khosla C, 1999, ANNU REV BIOCHEM, V68, P219, DOI 10.1146/annurev.biochem.68.1.219; KIM ES, 1995, J BACTERIOL, V177, P1202, DOI 10.1128/jb.177.5.1202-1207.1995; KITZ R, 1962, J BIOL CHEM, V237, P3235; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; KREUZALER F, 1978, FEBS LETT, V94, P175, DOI 10.1016/0014-5793(78)80931-4; KREUZALER F, 1975, EUR J BIOCHEM, V56, P203; KYTE J, 1995, STRUCTURE PROTEIN CH, P59; LANZ T, 1991, J BIOL CHEM, V266, P9971; LEWIS SD, 1976, BIOCHEMISTRY-US, V15, P5009, DOI 10.1021/bi00668a010; LEWIS SD, 1981, BIOCHEMISTRY-US, V20, P48, DOI 10.1021/bi00504a009; Li RS, 1995, J MED CHEM, V38, P5031, DOI 10.1021/jm00026a010; LONG SR, 1989, CELL, V56, P203, DOI 10.1016/0092-8674(89)90893-3; OESTERHELT D, 1977, EUR J BIOCHEM, V79, P173, DOI 10.1111/j.1432-1033.1977.tb11795.x; OLEARY MH, 1992, ENZYMES, V20, P235; POLGAR L, 1987, J BIOL CHEM, V262, P14448; PREISIGMULLER R, 1995, ARCH BIOCHEM BIOPHYS, V317, P201, DOI 10.1006/abbi.1995.1154; Schlegel BP, 1998, BIOCHEMISTRY-US, V37, P3538, DOI 10.1021/bi9723055; SCHRODER G, 1988, EUR J BIOCHEM, V172, P161, DOI 10.1111/j.1432-1033.1988.tb13868.x; Schroder J, 1997, TRENDS PLANT SCI, V2, P373, DOI 10.1016/S1360-1385(97)01104-7; Setchell KDR, 1999, J NUTR, V129, p758S, DOI 10.1093/jn/129.3.758S; Siggaard-Andersen Mads, 1993, Protein Sequences and Data Analysis, V5, P325; STOECKIGT J, 1975, Zeitschrift fuer Naturforschung Teil C Biochemie Biophysik Biologie Virologie, V30, P352; STOOPS JK, 1983, J BIOL CHEM, V258, P2482; STORER AC, 1994, METHOD ENZYMOL, V244, P486; Tipton K F, 1979, Methods Enzymol, V63, P183; TROPF S, 1995, J BIOL CHEM, V270, P7922, DOI 10.1074/jbc.270.14.7922; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WALSH CT, 1979, ENZYMATIC REACTION M, P26; Witkowski A, 1999, BIOCHEMISTRY-US, V38, P11643, DOI 10.1021/bi990993h; Zwaagstra ME, 1997, J MED CHEM, V40, P1075, DOI 10.1021/jm960628d	51	112	127	3	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39640	39646		10.1074/jbc.M008569200	http://dx.doi.org/10.1074/jbc.M008569200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11006298	hybrid			2022-12-25	WOS:000165953100091
J	Urizar, NL; Dowhan, DH; Moore, DD				Urizar, NL; Dowhan, DH; Moore, DD			The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; PRIMARY BILIARY-CIRRHOSIS; NUCLEAR RECEPTOR; IDENTIFICATION; CHOLESTEROL; LIGANDS	Bile acids facilitate the absorption of dietary lipids and fat-soluble vitamins and are physiological ligands for the farnesoid X-activated receptor (FXR), a member of the nuclear hormone receptor superfamily, FXR functions as a heterodimer with the retinoid X receptor and in the presence of ligand, the heterodimer binds to specific DNA sequences in the promoters of target genes to regulate gene transcription. Phospholipid transfer protein (PLTP) has been identified as a possible target gene for FXR because the human promoter contains a potential FXR response element, an inverted repeat in which consensus receptor-binding hexamers are separated by one nucleotide (inverted repeat-1). PLTP is essential in the transfer of very low density lipoprotein phospholipids into high density lipoprotein (Jiang, X, C., Bruce, C., Mar, J., Lin, M., Ji, Y., Francone, O. L., and Tall, A. R. (1999) J. Clin. Invest. 103, 907-914), Here we report the regulation of PLTP gene expression by FXR and bile acids. In CV-1 cells, cotransfection of FXR and the retinoid X receptor resulted in bile acid-dependent transactivation of a luciferase reporter construct containing the human PLTP promoter. Mutation analysis demonstrated that the inverted repeat-1 (IR-l) in the PLTP promoter is required for this transactivation. Finally, we demonstrate that bile acids are able to regulate PLTP gene expression in vivo. Mice fed a chow diet supplemented with bile acid showed increased hepatic PLTP mRNA levels. These results suggest that FXR may play a role in high density lipoprotein metabolism via the regulation of PLTP gene expression.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Moore, DD (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053366] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK53366] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERS JJ, 1995, BBA-LIPID LIPID MET, V1258, P27, DOI 10.1016/0005-2760(95)00091-P; Auwerx J, 1999, CELL, V97, P161; Bruce C, 1998, ANNU REV NUTR, V18, P297, DOI 10.1146/annurev.nutr.18.1.297; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; CHIBA H, 1991, BIOCHEM MED METAB B, V46, P329, DOI 10.1016/0885-4505(91)90082-V; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COULHON MP, 1985, CLIN CHIM ACTA, V145, P163, DOI 10.1016/0009-8981(85)90283-9; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; GYLLING H, 1995, HEPATOLOGY, V21, P89, DOI 10.1016/0270-9139(95)90413-1; HIRAOKA H, 1993, HEPATOLOGY, V18, P103, DOI 10.1016/0270-9139(93)90513-M; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Lagrost L, 1998, CURR OPIN LIPIDOL, V9, P203, DOI 10.1097/00041433-199806000-00004; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; POUPON RE, 1993, HEPATOLOGY, V17, P577, DOI 10.1002/hep.1840170408; Qin SC, 2000, J LIPID RES, V41, P269; Rader DJ, 2000, MOL MED TODAY, V6, P170, DOI 10.1016/S1357-4310(00)01673-7; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Srivastava RAK, 2000, EUR J BIOCHEM, V267, P4272, DOI 10.1046/j.1432-1327.2000.01473.x; Tallet F, 1996, CLIN CHIM ACTA, V244, P1, DOI 10.1016/0009-8981(95)06161-4; Tu AY, 1999, BIOCHEM BIOPH RES CO, V264, P802, DOI 10.1006/bbrc.1999.1597; Tu AY, 1995, BIOCHEM BIOPH RES CO, V217, P705, DOI 10.1006/bbrc.1995.2830; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909	28	198	213	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39313	39317		10.1074/jbc.M007998200	http://dx.doi.org/10.1074/jbc.M007998200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10998425	hybrid			2022-12-25	WOS:000165953100052
J	Velasco-Guillen, I; Guerrero, JR; Gomez-Fernandez, JC; Teruel, JA				Velasco-Guillen, I; Guerrero, JR; Gomez-Fernandez, JC; Teruel, JA			Labeling the Ca2+-ATPase of skeletal muscle sarcoplasmic reticulum with maleimidylsalicylic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE SULFHYDRYL-GROUPS; FLUORESCENCE ENERGY-TRANSFER; ADENOSINE-TRIPHOSPHATASE; N-ETHYLMALEIMIDE; CA-ATPASE; ACTIVE-SITE; CONFORMATIONAL CHANGE; CYTOPLASMIC LOOP; TRANSPORT SITES; BINDING SITE	Maleimidylsalicylic acid reacts with the Ca2+-ATPase of skeletal muscle sarcoplasmic reticulum with high affinity and inhibits the ATPase activity following a pseudo-first-order kinetic with a rate constant of 8.3 M-1 s(-1) Calcium binding remains unaffected in the maleimide-inhibited ATPase. However, the presence of ATP, ADP, and, to a lesser extent, AMP protects the enzyme against inhibition. Furthermore, ATPase inhibition is accompanied by a concomitant decrease in ATP binding. The stoichiometry of the nucleotide-dependent maleimidylsalicylic acid binding is 6-10 nmol/mg ATPase, which corresponds to the binding of up to one molecule of maleimide/molecule of ATPase. The stoichiometry of maleimide binding is decreased in the presence of nucleotides and in the ATPase previously labeled with fluorescein-5'-isothiocyanate or N-ethylmaleimide A fluorescent peptide was isolated by high performance liquid chromatography after trypsin digestion of the maleimide-labeled ATPase. Analysis of the sequence and mass spectrometry of the peptide leads us to propose Cys(344) as the target for maleimidylsalicylic acid in the inhibition reaction. The effect of Cys(344) modification on the nucleotide site is discussed.	Univ Murcia, Fac Vet, Dept Bioquim & Biol Mol A, E-30100 Murcia, Spain	University of Murcia	Teruel, JA (corresponding author), Univ Murcia, Fac Vet, Dept Bioquim & Biol Mol A, Campus Espinardo, E-30100 Murcia, Spain.	teruel@um.es	Gomez-Fernandez, Juan C/K-6758-2014; Puche, José Antonio Teruel/R-4137-2018	Gomez-Fernandez, Juan C/0000-0002-5331-9029; Puche, José Antonio Teruel/0000-0003-2256-3368				ALLEN G, 1976, FEBS LETT, V63, P188, DOI 10.1016/0014-5793(76)80223-2; ANDERSEN JP, 1982, J BIOL CHEM, V257, P8300; BAILIN G, 1989, BIOCHIM BIOPHYS ACTA, V995, P122, DOI 10.1016/0167-4838(89)90070-8; BASTIDE F, 1973, J BIOL CHEM, V248, P8485; BIGELOW DJ, 1991, BIOCHEMISTRY-US, V30, P2113, DOI 10.1021/bi00222a016; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CHAMPEIL P, 1986, BIOCHEMISTRY-US, V25, P7623, DOI 10.1021/bi00371a053; Chen L, 1996, J BIOL CHEM, V271, P10745, DOI 10.1074/jbc.271.18.10745; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CORBALANGARCIA S, 1993, EUR J BIOCHEM, V217, P737, DOI 10.1111/j.1432-1033.1993.tb18300.x; DAVIDSON GA, 1987, J BIOL CHEM, V262, P7041; DEGANI C, 1973, J BIOL CHEM, V248, P8222; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; Falson P, 1997, J BIOL CHEM, V272, P17258, DOI 10.1074/jbc.272.28.17258; GOMEZFERNANDEZ JC, 1980, BIOCHIM BIOPHYS ACTA, V598, P502, DOI 10.1016/0005-2736(80)90031-0; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1990, J MEMBRANE BIOL, V116, P1, DOI 10.1007/BF01871666; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; KAWAKITA M, 1987, J BIOCHEM-TOKYO, V102, P103, DOI 10.1093/oxfordjournals.jbchem.a122021; LACAPERE JJ, 1993, BIOCHEMISTRY-US, V32, P3414, DOI 10.1021/bi00064a027; Lovry O.H., 1951, J BIOL CHEM, V193, P265; MAHANEY JE, 1995, BIOCHEMISTRY-US, V34, P4864, DOI 10.1021/bi00014a044; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; Mintz E, 1997, BBA-BIOENERGETICS, V1318, P52, DOI 10.1016/S0005-2728(96)00132-6; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MOUTIN MJ, 1994, J BIOL CHEM, V269, P11147; NAKAMURA S, 1994, J BIOL CHEM, V269, P16015; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SAITONAKATSUKA K, 1987, J BIOCHEM-TOKYO, V101, P365, DOI 10.1093/oxfordjournals.jbchem.a121921; SQUIER TC, 1987, J BIOL CHEM, V262, P4748; Suzuki H, 1999, BIOCHEMISTRY-US, V38, P820, DOI 10.1021/bi981809f; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; TERUEL JA, 1988, BIOCHEMISTRY-US, V27, P5885, DOI 10.1021/bi00416a010; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Velasco-Guillen I, 1999, ARCH BIOCHEM BIOPHYS, V372, P121, DOI 10.1006/abbi.1999.1464; WAKABAYASHI S, 1990, J BIOCHEM-TOKYO, V107, P563, DOI 10.1093/oxfordjournals.jbchem.a123087; WAWRZYNOW A, 1993, BIOCHIM BIOPHYS ACTA, V1203, P60, DOI 10.1016/0167-4838(93)90036-Q; YAMAMOTO H, 1989, J BIOCHEM-TOKYO, V106, P1121, DOI 10.1093/oxfordjournals.jbchem.a122976; YAMASAKI K, 1990, J BIOCHEM-TOKYO, V108, P918, DOI 10.1093/oxfordjournals.jbchem.a123315; YAMASHITA T, 1987, J BIOCHEM, V101, P377, DOI 10.1093/oxfordjournals.jbchem.a121922	43	1	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39103	39109		10.1074/jbc.M001871200	http://dx.doi.org/10.1074/jbc.M001871200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993876	hybrid			2022-12-25	WOS:000165953100023
J	Appleyard, SM; McLaughlin, JP; Chavkin, C				Appleyard, SM; McLaughlin, JP; Chavkin, C			Tyrosine phosphorylation of the kappa-opioid receptor regulates agonist efficacy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAT ADIPOCYTES; INSULIN; DESENSITIZATION; INVOLVEMENT; GENISTEIN; SUBUNITS; CHANNELS; MUTATION; PATHWAY	To explore the role of highly conserved tyrosine residues in the putative cytoplasmic domains of the seven transmembrane G protein coupled opioid receptors, we expressed the rat kappa -opioid receptor (KOR) in Xenopus oocytes and then activated the intrinsic insulin receptor tyrosine kinase, KOR activation by the agonist U69593 produced a strong increase in potassium current through coexpressed G protein-gated inwardly rectifying potassium channels (K(IR)3), Brief pretreatment with insulin caused a 60% potentiation of the KOR-activated response. The insulin-induced increase in kappa -opioid response was blocked by the tyrosine kinase inhibitor genistein. In contrast, insulin had no effect on the basal activity of K(IR)3, suggesting that KOR is the target of the tyrosine kinase cascade. Mutation of tyrosine residues to phenylalanines in either the first or second intracellular loop of KOR to produce KOR(Y87F) and KOR(Y157F) had no effect on either the potency or maximal effect of U69593, However, neither KOR(Y87F)- nor KOR(Y157F)-mediated responses were potentiated by insulin treatment. Insulin pretreatment shifted the dose-response curve for U69593 activation of KOR by increasing the maximal response without changing the EC50 value for U69593. These results suggest that insulin increases the efficacy of KOR activation by phosphorylating two tyrosine residues in the first and second intracellular loops of the receptor. Thus, tyrosine phosphorylation may provide an important mechanism for modulation of G protein-coupled receptor signaling.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Neurobiol Program, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Chavkin, C (corresponding author), Univ Washington, Dept Pharmacol, POB 357280, Seattle, WA 98195 USA.		Chavkin, Charles/G-2797-2010		NIDA NIH HHS [DA07278, DA11672, R37 DA011672] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA011672, T32DA007278, R01DA011672] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ABLER A, 1992, J BIOL CHEM, V267, P3946; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Appleyard SM, 1999, J BIOL CHEM, V274, P23802, DOI 10.1074/jbc.274.34.23802; Belcheva MM, 1998, J NEUROCHEM, V70, P635; Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; Fukuda K, 1996, J NEUROCHEM, V67, P1309; Georgoussi Z, 1997, BBA-MOL CELL RES, V1359, P263, DOI 10.1016/S0167-4889(97)00097-9; GRIGORESCU F, 1994, HORM RES, V42, P55, DOI 10.1159/000184146; HENRY DJ, 1995, MOL PHARMACOL, V47, P551; Janez A, 2000, J BIOL CHEM, V275, P26870; Karoor V, 1998, J BIOL CHEM, V273, P33035, DOI 10.1074/jbc.273.49.33035; Koch T, 2000, MOL PHARMACOL, V58, P328, DOI 10.1124/mol.58.2.328; Koch T, 1997, J NEUROCHEM, V69, P1767; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; LEONARD JP, 1991, MOL NEUROBIOLOGY PRA, P161; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Nystrom FH, 1999, CELL SIGNAL, V11, P563, DOI 10.1016/S0898-6568(99)00025-X; Olson GA, 1998, PEPTIDES, V19, P1791, DOI 10.1016/S0196-9781(98)00137-5; Pak Y, 1999, J BIOL CHEM, V274, P27610, DOI 10.1074/jbc.274.39.27610; Polakiewicz RD, 1998, J BIOL CHEM, V273, P12402, DOI 10.1074/jbc.273.20.12402; Rogalski SL, 2000, J BIOL CHEM, V275, P25082, DOI 10.1074/jbc.M000183200; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Schmidt H, 2000, J NEUROCHEM, V74, P414, DOI 10.1046/j.1471-4159.2000.0740414.x; Taha C, 1999, J MEMBRANE BIOL, V169, P1, DOI 10.1007/PL00005896; VALIQUETTE M, 1995, EMBO J, V14, P5542, DOI 10.1002/j.1460-2075.1995.tb00241.x; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; Wischmeyer E, 1998, J BIOL CHEM, V273, P34063, DOI 10.1074/jbc.273.51.34063	27	16	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38281	38285		10.1074/jbc.M006756200	http://dx.doi.org/10.1074/jbc.M006756200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10995763	hybrid			2022-12-25	WOS:000165739800022
J	Freedman, JE; Li, LQ; Sauter, R; Keaney, JF				Freedman, JE; Li, LQ; Sauter, R; Keaney, JF			alpha-tocopherol and protein kinase C inhibition enhance platelet-derived nitric oxide release	FASEB JOURNAL			English	Article									Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA; Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Sch Med, Evans Dept Med, Boston, MA 02118 USA	Georgetown University; Georgetown University; Boston University; Boston University	Freedman, JE (corresponding author), Georgetown Univ, Med Ctr, Dept Pharmacol, Med Dent Bldg,Rm NE 403,3900 Reservoir Rd NW, Washington, DC 20007 USA.								0	54	56	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2377	2379						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11024007				2022-12-25	WOS:000165723400003
J	Kapushoc, ST; Alfonzo, JD; Rubio, MAT; Simpson, L				Kapushoc, ST; Alfonzo, JD; Rubio, MAT; Simpson, L			End processing precedes mitochondrial importation and editing of tRNAs in Leishmania tarentolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODED TRANSFER-RNAS; IN-VITRO IMPORT; TRYPANOSOMA-BRUCEI; PLANT-MITOCHONDRIA; MAXICIRCLE DNA; PROTOZOAN; IDENTIFICATION; CHROMOSOMES; TETRAHYMENA; MARSUPIALS	All mitochondrial tRNAs in Leishmania tarentolae are encoded in the nuclear genome and imported into the mitochondrion from the cytosol, One imported tRNA (tRNA(Trp)) is edited by a C to U modification at the first position of the anticodon, To determine the in vivo substrates for mitochondrial tRNA importation as well as tRNA editing, we examined the subcellular localization and extent of 5'- and 3'-end maturation of tRNA(Trp)(CCA), tRNA(Ile)(UAU), tRNA(Gln)(CUG), tRNA(Lys)(UUU), and tRNA(Val)(CAC), Nuclear, cytosolic, and mitochondrial fractions were obtained with little cross-contamination, as determined by Northern analysis of specific marker RNAs, tRNA(Gln) was mainly cytosolic in localization; tRNA(Ile) and tRNA(Lys) were mainly mitochondrial; and tRNA(Trp) and tRNA(Val) were shared between the two compartments. 5'- and 3'-extended precursors of all five tRNAs were present only in the nuclear fraction, suggesting that the mature tRNAs represent the in vivo substrates for importation into the mitochondrion, Consistent with this model, T7-transcribed mature tRNA(Ile) underwent importation in vitro into isolated mitochondria more efficiently than 5'-extended precursor tRNA(Ile). 5'-Extended precursor tRNA(Trp) was found to be unedited, which is consistent with a mitochondrial localization of this editing reaction, T7-transcribed unedited tRNA(Trp) was imported in vitro more efficiently than edited tRNA(Trp), suggesting the presence of importation determinants in the anticodon.	Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Simpson, L (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, 675 Charles E YOung Dr S, Los Angeles, CA 90095 USA.	simpson@hhmi.ucla.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008375] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GM08375] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adhya S, 1997, J BIOL CHEM, V272, P21396, DOI 10.1074/jbc.272.34.21396; Alfonzo JD, 1999, EMBO J, V18, P7056, DOI 10.1093/emboj/18.24.7056; Aphasizhev R, 1998, MOL BIOCHEM PARASIT, V93, P73, DOI 10.1016/S0166-6851(98)00022-X; Bertrand E, 1998, GENE DEV, V12, P2463, DOI 10.1101/gad.12.16.2463; Borner GV, 1996, EMBO J, V15, P5949, DOI 10.1002/j.1460-2075.1996.tb00981.x; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; CAMPBELL DA, 1987, J MOL BIOL, V196, P113, DOI 10.1016/0022-2836(87)90514-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIETRICH A, 1992, ANNU REV CELL BIOL, V8, P115, DOI 10.1146/annurev.cb.08.110192.000555; GOLD HA, 1989, SCIENCE, V245, P1377, DOI 10.1126/science.2476849; GOMEZEICHELMANN MC, 1988, MOL BIOCHEM PARASIT, V27, P143, DOI 10.1016/0166-6851(88)90034-5; HANCOCK K, 1992, J BIOL CHEM, V267, P23963; HANCOCK K, 1990, J BIOL CHEM, V265, P19208; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; Hauser R, 1996, J CELL SCI, V109, P517; HAUSER R, 1995, EMBO J, V14, P4212, DOI 10.1002/j.1460-2075.1995.tb00095.x; Kazakova HA, 1999, FEBS LETT, V442, P193, DOI 10.1016/S0014-5793(98)01653-6; Kunzmann A, 1998, P NATL ACAD SCI USA, V95, P108, DOI 10.1073/pnas.95.1.108; LeBlanc AJ, 1999, J BIOL CHEM, V274, P21071, DOI 10.1074/jbc.274.30.21071; Lima BD, 1996, RNA, V2, P429; LYE LF, 1993, MOL BIOCHEM PARASIT, V58, P233, DOI 10.1016/0166-6851(93)90045-Y; MAHAPATRA S, 1994, NUCLEIC ACIDS RES, V22, P3381, DOI 10.1093/nar/22.16.3381; Mahapatra S, 1998, NUCLEIC ACIDS RES, V26, P2037, DOI 10.1093/nar/26.9.2037; Mahapatra S, 1996, J BIOL CHEM, V271, P20432, DOI 10.1074/jbc.271.34.20432; MASLOV DA, 1992, MOL CELL BIOL, V12, P56, DOI 10.1128/MCB.12.1.56; MORL M, 1995, NUCLEIC ACIDS RES, V23, P3380, DOI 10.1093/nar/23.17.3380; Nabholz CE, 1999, MOL BIOL CELL, V10, P2547, DOI 10.1091/mbc.10.8.2547; Reddy R, 1996, MOL BIOL REP, V22, P81, DOI 10.1007/BF00988710; Roberts TG, 1998, MOL CELL BIOL, V18, P4409, DOI 10.1128/MCB.18.8.4409; ROVAI L, 1992, MOL BIOCHEM PARASIT, V50, P115, DOI 10.1016/0166-6851(92)90249-J; Rubio MAT, 2000, RNA, V6, P988, DOI 10.1017/S1355838200991519; Rusconi CP, 1996, GENE DEV, V10, P2870, DOI 10.1101/gad.10.22.2870; Rusconi CP, 1996, EMBO J, V15, P3286, DOI 10.1002/j.1460-2075.1996.tb00693.x; Sampson JR, 1996, METHOD ENZYMOL, V267, P384; Sbicego S, 1998, NUCLEIC ACIDS RES, V26, P5251, DOI 10.1093/nar/26.23.5251; SCHNEIDER A, 1994, NUCLEIC ACIDS RES, V22, P3699, DOI 10.1093/nar/22.18.3699; SHAPIRO SZ, 1982, ANAL BIOCHEM, V127, P112, DOI 10.1016/0003-2697(82)90152-X; SHI XM, 1994, MOL BIOCHEM PARASIT, V65, P23, DOI 10.1016/0166-6851(94)90112-0; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; SIMPSON L, 1978, CELL, V14, P169, DOI 10.1016/0092-8674(78)90311-2; Suyama Y, 1998, BBA-GENE STRUCT EXPR, V1396, P138, DOI 10.1016/S0167-4781(97)00197-8; TOPPER JN, 1992, CELL, V70, P16, DOI 10.1016/0092-8674(92)90529-L; WAUGH DS, 1989, SCIENCE, V244, P1569, DOI 10.1126/science.2472671; Yermovsky-Kammerer AE, 1999, MOL CELL BIOL, V19, P6253	44	31	33	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37907	37914		10.1074/jbc.M007838200	http://dx.doi.org/10.1074/jbc.M007838200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10993905	hybrid			2022-12-25	WOS:000165618700081
J	Jakubowski, H				Jakubowski, H			Amino acid selectivity in the aminoacylation of coenzyme A and RNA minihelices by aminoacyl-tRNA synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE BIOSYNTHESIS; SITE	Coenzyme A (CoA-SH), a cofactor in carboxyl group activation reactions, carries out a function in nonribosomal peptide synthesis that is analogous to the function of tRNA in ribosomal protein synthesis. The amino acid selectivity in the synthesis of aminoacyl-thioesters by nonribosomal peptide synthetases is relaxed, whereas the amino acid selectivity in the synthesis of aminoacyl-tRNA by aminoacyl-tRNA synthetases is restricted. Here I show that isoleucyl-tRNA synthetase aminoacylates CoA-SH with valine, leucine, threonine, alanine, and serine in addition to isoleucine. Valyl-tRNA synthetase catalyzes aminoacylations of CoA-SH with valine, threonine, alanine, serine, and isoleucine. Lysyl-tRNA synthetase aminoacylates CoA-SH with lysine, leucine, threonine, alanine, valine, and isoleucine. Thus, isoleucyl-, valyl-, and lysyl-tRNA synthetases behave as aminoacyl-S-CoA synthetases with relaxed amino acid selectivity. In contrast, RNA minihelices comprised of the acceptor-T psiC helix of tRNA(Ile) or tRNA(Val) were aminoacylated by cognate synthetases selectively with isoleucine or valine, respectively. These and other data support a hypothesis that the present day aminoacyl-tRNA synthetases originated from ancestral forms that were involved in noncoded thioester-dependent peptide synthesis, functionally similar to the present day nonribosomal peptide synthetases.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Jakubowski, H (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, 185 S Orange Ave, Newark, NJ 07103 USA.		Jakubowski, Hieronim/A-2510-2017; Jakubowski, Hieronim/AAA-6834-2019	Jakubowski, Hieronim/0000-0001-5845-4409; 				DEDUVE C, 1994, VITAL DUST, P43; FRUGIER M, 1992, P NATL ACAD SCI USA, V89, P3990, DOI 10.1073/pnas.89.9.3990; Gillet S, 1997, PROTEIN SCI, V6, P2426; JAKUBOWSKI H, 1980, BIOCHEMISTRY-US, V19, P5071, DOI 10.1021/bi00563a021; Jakubowski H, 1996, BIOCHEMISTRY-US, V35, P8252, DOI 10.1021/bi960344v; JAKUBOWSKI H, 1995, NUCLEIC ACIDS RES, V23, P4608, DOI 10.1093/nar/23.22.4608; Jakubowski H, 1996, NUCLEIC ACIDS RES, V24, P2505, DOI 10.1093/nar/24.13.2505; Jakubowski H, 1998, BIOCHEMISTRY-US, V37, P5147, DOI 10.1021/bi972528v; Jakubowski H, 1999, BIOCHEMISTRY-US, V38, P8088, DOI 10.1021/bi990629i; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; Jakubowski H, 1997, BIOCHEMISTRY-US, V36, P11077, DOI 10.1021/bi970589n; JAKUBOWSKI H, 2000, ENCY LIFE SCI; Keating TA, 2000, BIOCHEMISTRY-US, V39, P2297, DOI 10.1021/bi992341z; Kleinkauf H, 1996, EUR J BIOCHEM, V236, P335, DOI 10.1111/j.1432-1033.1996.00335.x; LIPMANN F, 1971, SCIENCE, V173, P875, DOI 10.1126/science.173.4000.875; MARTINIS SA, 1992, P NATL ACAD SCI USA, V89, P65, DOI 10.1073/pnas.89.1.65; Nordin BE, 1999, J BIOL CHEM, V274, P6835, DOI 10.1074/jbc.274.11.6835; SCHIMMEL P, 1994, P NATL ACAD SCI USA, V91, P11283, DOI 10.1073/pnas.91.24.11283; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712	20	18	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34845	34848		10.1074/jbc.C000577200	http://dx.doi.org/10.1074/jbc.C000577200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10995737	hybrid			2022-12-25	WOS:000165422800004
J	Botchkarev, VA; Botchkareva, NV; Albers, KM; Chen, LH; Welker, P; Paus, R				Botchkarev, VA; Botchkareva, NV; Albers, KM; Chen, LH; Welker, P; Paus, R			A role for p75 neurotrophin receptor in the control of apoptosis-driven hair follicle regression	FASEB JOURNAL			English	Article						p75NTR; kerotinocyte catagen; NGF; NT-3; BDNF; alopecia	NERVE GROWTH-FACTOR; CHEMOTHERAPY-INDUCED ALOPECIA; CELL-DEATH; DIFFERENTIAL DEPENDENCY; CATAGEN TRANSFORMATION; SIGNAL-TRANSDUCTION; CYCLOSPORINE-A; TRK RECEPTORS; HIGH-AFFINITY; MURINE SKIN	To examine the mechanisms that underlie the neurotrophin-induced, apoptosis-driven hair follicle involution (catagen), the expression and function of p75 neurotrophin receptor (p75NTR), which is implicated iu apoptosis control, were studied during spontaneous catagen development in murine skin. By RT-PCR, high steady-state p75NTR mRNA skin levels were found during the anagen-catagen transition of the hair follicle. By immunohistochemistry, p75NTR alone was strongly expressed in TUNEL+/Bcl2- keratinocytes of the regressing outer root sheath, but both p75NTR and TrkB and/or TrkC were expressed by the nonregressing TUNEL/Bcl2+ secondary hair germ keratinocytes. To determine whether p75NTR is functionally involved in catagen control, spontaneous catagen development was compared in vivo between p75NTR knockout (-/-) and wild-type mice. There was significant catagen retardation in p75NTR knockout mice as compared to wild-type controls (P<0.05). Instead, transgenic mice-overexpressing NGF (promoter: K14) showed substantial acceleration of catagen (P<0.001). Although NGF, brain-derived neurotrophic factor (BDNF), and neurotrophin 3 (NT-3) accelerated catagen in the organ-cultured skin of C57BL/6 mice, these neurotrophins failed to promote catagen development in the organ-cultured p75NTR null skin. These findings suggest that p75NTR signaling is involved in the control of kerotinocyte apoptosis during catagen and that pharmacological manipulation of p75NTR signaling may prove useful for the treatment of hair disorders that display premature entry into catagen.	Univ Hamburg, Hosp Eppendorf, Dept Dermatol, D-20246 Hamburg, Germany; Univ Kentucky, Med Ctr, Dept Pathol & Lab Med, Lexington, KY 40536 USA; Humboldt Univ, Charite, Dept Dermatol, Berlin, Germany	University of Hamburg; University of Kentucky; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Paus, R (corresponding author), Univ Hamburg, Hosp Eppendorf, Dept Dermatol, Martinistr 52, D-20246 Hamburg, Germany.	paus@uke.uni-hamburg.de	Paus, Ralf/F-6243-2011	Botchkarev, Vladimir/0000-0002-5212-5353; Albers, Kathryn/0000-0003-4597-9323				ALBERS KM, 1994, J NEUROSCI, V14, P1422, DOI 10.1523/JNEUROSCI.14-03-01422.1994; Albers KM, 1996, J CELL BIOL, V134, P487, DOI 10.1083/jcb.134.2.487; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Bergmann I, 1997, EUR J NEUROSCI, V9, P18, DOI 10.1111/j.1460-9568.1997.tb01349.x; Botchkarev VA, 1999, NAT CELL BIOL, V1, P158, DOI 10.1038/11078; Botchkarev VA, 1998, AM J PATHOL, V153, P785, DOI 10.1016/S0002-9440(10)65621-0; Botchkarev VA, 1998, J INVEST DERMATOL, V111, P279, DOI 10.1046/j.1523-1747.1998.00277.x; Botchkarev VA, 1999, FASEB J, V13, P395, DOI 10.1096/fasebj.13.2.395; BOTCHKAREVA NV, 1998, ARCH DERMATOL RES, V290, P71; Bothwell M, 1996, SCIENCE, V272, P506, DOI 10.1126/science.272.5261.506; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Bowden PE, 1998, J INVEST DERMATOL, V110, P158, DOI 10.1046/j.1523-1747.1998.00097.x; BRONZETTI E, 1996, ITAL J ANAT EMBRY S1, V100, P565; BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124; Carter BD, 1997, NEURON, V18, P187, DOI 10.1016/S0896-6273(00)80259-7; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Cece R, 1996, LAB INVEST, V75, P601; Chao M, 1998, BRAIN RES REV, V26, P295, DOI 10.1016/S0165-0173(97)00036-2; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; CHASE HB, 1954, PHYSIOL REV, V34, P113, DOI 10.1152/physrev.1954.34.1.113; Chou TT, 1997, J NEUROSCI RES, V49, P522, DOI 10.1002/(SICI)1097-4547(19970901)49:5<522::AID-JNR2>3.3.CO;2-M; Commo S, 1997, BRIT J DERMATOL, V137, P31, DOI 10.1046/j.1365-2133.1997.17641854.x; Davies AM, 1997, CURR BIOL, V7, pR38, DOI 10.1016/S0960-9822(06)00016-9; Dechant G, 1997, J NEUROSCI, V17, P5281; Dechant G, 1997, CURR OPIN NEUROBIOL, V7, P413, DOI 10.1016/S0959-4388(97)80071-2; Foitzik K, 2000, FASEB J, V14, P752, DOI 10.1096/fasebj.14.5.752; Frade JM, 1998, NEURON, V20, P35, DOI 10.1016/S0896-6273(00)80432-8; Frade JM, 1996, NATURE, V383, P166; Fuchs E, 1995, ANNU REV CELL DEV BI, V11, P123, DOI 10.1146/annurev.cb.11.110195.001011; Fundin BT, 1997, DEV BIOL, V190, P94, DOI 10.1006/dbio.1997.8658; HANDJISKI BK, 1994, BRIT J DERMATOL, V131, P303, DOI 10.1111/j.1365-2133.1994.tb08515.x; HANSEN LS, 1984, ANAT REC, V210, P569, DOI 10.1002/ar.1092100404; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; Huang EJ, 1999, DEVELOPMENT, V126, P2869; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LI LN, 1992, IN VITRO CELL DEV-AN, V28A, P695; Lindner G, 1997, AM J PATHOL, V151, P1601; Maurer M, 1997, AM J PATHOL, V150, P1433; Maurer M, 1997, LAB INVEST, V77, P319; Muragaki Y, 1997, J NEUROSCI, V17, P530; Panteleyev AA, 1998, J INVEST DERMATOL, V110, P902, DOI 10.1046/j.1523-1747.1998.00219.x; Panteleyev AA, 1999, AM J PATHOL, V155, P159, DOI 10.1016/S0002-9440(10)65110-3; PARAKKAL PF, 1970, Z ZELLFORSCH MIK ANA, V107, P174, DOI 10.1007/BF00335223; PAUS R, 1994, AM J PATHOL, V144, P719; Paus R, 1997, J INVEST DERMATOL, V109, P518, DOI 10.1111/1523-1747.ep12336635; PAUS R, 1994, J INVEST DERMATOL, V103, P143, DOI 10.1111/1523-1747.ep12392542; PAUS R, 1994, BRIT J DERMATOL, V130, P174, DOI 10.1111/j.1365-2133.1994.tb02896.x; PAUS R, 1994, BRIT J DERMATOL, V130, P281, DOI 10.1111/j.1365-2133.1994.tb02922.x; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; PAUS R, 1996, CURR OPIN DERMATOL, V3, P248; Philpott M, 1998, MOL BASIS EPITHELIAL, P75; Philpott M P, 1994, J Dermatol Sci, V7 Suppl, pS55, DOI 10.1016/0923-1811(94)90036-1; PHILPOTT MP, 1994, J INVEST DERMATOL, V102, P857, DOI 10.1111/1523-1747.ep12382494; Pincelli C, 1997, J INVEST DERMATOL, V109, P757, DOI 10.1111/1523-1747.ep12340768; Poukka H, 1996, BIOCHEM BIOPH RES CO, V229, P565, DOI 10.1006/bbrc.1996.1844; Rice FL, 1998, DEV BIOL, V198, P57, DOI 10.1006/dbio.1998.8861; Rudman SM, 1997, J INVEST DERMATOL, V109, P770, DOI 10.1111/1523-1747.ep12340934; Schilli MB, 1997, J INVEST DERMATOL, V108, P928, DOI 10.1111/1523-1747.ep12294690; SEIBERG M, 1995, J INVEST DERMATOL, V104, P78, DOI 10.1111/1523-1747.ep12613555; Seidl K, 1998, J CELL PHYSIOL, V176, P10, DOI 10.1002/(SICI)1097-4652(199807)176:1<10::AID-JCP2>3.0.CO;2-B; Shibayama E, 1996, AM J PATHOL, V148, P1807; Soma T, 1998, J INVEST DERMATOL, V111, P948, DOI 10.1046/j.1523-1747.1998.00408.x; Stenn K., 1998, MOL BASIS EPITHELIAL, P111; STENN KS, 1994, J INVEST DERMATOL, V103, P107, DOI 10.1111/1523-1747.ep12391844; STENN KS, 2000, IN PRESS PHYSL REV; STRAILE WE, 1961, J EXP ZOOL, V148, P205, DOI 10.1002/jez.1401480304; WEEDON D, 1981, ACTA DERM-VENEREOL, V61, P335; Yaar M, 1998, J Investig Dermatol Symp Proc, V3, P47; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Yoon SO, 1998, J NEUROSCI, V18, P3273	75	79	80	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2000	14	13					1931	1942		10.1096/fj.99-0930com	http://dx.doi.org/10.1096/fj.99-0930com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023977				2022-12-25	WOS:000089634400012
J	Banelli, B; Casciano, I; Romani, M				Banelli, B; Casciano, I; Romani, M			Methylation-independent silencing of the p73 gene in neuroblastoma	ONCOGENE			English	Article						p73; methylation; neuroblastoma; chromosome 1	DNA METHYLATION; CELL-LINES; EXPRESSION; CANCER; IDENTIFICATION; AMPLIFICATION; SEQUENCES; MUTATION; ALLELE; ASSAY	p73 is a p53 homolog that, in vitro, inhibits cell growth and induce apoptosis, In some tumors p73 is mono-allelically expressed and this raised the possibility that this gene is subjected to imprinting, Silencing of p73 in acute leukemia and in Burkitt's lymphoma occurs in association with the aberrant methylation of the first exon of the gene, We have analysed the methylation pattern of the p73 promoter and of upstream and downstream sequences in neuroblastoma, Our results demonstrate that p73 expression in this tumor is not regulated by methylation. We concluded that it is unlikely that p73 is imprinted in neuroblastoma and that the methylation-dependent silencing of this gene, thus far, is a characteristic of hematologic malignancies.	IST Genova, Lab Populat Genet, Ist Nazl Ric Canc, I-16132 Genoa, Italy	University of Genoa; IRCCS AOU San Martino IST	Romani, M (corresponding author), IST Genova, Lab Populat Genet, Ist Nazl Ric Canc, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.		Banelli, Barbara/Y-1151-2019	Banelli, Barbara/0000-0003-1505-7141; casciano, ida/0000-0003-1776-670X				Bartolomei MS, 1997, ANNU REV GENET, V31, P493, DOI 10.1146/annurev.genet.31.1.493; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; Baylin SB, 1998, ADV CANCER RES, V72, P141; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; Chi SG, 1999, CANCER RES, V59, P2791; Corn PG, 1999, CANCER RES, V59, P3352; Ding Y, 1999, DNA Res, V6, P347, DOI 10.1093/dnares/6.5.347; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kawano S, 1999, BLOOD, V94, P1113; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Lo Cunsolo C, 1998, CYTOGENET CELL GENET, V82, P199, DOI 10.1159/000015099; Mai M, 1998, CANCER RES, V58, P2347; Mai M, 1998, ONCOGENE, V17, P1739, DOI 10.1038/sj.onc.1202099; Nomoto S, 1998, CANCER RES, V58, P1380; Peters UR, 1999, CANCER RES, V59, P4233; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; REESE MG, 1996, BIOC P 1996 PAC S; Romani M, 1999, ANAL BIOCHEM, V271, P204, DOI 10.1006/abio.1999.4152; Romani M, 1999, INT J CANCER, V84, P365, DOI 10.1002/(SICI)1097-0215(19990820)84:4<365::AID-IJC6>3.0.CO;2-X; Sadri R, 1996, NUCLEIC ACIDS RES, V24, P5058, DOI 10.1093/nar/24.24.5058; Scaruffi P, 2000, LEUKEMIA, V14, P518, DOI 10.1038/sj.leu.2401698; Toyota M, 1999, CANCER RES, V59, P2307; Zaika AI, 1999, CANCER RES, V59, P3257	27	30	30	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4553	4556		10.1038/sj.onc.1203807	http://dx.doi.org/10.1038/sj.onc.1203807			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002429				2022-12-25	WOS:000089236800013
J	Molina-Heredia, FP; Hervas, M; Navarro, JA; De la Rosa, MA				Molina-Heredia, FP; Hervas, M; Navarro, JA; De la Rosa, MA			A single arginyl residue in plastocyanin and in cytochrome c(6) from the cyanobacterium Anabaena sp PCC 7119 is required for efficient reduction of photosystem I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; FLASH ABSORPTION-SPECTROSCOPY; ELECTRON-TRANSFER; SYNECHOCYSTIS PCC-6803; REACTION-MECHANISM; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; TRIPLET-STATE; PROTEIN; PCC-7119	Positively charged plastocyanin from Anabaena sp. PCC 7119 was investigated by site-directed mutagenesis, The reactivity of its mutants toward photosystem I was analyzed by laser flash spectroscopy. Replacement of arginine at position 88, which is adjacent to the copper ligand His-87, by glutamine and, in particular, by glutamate makes plastocyanin reduce its availability for transferring electrons to photosystem I. Such a residue in the copper protein thus appears to be isofunctional with Arg-64 (which is close to the heme group) in cytochrome c(6) from Anabaena (Molina-Heredia, F. P., Diaz-Quintana, A., Hervas, M., Navarro, J. A., and De la Rose, M. A. (1999) J. Biol; Chem, 274, 33565-33570) and Synechocystis (De la Cerda, B., Diaz-Quintana, A., Navarro, J, A, Hervas, M., and De la Rosa, M, a. (1999) J. Biol. Chem. 274, 13292-13297), Other mutations concern specific residues of plastocyanin either at its positively charged east face (D49K, H57A, H57E, K58A, K58E, Y83A, and Y83F) or at its north hydrophobic pole (L12A, K33A, and K33E), Mutations altering the surface electrostatic potential distribution allow the copper protein to modulate its kinetic efficiency: the more positively charged the interaction site, the higher the rate constant, Whereas replacement of Tyr-83 by either alanine or phenylalanine has no effect on the kinetics of photosystem I reduction, Leu-12 and Lys-33 are essential for the reactivity of plastocyanin.	Univ Sevilla, Ctr Invest Cientif Isla Cartuja, Inst Bioquim Vegetal & Fotosintesis, Seville 41092, Spain; CSIC, Seville 41092, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF); Consejo Superior de Investigaciones Cientificas (CSIC)	De la Rosa, MA (corresponding author), Univ Sevilla, Ctr Invest Cientif Isla Cartuja, Inst Bioquim Vegetal & Fotosintesis, Americo Vespucio S-N, Seville 41092, Spain.		Molina-Heredia, Fernando P./F-7877-2015; De la Rosa, Miguel/B-2545-2014; navarro, jose a/B-6354-2015; Hervas, Manuel/K-9279-2014	Molina-Heredia, Fernando P./0000-0002-3637-0519; De la Rosa, Miguel/0000-0003-1187-5737; navarro, jose a/0000-0002-0536-6074; Hervas, Manuel/0000-0003-4523-8891				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BENDALL DS, 1999, PHOTOTROPHIC PROKARY, P315; De la Cerda B, 1999, J BIOL CHEM, V274, P13292, DOI 10.1074/jbc.274.19.13292; DelaCerda B, 1997, BIOCHEMISTRY-US, V36, P10125, DOI 10.1021/bi9708601; DIAZ A, 1994, EUR J BIOCHEM, V222, P1001, DOI 10.1111/j.1432-1033.1994.tb18951.x; FRAZAO C, 1995, STRUCTURE, V3, P1159, DOI 10.1016/S0969-2126(01)00252-0; Gross E. L., 1996, OXYGENIC PHOTOSYNTHE, P413; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HE S, 1991, EMBO J, V10, P4011, DOI 10.1002/j.1460-2075.1991.tb04976.x; HERVAS M, 1994, BBA-BIOENERGETICS, V1184, P235, DOI 10.1016/0005-2728(94)90228-3; Hervas M, 1996, BIOCHEMISTRY-US, V35, P2693, DOI 10.1021/bi951876z; HERVAS M, 1995, BIOCHEMISTRY-US, V34, P11321, DOI 10.1021/bi00036a004; HERVAS M, 1993, FEBS LETT, V319, P257, DOI 10.1016/0014-5793(93)80558-C; Hope AB, 2000, BBA-BIOENERGETICS, V1456, P5, DOI 10.1016/S0005-2728(99)00101-2; Inoue T, 1999, BIOCHEMISTRY-US, V38, P6063, DOI 10.1021/bi9824442; Ivkovic-Jensen MM, 1998, BIOCHEMISTRY-US, V37, P9557, DOI 10.1021/bi9802871; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MATHIS P, 1981, ISRAEL J CHEM, V21, P316; MEDINA M, 1993, EUR J BIOCHEM, V213, P1133, DOI 10.1111/j.1432-1033.1993.tb17863.x; Molina-Heredia FP, 1998, BIOCHEM BIOPH RES CO, V243, P302, DOI 10.1006/bbrc.1997.7953; Molina-Heredia FP, 1999, J BIOL CHEM, V274, P33565, DOI 10.1074/jbc.274.47.33565; Navarro JA, 1997, J BIOL INORG CHEM, V2, P11, DOI 10.1007/s007750050101; ORTEGA JM, 1988, EUR J BIOCHEM, V199, P239; ROGNER M, 1990, J BIOL CHEM, V265, P6189; Sambrook J., 2002, MOL CLONING LAB MANU; Sigfridsson K, 1998, PHOTOSYNTH RES, V57, P1, DOI 10.1023/A:1006067631076; Sigfridsson K, 1996, BIOCHEMISTRY-US, V35, P1249, DOI 10.1021/bi9520141; WATKINS JA, 1994, PROTEIN SCI, V3, P2104, DOI 10.1002/pro.5560031124	29	48	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					601	605		10.1074/jbc.M007081200	http://dx.doi.org/10.1074/jbc.M007081200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11013249	Green Published, hybrid			2022-12-25	WOS:000166280700081
J	Tangirala, RK; Pratico, D; FitzGerald, GA; Chun, S; Tsukamoto, K; Maugeais, C; Usher, DC; Pure, E; Rader, DJ				Tangirala, RK; Pratico, D; FitzGerald, GA; Chun, S; Tsukamoto, K; Maugeais, C; Usher, DC; Pure, E; Rader, DJ			Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOE-DEFICIENT MICE; HIGH-DENSITY-LIPOPROTEIN; DIRECTED GENE-TRANSFER; BONE-MARROW TRANSPLANTATION; LDL RECEPTOR-DEFICIENT; CHOLESTEROL EFFLUX; REDUCES ATHEROSCLEROSIS; REMNANT LIPOPROTEINS; A-I; PLASMA	Apolipoprotein E is a multifunctional protein synthesized by hepatocytes and macrophages. Plasma apoE is largely liver-derived and known to regulate lipoprotein metabolism. Macrophage-derived apoE has been shown to reduce the progression of atherosclerosis in mice. We tested the hypothesis that liver-derived apoE could directly induce regression of pre-existing advanced atherosclerotic lesions without reducing plasma cholesterol levels. Aged low density lipoprotein (LDL) receptor-deficient (LDLR-/-) mice were fed a western-type diet for 14 weeks to induce advanced atherosclerotic lesions. One group of mice was sacrificed for evaluation of atherosclerosis at base line, and two other groups were injected with a second generation adenoviruses encoding human apoE3 or a control empty virus. Hepatic apoE gene transfer increased plasma apoE levels by 4-fold at 1 week, and apoE levels remained at least S-fold higher than controls at 6 weeks. There were no significant changes in plasma total cholesterol levels or lipoprotein composition induced by expression of apoE, The liver-derived human apoE gained access to anal was retained in arterial wall. Compared with base-line mice, the control group demonstrated progression of atherosclerosis; in contrast, hepatic apoE expression induced highly significant regression of advanced atherosclerotic lesions. Regression of lesions was accompanied by the loss of macrophage-derived foam cells and a trend toward increase in extracellular matrix of lesions. As an index of in vivo oxidant stress, we quantitated the isoprostane iPF(2 alpha)-VI and found that expression of apoE markedly reduced urinary, LDL-associated, and arterial wall iPF(2 alpha)-VI levels. In summary, these results demonstrate that liver-derived apoE directly induced regression of advanced atherosclerosis and has anti-oxidant properties in vivo that may contribute to its anti-atherogenic effects.	Univ Penn, Med Ctr, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Delaware, Newark, DE 19711 USA; Wistar Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Delaware; The Wistar Institute	Rader, DJ (corresponding author), Univ Penn, Med Ctr, Sch Med, Dept Med, Rm 614 BRB II-III,421 Curie Blvd, Philadelphia, PA 19104 USA.		FitzGerald, Garret A/A-4222-2010; Pratico, Domenico/ABA-9590-2020		NHLBI NIH HHS [HL-57811, HL-59407] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059407, R01HL057811] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; BOISVERT WA, 1995, J CLIN INVEST, V96, P1118, DOI 10.1172/JCI118098; Dansky HM, 1999, CIRCULATION, V100, P1762, DOI 10.1161/01.CIR.100.17.1762; Desurmont C, 2000, ARTERIOSCL THROM VAS, V20, P435, DOI 10.1161/01.ATV.20.2.435; Fan JL, 1998, J CLIN INVEST, V101, P2151, DOI 10.1172/JCI1599; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; HARA H, 1991, J BIOL CHEM, V266, P3080; HUANG DY, 1995, EXP NEUROL, V136, P251, DOI 10.1006/exnr.1995.1101; Huang YD, 1997, ARTERIOSCL THROM VAS, V17, P2010, DOI 10.1161/01.ATV.17.10.2010; Huang YD, 1995, J CLIN INVEST, V96, P2693, DOI 10.1172/JCI118336; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; HUANG YD, 1994, P NATL ACAD SCI USA, V91, P1834, DOI 10.1073/pnas.91.5.1834; Ishigami M, 1998, J BIOL CHEM, V273, P20156, DOI 10.1074/jbc.273.32.20156; JI ZS, 1993, J BIOL CHEM, V268, P10160; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; KELLY ME, 1994, CELL IMMUNOL, V159, P124, DOI 10.1006/cimm.1994.1302; Krimbou L, 1997, J LIPID RES, V38, P35; Lawson JA, 1999, J BIOL CHEM, V274, P24441, DOI 10.1074/jbc.274.35.24441; Lee RT, 1997, ARTERIOSCL THROM VAS, V17, P1859, DOI 10.1161/01.ATV.17.10.1859; Linton MF, 1998, J CLIN INVEST, V101, P1726, DOI 10.1172/JCI2181; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Maugeais C, 2000, J LIPID RES, V41, P1673; Mazzone T, 1996, CURR OPIN LIPIDOL, V7, P303, DOI 10.1097/00041433-199610000-00008; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Osuga J, 1998, J CLIN INVEST, V102, P386, DOI 10.1172/JCI1124; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; Patrono C, 1997, ARTERIOSCL THROM VAS, V17, P2309, DOI 10.1161/01.ATV.17.11.2309; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; Rajagopalan S, 1996, J CLIN INVEST, V98, P2572, DOI 10.1172/JCI119076; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; Tangirala RK, 1999, CIRCULATION, V100, P1816, DOI 10.1161/01.CIR.100.17.1816; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; Thorngate FE, 2000, ARTERIOSCL THROM VAS, V20, P1939, DOI 10.1161/01.ATV.20.8.1939; Tsukamoto K, 1999, ARTERIOSCL THROM VAS, V19, P2162, DOI 10.1161/01.ATV.19.9.2162; Tsukamoto K, 2000, MOL THER, V1, P189, DOI 10.1006/mthe.2000.0028; Tsukamoto K, 2000, J LIPID RES, V41, P253; Tsukamoto K, 1997, J CLIN INVEST, V100, P107, DOI 10.1172/JCI119501; van Dijk KW, 1999, J LIPID RES, V40, P336; WILLNOW TE, 1995, J MOL MED, V73, P213; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9; Woollett LA, 1995, P NATL ACAD SCI USA, V92, P12500, DOI 10.1073/pnas.92.26.12500; YAMADA N, 1992, J CLIN INVEST, V89, P706, DOI 10.1172/JCI115639; Zhang WY, 1996, J BIOL CHEM, V271, P28641, DOI 10.1074/jbc.271.45.28641; ZHONGSHEN J, 1998, J BIOL CHEM, V273, P13452; Zhu YH, 1998, P NATL ACAD SCI USA, V95, P7585, DOI 10.1073/pnas.95.13.7585	48	98	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					261	266		10.1074/jbc.M003324200	http://dx.doi.org/10.1074/jbc.M003324200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024044	hybrid			2022-12-25	WOS:000166280700036
J	Cavadini, P; Adamec, J; Taroni, F; Gakh, O; Isaya, G				Cavadini, P; Adamec, J; Taroni, F; Gakh, O; Isaya, G			Two-step processing of human frataxin by mitochondrial processing peptidase - Precursor and intermediate forms are cleaved at different rates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRIEDREICHS-ATAXIA; IRON ACCUMULATION; YEAST FRATAXIN; PROTEINS; HOMOLOG; MATURATION; GENE; HOMEOSTASIS; MEMBRANES	We showed previously that maturation of the human frataxin precursor (p-fxn) involves two cleavages by the mitochondrial processing peptidase (MPP), This observation was not confirmed by another group, however, who reported only one cleavage. Here, we demonstrate conclusively that MPP cleaves p-fxn in two sequential steps, yielding a 18,826-Da intermediate (i-fxn) and a 17,255-Da mature (m-fxn) form, the latter corresponding to endogenous frataxin in human tissues. The two cleavages occur between residues 41-42 and 55-56, and both match the MPP consensus sequence RX down arrow (X/S). Recombinant rat and yeast MPP catalyze the p --> i step 4 and 40 times faster, respectively, than the i --> m step. In isolated rat mitochondria, p-fxn undergoes a sequence of cleavages, p --> i --> m --> d(1) --> d(2), with d(1) and d(2) representing two C-terminal fragments of m-Rm produced by an unknown protease, The i --> m step is limiting, and the overall rate of p --> i --> m does not exceed the rate of m --> d(1) --> d(2), such that the levels of m-fxn do not change during incubations as long as 3 h. Inhibition of the i --> m step by a disease-causing frataxin mutation (W173G) leads to nonspecific degradation of i-fxn, Thus, the second of the two processing steps catalyzed by MPP limits the levels of mature frataxin within mitochondria.	Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA; Ist Nazl Neurol Carlo Besta, Div Biochem & Genet, Milan, Italy; Acad Sci Czech Republic, Inst Microbiol, CR-14220 Prague, Czech Republic	Mayo Clinic; IRCCS Istituto Neurologico Besta; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Isaya, G (corresponding author), Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, 200 1st St SW, Rochester, MN 55905 USA.	isaya@mayo.edu		cavadini, patrizia/0000-0002-1774-5290	NATIONAL INSTITUTE ON AGING [R01AG015709] Funding Source: NIH RePORTER; NIA NIH HHS [AG15709] Funding Source: Medline; Telethon [E.0514] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Telethon(Fondazione Telethon)		Adamec J, 2000, AM J HUM GENET, V67, P549, DOI 10.1086/303056; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Bradley JL, 2000, HUM MOL GENET, V9, P275, DOI 10.1093/hmg/9.2.275; Branda SS, 1999, HUM MOL GENET, V8, P1099, DOI 10.1093/hmg/8.6.1099; Branda SS, 1999, J BIOL CHEM, V274, P22763, DOI 10.1074/jbc.274.32.22763; BRANDA SS, 1995, J BIOL CHEM, V270, P27366, DOI 10.1074/jbc.270.45.27366; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Cavadini P, 2000, HUM MOL GENET, V9, P2523, DOI 10.1093/hmg/9.17.2523; Cossee M, 2000, HUM MOL GENET, V9, P1219, DOI 10.1093/hmg/9.8.1219; Cossee M, 1999, ANN NEUROL, V45, P200, DOI 10.1002/1531-8249(199902)45:2<200::AID-ANA10>3.0.CO;2-U; FENTON WA, 1996, ADV MOL CEL, V17, P163; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GELI V, 1993, P NATL ACAD SCI USA, V90, P6247, DOI 10.1073/pnas.90.13.6247; Gordon DM, 1999, HUM MOL GENET, V8, P2255, DOI 10.1093/hmg/8.12.2255; HARDING AE, 1981, BRAIN, V104, P589, DOI 10.1093/brain/104.3.589; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; Knight SAB, 1998, J BIOL CHEM, V273, P18389, DOI 10.1074/jbc.273.29.18389; Koutnikova H, 1998, HUM MOL GENET, V7, P1485, DOI 10.1093/hmg/7.9.1485; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Puccio H, 2000, HUM MOL GENET, V9, P887, DOI 10.1093/hmg/9.6.887; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Villegas V, 1996, FOLD DES, V1, P29, DOI 10.1016/S1359-0278(96)00009-0; Voisine C, 2000, MOL CELL BIOL, V20, P3677, DOI 10.1128/MCB.20.10.3677-3684.2000	28	97	101	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41469	41475		10.1074/jbc.M006539200	http://dx.doi.org/10.1074/jbc.M006539200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11020385	Green Published, hybrid			2022-12-25	WOS:000166114600105
J	Okochi, M; Eimer, S; Bottcher, A; Baumeister, R; Romig, H; Walter, J; Capell, A; Steiner, H; Haass, C				Okochi, M; Eimer, S; Bottcher, A; Baumeister, R; Romig, H; Walter, J; Capell, A; Steiner, H; Haass, C			A loss of function mutant of the presenilin homologue SEL-12 undergoes aberrant endoproteolysis in Caenorhabditis elegans and increases A beta 42 generation in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; DISEASE-ASSOCIATED PRESENILIN-1; FAMILIAL ALZHEIMERS-DISEASE; BETA-PEPTIDE PRODUCTION; DROSOPHILA PRESENILIN; INTRACELLULAR DOMAIN; PROTEOLYTIC RELEASE; SECRETASE ACTIVITY; MEMBRANE TOPOLOGY; NOTCH	The familial Alzheimer's disease-associated presenilins (PSs) occur as a dimeric complex of proteolytically generated fragments, which functionally supports endoproteolysis of Notch and the beta -amyloid precursor protein (beta APP). A homologous gene, sel-12, has been identified in Caenorhabditis elegans, We now demonstrate that wild-type (wt) SEL-12 undergoes endoproteolytic cleavage in C. elegans similar to the PSs in human tissue. In contrast, SEL-12 C60S protein expressed from the sel-12(ar131) allele is miscleaved in C. elegans, resulting in a larger mutant N-terminal fragment. Neither SEL-12 wt nor C60S undergo endoproteolytic processing upon expression in human cells, suggesting that SEL-12 is cleaved by a C, elegans-specific endoproteolytic activity. The loss of function of sel-12 in C. elegans is not associated with a dominant negative activity in human cells, because SEL-12 C60S and the corresponding PS1 C92S mutation do not interfere with Notch1 cleavage. Moreover, both mutant variants increase the aberrant production of the highly amyloidogenic 42-amino acid version of amyloid beta -peptide similar to familial Alzheimer's disease-associated human PS mutants. Our data therefore demonstrate that the C60S mutation in SEL-12 is associated with aberrant endoproteolysis and a loss of function in C, elegans, whereas a gain of misfunction is observed upon expression in human cells.	Univ Munich, Genzentrum, D-81377 Munich, Germany; Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers Dis Res, D-80336 Munich, Germany; Boehringer Ingelheim KG, CNS Res, D-55216 Ingelheim, Germany	University of Munich; University of Munich; Boehringer Ingelheim	Baumeister, R (corresponding author), Univ Munich, Genzentrum, Feodor Lynen Str 25, D-81377 Munich, Germany.	bmeister@lmb.uni-muenchen.de; chaass@pbm.med.uni-muenchen.de	Eimer, Stefan/B-1865-2013; Wang, Caihong/T-5837-2019; Walter, Jochen/B-3677-2014	Wang, Caihong/0000-0002-6808-3709; Okochi, Masayasu/0000-0002-2318-7651; Walter, Jochen/0000-0002-4678-2912				Baumeister R, 1997, Genes Funct, V1, P149; Brockhaus M, 1998, NEUROREPORT, V9, P1481, DOI 10.1097/00001756-199805110-00043; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Citron M, 1998, NEUROBIOL DIS, V5, P107, DOI 10.1006/nbdi.1998.0183; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Davis JA, 1998, NEURON, V20, P603, DOI 10.1016/S0896-6273(00)80998-8; De Strooper B, 2000, NATURE, V405, P627, DOI 10.1038/35015193; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Grunberg J, 1998, BIOCHEMISTRY-US, V37, P2263, DOI 10.1021/bi972106l; Guo YQ, 1999, J NEUROSCI, V19, P8435; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Jacobsen H, 1999, J BIOL CHEM, V274, P35233, DOI 10.1074/jbc.274.49.35233; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Kulic L, 2000, P NATL ACAD SCI USA, V97, P5913, DOI 10.1073/pnas.100049897; Leimer U, 1999, BIOCHEMISTRY-US, V38, P13602, DOI 10.1021/bi991453n; Levitan D, 1998, DEVELOPMENT, V125, P3599; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; Li XJ, 1997, P NATL ACAD SCI USA, V94, P12204, DOI 10.1073/pnas.94.22.12204; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; LUO KX, 1991, METHOD ENZYMOL, V201, P149; Martinez I, 1996, J VIROL, V70, P6036, DOI 10.1128/JVI.70.9.6036-6043.1996; Murayama O, 1999, NEUROSCI LETT, V265, P61, DOI 10.1016/S0304-3940(99)00187-1; Nakai T, 1999, J BIOL CHEM, V274, P23647, DOI 10.1074/jbc.274.33.23647; Niwa M, 1999, CELL, V99, P691, DOI 10.1016/S0092-8674(00)81667-0; Nowotny P, 2000, MOL CELL NEUROSCI, V15, P88, DOI 10.1006/mcne.1999.0805; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Qian S, 1998, NEURON, V20, P611, DOI 10.1016/S0896-6273(00)80999-X; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Selkoe DJ, 2000, CURR OPIN NEUROBIOL, V10, P50, DOI 10.1016/S0959-4388(99)00054-9; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Shirotani K, 2000, J BIOL CHEM, V275, P3681, DOI 10.1074/jbc.275.5.3681; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Steiner H, 1999, J BIOL CHEM, V274, P7615, DOI 10.1074/jbc.274.12.7615; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; TERRENI L, 2000, NEUROBIOL AGING, V21, pS176; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1998, J BIOL CHEM, V273, P21153, DOI 10.1074/jbc.273.33.21153; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vito P, 1997, J BIOL CHEM, V272, P28315, DOI 10.1074/jbc.272.45.28315; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; Westlund B, 1999, P NATL ACAD SCI USA, V96, P2497, DOI 10.1073/pnas.96.5.2497; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Wittenburg N, 2000, NATURE, V406, P306, DOI 10.1038/35018575; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P11223, DOI 10.1021/bi991080q; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	77	34	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40925	40932		10.1074/jbc.M005254200	http://dx.doi.org/10.1074/jbc.M005254200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11013240	hybrid			2022-12-25	WOS:000166114600036
J	Schmitt-Ney, M; Habener, JF				Schmitt-Ney, M; Habener, JF			CHOP/GADD153 gene expression response to cellular stresses inhibited by prior exposure to ultraviolet light wavelength band C (UVC) - Inhibitory sequence mediating the UVC response localized to exon 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; PROTEIN (C/EBP)-RELATED GENE; AMINO-ACID LIMITATION; NF-KAPPA-B; DNA-DAMAGE; BINDING PROTEIN; GROWTH ARREST; CHOP GADD153; ENDOPLASMIC-RETICULUM; SIGNAL-TRANSDUCTION	CHOP/GADD153 is both an activating and repressing transcription factor that is markedly induced in response to a variety of cellular stresses. The CHOP/ GADD153 gene was originally cloned because of its inducibility by ultraviolet light wavelength band C UVC and has since been found to be activated in response to many different cellular stresses. Some of the recent studies have questioned the UVC responsiveness of the CHOP gene. Contradiction in our own data led us to reexamine the WC effects on CHOP expression. WC is capable of strongly activating the mouse CHOP promoter in stably transfected NIH 3T3 cells but has only a modest and transient effect on the level of the CHOP messenger RNA. In addition to its positive effect on CHOP promoter activity, we show that UVC negatively affects CHOP mRNA and protein expression. Pretreatment of NIH 3T3 cells with WC markedly attenuates the subsequent induction of CHOP mRNA by the cellular stress activators methylmethane sulfate, tunicamycin, glucose deprivation, and methionine deprivation for as long as at least 16 h. This inhibitory effect of UVC on CHOP expression in response to stress is independent of the presence or absence of p53 and does not involve mRNA degradation as opposed to the WC effect that inhibits p21 expression seen only in the absence of p53. The target of the inhibitory effect of WC on CHOP expression is located in the first exon of the gene, a 5'-untranslated region that is unusually conserved between different species. These findings suggest that an unknown function encoded by the 5'-untranslated region somehow modifies the response of CHOP gene transcription to WC.	Harvard Univ, Mol Endocrinol Lab, Sch Med, Massachusetts Gen Hosp,Howard Hughes Med Inst, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Howard Hughes Medical Institute	Habener, JF (corresponding author), Harvard Univ, Mol Endocrinol Lab, Sch Med, Massachusetts Gen Hosp,Howard Hughes Med Inst, 55 Fruit St,WEL320, Boston, MA 02114 USA.	jhabener@partners.org						Antson AA, 1999, NATURE, V401, P235, DOI 10.1038/45730; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; CHEN Q, 1992, J BIOL CHEM, V267, P8207; CHOI AMK, 1992, EXP CELL RES, V199, P85, DOI 10.1016/0014-4827(92)90464-J; CHOI AMK, 1995, J CELL PHYSIOL, V164, P65, DOI 10.1002/jcp.1041640109; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GARMYN M, 1992, J INVEST DERMATOL, V99, P743, DOI 10.1111/1523-1747.ep12614470; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; Herrlich P, 1997, BIOL CHEM, V378, P1217; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; JACKMAN J, 1994, CANCER RES, V54, P5656; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUETHY JD, 1994, CANCER RES, V54, pS1902; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; LUETHY JD, 1992, CANCER RES, V52, P5; MARTEN NW, 1994, FASEB J, V8, P538, DOI 10.1096/fasebj.8.8.8181673; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; MAYNE LV, 1982, CANCER RES, V42, P1473; Nishigori C, 1996, P NATL ACAD SCI USA, V93, P10354, DOI 10.1073/pnas.93.19.10354; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; PRICE BD, 1992, CANCER RES, V52, P3814; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; SYLVESTER SL, 1994, J BIOL CHEM, V269, P20119; Tornaletti S, 1996, BIOESSAYS, V18, P221, DOI 10.1002/bies.950180309; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; Tyrrell R M, 1996, EXS, V77, P255; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; Ubeda M, 1999, BIOCHEM BIOPH RES CO, V262, P31, DOI 10.1006/bbrc.1999.1140; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; WARMUTH I, 1994, CANCER RES, V54, P374; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; YAROSH DB, 1993, J INVEST DERMATOL, V100, P790, DOI 10.1111/1523-1747.ep12476573; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	59	23	23	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40839	40845		10.1074/jbc.M007440200	http://dx.doi.org/10.1074/jbc.M007440200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11010973	hybrid			2022-12-25	WOS:000166114600025
J	Veis, A; Tompkins, K; Alvares, K; Wei, KR; Wang, L; Wang, XS; Brownell, AG; Jengh, SM; Healy, KE				Veis, A; Tompkins, K; Alvares, K; Wei, KR; Wang, L; Wang, XS; Brownell, AG; Jengh, SM; Healy, KE			Specific amelogenin gene splice products have signaling effects on cells in culture and in implants in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROCYTE-SPECIFIC ENHANCER; BONE MORPHOGENETIC PROTEIN-2; DENTIN-MATRIX; OSTEOBLAST DIFFERENTIATION; TOOTH DEVELOPMENT; IN-VIVO; EXPRESSION PATTERNS; CARTILAGE FORMATION; ENAMEL PROTEINS; COLLAGEN GENE	Low molecular mass amelogenin-related polypeptides extracted from mineralized dentin have the ability to affect the differentiation pathway of embryonic muscle fibroblasts in culture and lead to the formation of mineralized matrix in in vivo implants. The objective of the present study was to determine whether the bioactive peptides could have been amelogenin protein degradation products or specific amelogenin gene splice products. Thus, the splice products were prepared, and their activities were determined in vitro and in vivo, A rat incisor tooth odontoblast pulp cDNA library was screened using probes based on the peptide amino acid sequencing data. Two specific cDNAs comprised from amelogenin gene exons 2,3,4,5,6d,7 and 2,3,5,6d,7 were identified. The corresponding recombinant proteins, designated r[A+4] (8.1 kDa) and r[A-4] (6.9 kDa), were produced. Both peptides enhanced in vitro sulfate incorporation into proteoglycan, the induction of type II collagen, and Sox9 or Cbfa1 mRNA expression. In vivo implant assays demonstrated implant mineralization accompanied by vascularization and the presence of the bone matrix proteins, BSP and BAG-75, We postulate that during tooth development these specific amelogenin gene splice products, [A+4] and [A-4], may have a role in preodontoblast maturation. The [A+4] and [A-4] may thus be tissue-specific epithelial mesenchymal signaling molecules.	Northwestern Univ, Sch Dent, Dept Basic & Behav Sci, Chicago, IL 60611 USA	Northwestern University	Veis, A (corresponding author), Northwestern Univ, Sch Dent, Dept Basic & Behav Sci, 303 E Chicago Ave, Chicago, IL 60611 USA.			Alvares, Keith/0000-0003-3710-4367	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE001374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE001374, R01DE008525] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE01374, DE08525] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aberg T, 1997, DEV DYNAM, V210, P383, DOI 10.1002/(SICI)1097-0177(199712)210:4<383::AID-AJA3>3.0.CO;2-C; AMAR S, 1991, J BIOL CHEM, V266, P8609; BANG G, 1967, ARCH SURG-CHICAGO, V94, P781; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; BESSHO K, 1990, J ORAL MAXIL SURG, V48, P162, DOI 10.1016/S0278-2391(10)80204-6; BESSHO K, 1991, J DENT RES, V70, P171, DOI 10.1177/00220345910700030301; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; BONASS WA, 1994, BIOCHEM BIOPH RES CO, V198, P755, DOI 10.1006/bbrc.1994.1109; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; Brodt-Eppley J, 1998, BIOL REPROD, V59, P878, DOI 10.1095/biolreprod59.4.878; BUTLER WT, 1977, J DENT RES, V56, P228, DOI 10.1177/00220345770560030601; Castagnola P, 1996, EXP CELL RES, V223, P215, DOI 10.1006/excr.1996.0075; CONOVER MA, 1979, J DENT RES, V58, P1911, DOI 10.1177/00220345790580091201; D'Souza RN, 1999, DEVELOPMENT, V126, P2911; DSouza RN, 1997, J BONE MINER RES, V12, P2040, DOI 10.1359/jbmr.1997.12.12.2040; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695; George A, 1998, EUR J ORAL SCI, V106, P221, DOI 10.1111/j.1600-0722.1998.tb02179.x; George A, 1995, Connect Tissue Res, V33, P67, DOI 10.3109/03008209509016984; GEORGE A, 1993, J BIOL CHEM, V268, P12624; GIBSON C, 1991, BIOCHEMISTRY-US, V30, P1075, DOI 10.1021/bi00218a028; GIBSON CW, 1992, BIOCHEMISTRY-US, V31, P8384, DOI 10.1021/bi00150a036; Hammarstrom L, 1997, J CLIN PERIODONTOL, V24, P658, DOI 10.1111/j.1600-051X.1997.tb00247.x; Healy C, 1999, DEV DYNAM, V215, P69, DOI 10.1002/(SICI)1097-0177(199905)215:1<69::AID-DVDY8>3.3.CO;2-E; Healy C, 1996, ANN NY ACAD SCI, V785, P261, DOI 10.1111/j.1749-6632.1996.tb56278.x; HEIKINHEIMO K, 1994, J DENT RES, V73, P590, DOI 10.1177/00220345940730030401; Helder MN, 1998, J DENT RES, V77, P545, DOI 10.1177/00220345980770040701; Hu CC, 1997, J DENT RES, V76, P641, DOI 10.1177/00220345970760020401; INAI T, 1991, ANAT REC, V229, P259, DOI 10.1002/ar.1092290213; Karg HA, 1997, CELL TISSUE RES, V288, P545, DOI 10.1007/s004410050840; Karsenty G, 1999, BONE, V25, P107, DOI 10.1016/S8756-3282(99)00111-8; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; KULKARNI GV, 2000, CHEM BIOL MIN TISS P, P161; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Lefebvre V, 1998, MATRIX BIOL, V16, P529; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LUMSDEN AGS, 1988, DEVELOPMENT, V103, P155; MINA M, 1987, ARCH ORAL BIOL, V32, P123, DOI 10.1016/0003-9969(87)90055-0; MoradianOldak J, 1996, CONNECT TISSUE RES, V35, P231, DOI 10.3109/03008209609029196; NAKAMURA M, 1994, ANAT RECORD, V238, P383, DOI 10.1002/ar.1092380313; Nebgen DR, 1999, J DENT RES, V78, P1484, DOI 10.1177/00220345990780090201; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PALMER RM, 1987, ARCH ORAL BIOL, V32, P281, DOI 10.1016/0003-9969(87)90022-7; RITCHIE HH, 1994, J BIOL CHEM, V269, P3698; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SALIDO EC, 1992, AM J HUM GENET, V50, P303; Sambrook J., 2002, MOL CLONING LAB MANU; SAWADA T, 1995, ARCH ORAL BIOL, V40, P1029, DOI 10.1016/0003-9969(95)00073-X; Shapiro I M, 1999, Clin Orthod Res, V2, P42; Simmer JP, 1995, CONNECT TISSUE RES, V32, P131, DOI 10.3109/03008209509013715; Slavkin H.C., 1975, EXTRACELLULAR MATRIX; Thesleff I, 1995, CONNECT TISSUE RES, V32, P9, DOI 10.3109/03008209509013700; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Urist M R, 1982, Prog Clin Biol Res, V101, P61; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; VEIS A, 1990, BIOMATERIALS, V11, P35; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; Whang K, 1998, J BIOMED MATER RES, V42, P491, DOI 10.1002/(SICI)1097-4636(19981215)42:4<491::AID-JBM3>3.0.CO;2-F; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15; Wurtz T, 1996, J BONE MINER RES, V11, P125; Xie WF, 1999, J BONE MINER RES, V14, P757, DOI 10.1359/jbmr.1999.14.5.757; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F; Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989	63	203	212	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41263	41272		10.1074/jbc.M002308200	http://dx.doi.org/10.1074/jbc.M002308200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10998415	hybrid			2022-12-25	WOS:000166114600081
J	Hixon, ML; Obejero-Paz, C; Muro-Cacho, C; Wagner, MW; Millie, E; Nagy, J; Hassold, TJ; Gualberto, A				Hixon, ML; Obejero-Paz, C; Muro-Cacho, C; Wagner, MW; Millie, E; Nagy, J; Hassold, TJ; Gualberto, A			Cks1 mediates vascular smooth muscle cell polyploidization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUSLY HYPERTENSIVE RATS; DIFFERENT AGE-GROUPS; GENETIC-HYPERTENSION; RESISTANCE VESSELS; BETA-ADRENOCEPTORS; SPINDLE CHECKPOINT; ANGIOTENSIN-II; HYPERTROPHY; KINASE; EXPRESSION	Vascular smooth muscle cells (VSMC) at capacitance arteries of hypertensive individuals and animals undergo dramatic polyploidization that contributes toward their hypertrophic phenotype. We report here the identification of a defective mitotic spindle cell cycle checkpoint in VSMC isolated from capacitance arteries of pre-hypertensive rats. These cells demonstrated a high predisposition to polyploidization in culture and failed to maintain cyclin B protein levels in response to colcemid, a mitotic inhibitor. Furthermore, this altered mitotic spindle checkpoint status was associated with the overexpression of Cks1, a Cdc2 adapter protein that promotes cyclin B degradation. Cks1 up-regulation, cyclin B down-regulation, and VSMC polyploidization were evidenced at the smooth muscle of capacitance arteries of genetically hypertensive and Goldblatt-operated rats. In addition, angiotensin II infusion dramatically increased Cks1 protein levels at capacitance arteries of normotensive rats, and angiotensin II treatment of isolated VSMC abrogated their ability to down-regulate Cks1 and maintain cyclin B protein expression in response to colcemid. Finally, transduction of VSMC from normotensive animals with a retrovirus that drives the expression of Cks1 was sufficient to alter their mitotic spindle cell cycle checkpoint status and promote unscheduled cyclin B metabolism, cell cycle re-entry, and polyploidization. These data demonstrate that Cks1 regulates cyclin B metabolism and ploidy in VSMC and may contribute to the understanding of the phenomena of VSMC polyploidization during hypertension.	Pfizer Global Res & Dev, Groton Labs, Dept Cardiovasc & Metab Dis, Groton, CT 06340 USA; Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Res Inst, Tampa, FL 33612 USA; Pfizer Global Res & Dev, Dept Cardiovasc & Metab Dis, Groton Labs, Groton, CT 06340 USA	Pfizer; Case Western Reserve University; Case Western Reserve University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Pfizer	Gualberto, A (corresponding author), Pfizer Global Res & Dev, Groton Labs, Dept Cardiovasc & Metab Dis, Eastern Point Rd, Groton, CT 06340 USA.	antonio_gualberto@groton.pfizer.com		Gualberto, Antonio/0000-0002-6590-839X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD021341] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021341] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041618] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41618] Funding Source: Medline; NICHD NIH HHS [HD21341] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARRETT TB, 1983, P NATL ACAD SCI-BIOL, V80, P882, DOI 10.1073/pnas.80.3.882; BASI G, 1995, MOL CELL BIOL, V15, P2028; BLACK MJ, 1995, J HYPERTENS, V13, P683, DOI 10.1097/00004872-199506000-00016; BLACK MJ, 1988, BLOOD VESSELS, V25, P89; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CHOBANIAN AV, 1987, CIRCULATION, V75, P102; CONYERS RB, 1995, J HYPERTENS, V13, P507, DOI 10.1097/00004872-199505000-00005; Conyers RB, 1997, CAN J PHYSIOL PHARM, V75, P375, DOI 10.1139/cjpp-75-5-375; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DEVLIN AM, 1995, J HUM HYPERTENS, V9, P497; Dominiczak AF, 1996, HYPERTENSION, V27, P752, DOI 10.1161/01.HYP.27.3.752; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gatzka CD, 1998, HYPERTENSION, V32, P575, DOI 10.1161/01.HYP.32.3.575; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Hixon ML, 1998, MOL CELL BIOL, V18, P6224, DOI 10.1128/MCB.18.11.6224; Kaiser P, 1999, GENE DEV, V13, P1190, DOI 10.1101/gad.13.9.1190; LEE RMKW, 1992, CAN J PHYSIOL PHARM, V70, P1496, DOI 10.1139/y92-212; LEITSCHUH M, 1987, HYPERTENSION, V9, P106; LICHTENSTEIN AH, 1986, HYPERTENSION, V8, P50; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; OWENS GK, 1983, CIRC RES, V53, P491, DOI 10.1161/01.RES.53.4.491; OWENS GK, 1982, CIRC RES, V51, P280, DOI 10.1161/01.RES.51.3.280; OWENS GK, 1988, HYPERTENSION, V11, P198, DOI 10.1161/01.HYP.11.2.198; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; Patra D, 1998, GENE DEV, V12, P2549, DOI 10.1101/gad.12.16.2549; PRINTSEVA OY, 1992, AM J HYPERTENS, V5, pS118, DOI 10.1093/ajh/5.6.118S; PRINTSEVA OY, 1989, EXP CELL RES, V184, P342, DOI 10.1016/0014-4827(89)90333-9; ROSEN EM, 1986, J CELL PHYSIOL, V128, P337, DOI 10.1002/jcp.1041280228; ROSENDORFF C, 1986, J HYPERTENS, V4, pS109; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; Sokal R. R., 2012, BIOMETRY; Sudakin V, 1997, J BIOL CHEM, V272, P18051, DOI 10.1074/jbc.272.29.18051; VANNECK JW, 1992, FEBS LETT, V297, P189, DOI 10.1016/0014-5793(92)80358-N; Walsh K, 1999, J CLIN INVEST, V104, P673, DOI 10.1172/JCI8203; YAMORI Y, 1987, CIRCULATION, V75, P92	39	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40434	40442		10.1074/jbc.M005059200	http://dx.doi.org/10.1074/jbc.M005059200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11005810	hybrid			2022-12-25	WOS:000166039500086
J	Tamai, I; Ohashi, R; Nezu, J; Sai, Y; Kobayashi, D; Oku, A; Shimane, M; Tsuji, A				Tamai, I; Ohashi, R; Nezu, J; Sai, Y; Kobayashi, D; Oku, A; Shimane, M; Tsuji, A			Molecular and functional characterization of organic cation/carnitine transporter family in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC CARNITINE DEFICIENCY; VISCERAL STEATOSIS MICE; LIPID STORAGE MYOPATHY; CATION TRANSPORTER; TISSUE DISTRIBUTION; CLONING; OCTN2; RAT; GENE; EXPRESSION	Carnitine is essential for beta -oxidation of fatty acids, and a defect of cell membrane transport of carnitine leads to fatal systemic carnitine deficiency. We have already shown that a defect of the organic cation/carnitine transporter OCTN2 is a primary cause of systemic carnitine deficiency. In the present study, we further isolated and characterized new members of the OCTN family, OCTN1 and -3, in mice. All three members were expressed commonly in kidney, and OCTN1 and -2 were also expressed in various tissues, whereas OCTN3 was characterized by predominant expression in testis. When their cDNAs were transfected into HEK293 cells, the cells exhibited transport activity for carnitine and/or the organic cation tetraethylammonium (TEA). Carnitine transport by OCTN1 and OCTN2 was Na+-dependent, whereas that by OCTN3 was Na+-independent. TEA was transported by OCTN1 and OCTN2 but not by OCTN3. The relative uptake activity ratios of carnitine to TEA were 1.78, 11.3, and 746 for OCTN1, -2, and -3, respectively, suggesting high specificity of OCTN3 for carnitine and significantly lower carnitine transport activity of OCTN1. Thus, OCTN3 is unique in its limited tissue distribution and Na+-independent carnitine transport, whereas OCTN1 efficiently transported TEA with minimal expression of carnitine transport activity and may have a different role from other members of the OCTN family.	Kanazawa Univ, Fac Pharmaceut Sci, Dept Pharmacobio Dynam, Kanazawa, Ishikawa 9200934, Japan; Japan Sci & Technol Corp, JST, CREST, Kawaguchi 3320012, Japan; Mol Med Inc, Chugai Res Inst, Ibaraki, Osaka 3004101, Japan	Kanazawa University; Japan Science & Technology Agency (JST)	Tsuji, A (corresponding author), Kanazawa Univ, Fac Pharmaceut Sci, Dept Pharmacobio Dynam, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.	tsuji@kenroku.kanazawa-u.ac.jp	Kobayashi, Daisuke/R-7792-2019; SAI, Yoshimichi/L-3828-2015; TAMAI, Ikumi/D-8412-2015	Kobayashi, Daisuke/0000-0003-2087-5130; SAI, Yoshimichi/0000-0003-2954-1532; 				Berardi S, 2000, EUR J BIOCHEM, V267, P1985, DOI 10.1046/j.1432-1327.2000.01198.x; BERARDI S, 1995, BIOCHEM J, V309, P389, DOI 10.1042/bj3090389; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASS EP, 1978, J BIOL CHEM, V253, P2688; BREMER J, 1983, PHYSIOL REV, V63, P1420, DOI 10.1152/physrev.1983.63.4.1420; BRENINGSTALL GN, 1990, PEDIATR NEUROL, V6, P75, DOI 10.1016/0887-8994(90)90037-2; Burwinkel B, 1999, BIOCHEM BIOPH RES CO, V261, P484, DOI 10.1006/bbrc.1999.1060; ENGEL AG, 1973, SCIENCE, V179, P899, DOI 10.1126/science.179.4076.899; FRITZ IB, 1964, AM J PHYSIOL, V206, P531, DOI 10.1152/ajplegacy.1964.206.3.531; Gorboulev V, 1997, DNA CELL BIOL, V16, P871, DOI 10.1089/dna.1997.16.871; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; HINTON BT, 1985, J ANDROL, V6, P300; HINTON BT, 1981, J REPROD FERTIL, V61, P59, DOI 10.1530/jrf.0.0610059; HOPPEL CL, 1986, BIOCHEM SOC T, V14, P673, DOI 10.1042/bst0140673; HORIUCHI M, 1993, FEBS LETT, V326, P267, DOI 10.1016/0014-5793(93)81805-A; Hosoyamada M, 1999, AM J PHYSIOL-RENAL, V276, pF122, DOI 10.1152/ajprenal.1999.276.1.F122; Jeulin C, 1996, HUM REPROD UPDATE, V2, P87, DOI 10.1093/humupd/2.2.87; JOHANSEN L, 1979, ARCH ANDROLOGY, V2, P117, DOI 10.3109/01485017908987302; Kekuda R, 1998, J BIOL CHEM, V273, P15971, DOI 10.1074/jbc.273.26.15971; Koizumi A, 1999, HUM MOL GENET, V8, P2247, DOI 10.1093/hmg/8.12.2247; KOIZUMI T, 1988, LAB ANIM, V22, P83, DOI 10.1258/002367788780746511; Kusuhara H, 1999, J BIOL CHEM, V274, P13675, DOI 10.1074/jbc.274.19.13675; Lamhonwah AM, 1998, BIOCHEM BIOPH RES CO, V252, P396, DOI 10.1006/bbrc.1998.9679; LopezNieto CE, 1997, J BIOL CHEM, V272, P6471, DOI 10.1074/jbc.272.10.6471; Lu KM, 1998, BIOCHEM BIOPH RES CO, V252, P590, DOI 10.1006/bbrc.1998.9708; MATSUISHI T, 1985, NEUROPEDIATRICS, V16, P6, DOI 10.1055/s-2008-1052536; Mayatepek E, 2000, Hum Mutat, V15, P118, DOI 10.1002/(SICI)1098-1004(200001)15:1<118::AID-HUMU28>3.0.CO;2-8; Nezu JI, 1999, NAT GENET, V21, P91, DOI 10.1038/5030; Ohashi R, 1999, J PHARMACOL EXP THER, V291, P778; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; Schweifer N, 1996, MAMM GENOME, V7, P735, DOI 10.1007/s003359900223; Sekine T, 1998, BIOCHEM BIOPH RES CO, V251, P586, DOI 10.1006/bbrc.1998.9521; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; SIMONSON GD, 1994, J CELL SCI, V107, P1065; STEINMANN B, 1987, PEDIATR RES, V21, P201, DOI 10.1203/00006450-198702000-00018; STIEGER B, 1995, BIOCHEM J, V309, P643, DOI 10.1042/bj3090643; Tamai I, 1997, FEBS LETT, V419, P107, DOI 10.1016/S0014-5793(97)01441-5; Tamai I, 1998, J BIOL CHEM, V273, P20378, DOI 10.1074/jbc.273.32.20378; Tang NLS, 1999, HUM MOL GENET, V8, P655, DOI 10.1093/hmg/8.4.655; TREEM WR, 1988, NEW ENGL J MED, V319, P1331, DOI 10.1056/NEJM198811173192006; Vaz FM, 1999, HUM GENET, V105, P157, DOI 10.1007/s004390051079; Wang YH, 1999, P NATL ACAD SCI USA, V96, P2356, DOI 10.1073/pnas.96.5.2356; Wu X, 2000, BBA-BIOMEMBRANES, V1466, P315, DOI 10.1016/S0005-2736(00)00189-9; Wu X, 1998, BIOCHEM BIOPH RES CO, V246, P589, DOI 10.1006/bbrc.1998.8669; Wu X, 1999, J PHARMACOL EXP THER, V290, P1482; Yabuuchi H, 1999, J PHARMACOL EXP THER, V289, P768; Yokogawa K, 1999, J PHARM PHARMACOL, V51, P935, DOI 10.1211/0022357991773195; Yokogawa K, 1999, HEPATOLOGY, V30, P997, DOI 10.1002/hep.510300423; Yokogawa K, 1999, J PHARMACOL EXP THER, V289, P224; Zhang L, 1997, MOL PHARMACOL, V51, P913, DOI 10.1124/mol.51.6.913; Zhu YW, 2000, P NATL ACAD SCI USA, V97, P1137, DOI 10.1073/pnas.97.3.1137	51	233	243	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40064	40072		10.1074/jbc.M005340200	http://dx.doi.org/10.1074/jbc.M005340200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11010964	hybrid			2022-12-25	WOS:000166039500038
J	Aguirre, A; Lopez, T; Lopez-Bayghen, E; Ortega, A				Aguirre, A; Lopez, T; Lopez-Bayghen, E; Ortega, A			Glutamate regulates kainate-binding protein expression in cultured chick Bergmann glia through an activator protein-1 binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIAL GLIA; RECEPTOR; CELLS; FAMILY; GENE; LOCALIZATION	The expression of the chick kainate-binding protein, a member of the ionotropic glutamate receptor family, is restricted to the cerebellum, specifically to Bergmann glia. Glutamate induces a membrane to nuclei signaling involved in gene expression regulation. Exposure of cultured chick Bergmann glia cells to glutamate leads to an increase in kainate binding protein and mRNA levels, suggesting a transcriptional level of regulation. The 5 ' proximal region of the chick kainate binding gene was cloned and transfected 4into Bergmann glia cells. Three main regulatory regions could be defined, a minimal promoter region, a negative regulatory region, and interestingly, a glutamate-responsive element. Deletion of this element abolishes the agonist effect. Moreover, electrophoretic mobility shift assays, cotransfection experiments, and site-directed mutagenesis clearly suggest that the glutamate effect is mediated through an AP-1 site by a Fos/Jun heterodimer. The present results favor the notion of a functional role of kainate-binding protein in glutamatergic cerebellar neurotransmission.	Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Genet & Mol Biol, Mexico City 07000, DF, Mexico	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico	Ortega, A (corresponding author), Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Genet & Mol Biol, Apartado Postal 14-740, Mexico City 07000, DF, Mexico.	arortega@mail.cinvestav.mx	Lopez-Bayghen, Esther/A-8006-2008; Ortega, Arturo/A-2282-2008	Lopez-Bayghen, Esther/0000-0002-2849-7587; Ortega, Arturo/0000-0002-9594-8114				Aguilera P, 1999, NEUROCHEM RES, V24, P981, DOI 10.1023/A:1021044424103; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark BA, 1997, J PHYSIOL-LONDON, V502, P335, DOI 10.1111/j.1469-7793.1997.335bk.x; Condorelli DF, 1999, ADV EXP MED BIOL, V468, P49; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; ESHHAR N, 1992, FEBS LETT, V297, P257, DOI 10.1016/0014-5793(92)80551-Q; Eykholt RL, 2000, BIOTECHNIQUES, V28, P864, DOI 10.2144/00285bm07; GREGOR P, 1992, MOL BRAIN RES, V16, P179, DOI 10.1016/0169-328X(92)90223-X; GREGOR P, 1988, EMBO J, V7, P2673, DOI 10.1002/j.1460-2075.1988.tb03120.x; HENLEY JM, 1994, TRENDS PHARMACOL SCI, V15, P182, DOI 10.1016/0165-6147(94)90146-5; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KIMURA N, 1993, MOL BRAIN RES, V17, P351, DOI 10.1016/0169-328X(93)90022-H; Latchman DS, 1999, J CELL PHYSIOL, V179, P126; LEONARD MW, 1993, DEVELOPMENT, V119, P519; Lopez T, 1998, MOL BRAIN RES, V58, P40, DOI 10.1016/S0169-328X(98)00094-1; Lopez T, 1997, FEBS LETT, V405, P245, DOI 10.1016/S0014-5793(97)00195-6; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; Myers SJ, 1999, ANNU REV PHARMACOL, V39, P221, DOI 10.1146/annurev.pharmtox.39.1.221; OTORI Y, 1994, MOL BRAIN RES, V27, P310, DOI 10.1016/0169-328X(94)90014-0; PECHAN PA, 1993, NEUROSCI LETT, V153, P111, DOI 10.1016/0304-3940(93)90089-4; SANCHEZ G, 1994, NEUROREPORT, V5, P2109, DOI 10.1097/00001756-199410270-00030; SOMOGYI P, 1990, NEUROSCIENCE, V35, P9, DOI 10.1016/0306-4522(90)90116-L; Villmann C, 1997, J NEUROSCI, V17, P7634, DOI 10.1523/jneurosci.17-20-07634.1997	24	23	23	4	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39246	39253		10.1074/jbc.M002847200	http://dx.doi.org/10.1074/jbc.M002847200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993879	hybrid			2022-12-25	WOS:000165953100042
J	Bandell, M; Lolkema, JS				Bandell, M; Lolkema, JS			Arg-425 of the citrate transporter CitP is responsible for high affinity binding of di- and tricarboxylatese	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTIC-ACID BACTERIA; LACTOCOCCUS-LACTIS; ESCHERICHIA-COLI; MEMBRANE; EXPRESSION; MECHANISM; INSERTION; NISIN; GENES	The citrate transporter of Leuconostoc mesenteroides (CitP) catalyzes exchange of divalent anionic citrate from the medium for monovalent anionic lactate, which is an end product of citrate degradation. The exchange generates a membrane potential and thus metabolic energy for the cell. The mechanism by which CitP transports both a divalent and a monovalent substrate was the subject of this investigation. Previous studies indicated that CitP is specific for substrates containing a 2-hydroxycarboxylate motif, HO-CR2-COO-. CitP has a high affinity for substrates that have a "second" carboxylate at one of the R groups, such as divalent citrate and (S)-malate (Bandell, M., and Lolkema, J. S. (1999) Biochemistry 38, 10352-10360). Monovalent anionic substrates that lack this second carboxylate were found to bind with a low affinity, In the present study we have constructed site-directed mutants, changing Arg-425 into a lysine or a cysteine residue. By using two substrates, Be. (S)-malate and 2-hydroxyisobutyrate, the substrate specificity of the mutants was analyzed. In both mutants the affinity for divalent (S)-malate was strongly decreased, whereas the affinity for monovalent 2-hydroxyisobutyrate was not. The largest effect was seen when the arginine was changed into the neutral cysteine, which reduced the affinity for (S)-malate over 50-fold. Chemical modification of the R425C mutant with the sulfhydryl reagent 2-aminoethyl methanethiosulfonate, which restores the positive charge at position 425, dramatically reactivated the mutant transporter. The R425C and R425K mutants revealed a substrate protectable inhibition by other sulfhydryl reagents and the lysine reagent 2,4,6-trinitrobenzene sulfonate, respectively. It is concluded that Arg-425 complexes the charged carboxylate present in divalent substrates but that is absent in monovalent substrates, and thus plays an important role in the generation of the membrane potential.	Univ Groningen, Dept Microbiol, Ctr Biol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Lolkema, JS (corresponding author), Univ Groningen, Dept Microbiol, Ctr Biol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.							AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Bandell M, 1999, BIOCHEMISTRY-US, V38, P10352, DOI 10.1021/bi9907577; Bandell M, 2000, BIOCHEMISTRY-US, V39, P13059, DOI 10.1021/bi0011882; Bandell M, 1997, J BIOL CHEM, V272, P18140, DOI 10.1074/jbc.272.29.18140; Bandell M, 1998, APPL ENVIRON MICROB, V64, P1594; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; Fields R, 1972, Methods Enzymol, V25, P464, DOI 10.1016/S0076-6879(72)25042-X; GRUBMEYER C, 1993, J BIOL CHEM, V268, P20299; HOLO H, 1989, APPL ENVIRON MICROB, V55, P3119, DOI 10.1128/AEM.55.12.3119-3123.1989; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KUIPERS OP, 1993, EUR J BIOCHEM, V216, P281, DOI 10.1111/j.1432-1033.1993.tb18143.x; LOLKEMA JS, 1996, HDB BIOL PHYSICS, P229; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Magni C, 1999, J BACTERIOL, V181, P1451, DOI 10.1128/JB.181.5.1451-1457.1999; MARTYTEYSSET C, 1995, J BIOL CHEM, V270, P25370, DOI 10.1074/jbc.270.43.25370; MITCHELL JBO, 1992, J MOL BIOL, V226, P251, DOI 10.1016/0022-2836(92)90137-9; Olami Y, 1997, J BIOL CHEM, V272, P1761, DOI 10.1074/jbc.272.3.1761; Putman M, 1999, BIOCHEMISTRY-US, V38, P1002, DOI 10.1021/bi981863w; Ramamoorthy S, 1998, METHOD ENZYMOL, V296, P347; Sambrook J., 2002, MOL CLONING LAB MANU; TEYSSET CM, 1996, J BACTERIOL, V178, P2178; van Geest M, 1999, J BIOL CHEM, V274, P29705, DOI 10.1074/jbc.274.42.29705; van Geest M, 1999, J BIOL CHEM, V274, P2816, DOI 10.1074/jbc.274.5.2816; vanGeest M, 1996, J BIOL CHEM, V271, P25582, DOI 10.1074/jbc.271.41.25582	25	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39130	39136		10.1074/jbc.M005940200	http://dx.doi.org/10.1074/jbc.M005940200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993891	Green Published, hybrid			2022-12-25	WOS:000165953100027
J	Jucker, BM; Ren, JM; Dufour, S; Cao, XY; Previs, SF; Cadman, KS; Shulman, GI				Jucker, BM; Ren, JM; Dufour, S; Cao, XY; Previs, SF; Cadman, KS; Shulman, GI			C-13/P-31 NMR assessment of mitochondrial energy coupling in skeletal muscle of awake fed and fasted rats - Relationship with uncoupling protein 3 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; FREE FATTY-ACIDS; CHROMATOGRAPHY MASS-SPECTROMETRY; GLUCOSE-METABOLISM; THYROID-HORMONE; MESSENGER-RNA; LEPTIN; C-13; THERMOGENESIS; GLUTAMATE	To examine the relationship between mitochondrial energy coupling in skeletal muscle and change in uncoupling protein 3 (UCP3) expression during the transition from the fed to fasted state, we used a novel noninvasive P-31/C-13 NMR spectroscopic approach to measure the degree of mitochondrial energy coupling in the hind limb muscles of awake rats before and after a 48-h fast. Compared with fed levels, UCP3 mRNA and protein levels in the gastrocnemius increased 1.7- (p < 0.01) and 2.9-fold (p < 0.001), respectively, following a 48-h fast. Tricarboxylic acid cycle flux measured using C-13 NMR as an index of mitochondrial substrate oxidation was 212 +/- 23 and 173 +/- 25 nmol/g/min (p not significant) in the fed and 48-h fasted groups, respectively Unidirectional ATP synthesis flux measured using (31)p NMR was 79 +/- 15 and 57 +/- 9 nmol/g/s (p not significant) in the fed and 48-h fasted groups, respectively. Mitochondrial energy coupling as expressed by the ratio of ATP synthesis to tricarboxylic acid cycle flux was not different between the fed and fasted states. To test the hypothesis that UCP3 may be involved in the translocation of long chain free fatty acids (FFA) into the mitochondrial matrix under conditions of elevated FFA availability, [U-C-13]palmitate/albumin was administered in a separate group of rats with (+) or without (-) etomoxir (an inhibitor of carnitine palmitoyltransferase I). The ratio of glutamate enrichment ((+) etomoxir/(-) etomoxir) in the hind limb muscles was the same between groups, indicating that UCP3 does not appear to function as a translocator for long chain FFA in skeletal muscle following a 48-h fast. In summary, these data demonstrate that despite a 2-3-fold increase in UCP3 mRNA and protein expression in skeletal muscle during the transition from the fed to fasted state, mitochondrial energy coupling does not change, Furthermore, UCP3 does not appear to have a major role in FFA translocation into the mitochondria, The physiological role of UCP3 following a 48-h fast in skeletal muscle remains to be elucidated.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Bristol Myers Squibb Co, Dept Metab Res, Princeton, NJ 08543 USA	Howard Hughes Medical Institute; Yale University; Yale University; Bristol-Myers Squibb	Shulman, GI (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, POB 9812,295 Congress Ave, New Haven, CT 06510 USA.	gerald.shulman@yale.edu	Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040936, P30DK045735] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK040936, R01 DK-40936, P30 DK-45735] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEYLOT M, 1993, ANAL BIOCHEM, V212, P532, DOI 10.1006/abio.1993.1364; Bienengraeber M, 1998, BIOCHEMISTRY-US, V37, P3, DOI 10.1021/bi972463w; Boss O, 1999, BIOCHEM BIOPH RES CO, V261, P870, DOI 10.1006/bbrc.1999.1145; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; Brand MD, 1999, INT J OBESITY, V23, pS4, DOI 10.1038/sj.ijo.0800936; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; CHANCE EM, 1983, J BIOL CHEM, V258, P3785; Chung WK, 1999, DIABETES, V48, P1890, DOI 10.2337/diabetes.48.9.1890; Cusin I, 1998, DIABETES, V47, P1014, DOI 10.2337/diabetes.47.7.1014; Field J, 1939, J CELL COMPAR PHYSL, V14, P143, DOI 10.1002/jcp.1030140202; FITZPATRICK SM, 1990, J CEREBR BLOOD F MET, V10, P170, DOI 10.1038/jcbfm.1990.32; GARLAND PB, 1964, BIOCHEM J, V93, P678, DOI 10.1042/bj0930678; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Gomez-Ambrosi J, 1999, CELL MOL LIFE SCI, V55, P992, DOI 10.1007/PL00013203; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; HIMMSHAGEN J, 1989, PROG LIPID RES, V28, P67, DOI 10.1016/0163-7827(89)90009-X; Hwang CS, 1999, BIOCHEM BIOPH RES CO, V258, P464, DOI 10.1006/bbrc.1999.0662; Jucker BM, 1998, J BIOL CHEM, V273, P12187, DOI 10.1074/jbc.273.20.12187; Jucker BM, 2000, P NATL ACAD SCI USA, V97, P6880, DOI 10.1073/pnas.120131997; Jucker BM, 1997, J BIOL CHEM, V272, P10464, DOI 10.1074/jbc.272.16.10464; KEESEY RE, 1988, HDB EATING DISORDE 2, P87; KLINGENBERG M, 1985, EMBO J, V4, P3087, DOI 10.1002/j.1460-2075.1985.tb04049.x; Larkin S, 1997, BIOCHEM BIOPH RES CO, V240, P222, DOI 10.1006/bbrc.1997.7636; Lee FYJ, 1999, AM J PHYSIOL-CELL PH, V276, pC386, DOI 10.1152/ajpcell.1999.276.2.C386; Lehrach H, 1985, Prog Clin Biol Res, V177, P7; MA SWY, 1986, CAN J PHYSIOL PHARM, V64, P1252, DOI 10.1139/y86-211; Mao WG, 1999, FEBS LETT, V443, P326, DOI 10.1016/S0014-5793(98)01713-X; MASON GF, 1992, J CEREBR BLOOD F MET, V12, P434, DOI 10.1038/jcbfm.1992.61; Mataix J, 1998, FREE RADICAL BIO MED, V24, P511, DOI 10.1016/S0891-5849(97)00288-8; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Oakes ND, 1997, DIABETES, V46, P1768, DOI 10.2337/diabetes.46.11.1768; POWERS L, 1995, J MASS SPECTROM, V30, P747, DOI 10.1002/jms.1190300514; RICQUIER D, 1986, J BIOL CHEM, V261, P13905; Samec S, 1998, DIABETES, V47, P1693, DOI 10.2337/diabetes.47.11.1693; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; SEMEC S, 1999, EUR J PHYSL, V438, P452; Sidossis LS, 1996, J CLIN INVEST, V98, P2244, DOI 10.1172/JCI119034; Sivitz WI, 1999, ENDOCRINOLOGY, V140, P1511, DOI 10.1210/en.140.4.1511; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; SMITH D, 1987, METABOLISM, V36, P1167, DOI 10.1016/0026-0495(87)90244-7; TREVISAN C, 1983, NEUROCHEM RES, V8, P551, DOI 10.1007/BF00964696; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Weigle DS, 1998, DIABETES, V47, P298, DOI 10.2337/diabetes.47.2.298; WINKLER E, 1994, J BIOL CHEM, V269, P2508; Yu X, 1995, BIOPHYS J, V69, P2090, DOI 10.1016/S0006-3495(95)80080-9; Zhang CY, 1999, FEBS LETT, V449, P129, DOI 10.1016/S0014-5793(99)00441-X	50	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39279	39286		10.1074/jbc.M007760200	http://dx.doi.org/10.1074/jbc.M007760200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995775	hybrid			2022-12-25	WOS:000165953100047
J	Thorsteinsson, MV; Kerby, RL; Conrad, M; Youn, H; Staples, CR; Lanzilotta, WN; Poulos, TJ; Serate, J; Roberts, GP				Thorsteinsson, MV; Kerby, RL; Conrad, M; Youn, H; Staples, CR; Lanzilotta, WN; Poulos, TJ; Serate, J; Roberts, GP			Characterization of variants altered at the N-terminal proline, a novel heme-axial ligand in CooA, the CO-sensing transcriptional activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC CIRCULAR-DICHROISM; SITE-DIRECTED MUTAGENESIS; SOLUBLE GUANYLATE-CYCLASE; CARBON-MONOXIDE; RHODOSPIRILLUM-RUBRUM; NITRIC-OXIDE; RECEPTOR PROTEIN; FLUORESCENCE POLARIZATION; MYOGLOBIN; LIGATION	Cook the carbon monoxide-sensing transcription factor from Rhodospirillum rubrum, binds CO through a heme moiety resulting in conformational changes that promote DNA binding. The crystal structure shows that the N-terminal Pro(2) Of one subunit (Met(1) is removed post-translationally provides one ligand to the heme of the other subunit in the Cook homodimer. To determine the importance of this novel ligand and the contiguous residues to Cook function, we have altered the N terminus through two approaches: site directed mutagenesis and regional randomization, and characterized the resulting Cook variants. While Pro(2) appears to be optimal for Cook function, it is not essential and a variety of studied variants at this position have substantial CO-sensing function. Surprisingly, even alterations that add a residue (where Pro(2) is replaced by Met(1)-Tyr(2), for example) accumulate heme-containing Cook with functional properties that are similar to those of wild-type Cook Other nearby residues, such as Phe(5) and Asn(6) appear to be important for either the structural integrity or the function of Cook These results are contrasted with those previously reported for alteration of the His(77) ligand on the opposite side of the heme.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA 92697 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Irvine	Roberts, GP (corresponding author), Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053228] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53228] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P44; Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Ausubel F. M., 1995, SHORT PROTOCOLS MOL, P21; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; BURSTYN JN, 1995, BIOCHEMISTRY-US, V34, P5896, DOI 10.1021/bi00017a019; CHECOVICH WJ, 1995, NATURE, V375, P254, DOI 10.1038/375254a0; DEDUVE C, 1948, ACTA CHEM SCAND, V2, P264, DOI 10.3891/acta.chem.scand.02-0264; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Denninger JW, 2000, BIOCHEMISTRY-US, V39, P4191, DOI 10.1021/bi992332q; Dhawan IK, 1999, BIOCHEMISTRY-US, V38, P12805, DOI 10.1021/bi991303c; Dykxhoorn DM, 1996, GENE, V177, P133, DOI 10.1016/0378-1119(96)00289-2; EGEBERG KD, 1990, BIOCHEMISTRY-US, V29, P9783, DOI 10.1021/bi00494a004; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Grillo AO, 1999, J MOL BIOL, V287, P539, DOI 10.1006/jmbi.1999.2625; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; KERBY RL, 1995, J BACTERIOL, V177, P2241, DOI 10.1128/jb.177.8.2241-2244.1995; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; Lukat-Rodgers GS, 1998, BIOCHEMISTRY-US, V37, P13543, DOI 10.1021/bi981439v; LukatRodgers GS, 1997, BIOCHEMISTRY-US, V36, P4178, DOI 10.1021/bi9628230; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; Makino R, 1999, J BIOL CHEM, V274, P7714, DOI 10.1074/jbc.274.12.7714; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Matsui T, 1996, BIOCHEMISTRY-US, V35, P13118, DOI 10.1021/bi960459z; MILLER CG, 1996, ESCHERICHIA COLI SAL, P945; Morita T, 1997, J BIOL CHEM, V272, P32804, DOI 10.1074/jbc.272.52.32804; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; SHELVER D, 1995, J BACTERIOL, V177, P2157, DOI 10.1128/jb.177.8.2157-2163.1995; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; Sigman JA, 1999, BIOCHEMISTRY-US, V38, P11122, DOI 10.1021/bi990815o; SONO M, 1982, J BIOL CHEM, V257, P8308; SONO M, 1982, J BIOL CHEM, V257, P5496; Stone JR, 1996, BIOCHEMISTRY-US, V35, P3258, DOI 10.1021/bi952386+; Stone JR, 1998, CHEM BIOL, V5, P255, DOI 10.1016/S1074-5521(98)90618-4; Thorsteinsson MV, 2000, BIOCHEMISTRY-US, V39, P8284, DOI 10.1021/bi000327c; TORII K, 1968, J BIOCHEM-TOKYO, V64, P171, DOI 10.1093/oxfordjournals.jbchem.a128877; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VOET D, 1995, BIOCHEMISTRY-US, P576; Vogel KM, 1999, BIOCHEMISTRY-US, V38, P2679, DOI 10.1021/bi982375r; Vogel KM, 1999, J BIOL INORG CHEM, V4, P804, DOI 10.1007/s007750050354; WINTER J, 1996, BACTERIOPHAGE DISPLA, P349; Zakhary R, 1997, P NATL ACAD SCI USA, V94, P14848, DOI 10.1073/pnas.94.26.14848	45	38	38	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39332	39338		10.1074/jbc.M007691200	http://dx.doi.org/10.1074/jbc.M007691200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11007793	hybrid			2022-12-25	WOS:000165953100055
J	Awad, MM; Enslen, H; Boylan, JM; Davis, RJ; Gruppuso, PA				Awad, MM; Enslen, H; Boylan, JM; Davis, RJ; Gruppuso, PA			Growth regulation via p38 mitogen-activated protein kinase in developing liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4E; MAP KINASE; CYCLIN D1; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; FETAL-RAT; TGF-BETA; STRESS; PATHWAY; PHOSPHORYLATION	During normal development in the rat, hepatocytes undergo marked changes in the rate of proliferation. We have previously observed transient G(1) growth arrest at term, re-activation of proliferation immediately after birth, and a gradual transition to the quiescent adult hepatocyte phenotype after postnatal day 4. We hypothesized that these changes in proliferation are due in part to growth inhibitory effects mediated by the p38 mitogen-activated protein kinase pathway. p38 kinase activity measurements showed an inverse relationship with hepatocyte proliferation during the perinatal and postnatal transitions, whereas p38 content remained constant. Anisomycin activated the p38 pathway in fetal hepatocyte cultures while inducing growth inhibition that was sensitive to the p38 inhibitor, SB203580. Activation of p38 in these cultures, via transient transfection with a constitutively active form of its upstream kinase MKK6, also inhibited DNA synthesis as well as reducing cyclin D1 content. Transfection with inactive MKK6 did neither. Furthermore, MKK6-induced growth arrest was sensitive to SB203580. Finally, administration of SB203580 to near-term fetal rats in utero abrogated the transient hepatocyte growth arrest that occurs at term. These findings indicate a role for the p38 mitogen-activated protein kinase pathway in the physiological regulation of hepatocyte proliferation during normal development in the rat.	Rhode Isl Hosp, Div Pediat Endocrinol & Metab, Dept Pediat, Providence, RI 02903 USA; Brown Univ, Providence, RI 02903 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Mol Med, Dept Biochem & Mol Biol, Worcester, MA 01605 USA	Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Gruppuso, PA (corresponding author), Rhode Isl Hosp, Div Pediat Endocrinol & Metab, Dept Pediat, Providence, RI 02903 USA.		Enslen, Hervé/M-3400-2017; Enslen, Hervé/AAH-4492-2021	Enslen, Hervé/0000-0001-9741-5293; Enslen, Hervé/0000-0001-9741-5293; Awad, Michael/0000-0002-6065-7050	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD024455] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD011343, R01HD035831, P01HD011343] Funding Source: NIH RePORTER; NICHD NIH HHS [HD35831, HD11343, HD24455] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Awad MM, 2000, CELL GROWTH DIFFER, V11, P325; Boylan JM, 1998, J BIOL CHEM, V273, P3784, DOI 10.1074/jbc.273.6.3784; Boylan JM, 1996, CELL GROWTH DIFFER, V7, P1261; CHAPMAN LM, 1984, J CELL PHYSIOL, V121, P7, DOI 10.1002/jcp.1041210103; Craxton A, 1998, J IMMUNOL, V161, P3225; CURRAT R, 1993, J PHYS IV, V3, P209, DOI 10.1051/jp4:1993242; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl NL, 2000, J EXP MED, V191, P321, DOI 10.1084/jem.191.2.321; Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857; FAUSTO N, 1990, ANN NY ACAD SCI, V593, P231, DOI 10.1111/j.1749-6632.1990.tb16115.x; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; GREENGARD O, 1972, J CELL BIOL, V52, P261, DOI 10.1083/jcb.52.2.261; Gruppuso PA, 1997, IN VITRO CELL DEV-AN, V33, P562; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee JC, 1999, PHARMACOL THERAPEUT, V82, P389, DOI 10.1016/S0163-7258(99)00008-X; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; Merritt C, 2000, MOL CELL BIOL, V20, P936, DOI 10.1128/MCB.20.3.936-946.2000; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Wysk M, 1999, P NATL ACAD SCI USA, V96, P3763, DOI 10.1073/pnas.96.7.3763; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Zhao M, 1999, MOL CELL BIOL, V19, P21; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	45	60	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38716	38721		10.1074/jbc.M008040200	http://dx.doi.org/10.1074/jbc.M008040200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10995779	hybrid			2022-12-25	WOS:000165739800080
J	Cao, WH; Luttrell, LM; Medvedev, AV; Pierce, KL; Daniel, KW; Dixon, TM; Lefkowitz, RJ; Collins, S				Cao, WH; Luttrell, LM; Medvedev, AV; Pierce, KL; Daniel, KW; Dixon, TM; Lefkowitz, RJ; Collins, S			Direct binding of activated c-Src to the beta(3)-adrenergic receptor is required for MAP kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ADRENERGIC-RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; BROWN ADIPOCYTES; STRUCTURAL BASIS; GAMMA-SUBUNITS; PHOSPHORYLATION; OBESITY; DOMAINS; DESENSITIZATION	Both beta (2)- and beta (3)-adrenergic receptors (ARs) are able to activate the extracellular signal-regulated kinase (ERK) pathway. We previously showed that c-Src is required for ERK activation by beta (2)AR and that it is recruited to activated beta (2)AR through binding of the Src homology 3 (SH3) domain to proline-rich regions of the adapter protein beta -arrestin1, Despite the absence of sites for phosphorylation and beta -arrestin binding, ERK activation by P(3)AR still requires c-Src. Agonist activation of beta (2)AR, but not beta (3)AR, led to redistribution of green fluorescent protein-tagged p-arrestin to the plasma membrane. In P-arrestin-deficient COS-7 cells, beta -affonist-dependent coprecipitation of c-Src with the beta (2)AR required exogenous p-arrestin, but activated beta (3)AR co-precipitated c-Src in the absence or presence of p-arrestin, ERK activation and Src co-precipitation with beta (3)AR also occurred in adipocytes in an agonist-dependent and pertussis toxin-sensitive manner. Protein interaction studies show that the beta (3)AR interacts directly with the SH3 domain of Src through proline-rich motifs (PXXP) in the third intracellular loop and the carboxyl terminus. ERK activation and Src co-precipitation were abolished in cells expressing point mutations in these PXXP motifs. Together, these data describe a novel mechanism of ERK activation by a G protein-coupled receptor in which the intracellular domains directly recruit c-Src.	Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Howard Hughes Medical Institute	Collins, S (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol, Box 3557, Durham, NC 27710 USA.	colli008@mc.duke.edu	Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949; Medvedev, Alexander/0000-0001-6983-1687				Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; ARCH JRS, 1984, NATURE, V309, P163, DOI 10.1038/309163a0; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Collins S, 1996, J BIOL CHEM, V271, P9437, DOI 10.1074/jbc.271.16.9437; Collins S, 1997, ENDOCRINOLOGY, V138, P405, DOI 10.1210/en.138.1.405; COLLINS S, 2000, IN PRESS RECENT PROG; COOPER DMF, 1979, J BIOL CHEM, V254, P8927; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Gutkind J.S, 2000, SCI STKE; HIMMSHAGEN J, 1994, AM J PHYSIOL, V266, pR1371, DOI 10.1152/ajpregu.1994.266.4.R1371; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Sasaki N, 1998, J VET MED SCI, V60, P465, DOI 10.1292/jvms.60.465; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Soeder KJ, 1999, J BIOL CHEM, V274, P12017, DOI 10.1074/jbc.274.17.12017; Souza SC, 1998, DIABETES, V47, P691, DOI 10.2337/diabetes.47.4.691; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Strosberg AD, 1996, TRENDS PHARMACOL SCI, V17, P373, DOI 10.1016/S0165-6147(96)80011-3; Strosberg AD, 1997, ANNU REV PHARMACOL, V37, P421, DOI 10.1146/annurev.pharmtox.37.1.421; VAN BT, 1995, NATURE, V376, P781; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	40	160	166	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38131	38134		10.1074/jbc.C000592200	http://dx.doi.org/10.1074/jbc.C000592200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11013230	hybrid			2022-12-25	WOS:000165739800002
J	Churchill, GC; Galione, A				Churchill, GC; Galione, A			Spatial control of Ca2+ signaling by nicotinic acid adenine dinucleotide phosphate diffusion and gradients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-ADP-RIBOSE; SEA-URCHIN EGGS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; XENOPUS OOCYTES; ENDOPLASMIC-RETICULUM; RELEASE CHANNEL; LAEVIS OOCYTES; CALCIUM WAVES; TRISPHOSPHATE; FERTILIZATION	Intracellular Ca2+ is able to control numerous cellular responses through complex spatiotemporal organization. Ca2+ waves mediated by inositol trisphosphate or ryanodine receptors propagate by Ca2+-induced Ca2+ release and therefore do not have an absolute requirement for a gradient in either inositol trisphosphate or cyclic ADP-ribose, respectively. In contrast, we report that although Ca2+ increases induced by nicotinic acid adenine dinucleotide phosphate (NAADP) are amplified by Ca2+-induced Ca2+ release locally, Ca2+ waves mediated by NAADP have an absolute requirement for an NAADP gradient. If NAADP is increased such that its concentration is spatially uniform in one region of an egg, the Ca2+ increase occurs simultaneously throughout this area, and only where there is diffusion out of this area to establish an NAADP gradient is there a Ca2+ wave. A local increase in NAADP results in a Ca2+ increase that spreads by NAADP diffusion. NAADP diffusion is restricted at low but not high concentrations of NAADP, indicating that NAADP diffusion is strongly influenced by binding to immobile and saturable sites, probably the NAADP receptor itself. Thus, the range of action of NAADP can be tuned by its concentration from that of a local messenger, like Ca2+, to that of a global messenger, like IP3 or cyclic ADP-ribose.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	University of Oxford	Churchill, GC (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.	grant.churchill@pharm.ox.ac.uk	Galione, Antony/E-5884-2011	Galione, Antony/0000-0002-4132-7646				Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; Albrieux M, 1998, J BIOL CHEM, V273, P14566, DOI 10.1074/jbc.273.23.14566; ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; Bak J, 1999, CURR BIOL, V9, P751, DOI 10.1016/S0960-9822(99)80335-2; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Bird GS, 1999, J BIOL CHEM, V274, P20643, DOI 10.1074/jbc.274.29.20643; Boittin FX, 1998, CELL CALCIUM, V23, P303, DOI 10.1016/S0143-4160(98)90026-4; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Chini EN, 1996, BIOCHEM J, V316, P709, DOI 10.1042/bj3160709; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Fontanilla RA, 1998, BIOPHYS J, V75, P2079, DOI 10.1016/S0006-3495(98)77650-7; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Genazzani AA, 1997, TRENDS PHARMACOL SCI, V18, P108, DOI 10.1016/S0165-6147(96)01036-X; Genazzani AA, 1996, BIOCHEM J, V315, P721, DOI 10.1042/bj3150721; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; Hille B., 1992, IONIC CHANNELS EXCIT; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; Jaffe LF, 1999, BIOESSAYS, V21, P657, DOI 10.1002/(SICI)1521-1878(199908)21:8<657::AID-BIES5>3.3.CO;2-B; JAFFE LF, 1993, CELL CALCIUM, V14, P736, DOI 10.1016/0143-4160(93)90099-R; Koizumi S, 1999, NEURON, V22, P125, DOI 10.1016/S0896-6273(00)80684-4; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; Lee HC, 1997, J BIOL CHEM, V272, P4172, DOI 10.1074/jbc.272.7.4172; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; Marchant J, 1999, EMBO J, V18, P5285, DOI 10.1093/emboj/18.19.5285; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Navazio L, 2000, P NATL ACAD SCI USA, V97, P8693, DOI 10.1073/pnas.140217897; Parker I, 1996, CELL CALCIUM, V20, P105, DOI 10.1016/S0143-4160(96)90100-1; PARYS JB, 1994, DEV BIOL, V161, P466, DOI 10.1006/dbio.1994.1045; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; PerezTerzic CM, 1995, BIOCHEM J, V312, P955, DOI 10.1042/bj3120955; PETERSEN OH, 1995, J PHYSIOLOGY-PARIS, V89, P125, DOI 10.1016/0928-4257(96)80109-4; Santella L, 2000, J BIOL CHEM, V275, P8301, DOI 10.1074/jbc.275.12.8301; Stricker SA, 1999, DEV BIOL, V211, P157, DOI 10.1006/dbio.1999.9340; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; TAKAHASHI M, 1994, J BIOL CHEM, V269, P369; TERASAKI M, 1991, J CELL BIOL, V114, P929, DOI 10.1083/jcb.114.5.929; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; Wilson HL, 1998, BIOCHEM J, V331, P837, DOI 10.1042/bj3310837; YAO Y, 1992, J PHYSIOL-LONDON, V458, P319, DOI 10.1113/jphysiol.1992.sp019420	44	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38687	38692		10.1074/jbc.M005827200	http://dx.doi.org/10.1074/jbc.M005827200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11006280	hybrid			2022-12-25	WOS:000165739800075
J	Sasaki, N; Ohkura, R; Sutoh, K				Sasaki, N; Ohkura, R; Sutoh, K			Insertion or deletion of a single residue in the strut sequence of Dictyostelium myosin II abolishes strong binding to actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY LIGHT-CHAIN; DISCOIDEUM MYOSIN; MOTOR DOMAIN; CHIMERIC SUBSTITUTIONS; IN-VIVO; COMPLEX; SITE; LACKING; MGADP; LOOP	The strut loop, one of the three loops that connects the upper and lower 50K subdomains of myosin, plays a role as a "strut" to keep the relative disposition of the two subdomains. A single residue was either inserted into or deleted from this loop. The insertion or deletion mutation abolished the in vivo motor functions of myosin, as revealed by the fact that the mutant myosins did not complement the phenotypic defects of the myosin-null cells. In vitro studies of purified full-length myosins and their subfragment-1s (S1s) revealed that the insertion mutants virtually lost the strong binding to actin although their motor functions in the absence of actin remained almost normal, showing that only the hydrophobic actin-myosin association was selectively affected by the insertion mutations. Unlike the insertion mutants, the deletion mutant showed defects both in the strong-binding state and the rate limiting step of ATPase cycle. These results indicate the functional importance of the strut loop in establishing the strong-binding state of myosin and thereby achieving successful power strokes.	Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Tokyo 1538902, Japan	University of Tokyo	Sutoh, K (corresponding author), Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, 4-6-1 Komaba, Tokyo 1538902, Japan.							ASUKAGAWA H, 1999, MOL INTERACTIONS ACT; CHISHOLM RL, 1988, MOL CELL BIOL, V8, P794, DOI 10.1128/MCB.8.2.794; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; KUBALEK EW, 1992, MOL BIOL CELL, V3, P1455, DOI 10.1091/mbc.3.12.1455; Kuhlman PA, 1998, J MUSCLE RES CELL M, V19, P491, DOI 10.1023/A:1005304408812; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; OHALLORAN TJ, 1990, P NATL ACAD SCI USA, V87, P8110, DOI 10.1073/pnas.87.20.8110; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Rovner AS, 1995, J BIOL CHEM, V270, P30260, DOI 10.1074/jbc.270.51.30260; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; Sasaki N, 1998, J BIOL CHEM, V273, P20334, DOI 10.1074/jbc.273.32.20334; Sasaki N, 1999, J BIOL CHEM, V274, P37840, DOI 10.1074/jbc.274.53.37840; Shimada T, 1997, BIOCHEMISTRY-US, V36, P14037, DOI 10.1021/bi971837i; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Suzuki Y, 1998, NATURE, V396, P380, DOI 10.1038/24640; TAFURI SR, 1989, MOL CELL BIOL, V9, P3073, DOI 10.1128/MCB.9.7.3073; UYEDA TQP, 1993, SCIENCE, V262, P1867, DOI 10.1126/science.8266074; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; YOUNT RG, 1995, BIOPHYS J, V68, pS44	23	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38705	38709		10.1074/jbc.M001966200	http://dx.doi.org/10.1074/jbc.M001966200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11005804	hybrid			2022-12-25	WOS:000165739800078
J	Furukawa, K; Iwamura, K; Uchikawa, M; Sojka, BN; Wiels, J; Okajima, T; Urano, T; Furukawa, K				Furukawa, K; Iwamura, K; Uchikawa, M; Sojka, BN; Wiels, J; Okajima, T; Urano, T; Furukawa, K			Molecular basis for the p phenotype - Identification of distinct and multiple mutations in the (alpha 1,4-galactosyltransferase gene in Swedish and Japanese individuals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP; EXPRESSION; ANTIBODIES; INFECTION; ANTIGENS; SYSTEM; CELLS	p phenotype individuals lack both P-k (Gb3) and P (Gb4) glycolipid antigens of the P blood group system. To explore the molecular basis for this phenotype, DNA sequences of Gb3 synthase (alpha1,4-galactosyltransferase; alpha1,4Gal-T) in six p phenotype individuals from Japan and Sweden were analyzed. A missense mutation P251L and a nonsense mutation W261stop in three and one Japanese indivuiduals, respectively, and missense mutations M183K and G187D in one each of two Swedish p individuals were found, indicating that p individuals from Japan and Sweden have distinct and multiple homozygous point mutations in the coding region. In the function analysis of the mutated alpha1,4Gal-Ts by the transfection of the expression vectors, P251L and M183K mutations showed complete loss of enzyme function, and W261stop and G187D mutations resulted in the marginal activity. BLAST analysis of homologous sequences of alpha1,4Gal-T revealed that three residues, Met(183), Gly(187), and Pro(251), at which missense mutations were found, were highly conserved among all species examined, suggesting their importance for the function of alpha1,4Gal-T.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Japanese Red Cross, Cent Blood Ctr, Shibuya Ku, Tokyo 1500012, Japan; Umea Univ Hosp, Dept Transfus Med, S-90185 Umea, Sweden; Inst Gustave Roussy, CNRS, UMR 1598, F-94805 Villejuif, France	Nagoya University; Japanese Red Cross Medical Center; Umea University; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.	koichi@med.nagoya-u.ac.jp	Wiels, Joëlle/AGL-2319-2022; Okajima, Tetsuya/I-7332-2014	Wiels, Joëlle/0000-0002-3313-2937; Okajima, Tetsuya/0000-0002-3677-648X; Urano, Takeshi/0000-0003-3383-3554				Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Daniels GL, 1999, VOX SANG, V77, P52, DOI 10.1159/000031074; Hammache D, 1999, J VIROL, V73, P5244, DOI 10.1128/JVI.73.6.5244-5248.1999; KARMALI MA, 1989, CLIN MICROBIOL REV, V2, P15, DOI 10.1128/CMR.2.1.15-38.1989; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KIJIMOTOOCHIAI S, 1977, P NATL ACAD SCI USA, V74, P5407, DOI 10.1073/pnas.74.12.5407; KLEIN G, 1983, INT J CANCER, V31, P535, DOI 10.1002/ijc.2910310503; Kojima Y, 2000, J BIOL CHEM, V275, P15152, DOI 10.1074/jbc.M909620199; Kudo T, 1996, J BIOL CHEM, V271, P9830, DOI 10.1074/jbc.271.16.9830; Landsteiner K, 1927, P SOC EXP BIOL MED, V24, P941; Lopez M, 1998, J BIOL CHEM, V273, P33644, DOI 10.1074/jbc.273.50.33644; MANGENEY M, 1991, EUR J IMMUNOL, V21, P1131, DOI 10.1002/eji.1830210507; MARCUS DM, 1976, P NATL ACAD SCI USA, V73, P3263, DOI 10.1073/pnas.73.9.3263; NAIKI M, 1975, BIOCHEMISTRY-US, V14, P4837, DOI 10.1021/bi00693a010; NAIKI M, 1975, BIOCHEMISTRY-US, V14, P4831, DOI 10.1021/bi00693a009; Nakayama J, 1999, P NATL ACAD SCI USA, V96, P8991, DOI 10.1073/pnas.96.16.8991; Puri A, 1998, P NATL ACAD SCI USA, V95, P14435, DOI 10.1073/pnas.95.24.14435; SODERSTROM T, 1985, J IMMUNOL, V134, P1; Song Y, 1998, J BIOL CHEM, V273, P2517, DOI 10.1074/jbc.273.5.2517; Steffensen R, 2000, J BIOL CHEM, V275, P16723, DOI 10.1074/jbc.M000728200; TOMISAWA S, 1989, SCAND J INFECT DIS, V21, P403, DOI 10.3109/00365548909167444; WIELS J, 1981, P NATL ACAD SCI-BIOL, V78, P6485, DOI 10.1073/pnas.78.10.6485; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YOSHIDA H, 1994, TRANSFUSION, V34, P702, DOI 10.1046/j.1537-2995.1994.34894353467.x; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	25	38	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37752	37756		10.1074/jbc.C000625200	http://dx.doi.org/10.1074/jbc.C000625200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10993874	hybrid			2022-12-25	WOS:000165618700061
J	Pearson, G; Bumeister, R; Henry, DO; Cobb, MH; White, MA				Pearson, G; Bumeister, R; Henry, DO; Cobb, MH; White, MA			Uncoupling Raf1 from MEK1/2 impairs only a subset of cellular responses to Raf activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE ACTIVATION; RIBOSOMAL S6 KINASE; KAPPA-B-ALPHA; SIGNAL-TRANSDUCTION; ONCOGENIC RAF-1; IN-VITRO; TRANSFORMATION; EXPRESSION; PATHWAY; CELLS	The Raf family of serine/threonine protein kinases is intimately involved in the transmission of cell regulatory signals controlling proliferation and differentiation. The best characterized Raf substrates are MEK1 and MEK2. The activation of MEK1/2 by Raf is required to mediate many of the cellular responses to Raf activation, suggesting that MEK1/2 are the dominant Raf effector proteins. However, accumulating evidence suggests that there are additional Raf substrates and that subsets of Raf-induced regulatory events are mediated independently of Raf activation of MEK1/2. To examine the possibility that there is bifurcation at the level of Raf in activation of MEK1/2-dependent and MEK1/2-independent cell regulatory events, we engineered a kinase-active Raf1 variant (RafBXB(T481A)) with an amino acid substitution that disrupts MEK1 binding. We find that disruption of MEK1/2 association uncouples Raf from activation of ERK1/2, induction of serum-response element-dependent gene expression, and induction of growth and morphological transformation. However, activation of NF-kappaB-dependent gene expression and induction of neurite differentiation were unimpaired. In addition, Raf-dependent activation of p90 ribosomal S6 kinase was only slightly impaired. These results support the hypothesis that Raf kinases utilize multiple downstream effectors to regulate distinct cellular activities.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	White, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Cobb, Melanie/0000-0003-0833-5473	NCI NIH HHS [CA71443] Funding Source: Medline; NIDDK NIH HHS [DK34128] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034128, R37DK034128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; CHEN XR, 1995, J BIOL CHEM, V270, P18285, DOI 10.1074/jbc.270.31.18285; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; Janssen RAJ, 1998, J BIOL CHEM, V273, P32182, DOI 10.1074/jbc.273.48.32182; Jette C, 2000, FEBS LETT, V467, P1, DOI 10.1016/S0014-5793(00)01114-5; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; KHOSOUR SJ, 1995, SCIENCE, V13, P6443; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; Lin JH, 1999, J BIOL CHEM, V274, P14706, DOI 10.1074/jbc.274.21.14706; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Mineo C, 1997, J BIOL CHEM, V272, P10345; Naumann U, 1997, Recent Results Cancer Res, V143, P237; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Troppmair J, 1998, ONCOGENE, V17, P685, DOI 10.1038/sj.onc.1201981; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052; Zuker CS, 1999, SCIENCE, V283, P650, DOI 10.1126/science.283.5402.650	35	65	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37303	37306		10.1074/jbc.C000570200	http://dx.doi.org/10.1074/jbc.C000570200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	11018021	hybrid			2022-12-25	WOS:000165618700001
J	Pinto, YM; Bader, M; Pesquero, JB; Tschope, C; Scholtens, E; Van Gilst, WH; Buikema, H				Pinto, YM; Bader, M; Pesquero, JB; Tschope, C; Scholtens, E; Van Gilst, WH; Buikema, H			Increased kallikrein expression protects against cardiac ischemia	FASEB JOURNAL			English	Article									Univ Groningen Hosp, Dept Cardiol, NL-9713 GZ Groningen, Netherlands; Univ Groningen Hosp, Dept Clin Pharmacol, NL-9713 GZ Groningen, Netherlands; Max Delbruck Ctr Mol Med, Berlin, Germany; Univ Fed Sao Paulo, Escola Paulista Med, Dept Biophys, Sao Paulo, Brazil	University of Groningen; University of Groningen; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Universidade Federal de Sao Paulo (UNIFESP)	Pinto, YM (corresponding author), Univ Groningen Hosp, Dept Cardiol, Zone S4 Kamer 4-252,Hanzepl 1, NL-9713 GZ Groningen, Netherlands.		Bader, Michael/K-2124-2013; Pesquero, Joao/C-1470-2012; van Gilst, Wiek H/C-3828-2008; van Gilst, Wiek/R-1806-2019	Pesquero, Joao/0000-0002-4507-632X; van Gilst, Wiek/0000-0003-2968-8585; Tschope, Carsten/0000-0001-5243-8985; Bader, Michael/0000-0003-4780-4164					0	34	34	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					1861	1863						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023968				2022-12-25	WOS:000089634400002
J	Yamamoto, Y; Zolfaghari, R; Ross, AC				Yamamoto, Y; Zolfaghari, R; Ross, AC			Regulation of CYP26 (cytochrome P450RAI) mRNA expression and retinoic acid metabolism by retinoids and dietary vitamin A in liver of mice and rats	FASEB JOURNAL			English	Article						retinoic acid oxidation; vitamin A status; aging	AGING LEWIS RATS; ALL-TRANS; BINDING PROTEINS; MESSENGER-RNA; IN-VIVO; MOUSE; CELLS; 4-HYDROXYLASE; MICROSOMES; RECEPTORS	Retinoic acid (RA), through nuclear retinoid receptors, regulates the expression of numerous genes. However, little is known of the biochemical mechanisms that regulate RA concentration in vivo. CYP26 (P450RAI), a novel cytochrome P450, is expressed during embryonic development, induced by all-trans RA, and capable of catalyzing the oxidation of [H-3]RA to polar retinoids including 4-oxo-RA. Here we report that CYP26 expression in adult liver is regulated by all-trans RA and dietary vitamin A, and is correlated with the metabolism of all-trans RA to polar metabolites. In normal mouse and rat liver, CYP26 mRNA was barely detectable; however, after acute treatment with all-trans RA CYP26 mRNA and RA metabolism by liver microsomes were significantly induced. Aqueous-soluble RA metabolites were detected, but their formation was not induced. The expression of retinoid receptors, RAR-gamma and RXR-alpha, was not changed after RA treatment in vivo. In a model of chronic vitamin A ingestion during aging, CYP26 mRNA expression, determined by Northern blot and RT-PCR analysis, increased progressively with dietary vitamin A (P<0.0001; marginal < control < supplemented) and age (P<0.003). The relative expression of CYP26 mRNA was positively correlated with liver total retinol (log(10)), ranging from undetectable CYP26 expression at liver retinol concentrations below similar to 20 nmol/g to a three- to fourfold elevation at concentrations >10,000 nmol/g (r=0.90, P<0.0001). We conclude that CYP26 expression and RA metabolism are regulated in adult liver not only acutely by RA administration, as may be relevant to retinoid therapy but under chronic dietary conditions relevant to vitamin A nutrition in humans.	Penn State Univ, Dept Nutr, University Pk, PA 16802 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Ross, AC (corresponding author), Penn State Univ, Dept Nutr, 126-S Henderson Bldg, University Pk, PA 16802 USA.	acr6@psu.edu			NIA NIH HHS [AG09839] Funding Source: Medline; NIDDK NIH HHS [DK46869] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009839] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abu-Abed SS, 1998, J BIOL CHEM, V273, P2409, DOI 10.1074/jbc.273.4.2409; Blaner William S., 1994, P229; BLOMHOFF R, 1982, P NATL ACAD SCI-BIOL, V79, P7326, DOI 10.1073/pnas.79.23.7326; BLOMHOFF R, 1992, ANNU REV NUTR, V12, P37, DOI 10.1146/annurev.nu.12.070192.000345; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Dawson HD, 2000, J NUTR, V130, P1280, DOI 10.1093/jn/130.5.1280; Dawson HD, 1999, J NUTR, V129, P1510, DOI 10.1093/jn/129.8.1510; de Roos K, 1999, MECH DEVELOP, V82, P205, DOI 10.1016/S0925-4773(99)00016-7; DECICCO KL, 2000, J INFECT DIS, V130, P1280; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; DUNAGIN PE, 1966, BIOCHIM BIOPHYS ACTA, V124, P71, DOI 10.1016/0304-4165(66)90314-X; EDWARDS RB, 1992, EXP EYE RES, V54, P481, DOI 10.1016/0014-4835(92)90126-D; FIORELLA PD, 1994, J BIOL CHEM, V269, P10538; Fujii H, 1997, EMBO J, V16, P4163, DOI 10.1093/emboj/16.14.4163; Gaemers IC, 1996, ENDOCRINOLOGY, V137, P479, DOI 10.1210/en.137.2.479; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; HARRISON EH, 1995, J LIPID RES, V36, P1498; Kang S, 1996, J INVEST DERMATOL, V107, P183, DOI 10.1111/1523-1747.ep12329579; KATO S, 1992, BIOCHEM J, V286, P755, DOI 10.1042/bj2860755; KURLANDSKY SB, 1995, J BIOL CHEM, V270, P17850, DOI 10.1074/jbc.270.30.17850; LEO MA, 1989, J NUTR, V119, P993, DOI 10.1093/jn/119.7.993; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MUINDI JRF, 1994, LEUKEMIA, V8, P1807; Nadin L, 1999, BIOCHEM PHARMACOL, V58, P1201, DOI 10.1016/S0006-2952(99)00192-6; NAPOLI JL, 1987, ARCH BIOCHEM BIOPHYS, V255, P95, DOI 10.1016/0003-9861(87)90298-0; NAPOLI JL, 1991, BIOMED PHARMACOTHER, V45, P131, DOI 10.1016/0753-3322(91)90101-X; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; OLSON JA, 1984, J NATL CANCER I, V73, P1439; Ong David E., 1994, P283; Raner GM, 1996, MOL PHARMACOL, V49, P515; Ray WJ, 1997, J BIOL CHEM, V272, P18702, DOI 10.1074/jbc.272.30.18702; REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939; RIAZULHAQ, 1991, P NATL ACAD SCI USA, V88, P8272, DOI 10.1073/pnas.88.18.8272; ROBERTS AB, 1980, ARCH BIOCHEM BIOPHYS, V199, P374, DOI 10.1016/0003-9861(80)90293-3; ROBERTS ES, 1992, MOL PHARMACOL, V41, P427; ROSS AC, 1993, FASEB J, V7, P317, DOI 10.1096/fasebj.7.2.8440409; ROSS AC, 1982, J BIOL CHEM, V257, P2453; Ross AC, 2000, MODERN NUTR HLTH DIS, P305; SCHWARTZ EL, 1995, BIOCHEM PHARMACOL, V50, P923, DOI 10.1016/0006-2952(95)00213-J; Sonneveld E, 1999, DEV BIOL, V213, P390, DOI 10.1006/dbio.1999.9381; Teerlink T, 1997, J CHROMATOGR B, V694, P83, DOI 10.1016/S0378-4347(97)00109-6; VECCHINI F, 1994, BIOCHEM BIOPH RES CO, V201, P1205, DOI 10.1006/bbrc.1994.1833; Westin S, 1997, MOL CELL ENDOCRINOL, V129, P169, DOI 10.1016/S0303-7207(97)04055-0; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; White JA, 1996, J BIOL CHEM, V271, P29922, DOI 10.1074/jbc.271.47.29922; ZACHMAN RD, 1966, J LIPID RES, V7, P3; ZOLFAGHARI R, 1995, ARCH BIOCHEM BIOPHYS, V323, P258, DOI 10.1006/abbi.1995.9966	48	65	68	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2000	14	13					2119	2127		10.1096/fj.00-0061com	http://dx.doi.org/10.1096/fj.00-0061com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023996				2022-12-25	WOS:000089634400031
J	Lopez, I; Mak, EC; Ding, JR; Hamm, HE; Lomasney, JW				Lopez, I; Mak, EC; Ding, JR; Hamm, HE; Lomasney, JW			A novel bifunctional phospholipase C that is regulated by G alpha(12) and stimulates the Ras/mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; RAS-BINDING DOMAIN; BASIC-AMINO-ACIDS; COUPLED RECEPTORS; ALPHA-SUBUNITS; P115 RHOGEF; CELLS; C-DELTA-1; IDENTIFICATION; HYDROLYSIS	Three families of phospholipase C (PI-PLC beta, gamma, and delta) are known to catalyze the hydrolysis of polyphosphoinositides such as phosphatidylinositol 4,5-bisphosphate (PIP2) to generate the second messengers inositol 1,4,5 trisphosphate and diacylglycerol, leading to a cascade of intracellular responses that result in cell growth, cell differentiation, and gene expression. Here we describe the founding member of a novel, structurally distinct fourth family of PI-PLC, PLC epsilon not only contains conserved catalytic (X and Y) and regulatory domains (C2) common to other eukaryotic PLCs, but also contains two Res-associating (RA) domains and a Ras guanine nucleotide exchange factor (RasGEF) motif. PLC epsilon hydrolyzes PIP2, and this activity is stimulated selectively by a constitutively active form of the heterotrimeric G protein Ga alpha (12). PLC epsilon and a mutant (H1144L) incapable of hydrolyzing phosphoinositides promote formation of GTP-Ras, Thus PLC epsilon is a RasGEF, PLCe, the mutant H1144L, and the isolated GEF domain activate the mitogen-activated protein kinase pathway in a manner dependent on Res but independent of PIP, hydrolysis, Our findings demonstrate that PLC epsilon is a novel bifunctional enzyme that is regulated by the heterotrimeric G protein Ga alpha (12), and activates the small G protein Ras/mitogen-activated protein kinase signaling pathway.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Feinberg Cardiovasc Res Inst, Chicago, IL 60611 USA; Vet Affairs Chicago Hlth Care Syst, Lakeside Div, Chicago, IL 60611 USA	Northwestern University; Northwestern University	Lomasney, JW (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, Tarry Bldg 12-703,303 E Chicago Ave, Chicago, IL 60611 USA.		Hamm, Heidi E/G-2374-2014		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL055591, R01HL055591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03836, HL55591] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bokoch GM, 1996, FASEB J, V10, P1290, DOI 10.1096/fasebj.10.11.8836042; Bromann PA, 1997, J BIOL CHEM, V272, P16240, DOI 10.1074/jbc.272.26.16240; Cheng SD, 1995, MOL CRYST LIQ CRYS A, V270, P1, DOI 10.1080/10587259508031009; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; Kim MJ, 1998, J BIOL CHEM, V273, P3618, DOI 10.1074/jbc.273.6.3618; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lomasney JW, 1996, J BIOL CHEM, V271, P25316, DOI 10.1074/jbc.271.41.25316; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; Murai H, 1997, J BIOL CHEM, V272, P10483; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; Shibatohge M, 1998, J BIOL CHEM, V273, P6218, DOI 10.1074/jbc.273.11.6218; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wadsworth SJ, 1997, J BIOL CHEM, V272, P28829, DOI 10.1074/jbc.272.46.28829; WU DQ, 1993, J BIOL CHEM, V268, P3704; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417; Zu YL, 1996, BLOOD, V87, P5287, DOI 10.1182/blood.V87.12.5287.bloodjournal87125287	35	210	223	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2758	2765		10.1074/jbc.M008119200	http://dx.doi.org/10.1074/jbc.M008119200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11022047	hybrid			2022-12-25	WOS:000166784800063
J	Scott, PH; Cairns, CA; Sutcliffe, JE; Alzuherri, HM; McLees, A; Winter, AG; White, RJ				Scott, PH; Cairns, CA; Sutcliffe, JE; Alzuherri, HM; McLees, A; Winter, AG; White, RJ			Regulation of RNA polymerase III transcription during cell cycle entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING-PROTEIN; RETINOBLASTOMA SUSCEPTIBILITY GENE; CASEIN KINASE-II; SIGNALING PATHWAY; EXPRESSION; GROWTH; DIFFERENTIATION; PHOSPHORYLATION; TFIIIB; D1	Increased rates of RNA polymerase (pol) III transcription constitute a central feature of the mitogenic response, but little is known about the mechanism(s) responsible. We demonstrate that the retinoblastoma protein RE plays a major role in suppressing pol III transcription in growth-arrested fibroblasts. RE knockout cells are compromised in their ability to down-regulate pol III following serum withdrawal. RE binds and represses the pol III-specific transcription factor TFIIIB during G(0) and early G(1), but this interaction decreases as cells approach S phase. Full induction of pol III coincides with mid- to late G(1) phase, when RE becomes phosphorylated by cyclin D- and E-dependent kinases, TFIIIB only associates with the underphosphorylated form of RE, and overexpression of cyclins D and E stimulates pol III transcription in vivo. The RE-related protein p130 also contributes to the repression of TFIIIB in growth-arrested fibroblasts, These observations provide insight into the mechanisms responsible for controlling pol III transcription during the switch between growth and quiescence.	Univ Glasgow, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	White, RJ (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.			Scott, Pam/0000-0001-5548-4039				Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alzuherri HM, 1998, J BIOL CHEM, V273, P17166, DOI 10.1074/jbc.273.27.17166; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BOYIAN JF, 1999, EXP CELL RES, V248, P110; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Chu WM, 1997, J BIOL CHEM, V272, P14755, DOI 10.1074/jbc.272.23.14755; DEAN N, 1988, MOL CELL BIOL, V8, P3017, DOI 10.1128/MCB.8.8.3017; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ghavidel A, 1997, GENE DEV, V11, P2780, DOI 10.1101/gad.11.21.2780; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hockman DJ, 1996, MOL CELL BIOL, V16, P892; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JOHNSON LF, 1974, CELL, V1, P95, DOI 10.1016/0092-8674(74)90068-3; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KILLANDER D, 1965, EXP CELL RES, V40, P12, DOI 10.1016/0014-4827(65)90285-5; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; LANIA L, 1987, FEBS LETT, V219, P400, DOI 10.1016/0014-5793(87)80260-0; Larminie CGC, 1999, MOL CELL BIOL, V19, P4927; Larminie CGC, 1998, J MOL MED, V76, P94, DOI 10.1007/s001090050196; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MAUCK JC, 1974, CELL, V3, P171, DOI 10.1016/0092-8674(74)90122-6; Mayol X, 1996, ONCOGENE, V13, P237; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nasmyth K, 1996, NATURE, V382, P28, DOI 10.1038/382028a0; Nylandsted J, 1998, FEBS LETT, V436, P41, DOI 10.1016/S0014-5793(98)01089-8; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; REDPATH NT, 1994, BBA-MOL CELL RES, V1220, P147, DOI 10.1016/0167-4889(94)90130-9; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rosenwald IB, 1996, BIOESSAYS, V18, P243, DOI 10.1002/bies.950180312; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; Shen YH, 1996, MOL CELL BIOL, V16, P4163; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SINN E, 1995, GENE DEV, V9, P675, DOI 10.1101/gad.9.6.675; Sutcliffe JE, 1999, MOL CELL BIOL, V19, P4255; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; TERASIMA T, 1966, EXP CELL RES, V44, P669, DOI 10.1016/0014-4827(66)90482-4; TOWER J, 1988, MOL CELL BIOL, V8, P1001, DOI 10.1128/MCB.8.2.1001; Wang HD, 1997, MOL CELL BIOL, V17, P6838, DOI 10.1128/MCB.17.12.6838; White R. J., 1998, RNA POLYMERASE 3 TRA; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; White RJ, 1997, TRENDS BIOCHEM SCI, V22, P77, DOI 10.1016/S0968-0004(96)10067-0; Zaragoza D, 1998, MOL CELL BIOL, V18, P4463, DOI 10.1128/MCB.18.8.4463; ZARKOWSKA T, 1997, J BIOL CHEM, V272, P1238	65	55	62	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1005	1014		10.1074/jbc.M005417200	http://dx.doi.org/10.1074/jbc.M005417200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11024049	hybrid			2022-12-25	WOS:000166430900021
J	Harmon, FG; Kowalczykowski, SC				Harmon, FG; Kowalczykowski, SC			Biochemical characterization of the DNA helicase activity of the Escherichia coli RecQ helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; SYNDROME GENE-PRODUCT; BLOOMS-SYNDROME; ATP HYDROLYSIS; RECBCD ENZYME; CONJUGATIONAL RECOMBINATION; UNWINDING ACTIVITY; DEPENDENT ATPASE; SSB PROTEIN; BINDING	We demonstrate that RecQ helicase from Escherichia coli is a catalytic helicase whose activity depends on the concentration of ATP, free magnesium ion, and single-stranded DNA-binding (SSB) protein. Helicase activity is cooperative in ATP concentration, with an apparent S-0.5 value for ATP of 200 muM and a Hill coefficient of 3.3 +/- 0.3, Therefore, RecQ helicase utilizes multiple, interacting ATP-binding sites to mediate double-stranded DNA (dsDNA) unwinding, implicating a multimer of at least three subunits as the active unwinding species. Unwinding activity is independent of dsDNA ends, indicating that RecQ helicase can unwind from both internal regions and ends of dsDNA. The K-M for dsDNA is 0.5-0.9 mum base pairs; the K-cat for DNA unwinding is 2.3-2.7 base pairs/s/monomer of RecQ helicase; and unexpectedly, helicase activity is optimal at a free magnesium ion concentration of 0.05 mM. Omitting Escherichia coli SSB protein lowers the rate and extent of dsDNA unwinding, suggesting that RecQ helicase associates with the single-stranded DNA (ssDNA) product. In agreement, the ssDNA-dependent ATPase activity is reduced in proportion to the SSB protein concentration; in its absence, ATPase activity saturates at six nucleotides/RecQ helicase monomer and yields a k(cat) of 24 s(-1). Thus, we conclude that SSB protein stimulates RecQ helicase-mediated unwinding by both trapping the separated ssDNA strands after unwinding and preventing the formation of non-productive enzyme-ssDNA complexes.	Univ Calif Davis, Microbiol Sect, Div Biol Sci, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Div Biol Sci, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Microbiol Sect, Div Biol Sci, Hutchison Hall, Davis, CA 95616 USA.	sckowalczykowski@ucdavis.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041347] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-41347] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DG, 1998, J MOL BIOL, V282, P275, DOI 10.1006/jmbi.1998.2013; ARAI K, 1981, J BIOL CHEM, V256, P5253; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; Cantor C., 1980, BIOPHYSICAL CHEM 3, P859; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Cogoni C, 1999, SCIENCE, V286, P2342, DOI 10.1126/science.286.5448.2342; Eggleston AK, 1996, NUCLEIC ACIDS RES, V24, P1179, DOI 10.1093/nar/24.7.1179; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Fry M, 1998, NAT GENET, V19, P308, DOI 10.1038/1188; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; GUERRERO R, 1984, J GEN MICROBIOL, V130, P2247; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Harmon FG, 1999, MOL CELL, V3, P611, DOI 10.1016/S1097-2765(00)80354-8; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; IRINO N, 1986, MOL GEN GENET, V205, P298, DOI 10.1007/BF00430442; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kusano K, 1999, GENETICS, V151, P1027; LANZOV V, 1991, BIOCHIMIE, V73, P305, DOI 10.1016/0300-9084(91)90217-O; LEBOWITZ J, 1985, BIOCH MECH STRAND IN; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; Lindor NM, 2000, AM J MED GENET, V90, P223, DOI 10.1002/(SICI)1096-8628(20000131)90:3<223::AID-AJMG7>3.0.CO;2-Z; LLOYD RG, 1995, GENETICS, V139, P1123; LLOYD RG, 1984, MOL GEN GENET, V197, P328, DOI 10.1007/BF00330981; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Marrione PE, 1996, BIOCHEMISTRY-US, V35, P11228, DOI 10.1021/bi960316c; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1987, J BIOL CHEM, V262, P2066; MENDONCA VM, 1995, J BACTERIOL, V177, P1326, DOI 10.1128/jb.177.5.1326-1335.1995; NAKAYAMA H, 1984, MOL GEN GENET, V195, P474, DOI 10.1007/BF00341449; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; RUYECHAN WT, 1976, BIOCHEMISTRY-US, V15, P5057, DOI 10.1021/bi00668a017; Sambrook J., 1989, MOL CLONING, pA1; Sinclair DA, 1998, TRENDS BIOCHEM SCI, V23, P131, DOI 10.1016/S0968-0004(98)01188-8; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; TAYLOR AF, 1985, J MOL BIOL, V185, P431, DOI 10.1016/0022-2836(85)90414-0; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; UMEZU K, 1993, J MOL BIOL, V230, P1145, DOI 10.1006/jmbi.1993.1231; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Wong I, 1996, BIOCHEMISTRY-US, V35, P5726, DOI 10.1021/bi952959i; WOOD ER, 1987, J BIOL CHEM, V262, P15269; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Zaitsev EN, 1998, NUCLEIC ACIDS RES, V26, P650, DOI 10.1093/nar/26.2.650	58	102	121	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					232	243		10.1074/jbc.M006555200	http://dx.doi.org/10.1074/jbc.M006555200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024023	hybrid			2022-12-25	WOS:000166280700033
J	Wei, CC; Wang, ZQ; Wang, Q; Meade, AL; Hemann, C; Hille, R; Stuehr, DJ				Wei, CC; Wang, ZQ; Wang, Q; Meade, AL; Hemann, C; Hille, R; Stuehr, DJ			Rapid kinetic studies link tetrahydrobiopterin radical formation to heme-dioxy reduction and arginine hydroxylation in inducible nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE GENERATION; ELECTRON-TRANSFER; LOW-TEMPERATURE; COMPLEX; INTERMEDIATE; DOMAIN; PTERIN; INHIBITION; CATALYSIS; BINDING	To understand how heme and (6R)-5,6,7,8-tetrahydro-L-biopterin (H4B) participate in nitric-oxidle synthesis, we followed ferrous-dioxy heme ((FeO2)-O-II,) formation and disappearance, H4B radical formation, and Arg hydroxylation during a single catalytic turnover by the inducible nitric-oxide synthase oxygenase domain (iNOSoxy), In all cases, prereduced (ferrous) enzyme was rapidly mixed with an O-2-containing buffer to start the reaction, A ferrous-dioxy intermediate formed quickly (53 s(-1)) and then decayed with concurrent buildup of ferric iNOSoxy, The buildup of the ferrous-dioxy intermediate preceded both H4B radical formation and Arg hydroxylation, However, the rate of ferrous-dioxy decay (12 s(-1)) was equivalent to the rate of H4B radical formation and s(-1) ) and the rate of Arg hydroxylation (9 s(-1)). Practically all bound H4B was oxidized to a radical during the reaction and was associated with hydroxylation of 0.6 mol of Arg/mol of heme, In dihydrobiopterin-containing iN-OSoxy, ferrous-dioxy decay was much slower and was not associated with Arg hydroxylation. These results establish kinetic and quantitative links among ferrous-dioxy disappearance, H4B oxidation, and Arg hydroxylation and suggest a mechanism whereby H4B transfers an electron to the ferrous-dioxy intermediate to enable the formation of a heme-based oxidant that rapidly hydroxylates Arg.	Cleveland Clin Fdn, Dept Immunol NB3, Lerner Res Inst, Cleveland, OH 44195 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	Cleveland Clinic Foundation; University System of Ohio; Ohio State University	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Dept Immunol NB3, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	stuehrd@ccf.org		Hemann, Craig/0000-0002-7380-4072; Wei, Chin-Chuan/0000-0001-6453-9409	NCI NIH HHS [CA53914] Funding Source: Medline; NIGMS NIH HHS [GM58481, GM51491] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA053914, R01CA053914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491, R01GM058481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 2000, J BIOL CHEM, V275, P17349, DOI 10.1074/jbc.M000050200; AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; Adak S, 1999, J BIOL CHEM, V274, P26907, DOI 10.1074/jbc.274.38.26907; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Benson DE, 1997, BIOCHEMISTRY-US, V36, P5104, DOI 10.1021/bi963170q; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; Couture M, 2000, J BIOL CHEM, V275, P3201, DOI 10.1074/jbc.275.5.3201; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Ghosh S, 1999, J BIOL CHEM, V274, P24100, DOI 10.1074/jbc.274.34.24100; Hemmens B, 1998, METH MOL B, V100, P1; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; Iwanaga T, 1999, BIOCHEMISTRY-US, V38, P16629, DOI 10.1021/bi991277i; Ledbetter AP, 1999, BIOCHEMISTRY-US, V38, P8014, DOI 10.1021/bi990619h; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; Ortiz de Montellano PR, 1986, CYTOCHROME P450 STRU, P217; Pou S, 1999, J BIOL CHEM, V274, P9573, DOI 10.1074/jbc.274.14.9573; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Sagami I, 2000, J BIOL CHEM, V275, P26150, DOI 10.1074/jbc.M000534200; Sato H, 1998, BIOCHEM BIOPH RES CO, V253, P845, DOI 10.1006/bbrc.1998.9851; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; Stuehr DJ, 2000, HANDB EXP PHARMACOL, V143, P33; Vasquez-Vivar J, 1999, J BIOL CHEM, V274, P26736, DOI 10.1074/jbc.274.38.26736	26	129	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					315	319		10.1074/jbc.M008441200	http://dx.doi.org/10.1074/jbc.M008441200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11020389	hybrid			2022-12-25	WOS:000166280700043
J	Dowell, P; Flexner, C; Kwiterovich, PO; Lanes, MD				Dowell, P; Flexner, C; Kwiterovich, PO; Lanes, MD			Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER BINDING-PROTEIN; IMMUNODEFICIENCY-VIRUS INFECTION; RESPONSIVE GLUCOSE TRANSPORTER; FATTY-ACID SYNTHETASE; 3T3-L1 PREADIPOCYTES; GENE-EXPRESSION; CELL-DEATH; PPAR-GAMMA; TRANSCRIPTION; APOPTOSIS	Many human immunodeficiency virus (HIV)-infected patients taking combination antiretroviral therapy that includes HIV protease inhibitors experience atrophy of peripheral subcutaneous adipose tissue. We investigated the effects of HIV protease inhibitors on adipogenesis and adipocyte survival using the 3T3-L1 preadipocyte cell line. Several HIV protease inhibitors were found either to inhibit preadipocyte differentiation or to promote adipocyte cell death. One protease inhibitor, nelfinavir, elicited both of these effects strongly. When induced to differentiate in the presence of nelfinavir, 3T3-L1 preadipocytes failed to accumulate cytoplasmic triacylglycerol and failed to express normal levels of the adipogenic transcription factors CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. The level of the proteolytically processed, active 68-kDa form of sterol regulatory element-binding protein-1, a transcription factor known to promote lipogenic gene expression, also was reduced markedly in nelfinavir-treated cells, whereas the level of the 125-kDa precursor form of this protein was unaffected. The inhibitory effect of nelfinavir occurred subsequent to critical early events in preadipocyte differentiation, expression of CCAAT/enhancer-binding protein beta and completion of the mitotic clonal expansion phase, because these events were unaffected by nelfinavir treatment. In addition, nelfinavir treatment of fully differentiated 3T3-L1 adipocytes resulted in DNA strand cleavage and severe loss of cell viability. In contrast, cell proliferation and viability of preadipocytes were unaffected by nelfinavir treatment. Thus, molecular or cellular changes that occur during acquisition of the adipocyte phenotype promote susceptibility to nelfinavir-induced cell death. When considered together, these results suggest that nelfinavir may promote adipose tissue atrophy by compromising adipocyte viability and preventing replacement of lost adipocytes by inhibiting preadipocyte differentiation.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Dowell, P (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 509 WBSB,725 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009894] Funding Source: NIH RePORTER; NIDDK NIH HHS [F32DK09894] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARENDS MJ, 1990, AM J PATHOL, V136, P593; Beach JW, 1998, CLIN THER, V20, P2; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Carr A, 2000, CLIN INFECT DIS, V30, pS135, DOI 10.1086/313854; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Domingo P, 1999, AIDS, V13, P2261, DOI 10.1097/00002030-199911120-00008; Dong Z, 1997, AM J PATHOL, V151, P1205; Dube MP, 1997, LANCET, V350, P713, DOI 10.1016/S0140-6736(05)63513-1; Eastone JA, 1997, ANN INTERN MED, V127, P948, DOI 10.7326/0003-4819-127-10-199711150-00017; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; Gervasoni C, 1999, AIDS, V13, P465, DOI 10.1097/00002030-199903110-00004; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hengel RL, 1997, LANCET, V350, P1596, DOI 10.1016/S0140-6736(05)64011-1; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; Hwang CS, 1997, ANNU REV CELL DEV BI, V13, P231, DOI 10.1146/annurev.cellbio.13.1.231; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KAN O, 1994, J EXP MED, V180, P917, DOI 10.1084/jem.180.3.917; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kotler DP, 1999, J ACQ IMMUN DEF SYND, V20, P228, DOI 10.1097/00042560-199903010-00003; Lenhard JM, 2000, ANTIVIR RES, V47, P121, DOI 10.1016/S0166-3542(00)00102-9; Lenhard JM, 2000, BIOCHEM PHARMACOL, V59, P1063, DOI 10.1016/S0006-2952(00)00246-X; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; Loftus TM, 1998, P NATL ACAD SCI USA, V95, P14168, DOI 10.1073/pnas.95.24.14168; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Madge S, 1999, AIDS, V13, P735, DOI 10.1097/00002030-199904160-00020; Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5; Mulligan K, 2000, J ACQ IMMUN DEF SYND, V23, P35, DOI 10.1097/00042560-200001010-00005; Murata H, 2000, J BIOL CHEM, V275, P20251, DOI 10.1074/jbc.C000228200; Periard D, 1999, CIRCULATION, V100, P700, DOI 10.1161/01.CIR.100.7.700; Rosen ED, 2000, GENE DEV, V14, P1293; Roth VR, 1998, CLIN INFECT DIS, V27, P65, DOI 10.1086/514639; Saint-Marc T, 1999, AIDS, V13, P1659, DOI 10.1097/00002030-199909100-00009; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Staiger H, 1998, EUR J CELL BIOL, V77, P220, DOI 10.1016/S0171-9335(98)80110-6; Stocker DN, 1998, LANCET, V352, P320, DOI 10.1016/S0140-6736(05)60295-4; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; WALKER PR, 1994, EXP CELL RES, V213, P100, DOI 10.1006/excr.1994.1178; Walli R, 1998, AIDS, V12, pF167, DOI 10.1097/00002030-199815000-00001; Wentworth JM, 2000, J ENDOCRINOL, V164, pR7, DOI 10.1677/joe.0.164R007; Yanovski JA, 1999, J CLIN ENDOCR METAB, V84, P1925, DOI 10.1210/jc.84.6.1925; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zhang B, 1999, J CLIN ENDOCR METAB, V84, P4274, DOI 10.1210/jc.84.11.4274; ZHU Y, 1995, P NATL ACAD SCI USA, V15, P7921	59	187	191	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41325	41332		10.1074/jbc.M006474200	http://dx.doi.org/10.1074/jbc.M006474200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018036	hybrid			2022-12-25	WOS:000166114600088
J	Ichiyama, S; Kurihara, T; Li, YF; Kogure, Y; Tsunasawa, S; Esaki, N				Ichiyama, S; Kurihara, T; Li, YF; Kogure, Y; Tsunasawa, S; Esaki, N			Novel catalytic mechanism of nucleophilic substitution by asparagine residue involving cyanoalanine intermediate revealed by mass spectrometric monitoring of an enzyme reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS SP. YL; P-TYPE ATPASE; L-2-HALOACID DEHALOGENASE; BETA-CYANOALANINE; ESTER INTERMEDIATE; SITE; PURIFICATION; IDENTIFICATION; MUTAGENESIS; SYNTHASE	L-2-Haloacid dehalogenase from Pseudomonas sp. YL catalyzes the hydrolytic dehalogenation, in which Asp(10) acts as a nucleophile to attack the Lu-carbon of L-2-haloalkanoates to form an ester intermediate, which is subsequently: hydrolyzed to produce D-2-hydroxyalkanoates. Surprisingly, replacement of the catalytic residue, Asp(10), by Asn did not result in total inactivation of the enzyme (Kurihara, T., Liu, J.-Q., Nardi-Dei, V., Koshikawa, H.,Esaki, N., and Soda, K. (1995) J. Biochem. 117, 1917-1322). In this study, we monitored the D10N mutant enzyme reaction by ion-spray mass spectrometry, and found that the enzyme shows a unique structural change when it was incubated with the substrate, L-2-chloropropionate. LC/MS and tandem MS/MS analyses revealed that Asn(10) attacks the substrate to form an imidate, and a proton and D-lactic acid are eliminated to produce a nitrile (beta -cyanoalanine residue), followed by hydrolysis to reproduce Asn(10). This is the first report of the function of Asn to catalyze nucleophilic substitution through its conversion to beta -cyanoalanine residue as an intermediate structure. Also, these results demonstrate that mass spectrometry is remarkably useful in monitoring enzyme reactions.	Kyushu Univ, Chem Res Inst, Microbial Biochem Lab, Uji, Kyoto 6110011, Japan; Takara Shuzo Co Ltd, Biotechnol Res Labs, Shiga 5250055, Japan	Kyushu University; Takara Holdings Inc.	Esaki, N (corresponding author), Kyushu Univ, Chem Res Inst, Microbial Biochem Lab, Uji, Kyoto 6110011, Japan.	esaki@scl.kyoto-u.ac.jp						AKOPYAN TN, 1975, P NATL ACAD SCI USA, V72, P1617, DOI 10.1073/pnas.72.4.1617; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; CASTRIC PA, 1971, J BACTERIOL, V108, P132, DOI 10.1128/JB.108.1.132-136.1971; DUNNILL PM, 1965, NATURE, V208, P1206, DOI 10.1038/2081206a0; IWASAKI I, 1956, B CHEM SOC JPN, V29, P860, DOI 10.1246/bcsj.29.860; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURIHARA T, 1995, J BIOCHEM, V117, P1317, DOI 10.1093/oxfordjournals.jbchem.a124861; Li YF, 1998, J BIOL CHEM, V273, P15035, DOI 10.1074/jbc.273.24.15035; LIU JQ, 1995, J BIOL CHEM, V270, P18309, DOI 10.1074/jbc.270.31.18309; LIU JQ, 1994, APPL ENVIRON MICROB, V60, P2389, DOI 10.1128/AEM.60.7.2389-2393.1994; Liu JQ, 1997, J BIOL CHEM, V272, P3363, DOI 10.1074/jbc.272.6.3363; Maruyama A, 1998, PLANT CELL PHYSIOL, V39, P671, DOI 10.1093/oxfordjournals.pcp.a029421; MOTOSUGI K, 1984, BIOTECHNOL BIOENG, V26, P805, DOI 10.1002/bit.260260729; Nardi-Dei V, 1999, J BIOL CHEM, V274, P20977, DOI 10.1074/jbc.274.30.20977; PRIES F, 1995, FEBS LETT, V358, P171, DOI 10.1016/0014-5793(94)01420-6; Ridder IS, 1999, BIOCHEM J, V339, P223, DOI 10.1042/0264-6021:3390223; ROY U, 1983, INT J PEPT PROT RES, V22, P525; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; Stokes DL, 2000, BIOPHYS J, V78, P1765, DOI 10.1016/S0006-3495(00)76727-0; SYKES P, 1986, GUIDEBOOK MECH ORGAN, P244; Tarr G E, 1977, Methods Enzymol, V47, P335; TENNANT G, 1979, COMPREHENSIVE ORGANI, V2, P490; TOLOSA EA, 1975, EUR J BIOCHEM, V53, P429, DOI 10.1111/j.1432-1033.1975.tb04083.x; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; WAKABAYASHI S, 1995, THEORY PRACTICE ENZY, P467	26	22	27	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40804	40809		10.1074/jbc.M008065200	http://dx.doi.org/10.1074/jbc.M008065200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11006296	hybrid			2022-12-25	WOS:000166114600021
J	Jongbloed, JDH; Martin, U; Antelmann, H; Hecker, M; Tjalsma, H; Venema, G; Bron, S; van Dijl, JM; Muller, J				Jongbloed, JDH; Martin, U; Antelmann, H; Hecker, M; Tjalsma, H; Venema, G; Bron, S; van Dijl, JM; Muller, J			TatC is a specificity determinant for protein secretion via the twin-arginine translocation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL PEPTIDASE-I; TEMPORALLY CONTROLLED EXPRESSION; COMPLETE GENOME SEQUENCE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; THYLAKOID MEMBRANE; ALKALINE-PHOSPHATASE; POLYACRYLAMIDE GELS; EXPORT PATHWAY; ALPHA-AMYLASE	The recent discovery of a ubiquitous translocation pathway, specifically required for proteins with a twin-arginine motif in their signal peptide, has focused interest on its membrane-bound components, one of which is known as TatC. Unlike most organisms of which the genome has been sequenced completely, the Gram-positive eubacterium Bacillus subtilis contains two tatC-like genes denoted tatCd and tatCy. The corresponding TatCd and TatCy proteins have the potential to be involved in the translocation of 27 proteins with putative twin-arginine signal peptides of which similar to6-14 are likely to be secreted into the growth medium. Using a proteomic approach, we show that PhoD of B. subtilis, a phosphodiesterase belonging to a novel protein family of which all known members are synthesized with typical twin-arginine signal peptides, is secreted via the twin-arginine translocation pathway. Strikingly, TatCd is of major importance for the secretion of PhoD, whereas TatCy is not required for this process. Thus, TatC appears to be a specificity determinant for protein secretion via the Tat pathway, Based on our observations, we hypothesize that the TatC determined pathway specificity is based on specific interactions between TatC-like proteins and other pathway components, such as TatA, of which three paralogues are present in B. subtilis.	Univ Groningen, Dept Pharmaceut Biol, NL-9713 AV Groningen, Netherlands; Groningen Biomol Sci & Biotechnol Inst, Dept Genet, NL-9751 NN Haren, Netherlands; Univ Jena, Inst Mol Biol, D-07745 Jena, Germany; Univ Greifswald, Inst Mikrobiol & Molekularbiol, D-17487 Greifswald, Germany	University of Groningen; University of Groningen; Friedrich Schiller University of Jena; Ernst Moritz Arndt Universitat Greifswald	van Dijl, JM (corresponding author), Univ Groningen, Dept Pharmaceut Biol, Deusinglaan 1, NL-9713 AV Groningen, Netherlands.		Tjalsma, Harold/I-7146-2012; van Dijl, Jan Maarten/G-1205-2013; Antelmann, Haike/I-3129-2019	Antelmann, Haike/0000-0002-1766-4386				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Antelmann H, 2000, J BACTERIOL, V182, P4478, DOI 10.1128/JB.182.16.4478-4490.2000; Antelmann H, 1997, J BACTERIOL, V179, P7251, DOI 10.1128/jb.179.23.7251-7256.1997; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Bernhardt J, 1997, MICROBIOL-UK, V143, P999, DOI 10.1099/00221287-143-3-999; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Bogsch E, 1997, EMBO J, V16, P3851, DOI 10.1093/emboj/16.13.3851; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Bolhuis A, 1999, J BIOL CHEM, V274, P15865, DOI 10.1074/jbc.274.22.15865; Bolhuis A, 1999, APPL ENVIRON MICROB, V65, P2934; Bolhuis A, 1996, MOL MICROBIOL, V22, P605, DOI 10.1046/j.1365-2958.1996.d01-4676.x; Brink S, 1998, FEBS LETT, V434, P425, DOI 10.1016/S0014-5793(98)01028-X; BRON S, 1972, MUTAT RES, V15, P1, DOI 10.1016/0027-5107(72)90086-3; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; Chanal A, 1998, MOL MICROBIOL, V30, P674, DOI 10.1046/j.1365-2958.1998.01095.x; Cristobal S, 1999, EMBO J, V18, P2982, DOI 10.1093/emboj/18.11.2982; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; DONOVAN W, 1987, J MOL BIOL, V196, P1, DOI 10.1016/0022-2836(87)90506-7; Eder S, 1996, MICROBIOL-SGM, V142, P2041, DOI 10.1099/13500872-142-8-2041; Eymann C, 1996, MICROBIOL-UK, V142, P3163, DOI 10.1099/13500872-142-11-3163; GueroutFleury AM, 1995, GENE, V167, P335, DOI 10.1016/0378-1119(95)00652-4; Hirose I, 2000, MICROBIOL-SGM, V146, P65, DOI 10.1099/00221287-146-1-65; HULETT FM, 1990, J BACTERIOL, V172, P735, DOI 10.1128/jb.172.2.735-740.1990; Hynds PJ, 1998, J BIOL CHEM, V273, P34868, DOI 10.1074/jbc.273.52.34868; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER JH, 1982, EXPT MOL BIOL; MOULD RM, 1991, J BIOL CHEM, V266, P12189; Muller JP, 1999, FEMS MICROBIOL LETT, V180, P287; Muller JP, 1997, MICROBIOL-SGM, V143, P947, DOI 10.1099/00221287-143-3-947; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; Otto A, 1996, ELECTROPHORESIS, V17, P1643, DOI 10.1002/elps.1150171027; Pragai Z, 1997, MICROBIOL-UK, V143, P1327, DOI 10.1099/00221287-143-4-1327; Qi Y, 1998, J BACTERIOL, V180, P4007, DOI 10.1128/JB.180.15.4007-4010.1998; ROBINSON C, 1994, EMBO J, V13, P279, DOI 10.1002/j.1460-2075.1994.tb06260.x; Rodrigue A, 1999, J BIOL CHEM, V274, P13223, DOI 10.1074/jbc.274.19.13223; Sambrook J., 2002, MOL CLONING LAB MANU; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Sargent F, 1999, J BIOL CHEM, V274, P36073, DOI 10.1074/jbc.274.51.36073; SCHAEFFER P, 1965, P NATL ACAD SCI USA, V271, P5463; Settles AM, 1998, TRENDS CELL BIOL, V8, P494, DOI 10.1016/S0962-8924(98)01387-7; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; SIMONEN M, 1993, MICROBIOL REV, V57, P109, DOI 10.1128/MMBR.57.1.109-137.1993; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; Stephenson K, 1998, APPL ENVIRON MICROB, V64, P2875; Swaving J, 1999, J BACTERIOL, V181, P7021, DOI 10.1128/JB.181.22.7021-7027.1999; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tjalsma H, 1997, J BIOL CHEM, V272, P25983, DOI 10.1074/jbc.272.41.25983; Tjalsma H, 1999, J BIOL CHEM, V274, P1698, DOI 10.1074/jbc.274.3.1698; Tjalsma H, 1998, GENE DEV, V12, P2318, DOI 10.1101/gad.12.15.2318; Tjalsma H, 2000, MICROBIOL MOL BIOL R, V64, P515, DOI 10.1128/MMBR.64.3.515-547.2000; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; VANDIJL JM, 1991, MOL GEN GENET, V227, P40, DOI 10.1007/BF00260704; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VANDIJL JM, 1991, J GEN MICROBIOL, V137, P2073, DOI 10.1099/00221287-137-9-2073; VIEIRA J, 1991, GENE, V100, P189, DOI 10.1016/0378-1119(91)90365-I; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; WERTMAN KF, 1986, GENE, V49, P253, DOI 10.1016/0378-1119(86)90286-6; Wexler M, 2000, J BIOL CHEM, V275, P16717, DOI 10.1074/jbc.M000800200; YU J, 1995, J BACTERIOL, V177, P6751, DOI 10.1128/jb.177.23.6751-6760.1995	66	133	145	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41350	41357		10.1074/jbc.M004887200	http://dx.doi.org/10.1074/jbc.M004887200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007775	hybrid			2022-12-25	WOS:000166114600091
J	Murat, A; Pellieux, C; Brunner, HR; Pedrazzini, T				Murat, A; Pellieux, C; Brunner, HR; Pedrazzini, T			Calcineurin blockade prevents cardiac mitogen-activated protein kinase activation and hypertrophy in renovascular hypertension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ANGIOTENSIN-II; T-LYMPHOCYTES; MOLECULAR MECHANISMS; CYCLOSPORINE; MICE; MYOCYTES; JNK; TRANSCRIPTION; STIMULATION	Chronic stimulation of the renin-angiotensin system induces an elevation of blood pressure and the development of cardiac hypertrophy via the actions of its effector, angiotensin II. In cardiomyocytes, mitogen-activated protein kinases as well as protein kinase C isoforms have been shown to be important in the transduction of trophic signals. The Ca2+/calmodulin-dependent phosphatase calcineurin has also been suggested to play a role in cardiac growth. In the present report, we investigate possible cross-talks between calcineurin, protein kinase C, and mitogen-activated protein kinase pathways in controlling angiotensin II-induced hypertrophy. Angiotensin II-stimulated cardiomyocytes and mice with angiotensin II-dependent renovascular hypertension were treated with the calcineurin inhibitor cyclosporin A. Calcineurin, protein kinase C, and mitogen-activated protein kinase activations were determined. We show that cyclosporin A blocks angiotensin II-induced mitogen-activated protein kinase activation in cultured primary cardiomyocytes and in the heart of hypertensive mice. Cyclosporin A also inhibits specific protein kinase C isoforms. In vivo, cyclosporin A prevents the development of cardiac hypertrophy, and this effect appears to be independent of hemodynamic changes. These data suggest cross-talks between the calcineurin pathway, the protein kinase C, and the mitogen-activated protein kinase signaling cascades in transducing angiotensin II-mediated stimuli in cardiomyocytes and could provide the basis for an integrated model of cardiac hypertrophy.	Univ Lausanne, Sch Med, Div Hypertens, CH-1011 Lausanne, Switzerland	University of Lausanne	Pedrazzini, T (corresponding author), Univ Lausanne, Sch Med, Div Hypertens, CH-1011 Lausanne, Switzerland.							ALEXANDER DR, 1990, BIOCHEM J, V268, P303, DOI 10.1042/bj2680303; Avraham A, 1998, EUR J IMMUNOL, V28, P2320, DOI 10.1002/(SICI)1521-4141(199808)28:08<2320::AID-IMMU2320>3.0.CO;2-K; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; BIERER BE, 1993, CURR OPIN IMMUNOL, V5, P763, DOI 10.1016/0952-7915(93)90135-F; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; DAHLOF B, 1995, J HUM HYPERTENS S5, V9, P37; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; Ding B, 1999, CIRC RES, V84, P729, DOI 10.1161/01.RES.84.6.729; Dostal DE, 1997, J MOL CELL CARDIOL, V29, P2893, DOI 10.1006/jmcc.1997.0524; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Kanno T, 1996, J IMMUNOL, V157, P5277; Kudoh S, 1997, CIRC RES, V80, P139, DOI 10.1161/01.RES.80.1.139; Lee DBN, 1997, KIDNEY INT, V52, P248, DOI 10.1038/ki.1997.328; Luo ZY, 1998, NAT MED, V4, P1092, DOI 10.1038/2578; Meguro T, 1999, CIRC RES, V84, P735, DOI 10.1161/01.RES.84.6.735; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MULLER JG, 1998, SCIENCE, V282, P1007; Pellieux C, 2000, P NATL ACAD SCI USA, V97, P1595, DOI 10.1073/pnas.030533197; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; Sealey JE, 1990, HYPERTENSION PATHOPH, P1287; Shimoyama M, 1999, CIRCULATION, V100, P2449, DOI 10.1161/01.CIR.100.24.2449; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; THIEL G, 1986, CLIN NEPHROL S1, V25, P199; THUERAUF DJ, 1994, J BIOL CHEM, V269, P17772; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Wiesel P, 1997, HYPERTENSION, V29, P1025, DOI 10.1161/01.HYP.29.4.1025; Wiesner RJ, 1997, CIRCULATION, V95, P1253; Zhang WG, 1999, CIRC RES, V84, P722, DOI 10.1161/01.RES.84.6.722	33	55	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40867	40873		10.1074/jbc.M008071200	http://dx.doi.org/10.1074/jbc.M008071200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11016940	hybrid			2022-12-25	WOS:000166114600028
J	Vallee, F; Karaveg, K; Herscovics, A; Moremen, KW; Howell, PL				Vallee, F; Karaveg, K; Herscovics, A; Moremen, KW; Howell, PL			Structural basis for catalysis and inhibition of N-glycan processing class I alpha 1,2-mannosidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; ACID ALPHA-MANNOSIDASE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; GLYCOPROTEIN-BIOSYNTHESIS; ASPERGILLUS-ORYZAE; CRYSTAL-STRUCTURES; SECRETORY PATHWAY; PICHIA-PASTORIS; CALCIUM-BINDING	Endoplasmic reticulum (ER) class I alpha1,2-mannosidase (also known as ER alpha -mannosidase I) is a critical enzyme in the maturation of N-linked oligosaccharides and ER-associated degradation. Trimming of a single mannose residue acts as a signal to target misfolded glycoproteins for degradation by the proteasome. Crystal structures of the catalytic domain of human ER class I alpha1,2-mannosidase have been determined both in the presence and absence of the potent inhibitors kifunensine and 1-deoxymannojirimycin. Both inhibitors bind to the protein at the bottom of the active-site cavity, with the essential calcium ion coordinating the O-2' and O-3' hydroxyls and stabilizing the six-membered rings of both inhibitors in a C-1(4) conformation. This is the first direct evidence of the role of the calcium ion. The lack of major conformational changes upon inhibitor binding and structural comparisons with the yeast alpha1,2-mannosidase enzyme product complex suggest that this class of inverting enzymes has a novel catalytic mechanism. The structures also provide insight into the specificity of this class of enzymes and provide a blueprint for the future design of novel inhibitors that prevent degradation of misfolded proteins in genetic diseases.	Hosp Sick Children, Res Inst, Program Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada; Univ Toronto, Fac Med, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; McGill University; University of Toronto	Howell, PL (corresponding author), Hosp Sick Children, Res Inst, Program Struct Biol & Biochem, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Moremen, Kelley/AAD-4661-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047533] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05351] Funding Source: Medline; NIGMS NIH HHS [GM31265, GM47533] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUSE E, 1992, EUR J BIOCHEM, V208, P451, DOI 10.1111/j.1432-1033.1992.tb17207.x; BETZEL C, 1988, EUR J BIOCHEM, V178, P155, DOI 10.1111/j.1432-1033.1988.tb14440.x; BISCHOFF J, 1984, BIOCHEM BIOPH RES CO, V125, P324, DOI 10.1016/S0006-291X(84)80371-X; Blisnick T, 1998, EUR J BIOCHEM, V252, P537, DOI 10.1046/j.1432-1327.1998.2520537.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BYRD JC, 1982, J BIOL CHEM, V257, P4657; CAMIRAND A, 1991, J BIOL CHEM, V266, P15120; Chung DH, 2000, J BIOL CHEM, V275, P4981, DOI 10.1074/jbc.275.7.4981; CREGG JM, 1993, BIO-TECHNOL, V11, P905, DOI 10.1038/nbt0893-905; CREGG JM, 1985, MOL CELL BIOL, V5, P3376, DOI 10.1128/MCB.5.12.3376; DANIEL PF, 1994, GLYCOBIOLOGY, V4, P551, DOI 10.1093/glycob/4.5.551; Davies GJ, 1995, BIOCHEMISTRY-US, V34, P16210, DOI 10.1021/bi00049a037; Degano M, 1998, BIOCHEMISTRY-US, V37, P6277, DOI 10.1021/bi973012e; ELBEIN AD, 1990, J BIOL CHEM, V265, P15599; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Gonzalez DS, 1999, J BIOL CHEM, V274, P21375, DOI 10.1074/jbc.274.30.21375; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; Herscovics A, 1999, BBA-GEN SUBJECTS, V1426, P275, DOI 10.1016/S0304-4165(98)00129-9; HERSCOVICS A, 1999, COMPREHENSIVE NATURA, V3, P13; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; Ichishima E, 1999, BIOCHEM J, V339, P589, DOI 10.1042/0264-6021:3390589; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; JELINEKKELLY S, 1985, J BIOL CHEM, V260, P2253; KADZIOLA A, 1994, J MOL BIOL, V239, P104, DOI 10.1006/jmbi.1994.1354; Kawar Z, 2000, GLYCOBIOLOGY, V10, P347, DOI 10.1093/glycob/10.4.347; Knop M, 1996, YEAST, V12, P1229, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1229::AID-YEA15>3.0.CO;2-H; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAL A, 1994, J BIOL CHEM, V269, P9872; Lal A, 1998, GLYCOBIOLOGY, V8, P981, DOI 10.1093/glycob/8.10.981; LASKOWSKI R, 1993, J APPL CRYSTALLOGR, V26, P91; Liao YF, 1996, J BIOL CHEM, V271, P28348, DOI 10.1074/jbc.271.45.28348; LIPARI F, 1995, BIOCHEM BIOPH RES CO, V209, P322, DOI 10.1006/bbrc.1995.1506; Lipari F, 1999, BIOCHEMISTRY-US, V38, P1111, DOI 10.1021/bi981643i; Lipari F, 1996, J BIOL CHEM, V271, P27615, DOI 10.1074/jbc.271.44.27615; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; LOLL PJ, 1995, BIOCHEMISTRY-US, V34, P4316, DOI 10.1021/bi00013a021; Marcus NY, 2000, J BIOL CHEM, V275, P1987, DOI 10.1074/jbc.275.3.1987; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; Merkle RK, 1997, BBA-GEN SUBJECTS, V1336, P132, DOI 10.1016/S0304-4165(97)00023-8; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moremen K., 2000, OLIGOSACCHARIDES CHE, VII, P81; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; Parsiegla G, 1998, EMBO J, V17, P5551, DOI 10.1093/emboj/17.19.5551; Romero PA, 2000, J BIOL CHEM, V275, P11071, DOI 10.1074/jbc.275.15.11071; ROUSSEL A, 1991, TURBO FRODO GRAPHICS; Schmidt A, 1998, PROTEIN SCI, V7, P2081, DOI 10.1002/pro.5560071004; SCHNEIKERT J, 1994, GLYCOBIOLOGY, V4, P445, DOI 10.1093/glycob/4.4.445; SCHUTZBACH JS, 1990, J BIOL CHEM, V265, P2546; Spurway TD, 1997, J BIOL CHEM, V272, P17523, DOI 10.1074/jbc.272.28.17523; SU K, 1993, J BIOL CHEM, V268, P14301; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tremblay LO, 1998, GLYCOBIOLOGY, V8, P585, DOI 10.1093/glycob/8.6.585; Tremblay LO, 1999, GLYCOBIOLOGY, V9, P1073, DOI 10.1093/glycob/9.10.1073; Vallee F, 2000, EMBO J, V19, P581, DOI 10.1093/emboj/19.4.581; van Santen Y, 1999, J BIOL CHEM, V274, P30474, DOI 10.1074/jbc.274.43.30474; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VUILLARD L, 1994, FEBS LETT, V353, P294, DOI 10.1016/0014-5793(94)01060-9; Wang Y, 2000, BIOCHEM BIOPH RES CO, V271, P22, DOI 10.1006/bbrc.2000.2577; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Weng SA, 1996, ARCH BIOCHEM BIOPHYS, V325, P113, DOI 10.1006/abbi.1996.0014; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Yoshida T, 1998, BIOSCI BIOTECH BIOCH, V62, P309, DOI 10.1271/bbb.62.309	74	123	125	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41287	41298		10.1074/jbc.M006927200	http://dx.doi.org/10.1074/jbc.M006927200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10995765	hybrid			2022-12-25	WOS:000166114600084
J	Bjorbaek, C; Lavery, HJ; Bates, SH; Olson, RK; Davis, SM; Flier, JS; Myers, MG				Bjorbaek, C; Lavery, HJ; Bates, SH; Olson, RK; Davis, SM; Flier, JS; Myers, MG			SOCS3 mediates feedback inhibition of the leptin receptor via Tyr(985)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JANUS TYROSINE KINASE; SIGNAL-TRANSDUCTION; OB-R; CYTOKINE RECEPTORS; SH2 DOMAIN; ACTIVATION LOOP; BODY-WEIGHT; BOX MOTIF; PROTEINS; RESISTANCE	During leptin signaling, each of the phosphorylated tyrosine residues on the long form of the leptin receptor (LRb) mediates distinct signals. Phosphorylated Tyr(1138) binds STAT3 to mediate its tyrosine phosphorylation and transcriptional activation, while phosphorylated Tyr(985) binds the tyrosine phosphatase SHP-2 and reportedly mediates both activation of ERK kinases and inhibition of LRb-mediated STAT3 activation. We show here that although mutation of Tyr985 does not alter STAT3 signaling by erythropoietin receptor-LRb (ELR) chimeras in transfected 293 cells at short times of stimulation, this mutation enhances STAT3 signaling at longer times of stimulation (>6 h). These data suggest that Tyr(985) may mediate feedback inhibition of LRb signaling by an LRb-induced LRb inhibitor, such as SOCS3. Indeed, SOCS3 binds specifically to phosphorylated Tyr(985) Of LRb, and SOCS3 fails to inhibit transcription by ELR following mutation of Tyr985, suggesting that SOCS3 inhibits LRb signaling by binding to phosphorylated Tyr(985). Additionally, overexpression of SOCS3, but not SHP-2, impairs ELR signaling, and the overexpression of SHP-2 blunts SOCS3-mediated inhibition of ELR signaling. Thus, our data suggest that in addition to mediating SHP-2 binding and ERK activation during acute stimulation, Tyr985 Of LRb mediates feedback inhibition of LRb signaling by binding to LRb-induced SOCS3.	Joslin Diabet Ctr, Div Res, Sect Obes, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Endocrinol, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Myers, MG (corresponding author), Joslin Diabet Ctr, Div Res, Sect Obes, 1 Joslin Pl, Boston, MA 02215 USA.	Martin.myers@joslin.harvard.edu	Bjorbaek, Christian/S-4727-2019; Flier, jeffrey/AAG-6223-2019		NIDDK NIH HHS [DKR0156731, DKR3728082] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK028082, R01DK056731] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander WS, 1999, J LEUKOCYTE BIOL, V66, P588, DOI 10.1002/jlb.66.4.588; Banks AS, 2000, J BIOL CHEM, V275, P14563, DOI 10.1074/jbc.275.19.14563; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bjorbaek C, 1999, ENDOCRINOLOGY, V140, P2035, DOI 10.1210/en.140.5.2035; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Boden G, 1996, DIABETES CARE, V19, P394, DOI 10.2337/diacare.19.4.394; Bornstein SR, 1997, DIABETES, V46, P1235, DOI 10.2337/diabetes.46.7.1235; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Carpenter LR, 1998, P NATL ACAD SCI USA, V95, P6061, DOI 10.1073/pnas.95.11.6061; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Couce ME, 1997, NEUROENDOCRINOLOGY, V66, P145, DOI 10.1159/000127232; De Sepulveda P, 1999, EMBO J, V18, P904; Devos R, 1997, J BIOL CHEM, V272, P18304, DOI 10.1074/jbc.272.29.18304; El-Haschimi K, 2000, J CLIN INVEST, V105, P1827, DOI 10.1172/JCI9842; Elmquist JK, 1999, NEURON, V22, P221, DOI 10.1016/S0896-6273(00)81084-3; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Ghilardi N, 1997, MOL ENDOCRINOL, V11, P393, DOI 10.1210/me.11.4.393; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Haque SJ, 2000, J BIOL CHEM, V275, P26500, DOI 10.1074/jbc.275.34.26500; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hinney A, 1997, INT J OBESITY, V21, P1190, DOI 10.1038/sj.ijo.0800534; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kim H, 1999, MOL CELL BIOL, V19, P5326; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Koistinen HA, 1998, EUR J CLIN INVEST, V28, P894; Krebs DL, 2000, J CELL SCI, V113, P2813; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Leibel RL, 1997, J BIOL CHEM, V272, P31937, DOI 10.1074/jbc.272.51.31937; Li C, 1999, P NATL ACAD SCI USA, V96, P9677, DOI 10.1073/pnas.96.17.9677; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Morton NM, 1999, J MOL ENDOCRINOL, V22, P173, DOI 10.1677/jme.0.0220173; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Nakashima K, 1997, FEBS LETT, V403, P79, DOI 10.1016/S0014-5793(97)00013-6; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Novak U, 1999, GROWTH FACTORS, V16, P305, DOI 10.3109/08977199909069148; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Suzuki R, 1998, ONCOGENE, V17, P2271, DOI 10.1038/sj.onc.1202143; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; White DW, 1997, J BIOL CHEM, V272, P4065, DOI 10.1074/jbc.272.7.4065; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Zamorano PL, 1997, NEUROENDOCRINOLOGY, V65, P223, DOI 10.1159/000127276; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	65	407	424	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40649	40657		10.1074/jbc.M007577200	http://dx.doi.org/10.1074/jbc.M007577200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11018044	hybrid			2022-12-25	WOS:000166039500114
J	Fax, P; Lehmkuhler, O; Kuhn, C; Esche, H; Brockmann, D				Fax, P; Lehmkuhler, O; Kuhn, C; Esche, H; Brockmann, D			E1A(12S)-mediated activation of the adenovirus type 12 E2 promoter depends on the histone acetyltransferase activity of p300/CBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENERAL TRANSCRIPTION FACTORS; RNA-POLYMERASE-II; COACTIVATORS P300; ONCOPROTEIN E1A; ONCOGENIC ADENOVIRUS-TYPE-12; TRANSACTIVATION FUNCTION; CBP; ACETYLATION; PROTEINS; PCAF	Activation of the transcription unit early region 2 (E2) promoter of the oncogenic adenovirus serotype 12 (Ad12), which regulates the expression of proteins essential for viral replication, requires the assembly of a ternary complex consisting of cAMP response element-binding protein (CREB)-1/activating transcription factor (ATF)-1, the Ad12 12S oncogene product of early region 1A (E1A(12S)), and the co-activator p300/CBP on the E2(Ad12) cAMP response element (ES-CRE). Here we show that the active E2(Ad12) promoter is associated with acetylated histone H4 whereas an E2-CRE point-mutated promoter which is transcriptionally inactive due to its inability to assemble this ternary complex is not bound by acetylated histone H4. The histone deacetylase 1 as well as Roscovitine, which blocks the activation of the histone acetyltransferase (HAT) activity of CBP by cyclin E-Cdk2, prevents E2(Ad12) promoter activation through E1A(12S). p300/CBP counteracts the repressive function of histone deacetylase 1 in a HAT domain-dependent manner whereas the p300/CBP-associated factor PCAF failed to rescue E2(Ad12) promoter activity. E1A(12S) bound p300/CBP displays strong HAT activity. Most interestingly, E1A(12S)-mediated activation of the E2(Ad12) promoter correlates well with the ability of the viral protein to associate with the HAT activity of p300/CBP in vivo. Taken together these data indicate that the recruitment of the HAT activity of p300/CBP by E1A(12S) plays an important role in E2(Ad12) promoter activation.	Univ Essen Gesamthsch, Sch Med, Inst Mol Biol Canc Res, D-45122 Essen, Germany	University of Duisburg Essen	Fax, P (corresponding author), Univ Essen Gesamthsch, Sch Med, Inst Mol Biol, Hufelandstr 55, D-45122 Essen, Germany.							Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BAYLEY ST, 1994, INT J ONCOL, V5, P425; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BROCKMANN D, 1990, VIROLOGY, V179, P585, DOI 10.1016/0042-6822(90)90125-B; BROCKMANN D, 1995, CURR TOP MICROBIOL, V199, P81; BROCKMANN D, 1995, J BIOL CHEM, V270, P10754, DOI 10.1074/jbc.270.18.10754; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; DEDON PC, 1991, ANAL BIOCHEM, V197, P83, DOI 10.1016/0003-2697(91)90359-2; DERY CV, 1985, J GEN VIROL, V66, P2671, DOI 10.1099/0022-1317-66-12-2671; Fax P, 2000, J BIOL CHEM, V275, P8911, DOI 10.1074/jbc.275.12.8911; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kung AL, 2000, GENE DEV, V14, P272; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Lipinski KS, 1999, VIROLOGY, V255, P94, DOI 10.1006/viro.1998.9583; Lipinski KS, 1998, VIRUS RES, V54, P99, DOI 10.1016/S0168-1702(98)00003-3; Lipinski KS, 1997, J GEN VIROL, V78, P413, DOI 10.1099/0022-1317-78-2-413; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SWAMINATHAN S, 1995, CURR TOP MICROBIOL, V199, P177; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	44	26	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40554	40560		10.1074/jbc.M004626200	http://dx.doi.org/10.1074/jbc.M004626200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11006273	hybrid			2022-12-25	WOS:000166039500101
J	Wen, KK; Kuang, B; Rubenstein, PA				Wen, KK; Kuang, B; Rubenstein, PA			Tropomyosin-dependent filament formation by a polymerization-defective mutant yeast actin (V266G,L267G)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TROPOMYOSIN; MUSCLE TROPOMYOSIN; POINTED END; F-ACTIN; BINDING; DEPOLYMERIZATION; IDENTIFICATION; PURIFICATION; STABILITY; TROPONIN	A major function of tropomyosin (TPM) in nonmuscle cells may be stabilization of F-actin by binding longitudinally along the actin filament axis. However, no clear evidence exists in vitro that TPM can significantly affect the critical concentration of actin, We previously made a polymerization-defective mutant actin, GG (V266G, L267G). This actin will not polymerize alone at 25 degreesC but will in the presence of phalloidin or beryllium fluoride, With beryllium fluoride, but not phalloidin, this polymerization rescue is cold-sensitive. We show here that GG-actin polymerizability was restored by cardiac tropomyosin and yeast TPM1 and TPM2 at 25 degreesC with rescue efficiency inversely proportional to TPM length (TPM2 > TPM1 > cardiac tropomyosin), indicating the importance of the ends in polymerization rescue. In the presence of TPM, the apparent critical concentration of actin is 5.5 muM, 10-15-fold higher than that of wild type actin but well below that of the GG-actin alone (>20 muM). Non N-acetylated TPMs did not rescue GG-actin polymerization, The TPMs did not prevent cold-induced depolymerization of GG F-actin, TPM-dependent GG-actin polymerization did not occur at temperatures below 20 degreesC, Polymerization rescue may depend initially on the capture of unstable GG-F-actin oligomers by the TPM, resulting in the strengthening of actin monomer-monomer contacts along the filament axis.	Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Rubenstein, PA (corresponding author), Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA.	peter-rubenstein@uiowa.edu	谢, 飞/C-7706-2009	Rubenstein, Peter/0000-0003-1225-4414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33689] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROSCHAT KO, 1990, J BIOL CHEM, V265, P21323; BROSCHAT KO, 1989, BIOCHEMISTRY-US, V28, P8501, DOI 10.1021/bi00447a035; BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; CHEN X, 1993, J CELL BIOL, V123, P1185, DOI 10.1083/jcb.123.5.1185; Cheng DM, 1999, J BIOL CHEM, V274, P35873, DOI 10.1074/jbc.274.50.35873; COOK RK, 1992, J BIOL CHEM, V267, P9430; DREES B, 1995, J CELL BIOL, V128, P383, DOI 10.1083/jcb.128.3.383; DRUBIN DG, 1993, MOL BIOL CELL, V4, P1277, DOI 10.1091/mbc.4.12.1277; GREENFIELD NJ, 1994, PROTEIN SCI, V3, P402; HILL LE, 1992, J BIOL CHEM, V267, P16106; HitchcockDeGregori SE, 1996, J BIOL CHEM, V271, P3600; HITCHCOCKDEGREGORI SE, 1988, BIOCHEMISTRY-US, V27, P9182, DOI 10.1021/bi00426a016; HUXLEY HE, 1973, NATURE, V244, P445, DOI 10.1038/243445a0; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kuang B, 1997, J BIOL CHEM, V272, P4412, DOI 10.1074/jbc.272.7.4412; LAL AA, 1986, BIOCHEMISTRY-US, V25, P1154, DOI 10.1021/bi00353a031; Landis C, 1999, J BIOL CHEM, V274, P31279, DOI 10.1074/jbc.274.44.31279; LIU HP, 1989, P NATL ACAD SCI USA, V86, P90, DOI 10.1073/pnas.86.1.90; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MATSUMURA F, 1985, J BIOL CHEM, V260, P3851; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; ORLOVA A, 1992, J MOL BIOL, V227, P1043, DOI 10.1016/0022-2836(92)90520-T; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; STRZELECKAGOLASZEWSKA H, 1993, EUR J BIOCHEM, V211, P731, DOI 10.1111/j.1432-1033.1993.tb17603.x; TOBACMAN LS, 1982, J BIOL CHEM, V257, P4166	26	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40594	40600		10.1074/jbc.M007201200	http://dx.doi.org/10.1074/jbc.M007201200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10998421	hybrid			2022-12-25	WOS:000166039500106
J	Law, BK; Waltner-Law, ME; Entingh, AJ; Chytil, A; Aakre, ME; Norgaard, P; Moses, HL				Law, BK; Waltner-Law, ME; Entingh, AJ; Chytil, A; Aakre, ME; Norgaard, P; Moses, HL			Salicylate-induced growth arrest is associated with inhibition of p70(s6k) and down-regulation of c-Myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; S6 KINASE; SODIUM-SALICYLATE; FARNESYLTRANSFERASE INHIBITOR; DNA-SYNTHESIS; PHOSPHORYLATION; EXPRESSION; ASPIRIN	Salicylate and its pro-drug form aspirin are widely used medicinally for their analgesic and anti-inflammatory properties, and more recently for their ability to protect against colon cancer and cardiovascular disease, Despite the wide use of salicylate, the mechanisms underlying its biological activities are largely unknown. Recent reports suggest that salicylate may produce some of its effects by modulating the activities of protein kinases. Since we have previously shown that the farnesyltransferase inhibitor L-744,832 inhibits cell proliferation and p70(s6k) activity, and salicylate inhibits cell proliferation, we examined whether salicylate affects p70(s6k) activity. We find that salicylate potently inhibits p70(s6k) activation and phosphorylation in a p38 MAPK-independent manner. Interestingly, low salicylate concentrations (less than or equal to 250 muM) inhibit p70(s6k) activation by phorbol myristate acetate, while higher salicylate concentrations (greater than or equal to5 mM) are required to block p70(s6k) activation by epidermal growth factor + insulin-like growth factor-1, These data suggest that salicylate may selectively inhibit p70(s6k) activation in response to specific stimuli. Inhibition of p70(s6k) by salicylate occurs within 5 min, is independent of the phosphatidylinositol 3-kinase pathway, and is associated with dephosphorylation of p70(s6k) on its major rapamycin-sensitive site, Thr(389). A rapamycin-resistant mutant of p70(s6k) is resistant to salicylate-induced Thr(389) dephosphorylation.	Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Glostrup Univ Hosp, Inst Pathol Anat, DK-2600 Glostrup, Denmark	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Copenhagen	Moses, HL (corresponding author), Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, 649 Preston Bldg MRBII, Nashville, TN 37232 USA.	hal.moses@mcmail.vanderbilt.edu	Law, Brian/L-6043-2019		NCI NIH HHS [CA85492, CA42572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085492, R35CA042572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Baron JA, 2000, ANNU REV MED, V51, P511, DOI 10.1146/annurev.med.51.1.511; BLENIS J, 1987, J BIOL CHEM, V262, P14373; Chen Y, 1996, ONCOGENE, V13, P1765; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; FEUERSTEIN N, 1995, J BIOL CHEM, V270, P9454, DOI 10.1074/jbc.270.16.9454; Fukazawa H, 2000, CANCER RES, V60, P2104; GILMAN AG, 1990, PHARMACOLOGICAL BASI; Grewe M, 1999, CANCER RES, V59, P3581; Hall-Jackson CA, 1999, ONCOGENE, V18, P2047, DOI 10.1038/sj.onc.1202603; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Javier AF, 1997, J CLIN INVEST, V99, P2094, DOI 10.1172/JCI119382; JAYARAMAN T, 1993, J BIOL CHEM, V268, P25385; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Law BK, 1999, J BIOL CHEM, V274, P4743, DOI 10.1074/jbc.274.8.4743; Law BK, 2000, J BIOL CHEM, V275, P10796, DOI 10.1074/jbc.275.15.10796; Luo Y, 1996, MOL CELL BIOL, V16, P6744; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Oliff A, 1999, BBA-REV CANCER, V1423, pC19, DOI 10.1016/S0304-419X(99)00007-4; Parrott LA, 1999, J BIOL CHEM, V274, P24731, DOI 10.1074/jbc.274.35.24731; Patrignani P, 2000, TOXICOL LETT, V112, P493, DOI 10.1016/S0378-4274(99)00210-6; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Perugini RA, 2000, J GASTROINTEST SURG, V4, P24, DOI 10.1016/S1091-255X(00)80029-3; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; Sawa H, 1998, ONCOGENE, V16, P1701, DOI 10.1038/sj.onc.1201691; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Seufferlein T, 1996, CANCER RES, V56, P3895; Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593; SPOHN M, 1980, BIOCHIM BIOPHYS ACTA, V608, P409, DOI 10.1016/0005-2787(80)90186-0; Stevenson MA, 1999, J IMMUNOL, V163, P5608; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vilella-Bach M, 1999, J BIOL CHEM, V274, P4266, DOI 10.1074/jbc.274.7.4266; Vinals F, 1999, J BIOL CHEM, V274, P26776, DOI 10.1074/jbc.274.38.26776; WENG QP, 1995, MOL CELL BIOL, V15, P2333; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; Xu XM, 1999, P NATL ACAD SCI USA, V96, P5292, DOI 10.1073/pnas.96.9.5292; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	46	70	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38261	38267		10.1074/jbc.M005545200	http://dx.doi.org/10.1074/jbc.M005545200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10993886	hybrid			2022-12-25	WOS:000165739800019
J	Norton, AW; D'Amours, MR; Grazio, HJ; Hebert, TL; Cote, RH				Norton, AW; D'Amours, MR; Grazio, HJ; Hebert, TL; Cote, RH			Mechanism of transducin activation of frog rod photoreceptor phosphodiesterase - Allosteric interactions between the inhibitory gamma subunit and the noncatalytic cGMP-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; OUTER SEGMENTS; RETINAL RODS; NUCLEOTIDE PHOSPHODIESTERASES; CATALYTIC SUBUNITS; G-PROTEIN; KINETIC-PARAMETERS; ALPHA-SUBUNIT; HIGH-AFFINITY; BOVINE	The rod photoreceptor phosphodiesterase (PDE) is unique among all known vertebrate PDE families for several reasons. It is a catalytic heterodimer (alpha beta); it is directly activated by a G-protein, transducin; and its active sites are regulated by inhibitory gamma subunits, Rod PDE binds cGMP at two noncatalytic sites on the ap dimer, but their function is unclear. We show that transducin activation of frog rod PDE introduces functional heterogeneity to both the noncatalytic and catalytic sites. Upon PDE activation, one noncatalytic site is converted from a high affinity to low affinity state, whereas the second binding site undergoes modest decreases in binding. Addition of gamma to transducin-activated PDE can restore high affinity binding as well as reducing cGMP exchange kinetics at both sites. A strong correlation exists between cGMP binding and gamma binding to activated PDE; dissociation of bound cGMP accompanies gamma dissociation from PDE, whereas addition of either cGMP or gamma to clip dimers can restore high affinity binding of the other molecule, At the active site, transducin can activate PDE to about one-half the turnover number for catalytic cup dimers completely lacking bound gamma subunit, These results suggest a mechanism in which transducin interacts primarily with one PDE catalytic subunit, releasing its full catalytic activity as well as inducing rapid cGMP dissociation from one noncatalytic site, The state of occupancy of the noncatalytic sites on PDE determines whether gamma remains bound to activated PDE or dissociates from the holoenzyme, and may be relevant to light adaptation in photoreceptor cells.	Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA	University System Of New Hampshire; University of New Hampshire	Cote, RH (corresponding author), Univ New Hampshire, Dept Biochem & Mol Biol, 46 Coll Rd, Durham, NH 03824 USA.		Cote, Rick H/G-3363-2013	Cote, Rick H/0000-0002-1573-6526	NEI NIH HHS [EY05798, R01 EY005798] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005798] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Arshavsky VY, 1998, NEURON, V20, P11, DOI 10.1016/S0896-6273(00)80430-4; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; Artemyev NO, 1998, METHODS, V14, P93, DOI 10.1006/meth.1997.0568; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; BENNETT N, 1989, P NATL ACAD SCI USA, V86, P3634, DOI 10.1073/pnas.86.10.3634; Berger AL, 1999, BIOCHEMISTRY-US, V38, P1293, DOI 10.1021/bi981683m; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; BRUCKERT F, 1994, BIOCHEMISTRY-US, V33, P12625, DOI 10.1021/bi00208a013; BURNS F, 1992, BIOCHEM J, V283, P487, DOI 10.1042/bj2830487; Calvert PD, 1998, J GEN PHYSIOL, V111, P39, DOI 10.1085/jgp.111.1.39; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CLERC A, 1992, J BIOL CHEM, V267, P19948; CLERC A, 1992, J BIOL CHEM, V267, P6620; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; COTE RH, 1993, J BIOL CHEM, V268, P17190; COTE RH, 1994, P NATL ACAD SCI USA, V91, P4845, DOI 10.1073/pnas.91.11.4845; Cote RH, 2000, METHOD ENZYMOL, V315, P646; D'Amours MR, 1999, BIOCHEM J, V340, P863, DOI 10.1042/0264-6021:3400863; D'Amours MR, 1999, MOL PHARMACOL, V55, P508; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; DUMKE CL, 1994, J GEN PHYSIOL, V103, P1071, DOI 10.1085/jgp.103.6.1071; Fawcett L, 2000, P NATL ACAD SCI USA, V97, P3702, DOI 10.1073/pnas.050585197; FORGET RS, 1993, ANAL BIOCHEM, V215, P159, DOI 10.1006/abio.1993.1570; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; Gallagher S., 1998, CURRENT PROTOCOLS PR; Granovsky AE, 1997, J BIOL CHEM, V272, P11686, DOI 10.1074/jbc.272.18.11686; Granovsky AE, 2000, METHOD ENZYMOL, V315, P635; GUTFREUD H, 1995, KINETICS LIFE SCI RE; HAMM HE, 1984, J GEN PHYSIOL, V84, P265, DOI 10.1085/jgp.84.2.265; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Helmreich EJM, 1996, BBA-REV BIOMEMBRANES, V1286, P285, DOI 10.1016/S0304-4157(96)00013-5; Hulme E. C., 1992, RECEPTOR LIGAND INTE, P63; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loughney K, 1996, J BIOL CHEM, V271, P796, DOI 10.1074/jbc.271.2.796; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Manganiello VC, 1999, THROMB HAEMOSTASIS, V82, P407, DOI 10.1055/s-0037-1615860; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; Melia TJ, 2000, J BIOL CHEM, V275, P3535, DOI 10.1074/jbc.275.5.3535; Mou HM, 1999, J BIOL CHEM, V274, P18813, DOI 10.1074/jbc.274.26.18813; Natochin M, 1996, J BIOL CHEM, V271, P19964, DOI 10.1074/jbc.271.33.19964; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; STRYER L, 1991, J BIOL CHEM, V266, P10711; TAKEMOTO DJ, 1993, CELL SIGNAL, V5, P549, DOI 10.1016/0898-6568(93)90050-V; Tsang SH, 1996, SCIENCE, V272, P1026, DOI 10.1126/science.272.5264.1026; Turko IV, 1998, BIOCHEM J, V329, P505; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WHALEN MM, 1989, BIOCHEM J, V259, P13, DOI 10.1042/bj2590013; WHALEN MM, 1990, BIOCHEM J, V265, P655, DOI 10.1042/bj2650655; YAMAMOTO T, 1983, J BIOL CHEM, V258, P2526; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; Yamazaki A, 1996, J BIOL CHEM, V271, P32495, DOI 10.1074/jbc.271.51.32495; Yamazaki A, 1996, BIOCHEM BIOPH RES CO, V222, P488, DOI 10.1006/bbrc.1996.0771; Yuasa K, 2000, J BIOL CHEM, V275, P31469, DOI 10.1074/jbc.M003041200	64	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38611	38619		10.1074/jbc.M004606200	http://dx.doi.org/10.1074/jbc.M004606200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10993884	hybrid			2022-12-25	WOS:000165739800064
J	Soyez, D; Toullec, JY; Ollivaux, C; Geraud, G				Soyez, D; Toullec, JY; Ollivaux, C; Geraud, G			L to D amino acid isomerization in a peptide hormone is a late post-translational event occurring in specialized neurosecretory cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRUSTACEAN HYPERGLYCEMIC-HORMONE; PRECURSOR; ISOFORMS; RESIDUE	Modification of the chirality of a single amino acid residue within a peptide chain appears to be novel additional mechanism leading to structural and functional diversification of eukaryotic bioactive peptides. This phenomenon has been studied at the cellular level in a neuroendocrine organ which elaborates a mixture of diastereoisomers of a 72-residue neuropeptide, crustacean hyperglycemic hormone. For the first time, amino acid isomerization has been shown to occur in the perikarya of fully specialized neurosecretory cells, as a late step of the maturation of the hyperglycemic hormone precursor and after propeptide cleavage. The specificity and efficiency of this phenomenon indicates the existence of a new enzyme family involved in the biogenesis of peptide hormones.	Univ Paris 06, Ecole Normale Super, CNRS EP2028, Lab Signaux Endocrines & Toxines Invertebres, F-75005 Paris, France; Univ Paris 06, Inst Jacques Monod, Serv Imagerie, CNRS, F-75251 Paris 05, France; Univ Paris 07, F-75251 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Soyez, D (corresponding author), Univ Paris 06, Ecole Normale Super, CNRS EP2028, Lab Signaux Endocrines & Toxines Invertebres, 46 Rue Ulm, F-75005 Paris, France.	soyez@biologie.ens.fr						Chung JS, 1996, EUR J BIOCHEM, V240, P358, DOI 10.1111/j.1432-1033.1996.0358h.x; Chung JS, 1998, REGUL PEPTIDES, V77, P17, DOI 10.1016/S0167-0115(98)00024-X; DEKLEIJN DPV, 1994, EUR J BIOCHEM, V224, P623, DOI 10.1111/j.1432-1033.1994.00623.x; HECK SD, 1994, SCIENCE, V266, P1065, DOI 10.1126/science.7973665; Herp F. van, 1998, Recent advances in arthropod endocrinology., P53; Jimenez EC, 1996, J BIOL CHEM, V271, P28002, DOI 10.1074/jbc.271.45.28002; Keller R., 1999, RECENT DEV COMP ENDO, P209; KREIL G, 1994, J BIOL CHEM, V269, P10967; Kreil G, 1997, ANNU REV BIOCHEM, V66, P337, DOI 10.1146/annurev.biochem.66.1.337; KUWADA M, 1994, MOL PHARMACOL, V46, P587; MOR A, 1992, TRENDS BIOCHEM SCI, V17, P481, DOI 10.1016/0968-0004(92)90333-5; MOR A, 1991, J BIOL CHEM, V266, P6264; Ollivaux C, 2000, EUR J BIOCHEM, V267, P5106, DOI 10.1046/j.1432-1327.2000.01574.x; ORCI L, 1984, CELL, V39, P39, DOI 10.1016/0092-8674(84)90189-2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Seidah NG, 1998, ANN NY ACAD SCI, V839, P9, DOI 10.1111/j.1749-6632.1998.tb10727.x; SHIKATA Y, 1995, J BIOL CHEM, V270, P16719, DOI 10.1074/jbc.270.28.16719; Soyez D, 1998, NEUROSCIENCE, V82, P935; SOYEZ D, 1994, J BIOL CHEM, V269, P18295; Van Harreveld A, 1936, P SOC EXP BIOL MED, V34, P428; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; YASUDA A, 1994, GEN COMP ENDOCR, V95, P387, DOI 10.1006/gcen.1994.1138; Yasuda-Kamatani Y., 1998, EXS, V85, P37	23	59	62	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37870	37875		10.1074/jbc.M007302200	http://dx.doi.org/10.1074/jbc.M007302200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10993902	hybrid			2022-12-25	WOS:000165618700076
J	McElhinny, AS; Kolmerer, B; Fowler, VM; Labeit, S; Gregorio, CC				McElhinny, AS; Kolmerer, B; Fowler, VM; Labeit, S; Gregorio, CC			The N-terminal end of nebulin interacts with tropomodulin at the pointed ends of the thin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPOMYOSIN-BINDING PROTEIN; SKELETAL-MUSCLE; ACTIN-FILAMENTS; STRIATED-MUSCLE; LENGTH; CAPS; IDENTIFICATION; MYOFIBRILS; NEBULETTE; SEQUENCE	Strict regulation of actin thin filament length is critical for the proper functioning of sarcomeres, the basic contractile units of myofibrils. It has been hypothesized that a molecular template works with actin filament capping proteins to regulate thin filament lengths. Nebulin is a giant protein (similar to 800 kDa) in skeletal muscle that has been proposed to act as a molecular ruler to specify the thin filament lengths characteristic of different muscles. Tropomodulin (Tmod), a pointed end thin filament capping protein, has been shown to maintain the final length of the thin filaments. Immunofluorescence microscopy revealed that the N-terminal end of nebulin colocalizes with Tmod at the pointed ends of thin filaments. The three extreme N-terminal modules (M1-M2-M3) of nebulin bind specifically to Tmod as demonstrated by blot overlay, bead binding, and solid phase binding assays. These data demonstrate that the N terminus of the nebulin molecule extends to the extreme end of the thin filament and also establish a novel biochemical function for this end. Two Tmod isoforms, erythrocyte Tmod (E-Tmod), expressed in embryonic and slow skeletal muscle, and skeletal Tmod (Sk-Tmod), expressed late in fast skeletal muscle differentiation, bind on overlapping sites to recombinant N-terminal nebulin fragments. Sk-Tmod binds nebulin with higher affinity than E-Tmod does, suggesting that the Tmod/ nebulin interaction exhibits isoform specificity.These data provide evidence that Tmod and nebulin may work together as a linked mechanism to control thin filament lengths in skeletal muscle.	Univ Arizona, Dept Cell Biol & Anat, Tucson, AZ 85724 USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; European Mol Biol Lab, D-69012 Heidelberg, Germany; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of Arizona; University of Arizona; European Molecular Biology Laboratory (EMBL); Scripps Research Institute	Gregorio, CC (corresponding author), Univ Arizona, Dept Cell Biol & Anat, LSN455,1501 N Campbell Ave, Tucson, AZ 85724 USA.	gregorio@u.arizona.edu			NHLBI NIH HHS [HL57461, HL03985] Funding Source: Medline; NIGMS NIH HHS [GM3425] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057461, R29HL057461] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Almenar-Queralt A, 1999, J BIOL CHEM, V274, P28466, DOI 10.1074/jbc.274.40.28466; Almenar-Queralt A, 1999, J CELL SCI, V112, P1111; AO XL, 1995, J CELL SCI, V108, P3397; BABCOCK GG, 1994, J BIOL CHEM, V269, P27510; BANG ML, 2000, IN PRESS MOL BIOL S; BROSCHAT KO, 1990, J BIOL CHEM, V265, P21323; CALDWELL JE, 1989, BIOCHEMISTRY-US, V28, P8506, DOI 10.1021/bi00447a036; CASELLA JF, 1986, J BIOL CHEM, V261, P915; Centner T, 2000, ADV EXP MED BIOL, V481, P35; CHEN MJG, 1993, J BIOL CHEM, V268, P20327; Cox PR, 2000, GENOMICS, V63, P97, DOI 10.1006/geno.1999.6061; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; Fowler VM, 1996, CURR OPIN CELL BIOL, V8, P86, DOI 10.1016/S0955-0674(96)80052-4; FOWLER VM, 1993, J CELL BIOL, V120, P411, DOI 10.1083/jcb.120.2.411; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; FOWLER VM, 1987, J BIOL CHEM, V262, P12792; Fowler VM, 1997, SOC GEN PHY, V52, P79; Fuchs H, 1995, J IMMUNOL METHODS, V188, P197, DOI 10.1016/0022-1759(95)00202-2; GRANZIER HLM, 1993, ELECTROPHORESIS, V14, P56, DOI 10.1002/elps.1150140110; GRANZIER HLM, 1991, AM J PHYSIOL, V260, pC1060, DOI 10.1152/ajpcell.1991.260.5.C1060; GREGORIO CC, 1995, J CELL BIOL, V129, P683, DOI 10.1083/jcb.129.3.683; GREGORIO CC, 1995, NATURE, V377, P83, DOI 10.1038/377083a0; Gregorio CC, 1998, J CELL BIOL, V143, P1013, DOI 10.1083/jcb.143.4.1013; Herrera AH, 2000, CELL MOTIL CYTOSKEL, V45, P211, DOI 10.1002/(SICI)1097-0169(200003)45:3<211::AID-CM4>3.3.CO;2-P; Horowits R, 1996, ADV BIOPHYS, V33, P143; JIN JP, 1991, J BIOL CHEM, V266, P21215; KELLER CS, 1995, CURR OPIN CELL BIOL, V7, P32, DOI 10.1016/0955-0674(95)80042-5; KRUGER M, 1991, J CELL BIOL, V115, P97, DOI 10.1083/jcb.115.1.97; LABEIT S, 1991, FEBS LETT, V282, P313, DOI 10.1016/0014-5793(91)80503-U; Littlefield R, 1998, ANNU REV CELL DEV BI, V14, P487, DOI 10.1146/annurev.cellbio.14.1.487; Luo G, 1997, CELL MOTIL CYTOSKEL, V38, P75; MCLELLAN C, 2000, INPRESS MYOFIBRILLOG; Millevoi S, 1998, J MOL BIOL, V282, P111, DOI 10.1006/jmbi.1998.1999; Moncman CL, 2000, J MUSCLE RES CELL M, V21, P153, DOI 10.1023/A:1005697226465; Moncman CL, 1999, CELL MOTIL CYTOSKEL, V44, P1, DOI 10.1002/(SICI)1097-0169(199909)44:1<1::AID-CM1>3.0.CO;2-8; MONCMAN CL, 1995, CELL MOTIL CYTOSKEL, V32, P205, DOI 10.1002/cm.970320305; OHTSUKI I, 1979, J BIOCHEM-TOKYO, V85, P1377; Ojima K, 2000, J CELL BIOL, V150, P553, DOI 10.1083/jcb.150.3.553; PATEL K, 1988, J NEUROL SCI, V87, P315, DOI 10.1016/0022-510X(88)90256-0; Pelin K, 1999, P NATL ACAD SCI USA, V96, P2305, DOI 10.1073/pnas.96.5.2305; Pfuhl M, 1996, J MOL BIOL, V257, P367, DOI 10.1006/jmbi.1996.0169; PFUHL M, 1994, EMBO J, V13, P1782, DOI 10.1002/j.1460-2075.1994.tb06446.x; ROBINSON TF, 1979, J PHYSIOL-LONDON, V286, P607, DOI 10.1113/jphysiol.1979.sp012640; ROOT DD, 1994, BIOCHEMISTRY-US, V33, P12581, DOI 10.1021/bi00208a008; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHAFER DA, 1995, J CELL BIOL, V128, P61, DOI 10.1083/jcb.128.1.61; SCHAFER DA, 1995, ANNU REV CELL DEV BI, V12, P97; Shih CL, 1997, BIOCHEMISTRY-US, V36, P1814, DOI 10.1021/bi961236b; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SOSA H, 1994, BIOPHYS J, V67, P283, DOI 10.1016/S0006-3495(94)80479-5; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUNG LA, 1992, J BIOL CHEM, V267, P2616; Sussman MA, 1998, CIRC RES, V82, P94; Sussman MA, 1998, J CLIN INVEST, V101, P51, DOI 10.1172/JCI1167; TRINICK J, 1994, TRENDS BIOCHEM SCI, V19, P405, DOI 10.1016/0968-0004(94)90088-4; Wallgren-Pettersson C, 1999, NEUROMUSCULAR DISORD, V9, P564, DOI 10.1016/S0960-8966(99)00061-9; Wang K, 1996, J BIOL CHEM, V271, P4304; WANG K, 1988, J CELL BIOL, V107, P2199, DOI 10.1083/jcb.107.6.2199; Wang K, 1996, ADV BIOPHYS, V33, P123; Watakabe A, 1996, J CELL SCI, V109, P2299; Weber A, 1999, MOL CELL BIOCHEM, V190, P67, DOI 10.1023/A:1006984010267; Weber A, 1999, J BIOL CHEM, V274, P34637, DOI 10.1074/jbc.274.49.34637; WEBER A, 1994, J CELL BIOL, V127, P1627, DOI 10.1083/jcb.127.6.1627; WRIGHT J, 1993, J MUSCLE RES CELL M, V14, P476, DOI 10.1007/BF00297210; Zhukarev V, 1997, CELL MOTIL CYTOSKEL, V37, P363	65	96	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					583	592		10.1074/jbc.M005693200	http://dx.doi.org/10.1074/jbc.M005693200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11016930	hybrid			2022-12-25	WOS:000166280700079
J	Chen, DG; Huang, SM; Stallcup, MR				Chen, DG; Huang, SM; Stallcup, MR			Synergistic, p160 coactivator-dependent enhancement of estrogen receptor function by CARM1 and p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; HISTONE ACETYLTRANSFERASES; HORMONE RECEPTORS; STEROID-RECEPTORS; ACTIVATION; BINDING; CBP; PROTEIN; COMPLEXES	Members of the p160 coactivator family (steroid receptor coactivator-l (SRC-1), glucocorticoid receptor interacting protein 1 (GRIP1), and activator of thyroid and retinoic acid receptors (ACTR)) mediate transcriptional activation by nuclear receptors, After being recruited to the promoter by nuclear receptors, the p160 coactivator transmits the activating signal via two C-terminal activation domains, AD1 and AD2, AD1 is a binding site for the related coactivators cAMP-response element binding protein binding protein (CBP) and p300, whereas AD2 binds to another coactivator, coactivator-associated arginine methyltransferase 1 (CARM1), a protein-arginine methyltransferase. The current study explored the cooperative functional and mechanistic relationships among GRIP1, CARM1, and p300 in transient transfection assays, where they enhanced the ability of the estrogen receptor (ER) to activate transcription of a reporter gene. The coactivator functions of p300 and CARM1 depended on the co-expression of GRIP1. Simultaneous co-expression of all three coactivators caused a synergistic enhancement of ER function. Deletion of the AD1 domain of GRIP1 abolished the ability of p300 to potentiate ER activity but had no effect on CARM1-mediated stimulation. In contrast, when the AD2 domain of GRIP1 was deleted, p300 still stimulated ER function through the mutant GRIP1, but CARM1 failed to do so. Thus, both binding of p300 to AD1 and binding of CARM1 to AD2 are required for their respective coactivator functions and for their synergy. Furthermore, CARM1 and p300 function independently through different activating domains of GRIP1, and their synergy suggests that they enhance transcription by different, complementary. mechanisms.	Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Stallcup, MR (corresponding author), Univ So Calif, Dept Pathol, HMR 301,2011 Zonal Ave, Los Angeles, CA 90089 USA.		zhang, shijun/K-3688-2013		NIDDK NIH HHS [DK55274] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK055274, R01DK055274] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Glass CK, 2000, GENE DEV, V14, P121; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Gregory PD, 1998, CURR OPIN CELL BIOL, V10, P339, DOI 10.1016/S0955-0674(98)80009-4; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Ma H, 1999, MOL CELL BIOL, V19, P6164; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Sladek FM, 1999, MOL CELL BIOL, V19, P6509; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5	37	199	203	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40810	40816		10.1074/jbc.M005459200	http://dx.doi.org/10.1074/jbc.M005459200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11010967	hybrid			2022-12-25	WOS:000166114600022
J	King, CC; Gardiner, EMM; Zenke, FT; Bohl, BP; Newton, AC; Hemmings, BA; Bokoch, GM				King, CC; Gardiner, EMM; Zenke, FT; Bohl, BP; Newton, AC; Hemmings, BA; Bokoch, GM			p21-activated kinase (PAK1) is phosphorylated and activated by 3-phosphoinositide-dependent kinase-1 (PDK1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CELLS; FAMILY; ACTIN; SPHINGOSINE; EXPRESSION; HOMOLOGY; MEMBRANE; SPHINGOSINE-1-PHOSPHATE; TRANSLOCATION	In this study, we show that phosphorylated 3-phosphoinositide-dependent kinase 1 (PDK1) phosphorylates pal-activated kinase 1 (PAK1) in the presence of sphingosine. We identify threonine 423, a conserved threonine in the activation loop of kinase subdomain VIII, as the PDK1 phosphorylation site on PAK1. Threonine 423 is a previously identified PAK1 autophosphorylation site that lies within a PAK consensus phosphorylation sequence. After pretreatment with phosphatases, autophosphorylation of PAK1 occurred at all major sites except threonine 423. A phosphothreonine 423-specific antibody detected phosphorylation of recombinant, catalytically inactive PAK1 after incubation with wild-type PAK1, indicating phosphorylation of threonine 423 occurs by an intermolecular mechanism. The biological significance of PDK1 phosphorylation of PAK1 at threonine 423 in vitro is supported by the observation that these two proteins interact in vivo and that PDK1-phosphorylated PAK1 has an increased activity toward substrate. An increase of phosphorylation of catalytically inactive PAK1 was observed in COS-7 cells expressing wild-type, but not catalytically inactive, PDK1 upon elevation of intracellular sphingosine levels. PDK1 phosphorylation of PAK1 was not blocked by pretreatment with wortmannin or when PDK1 was mutated to prevent phosphatidylinositol binding, indicating this process is independent of phosphatidylinositol 3-kinase activity. The data presented here provide evidence for a novel mechanism for PAK1 regulation and activation.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Scripps Research Institute; Scripps Research Institute; University of California System; University of California San Diego; Friedrich Miescher Institute for Biomedical Research	Bokoch, GM (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	bokoch@scripps.edu		Zenke, Frank/0000-0002-2226-3755	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043154, R01GM043154, R01GM039434] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39434, GM43154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Deak M, 1999, FEBS LETT, V451, P220, DOI 10.1016/S0014-5793(99)00556-6; DESAI NN, 1992, J BIOL CHEM, V267, P23122; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Fatatis A, 1997, J BIOL CHEM, V272, P4351, DOI 10.1074/jbc.272.7.4351; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; JACOBS LS, 1993, AM J PHYSIOL, V265, pC740, DOI 10.1152/ajpcell.1993.265.3.C740; King CC, 2000, J BIOL CHEM, V275, P18108, DOI 10.1074/jbc.M909663199; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Niederberger C, 1999, MOL GEN GENET, V261, P177, DOI 10.1007/s004380050955; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rudel T, 1998, J IMMUNOL, V160, P7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tuazon PT, 1997, BIOCHEMISTRY-US, V36, P16059, DOI 10.1021/bi9717845; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Wu CL, 1998, J BIOL CHEM, V273, P28107, DOI 10.1074/jbc.273.43.28107; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	53	173	178	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41201	41209		10.1074/jbc.M006553200	http://dx.doi.org/10.1074/jbc.M006553200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10995762	hybrid			2022-12-25	WOS:000166114600073
J	Laumonnier, Y; Nadaud, S; Agrapart, M; Soubrier, F				Laumonnier, Y; Nadaud, S; Agrapart, M; Soubrier, F			Characterization of an upstream enhancer region in the promoter of the human endothelial nitric-oxide synthase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETS TRANSCRIPTION FACTORS; MESSENGER-RNA; CORE PROMOTER; DNA-BINDING; CELLS; EXPRESSION; ACTIVATION; SITE; SP1; CHROMATIN	The endothelial nitric-oxide synthase gene is constitutively expressed in endothelial cells. Several transcriptionally active regulatory elements have been identified in the proximal promoter, including a GATA-2 and an Sp-l binding site. Because they cannot account for the constitutive expression of endothelial nitric-oxide synthase gene in a restricted number of cells, we have searched for other cell-specific regulatory elements. By DNase I hypersensitivity mapping and deletion studies we have identified a 269-base pair activator element located 4.9 kilobases upstream from the transcription start site that acts as an enhancer. DNase I footprinting and linker-scanning experiments showed that several regions within the 269-base pair enhancer are important for transcription factor binding and for full enhancer activity,:The endothelial specificity of this activation seems partly due to interaction between this enhancer in its native configuration and the promoter in endothelial cells. EMSA experiments suggested the implication of MZF-like, AP-2, Sp-1-related, and Ets-related factors, Among Ets factors, Erg was the only one able to bind to cognate sites in the enhancer, as found by EMSA and supershift experiments, and to activate the transcriptional activity of the enhancer in cotransfection experiments, Therefore, multiple protein complexes involving Erg, other Ets-related factors, AP-2, Sp-l-related factor, and MZF-like factors are important for the function of this enhancer in endothelial cells.	Hop St Louis, INSERM U525, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Soubrier, F (corresponding author), Fac Med Pitie Salpetriere, INSERM U525, 91 Bd Hop, F-75013 Paris, France.		Nadaud, Sophie/A-7063-2013; Nadaud, Sophie/GXV-0505-2022; Laumonnier, yves/F-6348-2018	Nadaud, Sophie/0000-0002-1452-6009; 				ALHEID U, 1987, THROMB RES, V47, P561, DOI 10.1016/0049-3848(87)90361-6; Buttice G, 1996, ONCOGENE, V13, P2297; Cieslik K, 1998, J BIOL CHEM, V273, P14885, DOI 10.1074/jbc.273.24.14885; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; Fleming I, 1999, CARDIOVASC RES, V43, P532, DOI 10.1016/S0008-6363(99)00094-2; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; Guillot PV, 1999, J CLIN INVEST, V103, P799, DOI 10.1172/JCI6017; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JOHN S, 1995, MOL CELL BIOL, V15, P1786; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Kida M, 1999, J BIOL CHEM, V274, P6138, DOI 10.1074/jbc.274.10.6138; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Mager AM, 1998, INT J DEV BIOL, V42, P561; MORRIS JF, 1995, BLOOD, V86, P3640; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; NADAUD S, 1994, BIOCHEM BIOPH RES CO, V198, P1027, DOI 10.1006/bbrc.1994.1146; Navarro-Antolin J, 2000, J BIOL CHEM, V275, P3075, DOI 10.1074/jbc.275.5.3075; PALMER RMJ, 1988, BIOCHEM BIOPH RES CO, V153, P1251, DOI 10.1016/S0006-291X(88)81362-7; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; Schwachtgen JL, 1997, ONCOGENE, V15, P3091, DOI 10.1038/sj.onc.1201502; Shewchuk BM, 1999, J BIOL CHEM, V274, P35725, DOI 10.1074/jbc.274.50.35725; STEWART AF, 1991, NUCLEIC ACIDS RES, V19, P3157, DOI 10.1093/nar/19.11.3157; TANG JL, 1995, BIOCHEM BIOPH RES CO, V213, P673, DOI 10.1006/bbrc.1995.2184; Teichert AM, 2000, AM J PHYSIOL-HEART C, V278, pH1352, DOI 10.1152/ajpheart.2000.278.4.H1352; WARIISHI S, 1995, BIOCHEM BIOPH RES CO, V216, P729, DOI 10.1006/bbrc.1995.2682; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320; Ziegler T, 1998, HYPERTENSION, V32, P351, DOI 10.1161/01.HYP.32.2.351	32	47	48	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40732	40741		10.1074/jbc.M004696200	http://dx.doi.org/10.1074/jbc.M004696200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11013235	hybrid			2022-12-25	WOS:000166114600012
J	Xie, YQ; Sun, LP; Kodadek, T				Xie, YQ; Sun, LP; Kodadek, T			TATA-binding protein and the Gal4 transactivator do not bind to promoters cooperatively	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION DOMAIN; BOX-BINDING; GLOBAL REPRESSOR; TERMINAL DOMAIN; TBP BINDING; DNA-BINDING; GENE; COMPLEX; P53	The yeast Ga14 protein, like many activators, binds TATA-binding protein (TBP) directly in vitro. It has been speculated that this protein-protein interaction is important for Ga14p-mediated activation of transcription, but little work has been done to test specific models involving this interaction, In this study, the effect of Ga14p on TBP-TATA binding is addressed. Specifically, it is asked if the Ga14p-TBP interaction can support cooperative binding of the two factors to promoters. It is easy to see how such an event could stimulate transcription, particularly horn promoters with a non-consensus TATA box. In vitro, however, a derivative of GaMp (Ga14(1-93+768-881)) containing the DNA-binding, dimerization, and activation domains does not bind to promoter DNA cooperatively with either recombinant, purified TBP, or with protein from a yeast crude extract. In vivo, reporter gene experiments using promoters with differing TBP affinities reveal no major GaMp-mediated stimulation of TBP function from weak TATA boxes, as would be predicted if the proteins bind cooperatively. Furthermore, native Gal4p and a potent Ga14p-based artificial activator lacking a TBP-binding activation domain support similar ratios of transcription from a series of promoters identical except for mutations in the TATA box. It is concluded that Ga14p and TBP do not bind cooperatively to promoters and that this mechanism does not contribute substantially to Ga14p-mediated transcriptional activation.	Univ Texas, SW Med Ctr, Ryburn Ctr Mol Cardiol, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ryburn Ctr Mol Cardiol, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kodadek, T (corresponding author), Univ Texas, SW Med Ctr, Ryburn Ctr Mol Cardiol, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	thomas.kodadek@utsouthwestern.edu		Kodadek, Thomas/0000-0003-1930-4795				AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; Gaudreau L, 1999, P NATL ACAD SCI USA, V96, P2668, DOI 10.1073/pnas.96.6.2668; GILMOUR DS, 1986, MOL CELL BIOL, V6, P3984, DOI 10.1128/MCB.6.11.3984; GonzalezCouto E, 1997, P NATL ACAD SCI USA, V94, P8036, DOI 10.1073/pnas.94.15.8036; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; INOSTROZA JA, 1992, CELL, V70, P477; Jackson-Fisher AJ, 1999, MOL CELL, V3, P717, DOI 10.1016/S1097-2765(01)80004-6; JOHNSTON SA, 1987, CELL, V50, P143, DOI 10.1016/0092-8674(87)90671-4; Kim S, 1997, P NATL ACAD SCI USA, V94, P820, DOI 10.1073/pnas.94.3.820; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM TK, 1995, J BIOL CHEM, V270, P10976, DOI 10.1074/jbc.270.18.10976; KODADEK T, 1995, CHEM BIOL, V2, P187, DOI 10.1016/1074-5521(95)90268-6; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; Kotani T, 2000, P NATL ACAD SCI USA, V97, P7178, DOI 10.1073/pnas.120074297; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; Mason PB, 1997, J BIOL CHEM, V272, P33227, DOI 10.1074/jbc.272.52.33227; MELCHER K, 1995, MOL CELL BIOL, V15, P2839; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; POON D, 1993, J BIOL CHEM, V268, P15325; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; REECE RJ, 1993, GENE, V126, P105, DOI 10.1016/0378-1119(93)90596-U; Reindl A, 1998, FEBS LETT, V436, P318, DOI 10.1016/S0014-5793(98)01152-1; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRUANT R, 1993, J BIOL CHEM, V268, P2284; VASHEE S, 1993, J BIOL CHEM, V268, P24699; VASHEE S, 1995, P NATL ACAD SCI USA, V92, P10683, DOI 10.1073/pnas.92.23.10683; Wu YB, 1996, EMBO J, V15, P3951, DOI 10.1002/j.1460-2075.1996.tb00769.x; XIAO H, 1995, MOL CELL BIOL, V15, P5757; Xie YQ, 2000, J BIOL CHEM, V275, P31914, DOI 10.1074/jbc.M003760200; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; Yean D, 1997, MOL CELL BIOL, V17, P3809, DOI 10.1128/MCB.17.7.3809	47	3	3	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40797	40803		10.1074/jbc.M007019200	http://dx.doi.org/10.1074/jbc.M007019200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11006288	hybrid			2022-12-25	WOS:000166114600020
J	Putsep, K; Axelsson, LG; Boman, A; Midtvedt, T; Normark, S; Boman, HG; Andersson, M				Putsep, K; Axelsson, LG; Boman, A; Midtvedt, T; Normark, S; Boman, HG; Andersson, M			Germ-free and colonized mice generate the same products from enteric prodefensins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH PEPTIDES; ANTIMICROBIAL PEPTIDES; DEFENSINS; CRYPTDIN; FAMILY; MATRILYSIN; SECRETION; INTESTINE; IMMUNITY; CELLS	The use of germ-free mice offers the possibility to study antibacterial components in a gut uncolonized by bacteria. We have developed a method to extract and high pressure liquid chromatography-fractionate the antibacterial factors present in the small intestine of a single mouse. By mass spectrometry and sequence analyses of fractions exhibiting antimicrobial activity, we identified and characterized the defensin region in germ-free mice as well as in colonized mice. Defensins made up around 15% of the total antibacterial activity both in germ-free and colonized mice. The intestine of germ-free mice exhibited the same set of mature enteric defensins (defensins 1, 2, 3, 4, and 6) as mice colonized by a normal microflora. Mature defensins are generated through processing of larger precursors by enzymatic removal of a signal peptide and a propiece, We found that all prodefensins were cleaved at a Ser/Ala-Leu bond, giving 34-residue propiece peptides and only trace amounts of the predicted 39-residue peptide. This first step must be followed by the removal of a residual peptide to render the mature defensins, indicating that the processing is more complex than previously anticipated. The same propieces were found in both germ-free and colonized mice, suggesting that the same processing operates independent of bacterial presence in the intestine.	Karolinska Inst, Ctr Microbiol & Tumor Biol, Lab Med Microbial Ecol, SE-17177 Stockholm, Sweden	Karolinska Institutet	Andersson, M (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, Lab Med Microbial Ecol, Box 280, SE-17177 Stockholm, Sweden.	mate.andersson@mbb.ki.se	Andersson, Mats L/M-9124-2014; Andersson, Mats/A-2903-2008	Andersson, Mats L/0000-0001-7582-8791; 				Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Bevins CL, 1999, GUT, V45, P911, DOI 10.1136/gut.45.6.911; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOMAN HG, 1989, J BIOL CHEM, V264, P5852; BRY L, 1994, P NATL ACAD SCI USA, V91, P10335, DOI 10.1073/pnas.91.22.10335; DECKX RJ, 1967, BIOCHIM BIOPHYS ACTA, V139, P204, DOI 10.1016/0005-2744(67)90136-2; EISENHAUER PB, 1992, INFECT IMMUN, V60, P3446, DOI 10.1128/IAI.60.8.3446-3447.1992; Elsbach P, 1997, PROG SURG, V24, P17, DOI 10.1159/000075479; Falk PG, 1998, MICROBIOL MOL BIOL R, V62, P1157, DOI 10.1128/MMBR.62.4.1157-1170.1998; GANZ T, 1994, CIBA F SYMP, V186, P62; HARWIG SSL, 1992, BLOOD, V79, P1532; HULTMARK D, 1983, EMBO J, V2, P571, DOI 10.1002/j.1460-2075.1983.tb01465.x; HUTTNER KM, 1994, GENOMICS, V19, P448, DOI 10.1006/geno.1994.1093; HUTTNER KM, 1994, GENOMICS, V24, P99, DOI 10.1006/geno.1994.1586; Lencer WI, 1997, P NATL ACAD SCI USA, V94, P8585, DOI 10.1073/pnas.94.16.8585; Lopez-Boado YS, 2000, J CELL BIOL, V148, P1305, DOI 10.1083/jcb.148.6.1305; LOW TLK, 1984, J CHROMATOGR, V301, P221, DOI 10.1016/S0021-9673(01)89190-1; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; OUELLETTE AJ, 1990, J BIOL CHEM, V265, P9831; Ouellette AJ, 1999, AM J PHYSIOL-GASTR L, V277, pG257, DOI 10.1152/ajpgi.1999.277.2.G257; Porter EM, 1998, FEBS LETT, V434, P272, DOI 10.1016/S0014-5793(98)00994-6; Qu XD, 1996, INFECT IMMUN, V64, P5161, DOI 10.1128/IAI.64.12.5161-5165.1996; QUELLETTE AJ, 1994, INFECT IMMUN, V62, P4040; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; SELSTED ME, 1989, J BIOL CHEM, V264, P4003; VALORE EV, 1992, BLOOD, V79, P1538; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113	28	111	113	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40478	40482		10.1074/jbc.M007816200	http://dx.doi.org/10.1074/jbc.M007816200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11010975	hybrid			2022-12-25	WOS:000166039500091
J	Underhill, C; Qutob, MS; Yee, SP; Torchia, J				Underhill, C; Qutob, MS; Yee, SP; Torchia, J			A novel nuclear receptor corepressor complex, N-CoR, contains components of the mammalian SWI/SNF complex and the corepressor KAP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; MEDIATED REPRESSION; NEGATIVE REGULATOR; TIF1 BETA; PROTEIN; BINDING; FAMILY; NUCLEOSOME; INTERACTS	Transcriptional silencing by many transcription factors is mediated by the nuclear receptor corepressor (N-CoR). The mechanism by which N-CoR represses basal transcription involves the direct or indirect recruitment of histone deacetylases (HDACs). We have isolated two multiprotein N-CoR complexes, designated N-CoR-1 and N-CoR-2, which possess histone deacetylase activity that is mediated by distinct HDACs. Based on Western blotting using antibodies against known subunits, the only HDAC found in the N-CoR-1 complex was HDAC3. In contrast, N-CoR-2 contained predominantly HDAC1 and HDAC2 as well as several other subunits that are found in the Sin3A HDAC complex. Using mass spectrometry and Western blotting, we have identified several novel components of the N-CoR-1 complex including the SWI/SNF-related proteins BRG1, BAF 170, BAF 155, BAF 47/INI1, and the corepressor KAP-1 that is involved in silencing heterochromatin. Indirect immunofluorescence has revealed that both KAP-1 and N-CoR colocalize throughout the nucleus. These results suggest that N-CoR is found in distinct multiprotein complexes, which are involved in multiple pathways of transcriptional repression.	Univ Western Ontario, Canc Res Labs, London Reg Canc Ctr, Dept Pharmacol & Toxicol, London, ON N6A 4L6, Canada; Univ Western Ontario, Canc Res Labs, London Reg Canc Ctr, Dept Oncol, London, ON N6A 4L6, Canada; Univ Western Ontario, Canc Res Labs, London Reg Canc Ctr, Dept Biochem, London, ON N6A 4L6, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Torchia, J (corresponding author), Univ Western Ontario, Canc Res Labs, London Reg Canc Ctr, Dept Pharmacol & Toxicol, 790 Commissioners Rd E,Rm 4020, London, ON N6A 4L6, Canada.	jtorchia@julian.uwo.ca						Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Das BK, 1999, MOL CELL BIOL, V19, P6796; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Glass CK, 2000, GENE DEV, V14, P121; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guenther MG, 2000, GENE DEV, V14, P1048; Harlow E., 1999, USING ANTIBODIES LAB; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang EY, 2000, GENE DEV, V14, P45; Johnston H, 1999, J BIOL CHEM, V274, P16370, DOI 10.1074/jbc.274.23.16370; Kao HY, 2000, GENE DEV, V14, P55; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; KRAMER A, 1995, RNA, V1, P260; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEE J, 2000, EMBO J, V19, P1; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Urnov FD, 2000, EMBO J, V19, P4074, DOI 10.1093/emboj/19.15.4074; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wakimoto BT, 1998, CELL, V93, P321, DOI 10.1016/S0092-8674(00)81159-9; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	60	243	253	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40463	40470		10.1074/jbc.M007864200	http://dx.doi.org/10.1074/jbc.M007864200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11013263	hybrid			2022-12-25	WOS:000166039500089
J	Wick, MJ; Dong, LQ; Riojas, RA; Ramos, FJ; Liu, F				Wick, MJ; Dong, LQ; Riojas, RA; Ramos, FJ; Liu, F			Mechanism of phosphorylation of protein kinase B/Akt by a constitutively active 3-phosphoinositide-dependent protein kinase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4 TRANSLOCATION; AKT KINASE; ACTIVATION; PDK1; HOMOLOGY; ADIPOCYTES; APOPTOSIS; CERAMIDE; ALPHA	Phosphorylation of Thr(308) in the activation loop and Ser(473) at the carboxyl terminus is essential for protein kinase B (PKB/Akt) activation. However, the biochemical mechanism of the phosphorylation remains to be characterized. Here we show that expression of a constitutively active mutant of mouse 3-phosphoinositide-dependent protein kinase-1 (PDK1(A280V)) in Chinese hamster ovary cells overexpressing the insulin receptor was sufficient to induce PKB phosphorylation at Thr(308) to approximately the same extent as insulin stimulation. Phosphorylation of PKB by PDK1(A280V) was not affected by treatment of cells with inhibitors of phosphatidylinositol S-kinase or by deletion of the pleckstrin homology (PH) domain of PKB. C-2-ceramide, a cell-permeable, indirect inhibitor of PKB phosphorylation, did not inhibit PDK1(A280V)-catalyzed PKB phosphorylation in cells and had no effect on PDK1 activity in vitro. On the other hand, co-expression of full-length protein kinase C-related kinase-l (PRK1/PKN) or 2 (PRK2) inhibited PDK1(A280V)-mediated PKB phosphorylation, Replacing alanine at position 280 with valine or deletion of the PH domain enhanced PDK1 autophosphorylation in vitro. However, deletion of the PH domain of PDK1(A280V) Significantly reduced PDK1(A280V)-mediated phosphorylation of PKB in cells. In resting cells, PDK1(A280V) localized in the cytosol and at the plasma membrane. However, PDK1(A280V) lacking the PH domain localized predominantly in the cytosol. Taken together, our findings suggest that the wild-type PDK1 may not be constitutively active in cells. In addition, activation of PDK1 is sufficient to phosphorylate PRE at Thr(308) in the cytosol. Furthermore, the PH domain of PDK1 may play both positive and negative roles in regulating the in vivo function of the enzyme. Finally, unlike the carboxyl-terminal fragment of PRK2, which has been shown to bind PDK1 and allow the enzyme to phosphorylate PKB at both Thr(308) and Ser(473), full-length PRK2 and its related kinase PRK1/PKN may both play negative roles in PKB-mediated downstream biological events.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Liu, F (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.				NIDDK NIH HHS [DK56166] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056166] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Coffer PJ, 1998, BIOCHEM J, V335, P1; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Dong LQ, 2000, P NATL ACAD SCI USA, V97, P5089, DOI 10.1073/pnas.090491897; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Hill MM, 1999, MOL CELL BIOL, V19, P7771; King CC, 2000, J BIOL CHEM, V275, P18108, DOI 10.1074/jbc.M909663199; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Meier R, 1999, J RECEPT SIGNAL TR R, V19, P121, DOI 10.3109/10799899909036639; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Salinas M, 2000, MOL CELL NEUROSCI, V15, P156, DOI 10.1006/mcne.1999.0813; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang CN, 1998, DIABETES, V47, P24, DOI 10.2337/diabetes.47.1.24; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	29	113	116	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40400	40406		10.1074/jbc.M003937200	http://dx.doi.org/10.1074/jbc.M003937200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11006271	hybrid			2022-12-25	WOS:000166039500082
J	Compton, SJ; Cairns, JA; Palmer, KJ; Al-Ani, B; Hollenberg, MD; Walls, AF				Compton, SJ; Cairns, JA; Palmer, KJ; Al-Ani, B; Hollenberg, MD; Walls, AF			A polymorphic protease-activated receptor 2 (PAR2) displaying reduced sensitivity to trypsin and differential responses to PAR agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELL TRYPTASE; THROMBIN RECEPTOR; MOLECULAR-CLONING; ENDOTHELIAL-CELLS; CROSS-REACTIVITY; EXPRESSION; PEPTIDES; RECOGNITION; KERATINOCYTES; ANTAGONIST	Protease-activated receptor 2 (PAR2) is a trypsin-activated member of a family of G-protein-coupled PARs. We have identified a polymorphic form of human PARS (PAR(2)F240S) characterized by a phenylalanine to serine mutation at residue 240 within extracellular loop 2, with allelic frequencies of 0.916 (Phe(240)) and 0.084 (Ser(240)) for the wild-type and mutant alleles, respectively. Elevations in intracellular calcium were measured in permanently transfected cell lines expressing the receptors. PAR(2)F240S displayed a significant reduction in sensitivity toward trypsin (similar to3.7-fold) and the PARS-activating peptides, SLIGKV-NH2 (similar to2.5-fold) and SLIGRL-NH2 (similar to2.8-fold), but an increased sensitivity toward the selective PARS agonist, trans- cinnamoyl-LIGRLO-NH2 (similar to4-fold). Increased sensitivity was also observed toward the selective PAR-1 agonist, TFLLR-NH2 (similar to7-fold), but not to other PAR-1 agonists tested. Furthermore, we found that TLIGRL-NH2 and a PAR4-derived peptide, trans-cinnamoyl-YPGKF-NH2, were selective PAR(2)F240S agonists. By introducing the F240S mutation into rat PARS, we observed shifts in agonist potencies that mirrored the human PAR,F240S, suggesting that Phe240 is involved in determining agonist specificity of PARS. Finally, differences in receptor signaling were paralleled in a cell growth assay. We suggest that the distinct pharmacological profile induced by this polymorphism will have important implications for the design of PAR-targeted agonists/antagonists and may contribute to, or be predictive of, an inflammatory disease.	Univ Calgary, Fac Med, Dept Pharmacol & Therapeut, Endocrine Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Med, Calgary, AB T2N 4N1, Canada; Southampton Gen Hosp, Immunopharmacol Grp, Southampton SO16 6YD, Hants, England; Univ Southampton, Southampton Gen Hosp, Surg Unit, Southampton SO16 6YD, Hants, England	University of Calgary; University of Calgary; University of Southampton; University of Southampton	Compton, SJ (corresponding author), Univ Calgary, Fac Med, Dept Pharmacol & Therapeut, Endocrine Res Grp, Calgary, AB T2N 4N1, Canada.		Hollenberg, Morley/AFV-6966-2022	Walls, Andrew/0000-0003-4803-4595				Al-Ani B, 1999, J PHARMACOL EXP THER, V290, P753; Al-Ani B, 1999, BRIT J PHARMACOL, V128, P1105, DOI 10.1038/sj.bjp.0702834; ALANI B, 1995, CAN J PHYSIOL PHARM, V73, P1203, DOI 10.1139/y95-172; Andrade-Gordon P, 1999, P NATL ACAD SCI USA, V96, P12257, DOI 10.1073/pnas.96.22.12257; Bernatowicz MS, 1996, J MED CHEM, V39, P4879, DOI 10.1021/jm960455s; Bertog M, 1999, J PHYSIOL-LONDON, V521, P3, DOI 10.1111/j.1469-7793.1999.00003.x; Blackhart BD, 1996, J BIOL CHEM, V271, P16466, DOI 10.1074/jbc.271.28.16466; Bohm SK, 1996, BIOCHEM J, V314, P1009; Brain SD, 2000, NAT MED, V6, P134, DOI 10.1038/72218; CHEN J, 1994, J BIOL CHEM, V269, P16041; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Compton SJ, 1998, J IMMUNOL, V161, P1939; Corvera CU, 1999, J PHYSIOL-LONDON, V517, P741, DOI 10.1111/j.1469-7793.1999.0741s.x; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Faruqi TR, 2000, J BIOL CHEM, V275, P19728, DOI 10.1074/jbc.M909960199; Hollenberg MD, 1999, TRENDS PHARMACOL SCI, V20, P271, DOI 10.1016/S0165-6147(99)01333-4; Hollenberg MD, 1997, CAN J PHYSIOL PHARM, V75, P832, DOI 10.1139/cjpp-75-7-832; Howells GL, 1997, J CELL SCI, V110, P881; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; JONES AS, 1963, NATURE, V199, P280, DOI 10.1038/199280b0; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Kawabata A, 1999, J PHARMACOL EXP THER, V288, P358; Lerner DJ, 1996, J BIOL CHEM, V271, P13943, DOI 10.1074/jbc.271.24.13943; Mari B, 1996, FASEB J, V10, P309, DOI 10.1096/fasebj.10.2.8641564; Mirza H, 1997, BLOOD, V90, P3914, DOI 10.1182/blood.V90.10.3914; Molino M, 1997, J BIOL CHEM, V272, P11133; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; NANEVICZ T, 1995, J BIOL CHEM, V270, P21619, DOI 10.1074/jbc.270.37.21619; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Steinhoff M, 1999, EXP DERMATOL, V8, P282; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Vergnolle N, 1999, J IMMUNOL, V163, P5064; Vergnolle N, 1999, BRIT J PHARMACOL, V126, P1262, DOI 10.1038/sj.bjp.0702408; Vergnolle N, 1999, BRIT J PHARMACOL, V127, P1083, DOI 10.1038/sj.bjp.0702634; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wakita H, 1997, P ASSOC AM PHYSICIAN, V109, P190; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	40	59	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39207	39212		10.1074/jbc.M007215200	http://dx.doi.org/10.1074/jbc.M007215200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995771	hybrid			2022-12-25	WOS:000165953100037
J	Paquet, Y; Trottier, E; Beaudet, MJ; Anderson, A				Paquet, Y; Trottier, E; Beaudet, MJ; Anderson, A			Mutational analysis of the CYP2B2 phenobarbital response unit and inhibitory effect of the constitutive androstane receptor on phenobarbital responsiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOCYTE CULTURES; 5'-FLANKING REGION; GENE-TRANSCRIPTION; ENHANCER MODULE; OKADAIC ACID; INDUCTION; CAR; TRANSLOCATION; EXPRESSION; ELEMENTS	A 163-base pair enhancer in the CYP2B2 5' flank confers phenobarbital (PB) inducibility and constitutes a PB response unit (PBRU), By transfection of primary hepatocytes, we analyzed the function of elements comprising the PBRU and evaluated the role of the constitutive androstane receptor (CAR) in PB responsiveness. A 51-base pair PR-responsive enhancer module (PBREM) within the PBRU confers near-maximal PB response when fused to a th promoter. However, replacing the PBRU with the PBREM in the CYP2B2 5' flank in the natural sequence context reduced PB responsiveness by approximately C-fold. Mutational analysis also demonstrated that PBRU sequence elements outside the PBREM are essential for maximal PB responsiveness. The PBRU contains two putative nuclear receptor binding sites, NR1 and NR2, CAR binds to retinoic acid beta2 response elements (beta RARE) and to the NR1 and NR2 sites of the PBRU and activates transcription of reporter genes in cell lines. However, conversion of NR1 into beta RARE was the equivalent of an inactivating mutation, indicating that CAR does not activate PB-dependent transcription via NR1 in the natural sequence context. A beta RARE x 2-tk reporter construct was inducible by all-trans-retinoic acid (at-RA) as expected and also responded to PB, The latter can be attributed to nuclear accumulation of CAR after PB exposure. Exogenous CAR increased both the basal and PB-induced response of beta RAREx2-tk but reduced PBRU dependent PB response. Furthermore, exogenous CAR also reduced the at-RA response of the beta RARE x 2-tk construct, Thus, CAR acts negatively on PB responsiveness mediated by the CYP2B2 PBRU just as it prevents maximal at-RA responsiveness mediated by beta RARE.	Univ Laval, Hotel Dieu, Ctr Rech Cancerol, Ctr Hosp Univ Quebec, Quebec City, PQ G1R 2J6, Canada; Univ Laval, Dept Biol, St Foy, PQ G1K 7P4, Canada	Laval University; Laval University	Anderson, A (corresponding author), Hotel Dieu, Ctr Rech, 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada.							BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; CHRISTOU M, 1987, ARCH BIOCHEM BIOPHYS, V258, P519, DOI 10.1016/0003-9861(87)90374-2; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Handschin C, 2000, J BIOL CHEM, V275, P13362, DOI 10.1074/jbc.275.18.13362; Honkakoski P, 1997, J BIOL CHEM, V272, P14943, DOI 10.1074/jbc.272.23.14943; Honkakoski P, 1998, MOL PHARMACOL, V53, P597, DOI 10.1124/mol.53.4.597; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Honkakoski P, 2000, BIOCHEM J, V347, P321, DOI 10.1042/0264-6021:3470321; Honkakoski P, 1998, J BIOCHEM MOL TOXIC, V12, P3; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; Kassam A, 2000, J BIOL CHEM, V275, P4345, DOI 10.1074/jbc.275.6.4345; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kemper B, 1998, PROG NUCLEIC ACID RE, V61, P25, DOI 10.1016/S0079-6603(08)60824-7; Kim J, 1997, J BIOL CHEM, V272, P29423, DOI 10.1074/jbc.272.47.29423; Kim J, 2000, NUCLEIC ACIDS RES, V28, P1126, DOI 10.1093/nar/28.5.1126; Liu SQ, 1998, DNA CELL BIOL, V17, P461, DOI 10.1089/dna.1998.17.461; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Park YK, 1996, J BIOL CHEM, V271, P23725, DOI 10.1074/jbc.271.39.23725; POLAND A, 1981, MOL PHARMACOL, V20, P442; Prima V, 2000, J STEROID BIOCHEM, V72, P1, DOI 10.1016/S0960-0760(99)00146-6; Ramsden R, 1999, GENE, V228, P169, DOI 10.1016/S0378-1119(98)00612-X; Sidhu JS, 1997, J PHARMACOL EXP THER, V282, P1122; Stoltz C, 1999, BIOCHEM PHARMACOL, V57, P1073, DOI 10.1016/S0006-2952(98)00367-0; Stoltz C, 1998, J BIOL CHEM, V273, P8528, DOI 10.1074/jbc.273.14.8528; TROTTIER E, 1995, GENE, V158, P263, DOI 10.1016/0378-1119(94)00916-G; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; Wang JC, 1999, MOL ENDOCRINOL, V13, P604, DOI 10.1210/me.13.4.604; WAXMAN DJ, 1990, BIOCHEM J, V271, P113, DOI 10.1042/bj2710113; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351	34	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38427	38436		10.1074/jbc.M005776200	http://dx.doi.org/10.1074/jbc.M005776200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10993889	hybrid			2022-12-25	WOS:000165739800040
J	Shan, JG; Moran-Jones, K; Munro, TP; Kidd, GJ; Winzor, DJ; Hoek, KS; Smith, B				Shan, JG; Moran-Jones, K; Munro, TP; Kidd, GJ; Winzor, DJ; Hoek, KS; Smith, B			Binding of an RNA trafficking response element to heterogeneous nuclear ribonucleoproteins A1 and A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN MESSENGER-RNA; HNRNP A1; CRYSTAL-STRUCTURE; U1A PROTEIN; ANGSTROM RESOLUTION; PREMESSENGER RNA; TELOMERIC DNA; DOMAINS; SEQUENCE; RECOGNITION	Heterogeneous nuclear ribonucleoprotein (hnRNP) A2 binds a 21-nucleotide myelin basic protein mRNA response element, the A2RE, and A2RE-like sequences in other localized mRNAs, and is a trans-acting factor in oligodendrocyte cytoplasmic RNA trafficking. Recombinant human hnRNPs A1 and A2 were used in a biosensor to explore interactions with A2RE and the cognate oligodeoxyribonucleotide. Both proteins have a single site that bound oligonucleotides with markedly different sequences but did not bind in the presence of heparin. Both also possess a second, specific site that bound only A2RE and was unaffected by heparin, hnRNP A2 bound A2RE in the latter site with a K-d near 50 nM, whereas the K-d for hnRNP A1 was above 10 muM. UV cross-linking assays led to a similar conclusion. Mutant A2RE sequences, that in earlier qualitative studies appeared not to bind hnRNP A2 or support RNA trafficking in oligodendrocytes, had dissociation constants above 5 muM for this protein. The two concatenated RNA recognition motifs (RRMs), but not the individual RRMs, mimicked the binding behavior of hnRNP A2. These data highlight the specificity of the interaction of A2RE with these hnRNPs and suggest that the sequence-specific A2RE-binding site on hnRNP A2 is formed by both RRMs acting in cis.	Univ Queensland, Dept Biochem, St Lucia, Qld 4072, Australia	University of Queensland	Smith, B (corresponding author), Univ Queensland, Dept Biochem, St Lucia, Qld 4072, Australia.		Munro, Trent/AAC-1129-2020; Munro, Trent/B-4856-2009	Munro, Trent/0000-0003-1987-2020; Kidd, Grahame/0000-0003-3956-2206				AbdulMana N, 1996, BIOCHEMISTRY-US, V35, P3545, DOI 10.1021/bi952298p; AbdulManan N, 1996, NUCLEIC ACIDS RES, V24, P4063, DOI 10.1093/nar/24.20.4063; Ainger K, 1997, J CELL BIOL, V138, P1077, DOI 10.1083/jcb.138.5.1077; AMURUMARJEE S, 1993, J NEUROSCI RES, V36, P99, DOI 10.1002/jnr.490360111; Antson AA, 2000, CURR OPIN STRUC BIOL, V10, P87, DOI 10.1016/S0959-440X(99)00054-8; Avis JM, 1996, J MOL BIOL, V257, P398, DOI 10.1006/jmbi.1996.0171; BARNETT SF, 1991, MOL CELL BIOL, V11, P864, DOI 10.1128/MCB.11.2.864; BEYER AL, 1977, CELL, V11, P127, DOI 10.1016/0092-8674(77)90323-3; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; Carson JH, 1998, CURR OPIN NEUROBIOL, V8, P607, DOI 10.1016/S0959-4388(98)80088-3; CASASFINET JR, 1993, J MOL BIOL, V229, P873, DOI 10.1006/jmbi.1993.1093; CHOI YD, 1984, P NATL ACAD SCI-BIOL, V81, P7471, DOI 10.1073/pnas.81.23.7471; COBIANCHI F, 1988, J BIOL CHEM, V263, P1603; DAVIES RJ, 1994, TECHNIQUES PROTEIN C, V5; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; EDWARDS PR, 1995, ANAL BIOCHEM, V231, P210, DOI 10.1006/abio.1995.1522; GORLACH M, 1994, J BIOL CHEM, V269, P23074; Hall DR, 1997, ANAL BIOCHEM, V244, P152, DOI 10.1006/abio.1996.9867; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Hoek KS, 1998, BIOCHEMISTRY-US, V37, P7021, DOI 10.1021/bi9800247; Howe PWA, 1998, J BIOMOL NMR, V11, P59, DOI 10.1023/A:1008297502874; HUANG M, 1994, MOL CELL BIOL, V14, P518, DOI 10.1128/MCB.14.1.518; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; KANAAR R, 1995, EMBO J, V14, P4530, DOI 10.1002/j.1460-2075.1995.tb00132.x; KOZU T, 1995, GENOMICS, V25, P365, DOI 10.1016/0888-7543(95)80035-K; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; KUMAR A, 1986, J BIOL CHEM, V261, P1266; Kwon S, 1999, J CELL BIOL, V147, P247, DOI 10.1083/jcb.147.2.247; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MAYEDA A, 1994, EMBO J, V13, P5483, DOI 10.1002/j.1460-2075.1994.tb06883.x; McAfee JG, 1996, BIOCHEMISTRY-US, V35, P1212, DOI 10.1021/bi951974k; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P1387, DOI 10.1093/nar/20.6.1387; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P6461, DOI 10.1093/nar/20.24.6461; Munro TP, 1999, J BIOL CHEM, V274, P34389, DOI 10.1074/jbc.274.48.34389; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; SCHENKEL J, 1988, EUR J BIOCHEM, V171, P565, DOI 10.1111/j.1432-1033.1988.tb13825.x; SCHUMACHER JM, 1995, J CELL BIOL, V129, P1023, DOI 10.1083/jcb.129.4.1023; Shamoo Y, 1997, NAT STRUCT BIOL, V4, P215, DOI 10.1038/nsb0397-215; SHAMOO Y, 1994, BIOCHEMISTRY-US, V33, P8272, DOI 10.1021/bi00193a014; SHAMOO Y, 1995, NUCLEIC ACIDS RES, V23, P725, DOI 10.1093/nar/23.5.725; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; WARD LD, 1995, BIOCHEMISTRY-US, V34, P2901, DOI 10.1021/bi00009a021; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; WILK HE, 1985, EUR J BIOCHEM, V146, P71, DOI 10.1111/j.1432-1033.1985.tb08621.x; Williams DJ, 1996, J MOL BIOL, V257, P265; Xu RM, 1997, STRUCTURE, V5, P559, DOI 10.1016/S0969-2126(97)00211-6	50	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38286	38295		10.1074/jbc.M007642200	http://dx.doi.org/10.1074/jbc.M007642200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11024030	hybrid			2022-12-25	WOS:000165739800023
J	Aridor, M; Balch, WE				Aridor, M; Balch, WE			Kinase signaling initiates coat complex II (COPII) recruitment and export from the mammalian endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE FORMATION; GOLGI TRANSPORT; PROTEIN; CARGO; ER; CELLS; PATHWAY; SAR1	The events regulating coat complex II (COPII) vesicle formation involved in the export of cargo from the endoplasmic reticulum (ER) are unknown. COPII recruitment to membranes is initiated by the activation of the small GTPase Sari. We have utilized purified COPII components in both membrane recruitment and cargo export assays to analyze the possible role of kinase regulation in ER export. We now demonstrate that Sari recruitment to membranes requires ATP. We find that the serine/threonine kinase inhibitor H89 abolishes membrane recruitment of Sari, thereby preventing COPII polymerization by interfering with the recruitment of the cytosolic Sec23/24 COPII coat complex. Inhibition of COPII recruitment prevents export of cargo from the ER. These results demonstrate that ER export and initiation of COPII vesicle formation in mammalian cells is under kinase regulation.	Scripps Res Inst, Dept Cell, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Inst Childhood & Neglected Dis, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Balch, WE (corresponding author), Scripps Res Inst, Dept Cell, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	webalch@scripps.edu			NIGMS NIH HHS [GM42336] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aridor M, 1996, TRENDS CELL BIOL, V6, P315, DOI 10.1016/0962-8924(96)10027-1; Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Aridor M, 1999, J BIOL CHEM, V274, P4389, DOI 10.1074/jbc.274.7.4389; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; Bannykh S, 1995, COLD SPRING HARB SYM, V60, P127, DOI 10.1101/SQB.1995.060.01.016; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FABBRI M, 1994, J BIOL CHEM, V269, P26848; Herrmann JM, 1999, TRENDS CELL BIOL, V9, P5, DOI 10.1016/S0962-8924(98)01414-7; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cb.11.110195.003333; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee TH, 2000, MOL BIOL CELL, V11, P2577, DOI 10.1091/mbc.11.8.2577; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Nelson WJ, 2000, J CELL BIOL, V149, P243, DOI 10.1083/jcb.149.2.243; Rowe T, 1996, J CELL BIOL, V135, P895, DOI 10.1083/jcb.135.4.895; ROWE T, 1995, METHOD ENZYMOL, V257, P49; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236	28	95	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35673	35676		10.1074/jbc.C000449200	http://dx.doi.org/10.1074/jbc.C000449200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	11001944	hybrid			2022-12-25	WOS:000165382000005
J	Aoki, Y; Huang, ZH; Thomas, SS; Bhide, PG; Huang, I; Moskowitz, MA; Reeves, SA				Aoki, Y; Huang, ZH; Thomas, SS; Bhide, PG; Huang, I; Moskowitz, MA; Reeves, SA			Increased susceptibility to ischemia-induced brain damage in transgenic mice overexpressing a dominant negative form of SHP2	FASEB JOURNAL			English	Article						protein tyrosine phosphatase; cell survival; cerebral ischemia; neuron	PROTEIN-TYROSINE-PHOSPHATASE; FOCAL CEREBRAL-ISCHEMIA; TRANSIENT FOREBRAIN ISCHEMIA; NERVE GROWTH-FACTOR; REACTIVE ASTROCYTES; PROGENITOR CELLS; MESSENGER-RNA; RAT-BRAIN; DIFFERENTIAL REGULATION; SIGNAL-TRANSDUCTION	Cell culture studies have established SH2 domain-containing protein tyrosine phosphatase-2 (SHP2) as an important factor in growth factor and cytokine-activated signaling pathways. However, the significance of SHP2 in the mammalian central nervous system (CNS) is not known since early embryonic lethality occurs in shp2 null mice. To bypass this embryonic lethality, transgenic animals containing a catalytically inactive mutant of SHP2 (SHP2-CS) under the control of a nestin intron II/thymidiue kinase minimal promoter were generated. In the developing CNS of these animals, although high-level transgene expression was detected in the neuroepithelium, there was no obvious abnormality in progenitor cell proliferation or migration. In the adult brain, high-level transgene expression was detected in the subventricular zone, rostral migratory stream, dentate gyrus of hippocampus, and cerebellum. Because SHP2 function is Likely important in cell survival pathways, we used a focal cerebral ischemia model to examined whether SHP2 is important during CNS injury. Ischemia-induced damage and neuronal death was found to be significantly greater in nestin-SHP2-CS mice than in wildtype littermates. These findings indicate that SHP2 is a required factor in signaling pathway(s) important for neuronal survival.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, CNS Signaling Lab, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Reeves, SA (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, CNS Signaling Lab, 149 13th St, Charlestown, MA 02129 USA.		Moskowitz, Michael A/D-9916-2011	Bhide, Pradeep/0000-0003-4236-9415	NINDS NIH HHS [R01NS3599601] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035996] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; Arrandale JM, 1996, J BIOL CHEM, V271, P21353, DOI 10.1074/jbc.271.35.21353; Beck KD, 1996, NEURON, V16, P665, DOI 10.1016/S0896-6273(00)80085-9; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BETZ AL, 1983, J CEREBR BLOOD F MET, V3, P193, DOI 10.1038/jcbfm.1983.26; Chan KM, 1996, NEUROCHEM RES, V21, P763, DOI 10.1007/BF02532298; Doetsch F, 1997, J NEUROSCI, V17, P5046; Duggal N, 1997, BRAIN RES, V768, P1, DOI 10.1016/S0006-8993(97)00588-X; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FINKLESTEIN SP, 1990, STROKE, V21, P122; Frearson JA, 1998, J EXP MED, V187, P1417, DOI 10.1084/jem.187.9.1417; Fujii M, 1997, STROKE, V28, P1805, DOI 10.1161/01.STR.28.9.1805; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K; Guegan C, 1998, MOL BRAIN RES, V55, P133, DOI 10.1016/S0169-328X(97)00372-0; Hogan B, 1994, MANIPULATING MOUSE E; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLEMPT ND, 1992, MOL BRAIN RES, V13, P93, DOI 10.1016/0169-328X(92)90048-G; KOKETSU N, 1994, ANN NEUROL, V35, P451, DOI 10.1002/ana.410350413; LEE WH, 1993, ANN NY ACAD SCI, V679, P418, DOI 10.1111/j.1749-6632.1993.tb18332.x; Li Y, 1999, BRAIN RES, V838, P1, DOI 10.1016/S0006-8993(99)01502-4; LIN RCS, 1995, NEUROBIOL DIS, V2, P79, DOI 10.1006/nbdi.1995.0008; Lin TN, 1998, MOL BRAIN RES, V55, P71, DOI 10.1016/S0169-328X(97)00367-7; Lin TN, 1997, MOL BRAIN RES, V49, P255, DOI 10.1016/S0169-328X(97)00152-6; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; Lothian C, 1997, EUR J NEUROSCI, V9, P452, DOI 10.1111/j.1460-9568.1997.tb01622.x; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Reeves SA, 1996, NEUROSCIENCE, V71, P1037, DOI 10.1016/0306-4522(95)00491-2; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Sakakibara S, 1997, J NEUROSCI, V17, P8300; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Servidei T, 1998, NEUROSCIENCE, V82, P529; Servidei T, 1998, J BIOL CHEM, V273, P6233, DOI 10.1074/jbc.273.11.6233; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; TAKAHASHI T, 1992, J NEUROCYTOL, V21, P185, DOI 10.1007/BF01194977; TAKAHASHI T, 1993, J NEUROSCI, V13, P820; TAKAMI K, 1992, EXP BRAIN RES, V90, P1; TAKEDA A, 1992, BRAIN RES, V569, P177, DOI 10.1016/0006-8993(92)90388-P; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Thomas LB, 1996, GLIA, V17, P1; VANUITERT RL, 1978, STROKE, V9, P67, DOI 10.1161/01.STR.9.1.67; Wright JH, 1997, MOL BIOL CELL, V8, P1575, DOI 10.1091/mbc.8.8.1575; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P14871, DOI 10.1074/jbc.270.25.14871; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHU CZ, 1994, J CEREBR BLOOD F MET, V14, P237, DOI 10.1038/jcbfm.1994.30; ZIMMERMAN L, 1994, NEURON, V12, P11, DOI 10.1016/0896-6273(94)90148-1	52	40	43	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					1965	1973		10.1096/fj.00-0105com	http://dx.doi.org/10.1096/fj.00-0105com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023980				2022-12-25	WOS:000089634400015
J	Schroder, HC; Krasko, A; Batel, R; Skorokhod, A; Pahler, S; Kruse, M; Muller, IM; Muller, WEG				Schroder, HC; Krasko, A; Batel, R; Skorokhod, A; Pahler, S; Kruse, M; Muller, IM; Muller, WEG			Stimulation of protein (collagen) synthesis in sponge cells by a cardiac myotrophin-related molecule from Suberites domuncula	FASEB JOURNAL			English	Article						Porifera; myotrophin-like molecule; collagen; primmorphs; signal transduction	GEODIA-CYDONIUM; ADHESION RECEPTORS; GENE-EXPRESSION; MARINE SPONGES; ORIGIN; CLONING; SEQUENCE; SYSTEMS; IDENTIFICATION; INVERTEBRATES	The body wall of sponges (Porifera), the lowest metazoan phylum, is formed by two epithelial cell layers of exopinacocytes and endopinacocytes, both of which are associated with collagen fibrils. Here we show that a myotrophin-like polypeptide from the sponge Suberites domuncula causes the expression of collagen in cells from the same sponge in vitro. The cDNA of the sponge myotrophin was isolated; the potential open reading frame of 360 nt encodes a 120 aa long protein (M-r of 12,837). The sequence SUBDOMYOL shares high similarity with the known metazoan myotrophin sequences. The expression of SUBDOMYOL is lo tv in single cells but high after formation of primmorph aggregates as well as in intact animals. Recombinant myotrophin was found to stimulate protein synthesis by fivefold, as analyzed by incorporation studies using [H-3] lysine. In addition, it is shown that after incubation of single cells with myotrophin, the primmorphs show an unusual elongated, oval-shaped appearance. It is demonstrated that in the presence of recombinant myotrophin, the cells up-regulate the expression of the collagen gene. The cDNA for S. domuncula collagen was isolated; the deduced aa sequence shows that the collagenous internal domain is rather short, with only 24 G-x-y collagen triplets. We conclude that the sponge myotrophin causes in homologous cells the same/similar effect as the cardiac myotrophin in mammalian cells, where it is involved in initiation of cardial ventricular hypertrophy. We assume that an understanding of sponge molecular cell biology will also contribute to a further elucidation of human diseases, here of the cardiovascular system.	Johannes Gutenberg Univ Mainz, Inst Physiol Chem, Angew Mol Biol Abt, D-55099 Mainz, Germany; Rudjer Boskovic Inst, Ctr Marine Res, HR-52210 Rovinj, Croatia; Max Planck Inst Zuchtungsforsch, D-50829 Cologne, Germany	Johannes Gutenberg University of Mainz; Rudjer Boskovic Institute; Max Planck Society	Muller, WEG (corresponding author), Johannes Gutenberg Univ Mainz, Inst Physiol Chem, Angew Mol Biol Abt, Duesbergweg 6, D-55099 Mainz, Germany.	WMUELLER@mail.UNI-Mainz.DE	Müller, W. E. G./AAR-8651-2020	Müller, W. E. G./0000-0002-8223-3689; Schroder, Heinz C./0000-0003-0992-6427				Asahina K, 1999, DEV DYNAM, V216, P59, DOI 10.1002/(SICI)1097-0177(199909)216:1<59::AID-DVDY8>3.3.CO;2-2; Asahina K, 1999, MATRIX BIOL, V18, P89, DOI 10.1016/S0945-053X(99)00005-0; Bisoffi M, 1996, PARASITOLOGY, V113, P145, DOI 10.1017/S0031182000066397; Blumbach B, 1999, IMMUNOGENETICS, V49, P751, DOI 10.1007/s002510050549; Blumbach B, 1998, J CELL SCI, V111, P2635; Brooks WW, 1997, HYPERTENSION, V30, P1362, DOI 10.1161/01.HYP.30.6.1362; Celerin M, 1996, EMBO J, V15, P4445, DOI 10.1002/j.1460-2075.1996.tb00821.x; Chan SL, 1999, J BIOL CHEM, V274, P32461, DOI 10.1074/jbc.274.45.32461; Custodio MR, 1998, MECH AGEING DEV, V105, P45, DOI 10.1016/S0047-6374(98)00078-5; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; Eble J.A., 1997, INTEGRIN LIGAND INTE; EXPOSITO JY, 1991, J BIOL CHEM, V266, P21923; EXPOSITO JY, 1990, P NATL ACAD SCI USA, V87, P6669, DOI 10.1073/pnas.87.17.6669; Felsenstein J., 1993, PHYLIP VER 3 5; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; Garrone R, 1998, Prog Mol Subcell Biol, V21, P119; Garrone R., 1978, PHYLOGENESIS CONNECT; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; *INT INC, 1995, PC GENE DAT BANKS CD; KOROTKOVA GP, 1970, BIOL PORIFERA, V25, P423; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Koziol C, 1998, MECH AGEING DEV, V100, P107, DOI 10.1016/S0047-6374(97)00120-6; Kruse M, 1997, MOL BIOL EVOL, V14, P1326, DOI 10.1093/oxfordjournals.molbev.a025742; KURZ EM, 1991, J CELL BIOL, V115, P1159, DOI 10.1083/jcb.115.4.1159; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lorenz B, 1996, CELL SIGNAL, V8, P517, DOI 10.1016/S0898-6568(96)00108-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYNE R, 1985, ANN NY ACAD SCI, V460, P38, DOI 10.1111/j.1749-6632.1985.tb51155.x; Moore DD, 1995, GLOB MOB SURV; MUKHERJEE D, 1992, CIRCULATION S1, V86, P1; Muller WEG, 1999, DNA CELL BIOL, V18, P885, DOI 10.1089/104454999314746; MULLER WEG, 1977, CANCER RES, V37, P3824; Muller WEG, 1999, TRANSPLANTATION, V68, P1215; Muller WEG, 1999, MAR ECOL PROG SER, V178, P205, DOI 10.3354/meps178205; Muller WEG, 1997, CELL TISSUE RES, V289, P383, DOI 10.1007/s004410050885; MULLER WEG, 1995, NATURWISSENSCHAFTEN, V82, P321; MUNRO HN, 1966, ANALYST, V91, P78, DOI 10.1039/an9669100078; Nicholas KB., 1997, GENEDOC TOOL EDITING; Pahler S, 1998, P ROY SOC B-BIOL SCI, V265, P421, DOI 10.1098/rspb.1998.0311; Pancer Z, 1997, MOL BIOL EVOL, V14, P391, DOI 10.1093/oxfordjournals.molbev.a025775; Perovic S, 1999, CELL TISSUE RES, V296, P395, DOI 10.1007/s004410051299; PFEIFER K, 1993, GLYCOBIOLOGY, V3, P179, DOI 10.1093/glycob/3.2.179; Sawada K, 1996, INT J DEV BIOL, V40, P531; SCHACKE H, 1994, IMMUNOL TODAY, V15, P497, DOI 10.1016/0167-5699(94)90198-8; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SEN S, 1990, J BIOL CHEM, V265, P16635; Sil P, 1998, CIRC RES, V82, P1173, DOI 10.1161/01.RES.82.11.1173; Simpson T., 1984, CELL BIOL SPONGES; Sivasubramanian N, 1996, J BIOL CHEM, V271, P2812, DOI 10.1074/jbc.271.5.2812; STANLEY PE, 1990, BIOLUMINESCENCE CHEM; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; TAOKA M, 1994, J BIOL CHEM, V269, P9946; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vacelet Jean, 1999, Memoirs of the Queensland Museum, V44, P27; Westheide W, 1996, SPEZIELLE ZOOLOGIE 1; Wiens M, 2000, CELL DEATH DIFFER, V7, P461, DOI 10.1038/sj.cdd.4400671; Wiens M, 1999, FEBS LETT, V462, P12, DOI 10.1016/S0014-5793(99)01478-7; Wiens M, 1998, MAR ECOL PROG SER, V165, P247, DOI 10.3354/meps165247; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wimmer W, 1999, EUR J BIOCHEM, V260, P156, DOI 10.1046/j.1432-1327.1999.00146.x; Yang JJ, 1997, TOP GERIATR REHABIL, V13, P13	61	61	66	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2000	14	13					2022	2031		10.1096/fj.00-0043com	http://dx.doi.org/10.1096/fj.00-0043com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023986				2022-12-25	WOS:000089634400021
J	Fischer, S; Graber, P; Turina, P				Fischer, S; Graber, P; Turina, P			The activity of the ATP synthase from Escherichia coli is regulated by the transmembrane proton motive force	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SITE NUCLEOTIDE; MITOCHONDRIAL F1-ATPASE; INHIBITOR PROTEIN; BINDING SITES; DELTA-PH; INORGANIC-PHOSPHATE; COUPLING FACTOR; H+-ATPASE; ADP; HYDROLYSIS	The ATP synthase from Escherichia coli was reconstituted into liposomes from phosphatidylcholine/phosphatidic acid. The proteoliposomes were energized by an acid-base transition and a K+/valinomycin diffusion potential, and one second after energization, the electrochemical proton gradient was dissipated by uncouplers, and the ATP hydrolysis measurement was started. In the presence of ADP and P-i, the initial rate of ATP hydrolysis was up to 9-fold higher with pre-energized proteoliposomes than with proteoliposomes that had not seen an electrochemical proton gradient. After dissipating the electrochemical proton gradient, the high rate of ATP hydrolysis decayed to the rate without preenergization within about 15 s. During this decay the enzyme carried out approximately 100 turnovers. In the absence of ADP and P-i, the rate of ATP hydrolysis was already high and could not be significantly increased by pre-energization. It is concluded that ATP hydrolysis is inhibited when ADP and P-i are bound to the enzyme and that a high Delta<(mu)over tilde>(H)+ is required to release ADP and P-i and to convert the enzyme into a high activity state. This high activity state is metastable and decays slowly when Delta<(mu)over tilde>(H)+ is abolished. Thus, the proton motive force does not only supply energy for ATP synthesis but also regulates the fraction of active enzymes.	Univ Bologna, Dept Biol, Biochem & Biophys Lab, I-40126 Bologna, Italy; Univ Freiburg, Inst Phys Chem, D-79104 Freiburg, Germany	University of Bologna; University of Freiburg	Turina, P (corresponding author), Univ Bologna, Dept Biol, Biochem & Biophys Lab, Via Irnerio 42, I-40126 Bologna, Italy.		Turina, Paola/P-9342-2015; Turina, Paola/GYJ-0656-2022	Turina, Paola/0000-0001-9174-511X; 				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BOKRANZ M, 1985, BIOCHIM BIOPHYS ACTA, V810, P332, DOI 10.1016/0005-2728(85)90218-X; Boyer PD, 1998, BBA-BIOENERGETICS, V1365, P3, DOI 10.1016/S0005-2728(98)00066-8; CARMELI C, 1972, BIOCHIM BIOPHYS ACTA, V267, P86, DOI 10.1016/0005-2728(72)90140-5; CHERNYAK BV, 1992, ARCH BIOCHEM BIOPHYS, V295, P247, DOI 10.1016/0003-9861(92)90514-W; DIPIETRO A, 1986, BIOCHIM BIOPHYS ACTA, V851, P283, DOI 10.1016/0005-2728(86)90136-2; DROBINSKAYA IY, 1985, FEBS LETT, V182, P419, DOI 10.1016/0014-5793(85)80346-X; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNHAM KR, 1981, J BIOL CHEM, V256, P44; Fillingame RH, 2000, J EXP BIOL, V203, P9; Fischer S, 1999, FEBS LETT, V457, P327, DOI 10.1016/S0014-5793(99)01060-1; FISCHER S, 1994, EUR J BIOCHEM, V225, P167, DOI 10.1111/j.1432-1033.1994.00167.x; Galkin MA, 1999, FEBS LETT, V448, P123, DOI 10.1016/S0014-5793(99)00347-6; GRABER P, 1977, BIOCHIM BIOPHYS ACTA, V461, P426, DOI 10.1016/0005-2728(77)90231-6; GRABER P, 1984, BER BUNSEN PHYS CHEM, V88, P599, DOI 10.1002/bbpc.19840880706; HARRIS DA, 1978, BIOCHIM BIOPHYS ACTA, V502, P87, DOI 10.1016/0005-2728(78)90134-2; HARRIS DA, 1979, BIOCHIM BIOPHYS ACTA, V548, P72, DOI 10.1016/0005-2728(79)90188-9; HUSAIN I, 1983, FEBS LETT, V160, P110, DOI 10.1016/0014-5793(83)80947-8; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; JUNESCH U, 1987, BIOCHIM BIOPHYS ACTA, V893, P275, DOI 10.1016/0005-2728(87)90049-1; JUNGE W, 1970, EUR J BIOCHEM, V14, P582, DOI 10.1111/j.1432-1033.1970.tb00327.x; KLEEFELD S, 1990, BIOCHIM BIOPHYS ACTA, V1019, P11, DOI 10.1016/0005-2728(90)90119-O; KRAMER DM, 1990, PHOTOSYNTH RES, V26, P213, DOI 10.1007/BF00033134; KRAMER DM, 1989, BIOCHIM BIOPHYS ACTA, V976, P28, DOI 10.1016/S0005-2728(89)80186-0; LIPPE G, 1988, BIOCHIM BIOPHYS ACTA, V933, P12, DOI 10.1016/0005-2728(88)90051-5; Lobau S, 1998, BIOCHEMISTRY-US, V37, P10846, DOI 10.1021/bi9807153; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MILGROM YM, 1990, BIOCHIM BIOPHYS ACTA, V1020, P43, DOI 10.1016/0005-2728(90)90091-H; MILLS JD, 1984, BIOCHIM BIOPHYS ACTA, V764, P93, DOI 10.1016/0005-2728(84)90145-2; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; MORIYAMA Y, 1991, J BIOL CHEM, V266, P22141; MUNEYUKI E, 1991, BIOCHIM BIOPHYS ACTA, V1058, P304, DOI 10.1016/S0005-2728(05)80251-8; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; ORT DR, 1992, ANNU REV PLANT PHYS, V43, P269, DOI 10.1146/annurev.pp.43.060192.001413; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; POPOV N, 1975, ACTA BIOL MED GER, V34, P1441; RIGAUD JL, 1988, BIOCHEMISTRY-US, V27, P2677, DOI 10.1021/bi00408a007; ROSING J, 1976, BIOCHEM BIOPH RES CO, V72, P1, DOI 10.1016/0006-291X(76)90952-9; ROSING J, 1972, BIOCHIM BIOPHYS ACTA, V267, P275, DOI 10.1016/0005-2728(72)90116-8; ROSING J, 1975, BIOCHIM BIOPHYS ACTA, V376, P13, DOI 10.1016/0005-2728(75)90201-7; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SCHLODDER E, 1982, ELECTRON TRANSPORT P, P105; SCHUMANN J, 1981, PHOTOSYNTHESIS, V2, P881; SCHWERZMANN K, 1986, ARCH BIOCHEM BIOPHYS, V250, P1, DOI 10.1016/0003-9861(86)90695-8; SHOSHAN V, 1980, J BIOL CHEM, V255, P996; SLOOTEN L, 1989, BIOCHIM BIOPHYS ACTA, V976, P150, DOI 10.1016/S0005-2728(89)80224-5; SLOOTEN L, 1981, BIOCHIM BIOPHYS ACTA, V638, P305, DOI 10.1016/0005-2728(81)90241-3; Strotmann H., 1984, ADV PHOTOSYNTHESIS R, V2, P477; Tsunoda SP, 2000, FEBS LETT, V470, P244, DOI 10.1016/S0014-5793(00)01336-3; TURINA P, 1991, EUR J BIOCHEM, V196, P225, DOI 10.1111/j.1432-1033.1991.tb15808.x; TURINA P, 1992, J BIOL CHEM, V267, P11057; Vinogradov AD, 2000, J EXP BIOL, V203, P41; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEBER J, 1995, J BIOL CHEM, V270, P12653, DOI 10.1074/jbc.270.21.12653; ZHOU JM, 1988, BIOCHEMISTRY-US, V27, P5129, DOI 10.1021/bi00414a027	56	68	72	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30157	30162		10.1074/jbc.275.39.30157	http://dx.doi.org/10.1074/jbc.275.39.30157			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	11001951	hybrid			2022-12-25	WOS:000089577900035
J	Rae, TD; Torres, AS; Pufahl, RA; O'Halloran, TV				Rae, TD; Torres, AS; Pufahl, RA; O'Halloran, TV			Mechanism of Cu,Zn-superoxide dismutase activation by the human metallochaperone hCCS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MERCURIC ION REDUCTASE; HUMAN COPPER CHAPERONE; SUPEROXIDE-DISMUTASE; ATX1 METALLOCHAPERONE; CRYSTAL-STRUCTURE; ACTIVE-SITE; PROTEIN; DOMAIN; DETOXIFICATION; MUTAGENESIS	The mechanism for copper loading of the antioxidant enzyme copper, zinc superoxide dismutase (SOD1) by its partner metallochaperone protein is not well understood. Here we show the human copper chaperone for Cu,Zn-SOD1 (hCCS) activates either human or yeast enzymes in vitro by direct protein to protein transfer of the copper cofactor. Interestingly, when denatured with organic solvents, the ape-form of human SOD1 cannot be reactivated by added copper ion alone, suggesting an additional function of hCCS such as facilitation of an active folded state of the enzyme. While hCCS can bind several copper ions, metal binding studies in the presence of excess copper scavengers that mimic the intracellular chelation capacity indicate a limiting stoichiometry of one copper and one zinc per hCCS monomer. This protein is active and unlike the yeast protein, is a homodimer regardless of copper occupancy. Matrix-assisted laser desorption ionization-mass spectrometry and metal binding studies suggest that Cu(I) is bound by residues from the first and third domains and no bound copper is detected for the second domain of hCCS in either the full-length or truncated forms of the protein. Copper-induced conformational changes in the essential C-terminal peptide of hCCS are consistent with a "pivot, insert, and release" mechanism that is similar to one proposed for the well characterized metal handling enzyme, mercuric ion reductase.	Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University; Northwestern University	O'Halloran, TV (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.		O'Halloran, Thomas/ABE-6125-2021	O'Halloran, Thomas/0000-0001-8732-5059	NCRR NIH HHS [S10 RR11320, S10 RR13810] Funding Source: Medline; NIGMS NIH HHS [GM 19457, GM54111, R01 GM054111] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013810, S10RR011320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054111, F32GM019457] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANCI L, 2001, IN PRESS J BIOL CHEM, V276; Blair D., 1961, TALANTA LONDON, V7, P163; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DISTEFANO MD, 1989, BIOCHEMISTRY-US, V28, P1168, DOI 10.1021/bi00429a035; Eisses JF, 2000, BIOCHEMISTRY-US, V39, P7337, DOI 10.1021/bi000690j; Engst S, 1999, BIOCHEMISTRY-US, V38, P3519, DOI 10.1021/bi982680c; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; FRIDOVICH I, 1985, CRC HDB METHODS OXYG, P213; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Hall LT, 2000, BIOCHEMISTRY-US, V39, P3611, DOI 10.1021/bi992716g; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; HARTZ JW, 1972, J BIOL CHEM, V247, P7043; Hejtmancik JF, 1997, PROTEIN ENG, V10, P1347, DOI 10.1093/protein/10.11.1347; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Hung IH, 1998, J BIOL CHEM, V273, P1749, DOI 10.1074/jbc.273.3.1749; JABUSCH JR, 1980, BIOCHEMISTRY-US, V19, P2310, DOI 10.1021/bi00552a005; Lamb AL, 1999, NAT STRUCT BIOL, V6, P724; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P1589, DOI 10.1021/bi992822i; Lin SJ, 1997, J BIOL CHEM, V272, P9215; MILLER SM, 1989, BIOCHEMISTRY-US, V28, P1194, DOI 10.1021/bi00429a037; MOORE MJ, 1989, BIOCHEMISTRY-US, V28, P1183, DOI 10.1021/bi00429a036; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Portnoy ME, 1999, J BIOL CHEM, V274, P15041, DOI 10.1074/jbc.274.21.15041; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Rosenzweig AC, 1999, STRUCTURE, V7, P605, DOI 10.1016/S0969-2126(99)80082-3; SCHIERING N, 1991, NATURE, V352, P168, DOI 10.1038/352168a0; Schmidt PJ, 1999, J BIOL CHEM, V274, P36952, DOI 10.1074/jbc.274.52.36952; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; STANSELL MJ, 1965, J BIOL CHEM, V240, P4306; Valentine JS, 1997, SCIENCE, V278, P817, DOI 10.1126/science.278.5339.817; VALENTINE JS, 1982, COPPER PROTEINS, P292; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197; Zhu HN, 2000, BIOCHEMISTRY-US, V39, P5413, DOI 10.1021/bi992727+	36	93	94	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5166	5176		10.1074/jbc.M008005200	http://dx.doi.org/10.1074/jbc.M008005200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11018045	hybrid			2022-12-25	WOS:000168484300086
J	Granovsky, AE; Artemyev, NO				Granovsky, AE; Artemyev, NO			Identification of the gamma subunit-interacting residues on photoreceptor cGMP phosphodiesterase, PDEG alpha '*	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; ROD OUTER SEGMENTS; CATALYTIC SUBUNITS; BINDING-SITES; VISUAL TRANSDUCTION; INHIBITORY SUBUNITS; AMINO-ACIDS; CDNA CLONE; DOMAIN; MUTAGENESIS	Photoreceptor cGMP phosphodiesterase (PDE6) is the effector enzyme in the G protein-mediated visual transduction cascade. In the dark, the activity of PDE6 is shut off by the inhibitory gamma subunit (P gamma), Chimeric proteins between cone PDE6 alpha' and cGMP-binding and cGMP-specific PDE (PDE5) have been constructed and expressed in Sf9 cells to study the mechanism of inhibition of PDE6 catalytic activity by P gamma. Substitution of the segment PDE5-(773-820) by the corresponding PDE6 alpha'-(737-784) sequence in the wild-type PDE5 or in a PDE5/PDE6 alpha' chimera containing the catalytic domain of PDE5 results in chimeric enzymes capable of inhibitory interaction with P gamma. The catalytic properties of the chimeric PDEs remained similar to those of PDE5. Ala-scanning mutational analysis of the P gamma -binding region, PDE6 alpha'-(750-760), revealed PDE6 alpha' residues essential for the interaction. The M758A mutation markedly impaired and the Q752A mutation moderately impaired the inhibition of chimeric PDE by P gamma. The analysis of the catalytic properties of mutant PDEs and a model of the PDE6 catalytic domain suggest that residues Met(758) and Gln(752) directly bind P gamma. A model of the PDE6 catalytic site shows that PDE6 alpha'-(750-760) forms a loop at the entrance to the cGMP-binding pocket. Binding of P gamma to Met(758) would effectively block access of cGMP to the catalytic cavity, providing a structural basis for the mechanism of PDE6 inhibition.	Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Artemyev, NO (corresponding author), Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA.		Alex, Granovsky/EUV-7323-2022	Artemyev, Nikolai/0000-0002-5266-6854	NEI NIH HHS [EY10843] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010843] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Artemyev NO, 1996, P NATL ACAD SCI USA, V93, P5407, DOI 10.1073/pnas.93.11.5407; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; Artemyev NO, 1998, METHODS, V14, P93, DOI 10.1006/meth.1997.0568; BAEHR W, 1979, J BIOL CHEM, V254, P1669; Ballard SA, 1998, J UROLOGY, V159, P2164, DOI 10.1016/S0022-5347(01)63299-3; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; COTE RH, 1994, P NATL ACAD SCI USA, V91, P4845, DOI 10.1073/pnas.91.11.4845; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; Francis SH, 2000, BIOCHEMISTRY-US, V39, P9591, DOI 10.1021/bi000392m; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GILLESPIE PG, 1989, MOL PHARMACOL, V36, P773; Granovsky AE, 1998, J BIOL CHEM, V273, P24485, DOI 10.1074/jbc.273.38.24485; Granovsky AE, 1997, J BIOL CHEM, V272, P11686, DOI 10.1074/jbc.272.18.11686; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAMILTON SE, 1993, FEBS LETT, V318, P157, DOI 10.1016/0014-5793(93)80012-J; HAMILTON SE, 1990, J BIOL CHEM, V265, P11259; He F, 2000, J BIOL CHEM, V275, P20572, DOI 10.1074/jbc.M000440200; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; Mou HM, 1999, J BIOL CHEM, V274, P18813, DOI 10.1074/jbc.274.26.18813; Natochin M, 2000, METHOD ENZYMOL, V315, P539; PIRIEV NI, 1993, P NATL ACAD SCI USA, V90, P9340, DOI 10.1073/pnas.90.20.9340; QIN N, 1994, J BIOL CHEM, V269, P3265; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; TAKEMOTO DJ, 1992, BIOCHEM J, V281, P637, DOI 10.1042/bj2810637; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Turko IV, 1999, MOL PHARMACOL, V56, P124, DOI 10.1124/mol.56.1.124; Turko IV, 1996, J BIOL CHEM, V271, P22240, DOI 10.1074/jbc.271.36.22240; Turko IV, 1998, BIOCHEMISTRY-US, V37, P4200, DOI 10.1021/bi972448r; Turko IV, 1998, J BIOL CHEM, V273, P6460, DOI 10.1074/jbc.273.11.6460; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	40	24	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41258	41262		10.1074/jbc.M008094200	http://dx.doi.org/10.1074/jbc.M008094200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024033	hybrid			2022-12-25	WOS:000166114600080
J	Nix, SL; Chishti, AH; Anderson, JM; Walther, Z				Nix, SL; Chishti, AH; Anderson, JM; Walther, Z			hCASK and hDlg associate in epithelia, and their Src homology 3 and guanylate kinase domains participate in both intramolecular and intermolecular interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; TIGHT JUNCTION; GLYCOPHORIN-C; MAGUK FAMILY; MOLECULAR CHARACTERIZATION; BASOLATERAL MEMBRANE; PLASMA-MEMBRANE; SH3 DOMAINS; PDZ DOMAIN; COMPLEX	Membrane associated guanylate kinase (MAGUK) proteins act as molecular scaffolds organizing multiprotein complexes at specialized regions of the plasma membrane. All MAGUKs contain a Src homology 3 (SH3) domain and a region homologous to yeast guanylate kinase (GUK). We showed previously that one MAGUK protein, human CASK (hCASK), is widely expressed and associated with epithelial basolateral plasma membranes. We now report that hCASK binds another MAGUK, human discs large (hDlg). Immunofluorescence microscopy demonstrates that hCASK and hDlg colocalize at basolateral membranes of epithelial cells in small and large intestine. These proteins co-precipitate from lysates of an intestinal cell line, Caco-2, The GUK domain of hCASK binds the SH3 domain of hDlg in both yeast two-hybrid and fusion protein binding assays, and it is required for interaction with hDlg in transfected HEK293 cells. In addition, the SH3 and GUK domains of each protein participate in intramolecular binding that in vitro predominates over intermolecular binding. The SH3 and GUK domains of human p55 display the same interactions in yeast two-hybrid assays as those of hCASK. Not all SH3-GUK interactions among these MAGUKs are permissible, however, implying specificity to SH3-GUK interactions in vivo. These results suggest MAGUK scaffold assembly may be regulated through effects on intramolecular SH3-GUK binding.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Tufts Univ, Div Hematol Res, St Elizabeths Med Ctr, Sch Med, Boston, MA 02135 USA	Yale University; Yale University; Yale University; St. Elizabeth's Medical Center; Tufts University	Walther, Z (corresponding author), Yale Univ, Sch Med, Dept Internal Med, 333 Cedar St,1080 LMP,POB 208019, New Haven, CT 06520 USA.		House, Stacey/C-8796-2012	Anderson, James/0000-0003-2765-7996	NATIONAL CANCER INSTITUTE [P01CA066263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007017, P30DK034989] Funding Source: NIH RePORTER; NCI NIH HHS [CA66263] Funding Source: Medline; NIDDK NIH HHS [DK34989, T32DK07017] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLOISIO N, 1993, BLOOD, V82, P1323, DOI 10.1182/blood.V82.4.1323.bloodjournal8241323; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Brenman JE, 1998, J NEUROSCI, V18, P8805; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; Deguchi M, 1998, J BIOL CHEM, V273, P26269, DOI 10.1074/jbc.273.41.26269; Dimitratos SD, 1997, MECH DEVELOP, V63, P127, DOI 10.1016/S0925-4773(97)00668-0; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Hata Y, 1996, J NEUROSCI, V16, P2488; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hsueh YP, 1999, J BIOL CHEM, V274, P532, DOI 10.1074/jbc.274.1.532; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Irie M, 1999, ONCOGENE, V18, P2811, DOI 10.1038/sj.onc.1202652; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kamberov E, 2000, J BIOL CHEM, V275, P11425, DOI 10.1074/jbc.275.15.11425; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KISTNER U, 1995, FEBS LETT, V359, P159, DOI 10.1016/0014-5793(95)00030-D; Kuhlendahl S, 1998, EUR J BIOCHEM, V252, P305, DOI 10.1046/j.1432-1327.1998.2520305.x; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; MARFATIA SM, 1994, J BIOL CHEM, V269, P8631; MARFATIA SM, 1997, MOL BIOL CELL, V8, P292; Masuko N, 1999, J BIOL CHEM, V274, P5782, DOI 10.1074/jbc.274.9.5782; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MAZOYER S, 1995, GENOMICS, V28, P25, DOI 10.1006/geno.1995.1101; McGee AW, 1999, J BIOL CHEM, V274, P17431, DOI 10.1074/jbc.274.25.17431; Metzenberg Aida B., 1992, Human Molecular Genetics, V1, P97, DOI 10.1093/hmg/1.2.97; Montell C, 1999, ANNU REV CELL DEV BI, V15, P231, DOI 10.1146/annurev.cellbio.15.1.231; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Mullins RD, 2000, CURR OPIN CELL BIOL, V12, P91, DOI 10.1016/S0955-0674(99)00061-7; NEITHAMMER M, 1996, J NEUROSCI, V16, P2157; NORTON AJ, 1994, J PATHOL, V173, P371, DOI 10.1002/path.1711730413; RIGGS P, 1994, CURRENT PROTOCOLS MO; ROUSSET M, 1986, BIOCHIMIE, V68, P1035, DOI 10.1016/S0300-9084(86)80177-8; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; SMITH DB, 1994, CURRENT PROTOCOLS MO; Smith SA, 1996, GENOMICS, V31, P145, DOI 10.1006/geno.1996.0025; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Wu HJ, 1998, J CELL SCI, V111, P2365	56	90	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41192	41200		10.1074/jbc.M002078200	http://dx.doi.org/10.1074/jbc.M002078200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10993877	hybrid			2022-12-25	WOS:000166114600072
J	Wang, SK; Gustafson, E; Pang, L; Qiao, XD; Behan, J; Maguire, M; Bayne, M; Laz, T				Wang, SK; Gustafson, E; Pang, L; Qiao, XD; Behan, J; Maguire, M; Bayne, M; Laz, T			A novel hepatointestinal leukotriene B-4 receptor - Cloning and functional characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY BOWEL-DISEASE; POLYMORPHONUCLEAR LEUKOCYTES; BIOLOGICAL-ACTIVITY; HUMAN-NEUTROPHILS; EXPRESSION; INHIBITION; ANTAGONIST; BINDING; LIVER; GENE	Leukotriene B-4 (LTB4) is a product of eicosanoid metabolism and acts as an extremely potent chemotactic mediator for inflammation, LTB4 exerts positive effects on the immigration and activation of leukocytes. These effects suggest an involvement of LTB4 in several diseases: inflammatory bowel disease, psoriasis, arthritis, and asthma. LTB4 elicits actions through interaction with one or more cell surface receptors that lead to chemotaxis and inflammation, One leukotriene B-4 receptor-has been recently identified (LTB4-R1). In this report we describe cloning of a cDNA encoding a novel 358-amino acid receptor (LTB4-R2) that possesses seven membrane-spanning domains and is homologous (42%) and genetically linked to LTB4-R1. Expression of LTB4-R2 is broad but highest in liver, intestine, spleen, and kidney. In radioligand binding assays, membranes prepared from COS-7 cells transfected with LTB4-R2 cDNA displayed high affinity (K-d = 0.17 nM) for [H-3]LTB4. Radioligand competition assays revealed high affinities of the receptor for LTB4 and LTB5, and 20-hydroxy-LTB4, and intermediate affinities for 15(5)HETE and 12-oxo-ETE. Three LTB, receptor antagonistst 14,15-dehydro-LTB4, LTB4-3-aminopropylamide, and U-75302, had high affinity for LTB4-R1 but not for LTB4-R2. No apparent affinity binding for the receptors was detected for the CysLT1-selective antagonists montelukast and zafirlukast. LTB, functionally mobilized intracellular calcium and inhibited forskolin-stimulated cAMP production in 293 cells. The discovery of this new receptor should aid in further understanding the roles of LTB, in pathologies in these tissues and may provide a tool in identification of specific antagonists/ agonists for potential therapeutic treatments.	Schering Plough Corp, Inst Res, Kenilworth, NJ 07033 USA	Merck & Company; Schering Plough Corporation	Wang, SK (corresponding author), Schering Plough Corp, Inst Res, 2015 Galloping Hill Rd,K15-E119, Kenilworth, NJ 07033 USA.	suke.wang@spcorp.com						ASANO F, 1993, J GASTROEN HEPATOL, V8, P228, DOI 10.1111/j.1440-1746.1993.tb01191.x; BORGEAT P, 1990, CLIN BIOCHEM, V23, P459, DOI 10.1016/0009-9120(90)90272-V; BRACH MA, 1992, EUR J IMMUNOL, V22, P2705, DOI 10.1002/eji.1830221034; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; CHENG JB, 1986, J PHARMACOL EXP THER, V236, P126; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CLANCY RM, 1984, P NATL ACAD SCI-BIOL, V81, P5729, DOI 10.1073/pnas.81.18.5729; DAHINDEN CA, 1984, J IMMUNOL, V133, P1477; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; DOI F, 1993, HEPATOLOGY, V17, P1086, DOI 10.1016/0270-9139(93)90127-9; GOLDMAN DW, 1987, FASEB J, V46, P200; HEIN J, 1990, METHOD ENZYMOL, V183, P626; HUGHES H, 1992, PROSTAG LEUKOTR ESS, V45, P113, DOI 10.1016/0952-3278(92)90226-9; Jackson W T, 1996, Prog Drug Res, V46, P115; Jackson WT, 1999, J PHARMACOL EXP THER, V288, P286; Kasirga E, 1999, TURKISH J PEDIATR, V41, P457; KISHIKAWA K, 1992, PROSTAGLANDINS, V44, P261, DOI 10.1016/0090-6980(92)90002-B; LEVINE JD, 1984, SCIENCE, V225, P743, DOI 10.1126/science.6087456; LIN AH, 1988, ANN NY ACAD SCI, V524, P196, DOI 10.1111/j.1749-6632.1988.tb38542.x; LOBOS EA, 1987, DIGEST DIS SCI, V32, P1380, DOI 10.1007/BF01296664; Lynch KR, 1999, NATURE, V399, P789; Nagata K, 1999, J IMMUNOL, V162, P1278; Nakao A, 1997, KIDNEY INT, pS236; NANJI AA, 1993, ALCOHOL, V10, P443, DOI 10.1016/0741-8329(93)90062-S; Noiri E, 2000, P NATL ACAD SCI USA, V97, P823, DOI 10.1073/pnas.97.2.823; Raport CJ, 1996, J LEUKOCYTE BIOL, V59, P18, DOI 10.1002/jlb.59.1.18; ROHRER L, 1993, P NATL ACAD SCI USA, V90, P4196, DOI 10.1073/pnas.90.9.4196; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; SEGGEV JS, 1995, ANN ALLERG ASTHMA IM, V75, P365; SHAAFI RI, 1981, J CELL PHYSIOL, V108, P401, DOI 10.1002/jcp.1041080314; SHARON P, 1984, GASTROENTEROLOGY, V86, P453; SHIMAZAKI T, 1990, PROSTAGLANDINS, V39, P459, DOI 10.1016/0090-6980(90)90126-G; Showell HJ, 1998, J PHARMACOL EXP THER, V285, P946; SMITH MJH, 1980, J PHARM PHARMACOL, V32, P517, DOI 10.1111/j.2042-7158.1980.tb12985.x; STANKOVA J, 1992, BIOCHEM J, V282, P625; TAYLOR BM, 1991, PROSTAG OTH LIPID M, V42, P211, DOI 10.1016/0090-6980(91)90111-R; Urade M, 1996, HEPATOLOGY, V23, P544; Weringer EJ, 1999, TRANSPLANTATION, V67, P808, DOI 10.1097/00007890-199903270-00005; YAMAMOTO S, 1993, PROSTAGLANDINS, V45, P527, DOI 10.1016/0090-6980(93)90016-Z; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; YOUNG RN, 1983, PROSTAGLANDINS, V26, P605, DOI 10.1016/0090-6980(83)90197-1	42	59	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40686	40694		10.1074/jbc.M004512200	http://dx.doi.org/10.1074/jbc.M004512200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11006272	hybrid			2022-12-25	WOS:000166114600006
J	Pratta, MA; Tortorella, MD; Arner, EC				Pratta, MA; Tortorella, MD; Arner, EC			Age-related changes in aggrecan glycosylation affect cleavage by aggrecanase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SYNOVIAL-FLUID; INTERGLOBULAR DOMAIN; ARTICULAR-CARTILAGE; ADAMTS FAMILY; CATABOLISM; PROTEOGLYCAN; DEGRADATION; FRAGMENTS; SITE; IDENTIFICATION	Aggrecan degradation involves proteolytic cleavage of the core protein within the interglobular domain. Because aggrecan is highly glycosylated with chondroitin sulfate (CS) and keratan sulfate (KS), we investigated whether glycosylation affects digestion by aggrecanase at the Glu(373)-Ala(374) bond. Treatment of bovine aggrecan monomers to remove CS and BS resulted in loss of cleavage at this site, suggesting that glycosaminoglycans (GAGs) play a role in cleavage at the Glu(373)-Ala(374) bond. In contrast, MMP3 cleavage at the Ser(341)-Phe(342) bond was not affected by glycosidase treatment of aggrecan. Removal of KS, but not CS, prevented cleavage at the Glu(373)-Ala(374) bond. Thus, KS residues may be important for recognition of this cleavage site by aggrecanase. KS glycosylation has been observed at sites adjacent to the Glu(373)-Ala(374) bond in steer aggrecan, but not in calf aggrecan (Barry, F. P., Rosenberg, L. C., Gaw, J. U., Gaw, J. U., Koob, T. J., and Neame, P. J. (1995) J. Biol. Chem. 270, 20516-20524). Interestingly, although we found that aggrecanase degraded both calf and steer cartilage aggrecan, the proportion of fragments generated by cleavage at the Glu(373)-Ala(374) bond was higher in steer than in calf, consistent with our observations using aggrecan treated to remove BS. me conclude that the GAG content of aggrecan influences the specificity of aggrecanase for cleavage at the Glu(373)-Ala(374) bond and suggest that age may be a factor in aggrecanase degradation of cartilage.	Dupont Merck Pharmaceut Co, Expt Stn E400 4237, Inflammatory Dis Res, Wilmington, DE 19880 USA	DuPont	Pratta, MA (corresponding author), Dupont Merck Pharmaceut Co, Expt Stn E400 4237, Inflammatory Dis Res, POB 80400, Wilmington, DE 19880 USA.	Michael.A.Pratta@dupontpharma.com						Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Arner EC, 1999, ANN NY ACAD SCI, V878, P92, DOI 10.1111/j.1749-6632.1999.tb07676.x; Arner EC, 1998, OSTEOARTHR CARTILAGE, V6, P214, DOI 10.1053/joca.1998.0114; Arner EC, 1999, J BIOL CHEM, V274, P6594, DOI 10.1074/jbc.274.10.6594; BARRY FP, 1995, J BIOL CHEM, V270, P20516, DOI 10.1074/jbc.270.35.20516; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; FOSANG AJ, 1995, BIOCHEM J, V310, P337, DOI 10.1042/bj3100337; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; FOSANG AJ, 1993, BIOCHEM J, V295, P273, DOI 10.1042/bj2950273; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; HARDINGHAM TE, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P5; HASCALL VC, 1982, METHOD ENZYMOL, V82, P769; HUANG JJ, 1987, MOL BIOL MED, V4, P169; Hughes CE, 1997, J BIOL CHEM, V272, P20269, DOI 10.1074/jbc.272.32.20269; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; HUTTON S, 1996, T ORTHOP RES SOC, V21, P150; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; MANKIN HJ, 1970, J BONE JOINT SURG AM, VA 52, P424, DOI 10.2106/00004623-197052030-00002; MARCY AI, 1991, BIOCHEMISTRY-US, V30, P6476, DOI 10.1021/bi00240a018; Mercuri FA, 1999, J BIOL CHEM, V274, P32387, DOI 10.1074/jbc.274.45.32387; OIKE Y, 1980, BIOCHEM J, V191, P203, DOI 10.1042/bj1910203; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; Sandy JD, 1995, ACTA ORTHOP SCAND, V66, P26, DOI 10.3109/17453679509157643; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; SANDY JD, 1991, J BIOL CHEM, V266, P8198; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; XUE CB, 1997, Patent No. 9718207	35	66	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39096	39102		10.1074/jbc.M006201200	http://dx.doi.org/10.1074/jbc.M006201200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10991945	hybrid			2022-12-25	WOS:000165953100022
J	Liochev, SI; Fridovich, I				Liochev, SI; Fridovich, I			Copper- and zinc-containing superoxide dismutase can act as a superoxide reductase and a superoxide oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; ESCHERICHIA-COLI; PULSE RADIOLYSIS; CU,ZN-SUPEROXIDE DISMUTASE; ENZYME; SENSITIVITY; MECHANISM	The copper- and zinc-containing superoxide dismutase can catalyze the oxidation of ferrocyanide by O-2(.-) as well as the reduction of ferricyanide by O-2(.-) Thus, it can act as a superoxide dismutase (SOD), a superoxide reductase (SOR), and a superoxide oxidase (SOO). The human manganese-containing SOD does not exert SOR or SOO activities with ferrocyanide or ferricyanide as the redox partners. It is possible that some biological reductants can take the place of ferrocyanide and can also interact with human manganese-containing superoxide dismutase, thus making the SOR activity a reality for both SODs. The consequences of this possibility vis a vis H2O2 production, the overproduction of SODs, and the role of copper- and zinc-containing superoxide dismutase mutations in causing familial amyotrophic lateral sclerosis are discussed, as well as the likelihood that the biologically effective SOD mimics, as described to date, actually function as SORs.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Fridovich, I (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.							AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; FRIDOVICH I, 1958, J BIOL CHEM, V233, P1581; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; Jovanovic T, 2000, J BIOL CHEM, V275, P28439, DOI 10.1074/jbc.M003314200; KEELE BB, 1970, J BIOL CHEM, V245, P6176; KLUG D, 1972, J BIOL CHEM, V247, P4839; Liochev SI, 1997, J BIOL CHEM, V272, P25573, DOI 10.1074/jbc.272.41.25573; Lombard M, 2000, J BIOL CHEM, V275, P27021; Lombard M, 2000, J BIOL CHEM, V275, P115, DOI 10.1074/jbc.275.1.115; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Offer T, 2000, FASEB J, V14, P1215, DOI 10.1096/fasebj.14.9.1215; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P465, DOI 10.1016/0891-5849(90)90123-Z; ROTILIO G, 1973, BIOCHIM BIOPHYS ACTA, V302, P229, DOI 10.1016/0005-2744(73)90151-4; ROTILIO G, 1972, BIOCHIM BIOPHYS ACTA, V268, P605, DOI 10.1016/0005-2744(72)90359-2; SCHELLENBERG KA, 1958, J BIOL CHEM, V231, P547; SCOTT MD, 1989, J BIOL CHEM, V264, P2498; WAUD WR, 1975, ARCH BIOCHEM BIOPHYS, V169, P695, DOI 10.1016/0003-9861(75)90214-3; YOST FJ, 1973, J BIOL CHEM, V248, P4905; Youn HD, 1996, BIOCHEM J, V318, P889, DOI 10.1042/bj3180889; ZEHAVI D, 1972, J PHYS CHEM-US, V76, P3703, DOI 10.1021/j100669a006	23	78	79	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38482	38485		10.1074/jbc.M007891200	http://dx.doi.org/10.1074/jbc.M007891200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11005823	hybrid			2022-12-25	WOS:000165739800047
J	Nakayama, Y; Peng, T; Sands, JM; Bagnasco, SM				Nakayama, Y; Peng, T; Sands, JM; Bagnasco, SM			The TonE/TonEBP pathway mediates tonicity-responsive regulation of UT-A urea transporter expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDOSE REDUCTASE GENE; TRANSCRIPTION; CLONING; RAT; STRESS; INDUCTION; ELEMENT	The rat renal urea transporter UT-A includes four isoforms. UT-A1, UT-A3, and UT-A4 are transcribed from a single initiation site at the 5'-end of the gene; a distinct internal initiation site is used for UT-A2 transcription. We cloned 1.3 kilobases (kb) of the 5'-flanking region upstream of the transcription start site of UT-A1, UT-A3, and UT-A4. This region contains three CCAAT sequences but lacks a TATA motif, A tonicity-responsive enhancer (TonE) was identified at -377bp. The 1.3-kb full fragment subcloned into pGL3 vector induced luciferase activity in Madin-Darby canine kidney cells and in mouse inner medullary collecting duct cells in isotonic medium. Luciferase activity was increased significantly in hypertonic medium, whereas deletion or mutation of the TonE sequence abolished this response. Electrophoretic mobility shift assay using the 5' UT-A TonE sequence as DNA probe showed formation of a specific DNA-protein complex with nuclear extracts from cells exposed to hypertonic medium and was weakly detectable in isotonic controls. A supershift in the mobility of the DNA-protein complex was observed with antiserum targeted to the TonE-binding protein (TonEBP). Cotransfection with dominant-negative TonEBP abolished the luciferase activity induced by the UT-A 1.3-kb construct under hypertonic and isotonic conditions. These data suggest that the TonE/TonEBP pathway mediates tonicity-responsive transcriptional regulation of UT-A1, UT-A3, and UT-A4 expression.	Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Div Renal, Dept Med, Atlanta, GA 30322 USA	Emory University; Emory University	Bagnasco, SM (corresponding author), Emory Univ, Sch Med, Dept Pathol, WMB Rm 7105 A,1639 Pierce Dr NE, Atlanta, GA 30322 USA.				NIDDK NIH HHS [P01DK50268, R01DK41707, R01DK53917, R01 DK041707] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041707, R01DK053917, P01DK050268] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGNASCO S, 1986, J BIOL CHEM, V261, P5872; Bagnasco SM, 2000, J AM SOC NEPHROL, V11, P1980, DOI 10.1681/ASN.V11111980; BAGNASCO SM, 1987, P NATL ACAD SCI USA, V84, P1718, DOI 10.1073/pnas.84.6.1718; CHA JH, 1999, J AM SCO NEPHROL, V10, pA51; Ferraris JD, 1996, J BIOL CHEM, V271, P18318, DOI 10.1074/jbc.271.31.18318; Furuno M, 1996, AM J PHYSIOL-RENAL, V271, pF854, DOI 10.1152/ajprenal.1996.271.4.F854; HAND SC, 1982, J BIOL CHEM, V257, P734; Karakashian A, 1999, J AM SOC NEPHROL, V10, P230; Leroy C, 2000, BIOCHEM BIOPH RES CO, V271, P368, DOI 10.1006/bbrc.2000.2640; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Miyakawa H, 1998, AM J PHYSIOL-RENAL, V274, pF753, DOI 10.1152/ajprenal.1998.274.4.F753; Rim JS, 1998, J BIOL CHEM, V273, P20615, DOI 10.1074/jbc.273.32.20615; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; Shayakul C, 1996, J CLIN INVEST, V98, P2580, DOI 10.1172/JCI119077; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; SMITH CP, 1995, J CLIN INVEST, V96, P1556, DOI 10.1172/JCI118194; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; Tian W, 2000, AM J PHYSIOL-CELL PH, V278, pC372, DOI 10.1152/ajpcell.2000.278.2.C372; UCHIDA S, 1993, J CLIN INVEST, V91, P1604, DOI 10.1172/JCI116367; Woo SK, 2000, AM J PHYSIOL-CELL PH, V278, pC323, DOI 10.1152/ajpcell.2000.278.2.C323; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; YAMNAUCHI A, 1993, AM J PHYSIOL, V264, pF20; Zhang Z, 1999, AM J PHYSIOL-RENAL, V276, pF786, DOI 10.1152/ajprenal.1999.276.5.F786	23	113	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38275	38280		10.1074/jbc.M004678200	http://dx.doi.org/10.1074/jbc.M004678200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10995747	hybrid			2022-12-25	WOS:000165739800021
J	Schmauss, C				Schmauss, C			A single dose of methamphetamine leads to a long term reversal of the blunted dopamine D-1 receptor-mediated neocortical c-fos responses in mice deficient for D-2 and D-3 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSYCHOMOTOR STIMULANT; MESSENGER-RNA; D1 RECEPTORS; EXPRESSION; FOREBRAIN; HALOPERIDOL; CLOZAPINE; LACKING; DRUGS	Dopamine D-1 receptors play an essential role in the induction of expression of the immediate-early gene c-fos in response to pharmacological stimuli. In the forebrain of wild-type mice, administration of a D-1 receptor agonist leads to c-fos mRNA expression levels that are substantially higher than corresponding levels expressed after indirect stimulation of dopamine receptors with methamphetamine. In mice deficient for D-2 and D-3 receptors, c-fos mRNA levels expressed in response to D-1 agonist administration are significantly blunted. However, a single dose of methamphetamine (5 mg/kg) leads to a long lasting reversal of the blunted c-fos responses in these mutants, In the forebrain, this reversal is restricted to the neocortex. Moreover, methamphetamine also enhances c-fos expression levels in preadolescent wild-type mice that normally express low c-fos mRNA in response to D-1 agonist stimulation. Thus, a single dose of methamphetamine leads to a long term increase in D-1 receptor-dependent c-fos responses in brains with either low (preadolescent mice) or blunted (adult D-2 and D-3 mutant mice) c-fos expression levels. A similar long term reversal of the blunted c-fos responses is achieved with a single dose of a full D-1 agonist. These results indicate that the constitutive inactivation of D-2 and D-3 receptors leads to a decrease in agonist-promoted D-1 receptor activity that can be reversed by intermittent agonist stimulation.	Columbia Univ, NYSPI, Dept Psychiat & Neurosci, New York, NY 10032 USA; New York State Psychiat Inst, New York, NY 10032 USA	Columbia University; New York State Psychiatry Institute	Schmauss, C (corresponding author), Columbia Univ, NYSPI, Dept Psychiat & Neurosci, 1051 Riverside Dr,Box 42, New York, NY 10032 USA.				NIMH NIH HHS [MH56123] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH056123] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BALK JH, 1995, NATURE, V377, P424; Castner SA, 2000, SCIENCE, V287, P2020, DOI 10.1126/science.287.5460.2020; Curran EJ, 1996, NEUROCHEM RES, V21, P1425, DOI 10.1007/BF02532384; Fields RD, 1997, J NEUROSCI, V17, P7252; Harlan RE, 1998, MOL NEUROBIOL, V16, P221, DOI 10.1007/BF02741385; Jung MY, 1999, J BIOL CHEM, V274, P29406, DOI 10.1074/jbc.274.41.29406; Jung MY, 1999, NEUROSCIENCE, V91, P911, DOI 10.1016/S0306-4522(98)00705-2; MERCHANT KM, 1994, J PHARMACOL EXP THER, V271, P460; Moratalla R, 1996, P NATL ACAD SCI USA, V93, P14928, DOI 10.1073/pnas.93.25.14928; Okubo Y, 1997, NATURE, V385, P634, DOI 10.1038/385634a0; ROBERTSON GS, 1992, NEUROSCIENCE, V46, P315, DOI 10.1016/0306-4522(92)90054-6; SCHMAUSS C, 1989, NUCLEIC ACIDS RES, V17, P1733, DOI 10.1093/nar/17.4.1733; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; Vanderschuren LJMJ, 1999, J NEUROSCI, V19, P9579, DOI 10.1523/jneurosci.19-21-09579.1999; WILLIAMS GV, 1995, NATURE, V376, P572, DOI 10.1038/376572a0; Xu M, 1997, NEURON, V19, P837, DOI 10.1016/S0896-6273(00)80965-4	16	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38944	38948		10.1074/jbc.M005064200	http://dx.doi.org/10.1074/jbc.M005064200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11007776	hybrid			2022-12-25	WOS:000165739800109
J	Bloch, W; Huggel, K; Sasaki, T; Grose, R; Bugnon, P; Addicks, K; Timpl, R; Werner, S				Bloch, W; Huggel, K; Sasaki, T; Grose, R; Bugnon, P; Addicks, K; Timpl, R; Werner, S			The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing	FASEB JOURNAL			English	Article									ETH Honggerberg, Inst Cell Biol, Swiss Fed Inst Technol, CH-8093 Zurich, Switzerland; Univ Cologne, Inst Anat, D-50931 Cologne, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Cologne; Max Planck Society	Werner, S (corresponding author), ETH Honggerberg, Inst Cell Biol, Swiss Fed Inst Technol, CH-8093 Zurich, Switzerland.			Werner, Sabine/0000-0001-7397-8710; Grose, Richard/0000-0002-4738-0173					0	140	149	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2373	2376						4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11024009				2022-12-25	WOS:000165723400002
J	Feng, W; Liu, GH; Allen, PD; Pessah, IN				Feng, W; Liu, GH; Allen, PD; Pessah, IN			Transmembrane redox sensor of ryanodine receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; INOSITOL TRISPHOSPHATE; GLUTATHIONE DISULFIDE; MOLECULAR INTERACTION; FUNCTIONAL-ROLE; NITRIC-OXIDE; SKELETAL; DEHYDROASCORBATE; SULFHYDRYLS; ACTIVATION	Inositol 1,4,5-trisphosphate receptors (IP3R) and ryanodine receptors (RyR) mediate the release of endoplasmic and sarcoplasmic reticulum (ER/SR) Ca2+ stores and regulate Ca2+ entry through voltage-dependent or ligand-gated channels of the plasma membrane. A prominent property of ER/SR Ca2+ channels is exquisite sensitivity to sulfhydryl-modifying reagents. A plausible role for sulfhydryl chemistry in physiologic regulation of Ca2+ release channels and the fidelity of Ca2+ release from ER/SR is lacking. This study reveals the existence of a transmembrane redox sensor within the RS RI channel complex that confers tight regulation of channel activity in response to changes in transmembrane redox potential produced by cytoplasmic and luminal glutathione, A transporter selective for glutathione is co-localized with RyR1 within the SR membrane to maintain local redox potential gradients consistent with redox regulation of ER/SR Ca2+ release. Hyperreactive sulfhydryls previously shown to reside within the RyR1 complex (Liu, G., and Pessah, I. N. (1994) J, Biol, Chem. 269, 33028-33034) are an essential biochemical component of a transmembrane redox sensor. Transmembrane redox sensing may represent a fundamental mechanism by which ER/SR Ca2+ channels respond to localized changes in transmembrane glutathione redox potential produced by physiologic and pathophysiologic modulators of Ca2+ release from stores.	Univ Calif Davis, Dept Mol Biosci, Sch Vet Med, Davis, CA 95616 USA; Brigham & Womens Hosp, Dept Anesthesia, Boston, MA 02114 USA	University of California System; University of California Davis; Harvard University; Brigham & Women's Hospital	Pessah, IN (corresponding author), Univ Calif Davis, Dept Mol Biosci, Sch Vet Med, 1 Shield Ave, Davis, CA 95616 USA.	inpessah@ucdavis.edu	Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043140] Funding Source: NIH RePORTER; NIAMS NIH HHS [4PO1 AR17605, 5RO1 AR43140] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAMSON JJ, 1989, J BIOENERG BIOMEMBR, V21, P283, DOI 10.1007/BF00812073; Aghdasi B, 1997, J BIOL CHEM, V272, P25462, DOI 10.1074/jbc.272.41.25462; Banhegyi G, 1998, J BIOL CHEM, V273, P2758, DOI 10.1074/jbc.273.5.2758; Banhegyi G, 1997, J BIOL CHEM, V272, P13584, DOI 10.1074/jbc.272.21.13584; Banhegyi G, 1999, J BIOL CHEM, V274, P12213, DOI 10.1074/jbc.274.18.12213; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Dulhunty A, 2000, ANTIOXID REDOX SIGN, V2, P27, DOI 10.1089/ars.2000.2.1-27; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Feng W, 1999, MOL PHARMACOL, V55, P821; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JOSEPH SK, 1995, J BIOL CHEM, V270, P3588, DOI 10.1074/jbc.270.8.3588; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; LIU GH, 1994, J BIOL CHEM, V269, P33028; LIU GH, 1994, MOL PHARMACOL, V45, P189; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Marengo JJ, 1998, BIOPHYS J, V74, P1263, DOI 10.1016/S0006-3495(98)77840-3; MEISSNER G, 1988, METHOD ENZYMOL, V157, P417; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; Murayama T, 1999, J BIOL CHEM, V274, P17297, DOI 10.1074/jbc.274.24.17297; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Oba T, 2000, BIOPHYS J, V78, p123A; Pessah IN, 2000, ANTIOXID REDOX SIGN, V2, P17, DOI 10.1089/ars.2000.2.1-17; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; Salama G, 2000, ANTIOXID REDOX SIGN, V2, P5, DOI 10.1089/ars.2000.2.1-5; Sen CK, 1998, BIOCHEM PHARMACOL, V55, P1747, DOI 10.1016/S0006-2952(97)00672-2; Senft AP, 2000, ANAL BIOCHEM, V280, P80, DOI 10.1006/abio.2000.4498; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; Vanlingen S, 1999, CELL CALCIUM, V25, P107, DOI 10.1054/ceca.1998.0010; WELLS WW, 1990, J BIOL CHEM, V265, P15361; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Zable AC, 1997, J BIOL CHEM, V272, P7069, DOI 10.1074/jbc.272.11.7069	34	123	126	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35902	35907		10.1074/jbc.C000523200	http://dx.doi.org/10.1074/jbc.C000523200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10998414	hybrid			2022-12-25	WOS:000165382000038
J	Roth, W; Deussing, J; Botchkarev, VA; Pauly-Evers, M; Saftig, P; Hafner, A; Schmidt, P; Schmahl, W; Scherer, J; Anton-Lamprecht, I; Von Figura, K; Paus, R; Peters, C				Roth, W; Deussing, J; Botchkarev, VA; Pauly-Evers, M; Saftig, P; Hafner, A; Schmidt, P; Schmahl, W; Scherer, J; Anton-Lamprecht, I; Von Figura, K; Paus, R; Peters, C			Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling	FASEB JOURNAL			English	Article						epidermal hyperplasia; hair follicle development; lysosomal cysteine proteinase	CYSTEINE PROTEASE INHIBITORS; AMINO-ACID SEQUENCES; MHC CLASS-II; GROWTH-FACTOR; FUNCTIONAL EXPRESSION; REGRESSION CATAGEN; ENZYMATIC CHARACTERIZATION; CHROMOSOMAL LOCALIZATION; TISSUE DISTRIBUTION; LYMPHOID-CELLS	Lysosomal cysteine proteinases of the papain family are involved in lysosomal bulk proteolysis, major histocompatibility complex class II mediated antigen presentation, prohormone processing, and extracellular matrix remodeling. Cathepsin L (CTSL) is a ubiquitously expressed major representative of the papain-like family of cysteine proteinases. To investigate CTSL in vivo functions, the gene was inactivated by gene targeting in embryonic stem cells. CTSL-deficient mice develop periodic hair loss and epidermal hyperplasia, acanthosis, and hyperkeratosis. The hair loss is due to alterations of hair follicle morphogenesis and cycling, dilatation of hair follicle canals, and disturbed club hair formation. Hyperproliferation of hair follicle epithelial cells and basal epidermal keratinocytes-both of ectodermal origin-are the primary characteristics underlying the mutant phenotype. Pathological inflammatory responses have been excluded as a putative cause of the skin and hair disorder. The phenotype of CTSL-deficient mice is reminiscent of the spontaneous mouse mutant furless (fs). Analyses of the cfsl gene of fs mice revealed a G149R mutation inactivating the proteinase activity. CTSL is the first lysosomal proteinase shown to be essential for epidermal homeostasis id regular hair follicle morphogenesis and cycling.	Univ Freiburg, Inst Mol Med & Zellforsch, D-79106 Freiburg, Germany; Humboldt Univ, Charite, Hautklin, D-10117 Berlin, Germany; Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Biochem Abt 2, D-37073 Gottingen, Germany; Univ Munich, Tierarztliche Fak, D-80539 Munich, Germany; Univ Heidelberg, Hautklin, Inst Ultrastrukturforsch Haut, D-69115 Heidelberg, Germany	University of Freiburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Gottingen; University of Munich; Ruprecht Karls University Heidelberg	Peters, C (corresponding author), Univ Freiburg, Inst Mol Med & Zellforsch, Hugstetter Str 55, D-79106 Freiburg, Germany.		Paus, Ralf/F-6243-2011; Deussing, Jan M/ABB-5993-2021; Saftig, Paul/A-7966-2010	Botchkarev, Vladimir/0000-0002-5212-5353; Deussing, Jan/0000-0002-9329-5252				ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; BANDO Y, 1986, J BIOCHEM-TOKYO, V100, P35, DOI 10.1093/oxfordjournals.jbchem.a121703; BARRETT AJ, 1992, ANN NY ACAD SCI, V674, P1; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BERTI PJ, 1995, J MOL BIOL, V246, P273, DOI 10.1006/jmbi.1994.0083; Blake JA, 1997, NUCLEIC ACIDS RES, V25, P85, DOI 10.1093/nar/25.1.85; Botchkarev VA, 1998, AM J PATHOL, V153, P785, DOI 10.1016/S0002-9440(10)65621-0; Botchkarev VA, 1998, J INVEST DERMATOL, V111, P279, DOI 10.1046/j.1523-1747.1998.00277.x; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; Bromme D, 1999, BIOCHEMISTRY-US, V38, P2377, DOI 10.1021/bi982175f; BRYCE SD, 1994, GENOMICS, V24, P568, DOI 10.1006/geno.1994.1667; CALKINS CC, 1995, BIOL CHEM H-S, V376, P71; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; CHAUHAN SS, 1993, J BIOL CHEM, V268, P1039; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Deussing J, 1997, MAMM GENOME, V8, P241, DOI 10.1007/s003359900401; FAN YS, 1989, CYTOGENET CELL GENET, V51, P996; Fuchs E, 1995, ANNU REV CELL DEV BI, V11, P123, DOI 10.1146/annurev.cb.11.110195.001011; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; FUCHS R, 1989, NUCLEIC ACIDS RES, V17, P9471, DOI 10.1093/nar/17.22.9471; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; Gerdes Johannes, 1997, European Journal of Cell Biology, V72, P88; GREEN EL, 1954, J HERED, V45, P115, DOI 10.1093/oxfordjournals.jhered.a106453; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; HANDJISKI BK, 1994, BRIT J DERMATOL, V131, P303, DOI 10.1111/j.1365-2133.1994.tb08515.x; HANSEN LS, 1984, ANAT REC, V210, P569, DOI 10.1002/ar.1092100404; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Janeway CA., 2001, IMMUNOBIOLOGY IMMUNE, V5th edition; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; KATUNUMA N, 1995, METHOD ENZYMOL, V251, P382, DOI 10.1016/0076-6879(95)51142-3; KIRSCHKE H, 1987, LYSOSOMES THEIR ROLE, P193; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Laufer TM, 1996, NATURE, V383, P81, DOI 10.1038/383081a0; LI LN, 1992, IN VITRO CELL DEV-AN, V28A, P695; Lindner G, 1997, AM J PATHOL, V151, P1601; Linnevers C, 1997, FEBS LETT, V405, P253, DOI 10.1016/S0014-5793(97)00118-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; LYONS K, 1989, P NATL ACAD SCI USA, V86, P4554, DOI 10.1073/pnas.86.12.4554; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; Nakagawa TY, 1999, IMMUNITY, V10, P207, DOI 10.1016/S1074-7613(00)80021-7; OWNES JW, 1975, ARCH BIOCHEM BIOPHYS, V166, P258; PARIS A, 1995, FEBS LETT, V369, P326, DOI 10.1016/0014-5793(95)00777-7; Paus R, 1997, J INVEST DERMATOL, V109, P518, DOI 10.1111/1523-1747.ep12336635; PAUS R, 1994, J INVEST DERMATOL, V103, P143, DOI 10.1111/1523-1747.ep12392542; PAUS R, 1994, BRIT J DERMATOL, V130, P174, DOI 10.1111/j.1365-2133.1994.tb02896.x; PAUS R, 1994, BRIT J DERMATOL, V130, P281, DOI 10.1111/j.1365-2133.1994.tb02922.x; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; PAUS R, 1996, CURR OPIN DERMATOL, V3, P248; Pelsue SC, 1998, EUR J IMMUNOL, V28, P1379, DOI 10.1002/(SICI)1521-4141(199804)28:04<1379::AID-IMMU1379>3.0.CO;2-3; PHILPOTT MF, 1998, MOL BIOL SKIN APPEND; PILZ A, 1995, GENOMICS, V25, P139, DOI 10.1016/0888-7543(95)80119-7; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Santamaria I, 1998, CANCER RES, V58, P1624; Santamaria I, 1998, J BIOL CHEM, V273, P16816, DOI 10.1074/jbc.273.27.16816; SCHUERMANN M, 1990, NUCLEIC ACIDS RES, V18, P4945, DOI 10.1093/nar/18.16.4945; SHAW E, 1980, BIOCHEM J, V186, P385, DOI 10.1042/bj1860385; Shi GP, 1999, IMMUNITY, V10, P197, DOI 10.1016/S1074-7613(00)80020-5; STENN K, 1998, MOL BASIS EPITHELIAL; Stenn KS, 1996, DERMATOL CLIN, V14, P543, DOI 10.1016/S0733-8635(05)70383-1; STRAILE WE, 1961, J EXP ZOOL, V148, P205, DOI 10.1002/jez.1401480304; Sundberg, 1994, HDB MOUSE MUTATIONS; Sundberg JP., 1994, HDB MOUSE MUTATIONS, P57; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Tisljar K, 1999, FEBS LETT, V459, P299, DOI 10.1016/S0014-5793(99)01263-6; TROEN BR, 1987, BIOCHEM J, V246, P731, DOI 10.1042/bj2460731; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; VELASCO G, 1994, J BIOL CHEM, V269, P27136; VIELKIND U, 1995, ACTA ANAT, V152, P93; Wang B, 1998, J BIOL CHEM, V273, P32000, DOI 10.1074/jbc.273.48.32000	77	264	271	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					2075	2086		10.1096/fj.99-0970com	http://dx.doi.org/10.1096/fj.99-0970com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023992				2022-12-25	WOS:000089634400027
J	Rusnati, M; Taraboletti, G; Urbinati, C; Tulipano, G; Giuliani, R; Molinari-Tosatti, MP; Sennino, B; Giacca, M; Tyagi, M; Albini, A; Noonan, D; Giavazzi, R; Presta, M				Rusnati, M; Taraboletti, G; Urbinati, C; Tulipano, G; Giuliani, R; Molinari-Tosatti, MP; Sennino, B; Giacca, M; Tyagi, M; Albini, A; Noonan, D; Giavazzi, R; Presta, M			Thrombospondin-1/HIV-1 Tat protein interaction: modulation of the biological activity of extracellular Tat	FASEB JOURNAL			English	Article						AIDS; extracellular matrix; angiogenesis; oncogenesis	IMMUNODEFICIENCY-VIRUS TYPE-1; HEPARAN-SULFATE PROTEOGLYCANS; VASCULAR ENDOTHELIAL-CELLS; FIBROBLAST GROWTH-FACTOR; HIV-1 TAT; KAPOSIS-SARCOMA; TRANSGENIC MICE; IN-VITRO; TYROSINE PHOSPHORYLATION; PLATELET THROMBOSPONDIN	Tat protein, a trans-activating factor of the human immunodeficiency virus type 1, acts also as an extracellular molecule modulating gene expression, cell survival, growth, transformation, and angiogenesis. Here we demonstrate that human thrombospondin-1 (TSP), a plasma glycoprotein and constituent of the extracellular matrix, binds to glutathione-S-transferase (GST)-Tat protein but not to GST. Scatchard plot analysis of the binding of free GST-Tat to immobilized TSP reveals a high-affinity interaction (K-d equal to 25 nM). Accordingly, TSP inhibits cell internalization and HIV-1 LTR trans-activating activity of extracellular Tat in HL3T1 cells with ID50 equal to 10-30 nM. Also, TSP inhibits cell interaction and mitogenic activity of extracellular Tat in T53 Tat-less cells. TSP is instead ineffective when administered after the interaction of Tat with cell surface heparan-sulfate proteoglycans has occurred, in keeping with its ability to prevent but not disrupt Tat/heparin interaction in vitro. Finally, TSP inhibits the autocrine loop of stimulation exerted by endogenous Tat in parental T53 cells. Accordingly, TSP overexpression inhibits cell proliferation, angiogenic activity, and tumorigenic capacity of stable T53 transfectants. Our data demonstrate the ability of TSP to bind to Tat protein and to affect its LTR trans-activating, mitogenic, angiogenic, and tumorigenic activity. These findings suggest that TSP may be implicated in the progression of AIDS and in AIDS-associated pathologies by modulating the bioavailability and biological activity of extracellular Tat.	Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Chair Gen Pathol & Immunol, I-25123 Brescia, Italy; Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Unit Histol & Cytol, I-25123 Brescia, Italy; Ist Ric Farmacol Mario Negri, I-24125 Bergamo, Italy; Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Ist Nazl Ric Canc, I-16132 Genoa, Italy	University of Brescia; University of Brescia; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; International Center for Genetic Engineering & Biotechnology (ICGEB); University of Genoa; IRCCS AOU San Martino IST	Presta, M (corresponding author), Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Chair Gen Pathol & Immunol, Via Valsabbina 19, I-25123 Brescia, Italy.		Giavazzi, Raffaella/J-7424-2018; Giacca, Mauro/J-9287-2016; Giavazzi, Raffaella/ABB-9768-2020; Noonan, Douglas M/A-8620-2010; Rusnati, Marco/F-1168-2010; Presta, Marco/B-4345-2010; Taraboletti, Giulia/J-4089-2018	Giacca, Mauro/0000-0003-2927-7225; Giavazzi, Raffaella/0000-0001-5249-8208; Noonan, Douglas M/0000-0001-8058-0719; Rusnati, Marco/0000-0001-9968-5908; Taraboletti, Giulia/0000-0001-8780-5001; Albini, Adriana/0000-0002-9624-5103; PRESTA, Marco/0000-0002-4398-8376; Urbinati, Chiara Eva/0000-0002-0138-7871				ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004; Albini A, 1996, ONCOGENE, V12, P289; Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; ALBO D, 1994, BIOCHEM BIOPH RES CO, V203, P857, DOI 10.1006/bbrc.1994.2262; Auvinen M, 1997, CANCER RES, V57, P3016; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Bleuel K, 1999, P NATL ACAD SCI USA, V96, P2065, DOI 10.1073/pnas.96.5.2065; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; Cafaro A, 1999, NAT MED, V5, P643, DOI 10.1038/9488; CAMPIONI D, 1995, AIDS RES HUM RETROV, V11, P1039, DOI 10.1089/aid.1995.11.1039; Castle VP, 1997, LAB INVEST, V77, P51; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; CORALLINI A, 1993, CANCER RES, V53, P5569; Corallini A, 1996, AIDS, V10, P701, DOI 10.1097/00002030-199606001-00003; Crombie R, 1998, J EXP MED, V187, P25, DOI 10.1084/jem.187.1.25; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Demarchi F, 1996, J VIROL, V70, P4427, DOI 10.1128/JVI.70.7.4427-4437.1996; ElSolh A, 1997, IMMUNOL INVEST, V26, P351, DOI 10.3109/08820139709022692; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; Ensoli B, 1998, CRIT REV ONCOGENESIS, V9, P107, DOI 10.1615/CritRevOncog.v9.i2.20; Gallo RC, 1998, SCIENCE, V282, P1837, DOI 10.1126/science.282.5395.1837; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GIBELLINI D, 1995, BRIT J HAEMATOL, V89, P24, DOI 10.1111/j.1365-2141.1995.tb08915.x; Gibellini D, 1998, J IMMUNOL, V160, P3891; GOLDER H, 1996, ARION, V4, P1; Hamy F, 1998, BIOCHEMISTRY-US, V37, P5086, DOI 10.1021/bi972947s; HAVERSTICK DM, 1984, BIOCHEMISTRY-US, V23, P5597, DOI 10.1021/bi00318a033; HOGG PJ, 1994, THROMB HAEMOSTASIS, V72, P787; Hogg PJ, 1997, BIOCHEM J, V326, P709, DOI 10.1042/bj3260709; Holme PA, 1998, FASEB J, V12, P79, DOI 10.1096/fasebj.12.1.79; Incardona F, 1996, J CELL BIOCHEM, V62, P431, DOI 10.1002/(SICI)1097-4644(19960915)62:4<431::AID-JCB1>3.0.CO;2-N; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; JEANG KT, 1996, HUMAN RETROVIRUSES A; Kaaya EE, 1996, HISTOPATHOLOGY, V29, P337, DOI 10.1111/j.1365-2559.1996.tb01417.x; KIM CM, 1992, ONCOGENE, V7, P1525; Lamszus K, 1996, AM J PATHOL, V149, P805; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; LONGO F, 1995, BIOCHEM BIOPH RES CO, V206, P326, DOI 10.1006/bbrc.1995.1045; Lyon M, 1997, J BIOL CHEM, V272, P18000, DOI 10.1074/jbc.272.29.18000; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; MCCROHAN MB, 1987, THROMB HAEMOSTASIS, V58, P850; Menegon A, 1997, BIOCHEM BIOPH RES CO, V238, P800, DOI 10.1006/bbrc.1997.7393; Milani D, 1996, J BIOL CHEM, V271, P22961, DOI 10.1074/jbc.271.38.22961; Milani D, 1998, AIDS, V12, P1275, DOI 10.1097/00002030-199811000-00008; Mitola S, 1997, BLOOD, V90, P1365, DOI 10.1182/blood.V90.4.1365.1365_1365_1372; MOSHER DF, 1990, ANNU REV MED, V41, P85; MOULIGNIER A, 1994, CANCER, V74, P686, DOI 10.1002/1097-0142(19940715)74:2<686::AID-CNCR2820740222>3.0.CO;2-K; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; NICOSIA RF, 1994, J CELL BIOL, V124, P183, DOI 10.1083/jcb.124.1.183; POTASH MJ, 1992, BIOCHEM BIOPH RES CO, V189, P250, DOI 10.1016/0006-291X(92)91551-Z; Ribatti D, 1999, J PATHOL, V189, P590; ROBERTS DD, 1988, CANCER RES, V48, P6785; Rusnati M, 1997, AIDS, V11, P727, DOI 10.1097/00002030-199706000-00005; Rusnati M, 1998, J BIOL CHEM, V273, P16027, DOI 10.1074/jbc.273.26.16027; Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198; Rusnati M, 1996, INT J CLIN LAB RES, V26, P15, DOI 10.1007/BF02644769; Rusnati M, 1997, J BIOL CHEM, V272, P11313, DOI 10.1074/jbc.272.17.11313; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHON P, 1992, EUR J CELL BIOL, V59, P329; SCHWARTZ S, 1990, J VIROL, V64, P2519, DOI 10.1128/JVI.64.6.2519-2529.1990; SHEIBANI N, 1995, P NATL ACAD SCI USA, V92, P6788, DOI 10.1073/pnas.92.15.6788; Shugars DC, 1999, J INFECT DIS, V179, pS431, DOI 10.1086/314799; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Streit M, 1999, AM J PATHOL, V155, P441, DOI 10.1016/S0002-9440(10)65140-1; TARABOLETTI G, 1992, LAB INVEST, V67, P566; Taraboletti G, 1999, J PATHOL, V188, P76, DOI 10.1002/(SICI)1096-9896(199905)188:1<76::AID-PATH312>3.0.CO;2-A; Taraboletti G, 1997, CELL GROWTH DIFFER, V8, P471; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TORNESELLO ML, 1993, INTERVIROLOGY, V36, P57, DOI 10.1159/000150322; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; VOGEL J, 1991, CANCER RES, V51, P6686; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; WRIGHT CM, 1986, SCIENCE, V234, P988, DOI 10.1126/science.3490693; Wu ZH, 1998, AM J PATHOL, V152, P1599; YABKOWITZ R, 1989, J BIOL CHEM, V264, P10888; Zagury J F, 1998, J Hum Virol, V1, P282	82	25	26	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					1917	1930		10.1096/fj.99-0902com	http://dx.doi.org/10.1096/fj.99-0902com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023976				2022-12-25	WOS:000089634400011
J	Fenstermaker, RA; Ciesielski, MJ				Fenstermaker, RA; Ciesielski, MJ			Deletion and tandem duplication of exons 2-7 in the epidermal growth factor receptor gene of a human malignant glioma	ONCOGENE			English	Article						epidermal growth factor receptor; EGFR-vIII; glioma; oncogene; recombination; V(D)J	HUMAN GLIOBLASTOMA CELLS; CONFERS ENHANCED TUMORIGENICITY; CENTRAL-NERVOUS-SYSTEM; EGF-RECEPTOR; TYROSINE KINASE; FACTOR-ALPHA; EXPRESSION; TRANSFORMATION; AMPLIFICATION; RECOMBINATION	The epidermal growth factor receptor (EGFR) gene is frequently amplified and rearranged in malignant gliomas with expression of oncogenic deletion mutants (DM). The most common mutant EGFRvIII, which contains a deletion of exons 2-7, is constitutively autophosphorylated and inefficiently do downregulated. Other less common EGFR mRNA species in gliomas contain tandem duplication of exons, which encode the tyrosine kinase (TK) and calcium mediated receptor internalization (CAIN) domains of the molecule. We examined a panel of human malignant gliomas and found one tumor that expressed four related EGFR proteins, including 125-, 140-, 170-, and 180-kDa species. This tumor also contained four EGFR-related mRNA species, including both wild type EGFR and EGFRvIII transcripts. A third transcript contained a deletion of exons 2-7 and 12-13 corresponding to the 125-kDa protein. A fourth transcript contained an in-frame, tandem duplication of exons 2-7 (EGFR,TDM/2-7). The 180-kDa, tandem duplication mutant (TDM) exhibited enhanced basal phosphorylation and impaired downregulation, In contrast to the 140-kDa EGFRvIII; however, phosphorylation of the 180-kDa EGFR.TDM/2-7 was strongly induced by ligand, Expression of both deletion and tandem duplication mutants in the same tumor suggests that the mechanisms responsible for DM and TDM formation might be closely related.	Roswell Pk Canc Inst, Dept Neurosurg, Buffalo, NY 14263 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Neurosurg, Buffalo, NY 14209 USA	Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Fenstermaker, RA (corresponding author), Roswell Pk Canc Inst, Dept Neurosurg, Elm & Carlton St, Buffalo, NY 14263 USA.				NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16056-22] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKI T, 1991, BIOCHEM BIOPH RES CO, V181, P151, DOI 10.1016/S0006-291X(05)81394-4; Bailin T, 1999, MOL CELL BIOL, V19, P4664; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; BIGNER SH, 1990, CANCER RES, V50, P8017; BLASBAND AJ, 1990, ONCOGENE, V5, P1213; CALLAGHAN T, 1993, ONCOGENE, V8, P2939; Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; Ciesielski MJ, 2000, ONCOGENE, V19, P810, DOI 10.1038/sj.onc.1203409; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; Fenstermaker RA, 1998, ONCOGENE, V16, P3435, DOI 10.1038/sj.onc.1202156; Frederick L, 2000, CANCER RES, V60, P1383; Frisa PS, 1996, CELL GROWTH DIFFER, V7, P223; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; HUMPHREY PA, 1991, BIOCHEM BIOPH RES CO, V178, P1413, DOI 10.1016/0006-291X(91)91051-D; HUMPHREY PA, 1988, CANCER RES, V48, P2231; LEBEAU MM, 1986, ADV HUM GENET, V15, P1; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MARUNO M, 1991, J NEUROSURG, V75, P97, DOI 10.3171/jns.1991.75.1.0097; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; Moscatello DK, 1996, ONCOGENE, V13, P85; Nagane M, 1996, CANCER RES, V56, P5079; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; PANNEERSELVAM K, 1995, EUR J BIOCHEM, V230, P951, DOI 10.1111/j.1432-1033.1995.tb20641.x; SCHLEGEL J, 1994, INT J CANCER, V56, P72; STECK PA, 1988, CANCER RES, V48, P5433; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; TASHIRO S, 1994, ONCOGENE, V9, P1939; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; WYATT RT, 1992, J EXP MED, V175, P1575, DOI 10.1084/jem.175.6.1575	36	18	24	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4542	4548		10.1038/sj.onc.1203802	http://dx.doi.org/10.1038/sj.onc.1203802			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002427				2022-12-25	WOS:000089236800011
J	Liu, SH; Spinner, DS; Schmidt, MM; Danielsson, JA; Wang, SW; Schmidt, J				Liu, SH; Spinner, DS; Schmidt, MM; Danielsson, JA; Wang, SW; Schmidt, J			Interaction of MyoD family proteins with enhancers of acetylcholine receptor subunit genes in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-CELL CULTURES; E-BOX ELEMENTS; ELECTRICAL-ACTIVITY; MYOGENIC FACTORS; SKELETAL-MUSCLE; DENERVATION SUPERSENSITIVITY; DEPENDENT EXPRESSION; EPSILON-SUBUNIT; TRANSGENIC MICE; BINDING-SITE	The myogenic determination factors (MDFs) are transcriptional activators that target E boxes in many muscle-specific promoters, including those of the genes coding for the subunits of the acetylcholine receptor. It is not known, however, if in vivo a given E box in a transcriptionally active gene is occupied, either uniquely by one MDF or randomly by all MDFs. We have analyzed expression of MDF and acetylcholine receptor subunits in cultured mouse muscle cells and, using chromatin immunoprecipitation, have determined which individual MDFs reside at promoters of several receptor subunit genes. We find that before fusion, C2C12 cells express myf-5, MyoD, and myogenin, all of which take up residence at promoters of all subunits except epsilon. At this stage, herculin is present in limited amounts and is detected mainly at the gamma and delta subunit genes. On myotube formation, herculin reaches high levels; concomitantly, the epsilon subunit gene becomes a common MDF target and beans to be expressed, In general, any MDF protein that is expressed also is present on transcriptionally active receptor genes; transcriptional activity of target genes correlates with occupancy by MDF, in particular, herculin.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Schmidt, J (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Life Sci Bldg,Rm 412, Stony Brook, NY 11794 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020233] Funding Source: NIH RePORTER; NINDS NIH HHS [NS20233] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arnold HH, 1996, INT J DEV BIOL, V40, P345; BERBERICH C, 1993, EUR J BIOCHEM, V216, P395, DOI 10.1111/j.1432-1033.1993.tb18157.x; BESSEREAU JL, 1994, P NATL ACAD SCI USA, V91, P1304, DOI 10.1073/pnas.91.4.1304; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLOCK NE, 1992, MOL CELL BIOL, V12, P2484, DOI 10.1128/MCB.12.6.2484; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BRUNETTI A, 1990, J BIOL CHEM, V265, P5960; BUONANNO A, 1992, NUCLEIC ACIDS RES, V20, P539, DOI 10.1093/nar/20.3.539; DAUBAS P, 1988, NUCLEIC ACIDS RES, V16, P1251, DOI 10.1093/nar/16.4.1251; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCLERT A, 1991, NEUROREPORT, V2, P25, DOI 10.1097/00001756-199101000-00006; DURR I, 1994, EUR J BIOCHEM, V224, P353, DOI 10.1111/j.1432-1033.1994.00353.x; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; Fromm L, 1998, GENE DEV, V12, P3074, DOI 10.1101/gad.12.19.3074; GILMOUR BP, 1991, J BIOL CHEM, V266, P19871; GUNDERSEN K, 1995, MOL CELL BIOL, V15, P7127; HAUSCHKA SD, 1994, MYOLOGY BASIC CLIN, V1, P3; Hughes SM, 1997, MECH DEVELOP, V61, P151, DOI 10.1016/S0925-4773(96)00631-4; JIA HT, 1992, CELL MOL NEUROBIOL, V12, P241, DOI 10.1007/BF00712929; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; MONTARRAS D, 1991, NEW BIOL, V3, P592; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; Neville C, 1996, DEV GENET, V19, P157, DOI 10.1002/(SICI)1520-6408(1996)19:2<157::AID-DVG7>3.0.CO;2-8; Neville CM, 1998, J BIOL CHEM, V273, P14046, DOI 10.1074/jbc.273.22.14046; NEVILLE CM, 1992, CELL MOL NEUROBIOL, V12, P511, DOI 10.1007/BF00711232; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; PRODY CA, 1991, J BIOL CHEM, V266, P22588; PRODY CA, 1992, NUCLEIC ACIDS RES, V20, P2367, DOI 10.1093/nar/20.9.2367; Schaeffer L, 1998, EMBO J, V17, P3078, DOI 10.1093/emboj/17.11.3078; SUNYER T, 1993, J NEUROSCI RES, V36, P224, DOI 10.1002/jnr.490360213; VOYTIK SL, 1993, DEV DYNAM, V198, P214, DOI 10.1002/aja.1001980307; WANG Y, 1988, NEURON, V1, P527, DOI 10.1016/0896-6273(88)90183-3; WITZEMANN V, 1991, FEBS LETT, V282, P259, DOI 10.1016/0014-5793(91)80490-T; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; ZHOU JM, 1994, MOL CELL BIOL, V14, P6232, DOI 10.1128/MCB.14.9.6232; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898	36	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41364	41368		10.1074/jbc.M004172200	http://dx.doi.org/10.1074/jbc.M004172200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024014	hybrid			2022-12-25	WOS:000166114600093
J	Ng, DCH; Bogoyevitch, MA				Ng, DCH; Bogoyevitch, MA			The mechanism of heat shock activation of ERK mitogen-activated protein kinases in the interleukin 3-dependent ProB cell line BaF3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; EPIDERMAL GROWTH-FACTOR; RAS-DEPENDENT ACTIVATION; OKADAIC ACID; DIFFERENTIAL REGULATION; TYROSINE PHOSPHATASES; HEMATOPOIETIC-CELLS; CARDIAC MYOCYTES; RECEPTOR-BINDING; MAP KINASES	We have investigated heat shock stimulation of MAPK cascades in an interleukin 3-dependent cell line, BaF3. Following exposure to 42 degreesC, the stress-activated JNK MAPKs were phosphorylated and activated, but p38 MAPKs remained unaffected. Surprisingly, heat shock also activated ERK MAPKs in a potent (>60-fold), delayed (>30 min), and sustained (greater than or equal to 120 min) manner. These characteristics suggested a novel mechanism of ERK MAPK activation and became the focus of this study. A MEK-specific inhibitor, PD98059, inhibited heat shock ERK MAPK activation by >75%. Surprisingly, a role for Ras in the heat shock response was eliminated by the failure of a dominant-negative Ras(Asn-17) mutant to inhibit ERK MAPK activation and the failure to observe increases in Ras GTP. Heat shock also failed to stimulate activation of A-, B-, and c-Raf. Instead, a serine/threonine phosphatase inhibitor, okadaic acid, activated ERK MAPK in a similar manner to heat shock. Furthermore, pretreatment with suramin, generally recognized as abroad range inhibitor of growth factor receptors, inhibited both okadaic acid-stimulated and heat shock-stimulated ERK MAPK activity by >40%. Inhibiting ERK MAPK activation during heat shock with PD98059 enhanced losses in cell viability. These results demonstrate Ras- and Raf-independent ERK MAPK activation maintains cell viability following heat shock.	Univ Western Australia, Dept Biochem, Nedlands, WA 6907, Australia; Western Australian Inst Med Res, Perth, WA 6000, Australia	University of Western Australia; University of Western Australia	Bogoyevitch, MA (corresponding author), Univ Western Australia, Dept Biochem, Nedlands, WA 6907, Australia.		Ng, Dominic/C-7291-2015	Ng, Dominic/0000-0003-4657-159X; Bogoyevitch, Marie/0000-0001-9745-3716				Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Andersson MB, 1998, BIOCHEM BIOPH RES CO, V251, P328, DOI 10.1006/bbrc.1998.9476; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BENDINELLI P, 1995, BIOCHEM BIOPH RES CO, V216, P54, DOI 10.1006/bbrc.1995.2591; Benjamin IJ, 1998, CIRC RES, V83, P117, DOI 10.1161/01.RES.83.2.117; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; CANO E, 1995, J CELL SCI, V108, P3599; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CASILLAS AM, 1993, BIOCHEM J, V290, P545, DOI 10.1042/bj2900545; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; CHEN F, 1995, BIOCHEM J, V312, P341, DOI 10.1042/bj3120341; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DUBOIS MF, 1993, FEBS LETT, V324, P191, DOI 10.1016/0014-5793(93)81391-C; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Finlay D, 2000, CELL DEATH DIFFER, V7, P302, DOI 10.1038/sj.cdd.4400652; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; GRAZIOLI L, 1992, INT J IMMUNOPHARMACO, V14, P637, DOI 10.1016/0192-0561(92)90125-5; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Han SI, 2000, CELL BIOL INT, V24, P447, DOI 10.1006/cbir.2000.0512; Hu YH, 1997, J BIOL CHEM, V272, P9113; Kim Y, 1997, J CELL BIOCHEM, V67, P43, DOI 10.1002/(SICI)1097-4644(19971001)67:1<43::AID-JCB5>3.0.CO;2-W; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Krady MM, 1998, FEBS LETT, V434, P241, DOI 10.1016/S0014-5793(98)00989-2; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Li S, 1999, J ORTHOP RES, V17, P891, DOI 10.1002/jor.1100170614; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Muda M, 1996, J BIOL CHEM, V271, P4319; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Ping PP, 1999, AM J PHYSIOL-HEART C, V276, pH1468, DOI 10.1152/ajpheart.1999.276.5.H1468; RAMPAL AL, 1995, J BIOL CHEM, V270, P3938, DOI 10.1074/jbc.270.8.3938; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; ROBINS HI, 1995, CANCER LETT, V97, P195, DOI 10.1016/0304-3835(95)03976-4; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STEIN CA, 1993, CANCER RES, V53, P2239; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; van der Wijk T, 1998, BIOCHEM J, V331, P863, DOI 10.1042/bj3310863; Vigh L, 1998, TRENDS BIOCHEM SCI, V23, P369, DOI 10.1016/S0968-0004(98)01279-1; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhang YL, 1998, J BIOL CHEM, V273, P12281, DOI 10.1074/jbc.273.20.12281; Zhao ZZ, 1996, J BIOL CHEM, V271, P22251, DOI 10.1074/jbc.271.36.22251; Zhuang SG, 2000, AM J PHYSIOL-CELL PH, V278, pC102, DOI 10.1152/ajpcell.2000.278.1.C102	60	40	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40856	40866		10.1074/jbc.M004639200	http://dx.doi.org/10.1074/jbc.M004639200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11005808	hybrid			2022-12-25	WOS:000166114600027
J	Ludwig, MG; Bassett, P; Anglard, P				Ludwig, MG; Bassett, P; Anglard, P			Multiple regulatory elements in the murine stromelysin-3 promoter - Evidence for direct control by CCAAT/enhancer-binding protein beta and thyroid and retinoid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; MOUSE MAMMARY-GLAND; MATRIX METALLOPROTEINASE; BREAST-CARCINOMA; ACID RECEPTORS; TRANSCRIPTIONAL ACTIVATION; ATHEROSCLEROTIC LESIONS; HORMONE RECEPTORS; GENE-EXPRESSION; MESSENGER-RNA	Stromelysin-3 (ST3) belongs to the matrix metalloproteinase (MMPs) family, a protease family involved in tissue remodeling. Although this family of enzymes is regulated by nuclear receptors, few hormone-responsive elements have been demonstrated in MMP promoters. In order to identify regulatory elements and/or factors that control the expression of the mouse st3 gene, we have analyzed genomic sequences encompassing 5 kilobase pairs of the ST3 promoter. Analysis of these sequences revealed several CCAAT/enhancer-binding proteins (C/EBP) and retinoic acid-responsive elements (RAREs), as well as one thyroid-responsive element. However, in contrast to most MMP promoters, no AP-1-binding sites were identified. Specific binding activities were demonstrated for all elements. Consistent with previous reports, retinoid X receptor is required for maximal binding to the ST3 RAREs and the TRE. The ST3-C/EBP element was shown to mediate dose-dependent promoter activation by C/EBP beta, Among the RAREs, the proximal DR1-RARE was shown to be sufficient for ST3 promoter activation by ligand-bound retinoid receptors, whereas the two distal DR2-RAREs appear to be involved more in the control of base-line promoter activity. Accordingly, ST3 expression was induced by retinoic acid and was reduced in cells where specific retinoic acid receptors had been inactivated. The involvement of these conserved regulatory elements is discussed in the context of physiological or pathological situations associated with st3 expression. Our findings therefore assign to C/EBP, retinoids, and thyroid hormone important roles in the regulation of ST3 gene expression.	Univ Strasbourg 1, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France; CU Strasbourg, Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Anglard, P (corresponding author), Univ Strasbourg 1, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch, France.		Anglard, Patrick/M-6618-2019	Anglard, Patrick/0000-0001-5701-441X				Agarwal C, 1999, J BIOL CHEM, V274, P6190, DOI 10.1074/jbc.274.10.6190; Ahmad A, 1998, AM J PATHOL, V152, P721; ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; ANDERSON IC, 1995, CANCER RES, V55, P4120; ANGLARD P, 1995, J BIOL CHEM, V270, P20337, DOI 10.1074/jbc.270.35.20337; ASTROM A, 1994, J BIOL CHEM, V269, P22334; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; Chenard MP, 1996, INT J CANCER, V69, P448, DOI 10.1002/(SICI)1097-0215(19961220)69:6<448::AID-IJC5>3.3.CO;2-4; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; Chiba H, 1997, J CELL BIOL, V139, P735, DOI 10.1083/jcb.139.3.735; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Doyle GAR, 1997, J BIOL CHEM, V272, P11840, DOI 10.1074/jbc.272.18.11840; Dupe V, 1999, DEV BIOL, V208, P30, DOI 10.1006/dbio.1998.9176; FUTREAL PA, 1992, CANCER RES, V52, P2624; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; Ghyselinck NB, 1997, INT J DEV BIOL, V41, P425; Guerin E, 1997, J BIOL CHEM, V272, P11088; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; KLAMPFER L, 1994, MOL CELL BIOL, V14, P6561, DOI 10.1128/MCB.14.10.6561; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; LEFEBVRE O, 1995, DEVELOPMENT, V121, P947; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Li JW, 1998, NUCLEIC ACIDS RES, V26, P3018, DOI 10.1093/nar/26.12.3018; LOPEZBARAHONA M, 1995, EMBO J, V14, P1145, DOI 10.1002/j.1460-2075.1995.tb07098.x; Luo DC, 1999, J BIOL CHEM, V274, P37177, DOI 10.1074/jbc.274.52.37177; Maquoi E, 1997, PLACENTA, V18, P277, DOI 10.1016/S0143-4004(97)80062-8; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Noel AC, 1996, J CLIN INVEST, V97, P1924, DOI 10.1172/JCI118624; Okada A, 1997, J CELL BIOL, V137, P67, DOI 10.1083/jcb.137.1.67; OSTEEN KG, 1994, P NATL ACAD SCI USA, V91, P10129, DOI 10.1073/pnas.91.21.10129; PATTERTON D, 1995, DEV BIOL, V167, P252, DOI 10.1006/dbio.1995.1021; POLETTE M, 1993, PATHOL RES PRACT, V189, P1052; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; Puzianowska-Kuznicka M, 1997, MOL CELL BIOL, V17, P4738, DOI 10.1128/MCB.17.8.4738; RANJAN M, 1994, J BIOL CHEM, V269, P24699; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; Rodriguez-Leon J, 1999, NAT CELL BIOL, V1, P125, DOI 10.1038/10098; Sabatakos G, 1998, BIOCHEM J, V334, P205, DOI 10.1042/bj3340205; Schonbeck U, 1999, J EXP MED, V189, P843, DOI 10.1084/jem.189.5.843; SCHRADER M, 1994, DNA CELL BIOL, V13, P333, DOI 10.1089/dna.1994.13.333; Schroen DJ, 1996, GENE EXPRESSION, V6, P197; SELLITTI DF, 1983, CANCER RES, V43, P1030; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Taneja R, 1996, P NATL ACAD SCI USA, V93, P6197, DOI 10.1073/pnas.93.12.6197; Unden AB, 1996, J INVEST DERMATOL, V107, P147, DOI 10.1111/1523-1747.ep12329541; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; XIE B, 1994, J IMMUNOL, V152, P3637; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x	56	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39981	39990		10.1074/jbc.M007529200	http://dx.doi.org/10.1074/jbc.M007529200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10993903	hybrid			2022-12-25	WOS:000166039500027
J	Pate, P; Mochca-Morales, J; Wu, YJ; Zhang, JZ; Rodney, GG; Serysheva, II; Williams, BY; Anderson, ME; Hamilton, SL				Pate, P; Mochca-Morales, J; Wu, YJ; Zhang, JZ; Rodney, GG; Serysheva, II; Williams, BY; Anderson, ME; Hamilton, SL			Determinants for calmodulin binding on voltage-dependent Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(1C) SUBUNIT; CALCIUM CHANNELS; CA2+-SENSITIVE INACTIVATION; SKELETAL-MUSCLE; MOTIF; INHIBITION; PROTEINS; SEQUENCE	Calmodulin, bound to the alpha (1) subunit of the cardiac L-type calcium channel, is required for calcium-dependent inactivation of this channel. Several laboratories have suggested that the site of interaction of calmodulin with the channel is an IQ-Like motif in the carboxyl-terminal region of the cu, subunit. Mutations in this IQ motif are linked to L-type Ca2+ current (I-Ca) facilitation and inactivation. IQ peptides from L, P/Q, N, and R channels all bind Ca2+ calmodulin but not Ca2+-free calmodulin. Another peptide representing a carboxyl-terminal sequence found only in L-type channels (designated the CB domain) binds Ca2+ calmodulin and enhances Ca2+ dependent Ic, facilitation in cardiac myocytes, suggesting the CB domain is functionally important. Calmodulin blocks the binding of an antibody specific for the CB sequence to the skeletal muscle L-type Ca2+ channel, suggesting that this is a calmodulin binding site on the intact protein. The binding of the IQ and CB peptides to calmodulin appears to be competitive, signifying that the two sequences represent either independent or alternative binding sites for calmodulin rather than both sequences contributing to a single binding site.	Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; Vanderbilt Univ, Med Ctr,Sch Med, Dept Med, Div Cardiol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA	Baylor College of Medicine; Vanderbilt University; Vanderbilt University	Hamilton, SL (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, 1 Baylor Plaza, Houston, TX 77030 USA.			Hamilton, Susan/0000-0003-0241-9369	NIAMS NIH HHS [AR44864] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044864] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adams B, 1997, J GEN PHYSIOL, V110, P379, DOI 10.1085/jgp.110.4.379; Bernatchez G, 1998, BIOPHYS J, V75, P1727, DOI 10.1016/S0006-3495(98)77614-3; BERS DM, 1994, METHOD CELL BIOL, V40, P3; CALLAWAY C, 1994, J BIOL CHEM, V269, P15876; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; Gao TY, 2000, J BIOL CHEM, V275, P25436, DOI 10.1074/jbc.M003465200; Gerhardstein BL, 2000, J BIOL CHEM, V275, P8556, DOI 10.1074/jbc.275.12.8556; HADLEY RW, 1991, J PHYSIOL-LONDON, V444, P257, DOI 10.1113/jphysiol.1991.sp018876; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAMILTON SL, 1989, BIOCHEMISTRY-US, V28, P7820, DOI 10.1021/bi00445a044; Hofer GF, 1997, BIOPHYS J, V73, P1857, DOI 10.1016/S0006-3495(97)78216-X; Kepplinger KJF, 2000, FEBS LETT, V477, P161, DOI 10.1016/S0014-5793(00)01791-9; KRETSINGER RH, 1976, ANNU REV BIOCHEM, V45, P239, DOI 10.1146/annurev.bi.45.070176.001323; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; MARBAN E, 1982, J PHYSIOL-LONDON, V329, P589, DOI 10.1113/jphysiol.1982.sp014321; Mukherjea P, 1996, PROTEIN SCI, V5, P468; Peterson BZ, 2000, BIOPHYS J, V78, P1906, DOI 10.1016/S0006-3495(00)76739-7; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Soldatov NM, 1998, J BIOL CHEM, V273, P957, DOI 10.1074/jbc.273.2.957; Wu YJ, 1999, AM J PHYSIOL-HEART C, V276, pH2168, DOI 10.1152/ajpheart.1999.276.6.H2168; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301; Zuhlke RD, 2000, J BIOL CHEM, V275, P21121, DOI 10.1074/jbc.M002986200; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	27	118	119	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39786	39792		10.1074/jbc.M007158200	http://dx.doi.org/10.1074/jbc.M007158200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11005820	hybrid			2022-12-25	WOS:000165953100111
J	Repa, JJ; Lund, EG; Horton, JD; Leitersdorf, E; Russell, DW; Dietschy, JM; Turley, SD				Repa, JJ; Lund, EG; Horton, JD; Leitersdorf, E; Russell, DW; Dietschy, JM; Turley, SD			Disruption of the sterol 27-hydroxylase gene in mice results in hepatomegaly and hypertriglyceridemia - Reversal by cholic acid feeding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYMETHYLGLUTARYL-COA REDUCTASE; BILE-ACID; CEREBROTENDINOUS XANTHOMATOSIS; CHOLESTEROL; METABOLISM; BIOSYNTHESIS; RATES; HYPERCHOLESTEROLEMIA; CHOLESTYRAMINE; CIRCULATION	Sterol 27-hydroxylase (CYP27) participates in the conversion of cholesterol to bile acids, We examined lipid metabolism in mice lacking the Cyp27 gene. On normal rodent chow, Cyp27(-/-) mice have 40% larger livers, 45% larger adrenals, a-fold higher hepatic and plasma triacylglycerol concentrations, a 70% higher rate of hepatic fatty acid synthesis, and a 70% increase in the ratio of oleic to stearic acid in the liver versus Cyp27(+/+) controls, In Cyp27(-/-) mice, cholesterol 7 alpha -hydroxylase activity is increased B-fold, but bile acid synthesis and pool size are 47 and 27%, respectively, of those in Cyp27(+/+) mice, Intestinal cholesterol, absorption decreases from 54 to 4% in knockout mice, while fecal neutral sterol excretion increases 2.5-fold, A compensatory 2.5-fold increase in whole body cholesterol synthesis occurs in Cyp27(-/-) mice, principally in liver, adrenal, small intestine, lung, and spleen. The mRNA for the cholesterogenic transcription factor sterol regulatory element-binding protein-2 (SREBP-2) and mRNAs for SREBP-2-regulated cholesterol biosynthetic genes are elevated in livers of mutant mice. In addition, the mRNAs encoding the lipogenic transcription factor SREBP-1 and SREBP-1-regulated monounsaturated fatty acid biosynthetic enzymes are also increased. Hepatic synthesis of fatty acids and accumulation of triacylglycerols increases in Cyp27-/- mice and is associated with hypertriglyceridemia. Cholic acid feeding reverses hepatomegaly and hypertriglyceridemia but not adrenomegaly in Cyp27(-/-) mice, These studies confirm the importance of CYP27 in bile acid synthesis and they reveal an unexpected function of the enzyme in triacylglycerol metabolism.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Pharmacol, Dallas, TX 75390 USA; Hadassah Univ Hosp, Ctr Res Prevent & Treatment Atherosclerosis, Dept Med, IL-91120 Jerusalem, Israel	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Hebrew University of Jerusalem	Turley, SD (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Repa, Joyce/0000-0001-5740-1954; Russell, David/0000-0002-0277-403X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, R37HL009610, R01HL009610] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 09610, HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Babiker A, 1999, J LIPID RES, V40, P1417; BEIL U, 1982, METABOLISM, V31, P438, DOI 10.1016/0026-0495(82)90231-1; BJORKHEM I, 1992, J LIPID RES, V33, P455; BJORKHEM I, 1995, METABOLIC MOL BASES, V2, P2073; del Castillo-Olivares A, 2000, J BIOL CHEM, V275, P17793, DOI 10.1074/jbc.M000996200; DOBS AS, 1995, CARDIOVASC DRUG THER, V9, P677, DOI 10.1007/BF00878550; Duane WC, 1999, J LIPID RES, V40, P1194; ESTERMAN AL, 1983, J LIPID RES, V24, P1304; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Honda A, 1999, HEPATOLOGY, V30, p320A; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; Li-Hawkins J, 2000, J BIOL CHEM, V275, P16543, DOI 10.1074/jbc.M001810200; Li-Hawkins J, 2000, J BIOL CHEM, V275, P16536, DOI 10.1074/jbc.M001811200; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; LUND E, 1992, J BIOL CHEM, V267, P25092; MEIJER GW, 1989, ARTERY, V16, P286; MOLGAARD J, 1989, EUR J CLIN PHARMACOL, V36, P455, DOI 10.1007/BF00558069; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; RENNERT H, 1990, ENDOCRINOLOGY, V127, P738, DOI 10.1210/endo-127-2-738; Repa JJ, 1999, CURR OPIN BIOTECH, V10, P557, DOI 10.1016/S0958-1669(99)00031-2; Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SALEN G, 1973, J CLIN INVEST, V52, P2822, DOI 10.1172/JCI107478; SALEN G, 1985, J CLIN INVEST, V76, P744, DOI 10.1172/JCI112030; SALEN G, 1971, ANN INTERN MED, V75, P843, DOI 10.7326/0003-4819-75-6-843; Schwarz M, 1998, J LIPID RES, V39, P1833; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; TURLEY SD, 1981, J LIPID RES, V22, P551; TURLEY SD, 1994, J LIPID RES, V35, P328; Turley SD, 1999, HEPATOLOGY, V30, p320A; Turley SD, 1998, HEPATOLOGY, V28, P1088, DOI 10.1002/hep.510280425; TURLEY SD, 1988, LIVER BIOL PATHOBIOL, P617; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8	34	161	168	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39685	39692		10.1074/jbc.M007653200	http://dx.doi.org/10.1074/jbc.M007653200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11001949	hybrid			2022-12-25	WOS:000165953100097
J	Treves, S; Feriotto, G; Moccagatta, L; Gambari, R; Zorzato, F				Treves, S; Feriotto, G; Moccagatta, L; Gambari, R; Zorzato, F			Molecular cloning, expression, functional characterization, chromosomal localization, and gene structure of junctate, a novel integral calcium binding protein of sarco(endo)plasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL SARCOPLASMIC-RETICULUM; RABBIT SKELETAL-MUSCLE; CA-2+ RELEASE CHANNEL; RYANODINE RECEPTOR; DIHYDROPYRIDINE RECEPTOR; MALIGNANT HYPERTHERMIA; TERMINAL CISTERNAE; CA2+ RELEASE; CALSEQUESTRIN; OVEREXPRESSION	Screening a cDNA library from human skeletal muscle and cardiac muscle with a cDNA probe derived from junctin led to the isolation of two groups of cDNA clones, The first group displayed a deduced amino acid sequence that is 84% identical to that of dog heart junctin, whereas the second group had a single open reading frame that encoded a polypeptide with a predicted mass of 33 kDa, whose first 78 NH2-terminal residues are identical to junctin whereas its COOH terminus domain is identical to aspartyl beta -hydroxylase, a member of the alpha -ketoglutarate-dependent dioxygenase family. We named the latter amino acid sequence junctate, Northern blot analysis indicates that junctate is expressed in a variety of human tissues including heart, pancreas, brain, lung, liver, kidney, and skeletal muscle, Fluorescence in situ hybridization analysis revealed that the genetic loci of junctin and junctate map to the same cytogenetic band oh human chromosome 8, Analysis of intron/exon boundaries of the genomic BAC clones demonstrate that junctin, junctate, and aspartyl beta -hydroxylase result from alternative splicing of the same gene. The predicted lumenal portion of junctate is enriched in negatively charged residues and is able to bind calcium. Scatchard analysis of equilibrium Ca-45(2+) binding in the presence of a physiological concentration of KCl demonstrate that junctate binds 21.0 mol of Ca2+/mol protein with a k(D) of 217 +/- 20 muM (n = 5), Tagging recombinant junctate with green fluorescent protein and expressing the chimeric polypeptide in COS-7-transfected cells indicates that junctate is located in endoplasmic reticulum membranes and that its presence increases the peak amplitude and transient calcium released by activation of surface membrane receptors coupled to InsP(3) receptor activation. Our study shows that alternative splicing of the same gene generates the following functionally distinct proteins: an enzyme (aspartyl beta -hydroxylase), a structural protein of SR (junctin), and a membrane-bound calcium binding protein (junctate).	Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy; Kantonsspital, Dept Anaesthesia, CH-4031 Basel, Switzerland; Kantonsspital, Dept Res, CH-4031 Basel, Switzerland; Univ Ferrara, Ctr Biotechnol, I-44100 Ferrara, Italy; Univ Ferrara, Dept Biochem & Mol Biol, I-44100 Ferrara, Italy	University of Ferrara; Kantonsspital Aarau AG (KSA); University of Basel; Kantonsspital Aarau AG (KSA); University of Basel; University of Ferrara; University of Ferrara	Zorzato, F (corresponding author), Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, Via Borsari 46, I-44100 Ferrara, Italy.	zor@dns.unife.it	Gambari, Roberto/F-9555-2015	Gambari, Roberto/0000-0001-9205-6033; Treves, Susan/0000-0002-0007-9631	Telethon [908] Funding Source: Medline	Telethon(Fondazione Telethon)		ANDERSON K, 1995, J GEN PHYSIOL, V105, P363, DOI 10.1085/jgp.105.3.363; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; CASWELL AH, 1985, J BIOL CHEM, V260, P6892; Celio MR, 1996, GUIDEBOOK CALCIUM BI; Censier K, 1998, J CLIN INVEST, V101, P1233, DOI 10.1172/JCI993; CHU A, 1990, MOL PHARMACOL, V37, P735; COSTELLO B, 1986, J CELL BIOL, V103, P741, DOI 10.1083/jcb.103.3.741; Damiani E, 1997, CELL CALCIUM, V22, P129, DOI 10.1016/S0143-4160(97)90113-5; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIARMSTRONG C, 1987, J CELL BIOL, V105, P49, DOI 10.1083/jcb.105.1.49; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; GIROTTI M, 1992, BIOCHEM J, V281, P203, DOI 10.1042/bj2810203; Goetz J, 1996, J BIOL CHEM, V271, P29589, DOI 10.1074/jbc.271.47.29589; Grassel S, 1999, EUR J BIOCHEM, V263, P471, DOI 10.1046/j.1432-1327.1999.00523.x; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; GUO W, 1994, J BIOL CHEM, V269, P28359; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; Jones LR, 1998, J CLIN INVEST, V101, P1385, DOI 10.1172/JCI1362; Jones LR, 1995, J BIOL CHEM, V270, P30787, DOI 10.1074/jbc.270.51.30787; KAWASAKI T, 1994, BIOCHEM BIOPH RES CO, V199, P1120, DOI 10.1006/bbrc.1994.1347; KIM DH, 1988, BIOCHIM BIOPHYS ACTA, V945, P246, DOI 10.1016/0005-2736(88)90486-5; KIM KC, 1990, BIOCHEMISTRY-US, V29, P9281, DOI 10.1021/bi00491a025; Korenberg JR, 1999, GENOME RES, V9, P994, DOI 10.1101/gr.9.10.994; KORIOTH F, 1994, GENE, V150, P395, DOI 10.1016/0378-1119(94)90460-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LAMB GD, 1986, J PHYSIOL-LONDON, V376, P85, DOI 10.1113/jphysiol.1986.sp016143; Lavaissiere L, 1996, J CLIN INVEST, V98, P1313, DOI 10.1172/JCI118918; LIU GH, 1994, J BIOL CHEM, V269, P33028; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNAN DH, 1992, SCIENCE, V256, P789, DOI 10.1126/science.1589759; MacLennan DH, 1998, NAT STRUCT BIOL, V5, P409, DOI 10.1038/nsb0698-409; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; MARTY I, 1994, P NATL ACAD SCI USA, V91, P2270, DOI 10.1073/pnas.91.6.2270; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MELZER W, 1995, BBA-REV BIOMEMBRANES, V1241, P59, DOI 10.1016/0304-4157(94)00014-5; MENEGAZZI P, 1994, BIOCHEMISTRY-US, V33, P9078, DOI 10.1021/bi00197a008; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Mickelson JR, 1996, PHYSIOL REV, V76, P537, DOI 10.1152/physrev.1996.76.2.537; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; Murray BE, 1997, BIOCHEM J, V324, P689, DOI 10.1042/bj3240689; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; PESSAH IN, 1990, MOL PHARMACOL, V37, P503; Pinton P, 1998, BIOFACTORS, V8, P243, DOI 10.1002/biof.5520080312; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SLUPSKY JR, 1987, BIOCHEMISTRY-US, V26, P6539, DOI 10.1021/bi00394a038; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TREVES S, 1990, BIOCHEM J, V271, P473, DOI 10.1042/bj2710473; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	54	74	80	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39555	39568		10.1074/jbc.M005473200	http://dx.doi.org/10.1074/jbc.M005473200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11007777	hybrid			2022-12-25	WOS:000165953100082
J	Chen, MC; Hsu, TL; Luh, TY; Hsieh, SL				Chen, MC; Hsu, TL; Luh, TY; Hsieh, SL			Overexpression of Bcl-2 enhances LIGHT- and interferon-gamma-mediated apoptosis in Hep3BT2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR SUPERFAMILY; NECROSIS-FACTOR FAMILY; HERPESVIRUS ENTRY MEDIATOR; LYMPHOTOXIN BETA-RECEPTOR; ALPHA-INDUCED APOPTOSIS; NEWLY IDENTIFIED MEMBER; HUMAN HEPATOMA-CELLS; GROWTH-FACTOR-BETA; CYTOCHROME-C; TNF FAMILY	LIGHT is a member of the tumor necrosis factor superfamily and is the Ligand for LT-betaR, HVEM, and decoy receptor 3. LIGHT has a cytotoxic effect, which is further enhanced by the presence of interferon-gamma (IFN-gamma). Although LIGHT/IFN-gamma can activate caspase activity, neither benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethylketone nor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone can completely inhibit LIGHT/IFN-gamma -mediated apoptosis. Moreover, overexpression of Bcl-2 further enhances LIGHT/IFN-gamma -mediated apoptosis. It appears that LIGHT and IFN-gamma act synergistically to activate caspase-3, with the resultant cleavage of Bcl-2, removal of the BH4 domain, leading to conversion of Bcl-2 from an antiapoptotic to a proapoptotic form in p53-deficient hepatocellular carcinoma Hep3BT2 cells. Thus, LIGHT seems to be able to override the protective effect of Bcl-2 and induce cell death. Although benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethylketone and benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone can prevent the cleavage of Bcl-2 by LIGHT/IFN-gamma they only partially inhibit apoptosis in Hep3BT2 cells that are overexpressing Bcl-2. In contrast, both LIGHT/IFN-gamma -mediated apoptosis and Bcl-2 cleavage are inhibited by free radical scavengers, indicating that free radicals may play an essential role in LIGHT/IFN-gamma -mediated apoptosis at a step upstream of caspase-3 activation. These results suggest that LIGHT signaling may diverge into multiple, separate processes.	Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 11221, Taiwan; Natl Yang Ming Univ, Dept Immunol & Microbiol, Taipei 11221, Taiwan; Natl Taiwan Univ, Dept Chem, Taipei 11221, Taiwan; Natl Yang Ming Univ, Immunol Res Ctr, Taipei 11221, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Taiwan University; National Yang Ming Chiao Tung University	Hsieh, SL (corresponding author), Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 11221, Taiwan.	slhsieh@ym.edu.tw	Hsieh, Shie-Liang Edmond/ABA-9184-2021; Hsu, Tsui-Ling/AAE-8821-2019; Hsu, Tsui-Ling/H-6704-2015	Hsu, Tsui-Ling/0000-0002-2912-3261; Luh, Tien-Yau/0000-0002-0415-6454				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Brustugun OT, 1998, CELL DEATH DIFFER, V5, P660, DOI 10.1038/sj.cdd.4400399; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; COSSARIZZA A, 1995, EXP CELL RES, V220, P232, DOI 10.1006/excr.1995.1311; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; Deas O, 1998, J IMMUNOL, V161, P3375; DegliEsposti MA, 1997, J IMMUNOL, V158, P1756; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434; Eby MT, 2000, J BIOL CHEM, V275, P15336, DOI 10.1074/jbc.275.20.15336; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Ettinger R, 1996, P NATL ACAD SCI USA, V93, P13102, DOI 10.1073/pnas.93.23.13102; Fadeel B, 1999, LEUKEMIA, V13, P719, DOI 10.1038/sj.leu.2401411; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; GRUSS HJ, 1995, CYTOKINES MOL THER, V1, P75; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; Hirotani M, 1999, J BIOL CHEM, V274, P20415, DOI 10.1074/jbc.274.29.20415; HIRSCH A, 1994, ANGEW CHEM INT EDIT, V33, P437, DOI 10.1002/anie.199404371; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; Hsu SC, 1998, BLOOD, V91, P2658, DOI 10.1182/blood.V91.8.2658.2658_2658_2663; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Huang YL, 1998, EUR J BIOCHEM, V254, P38, DOI 10.1046/j.1432-1327.1998.2540038.x; Huang YL, 1998, J BIOMED SCI, V5, P185; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Kasahara Y, 1997, BLOOD, V89, P1748, DOI 10.1182/blood.V89.5.1748.1748_1748_1753; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kohno T, 1996, J IMMUNOL, V156, P4722; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; Kurokawa H, 1999, ONCOL REP, V6, P33; Kwon BS, 1999, J BIOL CHEM, V274, P6056, DOI 10.1074/jbc.274.10.6056; Kwon BS, 1997, J BIOL CHEM, V272, P14272, DOI 10.1074/jbc.272.22.14272; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LAMPARTH I, 1994, J CHEM SOC CHEM COMM, P1727, DOI 10.1039/c39940001727; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; Moore PA, 1999, SCIENCE, V285, P260, DOI 10.1126/science.285.5425.260; Mukhopadhyay A, 1999, J BIOL CHEM, V274, P15978, DOI 10.1074/jbc.274.23.15978; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANDSTROM PA, 1994, J LEUKOCYTE BIOL, V55, P221, DOI 10.1002/jlb.55.2.221; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Shu HB, 1999, J LEUKOCYTE BIOL, V65, P680, DOI 10.1002/jlb.65.5.680; Sidoti-de Fraisse C, 1998, ONCOGENE, V17, P1639, DOI 10.1038/sj.onc.1202094; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; Tamada K, 2000, NAT MED, V6, P283; Tanabe K, 1999, J BIOL CHEM, V274, P15725, DOI 10.1074/jbc.274.22.15725; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wang IC, 1999, J MED CHEM, V42, P4614, DOI 10.1021/jm990144s; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Xie KP, 1996, CANCER IMMUNOL IMMUN, V43, P109, DOI 10.1007/s002620050310; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Yu KY, 1999, J BIOL CHEM, V274, P13733, DOI 10.1074/jbc.274.20.13733; Yue TL, 1999, J BIOL CHEM, V274, P1479, DOI 10.1074/jbc.274.3.1479; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zhai YF, 1998, J CLIN INVEST, V102, P1142, DOI 10.1172/JCI3492; Zhai YF, 1999, FASEB J, V13, P181, DOI 10.1096/fasebj.13.1.181; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zheng TS, 2000, NAT BIOTECHNOL, V18, P717, DOI 10.1038/77276	79	42	49	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38794	38801		10.1074/jbc.M003292200	http://dx.doi.org/10.1074/jbc.M003292200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10993881	hybrid			2022-12-25	WOS:000165739800090
J	Yamauchi, H; Desgranges, P; Lecerf, L; Papy-Garcia, D; Tournaire, MC; Moczar, M; Loisance, D; Barritault, D				Yamauchi, H; Desgranges, P; Lecerf, L; Papy-Garcia, D; Tournaire, MC; Moczar, M; Loisance, D; Barritault, D			New agents for the treatment of infarcted myocardium	FASEB JOURNAL			English	Article									Univ Paris 12, UPRES CNRS 7053, CRRET Lab, F-94000 Creteil, France; Hop Henri Mondor, UPRES CNRS 7054, Assoc Claude Bernard, Ctr Rech Chirurg, F-94010 Creteil, France	Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Barritault, D (corresponding author), Univ Paris 12, UPRES CNRS 7053, CRRET Lab, Ave Gal Gaulle, F-94000 Creteil, France.			LECERF, LAURE/0000-0001-8342-5298					0	33	36	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2133	2134						2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11024002				2022-12-25	WOS:000165190800002
J	Sato, Y; Yamauchi, N; Takahashi, M; Sasaki, K; Fukaura, J; Neda, H; Fujii, S; Hirayama, M; Itoh, Y; Koshita, Y; Kogawa, K; Kato, J; Sakamaki, S; Niitsu, Y				Sato, Y; Yamauchi, N; Takahashi, M; Sasaki, K; Fukaura, J; Neda, H; Fujii, S; Hirayama, M; Itoh, Y; Koshita, Y; Kogawa, K; Kato, J; Sakamaki, S; Niitsu, Y			In vivo gene delivery to tumor cells by transferrin-streptavidin-DNA conjugate	FASEB JOURNAL			English	Article						plasmid DNA; gene therapy; transferrin receptor; tumor targeting; metastasis	RECEPTOR-MEDIATED ENDOCYTOSIS; PLASMID DNA; EXPRESSION; ADENOVIRUS; TRANSFECTION; CYTOTOXICITY; ENHANCEMENT; EFFICIENT; DIFFERENTIATION; PURIFICATION	To target disseminated tumors in vivo, transgenes [beta-galactosidase gene, green fluorescence protein (GFP) gene, herpes simplex virus thymidine kinase (HSV-TK)] were conjugated to transferrin (Tf) by a biotin-streptavidin bridging, which is stoichiometrically controllable, and Tf receptor (Tf-R) affinity chromatography, which selects Tf conjugates with intact receptor bindings sites from reacting with the linker. Tf-beta-galactosidase plasmid conjugate thus constructed was specifically transfected to human erythroleukemia cells (K562) via Tf-R without the aid of any lysosomotropic agents. The transfection efficiency of the conjugate was superior to those of lipofection (1% staining) and retroviral vector (5%) and slightly lower than that of adenovirus (70%). The high level of expression with our conjugate was confirmed using other tumor cells (M7609, TMK-1) whereas in normal diploid cells (HEL), which express low levels of Tf-R, expression was negligible. When GFP gene conjugates were systemically administered through the tail vein to nude mice subcutaneously inoculated with tumor, expression of GFP mRNA was found almost exclusively in tumors and to a much lesser extent in muscles, whereas GFP revealed by fluorescence microscopy was detected only in the former. To exploit a therapeutic applicability of this method, suicide gene therapy using Tf-HSV-TK gene conjugate for massively metastasized k562 tumors in severe combined immune-deficient mice was conducted, and a marked prolongation of survival and significant reduction of tumor burden were confirmed. Thus, this method could also be used for gene therapy to disseminated tumors.	Sapporo Med Univ, Sch Med, Dept Internal Med 4, Chuo Ku, Sapporo, Hokkaido 0608543, Japan	Sapporo Medical University	Niitsu, Y (corresponding author), Sapporo Med Univ, Sch Med, Dept Internal Med 4, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan.	niitsu@sapmed.ac.jp		KOSHITA, YOSHIKAZU/0000-0002-4597-9334; Sato, Yasushi/0000-0002-6776-4609				Ban N, 1996, CANCER RES, V56, P3577; BARABAS K, 1992, J BIOL CHEM, V267, P9437; BERGAMASCHI G, 1988, BRIT J HAEMATOL, V68, P379, DOI 10.1111/j.1365-2141.1988.tb04218.x; Cheng PW, 1996, HUM GENE THER, V7, P275, DOI 10.1089/hum.1996.7.3-275; COTTEN M, 1992, P NATL ACAD SCI USA, V89, P6094, DOI 10.1073/pnas.89.13.6094; COTTEN M, 1993, METHOD ENZYMOL, V217, P618; Cristiano RJ, 1996, CANCER GENE THER, V3, P49; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; FAULK WP, 1980, LANCET, V2, P390; FOSTER AC, 1985, NUCLEIC ACIDS RES, V13, P745; GATTER KC, 1983, J CLIN PATHOL, V36, P539, DOI 10.1136/jcp.36.5.539; GREEN NM, 1980, BIOCHEM J, V94, P1; Hirayama Y, 1998, BLOOD, V92, P46, DOI 10.1182/blood.V92.1.46.413k44_46_52; JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0; KARLSSON GB, 1991, ANAL BIOCHEM, V199, P219, DOI 10.1016/0003-2697(91)90093-9; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KOHGO Y, 1987, BLOOD, V70, P1955; KOHGO Y, 1990, JPN J CANCER RES, V81, P91, DOI 10.1111/j.1349-7006.1990.tb02512.x; Kuan CT, 1996, BIOCHEMISTRY-US, V35, P2872, DOI 10.1021/bi952047g; Kuriyama S, 1995, HEPATOLOGY, V22, P1838, DOI 10.1002/hep.1840220633; LARRICK JW, 1979, J SUPRAMOL STR CELL, V11, P579, DOI 10.1002/jss.400110415; Laske DW, 1997, NAT MED, V3, P1362, DOI 10.1038/nm1297-1362; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; MULFORD CA, 1988, J BIOL CHEM, V263, P5455; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; OKEEFE DO, 1985, J BIOL CHEM, V260, P932; PANACCIO M, 1987, IMMUNOL CELL BIOL, V65, P461, DOI 10.1038/icb.1987.55; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RASO V, 1984, J BIOL CHEM, V259, P1143; SAKAMAKI S, 1999, BLOOD, V94, P1; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SASAKI K, 1993, JPN J CANCER RES, V84, P191, DOI 10.1111/j.1349-7006.1993.tb02854.x; Sato Y, 1996, HUM GENE THER, V7, P1895, DOI 10.1089/hum.1996.7.15-1895; Schmidt W, 1997, GENE, V190, P211, DOI 10.1016/S0378-1119(96)00537-9; SCHOEMAN R, 1995, J DRUG TARGET, V2, P509, DOI 10.3109/10611869509015921; SHINTANI N, 1994, BLOOD, V83, P1209, DOI 10.1182/blood.V83.5.1209.bloodjournal8351209; SHPITZ B, 1994, ANTICANCER RES, V14, P1927; Suzuki M, 1999, NAT BIOTECHNOL, V17, P265, DOI 10.1038/7010; Takahashi M, 1996, J BIOL CHEM, V271, P26536, DOI 10.1074/jbc.271.43.26536; THEUER CP, 1993, CANCER RES, V53, P340; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P8318; VANAGTHOVEN A, 1984, EUR J BIOCHEM, V140, P433; VANDRIEL IR, 1984, J IMMUNOL, V133, P3220; VANRENSWOUDE J, 1982, P NATL ACAD SCI-BIOL, V79, P6186; VITETTA ES, 1987, SCIENCE, V238, P1098, DOI 10.1126/science.3317828; WAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363; Xu LN, 1997, HUM GENE THER, V8, P467, DOI 10.1089/hum.1997.8.4-467; Zauner W, 1997, EXP CELL RES, V232, P137, DOI 10.1006/excr.1997.3486; Zauner W, 1996, BIOTECHNIQUES, V20, P905; ZENKE M, 1990, P NATL ACAD SCI USA, V87, P3655, DOI 10.1073/pnas.87.10.3655; Zhang GF, 1999, HUM GENE THER, V10, P1735, DOI 10.1089/10430349950017734	55	45	48	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2000	14	13					2108	2118		10.1096/fj.99-1052com	http://dx.doi.org/10.1096/fj.99-1052com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023995				2022-12-25	WOS:000089634400030
J	Silva, JA; Araujo, RC; Baltatu, O; Oliveira, SM; Tschope, C; Fink, E; Hoffmann, S; Plehm, R; Chai, KX; Chao, L; Chao, J; Ganten, D; Pesquero, JB; Bader, M				Silva, JA; Araujo, RC; Baltatu, O; Oliveira, SM; Tschope, C; Fink, E; Hoffmann, S; Plehm, R; Chai, KX; Chao, L; Chao, J; Ganten, D; Pesquero, JB; Bader, M			Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene	FASEB JOURNAL			English	Article									Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Escola Paulista Med, Dept Biophys, Sao Paulo, Brazil; Free Univ Berlin, Univ Hosp Benjamin Franklin, Dept Cardiol, D-1000 Berlin, Germany; Free Univ Berlin, Univ Hosp Benjamin Franklin, Dept Clin Pharmacol, D-1000 Berlin, Germany; Univ Munich, Dept Clin Chem & Clin Biochem, D-80539 Munich, Germany; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Universidade Federal de Sao Paulo (UNIFESP); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munich; Medical University of South Carolina	Bader, M (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.		Baltatu, Ovidiu Constantin/E-5890-2011; Bader, Michael/K-2124-2013; Araujo, Ronaldo C/H-1618-2012; Pesquero, Joao/C-1470-2012; Silva, Jose A/B-9399-2012; Araujo, Ronaldo Carvalho/O-7569-2019; Silva, Jose Antonio/AAA-8100-2019	Baltatu, Ovidiu Constantin/0000-0001-9732-6039; Pesquero, Joao/0000-0002-4507-632X; Araujo, Ronaldo Carvalho/0000-0003-0095-4608; Silva, Jose Antonio/0000-0001-6904-9185; Tschope, Carsten/0000-0001-5243-8985; Bader, Michael/0000-0003-4780-4164					0	93	98	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					1858	1860						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023967				2022-12-25	WOS:000089634400001
J	Citron, BA; SantaCruz, KS; Davies, PJA; Festoff, BW				Citron, BA; SantaCruz, KS; Davies, PJA; Festoff, BW			Intron-exon swapping of transglutaminase mRNA and neuronal tau aggregation in Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; TISSUE-TYPE TRANSGLUTAMINASE; PIG LIVER TRANSGLUTAMINASE; CATALYZED CROSS-LINKING; AMYLOID BETA-A4 PEPTIDE; ACID-INDUCED EXPRESSION; RETINOIC ACID; DIFFERENTIAL EXPRESSION; RESPONSE ELEMENT; GENE PROMOTER	In order to understand the mechanism for insoluble neurotoxic protein polymerization in Alzheimer's disease (AD) brain neurons, we examined protein and gene expression for transglutaminase (TGase 2; tissue transglutaminase (tTG)) in hippocampus and isocortex. We found co-localization of tTG protein and activity with tau-positive neurofibrillary tangles, whereas mRNA and sequence analysis indicated an absolute increase in tTG; synthesized. Although apoptosis in AD hippocampus is now an established mode of neuronal cell death, no definite underlying mechanism(s) is known. Since TGase-mediated protein aggregation is implicated in polyglutamine ((CAG)(n)/Q(n) expansion) disorder apoptosis, and expanded Q(n) repeats are excellent TGase substrates, a role for TG;ase in AD is possible. However, despite such suggestions almost 20 years ago, the molecular mechanism remained elusive. We now present one possible molecular mechanism for tTG-mediated, neurotoxic protein polymerization leading to neuronal apoptosis in AD that involves not its substrates (like Q(n) repeats) but rather the unique presence of alternative transcripts of tTG; mRNA In addition to a full-length (L) isoform in aged non-demented brains, we found a short isoform (S) lacking a binding domain in all AD brains. Our current results identify intron-exon "switching" between L and S isoforms, implicating G-protein-coupled signaling pathways associated with tTG that may help to determine the dual roles of this enzyme in neuronal life and death processes.	Heartland Vet Integrated Serv Network, Neurobiol Res Lab, Kansas City, MO 64128 USA; Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Pharmacol Toxicol & Therapeut, Kansas City, KS 66160 USA; Univ Texas, Hlth Sci Ctr, Dept Integrated Biol Pharmacol & Physiol, Houston, TX 77225 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Texas System; University of Texas Health Science Center Houston	Festoff, BW (corresponding author), Vet Affairs Med Ctr, Neurobiol Res Lab 151, Heartland Vet Hlth Serv Network, 4801 Linwood Blvd, Kansas City, MO 64128 USA.	serpin@eagle.cc.ukans.edu						ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; Aeschlimann D, 1998, J BIOL CHEM, V273, P3452, DOI 10.1074/jbc.273.6.3452; ANDO M, 1993, BRAIN RES, V604, P64, DOI 10.1016/0006-8993(93)90352-N; Appelt DM, 1996, J HISTOCHEM CYTOCHEM, V44, P1421, DOI 10.1177/44.12.8985134; Appelt DM, 1997, BRAIN RES, V745, P21, DOI 10.1016/S0006-8993(96)01121-3; Barinaga M, 1998, SCIENCE, V281, P1303, DOI 10.1126/science.281.5381.1303; Birckbichler P J, 1980, Prog Clin Biol Res, V41, P845; Braak H, 1997, NEUROBIOL AGING, V18, pS85, DOI 10.1016/S0197-4580(97)00062-6; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Casadio R, 1999, EUR J BIOCHEM, V262, P672, DOI 10.1046/j.1432-1327.1999.00437.x; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; CHIOCCA EA, 1989, J CELL BIOCHEM, V39, P293, DOI 10.1002/jcb.240390309; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Citron BA, 2000, NEUROCHEM INT, V37, P337, DOI 10.1016/S0197-0186(00)00044-9; Cooper AJL, 1997, J NEUROCHEM, V69, P431; Cooper AJL, 1999, J NEUROCHEM, V72, P889, DOI 10.1046/j.1471-4159.1999.0720889.x; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; Cotman CW, 1998, NEUROBIOL AGING, V19, pS29, DOI 10.1016/S0197-4580(98)00042-6; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; DAVIES PJA, 1985, J BIOL CHEM, V260, P5166; DAVIES PJA, 1988, AM J MED SCI, V296, P164, DOI 10.1097/00000441-198809000-00004; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dieterich W, 1997, NAT MED, V3, P797, DOI 10.1038/nm0797-797; ELALAOUI S, 1991, INT J CANCER, V48, P221; Feng JF, 1999, BIOCHEMISTRY-US, V38, P2224, DOI 10.1021/bi9823176; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; Ferrari N, 1998, MOL CELL BIOL, V18, P6482, DOI 10.1128/MCB.18.11.6482; Fesus L, 1996, EXPERIENTIA, V52, P942, DOI 10.1007/BF01920102; FRAIJ BM, 1992, J BIOL CHEM, V267, P22616; Fraij BM, 1996, BIOCHEM BIOPH RES CO, V218, P45, DOI 10.1006/bbrc.1996.0009; Fraij BM, 1997, BBA-GENE STRUCT EXPR, V1354, P65, DOI 10.1016/S0167-4781(97)00132-2; Fraij BM, 1996, BBA-GENE STRUCT EXPR, V1306, P63, DOI 10.1016/0167-4781(95)00219-7; Gentile V, 1998, ARCH BIOCHEM BIOPHYS, V352, P314, DOI 10.1006/abbi.1998.0592; GENTILE V, 1991, J BIOL CHEM, V266, P478; Gill LS, 1998, BRAIN RES, V788, P95, DOI 10.1016/S0006-8993(97)01526-6; GOBBI G, 1992, LANCET, V340, P439; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1999, NEURON, V22, P416, DOI 10.1016/S0896-6273(00)80695-9; Han KJ, 1998, LIFE SCI, V62, P1809, DOI 10.1016/S0024-3205(98)00143-X; HO GJ, 1994, BIOMED PHARMACOTHER, V48, P296, DOI 10.1016/0753-3322(94)90175-9; HO GJ, 1994, FEBS LETT, V349, P151, DOI 10.1016/0014-5793(94)00663-6; Holmes FE, 1996, NEUROSCI LETT, V213, P185; Horn V, 1996, FASEB J, V10, P1071, DOI 10.1096/fasebj.10.9.8801169; HWANG KC, 1995, J BIOL CHEM, V270, P27058, DOI 10.1074/jbc.270.45.27058; Hyman BT, 1997, J NEUROPATH EXP NEUR, V56, P1095, DOI 10.1097/00005072-199710000-00002; Iismaa SE, 1997, BIOCHEMISTRY-US, V36, P11655, DOI 10.1021/bi970545e; IKURA K, 1993, FEBS LETT, V326, P109, DOI 10.1016/0014-5793(93)81772-R; IKURA K, 1994, BIOSCI BIOTECH BIOCH, V58, P1540, DOI 10.1271/bbb.58.1540; Im MJ, 1997, CELL SIGNAL, V9, P477, DOI 10.1016/S0898-6568(97)00049-1; Jellinger KA, 1998, J NEURAL TRANSM-SUPP, P77; JENSEN PH, 1995, BIOCHEM J, V310, P91, DOI 10.1042/bj3100091; Johnson GVW, 1997, BRAIN RES, V751, P323, DOI 10.1016/S0006-8993(96)01431-X; Kahlem P, 1996, P NATL ACAD SCI USA, V93, P14580, DOI 10.1073/pnas.93.25.14580; Kahlem P, 1998, MOL CELL, V1, P595, DOI 10.1016/S1097-2765(00)80059-3; Kahlem P, 1998, PATHOL BIOL, V46, P681; Karpuj MV, 1999, P NATL ACAD SCI USA, V96, P7388, DOI 10.1073/pnas.96.13.7388; Kim SY, 1999, J BIOL CHEM, V274, P30715, DOI 10.1074/jbc.274.43.30715; Klein ES, 1996, J BIOL CHEM, V271, P22692, DOI 10.1074/jbc.271.37.22692; KSIEZAKREDING H, 1995, J NEUROSCI RES, V41, P583, DOI 10.1002/jnr.490410504; Kuncio GS, 1998, AM J PHYSIOL-GASTR L, V274, pG240, DOI 10.1152/ajpgi.1998.274.2.G240; Lai TS, 1996, J BIOL CHEM, V271, P31191, DOI 10.1074/jbc.271.49.31191; Lefebvre O, 1999, CELL DEATH DIFFER, V6, P433, DOI 10.1038/sj.cdd.4400510; Lu S, 1997, P NATL ACAD SCI USA, V94, P4692, DOI 10.1073/pnas.94.9.4692; LU S, 1995, J BIOL CHEM, V270, P9748, DOI 10.1074/jbc.270.17.9748; MADDOX AM, 1988, EXP CELL BIOL, V56, P49; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; McLean CA, 1997, NEUROBIOL AGING, V18, pS89, DOI 10.1016/S0197-4580(97)00061-4; Melino G, 1997, J NEURO-ONCOL, V31, P65, DOI 10.1023/A:1005733430435; Melino G, 1997, EXP CELL RES, V235, P55, DOI 10.1006/excr.1997.3656; Monsonego A, 1997, J BIOL CHEM, V272, P3724, DOI 10.1074/jbc.272.6.3724; MURTAUGH MP, 1986, J BIOL CHEM, V261, P614; Nagy L, 1996, J BIOL CHEM, V271, P4355; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nanda N, 1999, ARCH BIOCHEM BIOPHYS, V366, P151, DOI 10.1006/abbi.1999.1189; Norlund MA, 1999, BRAIN RES, V851, P154, DOI 10.1016/S0006-8993(99)02179-4; O'Neill R R, 1989, Appl Theor Electrophor, V1, P163; PERRY MJM, 1995, NEUROSCIENCE, V65, P1063, DOI 10.1016/0306-4522(94)00556-K; PIACENTINI M, 1991, EUR J CELL BIOL, V54, P246; Piacentini M, 1995, Curr Top Microbiol Immunol, V200, P163; RASMUSSEN LK, 1994, FEBS LETT, V338, P161, DOI 10.1016/0014-5793(94)80356-0; Ritter SJ, 1998, J BIOL CHEM, V273, P12798, DOI 10.1074/jbc.273.21.12798; SCHUTZE S, 1992, SEMIN ONCOL, V19, P16; SELKOE DJ, 1982, P NATL ACAD SCI-BIOL, V79, P6070, DOI 10.1073/pnas.79.19.6070; Singh US, 1996, J BIOL CHEM, V271, P27292, DOI 10.1074/jbc.271.44.27292; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUTO N, 1993, J BIOL CHEM, V268, P7469; SWINGLER S, 1994, BIOCHEM BIOPH RES CO, V203, P623, DOI 10.1006/bbrc.1994.2228; Szondy Z, 1997, FEBS LETT, V404, P307, DOI 10.1016/S0014-5793(97)00140-3; TROJANOWSKI JQ, 1997, NEUROBIOL AGING S4, V18, P1; Yan ZH, 1996, MOL CELL ENDOCRINOL, V120, P203, DOI 10.1016/0303-7207(96)03826-9; Zainelli GM, 2000, J NEUROCHEM, V74, pS27; Zemaitiaitis MO, 2000, J NEUROCHEM, V74, pS27; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022; Zhang W, 1998, ACTA NEUROPATHOL, V96, P395, DOI 10.1007/s004010050910; Zhang W, 1997, LIFE SCI, V60, P2323, DOI 10.1016/S0024-3205(97)00288-9	96	85	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3295	3301		10.1074/jbc.M004776200	http://dx.doi.org/10.1074/jbc.M004776200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11013236	hybrid			2022-12-25	WOS:000166784900042
J	Song, C; Hu, CD; Masago, M; Kariya, K; Yamawaki-Kataoka, Y; Shibatohge, M; Wu, DM; Satoh, T; Kataoka, T				Song, C; Hu, CD; Masago, M; Kariya, K; Yamawaki-Kataoka, Y; Shibatohge, M; Wu, DM; Satoh, T; Kataoka, T			Regulation of a novel human phospholipase C, PLC epsilon, through membrane targeting by Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISSOCIATION STIMULATOR; ADENYLYL-CYCLASE; GOLGI-COMPLEX; MAP KINASE; ACTIVATION; PROTEIN; EFFECTOR; RAP1; TRANSFORMATION; IDENTIFICATION	Phosphoinositide-specific phospholipase C (PI-PLG) plays a pivotal role in regulation of intracellular signal transduction from various receptor molecules. More than 10 members of human PI-PLG isoforms have been identified and classified into three classes beta, gamma, and delta, which are regulated by distinct mechanisms. Here we report identification of a novel class of human PI-PLG, named PLG epsilon, which is characterized by the presence of a Res-associating domain at its C terminus and a CDC25-like domain at its N terminus. The Res-associating domain of PLGe specifically binds to the GTP-bound forms of Ha-Ras and Rap1A. The dissociation constant for Ha-Ras is estimated to be approximately 40 nM, comparable with those of other Res effecters. Co-expression of an activated Ha-Res mutant with PLGe induces its translocation from the cytosol to the plasma membrane. Upon stimulation with epidermal growth factor, similar translocation of ectopically expressed PLGe is observed, which is inhibited by co-expression of dominant-negative Ha-Res. Furthermore, using a liposome-based reconstitution assay, it is shown that the phosphatidylinositol 4,5-bisphosphate-hydrolyzing activity of PLC epsilon is stimulated in vitro by Ha-Ras in a GTP-dependent manner. These results indicate that Res directly regulates phosphoinositide breakdown through membrane targeting of PLCe.	Kobe Univ, Sch Med, Dept Physiol 2, Chuo Ku, Kobe, Hyogo 6500017, Japan; Univ Ryukyus, Sch Med, Dept Biochem 2, Okinawa 9030215, Japan	Kobe University; University of the Ryukyus	Kataoka, T (corresponding author), Kobe Univ, Sch Med, Dept Physiol 2, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	kataoka@kobe-u.ac.jp	Satoh, Takaya/K-2628-2014; song, chunhua/K-7882-2016; song, chunhua/K-7882-2016	song, chunhua/0000-0001-7563-0339; song, chunhua/0000-0002-4081-2543				Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HOMMA Y, 1997, SIGNALING INOSITIDES, P99; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Huang L, 1997, NAT STRUCT BIOL, V4, P609, DOI 10.1038/nsb0897-609; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; Matsubara K, 1999, ONCOGENE, V18, P1303, DOI 10.1038/sj.onc.1202425; MINATO T, 1994, J BIOL CHEM, V269, P20845; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Shibatohge M, 1998, J BIOL CHEM, V273, P6218, DOI 10.1074/jbc.273.11.6218; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Watari Y, 1998, GENE, V224, P53, DOI 10.1016/S0378-1119(98)00527-7; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	38	262	287	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2752	2757		10.1074/jbc.M008324200	http://dx.doi.org/10.1074/jbc.M008324200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11022048	hybrid			2022-12-25	WOS:000166784800062
J	Fukushi, Y; Kato, I; Takasawa, S; Sasaki, T; Ong, BH; Sato, M; Ohsaga, A; Sato, K; Shirato, K; Okamoto, H; Maruyama, Y				Fukushi, Y; Kato, I; Takasawa, S; Sasaki, T; Ong, BH; Sato, M; Ohsaga, A; Sato, K; Shirato, K; Okamoto, H; Maruyama, Y			Identification of cyclic ADP-ribose-dependent mechanisms in pancreatic muscarinic Ca2+ signaling using CD38 knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; SINGLE-CHANNEL CURRENTS; LEUKOCYTE ANTIGEN CD38; INOSITOL TRISPHOSPHATE; INSULIN-SECRETION; CALCIUM RELEASE; BETA-CELLS; RAT; MOBILIZATION; 1,4,5-TRISPHOSPHATE	We showed that muscarinic acetylcholine (ACh)-stimulation increased the cellular content of cADPR in the pancreatic acinar cells from normal mice but not in those from CD38 knockout mice. By monitoring ACh-evoked increases in the cytosolic Ca2+ concentration ([Ca2+](i)) using fura-2 microfluorimetry, we distinguished and characterized the Ca2+ release mechanisms responsive to cADPR, The Ca2+ response from the cells of the knockout mice (KO cells) lacked two components of the muscarinic Ca2+ release present in wild mice. The first component inducible by the low concentration of ACh contributed to regenerative Ca2+ spikes. This component was abolished by ryanodine treatment in the normal cells and was severely impaired in KO cells, indicating that the low ACh-induced regenerative spike responses were caused by cADPR-dependent Ca2+ release from a pool regulated by a class of ryanodine receptors, The second component inducible by the high concentration of ACh was involved in the phasic Ca2+ response, and it was not abolished by ryanodine treatment. Overall, we conclude that muscarinic Ca2+ signaling in pancreatic acinar cells involves a CD38-dependent pathway responsible for two cADPR-dependent Ca2+ release mechanisms in which the one sensitive to ryanodine plays a crucial role for the generation of repetitive Ca2+ spikes.	Tohoku Univ, Grad Sch Med, Dept Physiol 1, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Grad Sch Med, Dept Internal Med, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Grad Sch Med, Dept Biochem, Aoba Ku, Sendai, Miyagi 9808575, Japan	Tohoku University; Tohoku University; Tohoku University	Maruyama, Y (corresponding author), Tohoku Univ, Grad Sch Med, Dept Physiol 1, Aoba Ku, Seiryo Cho 2-1, Sendai, Miyagi 9808575, Japan.							BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; FUKUSHI Y, 1995, TOHOKU J EXP MED, V176, P83, DOI 10.1620/tjem.176.83; Fukushi Y, 1999, EUR J PHARMACOL, V364, P55, DOI 10.1016/S0014-2999(98)00824-3; Fukushi Y, 1997, EUR J PHARMACOL, V336, P89, DOI 10.1016/S0014-2999(97)01228-4; Fukushi Y, 1996, TOHOKU J EXP MED, V178, P399, DOI 10.1620/tjem.178.399; GALIONE A, 1992, TRENDS PHARMACOL SCI, V13, P304, DOI 10.1016/0165-6147(92)90096-O; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; IKEDA M, 1992, J PHYSIOL-LONDON, V447, P711, DOI 10.1113/jphysiol.1992.sp019025; Kato I, 1999, J BIOL CHEM, V274, P1869, DOI 10.1074/jbc.274.4.1869; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; MARTY A, 1989, J PHYSIOL-LONDON, V419, P665, DOI 10.1113/jphysiol.1989.sp017892; MARUYAMA Y, 1982, NATURE, V299, P159, DOI 10.1038/299159a0; MARUYAMA Y, 1988, J PHYSIOL-LONDON, V406, P299, DOI 10.1113/jphysiol.1988.sp017381; MARUYAMA Y, 1994, CELL CALCIUM, V16, P419, DOI 10.1016/0143-4160(94)90035-3; MARUYAMA Y, 1993, J PHYSIOL-LONDON, V463, P729, DOI 10.1113/jphysiol.1993.sp019619; MARUYAMA Y, 1982, NATURE, V300, P61, DOI 10.1038/300061a0; MARUYAMA Y, 1989, J PHYSIOL-LONDON, V417, P343, DOI 10.1113/jphysiol.1989.sp017805; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; Noguchi N, 1997, J BIOL CHEM, V272, P3133, DOI 10.1074/jbc.272.6.3133; Okamoto H, 1997, METHOD ENZYMOL, V280, P306; Ozawa T, 1997, J MEMBRANE BIOL, V156, P231, DOI 10.1007/s002329900203; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; TAKAHASHI K, 1995, FEBS LETT, V371, P204, DOI 10.1016/0014-5793(95)00914-U; Takasawa S, 1998, J BIOL CHEM, V273, P2497, DOI 10.1074/jbc.273.5.2497; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; Takasawa S, 1995, J BIOL CHEM, V270, P30257, DOI 10.1074/jbc.270.51.30257; TAYLOR CW, 1992, TRENDS BIOCHEM SCI, V17, P403, DOI 10.1016/0968-0004(92)90009-X; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S	39	69	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					649	655		10.1074/jbc.M004469200	http://dx.doi.org/10.1074/jbc.M004469200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11001947	hybrid			2022-12-25	WOS:000166280700087
J	Abrecht, H; Goormaghtigh, E; Ruysschaert, JM; Homble, F				Abrecht, H; Goormaghtigh, E; Ruysschaert, JM; Homble, F			Structure and orientation of two voltage-dependent anion-selective channel isoforms - An attenuated total reflection Fourier-transform infrared spectroscopy study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; SECONDARY STRUCTURE; NEUROSPORA-CRASSA; DICHROIC RATIOS; VDAC CHANNELS; CYTOCHROME-C; PORIN; PROTEINS; EXPRESSION; EXCHANGE	Two VDAC (voltage-dependent anion-selective channel) isoforms were purified from seed cotyledons of Phaseolus vulgaris by chromatofocusing chromatography. Attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy was used to study the structural properties of the two isoforms reconstituted in a mixture of asolectin and 5% stigmasterol. The IR spectra of the two VDAC isoforms were highly similar indicating 50 to 53% anti-parallel beta -sheet. The orientation of the beta -strands relative to the barrel axis was calculated from the experimentally obtained dichroic ratios of the amide I beta -sheet component and the amide II band. Comparing the IR spectra of the reconstituted VDAC isoforms with the IR spectra of the bacterial porin OmpF, for which a high resolution structure is available, provided evidence for a general structural organization of the VDAC isoforms similar to that of bacterial porins. Hydrogen-deuterium exchange measurements indicated that the exchange of the amide protons occurs to a higher extent in the two VDAC isoforms than in the OmpF porin.	Free Univ Brussels, Lab Physiol Vegetale, Fac Sci, B-1050 Brussels, Belgium; Free Univ Brussels, Fac Sci, Chim Phys Macromol Interfaces Lab, B-1050 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Homble, F (corresponding author), Free Univ Brussels, Lab Physiol Vegetale, Fac Sci, CP 206-2,Bld Triomphe, B-1050 Brussels, Belgium.		Homble, Fabrice/AAH-3780-2020	Homble, Fabrice/0000-0001-6031-136X; Goormaghtigh, Erik/0000-0002-2071-2262				Abrecht H, 2000, PLANT PHYSIOL, V124, P1181, DOI 10.1104/pp.124.3.1181; ADAMS V, 1991, BIOCHEM MED METAB B, V45, P271, DOI 10.1016/0885-4505(91)90032-G; Bechinger B, 1999, BIOPHYS J, V76, P552, DOI 10.1016/S0006-3495(99)77223-1; BENZ R, 1990, BIOCHIM BIOPHYS ACTA, V1022, P311, DOI 10.1016/0005-2736(90)90279-W; BENZ R, 1988, FEBS LETT, V231, P75, DOI 10.1016/0014-5793(88)80706-3; BENZ R, 1994, BBA-REV BIOMEMBRANES, V1197, P167, DOI 10.1016/0304-4157(94)90004-3; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; Cabiaux V, 1997, BIOPHYS J, V73, P406, DOI 10.1016/S0006-3495(97)78080-9; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DEJONGH HHJ, 1995, BIOCHEMISTRY-US, V34, P172, DOI 10.1021/bi00001a021; DEPINTO V, 1989, EUR J BIOCHEM, V183, P179; Dolder M, 1999, J STRUCT BIOL, V127, P64, DOI 10.1006/jsbi.1999.4141; DOUCE R, 1987, METHOD ENZYMOL, V148, P403; Elkeles A, 1997, J BIOL CHEM, V272, P6252, DOI 10.1074/jbc.272.10.6252; FORTE M, 1987, J BIOENERG BIOMEMBR, V19, P341, DOI 10.1007/BF00768537; FREITAG H, 1982, FEBS LETT, V145, P72, DOI 10.1016/0014-5793(82)81209-X; Fringeli U P, 1981, Mol Biol Biochem Biophys, V31, P270; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; GOORMAGHTIGH E, 1994, J BIOL CHEM, V269, P27409; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; GUO XW, 1995, J STRUCT BIOL, V114, P41, DOI 10.1006/jsbi.1995.1004; HARRIS AL, 1989, J MEMBRANE BIOL, V109, P243, DOI 10.1007/BF01870281; HAUSER H, 1988, BIOCHEMISTRY-US, V27, P9166, DOI 10.1021/bi00426a014; Hodge T, 1997, J MEMBRANE BIOL, V157, P271, DOI 10.1007/s002329900235; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; KLEFFEL B, 1985, EMBO J, V4, P1589, DOI 10.1002/j.1460-2075.1985.tb03821.x; Koppel DA, 1998, J BIOL CHEM, V273, P13794, DOI 10.1074/jbc.273.22.13794; Linden M, 1996, BIOCHEM BIOPH RES CO, V218, P833, DOI 10.1006/bbrc.1996.0148; Mannella CA, 1996, J BIOENERG BIOMEMBR, V28, P163, DOI 10.1007/BF02110647; Mannella CA, 1997, J BIOENERG BIOMEMBR, V29, P525, DOI 10.1023/A:1022489832594; Marsh D, 2000, J MOL BIOL, V297, P803, DOI 10.1006/jmbi.2000.3557; Marsh D, 1998, BIOPHYS J, V75, P354, DOI 10.1016/S0006-3495(98)77519-8; Marsh D, 1997, BIOPHYS J, V72, P2710, DOI 10.1016/S0006-3495(97)78914-8; MURZIN AG, 1994, J MOL BIOL, V236, P1369, DOI 10.1016/0022-2836(94)90064-7; NABEDRYK E, 1988, BIOPHYS J, V53, P671, DOI 10.1016/S0006-3495(88)83148-5; PFALLER R, 1990, EXPERIENTIA, V46, P153, DOI 10.1007/BF02027311; POPP B, 1995, BIOCHEMISTRY-US, V34, P3352, DOI 10.1021/bi00010a026; RAUCH G, 1994, BIOCHEM BIOPH RES CO, V200, P908, DOI 10.1006/bbrc.1994.1536; Roosens N, 2000, BBA-BIOMEMBRANES, V1463, P470, DOI 10.1016/S0005-2736(99)00246-1; Rostovtseva T, 1997, BIOPHYS J, V72, P1954, DOI 10.1016/S0006-3495(97)78841-6; Shao L, 1996, BIOPHYS J, V71, P778, DOI 10.1016/S0006-3495(96)79277-9; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Sonveaux N, 1996, J BIOL CHEM, V271, P24617, DOI 10.1074/jbc.271.40.24617; Tatulian SA, 1998, FEBS LETT, V423, P205, DOI 10.1016/S0014-5793(98)00091-X; THOMAS L, 1993, P NATL ACAD SCI USA, V90, P5446, DOI 10.1073/pnas.90.12.5446; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; Xu X, 1999, J MEMBRANE BIOL, V170, P89, DOI 10.1007/s002329900540	49	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40992	40999		10.1074/jbc.M006437200	http://dx.doi.org/10.1074/jbc.M006437200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018035	hybrid			2022-12-25	WOS:000166114600046
J	Cornea, RL; Autry, JM; Chen, ZH; Jones, LR				Cornea, RL; Autry, JM; Chen, ZH; Jones, LR			Reexamination of the role of the leucine/isoleucine zipper residues of phospholamban in inhibition of the Ca2+ pump of cardiac sarcoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-STRUCTURE; LIPID BILAYERS; CALCIUM-PUMP; PHOSPHORYLATION; CA2+-ATPASE; DOMAIN; FORMS; DEPOLYMERIZATION; COEXPRESSION; ACTIVATION	Phospholamban is a small phosphoprotein inhibitor of the Ca2+-pump in cardiac sarcoplasmic reticulum, which shows a distinct oligomeric distribution between monomers and homopentamers that are stabilized through Leu/Ile zipper interactions. A two-faced model of phospholamban inhibition of the Ca2+-pump was proposed, in which the Leu/Ile zipper residues located on one face of the transmembrane alpha -helix regulate the pentamer to monomer equilibrium, whereas residues on the other face of the helix bind to and inhibit the pump, Here we tested this two-faced model of phospholamban action by analyzing the functional effects of a new series of Leu/Ile zipper mutants. Pentameric stabilities of the mutants were quantified at different SDS concentrations. We show that several phospholamban mutants with hydrophobic amino acid substitutions at the Leu/Ile zipper region retain the ability to form pentamers but at the same time give the same or even stronger (i.e. L37I-PLB) inhibition of the Ca2+-pump than do mutants that are more completely monomeric. Steric constraints prevent the Leu/Ile zipper residues sequestered in the interior of the phospholamban pentamer from binding to the Ca2+-pump, leading. to the conclusion that the zipper residues access the pump from the phospholamban monomer, which is the active inhibitory species. A modified model of phospholamban transmembrane domain action is proposed, in which the membrane span of the phospholamban monomer maintains contacts with the Ca2+-pump around most of its circumference, including residues located in the Leu/Ile zipper region.	Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Jones, LR (corresponding author), Indiana Univ, Sch Med, Krannert Inst Cardiol, 1111 W 10th St, Indianapolis, IN 46202 USA.	lrjones@iupui.edu	Autry, Joseph M./X-6839-2019	Autry, Joseph M./0000-0002-1144-725X; Cornea, Razvan/0000-0001-5739-0992	NHLBI NIH HHS [HL49428] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049428, R37HL049428] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antipenko AY, 1997, BIOCHEMISTRY-US, V36, P12903, DOI 10.1021/bi971109v; Asahi M, 1999, J BIOL CHEM, V274, P32855, DOI 10.1074/jbc.274.46.32855; Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; Autry JM, 1998, ANN NY ACAD SCI, V853, P92, DOI 10.1111/j.1749-6632.1998.tb08259.x; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; Chu GX, 1998, J BIOL CHEM, V273, P33674, DOI 10.1074/jbc.273.50.33674; Cornea RL, 1997, BIOCHEMISTRY-US, V36, P2960, DOI 10.1021/bi961955q; FUJII J, 1989, J BIOL CHEM, V264, P12950; JONES LR, 1979, BIOCHIM BIOPHYS ACTA, V557, P230, DOI 10.1016/0005-2736(79)90105-6; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; KOVACS RJ, 1988, J BIOL CHEM, V263, P18364; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mahaney J, 1999, ARCH BIOCHEM BIOPHYS, V372, P408, DOI 10.1006/abbi.1999.1524; Odermatt A, 1996, J BIOL CHEM, V271, P14206, DOI 10.1074/jbc.271.24.14206; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; Reddy LG, 1999, BIOCHEMISTRY-US, V38, P3954, DOI 10.1021/bi981795d; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; TADA M, 1975, J BIOL CHEM, V250, P2640; Torres J, 2000, J MOL BIOL, V300, P677, DOI 10.1006/jmbi.2000.3885; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; WEGENER AD, 1984, J BIOL CHEM, V259, P1834; Zhai J, 2000, J BIOL CHEM, V275, P10538, DOI 10.1074/jbc.275.14.10538	25	59	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41487	41494		10.1074/jbc.M008195200	http://dx.doi.org/10.1074/jbc.M008195200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11016944	hybrid			2022-12-25	WOS:000166114600107
J	Kardassis, D; Pardali, K; Zannis, VI				Kardassis, D; Pardali, K; Zannis, VI			SMAD proteins transactivate the human apoCIII promoter by interacting physically and functionally with hepatocyte nuclear factor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-C-III; GROWTH-FACTOR-BETA; TGF-BETA; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; A-I; LIPOPROTEIN-LIPASE; SIGNALING PATHWAYS; PROXIMAL PROMOTER; TRANSGENIC MICE	Cotransfection of HepG2 cells with SMADs established that SMAD3 and SMAD3-SMAD4 transactivated (15-70-fold) the -890/+24 apoCIII promoter and shorter promoter segments, whereas cotransfection with a dominant negative SMAD4 mutant repressed the apoCIII promoter activity by 50%, suggesting that SMAD proteins participate in apoCIII gene regulation. Transactivation required the presence of a hormone response element, despite the fact that SMADs could not bind directly to it. Cotransfection of SMAD3-SMAD4 along with hepatocyte nuclear factor-4 resulted in a strong synergistic transactivation of the -890/+24 apoCIII promoter, proximal promoter segments, or synthetic promoters containing either the apoCIII enhancer or the proximal apoCIII hormone response element. Inhibition of endogenous hepatocyte nuclear factor-4 synthesis by an antisense ribozyme construct reduced the constitutive activity of the apoCIII promoter in HepG2 cells to 10% and abolished the SMAD-mediated transactivation. Co-immunoprecipitation and GST pull-down assays provided evidence for physical interactions between SMAD3, SMAD4, and hepatic nuclear factor-4, Our findings indicate that transforming growth factor beta and its signal transducer SMAD proteins can modulate gene transcription by novel mechanisms that involve their physical and functional interaction with hepatocyte nuclear factor-4, suggesting that SMAD proteins may play an important role in apolipoprotein gene expression and lipoprotein metabolism.	Univ Crete, Sch Med, Dept Basic Sci, GR-71110 Iraklion, Greece; FORTH, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Greece	University of Crete; Foundation for Research & Technology - Hellas (FORTH)	Kardassis, D (corresponding author), Univ Crete, Sch Med, Dept Basic Sci, GR-71110 Iraklion, Greece.			Pardali, Katerina/0000-0002-4360-730X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033952] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33952] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BISAHA JG, 1995, J BIOL CHEM, V270, P19979, DOI 10.1074/jbc.270.34.19979; BROWN WV, 1972, BIOCHEM BIOPH RES CO, V46, P375; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DESILVA HV, 1994, J BIOL CHEM, V269, P2324; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRUBER PJ, 1994, NUCLEIC ACIDS RES, V22, P2417, DOI 10.1093/nar/22.12.2417; Gu ZY, 1999, DEVELOPMENT, V126, P2551; HADDAD IA, 1986, J BIOL CHEM, V261, P3268; Hadzopoulou-Cladaras M, 1998, BIOCHEMISTRY-US, V37, P14078, DOI 10.1021/bi9804176; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; Hammann C, 1999, METHODS, V18, P273, DOI 10.1006/meth.1999.0784; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Herbert P. N., 1982, METABOLIC BASIS INHE, P589; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kan HY, 2000, J BIOL CHEM, V275, P30423, DOI 10.1074/jbc.M005641200; Kardassis D, 1998, J BIOL CHEM, V273, P17810, DOI 10.1074/jbc.273.28.17810; Kardassis D, 1997, ARTERIOSCL THROM VAS, V17, P222, DOI 10.1161/01.ATV.17.1.222; KARDASSIS D, 1992, J BIOL CHEM, V267, P2622; KRAUSS RM, 1973, CIRC RES, V33, P403, DOI 10.1161/01.RES.33.4.403; Ktistaki E, 1997, MOL CELL BIOL, V17, P2790, DOI 10.1128/MCB.17.5.2790; Lacorte JM, 1997, J BIOL CHEM, V272, P23578, DOI 10.1074/jbc.272.38.23578; Lacorte JM, 1997, FEBS LETT, V415, P217, DOI 10.1016/S0014-5793(97)01127-7; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lavrentiadou SN, 1999, BIOCHEMISTRY-US, V38, P964, DOI 10.1021/bi981068i; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nastos A, 1998, NUCLEIC ACIDS RES, V26, P5602, DOI 10.1093/nar/26.24.5602; OGAMI K, 1990, J BIOL CHEM, V265, P9808; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; SHELBURNE F, 1980, J CLIN INVEST, V65, P652, DOI 10.1172/JCI109710; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; TALIANIDIS I, 1995, BIOCHEMISTRY-US, V34, P10298, DOI 10.1021/bi00032a025; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; WINDLER E, 1980, J BIOL CHEM, V255, P8303; Yanagi Y, 1999, J BIOL CHEM, V274, P12971, DOI 10.1074/jbc.274.19.12971; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	48	37	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41405	41414		10.1074/jbc.M007896200	http://dx.doi.org/10.1074/jbc.M007896200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10995777	hybrid			2022-12-25	WOS:000166114600098
J	Li, JH; Yen, TY; Allende, ML; Joshi, RK; Cai, J; Pierce, WM; Jaskiewicz, E; Darling, DS; Macher, BA; Young, WW				Li, JH; Yen, TY; Allende, ML; Joshi, RK; Cai, J; Pierce, WM; Jaskiewicz, E; Darling, DS; Macher, BA; Young, WW			Disulfide bonds of GM2 synthase homodimers - Antiparallel orientation of the catalytic domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; GROWTH FACTOR-BB; COMPLEX GANGLIOSIDES; MEMBRANE-PROTEIN; ESCHERICHIA-COLI; GOLGI MEMBRANES; UDP-GALNAC; GLYCOSYLATION; EXPRESSION; ENZYME	GM2 synthase is a homodimer in which the subunits are joined by lumenal domain disulfide bond(s). To define the disulfide bond pattern of this enzyme, we analyzed a soluble form by chemical fragmentation, enzymatic digestion, and mass spectrometry and a full-length:form by site-directed mutagenesis. All Cys residues of the lumenal domain of GM2 synthase are disulfide bonded with Cys(429) and Cys(476) forming a disulfide-bonded pair while Cys(80) and Cys(82) are disulfide bonded in combination with Cys(412) and Cys(529). Partial reduction to produce monomers converted Cys(80) and Cys(82) to free thiols while the Cys(429) to Cys(476) disulfide remained intact. CNBr cleavage at amino acid 330 produced a monomer-sized band under nonreducing conditions which was converted upon reduction to a 40-kDa fragment and a 24-kDa myc-positive fragment. Double mutation of Cys(80) and Cys(82) to Ser produced monomers but not: dimers, In summary these results demonstrate that Cys(429) and Cys(476) form an intrasubunit disulfide while the intersubunit disulfides formed by both Cys(80) and Cys(82) with Cys(412) and Cys(529) are responsible for formation of the homodimer. This disulfide bond arrangement results in an antiparallel orientation of the catalytic domains of the GM2 synthase homodimer.	Univ Louisville, Sch Dent, Dept Mol Cellular & Craniofacial Biol, Louisville, KY 40292 USA; Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40292 USA; Univ Louisville, Dept Pharmacol, Louisville, KY 40292 USA; San Francisco State Univ, Dept Chem & Biochem, San Francisco, CA 94132 USA	University of Louisville; University of Louisville; University of Louisville; California State University System; San Francisco State University	Young, WW (corresponding author), Univ Louisville, Sch Dent, Dept Mol Cellular & Craniofacial Biol, 501 S Preston St, Louisville, KY 40292 USA.		Darling, Douglas S/D-4573-2009	Darling, Douglas/0000-0002-9039-1169	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042698] Funding Source: NIH RePORTER; NCRR NIH HHS [5P20RR11805] Funding Source: Medline; NIGMS NIH HHS [R01GM42698] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allende ML, 2000, GLYCOBIOLOGY, V10, P1025, DOI 10.1093/glycob/10.10.1025; ARAR C, 1995, J BIOL CHEM, V270, P3551, DOI 10.1074/jbc.270.8.3551; ASPRAY TE, 1979, J BIOL CHEM, V254, P1576; BERNINSONE P, 1995, J BIOL CHEM, V270, P14564, DOI 10.1074/jbc.270.24.14564; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; Birkle S, 1999, J NEUROCHEM, V72, P954, DOI 10.1046/j.1471-4159.1999.0720954.x; Borsig L, 1998, GLYCOBIOLOGY, V8, P259, DOI 10.1093/glycob/8.3.259; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; Chen C, 2000, J BIOL CHEM, V275, P13819, DOI 10.1074/jbc.275.18.13819; Chen X, 2000, J BIOL CHEM, V275, P31594, DOI 10.1074/jbc.M004005200; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P2413; Dan N, 1997, J BIOL CHEM, V272, P14214, DOI 10.1074/jbc.272.22.14214; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P1; Fritz VMR, 1997, BBA-GENE STRUCT EXPR, V1354, P153, DOI 10.1016/S0167-4781(97)00117-6; Gao XD, 2000, J BIOL CHEM, V275, P17718, DOI 10.1074/jbc.M909946199; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Hakomori S, 1996, CANCER RES, V56, P5309; HANIU M, 1993, BIOCHEMISTRY-US, V32, P2431, DOI 10.1021/bi00060a039; HARAGUCHI M, 1995, BIOCHEM J, V312, P273, DOI 10.1042/bj3120273; HENION TR, 1994, GLYCOBIOLOGY, V4, P193, DOI 10.1093/glycob/4.2.193; Holmes EH, 2000, J BIOL CHEM, V275, P24237, DOI 10.1074/jbc.M000888200; Imberty A, 1997, PROTEIN ENG, V10, P1353, DOI 10.1093/protein/10.12.1353; Jaskiewicz E, 1996, GLYCOCONJUGATE J, V13, P213, DOI 10.1007/BF00731496; Jaskiewicz E, 1996, J BIOL CHEM, V271, P26395, DOI 10.1074/jbc.271.42.26395; Jensen ON, 1999, METH MOL B, V112, P513; Kolhekar AS, 1997, BIOCHEMISTRY-US, V36, P10901, DOI 10.1021/bi9708747; Leal WS, 1999, FEBS LETT, V464, P85, DOI 10.1016/S0014-5793(99)01683-X; Ma JY, 1996, J BIOL CHEM, V271, P7758, DOI 10.1074/jbc.271.13.7758; MANDON E, 1994, J BIOL CHEM, V269, P11729; MANDON EC, 1994, P NATL ACAD SCI USA, V91, P10707, DOI 10.1073/pnas.91.22.10707; MINAMITAKE Y, 1990, J BIOCHEM-TOKYO, V107, P292, DOI 10.1093/oxfordjournals.jbchem.a123041; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NAVARATNAM N, 1988, EUR J BIOCHEM, V171, P623, DOI 10.1111/j.1432-1033.1988.tb13833.x; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; Opat AS, 2000, J BIOL CHEM, V275, P11836, DOI 10.1074/jbc.275.16.11836; Ouzzine M, 2000, J BIOL CHEM, V275, P28254; PATTERSON SD, 1994, ANAL CHEM, V66, P3727, DOI 10.1021/ac00093a030; PROUDFOOT AEI, 1991, FEBS LETT, V283, P61, DOI 10.1016/0014-5793(91)80553-F; Schutte CG, 1998, PROTEIN SCI, V7, P1039; Sheikh KA, 1999, P NATL ACAD SCI USA, V96, P7532, DOI 10.1073/pnas.96.13.7532; Shen GJ, 1999, J BIOL CHEM, V274, P35139, DOI 10.1074/jbc.274.49.35139; SMITH PL, 1994, J BIOL CHEM, V269, P15162; Takamiya K, 1998, P NATL ACAD SCI USA, V95, P12147, DOI 10.1073/pnas.95.21.12147; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VANECHTENDECKER.G, 1998, COMPREHENSIVE NATURA, V3, P87; VILLA S, 1989, ANAL BIOCHEM, V177, P161, DOI 10.1016/0003-2697(89)90032-8; Volchkova VA, 1998, VIROLOGY, V250, P408, DOI 10.1006/viro.1998.9389; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YAMAGUCHI N, 1995, J BIOL CHEM, V270, P12170, DOI 10.1074/jbc.270.20.12170; Yen TY, 2000, J MASS SPECTROM, V35, P990, DOI 10.1002/1096-9888(200008)35:8<990::AID-JMS27>3.0.CO;2-K; Zhu GF, 1998, GLYCOBIOLOGY, V8, P831, DOI 10.1093/glycob/8.8.831	55	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41476	41486		10.1074/jbc.M007480200	http://dx.doi.org/10.1074/jbc.M007480200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018043	hybrid			2022-12-25	WOS:000166114600106
J	Misenheimer, TM; Huwiler, KG; Annis, DS; Mosher, DF				Misenheimer, TM; Huwiler, KG; Annis, DS; Mosher, DF			Physical characterization of the procollagen module of human thrombospondin 1 expressed in insect cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL PROPEPTIDE; PREDICTING COILED COILS; CYSTEINE-RICH DOMAIN; TISSUE GROWTH-FACTOR; AMYLOID-P COMPONENT; C-REACTIVE PROTEIN; LAMININ G-LIKE; VONWILLEBRAND-FACTOR; CIRCULAR-DICHROISM; ENDOTHELIAL-CELLS	Thrombospondin 1 (TSP1) is a homotrimeric glycoprotein composed of 150-kDa subunits connected by disulfide bridges. The procollagen module of thrombospondin 1 has been implicated in antiangiogenic activity. Procollagen modules are found in a number of extracellular proteins and are identifiable by 10 cysteines with characteristic spacing. We expressed and studied the procollagen module (C) of human TSP1, both by itself and in the context of the adjoining oligomerization sequence (o) and N-terminal module (N). The coding sequences were introduced into baculoviruses along with an N-terminal signal sequence and C-terminal poly-histidine tag. Proteins were purified from conditioned medium of infected insect cells by nickel-chelate chromatography. NoC is a disulfide bonded trimer and cleaves readily at a site of preferential proteolysis to yield monomeric N and trimeric oC. These are known properties of full-length TSP1. Mass spectroscopy indicated that C is N-glycosylated, and all 10 cysteine residues of C are in disulfides. By equilibrium ultracentrifugation, C is a monomer in physiological salt solution. Circular dichroism, intrinsic fluorescence, and differential scanning calorimetry experiments suggest that the stability of C is determined by the disulfides. The two tryptophans of C are in a polar, exposed environment as assessed by iodide fluorescence quenching and solvent perturbation. The oC far UV circular dichroism spectrum could be modeled as the sum of C and a coiled-coil oligomerization domain. The results indicate that the recombinant C folds autonomously into its native structure, and trimerization of the modules in TSP1 does not perturb their structures.	Univ Wisconsin, Dept Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Misenheimer, TM (corresponding author), Univ Wisconsin, Dept Med, 1300 Univ Ave, Madison, WI 53706 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054462] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54462] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BALE MD, 1986, J BIOL CHEM, V261, P862; Beckmann G, 1998, J MOL BIOL, V275, P725, DOI 10.1006/jmbi.1997.1510; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BORK P, 1992, FEBS LETT, V307, P49, DOI 10.1016/0014-5793(92)80900-2; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; Bottazzi B, 1997, J BIOL CHEM, V272, P32817, DOI 10.1074/jbc.272.52.32817; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; CHAPMAN JA, 1989, BIOPOLYMERS, V28, P1367, DOI 10.1002/bip.360280803; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; ENGEL J, 1977, BIOCHEMISTRY-US, V16, P4026, DOI 10.1021/bi00637a014; FOUSER L, 1991, P NATL ACAD SCI USA, V88, P10158, DOI 10.1073/pnas.88.22.10158; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Herskovits TT, 1967, METHOD ENZYMOL, V11, P748; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; HUNT LT, 1987, BIOCHEM BIOPH RES CO, V144, P876, DOI 10.1016/S0006-291X(87)80046-3; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; Kanda S, 1999, EXP CELL RES, V252, P262, DOI 10.1006/excr.1999.4622; LAHAV J, 1998, BIOCHIM BIOPHYS ACTA, P1; Lakowicz J. R., 1983, PRINCIPLES FLUORESCE, P305; Larrain J, 2000, DEVELOPMENT, V127, P821; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1992, BIOCHEMISTRY-US, V31, P1173, DOI 10.1021/bi00119a029; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER JW, 1981, THROMB RES, V22, P267, DOI 10.1016/0049-3848(81)90119-5; Lehrer S S, 1978, Methods Enzymol, V49, P222; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; MERELO JJ, 1994, NEUROCOMPUTING, V6, P443, DOI 10.1016/0925-2312(94)90021-3; Mikhailenko I, 1997, J BIOL CHEM, V272, P6784, DOI 10.1074/jbc.272.10.6784; MIYAZAWA K, 1990, J IMMUNOL, V145, P650; MORADIAMELI M, 1994, MATRIX BIOL, V14, P233, DOI 10.1016/0945-053X(94)90187-2; MOSHER DF, 1990, ANNU REV MED, V41, P85; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; MURPHYULLRICH JE, 1985, BLOOD, V66, P1098; NELSON RE, 1994, EMBO J, V13, P3438, DOI 10.1002/j.1460-2075.1994.tb06649.x; Oelgeschlager M, 2000, NATURE, V405, P757, DOI 10.1038/35015500; Panetti TS, 2000, ARTERIOSCL THROM VAS, V20, P1013, DOI 10.1161/01.ATV.20.4.1013; Rademaker G J, 1996, Methods Mol Biol, V61, P231; RYAN MC, 1990, J BIOL CHEM, V265, P10334; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Schmid F. Z., 1997, PROTEIN STRUCTURE PR, P261; SCHONBAUM CP, 1992, DEV BIOL, V151, P431, DOI 10.1016/0012-1606(92)90183-H; SMITH KF, 1991, BIOCHEMISTRY-US, V30, P8000, DOI 10.1021/bi00246a018; SOTTILE J, 1991, BIOCHEMISTRY-US, V30, P6556, DOI 10.1021/bi00240a028; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TROMP G, 1988, BIOCHEM J, V253, P919, DOI 10.1042/bj2530919; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; WADA Y, 1996, PROTEIN PEPTIDE ANAL, P101; WOLF FW, 1990, GENOMICS, V6, P685, DOI 10.1016/0888-7543(90)90505-O; WOODBURY D, 1989, J BIOL CHEM, V264, P2735; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; WOOLFSON DN, 1995, PROTEIN SCI, V4, P1596, DOI 10.1002/pro.5560040818; WU CH, 1986, J BIOL CHEM, V261, P482; Zhu Y, 1999, J CELL BIOL, V144, P1069, DOI 10.1083/jcb.144.5.1069	66	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40938	40945		10.1074/jbc.M007022200	http://dx.doi.org/10.1074/jbc.M007022200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11016937	hybrid			2022-12-25	WOS:000166114600038
J	Paramio, JM; Segrelles, C; Casanova, ML; Jorcano, JL				Paramio, JM; Segrelles, C; Casanova, ML; Jorcano, JL			Opposite functions for E2F1 and E2F4 in human epidermal keratinocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; UBIQUITIN-PROTEASOME PATHWAY; RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F1; DEREGULATED EXPRESSION; FIBROBLASTS LEADS; FAMILY PROTEINS; PROLIFERATION; MEMBER; APOPTOSIS	Proteins of the retinoblastoma family (pRb, p107, and p130) modulate cell proliferation, a function related to their capacity to control the activity of the E2F transcription factor family. The Rb proteins also control cell differentiation in different tissues. We have recently described their involvement in human epidermal keratinocyte differentiation (Paramio, J. M., Lain, S., Segrelles, C., Lane, E. B., and Jorcano, J. L. (1998) Oncogene 17, 949-957), Here we show that E2F proteins are also involved in this process. We found that E2F1 and E2F4 are expressed differentially during the in vitro differentiation of human epidermal keratinocytes, with the former uniformly present throughout the process, whereas the second is predominantly expressed at the onset of differentiation. This pattern is also observed in human skin by confocal microscopy. Electrophoretic mobility shift assays and immunoprecipitation experiments demonstrated that the complexes formed by E2F1 and E2F4 and Rb family proteins vary throughout in vitro keratinocyte differentiation. In agreement with this observation, several E2F-responsive genes are differentially regulated during this process. To test the functional implications of these observations, we transfected Ha-CaT keratinocytes with plasmids coding for E2F1 and E2F4. Transfected cells display opposite in vitro differentiation properties. Although E2F1-transfected cells are unable to differentiate, E2F4-transfected cells show an increased differentiation rate compared with Neo-transfected control cells. Our data demonstrate that the differential and coordinated expression and interaction of E2F and Rb proteins modulate the process of epidermal differentiation and provide clear evidence that members of the E2F family of transcription factors play specific and opposite roles during cell differentiation.	CIEMAT, Cell & Mol Biol Program, E-28040 Madrid, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas	Paramio, JM (corresponding author), CIEMAT, Cell & Mol Biol Program, Edificio 7,Av Complutense 22, E-28040 Madrid, Spain.		Paramio, Jesus M/M-8482-2014; Segrelles, Carmen/E-3655-2016	Paramio, Jesus M/0000-0001-7520-3177; Segrelles, Carmen/0000-0001-9340-2102; Casanova, M. Llanos/0000-0001-7742-8265				BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Botz J, 1996, MOL CELL BIOL, V16, P3401; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dagnino L, 1997, CELL GROWTH DIFFER, V8, P553; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; Geng Y, 1996, ONCOGENE, V12, P1173; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Huet X, 1996, MOL CELL BIOL, V16, P3789; JOHNSON DG, 1993, NATURE, V365, P849; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Paramio JM, 1997, BRIT J DERMATOL, V137, P44, DOI 10.1111/j.1365-2133.1997.tb03699.x; Paramio JM, 1998, ONCOGENE, V17, P949, DOI 10.1038/sj.onc.1202031; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Richon VM, 1996, CELL GROWTH DIFFER, V7, P31; Rodriguez-Puebla ML, 1998, ONCOGENE, V17, P2251, DOI 10.1038/sj.onc.1202131; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SARDET C, 1997, ONCOGENES TRANSCRIPT, V2, P1; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Soucek T, 1997, ONCOGENE, V14, P2251, DOI 10.1038/sj.onc.1201061; Strom DK, 1998, CELL GROWTH DIFFER, V9, P59; Tevosian SG, 1996, CELL GROWTH DIFFER, V7, P43; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; WANG J, 1995, CELL GROWTH DIFFER, V6, P1299; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zacksenhaus E, 1996, EMBO J, V15, P5917, DOI 10.1002/j.1460-2075.1996.tb00978.x	54	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41219	41226		10.1074/jbc.M004973200	http://dx.doi.org/10.1074/jbc.M004973200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11005809	hybrid			2022-12-25	WOS:000166114600075
J	Ranganathan, G; Li, CL; Kern, PA				Ranganathan, G; Li, CL; Kern, PA			The translational regulation of lipoprotein lipase in diabetic rats involves the 3 '-untranslated region of the lipoprotein lipase mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ADIPOSE-TISSUE; SUBUNIT MESSENGER-RNAS; GENE-EXPRESSION; THYROID-HORMONE; HEAVY-SUBUNIT; ADIPOCYTES; PROTEIN; FERRITIN; SEQUENCE; EPINEPHRINE	Adipose tissue:lipoprotein lipase (LPL) activity is decreased in patients with poorly controlled diabetes, and this contributes to the dyslipidemia of diabetes. To study the mechanism of this decrease in LPL, we studied adipose tissue LPL expression in male rats with streptozotocin-induced diabetes. Heparin releasable and extractable LPL activity in the epididymal fat decreased by 75-80% in the diabetic group and treatment of the rats with insulin prior to sacrifice reversed this effect, Northern blot analysis indicated no corresponding change in LPL mRNA levels. However, LPL synthetic rate, measured using [S-35]methionine pulse labeling, was decreased by 75% in the diabetic adipocytes, and insulin treatment reversed this effect. These results suggested regulation of LPL at the level of translation, Diabetic adipocytes demonstrated no change in the distribution of LPL mRNA associated with polysomes, suggesting no inhibition of translation initiation. Addition of cytoplasmic extracts from control and diabetic adipocytes to a reticulocyte lysate system demonstrated the inhibition of LPL translation in vitro. Using different LPL mRNA transcripts in this in vitro translation assay, we found that the 3'-untranslated region (UTR) of the LPL mRNA was important in controlling translation inhibition by the cytoplasmic extracts, To identify the specific region involved, gel shift analysis was performed. A specific shift in mobility was observed when diabetic cytoplasmic extract was added to a transcript containing nucleotides 1818-2000 of the LPL 3'-UTR, Thus, inhibition of translation is the predominant mechanism for the decreased adipose tissue LPL in this insulin-deficient model of diabetes. Translation inhibition involves the interaction of a cytoplasmic factor, probably an RNA-binding protein, with specific sequences of the LPL 3'-UTR.	Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Div Endocrinol, Dept Med, Little Rock, AR 72205 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System; University of Arkansas System; University of Arkansas Medical Sciences	Kern, PA (corresponding author), Cent Arkansas Vet Healthcare Syst 151LR, 4300 W 7th St, Little Rock, AR 72205 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039176, R01DK039176, R29DK039176] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39176] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHNG JL, 1990, SCIENCE, V245, P1003; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGIROLAMO M, 1971, AM J PHYSIOL, V221, P850, DOI 10.1152/ajplegacy.1971.221.3.850; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; ECKEL RH, 1987, LIPOPROTEIN LIPASE, P79; ENERBACK S, 1993, BIOCHIM BIOPHYS ACTA, V1169, P107, DOI 10.1016/0005-2760(93)90196-G; ENERBACK S, 1988, GENE, V64, P97, DOI 10.1016/0378-1119(88)90484-2; GOERS JWF, 1987, ANAL BIOCHEM, V166, P27, DOI 10.1016/0003-2697(87)90541-0; HARFORD JB, 1990, ENZYME, V44, P28, DOI 10.1159/000468745; HOLM C, 1988, SCIENCE, V241, P1503, DOI 10.1126/science.3420405; KERN PA, 1985, J CLIN INVEST, V75, P199, DOI 10.1172/JCI111675; Kern PA, 1996, J LIPID RES, V37, P2332; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Mead JR, 1999, FEBS LETT, V462, P1, DOI 10.1016/S0014-5793(99)01495-7; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; ONG JM, 1989, J CLIN INVEST, V84, P305, DOI 10.1172/JCI114155; ONG JM, 1988, J BIOL CHEM, V263, P12933; ONG JM, 1992, MOL ENDOCRINOL, V6, P61, DOI 10.1210/me.6.1.61; ONG JM, 1994, J LIPID RES, V35, P1542; PFEIFER MA, 1983, DIABETES, V32, P525, DOI 10.2337/diabetes.32.6.525; PYKALISTO OJ, 1975, J CLIN INVEST, V56, P1108, DOI 10.1172/JCI108185; Ranganathan G, 1997, J BIOL CHEM, V272, P2515; Ranganathan G, 1999, J BIOL CHEM, V274, P9122, DOI 10.1074/jbc.274.13.9122; RANGANATHAN G, 1995, J BIOL CHEM, V270, P7149, DOI 10.1074/jbc.270.13.7149; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; SAFFARI B, 1992, J LIPID RES, V33, P241; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; SIMSOLO RB, 1992, J LIPID RES, V33, P89; TASKINEN M-R, 1987, Diabetes Metabolism Reviews, V3, P551; TASKINEN MR, 1979, DIABETOLOGIA, V17, P351, DOI 10.1007/BF01236268; TAVANGAR K, 1992, J CLIN INVEST, V90, P1672, DOI 10.1172/JCI116039; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; WORMINGTON M, 1994, BIOESSAYS, V16, P533, DOI 10.1002/bies.950160804; YUKHT A, 1995, J CLIN INVEST, V96, P2438, DOI 10.1172/JCI118301; Zechner R, 1997, CURR OPIN LIPIDOL, V8, P77, DOI 10.1097/00041433-199704000-00005	38	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40986	40991		10.1074/jbc.M008775200	http://dx.doi.org/10.1074/jbc.M008775200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024042	hybrid			2022-12-25	WOS:000166114600045
J	Schmidt, M; Goebeler, M; Posern, G; Feller, SM; Seitz, CS; Brocker, EB; Rapp, UR; Ludwig, S				Schmidt, M; Goebeler, M; Posern, G; Feller, SM; Seitz, CS; Brocker, EB; Rapp, UR; Ludwig, S			Ras-independent activation of the Raf/MEK/ERK pathway upon calcium-induced differentiation of keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-REGULATED KINASE; NERVE GROWTH-FACTOR; EXTRACELLULAR CALCIUM; TYROSINE KINASE; EPIDERMAL DIFFERENTIATION; TERMINAL DIFFERENTIATION; RAF-1 KINASE; IN-VITRO; CELLS	MAPKs are crucially involved in the regulation of growth and differentiation of a variety of cells. To elucidate the role of MAPKs in keratinocyte differentiation, activation of ERK, JNK, and p38 in response to stimulation with extracellular calcium was analyzed. We provide evidence that calcium-induced differentiation of keratinocytes is associated with rapid and transient activation of the Raf/MEK/ERK pathway. Stimulation of keratinocytes with extracellular calcium resulted in activation of Raf isozymes and their downstream effector ERK within 10-15 min, but did not increase JNK or p38 activity. Calcium-induced ERK activation differed in kinetics from mitogenic ERK activation by epidermal growth factor and could be modulated by alterations of intracellular calcium levels. Interestingly, calcium stimulation led to down-regulation of Ras activity at the same time that ERK activation was initiated. Expression of a dominant-negative mutant of Ras also did not significantly impair calcium-induced ERK activation, indicating that calcium-mediated ERK activation does not require active Ras, Despite the transient nature of ERK activation, calcium-induced expression of the cyclin-dependent kinase inhibitor p21/Cip1 and the differentiation marker involucrin was sensitive to MEK inhibition, which suggests a role for the Raf/MEK/ERK pathway in early stages of keratinocyte differentiation.	Univ Wurzburg, MSZ, D-97080 Wurzburg, Germany; Univ Wurzburg, Klin & Poliklin Haut & Geschlechtskrankheiten, D-97080 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Ludwig, S (corresponding author), Univ Wurzburg, MSZ, Versbacher Str 5, D-97080 Wurzburg, Germany.	s.ludwig@mail.uni-wuerzburg.de	Schmidt, Marc/E-8821-2010; Goebeler, Matthias/P-3612-2019; Goebeler, Matthias/F-7118-2013	Schmidt, Marc/0000-0002-8643-1615; Ludwig, Stephan/0000-0003-4490-3052				ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bikle DD, 1996, J CLIN INVEST, V97, P1085, DOI 10.1172/JCI118501; BIKLE DD, 1993, ENDOCR REV, V14, P3, DOI 10.1210/er.14.1.3; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CALAUTTI E, 1995, GENE DEV, V9, P2279, DOI 10.1101/gad.9.18.2279; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; Dotto Paolo, 1998, Frontiers in Bioscience, V3, pD502; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FILVAROFF E, 1992, MOL CELL BIOL, V12, P5319, DOI 10.1128/MCB.12.12.5319; FILVAROFF E, 1990, MOL CELL BIOL, V10, P1164, DOI 10.1128/MCB.10.3.1164; Flory E, 1996, J VIROL, V70, P2260, DOI 10.1128/JVI.70.4.2260-2268.1996; Forslind B, 1997, MICROSC RES TECHNIQ, V38, P373, DOI 10.1002/(SICI)1097-0029(19970815)38:4<373::AID-JEMT5>3.0.CO;2-K; FUCHS E, 1993, J CELL SCI, P197; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Haase I, 1997, J INVEST DERMATOL, V108, P748, DOI 10.1111/1523-1747.ep12292135; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; JAKEN S, 1988, CARCINOGENESIS, V9, P1033, DOI 10.1093/carcin/9.6.1033; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LI LW, 1995, J CELL PHYSIOL, V163, P105, DOI 10.1002/jcp.1041630112; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McNeil SE, 1998, J BIOL CHEM, V273, P1114, DOI 10.1074/jbc.273.2.1114; MEDEMA JP, 1994, MOL CELL BIOL, V14, P7078, DOI 10.1128/MCB.14.11.7078; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Oda Y, 2000, J BIOL CHEM, V275, P1183, DOI 10.1074/jbc.275.2.1183; Puri PL, 2000, GENE DEV, V14, P574; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; REISS M, 1991, J CELL PHYSIOL, V147, P281, DOI 10.1002/jcp.1041470213; Rheinwald J G, 1980, Methods Cell Biol, V21A, P229, DOI 10.1016/S0091-679X(08)60769-4; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Sharma SV, 1997, ONCOGENE, V14, P2641, DOI 10.1038/sj.onc.1201115; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STACEY DW, 1991, ONCOGENE, V6, P2297; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Todd C, 1998, AM J PATHOL, V153, P39, DOI 10.1016/S0002-9440(10)65543-5; Wixler V, 1996, FEBS LETT, V385, P131, DOI 10.1016/0014-5793(96)00363-8; Wojnowski L, 1998, MECH DEVELOP, V76, P141, DOI 10.1016/S0925-4773(98)00111-7; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193	54	87	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41011	41017		10.1074/jbc.M003716200	http://dx.doi.org/10.1074/jbc.M003716200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018025	hybrid			2022-12-25	WOS:000166114600049
J	Urlaub, H; Hartmuth, K; Kostka, S; Grelle, G; Luhrmann, R				Urlaub, H; Hartmuth, K; Kostka, S; Grelle, G; Luhrmann, R			A general approach for identification of RNA-Protein cross-linking sites within native human spliceosomal small nuclear ribonucleoproteins (snRNPs) - Analysis of RNA-protein contacts in native U1 and U4/U6.U5 snRNPs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SM-LIKE PROTEINS; IONIZATION MASS-SPECTROMETRY; U5 SNRNP; U6 SNRNA; CRYSTAL-STRUCTURE; SEQUENCE-ANALYSIS; GU DINUCLEOTIDE; CATALYTIC STEP; BINDING DOMAIN; RIBOSOMAL-RNA	We describe a novel approach to identify RNA-protein cross-linking sites within native small nuclear ribonucleoprotein (snRNP) particles from HeLa cells. It combines immunoprecipitation of the UV-irradiated particles under semi-denaturing conditions with primer extension analysis of the cross-linked RNA moiety. In a feasibility study, we initially identified the exact crosslinking sites of the U1 70-kDa (70K) protein in stem-loop I of U1 small nuclear RNA (snRNA) within purified U1 snRNPs and then confirmed the results by a large-scale preparation that allowed N-terminal sequencing and matrix-assisted laser desorption ionization mass spectrometry of purified cross-linked peptide-oligonucleotide complexes. We identified Tyr(112) and Leu(175) within the RNA-binding domain of the U1 70K protein to be cross-linked to G(28) and U-30 in stem-loop I, respectively. We further applied our immunoprecipitation approach to HeLa US snRNP, as part of purified 25 S U4/U6.U5 tri-snRNPs. Cross-linking sites between the US-specific 220-kDa protein (human homologue of Prp8p) and the U5 snRNA were located at multiple nucleotides within the highly conserved loop I and at one site in internal loop 1 of U5 snRNA The cross-linking of four adjacent nucleotides indicates an extended interaction surface between loop 1 and the 220-kDa protein. In summary, our approach provides a rapid method for identification of RNA-protein contact sites within native snRNP particles as well as other ribonucleoprotein particles.	Max Planck Inst Biophys Chem, Abt Zellulare Biochem, D-37077 Gottingen, Germany; Max Delbruck Ctr Mol Med, Prot Chem Abt, D-13125 Berlin, Germany	Max Planck Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Luhrmann, R (corresponding author), Max Planck Inst Biophys Chem, Abt Zellulare Biochem, Fassberg 11, D-37077 Gottingen, Germany.	reinhard.luehrmann@mpi-bpc.mpg.de						Achsel T, 1999, EMBO J, V18, P5789, DOI 10.1093/emboj/18.20.5789; Achsel T, 1998, MOL CELL BIOL, V18, P6756, DOI 10.1128/MCB.18.11.6756; BACH M, 1990, NUCLEIC ACIDS RES, V18, P449, DOI 10.1093/nar/18.3.449; Burge CB, 1999, RNA WORLD, P525; Chiara MD, 1997, EMBO J, V16, P4746, DOI 10.1093/emboj/16.15.4746; Collins CA, 1999, GENE DEV, V13, P1970, DOI 10.1101/gad.13.15.1970; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dix I, 1998, RNA, V4, P1674, DOI 10.1017/S1355838298412998; Fabrizio P, 1997, EMBO J, V16, P4092, DOI 10.1093/emboj/16.13.4092; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Hartmuth K, 1999, J MOL BIOL, V285, P133, DOI 10.1006/jmbi.1998.2300; HEINRICHS V, 1992, J MOL BIOL, V227, P15, DOI 10.1016/0022-2836(92)90678-D; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; Kambach C, 1999, CURR OPIN STRUC BIOL, V9, P222, DOI 10.1016/S0959-440X(99)80032-3; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; KASTNER B, 1992, J CELL BIOL, V116, P839, DOI 10.1083/jcb.116.4.839; Kastner B., 1998, RNP PARTICLES SPLICI, P95; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Laggerbauer B, 1996, NUCLEIC ACIDS RES, V24, P868, DOI 10.1093/nar/24.5.868; Lauber J, 1996, EMBO J, V15, P4001, DOI 10.1002/j.1460-2075.1996.tb00774.x; LUTZREYERMUTH C, 1989, MOL CELL BIOL, V9, P2975, DOI 10.1128/MCB.9.7.2975; Mayes AE, 1999, EMBO J, V18, P4321, DOI 10.1093/emboj/18.15.4321; METZBOUTIGUE MH, 1989, FEBS LETT, V245, P194, DOI 10.1016/0014-5793(89)80220-0; NELISSEN RLH, 1994, EMBO J, V13, P4113, DOI 10.1002/j.1460-2075.1994.tb06729.x; Newman AJ, 1995, RNA, V1, P968; NORDHOFF E, 1993, NUCLEIC ACIDS RES, V21, P3347, DOI 10.1093/nar/21.15.3347; Nottrott S, 1999, EMBO J, V18, P6119, DOI 10.1093/emboj/18.21.6119; OKeefe RT, 1996, CELL, V86, P679, DOI 10.1016/S0092-8674(00)80140-3; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; QUERY CC, 1989, MOL CELL BIOL, V9, P4872, DOI 10.1128/MCB.9.11.4872; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; Reyes J, 1996, RNA, V2, P213; Reyes JL, 1999, RNA, V5, P167, DOI 10.1017/S1355838299981785; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Salgado-Garrido J, 1999, EMBO J, V18, P3451, DOI 10.1093/emboj/18.12.3451; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; Segault V, 1999, MOL CELL BIOL, V19, P2782; Siatecka M, 1999, GENE DEV, V13, P1983, DOI 10.1101/gad.13.15.1983; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; SUROWY CS, 1989, MOL CELL BIOL, V9, P4179, DOI 10.1128/MCB.9.10.4179; TEIGELKAMP S, 1995, EMBO J, V14, P2602, DOI 10.1002/j.1460-2075.1995.tb07258.x; Thiede B, 1999, METH MOL B, V118, P63; Umen JG, 1996, GENETICS, V143, P723; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; Urlaub H, 1997, J BIOL CHEM, V272, P14547, DOI 10.1074/jbc.272.23.14547; URLAUB H, 1995, EMBO J, V14, P4578, DOI 10.1002/j.1460-2075.1995.tb00137.x; Vidal VPI, 1999, RNA, V5, P1470, DOI 10.1017/S1355838299991355; Will CL, 1997, CURR OPIN CELL BIOL, V9, P320, DOI 10.1016/S0955-0674(97)80003-8; WILL CL, 1997, EUKARYOTIC MRNA PROC, P130; WILLIS MC, 1994, NUCLEIC ACIDS RES, V22, P4947, DOI 10.1093/nar/22.23.4947; WOPPMANN A, 1988, NUCLEIC ACIDS RES, V16, P10985, DOI 10.1093/nar/16.23.10985	57	52	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41458	41468		10.1074/jbc.M007434200	http://dx.doi.org/10.1074/jbc.M007434200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11006293	hybrid			2022-12-25	WOS:000166114600104
J	Volynski, KE; Meunier, FA; Lelianova, VG; Dudina, EE; Volkova, TM; Rahman, MA; Manser, C; Grishin, EV; Dolly, JO; Ashley, RH; Ushkaryov, YA				Volynski, KE; Meunier, FA; Lelianova, VG; Dudina, EE; Volkova, TM; Rahman, MA; Manser, C; Grishin, EV; Dolly, JO; Ashley, RH; Ushkaryov, YA			Latrophilin, neurexin, and their signaling-deficient mutants facilitate alpha-latrotoxin insertion into membranes but are not involved in pore formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WIDOW SPIDER VENOM; ADRENAL CHROMAFFIN CELLS; CALCIUM-INDEPENDENT RECEPTOR; TRANSMITTER RELEASE; BRAIN SYNAPTOSOMES; SYNAPTIC VESICLES; QUANTAL RELEASE; NERVE-TERMINALS; STORED CA2+; I-ALPHA	Pure alpha -latrotoxin is very inefficient at forming channels/pores in artificial lipid bilayers or in the plasma membrane of non-secretory cells. However, the toxin induces pores efficiently in COS-7 cells transfected with the heptahelical receptor latrophilin or the monotopic receptor neurexin. Signaling-deficient (truncated) mutants of latrophilin and latrophilin-neurexin hybrids also facilitate pore induction, which correlates with toxin binding irrespective of receptor structure. This rules out the involvement of signaling in pore formation. With any receptor, the alpha -latrotoxin pores are permeable to Ca2+ and small molecules including fluorescein isothiocyanate and norepinephrine. Bound alpha -latrotoxin remains on the cell surface without penetrating completely into the cytosol. Higher temperatures facilitate insertion of the toxin into the plasma membrane, where it co-localizes with latrophilin (under all conditions) and with neurexin tin the presence of Ca2+). Interestingly, on subsequent removal of Ca2+, alpha -latrotoxin dissociates from neurexin but remains in the membrane and continues to form pores. These receptor-independent pores are inhibited by anti-alpha -latrotoxin antibodies. Our results indicate that (i) c alpha -latrotoxin is a pore-forming toxin, (ii) receptors that bind alpha -latrotoxin facilitate its insertion into the membrane, (iii) the receptors are not physically involved in the pore structure, (iv) alpha -latrotoxin pores may be independent of the receptors, and (v) pore formation does not require alpha -latrotoxin interaction with other neuronal proteins.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England; Univ Edinburgh, Dept Biomed Sci, Edinburgh EH8 9XD, Midlothian, Scotland; Russian Acad Sci, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Moscow 117871, Russia	Imperial College London; University of Edinburgh; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences	Ushkaryov, YA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England.		Meunier, Frederic A/C-8161-2009; Dolly, Oliver/ABH-6677-2020; Ushkaryov, Yuri/AAQ-2985-2020; Dolly, Oliver/G-1532-2012	Meunier, Frederic A/0000-0001-6400-1107; Dolly, Oliver/0000-0002-0861-5320; Ushkaryov, Yuri/0000-0002-5712-8297; Dolly, Oliver/0000-0002-0861-5320; Volynski, Kirill/0000-0001-8208-1905				Ashley RH, 1995, ESSAYS BIOCHEM, V30, P97; Ashton AC, 2000, BIOCHIMIE, V82, P453, DOI 10.1016/S0300-9084(00)00199-1; Barnett DW, 1996, PFLUG ARCH EUR J PHY, V432, P1039, DOI 10.1007/s004240050232; Bittner MA, 1998, J NEUROSCI, V18, P2914; Davletov BA, 1998, EMBO J, V17, P3909, DOI 10.1093/emboj/17.14.3909; DAVLETOV BA, 1995, J BIOL CHEM, V270, P23903, DOI 10.1074/jbc.270.41.23903; Davletov BA, 1996, J BIOL CHEM, V271, P23239, DOI 10.1074/jbc.271.38.23239; DePotter WP, 1997, SYNAPSE, V25, P44, DOI 10.1002/(SICI)1098-2396(199701)25:1<44::AID-SYN6>3.0.CO;2-F; DERI Z, 1993, J NEUROCHEM, V60, P1065, DOI 10.1111/j.1471-4159.1993.tb03255.x; FILIPPOV AK, 1994, NEUROSCIENCE, V61, P179, DOI 10.1016/0306-4522(94)90070-1; FINKELSTEIN A, 1976, SCIENCE, V193, P1009, DOI 10.1126/science.948756; FRONTALI N, 1976, J CELL BIOL, V68, P462, DOI 10.1083/jcb.68.3.462; Geppert M, 1998, J BIOL CHEM, V273, P1705, DOI 10.1074/jbc.273.3.1705; GORIO A, 1978, J CELL BIOL, V78, P716, DOI 10.1083/jcb.78.3.716; GORIO A, 1978, J NEUROCYTOL, V7, P193, DOI 10.1007/BF01217918; GRASSO A, 1980, NATURE, V283, P774, DOI 10.1038/283774a0; Hlubek MD, 2000, MOL PHARMACOL, V57, P519, DOI 10.1124/mol.57.3.519; HURLBUT WP, 1994, J MEMBRANE BIOL, V138, P91, DOI 10.1007/BF00211072; Ichtchenko K, 1998, EMBO J, V17, P6188, DOI 10.1093/emboj/17.21.6188; KOBAYASHI H, 1986, NEUROSCI LETT, V65, P114, DOI 10.1016/0304-3940(86)90130-8; KRASILNIKOV OV, 1992, BIOCHIM BIOPHYS ACTA, V1112, P124, DOI 10.1016/0005-2736(92)90262-K; Krasnoperov V, 1999, J BIOL CHEM, V274, P3590, DOI 10.1074/jbc.274.6.3590; Krasnoperov VG, 1996, BIOCHEM BIOPH RES CO, V227, P868, DOI 10.1006/bbrc.1996.1598; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Liu J, 1998, J NEUROSCI, V18, P6113; Liu J, 1998, BRAIN RES, V799, P55, DOI 10.1016/S0006-8993(98)00467-3; MAGAZANIK LG, 1992, NEUROSCIENCE, V46, P181, DOI 10.1016/0306-4522(92)90017-V; Mathi SK, 1997, MOL ENDOCRINOL, V11, P424, DOI 10.1210/me.11.4.424; MCMAHON HT, 1990, J NEUROCHEM, V55, P2039, DOI 10.1111/j.1471-4159.1990.tb05793.x; MELDOLESI J, 1982, J NEUROCHEM, V38, P1559, DOI 10.1111/j.1471-4159.1982.tb06633.x; MELDOLESI J, 1984, P NATL ACAD SCI-BIOL, V81, P620, DOI 10.1073/pnas.81.2.620; Meunier FA, 1997, NEUROSCIENCE, V78, P883, DOI 10.1016/S0306-4522(96)00568-4; MIRONOV SL, 1986, BIOCHIM BIOPHYS ACTA, V862, P185, DOI 10.1016/0005-2736(86)90482-7; NICHOLLS DG, 1982, P NATL ACAD SCI-BIOL, V79, P7924, DOI 10.1073/pnas.79.24.7924; Okamoto Y, 1997, J BIOL CHEM, V272, P21589, DOI 10.1074/jbc.272.34.21589; Orlova EV, 2000, NAT STRUCT BIOL, V7, P48, DOI 10.1038/71247; Rahman MA, 1999, PHILOS T ROY SOC B, V354, P379, DOI 10.1098/rstb.1999.0390; ROSENTHAL L, 1990, MOL PHARMACOL, V38, P917; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; Rucklidge GJ, 1996, ANAL BIOCHEM, V243, P158, DOI 10.1006/abio.1996.0495; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; Tse FW, 1999, ENDOCRINOLOGY, V140, P3025, DOI 10.1210/en.140.7.3025; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1986, BIOORG KHIM+, V12, P71; Van Renterghem C, 2000, EUR J NEUROSCI, V12, P3953, DOI 10.1046/j.1460-9568.2000.00282.x; VICENTINI LM, 1984, BIOCHEM BIOPH RES CO, V121, P538, DOI 10.1016/0006-291X(84)90215-8; WANKE E, 1986, BIOCHEM BIOPH RES CO, V134, P320, DOI 10.1016/0006-291X(86)90565-6; WESS J, 1995, LIFE SCI, V56, P915, DOI 10.1016/0024-3205(95)00028-5; Williams A. J., 1995, ION CHANNELS PRACTIC, P43	51	39	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41175	41183		10.1074/jbc.M005857200	http://dx.doi.org/10.1074/jbc.M005857200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024019	hybrid			2022-12-25	WOS:000166114600070
J	Kottom, TJ; Limper, AH				Kottom, TJ; Limper, AH			Cell wall assembly by Pneumocystis carinii - Evidence for a unique Gsc-1 subunit mediating beta-1,3-glucan deposition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; BETA-GLUCAN RECEPTORS; SACCHAROMYCES-CEREVISIAE; ALVEOLAR MACROPHAGES; CANDIDA-ALBICANS; 1,3-BETA-D-GLUCAN SYNTHASE; LIFE-CYCLE; CYST WALL; 1,3-BETA-GLUCAN SYNTHESIS; ARACHIDONIC-ACID	Pneumocystis carinii remains a persistent cause of severe pneumonia in immune compromised patients. Recent studies indicate that P. carinii is a fungal species possessing a glucan-rich cyst wall. Pneumocandin antagonists of beta -1,3-glucan synthesis rapidly suppress infection in animal models of P. carinii pneumonia. We, therefore, sought to define the molecular mechanisms of P-glucan cell wall assembly by P. carinii. Membrane extracts derived from freshly purified P. carinii incorporate uridine 5'-diphosphoglucose into insoluble carbohydrate, in a manner that was completely inhibited by the pneumocandin L733-560, an antagonist of Gsc-1-type p-glucan synthetases. Using degenerative polymerase chain reaction and library screening, the P. carinii Gsc-1 catalytic subunit of beta -1,3-glucan synthetase was cloned and characterized. P. carinii gsc1 exhibited homology to phylogenetically related fungal beta -1,3-glucan synthetases, encoding a predicted 214-kDa integral membrane protein with 12 transmembrane domain structure. Immunoprecipitation of P. carinii extracts, with a synthetic peptide anti-Gsc-1 antibody, specifically yielded a protein of 219.4 kDa, which was also capable of incorporating 5'-diphosphoglucose into insoluble glucan carbohydrate. As opposed to other fungi, the expression of gsc-1 mRNA is uniquely regulated over P. carinii's life cycle, having minimal expression in trophic forms, but substantial expression in the thick-walled cystic form of the organism. These results indicate that P. carinii contains a unique catalytic subunit of beta -1,3-glucan synthetase utilized in cyst wall formation. Because synthesis of beta -1,3-glucan is absent in mammalian cells, inhibition of the P. carinii Gsc-1 represents an attractive molecular target for therapeutic exploitation.	Mayo Clin, Thorac Dis Res Unit, Dept Med, Rochester, MN 55905 USA; Mayo Clin, Thorac Dis Res Unit, Dept Biochem, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Limper, AH (corresponding author), Mayo Clin, Thorac Dis Res Unit, Dept Med, 601C Guggenheim Bldg, Rochester, MN 55905 USA.				NHLBI NIH HHS [R01 HL062150] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062150] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BACON JSD, 1969, BIOCHEM J, V114, P557, DOI 10.1042/bj1140557; Bartlett MS, 1996, ANTIMICROB AGENTS CH, V40, P1811, DOI 10.1128/AAC.40.8.1811; Bruns TD, 1992, MOL PHYLOGENET EVOL, V1, P231, DOI 10.1016/1055-7903(92)90020-H; CABIB E, 1987, METHOD ENZYMOL, V138, P637; CAMPBELL WG, 1972, ARCH PATHOL, V93, P312; Carlson CR, 1997, YEAST, V13, P1329; CASTRO C, 1995, J BACTERIOL, V177, P5732, DOI 10.1128/jb.177.20.5732-5739.1995; CASTRO M, 1994, INFECT IMMUN, V62, P3138, DOI 10.1128/IAI.62.8.3138-3145.1994; CROSS CE, 1995, INFECT IMMUN, V63, P2604, DOI 10.1128/IAI.63.7.2604-2611.1995; CUSHION MT, 1993, INFECT IMMUN, V61, P4801, DOI 10.1128/IAI.61.11.4801-4813.1993; CZOP JK, 1985, P NATL ACAD SCI USA, V82, P2751, DOI 10.1073/pnas.82.9.2751; DAUM T, 1992, FEBS LETT, V309, P119, DOI 10.1016/0014-5793(92)81077-Y; DESTEFANO JA, 1990, J PROTOZOOL, V37, P428; DURKIN ME, 1991, J PROTOZOOL, V38, P210; EDMAN JC, 1988, NATURE, V334, P519, DOI 10.1038/334519a0; ELSADR W, 1988, AM REV RESPIR DIS, V137, P1264, DOI 10.1164/ajrccm/137.6.1264; ELSHERBEINI M, 1995, J BACTERIOL, V177, P3227, DOI 10.1128/jb.177.11.3227-3234.1995; ENDERLIN CS, 1994, P NATL ACAD SCI USA, V91, P9500, DOI 10.1073/pnas.91.20.9500; FLETCHER LD, 1993, GENE, V129, P167, DOI 10.1016/0378-1119(93)90265-5; FLETCHER LD, 1994, GENETICS, V137, P743; GIGLIOTTI F, 1993, J INFECT DIS, V168, P191, DOI 10.1093/infdis/168.1.191; HIDALGO HA, 1991, J PROTOZOOL, V38, pS30; HOFFMAN OA, 1993, J IMMUNOL, V150, P3932; HOFFMAN OA, 1993, IMMUNOL LETT, V37, P19, DOI 10.1016/0165-2478(93)90127-N; INOUE SB, 1995, EUR J BIOCHEM, V231, P845, DOI 10.1111/j.1432-1033.1995.tb20770.x; Itatani CA, 1996, J PARASITOL, V82, P163, DOI 10.2307/3284134; JANUSZ MJ, 1988, IMMUNOLOGY, V65, P181; JANUSZ MJ, 1987, J IMMUNOL, V138, P3897; Kelly R, 1996, J BACTERIOL, V178, P4381, DOI 10.1128/jb.178.15.4381-4391.1996; Kollar R, 1997, J BIOL CHEM, V272, P17762, DOI 10.1074/jbc.272.28.17762; Kurtz MB, 1996, INFECT IMMUN, V64, P3244, DOI 10.1128/IAI.64.8.3244-3251.1996; LIMPER AH, 1990, J CLIN INVEST, V85, P391, DOI 10.1172/JCI114451; Limper AH, 1997, J CLIN INVEST, V99, P2110, DOI 10.1172/JCI119384; LIMPER AH, 1989, AM REV RESPIR DIS, V140, P1204, DOI 10.1164/ajrccm/140.5.1204; Limper AH, 1997, J EUKARYOT MICROBIOL, V44, p32S, DOI 10.1111/j.1550-7408.1997.tb05756.x; Limper AH, 1998, J CLIN INVEST, V101, P1148, DOI 10.1172/JCI659; Limper AH, 1997, J LAB CLIN MED, V130, P132, DOI 10.1016/S0022-2143(97)90089-5; LINKE MJ, 1989, INFECT IMMUN, V57, P1547, DOI 10.1128/IAI.57.5.1547-1555.1989; LUNDGREN B, 1991, J CLIN INVEST, V87, P163, DOI 10.1172/JCI114966; MACNEILL SA, 1995, CELL CYCLE CONTROL, P63; MANNERS DJ, 1973, BIOCHEM J, V135, P19, DOI 10.1042/bj1350019; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; Merali S, 1999, P NATL ACAD SCI USA, V96, P2402, DOI 10.1073/pnas.96.5.2402; Mio T, 1997, J BACTERIOL, V179, P4096, DOI 10.1128/jb.179.13.4096-4105.1997; NOLLSTADT KH, 1994, ANTIMICROB AGENTS CH, V38, P2258, DOI 10.1128/AAC.38.10.2258; Olson EJ, 1996, INFECT IMMUN, V64, P3548, DOI 10.1128/IAI.64.9.3548-3554.1996; Powles MA, 1998, ANTIMICROB AGENTS CH, V42, P1985, DOI 10.1128/AAC.42.8.1985; RASSMUSSEN LT, 1992, J CELL BIOCHEM, V46, P60; Roth A, 1997, PARASITOL RES, V83, P177, DOI 10.1007/s004360050229; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMATZ DM, 1995, ANTIMICROB AGENTS CH, V39, P1320, DOI 10.1128/AAC.39.6.1320; SCHMATZ DM, 1990, P NATL ACAD SCI USA, V87, P5950, DOI 10.1073/pnas.87.15.5950; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SLOAND E, 1993, J EUKARYOT MICROBIOL, V40, P188, DOI 10.1111/j.1550-7408.1993.tb04902.x; STRINGER SL, 1993, J EUKARYOT MICROBIOL, V40, P821, DOI 10.1111/j.1550-7408.1993.tb04481.x; SUNKIN SM, 1995, J EUKARYOT MICROBIOL, V42, P12, DOI 10.1111/j.1550-7408.1995.tb01534.x; Tentler S, 1997, CURR MICROBIOL, V34, P303, DOI 10.1007/s002849900186; Thomas C F Jr, 1998, Semin Respir Infect, V13, P289; Thomas CF, 1999, INFECT IMMUN, V67, P6157, DOI 10.1128/IAI.67.11.6157-6160.1999; Thomas CF, 1998, AM J RESP CELL MOL, V18, P297, DOI 10.1165/ajrcmb.18.3.3122; THOMAS CF, 1998, AM J PHYSIOL, V275, P193; VANDEPEER Y, 1992, SYST APPL MICROBIOL, V15, P250, DOI 10.1016/S0723-2020(11)80099-8; Vassallo R, 1999, J LAB CLIN MED, V133, P535, DOI 10.1016/S0022-2143(99)90182-8; Yale SH, 1996, MAYO CLIN PROC, V71, P5, DOI 10.4065/71.1.5; Yasuoka A, 1996, CLIN DIAGN LAB IMMUN, V3, P197, DOI 10.1128/CDLI.3.2.197-199.1996; Yu ML, 1997, AM J PHYSIOL-LUNG C, V273, pL1103, DOI 10.1152/ajplung.1997.273.6.L1103	68	75	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40628	40634		10.1074/jbc.M002103200	http://dx.doi.org/10.1074/jbc.M002103200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11013231	hybrid			2022-12-25	WOS:000166039500111
J	Butt, AJ; Firth, SM; King, MA; Baxter, RC				Butt, AJ; Firth, SM; King, MA; Baxter, RC			Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; IGF-I RECEPTOR; GENE-EXPRESSION; FACTOR-BETA; RETINOIC ACID; DEATH; INHIBITION; FIBROBLASTS; INDUCTION; RESISTANCE	We report that transfection of insulin-like growth factor-binding protein-3 (IGPBP-3) cDNA in human breast cancer cell lines expressing either mutant p53 (T47D) or wild-type p53 (MCF-7) induces apoptosis, IGFBP-3 also increases the ratio of pro-apoptotic to anti-apoptotic members of the Bcl-2 family. In MCF-7, an increase in Bad and Bax protein expression and a decrease in Bcl-x(L) protein and Bcl-2 protein and mRNA were observed. In T47D, Bax and Bad proteins were up-regulated; Bcl-2 protein is undetectable in these cells. As T47D expresses mutant p53 protein, these modulations of pro-apoptotic proteins and induction of apoptosis are independent of p53. The effect of IGFBP-3 on the response of T47D to ionizing radiation (IR) was examined. These cells do not G(1) arrest in response to IR and are relatively radioresistant. Transfection of IGFBP-3 increased the radiosensitivity of T47D and increased IR-induced apoptosis but did not effect a rapid G(1) arrest. IR also caused a much greater increase in Bax protein in IGFBP-3 transfectants compared with vector controls. Thus, IGFBP-3 increases the expression of pro-apoptotic proteins and apoptosis both basally and in response to IR, suggesting it may be a p53-independent effector of apoptosis in breast cancer cells via its modulation of the Bax:Bcl-2 protein ratio.	Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia; Royal N Shore Hosp, Dept Clin Immunol, St Leonards, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research; Royal North Shore Hospital	Butt, AJ (corresponding author), Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia.		Baxter, Robert C/F-3927-2012	Baxter, Robert C/0000-0001-5061-2142; Butt, Alison/0000-0002-6216-5105				BAXTER RC, 1986, J CLIN INVEST, V78, P1504, DOI 10.1172/JCI112742; Blagosklonny MV, 1997, CANCER RES, V57, P130; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Butt AJ, 1999, IMMUNOL CELL BIOL, V77, P256, DOI 10.1046/j.1440-1711.1999.00822.x; CHEN JC, 1994, J CELL PHYSIOL, V158, P69, DOI 10.1002/jcp.1041580110; COHEN P, 1993, GROWTH REGULAT, V3, P23; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delhanty PJD, 1998, ENDOCRINOLOGY, V139, P260, DOI 10.1210/en.139.1.260; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; FIGUEROA JA, 1992, BREAST CANCER RES TR, V22, P81, DOI 10.1007/BF01833336; Firth SM, 1998, BIOCHEM BIOPH RES CO, V246, P325, DOI 10.1006/bbrc.1998.8615; Gill ZP, 1997, J BIOL CHEM, V272, P25602, DOI 10.1074/jbc.272.41.25602; Gucev ZS, 1996, CANCER RES, V56, P1545; Guo YP, 1999, CANCER RES, V59, P1366; Harima Y, 1998, J CANCER RES CLIN, V124, P503, DOI 10.1007/s004320050206; Kanatani Y, 1999, CELL GROWTH DIFFER, V10, P705; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Krajewski S, 1997, CLIN CANCER RES, V3, P199; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LOVE SW, 1993, NATURE, V362, P847; Martin JL, 1999, J BIOL CHEM, V274, P16407, DOI 10.1074/jbc.274.23.16407; MARTIN JL, 1995, ENDOCRINOLOGY, V136, P1219, DOI 10.1210/en.136.3.1219; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nickerson T, 1998, ENDOCRINOLOGY, V139, P807, DOI 10.1210/en.139.2.807; Nickerson T, 1999, J ENDOCRINOL, V160, P223, DOI 10.1677/joe.0.1600223; Nickerson T, 1997, BIOCHEM BIOPH RES CO, V237, P690, DOI 10.1006/bbrc.1997.7089; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; OH YM, 1993, J BIOL CHEM, V268, P14964; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OSBORNE CK, 1989, MOL ENDOCRINOL, V3, P1701, DOI 10.1210/mend-3-11-1701; OSBORNE RJ, 1991, CANCER RES, V51, P6194; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1355, DOI 10.1210/en.138.3.1355; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Rozen F, 1998, INT J ONCOL, V13, P865; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; Sakakura C, 1996, INT J CANCER, V67, P101, DOI 10.1002/(SICI)1097-0215(19960703)67:1<101::AID-IJC17>3.0.CO;2-H; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shen L, 1998, BIOCHEM PHARMACOL, V55, P1711, DOI 10.1016/S0006-2952(98)00045-8; Siles E, 1996, BRIT J CANCER, V73, P581, DOI 10.1038/bjc.1996.101; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Teramoto T, 1998, BIOCHEM BIOPH RES CO, V251, P56, DOI 10.1006/bbrc.1998.9411; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; Williams AC, 2000, CANCER RES, V60, P22; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509	51	176	186	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39174	39181		10.1074/jbc.M908888199	http://dx.doi.org/10.1074/jbc.M908888199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10998426	hybrid			2022-12-25	WOS:000165953100033
J	Shan, LX; Qiao, XD; Crona, JH; Behan, J; Wang, S; Laz, T; Bayne, M; Gustafson, EL; Monsma, FJ; Hedrick, JA				Shan, LX; Qiao, XD; Crona, JH; Behan, J; Wang, S; Laz, T; Bayne, M; Gustafson, EL; Monsma, FJ; Hedrick, JA			Identification of a novel neuromedin U receptor subtype expressed in the central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL-CHARACTERIZATION; CLONING; U-25	Neuromedin U is a neuropeptide prominently expressed in the upper gastrointestinal tract and central nervous system. Recently, GPR66/FM-3 (NmU-R1) was identified as a specific receptor for neuromedin U. A BLAST search of the GenBank(TM) genomic database using the NmU-R1 cDNA sequence revealed a human genomic fragment encoding a G protein-coupled receptor that we designated NmU-R2 based on its homology to NmU-R1. The full-length NmU-R2 cDNA was subsequently cloned stably expressed in 293 cells, and shown to mobilize intracellular calcium in response to neuromedin U. This response was dose-dependent (EC50 = 5 nm) and specific in that other neuromedins did not induce a calcium flux in receptor-transfected cells. Expression analysis of human NmU-R2 demonstrated its mRNA to be most highly expressed in central nervous system tissues. Based on these data, we conclude that NmU-R2 is a novel neuromedin U receptor subtype that is likely to mediate central nervous system-specific neuromedin U effects.	Schering Plough Res Inst, Human Genome Res, Kenilworth, NJ 07033 USA; Schering Plough Res Inst, Cardiovasc Cent Nervous Syst Res, Kenilworth, NJ 07033 USA	Merck & Company; Schering-Plough Research Institute; Merck & Company; Schering-Plough Research Institute	Hedrick, JA (corresponding author), Schering Plough Res Inst, Human Genome Res, 2015 Galloping Hill Rd,K-15-1-1800, Kenilworth, NJ 07033 USA.	joseph.hedrick@spcorp.com						AUSTIN C, 1995, J MOL ENDOCRINOL, V14, P157, DOI 10.1677/jme.0.0140157; BENITOORFILA MA, 1991, EUR J PHARMACOL, V193, P329, DOI 10.1016/0014-2999(91)90147-I; BOCKMAN CS, 1989, EUR J PHARMACOL, V171, P255, DOI 10.1016/0014-2999(89)90117-9; BROWN DR, 1988, EUR J PHARMACOL, V155, P159, DOI 10.1016/0014-2999(88)90415-3; CONLON JM, 1988, J NEUROCHEM, V51, P988, DOI 10.1111/j.1471-4159.1988.tb01837.x; Coward P, 1999, ANAL BIOCHEM, V270, P242, DOI 10.1006/abio.1999.4061; DOMIN J, 1992, REGUL PEPTIDES, V41, P1, DOI 10.1016/0167-0115(92)90508-R; Feighner SD, 1999, SCIENCE, V284, P2184, DOI 10.1126/science.284.5423.2184; Fujii R, 2000, J BIOL CHEM, V275, P21068, DOI 10.1074/jbc.M001546200; GARDINER SM, 1990, AM J PHYSIOL, V258, pR32, DOI 10.1152/ajpregu.1990.258.1.R32; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hedrick JA, 2000, MOL PHARMACOL, V58, P870, DOI 10.1124/mol.58.4.870; Hosoya M, 2000, J BIOL CHEM, V275, P29528, DOI 10.1074/jbc.M004261200; Howard AD, 2000, NATURE, V406, P70, DOI 10.1038/35017610; KAGE R, 1991, REGUL PEPTIDES, V33, P191, DOI 10.1016/0167-0115(91)90213-Z; LO G, 1992, MOL ENDOCRINOL, V6, P1538, DOI 10.1210/me.6.10.1538; MAGGI CA, 1990, BRIT J PHARMACOL, V99, P186, DOI 10.1111/j.1476-5381.1990.tb14675.x; Malendowicz L K, 1993, In Vivo, V7, P419; MALENDOWICZ LK, 1994, NEUROPEPTIDES, V26, P47, DOI 10.1016/0143-4179(94)90092-2; MINAMINO N, 1988, BIOCHEM BIOPH RES CO, V156, P355, DOI 10.1016/S0006-291X(88)80848-9; MINAMINO N, 1985, PEPTIDES, V6, P245, DOI 10.1016/0196-9781(85)90381-X; MINAMINO N, 1985, BIOCHEM BIOPH RES CO, V130, P1078, DOI 10.1016/0006-291X(85)91726-7; MURPHY R, 1990, PEPTIDES, V11, P613, DOI 10.1016/0196-9781(90)90066-E; Nandha KA, 1999, PEPTIDES, V20, P1203, DOI 10.1016/S0196-9781(99)00124-2; NANDHA KA, 1993, ENDOCRINOLOGY, V133, P482, DOI 10.1210/en.133.2.482; OHARTE F, 1991, PEPTIDES, V12, P11, DOI 10.1016/0196-9781(91)90159-M; Raddatz R, 2000, J BIOL CHEM, V275, P32452, DOI 10.1074/jbc.M004613200; Salmon AL, 2000, J BIOL CHEM, V275, P4549, DOI 10.1074/jbc.275.7.4549; Sullivan E, 1999, METH MOL B, V114, P125; SUMI S, 1987, LIFE SCI, V41, P1585, DOI 10.1016/0024-3205(87)90725-9; Szekeres PG, 2000, J BIOL CHEM, V275, P20247, DOI 10.1074/jbc.C000244200; Tan CP, 1998, GENOMICS, V52, P223, DOI 10.1006/geno.1998.5441	32	93	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39482	39486		10.1074/jbc.C000522200	http://dx.doi.org/10.1074/jbc.C000522200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11010960	hybrid			2022-12-25	WOS:000165953100074
J	Black, PN; DiRusso, CC; Sherin, D; MacColl, R; Knudsen, J; Weimar, JD				Black, PN; DiRusso, CC; Sherin, D; MacColl, R; Knudsen, J; Weimar, JD			Affinity labeling fatty acyl-CoA synthetase with 9-p-azidophenoxy nonanoic acid and the identification of the fatty acid-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR FADR; COENZYME-A SYNTHETASE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; RAT-LIVER; TRANSPORT PROTEIN; METABOLISM; BIOSYNTHESIS; ESTERS; SUPERFAMILY	Fatty acyl-CoA synthetase (FACS, fatty acid:CoA ligase, AMP-forming, EC 6.2.1.3) catalyzes the esterification of fatty acids to CoA thioesters for further metabolism and is hypothesized to play a pivotal role in the coupled transport and activation of exogenous long-chain fatty acids in Escherichia coli, Previous work on the bacterial enzyme identified a highly conserved region (FACS signature motif) common to long- and medium-chain acyl-CoA synthetases, which appears to contribute to the fatty acid binding pocket. In an effort to further define the fatty acid-binding domain within this enzyme, we employed the affinity labeled long-chain fatty acid [H-3]9-p-azidophenoxy nonanoic acid (APNA) to specifically modify the E. coli FAGS. [H-3]APNA labeling of the purified enzyme was saturable and specific for long-chain fatty acids as shown by the inhibition of modification with increasing concentrations of palmitate, The site of APNA modification was identified by digestion of [H-3]APNA cross-linked FAGS with trypsin and separation and purification of the resultant peptides using reverse phase high performance liquid chromatography, One specific H-3-labeled peptide, T33, was identified and following purification subjected to NH2-terminal sequence analysis. This approach yielded the peptide sequence PDATDEIIK which corresponded to residues 422 to 430 of FAGS. This peptide is immediately adjacent to the region of the enzyme that contains the FAGS signature motif (residues 431-455), This work represents the first direct identification of the carboxyl-containing substrate-binding domain within the adenylate-forming family of enzymes. The structural model for the E, coli FAGS predicts this moth lies within a cleft separating two distinct domains of the enzyme and is adjacent to a region that contains the AMP/ATP signature motif, which together are likely to represent the catalytic core of the enzyme.	Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA; Wadsworth Ctr, Div Mol Med, Albany, NY 12201 USA; Univ So Denmark, Inst Biochem & Mol Biol, Odense M, Denmark	Albany Medical College; Wadsworth Center; University of Southern Denmark	Black, PN (corresponding author), Albany Med Coll, Ctr Cardiovasc Sci, 47 New Scotland Ave,MC-8, Albany, NY 12208 USA.	blackp@mail.amc.edu	DiRusso, Concetta C/M-1884-2014	Black, Paul/0000-0002-6272-6881; DiRusso, Concetta/0000-0001-7388-9152				AIHAUD GP, 1994, FATTY ACIDS LIPIDS B; BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; Black PN, 2000, J NUTR, V130, p305S, DOI 10.1093/jn/130.2.305S; BLACK PN, 1992, J BIOL CHEM, V267, P25513; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; Chang KH, 1997, BIOCHEMISTRY-US, V36, P15650, DOI 10.1021/bi971262p; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DiRusso CC, 1999, MOL CELL BIOCHEM, V192, P41, DOI 10.1023/A:1006823831984; DiRusso CC, 2000, EUR J BIOCHEM, V267, P4422, DOI 10.1046/j.1432-1327.2000.01489.x; DiRusso CC, 1999, PROG LIPID RES, V38, P129, DOI 10.1016/S0163-7827(98)00022-8; DiRusso CC, 1998, J BIOL CHEM, V273, P33652, DOI 10.1074/jbc.273.50.33652; DIRUSSO CC, 1993, MOL MICROBIOL, V7, P311, DOI 10.1111/j.1365-2958.1993.tb01122.x; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; Faergeman N J, 2000, Subcell Biochem, V34, P175; Faergeman NJ, 1997, J BIOL CHEM, V272, P8531, DOI 10.1074/jbc.272.13.8531; FUJIMOTO Y, 1995, PROSTAG LEUKOTR ESS, V52, P255, DOI 10.1016/0952-3278(95)90046-2; FULCERI R, 1995, BIOCHEM J, V307, P391, DOI 10.1042/bj3070391; Gargiulo CE, 1999, J LIPID RES, V40, P881; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GORDON JI, 1991, J BIOL CHEM, V266, P8647; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; KAMEDA K, 1981, J BIOL CHEM, V256, P5702; KNOLL LJ, 1995, J BIOL CHEM, V270, P10861, DOI 10.1074/jbc.270.18.10861; KNOLL LJ, 1994, J BIOL CHEM, V269, P16348; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI JCK, 1993, RES COMMUN CHEM PATH, V82, P331; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Nimchuk Z, 2000, CELL, V101, P353, DOI 10.1016/S0092-8674(00)80846-6; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; PAVELAVRANCIC M, 1994, BIOCHEMISTRY-US, V33, P6276, DOI 10.1021/bi00186a030; Raman N, 1997, J BIOL CHEM, V272, P30645, DOI 10.1074/jbc.272.49.30645; RAMAN N, 1995, J BIOL CHEM, V270, P1092, DOI 10.1074/jbc.270.3.1092; RICH GT, 1995, BIOCHEM J, V306, P703, DOI 10.1042/bj3060703; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SHRAGO E, 1995, PROSTAG LEUKOTR ESS, V52, P163, DOI 10.1016/0952-3278(95)90016-0; Singh RK, 1996, COMPUT APPL BIOSCI, V12, P191; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; VANBEILEN JB, 1992, MOL MICROBIOL, V6, P3121; YAMASHITA A, 1995, BIOCHEM J, V312, P301, DOI 10.1042/bj3120301	44	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38547	38553		10.1074/jbc.M006413200	http://dx.doi.org/10.1074/jbc.M006413200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10995760	hybrid			2022-12-25	WOS:000165739800056
J	Razandi, M; Pedram, A; Levin, ER				Razandi, M; Pedram, A; Levin, ER			Estrogen signals to the preservation of endothelial cell form and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HEAT-SHOCK PROTEIN-27; MAPKAP KINASE-2; TRANSCRIPTION FACTORS; ACTIN POLYMERIZATION; GENE-TRANSCRIPTION; RESPONSE ELEMENT; OXIDATIVE STRESS; BINDING-SITES; CROSS-TALK	Estrogen is important for the primary prevention of vascular disease in young women, but the mechanisms of protection at the vascular cell are still largely unknown. Although traditionally thought of as a nuclear transcription factor, the estrogen receptor has also been identified in the cell plasma membrane to signal but serve largely undefined roles. Here we show that estradiol (E2) rapidly activates p38 beta mitogen-activated protein kinase in endothelial cells (EC), which activates the mitogen-activated protein kinase-activated protein kinase-2 and the phosphorylation of heat shock protein 27. The sex steroid preserves the EC stress fiber formation and actin and membrane integrity in the setting of metabolic insult. E2 also prevents hypoxia-induced apoptosis and induces both the migration of EC and the formation of primitive capillary tubes. These effects are reversed by the inhibition of p38 beta, by the expression of a dominant-negative mitogen-activated protein kinase-activated protein kinase-2 protein, or by the expression of a phosphorylation site mutant heat shock protein 27. E2 signaling from the membrane helps preserve the EC structure and function, defining potentially important vascular-protective effects of this sex steroid.	Vet Affairs Med Ctr, Div Endocrinol, Long Beach, CA 90822 USA; Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA; Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92717 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine	Levin, ER (corresponding author), Vet Affairs Med Ctr, Med Serv 3 1, 5901 E 7th St, Long Beach, CA 90822 USA.	ellis.levin@med.va.gov	Levin, Ellis/J-5402-2013		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059890] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59890] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Biegelsen ES, 1999, CORONARY ARTERY DIS, V10, P241; BLACKMORE PF, 1991, J BIOL CHEM, V266, P18655; Budhram-Mahadeo V, 1998, MOL CELL BIOL, V18, P1029, DOI 10.1128/MCB.18.2.1029; Carraway CAC, 1999, J BIOL CHEM, V274, P25659, DOI 10.1074/jbc.274.36.25659; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; GARRIDO C, 1993, GROWTH FACTORS, V8, P109, DOI 10.3109/08977199309046931; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; Huot J, 1996, CANCER RES, V56, P273; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KUHNE W, 1993, AM J PHYSIOL, V264, pH1599, DOI 10.1152/ajpheart.1993.264.5.H1599; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; Larsen JK, 1997, AM J PHYSIOL-LUNG C, V273, pL930, DOI 10.1152/ajplung.1997.273.5.L930; LeMellay V, 1997, J BIOL CHEM, V272, P11902, DOI 10.1074/jbc.272.18.11902; Lemieux Pierre, 1997, Invasion and Metastasis, V17, P113; Loktionova SA, 1998, AM J PHYSIOL-HEART C, V275, pH2147, DOI 10.1152/ajpheart.1998.275.6.H2147; Machesky LM, 1999, NATURE, V401, P542, DOI 10.1038/44044; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; MORALES DE, 1995, CIRCULATION, V91, P755, DOI 10.1161/01.CIR.91.3.755; Morey AK, 1997, ENDOCRINOLOGY, V138, P3330, DOI 10.1210/en.138.8.3330; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; OESTERREICH S, 1993, CANCER RES, V53, P4443; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; Piotrowicz RS, 1998, FASEB J, V12, P1481, DOI 10.1096/fasebj.12.14.1481; Porter W, 1996, MOL ENDOCRINOL, V10, P1371, DOI 10.1210/me.10.11.1371; Pugazhenthi S, 1999, J BIOL CHEM, V274, P2829, DOI 10.1074/jbc.274.5.2829; Razandi M, 2000, MOL ENDOCRINOL, V14, P1434, DOI 10.1210/me.14.9.1434; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; SHASBY DM, 1982, CIRC RES, V51, P657, DOI 10.1161/01.RES.51.5.657; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; Stevis PE, 1999, ENDOCRINOLOGY, V140, P5455, DOI 10.1210/en.140.11.5455; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; SUNNERGREN KP, 1987, AM J PHYSIOL, V252, pH1211, DOI 10.1152/ajpheart.1987.252.6.H1211; SVENDSEN JH, 1991, CIRC RES, V68, P174, DOI 10.1161/01.RES.68.1.174; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; Wagstaff MJD, 1999, J BIOL CHEM, V274, P5061, DOI 10.1074/jbc.274.8.5061; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; WEHLING M, 1995, STEROIDS, V60, P153, DOI 10.1016/0039-128X(94)00027-A; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WONG MKK, 1986, ARTERIOSCLEROSIS, V6, P212, DOI 10.1161/01.ATV.6.2.212; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	53	160	169	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38540	38546		10.1074/jbc.M007555200	http://dx.doi.org/10.1074/jbc.M007555200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10988297	hybrid			2022-12-25	WOS:000165739800055
J	Goldring, CEP; Reveneau, S; Chantome, A; Pance, A; Fleury, C; Hume, DA; Sester, D; Mignotte, B; Jeannin, JF				Goldring, CEP; Reveneau, S; Chantome, A; Pance, A; Fleury, C; Hume, DA; Sester, D; Mignotte, B; Jeannin, JF			Heat shock enhances transcriptional activation of the murine-inducible nitric oxide synthase gene	FASEB JOURNAL			English	Article									Univ Bourgogne, Canc Immunotherapy Lab, Ecole Prat Hautes Etud, Fac Med, F-21000 Dijon, France; Univ Bourgogne, INSERM U517, Fac Med, F-21000 Dijon, France; Univ Versailles, CNRS, UPRESA 8087, F-78035 Versailles, France; Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia	Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Queensland	Reveneau, S (corresponding author), Univ Bourgogne, Canc Immunotherapy Lab, Ecole Prat Hautes Etud, Fac Med, 7 Blvd Jeanne dArc, F-21000 Dijon, France.		Hume, David A/C-7695-2013; Pance, Alena/AAH-2878-2021; Mignotte, Bernard/A-3499-2009; Sester, David/GLR-2942-2022	Pance, Alena/0000-0002-9017-2644; Mignotte, Bernard/0000-0002-8512-8518; Hume, David/0000-0002-2615-1478					0	33	36	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2393	2395						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11024011				2022-12-25	WOS:000165723400008
J	Ettaiche, M; Pichot, R; Vincent, JP; Chabry, J				Ettaiche, M; Pichot, R; Vincent, JP; Chabry, J			In vivo cytotoxicity of the prion protein fragment 106-126	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; SCRAPIE AGENT; CELL-DEATH; MICE; PRP; NEUROTOXICITY; RESISTANT; DISEASE; RESIDUES-106-126; DEGENERATION	Transmissible spongiform encephalopathies are fatal neurological diseases characterized by astroglyosis, neuronal loss, and by the accumulation of the abnormal isoform of the prion protein, The amyloid prion protein fragment 106-126 (P106-126) has been shown to be toxic in cultured hippocampal neurons (1). Here, we show that P106-126 is also cytotoxic in vivo, Taking advantage of the fact that retina is an integral part of the central nervous system, the toxic effect of the peptide was investigated by direct intravitreous injection. Aged solutions of P106-126 induced apoptotic-mediated retinal cell death and irreversibly altered the electrical activity of the retina. Neither apoptosis nor electroretinogram damages were observed with freshly diluted P106-126, suggesting that the toxicity is linked to the aggregation state of the peptide. The retina provides a convenient in vivo system to look for potential inhibitors of cytotoxicity associated with spongiform encephalopathies.	IPMC, CNRS, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Chabry, J (corresponding author), IPMC, CNRS, 660 Route Lucioles, F-06560 Valbonne, France.		Chabry, Joelle/O-2101-2016					Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; Brown DR, 1998, EUR J CELL BIOL, V75, P29, DOI 10.1016/S0171-9335(98)80043-5; BROWN DR, 1994, NEUROREPORT, V5, P2057, DOI 10.1097/00001756-199410270-00017; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUYUKMIHCI N, 1980, P NATL ACAD SCI-BIOL, V77, P1169, DOI 10.1073/pnas.77.2.1169; BUYUKMIHCI NC, 1987, EXP NEUROL, V97, P201, DOI 10.1016/0014-4886(87)90294-9; CARLSON GA, 1994, P NATL ACAD SCI USA, V91, P5690, DOI 10.1073/pnas.91.12.5690; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Chishti MA, 1997, NEUROSCI LETT, V234, P11; Ettaiche M, 1999, INVEST OPHTH VIS SCI, V40, P729; Florio T, 1998, J NEUROSCI RES, V54, P341, DOI 10.1002/(SICI)1097-4547(19981101)54:3<341::AID-JNR5>3.0.CO;2-G; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; FRASER H, 1993, BRIT MED BULL, V49, P792, DOI 10.1093/oxfordjournals.bmb.a072647; GIESE A, 1995, BRAIN PATHOL, V5, P213, DOI 10.1111/j.1750-3639.1995.tb00597.x; Gray F, 1999, J NEUROPATH EXP NEUR, V58, P321, DOI 10.1097/00005072-199904000-00002; HOGAN RN, 1981, LAB INVEST, V44, P34; Hope J, 1996, NEURODEGENERATION, V5, P1, DOI 10.1006/neur.1996.0001; Jen LS, 1998, NATURE, V392, P140, DOI 10.1038/32327; Jobling MF, 1999, J NEUROCHEM, V73, P1557, DOI 10.1046/j.1471-4159.1999.0731557.x; Kawahara M, 2000, J BIOL CHEM, V275, P14077, DOI 10.1074/jbc.275.19.14077; Lasmezas CI, 1996, J GEN VIROL, V77, P1601, DOI 10.1099/0022-1317-77-7-1601; Lin MX, 1997, J BIOL CHEM, V272, P44; Manunta M, 2000, FEBS LETT, V474, P255, DOI 10.1016/S0014-5793(00)01603-3; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; MULLER WEG, 1993, EUR J PHARM-MOLEC PH, V246, P261, DOI 10.1016/0922-4106(93)90040-G; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SAFAR J, 1993, J BIOL CHEM, V268, P20276; Salmona M, 1999, BIOCHEM J, V342, P207, DOI 10.1042/0264-6021:3420207; SELVAGGINI C, 1993, BIOCHEM BIOPH RES CO, V194, P1380, DOI 10.1006/bbrc.1993.1977; TAGLIAVINI F, 1993, P NATL ACAD SCI USA, V90, P9678, DOI 10.1073/pnas.90.20.9678; Theil D, 1999, J COMP PATHOL, V121, P357, DOI 10.1053/jcpa.1999.0333; Tremblay P, 1998, P NATL ACAD SCI USA, V95, P12580, DOI 10.1073/pnas.95.21.12580	37	121	128	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36487	36490		10.1074/jbc.C000579200	http://dx.doi.org/10.1074/jbc.C000579200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	11007766	hybrid			2022-12-25	WOS:000165577700003
J	Solanes, G; Pedraza, N; Iglesias, R; Giralt, M; Villarroya, F				Solanes, G; Pedraza, N; Iglesias, R; Giralt, M; Villarroya, F			The human uncoupling protein-3 gene promoter requires MyoD and is induced by retinoic acid in muscle cells	FASEB JOURNAL			English	Article									Univ Barcelona, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain	University of Barcelona	Villarroya, F (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Avda Diagonal 645, E-08028 Barcelona, Spain.		Giralt, Marta/A-4756-2013; Pedraza González, Neus/C-6390-2011; Iglesias, Roser/C-5561-2017; Villarroya, Francesc/K-4357-2014	Giralt, Marta/0000-0001-7968-4190; Pedraza González, Neus/0000-0003-4749-5111; Iglesias, Roser/0000-0002-7107-8097; Villarroya, Francesc/0000-0003-1266-9142					0	49	49	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2141	2143						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11024001				2022-12-25	WOS:000165190800005
J	Vogel, S; Mendelsohn, CL; Mertz, JR; Piantedosi, R; Waldburger, C; Gottesman, ME; Blaner, WS				Vogel, S; Mendelsohn, CL; Mertz, JR; Piantedosi, R; Waldburger, C; Gottesman, ME; Blaner, WS			Characterization of a new member of the fatty acid-binding protein family that binds all-trans-retinol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; CRYSTAL-STRUCTURES; VITAMIN-A; ADIPOCYTE; METABOLISM; PURIFICATION; SPECIFICITY; HYDROLYSIS; PATTERN; CELLS	Cellular retinol-binding protein, type I (CRBP-T) and type IT (CRBP-II) are the only members of the fatty acid-binding protein (FABP) family that process intracellular retinol. Heart and skeletal muscle take up postprandial retinol but express little or no CRBP-I or CRBP-II. We have identified an intracellular retinol-binding protein in these tissues. The 134-amino acid protein is encoded by a cDNA that is expressed primarily in heart, muscle and adipose tissue. It shares 57 and 56% sequence identity with CRBP-I and CRBP-II, respectively, but less than 40% with other members of the FABP family, In situ hybridization demonstrates that the protein is expressed at least as early as day 10 in developing heart and muscle tissue of the embryonic mouse. Fluorescence titrations of purified recombinant protein with retinol. isomers indicates binding to all-trans-, 13-cis-, and 9-cis-retinol, with respective K-d values of 109, 83, and 130 nM. Retinoic acids (all-trans-, 13-cis-, and 9-cis-), retinals (all-trans-, 13-cis-, and 9-cis-), fatty acids (laurate, myristate, palmitate, oleate, linoleate, arachidonate, and docosahexanoate), or fatty alcohols (palmityl, petrosenlinyl, and ricinolenyl) fail to bind. The distinct tissue expression pattern and binding specificity suggest that we have identified a novel FABP family member, cellular retinol-binding protein, type III.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Inst Human Nutr, New York, NY 10032 USA; New England Coll Optometry, Dept Biol Sci, Boston, MA 02115 USA	Columbia University; Columbia University; Columbia University; Columbia University	Blaner, WS (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 701 W 168th St, New York, NY 10032 USA.	WSB2@columbia.edu	Mendelsohn, Cathy/H-4280-2016	Mendelsohn, Cathy/0000-0002-4026-4073	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061459, R01DK052444, R56DK082963] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK061459-08, R01 DK061459-06, R01 DK061459, R01 DK061459-07S1, R01 DK061459-07, R01 DK061459-09, R01 DK52444, R56 DK082963-01, R56 DK082963] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BAXA CA, 1989, BIOCHEMISTRY-US, V28, P8683, DOI 10.1021/bi00448a003; Bernlohr DA, 1997, ANNU REV NUTR, V17, P277, DOI 10.1146/annurev.nutr.17.1.277; Blaner W.S., 1999, HANDB EXP PHARM, P117; Blaner William S., 1994, P229; BLANER WS, 1987, J BIOL CHEM, V262, P53; BLANER WS, 1994, J BIOL CHEM, V269, P16559; CHENG L, 1991, J BIOL CHEM, V266, P24404; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; DOLLE P, 1990, DEVELOPMENT, V110, P1133; ERIKSSON U, 1984, J BIOL CHEM, V259, P3464; FERRARA P, 1993, TECHNIQUES PROTEIN C, V4, P379; Furr Harold C., 1994, P179; Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; Glatz JFC, 1998, ADV EXP MED BIOL, V441, P207; Hausman GJ, 1985, NEW PERSPECTIVES ADI, P1; JAKOBY MG, 1993, BIOCHEMISTRY-US, V32, P872, DOI 10.1021/bi00054a019; KATO M, 1984, J CELL BIOL, V98, P1696, DOI 10.1083/jcb.98.5.1696; KATO M, 1985, J BIOL CHEM, V260, P4832; KIRTLAND J, 1979, INT J OBESITY, V3, P15; LEVIN MS, 1987, J BIOL CHEM, V262, P7118; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; LI E, 1986, P NATL ACAD SCI USA, V83, P5779, DOI 10.1073/pnas.83.16.5779; MACDONALD PN, 1987, J BIOL CHEM, V262, P10550; MATARESE V, 1988, J BIOL CHEM, V263, P14544; Mendelsohn C, 1999, DEVELOPMENT, V126, P1139; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; NEWCOMER ME, 1995, FASEB J, V9, P229, DOI 10.1096/fasebj.9.2.7781925; Newcomer ME, 1998, SUB CELL BIOCHEM, V30, P53; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; NOY N, 1999, HANDB EXP PHARM, V139, P3; Ong David E., 1994, P283; ONG DE, 1982, J BIOL CHEM, V257, P13385; Palace VP, 1999, FREE RADICAL BIO MED, V26, P1501, DOI 10.1016/S0891-5849(99)00013-1; PEREZCASTRO AV, 1989, P NATL ACAD SCI USA, V86, P8813, DOI 10.1073/pnas.86.22.8813; RAJAN N, 1990, J LIPID RES, V31, P821; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; RODBELL M, 1964, J BIOL CHEM, V239, P375; STRUMP DG, 1991, J BIOL CHEM, V266, P4622; Subbarayan V, 2000, J CLIN INVEST, V105, P387, DOI 10.1172/JCI8150; TSUTSUMI C, 1992, J BIOL CHEM, V267, P1805; UYEMURA K, 1984, NEUROCHEM RES, V28, P8683; van Bennekum AM, 1999, J LIPID RES, V40, P565; VEERKAMP JH, 1993, PROSTAG LEUKOTR ESS, V49, P887, DOI 10.1016/0952-3278(93)90174-U; VEERKAMP JH, 1991, BIOCHIM BIOPHYS ACTA, V1081, P1, DOI 10.1016/0005-2760(91)90244-C; VOGEL S, 1999, HANDB EXP PHARM, V139, P31; WILSON JG, 1949, AM J ANAT, V85, P113, DOI 10.1002/aja.1000850106; WINTER NS, 1993, J MOL BIOL, V230, P1247, DOI 10.1006/jmbi.1993.1239; XU ZH, 1993, J BIOL CHEM, V268, P7874	52	94	97	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1353	1360		10.1074/jbc.M005118200	http://dx.doi.org/10.1074/jbc.M005118200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11022035	hybrid			2022-12-25	WOS:000166430900067
J	He, QF; Dolganov, N; Bjorkman, O; Grossman, AR				He, QF; Dolganov, N; Bjorkman, O; Grossman, AR			The high light-inducible polypeptides in Synechocystis PCC6803 - Expression and function in high light	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON SUPEROXIDE-DISMUTASE; MEMBRANE-PROTEIN DAMAGE; PHOTOSYSTEM-II; XANTHOPHYLL CYCLE; IN-VIVO; CHLOROPLAST MEMBRANES; NUCLEOTIDE-SEQUENCE; EXCITATION-ENERGY; STRESS; PLANTS	There are five Synechocystis PCC6803 genes encoding polypeptides with similarity to the Lhc polypeptides of plants. Four of the polypeptides, designated HliA-D (Dolganov, N. A M., Bhaya, D., and Grossman, A. R. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 636-640) (corresponding to ScpC, ScpD, ScpB, and ScpE in Funk, C., and Vermaas, W. (1999) Biochemistry 38, 9397-9404) contain a single transmembrane domain. The fifth polypeptide (HemH) represents a fusion between a ferrochelatase and an Hli-like polypeptide. By using an epitope tag to identify specifically the different Hli polypeptides, the accumulation of each (excluding HemH) was examined under various environmental conditions. The levels of all of the Hli polypeptides were elevated in high light and during nitrogen limitation, whereas HliA, HliB, and HliC also accumulated to high levels following exposure to sulfur deprivation and low temperature. The temporal pattern of accumulation was significantly different among the different Hli polypeptides. HliC rapidly accumulated in high light, and its level remained high for at least 24 h. HliA and HliB also accumulated rapidly, but their levels began to decline 9-12 h following the imposition of high light. HliD was transiently expressed in high light and was not detected 24 h after the initiation of high light exposure. These results demonstrate that there is specificity to the accumulation of the Hli polypeptides under a diverse range of environmental conditions. Furthermore, mutants for the individual and combinations of the hli genes were evaluated for their fitness to grow in high light. Although all of the mutants grew as fast as wild-type cells in low light, strains inactivated for hliA or hliC/hliD were unable to compete with wild-type cells during co-cultivation in high light. A mutant lacking all four hli genes gradually lost its photosynthesis capacity and died in high light. Hence, the Hli polypeptides are critical for survival when Synechocystis PCC6803 is absorbing excess excitation energy and may allow the cells to cope more effectively with the production of reactive oxygen species.	Carnegie Inst Sci, Dept Plant Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Carnegie Institution for Science; Stanford University	He, QF (corresponding author), Carnegie Inst Sci, Dept Plant Biol, 290 Panama St, Stanford, CA 94305 USA.	qingfang@andrew2.stanford.edu	He, Qingfang/I-4181-2013					ADAMSKA I, 1993, J BIOL CHEM, V268, P5438; ADAMSKA I, 1995, PLANT PHYSIOL, V107, P1167, DOI 10.1104/pp.107.4.1167; Adamska I, 1997, PHYSIOL PLANTARUM, V100, P794, DOI 10.1034/j.1399-3054.1997.1000406.x; ADAMSKA I, 1992, J BIOL CHEM, V267, P24732; ADAMSKA I, 1992, P NATL ACAD SCI USA, V89, P2610, DOI 10.1073/pnas.89.7.2610; Allakhverdiev SI, 1997, BIOCHEMISTRY-US, V36, P4149, DOI 10.1021/bi962170n; ANDERSSON B, 1992, J PHOTOCH PHOTOBIO B, V15, P15, DOI 10.1016/1011-1344(92)87003-R; ARO EM, 1993, PLANT PHYSIOL, V103, P835, DOI 10.1104/pp.103.3.835; ASADA K, 1992, PHYSIOL PLANTARUM, V85, P235, DOI 10.1111/j.1399-3054.1992.tb04728.x; ASADA K, 1992, PHOTOSYNTH RES, V34, P105; Banet G, 2000, PLANTA, V210, P947, DOI 10.1007/s004250050702; BARTLEY GE, 1995, PLANT CELL, V7, P1027, DOI 10.1105/tpc.7.7.1027; BIGGINS J, 1989, PHOTOSYNTH RES, V20, P1, DOI 10.1007/BF00028620; Boger P, 1996, J PESTIC SCI, V21, P473; BOWLER C, 1994, CRIT REV PLANT SCI, V13, P199, DOI 10.1080/713608062; BRAHAMSHA B, 1991, J BACTERIOL, V173, P2442, DOI 10.1128/jb.173.8.2442-2450.1991; COLLIER JL, 1992, J BACTERIOL, V174, P4718, DOI 10.1128/JB.174.14.4718-4726.1992; CRITCHLEY C, 1994, PHYSIOL PLANTARUM, V92, P188, DOI 10.1111/j.1399-3054.1994.tb06670.x; CROFTS J, 1991, BIOCHIM BIOPHYS ACTA, V1058, P187, DOI 10.1016/S0005-2728(05)80236-1; DELASRIVAS J, 1993, BIOCHIM BIOPHYS ACTA, V1142, P155, DOI 10.1016/0005-2728(93)90097-Y; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; DemmigAdams B, 1996, TRENDS PLANT SCI, V1, P21, DOI 10.1016/S1360-1385(96)80019-7; DOLGANOV NAM, 1995, P NATL ACAD SCI USA, V92, P636, DOI 10.1073/pnas.92.2.636; Durnford DG, 1997, PHOTOSYNTH RES, V53, P229, DOI 10.1023/A:1005815725371; DUYSENS LNM, 1972, BIOPHYS J, V12, P858, DOI 10.1016/S0006-3495(72)86129-0; El Bissati K, 2000, BBA-BIOENERGETICS, V1457, P229, DOI 10.1016/S0005-2728(00)00104-3; FOYER CH, 1994, PLANT CELL ENVIRON, V17, P507, DOI 10.1111/j.1365-3040.1994.tb00146.x; Frank HA, 2000, BIOCHEMISTRY-US, V39, P2831, DOI 10.1021/bi9924664; FRANK HA, 1994, PHOTOSYNTH RES, V41, P389, DOI 10.1007/BF02183041; Fujita Y, 1997, PHOTOSYNTH RES, V53, P83, DOI 10.1023/A:1005870301868; Funk C, 1999, BIOCHEMISTRY-US, V38, P9397, DOI 10.1021/bi990545+; Gilmore AM, 1997, PHYSIOL PLANTARUM, V99, P197, DOI 10.1034/j.1399-3054.1997.990127.x; GREEN BR, 1995, PHOTOSYNTH RES, V44, P139, DOI 10.1007/BF00018304; GREEN BR, 1991, TRENDS BIOCHEM SCI, V16, P181, DOI 10.1016/0968-0004(91)90072-4; GRIMM B, 1987, EUR J CELL BIOL, V43, P21; Halliwell B., 1999, FREE RADICAL BIO MED, P1, DOI DOI 10.1093/ACPROF:OSO/9780198717478.001.0001; Havaux M, 1999, P NATL ACAD SCI USA, V96, P8762, DOI 10.1073/pnas.96.15.8762; He QF, 1998, P NATL ACAD SCI USA, V95, P5830, DOI 10.1073/pnas.95.10.5830; Heddad M, 2000, P NATL ACAD SCI USA, V97, P3741, DOI 10.1073/pnas.050391397; HERBERT SK, 1992, P NATL ACAD SCI USA, V89, P8716, DOI 10.1073/pnas.89.18.8716; HERTWIG B, 1992, PLANT PHYSIOL, V100, P1547, DOI 10.1104/pp.100.3.1547; Holtman WL, 1998, J EXP BOT, V49, P1303, DOI 10.1093/jexbot/49.325.1303; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; Hwang SY, 1999, PLANT GROWTH REGUL, V27, P167, DOI 10.1023/A:1006100508910; Iwasaki T, 1997, GENE, V185, P223, DOI 10.1016/S0378-1119(96)00646-4; Jansson S, 2000, PLANT MOL BIOL, V42, P345, DOI 10.1023/A:1006365213954; Kaneko T, 1997, PLANT CELL PHYSIOL, V38, P1171, DOI 10.1093/oxfordjournals.pcp.a029103; Kaneko T, 1996, DNA Res, V3, P109; Kloppstech K, 1997, PHYSIOL PLANTARUM, V100, P739, DOI 10.1034/j.1399-3054.1997.1000401.x; KOLANUS W, 1987, MOL GEN GENET, V209, P234, DOI 10.1007/BF00329648; KRUSE E, 1989, BIOL CHEM H-S, V370, P925; KYLE DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4070, DOI 10.1073/pnas.81.13.4070; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; MAID U, 1992, PLANT MOL BIOL, V19, P1001, DOI 10.1007/BF00040531; Melis A, 1999, TRENDS PLANT SCI, V4, P130, DOI 10.1016/S1360-1385(99)01387-4; Montane MH, 1997, PLANTA, V202, P293, DOI 10.1007/s004250050131; Montane MH, 1999, PLANTA, V208, P519, DOI 10.1007/s004250050589; Neale AD, 2000, PLANT CELL ENVIRON, V23, P265, DOI 10.1046/j.1365-3040.2000.00548.x; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; OHAD I, 1984, J CELL BIOL, V99, P481, DOI 10.1083/jcb.99.2.481; OQUIST G, 1992, J BIOL CHEM, V267, P16745; Park YI, 1999, MOL MICROBIOL, V32, P123, DOI 10.1046/j.1365-2958.1999.01332.x; PETER GF, 1991, J BIOL CHEM, V266, P16745; Polivka T, 1999, P NATL ACAD SCI USA, V96, P4914, DOI 10.1073/pnas.96.9.4914; POTTER E, 1993, EUR J BIOCHEM, V214, P779, DOI 10.1111/j.1432-1033.1993.tb17980.x; Reith M, 1995, PLANT MOL BIOL REP, V13, P333, DOI 10.1007/BF02669187; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Ruban AV, 1999, PLANT PHYSIOL, V119, P531, DOI 10.1104/pp.119.2.531; RUBAN AV, 1995, PLANT PHYSIOL, V108, P721, DOI 10.1104/pp.108.2.721; RUBAN AV, 1994, BBA-BIOENERGETICS, V1186, P123, DOI 10.1016/0005-2728(94)90143-0; RUBAN AV, 1993, J PHOTOCH PHOTOBIO B, V21, P229, DOI 10.1016/1011-1344(93)80188-F; Schweitzer RH, 1997, BIOCHEMISTRY-US, V36, P11351, DOI 10.1021/bi9709203; Stirewalt VL, 1995, PLANT MOL BIOL REP, V13, P327, DOI 10.1007/BF02669186; Thomas DJ, 1998, PLANT PHYSIOL, V116, P1593, DOI 10.1104/pp.116.4.1593; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; vonLintig J, 1997, PLANT J, V12, P625, DOI 10.1046/j.1365-313X.1997.00625.x; Windhovel U, 1997, PESTIC BIOCHEM PHYS, V57, P68, DOI 10.1006/pest.1997.2261; WOLFE GR, 1994, BBA-BIOENERGETICS, V1188, P357, DOI 10.1016/0005-2728(94)90056-6; Yamagata H, 1997, BIOSCI BIOTECH BIOCH, V61, P2143, DOI 10.1271/bbb.61.2143	79	174	183	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					306	314		10.1074/jbc.M008686200	http://dx.doi.org/10.1074/jbc.M008686200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024039	hybrid			2022-12-25	WOS:000166280700042
J	Heller, R; Unbehaun, A; Schellenberg, B; Mayer, B; Werner-Felmayer, G; Werner, ER				Heller, R; Unbehaun, A; Schellenberg, B; Mayer, B; Werner-Felmayer, G; Werner, ER			L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-CYCLOHYDROLASE-I; PERFORMANCE LIQUID-CHROMATOGRAPHY; DEPENDENT VASODILATION; BIOSYNTHETIC ACTIVITIES; SUPEROXIDE GENERATION; SYNTHASE; DYSFUNCTION; CELLS; CYTOKINES; ENHANCEMENT	Ascorbic acid has been shown to stimulate endothelial nitric oxide (NO) synthesis in a time- and concentration-dependent fashion without affecting NO synthase (NOS) expression or L-arginine uptake. The present study investigates if the underlying mechanism is related to the NOS cofactor tetrahydrobiopterin, Pretreatment of human umbilical vein endothelial cells with ascorbate (1 muM to 1 mM, 24 h) led to an up to 3-fold increase of intracellular tetrahydrobiopterin levels that was concentration-dependent and saturable at 100 mum. Accordingly, the effect of ascorbic acid on Ca2+-dependent formation of citrulline (co-product of NO) and cGMP (product of the NO-activated soluble guanylate cyclase) was abolished when intracellular tetrahydrobiopterin levels were increased by coincubation of endothelial cells with sepiapterin (0.001-100 muM, 24 h), In contrast, ascorbic acid did not modify the pterin affinity of endothelial NOS, which was measured in assays with purified tetrahydrobiopterin-free enzyme. The ascorbate-induced increase of endothelial tetrahydrobiopterin was not due to an enhanced synthesis of the compound. Neither the mRNA expression of the rate-limiting enzyme in tetrahydrobiopterin biosynthesis, GTP cyclohydrolase I, nor the activities of either GTP cyclohydrolase I or 6-pyruvoyl-tetrahydropterin synthase, the second enzyme in the de novo synthesis pathway, were altered by ascorbate, Our data demonstrate that ascorbic acid leads to a chemical stabilization of tetrahydrobiopterin, This was evident as an increase in the half-life of tetrahydrobiopterin in aqueous solution. Furthermore, the increase of tetrahydrobiopterin levels in intact endothelial cells coincubated with cytokines and ascorbate was associated with a decrease of more oxidized biopterin derivatives (7,8-dihydrobiopterin and biopterin) in cells and cell supernatants, The present study suggests that saturated ascorbic acid levels in endothelial cells are necessary to protect tetrahydrobiopterin from oxidation and to provide optimal conditions for cellular NO synthesis.	Univ Jena, Ctr Vasc Biol & Med, D-99089 Erfurt, Germany; Karl Franzens Univ Graz, Inst Pharmacol & Toxicol, A-8010 Graz, Austria; Univ Innsbruck, Inst Med Chem & Biochem, A-6020 Innsbruck, Austria	Friedrich Schiller University of Jena; University of Graz; University of Innsbruck	Heller, R (corresponding author), Univ Jena, Ctr Vasc Biol & Med, Nordhauser Str 78, D-99089 Erfurt, Germany.	heller@zmkh.ef.uni-jena.de	Mayer, Bernd/B-9391-2008; Heller, Regine/AAC-9353-2019	Werner-Felmayer, Gabriele/0000-0002-2340-8063; Werner, Ernst R./0000-0003-1948-3391; Mayer, Bernd/0000-0002-2921-3494				Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; Bult H, 1999, EUR J PHARMACOL, V375, P157, DOI 10.1016/S0014-2999(99)00328-3; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cooke JP, 1997, ANNU REV MED, V48, P489, DOI 10.1146/annurev.med.48.1.489; EK A, 1995, BIOCHEM PHARMACOL, V50, P1339; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GAL EM, 1978, NEUROCHEM RES, V3, P69, DOI 10.1007/BF00964361; Gokce N, 1999, CIRCULATION, V99, P3234, DOI 10.1161/01.CIR.99.25.3234; Gorren ACF, 1998, BIOCHEMISTRY-MOSCOW+, V63, P734; Hattori Y, 1997, BBA-MOL CELL RES, V1358, P61, DOI 10.1016/S0167-4889(97)00052-9; Heitzer T, 2000, CIRC RES, V86, pE36, DOI 10.1161/01.RES.86.2.e36; Heitzer T, 1996, CIRCULATION, V94, P6, DOI 10.1161/01.CIR.94.1.6; Heller R, 1999, J BIOL CHEM, V274, P8254, DOI 10.1074/jbc.274.12.8254; Hornig B, 1998, CIRCULATION, V97, P363; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; HYLAND K, 1985, J CHROMATOGR, V343, P35, DOI 10.1016/S0378-4347(00)84565-X; Ignarro LJ, 1999, J CARDIOVASC PHARM, V34, P879, DOI 10.1097/00005344-199912000-00016; Katusic ZS, 1998, ARTERIOSCL THROM VAS, V18, P27, DOI 10.1161/01.ATV.18.1.27; KAUFMAN S, 1993, ANNU REV NUTR, V13, P261, DOI 10.1146/annurev.nu.13.070193.001401; Kinoshita H, 1997, AM J PHYSIOL-HEART C, V273, pH718, DOI 10.1152/ajpheart.1997.273.2.H718; Leber A, 1999, J BIOL CHEM, V274, P37658, DOI 10.1074/jbc.274.53.37658; Levine GN, 1996, CIRCULATION, V93, P1107, DOI 10.1161/01.CIR.93.6.1107; Linscheid P, 1998, CIRCULATION, V98, P1703, DOI 10.1161/01.CIR.98.17.1703; Maier W, 2000, J CARDIOVASC PHARM, V35, P173, DOI 10.1097/00005344-200002000-00001; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; Pieper GM, 1997, J CARDIOVASC PHARM, V29, P8, DOI 10.1097/00005344-199701000-00002; RAMIREZ J, 1980, AM J CLIN NUTR, V33, P2079, DOI 10.1093/ajcn/33.10.2079; Rosenblum WI, 1997, STROKE, V28, P186, DOI 10.1161/01.STR.28.1.186; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; SCHECTMAN G, 1989, AM J PUBLIC HEALTH, V79, P158, DOI 10.2105/AJPH.79.2.158; SCHMIDT K, 1992, BIOCHEM J, V281, P297, DOI 10.1042/bj2810297; SCHOEDON G, 1993, BIOCHEM BIOPH RES CO, V196, P1343, DOI 10.1006/bbrc.1993.2400; Solzbach U, 1997, CIRCULATION, V96, P1513, DOI 10.1161/01.CIR.96.5.1513; Stroes E, 1997, J CLIN INVEST, V99, P41, DOI 10.1172/JCI119131; Tiefenbacher CP, 1996, CIRCULATION, V94, P1423, DOI 10.1161/01.CIR.94.6.1423; Ting HH, 1996, J CLIN INVEST, V97, P22, DOI 10.1172/JCI118394; Ting HH, 1997, CIRCULATION, V95, P2617, DOI 10.1161/01.CIR.95.12.2617; Tsutsui M, 1996, CIRC RES, V79, P336, DOI 10.1161/01.RES.79.2.336; Ueda S, 2000, J AM COLL CARDIOL, V35, P71, DOI 10.1016/S0735-1097(99)00523-9; VANAMSTERDAM JGC, 1992, EUR J PHARMACOL, V215, P349, DOI 10.1016/0014-2999(92)90056-A; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Vita JA, 1998, J AM COLL CARDIOL, V31, P980, DOI 10.1016/S0735-1097(98)00059-X; WALTER R, 1994, BIOCHEM BIOPH RES CO, V203, P1522, DOI 10.1006/bbrc.1994.2358; Werner ER, 2000, BIOCHEM J, V348, P579, DOI 10.1042/0264-6021:3480579; WERNER ER, 1990, J BIOL CHEM, V265, P3189; Werner ER, 1997, METHOD ENZYMOL, V281, P53; WERNERFELMAYER G, 1993, J BIOL CHEM, V268, P1842; Witteveen CFB, 1999, J BIOL CHEM, V274, P29755, DOI 10.1074/jbc.274.42.29755; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804	52	331	343	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					40	47		10.1074/jbc.M004392200	http://dx.doi.org/10.1074/jbc.M004392200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11022034	hybrid			2022-12-25	WOS:000166280700007
J	Kumar, A; Novoselov, V; Celeste, AJ; Wolfman, NM; ten Dijke, P; Kuehn, MR				Kumar, A; Novoselov, V; Celeste, AJ; Wolfman, NM; ten Dijke, P; Kuehn, MR			Nodal signaling uses activin and transforming growth factor-beta receptor-regulated smads	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY MOUSE EMBRYO; LEFT-RIGHT AXIS; TGF-BETA; MESODERM INDUCTION; TARGETED DISRUPTION; HEPG2 CELLS; GENE; EXPRESSION; XENOPUS; ACTIVATION	Nodal, a member of the transforming growth factor beta (TGF-beta) superfamily, is implicated in many events critical to the early vertebrate embryo, including mesoderm formation, anterior patterning, and left-right axis specification. Here we define the intracellular signaling pathway induced by recombinant nodal protein treatment of P19 embryonal carcinoma cells. Nodal signaling activates pAR3-Lux, a luciferase reporter previously shown to respond specifically to activin and TGF-beta. However, nodal is unable to induce pTlx2-Lux, a reporter specifically responsive to bone morphogenetic proteins. We also demonstrate that nodal induces p(CAGA)(12), a reporter previously shown to be specifically activated by Smad3. Expression of a dominant negative Smad2 significantly reduces the level of luciferase reporter activity induced by nodal treatment. Finally, we show that nodal signaling rapidly leads to the phosphorylation of Smad2. These results provide the first direct biochemical evidence that nodal signaling is mediated by both activin-TGF-beta pathway Smads, Smad2 and Smads. We also show here that the extracellular cripto protein is required for nodal signaling, making it distinct from activin or TGF-beta signaling.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; Genet Inst, Cambridge, MA 02140 USA; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Netherlands Cancer Institute	Kuehn, MR (corresponding author), NCI, Expt Immunol Branch, NIH, Bldg 10,Rm 4B-36,10 Ctr Dr, Bethesda, MD 20892 USA.		Kuehn, Michael R/A-4573-2014; Dijke, Peter ten/AAG-4660-2021	Kuehn, Michael R/0000-0002-7703-9160; Dijke, Peter ten/0000-0002-7234-342X				Chang CB, 1997, DEVELOPMENT, V124, P827; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CONLON FL, 1994, DEVELOPMENT, V120, P1919; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Ding JX, 1998, NATURE, V395, P702, DOI 10.1038/27215; DONO R, 1993, DEVELOPMENT, V118, P1157; Dyson S, 1997, CURR BIOL, V7, P81, DOI 10.1016/S0960-9822(06)00030-3; Gaio U, 1999, CURR BIOL, V9, P1339, DOI 10.1016/S0960-9822(00)80059-7; GERMAIN P, 1993, ANTICANCER RES, V13, P1581; Gritsman K, 1999, CELL, V97, P121, DOI 10.1016/S0092-8674(00)80720-5; Gu ZY, 1998, GENE DEV, V12, P844, DOI 10.1101/gad.12.6.844; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; Heyer J, 1999, P NATL ACAD SCI USA, V96, P12595, DOI 10.1073/pnas.96.22.12595; Hoodless PA, 1999, DEV BIOL, V207, P364, DOI 10.1006/dbio.1998.9168; IANNACCONE PM, 1992, DEV DYNAM, V194, P198, DOI 10.1002/aja.1001940305; JONES CM, 1995, DEVELOPMENT, V121, P3651; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kumar A, 1997, J LIPID RES, V38, P2240; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Pfendler KC, 2000, GENESIS, V28, P1, DOI 10.1002/1526-968X(200009)28:1<1::AID-GENE10>3.0.CO;2-X; Piek E, 1999, INT J CANCER, V80, P756, DOI 10.1002/(SICI)1097-0215(19990301)80:5<756::AID-IJC21>3.0.CO;2-N; Saijoh Y, 2000, MOL CELL, V5, P35, DOI 10.1016/S1097-2765(00)80401-3; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; SCHLUNEGGER MP, 1992, FEBS LETT, V303, P91, DOI 10.1016/0014-5793(92)80484-X; Shen MM, 1997, DEVELOPMENT, V124, P429; Song JW, 1999, DEV BIOL, V213, P157, DOI 10.1006/dbio.1999.9370; Tang SJ, 1998, DEVELOPMENT, V125, P1877; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Weinstein M, 1998, P NATL ACAD SCI USA, V95, P9378, DOI 10.1073/pnas.95.16.9378; Weisberg E, 1998, MECH DEVELOP, V79, P17, DOI 10.1016/S0925-4773(98)00160-9; Xu CH, 1999, DEVELOPMENT, V126, P483; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yan YT, 1999, GENE DEV, V13, P2527, DOI 10.1101/gad.13.19.2527; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yeo CY, 1999, J BIOL CHEM, V274, P26584, DOI 10.1074/jbc.274.37.26584; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	46	94	110	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					656	661		10.1074/jbc.M004649200	http://dx.doi.org/10.1074/jbc.M004649200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024047	hybrid			2022-12-25	WOS:000166280700088
J	Leclerc, S; Garnier, M; Hoessel, R; Marko, D; Bibb, JA; Snyder, GL; Greengard, P; Biernat, J; Wu, YZ; Mandelkow, EM; Eisenbrand, G; Meijer, L				Leclerc, S; Garnier, M; Hoessel, R; Marko, D; Bibb, JA; Snyder, GL; Greengard, P; Biernat, J; Wu, YZ; Mandelkow, EM; Eisenbrand, G; Meijer, L			Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease - A property common to most cycline-dependent kinase inhibitors?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE INHIBITOR; CARCINOMA CELLS; XENOPUS EMBRYOS; REPEAT DOMAIN; BETA-CATENIN; CDC2 KINASE; NEURONS; LITHIUM; CDK2; ACTIVATION	The bis-indole indirubin is an active ingredient of Danggui Longhui Wan, a traditional Chinese medicine recipe used in the treatment of chronic diseases such as leukemias. The antitumoral properties of indirubin appear to correlate with their antimitotic effects. Indirubins were recently described as potent (IC50: 50-100 nm) inhibitors of cyclin-dependent kinases (CDKs), We report here that indirubins are also powerful inhibitors (IC50: 5-50 nM) of an evolutionarily related kinase, glycogen synthase kinase-3 beta (GSK-3 beta), Testing of a series of indoles and bis-indoles against GSK-3 beta, CDK1/cyclin B, and CDK5/p25 shows that only indirubins inhibit these kinases, The structure-activity relationship study also suggests that indirubins bind to GSK-3 beta 's ATP binding pocket in a way similar to their binding to CDKs, the details of which were recently revealed by crystallographic analysis. GSK-3 beta, along with CDK5, is responsible for most of the abnormal hyperphosphorylation of the microtubule-binding protein tau observed in Alzheimer's disease. Indirubin-3'-monoxime inhibits tau phosphorylation in vitro and in vivo at Alzheimer's disease-specific sites. Indirubins may thus have important implications in the study and treatment of neurodegenerative disorders. Indirubin-3'-monoxime also inhibits the in vivo phosphorylation of DARPP-32 by CDK5 on Thr-75, thereby mimicking one of the effects of dopamine in the striatum, Finally, we show that many, but not all, reported CDK inhibitors are powerful inhibitors of GSK-3 beta, To which extent these GSK-3 beta effects of: CDK inhibitors actually contribute to their antimitotic and antitumoral properties remains to be determined. Indirubins constitute the first family of low nanomolar inhibitors of GSK-3 beta to be described.	CNRS, Biol Stn, Cell Cycle Grp, F-29682 Roscoff, France; Univ Kaiserslautern, Div Food Chem & Environm Toxicol, Dept Chem, D-67663 Kaiserslautern, Germany; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Max Planck Unit Struct Mol Biol, D-22603 Hamburg, Germany	Centre National de la Recherche Scientifique (CNRS); University of Kaiserslautern; Rockefeller University; Max Planck Society	Meijer, L (corresponding author), CNRS, Biol Stn, Cell Cycle Grp, BP 74, F-29682 Roscoff, France.	meijer@sb-roscoff.fr	Marko, Doris/B-9354-2014; Eisenbrand, Gerhard/AEQ-0284-2022	Marko, Doris/0000-0001-6568-2944; Eisenbrand, Gerhard/0000-0003-4079-2463; Garnier, Matthieu/0000-0001-7391-547X	NIMH NIH HHS [MH40899] Funding Source: Medline; PHS HHS [DQ10044] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Akiyama T, 1997, CANCER RES, V57, P1495; [Anonymous], 1992, CHIN DRUGS PLANT ORI; Balfour-Paul Jenny, 1998, INDIGO; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Bible KC, 1996, CANCER RES, V56, P4856; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; Biernat J, 1999, MOL BIOL CELL, V10, P727, DOI 10.1091/mbc.10.3.727; Borgne A, 1999, J BIOL CHEM, V274, P11977, DOI 10.1074/jbc.274.17.11977; BRUSSELBACH S, 1998, INT J CANCER, P1; Carlson BA, 1996, CANCER RES, V56, P2973; Chang CN, 1985, ADV CHINESE MED MAT, P369; Chang YT, 1999, CHEM BIOL, V6, P361, DOI 10.1016/S1074-5521(99)80048-9; Chen D. W., 1979, COMMUNICATIONS CHINE, V10, P7; CHEN DH, 1984, CHINESE TRAD HERBAL, V15, P6; Cohen P, 1999, PHILOS T R SOC B, V354, P485, DOI 10.1098/rstb.1999.0399; Cooperative Group of Clinical Therapy of Indirubin, 1980, CHINESE J INTERN MED, V1, P132; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DUNPHY WG, 1997, METHOD ENZYMOL, V283, P1; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; Emily-Fenouil F, 1998, DEVELOPMENT, V125, P2489; Gan WJ, 1985, CHIN ACAD MED SCI BE, V6, P611; Garrett MD, 1999, CURR OPIN GENET DEV, V9, P104, DOI 10.1016/S0959-437X(99)80015-X; Godemann R, 1999, FEBS LETT, V454, P157, DOI 10.1016/S0014-5793(99)00741-3; Gray N, 1999, CURR MED CHEM, V6, P859; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Haass Christian, 1999, Trends in Cell Biology, V9, P241, DOI 10.1016/S0962-8924(99)01576-7; HAN R, 1998, J ETHNOPHARMACOL, V24, P1; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; HUGHES K, 1992, EUR J BIOCHEM, V203, P305, DOI 10.1111/j.1432-1033.1992.tb19860.x; HURRY JB, 1930, WOOD PLANT ITS DYE; Imahori K, 1997, J BIOCHEM, V121, P179; Institute of Haematology Chinese Academy of Medical Sciences, 1979, CHINESE J INTERN MED, V18, P83; Institute of Hematology Chinese Academy of Medical Sciences, 1979, CHINESE J INTERN MED, V15, P86; JI XJ, 1981, ACTA PHARM SIN, V16, P146; KITAGAWA M, 1993, ONCOGENE, V8, P2425; Knockaert M, 2000, CHEM BIOL, V7, P411, DOI 10.1016/S1074-5521(00)00124-1; LEE KH, 1993, ACS SYM SER, V534, P170; Lee KY, 1999, NEUROSCI RES, V34, P21, DOI 10.1016/S0168-0102(99)00026-7; Li CM, 1996, B CHEM SOC JPN, V69, P1621, DOI 10.1246/bcsj.69.1621; LIU CX, 1984, ACTA PHARMACOL SIN, V5, P137; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; Lovestone S, 1999, BIOL PSYCHIAT, V45, P995, DOI 10.1016/S0006-3223(98)00183-8; Lucas FR, 1998, J CELL SCI, V111, P1351; Ma M Z, 1983, J Tradit Chin Med, V3, P245; Maggirwar SB, 1999, J NEUROCHEM, V73, P578, DOI 10.1046/j.1471-4159.1999.0730578.x; Mandelkow EM, 1998, TRENDS CELL BIOL, V8, P425, DOI 10.1016/S0962-8924(98)01368-3; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2000, CHEM BIOL, V7, P51, DOI 10.1016/S1074-5521(00)00063-6; Meijer L, 1997, METHOD ENZYMOL, V283, P113; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MunozMontano JR, 1997, FEBS LETT, V411, P183, DOI 10.1016/S0014-5793(97)00688-1; Nishi A, 1997, J NEUROSCI, V17, P8147; Park SG, 1996, MOL CELLS, V6, P679; RIALET V, 1991, ANTICANCER RES, V11, P1581; Schultz C, 1999, J MED CHEM, V42, P2909, DOI 10.1021/jm9900570; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Senderowicz AM, 1998, J CLIN ONCOL, V16, P2986, DOI 10.1200/JCO.1998.16.9.2986; Sengupta A, 1997, MOL CELL BIOCHEM, V167, P99, DOI 10.1023/A:1006883924775; Sharma P, 1999, P NATL ACAD SCI USA, V96, P11156, DOI 10.1073/pnas.96.20.11156; *SICH I TRAD CHIN, 1981, CHIN TRAD HERB DRUGS, V12, P27; Summers SA, 1999, J BIOL CHEM, V274, P17934, DOI 10.1074/jbc.274.25.17934; TAKAHASHI I, 1987, J ANTIBIOT, V40, P1782, DOI 10.7164/antibiotics.40.1782; Takashima A, 1998, NEUROSCI RES, V31, P317, DOI 10.1016/S0168-0102(98)00061-3; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Tang D, 1996, Prog Cell Cycle Res, V2, P205; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; VOGT PK, 1998, CURR TOP MICROBIOL I, V227, P1; WANG JH, 1981, ACTA PHARM SINICA, V2, P241; Wang JZ, 1999, ALZHEIMER'S DISEASE AND RELATED DISORDERS, P311; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wu G.Y., 1980, CHIN MED J, V60, P451; WU GY, 1982, SCI SIN B-CHEM B A M, V25, P1071; WU LM, 1979, COMM CHINESE HERBAL, V9, P6; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yu LJ, 1998, J BIOL CHEM, V273, P33455, DOI 10.1074/jbc.273.50.33455; Zaharevitz DW, 1999, CANCER RES, V59, P2566; ZHANG L, 1985, ACTA ACAD MED SIN, V7, P112; Zhang Z N, 1985, J Tradit Chin Med, V5, P246; ZHANG ZN, 1985, CHINESE J INTEGRATED, V5, P80; Zheng-Fischhofer QY, 1998, EUR J BIOCHEM, V252, P542, DOI 10.1046/j.1432-1327.1998.2520542.x	82	645	694	0	88	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					251	260		10.1074/jbc.M002466200	http://dx.doi.org/10.1074/jbc.M002466200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11013232	hybrid			2022-12-25	WOS:000166280700035
J	Pedraza-Alva, G; Sawasdikosol, S; Liu, YC; Merida, LB; Cruz-Munoz, ME; Oceguera-Yanez, F; Burakoff, SJ; Rosenstein, Y				Pedraza-Alva, G; Sawasdikosol, S; Liu, YC; Merida, LB; Cruz-Munoz, ME; Oceguera-Yanez, F; Burakoff, SJ; Rosenstein, Y			Regulation of Cbl molecular interactions by the co-receptor molecule CD43 in human T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOTYROSINE-BINDING DOMAIN; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; PHOSPHATIDYLINOSITOL 3-KINASE; MONOCLONAL-ANTIBODY; NEGATIVE REGULATOR; ANTIGEN RECEPTOR; RING FINGER; DIFFERENTIAL REGULATION	CD43, one of the most abundant glycoproteins on the T cell surface, has been implicated in selection and maturation of thymocytes and migration, adhesion, and activation of mature T cells. The adapter molecule Cbl has been shown to be a negative regulator of Pas, Furthermore, it may also regulate intracellular signaling through the formation of several multi-molecular complexes. Here we investigated the role of Cbl in the CD43-mediated signaling pathway in human T cells. Unlike T cell receptor signaling, the interaction of the adapter protein Cbl with Vav and phosphatidylinositol 3-kinase, resulting from CD QS-specific signals, is independent of Cbl tyrosine phosphorylation, suggesting an alternative mechanism of interaction. CD43 signals induced a Cbl serine phosphorylation-dependent interaction with the tau -isoform of 14-3-3. protein. Protein kinase C-mediated Cbl serine phosphorylation was required for this interaction, because the PKC inhibitor RO-31-8220 prevented it, as well as 14-3-3 dimerization. Moreover, mutation of Cbl serine residues 619, 623, 639, and 642 abolished the interaction between Cbl and 14-3-3, Overexpression of Cbl in Jurkat cells inhibited the CD43-dependent activation of the mitogen-activated protein kinase (MAPK) pathway and AP-1 transcriptional activity, confirming nevertheless a negative role for Cbl in T cell signaling. However, under normal conditions, PKC activation resulting from CD43 engagement was required to activate the MAPK pathway, suggesting that phosphorylation of Cbl on serine residues by PKC and its association with 14-3-3 molecules may play a role in preventing the Cbl inhibitory effect on the Ras-MAPK pathway. These data suggest that by inducing its phosphorylation on serine residues, CD43-mediated signals may regulate the molecular associations and functions of the Cbl adapter protein.	Univ Nacl Autonoma Mexico, Inst Biotecnol, Cuernavaca 62250, Morelos, Mexico; Dana Farber Canc Inst, Boston, MA 02115 USA; La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA	Universidad Nacional Autonoma de Mexico; Harvard University; Dana-Farber Cancer Institute; La Jolla Institute for Immunology	Rosenstein, Y (corresponding author), Univ Nacl Autonoma Mexico, Inst Biotecnol, APDO Postal 510-3, Cuernavaca 62250, Morelos, Mexico.	yvonne@ibt.unam.mx		LIU, YUN-CAI/0000-0002-0996-7109				AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; ALVARADO M, 1995, EUR J IMMUNOL, V25, P1051, DOI 10.1002/eji.1830250429; Anzai N, 1999, BLOOD, V93, P3317, DOI 10.1182/blood.V93.10.3317.410k12_3317_3326; AXELSSON B, 1988, J IMMUNOL, V141, P2912; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Corinti S, 1999, J IMMUNOL, V162, P6331; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Donda A, 1996, EUR J IMMUNOL, V26, P493, DOI 10.1002/eji.1830260232; Donovan JA, 1996, J BIOL CHEM, V271, P26369, DOI 10.1074/jbc.271.42.26369; Dubois T, 1997, J BIOL CHEM, V272, P28882, DOI 10.1074/jbc.272.46.28882; ELLIES LG, 1994, GLYCOBIOLOGY, V4, P885, DOI 10.1093/glycob/4.6.885; FanalesBelasio E, 1997, ADV EXP MED BIOL, V417, P207; FanalesBelasio E, 1997, J IMMUNOL, V159, P2203; Fernandez B, 1999, J BIOL CHEM, V274, P20244, DOI 10.1074/jbc.274.29.20244; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; Husson H, 1997, ONCOGENE, V14, P2331, DOI 10.1038/sj.onc.1201074; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Johnson GG, 1999, J IMMUNOL, V163, P5678; JONGEWARD GD, 1995, GENETICS, V139, P1553; Kanagasundaram V, 1996, BIOCHEM J, V320, P69, DOI 10.1042/bj3200069; Kishimoto H, 1999, J EXP MED, V190, P65, DOI 10.1084/jem.190.1.65; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Liu YC, 1997, J BIOL CHEM, V272, P168; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Liu YH, 1999, J IMMUNOL, V162, P7095; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; MANJUNATH N, 1993, J IMMUNOL, V151, P1528; MANJUNATH N, 1995, NATURE, V377, P535, DOI 10.1038/377535a0; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Marengere LEM, 1997, J IMMUNOL, V159, P70; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; Marshall CJ, 1998, NATURE, V392, P553, DOI 10.1038/33293; Matsuo T, 1996, FEBS LETT, V397, P113, DOI 10.1016/S0014-5793(96)01151-9; McEvoy LM, 1997, J EXP MED, V185, P1493, DOI 10.1084/jem.185.8.1493; Megidish T, 1998, J BIOL CHEM, V273, P21834, DOI 10.1074/jbc.273.34.21834; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Musci MA, 1997, J IMMUNOL, V159, P1639; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; PADILLANORIEGA L, 1993, J CLIN MICROBIOL, V31, P622, DOI 10.1128/JCM.31.3.622-628.1993; PARK JK, 1991, NATURE, V350, P706, DOI 10.1038/350706a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pedraza-Alva G, 1998, J BIOL CHEM, V273, P14218, DOI 10.1074/jbc.273.23.14218; PEDRAZAALVA G, 1994, J BIOL CHEM, V269, P6978; PedrazaAlva G, 1996, J BIOL CHEM, V271, P27564, DOI 10.1074/jbc.271.44.27564; PEREZ L, 1993, P NATL ACAD SCI USA, V90, P8113, DOI 10.1073/pnas.90.17.8113; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; PILLER F, 1988, J BIOL CHEM, V263, P15146; PINTADO CO, 1995, VET IMMUNOL IMMUNOP, V47, P333, DOI 10.1016/0165-2427(94)05403-F; PRATT JC, 1996, IMMUNOLOGIST, V4, P122; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROSENKRANZ AR, 1993, IMMUNOLOGY, V80, P431; SANCHEZMATEOS P, 1995, BLOOD, V86, P2228, DOI 10.1182/blood.V86.6.2228.bloodjournal8662228; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; Scaife RM, 2000, J CELL SCI, V113, P215; Serrador JM, 1998, BLOOD, V91, P4632, DOI 10.1182/blood.V91.12.4632.412k17_4632_4644; Seveau S, 1997, J CELL SCI, V110, P1465; SILVERMAN LB, 1989, J IMMUNOL, V142, P4194; SPERLING AI, 1995, J EXP MED, V182, P139, DOI 10.1084/jem.182.1.139; Stockl J, 1996, J EXP MED, V184, P1769, DOI 10.1084/jem.184.5.1769; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; Thien CBF, 1999, J IMMUNOL, V162, P7133; Thurman EC, 1998, INT IMMUNOL, V10, P691, DOI 10.1093/intimm/10.5.691; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Uemura N, 1999, J BIOL CHEM, V274, P37525, DOI 10.1074/jbc.274.53.37525; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Yankee TM, 1999, J IMMUNOL, V163, P5827; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zell T, 1998, CURR BIOL, V8, P814, DOI 10.1016/S0960-9822(98)70323-9; ZENNER G, 1995, BIOESSAYS, V17, P967, DOI 10.1002/bies.950171110	96	30	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					729	737		10.1074/jbc.M008494200	http://dx.doi.org/10.1074/jbc.M008494200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024037	hybrid			2022-12-25	WOS:000166280700098
J	Pernestig, AK; Melefors, O; Georgellis, D				Pernestig, AK; Melefors, O; Georgellis, D			Identification of UvrY as the cognate response regulator for the BarA sensor kinase in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-FLUORESCENS; SIGNAL-TRANSDUCTION; ADAPTIVE RESPONSES; HOMOSERINE LACTONE; GLOBAL CONTROL; OMPC GENES; IN-VITRO; PROTEIN; PHOSPHORYLATION; GACA	BarA is a membrane-associated protein that belongs to a subclass of tripartite sensors of the two-component signal transduction system family, In this study, we report that UvrY is the cognate response regulator for BarA of Escherichia coli, This conclusion is based upon homologies with analogous two-component systems and demonstrated by both biochemical and genetic means. We show that the purified BarA protein is able to autophosphorylate when incubated with [gamma-P-32]ATP but not with [alpha-P-32]ATP or [gamma-P-32]GTP. Phosphorylated BarA, in turn, acts as an efficient phosphoryl group donor to UvrY but not to the non-cognate response regulators ArcA, PhoB, or CpxR. The specificity of the transphosphorylation reaction is further supported by the fact that UvrY can receive the phosphoryl group from BarA-P but not from the non-cognate tripartite sensor ArcB-P or ATP, In addition, genetic evidence that BarA and UvrY mediate the same signal transduction pathway is provided by the finding that both uvrY and barA mutant strains exhibit the same hydrogen peroxide hypersensitive phenotype, These results provide the first biochemical evidence as well as genetic support for a link between BarA and UvrY, suggesting that the two proteins constitute a new two-component system for gene regulation in Eschcrichia coli.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Karolinska Inst, Microbiol & Tumorbiol Ctr, SE-17177 Stockholm, Sweden	Harvard University; Harvard Medical School; Karolinska Institutet	Georgellis, D (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.	dimitris_georgellis@hms.harvard.edu	Pernestig, Anna-Karin/X-8387-2018; Melefors, Öjar/N-6164-2015; Georgellis, Dimitris/U-2517-2017	Pernestig, Anna-Karin/0000-0003-4221-6013; Melefors, Öjar/0000-0003-4115-1190; Georgellis, Dimitris/0000-0002-6114-795X	NIGMS NIH HHS [GM-40993] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040993] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmer BMM, 1999, MOL MICROBIOL, V31, P971, DOI 10.1046/j.1365-2958.1999.01244.x; AIBA H, 1989, J BIOL CHEM, V264, P8563; Altier C, 2000, MOL MICROBIOL, V35, P635, DOI 10.1046/j.1365-2958.2000.01734.x; Bender CL, 1999, MICROBIOL MOL BIOL R, V63, P266, DOI 10.1128/MMBR.63.2.266-292.1999; Blumer C, 1999, P NATL ACAD SCI USA, V96, P14073, DOI 10.1073/pnas.96.24.14073; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; Eriksson ARB, 1998, MOL PLANT MICROBE IN, V11, P743, DOI 10.1094/MPMI.1998.11.8.743; Fisher SL, 1996, BIOCHEMISTRY-US, V35, P4732, DOI 10.1021/bi9525435; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; Frederick RD, 1997, MOL PLANT MICROBE IN, V10, P407, DOI 10.1094/MPMI.1997.10.3.407; Georgellis D, 1999, J BIOL CHEM, V274, P35950, DOI 10.1074/jbc.274.50.35950; Georgellis D, 1998, J BIOL CHEM, V273, P32864, DOI 10.1074/jbc.273.49.32864; Georgellis D, 1997, J BACTERIOL, V179, P5429, DOI 10.1128/jb.179.17.5429-5435.1997; Hengge-Aronis R, 2000, BACTERIAL STRESS RESPONSES, P161; Hoch JA, 1995, 2 COMPONENT SIGNAL T; HRABAK EM, 1993, MOL PLANT MICROBE IN, V6, P368, DOI 10.1094/MPMI-6-368; IGO MM, 1989, GENE DEV, V3, P598, DOI 10.1101/gad.3.5.598; IUCHI S, 1992, J BACTERIOL, V174, P5617, DOI 10.1128/JB.174.17.5617-5623.1992; JIN SG, 1990, J BACTERIOL, V172, P4945, DOI 10.1128/jb.172.9.4945-4950.1990; Johnston C, 1996, MOL MICROBIOL, V22, P715, DOI 10.1046/j.1365-2958.1996.d01-1719.x; Jourlin C, 1997, J MOL BIOL, V267, P770, DOI 10.1006/jmbi.1997.0919; Kinscherf TG, 1999, J BACTERIOL, V181, P4133, DOI 10.1128/JB.181.13.4133-4136.1999; Kitten T, 1998, MOL MICROBIOL, V28, P917, DOI 10.1046/j.1365-2958.1998.00842.x; LAVILLE J, 1992, P NATL ACAD SCI USA, V89, P1562, DOI 10.1073/pnas.89.5.1562; Liao CH, 1996, CAN J MICROBIOL, V42, P177, DOI 10.1139/m96-026; Liao CH, 1997, CAN J MICROBIOL, V43, P425, DOI 10.1139/m97-060; LIN ECC, 1996, REGULATION GENE EXPR; Lynch AS, 1996, J BACTERIOL, V178, P6238, DOI 10.1128/JB.178.21.6238-6249.1996; MAKINO K, 1989, J MOL BIOL, V210, P551, DOI 10.1016/0022-2836(89)90131-9; Mizuno T, 1997, DNA Res, V4, P161, DOI 10.1093/dnares/4.2.161; MOOLENAAR GF, 1987, NUCLEIC ACIDS RES, V15, P4273, DOI 10.1093/nar/15.10.4273; Mukhopadhyay S, 2000, MOL MICROBIOL, V37, P371, DOI 10.1046/j.1365-2958.2000.01999.x; NAGASAWA S, 1992, MOL MICROBIOL, V6, P799, DOI 10.1111/j.1365-2958.1992.tb01530.x; OBERHANSLI T, 1991, J GEN MICROBIOL, V137, P2273, DOI 10.1099/00221287-137-10-2273; Ogino T, 1998, MOL MICROBIOL, V27, P573, DOI 10.1046/j.1365-2958.1998.00703.x; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Pogliano J, 1997, GENE DEV, V11, P1169, DOI 10.1101/gad.11.9.1169; Reimmann C, 1997, MOL MICROBIOL, V24, P309, DOI 10.1046/j.1365-2958.1997.3291701.x; RICH JJ, 1994, J BACTERIOL, V176, P7468, DOI 10.1128/JB.176.24.7468-7475.1994; SACHERER P, 1994, FEMS MICROBIOL LETT, V116, P155, DOI 10.1111/j.1574-6968.1994.tb06694.x; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; Uhl MA, 1996, EMBO J, V15, P1028, DOI 10.1002/j.1460-2075.1996.tb00440.x; Uhl MA, 1996, J BIOL CHEM, V271, P33176, DOI 10.1074/jbc.271.52.33176; Whistler CA, 1998, J BACTERIOL, V180, P6635, DOI 10.1128/JB.180.24.6635-6641.1998; Wong SM, 1998, INFECT IMMUN, V66, P5854, DOI 10.1128/IAI.66.12.5854-5861.1998; Zhang JP, 1996, SCIENCE, V273, P1234, DOI 10.1126/science.273.5279.1234	47	123	128	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					225	231		10.1074/jbc.M001550200	http://dx.doi.org/10.1074/jbc.M001550200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11022030	hybrid			2022-12-25	WOS:000166280700032
J	Russo, LA; Calabro, SP; Filler, TA; Carey, DJ; Gardner, RM				Russo, LA; Calabro, SP; Filler, TA; Carey, DJ; Gardner, RM			In vivo regulation of syndecan-3 expression in the rat uterus by 17 beta-estradiol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; MESSENGER-RIBONUCLEIC-ACID; SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR; N-SYNDECAN; LUMINAL EPITHELIUM; ESTROGEN-RECEPTORS; FIBROBLAST GROWTH; INVIVO REGULATION; OVARIAN HORMONES	The immature rat uterus has been extensively used as an in vivo model system to study the molecular mechanisms of steroid hormone actions. In this study, we demonstrated the regulated expression of syndecan-3 in the rat uterus by the steroid hormone 17 beta -estradiol. Administration of a single physiological dose of 17 beta -estradiol (40 mug/kg) to ovariectomized immature animals induced a rapid and transient increase in uterine syndecan-3 mRNA Transcript levels reached a peak elevation of 3-fold above saline control tissues 4 h after hormone administration. Inhibition of message up-regulation by actinomycin D but not cycloheximide indicated a hormone response dependent on RNA transcription but not new protein synthesis. The estrogenic ligands estriol and tamoxifen were also effective at raising syndecan-3 mRNA levels; however, nonestrogenic ligands, including progesterone, 5 alpha -dihydrotestosterone, and dexamethasone, failed to stimulate a change in mRNA levels. Hormone-induced changes in mRNA led to transient changes in syndecan-3 protein content and significant alteration in the temporal and spatial expression in endometrial epithelial cells. Collectively, these data show that the steroid hormone 17 beta -estradiol, regulates transcription of the syndecan-3 gene in the uterus via an estrogen receptor-dependent mechanism. This estrogen-regulated expression of syndecan-3 may play an important role in changes in tissue ultrastructure crucial for proper uterine growth.	Villanova Univ, Dept Biol, Villanova, PA 19085 USA; Penn State Univ, Coll Med, Weis Ctr Res, Danville, PA 17822 USA	Villanova University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Russo, LA (corresponding author), Villanova Univ, Dept Biol, Mendel Hall,800 Lancaster Ave, Villanova, PA 19085 USA.	louise.russo@villanova.edu						ANDERSON JN, 1972, BIOCHEM BIOPH RES CO, V48, P1460, DOI 10.1016/0006-291X(72)90878-9; BACIU PC, 1995, MOL BIOL CELL, V6, P1503, DOI 10.1091/mbc.6.11.1503; BAKER HJ, 1978, J BIOL CHEM, V253, P4521; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BROCK ML, 1983, CELL, V34, P207, DOI 10.1016/0092-8674(83)90151-4; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; Carey DJ, 1997, J BIOL CHEM, V272, P2873, DOI 10.1074/jbc.272.5.2873; Carey DJ, 1997, BIOCHEM J, V327, P1; Chernousov MA, 1996, J BIOL CHEM, V271, P13844, DOI 10.1074/jbc.271.23.13844; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P53; CIZMECISMITH G, 1993, J BIOL CHEM, V268, P18740; CizmeciSmith G, 1997, ARTERIOSCL THROM VAS, V17, P172, DOI 10.1161/01.ATV.17.1.172; Couchman JR, 1996, J CELL BIOCHEM, V61, P578, DOI 10.1002/(SICI)1097-4644(19960616)61:4<578::AID-JCB11>3.0.CO;2-C; DAUVOIS S, 1993, STEROID HORMONE ACTI, P166; DIAUGUSTINE RP, 1988, ENDOCRINOLOGY, V122, P2355, DOI 10.1210/endo-122-6-2355; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; FREYSCHUSS B, 1994, J ENDOCRINOL, V142, P285, DOI 10.1677/joe.0.1420285; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; IKEDA K, 1989, J BIOL CHEM, V264, P15743; KAYE AM, 1972, BIOCHIM BIOPHYS ACTA, V261, P475, DOI 10.1016/0304-4165(72)90072-4; Klagsbrun M, 1990, CURR OPIN CELL BIOL, V2, P857, DOI 10.1016/0955-0674(90)90084-R; KLANGKALYA B, 1988, LIFE SCI, V42, P2307, DOI 10.1016/0024-3205(88)90183-X; KOUZIKOLIAKOS K, 1989, J BIOL CHEM, V264, P17971; LEBARON RG, 1988, J CELL BIOL, V106, P945, DOI 10.1083/jcb.106.3.945; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; LOOSEMITCHELL DS, 1988, MOL ENDOCRINOL, V2, P946, DOI 10.1210/mend-2-10-946; MORRIS JE, 1988, J BIOL CHEM, V263, P4712; MUKKU VR, 1985, J BIOL CHEM, V260, P9820; MURPHY CR, 1981, CELL BIOPHYS, V3, P305, DOI 10.1007/BF02785116; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1882, DOI 10.1210/endo-120-5-1882; MYERS MJ, 1986, LIFE SCI, V39, P313, DOI 10.1016/0024-3205(86)90649-1; PASTORE GN, 1992, BIOL REPROD, V47, P83, DOI 10.1095/biolreprod47.1.83; POTTER SW, 1992, ANAT REC, V234, P383, DOI 10.1002/ar.1092340308; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REYES AA, 1990, CELL REGUL, V1, P567, DOI 10.1091/mbc.1.8.567; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SCHLAFKE S, 1985, ANAT REC, V212, P47, DOI 10.1002/ar.1092120107; STACK G, 1985, ENDOCRINOLOGY, V117, P2024, DOI 10.1210/endo-117-5-2024; SUVA LJ, 1991, MOL ENDOCRINOL, V5, P829, DOI 10.1210/mend-5-6-829; THIEDE MA, 1991, ENDOCRINOLOGY, V128, P2317, DOI 10.1210/endo-128-5-2317; THURESSONKLEIN A, 1985, AM J OBSTET GYNECOL, V151, P506, DOI 10.1016/0002-9378(85)90279-0; WEBB DK, 1990, BIOCHEM BIOPH RES CO, V168, P721, DOI 10.1016/0006-291X(90)92381-9; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183	46	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					686	692		10.1074/jbc.M004106200	http://dx.doi.org/10.1074/jbc.M004106200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024013	hybrid			2022-12-25	WOS:000166280700092
J	Bai, RL; Covell, DG; Pei, XF; Ewell, JB; Nguyen, NY; Brossi, A; Hamel, E				Bai, RL; Covell, DG; Pei, XF; Ewell, JB; Nguyen, NY; Brossi, A; Hamel, E			Mapping the binding site of colchicinoids on beta-tubulin - 2-chloroacetyl-2-demethylthiocolchicine covalently reacts predominantly with cysteine 239 and secondarily with cysteine 354	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN; BIOLOGICAL PROPERTIES; NUCLEOCAPSID PROTEIN; INHIBITOR BINDING; THIOCOLCHICINE; AGENTS; IDENTIFICATION; SEPARATION; KINETICS; RESIDUE	2-Chloroacetyl-2-demethylthiocolchicine (2CTC) and 3-chloroacetyl-3-demethylthiocolchicine (3CTC) resemble colchicine in binding to tubulin and react covalently with beta -tubulin, forming adducts with cysteine residues 239 and 354. The adducts at Cys-239 are less stable than those at Cys-354 during formic acid digestion. Extrapolating to zero time, the Cys-239 to Cys-354 adduct ratio is 77:23 for 2CTC and 27:73 for 3CTC. Using energy minimization modeling to dock colchicinoids into the electron crystallographic model of P-tubulin in protofilaments (Nogales, E., Wolf, S. G., and Downing, K. H. (1998) Nature 391, 199-203), we found two potential binding sites. At one, entirely encompassed within beta -tubulin, the C2- and CS-oxygen atoms of 2CTC and 3CTC overlapped poorly with those of colchicine and thiocolchicine, but distances from the reactive carbon atoms of the analogs to the sulfur atoms of the cysteine residues were qualitatively consistent with reactivity. The other potential binding site was located at the alpha/beta interface. Here, the oxygen atoms of the analogs overlapped well with those of colchicine, but relative distances of the reactive carbons to the cysteine sulfur atoms did not correlate with the observed reactivity. A significant conformational change must occur in the colchicine binding site of tubulin in the transition from the unpolymerized to the polymerized state.	NCI, Screening Technol Branch, Dev Therapeut Program, Div Canc Treatment & Diag,Frederick Canc Res & De, Frederick, MD 21702 USA; NCI, Lab Expt & Computat Biol, Frederick Canc Res & Dev Ctr, Sci Applicat Int Corp, Frederick, MD 21702 USA; NIDDK, Struct Biol Lab, NIH, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Facil Biotechnol Resources, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); US Food & Drug Administration (FDA)	Hamel, E (corresponding author), NCI, Screening Technol Branch, Dev Therapeut Program, Div Canc Treatment & Diag,Frederick Canc Res & De, Bldg 469,Rm 104,POB B, Frederick, MD 21702 USA.				NCI NIH HHS [N01CO56000] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai RL, 1999, J BIOL CHEM, V274, P12710, DOI 10.1074/jbc.274.18.12710; Bai RL, 1996, J BIOL CHEM, V271, P12639, DOI 10.1074/jbc.271.21.12639; BAI RL, 1989, BIOCHEMISTRY-US, V28, P5606, DOI 10.1021/bi00439a040; BANERJEE A, 1988, J BIOL CHEM, V263, P3029; BANERJEE A, 1992, J BIOL CHEM, V267, P13335; BANERJEE A, 1994, J BIOL CHEM, V269, P10324; Banerjee A, 1999, BIOCHEM BIOPH RES CO, V254, P334, DOI 10.1006/bbrc.1998.9943; BANERJEE A, 1991, J BIOL CHEM, V266, P1689; Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828; BOYE O, 1992, J LABELLED COMPOUNDS, V33, P293; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; CHABIN RM, 1989, BIOCHEM BIOPH RES CO, V161, P544, DOI 10.1016/0006-291X(89)92633-8; Covell DG, 1998, THEOCHEM-J MOL STRUC, V423, P93, DOI 10.1016/S0166-1280(97)00122-X; Downing KH, 1998, EUR BIOPHYS J BIOPHY, V27, P431, DOI 10.1007/s002490050153; FLOYD LJ, 1989, BIOCHEMISTRY-US, V28, P8515, DOI 10.1021/bi00447a037; GROVER S, 1992, BIOCHEM BIOPH RES CO, V187, P1350, DOI 10.1016/0006-291X(92)90451-P; HAMEL E, 1984, BIOCHEMISTRY-US, V23, P4173, DOI 10.1021/bi00313a026; HASTIE SB, 1991, PHARMACOL THERAPEUT, V51, P377, DOI 10.1016/0163-7258(91)90067-V; Huang MJ, 1998, J MED CHEM, V41, P1371, DOI 10.1021/jm9708543; KANG GJ, 1990, J BIOL CHEM, V265, P10255; Landon, 1977, Methods Enzymol, V47, P145; LEE YC, 1974, J NEUROBIOL, V5, P317, DOI 10.1002/neu.480050404; LUDUENA RF, 1981, BIOCHEMISTRY-US, V20, P4444, DOI 10.1021/bi00518a032; LUDUENA RF, 1991, PHARMACOL THERAPEUT, V49, P133, DOI 10.1016/0163-7258(91)90027-J; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; RAO S, 1994, J BIOL CHEM, V269, P3132; Rice WG, 1996, J MED CHEM, V39, P3606, DOI 10.1021/jm960375o; Rice WG, 1997, NAT MED, V3, P341, DOI 10.1038/nm0397-341; Turpin JA, 1999, J MED CHEM, V42, P67, DOI 10.1021/jm9802517; UPPULURI S, 1993, P NATL ACAD SCI USA, V90, P11598, DOI 10.1073/pnas.90.24.11598; Wallqvist A, 1996, PROTEINS, V25, P403, DOI 10.1002/(SICI)1097-0134(199608)25:4<403::AID-PROT1>3.0.CO;2-E; WALLQVIST A, 1995, PROTEIN SCI, V4, P1881, DOI 10.1002/pro.5560040923; WILLIAMS RF, 1985, J BIOL CHEM, V260, P3794; WILSON L, 1973, J CELL BIOL, V58, P709, DOI 10.1083/jcb.58.3.709; WOLFF J, 1991, P NATL ACAD SCI USA, V88, P2820, DOI 10.1073/pnas.88.7.2820; YEH HJC, 1988, FEBS LETT, V229, P82, DOI 10.1016/0014-5793(88)80802-0; YOUNG L, 1994, PROTEIN SCI, V3, P717	38	93	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40443	40452		10.1074/jbc.M005299200	http://dx.doi.org/10.1074/jbc.M005299200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11005811	hybrid			2022-12-25	WOS:000166039500087
J	Chen, VC; Chao, L; Chao, J				Chen, VC; Chao, L; Chao, J			A positively charged loop on the surface of kallistatin functions to enhance tissue kallikrein inhibition by acting as a secondary binding site for kallikrein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-C INHIBITOR; HEPARIN COFACTOR-II; PLASMINOGEN-ACTIVATOR INHIBITOR-1; ANTITHROMBIN-III; URINARY KALLIKREIN; THROMBIN; SERPIN; ALPHA-1-ANTITRYPSIN; IDENTIFICATION; SPECIFICITY	Kallistatin is a serine proteinase inhibitor (serpin) that specifically inhibits tissue kallikrein, The inhibitory activity of kallistatin is abolished upon heparin binding. The loop between the H helix and C2 sheet of kallistatin containing clusters of basic amino acid residues has been identified as a heparin-binding site. In this study, we investigated the role of the basic residues in this region in tissue kallikrein inhibition. Kallistatin mutants containing double Ala substitutions for these basic residues displayed a 70-80% reduction of association rate constants, indicating the importance of these basic residues in tissue kallikrein inhibition. A synthetic peptide derived from the sequence between the H helix and C2 sheet of kallistatin was shown to suppress the kallistatin-kallikrein interaction through competition for tissue kallikrein binding. To further evaluate the function of this loop, we used alpha1-antitrypsin, a nonheparin-binding serpin and slow tissue kallikrein inhibitor as a scaffold to engineer kallikrein inhibitors. An alpha1-antitrypsin chimera harboring the P3-P2' residues and a sequence homologous to the positively charged region between the H helix and C2 sheet of kallistatin acquired heparin-suppressed inhibitory activity toward tissue kallikrein and exhibited an inhibitory activity 20-fold higher than that of the other chimera, which contained only kallistatin's P3-P2' sequence, and 2300-fold higher than that of wild-type alpha1-antitrypsin. The alpha1-antitrypsin chimera with inhibitory characteristics similar to those of ballistatin demonstrates that the loop between the H helix and C2 sheet of kallistatin is crucial in tissue kallikrein inhibition, and this functional loop can be used as a module to enhance the inhibitory activity of a serpin toward tissue kallikrein. In conclusion, our results indicate that a positively charged loop between the H helix and C2 sheet of a serpin can accelerate the association of a serpin with tissue kallikrein by acting as a secondary binding site.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Chao, J (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 171 Ashley Ave, Charleston, SC 29425 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044083] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44083] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BHOOLA KD, 1992, PHARMACOL REV, V44, P1; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHEN VC, 2001, IN PRESS J BIOL CHEM, V276; CHEN VC, 2000, IN PRESS BIOCH BIOPH; CHEN VC, 2000, IN PRESS J BIOL CHEM, V275; Djie MZ, 1997, J BIOL CHEM, V272, P16268, DOI 10.1074/jbc.272.26.16268; DONOVAN FM, 1994, J BIOL CHEM, V269, P17199; ECKE S, 1992, J BIOL CHEM, V267, P7048; EHRLICH HJ, 1992, J BIOL CHEM, V267, P11606; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; ErsdalBadju E, 1997, J BIOL CHEM, V272, P19393, DOI 10.1074/jbc.272.31.19393; EVANS DL, 1992, BIOCHEMISTRY-US, V31, P12629, DOI 10.1021/bi00165a013; GEIGER R, 1981, H-S Z PHYSIOL CHEM, V362, P317, DOI 10.1515/bchm2.1981.362.1.317; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; Jiang H, 1995, INSECT BIOCHEM MOLEC, V25, P1093, DOI 10.1016/0965-1748(95)00042-9; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; JOHANSEN H, 1987, MOL BIOL MED, V4, P291; Katz BA, 1998, PROTEIN SCI, V7, P875; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LEBONNIEC BF, 1995, BIOCHEMISTRY-US, V34, P12241, DOI 10.1021/bi00038a019; MADISON EL, 1990, J BIOL CHEM, V265, P21423; OWEN BA, 1990, BIOCHEMISTRY-US, V29, P9412, DOI 10.1021/bi00492a015; PATSTON PA, 1994, THROMB HAEMOSTASIS, V72, P166; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; PRATT CW, 1992, J BIOL CHEM, V267, P8795; PRATT CW, 1992, J BIOL CHEM, V267, P8789; ROGERS SJ, 1992, J BIOL CHEM, V267, P2613; SHIMAMOTO K, 1980, J CLIN ENDOCR METAB, V51, P840, DOI 10.1210/jcem-51-4-840; SHIRK RA, 1994, J BIOL CHEM, V269, P28690; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; WHINNA HC, 1991, J BIOL CHEM, V266, P8129; ZHOU GX, 1992, J BIOL CHEM, V267, P25873	35	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40371	40377		10.1074/jbc.M005691200	http://dx.doi.org/10.1074/jbc.M005691200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10991942	hybrid			2022-12-25	WOS:000166039500078
J	Cohen-Salmon, M; Frenz, D; Liu, W; Verpy, E; Voegeling, S; Petit, C				Cohen-Salmon, M; Frenz, D; Liu, W; Verpy, E; Voegeling, S; Petit, C			Fdp, a new fibrocyte-derived protein related to MIA/CD-RAP, has an in vitro effect on the early differentiation of the inner ear mesenchyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OTIC CAPSULE CHONDROGENESIS; ULTRASTRUCTURAL ANALYSIS; DEVELOPMENTAL DEFECTS; GROWTH-FACTOR; GENE DEFECT; DEAFNESS; CARTILAGE; MOUSE; EXPRESSION; MUTATIONS	During the course of a study aimed at isolating transcripts specifically or preferentially expressed in the inner ear, we identified a novel gene, encoding a fibrocyte-derived protein, that we named Fdp. Fdp is predicted to be a secreted 128-amino acid protein, which is highly homologous to the melanoma-inhibiting activity/cartilage-derived retinoic acid-sensitive protein (MIA/CD-RAP), a cartilage-specific protein also expressed in several tumors. Fdp and MIA/CD-RAP thus define a new family of proteins. Fdp is expressed from embryonic day 10.5 in the mesenchyme surrounding the otic epithelium. During development, these cells progressively aggregate, condense, and differentiate into cartilaginous cells forming the otic capsule, which no longer expresses Fdp, and into fibrocytes surrounding the epithelia, which strongly express Fdp. In order to address the function of Fdp, we developed an in vitro antisense oligonucleotide approach using microdissected periotic mesenchyme micromass cultures, and showed that Fdp antisense oligonucleotide treatment results in a significant reduction in chondrogenesis. Our results demonstrate that Fdp plays a role in the initiation of periotic mesenchyme chondrogenesis. Accordingly, Fdp and its human ortholog FDP, which map to chromosome 2 and band 20p11, respectively, could be candidate genes for forms of dearness associated with malformations of the otic capsule.	Inst Pasteur, CNRS, URA 1968, Unite Genet Deficits Sensoriels, F-75724 Paris 15, France; Yeshiva Univ Albert Einstein Coll Med, Dept Otolaryngol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; Inst Pasteur, Unite Genet Mammiferes, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Petit, C (corresponding author), Inst Pasteur, CNRS, URA 1968, Unite Genet Deficits Sensoriels, 25 Rue Dr Roux, F-75724 Paris 15, France.	cpetit@pasteur.fr		Cohen-Salmon, Martine/0000-0002-5312-8476; Petit, Christine/0000-0002-9069-002X				AHRENS PB, 1977, DEV BIOL, V60, P69, DOI 10.1016/0012-1606(77)90110-5; Alloisio N, 1999, EUR J HUM GENET, V7, P255, DOI 10.1038/sj.ejhg.5200273; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; BLESCH A, 1994, CANCER RES, V54, P5695; Bosserhoff AK, 1996, J BIOL CHEM, V271, P490, DOI 10.1074/jbc.271.1.490; Bosserhoff AK, 1997, DEV DYNAM, V208, P516, DOI 10.1002/(SICI)1097-0177(199704)208:4<516::AID-AJA7>3.0.CO;2-L; Chansky H, 1998, J ORTHOPAED RES, V16, P521, DOI 10.1002/jor.1100160502; Cohen-Salmon M, 1997, P NATL ACAD SCI USA, V94, P14450, DOI 10.1073/pnas.94.26.14450; DEKOK YJM, 1995, SCIENCE, V267, P685, DOI 10.1126/science.7839145; Denoyelle F, 1999, LANCET, V353, P1298, DOI 10.1016/S0140-6736(98)11071-1; Dietz UH, 1996, J BIOL CHEM, V271, P3311, DOI 10.1074/jbc.271.6.3311; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FRENZ DA, 1994, DEVELOPMENT, V120, P415; Frenz DA, 1996, ANN NY ACAD SCI, V785, P256, DOI 10.1111/j.1749-6632.1996.tb56277.x; FRENZ DA, 1992, DEV BIOL, V153, P324, DOI 10.1016/0012-1606(92)90117-Y; FRENZ DA, 1991, DEV BIOL, V144, P38, DOI 10.1016/0012-1606(91)90476-J; Frenz DA, 1998, GROWTH FACTORS, V15, P173, DOI 10.3109/08977199809002115; GROUP TEB, 1994, HUM MOL GENET, V3, P621; IURATO S, 1962, Z ZELLFORSCH MIK ANA, V56, P40, DOI 10.1007/BF00326848; KIKUCHI T, 1994, ACTA OTO-LARYNGOL, V114, P520, DOI 10.3109/00016489409126097; KIKUCHI T, 1995, ANAT EMBRYOL, V191, P101, DOI 10.1007/BF00186783; KNOWLTON VY, 1967, J MORPHOL, V121, P179, DOI 10.1002/jmor.1051210302; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lautermann J, 1998, CELL TISSUE RES, V294, P415, DOI 10.1007/s004410051192; Legan PK, 1997, J BIOL CHEM, V272, P8791, DOI 10.1074/jbc.272.13.8791; LEV R, 1964, J HISTOCHEM CYTOCHEM, V12, P309, DOI 10.1177/12.4.309; LOHNES D, 1994, DEVELOPMENT, V120, P2723; MCPHEE JR, 1986, J EMBRYOL EXP MORPH, V97, P1; Minowa O, 1999, SCIENCE, V285, P1408, DOI 10.1126/science.285.5432.1408; Mustapha M, 1999, HUM MOL GENET, V8, P409, DOI 10.1093/hmg/8.3.409; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; PETIT C, 2000, IN PRESS METABOLIC M; Phippard D, 1999, J NEUROSCI, V19, P5980, DOI 10.1523/JNEUROSCI.19-14-05980.1999; Phippard D, 1998, HEARING RES, V120, P77, DOI 10.1016/S0378-5955(98)00059-8; Robertson NG, 1997, GENOMICS, V46, P345, DOI 10.1006/geno.1997.5067; ROBERTSON NG, 1994, GENOMICS, V23, P42, DOI 10.1006/geno.1994.1457; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SHER AE, 1971, ACTA OTO-LARYNGOL, V285, P5; Simmler MC, 2000, NAT GENET, V24, P139, DOI 10.1038/72793; Spicer SS, 1996, HEARING RES, V100, P80, DOI 10.1016/0378-5955(96)00106-2; SPICER SS, 1991, HEARING RES, V56, P53, DOI 10.1016/0378-5955(91)90153-Z; TAKAHASHI T, 1970, Acta Oto-Laryngologica, V69, P46, DOI 10.3109/00016487009123335; Verhoeven K, 1998, NAT GENET, V19, P60, DOI 10.1038/ng0598-60; Verpy E, 1999, P NATL ACAD SCI USA, V96, P529, DOI 10.1073/pnas.96.2.529; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Xie WF, 1999, J BONE MINER RES, V14, P757, DOI 10.1359/jbmr.1999.14.5.757; Yasunaga S, 1999, NAT GENET, V21, P363, DOI 10.1038/7693	49	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40036	40041		10.1074/jbc.M002876200	http://dx.doi.org/10.1074/jbc.M002876200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10998416	hybrid			2022-12-25	WOS:000166039500034
J	Desai, R; Peretz, A; Idelson, H; Lazarovici, P; Attali, B				Desai, R; Peretz, A; Idelson, H; Lazarovici, P; Attali, B			Ca2+-activated K+ channels in human leukemic Jurkat T cells - Molecular cloning, biochemical, and functional characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; SMALL-CONDUCTANCE; CA CHANNEL; BEE VENOM; RAT-BRAIN; CALCIUM; APAMIN; LYMPHOCYTES; EXPRESSION; CALMODULIN	Previous studies have demonstrated the presence of apamin-sensitive, small-conductance Ca2+-activated K+ currents in human leukemic Jurkat T cells. Using a combined cDNA and reverse transcriptase-polymerase chain reaction cloning strategy, we have isolated from Jurkat T cells a 2.5-kilobase cDNA, hSK2, encoding the human isoform of SK2 channels. Northern blot analysis reveals the presence of a 2.5-kilobase hSK2 transcript in Jurkat T cells. While present in various human tissues, including brain, heart, skeletal muscle, kidney, and liver, no hSK2 mRNA could be detected in resting and activated normal human T cells. The hSK2 gene is encoded by 8 exons and could be assigned to chromosome 5 (q21.2-q22.1). The protein encoded by hSK2 is 579 amino acids long and exhibits 97% identity with its rat counterpart rSK2. When expressed in Chinese hamster ovary cells, hSK2 produces Ca2+-activated K+ currents with a unitary conductance of 9.5 pS and a K-0.5 for calcium of 0.7 muM; hSK2 currents are inhibited by apamin, scyllatoxin, and d-tubocurarine. Overexpression of the Src family tyrosine kinase p56(lck) in Jurkat cells, upregulates SK2 currents by 3-fold. While IKCa channels are transcriptionally induced upon activation of normal human T cells, our results show that in Jurkat cells SK2 channels are constitutively expressed and down-regulated following mitogenic stimulation.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Alomone Labs, IL-91042 Jerusalem, Israel; Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmacol & Expt Therapeut, IL-91120 Jerusalem, Israel	Weizmann Institute of Science; Hebrew University of Jerusalem	Attali, B (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	attali@weizmann.ac.il						ATTALI B, 1992, J BIOL CHEM, V267, P8650; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; CAI YC, 1992, DNA CELL BIOL, V11, P163, DOI 10.1089/dna.1992.11.163; CASTLE NA, 1989, TRENDS NEUROSCI, V12, P59, DOI 10.1016/0166-2236(89)90137-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Frohman Michael A., 1995, P381; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; GRISSMER S, 1992, J GEN PHYSIOL, V99, P63, DOI 10.1085/jgp.99.1.63; GRISSMER S, 1993, J GEN PHYSIOL, V102, P601, DOI 10.1085/jgp.102.4.601; Gulbins E, 1997, P NATL ACAD SCI USA, V94, P7661, DOI 10.1073/pnas.94.14.7661; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hanselmann C, 1996, J PHYSIOL-LONDON, V496, P627, DOI 10.1113/jphysiol.1996.sp021714; HUGUES M, 1982, EMBO J, V1, P1039, DOI 10.1002/j.1460-2075.1982.tb01293.x; HUGUES M, 1982, P NATL ACAD SCI-BIOL, V79, P1308, DOI 10.1073/pnas.79.4.1308; HUGUES M, 1982, J BIOL CHEM, V257, P2762; HUGUES M, 1982, LIFE SCI, V31, P437, DOI 10.1016/0024-3205(82)90328-9; HUGUES M, 1982, BIOCHEM BIOPH RES CO, V107, P1577, DOI 10.1016/S0006-291X(82)80180-0; Ishii TM, 1997, J BIOL CHEM, V272, P23195, DOI 10.1074/jbc.272.37.23195; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Jager H, 2000, FEBS LETT, V469, P196, DOI 10.1016/S0014-5793(00)01236-9; Jensen BS, 1998, AM J PHYSIOL-CELL PH, V275, pC848, DOI 10.1152/ajpcell.1998.275.3.C848; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; Keen JE, 1999, J NEUROSCI, V19, P8830, DOI 10.1523/JNEUROSCI.19-20-08830.1999; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAZDUNSKI M, 1985, BIOCHEM SOC SYMP, P31; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; MOCZYDLOWSKI E, 1988, J MEMBRANE BIOL, V105, P95, DOI 10.1007/BF02009164; MOURRE C, 1986, BRAIN RES, V382, P239, DOI 10.1016/0006-8993(86)91333-8; Pribnow D, 1999, MUSCLE NERVE, V22, P742, DOI 10.1002/(SICI)1097-4598(199906)22:6<742::AID-MUS11>3.0.CO;2-1; ROMEY G, 1984, J PHYSIOL-PARIS, V79, P259; Sah P, 1996, TRENDS NEUROSCI, V19, P150, DOI 10.1016/S0166-2236(96)80026-9; SCHMIDANTOMARCHI H, 1986, J BIOL CHEM, V261, P8633; Shah M, 2000, BRIT J PHARMACOL, V129, P627, DOI 10.1038/sj.bjp.0703111; Shirihai O, 1996, PFLUG ARCH EUR J PHY, V431, P632, DOI 10.1007/s004240050045; Sobko A, 1998, EMBO J, V17, P4723, DOI 10.1093/emboj/17.16.4723; Strobaek D, 2000, BRIT J PHARMACOL, V129, P991, DOI 10.1038/sj.bjp.0703120; STRONG PN, 1990, PHARMACOL THERAPEUT, V46, P137, DOI 10.1016/0163-7258(90)90040-9; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; VERHEUGEN JAH, 1995, J GEN PHYSIOL, V105, P765, DOI 10.1085/jgp.105.6.765; Wadsworth JDF, 1997, ARCH BIOCHEM BIOPHYS, V346, P151, DOI 10.1006/abbi.1997.0280; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758	47	48	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39954	39963		10.1074/jbc.M001562200	http://dx.doi.org/10.1074/jbc.M001562200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10991935	hybrid			2022-12-25	WOS:000166039500024
J	Mullins, LJ; Payne, CM; Kotelevtseva, N; Brooker, G; Fleming, S; Harris, S; Mullins, JJ				Mullins, LJ; Payne, CM; Kotelevtseva, N; Brooker, G; Fleming, S; Harris, S; Mullins, JJ			Granulation rescue and developmental marking of juxtaglomerular cells using "piggy-BAC" recombination of the mouse Ren locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; ESCHERICHIA-COLI; ARTIFICIAL CHROMOSOME; HOMOLOGOUS RECOMBINATION; GENE-EXPRESSION; REPORTER GENES; MURINE REN-1; DNA; CLONING; TRANSFORMATION	Mice lacking a functional Ren-1(d) gene exhibit a complete lack of renal juxtaglomerular cell granulation and atypical macula densa morphology. Transgenic mice carrying a 145-kilobase BAC clone encompassing the Ren-1(d) and Ren-2 loci were generated, characterized, and backcrossed with Ren-1(d-/-) mice. Homozygous Ren-1(d)-null mice expressing the BAC clone exhibited complete restoration of normal renal structure. Homologous recombination in Escherichia coli was used to generate a modified version of the BAC clone, in which an IRES beta -geo cassette was inserted specifically into the Ren-1(d) gene. When introduced into the germline, the modified clone provided a marker for juxtaglomerular cell differentiation and beta -geo was expressed appropriately in juxtaglomerular cells throughout development. Parallel backcross experiments onto the Ren-1(d)-null background demonstrated that the juxtaglomerular cells expressed the modified Ren-1(d) locus in the absence of regranulation. These data demonstrate that the nongranulated cells constitute bona fide juxtaglomerular cells despite their altered morphology, that overexpression of renin-2 cannot compensate for the loss of renin-1(d), and that primary structural differences between the two isoforms are responsible for the differences in granulation. The use of BAC modification as part of functional complementation studies illustrates the potential for in vivo molecular dissection of key physiological mechanisms.	Univ Edinburgh, Sch Med, Mol Physiol Lab, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Glaxo Wellcome Res & Dev Ltd, Mol Sci Div, Funct Genom Program, Med Res Ctr, Stevenage SG1 2NY, Herts, England	University of Edinburgh; University of Edinburgh; GlaxoSmithKline	Mullins, LJ (corresponding author), Univ Edinburgh, Sch Med, Mol Physiol Lab, Wilkie Bldg,Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.			Mullins, Linda/0000-0002-6743-8707				ABEL KJ, 1990, GENETICS, V124, P937; ABEL KJ, 1988, NUCLEIC ACIDS RES, V16, P2111, DOI 10.1093/nar/16.5.2111; ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; Clark AF, 1997, J BIOL CHEM, V272, P18185, DOI 10.1074/jbc.272.29.18185; CUI CQ, 1994, TRANSGENIC RES, V3, P182, DOI 10.1007/BF01973986; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; FABIAN JR, 1989, J BIOL CHEM, V264, P17589; GOMEZ RA, 1989, AM J PHYSIOL, V257, pF850, DOI 10.1152/ajprenal.1989.257.5.F850; HACKENTHAL E, 1990, PHYSIOL REV, V70, P1067, DOI 10.1152/physrev.1990.70.4.1067; Jessen JR, 1998, P NATL ACAD SCI USA, V95, P5121, DOI 10.1073/pnas.95.9.5121; MCGOWAN RA, 1987, THESIS SUNY BUFFALO; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; MULLINS JJ, 1982, EMBO J, V1, P1461, DOI 10.1002/j.1460-2075.1982.tb01338.x; MULLINS JJ, 1989, EMBO J, V8, P4065, DOI 10.1002/j.1460-2075.1989.tb08590.x; Mullins LJ, 1997, NUCLEIC ACIDS RES, V25, P2539, DOI 10.1093/nar/25.12.2539; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PANTHIER JJ, 1983, EMBO J, V2, P675, DOI 10.1002/j.1460-2075.1983.tb01483.x; Payne CM, 1999, J HUM HYPERTENS, V13, P845, DOI 10.1038/sj.jhh.1000921; PAYNE CM, 1999, VISUALISING REN 1 GE; SEALY JE, 1990, HYPERTENSION PATHOPH, V1, P1287; Sharp MGF, 1996, HYPERTENSION, V28, P1126, DOI 10.1161/01.HYP.28.6.1126; SHENG Y, 1995, NUCLEIC ACIDS RES, V23, P1990, DOI 10.1093/nar/23.11.1990; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SIGMUND CD, 1991, HYPERTENSION, V18, P446, DOI 10.1161/01.HYP.18.4.446; SIGMUND CD, 1990, BIOCHEM BIOPH RES CO, V170, P344, DOI 10.1016/0006-291X(90)91280-6; Sinn PL, 1999, J BIOL CHEM, V274, P35785, DOI 10.1074/jbc.274.50.35785; STERNBERG N, 1990, P NATL ACAD SCI USA, V87, P103, DOI 10.1073/pnas.87.1.103; TAUGNER R, 2000, JUXTAGLOMERULAR APPA, P215; THOREY IS, 1993, DEV BIOL, V160, P519, DOI 10.1006/dbio.1993.1326; TRONIK D, 1987, EMBO J, V6, P983, DOI 10.1002/j.1460-2075.1987.tb04848.x; Yan Y, 1998, HYPERTENSION, V32, P205, DOI 10.1161/01.HYP.32.2.205; Yanai K, 2000, J BIOL CHEM, V275, P5, DOI 10.1074/jbc.275.1.5; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859; Yang XW, 1999, NAT GENET, V22, P327, DOI 10.1038/11896; Zhang YM, 1998, NAT GENET, V20, P123, DOI 10.1038/2417	38	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40378	40384		10.1074/jbc.M007315200	http://dx.doi.org/10.1074/jbc.M007315200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10995772	hybrid			2022-12-25	WOS:000166039500079
J	Visai, L; Xu, Y; Casolini, F; Rindi, S; Hook, M; Speziale, P				Visai, L; Xu, Y; Casolini, F; Rindi, S; Hook, M; Speziale, P			Monoclonal antibodies to CNA, a collagen-binding microbial surface component recognizing adhesive matrix molecules, detach Staphylococcus aureus from a collagen substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN I/II FAMILY; MEDIATES ADHESION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; YADA PROTEIN; I-DOMAIN; INTEGRIN; ADHERENCE; RECEPTOR; ALPHA(1)BETA(1)	Previous studies showed that Staphylococcus aureus expresses a collagen-binding MSCRAMM (Microbial Surface Component Recognizing Adhesive Matrix Molecules), CNA, that is necessary and sufficient for S. aureus cells to adhere to cartilage and is a virulence factor in experimental septic arthritis. We have now used a monoclonal antibody (mAb) approach to further analyze the structure and function of CNA. 22 mAbs raised against the minimal ligand binding domain, CNA-(151-318), were shown to bind to the MSCRAMM with similar affinity. All mAbs appear to recognize conformation-dependent epitopes that were mapped throughout the CNA-(151-318) domain using a chimeric strategy where segments of CNA are grafted on ACE, a structurally related MSCRAMM from Enterococcus faecalis. These mAbs were able to inhibit I-125-collagen binding to CNA(151-318) as well as to intact S. aureus cells. They also interfered with the attachment of bacteria to collagen substrates. Furthermore, some of the mAbs could effectively displace I-125-collagen bound to the bacteria. These displacing mAbs were also able to detach bacteria that had adhered to a collagen substrate in a preincubation, raising the possibility that some of the mAbs may be used as therapeutic agents.	Univ Pavia, Dept Biochem, I-27100 Pavia, Italy; Texas A&M Univ Syst, Hlth Sci Ctr, Inst Biosci & Technol, Dept Biophys & Biochem, Houston, TX 77030 USA	University of Pavia; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Speziale, P (corresponding author), Univ Pavia, Dept Biochem, Viale Taramelli 3-B, I-27100 Pavia, Italy.	pspeziale@unipv.it	Visai, Livia/R-7397-2017	Visai, Livia/0000-0003-1181-3632				Carnoy C, 1997, MOL MICROBIOL, V23, P365, DOI 10.1046/j.1365-2958.1997.2231590.x; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; Eidhin DN, 1998, MOL MICROBIOL, V30, P245; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; GRIPENBERGLERCHE C, 1994, INFECT IMMUN, V62, P5568, DOI 10.1128/IAI.62.12.5568-5575.1994; Holmes AR, 1998, INFECT IMMUN, V66, P4633, DOI 10.1128/IAI.66.10.4633-4639.1998; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Love RM, 1997, INFECT IMMUN, V65, P5157, DOI 10.1128/IAI.65.12.5157-5164.1997; Nilsson IM, 1998, J CLIN INVEST, V101, P2640, DOI 10.1172/JCI1823; Nolte M, 1999, FEBS LETT, V452, P379, DOI 10.1016/S0014-5793(99)00666-3; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PATTI JM, 1993, BIOCHEMISTRY-US, V32, P11428, DOI 10.1021/bi00093a021; PATTI JM, 1995, J BIOL CHEM, V270, P12005, DOI 10.1074/jbc.270.20.12005; PATTI JM, 1994, INFECT IMMUN, V62, P152, DOI 10.1128/IAI.62.1.152-161.1994; Podbielski A, 1999, MOL MICROBIOL, V31, P1051, DOI 10.1046/j.1365-2958.1999.01241.x; Rich RL, 1999, J BIOL CHEM, V274, P26939, DOI 10.1074/jbc.274.38.26939; Rich RL, 1999, J BIOL CHEM, V274, P24906, DOI 10.1074/jbc.274.35.24906; Rich RL, 1998, BIOCHEMISTRY-US, V37, P15423, DOI 10.1021/bi981773r; ROGGENKAMP A, 1995, MOL MICROBIOL, V16, P1207, DOI 10.1111/j.1365-2958.1995.tb02343.x; Roos S, 1996, FEMS MICROBIOL LETT, V144, P33, DOI 10.1016/0378-1097(96)00334-5; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHULZEKOOPS H, 1992, INFECT IMMUN, V60, P2153, DOI 10.1128/IAI.60.6.2153-2159.1992; SCHULZEKOOPS H, 1995, ARTHRITIS RHEUM-US, V38, P1283, DOI 10.1002/art.1780380917; Sebghati TAS, 1998, INFECT IMMUN, V66, P2887, DOI 10.1128/IAI.66.6.2887-2894.1998; SPEZIALE P, 1986, J BACTERIOL, V167, P77, DOI 10.1128/jb.167.1.77-81.1986; STRAWICH E, 1971, BIOCHEMISTRY-US, V10, P3905, DOI 10.1021/bi00797a017; SWITALSKI LM, 1993, INFECT IMMUN, V61, P4119, DOI 10.1128/IAI.61.10.4119-4125.1993; SWITALSKI LM, 1989, J BIOL CHEM, V264, P21080; SWITALSKI LM, 1993, MOL MICROBIOL, V7, P99, DOI 10.1111/j.1365-2958.1993.tb01101.x; Symersky J, 1997, NAT STRUCT BIOL, V4, P833, DOI 10.1038/nsb1097-833; TAMM A, 1993, MOL MICROBIOL, V10, P995, DOI 10.1111/j.1365-2958.1993.tb00971.x; VISAI L, 1995, J BIOL CHEM, V270, P347, DOI 10.1074/jbc.270.1.347; Xiao JG, 1998, FEMS IMMUNOL MED MIC, V21, P287, DOI 10.1111/j.1574-695X.1998.tb01176.x	35	49	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39837	39845		10.1074/jbc.M005297200	http://dx.doi.org/10.1074/jbc.M005297200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10991941	hybrid			2022-12-25	WOS:000166039500009
J	Zheng, M; Zhang, SJ; Zhu, WZ; Ziman, B; Kobilka, BK; Xiao, RP				Zheng, M; Zhang, SJ; Zhu, WZ; Ziman, B; Kobilka, BK; Xiao, RP			beta(2)-adrenergic receptor-induced p38 MAPK activation is mediated by protein kinase A rather than by G(i) or G beta gamma in adult mouse cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASES; TYROSINE KINASE; CARDIAC-HYPERTROPHY; STRESS; STIMULATION; MYOCYTES; HEART; PHOSPHORYLATION; SPECIFICITY; INVOLVEMENT	Increasing evidence shows that stimulation of p-adrenergic receptor (AR) activates mitogen-activated protein kinases (MAPKs), in addition to the classical G(s) adenylyl cyclase-cAMP-dependent protein kinase (PKA) signaling cascade. In the present study, we demonstrate a novel beta (2)-AR-mediated cross-talk between PKA and p38 MAPK in adult mouse cardiac myocytes expressing beta (2)-AR, with a null background of beta (1)beta (2)-AR double knockout. beta (2)-AR stimulation by isoproterenol increased p38 MARK activity in a time- and dose-dependent manner. Inhibiting G(i) with pertussis toxin or scavenging G beta gamma with beta ARK-ct overexpression could not prevent beta (2)-AR-induced p38 MAPK activation. In contrast, a specific peptide inhibitor of PKA, PKI (5 muM), completely abolished the stimulatory effect of beta (2)-AR, suggesting that beta (2)-AR-induced p38 MAPK activation is mediated via a PKA-dependent mechanism, rather than by G(i) or G beta gamma. This conclusion was further supported by the ability of forskolin (10 muM), an adenylyl cyclase activator, to elevate p38 MAPK activity in a PKI-sensitive manner. Furthermore, inhibition of p38 MAPK with SB203580 (10 muM) markedly enhanced the beta (2)-AR-mediated contractile response, without altering base-line contractility. These results provide the first evidence that cardiac beta (2)-AR activates p38 MAPK via a PKA-dependent signaling pathway, rather than by G(i) or G beta gamma, and reveal a novel role of p38 MAPK in regulating cardiac contractility.	NIA, Gerontol Res Ctr, Cardiovasc Sci Lab, NIH, Baltimore, MD 21224 USA; Stanford Univ, Med Ctr, Howard Hughes Med Inst, Stanford, CA 94305 USA; Peking Univ, Hosp 3, Sch Med, Inst Vasc Med, Beijing 100083, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Howard Hughes Medical Institute; Stanford University; Peking University	Xiao, RP (corresponding author), NIA, Gerontol Res Ctr, Cardiovasc Sci Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	xiaor@grc.nia.nih.gov	Yimei, Wang/AAE-4083-2019; Xiao, Rui-Ping/AAE-2629-2019		NATIONAL INSTITUTE ON AGING [ZIAAG000287, Z01AG000855, Z01AG000287] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; Clerk A, 1998, J BIOL CHEM, V273, P7228, DOI 10.1074/jbc.273.13.7228; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Communal C, 2000, J BIOL CHEM, V275, P19395, DOI 10.1074/jbc.M910471199; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Gupta RC, 1996, AM J PHYSIOL-HEART C, V270, pH1159, DOI 10.1152/ajpheart.1996.270.4.H1159; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kuschel M, 1999, J BIOL CHEM, V274, P22048, DOI 10.1074/jbc.274.31.22048; Kuschel M, 1999, CIRCULATION, V99, P2458, DOI 10.1161/01.CIR.99.18.2458; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lim R, 1996, J BIOL CHEM, V271, P22953, DOI 10.1074/jbc.271.38.22953; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Skeberdis VA, 1997, J PHARMACOL EXP THER, V283, P452; VAN BT, 1995, NATURE, V376, P781; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Xiao RP, 1999, CIRC RES, V85, P1092; Xiao RP, 1999, CIRC RES, V84, P43; XIAO RP, 1995, MOL PHARMACOL, V47, P322; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; Zhou YY, 2000, AM J PHYSIOL-HEART C, V279, pH429; Zhou YY, 1997, AM J PHYSIOL-HEART C, V273, pH1611, DOI 10.1152/ajpheart.1997.273.3.H1611	35	103	106	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40635	40640		10.1074/jbc.M006325200	http://dx.doi.org/10.1074/jbc.M006325200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11018034	hybrid			2022-12-25	WOS:000166039500112
J	Strassheim, D; Williams, CL				Strassheim, D; Williams, CL			P2Y(2) purinergic and M-3 muscarinic acetylcholine receptors activate different phospholipase C-beta isoforms that are uniquely susceptible to protein kinase C-dependent phosphorylation and inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-BETA-3 PHOSPHORYLATION; COUPLED RECEPTORS; CELLS; DESENSITIZATION; FIBROBLASTS	Activation of phospholipase C-beta (PLC-beta) by G protein-coupled receptors typically results in rapid but transient second messenger generation. Although PLC-beta deactivation may contribute to the transient nature of this response, the mechanisms governing PLC-beta deactivation are poorly characterized. We investigated the involvement of protein kinase C (PKC) in the termination of PLC-beta activation induced by endogenous P2Y(2) purinergic receptors and transfected M-3 muscarinic acetylcholine receptors (mAChR) in Chinese hamster ovary cells. Activation of P2Y(2) receptors causes G alpha (q/11) to associate with PLC-beta3, whereas M3 mAChR activation causes G alpha (q/11) to associate with both PLC-beta1 and PLC-beta3 in these cells. Phosphorylation of PLC-beta3, but not PLC-beta1, is induced by activating either P2Y(2) receptors or M-3 mAChR. We demonstrate that PKC rather than protein kinase A mediates the G protein-coupled receptor-induced phosphorylation of PLC-beta3. The PKC-mediated phosphorylation of PLC-beta3 diminishes the interaction of G alpha (q/11) with PLC-beta3, thereby contributing to the termination PLC-beta3 activity. These findings indicate that the distinct temporal profiles of PLC activation by P2Y(2) receptors and mAChR may arise from the differential activation of PLC-beta1 and PLC-beta3 by the receptors, coupled with a selective PKC-mediated negative feedback mechanism that targets PLC-beta3 but not PLC-beta1.	Guthrie Res Inst, Mol Pharmacol Lab, Sayre, PA 18840 USA		Williams, CL (corresponding author), Guthrie Res Inst, Mol Pharmacol Lab, 1 Guthrie Sq, Sayre, PA 18840 USA.	cwilliam@inet.guthrie.org	STRASSHEIM, DEREK/AHB-1158-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063921] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL063921] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adamson DL, 2000, BASIC RES CARDIOL, V95, P114, DOI 10.1007/s003950050172; Ali H, 1998, J BIOL CHEM, V273, P11012, DOI 10.1074/jbc.273.18.11012; Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Dickenson JM, 1998, BRIT J PHARMACOL, V124, P1491, DOI 10.1038/sj.bjp.0701977; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Hipkin RW, 2000, J BIOL CHEM, V275, P5591, DOI 10.1074/jbc.275.8.5591; LOS GV, 1996, BIOCHEM J, V311, P225; May LG, 1999, CELL SIGNAL, V11, P179, DOI 10.1016/S0898-6568(98)00053-9; Murthy KS, 1998, J BIOL CHEM, V273, P4695, DOI 10.1074/jbc.273.8.4695; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; PLEVIN R, 1991, BIOCHEM J, V280, P609, DOI 10.1042/bj2800609; PLEVIN R, 1990, BIOCHEM J, V268, P605, DOI 10.1042/bj2680605; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Rosado JA, 2000, J BIOL CHEM, V275, P9110, DOI 10.1074/jbc.275.13.9110; RYU SH, 1990, J BIOL CHEM, V265, P17941; Strassheim D, 1998, MOL PHARMACOL, V53, P1047; Strassheim D, 1999, J BIOL CHEM, V274, P18675, DOI 10.1074/jbc.274.26.18675; Strassheim D, 2000, CANCER RES, V60, P2730; Tobin AB, 1997, PHARMACOL THERAPEUT, V75, P135, DOI 10.1016/S0163-7258(97)00053-3; Vazquez-Prado J, 2000, J BIOL CHEM, V275, P6553, DOI 10.1074/jbc.275.9.6553; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Willars GB, 1998, BIOCHEM J, V333, P301, DOI 10.1042/bj3330301; WILLIAMS CL, 1990, J BIOL CHEM, V265, P1443; Williams RL, 1999, BBA-MOL CELL BIOL L, V1441, P255, DOI 10.1016/S1388-1981(99)00150-X; Yue CP, 1998, J BIOL CHEM, V273, P18023, DOI 10.1074/jbc.273.29.18023	30	48	48	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39767	39772		10.1074/jbc.M007775200	http://dx.doi.org/10.1074/jbc.M007775200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995776	hybrid			2022-12-25	WOS:000165953100108
J	Tyagi, M; Rusnati, M; Presta, M; Giacca, M				Tyagi, M; Rusnati, M; Presta, M; Giacca, M			Internalization of HIV-1 Tat requires cell surface heparan sulfate proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FIBROBLAST GROWTH-FACTOR; NF-KAPPA-B; CARBOXY-TERMINAL DOMAIN; RNA-POLYMERASE-II; TYPE-1 TAT; BASIC DOMAIN; T-CELLS; ENDOTHELIAL-CELLS; IN-VIVO	Tat, the transactivator protein of human immunodeficiency virus-1, has the unusual capacity of being internalized by cells when present in the extracellular milieu. This property can be exploited for the cellular delivery of heterologous proteins fused to Tat both in cell culture and in living animals. Here we provide genetic and biochemical evidence that cell membrane heparan sulfate (HS) proteoglycans act as receptors for extracellular Tat uptake. Cells genetically defective in the biosynthesis of fully sulfated HS are selectively impaired in the internalization of recombinant Tat fused to the green fluorescent protein, as evaluated by both flow cytometry and functional assays. In wild type cells, Tat uptake is competitively inhibited by soluble heparin and by treatment with glycosaminoglycan lyases specifically degrading HS chains. Cell surface HS proteoglycans also mediate physiological internalization of Tat green fluorescent protein released from neighboring producing cells. In contrast to extracellular Tat uptake, both wild type cells and cells genetically impaired in proteoglycan synthesis are equally proficient in the extracellular release of Tat, thus indicating that proteoglycans are not required for this process. The ubiquitous distribution of HS proteoglycans is consistent with the efficient intracellular delivery of heterologous proteins fused with Tat to different mammalian cell types.	Int Ctr Genet Engn & Biotechnol, Mol Med Lab, I-34012 Trieste, Italy; Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, I-25123 Brescia, Italy; Scuola Normale Super Pisa, I-56126 Pisa, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB); University of Brescia; Scuola Normale Superiore di Pisa	Giacca, M (corresponding author), Int Ctr Genet Engn & Biotechnol, Mol Med Lab, Padriciano 99, I-34012 Trieste, Italy.	giacca@icgeb.trieste.it	Rusnati, Marco/F-1168-2010; Giacca, Mauro/J-9287-2016; Presta, Marco/B-4345-2010	Rusnati, Marco/0000-0001-9968-5908; Giacca, Mauro/0000-0003-2927-7225; PRESTA, Marco/0000-0002-4398-8376				ALBINI A, 1995, P NATL ACAD SCI USA, V92, P4838, DOI 10.1073/pnas.92.11.4838; Albini A, 1996, ONCOGENE, V12, P289; Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BISWAS DK, 1995, J VIROL, V69, P7437, DOI 10.1128/JVI.69.12.7437-7444.1995; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; CHIRMULE N, 1995, J VIROL, V69, P492, DOI 10.1128/JVI.69.1.492-498.1995; Corallini A, 1996, AIDS, V10, P701, DOI 10.1097/00002030-199606001-00003; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; Demarchi F, 1996, J VIROL, V70, P4427, DOI 10.1128/JVI.70.7.4427-4437.1996; Demarchi F, 1999, J VIROL, V73, P7080, DOI 10.1128/JVI.73.8.7080-7086.1999; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1986, J BIOL CHEM, V261, P5725; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FURLINI MCRG, 1995, J ACQ IMMUN DEF SYND, V10, P408, DOI 10.1097/00042560-199512000-00003; Gold MO, 1998, J VIROL, V72, P4448, DOI 10.1128/JVI.72.5.4448-4453.1998; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; HELLAND DE, 1991, J VIROL, V65, P4547, DOI 10.1128/JVI.65.8.4547-4549.1991; HOFMAN FM, 1994, J NEUROIMMUNOL, V54, P19, DOI 10.1016/0165-5728(94)90226-7; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Lafrenie RM, 1997, J IMMUNOL, V159, P4077; LAPPI DA, 1994, J BIOL CHEM, V269, P12552; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LOTZ M, 1994, J CELL BIOL, V124, P365, DOI 10.1083/jcb.124.3.365; LYON M, 1994, BIOCHEM SOC T, V22, P365, DOI 10.1042/bst0220365; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; Mitola S, 1997, BLOOD, V90, P1365, DOI 10.1182/blood.V90.4.1365.1365_1365_1372; NABELL LM, 1994, CELL GROWTH DIFFER, V5, P87; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nath A, 1996, J VIROL, V70, P1475, DOI 10.1128/JVI.70.3.1475-1480.1996; OPALENIK SR, 1995, J BIOL CHEM, V270, P17457, DOI 10.1074/jbc.270.29.17457; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; PHILIPPON V, 1994, VIROLOGY, V205, P519, DOI 10.1006/viro.1994.1673; POCSIK E, 1992, LYMPHOKINE CYTOK RES, V11, P317; PURI RK, 1992, CANCER RES, V52, P3787; PURVIS SF, 1992, CELL IMMUNOL, V144, P32, DOI 10.1016/0008-8749(92)90223-C; Rostand KS, 1997, INFECT IMMUN, V65, P1; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; Rusnati M, 1998, J BIOL CHEM, V273, P16027, DOI 10.1074/jbc.273.26.16027; Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198; Rusnati M, 1997, J BIOL CHEM, V272, P11313, DOI 10.1074/jbc.272.17.11313; SABATIER JM, 1991, J VIROL, V65, P961, DOI 10.1128/JVI.65.2.961-967.1991; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Sosnowski BA, 1996, J BIOL CHEM, V271, P33647, DOI 10.1074/jbc.271.52.33647; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; SUBRAMANYAM M, 1993, J IMMUNOL, V150, P2544; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; TAYLOR JP, 1992, P NATL ACAD SCI USA, V89, P9617, DOI 10.1073/pnas.89.20.9617; THOMAS CA, 1994, J IMMUNOL, V153, P3831; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; WEEKS BS, 1995, J NEUROSCI RES, V42, P34, DOI 10.1002/jnr.490420105; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTENDORP MO, 1994, J VIROL, V68, P4177, DOI 10.1128/JVI.68.7.4177-4185.1994; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; ZAULI G, 1993, CANCER RES, V53, P4481; ZAULI G, 1992, BLOOD, V80, P3036; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	71	595	626	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3254	3261		10.1074/jbc.M006701200	http://dx.doi.org/10.1074/jbc.M006701200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11024024	hybrid			2022-12-25	WOS:000166784900037
J	Almeida, PC; Nantes, IL; Chagas, JR; Rizzi, CCA; Faljoni-Alario, A; Carmona, E; Juliano, L; Nader, HB; Tersariol, ILS				Almeida, PC; Nantes, IL; Chagas, JR; Rizzi, CCA; Faljoni-Alario, A; Carmona, E; Juliano, L; Nader, HB; Tersariol, ILS			Cathepsin B activity regulation - Heparin-like glycosaminoglycans protect human cathepsin B from alkaline pH-induced inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE PROTEOGLYCANS; SULFATE PROTEOGLYCANS; OCCLUDING LOOP; CYSTEINE PROTEINASES; TUMOR PROGRESSION; ENZYME-ACTIVITY; INHIBITORS; PROTEASES; RECEPTOR; TISSUE	It has been shown that lysosomal cysteine proteinases, specially cathepsin B, has been implicated in a variety of diseases involving tissue remodeling states, such as inflammation, parasite infection, and tumor metastasis, by degradation of extracellular matrix components. Recently, we have shown that heparin and heparan sulfate bind to papain specifically; this interaction induces an increase of its alpha -helix content and stabilizes the enzyme structure even at alkaline pH (Almeida, P. C., Nantes, I. L,, Rizzi, C, C. A., Judice, W.A.S., Chagas, J. R., Juliano, L., Nader, H. B., and Tersariol, I. L. S. (1999) J. Biol. Chem. 274, 30433-30438). In the present work, a combination of circular dichroism analysis, affinity chromatography, cathepsin B mutants, and fluorogenic substrate assays were used to characterize the interaction of human cathepsin B with glycosaminoglycans. The nature of the cathepsin B-glycosaminoglycans interaction was sensitive to the charge and type of polysaccharide, Like papain, heparin and heparan sulfate bind cathepsin B specifically, and this interaction reduces the loss of cathepsin B alpha -helix content at alkaline pH. Our data show that the coupling of cathepsin B with heparin or heparan sulfate can potentiate the endopeptidase activity of the cathepsin B, increasing B-fold the half-life (t(1/2)) of the enzyme at alkaline pH, Most of these effects are related to the interaction of heparin and heparan sulfate with His(111) residue of the cathepsin B occluding loop. These results strongly suggest that heparan sulfate may be an important binding site for cathepsin B at cell surface, reporting a novel physiological role for heparan sulfate proteoglycans.	Univ Mogi das Cruzes, Ctr Interdisciplinar Invest Bioquim, Ctr Ciencias Technol, BR-08780911 Mogi Das Cruzes, SP, Brazil; Univ Sao Paulo, Inst Quim, Dept Bioquim, Sao Paulo, Brazil; Inst Butantan, Farmacol Lab, Sao Paulo, Brazil; Univ Fed Sao Paulo, Escola Paulista Med, Disciplina Biol Mol, Inst Nacl Farmacol, Sao Paulo, Brazil	Universidade de Mogi das Cruzes; Universidade de Sao Paulo; Instituto Butantan; Universidade Federal de Sao Paulo (UNIFESP)	Tersariol, ILS (corresponding author), Univ Mogi das Cruzes, Ctr Interdisciplinar Invest Bioquim, Ctr Ciencias Technol, Sala IS-15,Av Dr Candido C Almeida Souza 200, BR-08780911 Mogi Das Cruzes, SP, Brazil.	ivarne@ccb.umc.br	de Almeida, Paulo C/D-8285-2014; Nantes, Iseli Lourenço/B-9517-2012; Juliano, Luiz/D-7204-2012; Chagas, Jair R/A-1701-2012; Chagas, Jair Ribeiro/AFV-6501-2022; Dos Santos Tersariol, Ivarne Luis/G-4042-2012; de Almeida, Paulo/D-4794-2012; Nader, Helena Bonciani/D-9253-2012	de Almeida, Paulo C/0000-0002-5136-5152; Nantes, Iseli Lourenço/0000-0003-1434-3154; Juliano, Luiz/0000-0002-5589-2822; Chagas, Jair R/0000-0002-0357-8276; Chagas, Jair Ribeiro/0000-0002-0357-8276; Dos Santos Tersariol, Ivarne Luis/0000-0002-8399-4535; NADER, HELENA/0000-0002-7569-2166				Almeida PC, 1999, J BIOL CHEM, V274, P30433, DOI 10.1074/jbc.274.43.30433; Bahr MJ, 1999, HEPATOLOGY, V29, P839, DOI 10.1002/hep.510290333; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BIENKOWSKI MJ, 1984, J BIOL CHEM, V259, P2989; BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; CHAGAS JR, 1991, ANAL BIOCHEM, V192, P419, DOI 10.1016/0003-2697(91)90558-B; Conrad H. E., 1998, HEPARIN BINDING PROT; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DelNery E, 1997, J BIOL CHEM, V272, P25713, DOI 10.1074/jbc.272.41.25713; DeStafanis D, 1997, CELL TISSUE RES, V289, P109; Dietrich CP, 1998, CELL MOL BIOL, V44, P417; DIETRICH CP, 1983, BIOCHEM BIOPH RES CO, V111, P865, DOI 10.1016/0006-291X(83)91379-7; ELENIUS K, 1994, J CELL SCI, V107, P2975; ERMOLIEFF J, 1994, J BIOL CHEM, V269, P29502; Fath MA, 1998, J BIOL CHEM, V273, P13563, DOI 10.1074/jbc.273.22.13563; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; HANEWINKEL H, 1987, J BIOL CHEM, V262, P12351; Hirata IY, 1995, LETT PEPT SCI, V1, P299, DOI DOI 10.1007/BF00119771; IacobuzioDonahue CA, 1997, J BIOL CHEM, V272, P29190, DOI 10.1074/jbc.272.46.29190; Illy C, 1997, J BIOL CHEM, V272, P1197, DOI 10.1074/jbc.272.2.1197; IOZZO R, 1995, BIOCHEM J, V302, P625; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; Jerala R, 1998, J BIOL CHEM, V273, P11498, DOI 10.1074/jbc.273.19.11498; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; Kassam G, 1997, J BIOL CHEM, V272, P15093, DOI 10.1074/jbc.272.24.15093; KATUNUMA N, 1995, METHOD ENZYMOL, V251, P382, DOI 10.1016/0076-6879(95)51142-3; KATUNUMA N, 1989, INTRACELLULAR PROTEO; KOBLINSKI JE, 1997, MED ASPECTS PROTEASE, V110, P1235; KOGA H, 1991, J BIOCHEM-TOKYO, V110, P179, DOI 10.1093/oxfordjournals.jbchem.a123554; KORNFELD S, 1990, BIOCHEM SOC T, V18, P367, DOI 10.1042/bst0180367; Kos J, 1998, ONCOL REP, V5, P1349; KRAEMER PM, 1971, BIOCHEMISTRY-US, V10, P1437, DOI 10.1021/bi00784a026; Linebaugh BE, 1999, EUR J BIOCHEM, V264, P100, DOI 10.1046/j.1432-1327.1999.00582.x; Ma JX, 2000, J BIOL CHEM, V275, P12806, DOI 10.1074/jbc.275.17.12806; MACH L, 1994, J BIOL CHEM, V269, P13030; MENARD R, 1990, BIOCHEMISTRY-US, V29, P6706, DOI 10.1021/bi00480a021; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MORT JS, 1986, BIOCHEM J, V233, P57, DOI 10.1042/bj2330057; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; Nagler DK, 1997, BIOCHEMISTRY-US, V36, P12608, DOI 10.1021/bi971264+; Nagler DK, 1999, BIOCHEMISTRY-US, V38, P4868, DOI 10.1021/bi982632s; Quraishi O, 1999, BIOCHEMISTRY-US, V38, P5017, DOI 10.1021/bi981950o; REILAND J, 1993, J CELL SCI, V105, P1085; Sloane B F, 1988, Adv Exp Med Biol, V233, P259; SLOANE BF, 1986, P NATL ACAD SCI USA, V83, P2483, DOI 10.1073/pnas.83.8.2483; Sloane BF, 1996, NAT BIOTECHNOL, V14, P826, DOI 10.1038/nbt0796-826b; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; STARKEY PM, 1977, PROTEINASES MAMMALIA, P57; TURK B, 1994, BIOCHEMISTRY-US, V33, P14800, DOI 10.1021/bi00253a019; Turk B, 1997, BIOL CHEM, V378, P141; WEISS RE, 1990, J UROLOGY, V144, P798, DOI 10.1016/S0022-5347(17)39595-2; Yan SQ, 1998, BIOL CHEM, V379, P113; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YANAGISHITA M, 1984, J BIOL CHEM, V259, P260	56	154	162	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					944	951		10.1074/jbc.M003820200	http://dx.doi.org/10.1074/jbc.M003820200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11016923	hybrid			2022-12-25	WOS:000166430900013
J	Tsuchida, K; Arai, KY; Kuramoto, Y; Yamakawa, N; Hasegawa, Y; Sugino, H				Tsuchida, K; Arai, KY; Kuramoto, Y; Yamakawa, N; Hasegawa, Y; Sugino, H			Identification and characterization of a novel follistatin-like protein as a binding protein for the TGF-beta family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MORPHOGENETIC PROTEIN; GROWTH-FACTOR-BETA; ACTIVIN-BINDING; HEPARAN-SULFATE; XENOPUS EMBRYO; INHIBIN; CELL; CLONING; GENE; RECEPTORS	Follistatin is an activin-binding protein that prevents activin from binding to its receptors and neutralizes its activity. Follistatin also binds bone morphogenetic proteins (BMPs). In this study, we report the identification of a novel follistatin-like protein from mouse. The mouse cDNA encodes a 256-residue precursor and most likely a mouse homologue of human FLRG, which was found at the breakpoint of the chromosomal rearrangement in a B-cell line. Whereas follistatin has three follistatin domains, which are presumed to be growth factor binding motifs, FLRG possesses only two follistatin domains. Northern blotting revealed that mRNAs for FLRG were abundantly expressed in heart, lung, kidney, and testis in mouse. The recombinant mouse FLRG proteins were found to have binding activity for both activin and bone morphogenetic protein-2. Like follistatin, FLRG has higher affinity for activin than for BMP-S. The FLRG protein inhibited activin-induced and BMP-2-induced transcriptional responses in a dose-dependent manner. Glutathione S-transferase fusion proteins encoding various regions of FLRG were produced and studied. Ligand blotting using I-125-activin revealed that the COOH-terminal region containing the second follistatin domain was able to bind activin. Our finding implies that cellular signaling by activin and BMPs is tightly regulated by multiple members of the follistatin family.	Univ Tokushima, Inst Enzyme Res, Tokushima 7708503, Japan; Kitasato Univ, Sch Vet Med & Anim Sci, Lab Expt Anim Sci, Towada, Aomori 0348628, Japan	Tokushima University; Kitasato University	Tsuchida, K (corresponding author), Univ Tokushima, Inst Enzyme Res, 3-18-15 Kuramoto, Tokushima 7708503, Japan.	tsuchida@ier.tokushima-u.ac.jp	ARAI, Koji/G-1144-2013; Tsuchida, Kunihiro/A-4501-2012	Tsuchida, Kunihiro/0000-0002-3983-5756				Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; deWinter JP, 1996, MOL CELL ENDOCRINOL, V116, P105, DOI 10.1016/0303-7207(95)03705-5; Gray PC, 2000, J BIOL CHEM, V275, P3206, DOI 10.1074/jbc.275.5.3206; Guo QX, 1998, MOL ENDOCRINOL, V12, P96, DOI 10.1210/mend.12.1.0053; Hashimoto O, 2000, CELL SIGNAL, V12, P565, DOI 10.1016/S0898-6568(00)00099-1; Hashimoto O, 1997, J BIOL CHEM, V272, P13835, DOI 10.1074/jbc.272.21.13835; Hayette S, 1998, ONCOGENE, V16, P2949, DOI 10.1038/sj.onc.1201807; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; INOUYE S, 1992, MOL CELL ENDOCRINOL, V90, P1, DOI 10.1016/0303-7207(92)90094-M; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KRUMMEN LA, 1993, ENDOCRINOLOGY, V132, P431, DOI 10.1210/en.132.1.431; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; MAURER P, 1995, J MOL BIOL, V253, P347, DOI 10.1006/jmbi.1995.0557; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; McFarlane JR, 1999, ENDOCRINOLOGY, V140, P4745, DOI 10.1210/en.140.10.4745; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Okabayashi K, 1999, BIOCHEM BIOPH RES CO, V254, P42, DOI 10.1006/bbrc.1998.9892; Pearce JJH, 1999, DEV BIOL, V209, P98, DOI 10.1006/dbio.1999.9240; RAINES EW, 1992, P NATL ACAD SCI USA, V89, P1281, DOI 10.1073/pnas.89.4.1281; SCHNEYER AL, 1994, ENDOCRINOLOGY, V135, P667, DOI 10.1210/en.135.2.667; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SHIMASAKI S, 1988, BIOCHEM BIOPH RES CO, V152, P717, DOI 10.1016/S0006-291X(88)80097-4; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; Shoji H, 2000, J BIOL CHEM, V275, P5485, DOI 10.1074/jbc.275.8.5485; Smith WC, 1999, TRENDS GENET, V15, P3, DOI 10.1016/S0168-9525(98)01641-2; SUGINO K, 1993, J BIOL CHEM, V268, P15579; SUGINO K, 1989, BIOCHEM BIOPH RES CO, V159, P1323, DOI 10.1016/0006-291X(89)92255-9; Sumitomo K, 2000, CANCER LETT, V155, P37, DOI 10.1016/S0304-3835(00)00407-9; SUMITOMO S, 1995, BIOCHEM BIOPH RES CO, V208, P1, DOI 10.1006/bbrc.1995.1297; Tanaka M, 1998, INT IMMUNOL, V10, P1305, DOI 10.1093/intimm/10.9.1305; TSUCHIDA K, 1995, ENDOCRINOLOGY, V136, P5493, DOI 10.1210/en.136.12.5493; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; VALE W, 1988, RECENT PROG HORM RES, V44, P1; VAUGHAN JM, 1993, ENDOCRINOLOGY, V132, P2038, DOI 10.1210/en.132.5.2038; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Yamane Y, 1998, J BIOL CHEM, V273, P7375, DOI 10.1074/jbc.273.13.7375; ZWIJSEN A, 1994, EUR J BIOCHEM, V225, P937, DOI 10.1111/j.1432-1033.1994.0937b.x	42	166	182	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40788	40796		10.1074/jbc.M006114200	http://dx.doi.org/10.1074/jbc.M006114200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11010968	hybrid			2022-12-25	WOS:000166114600019
J	Ivanina, T; Blumenstein, Y; Shistik, E; Barzilai, R; Dascal, N				Ivanina, T; Blumenstein, Y; Shistik, E; Barzilai, R; Dascal, N			Modulation of L-type Ca2+ channels by G beta gamma and calmodulin via interactions with N and C termini of alpha(1C)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CALCIUM CHANNELS; G-PROTEIN MODULATION; RAT SYMPATHETIC NEURONS; I-II LOOP; XENOPUS-OOCYTES; ION CHANNELS; K+ CHANNEL; KINASE-C; DIFFERENTIAL INTERACTIONS; PREPULSE FACILITATION	Neuronal voltage-dependent Ca2+ channels of the N (alpha (1B)) and P/Q (alpha (1A)) type are inhibited by neurotransmitters that activate G(i/o) G proteins; a major part of the inhibition is voltage-dependent, relieved by depolarization, and results from a direct binding of G beta gamma subunit of G proteins to the channel. Since cardiac and neuronal L-type (alpha (1C)) voltage-dependent Ca2+ channels are not modulated in this way, they are presumed to lack interaction with G beta gamma. However, here we demonstrate that both G beta gamma and cahmodulin directly bind to cytosolic N and C termini of the alpha (1C) subunit. Coexpression of G beta gamma reduces the current via the L-type channels. The inhibition depends on the presence of calmodulin, occurs at basal cellular levels of Ca2+, and is eliminated by EGTA. The N and C termini of alpha (1C) appear to serve as partially independent but interacting inhibitory gates. Deletion of the N terminus or of the distal half of the C terminus eliminates the inhibitory effect of G beta gamma. Deletion of the N terminus profoundly impairs the Ca2+/calmodulin-dependent inactivation. We propose that G beta gamma and calmodulin regulate the L-type Ca2+ channel in a concerted manner via a molecular inhibitory scaffold formed by N and C termini of alpha (1C).	Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Dascal, N (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel.		Dascal, Nathan/O-3915-2015	Dascal, Nathan/0000-0002-5397-4146	PHS HHS [R0156260] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Akopian A, 2000, J NEUROSCI, V20, P929, DOI 10.1523/JNEUROSCI.20-03-00929.2000; Armstrong CM, 1998, NEURON, V20, P371, DOI 10.1016/S0896-6273(00)80981-2; BERNHEIM L, 1991, NEURON, V6, P859, DOI 10.1016/0896-6273(91)90226-P; BOURINET E, 1994, EMBO J, V13, P5032, DOI 10.1002/j.1460-2075.1994.tb06832.x; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; Bunemann M, 1999, J BIOL CHEM, V274, P33851, DOI 10.1074/jbc.274.48.33851; Canti C, 1999, J NEUROSCI, V19, P6855, DOI 10.1523/JNEUROSCI.19-16-06855.1999; Catterall WA, 1998, CELL CALCIUM, V24, P307, DOI 10.1016/S0143-4160(98)90055-0; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Dai SP, 1999, FEBS LETT, V442, P70, DOI 10.1016/S0014-5793(98)01632-9; DASCAL N, 1995, P NATL ACAD SCI USA, V92, P6758, DOI 10.1073/pnas.92.15.6758; Dascal N., 1992, METHODS MOL BIOL VOL, VVolume 13, P205; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; DIVERSEPIERLUISSI M, 1993, NEURON, V10, P753, DOI 10.1016/0896-6273(93)90175-Q; Dolphin AC, 1998, J PHYSIOL-LONDON, V506, P3, DOI 10.1111/j.1469-7793.1998.003bx.x; ECKERT R, 1984, PROG BIOPHYS MOL BIO, V44, P215, DOI 10.1016/0079-6107(84)90009-9; Finkbeiner S, 1998, J NEUROBIOL, V37, P171, DOI 10.1002/(SICI)1097-4695(199810)37:1<171::AID-NEU13>3.0.CO;2-H; Fraser IDC, 1999, NEURON, V23, P423, DOI 10.1016/S0896-6273(00)80795-3; Furukawa T, 1998, J BIOL CHEM, V273, P17595, DOI 10.1074/jbc.273.28.17595; Furukawa T, 1998, J BIOL CHEM, V273, P17585, DOI 10.1074/jbc.273.28.17585; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Garcia DE, 1998, J NEUROSCI, V18, P9163; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; HESCHELER J, 1994, ANN NY ACAD SCI, V733, P306, DOI 10.1111/j.1749-6632.1994.tb17280.x; Hille B., 1992, IONIC CHANNELS EXCIT; Hosey MM, 1996, TRENDS CARDIOVAS MED, V6, P265, DOI 10.1016/S1050-1738(96)00109-0; Ikeda SR, 1999, ADV SEC MESS PHOSPH, V33, P131; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; Jing J, 1999, EMBO J, V18, P1245, DOI 10.1093/emboj/18.5.1245; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLOCKNER U, 1995, J BIOL CHEM, V270, P17306, DOI 10.1074/jbc.270.29.17306; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Levitan IB, 1999, NEURON, V22, P645, DOI 10.1016/S0896-6273(00)80722-9; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Liu MY, 1997, J BIOL CHEM, V272, P18801, DOI 10.1074/jbc.272.30.18801; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; O'Connor V, 1999, SCIENCE, V286, P1180, DOI 10.1126/science.286.5442.1180; Page KM, 1998, J NEUROSCI, V18, P4815; Patil PG, 1996, BIOPHYS J, V71, P2509, DOI 10.1016/S0006-3495(96)79444-4; Perez-Reyes E, 1998, J BIOENERG BIOMEMBR, V30, P313, DOI 10.1023/A:1021981420839; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; ROSENTHAL W, 1988, EMBO J, V7, P1627, DOI 10.1002/j.1460-2075.1988.tb02989.x; Ruiz-Velasco V, 2000, J NEUROSCI, V20, P2183; SCULPTOREANU A, 1993, P NATL ACAD SCI USA, V90, P10135, DOI 10.1073/pnas.90.21.10135; Shapiro MS, 1999, P NATL ACAD SCI USA, V96, P10899, DOI 10.1073/pnas.96.19.10899; SHAPIRO MS, 1994, J NEUROSCI, V14, P7109; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; Shistik E, 1999, J BIOL CHEM, V274, P31145, DOI 10.1074/jbc.274.44.31145; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; SHISTIK E, 1995, J PHYSIOL-LONDON, V489, P55, DOI 10.1113/jphysiol.1995.sp021029; Simen AA, 1998, J NEUROSCI, V18, P3689; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; WEI XY, 1994, J BIOL CHEM, V269, P1635; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Ye CP, 1999, J MOL CELL CARDIOL, V31, P1771, DOI 10.1006/jmcc.1999.1015; Zamponi GW, 1998, CURR OPIN NEUROBIOL, V8, P351, DOI 10.1016/S0959-4388(98)80060-3; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zamponi GW, 1998, P NATL ACAD SCI USA, V95, P4035, DOI 10.1073/pnas.95.7.4035; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	73	103	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39846	39854		10.1074/jbc.M005881200	http://dx.doi.org/10.1074/jbc.M005881200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10995757	hybrid			2022-12-25	WOS:000166039500010
J	Kutay, U; Hartmann, E; Treichel, N; Calado, A; Carmo-Fonseca, M; Prehn, S; Kraft, R; Gorlich, D; Bischoff, FR				Kutay, U; Hartmann, E; Treichel, N; Calado, A; Carmo-Fonseca, M; Prehn, S; Kraft, R; Gorlich, D; Bischoff, FR			Identification of two novel RanGTP-binding proteins belonging to the importin beta superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRANSPORT FACTOR; EXPORT RECEPTOR; KARYOPHERIN-BETA; PORE COMPLEX; TRANSFER-RNA; RANBP1; CRM1; NUCLEOPORINS; DISSOCIATION; ASSOCIATION	Nucleo-cytoplasmic transport comprises a large number of distinct pathways, many of which are defined by members of the importin beta superfamily of nuclear transport receptors. These transport receptors all directly interact with RanGTP to modulate the compartment-specific binding of their transport substrates. To identify new members of the importin beta family, we used affinity chromatography on immobilized RanGTP and isolated Ran-binding protein (RanBP) 16 from HeLa cell extracts. RanBP16 and its close human homologue, RanBP17, are distant members of the importin beta family. Like the other members of the transport receptor superfamily, RanBP16 interacts with the nuclear pore complex and is able to enter the nucleus independent of energy and additional nuclear transport receptors.	Swiss Fed Inst Technol, Inst Biochem, CH-8092 Zurich, Switzerland; Univ Gottingen, Dept Biochem 2, D-37073 Gottingen, Germany; Univ Lisbon, Inst Histol & Embryol, P-1649028 Lisbon, Portugal; Humboldt Univ, Charite, Inst Biochem, D-10115 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Univ Heidelberg, ZMBH, D-69120 Heidelberg, Germany; German Canc Res Ctr, Div Mol Biol Mitosis, D-69120 Heidelberg, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Gottingen; Universidade de Lisboa; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Kutay, U (corresponding author), Swiss Fed Inst Technol, Inst Biochem, Univ Str 16, CH-8092 Zurich, Switzerland.		Görlich, Dirk/B-8296-2017; Calado, Ângelo Miguel Silva/Y-2296-2019; Hartmann, Enno/C-5687-2013	Görlich, Dirk/0000-0002-4343-5210; Calado, Ângelo Miguel Silva/0000-0003-0182-2615; Carmo-Fonseca, Maria/0000-0002-3402-7143				Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; Askjaer P, 1999, MOL CELL BIOL, V19, P6276; Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Deane R, 1997, MOL CELL BIOL, V17, P5087, DOI 10.1128/MCB.17.9.5087; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; Kataoka N, 1999, J CELL BIOL, V145, P1145, DOI 10.1083/jcb.145.6.1145; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Lipowsky G, 2000, EMBO J, V19, P4362, DOI 10.1093/emboj/19.16.4362; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Morgenstern B, 1998, BIOINFORMATICS, V14, P290, DOI 10.1093/bioinformatics/14.3.290; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Paraskeva E, 1999, J CELL BIOL, V145, P255, DOI 10.1083/jcb.145.2.255; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Sambrook J., 2002, MOL CLONING LAB MANU; Schlenstedt G, 1997, EMBO J, V16, P6237, DOI 10.1093/emboj/16.20.6237; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181	38	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40163	40168		10.1074/jbc.M006242200	http://dx.doi.org/10.1074/jbc.M006242200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11024021	hybrid, Green Published			2022-12-25	WOS:000166039500051
J	Ravanat, JL; Di Mascio, P; Martinez, GR; Medeiros, MHG; Cadet, J				Ravanat, JL; Di Mascio, P; Martinez, GR; Medeiros, MHG; Cadet, J			Singlet oxygen induces oxidation of cellular DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE DAMAGE; VISIBLE-LIGHT; 8-HYDROXY-2'-DEOXYGUANOSINE; RADIATION; ASSAY; ENDOPEROXIDE; THERMOLYSIS; RIBOFLAVIN; PRODUCTS; ACID	The aim of the present work was to evaluate the potential for O-1(2) to induce oxidation of cellular DNA. For this purpose cells were incubated in the presence of a water-soluble endoperoxide whose thermal decomposition leads to the formation of singlet oxygen. Thereafter, DNA was extracted and the level of several modified DNA bases was determined by HPLC analysis coupled to a tandem mass spectrometric detection. A significant increase in the level of 8-oxo-7,8-dihydro-2'-deoxyguanosine was observed upon incubation of the cells with the chemical generator of O-1(2), whereas the level of the other DNA bases measured remained unchanged. To demonstrate that singlet oxygen is directly involved in the formation of 8-oxo-7,8-dihydro-2'-deoxyguanosine, the corresponding O-18-labeled endoperoxide was used. Incubation of the cells with such a generator of O-18-labeled singlet oxygen results in the formation of O-18-labeled 8-oxo-7,8-dihydro-2'-deoxyguanosine in the nuclear DNA. This result clearly demonstrates that singlet oxygen, when released within cells, is able to directly oxidize cellular DNA.	CEA, SCIB,UMR CNRS 5046, DRFMC, Lab Les Acides Nucl, F-38054 Grenoble 9, France; Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05513970 Sao Paulo, SP, Brazil	CEA; Universidade de Sao Paulo	Cadet, J (corresponding author), CEA, SCIB,UMR CNRS 5046, DRFMC, Lab Les Acides Nucl, 17 Ave Martyrs, F-38054 Grenoble 9, France.		Medeiros, Marisa H. G./A-5212-2008; Cadet, Jean/M-2971-2018; Martinez, Glaucia Regina/I-3110-2016; Di Mascio, Paolo/D-1264-2014; Ravanat, Jean-Luc/E-3452-2018; de Medeiros, Marisa Helena Gennari/AAA-8015-2019	Medeiros, Marisa H. G./0000-0002-5438-1174; Cadet, Jean/0000-0003-2594-9485; Martinez, Glaucia Regina/0000-0002-2628-4406; Di Mascio, Paolo/0000-0003-4125-8350; Ravanat, Jean-Luc/0000-0002-7123-6358; de Medeiros, Marisa Helena Gennari/0000-0002-5438-1174				Alapetite C, 1996, INT J RADIAT BIOL, V69, P359, DOI 10.1080/095530096145922; BASUMODAK S, 1993, CANCER RES, V53, P4505; BUCHKO GW, 1992, NUCLEIC ACIDS RES, V20, P4847, DOI 10.1093/nar/20.18.4847; CADENAS E, 1983, HOPPESEYLERS Z PHYSL, V364, P515; CADET J, 1994, METHOD ENZYMOL, V234, P79; Cadet J, 1998, FREE RADICAL RES, V29, P541, DOI 10.1080/10715769800300581; Cadet J, 1997, BIOL CHEM, V378, P1275; CADET J, 1978, PHOTOCHEM PHOTOBIOL, V28, P661, DOI 10.1111/j.1751-1097.1978.tb06991.x; Cadet J, 2000, METHOD ENZYMOL, V319, P143; CLAYCAMP HG, 1993, INT J RADIAT BIOL, V63, P597, DOI 10.1080/09553009314450781; Dewilde A, 1996, J PHOTOCH PHOTOBIO B, V36, P23, DOI 10.1016/S1011-1344(96)07323-X; Dewilde A, 1998, BIOL CHEM, V379, P1377; DI MASCIO P, 1989, J AM CHEM SOC, V111, P2909, DOI 10.1021/ja00190a027; Douki T., 1995, P213; EPE B, 1991, CHEM-BIOL INTERACT, V80, P239, DOI 10.1016/0009-2797(91)90086-M; Frelon S, 2000, CHEM RES TOXICOL, V13, P1002, DOI 10.1021/tx000085h; Hall DB, 1996, NATURE, V382, P731, DOI 10.1038/382731a0; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KASAI H, 1992, J AM CHEM SOC, V114, P9692, DOI 10.1021/ja00050a078; KHAN AU, 1992, P NATL ACAD SCI USA, V89, P11428, DOI 10.1073/pnas.89.23.11428; Kielbassa C, 1997, CARCINOGENESIS, V18, P811, DOI 10.1093/carcin/18.4.811; Klotz LO, 1999, EUR J BIOCHEM, V260, P917, DOI 10.1046/j.1432-1327.1999.00255.x; Lafleur M V, 1987, Free Radic Res Commun, V2, P343, DOI 10.3109/10715768709065301; Loft S, 1996, J MOL MED, V74, P297, DOI 10.1007/BF00207507; LOFT S, 1993, J TOXICOL ENV HEALTH, V40, P391, DOI 10.1080/15287399309531806; Martinez GR, 2000, J AM CHEM SOC, V122, P10212, DOI 10.1021/ja0016452; Pierlot C, 1996, J PHOTOCH PHOTOBIO B, V36, P31, DOI 10.1016/S1011-1344(96)07324-1; Pierlot C, 2000, METHOD ENZYMOL, V319, P3; PIETTE J, 1991, J PHOTOCH PHOTOBIO B, V11, P241, DOI 10.1016/1011-1344(91)80030-L; PIETTE J, 1990, J PHOTOCH PHOTOBIO B, V4, P335, DOI 10.1016/1011-1344(90)85039-Y; Pouget JP, 1999, INT J RADIAT BIOL, V75, P51, DOI 10.1080/095530099140807; Ravanat JL, 1998, J CHROMATOGR B, V715, P349, DOI 10.1016/S0378-4347(98)00259-X; RAVANAT JL, 1995, CHEM RES TOXICOL, V8, P379, DOI 10.1021/tx00045a009; SHEU C, 1993, J AM CHEM SOC, V115, P10446, DOI 10.1021/ja00075a105; SHIGENAGA MK, 1989, P NATL ACAD SCI USA, V86, P9697, DOI 10.1073/pnas.86.24.9697; STEINBECK MJ, 1992, J BIOL CHEM, V267, P13425	37	247	251	1	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40601	40604		10.1074/jbc.M006681200	http://dx.doi.org/10.1074/jbc.M006681200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007783	hybrid, Green Published			2022-12-25	WOS:000166039500107
J	Smith, L; Chen, L; Reyland, ME; DeVries, TA; Talanian, RV; Omura, S; Smith, JB				Smith, L; Chen, L; Reyland, ME; DeVries, TA; Talanian, RV; Omura, S; Smith, JB			Activation of atypical protein kinase C zeta by caspase processing and degradation by the ubiquitin-proteasome system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; DRUG-INDUCED APOPTOSIS; DEPENDENT DEGRADATION; LEUKEMIA-CELLS; BETA-TRCP; IN-VITRO; CLEAVAGE; PHOSPHORYLATION; INHIBITION; GROWTH	Atypical protein kinase C zeta (PKC zeta) is known to transduce signals that influence cell proliferation and survival. Here we show that recombinant human caspases can process PKC zeta at three sites in the hinge region between the regulatory and catalytic domains. Caspase-3, -6, -7, and -8 chiefly cleaved human PKC zeta at EETD down arrow G, and caspase-3 and -7 also cleaved PKC zeta at DGMD down arrow G and DSED down arrow L, respectively. Processing of PKC zeta expressed in transfected cells occurred chiefly at EETD down arrow G and DGMD down arrow G and produced carboxyl-terminal polypeptides that contained the catalytic domain. Epitope-tagged PKC zeta that lacked the regulatory domain was catalytically active following expression in HeLa cells. Induction of apoptosis in HeLa cells by tumor necrosis factor cu plus cycloheximide evoked the conversion of full-length epitope-tagged PKC zeta to two catalytic domain polypeptides and increased PKC zeta activity. A caspase inhibitor, zVAD-fmk, prevented epitope-tagged PKC zeta processing and activation following the induction of apoptosis. Induction of apoptosis in rat parotid C5 cells produced catalytic domain polypeptides of endogenous PKC zeta and increased PKC zeta activity. Caspase inhibitors prevented the increase in PKC zeta activity and production of the catalytic domain polypeptides. Treatment with lactacystin, a selective inhibitor of the proteasome, caused polyubiquitin-PKC zeta conjugates to accumulate in cells transfected with the catalytic domain or full-length PKC alpha, or with a PKC zeta mutant that was resistant to caspase processing. We conclude that caspases process PKC zeta to carboxyl-terminal fragments that are catalytically active and that are degraded by the ubiquitin-proteasome pathway.	Univ Alabama, Sch Med, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; Univ Alabama, Sch Dent, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; Univ Colorado, Hlth Sci Ctr, Sch Dent, Dept Basic Sci & Oral Res, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Cell & Struct Biol, Denver, CO 80262 USA; BASF AG, Biores Corp, Worcester, MA 01605 USA; Kitasato Inst, Minato Ku, Tokyo 108, Japan	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; BASF	Smith, JB (corresponding author), Univ Alabama, Sch Med, Dept Pharmacol & Toxicol, Volker Hall G133E,1670 Univ Bldg, Birmingham, AL 35294 USA.				NIDDK NIH HHS [DK50690] Funding Source: Medline; NIGMS NIH HHS [GM60383] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060383] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Chen L, 2000, ARCH BIOCHEM BIOPHYS, V374, P306, DOI 10.1006/abbi.1999.1603; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Frutos S, 1999, J BIOL CHEM, V274, P10765, DOI 10.1074/jbc.274.16.10765; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; KUO JF, 1994, PROTEIN KINASE C, P1; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; Lee HW, 1997, MOL PHARMACOL, V51, P439; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; OMURA S, 1991, J ANTIBIOT, V44, P117, DOI 10.7164/antibiotics.44.117; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; PETERS JM, 1998, UBIQUITIN BIOL CELL, P1; PONGRACZ J, 1995, EXP CELL RES, V218, P430, DOI 10.1006/excr.1995.1176; Quissell DO, 1998, IN VITRO CELL DEV-AN, V34, P58; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; VAN AD, 1996, SCIENCE, V274, P787; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5	50	72	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40620	40627		10.1074/jbc.M908517199	http://dx.doi.org/10.1074/jbc.M908517199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11016947	hybrid			2022-12-25	WOS:000166039500110
J	Ray, A; Fields, AP; Ray, BK				Ray, A; Fields, AP; Ray, BK			Activation of transcription factor SAF involves its phosphorylation by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM-AMYLOID-A; ZINC-FINGER PROTEIN; GENE-EXPRESSION; MONOCYTE/MACROPHAGE CELLS; SYNOVIAL FIBROBLASTS; INDUCTION; PROMOTER; BINDING; COLLAGENASE; SEQUENCES	The transcription factor serum amyloid A (SAA)-activating factor (SAF), a family of zinc finger proteins, plays a significant role in the induced expression of the SAA gene. Activity of SAF is regulated by a phosphorylation event involving serine/threonine protein kinase (Ray, A, Schatten, H., and Ray, B. K. (1999) J. Biol. Chem. 274, 4300-4308; Ray, A., and Ray, B. K. (1998) Mol. Cell. Biol. 18, 7327-7335). However, the identity of the protein kinase has so far remained unknown, Induction of SAA by phorbol 12-myristate 13-acetate, a known agonist of protein kinase C (PKC), suggested a potential role of the PHC signaling pathway in the activation process. The DNA binding activity of endogenous SAF was increased by agonists of PKC. In vitro phosphorylation of SAF-1 by PRC-beta markedly increased its DNA binding ability. Consistent with these findings, treatment of cells with activators of PKC or overexpression of PKC-beta II in transfected cells increased expression of an SAF-regulated promoter. Further analysis with a GAL4 reporter system indicated that PKC-mediated phosphorylation mostly increases the DNA binding activity of SAF-1. Together these data indicated that the PKC signaling pathway plays a major role in controlling expression of SAF-regulated genes by increasing the interaction between promoter DNA and phosphorylated SAF.	Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA; Univ Texas, Med Branch, Dept Pharmacol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of Missouri System; University of Missouri Columbia; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Ray, BK (corresponding author), Univ Missouri, Dept Vet Pathobiol, 124 Connaway Hall, Columbia, MO 65211 USA.				NATIONAL CANCER INSTITUTE [R01CA056869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049205, R56DK049205] Funding Source: NIH RePORTER; NCI NIH HHS [CA56869] Funding Source: Medline; NIDDK NIH HHS [DK49205] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINCKERHOFF CE, 1989, SCIENCE, V243, P655, DOI 10.1126/science.2536953; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; EDBROOKE MR, 1989, MOL CELL BIOL, V9, P1908, DOI 10.1128/MCB.9.5.1908; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GANAPATHI MK, 1991, J IMMUNOL, V147, P1261; Gekeler V, 1996, BRIT J CANCER, V74, P897, DOI 10.1038/bjc.1996.454; GHEZZI P, 1988, LYMPHOKINE RES, V7, P157; Huberman E, 1985, Carcinog Compr Surv, V10, P263; HUSEBEKK A, 1985, SCAND J IMMUNOL, V21, P283, DOI 10.1111/j.1365-3083.1985.tb01431.x; JARVIS WD, 1994, CANCER RES, V54, P1704; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; Kolomytkin OV, 1999, AM J PHYSIOL-CELL PH, V276, pC9, DOI 10.1152/ajpcell.1999.276.1.C9; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; LOWELL CA, 1986, J BIOL CHEM, V261, P8453; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACKIEWICZ A, 1988, BIOCHEM J, V253, P851, DOI 10.1042/bj2530851; MASTRO AM, 1983, CELL BIOL INT REP, V7, P881, DOI 10.1016/0309-1651(83)90206-0; MITCHELL TI, 1991, J CLIN INVEST, V87, P1177, DOI 10.1172/JCI115116; MURRAY NR, 1997, PROTEIN KINASE C, P97; MURRAY NR, 1993, J BIOL CHEM, V268, P15747; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Parks CL, 1996, J BIOL CHEM, V271, P4417; PELICCI PG, 1983, HAEMATOLOGICA, V68, P411; Ray A, 1999, J BIOL CHEM, V274, P4300, DOI 10.1074/jbc.274.7.4300; Ray A, 1998, MOL CELL BIOL, V18, P7327, DOI 10.1128/MCB.18.12.7327; Ray A, 1996, MOL CELL BIOL, V16, P1584; Ray BK, 1999, DNA CELL BIOL, V18, P65, DOI 10.1089/104454999315637; Ray BK, 1997, BIOCHEMISTRY-US, V36, P4662, DOI 10.1021/bi9624595; Sambrook J., 2002, MOL CLONING LAB MANU; Strissel KJ, 1997, EXP CELL RES, V237, P275, DOI 10.1006/excr.1997.3783; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; URIELISHOVAL S, 1994, AM J PATHOL, V145, P650; VANDENBARK GR, 1984, J NATL CANCER I, V73, P1013	37	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39727	39733		10.1074/jbc.M007907200	http://dx.doi.org/10.1074/jbc.M007907200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995778	hybrid			2022-12-25	WOS:000165953100102
J	Zheng, XY; Johansson, M; Karlsson, A				Zheng, XY; Johansson, M; Karlsson, A			Retroviral transduction of cancer cell lines with the gene encoding Drosophila melanogaster multisubstrate deoxyribonucleoside kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX-VIRUS TYPE-1; HUMAN DEOXYCYTIDINE KINASE; THYMIDINE KINASE; SUICIDE GENE; NUCLEOSIDE ANALOGS; TUMOR-CELLS; THERAPY; ADENOVIRUS; VECTOR; CYTOTOXICITY	Nucleoside kinases from several species are investigated as "suicide genes" for treatment of malignant tumors by combined gene/chemotherapy, We have recently cloned a multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster (Dm-dNK), and we have shown that the enzyme phosphorylates cytotoxic pyrimidine and purine nucleoside analogs. The broad substrate specificity of the enzyme, as well as its very high catalytic rate, makes it a unique member of the nucleoside kinase enzyme family. In the present study, we evaluated Dm-dNK as a suicide gene by constructing a replication-deficient retroviral vector that expresses the enzyme, The human pancreatic adenocarcinoma cell line MIA PaCa-2 and a thymidine kinase deficient osteosarcoma cell line were transduced with the recombinant virus. We showed that Dm-dNK can be expressed in human cells, that the enzyme retained its enzymatic activity, and that it is localized in the cell nuclei due to a nuclear localization signal in its C-terminal region. The cells expressing Dm-dNK exhibited increased sensitivity to several cytotoxic nucleoside analogs, such as 1-beta -D-arabinofuranosylcytosine, 1-beta -D-arabinofuranosylthymine, (E)-5-(2-bromovinyl)-2'-deoxyuridine, 2-chloro-2'-deoxyadenosine, and 2',2'-difluorodeoxycytidine. These findings suggest that Dm-dNK may be used as a suicide gene in combined gene/chemotherapy of cancer.	Huddinge Univ Hosp, Karolinska Inst, Div Clin Virol, S-14186 Huddinge, Sweden	Karolinska Institutet	Karlsson, A (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Div Clin Virol, S-14186 Huddinge, Sweden.	anna.karlsson@mbb.bi.se	Karlsson, Anna/E-7945-2018; Zheng, Xinyu/O-9847-2018	Zheng, Xinyu/0000-0001-8425-3379; Karlsson, Anna/0000-0001-6843-6685				ARNER ESJ, 1992, BIOCHEM BIOPH RES CO, V188, P712, DOI 10.1016/0006-291X(92)91114-6; BALZARINI J, 1993, J BIOL CHEM, V268, P6332; Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; BERK AJ, 1973, J BIOL CHEM, V248, P2722; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Black ME, 1996, P NATL ACAD SCI USA, V93, P3525, DOI 10.1073/pnas.93.8.3525; Boucher PD, 2000, CANCER RES, V60, P1631; Cao G, 1999, GENE THER, V6, P83, DOI 10.1038/sj.gt.3300823; Chen J, 1998, CANCER RES, V58, P3504; Christians FC, 1999, NAT BIOTECHNOL, V17, P259, DOI 10.1038/7003; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; Davis AF, 1996, J CELL BIOL, V135, P883, DOI 10.1083/jcb.135.4.883; Degreve B, 1998, J VIROL, V72, P9535; Degreve B, 1997, GENE THER, V4, P1107, DOI 10.1038/sj.gt.3300502; FREEMAN SM, 1993, CANCER RES, V53, P5274; GrignetDebrus C, 1997, GENE THER, V4, P560, DOI 10.1038/sj.gt.3300435; Hapke DM, 1996, CANCER RES, V56, P2343; Hui YF, 1997, AM J HEALTH-SYST PH, V54, P162, DOI 10.1093/ajhp/54.2.162; Johansson M, 1999, J BIOL CHEM, V274, P23814, DOI 10.1074/jbc.274.34.23814; Johansson M, 1997, P NATL ACAD SCI USA, V94, P11941, DOI 10.1073/pnas.94.22.11941; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Klatzmann D, 1998, HUM GENE THER, V9, P2595, DOI 10.1089/hum.1998.9.17-2595; Kokoris MS, 1999, GENE THER, V6, P1415, DOI 10.1038/sj.gt.3300966; Latham JPF, 2000, CANCER RES, V60, P334; Manome Y, 1996, NAT MED, V2, P567, DOI 10.1038/nm0596-567; Mawatari F, 1998, CANCER GENE THER, V5, P301; Mesnil M, 1996, P NATL ACAD SCI USA, V93, P1831, DOI 10.1073/pnas.93.5.1831; MOOLTEN FL, 1986, CANCER RES, V46, P5276; MOOLTEN FL, 1990, J NATL CANCER I, V82, P297, DOI 10.1093/jnci/82.4.297; Munch-Petersen B, 2000, J BIOL CHEM, V275, P6673, DOI 10.1074/jbc.275.9.6673; Munch-Petersen B, 1998, J BIOL CHEM, V273, P3926, DOI 10.1074/jbc.273.7.3926; Ram Z, 1997, NAT MED, V3, P1354, DOI 10.1038/nm1297-1354; REARDON JE, 1989, J BIOL CHEM, V264, P19039; Romano G, 2000, STEM CELLS, V18, P19, DOI 10.1634/stemcells.18-1-19; Siders WM, 1998, CANCER GENE THER, V5, P281; SODERLUND JCF, 1994, ADV EXP MED BIOL, V370, P201; Wettin K, 1999, FEBS LETT, V460, P103, DOI 10.1016/S0014-5793(99)01325-3; WILDIERS J, 1984, EUR J CANCER CLIN ON, V20, P471, DOI 10.1016/0277-5379(84)90231-1; Wildner O, 1999, CANCER RES, V59, P410; Zhu CY, 1998, J BIOL CHEM, V273, P14707, DOI 10.1074/jbc.273.24.14707	40	53	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39125	39129		10.1074/jbc.M006212200	http://dx.doi.org/10.1074/jbc.M006212200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993893	hybrid			2022-12-25	WOS:000165953100026
J	Baumer, M; Kunzler, M; Steigemann, P; Braus, GH; Irniger, S				Baumer, M; Kunzler, M; Steigemann, P; Braus, GH; Irniger, S			Yeast Ran-binding protein Yrb1p is required for efficient proteolysis of cell cycle regulatory proteins Pds1p and Sic1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEAR IMPORT; CHROMOSOME SEGREGATION; PHOSPHATASE CDC14; TRANSPORT; IDENTIFICATION; KINASE; EXIT; PHOSPHORYLATION; EXPRESSION	Ubiquitin dependent proteolysis of specific target proteins is required for several important steps during the cell cycle, Degradation of such proteins is strictly cell cycle-regulated and triggered by two large ubiquitin ligases, termed anaphase-promoting complex (APC) and Skp1/Cullin/F-box complex (SCF), Here we show that yeast Ran-binding protein 1 (Yrb1p), a predominantly cytoplasmic protein implicated in nucleocytoplasmic transport, is required for cell cycle regulated protein degradation. Depletion of Yrb1p results in the accumulation of unbudded G(1) cells and of cells arrested in mitosis implying a function of Yrb1p in the G(1)/S transition and in the progression through mitosis, Temperature-sensitive yrb1-51 mutants are defective in APC-mediated degradation of the anaphase inhibitor protein Pds1p and in degradation of the cyclin-dependent kinase inhibitor Sic1p, a target of SCF. Thus, Yrb1p is crucial for efficient APC- and SCF-mediated proteolysis of important cell cycle regulatory proteins. We have identified the UBS1 gene as a multicopy suppressor of yrb1-51 mutants. Ubs1p is a nuclear protein, and its deletion is synthetic lethal with a yrb1-51 mutation. Interestingly, UBS1 was previously identified as a multicopy suppressor of cdc34-2 mutants, which are defective in SCF activity. We suggest that Ubs1p may represent a link between nucleocytoplasmic transport and ubiquitin ligase activity.	Univ Gottingen, Inst Genet & Microbiol, D-37077 Gottingen, Germany; Heidelberg Univ, Zentrum Biochem, D-69120 Heidelberg, Germany	University of Gottingen; Ruprecht Karls University Heidelberg	Irniger, S (corresponding author), Univ Gottingen, Inst Genet & Microbiol, Grisebachstr 8, D-37077 Gottingen, Germany.	sirnige@gwdg.de	Braus, Gerhard H/G-3999-2012; Braus, Gerhard/ABC-6293-2021	Braus, Gerhard H/0000-0002-3117-5626; Braus, Gerhard/0000-0002-3117-5626; Kunzler, Markus/0000-0003-1275-0629				Adam SA, 1999, CURR OPIN CELL BIOL, V11, P402, DOI 10.1016/S0955-0674(99)80056-8; Azuma Y, 2000, CURR OPIN CELL BIOL, V12, P302, DOI 10.1016/S0955-0674(00)00093-4; Battistoni A, 1997, J CELL SCI, V110, P2345; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; BUTLER G, 1994, BBA-GENE STRUCT EXPR, V1219, P711, DOI 10.1016/0167-4781(94)90233-X; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Deshaies RJ, 1997, CURR OPIN GENET DEV, V7, P7, DOI 10.1016/S0959-437X(97)80103-7; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Goldfarb DS, 1997, SCIENCE, V276, P1814, DOI 10.1126/science.276.5320.1814; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; IMIGER S, 1995, CELL, V81, P269; Jones AL, 2000, P NATL ACAD SCI USA, V97, P3224, DOI 10.1073/pnas.050432997; Jorgensen P, 1999, CURR OPIN MICROBIOL, V2, P610, DOI 10.1016/S1369-5274(99)00030-2; Kalab P, 1999, CURR BIOL, V9, P481, DOI 10.1016/S0960-9822(99)80213-9; KATZ ME, 1987, GENETICS, V115, P627; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Knapp D, 1996, MOL CELL BIOL, V16, P5701; Kunzler M, 2000, MOL CELL BIOL, V20, P4295, DOI 10.1128/MCB.20.12.4295-4308.2000; Lau D, 2000, J BIOL CHEM, V275, P467, DOI 10.1074/jbc.275.1.467; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Ogryzko VV, 1997, BIOCHEMISTRY-US, V36, P9493, DOI 10.1021/bi970236o; OUSPENSKI II, 1995, J BIOL CHEM, V270, P1975, DOI 10.1074/jbc.270.5.1975; Ouspenski II, 1998, EXP CELL RES, V244, P171, DOI 10.1006/excr.1998.4174; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Plafker K, 2000, MOL CELL BIOL, V20, P3510, DOI 10.1128/MCB.20.10.3510-3521.2000; Prendergast JA, 1996, MOL CELL BIOL, V16, P677; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Rose M, 1990, LAB COURSE MANUAL ME; SCHAAFFGERSTENSCHLAGER I, 1993, YEAST, V9, P915, DOI 10.1002/yea.320090811; SCHIRMAIER F, 1984, EMBO J, V3, P3311, DOI 10.1002/j.1460-2075.1984.tb02295.x; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Willems AR, 1999, PHILOS T ROY SOC B, V354, P1533, DOI 10.1098/rstb.1999.0497; XIAO ZX, 1993, MOL CELL BIOL, V13, P4691, DOI 10.1128/MCB.13.8.4691; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zachariae W, 1999, CURR OPIN CELL BIOL, V11, P708, DOI 10.1016/S0955-0674(99)00041-1	57	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38929	38937		10.1074/jbc.M007925200	http://dx.doi.org/10.1074/jbc.M007925200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10991951	hybrid			2022-12-25	WOS:000165739800107
J	Chui, KK; Rogers, GC; Kashina, AM; Wedaman, KP; Sharp, DJ; Nguyen, DT; Wilt, F; Scholey, JM				Chui, KK; Rogers, GC; Kashina, AM; Wedaman, KP; Sharp, DJ; Nguyen, DT; Wilt, F; Scholey, JM			Roles of two homotetrameric kinesins in sea urchin embryonic cell division	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE BUNDLES; MITOTIC SPINDLES; BIPOLAR KINESIN; PROTEIN; MOTOR; ANTIBODY; IDENTIFICATION; CYTOKINESIS; EGGS	To improve our understanding of the roles of microtubule cross-linking motors in mitosis, we analyzed two sea urchin embryonic kinesin-related proteins. It is striking to note that both of these proteins behave as homotetramers, but one behaves as a more compact molecule than the other. These observations suggest that these two presumptive motors could cross-link microtubules into bundles with different spacing. Both motors localize to mitotic spindles, and antibody microinjection experiments suggest that they have mitotic functions. Thus, one of these kinesin-related proteins may crosslink spindle microtubules into loose bundles that are "tightened" by the other.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA	University of California System; University of California Davis; University of California System; University of California Berkeley	Scholey, JM (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, 1 Shields Ave, Davis, CA 95616 USA.	jmscholey@ucdavis.edu			NIGMS NIH HHS [GM55507] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams RR, 1998, GENE DEV, V12, P1483, DOI 10.1101/gad.12.10.1483; Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; BUSTER D, 1991, J CELL SCI, P109; COLE DG, 1994, J BIOL CHEM, V269, P22913; Field CM, 1998, METHOD ENZYMOL, V298, P525, DOI 10.1016/S0076-6879(98)98043-0; Gordon DM, 1999, J BIOL CHEM, V274, P28779, DOI 10.1074/jbc.274.40.28779; Jantsch-Plunger V, 2000, J CELL BIOL, V149, P1391, DOI 10.1083/jcb.149.7.1391; Kashina AS, 1996, NATURE, V384, P225, DOI 10.1038/384225a0; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Morris RL, 1997, J CELL BIOL, V138, P1009, DOI 10.1083/jcb.138.5.1009; NISLOW C, 1990, J CELL BIOL, V111, P511, DOI 10.1083/jcb.111.2.511; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; Powers J, 1998, CURR BIOL, V8, P1133, DOI 10.1016/S0960-9822(98)70470-1; Raich WB, 1998, MOL BIOL CELL, V9, P2037, DOI 10.1091/mbc.9.8.2037; RAPPAPORT R, 1996, CYTOKINESIS ANIMAL C, P1; Robinson DN, 2000, TRENDS CELL BIOL, V10, P228, DOI 10.1016/S0962-8924(00)01747-5; Rogers GC, 2000, J CELL BIOL, V150, P499, DOI 10.1083/jcb.150.3.499; Rogers GC, 1999, J MOL BIOL, V294, P1, DOI 10.1006/jmbi.1999.3249; Savoian MS, 1999, MOL BIOL CELL, V10, P297, DOI 10.1091/mbc.10.2.297; SCHOLEY JM, 1984, J BIOL CHEM, V259, P6516; Scholey JM, 1998, CELL MOTIL CYTOSKEL, V39, P257, DOI 10.1002/(SICI)1097-0169(1998)39:4<257::AID-CM1>3.0.CO;2-0; SCHOLEY JM, 1985, NATURE, V318, P483, DOI 10.1038/318483a0; SELLITTO C, 1988, J CELL BIOL, V106, P431, DOI 10.1083/jcb.106.2.431; Sharp DJ, 2000, MOL BIOL CELL, V11, P241, DOI 10.1091/mbc.11.1.241; Sharp DJ, 1999, J CELL BIOL, V144, P125, DOI 10.1083/jcb.144.1.125; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7; WRIGHT BD, 1993, J CELL BIOL, V123, P681, DOI 10.1083/jcb.123.3.681; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3	30	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38005	38011		10.1074/jbc.M005948200	http://dx.doi.org/10.1074/jbc.M005948200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	11006281	hybrid			2022-12-25	WOS:000165618700094
J	Theilmeier, G; De Geest, B; Van Veldhoven, PP; Stengel, D; Michiels, C; Lox, M; Landeloos, M; Chapman, MJ; Ninio, E; Collen, D; Himpens, B; Holvoet, P				Theilmeier, G; De Geest, B; Van Veldhoven, PP; Stengel, D; Michiels, C; Lox, M; Landeloos, M; Chapman, MJ; Ninio, E; Collen, D; Himpens, B; Holvoet, P			HDL-associated PAF-AH reduces endothelial adhesiveness in apoE(-/-) mice	FASEB JOURNAL			English	Article						atherosclerosis; lipoproteins; leukocytes; cell adhesion molecules; signal transduction	HIGH-DENSITY-LIPOPROTEIN; ACTIVATING-FACTOR-ACETYLHYDROLASE; E-DEFICIENT MICE; CELL-ADHESION MOLECULE-1; CORONARY-ARTERY DISEASE; GENE-TRANSFER; EXPRESSION; ATHEROSCLEROSIS; PLASMA; PROGRESSION	Macrophage infiltration into the subendothelial space at lesion prone sites is the primary event in atherogenesis. Inhibition of macrophage homing might therefore prevent atherosclerosis. Since HDL levels are inversely correlated with cardiovascular risk, their effect on macrophage homing was assessed in apoE-deficient (apoE(-/-)) mice. Overexpression of human apolipoprotein AI in apoE(-/-) mice increased HDL levels 3-fold and reduced macrophage accumulation in an established assay of leukocyte homing to aortic root endothelium 3.2-fold (P<0.005). This was due to reduced in vivo beta VLDL oxidation, reduced beta VLDL triggered endothelial cytosolic Ca2+ signaling through PAF-like bioactivity, lower ICAM-1 and VCAM-1 expression, and diminished ex vivo leukocyte adhesion. Adenoviral gene transfer of human PAF-acetylhydrolase (PAF-AH) in apoE(-/-) mice increased PAF-AH activity 1.5-fold (P<0.001), reduced beta VLDL-induced ex vivo macrophage adhesion 3.5-fold (P<0.01), and reduced in vivo macrophage homing 2.6-fold (P<0.02). These inhibitory effects were observed in the absence of increased HDL cholesterol levels. In conclusion, HDL reduces macrophage homing to endothelium by reducing oxidative stress via its associated PAF-AH activity. This protective mechanism is independent of the function of HDL as cholesterol acceptor. Modulation of lipoprotein oxidation by PAF-AH may prevent leukocyte recruitment to the vessel wall, a key feature in atherogenesis.	Katholieke Univ Leuven, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Dept Pharmacol, B-3000 Louvain, Belgium; FUNDP, Lab Biochim & Biol Cellulaire, Namur, Belgium; Hop Pitie, INSERM, U321, F-75651 Paris, France; Katholieke Univ Leuven, Dept Physiol, B-3000 Louvain, Belgium	KU Leuven; KU Leuven; University of Namur; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; KU Leuven	Holvoet, P (corresponding author), Katholieke Univ Leuven, Ctr Expt Surg & Anesthesiol, Herestr 49, B-3000 Louvain, Belgium.		, Van Veldhoven Paul/U-6359-2019; De Geest, Bart/AHB-0394-2022; chapman, john/Y-2742-2019; HOLVOET, PAUL/T-8434-2017	, Van Veldhoven Paul/0000-0002-4478-2564; HOLVOET, PAUL/0000-0001-9201-0772; De Geest, Bart/0000-0001-5580-686X; Lox, Marleen/0000-0002-0837-7852				Benoit P, 1999, CIRCULATION, V99, P105, DOI 10.1161/01.CIR.99.1.105; COCKERILL GW, 1995, ARTERIOSCL THROM VAS, V15, P1987, DOI 10.1161/01.ATV.15.11.1987; Dansky HM, 1999, J CLIN INVEST, V104, P31, DOI 10.1172/JCI6577; DeGeest B, 1997, CIRCULATION, V96, P4349; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; Holvoet P, 1998, CIRCULATION, V98, P1487, DOI 10.1161/01.CIR.98.15.1487; Holvoet P, 1998, J CLIN INVEST, V102, P379, DOI 10.1172/JCI3038; HOLVOET P, 1995, J CLIN INVEST, V95, P2611, DOI 10.1172/JCI117963; KINASHI T, 1995, J LEUKOCYTE BIOL, V57, P168, DOI 10.1002/jlb.57.1.168; Lee C, 1999, ARTERIOSCL THROM VAS, V19, P1437, DOI 10.1161/01.ATV.19.6.1437; MACKNESS MI, 1993, ATHEROSCLEROSIS, V104, P129, DOI 10.1016/0021-9150(93)90183-U; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MAZER B, 1991, J IMMUNOL, V146, P1914; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; Patel SS, 1998, CIRCULATION, V97, P75, DOI 10.1161/01.CIR.97.1.75; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; SCHEYNIUS A, 1993, J IMMUNOL, V150, P655; Serebruany VL, 1998, CARDIOLOGY, V90, P127, DOI 10.1159/000006831; SHAH PK, 1992, CIRCULATION, V85, P1279, DOI 10.1161/01.CIR.85.4.1279; Shah PK, 1998, CIRCULATION, V97, P780, DOI 10.1161/01.CIR.97.8.780; Staley D, 1997, COMPR PSYCHIAT, V38, P6, DOI 10.1016/S0010-440X(97)90047-X; Theilmeier G, 1999, BLOOD, V94, P2725, DOI 10.1182/blood.V94.8.2725.420k18_2725_2734; THOMAS JE, 1993, ONCOGENE, V8, P2521; TSELEPIS AD, 1995, ARTERIOSCL THROM VAS, V15, P1764, DOI 10.1161/01.ATV.15.10.1764; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; Yamada Y, 1998, METABOLISM, V47, P177, DOI 10.1016/S0026-0495(98)90216-5	32	126	135	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					2032	2039		10.1096/fj.99-1029com	http://dx.doi.org/10.1096/fj.99-1029com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023987				2022-12-25	WOS:000089634400022
J	Ramamurthy, L; Barbour, V; Tuckfield, A; Clouston, DR; Topham, D; Cunningham, JM; Jane, SM				Ramamurthy, L; Barbour, V; Tuckfield, A; Clouston, DR; Topham, D; Cunningham, JM; Jane, SM			Targeted disruption of the CP2 gene, a member of the NTF family of transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; BETA-GLOBIN LOCUS; DNA-BINDING; FACTOR GRAINYHEAD; FACTOR NF-E2; IN-VITRO; DROSOPHILA; EXPRESSION; PROTEIN; LSF	The NTF-like family of transcription factors have been implicated in developmental regulation in organisms as diverse as Drosophila and man. The two mammalian members of this family, CP2 (LBP-1c/LSF) and LBP-1a (NF2d9), are highly related proteins sharing an overall amino acid identity of 72%. CP2, the best characterized of these factors, is a ubiquitously expressed 66-kDa protein that binds the regulatory regions of many diverse genes. Consequently, a role for CP2 has been proposed in globin gene expression, T-cell responses to mitogenic stimulation, and several other cellular processes. To elucidate the in vivo role of CP2, we have generated mice nullizygous for the CP2 allele, These animals were born in a normal Mendelian distribution and displayed no defects in growth, behavior, fertility, or development. Specifically, no perturbation of hematopoietic differentiation, globin gene expression, or immunological responses to T- and B-cell mitogenic stimulation was observed. RNA and protein analysis confirmed that the nullizygous mice expressed no full-length or truncated version of CP2. Electrophoretic mobility shift assays with nuclear extracts from multiple tissues demonstrated loss of CP2 DNA binding activity in the -/- lines. However, a slower migrating complex that was ablated with antiserum to NF2d9, the murine homologue of LBP-1a, was observed with these extracts. Furthermore, we demonstrate that recombinant LBP-1a can bind to known CP2 consensus sites and form protein complexes with previously defined heteromeric partners of CP2. These results suggest that LBP-1a/NF2d9 may compensate for loss of CP2 expression in vivo and that further analysis of the role of the NTF family of proteins requires the targeting of the NF2d9 gene.	St Jude Childrens Res Hosp, Div Expt Hematol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; Royal Melbourne Hosp Res Fdn, Rotary Bone Marrow Res Lab, Parkville, Vic 3050, Australia	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; Royal Melbourne Hospital	Cunningham, JM (corresponding author), St Jude Childrens Res Hosp, Div Expt Hematol, 332 N Lauderdale St, Memphis, TN 38105 USA.		Jane, Stephen/D-6659-2011	Barbour, Virginia/0000-0002-2358-2440; Jane, Stephen Marsden/0000-0002-1045-0481	NCI NIH HHS [P30 CA 21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL53749] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amrolia PJ, 1998, J BIOL CHEM, V273, P13593, DOI 10.1074/jbc.273.22.13593; ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; BRAY SJ, 1991, GENE DEV, V5, P1672, DOI 10.1101/gad.5.9.1672; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAENSLER KML, 1993, P NATL ACAD SCI USA, V90, P11381, DOI 10.1073/pnas.90.23.11381; GUMUCIO DL, 1994, J BIOL CHEM, V269, P15371; GUMUCIO DL, 1993, P NATL ACAD SCI USA, V90, P6018, DOI 10.1073/pnas.90.13.6018; Huang JD, 1995, GENE DEV, V9, P3177, DOI 10.1101/gad.9.24.3177; JANE SM, 1995, EMBO J, V14, P97, DOI 10.1002/j.1460-2075.1995.tb06979.x; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KIM CH, 1987, P NATL ACAD SCI USA, V84, P6025, DOI 10.1073/pnas.84.17.6025; Liaw GJ, 1995, GENE DEV, V9, P3163, DOI 10.1101/gad.9.24.3163; LIM LC, 1993, J BIOL CHEM, V268, P18008; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; PARADA CA, 1995, J BIOL CHEM, V270, P2274, DOI 10.1074/jbc.270.5.2274; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P11207, DOI 10.1073/pnas.90.23.11207; Romerio F, 1997, J VIROL, V71, P9375, DOI 10.1128/JVI.71.12.9375-9382.1997; Shavit JA, 1998, GENE DEV, V12, P2164, DOI 10.1101/gad.12.14.2164; SHIRRA MK, 1994, MOL CELL BIOL, V14, P5076, DOI 10.1128/MCB.14.8.5076; Shirra MK, 1998, J BIOL CHEM, V273, P19260, DOI 10.1074/jbc.273.30.19260; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; SUEYOSHI T, 1995, MOL CELL BIOL, V15, P4158; SWENDEMAN SL, 1994, J BIOL CHEM, V269, P11663; Uv AE, 1997, MOL CELL BIOL, V17, P6727, DOI 10.1128/MCB.17.11.6727; UV AE, 1994, MOL CELL BIOL, V14, P4020, DOI 10.1128/MCB.14.6.4020; Volker JL, 1997, GENE DEV, V11, P1435, DOI 10.1101/gad.11.11.1435; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; YOON JB, 1994, MOL CELL BIOL, V14, P1776, DOI 10.1128/MCB.14.3.1776; Zindy F, 1997, CELL GROWTH DIFFER, V8, P1139	34	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7836	7842		10.1074/jbc.M004351200	http://dx.doi.org/10.1074/jbc.M004351200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	10995745	Green Published, hybrid			2022-12-25	WOS:000167474900024
J	Li, CQ; Vindigni, A; Sadler, JE; Wardell, MR				Li, CQ; Vindigni, A; Sadler, JE; Wardell, MR			Platelet glycoprotein Ib alpha binds to thrombin anion-binding exosite II inducing allosteric changes in the activity of thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; GLA DOMAIN; PROCOAGULANT ACTIVITY; ANTITHROMBIN-III; MEMBRANE-BINDING; LIGAND-BINDING; IX COMPLEX; FACTOR-X; RECEPTOR; HEPARIN	The glycoprotein (GP) Ib-IX complex is a platelet surface receptor that binds thrombin as one of its ligands, although the biological significance of thrombin interaction remains unclear. In this study we have used several approaches to investigate the GPIb alpha -thrombin interaction in more detail and to study its effect on the thrombin-induced elaboration of fibrin. We found that both glycocalicin and the amino terminal fragment of GPIb alpha reduced the release of fibrinopeptide A from fibrinogen by about 50% by a noncompetitive allosteric mechanism. Similarly, GPIb alpha caused in thrombin an allosteric reduction in the rate of turnover of the small peptide substrate D-Phe-Pro-Arg-pNA. The K-d for the glycocalicin-thrombin interaction was 1 muM at physio logical ionic strength but was highly salt-dependent, decreasing to 0.19 muM at 100 mM NaCl (Gamma (salt) = -4.2). The salt dependence was characteristic of other thrombin ligands that bind to exosite II of this enzyme, and we confirmed this as the GPIb alpha -binding site on thrombin by using thrombin mutants and by competition binding studies. R68E or R70E mutations in exosite I of thrombin had little effect on its interaction with GPIb alpha. Both the allosteric inhibition of fibrinogen turnover caused by GPIb alpha binding to these mutants, and the K-d values for their interactions with GPIb alpha were similar to those of wild type thrombin. In contrast, R89E and K248E mutations in exosite II of thrombin markedly increased the K-d values for the interactions of these thrombin mutants with GPIb alpha by 10- and 25-fold, respectively. Finally, me demonstrated that low molecular weight heparin (which binds to thrombin exosite II) but not hirugen (residues 54-65 of hirudin, which binds to exosite I of thrombin) inhibited thrombin binding to GPIb alpha. These data demonstrate that GPIb alpha binds to thrombin exosite II and in so doing causes a conformational change in the active site of thrombin by an allosteric mechanism that alters the accessibility of both its natural substrate, fibrinogen, and the small peptidyl substrate D-Phe-Pro-Arg-pNA.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Wardell, MR (corresponding author), New Century Pharmaceut Inc, 895 Martin Rd, Huntsville, AL 35824 USA.	mwardell@newcenturypharm.com	Sadler, Evan/D-8556-2011	Sadler, J. Evan/0000-0001-5705-469X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060617] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60617] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERNDT MC, 1986, ANN NY ACAD SCI, V485, P374, DOI 10.1111/j.1749-6632.1986.tb34598.x; BEVERS EM, 1991, BLOOD REV, V5, P146, DOI 10.1016/0268-960X(91)90031-7; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; DANG QD, 1994, J PROTEIN CHEM, V13, P367, DOI 10.1007/BF01901692; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; De Candia E, 1999, CIRCULATION, V99, P3308, DOI 10.1161/01.CIR.99.25.3308; de Cristofaro R, 1998, BIOCHEM J, V332, P643, DOI 10.1042/bj3320643; De Cristofaro R, 2000, J BIOL CHEM, V275, P3887, DOI 10.1074/jbc.275.6.3887; DeCandia E, 1997, THROMB HAEMOSTASIS, V77, P735; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; DEMARCO L, 1994, J BIOL CHEM, V269, P6478; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; Dong JF, 1997, BLOOD, V89, P4355, DOI 10.1182/blood.V89.12.4355; Dormann D, 2000, BLOOD, V96, P2469, DOI 10.1182/blood.V96.7.2469.h8002469_2469_2478; ENDO T, 1981, J BIOL CHEM, V256, P2485; Fredenburgh JC, 1997, J BIOL CHEM, V272, P25493, DOI 10.1074/jbc.272.41.25493; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GANGULY P, 1979, BRIT J HAEMATOL, V42, P137, DOI 10.1111/j.1365-2141.1979.tb03706.x; GRALNICK HR, 1994, P NATL ACAD SCI USA, V91, P6334, DOI 10.1073/pnas.91.14.6334; HARMON JT, 1986, J BIOL CHEM, V261, P3224; HESS D, 1991, EUR J BIOCHEM, V199, P389, DOI 10.1111/j.1432-1033.1991.tb16135.x; HOPFNER KP, 1993, BIOCHEMISTRY-US, V32, P2947, DOI 10.1021/bi00063a004; HORTIN GL, 1991, J BIOL CHEM, V266, P6866; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; ISHII K, 1995, J BIOL CHEM, V270, P16435, DOI 10.1074/jbc.270.27.16435; JAMIESON GA, 1978, J CLIN INVEST, V61, P861, DOI 10.1172/JCI109000; JANDROTPERRUS M, 1992, BLOOD, V80, P2781; JANDROTPERRUS M, 1991, THROMB HAEMOSTASIS, V66, P300; JandrotPerrus M, 1996, SEMIN THROMB HEMOST, V22, P151, DOI 10.1055/s-2007-999003; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; LARSEN NE, 1981, BIOCHEMISTRY-US, V20, P4141, DOI 10.1021/bi00517a030; Li CQ, 2000, BLOOD, V95, P205, DOI 10.1182/blood.V95.1.205.001k14_205_211; LI CQ, 1995, J BIOL CHEM, V270, P16302, DOI 10.1074/jbc.270.27.16302; Li CQ, 1997, BLOOD, V90, P1911; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; MARCHESE P, 1995, J BIOL CHEM, V270, P9571, DOI 10.1074/jbc.270.16.9571; Mazzucato M, 1998, J BIOL CHEM, V273, P1880, DOI 10.1074/jbc.273.4.1880; McGee MP, 1998, BIOCHEM J, V330, P533; MILETICH JP, 1977, P NATL ACAD SCI USA, V74, P4033, DOI 10.1073/pnas.74.9.4033; Miura S, 2000, J BIOL CHEM, V275, P7539, DOI 10.1074/jbc.275.11.7539; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P6886; OKUMURA T, 1978, J BIOL CHEM, V253, P3435; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1994, SEMIN THROMB HEMOST, V20, P373, DOI 10.1055/s-2007-1001928; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; Smith RD, 1999, BIOCHEMISTRY-US, V38, P8936, DOI 10.1021/bi9827518; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; STONE SR, 1989, BIOCHEMISTRY-US, V28, P6857, DOI 10.1021/bi00443a012; STONE SR, 1987, EUR J BIOCHEM, V169, P373, DOI 10.1111/j.1432-1033.1987.tb13622.x; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; SUNNERHAGEN M, 1995, NAT STRUCT BIOL, V2, P504, DOI 10.1038/nsb0695-504; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; Vindigni A, 1997, BIOCHEMISTRY-US, V36, P6674, DOI 10.1021/bi962766a; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEISS HJ, 1975, NEW ENGL J MED, V293, P531, DOI 10.1056/NEJM197509112931105; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; WICKI AN, 1985, EUR J BIOCHEM, V153, P1, DOI 10.1111/j.1432-1033.1985.tb09259.x; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; Zhang EL, 1997, BIOPHYS CHEM, V63, P185, DOI 10.1016/S0301-4622(96)02227-2	64	57	62	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6161	6168		10.1074/jbc.M004164200	http://dx.doi.org/10.1074/jbc.M004164200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11024046	hybrid			2022-12-25	WOS:000167261000016
J	Fujii, T; Brandsma, JL; Peng, XY; Srimatkandada, S; Li, L; Canaan, A; Deisseroth, AB				Fujii, T; Brandsma, JL; Peng, XY; Srimatkandada, S; Li, L; Canaan, A; Deisseroth, AB			High and low levels of cottontail rabbit papillomavirus E2 protein generate opposite effects on gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECURRENT RESPIRATORY PAPILLOMATOSIS; CELLULAR TRANSCRIPTION FACTORS; OPEN READING FRAMES; DNA-BINDING DOMAIN; BOVINE PAPILLOMAVIRUS; REPLICATION PROTEIN; ACTIVATION DOMAINS; CRYSTAL-STRUCTURE; IN-VIVO; E1	The papillomavirus E2 protein plays an important role in viral transcriptional regulation and replication. We chose to study the cottontail rabbit papillomavirus (CRPV) E2 protein as a transcriptional regulator because of the availability of an animal model for papilloma formation, which may be relevant for human papillomavirus (HPV) infection and replication. We studied the effect of expression levels of E2 on the long control region, which contains transcriptional promoter and enhancer elements, and synthetic E2-dependent artificial promoters in which the E2 was the dominant factor in the transcriptional activation. These experiments indicated that high levels of E2 were inhibitory and low levels were stimulatory for transactivation. In addition, we showed that the complex formed between CRPV E2 and the cognate binding site was less stable than the complex formed between HPV E2 and the same cognate binding site, Furthermore, we showed that CRPV E2 binding to its transcriptional regulatory sequence was stabilized by other proteins such as El, which produced increments in transcriptional activation of E2-dependent genes. The data may be used to define conditions in which the rabbit model can be used for the screening of drugs which are inhibitory to the HPV and CRPV replication and gene expression.	Yale Univ, Sch Med, Dept Internal Med, Sect Med Oncol, New Haven, CT 06520 USA; Yale Univ, Ctr Canc, Genet Therapy Program, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Comparat Med, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Deisseroth, AB (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Sect Med Oncol, 333 Cedar St, New Haven, CT 06520 USA.	albert.deisseroth@yale.edu						Antson AA, 2000, NATURE, V403, P805, DOI 10.1038/35001638; BARBOSA MS, 1988, J VIROL, V62, P3242, DOI 10.1128/JVI.62.9.3242-3249.1988; Berg M, 1997, J VIROL, V71, P3853, DOI 10.1128/JVI.71.5.3853-3863.1997; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; BRANDSMA JL, 1995, J VIROL, V69, P2716, DOI 10.1128/JVI.69.4.2716-2721.1995; BRANDSMA JL, 1993, J VIROL, V67, P567, DOI 10.1128/JVI.67.1.567-571.1993; BRANDSMA JL, 1994, INTERVIROLOGY, V37, P189, DOI 10.1159/000150377; CHIANG CM, 1992, P NATL ACAD SCI USA, V89, P5799, DOI 10.1073/pnas.89.13.5799; COBB MW, 1990, J AM ACAD DERMATOL, V22, P547, DOI 10.1016/0190-9622(90)70073-Q; Coll DA, 1997, AM J OTOLARYNG, V18, P283, DOI 10.1016/S0196-0709(97)90012-0; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; Demeret C, 1998, VIROLOGY, V242, P378, DOI 10.1006/viro.1997.9023; GIRI I, 1985, P NATL ACAD SCI USA, V82, P1580, DOI 10.1073/pnas.82.6.1580; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; HAM J, 1994, EMBO J, V13, P147, DOI 10.1002/j.1460-2075.1994.tb06244.x; HAM J, 1991, EMBO J, V10, P2931, DOI 10.1002/j.1460-2075.1991.tb07843.x; Harris SF, 1999, SCIENCE, V284, P1673, DOI 10.1126/science.284.5420.1673; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hegde RS, 1998, J MOL BIOL, V284, P1479, DOI 10.1006/jmbi.1998.2260; Ilves I, 1999, J VIROL, V73, P4404, DOI 10.1128/JVI.73.5.4404-4412.1999; KASHIMA H, 1993, ANN OTO RHINOL LARYN, V102, P580, DOI 10.1177/000348949310200802; Kovelman R, 1996, J VIROL, V70, P7549, DOI 10.1128/JVI.70.11.7549-7560.1996; KREIDER JW, 1981, ADV CANCER RES, V35, P81, DOI 10.1016/S0065-230X(08)60909-4; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; Lehman CW, 1998, P NATL ACAD SCI USA, V95, P4338, DOI 10.1073/pnas.95.8.4338; LEMOAL MA, 1994, J VIROL, V68, P1085, DOI 10.1128/JVI.68.2.1085-1093.1994; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; MEYERS C, 1991, VIROLOGY, V181, P637, DOI 10.1016/0042-6822(91)90897-K; Morgan IM, 1998, J GEN VIROL, V79, P501, DOI 10.1099/0022-1317-79-3-501; MULLER F, 1994, J BIOL CHEM, V269, P17086; Phelps WC, 1998, ANTIVIR CHEM CHEMOTH, V9, P359, DOI 10.1177/095632029800900501; PICCINI A, 1995, J GEN VIROL, V76, P2909, DOI 10.1099/0022-1317-76-11-2909; RANK NM, 1995, J VIROL, V69, P6323, DOI 10.1128/JVI.69.10.6323-6334.1995; RIESE DJ, 1990, J VIROL, V64, P944, DOI 10.1128/JVI.64.2.944-949.1990; SANDERS CM, 1994, NUCLEIC ACIDS RES, V22, P4890, DOI 10.1093/nar/22.23.4890; Sanders CM, 1998, EMBO J, V17, P7044, DOI 10.1093/emboj/17.23.7044; SANDLER AB, 1993, J VIROL, V67, P5079, DOI 10.1128/JVI.67.9.5079-5087.1993; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sedman T, 1997, J VIROL, V71, P2887, DOI 10.1128/JVI.71.4.2887-2896.1997; SHAH KV, 1988, ANNU REV MED, V39, P371, DOI 10.1146/annurev.med.39.1.371; SPALHOLZ BA, 1985, CELL, V42, P183, DOI 10.1016/S0092-8674(85)80114-8; Steger G, 1997, J VIROL, V71, P50, DOI 10.1128/JVI.71.1.50-58.1997; STEGER G, 1995, EMBO J, V14, P329, DOI 10.1002/j.1460-2075.1995.tb07007.x; TAN SH, 1994, J VIROL, V68, P6411, DOI 10.1128/JVI.68.10.6411-6420.1994; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Thain A, 1997, J BIOL CHEM, V272, P8236, DOI 10.1074/jbc.272.13.8236; USHIKAI M, 1994, J VIROL, V68, P6655, DOI 10.1128/JVI.68.10.6655-6666.1994; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x	49	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					867	874		10.1074/jbc.M007120200	http://dx.doi.org/10.1074/jbc.M007120200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11013251	hybrid			2022-12-25	WOS:000166430900003
J	Yousef, GM; Scorilas, A; Jung, K; Ashworth, LK; Diamandis, EP				Yousef, GM; Scorilas, A; Jung, K; Ashworth, LK; Diamandis, EP			Molecular cloning of the human kallikrein 15 gene (KLK15) - Up-regulation in prostate cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNEUM CHYMOTRYPTIC ENZYME; HUMAN GLANDULAR KALLIKREIN; SERINE-PROTEASE; MESSENGER-RNA; SEQUENCE-ANALYSIS; HUMAN NEUROPSIN; EXPRESSION; ANTIGEN; BREAST; IDENTIFICATION	Kallikreins are a subgroup of serine proteases with diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis. By using molecular cloning techniques, we identified a new human kallikrein gene, tentatively named KLK15 (for Kallikrein 15 gene). This new gene maps to chromosome 19q13.4 and is located between the KLK1 and KLK3 genes. KLK15 is formed of five coding exons and four introns, and shows structural similarity to other kallikreins and kallikrein-like genes. KLK15 has three alternatively spliced forms and is primarily expressed in the thyroid gland and to a lower extent in the prostate, salivary, and adrenal glands and in the colon testis and kidney. Our preliminary results indicate that the expression of KLK15 is up-regulated by steroid hormones in the LNCaP prostate cancer cell line. The KLK15 gene is also up-regulated, at the mRNA level, in prostate cancer in comparison to normal prostatic tissue. KLK15 up-regulation was found to be associated with more aggressive forms of prostate cancer. This newly discovered gene has the potential of being used as a diagnostic and/or prognostic marker for prostate cancer.	Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada; Humboldt Univ, Univ Hosp Berlin, Charite, Dept Urol, D-10048 Berlin, Germany; Lawrence Livermore Natl Lab, Biol & Biotechnol Program, Livermore, CA 94551 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Diamandis, EP (corresponding author), Mt Sinai Hosp, Dept Pathol & Lab Med, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	ediamandis@mtsinai.on.ca	Jung, Klaus/Z-2122-2018	Jung, Klaus/0000-0001-9797-5362; Scorilas, Andreas/0000-0003-2427-4949; Diamandis, Eleftherios/0000-0002-1589-820X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anisowicz A, 1996, MOL MED, V2, P624, DOI 10.1007/BF03401646; ASHLEY PL, 1985, BIOCHEMISTRY-US, V24, P4520, DOI 10.1021/bi00338a006; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Black MH, 1999, CLIN CHEM, V45, P790; CHEN LM, 1994, BRAZ J MED BIOL RES, V27, P1829; CLEMENTS J, 1997, KININ SYSTEM, P71; CUMMING AD, 1994, CLIN SCI, V87, P5, DOI 10.1042/cs0870005; DAYHOFF MO, 1978, NATL BIOMED RES FOUN, V5, P79; Diamandis EP, 2000, CLIN CHEM, V46, P1855; Diamandis EP, 1998, TRENDS ENDOCRIN MET, V9, P310, DOI 10.1016/S1043-2760(98)00082-4; Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8; Ekholm E, 1999, ARCH DERMATOL RES, V291, P195, DOI 10.1007/s004030050393; EVANS BA, 1987, J BIOL CHEM, V262, P8027; Goyal J, 1998, CANCER RES, V58, P4782; HANSSON L, 1994, J BIOL CHEM, V269, P19420; Heuze N, 1999, CANCER RES, V59, P2820; IIDA Y, 1990, J THEOR BIOL, V145, P523, DOI 10.1016/S0022-5193(05)80486-2; JAFFA AA, 1992, KIDNEY INT, V41, P789, DOI 10.1038/ki.1992.122; Keil B., 1971, ENZYMES, V3, P249, DOI [10.1016/S1874-6047(08)60399-6., 10.1021/bi00843a047, DOI 10.1021/BI00843A047]; Kishi A, 1999, J BIOL CHEM, V274, P4220, DOI 10.1074/jbc.274.7.4220; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kraut H, 1930, H-S Z PHYSIOL CHEM, V189, P97, DOI 10.1515/bchm2.1930.189.3-4.97; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Little SP, 1997, J BIOL CHEM, V272, P25135, DOI 10.1074/jbc.272.40.25135; Liu XL, 1996, CANCER RES, V56, P3371; Luo LY, 1998, BIOCHEM BIOPH RES CO, V247, P580, DOI 10.1006/bbrc.1998.8793; MARGOLIUS HS, 1974, CIRC RES, V35, P820, DOI 10.1161/01.RES.35.6.820; Meyer A, 1997, INT J CANCER, V74, P630, DOI 10.1002/(SICI)1097-0215(19971219)74:6<630::AID-IJC13>3.0.CO;2-9; Mitsui S, 1999, EUR J BIOCHEM, V260, P627, DOI 10.1046/j.1432-1327.1999.00213.x; MIYATA T, 1979, J MOL EVOL, V12, P219, DOI 10.1007/BF01732340; Momota Y, 1998, EUR J NEUROSCI, V10, P760, DOI 10.1046/j.1460-9568.1998.00068.x; Nelson PS, 1999, P NATL ACAD SCI USA, V96, P3114, DOI 10.1073/pnas.96.6.3114; Partin AW, 1999, UROLOGY, V54, P839, DOI 10.1016/S0090-4295(99)00270-8; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REIGMAN PHJ, 1989, BIOCHEM BIOPH RES CO, V159, P95, DOI 10.1016/0006-291X(89)92409-1; RIEGMAN PHJ, 1991, MOL CELL ENDOCRINOL, V76, P181, DOI 10.1016/0303-7207(91)90272-T; RIEGMAN PHJ, 1988, BIOCHEM BIOPH RES CO, V155, P181, DOI 10.1016/S0006-291X(88)81066-0; RIEGMAN PHJ, 1992, GENOMICS, V14, P6, DOI 10.1016/S0888-7543(05)80275-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; Sondell B, 1996, ACTA DERM-VENEREOL, V76, P177; Stenman UH, 1999, CLIN CHEM, V45, P753; Tanimoto H, 1999, CANCER, V86, P2074, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2074::AID-CNCR27>3.3.CO;2-V; Underwood LJ, 1999, CANCER RES, V59, P4435; Werle E, 1934, BIOCHEM Z, V269, P415; Yoshida S, 1998, GENE, V213, P9, DOI 10.1016/S0378-1119(98)00232-7; Yousef GM, 2000, GENOMICS, V65, P184, DOI 10.1006/geno.2000.6159; Yousef GM, 2000, J BIOL CHEM, V275, P11891, DOI 10.1074/jbc.275.16.11891; Yousef GM, 2000, BIOCHEM BIOPH RES CO, V276, P125, DOI 10.1006/bbrc.2000.3448; Yousef GM, 1999, CANCER RES, V59, P4252; Yousef GM, 1999, GENOMICS, V62, P251, DOI 10.1006/geno.1999.6012; Yousef GM, 1999, J BIOL CHEM, V274, P37511, DOI 10.1074/jbc.274.53.37511; Yousef GM, 1999, ANTICANCER RES, V19, P2843	55	102	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					53	61		10.1074/jbc.M005432200	http://dx.doi.org/10.1074/jbc.M005432200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11010966	hybrid			2022-12-25	WOS:000166280700009
J	Martin-Belmonte, F; Alonso, MA; Zhang, XQ; Arvan, P				Martin-Belmonte, F; Alonso, MA; Zhang, XQ; Arvan, P			Thyroglobulin is selected as luminal protein cargo for apical transport via detergent-resistant membranes in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEINS; INFLUENZA-VIRUS HEMAGGLUTININ; RAFT-ASSOCIATED PROTEIN; CANINE KIDNEY-CELLS; RAT PAROTID-GLAND; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; MDCK CELLS; POLARIZED SECRETION; MOLECULAR CHAPERONE	Thyroid hormone synthesis by thyrocytes depends upon apical secretion of thyroglobulin (Tg), the glycoprotein prohormone, In stably transfected MDCK cells, recombinant Tg is also secreted apically. All secreted Tg has undergone Golgi carbohydrate modification, whereas most intracellular Tg (which is slow to exit the endoplasmic reticulum) is sensitive to digestion with endoglycosidase H. However, in MDCK cells and PC C13 thyrocytes, a subpopulation of newly synthesized recombinant and endogenous Tg, respectively, is recovered in a Triton X-100 insoluble, glycosphingolipid/cholesterol-enriched (GEM/raft) fraction, and this small subpopulation is overwhelmingly endoglycosidase H resistant. Upon apical secretion, Tg solubility is restored. Apical secretion of Tg is inhibited by cellular cholesterol depletion. In FRT cells, recombinant Tg becomes Triton X-100 insoluble within 60 min after synthesis and a portion is actually endoglycosidase H-sensitive, suggesting early Tg entry into GEMs/rafts, Interestingly in FRT cells,Tg remains associated with the apical plasma membrane upon exocytosis, and all surface Tg is GEM/raft-associated. Thus, Tg is the first secretory protein demonstrated to enter Triton X-100 insoluble membranes en route to the apical surface of epithelial cells. The data imply that Tg utilizes a cargo-selective mechanism for apical sorting.	Albert Einstein Coll Med, Div Endocrinol, Bronx, NY 10461 USA; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Yeshiva University; Albert Einstein College of Medicine	Arvan, P (corresponding author), Albert Einstein Coll Med, Div Endocrinol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	arvan@aecom.yu.edu	Alonso, Miguel A/J-3945-2016; Martin-Belmonte, Fernando/J-8029-2014	Alonso, Miguel A/0000-0002-7001-8826; Martin-Belmonte, Fernando/0000-0002-2564-4430	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040344, R01DK040344] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40344] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; Alonso MA, 1997, J BIOL CHEM, V272, P30748, DOI 10.1074/jbc.272.49.30748; Arvan P, 1997, THYROID, V7, P89, DOI 10.1089/thy.1997.7.89; Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; ARVAN P, 1982, J CELL BIOL, V95, P8, DOI 10.1083/jcb.95.1.8; ARVAN P, 1991, J CELL BIOL, V112, P365, DOI 10.1083/jcb.112.3.365; ARVAN P, 1987, J CELL BIOL, V104, P243, DOI 10.1083/jcb.104.2.243; BALCAROVASTANDER J, 1984, EMBO J, V3, P2687, DOI 10.1002/j.1460-2075.1984.tb02194.x; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; BJORKMAN U, 1978, ENDOCRINOLOGY, V102, P460, DOI 10.1210/endo-102-2-460; Blazquez M, 2000, BIOCHEM J, V349, P843, DOI 10.1042/bj3490843; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CAMERON RS, 1984, J MEMBRANE BIOL, V79, P127, DOI 10.1007/BF01872117; CAPLAN MJ, 1987, NATURE, V329, P632, DOI 10.1038/329632a0; CHAMBARD M, 1990, J MOL ENDOCRINOL, V4, P193, DOI 10.1677/jme.0.0040193; Cheong KH, 1999, P NATL ACAD SCI USA, V96, P6241, DOI 10.1073/pnas.96.11.6241; DESRUISSEAUGONZALVEZ S, 1993, IN VITRO CELL DEV-AN, V29, P161; Dhanvantari S, 2000, J BIOL CHEM, V275, P29887, DOI 10.1074/jbc.M005364200; EKHOLM R, 1990, INT REV CYTOL, V120, P243; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FORMISANO S, 1983, ARCH BIOCHEM BIOPHYS, V227, P351, DOI 10.1016/0003-9861(83)90463-0; Graichen R, 1996, J BIOL CHEM, V271, P15854, DOI 10.1074/jbc.271.27.15854; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; HERZOG V, 1984, INT REV CYTOL, V91, P107; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; KIM PS, 1991, J BIOL CHEM, V266, P12412; KIM PS, 1993, J BIOL CHEM, V268, P4873; Kim PS, 1996, J CELL BIOL, V133, P517, DOI 10.1083/jcb.133.3.517; Kim PS, 1998, P NATL ACAD SCI USA, V95, P9909, DOI 10.1073/pnas.95.17.9909; KOSTROUCH Z, 1991, ENDOCRINOLOGY, V129, P2202, DOI 10.1210/endo-129-4-2202; Lipardi C, 1999, BIOCHIMIE, V81, P347, DOI 10.1016/S0300-9084(99)80080-7; Lipardi C, 2000, MOL BIOL CELL, V11, P531, DOI 10.1091/mbc.11.2.531; Marino M, 2000, J BIOL CHEM, V275, P7125, DOI 10.1074/jbc.275.10.7125; Marino M, 2000, THYROID, V10, P461, DOI 10.1089/thy.2000.10.461; Marzolo MP, 1997, P NATL ACAD SCI USA, V94, P1834, DOI 10.1073/pnas.94.5.1834; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; MEDEIROSNETO G, 1993, ENDOCR REV, V14, P165, DOI 10.1210/er.14.2.165; Mora R, 1999, J BIOL CHEM, V274, P25708, DOI 10.1074/jbc.274.36.25708; Muniz M, 2000, EMBO J, V19, P10, DOI 10.1093/emboj/19.1.10; Muresan Z, 1997, J BIOL CHEM, V272, P26095, DOI 10.1074/jbc.272.42.26095; Muresan Z, 1998, MOL ENDOCRINOL, V12, P458, DOI 10.1210/me.12.3.458; Parolini I, 1999, J BIOL CHEM, V274, P25718, DOI 10.1074/jbc.274.36.25718; PETELL JK, 1990, EXP CELL RES, V187, P299, DOI 10.1016/0014-4827(90)90095-R; Prabakaran D, 1999, J CELL SCI, V112, P1247; PRABAKARAN D, 1993, J BIOL CHEM, V268, P9041; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Puertollano R, 1999, MOL BIOL CELL, V10, P3435, DOI 10.1091/mbc.10.10.3435; Puertollano R, 1999, J CELL BIOL, V145, P141, DOI 10.1083/jcb.145.1.141; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Zhang XQ, 2000, J BIOL CHEM, V275, P31946, DOI 10.1074/jbc.M003559200; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031; ZURZOLO C, 1992, J CELL BIOL, V117, P551, DOI 10.1083/jcb.117.3.551; ZURZOLO C, 1994, EMBO J, V13, P42, DOI 10.1002/j.1460-2075.1994.tb06233.x	57	27	27	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41074	41081		10.1074/jbc.M005429200	http://dx.doi.org/10.1074/jbc.M005429200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11013241	hybrid			2022-12-25	WOS:000166114600056
J	Oshiro, J; Rangaswamy, S; Chen, XM; Han, GS; Quinn, JE; Carman, GM				Oshiro, J; Rangaswamy, S; Chen, XM; Han, GS; Quinn, JE; Carman, GM			Regulation of the DPP1-encoded diacylglycerol pyrophosphate (DGPP) phosphatase by inositol and growth phase - Inhibition of DGPP phosphatase activity by CDP-diacylglycerol and activation of phosphatidylserine synthase activity by DGPP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE METHYLATION PATHWAY; AFFECTING MITOCHONDRIAL DEVELOPMENT; YEAST SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPID BIOSYNTHESIS; TRANSFER PROTEIN; PHOSPHATIDYLGLYCEROLPHOSPHATE SYNTHASE; MYO-INOSITOL-1-PHOSPHATE SYNTHASE; PHOSPHATIDYLINOSITOL SYNTHASE; FUNCTIONAL-CHARACTERIZATION; COORDINATE REGULATION	The regulation of the Saccharomyces cerevisiae DPP1-encoded diacylglycerol pyrophosphate (DGPP) phosphatase by inositol supplementation and growth phase was examined. Addition of inositol to the growth medium resulted in a dose-dependent increase in the level of DGPP phosphatase activity in both exponential and stationary phase cells. Activity was greater in stationary phase cells when compared with exponential phase cells, and the inositol- and growth phase-dependent regulations of DGPP phosphatase were additive. Analyses of DG;PP phosphatase mRNA and protein levels, and expression of beta -galactosidase activity driven by a P-DPP1-lacZ reporter gene, indicated that a transcriptional mechanism was responsible for this regulation. Regulation of DGPP phosphatase by inositol and growth phase occurred in a manner that was opposite that of many phospholipid biosynthetic enzymes. Regulation of DGPP phosphatase expression by inositol supplementation, but not growth phase, was altered in opi1 Delta, ino2 Delta, and ino4 Delta phospholipid synthesis regulatory mutants. CDP-diacylglycerol, a phospholipid pathway intermediate used for the synthesis of phosphatidylserine and phosphatidylinositol, inhibited DGPP phosphatase activity by a mixed mechanism that caused an increase in K-m and a decrease in V-max. DGPP stimulated the activity of pure phosphatidylserine synthase by a mechanism that increased the affinity of the enzyme for its substrate CDP-diacylglycerol, Phospholipid composition analysis of a dpp1 Delta mutant showed that DGPP phosphatase played a role in the regulation of phospholipid metabolism by inositol, as well as regulating the cellular levels of phosphatidylinositol.	Rutgers State Univ, New Jersey Agr Expt Stn, Cook Coll, Dept Food Sci, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, New Jersey Agr Expt Stn, Cook Coll, Dept Food Sci, 65 Dudley Rd, New Brunswick, NJ 08901 USA.		Oshiro, June/ACF-4163-2022	Oshiro, June/0000-0003-1134-5023	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028140, R01GM028140] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28140] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; Anderson MS, 1996, J BIOL CHEM, V271, P26596, DOI 10.1074/jbc.271.43.26596; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BAELEE M, 1990, J BIOL CHEM, V265, P7221; BAELEE MS, 1984, J BIOL CHEM, V259, P857; BAILIS AM, 1992, NUCLEIC ACIDS RES, V20, P1411, DOI 10.1093/nar/20.6.1411; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; Balboa MA, 1999, J BIOL CHEM, V274, P522, DOI 10.1074/jbc.274.1.522; BECKER GW, 1977, J BIOL CHEM, V252, P8684; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CARMAN GM, 1992, METHOD ENZYMOL, V209, P305; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CARMAN GM, 1989, PHOSPHATIDYLCHOLINE, P165; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; CRAVEN GR, 1965, J BIOL CHEM, V240, P2468; CULBERTSON MR, 1976, J BACTERIOL, V126, P232, DOI 10.1128/JB.126.1.232-242.1976; CULBERTSON MR, 1976, J BACTERIOL, V126, P243, DOI 10.1128/JB.126.1.243-250.1976; CULBERTSON MR, 1975, GENETICS, V80, P23; DEANJOHNSON M, 1989, J BIOL CHEM, V264, P1274; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; Furneisen JM, 2000, BBA-MOL CELL BIOL L, V1484, P71, DOI 10.1016/S1388-1981(99)00202-4; GAYNOR PM, 1991, J BACTERIOL, V173, P6124, DOI 10.1128/jb.173.19.6124-6131.1991; Graves JA, 2000, GENETICS, V154, P1485; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; GREENBERG ML, 1982, MOL GEN GENET, V186, P157, DOI 10.1007/BF00331845; GREENBERG ML, 1988, MOL CELL BIOL, V8, P4773, DOI 10.1128/MCB.8.11.4773; HAID A, 1983, METHOD ENZYMOL, V96, P192; HAMAMATSU S, 1994, FEBS LETT, V348, P33, DOI 10.1016/0014-5793(94)00576-1; Harlow E., 1988, ANTIBODIES LAB MANUA; Henry S. A., 1982, MOL BIOL YEAST SACCH, P101; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HENRY SA, 1977, J BACTERIOL, V130, P472, DOI 10.1128/JB.130.1.472-484.1977; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOMANN MJ, 1987, J BACTERIOL, V169, P3276, DOI 10.1128/jb.169.7.3276-3280.1987; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; Jiang F, 1999, MOL MICROBIOL, V31, P373, DOI 10.1046/j.1365-2958.1999.01181.x; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; Kim KS, 1999, J BIOL CHEM, V274, P14857, DOI 10.1074/jbc.274.21.14857; KLIG LS, 1984, P NATL ACAD SCI-BIOL, V81, P3816, DOI 10.1073/pnas.81.12.3816; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KLIG LS, 1988, J BACTERIOL, V170, P1878, DOI 10.1128/jb.170.4.1878-1886.1988; KODAKI T, 1987, J BIOL CHEM, V262, P15428; KODAKI T, 1989, EUR J BIOCHEM, V185, P243, DOI 10.1111/j.1432-1033.1989.tb15109.x; KODAKI T, 1991, J BACTERIOL, V173, P7992, DOI 10.1128/jb.173.24.7992-7995.1991; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTENBERG D, 1983, BIOCHIM BIOPHYS ACTA, V737, P285, DOI 10.1016/0304-4157(83)90004-7; LOEWY BS, 1984, MOL CELL BIOL, V4, P2479, DOI 10.1128/MCB.4.11.2479; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MCGRAW P, 1989, GENETICS, V122, P317; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; Munnik T, 2000, PLANT J, V22, P147, DOI 10.1046/j.1365-313x.2000.00725.x; Munnik T, 1996, J BIOL CHEM, V271, P15708, DOI 10.1074/jbc.271.26.15708; Munnik T, 1998, BBA-LIPID LIPID MET, V1389, P222, DOI 10.1016/S0005-2760(97)00158-6; Murray M, 1997, MOL MICROBIOL, V25, P541, DOI 10.1046/j.1365-2958.1997.4881840.x; Murray M, 2000, MOL MICROBIOL, V36, P651, DOI 10.1046/j.1365-2958.2000.01886.x; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; NIKOLOFF DM, 1994, J BIOL CHEM, V269, P7402; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; Pical C, 1999, J BIOL CHEM, V274, P38232, DOI 10.1074/jbc.274.53.38232; POOLE MA, 1986, J BACTERIOL, V168, P668, DOI 10.1128/jb.168.2.668-672.1986; Riedel B, 1997, PLANT SCI, V128, P1, DOI 10.1016/S0168-9452(97)00120-9; ROBSON RJ, 1983, ACCOUNTS CHEM RES, V16, P251, DOI 10.1021/ar00091a003; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Segel IH, 1975, ENZYME KINETICS BEHA; Shen HF, 1998, J BIOL CHEM, V273, P11638, DOI 10.1074/jbc.273.19.11638; SUMMERS EF, 1988, GENETICS, V120, P909; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Toke DA, 1998, J BIOL CHEM, V273, P3278, DOI 10.1074/jbc.273.6.3278; Toke DA, 1998, J BIOL CHEM, V273, P14331, DOI 10.1074/jbc.273.23.14331; Toke DA, 1999, BIOCHEMISTRY-US, V38, P14606, DOI 10.1021/bi991472x; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; WHITE MJ, 1991, J BIOL CHEM, V266, P863; WISSING JB, 1993, FEBS LETT, V315, P95, DOI 10.1016/0014-5793(93)81141-L; Wu WI, 1996, J BIOL CHEM, V271, P1868, DOI 10.1074/jbc.271.4.1868; Xie ZG, 1998, P NATL ACAD SCI USA, V95, P12346, DOI 10.1073/pnas.95.21.12346; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503	95	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40887	40896		10.1074/jbc.M008144200	http://dx.doi.org/10.1074/jbc.M008144200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11016943	hybrid			2022-12-25	WOS:000166114600031
J	Pruitt, K; Pestell, RG; Der, CJ				Pruitt, K; Pestell, RG; Der, CJ			Ras inactivation of the retinoblastoma pathway by distinct mechanisms in NIH 3T3 fibroblast and RIE-1 epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN D1; DOWN-REGULATION; KINASE CASCADE; G(1) PROGRESSION; S-PHASE; TRANSFORMATION; PROTEIN; EXPRESSION; GROWTH; ACTIVATION	Although Ras and Raf cause transformation of NIH 3T3 fibroblasts, only Ras causes transformation of RIE-1 intestinal epithelial cells. To determine if the inability of Raf to transform RIE-1 cells is due to a failure to deregulate cell cycle progression, we evaluated the consequences of sustained Ras and Raf activation on steady state levels of cyclin D1, p21(CIP/WAF), and p27(KIP1). Both Ras- and Raf-transformed NIH 3T3 cells showed up-regulated expression of cyclin D1, p21, and p27 protein, increased retinoblastoma (Rb) hyperphosphorylation, and increased activation of E2F-mediated transcription. Similarly, Ras transformed RIE-1 cells also showed upregulation of cyclin D1, p21, and hyperphosphorylated Rb, In contrast, Ras-mediated down-regulation of p27 was seen in RIE-1 cells. Conversely, stable expression of activated Raf alone caused only a partial up-regulation of p21 and Rb hyperphosphorylation but no activation of E2F-responsive transcription or down-regulation of p27 in RIE-1 cells. Moreover, we found that the AP-I site was dispensable for Ras-mediated stimulation of the cyclin-D1 promoter in NIH 3T3 cells but was essential for Ras-mediated stimulation in RIE-1 cells. Thus, up-regulation of p21, rather than the down-regulation seen in previous transient expression studies, is seen with sustained Ras activation. Additionally, p27 may serve a positive (NIH 3T3) or negative (RIE-1) regulatory role in Ras transformation that is cell type-dependent. The involvement of Raf and phosphatidylinositol 3-kinase in mediating Ras changes in cyclin D1, pal, and p27 was also very distinct in NIH 3T3 and RIE-1 cells. Taken together, these results demonstrate the importance of Raf-independent pathways in mediating oncogenic Ras deregulation of cell cycle progression in epithelial cells.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Albert Einstein Canc Ctr, Dept Med, Bronx, NY 10461 USA; Albert Einstein Canc Ctr, Dept Dev & Mol Biol, Bronx, NY 10461 USA	University of North Carolina; University of North Carolina Chapel Hill; Yeshiva University; Yeshiva University	Der, CJ (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, CB 7295, Chapel Hill, NC 27599 USA.			Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA55008, CA63071, CA42978] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055008, R01CA063071, R01CA042978] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Arber N, 1996, ONCOGENE, V12, P1903; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BOS JL, 1989, CANCER RES, V49, P4682; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Downward J, 1997, CURR BIOL, V7, P258; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; FILMUS J, 1994, ONCOGENE, V9, P3627; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; Florenes VA, 1996, ONCOGENE, V13, P2447; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; Michieli P, 1996, ONCOGENE, V12, P775; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Phelps DE, 1997, METHOD ENZYMOL, V283, P194; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Rivard N, 1999, AM J PHYSIOL-CELL PH, V277, pC652, DOI 10.1152/ajpcell.1999.277.4.C652; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586; YANG JJ, 1996, MOL CELL BIOL, V16, P3370; YEN A, 1994, EUR J CELL BIOL, V65, P103	57	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40916	40924		10.1074/jbc.M006682200	http://dx.doi.org/10.1074/jbc.M006682200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007784	hybrid, Green Published			2022-12-25	WOS:000166114600035
J	Patel, PH; Loeb, LA				Patel, PH; Loeb, LA			Multiple amino acid substitutions allow DNA polymerases to synthesize RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I KLENOW FRAGMENT; REVERSE-TRANSCRIPTASE; TERNARY COMPLEXES; CRYSTAL-STRUCTURE; SINGLE RESIDUE; PURIFICATION; SITE	DNA and RNA polymerase exhibit similarities in structures and catalytic mechanisms, suggesting that both classes of enzymes are evolutionarily related. To probe the biochemical and structure-function relationship between the two classes of polymerases, a large library (200,000 members) of mutant Thermus aquaticus DNA polymerase I (Taq pol I) was created containing random substitutions within a portion of the dNTP binding site (motif A; amino acids 605-617), and a fraction of all selected active Tag pol I (291 of 8000) was tested for the ability to incorporate successive ribonucleotides; 23 unique mutants that added rNTPs into a growing polynucleotide chain were identified and sequenced. These mutants, each containing one to four substitutions, incorporate ribonucleotides at a efficiency approaching 10(3)-fold greater than that of wild type Tag pol I. Several mutants added successive ribonucleotides and thus can catalyze the synthesis of RNA. Sequence analysis of these mutants demonstrates that at least two amino acid residues are involved in excluding ribonucleotides from the active site. Interestingly, wild type DNA polymerases from several distinct families selectively discriminate against rUTP. This study suggests that current DNA and RNA polymerases could have evolved by divergent evolution from an ancestor that shared a common mechanism for polynucleotide synthesis.	Univ Washington, Sch Med, Dept Pathol, Joseph Gottstein Mem Canc Lab, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Loeb, LA (corresponding author), Univ Washington, Sch Med, Dept Pathol, Joseph Gottstein Mem Canc Lab, Seattle, WA 98195 USA.	laloeb@u.washington.edu			NATIONAL CANCER INSTITUTE [R35CA039903, R01CA078885] Funding Source: NIH RePORTER; NCI NIH HHS [R35CA39903, CA78885] Funding Source: Medline; PHS HHS [5T3207266] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Astatke M, 1998, P NATL ACAD SCI USA, V95, P3402, DOI 10.1073/pnas.95.7.3402; BARNES WM, 1978, J MOL BIOL, V119, P83, DOI 10.1016/0022-2836(78)90271-1; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; Bonnin A, 1999, J MOL BIOL, V290, P241, DOI 10.1006/jmbi.1999.2900; BONURA T, 1982, BIOCHEMISTRY-US, V21, P2548, DOI 10.1021/bi00539a039; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DESAI UJ, 1995, BIOTECHNIQUES, V19, P780; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; DUNCAN BK, 1982, J BACTERIOL, V151, P750, DOI 10.1128/JB.151.2.750-755.1982; ENGELKE DR, 1990, ANAL BIOCHEM, V191, P396, DOI 10.1016/0003-2697(90)90238-5; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; GRIMM E, 1995, NUCLEIC ACIDS RES, V23, P4518, DOI 10.1093/nar/23.21.4518; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Joyce GF, 1996, CURR BIOL, V6, P965, DOI 10.1016/S0960-9822(02)00640-1; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; Kornberg A., 1992, DNA REPLICATION; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; Moreira LM, 1997, ARCH MICROBIOL, V168, P92, DOI 10.1007/s002030050474; OLIVERA BM, 1979, J MOL BIOL, V128, P265, DOI 10.1016/0022-2836(79)90087-1; Patel PH, 2000, P NATL ACAD SCI USA, V97, P5095, DOI 10.1073/pnas.97.10.5095; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361	28	84	89	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40266	40272		10.1074/jbc.M005757200	http://dx.doi.org/10.1074/jbc.M005757200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11005812	hybrid			2022-12-25	WOS:000166039500065
J	Larouche, K; Leclerc, S; Salesse, C; Guerin, SL				Larouche, K; Leclerc, S; Salesse, C; Guerin, SL			Expression of the alpha(5) integrin subunit gene promoter is positively regulated by the extracellular matrix component fibronectin through the transcription factor Sp1 in corneal epithelial cells in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; DNA-BINDING; BASEMENT-MEMBRANE; GROWTH-FACTOR; 5-FLANKING REGION; ONCOSTATIN M; RECEPTOR; KINASE; SITE; PHOSPHORYLATION	The accumulation of fibronectin (FN) in response to corneal epithelium injury has been postulated to turn on expression of the FN-binding integrin alpha (5)beta (1). In this work, we determined whether the activity directed by the ct, gene promoter can be modulated by FN in rabbit corneal epithelial cells (RCEC). The activity driven by chloramphenicol acetyltransferase/alpha (5) promoter-bearing plasmids was drastically increased when transfected into RCEC grown on FN-coated culture dishes. The promoter sequence mediating FN responsiveness was shown to bear a perfect inverted repeat that we designated the fibronectin-responsive element (FRE). Analyses in electrophoretic mobility shift assays provided evidence that Spl is the predominant transcription factor binding the FRE. Its DNA binding affinity was found to be increased when RCEC are grown on FN-coated dishes. The addition of the MER kinase inhibitor PD98059 abolished FN responsiveness suggesting that alteration in the state of phosphorylation of Spl likely accounts for its increased binding to the a, FRE. The FRE also proved sufficient to confer FN responsiveness to an otherwise unresponsive heterologous promoter. However, site-directed mutagenesis indicated that only the 3 ' half-site of the FRE was required to direct FN responsiveness. Collectively, binding of FN to its alpha (5)beta (1) integrin activates a signal transduction pathway that results in the transcriptional activation of the alpha (5) gene likely through altering the phosphorylation state of Sp1.	CHU Laval, Res Ctr, Oncol & Mol Endocrinol Res Ctr, Quebec City, PQ G1V 4G2, Canada; CHU Laval, CHUQ, Ophthalmol Res Unit, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University; Laval University	Guerin, SL (corresponding author), CHU Laval, Res Ctr, Oncol & Mol Endocrinol Res Ctr, 2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	Sylvain.guerin@crchul.ulaval.ca		Salesse, Christian/0000-0003-1795-7338; Guerin, Sylvain/0000-0002-6767-5833				Alroy I, 1999, MOL CELL BIOL, V19, P1961; ARAKI K, 1994, CURR EYE RES, V13, P203, DOI 10.3109/02713689408995778; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; BALDWIN TJ, 1989, NATURE, V341, P716, DOI 10.1038/341716a0; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BOISJOLY HM, 1993, EXP EYE RES, V57, P293, DOI 10.1006/exer.1993.1127; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; CAI XX, 1993, INVEST OPHTH VIS SCI, V34, P3585; CHEN QM, 1994, J BIOL CHEM, V269, P26602; DALTON SL, 1992, J BIOL CHEM, V267, P8186; DEVRIES E, 1987, EMBO J, V6, P161, DOI 10.1002/j.1460-2075.1987.tb04734.x; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ESKILD W, 1994, MOL ENDOCRINOL, V8, P732, DOI 10.1210/me.8.6.732; ESPAILLAT A, 1994, CURR EYE RES, V13, P325, DOI 10.3109/02713689409167295; FUJIKAWA LS, 1981, LAB INVEST, V45, P120; FUJIKAWA LS, 1984, J CELL BIOL, V98, P128, DOI 10.1083/jcb.98.1.128; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GARANA RMR, 1992, INVEST OPHTH VIS SCI, V33, P3271; Giancotti FG, 2000, NAT CELL BIOL, V2, pE13, DOI 10.1038/71397; GUERIN SL, 1990, J BIOL CHEM, V265, P22035; Gundorova R A, 1994, Eur J Ophthalmol, V4, P202; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUANG S, 1994, J CELL PHYSIOL, V161, P470, DOI 10.1002/jcp.1041610310; HUMPHRIES MJ, 1989, CANCER INVEST, V7, P373, DOI 10.3109/07357908909039866; HYNES RO, 1986, SCI AM, V254, P42, DOI 10.1038/scientificamerican0686-42; Laniel MA, 1997, BIOCHEM CELL BIOL, V75, P427, DOI 10.1139/bcb-75-4-427; Li C, 1999, J BIOL CHEM, V274, P6747, DOI 10.1074/jbc.274.10.6747; Lin CS, 1997, DNA CELL BIOL, V16, P929, DOI 10.1089/dna.1997.16.929; Liu JW, 1997, J LIPID RES, V38, P2035; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; MILLS JS, 1987, EMBO J, V6, P3711, DOI 10.1002/j.1460-2075.1987.tb02705.x; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MOORADIAN DL, 1993, INVEST OPHTH VIS SCI, V34, P153; MURAKAMI J, 1992, J LAB CLIN MED, V120, P86; Nakamura M, 1997, EXP EYE RES, V64, P1043, DOI 10.1006/exer.1997.0302; NISHIDA T, 1988, INVEST OPHTH VIS SCI, V29, P1820; NISHIDA T, 1990, J CELL PHYSIOL, V145, P549, DOI 10.1002/jcp.1041450323; OHagan RC, 1996, ONCOGENE, V13, P1323; Omigbodun A, 1998, ENDOCRINOLOGY, V139, P2190, DOI 10.1210/en.139.4.2190; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; Rajagopal S, 1997, J CELL PHYSIOL, V170, P138, DOI 10.1002/(SICI)1097-4652(199702)170:2<138::AID-JCP5>3.0.CO;2-P; REGNAULT V, 1990, REV FR TRANSFUS HEM, V33, P391, DOI 10.1016/S1140-4639(05)80056-5; Reim M, 1997, PROG RETIN EYE RES, V16, P183, DOI 10.1016/S1350-9462(96)00031-6; ROBIDOUX S, 1992, MOL CELL BIOL, V12, P3796, DOI 10.1128/MCB.12.9.3796; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; ROY RJ, 1991, BIOTECHNIQUES, V11, P770; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SAIKA S, 1993, CORNEA, V12, P383, DOI 10.1097/00003226-199309000-00003; SCHNEIDER R, 1986, NUCLEIC ACIDS RES, V14, P1303, DOI 10.1093/nar/14.3.1303; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SRAMEK SJ, 1987, INVEST OPHTH VIS SCI, V28, P500; Stepp MA, 1997, J HISTOCHEM CYTOCHEM, V45, P189, DOI 10.1177/002215549704500205; Stepp MA, 1996, INVEST OPHTH VIS SCI, V37, P1593; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; SUSKE G, 2000, METHOD MOL BIOL, V130, P176; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tuori A, 1996, CORNEA, V15, P286, DOI 10.1097/00003226-199605000-00010; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZHU L, 1996, INVEST OPHTH VIS SCI, V37, pS1011; Zutter MM, 1997, BLOOD, V90, P678, DOI 10.1182/blood.V90.2.678.678_678_689	63	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39182	39192		10.1074/jbc.M002945200	http://dx.doi.org/10.1074/jbc.M002945200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995740	hybrid			2022-12-25	WOS:000165953100034
J	Mueller, HT; Borg, JP; Margolis, B; Turner, RS				Mueller, HT; Borg, JP; Margolis, B; Turner, RS			Modulation of amyloid precursor protein metabolism by X11 alpha/Mint-1 - A deletion analysis of protein-protein interaction domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN; INTRACELLULAR DOMAIN; NMDA RECEPTOR; FE65 PROTEIN; X11 PROTEIN; COMPLEX; FAMILY; ASSOCIATION; SECRETION; HOMOLOG	Modulation of amyloid precursor protein (APP) metabolism plays a pivotal role in the pathogenesis of Alzheimer's disease. The phosphotyrosine-binding/protein interaction (PTB/PI) domain of X11 alpha, a neuronal cytosolic adaptor protein, binds to the YENPTY sequence in the cytoplasmic carboxyl terminus of APP. This interaction prolongs the half-life of APP and inhibits A beta 40 and A beta 42 secretion. X11 alpha /Mint-1 has multiple protein-protein interaction domains, a (M) under bar unc-18 (int) under bar eraction domain (MID), a Cask/Lin-2 interaction domain (CID), a PTB/PI domain, and two PDZ domains. These X11 alpha protein interaction domains may modulate its effect on APP processing. To test this hypothesis, we performed a deletion analysis of X11 alpha: effects on metabolism of APP,,, Swedish (K595N/M596L) (APP,) by transient cotransfection of HEK 293 cells with: 1) X11 alpha (X11 alpha -wt, N-MID-CID-PTB-PDZ-PDZ-C), 2) amino-terminal deletion (X11 alpha-DeltaN, PTB-PDZ-PDZ), 3) carboxyl-terminal deletion (X11 alpha-Delta PDZ, MID-CID-PTB), or 4) deletion of both termini (PTB domain only, PTB), The carboxyl terminus of X11 alpha was required for stabilization of APP, in cells. In contrast, the amino terminus of X11 alpha was required to stimulate APPs secretion. X11 alpha, X11 alpha-DeltaN, and X11 alpha -PTB, but not X11 alpha-Delta PDZ, were effective inhibitors of A beta 40 and A beta 42 secretion. These results suggest that additional protein interaction domains of X11 alpha modulate various aspects of APP metabolism.	Univ Michigan, Med Ctr, Program Neurosci, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Neurol, Ann Arbor, MI 48109 USA; Vet Adm Med Ctr, GRECC, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Turner, RS (corresponding author), Vet Adm Med Ctr, GRECC, 2215 Fuller Rd, Ann Arbor, MI 48105 USA.	raymondt@umich.edu	Borg, Jean-Paul/AAX-8096-2020; Turner, Raymond Scott/G-2263-2011	Borg, Jean-Paul/0000-0001-8418-3382; Turner, Raymond Scott/0000-0001-7534-2935	NATIONAL INSTITUTE ON AGING [P50AG008671] Funding Source: NIH RePORTER; NIA NIH HHS [P50 AG08671, P50 AG008671] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1999, J NEUROSCI, V19, P1307; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Bredt DS, 1998, CELL, V94, P691, DOI 10.1016/S0092-8674(00)81727-4; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Davis GW, 2000, NEURON, V26, P551, DOI 10.1016/S0896-6273(00)81190-3; De Strooper B, 2000, J CELL SCI, V113, P1857; Duilio A, 1998, BIOCHEM J, V330, P513, DOI 10.1042/bj3300513; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Feng J, 2000, P NATL ACAD SCI USA, V97, P9287, DOI 10.1073/pnas.97.16.9287; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Forman MS, 1997, J BIOL CHEM, V272, P32247, DOI 10.1074/jbc.272.51.32247; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Guenette SY, 1999, J NEUROCHEM, V73, P985, DOI 10.1046/j.1471-4159.1999.0730985.x; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Homayouni R, 1999, J NEUROSCI, V19, P7507, DOI 10.1523/JNEUROSCI.19-17-07507.1999; Ide N, 1998, BIOCHEM BIOPH RES CO, V244, P258, DOI 10.1006/bbrc.1998.8243; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lee DS, 2000, J BIOL CHEM, V275, P23134, DOI 10.1074/jbc.C000302200; MARTIN BL, 1995, J BIOL CHEM, V270, P26727, DOI 10.1074/jbc.270.45.26727; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; McLoughlin DM, 1999, EUR J NEUROSCI, V11, P1988, DOI 10.1046/j.1460-9568.1999.00610.x; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; Perez RG, 1997, J NEUROSCI, V17, P9407; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Rao A, 2000, NAT NEUROSCI, V3, P747, DOI 10.1038/77636; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Tanahashi H, 1999, BIOCHEM BIOPH RES CO, V255, P663, DOI 10.1006/bbrc.1999.0265; Tanahashi H, 1999, NEUROREPORT, V10, P2575, DOI 10.1097/00001756-199908200-00025; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Torroja L, 1999, J NEUROSCI, V19, P7793; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; Whitfield CW, 1999, MOL BIOL CELL, V10, P2087, DOI 10.1091/mbc.10.6.2087; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399; Zhang ZT, 1997, EMBO J, V16, P6141, DOI 10.1093/emboj/16.20.6141	48	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39302	39306		10.1074/jbc.M008453200	http://dx.doi.org/10.1074/jbc.M008453200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11010978	hybrid			2022-12-25	WOS:000165953100050
J	Overall, CM; Tam, E; McQuibban, GA; Morrison, C; Wallon, UM; Bigg, HF; King, AE; Roberts, CR				Overall, CM; Tam, E; McQuibban, GA; Morrison, C; Wallon, UM; Bigg, HF; King, AE; Roberts, CR			Domain interactions in the gelatinase A center dot TIMP-2 center dot MT1-MMP activation complex - The ectodomain of the 44-kDa form of membrane type-I matrix metalloproteinase does not modulate gelatinase A activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; HUMAN 72-KDA GELATINASE; HIGH-AFFINITY BINDING; HEMOPEXIN-LIKE DOMAIN; 72 KDA PROGELATINASE; TISSUE INHIBITOR; CELL-SURFACE; EXTRACELLULAR-MATRIX; FULL-LENGTH; CRYSTAL-STRUCTURE	On the cell surface, the 59-kDa membrane type I-matrix metalloproteinase (MT1-MMP) activates the 72-kDa progelatinase A (MMP-2) after binding the tissue inhibitor of metalloproteinases (TIMP)-2, A 44-kDa remnant of MT1-MMP, with an N terminus at Gly(285), is also present on the cell after autolytic shedding of the catalytic domain from the hemopexin carboxyl (C) domain, but its role in gelatinase A activation is unknown. We investigated intermolecular interactions in the gelatinase A activation complex using recombinant proteins, domains, and peptides, yeast two-hybrid analysis, solid- and solution-phase assays, cell culture, and immunocytochemistry, A strong interaction between the TIMP-2 C domain (Glu(153)-Pro(221)) and the gelatinase A hemopexin C domain (Gly(446)-Cys(660)) was demonstrated by the yeast two-hybrid system, Epitope masking studies showed that the anionic TIMP-2 C tail lost immunoreactivity after binding, indicating that the tail was buried in the complex. Using recombinant MT1-MMP hemopexin C domain (Gly(285)-Cys(508)), no direct role for the 44-kDa form of MT1-MMP in cell surface activation of progelatinase A was found, Exogenous hemopexin C domain of gelatinase A, but not that of MT1-MMP, blocked the cleavage of the 68-kDa gelatinase A activation intermediate to the fully active 66-kDa enzyme by concanavalin A-stimulated cells. The MT1-MMP hemopexin C domain did not form homodimers nor did it bind the gelatinase A hemopexin C domain, the C tail of TIMP-2, or full-length TIMP-2, Hence, the ectodomain of the remnant 44-kDa form of MT1-MMP appears to play little if any role in the activation of gelatinase A favoring the hypothesis that it accumulates on the cell surface as an inactive, stable degradation product.	Univ British Columbia, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Overall, CM (corresponding author), Univ British Columbia, Dept Oral Biol & Med Sci, 2199 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.							Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; AZZAM HS, 1992, CANCER RES, V52, P4540; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; CRABBE T, 1993, EUR J BIOCHEM, V218, P431, DOI 10.1111/j.1432-1033.1993.tb18393.x; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; Ellerbroek SM, 1999, CANCER RES, V59, P1635; EMMERTBUCK MR, 1995, FEBS LETT, V364, P28, DOI 10.1016/0014-5793(95)00345-A; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; Gilles C, 1997, LAB INVEST, V76, P651; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Higashi S, 1999, J BIOL CHEM, V274, P10497, DOI 10.1074/jbc.274.15.10497; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; Hutton M, 1998, BIOCHEMISTRY-US, V37, P10094, DOI 10.1021/bi980616p; Itoh Y, 1998, J BIOL CHEM, V273, P24360, DOI 10.1074/jbc.273.38.24360; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; LIBSON AM, 1995, NAT STRUCT BIOL, V2, P938, DOI 10.1038/nsb1195-938; Miller J.H., 1972, EXPT MOL GENETICS; Morrison CJ, 1997, BIOTECHNOL BIOENG, V53, P594, DOI 10.1002/(SICI)1097-0290(19970320)53:6<594::AID-BIT7>3.3.CO;2-M; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Olsen M.W., 1997, J BIOL CHEM, V272, P29975; Overall CM, 1999, J BIOL CHEM, V274, P4421, DOI 10.1074/jbc.274.7.4421; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Stanton H, 1998, J CELL SCI, V111, P2789; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; Steffensen B, 1998, J BIOL CHEM, V273, P20622, DOI 10.1074/jbc.273.32.20622; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WILCHEK M, 1980, BIOCHEM BIOPH RES CO, V92, P1215, DOI 10.1016/0006-291X(80)90416-7; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Wingfield PT, 1999, J BIOL CHEM, V274, P21362, DOI 10.1074/jbc.274.30.21362; ZUCKER S, 1990, INT J CANCER, V45, P1137, DOI 10.1002/ijc.2910450625	52	82	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39497	39506		10.1074/jbc.M005932200	http://dx.doi.org/10.1074/jbc.M005932200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10991943	hybrid			2022-12-25	WOS:000165953100076
J	Ram, PK; Waxman, DJ				Ram, PK; Waxman, DJ			Role of the cytokine-inducible SH2 protein CIS in desensitization of STAT5b signaling by continuous growth hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOCS-BOX MOTIF; TYROSINE PHOSPHORYLATION; RAT-LIVER; SEXUAL DIMORPHISM; GENE-EXPRESSION; CYTOPLASMIC DOMAIN; BINDING PROTEIN; DOWN-REGULATION; GH RECEPTOR; ACTIVATION	Growth hormone (GH)-inducible suppressors of cytokine signaling (SOCS/CIS proteins) inhibit GH receptor (GHR) signaling to STAT5b via phosphotyrosine-dependent binding interactions with the tyrosine kinase JAK2 (SOCS-1) and/or the cytoplasmic tail of GHR (CIS and SOCS-3). Presently, we investigate the mechanism of CLS inhibition and CIS's role in down-regulating GHR JAK2 signaling to STAT5b in cells exposed to GH continuously, CLS is shown to inhibit GHR-JAK2 signaling by two distinct mechanisms: by a partial inhibition that is decreased at elevated STAT5b levels and may involve competition between CLS and STAT5b for common GHR cytoplasmic tail phosphotyrosine-binding sites; and by a time-dependent inhibition, not seen with SOCS-1 or SOCS-3, that involves proteasome action. Investigation of the latter mechanism revealed that GH stimulates degradation of CIS, but not SOCS-3, The proteasome inhibitor MG132 blocked this protein degradation and also blocked the inhibitory action of CIS, but not that of SOCS-1 or SOCS-3, on STAT5b signaling. Proteasome-dependent degradation of CIS, most likely in the form of a (GHR-JAK2)-CIS complex, is therefore proposed to be an important step in the time-dependent CIS inhibition mechanism. Finally, the down-regulation of GHR-JAK2 signaling to STAT5b seen in continuous GH-treated cells could be prevented by treatment of cells with the proteasome inhibitor MG132 or by expression of CIS-R107K, a selective, dominant-negative inhibitor of CIS activity. These findings lead us to propose that the cytokine signaling inhibitor CIS is a key mediator of the STAT5b desensitization response seen in cells and tissues exposed to GH chronically, such as adult female rat liver.	Boston Univ, Dept Biol, Div Cell & Mol Biol, Boston, MA 02215 USA	Boston University	Waxman, DJ (corresponding author), Boston Univ, Dept Biol, Div Cell & Mol Biol, 5 Cummington St, Boston, MA 02215 USA.			Waxman, David/0000-0001-7982-9206	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033765] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK033765, DK33765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; ALLEVATO G, 1995, J BIOL CHEM, V270, P17210, DOI 10.1074/jbc.270.29.17210; Aman MJ, 1999, J BIOL CHEM, V274, P30266, DOI 10.1074/jbc.274.42.30266; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; Choi HK, 1999, ENDOCRINOLOGY, V140, P5126, DOI 10.1210/en.140.11.5126; Choi HK, 2000, ENDOCRINOLOGY, V141, P3245, DOI 10.1210/en.141.9.3245; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Davey HW, 1999, AM J HUM GENET, V65, P959, DOI 10.1086/302599; Davey HW, 1999, J BIOL CHEM, V274, P35331, DOI 10.1074/jbc.274.50.35331; Davey HW, 1999, MOL CELL ENDOCRINOL, V158, P111, DOI 10.1016/S0303-7207(99)00175-6; Fernandez L, 1998, ENDOCRINOLOGY, V139, P1815, DOI 10.1210/en.139.4.1815; Ganguly TC, 1997, J CLIN INVEST, V99, P2906, DOI 10.1172/JCI119485; Gebert CA, 1999, MOL ENDOCRINOL, V13, P213, DOI 10.1210/me.13.2.213; Gebert CA, 1999, MOL ENDOCRINOL, V13, P38, DOI 10.1210/me.13.1.38; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Hackett RH, 1997, J BIOL CHEM, V272, P11128; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Hansen JA, 1997, J MOL ENDOCRINOL, V18, P213, DOI 10.1677/jme.0.0180213; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; JANSSON JO, 1985, ENDOCR REV, V6, P128, DOI 10.1210/edrv-6-2-128; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Karlsson H, 1999, MOL CELL ENDOCRINOL, V154, P37, DOI 10.1016/S0303-7207(99)00101-X; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Maamra M, 1999, J BIOL CHEM, V274, P14791, DOI 10.1074/jbc.274.21.14791; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 1999, MOL CELL BIOL, V19, P6396; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Okabe S, 1999, EXP HEMATOL, V27, P1542, DOI 10.1016/S0301-472X(99)00094-6; Park SH, 1999, J BIOL CHEM, V274, P7421, DOI 10.1074/jbc.274.11.7421; Pezet A, 1999, J BIOL CHEM, V274, P24497, DOI 10.1074/jbc.274.35.24497; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tollet-Egnell P, 1999, ENDOCRINOLOGY, V140, P3693, DOI 10.1210/en.140.8.3693; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Vleurick L, 1999, MOL ENDOCRINOL, V13, P1823, DOI 10.1210/me.13.11.1823; Wang XZ, 1996, MOL ENDOCRINOL, V10, P1249, DOI 10.1210/me.10.10.1249; Waxman D J, 2000, Novartis Found Symp, V227, P61; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; Waxman DJ, 2000, PRINCIPLES OF MOLECULAR REGULATION, P55; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yi WS, 1996, MOL ENDOCRINOL, V10, P1425, DOI 10.1210/me.10.11.1425; Yoshimura A, 1998, CYTOKINE GROWTH F R, V9, P197, DOI 10.1016/S1359-6101(98)00019-7; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	60	91	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39487	39496		10.1074/jbc.M004755200	http://dx.doi.org/10.1074/jbc.M004755200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10991939	hybrid			2022-12-25	WOS:000165953100075
J	Pani, G; Colavitti, R; Bedogni, B; Anzevino, R; Borrello, S; Galeotti, T				Pani, G; Colavitti, R; Bedogni, B; Anzevino, R; Borrello, S; Galeotti, T			A redox signaling mechanism for density-dependent inhibition of cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHATASES; HYDROGEN-PEROXIDE; OXYGEN RADICALS; FACTOR RECEPTOR; PHOSPHORYLATION; FIBROBLASTS; RAC; PROLIFERATION; GENERATION; ACTIVATION	Reactive oxygen species (ROS) have recently drawn significant attention as putative mitogenic mediators downstream of activated growth factor receptors and oncogenic Ras; however, the possibility that a redox-related mechanism also operates in the negative control of cell proliferation by inhibitory signals has not been investigated thus far. Here we show that the arrest of growth induced by cell confluence ("contact inhibition") is due, at least in part, to a decrease in the steady-state levels of intracellular ROS and the consequent impairment of mitogenic redox signaling. In confluent fibroblast cultures, the decrease in the concentration of oxygen species was associated with diminished activity of the small GTPase Rac-1, a signal transducer directly involved in the ligand dependent generation of oxygen-derived molecules, and was effectively mimicked by exposure of sparse cultures to dithiothreitol (DTT) and inhibitors of enzymes (phospholipase A2 and Lipoxygenase) acting in the arachidonic acid cascade downstream of growth factor receptors and Rac-1, Sparse fibroblasts treated with nontoxic amounts of DTT underwent growth arrest, whereas a low concentration of hydrogen peroxide significantly increased thymidine incorporation in confluent cultures, demonstrating a causal link between redox changes and growth control by cell density. Removal of oxygen species from sparse cultures was accompanied by a drastic decrease of protein tyrosine phosphorylation after epidermal growth factor stimulation, which, at a biochemical level, reproduced the signaling hallmarks of contact inhibition, Moreover, the cytosolic tyrosine phosphatase SHP-2 was identified as a putative target for redox signaling by cell density because the enzyme itself and the associated substrates appear markedly dephosphorylated in both confluent and reductant-treated cells after exposure to epidermal growth factor, and SHP-2 enzymatic activity is strongly activated by DTT in vitro. Taken together, these data support a model in which impaired generation of ROS and increased protein tyrosine phosphatase activity impede mitogenic signaling in contact-inhibited cells.	Univ Cattolica Sacro Cuore, Inst Gen Pathol, Sch Med, I-00168 Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Galeotti, T (corresponding author), Univ Cattolica Sacro Cuore, Inst Gen Pathol, Sch Med, Largo F Vito 1, I-00168 Rome, Italy.	Tgaleotti@rm.unicatt.it	Pani, Giovambattista/AAB-1446-2019	Pani, Giovambattista/0000-0001-7133-8728				Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Batt DB, 1998, J BIOL CHEM, V273, P3408, DOI 10.1074/jbc.273.6.3408; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ELING TE, 1994, CANCER METAST REV, V13, P397, DOI 10.1007/BF00666106; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fialkow L, 1997, J IMMUNOL, V158, P5409; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Huang S, 1998, MOL BIOL CELL, V9, P3179, DOI 10.1091/mbc.9.11.3179; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; Lallemand D, 1998, EMBO J, V17, P5615, DOI 10.1093/emboj/17.19.5615; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Monteiro HP, 1996, FREE RADICAL BIO MED, V21, P323, DOI 10.1016/0891-5849(96)00051-2; Moore KA, 1997, BIOCHEM J, V326, P17, DOI 10.1042/bj3260017; ODonnell VB, 1996, BIOCHEM J, V318, P805, DOI 10.1042/bj3180805; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; Pani G, 1997, CLIN IMMUNOL IMMUNOP, V84, P1, DOI 10.1006/clin.1996.4326; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; Pani G, 2000, BIOCHEM J, V347, P173, DOI 10.1042/0264-6021:3470173; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sorby M, 1996, J BIOL CHEM, V271, P10963; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TRUDEL S, 1991, BIOCHEM J, V276, P611, DOI 10.1042/bj2760611; WIESER RJ, 1990, J CELL BIOL, V111, P2681, DOI 10.1083/jcb.111.6.2681; WIESER RJ, 1990, ENVIRON HEALTH PERSP, V88, P251, DOI 10.2307/3431085	45	124	131	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38891	38899		10.1074/jbc.M007319200	http://dx.doi.org/10.1074/jbc.M007319200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10988296	hybrid			2022-12-25	WOS:000165739800102
J	Clark, AB; Valle, F; Drotschmann, K; Gary, RK; Kunkel, TA				Clark, AB; Valle, F; Drotschmann, K; Gary, RK; Kunkel, TA			Functional interaction of proliferating cell nuclear antigen with MSH2-MSH6 and MSH2-MSH3 complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-DELTA; BASE EXCISION-REPAIR; MISMATCH REPAIR; SACCHAROMYCES-CEREVISIAE; PCNA BINDING; REPLICATION; IDENTIFICATION; MUTATIONS; P21(WAF1); INHIBITOR	Eukaryotic DNA mismatch repair requires the concerted action of several proteins, including proliferating cell nuclear antigen (PCNA) and heterodimers of MSH2 complexed with either MSH3 or MSH6. Here we report that MSH3 and MSH6, but not MSH2, contain N-terminal sequence moths characteristic of proteins that bind to PCNA. MSH3 and MSH6 peptides containing these motifs bound PCNA, as did the intact Msh2-Msh6 complex. This binding was strongly reduced when alanine was substituted for conserved residues in the moth. Yeast strains containing alanine substitutions in the PCNA binding motif of Msh6 or Msh3 had elevated mutation rates, indicating that these interactions are important for genome stability. When human MSH3 or MSH6 peptides containing the PCNA binding motif were added to a human cell extract, mismatch repair activity was inhibited at a step preceding DNA resynthesis. Thus, MSH3 and MSH6 interactions with PCNA may facilitate early steps in DNA mismatch repair and may also be important for other roles of these eukaryotic MutS homologs.	NIEHS, Mol Genet Lab, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, Res Triangle Pk, NC 27709 USA; Univ Nevada, Dept Chem, Las Vegas, NV 89154 USA; Univ Nevada, UNLV Canc Inst, Las Vegas, NV 89154 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Nevada System of Higher Education (NSHE); University of Nevada Las Vegas; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas	Kunkel, TA (corresponding author), NIEHS, Mol Genet Lab, Res Triangle Pk, NC 27709 USA.		Kunkel, Thomas A./D-5088-2019; Gary, Ronald K/A-8650-2008	Kunkel, Thomas A./0000-0002-9900-1788; Gary, Ronald K/0000-0001-5079-1953	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065089, Z01ES065089] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Chen C, 1999, MOL CELL BIOL, V19, P7801; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Drotschmann K, 1999, P NATL ACAD SCI USA, V96, P2970, DOI 10.1073/pnas.96.6.2970; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Gary R, 1999, MOL CELL BIOL, V19, P5373; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Harfe BD, 2000, GENETICS, V156, P571; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; Kokoska RJ, 1999, GENETICS, V151, P511; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Longley MJ, 1997, J BIOL CHEM, V272, P10917; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Thomas David C., 1995, Methods (Orlando), V7, P187, DOI 10.1006/meth.1995.1024; Tran HT, 1997, MOL CELL BIOL, V17, P2859, DOI 10.1128/MCB.17.5.2859; Tran HT, 1999, MOL CELL BIOL, V19, P2000; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3	30	177	184	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36498	36501		10.1074/jbc.C000513200	http://dx.doi.org/10.1074/jbc.C000513200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	11005803	hybrid			2022-12-25	WOS:000165577700006
J	Lin, X; Liang, M; Feng, XH				Lin, X; Liang, M; Feng, XH			Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED TRANSCRIPTION; TUMOR-SUPPRESSOR; PROTEIN; COACTIVATORS; SMAD4/DPC4; COOPERATION; ONCOPROTEIN; RESPONSES; ACTIVATOR; CBP/P300	Smads are important intracellular signaling effecters for transforming growth factor-beta (TGF-beta) and related factors. Proper TGF-beta signaling requires precise control of Smad functions. In this study, we have identified a novel HECT class ubiquitin E3 ligase, designated Smurf2, that negatively regulates Smad2 signaling. In both yeast two-hybrid and in vitro binding assays, we found that Smurf2 could interact with receptor-activated Smads (R-Smads), including Smad1, Smad2, and Smad3 but not Smad4. Ectopic expression of Smurf2 was sufficient to reduce the steady-state levels of Smad1 and Smad2 but not Smad8 or Smad4. Significantly, Smurf2 displayed preference to Smad2 as its target for degradation. Furthermore, Smurf2 exhibited higher binding affinity to activated Smad2 upon TGF-beta stimulation. The ability of Smurf2 to promote Smad2 destruction required the HECT catalytic activity of Smurf2 and depended on the proteasome-dependent pathway. Consistent with these results, Smurf2 potently reduced the transcriptional activity of Smad2. These data suggest that a ubiquitin/proaeasome-dependent mechanism is important for proper regulation of TGF-beta signaling.	Baylor Coll Med, Dept Surg, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Feng, XH (corresponding author), Baylor Coll Med, Dept Surg, 1 Baylor Plaza,404D, Houston, TX 77030 USA.							Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Datto M, 2000, CYTOKINE GROWTH F R, V11, P37, DOI 10.1016/S1359-6101(99)00027-1; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Massague J, 2000, GENE DEV, V14, P627; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Roberts AB, 1999, MICROBES INFECT, V1, P1265, DOI 10.1016/S1286-4579(99)00258-0; Sambrook J., 2002, MOL CLONING LAB MANU; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	36	387	414	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36818	36822		10.1074/jbc.C000580200	http://dx.doi.org/10.1074/jbc.C000580200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	11016919	hybrid			2022-12-25	WOS:000165577700054
J	Galun, E; Zeira, E; Pappo, O; Peters, M; Rose-John, S				Galun, E; Zeira, E; Pappo, O; Peters, M; Rose-John, S			Liver regeneration induced by a designer human IL-6/sIL-6R fusion protein reverses severe hepatocellular injury	FASEB JOURNAL			English	Article						interleukin 6; chimeric protein; hyper-IL-6; cytokines; hepatotoxicity; liver failure	TUMOR-NECROSIS-FACTOR; FULMINANT HEPATIC-FAILURE; IN-VIVO; IL-6 RECEPTOR; TRANSGENIC MICE; D-GALACTOSAMINE; INTERLEUKIN-6 RECEPTOR; GENE-TRANSCRIPTION; INDUCED APOPTOSIS; CELLS	The cytokine IL-6 plays a significant role in liver regeneration in conjunction with additional growth factors (HGF, TNF-alpha, and TGF-alpha). Many IL-6 effects depend on a naturally occurring soluble IL-6 receptor (sIL-6R). Here, the chimeric protein hyper-IL-6, constructed from the human IL-6 protein fused to a truncated form of its receptor, was found to have superagonistic IL-6 properties, and as such, enhanced liver cell regeneration. Hyper-IL-6 reversed the state of hepatotoxicity and enhanced the survival rates of rats suffering from fulminant hepatic failure after D-galactosamine administration. The hyper-IL-6 protein has a significant potential for use in the treatment of set ere human liver diseases.	Hadassah Univ Hosp, Goldyne Savad Inst Gene therapy, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Liver Unit, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Pathol, IL-91120 Jerusalem, Israel; Univ Mainz, Med Klin 1, Abt Pathophysiol, D-6500 Mainz, Germany	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Johannes Gutenberg University of Mainz	Galun, E (corresponding author), Hadassah Univ Hosp, Goldyne Savad Inst Gene therapy, IL-91120 Jerusalem, Israel.		Rose-John, Stefan/A-7998-2010; Galun, Eithan/AAD-9117-2022	Rose-John, Stefan/0000-0002-7519-3279; Galun, Eithan/0000-0002-6243-6702				ATILLASOY E, 1995, ANNU REV MED, V46, P181; Bruck R, 1998, HEPATOLOGY, V27, P1013, DOI 10.1002/hep.510270417; BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Fausto Nelson, 1994, P1059; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; Hellerbrand C, 1998, HEPATOLOGY, V27, P1285, DOI 10.1002/hep.510270514; Itokazu Y, 1999, BIOL PHARM BULL, V22, P1127; Katz A, 1998, CYTOKINES CELL MOL T, V4, P221; Leist M, 1997, GASTROENTEROLOGY, V112, P923, DOI 10.1053/gast.1997.v112.pm9041255; LUST J, 1995, CURR TOP MICROBIOL I, V194, P194; Maezono K, 1996, HEPATOLOGY, V24, P1211; Maione D, 1998, EMBO J, V17, P5588, DOI 10.1093/emboj/17.19.5588; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MULLBERG J, 1994, J IMMUNOL, V152, P4958; MURAKAMI M, 1993, SCIENCE, V260, P1080; Okano J, 1997, HEPATOLOGY, V26, P1241; Oritani K, 1999, BLOOD, V93, P1346, DOI 10.1182/blood.V93.4.1346.404k15_1346_1354; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; Peters M, 1996, J EXP MED, V183, P1399, DOI 10.1084/jem.183.4.1399; Peters M, 1998, BLOOD, V92, P3495, DOI 10.1182/blood.V92.10.3495.422k47_3495_3504; Peters M, 1998, J IMMUNOL, V161, P3575; Rakemann T, 1999, J BIOL CHEM, V274, P1257, DOI 10.1074/jbc.274.3.1257; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Schirmacher P, 1998, AM J PATHOL, V153, P639, DOI 10.1016/S0002-9440(10)65605-2; Shirin H, 1998, J HEPATOL, V29, P60, DOI 10.1016/S0168-8278(98)80179-7; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Stachlewitz RF, 1999, HEPATOLOGY, V29, P737, DOI 10.1002/hep.510290335; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Taub R, 1998, HEPATOLOGY, V27, P1445, DOI 10.1002/hep.510270538; Trautwein C, 1996, GASTROENTEROLOGY, V110, P1854, DOI 10.1053/gast.1996.v110.pm8964411; Webber EM, 1998, HEPATOLOGY, V28, P1226, DOI 10.1002/hep.510280509; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441	35	102	113	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					1979	1987		10.1096/fj.99-0913com	http://dx.doi.org/10.1096/fj.99-0913com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023982				2022-12-25	WOS:000089634400017
J	Wu, XL; McMurray, CT				Wu, XL; McMurray, CT			Calmodulin kinase II attenuation of gene transcription by preventing cAMP response element-binding protein (CREB) dimerization and binding of the CREB-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEIN; CYCLIC-AMP; PHOSPHORYLATED CREB; SECONDARY STRUCTURE; COACTIVATOR CBP; ACTIVATION; IV; DNA; EXPRESSION; MONOMERS	Calmodulin Kinase II (CamKII) inhibits the transcription of many CRE-dependent genes, but the mechanism of dominant transcriptional inhibition is unknown. Here we show that phosphorylation of serine 142 in CREB by CamKII leads to dissociation of the CREB dimer without impeding DNA binding capacity. CamKII-modified CREB binds to DNA efficiently as a monomer; however, monomeric CREB is unable to recruit the CREB-binding protein (CBP) even when phosphorylated at serine 133. Thus, CamKII confers a dominant inhibitory effect on transcription by preventing dimerization of CREB, and this mechanism may account for the attenuation of gene expression.	Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Grad Sch, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mol Neurosci Program, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	McMurray, CT (corresponding author), Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, 200 1st St SW, Rochester, MN 55905 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH056207] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43694-01A2] Funding Source: Medline; NIMH NIH HHS [MH-56207] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Blitzer RD, 1998, SCIENCE, V280, P1940, DOI 10.1126/science.280.5371.1940; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COLLINSHICOK J, 1994, MOL CELL BIOL, V14, P2837, DOI 10.1128/MCB.14.5.2837; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Hagiwara M, 1996, Adv Pharmacol, V36, P277, DOI 10.1016/S1054-3589(08)60586-4; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; Kohler JJ, 1999, P NATL ACAD SCI USA, V96, P11735, DOI 10.1073/pnas.96.21.11735; KRAJEWSKI W, 1994, MOL CELL BIOL, V14, P7204, DOI 10.1128/MCB.14.11.7204; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lisman J, 1997, SCIENCE, V276, P2001, DOI 10.1126/science.276.5321.2001; LORIAUX MM, 1993, P NATL ACAD SCI USA, V90, P9046, DOI 10.1073/pnas.90.19.9046; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Metallo SJ, 1997, NAT STRUCT BIOL, V4, P115, DOI 10.1038/nsb0297-115; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; ORR MD, 1972, ANAL BIOCHEM, V45, P68, DOI 10.1016/0003-2697(72)90008-5; Parker D, 1998, MOL CELL, V2, P353, DOI 10.1016/S1097-2765(00)80279-8; Press W. H., 1992, NUMERICAL RECIPES C, V2nd, P656; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Richards JP, 1996, J BIOL CHEM, V271, P13716, DOI 10.1074/jbc.271.23.13716; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Shimomura A, 1996, J BIOL CHEM, V271, P17957, DOI 10.1074/jbc.271.30.17957; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; SPIRO C, 1993, P NATL ACAD SCI USA, V90, P4606, DOI 10.1073/pnas.90.10.4606; SPIRO C, 1995, J BIOL CHEM, V270, P27702, DOI 10.1074/jbc.270.46.27702; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Tompa P, 1998, TRENDS NEUROSCI, V21, P97, DOI 10.1016/S0166-2236(97)01176-4; VANHOLDE KE, 1985, PHYSICAL BIOCH; Wu XL, 1998, J BIOL CHEM, V273, P20820, DOI 10.1074/jbc.273.33.20820; Xia ZG, 1997, CURR OPIN NEUROBIOL, V7, P391, DOI 10.1016/S0959-4388(97)80068-2; Zhang F, 1998, MOL CELL, V2, P141, DOI 10.1016/S1097-2765(00)80123-9	47	79	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1735	1741		10.1074/jbc.M006727200	http://dx.doi.org/10.1074/jbc.M006727200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11013247	hybrid			2022-12-25	WOS:000166528000013
J	Galan, A; Sot, B; Llorca, O; Carrascosa, JL; Valpuesta, JM; Muga, A				Galan, A; Sot, B; Llorca, O; Carrascosa, JL; Valpuesta, JM; Muga, A			Excluded volume effects on the refolding and assembly of an oligomeric protein - GroEL, a case study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; CHAPERONIN GROEL; MACROMOLECULAR STRUCTURE; MOLECULAR CHAPERONE; SELF-ASSOCIATION; LOW-TEMPERATURE; IN-VITRO; CYTOPLASM	We have studied the effect of macromolecular crowding reagents, such as polysaccharides and bovine serum albumin, on the refolding of tetradecameric GroEL from urea-denatured protein monomers, The results show that productive refolding and assembly strongly depends on the presence of nucleotides (ATP or ADP) and background macromolecules. Nucleotides are required to generate an assembly-competent monomeric conformation, suggesting that proper folding of the equatorial domain of the protein subunits into a native-like structure is essential for productive assembly. Crowding modulates GroEL oligomerization in two different ways. First, it increases the tendency of refolded, monomeric GroEL to undergo self-association at equilibrium. Second, crowding can modify the relative rates of the two competing self-association reactions, namely, productive assembly into a native tetradecameric structure and unproductive aggregation, This kinetic effect is most likely exerted by modifications of the diffusion coefficient of the refolded monomers, which in turn determine the conformational properties of the interacting subunits, If they are allowed to become assembly-competent before self-association, productive oligomerization occurs; otherwise, unproductive aggregation takes place. Our data demonstrate that the spontaneous refolding and assembly of homo-oligomeric proteins, such as GroEL, can occur efficiently (70%) under crowding conditions similar to those expected in vivo.	Univ Basque Country, Consejo Super Invest Cientificas, Unidad Biofis, E-48080 Bilbao, Spain; Univ Basque Country, Dept Bioquim & Biol Mol, E-48080 Bilbao, Spain; Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Muga, A (corresponding author), Univ Basque Country, Consejo Super Invest Cientificas, Unidad Biofis, E-48080 Bilbao, Spain.	gbpmuvia@lg.ehu.es	Sot, Begoña/H-2882-2015; Llorca, Oscar/P-2784-2019; Llorca, Oscar/K-1144-2014; Valpuesta, José M/T-1977-2017; Valpuesta, Jose M/AAA-6002-2019; Muga, Arturo/N-1174-2014	Sot, Begoña/0000-0001-8763-0651; Llorca, Oscar/0000-0001-5705-0699; Llorca, Oscar/0000-0001-5705-0699; Valpuesta, José M/0000-0001-7468-8053; Muga, Arturo/0000-0003-0345-6882				ARRONDO JLR, 1994, BIOCHEMISTRY-US, V33, P11650, DOI 10.1021/bi00204a029; BELNNOW A, 1995, BIOCHIM BIOPHYS ACTA, V1252, P68; BRAIG K, 1994, NATURE, V37, P1578; BURNETT BP, 1994, J BACTERIOL, V176, P6980, DOI 10.1128/JB.176.22.6980-6985.1994; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; Chen JW, 2000, BIOCHEMISTRY-US, V39, P4250, DOI 10.1021/bi992619n; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; ELLIS RJ, 1997, CURR BIOL, V7, P531; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; FABIAN H, 1995, BIOCHEMISTRY-US, V34, P13651, DOI 10.1021/bi00041a046; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; Galan A, 1999, EUR J BIOCHEM, V259, P347, DOI 10.1046/j.1432-1327.1999.00045.x; Golbik R, 1998, J MOL BIOL, V276, P505, DOI 10.1006/jmbi.1997.1538; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOROVITZ A, 1993, J BIOL CHEM, V268, P9957; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; Kumar S, 2000, PROTEIN SCI, V9, P10; LINDNER R, 1995, BIOPHYS CHEM, V57, P15, DOI 10.1016/0301-4622(95)00063-4; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; LISSIN NM, 1993, FEBS LETT, V324, P41, DOI 10.1016/0014-5793(93)81528-8; Llorca O, 1998, J BIOL CHEM, V273, P32587, DOI 10.1074/jbc.273.49.32587; Llorca O, 1997, J BIOL CHEM, V272, P32925, DOI 10.1074/jbc.272.52.32925; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; Llorca O, 1997, J STRUCT BIOL, V118, P31, DOI 10.1006/jsbi.1996.3832; LUBYPHELPS K, 1994, CURR OPIN CELL BIOL, V6, P3, DOI 10.1016/0955-0674(94)90109-0; LUBYPHELPS K, 1987, P NATL ACAD SCI USA, V84, P4910, DOI 10.1073/pnas.84.14.4910; Martin J, 1997, P NATL ACAD SCI USA, V94, P1107, DOI 10.1073/pnas.94.4.1107; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1995, BBA-PROTEIN STRUCT M, V1247, P209, DOI 10.1016/0167-4838(94)00231-5; MENDOZA JA, 1994, J BIOL CHEM, V269, P25963; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; Minton AP, 1997, CURR OPIN BIOTECH, V8, P65, DOI 10.1016/S0958-1669(97)80159-0; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; MINTON AP, 1981, BIOPOLYMERS, V20, P2093, DOI 10.1002/bip.1981.360201006; Minton AP, 2000, CURR BIOL, V10, pR97, DOI 10.1016/S0960-9822(00)00301-8; MINTON AP, 1992, BIOPHYS J, V63, P1090, DOI 10.1016/S0006-3495(92)81663-6; MINTON KW, 1982, P NATL ACAD SCI-BIOL, V79, P7107, DOI 10.1073/pnas.79.23.7107; MUGA A, 1991, BIOCHEMISTRY-US, V30, P2629, DOI 10.1021/bi00224a010; Rivas G, 1999, BIOCHEMISTRY-US, V38, P9379, DOI 10.1021/bi990355z; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; Surin AK, 1997, FEBS LETT, V405, P260, DOI 10.1016/S0014-5793(97)00199-3; TIMASHEFF SN, 1998, PROTEIN STRUCTURE PR, P331; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; Todd MJ, 1998, METHOD ENZYMOL, V290, P135, DOI 10.1016/S0076-6879(98)90012-X; van den Berg B, 1999, EMBO J, V18, P6927, DOI 10.1093/emboj/18.24.6927; Weber F, 1998, NAT STRUCT BIOL, V5, P977, DOI 10.1038/2952; WHITE ZW, 1995, J BIOL CHEM, V270, P20404, DOI 10.1074/jbc.270.35.20404; YBARRA J, 1995, J BIOL CHEM, V270, P22113, DOI 10.1074/jbc.270.38.22113; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	54	42	42	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					957	964		10.1074/jbc.M006861200	http://dx.doi.org/10.1074/jbc.M006861200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11020386	hybrid			2022-12-25	WOS:000166430900015
J	Hoy, M; Bokvist, K; Weng, XG; Hansen, J; Juhl, K; Berggren, PO; Buschard, K; Gromada, J				Hoy, M; Bokvist, K; Weng, XG; Hansen, J; Juhl, K; Berggren, PO; Buschard, K; Gromada, J			Phentolamine inhibits exocytosis of glucagon by G(i2) protein-dependent activation of calcineurin in rat pancreatic alpha-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNELS; BETA-CELLS; INSULIN RELEASE; A-CELLS; SECRETION; GLUCOSE; ISLETS; SULFONYLUREA; CURRENTS; LOCALIZATION	Capacitance measurements were used to investigate the molecular mechanisms by which imidazoline compounds inhibit glucagon release in rat pancreatic alpha -cells, The imidazoline compound phentolamine reversibly decreased depolarization-evoked exocytosis >80% without affecting the whole-cell Ca2+ current. During intracellular application through the recording pipette, phentolamine produced a concentration-dependent decrease in the rate of exocytosis (IC50 = 9.7 muM). Another imidazoline compound, RX871024, exhibited similar effects on exocytosis (IC50 = 13 muM). These actions were dependent on activation of pertussis toxin-sensitive G(i2) proteins but were not associated with stimulation of ATP-sensitive K+ channels or adenylate cyclase activity. The inhibitory effect of phentolamine on exocytosis resulted from activation of the protein phosphatase calcineurin and was abolished by cyclosporin A and deltamethrin. Exocytosis was not affected by intracellular application of specific alpha (2), I-1, and I-2, ligands. Phentolamine reduced glucagon release (IC50 = 1.2 muM) from intact islets by 40%, an effect abolished by pertussis toxin, cyclosporin A, and deltamethrin, These data suggest that imidazoline compounds inhibit glucagon secretion via G(i2)-dependent activation of calcineurin in the pancreatic alpha -cell, The imidazoline binding site is likely to be localized intracellularly and probably closely associated with the secretory granules.	Novo Nordisk AS, Lab Islet Cell Physiol, DK-2880 Bagsvaerd, Denmark; Kommunehosp, Bartholin Inst, DK-1353 Copenhagen, Denmark; Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res, S-17176 Stockholm, Sweden	Novo Nordisk; Karolinska Institutet	Gromada, J (corresponding author), Lilly Forsch GMBH, Lilly Res Labs, Essener Str 93, D-22419 Hamburg, Germany.			Buschard, Karsten/0000-0002-0126-7423; Berggren, Per-Olof/0000-0001-8991-413X				Ahnert-Hilger G, 1998, EMBO J, V17, P406, DOI 10.1093/emboj/17.2.406; AHNERTHILGER G, 1994, EUR J CELL BIOL, V65, P26; AMMALA C, 1993, J PHYSIOL-LONDON, V472, P665, DOI 10.1113/jphysiol.1993.sp019966; ARONIN N, 1992, J NEUROSCI, V12, P3435; BERROW NS, 1992, J MOL ENDOCRINOL, V8, P103, DOI 10.1677/jme.0.0080103; Bokvist K, 1999, PFLUG ARCH EUR J PHY, V438, P428, DOI 10.1007/s004240051058; BUSE MG, 1970, METABOLIS, V19, P219, DOI 10.1016/0026-0495(70)90055-7; CERASI E, 1969, LANCET, V2, P301; Detimary P, 1998, J BIOL CHEM, V273, P33905, DOI 10.1074/jbc.273.51.33905; DUNNE MJ, 1991, BRIT J PHARMACOL, V103, P1847, DOI 10.1111/j.1476-5381.1991.tb12340.x; DUNNE MJ, 1995, ANN NY ACAD SCI, V763, P242; Efanova IB, 1998, BIOCHEM BIOPH RES CO, V252, P162, DOI 10.1006/bbrc.1998.9635; EFENDIC S, 1975, DIABETOLOGIA, V11, P407, DOI 10.1007/BF00429908; GAGLIARDINO JJ, 1991, BIOCHIM BIOPHYS ACTA, V1091, P370, DOI 10.1016/0167-4889(91)90202-9; GARRINO MG, 1990, DIABETOLOGIA, V33, P145, DOI 10.1007/BF00404040; Gromada J, 1997, J GEN PHYSIOL, V110, P217, DOI 10.1085/jgp.110.3.217; HEIMBERG H, 1995, J BIOL CHEM, V270, P8971, DOI 10.1074/jbc.270.15.8971; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; ITOH H, 1988, J BIOL CHEM, V263, P6656; Jena BP, 1997, P NATL ACAD SCI USA, V94, P13317, DOI 10.1073/pnas.94.24.13317; JONAS JC, 1992, BRIT J PHARMACOL, V107, P8, DOI 10.1111/j.1476-5381.1992.tb14456.x; JONES DT, 1987, J BIOL CHEM, V262, P14241; Josefsen K, 1996, J ENDOCRINOL, V149, P145, DOI 10.1677/joe.0.1490145; KASHIWAGI A, 1986, DIABETES, V35, P1085, DOI 10.2337/diabetes.35.10.1085; LEE K, 1995, EUR J PHARMACOL, V285, P309, DOI 10.1016/0014-2999(95)00525-P; MARTELL AE, 1971, CRITICAL STABILITY C, V1; MISBIN RI, 1970, DIABETES, V19, P688, DOI 10.2337/diab.19.10.688; Mourtada M, 1997, BIOCHEM BIOPH RES CO, V236, P162, DOI 10.1006/bbrc.1997.6922; PLANT TD, 1990, BRIT J PHARMACOL, V101, P115, DOI 10.1111/j.1476-5381.1990.tb12099.x; Poulsen CR, 1999, DIABETES, V48, P2171, DOI 10.2337/diabetes.48.11.2171; Proks P, 1997, P NATL ACAD SCI USA, V94, P11716, DOI 10.1073/pnas.94.21.11716; Renstrom E, 1996, NEURON, V17, P513, DOI 10.1016/S0896-6273(00)80183-X; RORSMAN P, 1989, NATURE, V341, P233, DOI 10.1038/341233a0; RORSMAN P, 1986, J PHYSIOL-LONDON, V374, P531, DOI 10.1113/jphysiol.1986.sp016096; SAKURA H, 1995, FEBS LETT, V377, P228; Suzuki M, 1999, DIABETOLOGIA, V42, P1204, DOI 10.1007/s001250051293; Takano K, 1997, J PHYSIOL-LONDON, V502, P559, DOI 10.1111/j.1469-7793.1997.559bj.x; VITALE N, 1994, J BIOL CHEM, V269, P30293; Zaitsev SV, 1996, DIABETES, V45, P1610, DOI 10.2337/diabetes.45.11.1610	39	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					924	930		10.1074/jbc.M007562200	http://dx.doi.org/10.1074/jbc.M007562200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	10995774	hybrid			2022-12-25	WOS:000166430900010
J	Dwyer, TM; Rao, KS; Westover, JB; Kim, JJP; Frerman, FE				Dwyer, TM; Rao, KS; Westover, JB; Kim, JJP; Frerman, FE			The function of Arg-94 in the oxidation and decarboxylation of glutaryl-CoA by human glutaryl-CoA dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOOXYGENASE ACTIVE-SITE; COENZYME-A DEHYDROGENASE; ARACHIDONIC-ACID; PIG-KIDNEY; ACYL; INHIBITORS; MECHANISM; SUBSTRATE; LIVER; ARGININE-120	Glutaryl-CoA dehydrogenase catalyzes the oxidation and decarboxylation of glutaryl-CoA to crotonyl-CoA and CO2. Inherited defects in the protein cause glutaric acidemia type I, a fatal neurologic disease. Glutaryl-CoA dehydrogenase is the only member of the acyl-CoA dehydrogenase family with a cationic residue, Arg-94, situated in the binding site of the acyl moiety of the substrate. Crystallographic investigations suggest that Argc94 is within hydrogen bonding distance of the gamma -carboxylate of glutaryl-CoA Substitution of Arg-94 by glycine, a disease-causing mutation, and by glutamine, which is sterically more closely related to arginine, reduced K-cat of the mutant dehydrogenases to 2-3% of k(ca)t of the wild type enzyme. K-m of these mutant dehydrogenases for glutaryl-CoA increases 10- to 16-fold. The steady-state kinetic constants of alternative substrates, hexanoyl-CoA and glutaramyl-CoA, which are not decarboxylated, are modestly affected by the mutations. The latter changes are probably due to steric and polar effects. The dissociation constants of the non-oxidizable substrate analogs, 3-thiaglutaryl-CoA and acetoacetyl-CoA, are not altered by the mutations. However, abstraction of a cy-proton from 3-thiaglutaryl-CoA, to yield a charge transfer complex with the oxidized flavin, is severely limited. In contrast, abstraction of the alpha -proton of acetoacetyl-CoA by Arg-94 --> Gin mutant dehydrogenase is unaffected, and the resulting enolate forms a charge transfer complex with the oxidized flavin, These experiments indicate that Arg-94 does not make a major contribution to glutaryl-CoA binding. However, the electric field of Arg-94 may stabilize the dianions resulting from abstraction of the alpha -proton of glutaryl-CoA and 3-thiaglutaryl-CoA, both of which contain gamma -carbaxylates. It is also possible that Arg-94 may orient glutaryl-CoA and 3-thiaglutaryl-CoA for abstraction of an alpha -proton.	Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Human Med Genet Program, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Denver, CO 80262 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Medical College of Wisconsin	Frerman, FE (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pediat, Box C233,4200 E 9th Ave, Denver, CO 80262 USA.				NIGMS NIH HHS [GM29076] Funding Source: Medline; NINDS NIH HHS [NS39339] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039339] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERNERT JT, 1977, J BIOL CHEM, V252, P6736; Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; BYRON CM, 1990, BIOCHEMISTRY-US, V29, P3691, DOI 10.1021/bi00467a015; Dwyer TM, 2000, BIOCHEMISTRY-US, V39, P11488, DOI 10.1021/bi000700g; FRERMAN FE, 1980, J BIOL CHEM, V255, P2195; Gan QF, 1996, J BIOL CHEM, V271, P25412, DOI 10.1074/jbc.271.41.25412; Garavito RM, 1999, BBA-MOL CELL BIOL L, V1441, P278, DOI 10.1016/S1388-1981(99)00147-X; GATENBY AA, 1992, PLANT MOL BIOL, V19, P677, DOI 10.1007/BF00026793; GHISLA S, 1997, FLAVINS FLAVOPROTEIN, P629; GOMES B, 1981, BIOCHEMISTRY-US, V20, P1481, DOI 10.1021/bi00509a012; GOODMAN SI, 1995, HUM MOL GENET, V4, P1493; Goodman SI, 1998, HUM MUTAT, V12, P141, DOI 10.1002/(SICI)1098-1004(1998)12:3<141::AID-HUMU1>3.0.CO;2-K; GOODMAN SI, 1995, METABOLIC MOL BASIS, V1, P1451; JEFFERY GH, 1934, J CHEM SOC, P101; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; KIM JJP, 1999, FLAVINS FLAVOPROTEIN, P539; KUMAR NR, 1997, FLAVINS FLAVOPROTEIN, P633; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LAU SM, 1986, BIOCHEMISTRY-US, V25, P4184, DOI 10.1021/bi00363a003; LAU SM, 1988, BIOCHEMISTRY-US, V27, P5089, DOI 10.1021/bi00414a021; LEHMAN TC, 1990, BIOCHEMISTRY-US, V29, P10594, DOI 10.1021/bi00499a004; LENICH AC, 1986, J BIOL CHEM, V261, P4090; Loll PJ, 1996, BIOCHEMISTRY-US, V35, P7330, DOI 10.1021/bi952776w; MARQUEZ VE, 1980, J ORG CHEM, V45, P5308, DOI 10.1021/jo01314a018; MCKEAN MC, 1983, J BIOL CHEM, V258, P1866; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Rieke CJ, 1999, J BIOL CHEM, V274, P17109, DOI 10.1074/jbc.274.24.17109; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Tamaoki H, 1999, J BIOCHEM, V125, P285, DOI 10.1093/oxfordjournals.jbchem.a022285; Telford EAR, 1999, BBA-GENE STRUCT EXPR, V1446, P371, DOI 10.1016/S0167-4781(99)00102-5; THORPE C, 1995, FASEB J, V9, P718, DOI 10.1096/fasebj.9.9.7601336; Vock P, 1998, BIOCHEMISTRY-US, V37, P1848, DOI 10.1021/bi971827h; Zschocke J, 2000, J MED GENET, V37, P177, DOI 10.1136/jmg.37.3.177	33	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					133	138		10.1074/jbc.M007672200	http://dx.doi.org/10.1074/jbc.M007672200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024031	hybrid			2022-12-25	WOS:000166280700019
J	Hackam, AS; Yassa, AS; Singaraja, R; Metzler, M; Gutekunst, CA; Gan, L; Warby, S; Wellington, CL; Vaillancourt, J; Chen, NS; Gervais, FG; Raymond, L; Nicholson, DW; Hayden, MR				Hackam, AS; Yassa, AS; Singaraja, R; Metzler, M; Gutekunst, CA; Gan, L; Warby, S; Wellington, CL; Vaillancourt, J; Chen, NS; Gervais, FG; Raymond, L; Nicholson, DW; Hayden, MR			Huntingtin interacting protein 1 induces apoptosis via a novel caspase-dependent death effector domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; DNA FRAGMENTATION; SACCHAROMYCES-CEREVISIAE; INTRANUCLEAR INCLUSIONS; NUCLEAR-LOCALIZATION; POLYGLUTAMINE TRACT; MUTANT HUNTINGTIN; DISEASE STRIATUM; NECROSIS-FACTOR; REPEAT LENGTH	Huntington disease is a devastating neurodegenerative disease caused by the expansion of a polymorphic glutamine tract in huntingtin. The huntingtin interacting protein (HIP-1) was identified by its altered interaction with mutant huntingtin, However, the function of HIP-1 was not known. In this study, we identify HIP-I as a proapoptotic protein. Overexpression of HIP-1 resulted in rapid caspase 5-dependent cell death. Bioinformatics analyses identified a novel domain in HIP-1 with homology to death effector domains (DEDs) present in proteins involved in apoptosis. Expression of the HIP-1 DED alone resulted in cell death indistinguishable from HIP-1, indicating that the DED is responsible for HIP-1 toxicity. Furthermore, substitution of a conserved hydrophobic phenylalanine residue within the HIP-1 DED at position 398 eliminated HIP-1 toxicity entirely. HIP-1 activity was found to be independent of the DED-containing caspase 8 but was significantly inhibited by the antiapoptotic protein Bcl-x(L), implicating the intrinsic pathway of apoptosis in HIP-1-induced cell death. Coexpression of a normal huntingtin fragment capable of binding HIP-1 significantly reduced cell death. Our data identify HIP-1 as a novel proapoptotic mediator and suggest that HIP-1 may be a molecular accomplice in the pathogenesis of Huntington disease.	Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V5Z 4H4, Canada; Emory Univ, Sch Med, Atlanta, GA 30322 USA; Merck Frosst Canada Inc, Merck Frosst Ctr Therapeut Res, Pointe Claire, PQ H9R 4P8, Canada; Univ British Columbia, Dept Psychiat, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Div Neurosci, Vancouver, BC V5Z 4H4, Canada	University of British Columbia; University of British Columbia; Emory University; Merck & Company; University of British Columbia; University of British Columbia	Hayden, MR (corresponding author), Univ British Columbia, Ctr Mol Med & Therapeut, 980 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	mrh@cmmt.ubc.ca	Raymond, Lynn A./R-6707-2016; Raymond, Lynn A/A-6664-2010; Chen, Nansheng/E-6450-2012; Hayden, Michael R/D-8581-2011	Raymond, Lynn A./0000-0002-8610-1042; Raymond, Lynn A/0000-0002-8610-1042; Hayden, Michael R/0000-0001-5159-1419; Singaraja, Roshni/0000-0002-3418-3867				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Boutell JM, 1999, HUM MOL GENET, V8, P1647, DOI 10.1093/hmg/8.9.1647; Butterworth NJ, 1998, NEUROSCIENCE, V87, P49, DOI 10.1016/S0306-4522(98)00129-8; CARMICHAEL J, 1987, CANCER RES, V47, P936; Chai YH, 1999, J NEUROSCI, V19, P10338; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chopra VS, 2000, MAMM GENOME, V11, P1006, DOI 10.1007/s003350010195; Clarke G, 2000, NATURE, V406, P195, DOI 10.1038/35018098; Cohen O, 1999, J CELL BIOL, V146, P141; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DRAGUNOW M, 1995, NEUROREPORT, V6, P1053, DOI 10.1097/00001756-199505090-00026; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Engqvist-Goldstein AEY, 1999, J CELL BIOL, V147, P1503, DOI 10.1083/jcb.147.7.1503; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; Kim M, 1999, J NEUROSCI, V19, P964; Kim M, 1999, NEUROSCIENCE, V89, P1159, DOI 10.1016/S0306-4522(98)00400-X; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Leavitt BR, 1999, AM J HUM GENET, V65, pA457; Li HL, 1999, CURR OPIN CELL BIOL, V11, P261, DOI 10.1016/S0955-0674(99)80035-0; LI R, 1995, J CELL BIOL, V128, P599, DOI 10.1083/jcb.128.4.599; Li SH, 1998, HUM MOL GENET, V7, P777, DOI 10.1093/hmg/7.5.777; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAO SQ, 1995, J BIOL CHEM, V270, P6815, DOI 10.1074/jbc.270.12.6815; Neelands TR, 1998, J NEUROSCI, V18, P4993; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Rigamonti D, 2000, J NEUROSCI, V20, P3705, DOI 10.1523/JNEUROSCI.20-10-03705.2000; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Sawa A, 1999, NAT MED, V5, P1194, DOI 10.1038/13518; Seki N, 1998, J HUM GENET, V43, P268, DOI 10.1007/s100380050087; Sharp AH, 1996, NEUROBIOL DIS, V3, P3, DOI 10.1006/nbdi.1996.0002; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Steininger TL, 1997, J COMP NEUROL, V382, P302, DOI 10.1002/(SICI)1096-9861(19970609)382:3<302::AID-CNE2>3.0.CO;2-7; THOMAS LB, 1995, EXP NEUROL, V133, P265, DOI 10.1006/exnr.1995.1029; Vander Heiden MG, 1999, MOL CELL, V3, P159; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VISTICA DT, 1991, CANCER RES, V51, P2515; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; Wellington CL, 2000, J BIOL CHEM, V275, P19831, DOI 10.1074/jbc.M001475200; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Wellington CL, 1997, BRAIN PATHOL, V7, P979, DOI 10.1111/j.1750-3639.1997.tb00897.x; Wesp A, 1997, MOL BIOL CELL, V8, P2291, DOI 10.1091/mbc.8.11.2291; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597	58	102	105	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41299	41308		10.1074/jbc.M008408200	http://dx.doi.org/10.1074/jbc.M008408200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007801	hybrid			2022-12-25	WOS:000166114600085
J	Krnajski, Z; Gilberger, TW; Walter, RD; Muller, S				Krnajski, Z; Gilberger, TW; Walter, RD; Muller, S			Intersubunit interactions in Plasmodium falciparum thioredoxin reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI GLUTATHIONE-REDUCTASE; MERCURIC ION REDUCTASE; ENGINEERING SURFACE-CHARGE; ESCHERICHIA-COLI; ACTIVE-SITE; NADH OXIDASE; SELENOCYSTEINE; MECHANISM; CATALYSIS; SEQUENCE	The thioredoxin redox system is composed of the NADPH-dependent homodimeric flavoprotein thioredoxin reductase (TrxR) and the 12-kDa protein thioredoxin, It is responsible for the reduction of disulfide bridges in proteins such as ribonucleotide reductase and several transcription factors. Furthermore, thioredoxin is involved in the detoxification of hydrogen peroxide and protects the cell against oxidative damage. There exist two classes of TrxRs: the high M-r and the low IM,proteins, The well characterized Escherichia coli TrxR represents a member of the low IM, class of proteins, whereas the mammalian, Caenorhabditis elegans, and Plasmodium falciparum proteins belong to the family of high M-r proteins. The primary structure of these proteins is very similar to that of glutathione reductase and lipoamide dehydrogenase. However, the high M-r TrxRs possess, in addition to their redox active N-terminal pair of cysteines, a pair of cysteine residues or a selenenylsulfide; motif at their C terminus. These residues have been shown to be crucial for the reduction of thioredoxin, In this study we address the question whether the active site residues of P, falciparum TrxR are provided by one or both subunits. Differentially tagged wild-type and PfTrxR mutants were co-expressed in E, coli and the recombinant protein species were purified by affinity chromatography specific for the respective tags of the recombinant proteins. Co-expression of PfTrxR wild-type and mutant proteins resulted in the formation of three different protein species: homodimeric PfTrxR wild-type proteins, homodimeric mutant proteins, and heterodimers composed of one PfTrxR wild-type subunit and one PfTrxR mutant subunit. Go-expression of the double mutant PfTrxRC88AC535A with PfTxR wild-type generated an inactive heterodimer, which indicates that PfTrxR possesses intersubunit active sites. In addition, the data presented possibly imply a coopertive interaction between both active sites of PfTrxR.	Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany	Bernhard Nocht Institut fur Tropenmedizin	Muller, S (corresponding author), Univ Dundee, Wellcome Trust Bioctr, Sch Life Sci, Dundee DDE1 5EH, Scotland.			Gilberger, Tim-Wolf/0000-0002-7965-8272				Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buettner C, 1999, J BIOL CHEM, V274, P21598, DOI 10.1074/jbc.274.31.21598; DEONARAIN MP, 1992, BIOCHEMISTRY-US, V31, P1491, DOI 10.1021/bi00120a028; DEONARAIN MP, 1992, BIOCHEMISTRY-US, V31, P1498, DOI 10.1021/bi00120a029; DISTEFANO MD, 1990, BIOCHEMISTRY-US, V29, P2703, DOI 10.1021/bi00463a013; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; Gilberger TW, 1997, J BIOL CHEM, V272, P29584, DOI 10.1074/jbc.272.47.29584; Gilberger TW, 1998, FEBS LETT, V425, P407, DOI 10.1016/S0014-5793(98)00270-1; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Lennon BW, 2000, SCIENCE, V289, P1190, DOI 10.1126/science.289.5482.1190; Luba J, 1999, BIOCHEMISTRY-US, V38, P2725, DOI 10.1021/bi9825899; Mallett TC, 1998, BIOCHEMISTRY-US, V37, P8790, DOI 10.1021/bi9803630; Mallett TC, 1999, BIOCHEMISTRY-US, V38, P3000, DOI 10.1021/bi9817717; MILLER SM, 1991, BIOCHEMISTRY-US, V30, P2600, DOI 10.1021/bi00224a006; MOORE MJ, 1992, BIOCHEMISTRY-US, V31, P1677, DOI 10.1021/bi00121a015; MOORE MJ, 1989, BIOCHEMISTRY-US, V28, P1183, DOI 10.1021/bi00429a036; Muller S, 1996, MOL BIOCHEM PARASIT, V80, P215, DOI 10.1016/0166-6851(96)02694-1; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; NORDHOFF A, 1993, BIOCHEMISTRY-US, V32, P4060, DOI 10.1021/bi00066a029; RUSSEL M, 1988, J BIOL CHEM, V263, P9015; Sambrook J., 2002, MOL CLONING LAB MANU; SCRUTTON NS, 1990, P ROY SOC B-BIOL SCI, V242, P217, DOI 10.1098/rspb.1990.0127; THIEME R, 1981, J MOL BIOL, V152, P763, DOI 10.1016/0022-2836(81)90126-1; Wang PF, 1999, BIOCHEMISTRY-US, V38, P3187, DOI 10.1021/bi982674g; WANG PF, 1999, FLAVINS FLAVOPROTEIN, P695; WILLIAMS CH, 1995, FASEB J, V9, P1267, DOI 10.1096/fasebj.9.13.7557016; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897	30	20	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40874	40878		10.1074/jbc.M008443200	http://dx.doi.org/10.1074/jbc.M008443200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11022050	hybrid			2022-12-25	WOS:000166114600029
J	Terzano, S; Flora, A; Clementi, F; Fornasari, D				Terzano, S; Flora, A; Clementi, F; Fornasari, D			The minimal promoter of the human alpha(3) nicotinic receptor subunit gene - Molecular and functional characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; RESTRICTIVE SILENCER FACTOR; BOX-BINDING-PROTEINS; DNA-BINDING; NEGATIVE REGULATION; MESSENGER-RNA; SP1; ACTIVATION; EXPRESSION; CLONING	The minimal promoter of the human alpha (3) nicotinic receptor subunit gene has been mapped to a region of 60 base pairs and found to contain two Spl sites, one of which is essential for promoter activity, DNase footprinting has revealed the presence of another region of interaction with nuclear factors (named F2) immediately downstream of the Spl sites. This region has been found to be functional since it is capable of stimulating the minimal promoter. The F2 protection is completely and specifically competed by an AP2 consensus oligonucleotide that has been proved to bind AP2 alpha exclusively. However, the AP2 alpha recombinant protein was unable to bind the F2 region directly, thus suggesting that AP2 alpha may participate in F2 protection by protein-protein interactions with other nuclear factors, The minimal promoter has been shown to be stimulated by two additional regions, one located downstream of F2 and the other upstream of the minimal promoter itself. In neuronal cells, the combined stimulatory activities of these three regions have synergistic effects, whereas in nonneuronal cells, there is a negative interference between the upstream and downstream regions, These opposite transcriptional effects may account for at least part of the neuro-specific expression profile of the alpha (3) gene.	Univ Milan, CNR, Cellular & Mol Pharmacol Ctr, Dept Med Pharmacol, I-20129 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Milan	Fornasari, D (corresponding author), Univ Milan, CNR, Cellular & Mol Pharmacol Ctr, Dept Med Pharmacol, Via Vanvitelli 32, I-20129 Milan, Italy.		Flora, Adriano/A-9663-2008	Fornasari, Diego/0000-0002-9668-3103				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Bai G, 1998, J BIOL CHEM, V273, P1086, DOI 10.1074/jbc.273.2.1086; Battaglioli E, 1998, J NEUROCHEM, V71, P1261; BERG DK, 2000, HANDB EXP PHARM, V144, P247; Bessis A, 1997, P NATL ACAD SCI USA, V94, P5906, DOI 10.1073/pnas.94.11.5906; BESSIS A, 1995, NEUROSCIENCE, V69, P807, DOI 10.1016/0306-4522(95)00303-Z; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; Campos-Caro A, 1999, J BIOL CHEM, V274, P4693, DOI 10.1074/jbc.274.8.4693; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CIMINO M, 1992, NEUROSCIENCE, V51, P77, DOI 10.1016/0306-4522(92)90472-E; Clementi F., 2000, Neuronal nicotinic receptors, V144, P13, DOI 10.1007/978-3-642-57079-7_2; DENERIS ES, 2000, HANDB EXP PHARM, V144, P57; EBERT SN, 1995, J BIOL CHEM, V270, P17299, DOI 10.1074/jbc.270.29.17299; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; FISHER KD, 1993, J BIOL CHEM, V268, P23915; Flora A, 2000, J NEUROCHEM, V75, P18, DOI 10.1046/j.1471-4159.2000.0750018.x; FORNASARI D, 1997, MOL PHARMACOL, V51, P251; FORNASARI D, 1999, NEURONAL NICOTINIC R, P25; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Gotti C, 1997, PROG NEUROBIOL, V53, P199, DOI 10.1016/S0301-0082(97)00034-8; Green MR, 2000, TRENDS BIOCHEM SCI, V25, P59, DOI 10.1016/S0968-0004(99)01527-3; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; Johnson W, 1997, J BIOL CHEM, V272, P15405, DOI 10.1074/jbc.272.24.15405; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KRADY JK, 1995, MOL CELL BIOL, V15, P524, DOI 10.1128/MCB.15.1.524; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LINDSTROM J, 2000, HANDB EXP PHARM, V144, P101; MAJELLO B, 1995, ONCOGENE, V10, P1841; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Mannervik M, 1999, SCIENCE, V284, P606, DOI 10.1126/science.284.5414.606; MATTER JM, 2000, HANDB EXP PHARM, V144, P33; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Noti JD, 1996, MOL CELL BIOL, V16, P2940; PARK K, 1993, J BIOL CHEM, V268, P17811; Pena P, 1999, MOL ENDOCRINOL, V13, P1402, DOI 10.1210/me.13.8.1402; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Roztocil T, 1998, J BIOL CHEM, V273, P15131, DOI 10.1074/jbc.273.24.15131; SARGENT PB, 2000, HANDB EXP PHARM, V144, P163; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; SCHOENHERR CJ, 1995, CURR OPIN NEUROBIOL, V5, P566, DOI 10.1016/0959-4388(95)80060-3; Skak K, 1999, GENE, V236, P231, DOI 10.1016/S0378-1119(99)00286-3; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Yajima S, 1998, DNA CELL BIOL, V17, P471, DOI 10.1089/dna.1998.17.471; YANG XD, 1995, J BIOL CHEM, V270, P8514, DOI 10.1074/jbc.270.15.8514	61	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41495	41503		10.1074/jbc.M006197200	http://dx.doi.org/10.1074/jbc.M006197200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018033	hybrid			2022-12-25	WOS:000166114600108
J	Yuan, LW; Gambee, JE				Yuan, LW; Gambee, JE			Phosphorylation of p300 at serine 89 by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASES; TRANSCRIPTIONAL COACTIVATOR; MEDIATED TRANSCRIPTION; ESTROGEN-RECEPTOR; ONCOPROTEIN E1A; CELL-CYCLE; CBP; ACETYLATION; ACTIVATION; SEQUENCE	CREB-binding protein (CBP)/p300 plays an important role in the connection of many different signal transduction pathways and the promotion of certain differentiation and proliferation processes. This role depends upon the ability of CBP/p300 to serve as coactivator for transcription factors. It has been suggested that CBP/p300 is regulated by phosphorylation, but the nature of the phosphorylation, the responsible kinase in vivo, and its physiological significance are still unclear. Here, we demonstrate the first identification of an in vivo phosphorylation site, conserved serine 89, in p300. Signal-dependent protein kinase C is able to phosphorylate serine 89 and mediates this phosphorylation event in vivo. Different from other phosphorylation observed so far in CBP/p300, this serine 89-specific phosphorylation represses the transcriptional activity of p300. This phosphorylation-mediated regulation of p300 function represents a previously unrecognized signal transduction pathway for protein kinase C to regulate cell growth and differentiation.	Oregon Hlth & Sci Univ, Portland, OR 97201 USA; Shriners Hosp Children, Prot Struct Facil, Portland, OR 97201 USA	Oregon Health & Science University	Yuan, LW (corresponding author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA.	yuanlw@uswest.net						ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; Hu SC, 1999, NEURON, V22, P799, DOI 10.1016/S0896-6273(00)80738-2; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Johnson JE, 1997, J BIOL CHEM, V272, P30787, DOI 10.1074/jbc.272.49.30787; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Kung AL, 2000, GENE DEV, V14, P272; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Muraoka M, 1996, ONCOGENE, V12, P1565; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; Uberall F, 1997, J BIOL CHEM, V272, P4072, DOI 10.1074/jbc.272.7.4072; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Xu JH, 1997, J CELL BIOL, V136, P473, DOI 10.1083/jcb.136.2.473; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	54	100	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40946	40951		10.1074/jbc.M007832200	http://dx.doi.org/10.1074/jbc.M007832200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11020388	hybrid			2022-12-25	WOS:000166114600039
J	Chave, KJ; Auger, IE; Galivan, J; Ryan, TJ				Chave, KJ; Auger, IE; Galivan, J; Ryan, TJ			Molecular modeling and site-directed mutagenesis define the catalytic motif in human gamma-glutamyl hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; FOLYLPOLYGLUTAMATE SYNTHETASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; METHOTREXATE; POLYGLUTAMYLATION; RESISTANCE; RESIDUES; SUBUNIT; TRIAD	Human gamma -glutamyl hydrolase (hGH) is a central enzyme in folyl and antifolylpoly-gamma -glutamate metabolism, which functions by catalyzing the cleavage of the gamma -glutamyl chain of substrates. We previously reported that Cys-110 is essential for activity. Using the sequence of hGH as a query, alignment searches of protein data bases were made using the SSearch and TPROBE programs. Significant similarity was found between hGH and the glutamine amidotransferase type I domain of Escherichia coli carbamoyl phosphate synthetase. The resulting hypothesis is that the catalytic fold of hGH is similar to the folding of this domain in carbamoyl phosphate synthetase. This model predicts that Cys-110 of hGH is the active site nucleophile and forms a catalytic triad with residues His-220 and Glu-222. The hGH mutants C110A, H220A, and E222A were prepared. Consistent with the model, mutants C110A and H220A were inactive. However, the V-max of the E222A hGH mutant was reduced only g-fold relative to the wild-type enzyme. The model also predicted that His-171 in hGH may be involved in substrate binding. The H171N hGH mutant was found to have a 250-fold reduced V-max, These studies to determine the catalytic mechanism begin to define the three dimensional interactions of hGH with poly-gamma -glutamate substrates.	New York State Dept Hlth, Wadsworth Ctr Labs & Res, Div Mol Med, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center	Ryan, TJ (corresponding author), New York State Dept Hlth, Wadsworth Ctr Labs & Res, Div Mol Med, Albany, NY 12201 USA.	thomas.ryan@wadsworth.org			NATIONAL CANCER INSTITUTE [R01CA025933, R01CA082425] Funding Source: NIH RePORTER; NCI NIH HHS [CA25933, CA82425] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMURO N, 1985, J BIOL CHEM, V260, P4844; CHABNER BA, 1985, J CLIN INVEST, V76, P907, DOI 10.1172/JCI112088; Chave KJ, 1999, BIOCHEM J, V343, P551, DOI 10.1042/0264-6021:3430551; Chazal M, 1997, CLIN CANCER RES, V3, P553; GALIVAN J, 1980, MOL PHARMACOL, V17, P105; Galivan J, 2000, PHARMACOL THERAPEUT, V85, P207, DOI 10.1016/S0163-7258(99)00063-7; GALIVAN J, 1998, HDB PROTEOLYTIC ENZY, P7983; Hewagama A, 1998, BBA-PROTEIN STRUCT M, V1388, P489, DOI 10.1016/S0167-4838(98)00212-X; Huang XY, 1999, BIOCHEMISTRY-US, V38, P15909, DOI 10.1021/bi991805q; Knochel T, 1999, P NATL ACAD SCI USA, V96, P9479, DOI 10.1073/pnas.96.17.9479; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEVITT M, 1983, J MOL BIOL, V170, P723, DOI 10.1016/S0022-2836(83)80129-6; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Liu YN, 1998, BIOCHEM PHARMACOL, V55, P2031, DOI 10.1016/S0006-2952(98)00089-6; Longo GSA, 1997, ONCOL RES, V9, P259; MCCLOSKEY DE, 1991, J BIOL CHEM, V266, P6181; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MIRAN SG, 1991, BIOCHEMISTRY-US, V30, P7901, DOI 10.1021/bi00246a005; Neuwald AF, 1997, NUCLEIC ACIDS RES, V25, P1665, DOI 10.1093/nar/25.9.1665; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; PEARSON WR, 1995, PROTEIN SCI, V4, P1145, DOI 10.1002/pro.5560040613; RHEE MS, 1993, CANCER RES, V53, P2227; Rhee MS, 1998, MOL PHARMACOL, V53, P1040; Rots MG, 1999, BLOOD, V93, P1677, DOI 10.1182/blood.V93.5.1677.405a16_1677_1683; ROUX B, 1993, BIOCHEMISTRY-US, V32, P3763, DOI 10.1021/bi00065a031; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; RUMBERGER BG, 1990, CANCER COMMUN, V2, P305; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P16158, DOI 10.1021/bi991741j; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P8825, DOI 10.1021/bi9807761; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; VERNET T, 1995, J BIOL CHEM, V270, P16645, DOI 10.1074/jbc.270.28.16645; Waltham MC, 1997, MOL PHARMACOL, V51, P825, DOI 10.1124/mol.51.5.825; YAO R, 1995, MOL PHARMACOL, V48, P505	39	22	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40365	40370		10.1074/jbc.M007908200	http://dx.doi.org/10.1074/jbc.M007908200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11005824	hybrid			2022-12-25	WOS:000166039500077
J	Chi, MMY; Pingsterhaus, J; Carayannopoulos, M; Moley, KH				Chi, MMY; Pingsterhaus, J; Carayannopoulos, M; Moley, KH			Decreased glucose transporter expression triggers BAX-dependent apoptosis in the murine blastocyst	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; MOUSE; DEPRIVATION; EMBRYOS; PAX-3; MALFORMATIONS; PERICYTES; PATHWAY; DEATH; MICE	We report that a decrease in facilitative glucose transporter (GLUT1) expression and reduced glucose transport trigger apoptosis in the murine blastocyst. Inhibition of GLUT1 expression either by high glucose conditions or with antisense oligodeoxynucleotides significantly lowers protein expression and function of GLUT1 and as a result induces a high rate of apoptosis at the blastocyst stage. Similar to wild-type mice, embryos from streptozotocin-induced diabetic Box -/-mice experienced a significant decrease in glucose transport compared with embryos from non-diabetic Box -/- mice. However, despite this decrease, these blastocysts demonstrate significantly fewer apoptotic nuclei as compared with blastocysts from hyperglycemic wild-type mice. This decrease in preimplantation apoptosis correlates with a decrease in resorptions and malformations among the infants of the hyperglycemic Box -/- mice versus the Box +/+ and +/- mice. These findings suggest that hyperglycemia by decreasing glucose transport acts as a cell death signal to trigger a BAX-dependent apoptotic cascade in the murine blastocyst. This work also supports the hypothesis that increased apoptosis at a blastocyst stage because of maternal hyperglycemia may result in loss of key progenitor cells and manifest as a resorption or malformation, two adverse pregnancy outcomes more common in diabetic women.	Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Moley, KH (corresponding author), Washington Univ, Sch Med, Dept Obstet & Gynecol, 4911 Barnes Jewish Hosp Plaza,6th Floor Maternity, St Louis, MO 63110 USA.	moleyk@msnotes.wustl.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD034693] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030579] Funding Source: NIH RePORTER; NICHD NIH HHS [R03HD34693] Funding Source: Medline; NIDDK NIH HHS [T32DK38496-20, P60DK30579] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; BAUMGARTNERPARZER SM, 1995, DIABETES, V44, P1323, DOI 10.2337/diabetes.44.11.1323; Berridge MV, 1996, J IMMUNOL, V156, P4092; Bialik S, 1999, CIRC RES, V85, P403, DOI 10.1161/01.RES.85.5.403; Blackburn RV, 1999, FREE RADICAL BIO MED, V26, P419, DOI 10.1016/S0891-5849(98)00217-2; BRINSTER RL, 1966, EXP CELL RES, V42, P308, DOI 10.1016/0014-4827(66)90295-3; Brison Daniel R., 1994, Zygote, V2, P69; Brison DR, 1996, MOL REPROD DEV, V44, P171, DOI 10.1002/(SICI)1098-2795(199606)44:2&lt;171::AID-MRD5&gt;3.0.CO;2-K; Cai J, 1998, DIABETES, V47, P1803, DOI 10.2337/diabetes.47.11.1803; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CHI MMY, 1993, P NATL ACAD SCI USA, V90, P10023, DOI 10.1073/pnas.90.21.10023; Deckwerth TL, 1998, EXP NEUROL, V152, P150, DOI 10.1006/exnr.1998.6846; Di Wu Q, 1999, AM J PHYSIOL-CELL PH, V277, pC1229, DOI 10.1152/ajpcell.1999.277.6.C1229; Diabet Control Complications Trial Res Grp, 1996, AM J OBSTET GYNECOL, V174, P1343; Donath MY, 1999, DIABETES, V48, P738, DOI 10.2337/diabetes.48.4.738; Eriksson UJ, 1996, DIABETES, V45, P1497, DOI 10.2337/diabetes.45.11.1497; GREENE MF, 1989, TERATOLOGY, V39, P225, DOI 10.1002/tera.1420390303; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Hawthorne G, 1997, BRIT MED J, V315, P279, DOI 10.1136/bmj.315.7103.279; Hill AL, 1998, DEV GENES EVOL, V208, P128, DOI 10.1007/s004270050163; HOMMA S, 1994, J COMP NEUROL, V345, P377, DOI 10.1002/cne.903450305; KAN O, 1994, J EXP MED, V180, P917, DOI 10.1084/jem.180.3.917; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Lee YJ, 1997, J CELL SCI, V110, P681; Leese HJ, 1995, HUM REPROD UPDATE, V1, P63, DOI 10.1093/humupd/1.1.63; LEESE HJ, 1991, EARLY EMBRYO DEV PAR, P117; Li WY, 1998, INVEST OPHTH VIS SCI, V39, P1535; Malhotra R, 1999, J BIOL CHEM, V274, P12567, DOI 10.1074/jbc.274.18.12567; MANDARINO LJ, 1994, INVEST OPHTH VIS SCI, V35, P964; MARTIN KL, 1995, MOL REPROD DEV, V40, P436, DOI 10.1002/mrd.1080400407; Moley KH, 1998, AM J PHYSIOL-ENDOC M, V275, pE38, DOI 10.1152/ajpendo.1998.275.1.E38; Moley KH, 2000, APOPTOSIS, V5, P99, DOI 10.1023/A:1009697908332; Moley KH, 1998, NAT MED, V4, P1421, DOI 10.1038/4013; MOLEY KH, 1991, J REPROD FERTIL, V93, P325; Pantaleon M, 1997, P NATL ACAD SCI USA, V94, P3795, DOI 10.1073/pnas.94.8.3795; Phelan SA, 1997, DIABETES, V46, P1189, DOI 10.2337/diabetes.46.7.1189; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Siman CM, 1997, DIABETES, V46, P1054, DOI 10.2337/diabetes.46.6.1054; Siman CM, 1997, DIABETOLOGIA, V40, P1416, DOI 10.1007/s001250050844; WALES RG, 1986, J REPROD FERTIL, V76, P717, DOI 10.1530/jrf.0.0760717; Wentzel P, 1998, DIABETES, V47, P677, DOI 10.2337/diabetes.47.4.677	41	117	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40252	40257		10.1074/jbc.M005508200	http://dx.doi.org/10.1074/jbc.M005508200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10995754	hybrid			2022-12-25	WOS:000166039500063
J	Gonzalez-Huici, V; Salas, M; Hermoso, JM				Gonzalez-Huici, V; Salas, M; Hermoso, JM			Sequence requirements for protein-primed initiation and elongation of phage O29 DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLIDING-BACK MECHANISM; PHI-29 TERMINAL PROTEIN; IN-VITRO; BACTERIOPHAGE PRD1; LINEAR TEMPLATE; POLYMERASE; ORIGINS; RECOGNITION; ACTIVATION; FIDELITY	The double-stranded linear DNA of Bacillus subtilis phage empty set29 is replicated by a mechanism in which a terminal protein (TP) acts as a primer. The second 3'-terminal nucleotide of the template directs the incorporation of the 5'-terminal nucleotide into the TP, giving rise to the initiation complex TP-dAMP. Elongation then proceeds by a sliding-back mechanism in which the dAMP covalently linked to the TP pairs to the S'-terminal nucleotide of the template strand to recover full-length DNA, We have studied the sequence requirements for efficient initiation of replication using mutated TP-free double-stranded DNA fragments. Efficient initiation only requires the terminal repetition 5'-AA The S'-terminal T, although not used as template, increases the affinity of DNA polymerase for the initiator nucleotide; in addition, although to a minor extent, the third 3'-terminal position also directs the formation of the initiation complex and modulates the initiation rate at the second position. Efficient elongation requires a previous sliding-back, demanding again a repetition of two nucleotides at the 3' end; if the sliding-back is prevented, a residual elongation can proceed directly from the second position or after jumping back from the third to the first position.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Salas, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Salas, Margarita/J-9873-2014; Gonzalez-Huici, Victor/ABB-4680-2020	Salas, Margarita/0000-0001-5939-3441; Gonzalez Huici, Victor/0000-0002-6977-1060	NIGMS NIH HHS [2R02GM27242-20] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BLANCO L, 1992, J BIOL CHEM, V267, P1225; BRAVO A, 1994, GENE, V148, P107, DOI 10.1016/0378-1119(94)90242-9; CALDENTEY J, 1993, NUCLEIC ACIDS RES, V21, P3725, DOI 10.1093/nar/21.16.3725; deVega M, 1996, EMBO J, V15, P1182, DOI 10.1002/j.1460-2075.1996.tb00457.x; Donaldson AD, 1999, CURR OPIN GENET DEV, V9, P62, DOI 10.1016/S0959-437X(99)80009-4; ESTEBAN JA, 1992, BIOCHEMISTRY-US, V31, P350, DOI 10.1021/bi00117a006; ESTEBAN JA, 1993, J BIOL CHEM, V268, P2719; Gonzalez-Huici V, 2000, J BIOL CHEM, V275, P14678, DOI 10.1074/jbc.M910058199; Goodman MF, 1997, P NATL ACAD SCI USA, V94, P10493, DOI 10.1073/pnas.94.20.10493; GUTIERREZ J, 1986, VIROLOGY, V155, P474, DOI 10.1016/0042-6822(86)90209-6; GUTIERREZ J, 1988, NUCLEIC ACIDS RES, V16, P5895, DOI 10.1093/nar/16.13.5895; GUTIERREZ J, 1986, GENE, V43, P1, DOI 10.1016/0378-1119(86)90002-8; Illana B, 1999, J BIOL CHEM, V274, P15073, DOI 10.1074/jbc.274.21.15073; Illana B, 1996, J MOL BIOL, V264, P453, DOI 10.1006/jmbi.1996.0653; INCIARTE MR, 1976, VIROLOGY, V74, P314, DOI 10.1016/0042-6822(76)90338-X; KING AJ, 1994, EMBO J, V13, P5786, DOI 10.1002/j.1460-2075.1994.tb06917.x; Lazaro JM, 1995, METHOD ENZYMOL, V262, P42; Martin AC, 1996, J MOL BIOL, V260, P369, DOI 10.1006/jmbi.1996.0407; Mendez J, 1997, EMBO J, V16, P2519, DOI 10.1093/emboj/16.9.2519; MENDEZ J, 1992, P NATL ACAD SCI USA, V89, P9579, DOI 10.1073/pnas.89.20.9579; MESSER W, 1996, ESCHERICHIA COLI SAL, V2, P1579; Moran S, 1997, P NATL ACAD SCI USA, V94, P10506, DOI 10.1073/pnas.94.20.10506; Ritzi M, 2000, GENE, V245, P13, DOI 10.1016/S0378-1119(00)00020-2; Salas M, 1991, ANNU REV BIOCHEM, V60, P37; SALAS M, 1996, DNA REPLICATION EUKA, P131; TEMPERLEY SM, 1992, EMBO J, V11, P761, DOI 10.1002/j.1460-2075.1992.tb05109.x; YOO SK, 1991, J MOL BIOL, V218, P779, DOI 10.1016/0022-2836(91)90266-9	28	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40547	40553		10.1074/jbc.M007170200	http://dx.doi.org/10.1074/jbc.M007170200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11006291	hybrid			2022-12-25	WOS:000166039500100
J	Kataoka, H; Shimomura, T; Kawaguchi, T; Hamasuna, R; Itoh, H; Kitamura, N; Miyazawa, K; Koono, M				Kataoka, H; Shimomura, T; Kawaguchi, T; Hamasuna, R; Itoh, H; Kitamura, N; Miyazawa, K; Koono, M			Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SINGLE CHAIN FORM; 2 KUNITZ DOMAINS; SERINE-PROTEASE; PLACENTAL BIKUNIN; MOLECULAR-CLONING; TISSUE-INJURY; PRECURSOR; PURIFICATION; EXPRESSION	Hepatocyte growth factor activator (HGFA) is responsible for proteolytic activation of the precursor form of hepatocyte growth factor in injured tissues. To date, two specific inhibitors of HGFA have been identified, namely HGFA inhibitor type 1 (HAI-1) and type 2 (HAI-2)/placental bikunin (PB). Both inhibitors are first synthesized as integral membrane proteins having two Kunitz domains and a transmembrane domain, and are subsequently released from cell surface by shedding. Here we show that an active form of HGFA is specifically complexed with membrane-form HAI-1, but not with HAI-2/PB, on the surface of epithelial cells expressing both inhibitors. This binding required the enzyme activity of HGFA. The selective binding of HGFA to the cell surface HAI-1 was further confirmed in an engineered system using Chinese hamster ovary cells, in which only the cells expressing HAI-1 retained exogenous HGFA. The binding of HGFA to HAI-1 was reversible, and no irreversible modifications affecting the enzyme activity occurred during the binding. Importantly, HAI-1 and the HGFA HAI-1 complex were quickly released from the cell surface by treatment with phorbol 12-myristate 13-acetate or interleukin 1 beta accompanying the generation of 58-kDa fragments of HAI-1, which are less potent against HGFA, as well as significant recovery of HGFA activity in the culture supernatant. This regulated shedding was completely inhibited by BB3103, a synthetic zinc-metalloproteinase inhibitor. We conclude that HAI-1 is not only an inhibitor but also a specific acceptor of active HGFA, acting as a reservoir of this enzyme on the cell surface. The latter property appears to ensure the concentrated pericellular HGFA activity in certain cellular conditions, such as tissue injury and inflammation, via the up-regulated shedding of HGFA.HAI-1 complex. These findings shed light on a novel function of the integral membrane Kunitz-type inhibitor in the regulation of pericellular proteinase activity.	Miyazaki Med Coll, Dept Pathol 2, Miyazaki 8891692, Japan; Mitsubishi Tokyo Pharmaceut Inc, Yokohama Res Ctr, Aoba Ku, Yokohama, Kanagawa 2278502, Japan; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan	University of Miyazaki; Tokyo Institute of Technology	Kataoka, H (corresponding author), Miyazaki Med Coll, Dept Pathol 2, 5200 Kihara, Miyazaki 8891692, Japan.	mejina@fc.miyazaki-med.ac.jp	MIYAZAWA, KEIJI/I-9713-2014					Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; Delaria KA, 1997, J BIOL CHEM, V272, P12209, DOI 10.1074/jbc.272.18.12209; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Itoh H, 2000, BBA-GENE STRUCT EXPR, V1491, P295, DOI 10.1016/S0167-4781(00)00029-4; Itoh H, 2000, AM J PHYSIOL-GASTR L, V278, pG635, DOI 10.1152/ajpgi.2000.278.4.G635; Itoh M, 2000, EUR J BIOCHEM, V267, P3351, DOI 10.1046/j.1432-1327.2000.01368.x; Kataoka H, 1998, CANCER LETT, V128, P219, DOI 10.1016/S0304-3835(98)00067-6; Kataoka H, 1999, J HISTOCHEM CYTOCHEM, V47, P673, DOI 10.1177/002215549904700509; Kataoka H, 2000, CANCER LETT, V148, P127, DOI 10.1016/S0304-3835(99)00322-5; Kawaguchi T, 1997, J BIOL CHEM, V272, P27558, DOI 10.1074/jbc.272.44.27558; KAWAIDA K, 1994, P NATL ACAD SCI USA, V91, P4357, DOI 10.1073/pnas.91.10.4357; Kinoshita Y, 1997, DIGESTION, V58, P225, DOI 10.1159/000201448; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Marlor CW, 1997, J BIOL CHEM, V272, P12202, DOI 10.1074/jbc.272.18.12202; Matsubara Y, 1998, BIOCHEM BIOPH RES CO, V253, P477, DOI 10.1006/bbrc.1998.9808; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; Mitsiades N, 1998, AM J PATHOL, V153, P1947, DOI 10.1016/S0002-9440(10)65708-2; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; Miyazawa K, 1996, J BIOL CHEM, V271, P3615; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; MORISHITA H, 1994, THROMB RES, V73, P193, DOI 10.1016/0049-3848(94)90098-1; Muller-Pillasch F, 1998, BBA-GENE STRUCT EXPR, V1395, P88, DOI 10.1016/S0167-4781(97)00129-2; NAKA D, 1992, J BIOL CHEM, V267, P20114; Ohmichi H, 1996, AM J PHYSIOL-LUNG C, V270, pL1031, DOI 10.1152/ajplung.1996.270.6.L1031; Okajima A, 1997, HEPATOLOGY, V25, P97, DOI 10.1002/hep.510250118; PARK LS, 1986, J BIOL CHEM, V261, P205; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Qin L, 1998, FEBS LETT, V436, P111, DOI 10.1016/S0014-5793(98)01105-3; Schmassmann A, 1997, GASTROENTEROLOGY, V113, P1858, DOI 10.1016/S0016-5085(97)70005-2; Seguchi K, 1999, BIOL CHEM, V380, P473, DOI 10.1515/BC.1999.061; Shimomura T, 1999, J BIOCHEM-TOKYO, V126, P821, DOI 10.1093/oxfordjournals.jbchem.a022522; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; SHIMOMURA T, 1995, EUR J BIOCHEM, V229, P257, DOI 10.1111/j.1432-1033.1995.0257l.x; SHIMOMURA T, 1992, CYTOTECHNOLOGY, V8, P219, DOI 10.1007/BF02522039; SHIMOMURA T, 1993, J BIOL CHEM, V268, P22927; Stella MC, 1999, INT J BIOCHEM CELL B, V31, P1357, DOI 10.1016/S1357-2725(99)00089-8; TAMURA M, 1993, J BIOL CHEM, V268, P8140; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; Xu YB, 1998, J MOL BIOL, V276, P955, DOI 10.1006/jmbi.1997.1582	41	111	124	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40453	40462		10.1074/jbc.M006412200	http://dx.doi.org/10.1074/jbc.M006412200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11013244	hybrid			2022-12-25	WOS:000166039500088
J	Tsai, JC; Liu, LX; Cooley, BC; Dichiara, MR; Topper, JN; Aird, WC				Tsai, JC; Liu, LX; Cooley, BC; Dichiara, MR; Topper, JN; Aird, WC			The Egr-1 promoter contains information for constitutive and inducible expression in transgenic mice	FASEB JOURNAL			English	Article									Beth Israel Deaconess Med Ctr, Dept Mol Med, Boston, MA 02215 USA; Med Coll Wisconsin, Dept Orthopaed Surg, Milwaukee, WI 53226 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Harvard University; Beth Israel Deaconess Medical Center; Medical College of Wisconsin; Stanford University	Aird, WC (corresponding author), Beth Israel Deaconess Med Ctr, Dept Mol Med, RW-663,330 Brookline Ave, Boston, MA 02215 USA.								0	22	23	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					1870	1872						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023970				2022-12-25	WOS:000089634400005
J	Yamada, A; Yamada, M; Fujita, Y; Nishigami, T; Nakasho, K; Uematsu, K				Yamada, A; Yamada, M; Fujita, Y; Nishigami, T; Nakasho, K; Uematsu, K			Self-augmentation effect of male-specific products on sexually differentiated progesterone metabolism in adult male rat liver microsomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE; 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE; STEROID 5-ALPHA-REDUCTASE; HEPATIC CYTOCHROME-P450; DEPENDENT EXPRESSION; BINDING SITE; DWARF RATS; PROFILE; PLASMA; GENE	It is well known that several 3-keto-4-ene steroids such as progesterone and testosterone are metabolized in a gender-specific or -predominant manner by adult rat liver microsomes. In the male, these steroids are primarily metabolized into two oxidized (16 alpha -hydroxyl and 6 beta -hydroxyl) products mainly by the respective, male-specific cytochrome P450 subforms, CYP2C11 and CYP3A2, while they are primarily metabolized into the 5 alpha -reduced products by female-predominant 5 alpha -reductase in the female. These sexually differentiated enzyme activities are largely regulated at the transcription level under endocrine control. In the present study, we show that unlabeled 16 alpha -hydroxyprogesterone and 6 beta -hydroxyprogesterone inhibited the 5 alpha -reductive [H-3]progesterone metabolism by adult male rat liver microsomes without significantly inhibiting the CYP2C11 and CYP3A2 activities producing themselves, whereas 3 alpha -hydroxy-5 alpha -pregnan-20-one and 5 alpha -pregnane-3,20-dione not only stimulated the 5 alpha -reductive metabolism producing themselves but also inhibited the male-specific oxidative metabolism. This finding compels us to propose a novel hypothesis that adult male rat liver microsomes may possess a self-augmentation system regulated by the male-specific products on sexually differentiated steroid metabolism, besides regulation by gene expressions of the related enzymes.	Hyogo Coll Med, Dept Pathol 2, Nishinomiya, Hyogo 6638501, Japan; Hyogo Coll Med, Dept Chem, Nishinomiya, Hyogo 6638501, Japan	Hyogo College of Medicine; Hyogo College of Medicine	Yamada, A (corresponding author), Hyogo Coll Med, Dept Pathol 2, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.							AOSHIMA Y, 1964, ENDOCRINOLOGY, V74, P521, DOI 10.1210/endo-74-4-521; BIRMINGHAM MK, 1958, ENDOCRINOLOGY, V62, P47, DOI 10.1210/endo-62-1-47; BLANCK A, 1986, CANCER RES, V46, P5072; CARSIA RV, 1984, ENDOCRINOLOGY, V115, P2464, DOI 10.1210/endo-115-6-2464; CATANIA VA, 1995, BIOCHEM PHARMACOL, V50, P509, DOI 10.1016/0006-2952(95)00166-W; Chang TKH, 1996, J PHARMACOL EXP THER, V278, P1383; CORPECHOT C, 1993, ENDOCRINOLOGY, V133, P1003, DOI 10.1210/en.133.3.1003; DANNAN GA, 1986, J BIOL CHEM, V261, P728; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; HEINRICH.WL, 1966, STEROIDS, V7, P91, DOI 10.1016/0039-128X(66)90137-1; KINOSHITA Y, 1981, ENDOCRINOL JAPON, V28, P499; Lancel M, 1996, AM J PHYSIOL-ENDOC M, V271, pE763, DOI 10.1152/ajpendo.1996.271.4.E763; LEGRAVEREND C, 1992, FASEB J, V6, P711, DOI 10.1096/fasebj.6.2.1537461; MODE A, 1981, ENDOCRINOLOGY, V108, P2103, DOI 10.1210/endo-108-6-2103; MONSALVE A, 1977, STEROIDS, V30, P41, DOI 10.1016/0039-128X(77)90135-0; MURRAY M, 1991, ARCH BIOCHEM BIOPHYS, V286, P618, DOI 10.1016/0003-9861(91)90089-2; NORMINGTON K, 1992, J BIOL CHEM, V267, P19548; Pampori NA, 1999, ENDOCRINOLOGY, V140, P1245, DOI 10.1210/en.140.3.1245; Pampori NA, 1996, MOL PHARMACOL, V50, P1148; RIBEIRO V, 1992, ARCH BIOCHEM BIOPHYS, V293, P147, DOI 10.1016/0003-9861(92)90377-9; RUNGEMORRIS M, 1991, BIOCHEM BIOPH RES CO, V175, P1051, DOI 10.1016/0006-291X(91)91671-X; Shimada M, 1997, ARCH BIOCHEM BIOPHYS, V337, P34, DOI 10.1006/abbi.1996.9764; SMITHGALL TE, 1985, CANCER RES, V45, P4946; STOLZ A, 1991, J BIOL CHEM, V266, P15253; SWINNEY DC, 1990, DRUG METAB DISPOS, V18, P859; WAXMAN DJ, 1989, ENDOCRINOLOGY, V124, P2954, DOI 10.1210/endo-124-6-2954; WIEBEL FJ, 1971, ARCH BIOCHEM BIOPHYS, V144, P78, DOI 10.1016/0003-9861(71)90456-5; YAMADA M, 1974, ENDOCRINOLOGY, V94, P777, DOI 10.1210/endo-94-3-777; YAMADA M, 1990, J BIOL CHEM, V265, P11035; YAMADA M, 1994, HEPATOLOGY, V20, P1271, DOI 10.1016/0270-9139(94)90768-4; YAMAZOE Y, 1989, MOL PHARMACOL, V35, P707	31	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4604	4610		10.1074/jbc.M003355200	http://dx.doi.org/10.1074/jbc.M003355200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	10995741	hybrid			2022-12-25	WOS:000168484300013
J	Scott, RP; Ibanez, CF				Scott, RP; Ibanez, CF			Determinants of ligand binding specificity in the glial cell line-derived neurotrophic factor family receptor alpha s	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-RET PROTOONCOGENE; NERVE GROWTH-FACTOR; TYROSINE KINASE; CRYSTAL-STRUCTURE; GDNF; ACTIVATION; COMPLEX; PROTEIN; EXPRESSION; MECHANISMS	The glial cell line-derived neurotrophic factor (GDNF) family comprise a subclass of cystine-knot superfamily ligands that interact with a multisubunit receptor complex formed by the c-Ret tyrosine kinase and a cystine-rich glycosyl phosphatidylinositol-anchored binding subunit called GDNF family receptor alpha (GFR alpha). All four GDNF family ligands utilize c-Ret as a common signaling receptor, whereas specificity is conferred by differential binding to four distinct GFR alpha homologues. To understand how the different GFR alphas discriminate ligands, we have constructed a large set of chimeric and truncated receptors and analyzed their ligand binding and signaling capabilities. The major determinant of ligand binding was found in the most conserved region of the molecule, a central domain predicted to contain four conserved alpha helices and two beta strands. Distinct hydrophobic and positively charged residues in this central region were required for binding of GFR alpha1 to GDNF. Interaction of GFR alpha1 and GFR alpha2 with GDNF and neurturin required distinct subsegments within this central domain, which allowed the construction of chimeric receptors that responded equally well to both ligands, C-terminal segments adjacent to the central domain are necessary and have modulatory function in ligand binding. In contrast, the N-terminal domain was dispensable without compromising ligand binding specificity. Ligand-independent interaction with c-Ret also resides in the central domain of GFR alpha1, albeit within a distinct and smaller region than that required for ligand binding. Our results indicate that the central region of this class of receptors constitutes a novel binding domain for cystine-knot superfamily ligands.	Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, S-17177 Stockholm, Sweden	Karolinska Institutet	Ibanez, CF (corresponding author), Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, Berzelius Vag 1, S-17177 Stockholm, Sweden.		Scott, Rizaldy/Y-7584-2019; Scott, Rizaldy/AAC-5264-2020	Scott, Rizaldy/0000-0002-0288-8862; 				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Baloh RH, 2000, J BIOL CHEM, V275, P3412, DOI 10.1074/jbc.275.5.3412; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Eketjall S, 1999, EMBO J, V18, P5901, DOI 10.1093/emboj/18.21.5901; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; ILAG LL, 1994, J BIOL CHEM, V269, P19941; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Lindahl M, 2000, MOL CELL NEUROSCI, V15, P522, DOI 10.1006/mcne.2000.0845; Masure S, 1999, EUR J BIOCHEM, V266, P892, DOI 10.1046/j.1432-1327.1999.00925.x; Masure S, 2000, J BIOL CHEM, V275, P39427, DOI 10.1074/jbc.M003867200; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; MURRAYRUST J, 1993, STRUCTURE, V1, P153, DOI 10.1016/0969-2126(93)90029-G; Poteryaev D, 1999, FEBS LETT, V463, P63, DOI 10.1016/S0014-5793(99)01590-2; Rosenblad C, 2000, MOL CELL NEUROSCI, V15, P199, DOI 10.1006/mcne.1999.0817; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; Sariola H, 1999, INT J DEV BIOL, V43, P413; Thompson J, 1998, MOL CELL NEUROSCI, V11, P117, DOI 10.1006/mcne.1998.0682; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; Trupp M, 1997, J NEUROSCI, V17, P3554; Ultsch MH, 1999, J MOL BIOL, V290, P149, DOI 10.1006/jmbi.1999.2816; URFER R, 1994, EMBO J, V13, P5896, DOI 10.1002/j.1460-2075.1994.tb06935.x; Urfer R, 1997, BIOCHEMISTRY-US, V36, P4775, DOI 10.1021/bi962877+; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657; Wiesmann C, 1999, NATURE, V401, P184, DOI 10.1038/43705; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Wong YW, 1998, NEUROREPORT, V9, P3767, DOI 10.1097/00001756-199812010-00002; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619; Yu T, 1998, J NEUROSCI, V18, P4684	41	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1450	1458		10.1074/jbc.M006157200	http://dx.doi.org/10.1074/jbc.M006157200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11018032	hybrid			2022-12-25	WOS:000166430900079
J	Vyas, DR; McCarthy, JJ; Tsika, GL; Tsika, RW				Vyas, DR; McCarthy, JJ; Tsika, GL; Tsika, RW			Multiprotein complex formation at the beta myosin heavy chain distal muscle CAT element correlates with slow muscle expression but not mechanical overload responsiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX ZIPPER PROTEIN; SKELETAL-MUSCLE; TRANSCRIPTION FACTORS; REGULATORY ELEMENTS; GENE-EXPRESSION; CARDIAC-MUSCLE; ENHANCER; BINDING; TEF-1; MAX	To examine the role of the P-myosin heavy chain (beta MyHC) distal muscle CAT (MCAT) element in muscle fiber type-specific expression and mechanical overload (MOV) responsiveness, we conducted transgenic and in vitro experiments. In adult transgenic mice, mutation of the distal MCAT element led to significant reductions in chloramphenicol acetyltransferase (CAT) specific activity measured in control soleus and plantaris muscles when compared with wild type transgene beta 293WT but did not abolish MOV-induced CAT specific activity. Electrophoretic mobility shift assay revealed the formation of a specific low migrating nuclear protein complex (LMC) at the beta MyHC MCAT element that was highly enriched only when using either MOV plantaris or control soleus nuclear extract. Scanning mutagenesis of the beta MyHC distal MCAT element revealed that only the nucleotides comprising the core MCAT element were essential for LMC formation. The proteins within the LMC when using either MOV plantaris or control soleus nuclear extracts were antigenically related to nominal transcription enhancer factor 1 (NTEF-1), poly(ADP-ribose) polymerase (PARP), and Max, Only in vitro translated TEF-1 protein bound to the distal MCAT element, suggesting that this multiprotein complex is tethered to the DNA via TEF-1. Protein-protein interaction assays revealed interactions between nominal TEF-1, PARP, and Max. Our studies show that for transgene beta 293 the distal MCAT element is not required for MOV responsiveness but suggest that a multiprotein complex likely comprised of nominal TEF-1, PARP, and Max forms at this element to contribute to basal slow fiber expression.	Univ Missouri, Dept Vet Biomed Sci, Sch Vet Med, Columbia, MO 65211 USA; Univ Missouri, Sch Med, Dept Biochem, Columbia, MO 65211 USA; Univ Missouri, Dalton Cardiovasc Res Ctr, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Tsika, RW (corresponding author), Univ Missouri, Dept Vet Biomed Sci, Sch Vet Med, 1600 E Rollins Ave,W112 VET Med Bldg, Columbia, MO 65211 USA.				NIAMS NIH HHS [R01-AR47197, R01-AR41464] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041464, R01AR047197] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; FabreSuver C, 1996, J BIOL CHEM, V271, P4646, DOI 10.1074/jbc.271.9.4646; Farrance IKG, 1996, J BIOL CHEM, V271, P8266, DOI 10.1074/jbc.271.14.8266; Gupta MP, 1997, MOL CELL BIOL, V17, P3924, DOI 10.1128/MCB.17.7.3924; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; Gupta MP, 2000, NUCLEIC ACIDS RES, V28, P3168, DOI 10.1093/nar/28.16.3168; Homburg S, 2000, J CELL BIOL, V150, P293, DOI 10.1083/jcb.150.2.293; Jacquemin P, 1997, TRENDS CARDIOVAS MED, V7, P192, DOI 10.1016/S1050-1738(97)00052-2; Jacquemin P, 1996, J BIOL CHEM, V271, P21775, DOI 10.1074/jbc.271.36.21775; Jacquemin P, 1997, J BIOL CHEM, V272, P12928, DOI 10.1074/jbc.272.20.12928; Jiang SW, 2000, BIOCHEMISTRY-US, V39, P3505, DOI 10.1021/bi991048w; KNOTTS S, 1994, J BIOL CHEM, V269, P31275; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; LARKIN SB, 1999, HEART DEV, P307; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; McCarthy JJ, 1999, J BIOL CHEM, V274, P14270, DOI 10.1074/jbc.274.20.14270; McCarthy JJ, 1997, AM J PHYSIOL-REG I, V272, pR1552, DOI 10.1152/ajpregu.1997.272.5.R1552; Ojamaa K, 1995, J BIOL CHEM, V270, P31276, DOI 10.1074/jbc.270.52.31276; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; RINDT H, 1995, P NATL ACAD SCI USA, V92, P1540, DOI 10.1073/pnas.92.5.1540; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Tsika GL, 1996, AM J PHYSIOL-CELL PH, V271, pC690, DOI 10.1152/ajpcell.1996.271.2.C690; Tsika R W, 1994, Exerc Sport Sci Rev, V22, P361; TSIKA RW, 1995, AM J PHYSIOL-CELL PH, V269, pC665, DOI 10.1152/ajpcell.1995.269.3.C665; Ueyama T, 2000, J BIOL CHEM, V275, P17476, DOI 10.1074/jbc.M001970200; Vyas DR, 1999, J BIOL CHEM, V274, P30832, DOI 10.1074/jbc.274.43.30832; VYAS DR, 2000, BASIC APPL MYOL, V10, P5; Wiedenman JL, 1996, AM J PHYSIOL-CELL PH, V270, pC1111, DOI 10.1152/ajpcell.1996.270.4.C1111; Wiedenman JL, 1996, AM J PHYSIOL-REG I, V271, pR688, DOI 10.1152/ajpregu.1996.271.3.R688; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; [No title captured]	37	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1173	1184		10.1074/jbc.M007750200	http://dx.doi.org/10.1074/jbc.M007750200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11010974	hybrid			2022-12-25	WOS:000166430900045
J	Jutras, I; Seidah, NG; Reudelhuber, TL				Jutras, I; Seidah, NG; Reudelhuber, TL			A predicted alpha-helix mediates targeting of the proprotein convertase PC1 to the regulated secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; C-TERMINAL REGION; CARBOXYPEPTIDASE-E; PROHORMONE CONVERTASES; CPE(FAT)/CPE(FAT) MICE; CELLULAR TRAFFICKING; PRECURSOR PROTEINS; MEMBRANE-BINDING; ATT-20 CELLS; ACIDIC PH	The proprotein convertase PC1 is a protease whose activity is largely confined to the dense core secretory granules of neuroendocrine cells. Efficient processing of PC1 substrates in granules requires a mechanism that will both limit the activity of the enzyme to these organelles and promote its targeting to the nascent secretory granules. In the current study, we provide evidence that targeting of PC1 to secretory granules is mediated by alpha -helical structures in its C-terminal tail and, at least in part, is dependent on interactions with specific components of the secretory granule membrane.	Inst Rech Clin Montreal, Lab Mol Biochem Hypertens, Montreal, PQ H2W 1R7, Canada; Inst Rech Clin Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Reudelhuber, TL (corresponding author), Inst Rech Clin Montreal, Lab Mol Biochem Hypertens, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	reudelt@ircm.qc.ca	Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342				Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; Brechler V, 1996, J BIOL CHEM, V271, P20636, DOI 10.1074/jbc.271.34.20636; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; HILL RM, 1995, J NEUROCHEM, V65, P2318; Irminger JC, 1997, J BIOL CHEM, V272, P27532, DOI 10.1074/jbc.272.44.27532; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Jutras I, 1997, J BIOL CHEM, V272, P15184, DOI 10.1074/jbc.272.24.15184; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; Laine J, 1999, BIOCHEM J, V338, P289, DOI 10.1042/0264-6021:3380289; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lusson J, 1997, BIOCHEM J, V326, P737, DOI 10.1042/bj3260737; MITRA A, 1994, J BIOL CHEM, V269, P19876; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Natori S, 1996, P NATL ACAD SCI USA, V93, P4431, DOI 10.1073/pnas.93.9.4431; Rovere C, 1999, J BIOL CHEM, V274, P12461, DOI 10.1074/jbc.274.18.12461; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; SHENNAN KIJ, 1995, J BIOL CHEM, V270, P1402, DOI 10.1074/jbc.270.3.1402; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Varlamov O, 1996, J BIOL CHEM, V271, P6077, DOI 10.1074/jbc.271.11.6077; Varlamov O, 1997, ENDOCRINOLOGY, V138, P4883, DOI 10.1210/en.138.11.4883; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; YI Z, 1993, J BIOL CHEM, V268, P5615; Zhou A, 1998, J BIOL CHEM, V273, P11107, DOI 10.1074/jbc.273.18.11107; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509; ZHOU Y, 1994, J BIOL CHEM, V269, P18408; ZHOU Y, 1995, J BIOL CHEM, V270, P24702, DOI 10.1074/jbc.270.42.24702; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	37	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40337	40343		10.1074/jbc.M004757200	http://dx.doi.org/10.1074/jbc.M004757200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11006274	hybrid			2022-12-25	WOS:000166039500074
J	Barresi, R; Moore, SA; Stolle, CA; Mendell, JR; Campbell, KP; Campbell, P				Barresi, R; Moore, SA; Stolle, CA; Mendell, JR; Campbell, KP; Campbell, P			Expression of gamma-sarcoglycan in smooth muscle and its interaction with the smooth muscle sarcoglycan-sarcospan complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIRDLE MUSCULAR-DYSTROPHY; NITRIC-OXIDE SYNTHASE; DELTA-SARCOGLYCAN; BETA-SARCOGLYCAN; ALPHA-SARCOGLYCAN; EPSILON-SARCOGLYCAN; GLYCOPROTEIN; GENE; CARDIOMYOPATHY; PROTEIN	The sarcoglycan complex in striated muscle is a heterotetrameric unit integrally associated with sarcospan in the dystrophin-glycoprotein complex. The sarcoglycans, alpha, beta, gamma, and delta, are mutually dependent with regard to their localization at the sarcolemma, and mutations in any of the sarcoglycan genes lead to limb-girdle muscular dystrophies type 2C-2F. In smooth muscle beta- and delta -sarcoglycans are associated with epsilon -sarcoglycan, a glycoprotein homologous to alpha -sarcoglycan. Here, we demonstrate that gamma -sarcoglycan is also a component of the sarcoglycan complex in the smooth muscle. First, we show the presence of gamma -sarcoglycan in a number of smooth muscle containing organs, and we verify the existence of identical transcripts in skeletal and smooth muscle. The specificity of the expression of gamma -sarcoglycan in smooth muscle was confirmed by analysis of smooth muscle cells in culture. Next, we provide evidence for the association of gamma -sarcoglycan with the sarcoglycan-sarcospan complex by biochemical analysis and comparison among animal models for muscular dystrophy. Moreover, we find disruption of the sarcoglycan complex in the vascular smooth muscle of a patient with gamma -sarcoglycanopathy. Taken together, our results prove that the sarcoglycan complex in vascular and visceral smooth muscle consists of epsilon- beta-, gamma-, and delta -sarcogIycans and is associated with sarcospan.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA; Univ Penn, Sch Med, Genet Diagnost Lab, Philadelphia, PA 19104 USA; Ohio State Univ, Dept Neurol, Columbus, OH 43210 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa; University of Pennsylvania; Ohio State University	Campbell, KP (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, 400 EMRB, Iowa City, IA 52242 USA.	campbell@uiowa.edu	Barresi, Rita/AAB-9569-2022	Barresi, Rita/0000-0001-7351-959X; Moore, Steven/0000-0002-6353-7900; Campbell, Kevin/0000-0003-2066-5889	Fondazione Telethon Funding Source: Custom; Telethon [305/B] Funding Source: Medline	Fondazione Telethon(Fondazione Telethon); Telethon(Fondazione Telethon)		Araishi K, 1999, HUM MOL GENET, V8, P1589, DOI 10.1093/hmg/8.9.1589; Barresi R, 2000, J MED GENET, V37, P102, DOI 10.1136/jmg.37.2.102; Betto R, 1999, J BIOL CHEM, V274, P7907, DOI 10.1074/jbc.274.12.7907; Blake DJ, 1996, J BIOL CHEM, V271, P7802, DOI 10.1074/jbc.271.13.7802; BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Chang WJ, 1996, P NATL ACAD SCI USA, V93, P9142, DOI 10.1073/pnas.93.17.9142; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; Crosbie RH, 1999, J CELL BIOL, V145, P153, DOI 10.1083/jcb.145.1.153; Crosbie RH, 1997, J BIOL CHEM, V272, P31221, DOI 10.1074/jbc.272.50.31221; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; Durbeej M, 2000, MOL CELL, V5, P141, DOI 10.1016/S1097-2765(00)80410-4; Durbeej M, 1999, J BIOL CHEM, V274, P26609, DOI 10.1074/jbc.274.37.26609; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Ettinger AJ, 1997, J BIOL CHEM, V272, P32534, DOI 10.1074/jbc.272.51.32534; Gnecchi-Ruscone T, 1999, MUSCLE NERVE, V22, P1549, DOI 10.1002/(SICI)1097-4598(199911)22:11<1549::AID-MUS10>3.0.CO;2-A; Grady RM, 1999, NAT CELL BIOL, V1, P215, DOI 10.1038/12034; Hack AA, 2000, J CELL SCI, V113, P2535; Hack AA, 1998, J CELL BIOL, V142, P1279, DOI 10.1083/jcb.142.5.1279; Henry MD, 1999, CURR OPIN CELL BIOL, V11, P602, DOI 10.1016/S0955-0674(99)00024-1; Henry MD, 1996, CURR OPIN CELL BIOL, V8, P625, DOI 10.1016/S0955-0674(96)80103-7; Holt KH, 1998, J BIOL CHEM, V273, P34667, DOI 10.1074/jbc.273.52.34667; Holt KH, 1998, MOL CELL, V1, P841, DOI 10.1016/S1097-2765(00)80083-0; Jung D, 1996, J BIOL CHEM, V271, P32321, DOI 10.1074/jbc.271.50.32321; Lebakken CS, 2000, MOL CELL BIOL, V20, P1669, DOI 10.1128/MCB.20.5.1669-1677.2000; LEFAUCHEUR JP, 1995, ANAT REC, V242, P70, DOI 10.1002/ar.1092420109; Lim LE, 1998, CURR OPIN NEUROL, V11, P443, DOI 10.1097/00019052-199810000-00006; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; Liu LA, 1999, J BIOL CHEM, V274, P38171, DOI 10.1074/jbc.274.53.38171; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; McNally EM, 1998, FEBS LETT, V422, P27, DOI 10.1016/S0014-5793(97)01593-7; Moreira ES, 1998, J MED GENET, V35, P951, DOI 10.1136/jmg.35.11.951; Nigro V, 1996, HUM MOL GENET, V5, P1179, DOI 10.1093/hmg/5.8.1179; Nigro V, 1997, HUM MOL GENET, V6, P601, DOI 10.1093/hmg/6.4.601; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; Ozawa E, 1998, MUSCLE NERVE, V21, P421, DOI 10.1002/(SICI)1097-4598(199804)21:4<421::AID-MUS1>3.3.CO;2-W; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; PICCOLO F, 1995, NAT GENET, V10, P243, DOI 10.1038/ng0695-243; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; ROBERDS SL, 1993, J BIOL CHEM, V268, P23739; SadouletPuccio HM, 1996, HUM MOL GENET, V5, P489, DOI 10.1093/hmg/5.4.489; Sakamoto A, 1999, FEBS LETT, V447, P124, DOI 10.1016/S0014-5793(99)00267-7; Sakamoto A, 1997, P NATL ACAD SCI USA, V94, P13873, DOI 10.1073/pnas.94.25.13873; Straub V, 1999, J BIOL CHEM, V274, P27989, DOI 10.1074/jbc.274.39.27989; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; van der Kooi AJ, 1998, HEART, V79, P73, DOI 10.1136/hrt.79.1.73; WELLER B, 1990, J NEUROL SCI, V100, P9, DOI 10.1016/0022-510X(90)90005-8; YAMAMOTO H, 1994, J BIOCHEM-TOKYO, V115, P162, DOI 10.1093/oxfordjournals.jbchem.a124294	53	39	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38554	38560		10.1074/jbc.M007799200	http://dx.doi.org/10.1074/jbc.M007799200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10993904	hybrid			2022-12-25	WOS:000165739800057
J	Bruhns, P; Vely, F; Malbec, O; Fridman, WH; Vivier, E; Daeron, M				Bruhns, P; Vely, F; Malbec, O; Fridman, WH; Vivier, E; Daeron, M			Molecular basis of the recruitment of the SH2 domain-containing inositol 5-phosphatases SHIP1 and SHIP2 by Fc gamma RIIB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELL ACTIVATION; NEGATIVE REGULATION; INHIBITORY RECEPTORS; PHOSPHATASE SHIP; NK CELLS; TYROSINE; KILLER; MOTIFS; ASSOCIATION; RESPONSES	Fc gamma RIIB are single chain low affinity receptors for IgG that negatively regulate immunoreceptor tyrosine-based activation motif-dependent cell activation. They bear one immunoreceptor tyrosine-based inhibition motif (ITIM) that becomes tyrosyl-phosphorylated upon coaggregation of Fc gamma RIIB with immunoreceptor tyrosine-based activation motif-bearing receptors and that recruits SH2 domain-containing inositol 5-phosphatases (SHIPs) in vivo. Synthetic Fc gamma RIIB ITIM phosphopeptides, however, also bind SH2 domain-containing protein-tyrosine phosphatases (SHPs) in vitro. To identify SHIP-binding sites, we exchanged residues between the Fc gamma RIIB ITIM and the N-terminal ITIM of a killer cell Ig-like receptor that does not bind SHIPs, Loss of function and gain of function substitutions identified the Y+2 leucine, in the Fc gamma RIIB ITIM, as determining the binding of both SHIP1 and SHIPS, but not the binding of SHP-1 or SHP-2, Conversely, the Y-2 isoleucine that determines the in vitro binding of SHP-1 and SHP-2 affected neither the binding nor the recruitment of SHIP1 or SHIP2, One hydrophobic residue, in the ITIM. of Fc gamma RIIB therefore determines the affinity for SHIPs. This residue is symmetrical to the hydrophobic residue that determines the affinity of all ITIMs for SHPs, It defines a SHIP-binding site, distinct from a SHP-binding site, that enables Fc gamma RIIB to recruit SHIP1 and SHIP2 and that is preferentially used in vivo.	Inst Curie, INSERM U255, Lab Immunol Cellulaire & Clin, F-75005 Paris, France; Ctr Immunol, INSERM, CNRS, F-13288 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Daeron, M (corresponding author), Inst Curie, INSERM U255, Lab Immunol Cellulaire & Clin, 26 Rue Ulm, F-75005 Paris, France.		Vivier, Eric/F-8939-2010; Bruhns, Pierre/F-5567-2013; Vély, Frédéric/HHM-3894-2022	Vivier, Eric/0000-0001-7022-8287; Bruhns, Pierre/0000-0002-4709-8936; Vely, Frederic/0000-0002-1682-0949; fridman, wolf herman/0000-0002-1332-0973				Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; Blery M, 1997, J BIOL CHEM, V272, P8989; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Bruhns P, 1999, J IMMUNOL, V162, P3168; Burshtyn DN, 1997, J BIOL CHEM, V272, P13066, DOI 10.1074/jbc.272.20.13066; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Cambier JC, 1999, CURR TOP MICROBIOL, V244, P43; DAERON M, 1992, J IMMUNOL, V149, P1365; Daeron M, 1999, CURR TOP MICROBIOL, V244, P1; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; Fong DC, 2000, J IMMUNOL, V165, P4453, DOI 10.4049/jimmunol.165.8.4453; Fong DC, 1996, IMMUNOL LETT, V54, P83, DOI 10.1016/S0165-2478(96)02654-5; Gadina M, 1998, J IMMUNOL, V160, P4657; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kuroiwa A, 1998, J BIOL CHEM, V273, P1070, DOI 10.1074/jbc.273.2.1070; Lanier LL, 1997, IMMUNOL REV, V155, P145, DOI 10.1111/j.1600-065X.1997.tb00947.x; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Malbec O, 1998, J IMMUNOL, V160, P1647; Malbec O, 1999, J IMMUNOL, V162, P4424; Mason JM, 2000, J BIOL CHEM, V275, P4398, DOI 10.1074/jbc.275.6.4398; Moretta A, 1997, IMMUNOL REV, V155, P105, DOI 10.1111/j.1600-065X.1997.tb00943.x; Muraille E, 2000, IMMUNOL LETT, V72, P7, DOI 10.1016/S0165-2478(00)00162-0; Nakamura K, 1998, J IMMUNOL, V161, P684; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Sato K, 1998, J IMMUNOL, V161, P2716; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; SONGYANG Z, 1993, CELL, V72, P1; Symes A, 1997, CURR BIOL, V7, P697, DOI 10.1016/S0960-9822(06)00298-3; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; Tsubokawa H, 1996, J PHYSIOL-LONDON, V497, P67, DOI 10.1113/jphysiol.1996.sp021750; Vely F, 1997, EUR J IMMUNOL, V27, P1994, DOI 10.1002/eji.1830270825; Vivier E, 1997, IMMUNOL TODAY, V18, P286, DOI 10.1016/S0167-5699(97)80025-4; WAGTMANN N, 1995, IMMUNITY, V2, P439, DOI 10.1016/1074-7613(95)90025-X; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; Yamashita Y, 1998, J BIOCHEM-TOKYO, V123, P358, DOI 10.1093/oxfordjournals.jbchem.a021945; ZHENKUN L, 2000, J EXP MED, V191, P347	41	75	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37357	37364		10.1074/jbc.M003518200	http://dx.doi.org/10.1074/jbc.M003518200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	11016922	hybrid			2022-12-25	WOS:000165618700009
J	Albrecht-Buehler, G				Albrecht-Buehler, G			Reversible, excitation light-induced enhancement of fluorescence of live mammalian mitochondria	FASEB JOURNAL			English	Article									Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Northwestern University	Albrecht-Buehler, G (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 305 E Chicago Ave, Chicago, IL 60611 USA.	g-buehler@nwu.edu							0	9	18	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2000	14	13					1864	1866		10.1096/fj.00-0028fje	http://dx.doi.org/10.1096/fj.00-0028fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023966				2022-12-25	WOS:000089634400003
J	Egashira, K; Koyanagi, M; Kitamoto, S; Ni, WH; Kataoka, C; Morishita, R; Kaneda, Y; Akiyama, C; Nishida, KI; Sueishi, K; Takeshita, A				Egashira, K; Koyanagi, M; Kitamoto, S; Ni, WH; Kataoka, C; Morishita, R; Kaneda, Y; Akiyama, C; Nishida, KI; Sueishi, K; Takeshita, A			Anti-monocyte chemoattractant protein-1 gene therapy inhibits vascular remodeling in rats: blockade of MCP-1 activity after intramuscular transfer of a mutant gene inhibits vascular remodeling induced by chronic blockade of NO synthesis	FASEB JOURNAL			English	Article						endothelium-derived relaxing factors; remodeling; growth substances; inflammation; adhesion molecule; monocyte chemoattractant protein-1; gene transfer	NITRIC-OXIDE SYNTHESIS; ATHEROSCLEROTIC LESIONS; EXPRESSION; CHEMOKINES; INDUCTION; MICE	Monocyte chemoattractant protein-1 (MCP-1) may play an essential part in the formation of arteriosclerosis by recruiting monocytes into the arterial wall. Thus, we devised a new strategy for anti-MCP-1 gene therapy against arteriosclerosis by transfecting an amino-terminal deletion mutant (missing the amino-terminal amino acids 2 to 8) of the human MCP-1 gene into a remote organ (skeletal muscles), Intramuscular transduction with the mutant MCP-1 gene blocked monocyte recruitment induced by a subcutaneous injection of recombinant MCP-1. In a rat model in which the chronic inhibition of endothelial nitric oxide synthesis induces early vascular inflammation as well as subsequent coronary vascular remodeling, this strategy suppressed monocyte recruitment into the coronary vessels and the development of vascular medial thickening, but did not reduce perivascular fibrosis. Thus, MCP-1 is necessary far the development of medial thickening but not for fibrosis in this model. This new strategy may be a useful and feasible gene therapy against arteriosclerosis.	Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Pathol, Higashi Ku, Fukuoka 8128582, Japan; Osaka Univ, Sch Med, Div Gene Therapy Sci, Osaka, Japan; Daiichi Pharmaceut Co Ltd, New Prod Res Labs, Tokyo, Japan	Kyushu University; Kyushu University; Osaka University; Daiichi Sankyo Company Limited	Egashira, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; DE CR, 1995, J CLIN INVEST, V96, P60; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Katoh M, 1998, CIRC RES, V83, P743, DOI 10.1161/01.RES.83.7.743; Kumar AG, 1997, CIRCULATION, V95, P693, DOI 10.1161/01.CIR.95.3.693; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Takemoto M, 1997, J CLIN INVEST, V99, P278, DOI 10.1172/JCI119156; TAKEYA M, 1993, HUM PATHOL, V24, P534, DOI 10.1016/0046-8177(93)90166-E; Tomita H, 1998, ARTERIOSCL THROM VAS, V18, P1456, DOI 10.1161/01.ATV.18.9.1456; Tsao PS, 1997, CIRCULATION, V96, P934; Ueki T, 1999, NAT MED, V5, P226, DOI 10.1038/5593; Usui M, 2000, CIRCULATION, V101, P305, DOI 10.1161/01.CIR.101.3.305; Yamashiro S, 1998, INT ARCH ALLERGY IMM, V115, P15, DOI 10.1159/000023825; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; ZEIHER AM, 1995, CIRC RES, V76, P980, DOI 10.1161/01.RES.76.6.980; ZHANG YJ, 1995, MOL CELL BIOL, V15, P4851	19	75	80	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					1974	1978		10.1096/fj.00-0141com	http://dx.doi.org/10.1096/fj.00-0141com			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023981				2022-12-25	WOS:000089634400016
J	Rauen, U; Petrat, F; Li, TJ; De Groot, H				Rauen, U; Petrat, F; Li, TJ; De Groot, H			Hypothermia injury/cold-induced apoptosis - evidence of an increase in chelatable iron causing oxidative injury in spite of low O-2(-)/H2O2 formation	FASEB JOURNAL			English	Article						hydrogen peroxide; superoxide anion radical; hydroxyl radical; Fenton reaction; transition metal ions	LIVER ENDOTHELIAL-CELLS; ELECTRON-PARAMAGNETIC-RESONANCE; DESFERRIOXAMINE-AVAILABLE IRON; CULTURED RAT HEPATOCYTES; MOLECULAR-WEIGHT-IRON; REACTIVE OXYGEN; LIPID-PEROXIDATION; REOXYGENATION INJURY; REPERFUSION INJURY; HYDROGEN-PEROXIDE	When incubated at 4 degrees C, cultured rat hepatocytes or liver endothelial cells exhibit pronounced injury and, during earlier rewarming, marked apoptosis. Both processes are mediated by reactive oxygen species, and marked protective effects of iron chelators as well as the protection provided by various other antioxidants suggest that hydroxyl radicals, formed by classical Fenton chemistry, are involved. However, when we measured the Fenton chemistry educt hydrogen peroxide and its precursor, the superoxide anion radical, formation of both had markedly decreased and steady-state levels of hydrogen peroxide did not alter during cold incubation of either liver endothelial cells or hepatocytes. Similarly, there was no evidence of an increase in O-2(-)/H2O2 release contributing to cold-induced apoptosis occurring on rewarming. In contrast to the release/ level of O-2(-) and H2O2, cellular homeostasis of the transition metal iron is likely to play a key role during cold incubation of cultured hepatocytes: the hepatocellular pool of chelatable iron, measured on a single-cell level using laser scanning microscopy and the fluorescent indicator phen green, increased from 3.1 +/- 2.3 mu M (before cold incubation) to 7.7 +/- 2.4 mu M within 90 min after initiation of cold incubation. This increase in the cellular chelatable iron pool was reversible on rewarming after short periods of cold incubation. The cold-induced increase in the hepatocellular chelatable iron pool was confirmed using the calcein method. These data suggest that free radical-mediated hypothermia injury/cold-induced apoptosis is primarily evoked by alterations in the cellular iron homeostasis/a rapid increase in the cellular chelatable iron pool and not by increased formation of O-2(-)/H2O2.	Univ Klinikum Essen, Inst Physiol Chem, D-45132 Essen, Germany	University of Duisburg Essen	Rauen, U (corresponding author), Univ Klinikum Essen, Inst Physiol Chem, Hufelandstr 55, D-45132 Essen, Germany.	ursula.rauen@uni-essen.de	Li, Tongju/AAX-4655-2020; Rauen, Ursula/N-2137-2014	Li, Tongju/0000-0001-8896-5840; 				BALIGA R, 1993, BIOCHEM J, V291, P901, DOI 10.1042/bj2910901; BALLA G, 1990, J LAB CLIN MED, V116, P546; BLOUIN A, 1977, J CELL BIOL, V72, P441, DOI 10.1083/jcb.72.2.441; BREUER W, 1995, AM J PHYSIOL-CELL PH, V268, pC1354, DOI 10.1152/ajpcell.1995.268.6.C1354; BREUER W, 1995, J BIOL CHEM, V270, P24209, DOI 10.1074/jbc.270.41.24209; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; DEGROOT H, 1994, HEPATO-GASTROENTEROL, V41, P328; DEGROOT H, 1992, TOXICOL LETT, V63, P111, DOI 10.1016/0378-4274(92)90002-2; DEGROOT H, 1991, BIOL CHEM H-S, V372, P35, DOI 10.1515/bchm3.1991.372.1.35; Dieter P, 1995, BIOL SIGNAL, V4, P331; FRIED R, 1974, METHODEN ENZYMATISCH, P682; FULLER BJ, 1987, TRANSPLANTATION, V43, P604; Garner B, 1998, FREE RADICAL RES, V29, P103, DOI 10.1080/10715769800300121; Garner B, 1997, FREE RADICAL RES, V27, P487, DOI 10.3109/10715769709065788; Ghersi-Egea JF, 1998, FREE RADICAL BIO MED, V24, P1074, DOI 10.1016/S0891-5849(97)00387-0; GOWER JD, 1989, ANAL BIOCHEM, V180, P126, DOI 10.1016/0003-2697(89)90099-7; HALLEZ P, 1890, REV BIOL NORD FRANCE, V2, P1; HEALING G, 1990, BIOCHEM PHARMACOL, V39, P1239, DOI 10.1016/0006-2952(90)90269-Q; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; KOZLOV AV, 1992, FREE RADICAL BIO MED, V13, P9, DOI 10.1016/0891-5849(92)90159-E; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kuznetsov AV, 1999, TRANSPLANT P, V31, P992, DOI 10.1016/S0041-1345(98)01871-5; LITTAUER A, 1992, AM J PHYSIOL, V262, pG1015, DOI 10.1152/ajpgi.1992.262.6.G1015; MAGNI F, 1994, FREE RADICAL BIO MED, V16, P465, DOI 10.1016/0891-5849(94)90124-4; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; NIELSEN P, 1993, INT J BIOCHEM, V25, P223, DOI 10.1016/0020-711X(93)90010-C; NOLL T, 1987, ARCH BIOCHEM BIOPHYS, V252, P284, DOI 10.1016/0003-9861(87)90033-6; Ollinger K, 1997, J BIOL CHEM, V272, P23707, DOI 10.1074/jbc.272.38.23707; Peters SMA, 1998, TRANSPLANTATION, V65, P625, DOI 10.1097/00007890-199803150-00005; Petrat F, 1999, HEPATOLOGY, V29, P1171, DOI 10.1002/hep.510290435; Petrat F, 2000, ARCH BIOCHEM BIOPHYS, V376, P74, DOI 10.1006/abbi.2000.1711; Qian SY, 1999, FREE RADICAL BIO MED, V26, P1447, DOI 10.1016/S0891-5849(99)00002-7; RAUEN U, 1994, ZBL CHIR, V119, P322; Rauen U, 1997, FREE RADICAL BIO MED, V22, P17, DOI 10.1016/S0891-5849(96)00273-0; Rauen U, 1997, FREE RADICAL BIO MED, V23, P392, DOI 10.1016/S0891-5849(96)00618-1; Rauen U, 1998, FREE RADICAL BIO MED, V24, P1316, DOI 10.1016/S0891-5849(97)00456-5; Rauen U, 1997, HEPATOLOGY, V26, P351, DOI 10.1002/hep.510260215; RAUEN U, 1993, TRANSPLANTATION, V55, P469, DOI 10.1097/00007890-199303000-00002; Rauen U, 1999, FASEB J, V13, P155, DOI 10.1096/fasebj.13.1.155; ROOT RK, 1975, J CLIN INVEST, V55, P945, DOI 10.1172/JCI108024; ROSSER BG, 1995, GASTROENTEROLOGY, V108, P252, DOI 10.1016/0016-5085(95)90032-2; RYAN TP, 1992, CRIT REV TOXICOL, V22, P119, DOI 10.3109/10408449209146308; SERGENT O, 1995, BIOL TRACE ELEM RES, V47, P185, DOI 10.1007/BF02790116; Staubli A, 1998, AM J PHYSIOL-GASTR L, V274, pG1031, DOI 10.1152/ajpgi.1998.274.6.G1031; SteinlechnerMaran R, 1997, TRANSPLANTATION, V63, P136, DOI 10.1097/00007890-199701150-00025; Thomas F, 1999, J BIOL CHEM, V274, P13375, DOI 10.1074/jbc.274.19.13375; Turner CP, 1998, FREE RADICAL BIO MED, V24, P401, DOI 10.1016/S0891-5849(97)00270-0; Vreugdenhil PK, 1997, TRANSPLANT INT, V10, P379, DOI 10.1007/s001470050074; WOLFF SP, 1994, METHOD ENZYMOL, V233, P182; Young Stephen P., 1994, P597	51	158	164	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2000	14	13					1953	1964		10.1096/fj.00-0071com	http://dx.doi.org/10.1096/fj.00-0071com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023979				2022-12-25	WOS:000089634400014
J	Liang, FQ; Schaufele, F; Gardner, DG				Liang, FQ; Schaufele, F; Gardner, DG			Functional interaction of NF-Y and Sp1 is required for type a natriuretic peptide receptor gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT-BINDING PROTEIN; SMOOTH-MUSCLE CELLS; SEQUENCE IDENTITY; MICE LACKING; DNA COMPLEX; YEAST HAP2; B-SUBUNIT; CLASS-II; CBF-B; PROMOTER	The vasorelaxant and anti-mitogenic activities of the atrial and brain natriuretic peptides depend upon their binding to the type A natriuretic peptide receptor (NPR-A) expressed on the surface of vascular cells. Intervention strategies aimed at controlling NPR-A expression are limited by the paucity of studies in this area. Here we identify a sequence CCAAT between -141 and -137 of the NPR-A promoter that, when mutated, reduces promoter activity by 90% in rat aortic smooth muscle (RASM) cells. Protein/DNA cross-linking and immunoperturbation of electrophoretically shifted complexes formed between RASM nuclear extracts and an oligonucleotide surrounding the CCAAT sequence indicates that the heterotrimeric transcription factor NF-Y binds specifically to the wild-type, but not mutated, CCAAT element. Cotransfection of a dominant negative mutant of the NF-YA subunit results in a concentration-dependent decrease in the activity of the NPR-A promoter in RASM cells confirming that endogenous NF-Y is an activator of the promoter. Mutation of the CCAAT element, in conjunction with mutation of all three Spl sites previously shown to be involved in NPR-A promoter regulation, virtually eliminates NPR-A promoter activity in RASM cells. Coexpression of all three NF-Y subunits together with Spl in Drosophila cells deficient in these factors indicates that NF-Y and Spl act synergistically to reconstitute NPR-A promoter activity. A direct physical association between NF-Y and Spl can be demonstrated both in vitro by glutathione S-transferase pull-down assay and in the intact cell by coimmunoprecipitation and functional studies. Together, these studies show that NPR-A promoter activity is dominantly regulated through functional, and possibly physical, interactions of NF-Y and Spl.	Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gardner, DG (corresponding author), Univ Calif San Francisco, Metab Res Unit, 1109 HSW, San Francisco, CA 94143 USA.				NHLBI NIH HHS [HL45637] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045637] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CAO L, 1995, HYPERTENSION, V25, P227, DOI 10.1161/01.HYP.25.2.227; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Faniello MC, 1999, J BIOL CHEM, V274, P7623, DOI 10.1074/jbc.274.12.7623; FILATOV D, 1995, J BIOL CHEM, V270, P25239, DOI 10.1074/jbc.270.42.25239; GOOD L, 1995, J CELL PHYSIOL, V163, P636, DOI 10.1002/jcp.1041630326; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Hu QH, 2000, J BIOL CHEM, V275, P4435, DOI 10.1074/jbc.275.6.4435; ITOH H, 1990, J CLIN INVEST, V86, P1690, DOI 10.1172/JCI114893; ITOH H, 1992, HYPERTENSION, V19, P758, DOI 10.1161/01.HYP.19.6.758; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; Kim IS, 1996, MOL CELL BIOL, V16, P4003; Kishimoto I, 1996, P NATL ACAD SCI USA, V93, P6215, DOI 10.1073/pnas.93.12.6215; Krumm A, 1998, P NATL ACAD SCI USA, V95, P13501, DOI 10.1073/pnas.95.23.13501; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Levin ER, 1998, NEW ENGL J MED, V339, P321; Liang FQ, 1999, ENDOCRINOLOGY, V140, P1695, DOI 10.1210/en.140.4.1695; Liberati C, 1998, J BIOL CHEM, V273, P16880, DOI 10.1074/jbc.273.27.16880; LOPEZ MJ, 1995, NATURE, V378, P65, DOI 10.1038/378065a0; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; Oliver PM, 1997, P NATL ACAD SCI USA, V94, P14730, DOI 10.1073/pnas.94.26.14730; Osada S, 1996, J BIOL CHEM, V271, P3891; Schaufele F, 1996, J BIOL CHEM, V271, P21484, DOI 10.1074/jbc.271.35.21484; SCHAUFELE F, 1990, J BIOL CHEM, V265, P14592; Schwartzbauer G, 1998, J BIOL CHEM, V273, P24760, DOI 10.1074/jbc.273.38.24760; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; VANHUIJSDUIJNEN RAMH, 1987, NUCLEIC ACIDS RES, V15, P7265, DOI 10.1093/nar/15.18.7265; VUORIO T, 1990, J BIOL CHEM, V265, P22480; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; YAMAGUCHI M, 1990, J BIOL CHEM, V265, P20414; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	41	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1516	1522		10.1074/jbc.M006350200	http://dx.doi.org/10.1074/jbc.M006350200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11022037	hybrid			2022-12-25	WOS:000166430900088
J	Miura, K; Ohgiya, S; Hoshino, T; Nemoto, N; Suetake, T; Miura, A; Spyracopoulos, L; Kondo, H; Tsuda, S				Miura, K; Ohgiya, S; Hoshino, T; Nemoto, N; Suetake, T; Miura, A; Spyracopoulos, L; Kondo, H; Tsuda, S			NMR analysis of type III antifreeze protein intramolecular dimer - Structural basis for enhanced activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE RELAXATION; MODEL-FREE APPROACH; THERMAL HYSTERESIS; BINDING; MACROMOLECULES; ASSIGNMENTS; MECHANISM; DOMAIN; HELIX; H-1	The structure of a new antifreeze protein (AFP) variant, RD3, from antarctic eel pout (Rhigophila dearborni) with enhanced activity has been determined for the first time by nuclear magnetic resonance spectroscopy. RD3 comprises a unique translational topology of two homologous type III AFP globular domains, each containing one flat, ice binding plane. The ice binding plane of the N domain is located similar to3.5 Angstrom "behind" that of the C domain. The two ice binding planes are located laterally with an angle of 32 +/- 12 degrees between the planes. These results suggest that the C domain plane of RD3 binds first to the ice {1010} prism plane in the (0001) direction, which induces successive ice binding of the N domain in the (0101) direction. This manner of ice binding caused by the unique structural topology of RD3 is thought to be crucial for the significant enhancement of antifreeze activity, especially at low AFP concentrations.	Hokkaido Natl Ind Res Inst, Biosci & Chem Div, Sapporo, Hokkaido 0628517, Japan; Varian Japan, Minato Ku, Tokyo 1080023, Japan; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	National Institute of Advanced Industrial Science & Technology (AIST); University of Alberta	Tsuda, S (corresponding author), Hokkaido Natl Ind Res Inst, Biosci & Chem Div, 2-17-2-1 Tsukisamu Higashi, Sapporo, Hokkaido 0628517, Japan.	tsuda@hniri.go.jp	Hoshino, Tamotsu/F-3357-2017; Kondo, Hidemasa/M-7465-2018; NEMOTO, Nobuaki/ABA-8644-2020; HOSHINO, Tamotsu/R-2959-2019; Tsuda, Sakae/M-2756-2018; Ohgiya, Satoru/V-3117-2018	Hoshino, Tamotsu/0000-0001-5211-6425; Kondo, Hidemasa/0000-0003-2799-1775; Tsuda, Sakae/0000-0002-1399-0619; Ohgiya, Satoru/0000-0001-8257-8284				BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BRUNGER AT, 1987, XPLOR VERSION 3 1 SY; Davies PL, 1997, CURR OPIN STRUC BIOL, V7, P828, DOI 10.1016/S0959-440X(97)80154-6; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; DeLuca CI, 1998, BIOPHYS J, V74, P1502, DOI 10.1016/S0006-3495(98)77862-2; Graether SP, 2000, NATURE, V406, P325, DOI 10.1038/35018610; Graham LA, 1997, NATURE, V388, P727, DOI 10.1038/41908; HEW CL, 1992, EUR J BIOCHEM, V203, P33, DOI 10.1111/j.1432-1033.1992.tb19824.x; Hobbs P.V., 1974, ICE PHYSICS, P18; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Jia ZC, 1996, NATURE, V384, P285, DOI 10.1038/384285a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liou YC, 2000, NATURE, V406, P322, DOI 10.1038/35018604; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Low WK, 1998, J BIOL CHEM, V273, P23098, DOI 10.1074/jbc.273.36.23098; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miura K, 1999, J BIOCHEM-TOKYO, V126, P387, DOI 10.1093/oxfordjournals.jbchem.a022462; Miura K, 2000, J BIOMOL NMR, V16, P273, DOI 10.1023/A:1008326207444; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; SICHERI F, 1995, NATURE, V375, P427, DOI 10.1038/375427a0; SONNICHSEN FD, 1993, SCIENCE, V259, P1154, DOI 10.1126/science.8438165; Sonnichsen FD, 1996, STRUCTURE, V4, P1325, DOI 10.1016/S0969-2126(96)00140-2; WANG X, 1995, BBA-PROTEIN STRUCT M, V1247, P163, DOI 10.1016/0167-4838(94)00205-U; WILSON PW, 1994, CRYOBIOLOGY, V31, P406, DOI 10.1006/cryo.1994.1049; WILSON PW, 1993, CRYO-LETT, V14, P31; WISHART DS, 1994, VADAR COMPREHENSIVE; Worrall D, 1998, SCIENCE, V282, P115, DOI 10.1126/science.282.5386.115; Yang DSC, 1998, BIOPHYS J, V74, P2142, DOI 10.1016/S0006-3495(98)77923-8; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	33	43	50	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1304	1310		10.1074/jbc.M007902200	http://dx.doi.org/10.1074/jbc.M007902200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11010977	hybrid			2022-12-25	WOS:000166430900061
J	Carneiro, FA; Ferradosa, AS; Da Poian, AT				Carneiro, FA; Ferradosa, AS; Da Poian, AT			Low pH-induced conformational changes in vesicular stomatitis virus glycoprotein involve dramatic structure reorganization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEMLIKI-FOREST VIRUS; MEMBRANE-FUSION ACTIVITY; ENVELOPED VIRUSES; VIRAL FUSION; CELL-FUSION; G-PROTEIN; DOMAIN; FLUORESCENCE; INFLUENZA; MUTATIONS	Membrane fusion is the key step in the entry of enveloped animal viruses into their host cells. Fusion of vesicular stomatitis virus with membranes occurs at acidic pH and is mediated by its envelope glycoprotein, the G protein. To study the structural transitions induced by acidic pH on cr protein, we have extracted the protein from purified virus by incubation with nonionic detergent, At pH 6.0, purified G protein was able to mediate fusion of either phospholipid vesicles or Vero cells in culture. Intrinsic fluorescence studies revealed that changes in the environment of Trp residues occurred as pH decreases. In the absence of lipidic membranes, acidification led to G protein aggregation, whereas protein-protein interactions were substituted bg protein-lipid interactions in the presence of liposomes, 1,1'-Bis(4-aniline-5-naphthalene sulfonate) (bis-ANS) binding was utilized to probe the degree of exposure of hydrophobic regions of G protein during acidification. Bis-ANS binding was maximal at pH 6.2, suggesting that a hydrophobic segment is exposed to the medium at this pH, At pH 6.0, a dramatic decrease in bis-ANS binding was observed, probably due to loss of tridimensional structure during the conformational rearrangement. This hypothesis was confirmed by circular dichroism analysis at different pH values, which showed a great decrease in cu-helix content at pH values close to 6.0, suggesting that a reorganization of G protein secondary structure occurs during the fusion reaction. Our results indicate that G protein undergoes dramatic structural changes at acidic pH and acquires a conformational state able to interact with the target membrane.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	Da Poian, AT (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil.		CARNEIRO, FABIANA A/S-4525-2018; Da Poian, Andrea T./V-1699-2019; Carneiro, Fabiana/GVS-8458-2022	Da Poian, Andrea/0000-0002-3969-704X; Carneiro, Fabiana/0000-0002-6584-4875				BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Cantor C.R., 1980, BIOPHYSICAL CHEM 2, P838; Cleverley DZ, 1998, P NATL ACAD SCI USA, V95, P3425, DOI 10.1073/pnas.95.7.3425; Da Poian AT, 1998, J VIROL METHODS, V70, P45, DOI 10.1016/S0166-0934(97)00166-3; DaPoian AT, 1996, P NATL ACAD SCI USA, V93, P8268, DOI 10.1073/pnas.93.16.8268; DAPOIAN AT, 1994, BIOCHEMISTRY-US, V33, P8339, DOI 10.1021/bi00193a022; DURRER P, 1995, J BIOL CHEM, V270, P17575, DOI 10.1074/jbc.270.29.17575; EIDELMAN O, 1984, J BIOL CHEM, V259, P4622; FREDERICKSEN BL, 1995, J VIROL, V69, P1435, DOI 10.1128/JVI.69.3.1435-1443.1995; Freire E, 2000, J BIOL CHEM, V275, P817, DOI 10.1074/jbc.275.2.817; FULLER SD, 1995, CELL, V81, P715, DOI 10.1016/0092-8674(95)90533-2; GAUDIN Y, 1991, J VIROL, V65, P4853, DOI 10.1128/JVI.65.9.4853-4859.1991; GAUDIN Y, 1995, J GEN VIROL, V76, P1541, DOI 10.1099/0022-1317-76-7-1541; Hall MP, 1998, BBA-BIOMEMBRANES, V1415, P101, DOI 10.1016/S0005-2736(98)00186-2; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; HUANG RTC, 1981, VIROLOGY, V110, P243, DOI 10.1016/0042-6822(81)90030-1; Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404; JUSTMAN J, 1993, J VIROL, V67, P7597, DOI 10.1128/JVI.67.12.7597-7607.1993; LANZREIN M, 1994, BIOCHEM J, V302, P313, DOI 10.1042/bj3020313; Nandi PK, 1999, ARCH VIROL, V144, P1751, DOI 10.1007/s007050050702; NEWCOMB WW, 1981, J VIROL, V39, P295, DOI 10.1128/JVI.39.1.295-299.1981; Odell D, 1997, J VIROL, V71, P7996, DOI 10.1128/JVI.71.10.7996-8000.1997; Pak CC, 1997, BIOCHEMISTRY-US, V36, P8890, DOI 10.1021/bi9702851; PAL R, 1988, BIOCHEMISTRY-US, V27, P30, DOI 10.1021/bi00401a006; ROSE JK, 1981, J VIROL, V39, P519, DOI 10.1128/JVI.39.2.519-528.1981; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; Shokralla S, 1998, VIROLOGY, V242, P39, DOI 10.1006/viro.1997.8986; SILVA JL, 1992, J MOL BIOL, V223, P545, DOI 10.1016/0022-2836(92)90669-B; WAHLBERG JM, 1992, J CELL BIOL, V116, P339, DOI 10.1083/jcb.116.2.339; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; WHITE J, 1981, J CELL BIOL, V89, P674, DOI 10.1083/jcb.89.3.674; ZHANG L, 1994, J VIROL, V68, P2186, DOI 10.1128/JVI.68.4.2186-2193.1994	32	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					62	67		10.1074/jbc.M008753200	http://dx.doi.org/10.1074/jbc.M008753200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024041	hybrid			2022-12-25	WOS:000166280700010
J	Lee, MS; Zhu, YL; Chang, JE; Dannies, PS				Lee, MS; Zhu, YL; Chang, JE; Dannies, PS			Acquisition of Lubrol insolubility, a common step for growth hormone and prolactin in the secretory pathway of neuroendocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; SITE-DIRECTED MUTAGENESIS; GRANULE CONTENT PROTEINS; GH4C1 CELLS; CARBOXYPEPTIDASE-E; MOLECULAR-ORGANIZATION; MEMBRANE-PROTEINS; REGULATED PATHWAY; SECRETOGRANIN-II; GH(4)C(1) CELLS	Rat prolactin in the dense cores of secretory granules of the pituitary gland is a Lubrol-insoluble aggregate. In GH(4)C(1) cells, newly synthesized rat prolactin and growth hormone were soluble, but after 30 min about 40% converted to a Lubrol-insoluble form. Transport from the endoplasmic reticulum is necessary for conversion to Lubrol insolubility, since incubating cells with brefeldin A or at 15 degreesC reduced formation of insoluble rat S-35-prolactin, Formation of Lubrol-insoluble aggregates has protein and cell specificity; newly synthesized human growth hormone expressed in AtT20 cells underwent a 40% conversion to Lubrol insolubility with time, but albumin did not, and human growth hormone expressed in COS cells underwent less than 10% conversion to Lubrol insolubility. del32-46 growth hormone, a naturally occurring form of growth hormone, and P89L growth hormone underwent conversion, although they were secreted more slowly, indicating that there is some tolerance in structural requirements for aggregation. An intracellular compartment with an acidic pH is not necessary for conversion to Lubrol insolubility, because incubation with chloroquine or bafilomycin slowed, but did not prevent, the conversion. GH(4)G(1) cells treated with estradiol, insulin, and epidermal growth factor accumulate more secretory granules and store more prolactin, but not more growth hormone, than untreated cells; Lubrol-insoluble aggregates of prolactin and growth hormone formed to the same extent in hormone-treated or untreated GH(4)C(1) cells, but prolactin was retained longer in hormone-treated cells. These findings indicate that aggregation alone is not sufficient to cause retention of secretory granule proteins, and there is an additional selective process.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Dannies, PS (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.				NIDDK NIH HHS [DK 46807] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046807] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIZAWA T, 1985, ENDOCRINOLOGY, V116, P909, DOI 10.1210/endo-116-3-909; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; BAUMANN G, 1991, ENDOCR REV, V12, P424, DOI 10.1210/edrv-12-4-424; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; CUNNINGHAM BC, 1991, SCIENCE, V253, P545, DOI 10.1126/science.1907025; Dannies PS, 1999, ENDOCR REV, V20, P3, DOI 10.1210/er.20.1.3; DELBEKE D, 1985, MOL CELL ENDOCRINOL, V43, P15, DOI 10.1016/0303-7207(85)90037-1; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUQUESNOY P, 1998, END SOC 80 ANN M JUN; FARQUHAR MG, 1978, ENDOCRINOLOGY, V102, P296, DOI 10.1210/endo-102-1-296; FARQUHAR MG, 1974, COMP ENDOCRINOLOGY P; FREEDMAN SD, 1993, BIOCHEM BIOPH RES CO, V197, P992, DOI 10.1006/bbrc.1993.2577; FRICKER LD, 1990, NEUROENDOCRINOLOGY, V51, P658, DOI 10.1159/000125407; GIANNATTASIO G, 1975, J CELL BIOL, V64, P246, DOI 10.1083/jcb.64.1.246; Gorr SU, 1996, J BIOL CHEM, V271, P3575; GORR SU, 1989, AM J PHYSIOL, V257, pE247, DOI 10.1152/ajpendo.1989.257.2.E247; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; HINKLE PM, 1992, ENDOCRINOLOGY, V130, P3503, DOI 10.1210/en.130.6.3503; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LEBLOND FA, 1993, BIOCHEM J, V291, P289, DOI 10.1042/bj2910289; Lee MS, 2000, ENDOCRINOLOGY, V141, P883, DOI 10.1210/en.141.3.883; Lee MS, 2000, ENDOCRINOLOGY, V141, P3485, DOI 10.1210/en.141.9.3485; Lee MS, 1998, ENDOCRINOLOGY, V139, P2727, DOI 10.1210/en.139.6.2727; MAINS RE, 1988, J BIOL CHEM, V263, P7887; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; RAMBOURG A, 1992, ANAT RECORD, V232, P169, DOI 10.1002/ar.1092320202; REAVES BJ, 1990, MOL ENDOCRINOL, V4, P1017, DOI 10.1210/mend-4-7-1017; Rindler MJ, 1998, J BIOL CHEM, V273, P31180, DOI 10.1074/jbc.273.47.31180; SARASTE J, 1991, J CELL SCI, V100, P415; SEKSEK O, 1995, J BIOL CHEM, V270, P4967, DOI 10.1074/jbc.270.10.4967; SONG LX, 1995, J BIOL CHEM, V270, P7963, DOI 10.1074/jbc.270.14.7963; Song LX, 1997, BIOCHEM J, V323, P265, DOI 10.1042/bj3230265; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; SOSSIN WS, 1990, P NATL ACAD SCI USA, V87, P4845, DOI 10.1073/pnas.87.12.4845; STOLLER TJ, 1989, J BIOL CHEM, V264, P6922; Sun ZY, 1996, MOL ENDOCRINOL, V10, P265, DOI 10.1210/me.10.3.265; THOMPSON ME, 1992, ENDOCRINOLOGY, V131, P318, DOI 10.1210/en.131.1.318; Wada M, 1998, MOL ENDOCRINOL, V12, P146, DOI 10.1210/mend.12.1.0054; ZANINI A, 1980, J CELL BIOL, V86, P260, DOI 10.1083/jcb.86.1.260	46	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					715	721		10.1074/jbc.M008530200	http://dx.doi.org/10.1074/jbc.M008530200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024038	hybrid			2022-12-25	WOS:000166280700096
J	Jakupciak, JP; Wells, RD				Jakupciak, JP; Wells, RD			Gene conversion (recombination) mediates expansions of CTG-CAG repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTER-DOT-CAG; STRAND-BREAK REPAIR; MYOTONIC-DYSTROPHY GENE; FRAGILE-X-SYNDROME; ESCHERICHIA-COLI; TRIPLET REPEATS; MISMATCH REPAIR; TRINUCLEOTIDE REPEATS; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION	Genetic recombination is a robust mechanism for expanding CTG-CAG triplet repeats involved in the etiology of hereditary neurological diseases (Jakupciak, J. P., and Wells, R. D. (1999) J. Biol. Chem. 274, 23468-23479). This two-plasmid recombination system in Escherichia coli with derivatives of pUC19 and pACYC184 was used to investigate the effect of triplet repeat orientation on recombination and extent of expansions; tracts of 36, 50, 80, and 36, 100, and 175 repeats in length, respectively, in all possible permutations of length and in both orientations (relative to the unidirectional replication origins) revealed little or no effect of orientation of expansions. The extent of expansions was generally severalfold the length of the progenitor tract and frequently exceeded the combined length of the two tracts in the cotransformed plasmids. Expansions were much more frequent than deletions. Repeat tracts bearing two G-to-A interruptions (polymorphisms) within either 171- or 219-base pair tracts substantially reduced the expansions compared with uninterrupted repeat tracts of similar lengths. Gene conversion, rather than crossing over, was the recombination mechanism. Prior studies showed that DNA replication, repair, and tandem duplication also mediated genetic instabilities of the triplet repeat sequence. However, gene conversion (recombinational repair) is by far the most powerful expansion mechanism. Thus, we propose that gene conversion is the likely expansion mechanism for myotonic dystrophy, spinocerebellar ataxia type 8, and fragile X syndrome.	Texas A&M Univ, Texas Med Ctr, Ctr Genome Res, Inst Biosci & Technol, Houston, TX 77030 USA	Baylor College of Medicine; Texas A&M University System	Wells, RD (corresponding author), Texas A&M Univ, Texas Med Ctr, Ctr Genome Res, Inst Biosci & Technol, 2121 Holcombe Blvd, Houston, TX 77030 USA.	rwells@ibt.tamu.edu			NIGMS NIH HHS [GM52982] Funding Source: Medline; NINDS NIH HHS [NS37554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashizawa T, 1996, GENOMICS, V36, P47, DOI 10.1006/geno.1996.0424; Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; Balakumaran BS, 2000, HUM MOL GENET, V9, P93, DOI 10.1093/hmg/9.1.93; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Bowater RP, 1997, NUCLEIC ACIDS RES, V25, P2861, DOI 10.1093/nar/25.14.2861; BRINGHAM PM, 1995, NAT GENET, V9, P191; Brown WT, 1996, AM J MED GENET, V64, P287, DOI 10.1002/(SICI)1096-8628(19960809)64:2<287::AID-AJMG11>3.0.CO;2-B; Cohen H, 1999, MOL CELL BIOL, V19, P4153; Cordeiro-Stone M, 1999, J MOL BIOL, V289, P1207, DOI 10.1006/jmbi.1999.2847; Cox MM, 1998, GENES CELLS, V3, P65, DOI 10.1046/j.1365-2443.1998.00175.x; Cummings CJ, 1999, PHILOS T ROY SOC B, V354, P1079, DOI 10.1098/rstb.1999.0462; DARDENLYONS T, 1999, J BIOL CHEM, V274, P25975; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; Elliott B, 1998, MOL CELL BIOL, V18, P93, DOI 10.1128/MCB.18.1.93; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; GACY AM, 1995, CELL, V81, P533; Gangloff S, 1996, EMBO J, V15, P1715, DOI 10.1002/j.1460-2075.1996.tb00517.x; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; HANAHAN D, 1991, METHOD ENZYMOL, V204, P63; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Iyer RR, 2000, J BIOL CHEM, V275, P2174, DOI 10.1074/jbc.275.3.2174; Iyer RR, 1999, J BIOL CHEM, V274, P3865, DOI 10.1074/jbc.274.6.3865; Jakupciak JP, 1999, J BIOL CHEM, V274, P23468, DOI 10.1074/jbc.274.33.23468; JANSEN G, 1994, AM J HUM GENET, V54, P575; JAWORSKI A, 1987, SCIENCE, V238, P773, DOI 10.1126/science.3313728; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; Kang S, 1996, J MOL BIOL, V258, P543, DOI 10.1006/jmbi.1996.0266; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Kokoska RJ, 1998, MOL CELL BIOL, V18, P2779, DOI 10.1128/MCB.18.5.2779; Koob MD, 1999, NAT GENET, V21, P379, DOI 10.1038/7710; Kramer PR, 1996, HUM GENET, V98, P151, DOI 10.1007/s004390050179; Kunst CB, 1996, AM J HUM GENET, V58, P513; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; Lin YF, 1999, MOL CELL BIOL, V19, P8353; Losekoot M, 1997, J MED GENET, V34, P924, DOI 10.1136/jmg.34.11.924; Mangiarini L, 1997, NAT GENET, V15, P197, DOI 10.1038/ng0297-197; Maurer DJ, 1996, MOL CELL BIOL, V16, P6617; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Miret JJ, 1997, MOL CELL BIOL, V17, P3382, DOI 10.1128/MCB.17.6.3382; MITAS M, 1995, BIOCHEMISTRY-US, V34, P12803, DOI 10.1021/bi00039a041; Monckton DG, 1997, NAT GENET, V15, P193, DOI 10.1038/ng0297-193; Moore H, 1999, P NATL ACAD SCI USA, V96, P1504, DOI 10.1073/pnas.96.4.1504; OHOY KL, 1993, SCIENCE, V259, P809, DOI 10.1126/science.8094260; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Parniewski P, 1999, NUCLEIC ACIDS RES, V27, P616, DOI 10.1093/nar/27.2.616; Pearson CE, 1996, BIOCHEMISTRY-US, V35, P5041, DOI 10.1021/bi9601013; Richard GF, 1999, MOL GEN GENET, V261, P871, DOI 10.1007/s004380050031; RICHARDS RI, 1991, J MED GENET, V28, P818, DOI 10.1136/jmg.28.12.818; RICHARDS RI, 1992, NAT GENET, V1, P7, DOI 10.1038/ng0492-7; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schumacher S, 1998, J MOL BIOL, V279, P1101, DOI 10.1006/jmbi.1998.1827; Schweitzer JK, 1997, HUM MOL GENET, V6, P349, DOI 10.1093/hmg/6.3.349; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; SZEMRAJ J, 1995, GENE, V152, P261, DOI 10.1016/0378-1119(94)00709-2; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; TSILFIDIS C, 1992, NAT GENET, V1, P192, DOI 10.1038/ng0692-192; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; UZEST M, 1995, MOL MICROBIOL, V17, P1177, DOI 10.1111/j.1365-2958.1995.mmi_17061177.x; VANDENOUWELAND AMW, 1994, HUM MOL GENET, V3, P1823, DOI 10.1093/hmg/3.10.1823; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; Wells R.D., 1998, GENETIC INSTABILITIE; Wells RD, 1998, J BIOL CHEM, V273, P19532, DOI 10.1074/jbc.273.31.19532; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; Zhong N, 1996, AM J MED GENET, V64, P226, DOI 10.1002/(SICI)1096-8628(19960712)64:1<226::AID-AJMG41>3.0.CO;2-M	72	55	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40003	40013		10.1074/jbc.M007153200	http://dx.doi.org/10.1074/jbc.M007153200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11005819	hybrid			2022-12-25	WOS:000166039500030
J	Kanzok, SM; Schirmer, RH; Turbachova, I; Iozef, R; Becker, K				Kanzok, SM; Schirmer, RH; Turbachova, I; Iozef, R; Becker, K			The thioredoxin system of the malaria parasite Plasmodium falciparum - Glutathione reduction revisited	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN THIOREDOXIN; OXIDIZED GLUTATHIONE; ESCHERICHIA-COLI; REDOX REGULATION; HUMAN PLACENTA; ACTIVE-SITE; CELL; DEHYDROGENASE; MECHANISM; KINETICS	In most living cells, redox homeostasis is based both on the glutathione and the thioredoxin system. In the malaria parasite Plasmodium falciparum antioxidative proteins represent promising targets for the development of antiparasitic drugs. We cloned and expressed a thioredoxin of P. falciparum (pftrx), and we improved the stable expression of the thioredoxin reductase (PfTrxR) of the parasite by multiple silent mutagenesis. Both proteins were biochemically characterized and compared with the human host thioredoxin system. Intriguingly, the 13-kDa protein PfTrx is a better substrate for human TrxR (K-m = 2 muM, K-cat = 3300 min(-1)) than for P. falciparum TrxR (K-m = 10.4 muM, k(cat) = 3100 min(-1)). Possessing a midpoint potential of -270 mV, PfTrx was found to reduce the disease-related metabolites S-nitrosoglutathione and GSSG;. The rate constant Fz, for the reaction between reduced P. falciparum thioredoxin and GSSG was determined to be 0.039 muM(-1) min(-1) at 25 degreesC and pH 7.4. The k(2) for thioredoxins from man, Drosophila melanogaster, and Escherichia coli was similar to5 times lower. Our data suggest that GSSG reduction can be supported at a high rate by the TrxR/Trx system in glutathione reductase-deficient cells; this may be relevant for certain stages of the malarial parasite but also for cells containing high [GSSG] of other organisms like dormant forms of Neurospora, glutathione reductase-deficient yeast mutants, or CD4(+) lymphocytes of AIDS patients.	Univ Wurzburg, Res Ctr Infect Dis, D-97070 Wurzburg, Germany; Heidelberg Univ, Ctr Biochem, D-69120 Heidelberg, Germany; Ctr Mol Biol, D-69120 Heidelberg, Germany	University of Wurzburg; Ruprecht Karls University Heidelberg	Becker, K (corresponding author), Univ Wurzburg, Res Ctr Infect Dis, Roentgenring 11, D-97070 Wurzburg, Germany.	becker.katja@gmx.de						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; [Anonymous], 1989, COENZYMES COFACTORS; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 1999, METHOD ENZYMOL, V300, P226; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; Atamna H, 1997, EUR J BIOCHEM, V250, P670, DOI 10.1111/j.1432-1033.1997.00670.x; AUKRUST P, 1995, BLOOD, V86, P258, DOI 10.1182/blood.V86.1.258.bloodjournal861258; BECKER K, 1995, METHOD ENZYMOL, V251, P173, DOI 10.1016/0076-6879(95)51120-2; Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; Berggren M, 1996, ANTICANCER RES, V16, P3459; Butler D, 1997, NATURE, V386, P535, DOI 10.1038/42306; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P4061, DOI 10.1021/bi9628580; Clark IA, 1999, PARASITOL TODAY, V15, P458, DOI 10.1016/S0169-4758(99)01535-5; FAHEY RC, 1975, J BACTERIOL, V121, P144, DOI 10.1128/JB.121.1.144-151.1975; Farber PM, 1998, FEBS LETT, V422, P311, DOI 10.1016/S0014-5793(98)00031-3; Follmann H, 1995, BIOFACTORS, V5, P147; Gilberger TW, 2000, MOL BIOCHEM PARASIT, V107, P169, DOI 10.1016/S0166-6851(00)00188-2; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Gromer S, 1999, REDOX REP, V4, P221, DOI 10.1179/135100099101534936; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1998, OXIDATIVE STRESS CAN, P229; KrauthSiegel RL, 1996, EUR J BIOCHEM, V235, P345, DOI 10.1111/j.1432-1033.1996.00345.x; Lennon BW, 1996, BIOCHEMISTRY-US, V35, P4704, DOI 10.1021/bi952521i; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; Muller S, 1996, MOL BIOCHEM PARASIT, V80, P215, DOI 10.1016/0166-6851(96)02694-1; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; Pan WQ, 1999, NUCLEIC ACIDS RES, V27, P1094, DOI 10.1093/nar/27.4.1094; POWIS G, 1994, ONCOL RES, V6, P539; Savvides SN, 1996, J BIOL CHEM, V271, P8101, DOI 10.1074/jbc.271.14.8101; SCHIRMER RH, 1995, ANGEW CHEM INT EDIT, V34, P141, DOI 10.1002/anie.199501411; Schneider D, 2000, SCIENCE, V288, P2376, DOI 10.1126/science.288.5475.2376; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; Wang PF, 1999, BIOCHEMISTRY-US, V38, P3187, DOI 10.1021/bi982674g; Williams CH, 2000, EUR J BIOCHEM, V267, P6110, DOI 10.1046/j.1432-1327.2000.01702.x; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897	42	217	219	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40180	40186		10.1074/jbc.M007633200	http://dx.doi.org/10.1074/jbc.M007633200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11013257	hybrid			2022-12-25	WOS:000166039500054
J	Zhang, ZQ; Apse, K; Pang, JD; Stanton, RC				Zhang, ZQ; Apse, K; Pang, JD; Stanton, RC			High glucose inhibits glucose-6-phosphate dehydrogenase via cAMP in aortic endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; GROWTH-FACTOR; COMPLICATIONS; ACTIVATION; EXPRESSION; RELEASE; ENZYME	Recent studies have shown that hyperglycemia is a principal cause of cellular damage in patients with diabetes mellitus, A major consequence of hyperglycemia is increased oxidative stress. Glucose-8-phosphate dehydrogenase (G6PD) plays an essential role in the regulation of oxidative stress by primarily regulating NADPH, the main intracellular reductant. In this paper we show that increased glucose (10-25 mM) caused inhibition of G6PD resulting in decreased NADPH levels in bovine aortic endothelial cells (BAEC), Inhibition was seen within 15 min. High glucose-induced inhibition of G6PD predisposed cells to cell death. High glucose via increased activity of adenylate cyclase also stimulated an increase in cAMP levels in BAEC. Agents that increased cAMP caused a decrease in G6PD activity. Inhibition of cAMP-dependent protein kinase A ameliorated the high glucose-induced inhibition of G6PD, Finally, high glucose stimulated phosphorylation of G6PD. These results suggest that, in BAEC, high glucose stimulated increased cAMP, which led to increased protein kinase A activity, phosphorylation of G6PD, and inhibition of G6PD activity. We conclude that these changes in G6PD activity play an important role in high glucose-induced cell damage/death.	Beth Israel Deaconess Med Ctr, Joslin Diabet Ctr, Div Renal, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Joslin Diabet Ctr, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; So Connecticut State Univ, Dept Chem, New Haven, CT 06515 USA	Harvard University; Beth Israel Deaconess Medical Center; Joslin Diabetes Center, Inc.; Harvard University; Beth Israel Deaconess Medical Center; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Connecticut State University System; Southern Connecticut State University	Stanton, RC (corresponding author), Beth Israel Deaconess Med Ctr, Joslin Diabet Ctr, Div Renal, 1 Joslin Pl, Boston, MA 02215 USA.		Stanton, Robert C/AAG-7584-2020	Stanton, Robert C/0000-0002-3056-1277				ASAHINA T, 1995, DIABETES, V44, P520, DOI 10.2337/diabetes.44.5.520; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; Chakraborti T, 1998, MOL CELL BIOCHEM, V187, P1; Cramer C T, 1995, J Biochem Toxicol, V10, P293, DOI 10.1002/jbt.2570100603; FISHER AB, 1988, UPJ S OX RAD PARK CI, P34; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; FRIDOVICH I, 1988, UPJ S OX RAD PARK CI, P1; Giugliano D, 1996, DIABETES CARE, V19, P257, DOI 10.2337/diacare.19.3.257; HA HJ, 1994, KIDNEY INT, V46, P1620, DOI 10.1038/ki.1994.461; HORECKER BL, 1965, J CHEM EDUC, V42, P244, DOI 10.1021/ed042p244; JACKOWSKI MM, 1978, J CYCLIC NUCL PROT, V4, P323; Kamal K, 1998, J CELL BIOCHEM, V71, P491, DOI 10.1002/(SICI)1097-4644(19981215)71:4<491::AID-JCB4>3.0.CO;2-P; KLETZIEN RF, 1994, FASEB J, V8, P174, DOI 10.1096/fasebj.8.2.8119488; LOW PA, 1997, DIABETES S2, V46, P38; Morishita R, 1997, DIABETES, V46, P138, DOI 10.2337/diabetes.46.1.138; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; ROSA LFBPC, 1995, BIOCHEM J, V310, P709, DOI 10.1042/bj3100709; ROSENSTRAUS M, 1975, P NATL ACAD SCI USA, V72, P493, DOI 10.1073/pnas.72.2.493; Salvemini F, 1999, J BIOL CHEM, V274, P2750, DOI 10.1074/jbc.274.5.2750; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; STANTON RC, 1988, AM J PHYSIOL, V254, pC267, DOI 10.1152/ajpcell.1988.254.2.C267; STANTON RC, 1991, J BIOL CHEM, V266, P12442; Tian WN, 1998, J BIOL CHEM, V273, P10609, DOI 10.1074/jbc.273.17.10609; Tian WN, 1999, AM J PHYSIOL-CELL PH, V276, pC1121, DOI 10.1152/ajpcell.1999.276.5.C1121; TIAN WN, 1994, J BIOL CHEM, V269, P14798; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Ursini MV, 1997, BIOCHEM J, V323, P801, DOI 10.1042/bj3230801; Wang Hwei-Zu, 1997, Kaohsiung Journal of Medical Sciences, V13, P566; ZAWALICH WS, 1975, DIABETOLOGIA, V11, P231, DOI 10.1007/BF00422327; Zhang ZQ, 2000, ANAL BIOCHEM, V285, P163, DOI 10.1006/abio.2000.4701	32	171	181	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40042	40047		10.1074/jbc.M007505200	http://dx.doi.org/10.1074/jbc.M007505200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007790	hybrid			2022-12-25	WOS:000166039500035
J	Francis, JM; Heyworth, CM; Spooncer, E; Pierce, A; Dexter, TM; Whetton, AD				Francis, JM; Heyworth, CM; Spooncer, E; Pierce, A; Dexter, TM; Whetton, AD			Transforming growth factor-beta 1 induces apoptosis independently of p53 and selectively reduces expression of Bcl-2 in multipotent hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; COLONY-STIMULATING FACTOR; MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; BONE-MARROW-CELLS; TGF-BETA; RECEPTOR EXPRESSION; EPITHELIAL-CELLS; PROGENITOR CELLS; SUPPRESSOR GENE; TNF-ALPHA	Transforming growth factor-pi (TGF-beta1) can inhibit cell proliferation or induce apoptosis in multipotent hematopoietic cells. To study the mechanisms of TGF-beta1 action on primitive hematopoietic cells, we used the interleukin-3 (IL-3)-dependent, multipotent FDCP-Mix cell line. TGF-beta1-mediated growth inhibition was observed in high concentrations of IL-3, while at lower IL-3 concentrations TGF-beta1 induced apoptosis. The proapoptotic effects of TGF-beta1 occur via a p53-independent pathway, since p53(null) FDCP-Mix demonstrated the same responses to TGF-beta1. IL-3 has been suggested to enhance survival via an increase in (antiapoptotic) Bcl-x(L) expression. In FDCP-Mix cells, neither IL-3 nor TGF-beta1 induced any change in Bcl-x(L) protein levels or the proapoptotic proteins Bad or Bax. However, TGF-beta1 had a major effect on Bcl-2 levels, reducing them in the presence of high and low concentrations of IL-3. Overexpression of Bcl-2 in FDCP-Mix cells rescued them from TGF-beta1-induced apoptosis but was incapable of inhibiting TGF-beta1-mediated growth arrest. We conclude that TGF-beta1-induced cell death is independent of p53 and inhibited by Bcl-2, with no effect on Bcl-x(L). The significance of these results for stem cell survival in bone marrow are discussed.	Univ Manchester, Leukaemia Res Fund, Cellular Dev Unit, Manchester M60 1QD, Lancs, England; Univ Manchester, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Christie Hosp, NHS Trust, Paterson Inst Canc Res, Dept Expt Haematol,Canc Res Campaign, Manchester M20 9BX, Lancs, England	University of Manchester; University of Manchester; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Whetton, AD (corresponding author), Univ Manchester, Leukaemia Res Fund, Cellular Dev Unit, Sackville St, Manchester M60 1QD, Lancs, England.	Tony.Whetton@UMIST.ac.uk		WHETTON, ANTHONY D/0000-0002-1098-3878; Pierce, Andrew/0000-0001-5995-2469				BONNET D, 1995, EXP HEMATOL, V23, P551; BROXMEYER HE, 1996, BLOOD CELL BIOCH, P121; BURSUKER I, 1992, EXP HEMATOL, V20, P431; Cashman JD, 1998, BLOOD, V92, P2338, DOI 10.1182/blood.V92.7.2338.2338_2338_2344; CELADA A, 1992, J IMMUNOL, V148, P1102; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHEN AR, 1993, BLOOD, V81, P2539; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; Chen Q, 1997, ONCOGENE, V15, P2249, DOI 10.1038/sj.onc.1201371; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; delPeso L, 1997, SCIENCE, V278, P687; Dibbert B, 1998, BLOOD, V92, P778, DOI 10.1182/blood.V92.3.778.415k38_778_783; DUBOIS CM, 1994, BLOOD, V83, P3138; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; EAVES CJ, 1991, BLOOD, V78, P110; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FAN K, 1992, BLOOD, V79, P1679; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GOEY H, 1989, J IMMUNOL, V143, P877; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HESTDAL K, 1993, EXP HEMATOL, V21, P799; HEYWORTH CM, 1995, GROWTH FACTORS, V12, P165, DOI 10.3109/08977199509036876; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; JACOBSEN FW, 1995, BLOOD, V86, P2957; JACOBSEN SEW, 1993, J IMMUNOL, V151, P4534; JACOBSEN SEW, 1991, BLOOD, V77, P1706; JACOBSEN SEW, 1991, BLOOD, V78, P2239, DOI 10.1182/blood.V78.9.2239.bloodjournal7892239; JETTEN AM, 1986, EXP CELL RES, V167, P539, DOI 10.1016/0014-4827(86)90193-X; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KELLER JR, 1994, BLOOD, V84, P2175; KELLER JR, 1988, J EXP MED, V168, P737, DOI 10.1084/jem.168.2.737; KELLER JR, 1991, P NATL ACAD SCI USA, V88, P7190, DOI 10.1073/pnas.88.16.7190; KLETSAS D, 1995, EXP CELL RES, V217, P477, DOI 10.1006/excr.1995.1112; KUROKOWA M, 1987, BIOCHEM BIOPH RES CO, V142, P775, DOI 10.1016/0006-291X(87)91481-1; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; LOTEM J, 1992, BLOOD, V80, P1750; MARVEL J, 1994, ONCOGENE, V9, P1117; MAY WS, 1994, J BIOL CHEM, V269, P26865; MICHISHITA M, 1991, EXP CELL RES, V196, P107, DOI 10.1016/0014-4827(91)90461-3; Migdalska A, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104820; Motyl T, 1998, EUR J CELL BIOL, V75, P367, DOI 10.1016/S0171-9335(98)80070-8; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; NAAS SJ, 1996, BIOCH CELL BIOL COMM, V227, P248; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OTTMANN OG, 1988, J IMMUNOL, V140, P2661; Pierce A, 1998, J CELL SCI, V111, P815; REDDY KB, 1993, J CELL PHYSIOL, V156, P48, DOI 10.1002/jcp.1041560108; REISS M, 1992, ONCOL RES, V4, P349; REISS M, 1993, CANCER RES, V53, P899; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; Saltzman A, 1998, EXP CELL RES, V242, P244, DOI 10.1006/excr.1998.4096; Sasaki H, 1997, LEUKEMIA, V11, P239, DOI 10.1038/sj.leu.2400548; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; Silva A, 1997, BLOOD, V89, P2717, DOI 10.1182/blood.V89.8.2717; Sitnicka E, 1996, BLOOD, V88, P82; SMELAND EB, 1987, EXP CELL RES, V171, P213, DOI 10.1016/0014-4827(87)90264-3; Soma T, 1996, BLOOD, V87, P4561, DOI 10.1182/blood.V87.11.4561.bloodjournal87114561; SPOONCER E, 1994, LEUKEMIA, V8, P620; SPOONCER E, 1985, NATURE, V316, P62, DOI 10.1038/316062a0; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; STOECK M, 1989, J CELL PHYSIOL, V141, P65, DOI 10.1002/jcp.1041410111; TAETLE R, 1993, CANCER RES, V53, P3386; Teramoto T, 1998, BIOCHEM BIOPH RES CO, V251, P56, DOI 10.1006/bbrc.1998.9411; TSUKADA T, 1995, BIOCHEM BIOPH RES CO, V210, P1076, DOI 10.1006/bbrc.1995.1766; Veiby OP, 1996, J IMMUNOL, V157, P2953; WeberNordt RM, 1996, BLOOD, V88, P2549, DOI 10.1182/blood.V88.7.2549.bloodjournal8872549; WYLLIE FS, 1991, MOL CELL ENDOCRINOL, V76, P13, DOI 10.1016/0303-7207(91)90255-Q; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	74	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39137	39145		10.1074/jbc.M007212200	http://dx.doi.org/10.1074/jbc.M007212200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993901	hybrid			2022-12-25	WOS:000165953100028
J	Klostermann, A; Lutz, B; Gertler, F; Behl, C				Klostermann, A; Lutz, B; Gertler, F; Behl, C			The orthologous human and murine semaphorin 6A-1 proteins (SEMA6A-1/Sema6A-1) bind to the enabled/vasodilator-stimulated phosphoprotein-like protein (EVL) via a novel carboxyl-terminal zyxin-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; EVH1 DOMAIN; GUIDANCE; EXPRESSION; RECEPTOR; VASP; MENA; ABL; DYNAMICS; PROFILIN	Neuronal development and apoptosis critically depend on the transformation of extracellular signals to intracellular actions resulting in cytoskeletal rearrangements. Ena/VASP (enabled/vasodilator-stimulated phosphoprotein) proteins play an important role in actin and filament dynamics, whereas members of the semaphorin protein family are guidance signals in embryo- and organogenesis. Here, we report the identification of two novel transmembranous human and murine semaphorins, (HSA)SEMA6A-1 and (MMU)Sema6A-1. These semaphorin 6 variants directly link the Ena/VASP and the semaphorin protein family, since SEMA6A-1/Sema6A-1 is capable of a selective binding to the protein EVL (Ena/VASP-like protein). EVL is the third member of the Ena/VASP family of proteins that was identified sharing the same structural features as Mena (mammalian enabled) and VASP, although its functionality seems to be different from that of the other members. Here we demonstrate that SEMA6A-1/Sema6A-1 is colocalized with EVL via its zyxin-like carboxyl-terminal domain that contains a modified binding motif, which further stresses the existence of functional differences between EVL and Mena/VASP, In addition these findings suggest a completely new role for transmembranous semaphorins such as SEMA6A-1/Sema6A-1 in retrograde signaling.	MPI Psychiat, Independent Res Grp Neurodegenerat, D-80804 Munich, Germany; MPI Psychiat, Independent Res Grp Mol Genet Behav, D-80804 Munich, Germany; MIT, Dept Biol, Cambridge, MA 02142 USA	Max Planck Society; Max Planck Society; Massachusetts Institute of Technology (MIT)	Behl, C (corresponding author), MPI Psychiat, Independent Res Grp Neurodegenerat, Kraepelinstr 2, D-80804 Munich, Germany.	chris@mpipsykl.mpg.de	Lutz, Beat/AFK-6229-2022	Behl, Christian/0000-0001-8453-2378				Ahern-Djamali SM, 1999, P NATL ACAD SCI USA, V96, P4977, DOI 10.1073/pnas.96.9.4977; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Carl UD, 1999, CURR BIOL, V9, P715, DOI 10.1016/S0960-9822(99)80315-7; Culotti JG, 1996, CURR OPIN NEUROBIOL, V6, P81, DOI 10.1016/S0959-4388(96)80012-2; Drees BE, 1999, J CELL BIOL, V147, P1549, DOI 10.1083/jcb.147.7.1549; Eckhardt F, 1997, MOL CELL NEUROSCI, V9, P409, DOI 10.1006/mcne.1997.0644; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Fedorov AA, 1999, NAT STRUCT BIOL, V6, P661, DOI 10.1038/10717; Gagliardini V, 1999, MOL CELL NEUROSCI, V14, P301, DOI 10.1006/mcne.1999.0787; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1990, SCIENCE, V248, P857, DOI 10.1126/science.2188361; Goodman CS, 1999, CELL, V97, P551, DOI 10.1016/S0092-8674(00)80766-7; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; Holder N, 1999, DEVELOPMENT, V126, P2033; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Klein R, 1999, CURR BIOL, V9, pR691, DOI 10.1016/S0960-9822(99)80441-2; Klostermann A, 1998, J BIOL CHEM, V273, P7326, DOI 10.1074/jbc.273.13.7326; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Koppel AM, 1998, J BIOL CHEM, V273, P15708, DOI 10.1074/jbc.273.25.15708; LAMBRECHTS A, 2000, IN PRESS J BIOL CHEM; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Macalma T, 1996, J BIOL CHEM, V271, P31470, DOI 10.1074/jbc.271.49.31470; Marsicano G, 1999, EUR J NEUROSCI, V11, P4213, DOI 10.1046/j.1460-9568.1999.00847.x; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; Puschel AW, 1999, NAT NEUROSCI, V2, P777, DOI 10.1038/12140; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Rottner K, 1999, NAT CELL BIOL, V1, P321, DOI 10.1038/13040; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schafer DA, 1995, ANNU REV CELL DEV BI, V11, P497, DOI 10.1146/annurev.cellbio.11.1.497; Shirvan A, 1999, J NEUROCHEM, V73, P961, DOI 10.1046/j.1471-4159.1999.0730961.x; Strittmatter SM, 2000, NATURE, V404, P557, DOI 10.1038/35007181; Ueno K, 1998, HUM GENET, V102, P63, DOI 10.1007/s004390050655; Van Vactor D, 1999, CURR BIOL, V9, pR201; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Wills Z, 1999, NEURON, V22, P291, DOI 10.1016/S0896-6273(00)81090-9; Wills Z, 1999, NEURON, V22, P301, DOI 10.1016/S0896-6273(00)81091-0; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Wong JTW, 1999, NAT NEUROSCI, V2, P798, DOI 10.1038/12168; Xu XM, 2000, J NEUROSCI, V20, P2638; Zhou L, 1997, MOL CELL NEUROSCI, V9, P26, DOI 10.1006/mcne.1997.0607	49	58	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39647	39653		10.1074/jbc.M006316200	http://dx.doi.org/10.1074/jbc.M006316200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993894	hybrid			2022-12-25	WOS:000165953100092
J	Walter, JC				Walter, JC			Evidence for sequential action of cdc7 and cdk2 protein kinases during initiation of DNA replication in Xenopus egg extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; REGULATORY SUBUNIT; MCM PROTEINS; ORIGINS; CHROMATIN; INHIBITOR; ASSOCIATION; REQUIRES	To investigate how the protein kinase cdc7 stimulates DNA replication in metazoans, a soluble cell-free replication system derived from Xenopus eggs was used. DNA was incubated in egg cytosol to form prereplication complexes and then in nucleoplasmic extract to initiate DNA synthesis. We find that cdc7 is greatly enriched in nucleoplasmic extract and that this high concentration is essential for efficient DNA replication, supporting previous models that the nucleus activates replication indirectly by sequestering essential components, cdc7 binds to chromatin at the G(1)/S transition before initiation occurs, and it dissociates from chromatin as S phase progresses, The chromatin association of cdc7 requires chromatin-bound MCM. In turn, cdc7 is required to load the initiation factor cdc45 onto the DNA,Finally, efficient replication is observed when chromatin is exposed first to cdc7 and then to cdk2 but not when it is exposed to cdk2 before cdc7. Therefore, the cdc7- and cdk2-dependent initiation steps can be separated, indicating the existence of a novel, stable initiation intermediate. Moreover, the data suggest that cdk2 can only act after cdc7 has executed its function.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Walter, JC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	johannes_walter@hms.harvard.edu		Walter, Johannes/0000-0002-4186-7570				Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Dimitrova DS, 1999, CRIT REV EUKAR GENE, V9, P353, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.200; Donaldson AD, 1998, MOL CELL, V2, P173, DOI 10.1016/S1097-2765(00)80127-6; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; Geraghty DS, 2000, J BIOL CHEM, V275, P18011, DOI 10.1074/jbc.M909787199; Hardy CFJ, 1997, P NATL ACAD SCI USA, V94, P3151, DOI 10.1073/pnas.94.7.3151; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Jares P, 2000, GENE DEV, V14, P1528; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mimura S, 2000, GENES CELLS, V5, P439, DOI 10.1046/j.1365-2443.2000.00340.x; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Nougarede R, 2000, MOL CELL BIOL, V20, P3795, DOI 10.1128/MCB.20.11.3795-3806.2000; Owens JC, 1997, P NATL ACAD SCI USA, V94, P12521, DOI 10.1073/pnas.94.23.12521; Pasero P, 1999, GENE DEV, V13, P2159, DOI 10.1101/gad.13.16.2159; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Roberts BT, 1999, P NATL ACAD SCI USA, V96, P2800, DOI 10.1073/pnas.96.6.2800; Rowles A, 1999, J CELL SCI, V112, P2011; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; Sclafani RA, 2000, J CELL SCI, V113, P2111; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Tanaka TU, 1998, EMBO J, V17, P5182, DOI 10.1093/emboj/17.17.5182; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Waiter J, 1997, SCIENCE, V275, P993, DOI 10.1126/science.275.5302.993; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; You ZY, 1999, MOL CELL BIOL, V19, P8003; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	43	122	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39773	39778		10.1074/jbc.M008107200	http://dx.doi.org/10.1074/jbc.M008107200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11005825	hybrid			2022-12-25	WOS:000165953100109
J	Zheng, WH; Kar, S; Quirion, R				Zheng, WH; Kar, S; Quirion, R			Insulin-like growth factor-1-induced phosphorylation of the Forkhead family transcription factor FKHRL1 is mediated by Akt kinase in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; ACTIVATED PROTEIN-KINASE; SERINE-THREONINE KINASE; FACTOR-I RECEPTOR; NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3'-KINASE; CAENORHABDITIS-ELEGANS; SIGNAL-TRANSDUCTION; GENE; INHIBITOR	The Forkhead family transcription factor FKHRL1, a mammalian homolog of DAF16 in the nematode Caenorhabditis elegans, is an inducer of apoptosis in its unphosphorylated form and was recently reported as a substrate of Akt kinases. Insulin-like growth factor (IGF-I) is a potent stimulant of Akt kinase, leading to inhibition of the apoptotic pathway. In this study, we characterized the phosphorylation of FKHRL1 induced by IGF-1 in PC12 cells and various neuronal cell types and examined the potential role of Akt in this regard. IGF-I rapidly induced the phosphorylation of Akt and FKHRL1 in PC12 cells. The phosphorylation of Akt and FRHRL1 induced by 10 nM IGF-1 was inhibited by the phosphatidylinositide S-kinase (PI3K) inhibitors wort-mannin (0.25-2 muM) and LY294002 (12.5-100 muM), but not by the MEK inhibitor PD98059 (50 muM) or the p70 S6 kinase pathway inhibitor rapamycin (50 nM), suggesting that the phosphorylation of FKHRL1 induced by IGF-I is mediated by the PI3K pathway. As observed for IGF-1, an in vitro kinase assay with purified active Akt kinase demonstrated that the kinase is capable of directly phosphorylating FKHRL1 at Thr(32) and Ser(253), leading to inhibition of its pro-apoptotic properties. Moreover, transient expression of constitutively active Akt (MS-Akt, where MS is a myristylation signal) increased the phosphorylation of FKHRL1, whereas the expression of kinase-dead Akt (M179A Akt) attenuated the phosphorylation of FKHRL1 induced by 10 nM IGF-1 in PC12 cells. Interestingly, FKHRL1 co-immunoprecipitated with Akt in PC12 cells, indicating that these two proteins can associate in these cells. As IGF-1 also induced the phosphorylation of FKHRL1 in primary cortical and cerebellar neuronal cultures, these data, taken together, demonstrate that IGF-1, acting via the PI3K/Akt kinase pathway, can regulate the phosphorylation of FKHRL1, leading to inhibition of this apoptotic transcription factor in neuronal cells.	Douglas Hosp, Res Ctr, Dept Psychiat, Verdun, PQ H4H 1R3, Canada; McGill Univ, Dept Pharmacol & Therapeut, Verdun, PQ H4H 1R3, Canada	McGill University; McGill University	Quirion, R (corresponding author), Douglas Hosp, Res Ctr, Dept Psychiat, 6875 LaSalle Blvd, Verdun, PQ H4H 1R3, Canada.	Quirem@douglas.mcgill.ca	yang, chao/AAV-5929-2021					Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; delPeso L, 1997, SCIENCE, V278, P687; Dore S, 1997, P NATL ACAD SCI USA, V94, P4772, DOI 10.1073/pnas.94.9.4772; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ozes ON, 1999, NATURE, V401, P82; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wijkander J, 1997, J BIOL CHEM, V272, P21520, DOI 10.1074/jbc.272.34.21520; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zheng WH, 2000, J BIOL CHEM, V275, P13377, DOI 10.1074/jbc.275.18.13377; Zheng WH, 1996, J NEUROCHEM, V66, P1868	52	129	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39152	39158		10.1074/jbc.M002417200	http://dx.doi.org/10.1074/jbc.M002417200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995739	hybrid			2022-12-25	WOS:000165953100030
J	McLendon, C; Xin, TP; Ziani-Cherif, C; Murphy, MP; Findlay, KA; Lewis, PA; Pinnix, I; Sambamurti, K; Wang, R; Fauq, A; Golde, TE				McLendon, C; Xin, TP; Ziani-Cherif, C; Murphy, MP; Findlay, KA; Lewis, PA; Pinnix, I; Sambamurti, K; Wang, R; Fauq, A; Golde, TE			Cell-free assays for gamma-secretase activity	FASEB JOURNAL			English	Article									Mayo Clin Jacksonville, Dept Pharmacol, Jacksonville, FL 32224 USA; Rockefeller Univ, Lab Mass Spect, New York, NY 10021 USA	Mayo Clinic; Rockefeller University	Golde, TE (corresponding author), Mayo Clin Jacksonville, Dept Pharmacol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.		Lewis, Patrick A./C-3674-2009; Wang, Rong/A-8721-2009; Sambamurti, Kumar/J-6102-2013	Sambamurti, Kumar/0000-0001-9507-9214; Lewis, Patrick/0000-0003-4537-0489; ziani-cherif, chewki/0000-0001-5759-8275					0	105	120	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2383	2386						4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11024004				2022-12-25	WOS:000165723400005
J	Napoli, C; Quehenberger, O; De Nigris, F; Abete, P; Glass, CK; Palinski, W				Napoli, C; Quehenberger, O; De Nigris, F; Abete, P; Glass, CK; Palinski, W			Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells	FASEB JOURNAL			English	Article						oxidized LDL; atherosclerosis; FasL; TNF receptors; caspases; MAPK; JunK	HUMAN ATHEROSCLEROTIC PLAQUES; SMOOTH-MUSCLE CELLS; NF-KAPPA-B; IN-VITRO; OXYGEN RADICALS; LDL; DEATH; MACROPHAGES; EXPRESSION; OXIDATION	Apoptosis of arterial cells induced by oxidized low density lipoproteins (OxLDL) is thought to contribute to the progression of atherosclerosis. However, most data on apoptotic effects and mechanisms of OxLDL were obtained with extensively oxidized LDL unlikely to occur in early stages of atherosclerotic lesions. We now demonstrate that mildly oxidized LDL generated by incubation with oxygen radical-producing xanthine/xanthine oxidase (X/XO) induces apoptosis in primary cultures of human coronary endothelial and SMC, as determined by TUNEL technique, DNA laddering, and FAGS analysis. Apoptosis was markedly reduced when X/XO-LDL was generated in the presence of different oxygen radical scavengers. Apoptotic signals were mediated by intramembrane domains of both Fas and tumor necrosis factor (TNF) receptors I and II. Blocking of Fas ligand (FasL) reduced apoptosis by 50% and simultaneous blocking of FasL and TNF receptors by 70%. Activation of apoptotic receptors was accompanied by an increase of proapoptotic and a decrease in antiapoptotic proteins of the Bcl-2 family: and resulted in marked activation of class I and II caspases. Mildly oxidized LDL also activated MAP and Jun kinases and increased p53 and other transcription factors (ATF-2, ELK-1, CREB, AP-1). Inhibitors of Map and Jun kinase significantly reduced apoptosis. Our results provide the first evidence that OxLDL-induced apoptosis involves TNF receptors and Jun activation. More important, they demonstrate that even mildly oxidized LDL formed in atherosclerotic lesions may activate a broad cascade of oxygen radical-sensitive signaling pathways affecting apoptosis and other processes influencing the evolution of plaques. Thus, we suggest that extensive oxidative modifications of LDL are not necessary to influence signal transduction and transcription in vivo.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Naples Federico II, Dept Clin & Expt Med, I-80131 Naples, Italy; Univ Naples Federico II, Dept Gerontol, I-80131 Naples, Italy	University of California System; University of California San Diego; University of Naples Federico II; University of Naples Federico II	Palinski, W (corresponding author), Univ Calif San Diego, Dept Med, 0682,9500 Gilman Dr,MTF 110, La Jolla, CA 92093 USA.	wpalinski@ucsd.edu/cnapoli.ucsd.edu	Glass, Christopher/AAI-3933-2021; Abete, Pasquale/AAC-2455-2022; Palinski, Wulf/AAW-8032-2021	Glass, Christopher/0000-0003-4344-3592; Abete, Pasquale/0000-0002-4585-5390; Palinski, Wulf/0000-0002-5113-0169; de nigris, filomena/0000-0002-2322-1557; Napoli, Claudio/0000-0002-5455-555X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056989] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56989] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMBROSIO G, 1994, J CLIN INVEST, V93, P2408, DOI 10.1172/JCI117248; Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P47, DOI 10.1016/S0968-0004(98)01341-3; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Battista S, 1998, ONCOGENE, V17, P377, DOI 10.1038/sj.onc.1201953; BJORKERUD S, 1995, AM J PATHOL, V147, P267; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; de Nigris F, 2000, BIOCHEM PHARMACOL, V59, P1477, DOI 10.1016/S0006-2952(00)00275-6; Dimmeler S, 1997, CIRCULATION, V95, P1760; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Fruebis J, 1997, ARTERIOSCL THROM VAS, V17, P1289, DOI 10.1161/01.ATV.17.7.1289; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GENG YJ, 1995, AM J PATHOL, V147, P251; Geng YJ, 1997, ARTERIOSCL THROM VAS, V17, P2200, DOI 10.1161/01.ATV.17.10.2200; Hamilton TA, 1998, J LEUKOCYTE BIOL, V64, P667, DOI 10.1002/jlb.64.5.667; Harada-Shiba M, 1998, J BIOL CHEM, V273, P9681, DOI 10.1074/jbc.273.16.9681; HARLOW E, 1989, IMMUNOBLOTTING LAB M; Jovinge S, 1997, ARTERIOSCL THROM VAS, V17, P2225, DOI 10.1161/01.ATV.17.10.2225; Kinscherf R, 1998, FASEB J, V12, P461, DOI 10.1096/fasebj.12.6.461; Kockx MM, 2000, CARDIOVASC RES, V45, P736, DOI 10.1016/S0008-6363(99)00235-7; Kockx MM, 1998, CIRCULATION, V97, P2307, DOI 10.1161/01.CIR.97.23.2307; Kolodgie FD, 1999, APOPTOSIS, V4, P5, DOI 10.1023/A:1009645730270; Kusuhara M, 1997, ARTERIOSCL THROM VAS, V17, P141, DOI 10.1161/01.ATV.17.1.141; Lee JW, 1999, J MOL CELL CARDIOL, V31, P113, DOI 10.1006/jmcc.1998.0850; LI D, 1998, AM J PHYSIOL, V275, P568; Liguori A, 1999, EUR J CLIN PHARMACOL, V55, P117, DOI 10.1007/s002280050605; Mallat Z, 1997, CIRCULATION, V96, P424; Maziere C, 1999, FEBS LETT, V448, P49, DOI 10.1016/S0014-5793(99)00324-5; Meilhac O, 1999, FASEB J, V13, P485, DOI 10.1096/fasebj.13.3.485; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Napoli C, 1996, J AM COLL CARDIOL, V28, P1637, DOI 10.1016/S0735-1097(96)90208-9; Napoli C, 1997, STROKE, V28, P2266, DOI 10.1161/01.STR.28.11.2266; Napoli C, 1997, AM HEART J, V133, P585, DOI 10.1016/S0002-8703(97)70155-8; Napoli C, 1997, J BIOCHEM-TOKYO, V121, P1096; Napoli C, 2000, P NATL ACAD SCI USA, V97, P3678, DOI 10.1073/pnas.97.7.3678; Napoli C, 1999, LANCET, V354, P1234, DOI 10.1016/S0140-6736(99)02131-5; Napoli C, 1995, ATHEROSCLEROSIS, V118, P259, DOI 10.1016/0021-9150(95)05612-2; Palinski W, 2000, J INTERN MED, V247, P371, DOI 10.1046/j.1365-2796.2000.00656.x; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; REID VC, 1993, J PATHOL, V171, P321, DOI 10.1002/path.1711710413; REID VC, 1993, FEBS LETT, V332, P218, DOI 10.1016/0014-5793(93)80635-8; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; Sata M, 1998, J CLIN INVEST, V102, P1682, DOI 10.1172/JCI3531; SHARAD K, 1999, TRENDS BIOCHEM SCI, V24, P1; Siow RCM, 1999, ARTERIOSCL THROM VAS, V19, P2387, DOI 10.1161/01.ATV.19.10.2387; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; Vieira O, 2000, FASEB J, V14, P532, DOI 10.1096/fasebj.14.3.532; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0	53	181	188	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2000	14	13					1996	2007		10.1096/fj.99-0986com	http://dx.doi.org/10.1096/fj.99-0986com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023984				2022-12-25	WOS:000089634400019
J	Hannemann, F; Rottmann, M; Schiffler, B; Zapp, J; Bernhardt, R				Hannemann, F; Rottmann, M; Schiffler, B; Zapp, J; Bernhardt, R			The loop region covering the iron-sulfur cluster in bovine adrenodoxin comprises a new interaction site for redox partners	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ELECTRON-TRANSFER FUNCTION; DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; FERREDOXIN REDUCTASE; MOLECULAR-CLONING; 2FE-2S FERREDOXIN; EXPRESSION; BINDING; IDENTIFICATION	The amino acid in position 49 in bovine adrenodoxin is conserved among vertebrate [2Fe-2S] ferredoxins as hydroxyl function. A corresponding residue is missing in the cluster-coordinating loop of plant-type [2Fe-2S] ferredoxins. To probe the function of Thr-49 in a vertebrate ferredoxin, replacement mutants T49A, T49S, T49L, and T49Y, and a deletion mutant, T49 Delta, were generated and expressed in Escherichia cold, CD spectra of purified proteins indicate changes of the [2Fe-2S] center geometry only for mutant T49 Delta, whereas NMR studies reveal no transduction of structural changes to the interaction domain. The redox potential of T49 Delta (-370 mV) is lowered by similar to 100 mV compared with wild type adrenodoxin and reaches the potential range of plant-type ferredoxins (-305 to -455 mV), Substitution mutants show moderate changes in the binding affinity to the redox partners. In contrast, the binding affinity of T49 Delta to adrenodoxin reductase and cytochrome P-450 11A1 (CYP11A1) is dramatically reduced. These results led to the conclusion that Thr-49 modulates the redox potential in adrenodoxin and that the cluster-binding loop around Thr-49 represents a new interaction region with the redox partners adrenodoxin reductase and CYP11A1, In addition, variations of the apparent rate constants of all mutants for CYP11A1 reduction indicate the participation of residue 49 in the electron transfer pathway between adrenodoxin and CYP11A1.	Univ Saarlandes, Fachrichtung Biochem 8 8, D-60041 Saarbrucken, Germany; Univ Saarlandes, Fachrichtung Pharmakognosie & Analyt Phytochem 8, D-60041 Saarbrucken, Germany	Saarland University; Saarland University	Bernhardt, R (corresponding author), Univ Saarlandes, Fachrichtung Biochem 8 8, D-60041 Saarbrucken, Germany.			Hannemann, Frank/0000-0001-7991-9033; Rottmann, Matthias/0000-0002-2207-7899				AKHREM AA, 1979, ACTA BIOL MED GER, V38, P257; BECKERT V, 1995, EUR J BIOCHEM, V231, P226, DOI 10.1111/j.1432-1033.1995.tb20691.x; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; Bernhardt R, 1996, REV PHYSIOL BIOCH P, V127, P137, DOI 10.1007/BFb0048267; BOHME H, 1988, MOL GEN GENET, V214, P278, DOI 10.1007/BF00337722; BRANDT ME, 1993, J BIOL CHEM, V268, P17126; BUROVA TV, 1995, PROTEIN SCI, V4, P909; CAMMACK R, 1977, BIOCHEM J, V168, P205, DOI 10.1042/bj1680205; COGHLAN VM, 1991, J BIOL CHEM, V266, P18606; ESTABROOK RW, 1973, IRON SULPHUR PROTEIN, V1, P193; Farver O, 1997, J AM CHEM SOC, V119, P5453, DOI 10.1021/ja964386i; Grinberg AV, 1998, PROTEIN ENG, V11, P1057, DOI 10.1093/protein/11.11.1057; Grinberg AV, 2000, PROTEINS, V40, P590, DOI 10.1002/1097-0134(20000901)40:4<590::AID-PROT50>3.0.CO;2-P; HASE T, 1980, BIOCHIM BIOPHYS ACTA, V623, P139, DOI 10.1016/0005-2795(80)90016-1; HASE T, 1976, J BIOCHEM-TOKYO, V79, P329, DOI 10.1093/oxfordjournals.jbchem.a131076; HASE T, 1977, J BIOCHEM-TOKYO, V82, P277, DOI 10.1093/oxfordjournals.jbchem.a131680; HIWATASHI A, 1976, BIOCHEMISTRY-US, V15, P3091, DOI 10.1021/bi00659a024; Holden M, 1997, J BIOL CHEM, V272, P21720, DOI 10.1074/jbc.272.35.21720; ICHIKAWA Y, 1987, IRON SULFUR PROTEIN, P97; KIDO T, 1979, J BIOL CHEM, V254, P1806; Kimura T., 1968, STRUCTURE BONDING, V5, P1; LAMBETH JD, 1979, J BIOL CHEM, V254, P2766; LAMBETH JD, 1985, J BIOL CHEM, V260, P8810; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; Muller A, 1998, STRUCTURE, V6, P269, DOI 10.1016/S0969-2126(98)00031-8; OKAMURA T, 1985, P NATL ACAD SCI USA, V82, P5705, DOI 10.1073/pnas.82.17.5705; PETERSON JA, 1990, J BIOL CHEM, V265, P6066; PETERSON JA, 1992, J BIOL CHEM, V267, P14193; Pikuleva IA, 2000, ARCH BIOCHEM BIOPHYS, V373, P44, DOI 10.1006/abbi.1999.1536; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; SAGARA Y, 1993, BIOL PHARM BULL, V16, P627; Shimada H, 1999, J BIOL CHEM, V274, P9363, DOI 10.1074/jbc.274.14.9363; SLIGAR SG, 1976, P NATL ACAD SCI USA, V73, P1078, DOI 10.1073/pnas.73.4.1078; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; Sugano S, 1996, J BIOCHEM-TOKYO, V120, P780; TA DT, 1992, J BIOL CHEM, V267, P11120; TUCKEY RC, 1983, J BIOL CHEM, V258, P4232; UHLMANN H, 1994, J BIOL CHEM, V269, P22557; UHLMANN H, 1995, J BIOL CHEM, V270, P29959; UHLMANN H, 1992, BIOCHEM BIOPH RES CO, V188, P1131, DOI 10.1016/0006-291X(92)91349-U; Vickery LE, 1997, STEROIDS, V62, P124, DOI 10.1016/S0039-128X(96)00170-5; VIDAKOVIC M, 1995, BIOCHEMISTRY-US, V34, P13906, DOI 10.1021/bi00042a023; WADA A, 1992, J BIOL CHEM, V267, P22877; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3	45	35	35	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1369	1375		10.1074/jbc.M007589200	http://dx.doi.org/10.1074/jbc.M007589200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11013256	hybrid			2022-12-25	WOS:000166430900069
J	Hong, TM; Chen, JJW; Peck, K; Yang, PC; Wu, CW				Hong, TM; Chen, JJW; Peck, K; Yang, PC; Wu, CW			p53 amino acids 339-346 represent the minimal p53 repression domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TATA-BINDING PROTEIN; TRANSCRIPTIONAL REPRESSION; TUMOR-SUPPRESSOR; OLIGOMERIZATION DOMAIN; HISTONE DEACETYLASES; CRYSTAL-STRUCTURE; SITE; ACTIVATION; MUTATIONS	The p53 tumor suppressor protein functions as an activator and also as a repressor of gene transcription. Currently, the mechanism of transcriptional repression by p53 remains poorly understood. To help clarify this mechanism, we carried out studies designed to identify the minimal repression domain that inhibits p53 transcriptional activities. We found only eight amino acids (339-346) of the COOH-terminal domain (termed P53MRD) that possess activities of repression, The exact location of this minimal domain is on the EG-binding region, and it lacks the ability of tetramerization. P53MRD is able to repress the transcription of p53 while not affecting VP16. The mutants (amino acids M340P and F341D) of native p53 also lost transcriptional repression of the thymidine kinase chloramphenicol acetyltransferase promoter. These results suggest that this eight-amino acid element is required for the repression of p53.	Natl Taiwan Univ, Coll Med, Grad Inst Mol Biol, Taipei 100, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Natl Taiwan Univ Hosp, Off Clin Res, Taipei 100, Taiwan; Natl Taiwan Univ, Sch Med, Dept Internal Med, Taipei 100, Taiwan; Natl Hlth Res Inst, Taipei 115, Taiwan	National Taiwan University; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Health Research Institutes - Taiwan	Yang, PC (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, 7 Chung Shan S Rd, Taipei 100, Taiwan.		Yang, Pan-Chyr/B-8808-2009	YANG, PAN-CHYR/0000-0001-6330-6048; Chen, Jeremy J.W./0000-0003-1049-3825				BIRCH JM, 1994, CANCER RES, V54, P1298; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HELLSTEIN M, 1991, SCIENCE, V253, P49; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HORIO Y, 1994, ONCOGENE, V9, P1231; HSU YS, 1995, J BIOL CHEM, V270, P6966, DOI 10.1074/jbc.270.12.6966; HUANG JY, 1995, J BIOL CHEM, V270, P23899; ISHIOKA C, 1995, ONCOGENE, V10, P1485; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; JOLLY KW, 1994, ONCOGENE, V9, P97; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEE W, 1994, STRUCT BIOL, V1, P887; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MAZOYER S, 1994, ONCOGENE, V9, P1237; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; PELLEGATA NS, 1995, ONCOGENE, V11, P337; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Tung SF, 1999, J BIOL CHEM, V274, P7748, DOI 10.1074/jbc.274.12.7748; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	44	19	21	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1510	1515		10.1074/jbc.M008231200	http://dx.doi.org/10.1074/jbc.M008231200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11007800	hybrid			2022-12-25	WOS:000166430900087
J	Arlandson, M; Decker, T; Roongta, VA; Bonilla, L; Mayo, KH; MacPherson, JC; Hazen, SL; Slungaard, A				Arlandson, M; Decker, T; Roongta, VA; Bonilla, L; Mayo, KH; MacPherson, JC; Hazen, SL; Slungaard, A			Eosinophil peroxidase oxidation of thiocyanate - Characterization of major reaction products and a potential sulfhydryl-targeted cytotoxicity system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOPEROXIDASE-CATALYZED OXIDATION; NUCLEAR-MAGNETIC-RESONANCE; SCHISTOSOMA-MANSONI; HYDROGEN-PEROXIDE; MOLECULAR-CLONING; VIRUS TYPE-1; INHIBITION; TOXICITY; INVITRO; MYELOPEROXIDASE	Although the pseudohalide thiocyanate (SCN-) is the preferred substrate for eosinophil peroxidase (EPO) in fluids of physiologic halide composition, the product(s) of this reaction have not been directly identified, and mechanisms underlying their cytotoxic potential are poorly characterized. We used nuclear magnetic resonance spectroscopy (NMR), electrospray ionization mass spectrometry, and quantitative chemical analysis to identify the principal reaction products of both the EPO/SCN-/H2O2 system and activated eosinophils as roughly equimolar amounts of OSCN- (hypothiocyanite) and OCN- (cyanate). Red blood cells exposed to increasing concentrations of OSCN-/OCN- are first depleted of glutathione, after which glutathione S-transferase and glyceraldehyde-3-phosphate dehydrogenase then ATPases undergo sulfhydryl (SH) reductant-reversible inactivation before lysing. OSCN-/OCN- inactivates red blood cell membrane ATPases 10-1000 times more potently than do HOCl, HOBr, and H2O2. Exposure of glutathione S-transferase to [C-14]OSCN-/OCN- causes SH reductant-reversible disulfide bonding and covalent isotope labeling. We propose that EPO/SCN-/H2O2 reaction products comprise a potential SH-targeted cytotoxic system that functions in striking contrast to HOCl, the highly but relatively indiscriminantly reactive product of the neutrophil myeloperoxidase system.	Univ Minnesota, Ctr Canc, Dept Internal Med, Sch Med, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Dept Biochem, Sch Med, Minneapolis, MN 55455 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Slungaard, A (corresponding author), Univ Minnesota, Ctr Canc, Dept Internal Med, Sch Med, Box 480 FUMC, Minneapolis, MN 55455 USA.	slung001@tc.umn.edu	Hazen, Stanley L/ABD-5845-2021		NHLBI NIH HHS [HL 61878, R0-1-HL48915] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061878, R01HL048915] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUGHAZALEH RI, 1992, J LEUKOCYTE BIOL, V52, P611, DOI 10.1002/jlb.52.6.611; AGOSTI JM, 1987, J ALLERGY CLIN IMMUN, V79, P496, DOI 10.1016/0091-6749(87)90368-X; ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; Andersson LA, 1996, J BIOL CHEM, V271, P3406, DOI 10.1074/jbc.271.7.3406; AUNE TM, 1977, BIOCHEMISTRY-US, V16, P4611, DOI 10.1021/bi00640a013; BAGINSKI ES, 1967, CLIN CHIM ACTA, V15, P155, DOI 10.1016/0009-8981(67)90340-3; BHARGAVA KK, 1983, MOL BIOCHEM PARASIT, V9, P29, DOI 10.1016/0166-6851(83)90054-3; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V784, P177, DOI 10.1016/0167-4838(84)90125-0; BRODIE AE, 1990, ARCH BIOCHEM BIOPHYS, V276, P212, DOI 10.1016/0003-9861(90)90028-W; CARLSON MGC, 1985, J IMMUNOL, V134, P1875; DIRNHUBER P, 1948, BIOCHEM J, V42, P628, DOI 10.1042/bj0420628; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FREEDMAN ML, 1975, J PHARMACOL EXP THER, V195, P340; GLADER BE, 1972, NATURE, V237, P336, DOI 10.1038/237336a0; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GRISHAM MB, 1990, AM J PHYSIOL, V258, pC115, DOI 10.1152/ajpcell.1990.258.1.C115; GUILLOTON M, 1985, ANAL BIOCHEM, V149, P291, DOI 10.1016/0003-2697(85)90572-X; HANSEL TT, 1990, J IMMUNOL METHODS, V127, P153, DOI 10.1016/0022-1759(90)90064-3; HEBBEL RP, 1986, BIOCHIM BIOPHYS ACTA, V862, P8, DOI 10.1016/0005-2736(86)90463-3; HIMMELHOCH SR, 1969, BIOCHEMISTRY-US, V8, P914, DOI 10.1021/bi00831a022; HOLZBECHER J, 1980, CLIN BIOCHEM, V13, P277, DOI 10.1016/S0009-9120(80)80009-9; IDE M, 1994, J IMMUNOL METHODS, V168, P187, DOI 10.1016/0022-1759(94)90054-X; JONG EC, 1984, AM J TROP MED HYG, V33, P104, DOI 10.4269/ajtmh.1984.33.104; JONG EC, 1981, J IMMUNOL, V126, P468; JONG EC, 1980, J IMMUNOL, V124, P1949; JONG EC, 1980, J IMMUNOL, V124, P1378; KAZURA JW, 1981, J CLIN INVEST, V67, P93, DOI 10.1172/JCI110037; Klebanoff S.J., 1982, ADV HOST DEFENSE MEC, P111; Klebanoff SJ, 1996, AIDS RES HUM RETROV, V12, P25, DOI 10.1089/aid.1996.12.25; LENANDERLUMIKARI M, 1992, ORAL MICROBIOL IMMUN, V7, P315, DOI 10.1111/j.1399-302X.1992.tb00595.x; LOVAAS E, 1992, FREE RADICAL BIO MED, V13, P187, DOI 10.1016/0891-5849(92)90014-8; MAYENO AN, 1989, J BIOL CHEM, V264, P5660; Mazumdar A, 1996, BIOCHEM J, V314, P413, DOI 10.1042/bj3140413; MIKOLA H, 1995, ANTIVIR RES, V26, P161, DOI 10.1016/0166-3542(94)00073-H; MKOJI GM, 1989, BIOCHEM PHARMACOL, V38, P4307, DOI 10.1016/0006-2952(89)90530-3; MODI S, 1991, BIOCHEMISTRY-US, V30, P118, DOI 10.1021/bi00215a018; MOON RB, 1974, PHYSIOL CHEM PHYS M, V6, P31; NATHAN CF, 1982, J EXP MED, V155, P1291, DOI 10.1084/jem.155.5.1291; OKA S, 1981, ANAL CHEM, V53, P588, DOI 10.1021/ac00227a007; POLLOCK JR, 1992, BIOCHIM BIOPHYS ACTA, V1159, P279, DOI 10.1016/0167-4838(92)90057-K; Qian MW, 1997, BIOCHEM J, V326, P159, DOI 10.1042/bj3260159; RIVOLTINI L, 1993, INT J CANCER, V54, P8, DOI 10.1002/ijc.2910540103; ROSEN H, 1982, J BIOL CHEM, V257, P13731; SAKAMAKI K, 1989, J BIOL CHEM, V264, P16828; SALMASO BLN, 1994, BIOPHYS J, V67, P436, DOI 10.1016/S0006-3495(94)80499-0; SCHRAUFSTATTER IU, 1990, J CLIN INVEST, V85, P554, DOI 10.1172/JCI114472; SHEN H, 1991, ARCH BIOCHEM BIOPHYS, V286, P178, DOI 10.1016/0003-9861(91)90025-E; SIBBETT SS, 1985, FEBS LETT, V189, P271, DOI 10.1016/0014-5793(85)81038-3; SLUNGAARD A, 1991, J EXP MED, V173, P117, DOI 10.1084/jem.173.1.117; SLUNGAARD A, 1991, J BIOL CHEM, V266, P4903; SLUNGAARD A, 1992, BLOOD, V80, P96; STARK GR, 1960, J BIOL CHEM, V235, P3177; Tanigawa T, 1996, J CHROMATOGR B, V683, P135, DOI 10.1016/0378-4347(96)00115-6; TEN RM, 1989, J EXP MED, V169, P1757, DOI 10.1084/jem.169.5.1757; TENOVUO J, 1984, ARCH ORAL BIOL, V29, P445, DOI 10.1016/0003-9969(84)90025-6; THOMAS EL, 1986, J BIOL CHEM, V261, P9694; Thomas EL, 1985, LACTOPEROXIDASE SYST, P31; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; Wu WJ, 2000, J CLIN INVEST, V105, P1455, DOI 10.1172/JCI9702; Wu WJ, 1999, J BIOL CHEM, V274, P25933, DOI 10.1074/jbc.274.36.25933; Wu WJ, 1999, BIOCHEMISTRY-US, V38, P3538, DOI 10.1021/bi982401l	62	110	110	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					215	224		10.1074/jbc.M004881200	http://dx.doi.org/10.1074/jbc.M004881200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11013238	hybrid			2022-12-25	WOS:000166280700031
J	Chen, GX; Hohmeier, HE; Newgard, CB				Chen, GX; Hohmeier, HE; Newgard, CB			Expression of the transcription factor STAT-1 alpha in insulinoma cells protects against cytotoxic effects of multiple cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS-MEDIATED TRANSFER; NITRIC-OXIDE SYNTHASE; BETA-CELLS; RECOMBINANT ADENOVIRUS; INTERFERON-GAMMA; GENE-THERAPY; ISLETS; DESTRUCTION; REPLACEMENT; LANGERHANS	Destruction of pancreatic islet beta -cells in type 1 diabetes appears to result from direct contact with infiltrating T-cells and macrophages and exposure to inflammatory cytokines such as interferon (IFN)-gamma interleukin (IL)-1 beta, and tumor necrosis factor TNF-alpha that such cells produce. We recently reported on a method for selection of insulinoma cells that are resistant to the cytotoxic effects of inflammatory cytokines (INS-1(res)), involving their growth in progressively increasing concentrations of IL-1 beta plus IFN-gamma, and selection of surviving cells. In the current study, we have investigated the molecular mechanism of cytokine resistance in INS-1(res) cells. By focusing on the known components of the IFN-gamma receptor signaling pathway, we have discovered that expression levels of signal transducer and activator of transcription (STAT)-1 alpha are closely correlated with the cytokine-resistant and -sensitive phenotypes, That STAT-1 alpha is directly involved in development of cytokine resistance is demonstrated by an increase of viability from 10 +/- 2% in control cells to 50 +/- 6% in cells with adenovirus-mediated overexpression of STAT-1 alpha (p < 0.001) after culture of both cell groups in the presence of 100 units/ml IFN-<gamma> plus 10 ng/ml IL-1 beta for 48 h. The resistance to IL-1 beta plus IFN-gamma in STAT-1 alpha -expressing cells is due in part to interference with IL-1 beta -mediated stimulation of inducible nitric-oxide synthase expression and nitric oxide production. Furthermore, overexpression of STAT-1 alpha does not impair robust glucose-stimulated insulin secretion in the INS-1-derived cell line 832/13. We conclude that expression of STAT-1 alpha may be a means of protecting insulin-producing cell lines from cytokine damage, which, in conjunction with appropriate cell-impermeant macroencapsulation devices, may allow such cells to be used for insulin replacement in type 1 diabetes.	Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; BetaGene Inc, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Newgard, CB (corresponding author), Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, 5323 Harry Hines Blvd,Room Y8-212, Dallas, TX 75235 USA.				NIDDK NIH HHS [DK-55188] Funding Source: Medline; NIGMS NIH HHS [T32 GM08203] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055188] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008203] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BECKER TC, 1994, J BIOL CHEM, V269, P21234; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Brendel M, 1999, INT ISLET TRANSPLANT, P1; Chen GX, 2000, DIABETES, V49, P562, DOI 10.2337/diabetes.49.4.562; CORBETT JA, 1992, DIABETES, V41, P897, DOI 10.2337/diabetes.41.8.897; Dupraz P, 1999, GENE THER, V6, P1160, DOI 10.1038/sj.gt.3300922; Efrat Shimon, 1996, P438; Eizirik DL, 1996, DIABETOLOGIA, V39, P875; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; Heitmeier MR, 1999, J BIOL CHEM, V274, P29266, DOI 10.1074/jbc.274.41.29266; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Hohmeier HE, 1998, J CLIN INVEST, V101, P1811, DOI 10.1172/JCI1489; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Levine F, 1997, DIABETES METAB REV, V13, P209; MandrupPoulsen T, 1996, DIABETOLOGIA, V39, P1005, DOI 10.1007/BF00400649; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; NEWGARD CB, 1994, DIABETES, V43, P341, DOI 10.2337/diabetes.43.3.341; NEWGARD CB, 1997, DIABETOLOGIA, V40, P42; NEWGARD CB, 1999, CAN J DIABETES CARC, V23, P52; Rabinovitch A, 1999, DIABETES, V48, P1223, DOI 10.2337/diabetes.48.6.1223; RABINOVITCH A, 1993, DIABETES REV, V1, P215; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Sutherland DER, 1996, DIABETES METAB REV, V12, P137; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Zhou YP, 2000, AM J PHYSIOL-ENDOC M, V278, pE340, DOI 10.1152/ajpendo.2000.278.2.E340	32	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					766	772		10.1074/jbc.M008330200	http://dx.doi.org/10.1074/jbc.M008330200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024034	hybrid			2022-12-25	WOS:000166280700103
J	Bjorge, JD; Pang, A; Fujita, DJ				Bjorge, JD; Pang, A; Fujita, DJ			Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE REGULATORY SITE; KINASE-ACTIVITY; SH2 DOMAIN; FAMILY KINASES; TRANSFORMING PROTEIN; MEDIATED ADHESION; CATALYTIC DOMAIN; PDGF RECEPTOR; SARCOMA VIRUS; NEU ONCOGENE	c-Src tyrosine kinase activity is elevated in several types of human cancer, and this has been attributed to elevated c-Src expression levels, increased c-Src specific activity, and activating mutations in c-Src, We have found a number of human breast cancer cell lines with elevated c-Src specific activity that also possess elevated phosphatase activity directed against the carboxyl-terminal negative regulatory domain of Src family kinases, To identify this phosphatase, cell extracts from MDA-MB-435S cells were chromatographed and the fractions were assayed for phosphatase activity. Four peaks of phosphatase activity directed against the nonspecific substrate poly(Glu/Tyr) were detected. One peak also dephosphorylated a peptide modeled against the c-Src carboxyl-terminal negative regulatory domain and intact human c-Src. Immunoblotting and immunodepletion experiments identified the phosphatase as protein-tyrosine phosphatase 1B (PTP1B), Examination of several human breast cancer cell lines with increased c-Src activity showed elevated levels of PTP1B protein relative to normal control breast cells. In vitro c-Src reactivation experiments confirmed the ability of PTP1B to dephosphorylate and activate c-Src, In vivo overexpression of PTP1B in 293 cells caused a 2-fold increase of endogenous c-Src kinase activity. Our findings indicate that PTP1B is the primary protein-tyrosine phosphatase capable of dephosphorylating c-Src in several human breast cancer cell lines and suggests a regulatory role for PTP1B in the control of c-Src kinase activity.	Univ Calgary, Dept Biochem & Mol Biol, Hlth Sci Ctr, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba	Fujita, DJ (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Hlth Sci Ctr, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada.							Agostinis P, 1996, EUR J BIOCHEM, V236, P548, DOI 10.1111/j.1432-1033.1996.00548.x; AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Albrecht JC, 1999, J VIROL, V73, P4631, DOI 10.1128/JVI.73.6.4631-4639.1999; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Balsamo J, 1998, J CELL BIOL, V143, P523, DOI 10.1083/jcb.143.2.523; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; BJORGE JD, 2000, IN PRESS ONCOGENE; Broome MA, 1997, ONCOGENE, V14, P17, DOI 10.1038/sj.onc.1200798; BROWNSHIMER S, 1992, CANCER RES, V52, P478; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHENG HC, 1992, J BIOL CHEM, V267, P9248; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; Egan C, 1999, ONCOGENE, V18, P1227, DOI 10.1038/sj.onc.1202233; FANG KS, 1994, J BIOL CHEM, V269, P20194; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; GERVAIS FG, 1993, MOL CELL BIOL, V13, P7112, DOI 10.1128/MCB.13.11.7112; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; Grgurevich S, 1997, GROWTH FACTORS, V14, P103, DOI 10.3109/08977199709021514; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; JACOBS C, 1983, CANCER RES, V43, P1696; Jung EJ, 1998, BIOCHEM BIOPH RES CO, V246, P238, DOI 10.1006/bbrc.1998.8605; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LaMontagne KR, 1998, MOL CELL BIOL, V18, P2965, DOI 10.1128/MCB.18.5.2965; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; LIU XQ, 1993, ONCOGENE, V8, P1119; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Pellegrini MC, 1998, BIOCHEMISTRY-US, V37, P15598, DOI 10.1021/bi981427+; PENG ZY, 1995, ONCOGENE, V11, P1955; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; Stover DR, 1996, J BIOL CHEM, V271, P12481, DOI 10.1074/jbc.271.21.12481; Sun GQ, 1998, ONCOGENE, V17, P1587, DOI 10.1038/sj.onc.1202076; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TANAKA A, 1986, MOL CELL BIOL, V6, P3900, DOI 10.1128/MCB.6.11.3900; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Walter AO, 1999, ONCOGENE, V18, P1911, DOI 10.1038/sj.onc.1202513; WIENER JR, 1994, AM J OBSTET GYNECOL, V170, P1177, DOI 10.1016/S0002-9378(94)70118-0; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372; ZHAI YF, 1993, CANCER RES, V53, P2272; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	67	257	270	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41439	41446		10.1074/jbc.M004852200	http://dx.doi.org/10.1074/jbc.M004852200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007774	hybrid			2022-12-25	WOS:000166114600102
J	Hermanns, HM; Radtke, S; Schaper, F; Heinrich, PC; Behrmann, I				Hermanns, HM; Radtke, S; Schaper, F; Heinrich, PC; Behrmann, I			Non-redundant signal transduction of interleukin-6-type cytokines - The adapter protein Shc is specifically recruited to the oncostatin M receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; GROWTH-FACTOR RECEPTOR; PHOSPHOTYROSINE-BINDING DOMAIN; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE 5-PHOSPHATASE; TYROSINE-PHOSPHATASE SHP-2; COLONY-STIMULATING FACTOR; CELL-CYCLE PROGRESSION; GENE-EXPRESSION; KINASE ACTIVATION; MITOGEN	The common use of the cytokine receptor gp130 has served as an explanation for the extremely redundant biological activities exerted by interleukin (IL)-6-type cytokines.Indeed, hardly any differences in signal transduction initiated by these cytokines are known. In the present study, we demonstrate that oncostatin M (OSM), but not IL-6 or leukemia inhibitory factor, induces tyrosine phosphorylation of the Shc isoforms p52 and p66 and their association with Grb2. Concomitantly, OSM turns out to be a stronger activator of ERK1/2 MAPKs, Shc is recruited to the OSM receptor (OSMR), but not to gp130. Binding involves Tyr(816) Of the OSMR, located within a consensus binding sequence for the Shc PTB domain. Moreover, Tyr(861) is essential for activation of ERK1/2 and for full activation of the alpha (2)-macroglobulin promoter, but not for an exclusively STAT-responsive promoter. This study therefore provides evidence for qualitative differential signaling mechanisms exerted by IL-6-type cytokines.	Rhein Westfal TH Klinikum, Inst Biochem, D-52074 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital	Behrmann, I (corresponding author), Rhein Westfal TH Klinikum, Inst Biochem, Pauwelsstr 30, D-52074 Aachen, Germany.		Schaper, Fred/F-1403-2013	Schaper, Fred/0000-0002-8899-5414; Behrmann, Iris/0000-0003-3688-3645				ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Bamber B, 1998, J MOL MED-JMM, V76, P61, DOI 10.1007/s109-1998-8105-3; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; Behrmann I, 1997, J BIOL CHEM, V272, P5269, DOI 10.1074/jbc.272.8.5269; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Berger LC, 1997, BLOOD, V89, P261, DOI 10.1182/blood.V89.1.261.261_261_271; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; Collins LR, 1999, J CELL BIOL, V147, P1561, DOI 10.1083/jcb.147.7.1561; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gatsios P, 1996, EUR J BIOCHEM, V241, P56, DOI 10.1111/j.1432-1033.1996.0056t.x; Giordano V, 1997, J IMMUNOL, V158, P4097; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Grant SL, 1999, MOL MED TODAY, V5, P406, DOI 10.1016/S1357-4310(99)01540-3; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hermanns HM, 1999, J IMMUNOL, V163, P6651; Ichihara M, 1997, BLOOD, V90, P165; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; KUMAR G, 1994, J IMMUNOL, V153, P4436; Kuropatwinski KK, 1997, J BIOL CHEM, V272, P15135, DOI 10.1074/jbc.272.24.15135; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; LANFRANCONE L, 1995, ONCOGENE, V10, P907; Li WQ, 1998, J IMMUNOL, V161, P5000; Liu JW, 1997, CELL GROWTH DIFFER, V8, P667; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Neumann C, 1996, EUR J IMMUNOL, V26, P379, DOI 10.1002/eji.1830260217; Ogata A, 1997, J IMMUNOL, V159, P2212; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; OWENLYNCH PJ, 1995, J BIOL CHEM, V270, P5956, DOI 10.1074/jbc.270.11.5956; Palmer HJ, 1999, J BIOL CHEM, V274, P11424, DOI 10.1074/jbc.274.16.11424; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pratt JC, 1996, J BIOL CHEM, V271, P12137, DOI 10.1074/jbc.271.21.12137; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; RICHARDS CD, 1993, J IMMUNOL, V150, P5596; Sakaguchi K, 1998, MOL ENDOCRINOL, V12, P536, DOI 10.1210/me.12.4.536; SALCINI AE, 1994, ONCOGENE, V9, P2827; Sato K, 1997, FEBS LETT, V410, P136, DOI 10.1016/S0014-5793(97)00539-5; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; Schiemann WP, 1997, J BIOL CHEM, V272, P16631, DOI 10.1074/jbc.272.26.16631; Schmitz J, 2000, J IMMUNOL, V164, P848, DOI 10.4049/jimmunol.164.2.848; Senaldi G, 1999, P NATL ACAD SCI USA, V96, P11458, DOI 10.1073/pnas.96.20.11458; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Stevenson LE, 1999, CELL GROWTH DIFFER, V10, P61; Symes A, 1997, CURR BIOL, V7, P697, DOI 10.1016/S0960-9822(06)00298-3; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; THOMA B, 1994, J BIOL CHEM, V269, P6215; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Wallace PM, 1999, J IMMUNOL, V162, P5547; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; ZHOU MM, 1995, P NATL ACAD SCI USA, V92, P7784, DOI 10.1073/pnas.92.17.7784	73	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40742	40748		10.1074/jbc.M005408200	http://dx.doi.org/10.1074/jbc.M005408200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11016927	hybrid			2022-12-25	WOS:000166114600013
J	Lutz, LB; Kim, B; Jahani, D; Hammes, SR				Lutz, LB; Kim, B; Jahani, D; Hammes, SR			G protein beta gamma subunits inhibit nongenomic progesterone-induced signaling and maturation in Xenopus laevis oocytes - Evidence for a release of inhibition mechanism for cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; NITRIC-OXIDE SYNTHASE; NUCLEOTIDE REGULATORY PROTEIN; ACTIVATED K+ CHANNEL; MAP KINASE; ADENYLATE-CYCLASE; PERTUSSIS TOXIN; MEIOTIC MATURATION; STARFISH OOCYTE; VITAMIN-D3 METABOLITES	Progesterone-induced maturation of Xenopus oocytes is a well known example of nongenomic signaling by steroids; however, little is known about the early signaling events involved in this process. Previous work has suggested that G proteins and G protein-coupled receptors may be involved in progesterone-mediated oocyte maturation as well as in other nongenomic steroid-induced signaling events. To investigate the role of G proteins in nongenomic signaling by progesterone, the effects of modulating G alpha and G beta gamma levels in Xenopus oocytes on progesterone-induced signaling and maturation were examined. Our results demonstrate that G beta gamma subunits, rather than G alpha, are the principal mediators of progesterone action in this system. We show that overexpression of G beta gamma inhibits both progesterone-induced maturation and activation of the MAPK pathway, whereas sequestration of endogenous G beta gamma subunits enhances: progesterone-mediated signaling and maturation. These data are consistent with a model whereby endogenous free Xenopus G beta gamma subunits constitutively inhibit oocyte maturation. Progesterone may induce maturation by antagonizing this inhibition and therefore allowing cell cycle progression to occur. These studies offer new insight into the early signaling events mediated by progesterone and may be useful in characterizing and identifying the membrane progesterone receptor in oocytes.	Univ Texas, SW Med Sch, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hammes, SR (corresponding author), Univ Texas, SW Med Sch, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	stephen.hammes@email.swmed.edu						BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BLONDEAU JP, 1984, BIOCHEM J, V219, P785, DOI 10.1042/bj2190785; CAFFREY JM, 1989, J BIOL CHEM, V264, P20265; CHEN Y, 1994, J BIOL CHEM, V269, P7839; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; CHIBA K, 1995, DEV BIOL, V169, P415, DOI 10.1006/dbio.1995.1157; CHIBA K, 1993, MOL BIOL CELL, V4, P1027, DOI 10.1091/mbc.4.10.1027; Chiba K, 1995, Prog Cell Cycle Res, V1, P255; CHRIST M, 1995, HYPERTENSION, V25, P117, DOI 10.1161/01.HYP.25.1.117; CHRIST M, 1993, J CLIN ENDOCR METAB, V77, P1452, DOI 10.1210/jc.77.6.1452; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P6596, DOI 10.1073/pnas.90.14.6596; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; GODEAU JF, 1978, P NATL ACAD SCI USA, V75, P2353, DOI 10.1073/pnas.75.5.2353; GOODHARDT M, 1984, EMBO J, V3, P2653, DOI 10.1002/j.1460-2075.1984.tb02189.x; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; Grazzini E, 1998, NATURE, V392, P509, DOI 10.1038/33176; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; JAFFE LA, 1993, J CELL BIOL, V121, P775, DOI 10.1083/jcb.121.4.775; Jing J, 1999, EMBO J, V18, P1245, DOI 10.1093/emboj/18.5.1245; Kirsch EA, 1999, AM J RESP CELL MOL, V20, P658, DOI 10.1165/ajrcmb.20.4.3241; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOSAKO H, 1994, J CELL SCI, P115; LIEBERHERR M, 1987, J BIOL CHEM, V262, P13168; Lin HC, 1998, P NATL ACAD SCI USA, V95, P5057, DOI 10.1073/pnas.95.9.5057; LIU ZM, 1993, BIOL REPROD, V49, P980, DOI 10.1095/biolreprod49.5.980; Luchian T, 1997, J PHYSIOL-LONDON, V505, P13, DOI 10.1111/j.1469-7793.1997.013bc.x; MAGUIRE ME, 1976, MOL PHARMACOL, V12, P335; Maller J L, 1980, Curr Top Cell Regul, V16, P271; MALLER JL, 1977, J BIOL CHEM, V252, P1712; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; Meier CA, 1997, J RECEPT SIGNAL TR R, V17, P319, DOI 10.3109/10799899709036612; Miller BA, 1996, J CLIN INVEST, V98, P1728, DOI 10.1172/JCI118971; MULNER O, 1985, FEBS LETT, V181, P397, DOI 10.1016/0014-5793(85)80300-8; Nagahama Y, 1997, STEROIDS, V62, P190, DOI 10.1016/S0039-128X(96)00180-8; NAGAHAMA Y, 1995, CURR TOP DEV BIOL, V30, P103, DOI 10.1016/S0070-2153(08)60565-7; Norman AW, 1996, J STEROID BIOCHEM, V56, P13, DOI 10.1016/0960-0760(95)00219-7; OLATE J, 1990, FEBS LETT, V268, P27, DOI 10.1016/0014-5793(90)80964-K; OLATE J, 1984, FEBS LETT, V175, P25; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SADLER SE, 1984, MOL PHARMACOL, V26, P526; SADLER SE, 1985, ADV CYCLIC NUCL PROT, V19, P179; SADLER SE, 1983, J BIOL CHEM, V258, P7935; SADLER SE, 1981, J BIOL CHEM, V256, P6368; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; Schneider M, 1997, AM J PHYSIOL-ENDOC M, V272, pE616, DOI 10.1152/ajpendo.1997.272.4.E616; Shaul PW, 1999, STEROIDS, V64, P28, DOI 10.1016/S0039-128X(98)00105-6; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; Shibuya EK, 1996, CELL GROWTH DIFFER, V7, P235; SHILLING F, 1989, DEV BIOL, V133, P605, DOI 10.1016/0012-1606(89)90063-8; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; SMITH LD, 1969, DEV BIOL, V19, P281, DOI 10.1016/0012-1606(69)90065-7; TADENUMA H, 1992, BIOCHEM BIOPH RES CO, V186, P114, DOI 10.1016/S0006-291X(05)80782-X; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEHLING M, 1992, MOL CELL ENDOCRINOL, V90, pC5, DOI 10.1016/0303-7207(92)90092-K; WEHLING M, 1994, BIOCHEM BIOPH RES CO, V204, P475, DOI 10.1006/bbrc.1994.2484; WEHLING M, 1995, CIRC RES, V76, P973, DOI 10.1161/01.RES.76.6.973; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939	67	84	89	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41512	41520		10.1074/jbc.M006757200	http://dx.doi.org/10.1074/jbc.M006757200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018039	hybrid			2022-12-25	WOS:000166114600110
J	Matsuo, M; Trapp, S; Tanizawa, Y; Kioka, N; Amachi, T; Oka, Y; Ashcroft, FM; Ueda, K				Matsuo, M; Trapp, S; Tanizawa, Y; Kioka, N; Amachi, T; Oka, Y; Ashcroft, FM; Ueda, K			Functional analysis of a mutant sulfonylurea receptor, SUR1-R1420C, that is responsible for persistent hyperinsulinemic hypoglycemia of infancy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNEL; SENSITIVE POTASSIUM CHANNELS; PANCREATIC BETA-CELLS; FAMILIAL HYPERINSULINISM; SUBUNIT STOICHIOMETRY; INSULIN-SECRETION; KIR6.2; SUR1; MUTATIONS; GENE	The ATP-sensitive potassium (K-ATP(+)) channel is crucial for the regulation of insulin secretion from the pancreatic beta -cell, and mutations in either the sulfonylurea receptor:type 1 (SUR1) or Kir6.2 subunit of this channel can cause persistent hyperinsulinemic hypoglycemia of infancy (PHHI), We analyzed the functional consequences of the PHHI missense mutation R1420C, which lies in the second nucleotide-binding fold (NBF2) of SUR1, Mild tryptic digestion of SUR1 after photoaffinity labeling allowed analysis of the nucleotide-binding properties of NBF1 and NBF2, Labeling of NBF1 with 8-azido-[alpha-P-32]ATP was inhibited by MgATP and MgADP with similar K-i for wild-type SUR1 and SUR1-R1420C. However, the MgATP and MgADP affinities of NBF2 of SUR1-R1420C were about 5-fold lower than those of wild-type SUR1, MgATP and MgADP stabilized 8-azido-ATP binding at NBF1 of wild-type SUR1 by interacting with NBF2, but this cooperative nucleotide binding was not observed for SUR1-R1420C. Studies on macroscopic currents recorded in inside-out membrane patches revealed that the SUR1-R1420C mutation exhibits reduced expression but does not affect inhibition by ATP or tolbutamide or activation by diazoxide, However, co-expression with Kir6.2-R50G, which renders the channel less sensitive to ATP inhibition, revealed that the SUR1-R1420C mutation increases the EC50 for MgADP activation from 74 to 197 muM. We suggest that the lower expression of the mutant channel and the reduced affinity of NBF2 for MgADP may lead to a smaller K-ATP(+) current in R1420C-PHHI beta -cells and thereby to the enhanced insulin secretion. We also propose a new model for nucleotide activation of K-ATP(+) channels.	Kyoto Univ, Grad Sch Agr, Biochem Lab, Div Appl Life Sci, Kyoto 6068502, Japan; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Yamaguchi Univ, Sch Med, Dept Internal Med 3, Ube, Yamaguchi 7558505, Japan	Kyoto University; University of Oxford; Yamaguchi University	Ueda, K (corresponding author), Kyoto Univ, Grad Sch Agr, Biochem Lab, Div Appl Life Sci, Kyoto 6068502, Japan.		Trapp, Stefan/D-9240-2011	Trapp, Stefan/0000-0003-0665-4948; Kioka, Noriyuki/0000-0002-2708-537X; Ueda, Kazumitsu/0000-0003-2980-6078				Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Dunne MJ, 1997, NEW ENGL J MED, V336, P703, DOI 10.1056/NEJM199703063361005; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; Gribble FM, 1998, P NATL ACAD SCI USA, V95, P7185, DOI 10.1073/pnas.95.12.7185; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Kane C, 1996, NAT MED, V2, P1344, DOI 10.1038/nm1296-1344; KOZLOWSKI RZ, 1989, BRIT J PHARMACOL, V97, P1039, DOI 10.1111/j.1476-5381.1989.tb12560.x; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; Nestorowicz A, 1996, HUM MOL GENET, V5, P1813, DOI 10.1093/hmg/5.11.1813; Nestorowicz A, 1997, DIABETES, V46, P1743, DOI 10.2337/diabetes.46.11.1743; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Otonkoski T, 1999, DIABETES, V48, P408, DOI 10.2337/diabetes.48.2.408; Proks P, 1999, J PHYSIOL-LONDON, V514, P19, DOI 10.1111/j.1469-7793.1999.019af.x; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Shyng SL, 1998, DIABETES, V47, P1145, DOI 10.2337/diabetes.47.7.1145; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Tanabe K, 2000, BIOCHEM BIOPH RES CO, V272, P316, DOI 10.1006/bbrc.2000.2780; Tanabe K, 1999, J BIOL CHEM, V274, P3931, DOI 10.1074/jbc.274.7.3931; Tanizawa Y, 2000, DIABETES, V49, P114, DOI 10.2337/diabetes.49.1.114; Thomas P, 1996, HUM MOL GENET, V5, P1809, DOI 10.1093/hmg/5.11.1809; Thomas PM, 1996, AM J HUM GENET, V59, P510; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Trapp S, 1997, P NATL ACAD SCI USA, V94, P8872, DOI 10.1073/pnas.94.16.8872; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Ueda K, 1999, BBA-BIOMEMBRANES, V1461, P305, DOI 10.1016/S0005-2736(99)00157-1; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; Verkarre V, 1998, J CLIN INVEST, V102, P1286, DOI 10.1172/JCI4495; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	39	36	36	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41184	41191		10.1074/jbc.M006503200	http://dx.doi.org/10.1074/jbc.M006503200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10993895	hybrid			2022-12-25	WOS:000166114600071
J	Thomas, D; Becker, A; Surdin-Kerjan, Y				Thomas, D; Becker, A; Surdin-Kerjan, Y			Reverse methionine biosynthesis from S-adenosylmethionine in eukaryotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE DISRUPTION; METHYLMETHIONINE; METABOLISM; DNA; METHYLTRANSFERASES; HYBRIDIZATION; HOMOCYSTEINE; EXPRESSION; DEPLETION	The intracellular ratio between methionine and its activated form S-adenosylmethionine (AdoMet) is of crucial importance for the one-carbon metabolism, AdoMet recycling into methionine was believed to be largely achieved through the methyl and the thiomethyladenosine cycles. We show here that in yeast, AdoMet recycling: actually occurs mainly through the direct AdoMet-dependent remethylation of homocysteine, Compelling evidences supporting this result were obtained owing to the identification and functional characterization of two new genes, SAM4 and MHT1, that encode the yeast AdoMet-homocysteine methyltransferase and S-methylmethionine-homocysteine methyltransferase, respectively. Homologs of the Sam4 and Mht1 proteins exist in other eucaryotes, indicating that such enzymes would be universal and not restricted to the bacterial or fungal kingdoms. New pathways for AdoMet or S-methylmethionine-dependent methionine synthesis are presented.	CNRS, Ctr Mol Genet, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Surdin-Kerjan, Y (corresponding author), CNRS, Ctr Mol Genet, F-91198 Gif Sur Yvette, France.	yolande.kerjan@cgm.cnrs-gif.fr						BACKLUND PS, 1981, J BIOL CHEM, V256, P1533; BACKLUND PS, 1982, BIOCHEM BIOPH RES CO, V108, P687, DOI 10.1016/0006-291X(82)90884-1; BURTON E, 1969, BIOCHEM J, V111, P793, DOI 10.1042/bj1110793; CANTONI GL, 1977, BIOCH ADENOSYLMETHIO, P557; CHEREST H, 1992, GENETICS, V130, P51; Cornell KA, 1996, BIOCHEM J, V317, P285, DOI 10.1042/bj3170285; CSAIKL U, 1986, GENE, V46, P207, DOI 10.1016/0378-1119(86)90405-1; DICKSON DM, 1980, PLANTA, V150, P158, DOI 10.1007/BF00582360; DICKSON DMJ, 1986, PLANTA, V167, P536, DOI 10.1007/BF00391230; Donoviel MS, 1996, GENETICS, V143, P1137; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HANSEN J, 1994, J BACTERIOL, V176, P6050, DOI 10.1128/jb.176.19.6050-6058.1994; Higgins D G, 1994, Methods Mol Biol, V25, P307; HODGSON CP, 1987, NUCLEIC ACIDS RES, V15, P6295, DOI 10.1093/nar/15.15.6295; Hoshiya Y, 1997, ANTICANCER RES, V17, P4371; Kokkinakis DM, 1997, NUTR CANCER, V29, P195, DOI 10.1080/01635589709514624; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; Malinow MR, 1997, ARTERIOSCL THROM VAS, V17, P1157, DOI 10.1161/01.ATV.17.6.1157; Mallet L, 1996, YEAST, V12, P1351, DOI 10.1002/(SICI)1097-0061(199610)12:13<1351::AID-YEA24>3.0.CO;2-6; MOUNTAIN HA, 1991, YEAST, V7, P781, DOI 10.1002/yea.320070804; MUDD SH, 1990, PLANT PHYSIOL, V93, P623, DOI 10.1104/pp.93.2.623; Neuhierl B, 1999, J BIOL CHEM, V274, P5407, DOI 10.1074/jbc.274.9.5407; OLD IG, 1991, PROG BIOPHYS MOL BIO, V56, P145, DOI 10.1016/0079-6107(91)90012-H; Ranocha P, 2000, J BIOL CHEM, V275, P15962, DOI 10.1074/jbc.M001116200; Rouillon A, 2000, EMBO J, V19, P282, DOI 10.1093/emboj/19.2.282; Rouillon A, 1999, J BIOL CHEM, V274, P28096, DOI 10.1074/jbc.274.40.28096; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SHAPIRO SK, 1964, J BIOL CHEM, V239, P1551; SHERMAN F, 1979, METHODS YEAST GENETI, P61; SIKORSKI RS, 1989, GENETICS, V122, P19; SPENCE KD, 1977, BIOCH ADENOSYLMETHIO, P77; THOMAS D, 1988, MOL CELL BIOL, V8, P5132, DOI 10.1128/MCB.8.12.5132; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; Trossat C, 1998, PLANT PHYSIOL, V116, P165, DOI 10.1104/pp.116.1.165	35	36	39	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40718	40724		10.1074/jbc.M005967200	http://dx.doi.org/10.1074/jbc.M005967200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11013242	hybrid			2022-12-25	WOS:000166114600010
J	Yeung, F; Li, XY; Ellett, J; Trapman, J; Kao, CH; Chung, LWK				Yeung, F; Li, XY; Ellett, J; Trapman, J; Kao, CH; Chung, LWK			Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED GENE-EXPRESSION; RECEPTOR GENE; TRANSCRIPTIONAL SYNERGY; HORMONAL-REGULATION; RESPONSIVE ELEMENT; LNCAP MODEL; LINE LNCAP; PROTEIN; KINASE; ADENOCARCINOMA	Prostate-specific antigen (PSA) is expressed primarily by both normal prostate epithelium and the vast majority of prostate cancers. Increases in serum PSA during endocrine therapy are generally considered as evidence for prostate cancer recurrence or progression to androgen independence. The mechanisms by which PSA upregulation occurs in androgen-refractory prostate cancer cells are unknown. In this study, by using LNCaP and its lineage-derived androgen-independent PSA-producing subline, C4-2, we identified two cis-elements within the 5.8-bilobase pair PSA promoter that are essential for the androgen-independent activity of PSA promoter in prostate cancer cells. First, a previously reported 440-bp androgen-responsive Element enhancer core (AREc) was found to be important for the high basal PSA promoter activity in C4-2 cells. Both mutation analysis and supershift experiments demonstrated that androgen receptor (AR) binds to the AREs within the AREc and activate the basal PSA promoter activity in C4-2 cells under androgen-deprived conditions. Second, a 150-bp pN/H region was demonstrated to be a strong AR-independent positive-regulatory element of the PSA promoter in both LNCaP and C4-2 cells. Through DNase I footprinting and linker scan mutagenesis, a 17-bp RI site was identified as the key cis-element within the pN/H region. Data from electrophoretic mobility shift analysis and UV cross-linking experiments further indicated that a 45-kDa (p45) cell-specific transcription factor associates with RI in prostate cancer cells and may be responsible for driving the PSA promoter activity independent of androgen and AR. Furthermore, by juxtaposing AREc and pN/H, we produced a chimeric PSA promoter (supra-PSA) that exhibits 2-3-fold higher activity than the wild type PSA promoter in both LNCaP and C4-2 cells.	Univ Virginia, Dept Cell Biol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Urol, Charlottesville, VA 22908 USA; Erasmus Univ, Dept Pathol, NL-3000 DR Rotterdam, Netherlands; Indiana Canc Pavil, Dept Urol, Indianapolis, IN 46202 USA	University of Virginia; University of Virginia; Erasmus University Rotterdam	Chung, LWK (corresponding author), Univ Virginia, Dept Cell Biol, Charlottesville, VA 22908 USA.				NATIONAL CANCER INSTITUTE [R29CA074042, R01CA076620, R01CA074042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008136] Funding Source: NIH RePORTER; NCI NIH HHS [CA76620, CA74042] Funding Source: Medline; NIGMS NIH HHS [5T32GMO8136] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUMULLER G, 1990, PROSTATE, V17, P31, DOI 10.1002/pros.2990170105; Ausubel F., 1999, CURRENT PROTOCOLS MO; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Carey M, 2000, TRANSCRIPTIONAL REGU; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; CULIG Z, 1994, CANCER RES, V54, P5474; DERUITER PE, 1995, MOL CELL ENDOCRINOL, V110, pR1, DOI 10.1016/0303-7207(95)03534-E; ELO JP, 1995, J CLIN ENDOCR METAB, V80, P3494, DOI 10.1210/jc.80.12.3494; GLEAVE M, 1991, CANCER RES, V51, P3753; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; HSIEH JT, 1993, CANCER RES, V53, P2852; Huang WB, 1999, J BIOL CHEM, V274, P25756, DOI 10.1074/jbc.274.36.25756; IKONEN T, 1994, ENDOCRINOLOGY, V135, P1359, DOI 10.1210/en.135.4.1359; Koivisto PA, 1999, J PATHOL, V189, P219, DOI 10.1002/(SICI)1096-9896(199910)189:2<219::AID-PATH423>3.0.CO;2-F; KUIPER GGJM, 1993, BIOCHEM J, V291, P95, DOI 10.1042/bj2910095; LILJA H, 1985, J CLIN INVEST, V76, P1899, DOI 10.1172/JCI112185; Marcelli M, 2000, CANCER RES, V60, P944; MEPHAUL MJ, 1996, ANDROGEN RECEPTOR PR, P307; MONTGOMERY BT, 1992, PROSTATE, V21, P63, DOI 10.1002/pros.2990210107; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; Reinikainen P, 1996, ENDOCRINOLOGY, V137, P4351, DOI 10.1210/en.137.10.4351; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Sambrook J., 2002, MOL CLONING LAB MANU; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; STAMEY TA, 1989, J UROLOGY, V141, P1088, DOI 10.1016/S0022-5347(17)41177-3; SUZUKI H, 1993, J STEROID BIOCHEM, V46, P759, DOI 10.1016/0960-0760(93)90316-O; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; THALMANN GN, 1994, CANCER RES, V54, P2577; Thalmann GN, 2000, PROSTATE, V44, P91; Trapman J, 1997, SEMIN CANCER BIOL, V8, P29, DOI 10.1006/scbi.1997.0050; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; Yeh SY, 1999, ENDOCRINE, V11, P195, DOI 10.1385/ENDO:11:2:195; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; YOUNG CYF, 1991, CANCER RES, V51, P3748; Zhang SB, 1997, BIOCHEM BIOPH RES CO, V231, P784, DOI 10.1006/bbrc.1997.6197; Zhau HE, 1997, IN VITRO CELL DEV-AN, V33, P375	45	61	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40846	40855		10.1074/jbc.M002755200	http://dx.doi.org/10.1074/jbc.M002755200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11006269	hybrid			2022-12-25	WOS:000166114600026
J	Zhang, W; Efanov, A; Yang, SN; Fried, G; Kolare, S; Brown, H; Zaitsev, S; Berggren, PO; Meister, B				Zhang, W; Efanov, A; Yang, SN; Fried, G; Kolare, S; Brown, H; Zaitsev, S; Berggren, PO; Meister, B			Munc-18 associates with syntaxin and serves as a negative regulator of exocytosis in the pancreatic beta-cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNC-18 GENE ENCODES; NEUROTRANSMITTER RELEASE; SYNAPTIC TRANSMISSION; SEC1 HOMOLOG; CAENORHABDITIS-ELEGANS; CHROMAFFIN GRANULES; SECRETORY PATHWAY; 3T3-L1 ADIPOCYTES; CALCIUM CHANNELS; MEMBRANE-FUSION		Karolinska Inst, Dept Neurosci, SE-17177 Stockholm, Sweden; Karolinska Inst, Rolf Luft Ctr Diabet Res, Dept Mol Med, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Women & Childrens Hlth, SE-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet	Meister, B (corresponding author), Karolinska Inst, Dept Neurosci, Berzelius Vag 1,5th Floor,Rm 5D 07, SE-17177 Stockholm, Sweden.		Tuluc, Petronel/C-2527-2011; Efanov, Alexander/R-3630-2019	Efanov, Alexander/0000-0002-8630-1503; Kolare Jeffrey, Susanne/0000-0003-3370-1965; Berggren, Per-Olof/0000-0001-8991-413X				AAITO MK, 1993, EMBO J, V12, P4095; AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; Araki S, 1997, BIOCHEM BIOPH RES CO, V234, P257, DOI 10.1006/bbrc.1997.6560; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BROADIE KS, 1995, J PHYSIOLOGY-PARIS, V89, P59, DOI 10.1016/0928-4257(96)80552-3; BUCHAN AMJ, 1985, HISTOCHEMISTRY, V83, P175, DOI 10.1007/BF00495150; Dresbach T, 1998, J NEUROSCI, V18, P2923; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; GengyoAndo K, 1996, J NEUROSCI, V16, P6695; GENGYOANDO K, 1993, NEURON, V11, P703, DOI 10.1016/0896-6273(93)90080-B; Halachmi N, 1996, J NEUROCHEM, V66, P889; Hames BD., 1990, GEL ELECTROPHORESIS, P1; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Haynes LP, 1999, BIOCHEM J, V342, P707, DOI 10.1042/0264-6021:3420707; HILL RS, 1985, DIABETES, V34, P115, DOI 10.2337/diabetes.34.2.115; HODEL A, 1994, J BIOL CHEM, V269, P8623; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; Jahn R, 1998, NATURE, V393, P14, DOI 10.1038/29871; KATAGIRI H, 1995, J BIOL CHEM, V270, P4963, DOI 10.1074/jbc.270.10.4963; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN F, 1995, DIABETOLOGIA, V38, P860, DOI 10.1007/s001250050364; Martin F, 1996, BIOCHEM J, V320, P201, DOI 10.1042/bj3200201; Matsuo N, 1997, J BIOL CHEM, V272, P16438, DOI 10.1074/jbc.272.26.16438; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Nagamatsu S, 1996, J BIOL CHEM, V271, P1160, DOI 10.1074/jbc.271.2.1160; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; Pelham HRB, 1997, EUR J CELL BIOL, V74, P311; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; Riento K, 1996, EUR J BIOCHEM, V239, P638, DOI 10.1111/j.1432-1033.1996.0638u.x; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Tamori Y, 1998, J BIOL CHEM, V273, P19740, DOI 10.1074/jbc.273.31.19740; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; Wu MN, 1998, EMBO J, V17, P127, DOI 10.1093/emboj/17.1.127; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Yang SN, 1999, P NATL ACAD SCI USA, V96, P10164, DOI 10.1073/pnas.96.18.10164	62	73	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41521	41527		10.1074/jbc.M005479200	http://dx.doi.org/10.1074/jbc.M005479200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024017	hybrid			2022-12-25	WOS:000166114600111
J	Aimond, F; Rauzier, JM; Bony, C; Vassort, G				Aimond, F; Rauzier, JM; Bony, C; Vassort, G			Simultaneous activation of p38 MAPK and p42/44 MAPK by ATP stimulates the K+ current I-TREK in cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); POLYUNSATURATED FATTY-ACIDS; PIG ATRIAL CELLS; PROTEIN-KINASE; EXTRACELLULAR ATP; CARDIAC MYOCYTES; ARACHIDONIC-ACID; FUNCTIONAL EXPRESSION; VENTRICULAR MYOCYTES; POTASSIUM CHANNELS	Living cells exhibit multiple K+ channel proteins; among these is the recently reported atypical two-pore domain K+ channel protein TREK-1. Most K+ currents are modulated by neurohormones and under various pathological conditions. Here, in rat ventricular cardiomyocytes using the whole-cell patch-clamp technique, we characterize for the first time a native TREK-1-like current (I-TREK) that is activated by ATP, a purine agonist applied at a micromolar range. This current is sensitive to arachidonic acid, intracellular acidosis, and various K+ current inhibitors. Reverse transcription-polymerase chain reaction reveals the presence of a TREK-1-Iike mRNA in rat cardiomyocytes that shows 93% identity with mouse TREK-1. ATP effects are greatly attenuated in the presence of arachidonic acid or HCO3--induced intracellular acidosis. Using a series of inhibitors, we further demonstrate that the ATP-induced stimulation of I-TREK implies the activation of cytosolic phospholipase A(2) and the release of arachidonic acid. These events require the simultaneous involvement of p38 MAPK and p42/44 MAPK, respectively, via a cAMP-dependent protein kinase and a tyrosine kinase pathway, whereas the two MAPKs conjugate to activate a mitogen- and stress-activated protein kinase (MSK-1). Our results thus demonstrate the occurrence of a TREK-1-like current in cardiac cells whose activation by purine agonists implies a dual-MAPK cytosolic pathway.	CHU Arnaud Villleneuve, IFR N 3, INSERM, U390, F-34295 Montpellier 5, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Vassort, G (corresponding author), CHU Arnaud Villleneuve, IFR N 3, INSERM, U390, F-34295 Montpellier 5, France.		AIMOND, Franck/B-6024-2017	AIMOND, Franck/0000-0001-9124-0066				Aimond F, 1999, CARDIOVASC RES, V42, P402, DOI 10.1016/S0008-6363(99)00070-X; Barry DM, 1996, ANNU REV PHYSIOL, V58, P363, DOI 10.1146/annurev.ph.58.030196.002051; Blanco-Aparicio C, 1999, J CELL BIOL, V147, P1129, DOI 10.1083/jcb.147.6.1129; Bogdanov KY, 1998, AM J PHYSIOL-HEART C, V274, pH571, DOI 10.1152/ajpheart.1998.274.2.H571; Bolego C, 1997, BRIT J PHARMACOL, V121, P1692, DOI 10.1038/sj.bjp.0701294; Borsch-Haubold AG, 1999, EUR J BIOCHEM, V265, P195, DOI 10.1046/j.1432-1327.1999.00722.x; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Firestein BL, 1996, AM J PHYSIOL-RENAL, V271, pF610, DOI 10.1152/ajprenal.1996.271.3.F610; Gao ZH, 1999, J BIOL CHEM, V274, P5972, DOI 10.1074/jbc.274.9.5972; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Hazan-Halevy I, 2000, J BIOL CHEM, V275, P12416, DOI 10.1074/jbc.275.17.12416; Hiller G, 1999, CELL SIGNAL, V11, P863, DOI 10.1016/S0898-6568(99)00058-3; HONORE E, 1994, P NATL ACAD SCI USA, V91, P1937, DOI 10.1073/pnas.91.5.1937; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; Kim D, 1998, CIRC RES, V82, P513, DOI 10.1161/01.RES.82.4.513; KIM DH, 1990, CIRC RES, V67, P1040, DOI 10.1161/01.RES.67.4.1040; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Kuzmin AI, 1998, AM J PHYSIOL-CELL PH, V275, pC766, DOI 10.1152/ajpcell.1998.275.3.C766; Lesage F, 1997, FEBS LETT, V402, P28, DOI 10.1016/S0014-5793(96)01491-3; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Maingret F, 1999, J BIOL CHEM, V274, P26691, DOI 10.1074/jbc.274.38.26691; Matsubayashi T, 1999, PFLUG ARCH EUR J PHY, V437, P635; Matsuura H, 1996, J PHYSIOL-LONDON, V490, P659, DOI 10.1113/jphysiol.1996.sp021175; Matsuura H, 1997, J PHYSIOL-LONDON, V503, P45, DOI 10.1111/j.1469-7793.1997.045bi.x; Ni H, 1998, BIOCHEM BIOPH RES CO, V243, P492, DOI 10.1006/bbrc.1998.8135; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Puceat M, 1998, J CELL BIOL, V141, P1637, DOI 10.1083/jcb.141.7.1637; PUCEAT M, 1991, BIOCHEM J, V274, P55, DOI 10.1042/bj2740055; Puceat M, 1998, FEBS LETT, V431, P189, DOI 10.1016/S0014-5793(98)00747-9; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; Ralevic V, 1998, PHARMACOL REV, V50, P413; Richards SM, 1999, J CELL SCI, V112, P1519; Ryder JW, 2000, J BIOL CHEM, V275, P1457, DOI 10.1074/jbc.275.2.1457; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Wu ML, 2000, CIRC RES, V86, pE55; Xing MB, 1996, J CLIN INVEST, V97, P1302, DOI 10.1172/JCI118546; ZHENG JS, 1994, CIRC RES, V74, P1034, DOI 10.1161/01.RES.74.6.1034; [No title captured]	49	79	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39110	39116		10.1074/jbc.M008192200	http://dx.doi.org/10.1074/jbc.M008192200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993907	hybrid			2022-12-25	WOS:000165953100024
J	Besset, V; Scott, RP; Ibanez, CF				Besset, V; Scott, RP; Ibanez, CF			Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; MICE LACKING GDNF; SYMPATHETIC NEURON SURVIVAL; NEOPLASIA TYPE 2B; NEUROTROPHIC FACTOR; ADAPTER PROTEINS; TRANSDUCTION PATHWAYS; CELL; SHC; MUTATION	Proximal signaling events and protein-protein interactions initiated after activation of the c-Ret receptor tyrosine kinase by its ligand, glial cell line-derived neurotrophic factor (GDNF), were investigated in cells carrying native and mutated forms of this receptor. Mutation of Tyr-1062 (Y1062F) in the cytoplasmic tail of c-Ret abolished receptor binding and phosphorylation of the adaptor Shc and eliminated activation of Ras by GDNF. Phosphorylation of Erk kinases was also greatly attenuated but not eliminated by this mutation. This residual wave of Erk phosphorylation was independent of the kinase activity of c-Ret. Mutation of Tyr-1096 (Y1096F), a binding site for the adaptor Grb2, had no effect on Erk activation by GDNF, Activation of phosphatidylinositol-3 kinase (PI3K) and its downstream effector Akt was also reduced in the Y1082F mutant but not completely abolished unless Tyr-1096 was also mutated, Ligand stimulation of neuronal cells induced the assembly of a large protein complex containing c-Ret, Grb2, and tyrosine-phosphorylated forms of Shc, p85(PI3K), the adaptor Gab2, and the protein-tyrosine phosphatase SHP-2. In agreement with Ras-independent activation of PI3K by GDNF in neuronal cells, survival of sympathetic neurons induced by GDNF was dependent on PI3K but was not affected by microinjection of blocking anti-Pas antibodies, which did compromise neuronal survival by nerve growth factor, suggesting that Ras is not required for GDNF-induced survival of sympathetic neurons. These results indicate that upon ligand stimulation, at least two distinct protein complexes assemble on phosphorylated Tyr-1062 of c-Ret via Shc, one leading to activation of the Ras/Erk pathway through recruitment of Grb2/Sos and another to the PI3K/Akt pathway through recruitment of Grb2/Gab2 followed by p85(PI3K) and SHP-2. This latter complex can also assemble directly onto phosphorylated Tyr-1096, offering an alternative route to PI3K activation by GDNF.	Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, S-17177 Stockholm, Sweden	Karolinska Institutet	Ibanez, CF (corresponding author), Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, Berzelius Vag 1, S-17177 Stockholm, Sweden.		Scott, Rizaldy/Y-7584-2019; Scott, Rizaldy/AAC-5264-2020	Scott, Rizaldy/0000-0002-0288-8862; 				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Bocciardi R, 1997, ONCOGENE, V15, P2257, DOI 10.1038/sj.onc.1201413; BORRELLO MG, 1994, ONCOGENE, V9, P1661; Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; Edery P, 1997, BIOESSAYS, V19, P389, DOI 10.1002/bies.950190506; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Ishiguro Y, 1999, ENDOCRINOLOGY, V140, P3992, DOI 10.1210/en.140.9.3992; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Klesse LJ, 1998, J NEUROSCI, V18, P10420; Korhonen JM, 1999, J BIOL CHEM, V274, P37307, DOI 10.1074/jbc.274.52.37307; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Mazzoni IE, 1999, J NEUROSCI, V19, P9716; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Murakami H, 1999, BIOCHEM BIOPH RES CO, V262, P68, DOI 10.1006/bbrc.1999.1186; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; NOBES CD, 1995, EUR J NEUROSCI, V7, P344, DOI 10.1111/j.1460-9568.1995.tb01069.x; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; Ohiwa M, 1997, BIOCHEM BIOPH RES CO, V237, P747, DOI 10.1006/bbrc.1997.7225; PARATCHA G, IN PRESS NEURON; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Poteryaev D, 1999, FEBS LETT, V463, P63, DOI 10.1016/S0014-5793(99)01590-2; Rizzo C, 1996, J BIOL CHEM, V271, P29497, DOI 10.1074/jbc.271.46.29497; SALAZARGRUESO EF, 1991, NEUROREPORT, V2, P505, DOI 10.1097/00001756-199109000-00002; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Santoro W, 1999, J ENDOCRINOL INVEST, V22, P811, DOI 10.1007/BF03343650; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Yu T, 1998, J NEUROSCI, V18, P4684; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	54	199	205	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39159	39166		10.1074/jbc.M006908200	http://dx.doi.org/10.1074/jbc.M006908200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995764	hybrid			2022-12-25	WOS:000165953100031
J	Chan, SY; Wong, RWC				Chan, SY; Wong, RWC			Expression of epidermal growth factor in transgenic mice causes growth retardation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING PROTEIN-3; EGF-RECEPTOR; TGF-ALPHA; FACTOR PRECURSOR; FACTOR-I; SIGNALING NETWORK; MAMMARY-GLAND; HUMAN-FETUS; GENE; OVEREXPRESSION	The epidermal growth factor (EGF) family of peptides signals through the erbB family of receptor tyrosine kinases and plays important roles in development and tumorigenesis. Both EGF and transforming growth factor (TGF)-alpha only bind to erbB1 and activate it. The precursor of EGF is distinct from that of TGF-alpha in having eight additional EGF-like repeats. We have recently shown that the EGF precursor without these repeats is biologically active and leads to hypospermatogenesis in transgenic mice. Here we present evidence that the growth of transgenic mice widely expressing this engineered EGF precursor is also stunted. These mice were consistently born at half the normal weight and reached almost 80% of normal weight at adulthood. The mechanism involved a reduction of serum insulin-like growth factor-binding protein-3. Chondrocyte development in the growth plate was affected, and osteoblasts accumulated in the endosteum and periosteum. Besides these novel findings on the in vivo effects of EGF on bone development, we observed no sign of tumor formation in our transgenic animals. In contrast to previous reports on TGF-alpha transgenic mice, we show that the biological functions of EGF and TGF-alpha are clearly distinct.	Univ Hong Kong, Queen Mary Hosp, Dept Paediat, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Chan, SY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Paediat, Hong Kong, Hong Kong, Peoples R China.		Wong, Richard W./E-9155-2011	Chan, Siu Yuen/0000-0001-7262-1293				Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BAXTER RC, 1986, J CLIN INVEST, V78, P1504, DOI 10.1172/JCI112742; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BROWN G, 1978, INTRO HISTOLOGY MANU; CHARD T, 1989, J ENDOCRINOL, V123, P3, DOI 10.1677/joe.0.1230003; COHEN S, 1962, J BIOL CHEM, V237, P1555; Cook PW, 1997, J CLIN INVEST, V100, P2286, DOI 10.1172/JCI119766; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DeBenedetti F, 1997, J CLIN INVEST, V99, P643, DOI 10.1172/JCI119207; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; Edmondson SR, 1999, J CELL PHYSIOL, V179, P201, DOI 10.1002/(SICI)1097-4652(199905)179:2<201::AID-JCP10>3.0.CO;2-9; FREY P, 1979, P NATL ACAD SCI USA, V76, P6294, DOI 10.1073/pnas.76.12.6294; Frystyk J, 1996, GROWTH REGULAT, V6, P48; Giovannucci E, 1999, HORM RES, V51, P34, DOI 10.1159/000053160; Giraud AS, 2000, AM J PHYSIOL-GASTR L, V278, pG501, DOI 10.1152/ajpgi.2000.278.4.G501; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; HEMBREE JR, 1994, CANCER RES, V54, P3160; Hui YF, 1996, BLOOD, V88, P4021, DOI 10.1182/blood.V88.10.4021.bloodjournal88104021; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Kwan RWP, 1999, INT J ONCOL, V15, P281; LASSARRE C, 1991, PEDIATR RES, V29, P219, DOI 10.1203/00006450-199103000-00001; Lee DCW, 1998, J UROLOGY, V159, P291, DOI 10.1016/S0022-5347(01)64084-9; LEFEBVRE V, 1995, J CELL BIOL, V128, P239, DOI 10.1083/jcb.128.1.239; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MARTINEAUDOIZE B, 1988, ENDOCRINOLOGY, V123, P841, DOI 10.1210/endo-123-2-841; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; MROCZKOWSKI B, 1989, MOL CELL BIOL, V9, P2771, DOI 10.1128/MCB.9.7.2771; MURPHY LJ, 1995, J MOL ENDOCRINOL, V15, P293, DOI 10.1677/jme.0.0150293; MURPHY RA, 1980, J HISTOCHEM CYTOCHEM, V28, P890, DOI 10.1177/28.8.6969274; Niemeyer CC, 1999, INT J CANCER, V81, P588, DOI 10.1002/(SICI)1097-0215(19990517)81:4<588::AID-IJC14>3.0.CO;2-I; RAISZ LG, 1980, ENDOCRINOLOGY, V107, P270, DOI 10.1210/endo-107-1-270; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; Schneider MR, 2000, FASEB J, V14, P629, DOI 10.1096/fasebj.14.5.629; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; TAJIMA Y, 1993, J ANAT, V182, P291; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; van Neck JW, 2000, J ENDOCRINOL, V165, P115, DOI 10.1677/joe.0.1650115; WEBBER EM, 1994, AM J PATHOL, V145, P398; Wong RWC, 2000, J BIOL CHEM, V275, P18297, DOI 10.1074/jbc.M001965200; Wong RWC, 2000, MOL BIOTECHNOL, V15, P155, DOI 10.1385/MB:15:2:155; Wong RWC, 2000, MOL BIOTECHNOL, V15, P65, DOI 10.1385/MB:15:1:65; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	49	59	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38693	38698		10.1074/jbc.M004189200	http://dx.doi.org/10.1074/jbc.M004189200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11001946	hybrid			2022-12-25	WOS:000165739800076
J	Hu, LYA; Tang, YT; Miller, WE; Cong, M; Lau, AG; Lefkowitz, RJ; Hall, RA				Hu, LYA; Tang, YT; Miller, WE; Cong, M; Lau, AG; Lefkowitz, RJ; Hall, RA			beta 1-adrenergic receptor association with PSD-95 - Inhibition of receptor internalization and facilitation of beta(1)-adrenergic receptor interaction with N-methyl-D-aspartate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; LONG-TERM POTENTIATION; EXCHANGER REGULATORY FACTOR; HIPPOCAMPAL CA1 REGION; BETA(2)-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTORS; SYNAPTIC PLASTICITY; PDZ-DOMAIN; IN-VIVO; FREQUENCY STIMULATION	The beta (1)-adrenergic receptor (beta (1)AR) is the most abundant subtype of beta -adrenergic receptor in the mammalian brain and is known to potently regulate synaptic plasticity. To search for potential neuronal beta (1)AR-interacting proteins, we screened a rat brain cDNA library using the beta (1)AR carboxyl terminus (beta (1)AR-CT) as bait in the yeast two-hybrid system. These screens identified PSD-95, a multiple PDZ domain-containing scaffolding protein, as a specific binding partner of the beta (1)AR-CT. This interaction was confirmed by in vitro fusion protein pull-down and blot overlay experiments, which demonstrated that the beta (1)ARCT binds specifically to the third PDZ domain of PSD-95, Furthermore, the full-length beta (1)AR associates with PSD-95 in cells, as determined by co-immunoprecipitation experiments and immunofluorescence co-localization studies. The interaction between beta (1)AR and PSD-95 is mediated by the last few amino acids of the beta (1)AR, and mutation of the beta (1)AR carboxyl terminus eliminated the binding and disrupted the co-localization of the beta (1)AR and PSD-95 in cells. Agonist-induced internalization of the beta (1)AR in HEK-293 cells was markedly attenuated by PSD-95 co-expression, whereas co-expression of PSD-95 has no significant effect on either desensitization of the beta (1)AR or beta (1)AR-induced cAMP accumulation. Furthermore, PSD-95 facilitated the formation of a complex between the beta (1)AR and N-methyl-D-aspartate receptors, as assessed by co-immunoprecipitation. These data reveal that PSD-95 is a specific beta (1)AR binding partner that modulates beta (1)AR function and facilitates physical association of the beta (1)AR with synaptic proteins, such as the N-methyl-D-aspartate receptors, which are known to be regulated by beta (1)AR stimulation.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA; Emory Univ, Sch Med, Rollins Res Ctr, Dept Pharmacol, Atlanta, GA 30322 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Emory University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Box 3821, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021	Hall, Randy/0000-0002-8318-8728	NHLBI NIH HHS [HL16037] Funding Source: Medline; NIGMS NIH HHS [GM60982] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060982] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOKI C, 1987, BRAIN RES, V437, P264, DOI 10.1016/0006-8993(87)91642-8; BELLOREUSS E, 1980, AM J PHYSIOL, V238, pF347, DOI 10.1152/ajprenal.1980.238.5.F347; Bramham CR, 1997, NEUROREPORT, V8, P719, DOI 10.1097/00001756-199702100-00028; CAHILL L, 1994, NATURE, V371, P702, DOI 10.1038/371702a0; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; CASH R, 1986, BRAIN RES, V370, P127, DOI 10.1016/0006-8993(86)91112-1; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Chruscinski AJ, 1999, J BIOL CHEM, V274, P16694, DOI 10.1074/jbc.274.24.16694; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; Cohen AS, 1999, J NEUROPHYSIOL, V82, P3139, DOI 10.1152/jn.1999.82.6.3139; FLEXNER JB, 1985, P NATL ACAD SCI USA, V82, P7458, DOI 10.1073/pnas.82.21.7458; FOWLER JC, 1988, EUR J PHARMACOL, V153, P105, DOI 10.1016/0014-2999(88)90593-6; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17935; GEAN PW, 1992, BRAIN RES, V594, P331, DOI 10.1016/0006-8993(92)91146-6; GREEN SA, 1994, J BIOL CHEM, V269, P26215; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; HOPKINS WF, 1988, J NEUROPHYSIOL, V59, P667, DOI 10.1152/jn.1988.59.2.667; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; HUANG CC, 1993, NEUROSCI LETT, V161, P207, DOI 10.1016/0304-3940(93)90295-V; Huang YY, 1996, NEURON, V16, P611, DOI 10.1016/S0896-6273(00)80080-X; Ikegaya Y, 1997, NEUROREPORT, V8, P3143, DOI 10.1097/00001756-199709290-00027; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Jugloff DGM, 2000, J BIOL CHEM, V275, P1357, DOI 10.1074/jbc.275.2.1357; Katsuki H, 1997, J NEUROPHYSIOL, V77, P3013, DOI 10.1152/jn.1997.77.6.3013; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lefkowitz RJ, 1996, GOODMAN GILMANS PHAR, P105; MADISON DV, 1986, J PHYSIOL-LONDON, V372, P221, DOI 10.1113/jphysiol.1986.sp016006; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; MANTYH PW, 1995, J NEUROSCI, V15, P152; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; Moody TD, 1998, BRAIN RES, V794, P75, DOI 10.1016/S0006-8993(98)00217-0; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; NIELSON KA, 1994, BEHAV NEURAL BIOL, V62, P190, DOI 10.1016/S0163-1047(05)80017-2; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Niethammer M, 1996, J NEUROSCI, V16, P2157; Przybyslawski J, 1999, J NEUROSCI, V19, P6623; Raman IM, 1996, NEURON, V16, P415, DOI 10.1016/S0896-6273(00)80059-8; Rohrer DK, 1999, J BIOL CHEM, V274, P16701, DOI 10.1074/jbc.274.24.16701; Rousseau G, 1996, MOL PHARMACOL, V49, P752; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; SEGAL M, 1991, PROG BRAIN RES, V88, P323; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STRADER CD, 1983, P NATL ACAD SCI-BIOL, V80, P1840, DOI 10.1073/pnas.80.7.1840; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; Thomas MJ, 1996, NEURON, V17, P475, DOI 10.1016/S0896-6273(00)80179-8; Topinka JR, 1998, NEURON, V20, P125, DOI 10.1016/S0896-6273(00)80440-7; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; van Stegeren AH, 1998, PSYCHOPHARMACOLOGY, V138, P305, DOI 10.1007/s002130050675; WAEBER C, 1991, SYNAPSE, V8, P270, DOI 10.1002/syn.890080405; Wang SJ, 1999, J NEUROSCI, V19, P570; Watanabe Y, 1996, NEUROSCIENCE, V71, P1031, DOI 10.1016/0306-4522(95)00498-X; WEINMAN EJ, 1982, J MEMBRANE BIOL, V69, P107, DOI 10.1007/BF01872270; Winder DG, 1999, NEURON, V24, P715, DOI 10.1016/S0896-6273(00)81124-1; XIAO RP, 1994, J BIOL CHEM, V269, P19151; XIAO RP, 1993, CIRC RES, V73, P286, DOI 10.1161/01.RES.73.2.286; Zhang WD, 1999, J NEUROSCI, V19, P96, DOI 10.1523/JNEUROSCI.19-01-00096.1999	60	135	140	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38659	38666		10.1074/jbc.M005938200	http://dx.doi.org/10.1074/jbc.M005938200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10995758	hybrid			2022-12-25	WOS:000165739800071
J	Chi, A; Kemp, RG				Chi, A; Kemp, RG			The primordial high energy compound: ATP or inorganic pyrophosphate?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPI-DEPENDENT PHOSPHOFRUCTOKINASE; ESCHERICHIA-COLI; IDENTIFICATION; SPECIFICITY	The pyrophosphate-dependent phosphofructokinase (PPi-PFK) of Entamoeba histolytica displays a millionfold preference for inorganic pyrophosphate (PP,) over ATP (calculated as the ratio of k(cat)/K-m). The introduction of a single mutation by site-directed mutagenesis changes its preference from PP, to ATP. The single mutant has an 8-fold preference for ATP whereas a related double mutant shows a preference exceeding 10,000-fold. The results suggest the presence of a latent nucleotide binding site aligned for a catalytic role in PPi-PFK. It is proposed that the ancestral PFK was an ATP-dependent enzyme and that PPi-PFKs are a later evolving adaptation.	Chicago Med Sch, Dept Biochem & Mol Biol, N Chicago, IL 60064 USA	Chicago Medical School	Kemp, RG (corresponding author), Chicago Med Sch, Dept Biochem & Mol Biol, 3333 Green Bay Rd, N Chicago, IL 60064 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034527] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34527] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alves AMCR, 1997, APPL ENVIRON MICROB, V63, P956, DOI 10.1128/AEM.63.3.956-961.1997; Calvin M., 1963, GRADUATE J, V5, P319; CHEN RD, 1995, P NATL ACAD SCI USA, V92, P11666, DOI 10.1073/pnas.92.25.11666; Deng ZH, 1998, BIOCHEM J, V329, P659, DOI 10.1042/bj3290659; Hinds RM, 1998, ARCH BIOCHEM BIOPHYS, V349, P47, DOI 10.1006/abbi.1997.0434; LINDBERG M, 1975, EUR J BIOCHEM, V53, P481, DOI 10.1111/j.1432-1033.1975.tb04089.x; Lipmann F., 1965, The origins of pre-biological systems and of their molecular matrices., P259; Mertens E, 1998, J MOL EVOL, V47, P739, DOI 10.1007/PL00006433; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; Siebers B, 1998, J BACTERIOL, V180, P2137, DOI 10.1128/JB.180.8.2137-2143.1998; Wang XJ, 1999, BIOCHEMISTRY-US, V38, P4313, DOI 10.1021/bi982940q	11	51	55	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35677	35679		10.1074/jbc.C000581200	http://dx.doi.org/10.1074/jbc.C000581200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	11001940	hybrid			2022-12-25	WOS:000165382000006
J	Petrocelli, T; Slingerland, J				Petrocelli, T; Slingerland, J			UVB induced cell cycle checkpoints in an early stage human melanoma line, WM35	ONCOGENE			English	Article						UVB; cell cycle; checkpoint; DNA damage; Cdc25A	PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3-BETA; DNA-DAMAGE CHECKPOINT; D-DEPENDENT KINASE; RETINOBLASTOMA PROTEIN; TYROSINE PHOSPHORYLATION; FISSION YEAST; INHIBITORY PHOSPHORYLATION; ULTRAVIOLET-IRRADIATION; PHASE PROGRESSION	The activation of cell cycle checkpoints in response to genotoxic stressors is essential for the maintenance of genomic integrity. Although most prior studies of cell cycle effects of UV irradiation have used UVC, this UV range does not penetrate the earth's atmosphere. Thus, we have investigated the mechanisms of ultraviolet B (UVB) irradiation-induced cell cycle arrest in biologically relevant target cell type, the early stage human melanoma cell line, WM35. Irradiation of WM35 cells with UVB resulted in arrests throughout the cell cycle: at the G1/S transition, in S phase and in G2. G1 arrest was accompanied by increased association of p21 with cyclin E/cdk2 and cyclin A/cdk2, increased binding of p27 to cyclin E/cdk2 and inhibition of these Kinases, A loss of Cdc25A expression was associated with an increased inhibitory phosphotyrosine content of cyclin and cyclin A-associated cdk2 and may also contribute to G1 arrest following UVB irradiation. The association of Cdc25A with 14-3-3 was increased by UVB, Reduced cyclin D1 protein and increased binding of p21 and p27 to cyclin D1/cdk4 complexes were also observed. The loss of cyclin D1 could not be attributed to inhibition of either MAPK or PI3K/PKB pathways, since both were activated by UVB. Cdc25B levels fell and the remaining protein showed an increased association with 14-3-3 in response to UVB, Losses in cyclin B1 expression and an increased binding of p21 to cyclin B1/cdk1 complexes also contributed to inhibition of this kinase activity, and G2/M arrest.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto Sunnybrook Reg Canc Ctr, Div Canc Biol Res, Toronto, ON M4N 3M5, Canada; Univ Toronto, Toronto, ON, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Slingerland, J (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto Sunnybrook Reg Canc Ctr, Div Canc Biol Res, Res Bldg,S-218,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.							Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARKER D, 1995, CANCER RES, V55, P4041; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EPSTEIN JH, 1983, J AM ACAD DERMATOL, V9, P487, DOI 10.1016/S0190-9622(83)70160-X; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; Florenes VA, 1996, ONCOGENE, V13, P2447; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HERZINGER T, 1995, ONCOGENE, V11, P2151; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO J, 1993, GENE DEV, V7, P331; KAUFMANN WK, 1991, MOL CELL BIOL, V11, P3711, DOI 10.1128/MCB.11.7.3711; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAU CC, 1994, P NATL ACAD SCI USA, V79, P7491; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; LI JJ, 1993, CELL, V74, P223, DOI 10.1016/0092-8674(93)90413-K; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; LIU M, 1995, ONCOGENE, V10, P1955; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Pedley J, 1996, ONCOGENE, V13, P1335; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Petrocelli T, 1996, ONCOGENE, V12, P1387; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; REED SI, 1994, J CELL SCI, P69; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Rigel DS, 1996, J AM ACAD DERMATOL, V35, P1012, DOI 10.1016/S0190-9622(96)90139-5; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Solomon M J, 1998, Results Probl Cell Differ, V22, P79; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG XQ, 1994, EXP CELL RES, V212, P176, DOI 10.1006/excr.1994.1133; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	82	23	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2000	19	39					4480	4490		10.1038/sj.onc.1203808	http://dx.doi.org/10.1038/sj.onc.1203808			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002421				2022-12-25	WOS:000089236800005
J	Pietri, S; Martel, S; Culcasi, M; Delmas-Beauvieux, MC; Canioni, P; Gallis, JL				Pietri, S; Martel, S; Culcasi, M; Delmas-Beauvieux, MC; Canioni, P; Gallis, JL			Use of diethyl(2-methylpyrrolidin-2-yl)phosphonate as a highly sensitive extra- and intracellular P-31 NMR pH indicator in isolated organs - Direct NMR evidence of acidic compartments in the ischemic and reperfused rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; HEART; SPECTROSCOPY; METHYLPHOSPHONATE; HEPATOCYTES; PHOSPHONATE; PHOSPHATE; EXCHANGE; VOLUME; CELLS	The novel phosphorylated pyrrolidine diethyl(2-methylpyrrolidin-2-yl)phosphonate (DEPMPH) was evaluated as a P-31 NMR probe of the pH changes associated with ischemia/reperfusion of rat isolated hearts and livers. In vitro titration curves indicated that DEPMPH exhibited a 4-fold larger amplitude of chemical shift variation than inorganic phosphate yielding an enhanced NMR sensitivity in the pH range of 5.0-7.5 that allowed us to assess pH variations of less than 0.1 pH units. At the non-toxic concentration of 5 mM, DEPMPH distributed into external and cytosolic compartments in both normoxic organs, as assessed by the appearance of two resonance peaks. An additional peak was observed in normoxic and ischemic livers, assigned to DEPMPH in acidic vesicles (pH 5.3-5.6). During severe myocardial ischemia, a third peak corresponding to DEPMPH located in ventricular and atrial cavities appeared (pH 6.9). Mass spectrometry and NMR analyses of perchloric extracts showed that no significant metabolism of DEPMPH occurred in the ischemic liver. Reperfusion with plain buffer resulted in a rapid washout of DEPMPH from both organs. It was concluded that the highly pH-sensitive DEPMPH could be of great interest in noninvasive ex vivo studies of pH gradients that may be involved in many pathological processes.	Univ Aix Marseille 1, SREP, CNRS, UMR 6517, F-13397 Marseille 20, France; Univ Aix Marseille 3, SREP, CNRS, UMR 6517, F-13397 Marseille, France; Univ Bordeaux 2, CNRS, UMR 5536, F-33076 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Pietri, S (corresponding author), Univ Aix Marseille 1, SREP, CNRS, UMR 6517, Case 521,Ave Escadrille Normandie Niemen, F-13397 Marseille 20, France.							ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; BOYER JL, 1992, ANNU REV PHYSIOL, V54, P415, DOI 10.1146/annurev.ph.54.030192.002215; BRENOT F, 1992, BIOCHIMIE, V74, P883, DOI 10.1016/0300-9084(92)90072-M; BRONK SF, 1991, HEPATOLOGY, V14, P626; Bruynseels K, 1997, NMR BIOMED, V10, P263, DOI 10.1002/(SICI)1099-1492(199709)10:6<263::AID-NBM472>3.0.CO;2-J; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; CLARKE K, 1994, MAGNET RESON MED, V32, P181, DOI 10.1002/mrm.1910320206; CLARKE K, 1993, NMR BIOMED, V6, P278, DOI 10.1002/nbm.1940060407; COHEN SM, 1983, J BIOL CHEM, V258, P4294; CONOREV EA, 1991, CARDIOVASC RES, V25, P164, DOI 10.1093/cvr/25.2.164; DAVIES L, 1993, CELL, V75, P321, DOI 10.1016/0092-8674(93)80073-N; DEFRONZO M, 1987, J BIOL CHEM, V262, P11032; DESMOULIN F, 1987, HEPATOLOGY, V7, P315, DOI 10.1002/hep.1840070217; Dufour S, 1996, J MAGN RESON SER B, V113, P125, DOI 10.1006/jmrb.1996.0165; DURAND T, 1993, AM J PHYSIOL, V265, pG43, DOI 10.1152/ajpgi.1993.265.1.G43; FISHER MJ, 1987, CIRC RES, V60, P472, DOI 10.1161/01.RES.60.4.472; GARLICK PB, 1979, BIOCHEM J, V184, P547, DOI 10.1042/bj1840547; GILLIES RJ, 1994, AM J PHYSIOL, V267, pC195, DOI 10.1152/ajpcell.1994.267.1.C195; GILLIES RJ, 1982, INTRACELLULAR PH ITS, P79; HENDERSON RM, 1987, AM J PHYSIOL, V252, pG109, DOI 10.1152/ajpgi.1987.252.1.G109; INGWALL JS, 1982, AM J PHYSIOL, V242, pH729, DOI 10.1152/ajpheart.1982.242.5.H729; JACOBUS WE, 1982, INTRACELLULAR PH ITS, P537; KELLER SK, 1986, AM J PHYSIOL, V250, pC124, DOI 10.1152/ajpcell.1986.250.1.C124; LABOTKA RJ, 1983, BIOCHEMISTRY-US, V22, P6089, DOI 10.1021/bi00295a008; LIN LE, 1985, AM J PHYSIOL, V248, pC177, DOI 10.1152/ajpcell.1985.248.1.C177; LUNDBERG P, 1990, ANAL BIOCHEM, V191, P193, DOI 10.1016/0003-2697(90)90210-Z; MCLAUGHLIN AC, 1978, FRONTIERS BIOL ENERG, V2, P1351; MOON RB, 1973, J BIOL CHEM, V248, P7276; NAVON G, 1979, BIOCHEMISTRY-US, V18, P4487, DOI 10.1021/bi00588a006; Pietri S, 1998, EUR J BIOCHEM, V254, P256, DOI 10.1046/j.1432-1327.1998.2540256.x; Pietri S, 2000, J BIOL CHEM, V275, P19505, DOI 10.1074/jbc.M001784200; Piper HM, 1996, BASIC RES CARDIOL, V91, P191, DOI 10.1007/BF00788905; PISSAREK M, 1995, MOL CELL BIOCHEM, V145, P121, DOI 10.1007/BF00935484; Raghunand N, 1999, BIOCHEM PHARMACOL, V57, P309, DOI 10.1016/S0006-2952(98)00306-2; RENNER EL, 1989, AM J PHYSIOL, V256, pG44, DOI 10.1152/ajpgi.1989.256.1.G44; SALHANY JM, 1979, J MOL CELL CARDIOL, V11, P601, DOI 10.1016/0022-2828(79)90434-6; SCHARSCHMIDT BF, 1997, ANNU REV PHYSIOL, V49, P69; SCHLISELFELD LH, 1982, BIOCHEMISTRY-US, V21, P317, DOI 10.1021/bi00531a018; SLONCZEWSKI JL, 1981, P NATL ACAD SCI-BIOL, V78, P6271, DOI 10.1073/pnas.78.10.6271; STEWART IM, 1986, BIOCHIM BIOPHYS ACTA, V885, P23, DOI 10.1016/0167-4889(86)90034-0; SZWERGOLD BS, 1992, ANNU REV PHYSIOL, V54, P775, DOI 10.1146/annurev.ph.54.030192.004015; SZWERGOLD BS, 1989, J CELL PHYSIOL, V138, P227, DOI 10.1002/jcp.1041380203; THOMA WJ, 1986, BIOCHEM BIOPH RES CO, V138, P1106, DOI 10.1016/S0006-291X(86)80396-5; *US DEP HHS, 1985, NIH PUBL, V8523; Vidal G, 2000, NMR BIOMED, V13, P289, DOI 10.1002/1099-1492(200008)13:5<289::AID-NBM647>3.3.CO;2-7; VOOGD A, 1992, J CLIN INVEST, V90, P2050, DOI 10.1172/JCI116086; WADSWORTH SJ, 1994, J MEMBRANE BIOL, V142, P21, DOI 10.1007/BF00233380	47	25	29	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1750	1758		10.1074/jbc.M008023200	http://dx.doi.org/10.1074/jbc.M008023200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11013264	hybrid			2022-12-25	WOS:000166528000015
J	Chen, C; Yang, MCK; Yang, TP				Chen, C; Yang, MCK; Yang, TP			Evidence that silencing of the HPRT promoter by DNA methylation is mediated by critical CpG sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE GENE; INACTIVE X-CHROMOSOMES; HISTONE DEACETYLASE; TRICHOSTATIN-A; 5' REGION; CHROMATIN STRUCTURE; LINKED GENES; EXPRESSION; TRANSCRIPTION; DEMETHYLATION	The strong correlation between promoter hypermethylation and gene silencing suggests that promoter methylation represses transcription. To identify methylation sites that may be critical for maintaining repression of the human HPRT gene, we treated human/hamster hybrid cells containing an inactive human X chromosome with the DNA demethylating agent 5-azadeoxycytidine (5aCdr), and we then examined the high resolution methylation pattern of the HPRT promoter in single cell-derived lines. Reactivation of HPRT correlated with complete promoter demethylation, In contrast, the 61 BaCdr-treated clones that failed to reactivate HPRT exhibited sporadic promoter demethylation. However, three specific CpG sites remained methylated in all unreactivated clones, suggesting these sites may be critical for maintaining transcriptional silencing of the HPRT gene. Re-treatment of partially demethylated land unreactivated) clones with a second round of 5aCdr did not increase the frequency of HPRT reactivation. This is consistent with mechanisms of methylation-mediated repression requiring methylation at specific critical sites and argues against models invoking overall levels or a threshold of promoter methylation. Treatment of cells with the histone deacetylase inhibitor, trichostatin A, failed to reactivate HPRT on the inactive X chromosome, even when the promoter was partially demethylated by 5aCdr treatment, suggesting that transcriptional repression by DNA methylation is unlikely to depend upon a trichostatin A-sensitive histone deacetylase.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Ctr Mammalian Genet, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Div Pediat Genet, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Stat, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Yang, TP (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, 1600 SW Archer Rd, Gainesville, FL 32610 USA.	yang@cmg.health.ufl.edu		Chen, Chien/0000-0002-8406-9659	NIGMS NIH HHS [R01 GM44286] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044286] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Broday L, 1999, MOL CELL BIOL, V19, P3198; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Carmen AA, 1999, P NATL ACAD SCI USA, V96, P12356, DOI 10.1073/pnas.96.22.12356; DRACOPOLI NC, 1985, AM J HUM GENET, V37, P199; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; ELLIS N, 1987, SOMAT CELL MOLEC GEN, V13, P191, DOI 10.1007/BF01535202; Hata K, 1997, GENE, V189, P227, DOI 10.1016/S0378-1119(96)00856-6; HORNSTRA IK, 1993, ANAL BIOCHEM, V213, P179, DOI 10.1006/abio.1993.1407; HORNSTRA IK, 1994, MOL CELL BIOL, V14, P1419, DOI 10.1128/MCB.14.2.1419; HORNSTRA IK, 1992, MOL CELL BIOL, V12, P5345, DOI 10.1128/MCB.12.12.5345; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; KIM SH, 1986, NUCLEIC ACIDS RES, V14, P3103, DOI 10.1093/nar/14.7.3103; LEVINE A, 1992, P NATL ACAD SCI USA, V89, P10119, DOI 10.1073/pnas.89.21.10119; Litt MD, 1996, MOL CELL BIOL, V16, P6190; Maxam A M, 1980, Methods Enzymol, V65, P499; MIYASHITA T, 1994, FEBS LETT, V353, P225, DOI 10.1016/0014-5793(94)01034-X; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; PARK JG, 1994, MOL CELL BIOL, V14, P7975, DOI 10.1128/MCB.14.12.7975; PATEL PI, 1986, MOL CELL BIOL, V6, P393, DOI 10.1128/MCB.6.2.393; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; Riggs AD, 1998, CIBA F SYMP, V214, P214; SASAKI T, 1992, MOL CELL BIOL, V12, P3819, DOI 10.1128/MCB.12.9.3819; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P3418, DOI 10.1073/pnas.79.11.3418; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; TOMMASI S, 1993, SOMAT CELL MOLEC GEN, V19, P529, DOI 10.1007/BF01233380; TONIOLO D, 1988, EMBO J, V7, P401, DOI 10.1002/j.1460-2075.1988.tb02827.x; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4; YISRAELI J, 1988, P NATL ACAD SCI USA, V85, P4638, DOI 10.1073/pnas.85.13.4638; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	39	42	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					320	328		10.1074/jbc.M007096200	http://dx.doi.org/10.1074/jbc.M007096200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11013250	hybrid			2022-12-25	WOS:000166280700044
J	Harrington, RH; Sharma, A				Harrington, RH; Sharma, A			Transcription factors recognizing overlapping C1-A2 binding sites positively regulate insulin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CELL LINE; NF-KAPPA-B; HOMEODOMAIN PROTEIN; TRANSGENIC MICE; II GENE; PANCREATIC MESENCHYME; GLUCOSE-CONCENTRATION; CHRONIC EXPOSURE; CONTROL ELEMENT; ISLET CELLS	Transcription factors binding the insulin enhancer region, RIPE3b, mediate beta -cell type-specific and glucose-responsive expression of the insulin gene. Earlier studies demonstrate that activator present in the beta -cell-specific RIPE3b1-binding complex is critical for these actions. The DNA binding activity of the RIPE3b1 activator is induced in response to glucose stimulation and is inhibited under glucotoxic conditions. The C1 element within the RIPE3b region has been implicated as the binding site for RIPE3b1 activator. The RTPE3b region also contains an additional element, A2, which shares homology with the A elements in the insulin enhancer. Transcription factors (PDX-1 and HNF-1 alpha) binding to A elements are critical regulators of insulin gene expression and/or pancreatic development. Hence, to understand the roles of C1 and A2 elements in regulating insulin gene expression, we have systematically mutated the RIPE3b region and analyzed the effect of these mutations on gene expression. Our results demonstrate that both C1 and A2 elements together constitute the binding site for the RIPE3b1 activator, In addition to C1-A2 (RIPE3b) binding complexes, three binding complexes that specifically recognize A2 elements are found in nuclear extracts from insulinoma cell lines; the A2.2 complex is detected only in insulin-producing cell lines. Furthermore, two base pairs in the A2 element were critical for binding of both RIPE3b1 and A2.2 activators. Transient transfection results indicate that both C1-A2 and A2-specific binding activators cooperatively activate insulin gene expression. In addition, RIPE3b1- and A2-specific activators respond differently to glucose, suggesting that their overlapping binding specificity and functional cooperation may play an important role in regulating insulin gene expression.	Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Sharma, A (corresponding author), Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, 1 Joslin Pl, Boston, MA 02215 USA.				NIDDK NIH HHS [DK-36836] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Behre G, 1999, BIOTECHNIQUES, V26, P24, DOI 10.2144/99261bm03; Bennett BL, 1997, J BIOL CHEM, V272, P10212; BOAM DSW, 1990, J BIOL CHEM, V265, P8285; CROWE DT, 1989, MOL CELL BIOL, V9, P1784, DOI 10.1128/MCB.9.4.1784; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; DANDOYDRON F, 1991, NUCLEIC ACIDS RES, V19, P4925, DOI 10.1093/nar/19.18.4925; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EFRAT S, 1991, J BIOL CHEM, V266, P11141; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P3576, DOI 10.1073/pnas.92.8.3576; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HWUNG YP, 1990, MOL CELL BIOL, V10, P1784, DOI 10.1128/MCB.10.4.1784; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; Lu M, 1997, J BIOL CHEM, V272, P28349, DOI 10.1074/jbc.272.45.28349; MACFARLANE WM, 1994, BIOCHEM J, V303, P625, DOI 10.1042/bj3030625; Matsukura S, 1999, J IMMUNOL, V163, P6876; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Odagiri H, 1996, J BIOL CHEM, V271, P1909, DOI 10.1074/jbc.271.4.1909; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OHLSSON H, 1991, MOL ENDOCRINOL, V5, P897, DOI 10.1210/mend-5-7-897; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; OLSON LK, 1995, P NATL ACAD SCI USA, V92, P9127, DOI 10.1073/pnas.92.20.9127; OLSON LK, 1993, J CLIN INVEST, V92, P514, DOI 10.1172/JCI116596; Peshavaria M, 1997, MOL CELL BIOL, V17, P3987, DOI 10.1128/MCB.17.7.3987; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; PEYTON M, 1994, J BIOL CHEM, V269, P25936; PLLIZZARI L, 1997, FEBS LETT, V407, P320; Poitout V, 1996, J CLIN INVEST, V97, P1041, DOI 10.1172/JCI118496; Raychowdhury R, 1999, J BIOL CHEM, V274, P20961, DOI 10.1074/jbc.274.30.20961; ROBINSON GLWG, 1994, J BIOL CHEM, V269, P2452; RUDNICK A, 1994, P NATL ACAD SCI USA, V91, P12203, DOI 10.1073/pnas.91.25.12203; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sharma A, 1999, DIABETES, V48, P507, DOI 10.2337/diabetes.48.3.507; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1468, DOI 10.1210/me.9.11.1468; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1127, DOI 10.1210/me.9.9.1127; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; SHIEH SY, 1995, J BIOL CHEM, V270, P21503, DOI 10.1074/jbc.270.37.21503; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; STEIN R, 1993, TRENDS ENDOCRIN MET, V4, P96, DOI 10.1016/1043-2760(93)90086-T; Stellrecht CMM, 1997, J BIOL CHEM, V272, P3567, DOI 10.1074/jbc.272.6.3567; Sussel L, 1998, DEVELOPMENT, V125, P2213; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; Thomas MA, 1999, EUR J BIOCHEM, V265, P300, DOI 10.1046/j.1432-1327.1999.00732.x; Tomonari A, 1996, DIABETOLOGIA, V39, P1462, DOI 10.1007/s001250050599; Weiler S, 1998, J BIOL CHEM, V273, P10994, DOI 10.1074/jbc.273.18.10994; WHELAN J, 1990, MOL CELL BIOL, V10, P1564, DOI 10.1128/MCB.10.4.1564; Xiao S, 1999, EUR J IMMUNOL, V29, P3456, DOI 10.1002/(SICI)1521-4141(199911)29:11<3456::AID-IMMU3456>3.3.CO;2-2; Zangen DH, 1997, DIABETES, V46, P258, DOI 10.2337/diabetes.46.2.258; Zhao L, 2000, J BIOL CHEM, V275, P10532, DOI 10.1074/jbc.275.14.10532	67	22	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					104	113		10.1074/jbc.M008415200	http://dx.doi.org/10.1074/jbc.M008415200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024035	hybrid			2022-12-25	WOS:000166280700016
J	Haurie, V; Perrot, M; Mini, T; Jeno, P; Sagliocco, F; Boucherie, H				Haurie, V; Perrot, M; Mini, T; Jeno, P; Sagliocco, F; Boucherie, H			The transcriptional activator Cat8p provides a major contribution to the reprogramming of carbon metabolism during the diauxic shift in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA; GLUCONEOGENIC ENZYMES; PROTEIN-SYNTHESIS; GENE-EXPRESSION; HEAT-SHOCK; YEAST; IDENTIFICATION; DEREPRESSION; TRANSPORTER; REPRESSION	In yeast, the transition between the fermentative and the oxidative metabolism, called the diauxic shift, is associated with major changes in gene expression and protein synthesis. The zinc cluster protein Cat8p is required for the derepression of nine genes under nonfermentative growth conditions (ACS1, FBP1, ICL1, IDP2, JEN1, MLS1, PCK1, SFCI, and SIP4). To investigate whether the transcriptional control mediated by Cat8p can be extended to other genes and whether this control is the main control for the changes in the synthesis of the respective proteins during the adaptation to growth on ethanol, we analyzed the transcriptome and the proteome of a cat8 Delta strain during the diauxic shift. In this report, we demonstrate that, in addition to the nine genes known as Cat8p-dependent, there are 25 other genes or open reading frames whose expression at the diauxic shift is altered in the absence of Cat8p, For all of the genes characterized here, the Cat8p-dependent control results in a parallel alteration in mRNA and protein synthesis. It appears that the biochemical functions of the proteins encoded by Cat8p-dependent genes are essentially related to the first steps of ethanol utilization, the glyogylate cycle, and gluconeogenesis. Interestingly, no function involved in the tricarboxylic cycle and the oxidative phosphorylation seems to be controlled by Cat8p.	Inst Biochim & Genet Cellulaires, UMR 5095, Bordeaux, France; Univ Basel, Biozentrum, Dept Biochem, CH-4056 Basel, Switzerland	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; University of Basel	Sagliocco, F (corresponding author), Inst Biochim & Genet Cellulaires, UMR 5095, Bordeaux, France.							BATAILLE N, 1991, YEAST, V7, P367, DOI 10.1002/yea.320070407; Bojunga N, 1998, MOL GEN GENET, V260, P453, DOI 10.1007/s004380050916; Bojunga N, 1999, MOL GEN GENET, V262, P869, DOI 10.1007/s004380051152; BOUCHERIE H, 1995, YEAST, V11, P601, DOI 10.1002/yea.320110702; Boy-Marcotte E, 1998, J BACTERIOL, V180, P1044, DOI 10.1128/JB.180.5.1044-1052.1998; BoyMarcotte E, 1996, MICROBIOL-UK, V142, P459, DOI 10.1099/13500872-142-3-459; Carlson M, 1998, CURR OPIN GENET DEV, V8, P560, DOI 10.1016/S0959-437X(98)80011-7; Casal M, 1999, J BACTERIOL, V181, P2620, DOI 10.1128/JB.181.8.2620-2623.1999; Caspary F, 1997, MOL GEN GENET, V255, P619, DOI 10.1007/s004380050536; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DEWINDE JH, 1993, PROG NUCLEIC ACID RE, V46, P51, DOI 10.1016/S0079-6603(08)61018-1; ENTIAN KD, 1997, YEAST SUGAR METABOLI, P409; FERNANDEZ M, 1994, MOL GEN GENET, V242, P727; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; HEDGES D, 1995, MOL CELL BIOL, V15, P1915; Kal AJ, 1999, MOL BIOL CELL, V10, P1859, DOI 10.1091/mbc.10.6.1859; Karpichev IV, 1998, MOL CELL BIOL, V18, P6560, DOI 10.1128/MCB.18.11.6560; Kratzer S, 1997, MOL MICROBIOL, V26, P631, DOI 10.1046/j.1365-2958.1997.5611937.x; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LINDQUIST S, 1981, NATURE, V293, P311, DOI 10.1038/293311a0; Liu ZC, 1999, MOL CELL BIOL, V19, P6720; Lodi T, 1999, MOL GEN GENET, V262, P623, DOI 10.1007/s004380051125; MILLER MJ, 1979, P NATL ACAD SCI USA, V76, P5222, DOI 10.1073/pnas.76.10.5222; Palmieri L, 1999, FEBS LETT, V462, P472, DOI 10.1016/S0014-5793(99)01555-0; Perrot M, 1999, ELECTROPHORESIS, V20, P2280, DOI 10.1002/(SICI)1522-2683(19990801)20:11<2280::AID-ELPS2280>3.3.CO;2-H; Rahner A, 1999, MOL MICROBIOL, V34, P146, DOI 10.1046/j.1365-2958.1999.01588.x; Rahner A, 1996, NUCLEIC ACIDS RES, V24, P2331, DOI 10.1093/nar/24.12.2331; RandezGil F, 1997, MOL CELL BIOL, V17, P2502, DOI 10.1128/MCB.17.5.2502; RONNE H, 1995, TRENDS GENET, V11, P12, DOI 10.1016/S0168-9525(00)88980-5; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMALIX W, 1993, J BIOL CHEM, V268, P27428; TU J, 1995, EMBO J, V14, P6789; Tzschoppe K, 1999, YEAST, V15, P1645, DOI 10.1002/(SICI)1097-0061(199911)15:15<1645::AID-YEA491>3.0.CO;2-G; van Roermund CWT, 1999, EMBO J, V18, P5843, DOI 10.1093/emboj/18.21.5843; Vincent O, 1998, EMBO J, V17, P7002, DOI 10.1093/emboj/17.23.7002; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C	36	121	124	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					76	85		10.1074/jbc.M008752200	http://dx.doi.org/10.1074/jbc.M008752200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024040	hybrid			2022-12-25	WOS:000166280700012
J	Sasai, K; Ikeda, Y; Tsuda, T; Ihara, H; Korekane, H; Shiota, K; Taniguchi, N				Sasai, K; Ikeda, Y; Tsuda, T; Ihara, H; Korekane, H; Shiota, K; Taniguchi, N			The critical role of the stem region as a functional domain responsible for the oligomerization and Golgi localization of N-acetylglucosaminyltransferase V - The involvement of a domain homophilic interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYL-TRANSPEPTIDASE; SECONDARY-STRUCTURE; CDNA CLONING; TRANSFERASE TRANSPEPTIDASE; KIN RECOGNITION; HELA-CELLS; PROTEIN; EXPRESSION; SEQUENCE; OLIGOSACCHARIDES	We demonstrated that a region in the stem of N-acetyl- glucosaminyltransferase V (GnT-V), a Golgi resident protein, is not required for enzyme activity but serves as functional domain, responsible for intracellular localization. Deletion of the domain led to complete retention of the kinetic properties but resulted in the cell surface localization of the enzyme as well as its efficient secretion into the medium. The lack of this domain concomitantly abolished the disulfide-mediated oligomerization of GnT-V, which appears to confer the Golgi retention. When the domain was inserted into the stem region of a cell surface-localized type II membrane protein, the resulting chimeric protein was substantially oligomerized and predominantly localized in the intracellular organelle, Furthermore, it was found that the presence of this domain is exclusively responsible for homo-oligomer formation. This homophilic interaction appears to involve a hydrophobic cluster of residues in the alpha -helix of the domain, as indicated by secondary structure predictions. These findings suggest that the domain specifically participates in the Golgi retention of GnT-V, probably via inducing homo-oligomer formation, and would also provide a possible mechanism for the oligomerization, which is critical for localization in the Golgi.	Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Univ Tokyo, Dept Anim Resource Sci, Lab Cellular Biochem, Bunkyo Ku, Tokyo 1138657, Japan	Osaka University; University of Tokyo	Taniguchi, N (corresponding author), Osaka Univ, Sch Med, Dept Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	proftani@biochem.med.osaka-u.ac.jp	Sasai, Kazumi/GLV-2527-2022; Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968; Ihara, Hideyuki/0000-0003-0490-6355				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen C, 2000, J BIOL CHEM, V275, P13819, DOI 10.1074/jbc.275.18.13819; CHEN L, 1995, GLYCOCONJUGATE J, V12, P813, DOI 10.1007/BF00731243; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1989, CANCER RES, V49, P945; EARL PL, 1991, J VIROL, V65, P2047, DOI 10.1128/JVI.65.4.2047-2055.1991; GARDELL SJ, 1979, J BIOL CHEM, V254, P4942; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; IKEDA Y, 1993, J BIOL CHEM, V268, P3980; IKEDA Y, 1995, J BIOL CHEM, V270, P22223, DOI 10.1074/jbc.270.38.22223; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; LUTHY R, 1991, PROTEINS, V10, P229, DOI 10.1002/prot.340100307; MASIBAY AS, 1993, J BIOL CHEM, V268, P9908; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; Nagai K, 1997, GLYCOBIOLOGY, V7, P769, DOI 10.1093/glycob/7.6.769; NASH B, 1982, J BIOL CHEM, V257, P585; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; Nilsson T, 1996, J CELL SCI, V109, P1975; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; Opat AS, 2000, J BIOL CHEM, V275, P11836, DOI 10.1074/jbc.275.16.11836; PIERCE M, 1987, BIOCHEM BIOPH RES CO, V146, P679, DOI 10.1016/0006-291X(87)90582-1; Pierce M, 1997, GLYCOCONJUGATE J, V14, P623, DOI 10.1023/A:1018592627696; Poumbourios P, 1997, J VIROL, V71, P2041, DOI 10.1128/JVI.71.3.2041-2049.1997; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; Seberger PJ, 1999, GLYCOBIOLOGY, V9, P235, DOI 10.1093/glycob/9.3.235; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; Taniguchi N, 1999, BBA-MOL BASIS DIS, V1455, P287, DOI 10.1016/S0925-4439(99)00066-6; TANIGUCHI N, 1985, CANCER RES, V45, P5835; TANIGUCHI N, 1989, METHOD ENZYMOL, V179, P397; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580	37	41	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					759	765		10.1074/jbc.M004972200	http://dx.doi.org/10.1074/jbc.M004972200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024048	hybrid			2022-12-25	WOS:000166280700102
J	Pleschke, JM; Kleczkowska, HE; Strohm, M; Althaus, FR				Pleschke, JM; Kleczkowska, HE; Strohm, M; Althaus, FR			Poly(ADP-ribose) binds to specific domains in DNA damage checkpoint proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CYCLIN-DEPENDENT KINASES; BASE EXCISION-REPAIR; MAMMALIAN-CELLS; KU AUTOANTIGEN; XRCC1 PROTEIN; POLYMERASE; P21; APOPTOSIS; INHIBITOR	Poly(ADP-ribose) is formed in possibly all multicellular organisms by a familiy of poly(ADP-ribose) polymerases (PARPs). PARP-1, the best understood and until recently the only known member of this family, is a DNA damage signal protein catalyzing its automodification with multiple, variably sized ADP-ribose polymers that may contain up to 200 residues and several branching points. Through these polymers, PARP-1 can interact noncovalently with other proteins and alter their functions. Here we report the discovery of a poly(ADP-ribose)-binding sequence motif in several important DNA damage checkpoint proteins. The 20-amino acid motif contains two conserved regions: (i) a cluster rich in basic amino acids and (ii) a pattern of hydrophobic amino acids interspersed with basic residues. Using a combination of alanine scanning, polymer blot analysis, and photoaffinity labeling, we have identified poly(ADP-ribose)-binding sites in the following proteins: p53, p21(CIP1/WAF1) xeroderma pigmentosum group A complementing protein, MSH6, DNA ligase III, XRCC1, DNA polymerase epsilon, DNA-PKCS, Ku70, NF-kappaB, inducible nitric-oxide synthase , caspase-activated DNase, and telomerase. The poly(ADP-ribose)-binding motif was found to overlap with five important functional domains responsible for (i) protein-protein interactions, (ii) DNA binding, (iii) nuclear localization, (iv) nuclear export, and (v) protein degradation. Thus, PARPs may target specific signal network proteins via poly(ADP-ribose) and regulate their domain functions.	Univ Zurich, Inst Pharmacol & Toxicol, Tierspital, CH-8057 Zurich, Switzerland	University of Zurich	Althaus, FR (corresponding author), Univ Zurich, Inst Pharmacol & Toxicol, Tierspital, Winterthurerstr 260, CH-8057 Zurich, Switzerland.	fra@vetpharm.unizh.ch						Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Berghammer H, 1999, FEBS LETT, V449, P259, DOI 10.1016/S0014-5793(99)00448-2; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Bryan TM, 1999, CURR OPIN CELL BIOL, V11, P318, DOI 10.1016/S0955-0674(99)80043-X; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Greider CW, 1999, TRENDS GENET, V15, P109, DOI 10.1016/S0168-9525(98)01681-3; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; HARPER JW, 1993, CELL, V75, P805; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; HAUSCHILDT S, 1992, BIOCHEM J, V288, P255, DOI 10.1042/bj2880255; HUPPI K, 1994, ONCOGENE, V9, P3017; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Inohara N, 1999, J BIOL CHEM, V274, P270, DOI 10.1074/jbc.274.1.270; Jacobson MK, 1999, TRENDS BIOCHEM SCI, V24, P415, DOI 10.1016/S0968-0004(99)01481-4; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kickhoefer VA, 1996, TRENDS CELL BIOL, V6, P174, DOI 10.1016/0962-8924(96)10014-3; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; KIEHLBAUCH CC, 1993, ANAL BIOCHEM, V208, P26, DOI 10.1006/abio.1993.1004; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Malanga M, 1998, BBA-GENE STRUCT EXPR, V1399, P154, DOI 10.1016/S0167-4781(98)00110-9; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; MASUTANI M, 1995, BIOCHIMIE, V77, P462, DOI 10.1016/0300-9084(96)88161-2; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; Oei SL, 2000, J BIOL CHEM, V275, P23234, DOI 10.1074/jbc.M002429200; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; PANZETER PL, 1992, BIOCHEMISTRY-US, V31, P1379, DOI 10.1021/bi00120a014; PANZETER PL, 1993, J BIOL CHEM, V268, P17662; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; Sallmann FR, 2000, J BIOL CHEM, V275, P15504, DOI 10.1074/jbc.275.20.15504; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; SATOH MS, 1993, J BIOL CHEM, V268, P5480; Schmitz AAP, 1998, BIOCHEMISTRY-US, V37, P9520, DOI 10.1021/bi973063b; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Wakasugi M, 1999, J BIOL CHEM, V274, P18759, DOI 10.1074/jbc.274.26.18759; Wu XT, 1996, MOL CELL BIOL, V16, P5186; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	61	425	440	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40974	40980		10.1074/jbc.M006520200	http://dx.doi.org/10.1074/jbc.M006520200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11016934	hybrid			2022-12-25	WOS:000166114600043
J	Shen, Q; Subauste, JS				Shen, Q; Subauste, JS			Dimerization interfaces of v-ErbA homodimers and heterodimers with retinoid X receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; DOMINANT-NEGATIVE ACTIVITY; AVIAN ERYTHROBLASTOSIS VIRUS; DNA-BINDING SPECIFICITY; DIRECT REPEATS; LIGAND-BINDING; TARGET GENES; RXR; ACID; DOMAIN	The oncoprotein v-ErbA, a member of the zinc finger transcription factor superfamily, is a mutated version of thyroid hormone receptor al that is virtually incapable of binding T3. v-ErbA and other members of this family can bind as homodimers and heterodimers with retinoid X receptors to specific DNA sequences arranged as direct, inverted, or everted repeats. At least two regions in the C-terminal domain, the I box (10 and 11 helices in v-ErbA and thyroid hormone receptors) and the 20-amino acid region are involved in dimerization. However, it has not been entirely understood how these receptors dimerize on differently oriented core motifs and whether the domain(s) responsible for homodimerization and heterodimerization are identical. Therefore, deletions of the entire 20-amino acid region, the 10 helix, the 11 helix, and point mutations within these regions of v-ErbA were made by site-directed mutagenesis. The mutant proteins were tested for their ability to form v-ErbA homodimers and heterodimers with retinoid X receptor Lu on differently oriented core motifs by electrophoretic mobility shift assay. Transient transfections were performed to determine the dominant negative activity of the v-ErbA mutants. The data indicate that different dimerization interfaces are used for v-ErbA homodimerization and heterodimerization with retinoid X receptor alpha, and different dimerization interfaces are used on differently oriented core motifs. The data are of:general interest because the information improves our understanding of the role of these dimerization interfaces in the mechanism of action not only of v-ErbA but also of other members of the superfamily.	GV Montgomery Vet Adm Med Ctr, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Div Endocrinol & Metab, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center	Subauste, JS (corresponding author), GV Montgomery Vet Adm Med Ctr, R&E Bldg,Rm 422,1500 E Woodrow Wilson Blvd, Jackson, MS 39216 USA.							AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Busch K, 2000, MOL ENDOCRINOL, V14, P201, DOI 10.1210/me.14.2.201; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEBUIRE B, 1984, SCIENCE, V224, P1456, DOI 10.1126/science.6328658; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Gothe S, 1999, GENE DEV, V13, P1329, DOI 10.1101/gad.13.10.1329; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; Hadzic E, 1998, J BIOL CHEM, V273, P10270, DOI 10.1074/jbc.273.17.10270; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; NAGAYA T, 1992, J BIOL CHEM, V267, P13014; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; ODONNELL AL, 1990, MOL ENDOCRINOL, V4, P715, DOI 10.1210/mend-4-5-715; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; PIEDRAFITA FJ, 1995, MOL ENDOCRINOL, V9, P563, DOI 10.1210/me.9.5.563; PROST E, 1988, NUCLEIC ACIDS RES, V16, P6248, DOI 10.1093/nar/16.13.6248; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; Reginato MJ, 1996, J BIOL CHEM, V271, P28199, DOI 10.1074/jbc.271.45.28199; ROSEN ED, 1993, J BIOL CHEM, V268, P11534; Safer JD, 1998, J BIOL CHEM, V273, P30175, DOI 10.1074/jbc.273.46.30175; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SUBAUSTE JS, 1995, J BIOL CHEM, V270, P7957, DOI 10.1074/jbc.270.14.7957; SUBAUSTE JS, 1994, J BIOL CHEM, V269, P30232; Subauste JS, 1998, MOL ENDOCRINOL, V12, P1380, DOI 10.1210/me.12.9.1380; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Yang YZ, 1996, J BIOL CHEM, V271, P28235, DOI 10.1074/jbc.271.45.28235; YEN PM, 1994, J BIOL CHEM, V269, P903; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; Zhao Q, 2000, J MOL BIOL, V296, P509, DOI 10.1006/jmbi.1999.3457	42	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41018	41027		10.1074/jbc.M006111200	http://dx.doi.org/10.1074/jbc.M006111200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018031	hybrid			2022-12-25	WOS:000166114600050
J	Suzuma, K; Naruse, K; Suzuma, I; Takahara, N; Ueki, K; Aiello, LP; King, GL				Suzuma, K; Naruse, K; Suzuma, I; Takahara, N; Ueki, K; Aiello, LP; King, GL			Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-Akt-dependent pathways in retinal vascular cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FACTOR GENE-EXPRESSION; ANGIOGENESIS IN-VIVO; GLUCOSE-TRANSPORT; INSULIN STIMULATION; RECOMBINANT ADENOVIRUSES; DIABETIC-RETINOPATHY; FLK-1/KDR ACTIVATION; SIGNAL-TRANSDUCTION; TYROSINE KINASE	Fibroblastic proliferation accompanies many angiogenesis-related retinal and systemic diseases. Since connective tissue growth factor (CTGF) is a potent mitogen for fibrosis, extracellular matrix production, and angiogenesis, we have studied the effects and mechanism by which vascular endothelial growth factor (VEGF) regulates CTGF gene expression in retinal capillary cells. In our study, VEGF increased CTGF mRNA levels in a time and concentration-dependent manner in bovine retinal endothelial cells and pericytes, without the need of new protein synthesis and without altering mRNA stability. VEGF activated the tyrosine receptor phosphorylation of KDR and Flt1 and increased the binding of phosphatidylinositol 3-kinase (PIS-kinase) p85 subunit to KDR and Flt1, both of which could mediate CTGF gene induction. VEGF-induced CTGF expression was mediated primarily by PI3-kinase activation, whereas PKC and ERK pathways made only minimal contributions. Furthermore, overexpression of constitutive active Akt was sufficient to induce CTGF gene expression, and inhibition of Akt activation by overexpressing dominant negative mutant of Akt abolished the VEGF-induced CTGF expression. These data suggest that VEGF can increase CTGF gene expression in bovine retinal capillary cells via KDR or Fit receptors and the activation of PI3-kinase-Akt pathway independently of PKC or Ras-ERK pathway, possibly inducing the fibrosis observed in retinal neovascular diseases.	Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	King, GL (corresponding author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.		Sokabe, Masahiro/I-1565-2012		NEI NIH HHS [EY5110] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Aiello LP, 1998, DIABETES CARE, V21, P143, DOI 10.2337/diacare.21.1.143; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Boes M, 1999, ENDOCRINOLOGY, V140, P1575, DOI 10.1210/en.140.4.1575; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Dammeier J, 1998, J BIOL CHEM, V273, P18185, DOI 10.1074/jbc.273.29.18185; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Firestein GS, 1999, J CLIN INVEST, V103, P3, DOI 10.1172/JCI5929; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Joukov V, 1996, EMBO J, V15, P290; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; KING GL, 1985, J CLIN INVEST, V75, P1028, DOI 10.1172/JCI111764; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Kuboki K, 2000, CIRCULATION, V101, P676, DOI 10.1161/01.CIR.101.6.676; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Murphy M, 1999, J BIOL CHEM, V274, P5830, DOI 10.1074/jbc.274.9.5830; NAYAK RC, 1988, J EXP MED, V167, P1003, DOI 10.1084/jem.167.3.1003; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Oemar BS, 1997, CIRCULATION, V95, P831; PARK JE, 1994, J BIOL CHEM, V269, P25646; Park JY, 2000, DIABETES, V49, P1239, DOI 10.2337/diabetes.49.7.1239; Pendurthi UR, 2000, J BIOL CHEM, V275, P14632, DOI 10.1074/jbc.275.19.14632; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; Ricupero DA, 2000, J BIOL CHEM, V275, P12475, DOI 10.1074/jbc.275.17.12475; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Standaert ML, 1999, J BIOL CHEM, V274, P25308, DOI 10.1074/jbc.274.36.25308; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Takagi H, 1996, DIABETES, V45, P1016, DOI 10.2337/diabetes.45.8.1016; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Wellner M, 1999, ARTERIOSCL THROM VAS, V19, P178, DOI 10.1161/01.ATV.19.1.178; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006	65	204	223	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40725	40731		10.1074/jbc.M006509200	http://dx.doi.org/10.1074/jbc.M006509200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018037	Green Published, hybrid			2022-12-25	WOS:000166114600011
J	van Breukelen, B; Kanellopoulos, PN; Tucker, PA; van der Vliet, PC				van Breukelen, B; Kanellopoulos, PN; Tucker, PA; van der Vliet, PC			The formation of a flexible DNA-binding protein chain is required for efficient DNA unwinding and adenovirus DNA chain elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; HELIX-DESTABILIZING PROPERTIES; STRANDED-DNA; REPLICATION INVITRO; COMPLEX; POLYMERASE; INITIATION; MECHANISM; VITRO; DISSOCIATION	The adenovirus DNA-binding protein (DBP) binds co-operatively to single-stranded DNA (ssDNA) and stimulates both initiation and elongation of DNA replication. DBP consists of a globular core domain and a C-terminal arm that hooks onto a neighboring DBP molecule to form a stable protein chain with the DNA bound to the internal surface of the chain. This multimerization is the driving force for ATP-independent DNA unwinding by DBP during elongation. As shown by x-ray diffraction of different crystal forms of the C-terminal domain, the C-terminal arm can adopt different conformations, leading to flexibility in the protein chain. This flexibility is a function of the hinge region, the part of the protein joining the C-terminal arm to the protein core. To investigate the function of the flexibility, proline residues were introduced in the hinge region, and the proteins were purified to homogeneity after baculovirus expression. The mutant proteins were still able to bind ss- and double-stranded DNA with approximately the same affinity as wild type, and the binding to ssDNA was found to be cooperative. All mutant proteins were able to stimulate the initiation of DNA replication to near wild type levels. However, the proline mutants could not support elongation of DNA replication efficiently. Even the elongation up to 26 nucleotides was severely impaired. This defect was also seen when DNA unwinding was studied. Binding studies of DBP to homo-oligonucleotides showed an inability of the proline mutants to bind to poly(dA)(40), indicating an inability to adapt to specific DNA conformations. Our data suggest that the flexibility of the protein chain formed by DBP is important in binding and unwinding of DNA during adenovirus DNA replication. A model explaining the need for flexibility of the C-terminal arm is proposed.	Univ Utrecht, Med Ctr, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; DESY, European Mol Biol Lab, D-22603 Hamburg, Germany	Utrecht University; Utrecht University; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	van der Vliet, PC (corresponding author), Univ Weg 100, NL-3584 CG Utrecht, Netherlands.	p.c.vandervliet@med.uu.nl						ANDERSON CW, 1983, J VIROL, V48, P31, DOI 10.1128/JVI.48.1.31-39.1983; ARIGA H, 1980, VIROLOGY, V101, P307, DOI 10.1016/0042-6822(80)90510-3; BOSHER J, 1990, New Biologist, V2, P1083; CHEN M, 1990, J BIOL CHEM, V265, P18634; CLEAT PH, 1989, EMBO J, V8, P1841, DOI 10.1002/j.1460-2075.1989.tb03579.x; CLEGHON V, 1989, J VIROL, V63, P2289, DOI 10.1128/JVI.63.5.2289-2299.1989; COENJAERTS FEJ, 1994, NUCLEIC ACIDS RES, V22, P5235, DOI 10.1093/nar/22.24.5235; de Jong RN, 1999, GENE, V236, P1, DOI 10.1016/S0378-1119(99)00249-8; Dekker J, 1997, EMBO J, V16, P1455, DOI 10.1093/emboj/16.6.1455; Dekker J, 1996, MOL CELL BIOL, V16, P4073; Dekker J, 1998, J MOL BIOL, V277, P825, DOI 10.1006/jmbi.1998.1652; Dekker Joe, 1996, P269; FRIEFELD BR, 1983, VIROLOGY, V124, P380, DOI 10.1016/0042-6822(83)90354-9; Harfst E, 1999, VIRUS GENES, V18, P97, DOI 10.1023/A:1008009630695; Hay R T, 1995, Curr Top Microbiol Immunol, V199 ( Pt 2), P31; KANELLOPOULOS PN, 1995, J STRUCT BIOL, V115, P113, DOI 10.1006/jsbi.1995.1035; Kanellopoulos PN, 1996, J MOL BIOL, V257, P1, DOI 10.1006/jmbi.1996.0141; KING AJ, 1994, EMBO J, V13, P5786, DOI 10.1002/j.1460-2075.1994.tb06917.x; King AJ, 1997, J BIOL CHEM, V272, P24617, DOI 10.1074/jbc.272.39.24617; KUIL ME, 1989, BIOCHEMISTRY-US, V28, P9795, DOI 10.1021/bi00451a038; LINDENBAUM JO, 1986, J BIOL CHEM, V261, P218; MONAGHAN A, 1994, NUCLEIC ACIDS RES, V22, P742, DOI 10.1093/nar/22.5.742; MUL YM, 1993, NUCLEIC ACIDS RES, V21, P641, DOI 10.1093/nar/21.3.641; NICOLAS JC, 1983, VIROLOGY, V126, P228, DOI 10.1016/0042-6822(83)90474-9; PRONK R, 1994, FEBS LETT, V337, P33, DOI 10.1016/0014-5793(94)80624-1; RUBENSTEIN FE, 1974, INTERVIROLOGY, V3, P170, DOI 10.1159/000149753; STUIVER MH, 1990, J VIROL, V64, P379, DOI 10.1128/JVI.64.1.379-386.1990; TSERNOGLOU D, 1985, FEBS LETT, V188, P248, DOI 10.1016/0014-5793(85)80381-1; TUCKER PA, 1994, EMBO J, V13, P2994, DOI 10.1002/j.1460-2075.1994.tb06598.x; Van der Vliet P C, 1995, Curr Top Microbiol Immunol, V199 ( Pt 2), P1; VANAMERONGEN H, 1987, BIOCHEMISTRY-US, V26, P4646, DOI 10.1021/bi00389a009; VERRIJZER CP, 1990, GENE DEV, V4, P1964, DOI 10.1101/gad.4.11.1964; ZIJDERVELD DC, 1994, J VIROL, V68, P8288, DOI 10.1128/JVI.68.12.8288-8295.1994; ZIJDERVELD DC, 1993, NUCLEIC ACIDS RES, V21, P2591, DOI 10.1093/nar/21.11.2591; ZIJDERVELD DC, 1994, J VIROL, V68, P1158, DOI 10.1128/JVI.68.2.1158-1164.1994	35	16	16	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40897	40903		10.1074/jbc.M005745200	http://dx.doi.org/10.1074/jbc.M005745200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11016931	hybrid			2022-12-25	WOS:000166114600032
J	Wei, LN; Hu, XL; Chandra, D; Seto, E; Farooqui, M				Wei, LN; Hu, XL; Chandra, D; Seto, E; Farooqui, M			Receptor-interacting protein 140 directly recruits histone deacetylases for gene silencing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; LIGAND-BINDING; NUCLEAR; COREPRESSOR; ACTIVATION; COMPLEX; YEAST; REPRESSION; MECHANISM	Receptor-interacting protein 140 (RIP140) encodes a histone deacetylase (HDAC) inhibitor-sensitive repressive activity. Direct interaction of RIP140 with HDAC1 and HDAC3 occurs in vitro and in vivo as demonstrated in co-immunoprecipitation and glutathione S-transferase pull-down experiments. The HDAC-interacting domain of RIP140 is mapped to its N-terminal domain, between amino acids 78 and 303 based upon glutathione S-transferase pull-down experiments. In chromatin immunoprecipitation assays, it is demonstrated that histone deacetylation occurs at the chromatin region of the Ga14 binding sites as a result of Ga14 DNA binding domain-tethered RIP expression. The immunocomplexes of RIP140 from cells transfected with RIP140 and HDAC are able to deacetylate histone proteins in vitro. This study presents the first evidence for RIP140 as a negative coregulator for nuclear receptor actions by directly recruiting histone deacetylases and categorizes RIP140 as a novel negative coregulator that is able to directly interact with HDACs.	Univ Minnesota, Dept Pharmacol, Sch Med, Minneapolis, MN 55455 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	University of Minnesota System; University of Minnesota Twin Cities; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Wei, LN (corresponding author), Univ Minnesota, Dept Pharmacol, Sch Med, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	weixx009@maroon.tc.umn.edu		Farooqui, Mariya/0000-0002-2136-8694; Chandra, Dhyan/0000-0001-7272-9384	NIDDK NIH HHS [DK54733] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054733] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen WY, 2000, P NATL ACAD SCI USA, V97, P377, DOI 10.1073/pnas.97.1.377; Chuang FM, 1997, MOL ENDOCRINOL, V11, P1332, DOI 10.1210/me.11.9.1332; Dudley MW, 2000, P NATL ACAD SCI USA, V97, P3696, DOI 10.1073/pnas.040558197; Eng FCS, 1998, J BIOL CHEM, V273, P28371, DOI 10.1074/jbc.273.43.28371; Grant PA, 1999, METH MOL B, V119, P311; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Hampsey M, 1997, TRENDS GENET, V13, P427, DOI 10.1016/S0168-9525(97)01292-4; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kolle D, 1998, METHODS, V15, P323, DOI 10.1006/meth.1998.0636; Lee CH, 1999, J BIOL CHEM, V274, P31320, DOI 10.1074/jbc.274.44.31320; Lee CH, 1998, MOL CELL BIOL, V18, P6745, DOI 10.1128/MCB.18.11.6745; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Masuyama H, 1997, MOL ENDOCRINOL, V11, P1507, DOI 10.1210/me.11.10.1507; Miyata KS, 1998, MOL CELL ENDOCRINOL, V146, P69; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Subramaniam N, 1999, J BIOL CHEM, V274, P18121, DOI 10.1074/jbc.274.25.18121; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TURNER BM, 1991, J CELL SCI, V99, P13; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400	42	124	130	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40782	40787		10.1074/jbc.M004821200	http://dx.doi.org/10.1074/jbc.M004821200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11006275	hybrid			2022-12-25	WOS:000166114600018
J	Cain, C; Miller, S; Ahn, J; Prives, C				Cain, C; Miller, S; Ahn, J; Prives, C			The N terminus of p53 regulates its dissociation from DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; PHOSPHORYLATED IN-VITRO; TRANSCRIPTIONAL ACTIVATION; BINDING FUNCTION; MUTANT P53; MONOCLONAL-ANTIBODIES; IONIZING-RADIATION; GROWTH SUPPRESSION; KINASE-C; DOMAIN	It is important to gain insight into p53 DNA binding and how it is regulated. By using electrophoretic mobility shift assays and DNase I footprinting, we show that a region within the N terminus of the protein controls the dissociation of p53 from a p53-binding site. When p53 is bound by a number of N-terminal-specific monoclonal antibodies, its rate of dissociation from DNA is reduced, and its ability to protect a cognate site from DNase I digestion is increased. Moreover, greatly reduced dissociation is observed with p53 protein lacking the N-terminal 96 amino acids. By contrast, deletion of the C terminus does not affect p53 dissociation from DNA or DNase I protection. p53 protein expressed in and purified from bacterial cells displays markedly more instability on its consensus DNA-binding site than does p53 produced in insect cells, suggesting that post-translational modifications may affect the stability of the protein. Our results provide evidence that the N terminus of p53 possesses an auto-inhibitory function that is mechanistically different from the inhibitory region at the C terminus.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.				NATIONAL CANCER INSTITUTE [R01CA077742] Funding Source: NIH RePORTER; NCI NIH HHS [CA77742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABARZUA P, 1995, CANCER RES, V55, P3490; Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; BRAIN R, 1994, ONCOGENE, V9, P1775; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Fourie AM, 1997, J BIOL CHEM, V272, P19471, DOI 10.1074/jbc.272.31.19471; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hansen S, 1996, J BIOL CHEM, V271, P3917; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jayaraman L, 1997, METHOD ENZYMOL, V283, P245; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; JAYARAMAN L, 1995, CELL, V81, P10021; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEGROS Y, 1994, ONCOGENE, V9, P2071; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; Liu L, 1999, MOL CELL BIOL, V19, P1202; LIU X, 1995, MOL CELL BIOL, V15, P6474; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; Martinez JD, 1997, ONCOGENE, V14, P2511, DOI 10.1038/sj.onc.1201095; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Scolnick DM, 1997, CANCER RES, V57, P3693; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TRUANT R, 1993, J BIOL CHEM, V268, P2284; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; VOJTESEK B, 1995, ONCOGENE, V10, P389; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	89	44	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39944	39953		10.1074/jbc.M002509200	http://dx.doi.org/10.1074/jbc.M002509200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10993878	hybrid			2022-12-25	WOS:000166039500023
J	Hamano-Takaku, F; Iwama, T; Saito-Yano, S; Takaku, K; Monden, Y; Kitabatake, M; Soll, D; Nishimura, S				Hamano-Takaku, F; Iwama, T; Saito-Yano, S; Takaku, K; Monden, Y; Kitabatake, M; Soll, D; Nishimura, S			A mutant Escherichia coli tyrosyl-tRNA synthetase utilizes the unnatural amino acid azatyrosine more efficiently than tyrosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIES SPECIFICITY; GENETIC-CODE; PROTEIN; BINDING; AMINOACYLATION; CONVERSION; EVOLUTION; CELLS; YEAST; RAS	Alloproteins, proteins that contain unnatural amino acids, have immense potential in biotechnology and medicine, Although various approaches for alloprotein production exist, there is no satisfactory method to produce large quantities of alloproteins containing unnatural amino acids in specific positions. The tyrosine analogue azatyrosine, L-beta-(5-hydroxy-2-pyridyl)-alanine, can convert the ras-transformed phenotype to normal phenotype, presumably by its incorporation into cellular proteins. This provided the stimulus for isolation of a mutant tyrosyl-tRNA synthetase (TyrRS) capable of charging azatyrosine to tRNA. A plasmid library of randomly mutated Escherichia coli tyrS (encoding TyrRS) was made by polymerase chain reaction techniques. The desired TyrRS mutants were selected by screening for in vivo azatyrosine incorporation of E. coli cells transformed with the mutant tyrS plasmids. One of the clones thus isolated, R-6-A-7, showed a 17-fold higher in vivo activity for azatyrosine incorporation than wild-type TyrRS, The mutant tyrS gene contained a single point mutation resulting in replacement of phenylalanine by serine at position 130 in the protein. Structural modeling revealed that position 130 is located close to Asp(182) which directly interacts with tyrosyladenylate. Kinetic analysis of aminoacyl-tRNA formation by the wild-type and mutated F130S TyrRS enzymes showed that the specificity for azatyrosine, measured by the ratios of k(cat)/K-m for tyrosine and the analogue, increased from 17 to 36 as a result of the F130S mutation. Thus, the high discrimination against azatyrosine is significantly reduced in the mutant enzyme. These results suggest that utilization of F130S TyrRS for in vivo protein biosynthesis may lead to efficient production of azatyrosine-containing alloproteins.	Merck Res Labs, Banyu Tsukuba Res Inst, Tsukuba, Ibaraki 3002611, Japan; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Merck & Company; Yale University	Nishimura, S (corresponding author), Merck Res Labs, Banyu Tsukuba Res Inst, Okubo 3, Tsukuba, Ibaraki 3002611, Japan.	nismrasm@banyu.co.jp						Agou F, 1998, BIOCHEMISTRY-US, V37, P11309, DOI 10.1021/bi9805590; BARKER DG, 1982, FEBS LETT, V150, P419, DOI 10.1016/0014-5793(82)80781-3; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BUOROCORE V, 1972, J BIOL CHEM, V247, P4843; DOCTOR BP, 1966, COLD SPRING HARB SYM, V31, P543, DOI 10.1101/SQB.1966.031.01.070; FERSHT AR, 1980, BIOCHEMISTRY-US, V19, P5520, DOI 10.1021/bi00565a009; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; GAY GD, 1993, FEBS LETT, V318, P167, DOI 10.1016/0014-5793(93)80014-L; HAYASHI H, 1966, J MOL BIOL, V19, P161, DOI 10.1016/S0022-2836(66)80058-X; HOBEN P, 1985, METHOD ENZYMOL, V113, P55; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; IBBA M, 1994, BIOCHEMISTRY-US, V33, P7107, DOI 10.1021/bi00189a013; INOUYE S, 1975, CHEM PHARM BULL, V23, P2669; JAKES R, 1975, BIOCHEMISTRY-US, V14, P3344, DOI 10.1021/bi00686a009; Kigawa T, 1999, FEBS LETT, V442, P15, DOI 10.1016/S0014-5793(98)01620-2; KOHNO T, 1990, J BIOL CHEM, V265, P6931; KOIDE H, 1988, P NATL ACAD SCI USA, V85, P6237, DOI 10.1073/pnas.85.17.6237; Leung DW, 1989, TECHNIQUE, V1, P11; Liu DR, 1999, P NATL ACAD SCI USA, V96, P4780, DOI 10.1073/pnas.96.9.4780; LOWE DM, 1987, BIOCHEMISTRY-US, V26, P6038, DOI 10.1021/bi00393a014; Monden Y, 1996, ONCOL REP, V3, P625; Monden Y, 1996, ONCOL REP, V3, P33; MONDEN Y, 2000, ANN NY ACAD SCI, V886, P109; Sever S, 1996, BIOCHEMISTRY-US, V35, P32, DOI 10.1021/bi952103d; SHINDOOKADA N, 1989, MOL CARCINOGEN, V2, P159, DOI 10.1002/mc.2940020309; Sprinzl M., 1989, Nucleic Acids Research, V17, P1; TEMPEST DW, 1970, J GEN MICROBIOL, V64, P171, DOI 10.1099/00221287-64-2-171; Wakasugi K, 1998, EMBO J, V17, P297, DOI 10.1093/emboj/17.1.297	30	32	101	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40324	40328		10.1074/jbc.M003696200	http://dx.doi.org/10.1074/jbc.M003696200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11006270	hybrid			2022-12-25	WOS:000166039500072
J	Buch-Pedersen, MJ; Venema, K; Serrano, R; Palmgren, MG				Buch-Pedersen, MJ; Venema, K; Serrano, R; Palmgren, MG			Abolishment of proton pumping and accumulation in the E1P conformational state of a plant plasma membrane H+-ATPase by substitution of a conserved aspartyl residue in transmembrane segment 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE ALPHA-SUBUNIT; SARCOPLASMIC-RETICULUM; COORDINATING RESIDUES; RENAL NA,K-ATPASE; ESCHERICHIA-COLI; K+ IONS; DOMAIN; YEAST; CA2+-ATPASE; ASP(804)	The plasma membrane H+-ATPase AHA2 ofArabidopsis thaliana, which belongs to the P-type ATPase superfamily of cation-transporting ATPases, pumps protons out of the cell, To investigate the mechanism of ion transport by P-type ATPases we have mutagenized Asp(684), a residue in transmembrane segment M6 of AHA2 that is conserved in Ca2+-, Na+/K+-, H+/K-, and H+-ATPases and which coordinates Ca2+ ions in the SERCA1 Ca2+-ATPase. We describe the expression, purification, and biochemical analysis of the Asp(684) -->Asn mutant, and provide evidence that Asp(684) in the plasma membrane H+-ATPase is required for any coupling between ATP hydrolysis, enzyme conformational changes, and H+-transport. Proton pumping by the reconstituted mutant enzyme was completely abolished, whereas ATP was still hydrolyzed, The mutant was insensitive to the inhibitor vanadate, which preferentially binds to P-type ATPases in the E-2 conformation. During catalysis the Asp684, Asn enzyme accumulated a phosphorylated intermediate whose stability was sensitive to addition of ADP. We conclude that the mutant enzyme is locked in the E-1 conformation and is unable to proceed through the E1P-E2P transition.	Royal Danish Vet & Agr Univ, Dept Plant Biol, DK-1871 Frederiksberg C, Denmark; Univ Politecn Valencia, Inst Biol Mol & Celular Plantas, S-22012 Valencia, Spain	University of Copenhagen; Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Politecnica de Valencia; CSIC-UPV - Instituto de Biologia Molecular y Celular de Plantas (IBMCP)	Palmgren, MG (corresponding author), Royal Danish Vet & Agr Univ, Dept Plant Biol, Thorvaldsensvej 40, DK-1871 Frederiksberg C, Denmark.	palmgren@biobase.dk	Venema, Kees/G-9558-2015; Palmgren, Michael/A-9808-2013	Venema, Kees/0000-0001-5177-6464; Palmgren, Michael/0000-0002-9982-6114				ADEBAYO AO, 1995, J BIOL CHEM, V270, P27812, DOI 10.1074/jbc.270.46.27812; Ambesi A, 2000, J BIOL CHEM, V275, P20545, DOI 10.1074/jbc.M001682200; Arguello JM, 1996, J BIOL CHEM, V271, P24610, DOI 10.1074/jbc.271.40.24610; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; Axelsen KB, 1999, BIOCHEMISTRY-US, V38, P7227, DOI 10.1021/bi982482l; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Briskin DP, 1998, PLANT PHYSIOL BIOCH, V36, P293, DOI 10.1016/S0981-9428(98)80043-0; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Dutra MB, 1998, J BIOL CHEM, V273, P17411, DOI 10.1074/jbc.273.28.17411; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Gatto C, 1999, J BIOL CHEM, V274, P13737, DOI 10.1074/jbc.274.20.13737; Gatto C, 1998, J BIOL CHEM, V273, P10578, DOI 10.1074/jbc.273.17.10578; Gupta SK, 1998, J BIOL CHEM, V273, P4282, DOI 10.1074/jbc.273.7.4282; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jahn T, 1997, PLANT CELL, V9, P1805, DOI 10.1105/tpc.9.10.1805; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; Lanfermeijer FC, 1998, PROTEIN EXPRES PURIF, V12, P29, DOI 10.1006/prep.1997.0788; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Morsomme P, 2000, BBA-BIOMEMBRANES, V1465, P1, DOI 10.1016/S0005-2736(00)00128-0; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; Pedersen PA, 1997, FEBS LETT, V400, P206, DOI 10.1016/S0014-5793(96)01381-6; REGENBERG B, 1995, PLANT CELL, V7, P1655, DOI 10.1105/tpc.7.10.1655; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; Sorensen T, 1997, J BIOL CHEM, V272, P30244, DOI 10.1074/jbc.272.48.30244; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VanHuysse JW, 1996, FEBS LETT, V389, P179, DOI 10.1016/0014-5793(96)00578-9; VENEMA K, 1995, J BIOL CHEM, V270, P19659, DOI 10.1074/jbc.270.33.19659; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; Vilsen B, 1997, BIOCHEMISTRY-US, V36, P13312, DOI 10.1021/bi971030q; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	40	43	45	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39167	39173		10.1074/jbc.M007537200	http://dx.doi.org/10.1074/jbc.M007537200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995773	hybrid			2022-12-25	WOS:000165953100032
J	Barthelmes, HU; Grue, P; Feineis, S; Straub, T; Boege, F				Barthelmes, HU; Grue, P; Feineis, S; Straub, T; Boege, F			Active DNA topoisomerase II alpha is a component of the salt-stable centrosome core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; PROTEIN-KINASE; HEAT-SHOCK; EXPRESSION; ORGANIZATION; ASSOCIATION; MITOSIS; TISSUES; KI-S1	Recently, we reported that the monoclonal antibody specific for human DNA topoisomerase II alpha, Ki-S1, stains not only the nuclei of human A431 cells but also extranuclear structures suggestive of centrosomes (Meyer, K. N., Kjeldsen, E., Straub, T., Knudsen, B. K., Kikuchi, A., Hickson, I. D., Kreipe, H., and Boege, F. (1997) J. Cell Biol. 136, 775-788). Here, we confirm colocalization of Ki-S1 with the centrosomal marker gamma -tubulin. In addition, we show labeling of centrosomes by peptide antibodies against the N and C termini of human topoisomerase II alpha. Probing Western blots of isolated centrosomes with topoisomerase II alpha antibodies, we demonstrate a protein band of 170 kDa. Moreover, isolated centrosomes exhibited DNA decatenation and relaxation activity correlated to the amount of topoisomerase II alpha protein in the same way as seen in the pure recombinant enzyme. Topoisomerase II alpha epitopes could not be removed from centrosomes by salt extraction, DNase treatment, or RNase treatment, procedures that completely removed the enzyme from nuclei. Taken together, these observations suggest that active topoisomerase II alpha is bound tightly to the centrosome in a DNA-independent manner. Because such centrosomal topoisomerase II alpha was also present in quiescent lymphocytes devoid of topoisomerase II alpha in the nuclei, we assume that it might be a long-lived storage form.	Univ Wurzburg, Med Poliklin, D-97070 Wurzburg, Germany	University of Wurzburg	Boege, F (corresponding author), Univ Wurzburg, Med Poliklin, Klin Str 6, D-97070 Wurzburg, Germany.		Boege, Fritz/H-3261-2019; Straub, Tobias/B-2023-2009	Straub, Tobias/0000-0002-0547-0453				Bobinnec Y, 1998, J CELL BIOL, V143, P1575, DOI 10.1083/jcb.143.6.1575; BOEGE F, 1995, AM J PATHOL, V146, P1302; BORNENS M, 1987, CELL MOTIL CYTOSKEL, V8, P238, DOI 10.1002/cm.970080305; BOVERI T, 1901, JENA Z MED NATURWISS, V28, P1; Brown CR, 1996, J BIOL CHEM, V271, P833, DOI 10.1074/jbc.271.2.833; Chaly N, 1996, CHROMOSOME RES, V4, P457, DOI 10.1007/BF02265053; COMPTON DA, 1993, J CELL BIOL, V120, P947, DOI 10.1083/jcb.120.4.947; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Gieseler F., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P209; Goswami PC, 1996, MOL CELL BIOL, V16, P1500; Grue P, 1998, J BIOL CHEM, V273, P33660, DOI 10.1074/jbc.273.50.33660; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Isaacs RJ, 1996, J BIOL CHEM, V271, P16741, DOI 10.1074/jbc.271.28.16741; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; KREIPE H, 1993, AM J PATHOL, V142, P3; KUBO T, 1995, CANCER RES, V55, P3860; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; MELLER VH, 1994, J CELL BIOL, V126, P1331, DOI 10.1083/jcb.126.6.1331; Meyer KN, 1997, J CELL BIOL, V136, P775, DOI 10.1083/jcb.136.4.775; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Pietromonaco SF, 1996, BLOOD CELL MOL DIS, V22, P225, DOI 10.1006/bcmd.1996.0103; Schmidt PH, 1999, J BIOL CHEM, V274, P3055, DOI 10.1074/jbc.274.5.3055; Stearns T, 1997, CELL, V91, P303, DOI 10.1016/S0092-8674(00)80414-6; SUMNER AT, 1996, CHROMOSOME RES, V4, P4; Turley H, 1997, BRIT J CANCER, V75, P1340, DOI 10.1038/bjc.1997.227; Warburton PE, 1997, BIOESSAYS, V19, P97, DOI 10.1002/bies.950190203; Wigley WC, 1999, J CELL BIOL, V145, P481; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; Yang X, 2000, SCIENCE, V287, P131, DOI 10.1126/science.287.5450.131; Young A, 2000, MOL BIOL CELL, V11, P2047, DOI 10.1091/mbc.11.6.2047; Zimmerman W, 1999, CURR OPIN CELL BIOL, V11, P122, DOI 10.1016/S0955-0674(99)80015-5	35	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38823	38830		10.1074/jbc.M007044200	http://dx.doi.org/10.1074/jbc.M007044200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11006289	hybrid			2022-12-25	WOS:000165739800093
J	O'Donnell, VB; Coles, B; Lewis, MJ; Crews, BC; Marnett, LJ; Freeman, BA				O'Donnell, VB; Coles, B; Lewis, MJ; Crews, BC; Marnett, LJ; Freeman, BA			Catalytic consumption of nitric oxide by prostaglandin H synthase-1 regulates platelet function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE SYNTHASE; HYDROGEN-PEROXIDE; ARACHIDONIC-ACID; RELAXING FACTOR; RABBIT AORTA; RELEASE; FLAVOHEMOGLOBIN; PEROXYNITRITE; AGGREGATION; ACTIVATION	Nitric oxide ((NO)-N-.) plays a central role in vascular homeostasis via regulation of smooth muscle relaxation and platelet aggregation. Although mechanisms for (NO)-N-. formation are well known, removal pathways are less well characterized, particularly in cells that respond to (NO)-N-. through activation of soluble guanylate cyclase. Herein, we report that (NO)-N-. is catalytically consumed by prostaglandin H synthase-1 (PGHS-1) through acting as a reducing peroxidase substrate. With purified ovine PGHS-1, (NO)-N-. consumption requires peroxide (LOOH or H2O2), with a K-m ((app)) for 15(S)hydroperoxyeicosatetraenoic acid (HPETE) of 3.27 +/- 0.35 muM. During this, 2 mol (NO)-N-. are consumed per mol HPETE, and loss of HPETE hydroperoxy group occurs with retention of the conjugated diene spectrum. Hydroperoxide-stimulated (NO)-N-. consumption requires heme incorporation, is not inhibited by indomethacin, and is further stimulated by the reducing peroxidase substrate, phenol. PGHS-1-dependent (NO)-N-. consumption also occurs during arachidonate, thrombin, or A23187 activation of platelets (1-2 muM.min(-1) for typical plasma platelet concentrations) and prevents (NO)-N-. stimulation of platelet soluble guanylate cyclase. Platelet sensitivity to (NO)-N-. as an inhibitor of aggregation is greater using a platelet-activating stimulus (U46619) that does not cause (NO)-N-. consumption, indicating that this mechanism overcomes the anti-aggregatory effects of (NO)-N-., Catalytic consumption of (NO)-N-. during eicosanoid synthesis thus represents both a novel pro-aggregatory function for PGHS-1 and a regulated mechanism for vascular (NO)-N-. removal.	Cardiff Univ, Wales Heart Res Inst, Cardiff CF4 4XN, S Glam, Wales; Vanderbilt Univ, Sch Med, Dept Biochem, Ctr Mol Toxicol, Nashville, TN 37232 USA; Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Dept Biochem, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Dept Mol Genet, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35233 USA	Cardiff University; Vanderbilt University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	O'Donnell, VB (corresponding author), Cardiff Univ, Wales Heart Res Inst, Heath Pk, Cardiff CF4 4XN, S Glam, Wales.	o-donnellvb@cardiff.ac.uk	Freeman, Bruce A/H-9342-2012; O'Donnell, Valerie/C-6948-2012	/0000-0003-4089-8460	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064937, P60HL058418, R01HL058115] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL58115, R01HL64937, P6HL58418] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKKERMAN JWN, 1979, ANAL BIOCHEM, V97, P387, DOI 10.1016/0003-2697(79)90090-3; AUERBACH BJ, 1992, ANAL BIOCHEM, V201, P375, DOI 10.1016/0003-2697(92)90354-A; BALDUINI CL, 1988, BIOCHEM BIOPH RES CO, V156, P823; Caccese D, 2000, THROMB HAEMOSTASIS, V83, P485, DOI 10.1055/s-0037-1613841; Crawford MJ, 1998, J BIOL CHEM, V273, P12543, DOI 10.1074/jbc.273.20.12543; Curtis JF, 1996, ARCH BIOCHEM BIOPHYS, V335, P369, DOI 10.1006/abbi.1996.0518; Freedman JE, 1997, J CLIN INVEST, V100, P350, DOI 10.1172/JCI119540; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; GASSAMADIAGNE A, 1992, J LIPID MEDIATOR, V5, P61; Glover RE, 1999, NITRIC OXIDE-BIOL CH, V3, P439, DOI 10.1006/niox.1999.0256; Goodwin DC, 1999, FASEB J, V13, P1121, DOI 10.1096/fasebj.13.10.1121; Goodwin DC, 1998, J BIOL CHEM, V273, P8903, DOI 10.1074/jbc.273.15.8903; Gunther MR, 1997, J BIOL CHEM, V272, P17086, DOI 10.1074/jbc.272.27.17086; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; IGNARRO LJ, 1988, J PHARMACOL EXP THER, V246, P218; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; Ischiropoulos H, 1996, FREE RADICAL BIO MED, V20, P373, DOI 10.1016/0891-5849(95)02098-5; KELM M, 1990, CIRC RES, V66, P1561, DOI 10.1161/01.RES.66.6.1561; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; LANTOINE F, 1995, BIOCHEM BIOPH RES CO, V215, P842, DOI 10.1006/bbrc.1995.2540; Liao JC, 1999, P NATL ACAD SCI USA, V96, P8757, DOI 10.1073/pnas.96.15.8757; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V194, P960, DOI 10.1006/bbrc.1993.1914; MALLE E, 1987, PROSTA LEUKOTR MED, V27, P53, DOI 10.1016/0262-1746(87)90059-X; Marnett L. J., 1991, PEROXIDASES CHEM BIO, V1, P293; MARNETT LJ, 1984, MOL PHARMACOL, V26, P328; McNicol A., 1996, PRACT APPROACH SER, P1; MINOR RL, 1990, J CLIN INVEST, V86, P2109, DOI 10.1172/JCI114949; O'Donnell VB, 1999, J BIOL CHEM, V274, P20083, DOI 10.1074/jbc.274.29.20083; ODENWALLER R, 1990, METHOD ENZYMOL, V187, P479; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Pigazzi A, 1999, J BIOL CHEM, V274, P14368, DOI 10.1074/jbc.274.20.14368; Pignatelli P, 1998, BLOOD, V91, P484, DOI 10.1182/blood.V91.2.484.484_484_490; RADOMSKI MW, 1992, BRIT J PHARMACOL, V107, P745, DOI 10.1111/j.1476-5381.1992.tb14517.x; SANE DC, 1989, BIOCHEM BIOPH RES CO, V165, P708, DOI 10.1016/S0006-291X(89)80024-5; SCHAFER AI, 1982, BIOCHIM BIOPHYS ACTA, V712, P535, DOI 10.1016/0005-2760(82)90281-8; SCHARFSTEIN JS, 1994, J CLIN INVEST, V94, P1432, DOI 10.1172/JCI117480; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; STAMLER JS, 1996, METHODS NITRIC OXIDE, P521; TSAI AL, 1994, ARCH BIOCHEM BIOPHYS, V313, P367, DOI 10.1006/abbi.1994.1400; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; VARGAS JR, 1982, PROSTAGLANDINS, V23, P929, DOI 10.1016/0090-6980(82)90135-6; VERBEUREN TJ, 1990, EUR J PHARMACOL, V191, P173, DOI 10.1016/0014-2999(90)94145-N; Wang GR, 1998, P NATL ACAD SCI USA, V95, P4888, DOI 10.1073/pnas.95.9.4888; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044	46	60	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38239	38244		10.1074/jbc.M001802200	http://dx.doi.org/10.1074/jbc.M001802200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10993875	hybrid			2022-12-25	WOS:000165739800016
J	Jiang, JC; Jaruga, E; Repnevskaya, MV; Jazwinski, SM				Jiang, JC; Jaruga, E; Repnevskaya, MV; Jazwinski, SM			An intervention resembling caloric restriction prolongs life span and retards aging in yeast	FASEB JOURNAL			English	Article									Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Jazwinski, SM (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1901 Perdido St,Box P7-2, New Orleans, LA 70112 USA.								0	266	275	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2135	2137						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11024000				2022-12-25	WOS:000165190800003
J	Bienengraeber, M; Alekseev, AE; Abraham, MR; Carrasco, AJ; Moreau, C; Vivaudou, M; Dzeja, PP; Terzic, A				Bienengraeber, M; Alekseev, AE; Abraham, MR; Carrasco, AJ; Moreau, C; Vivaudou, M; Dzeja, PP; Terzic, A			ATPase activity of the sulfonylurea receptor: a catalytic function for the K-ATP channel complex	FASEB JOURNAL			English	Article						ATP-sensitive K+ channels; enzyme; ABC proteins; nucleotide binding domains; potassium channel openers; Kir6.2; SUR	TRANSMEMBRANE CONDUCTANCE REGULATOR; NUCLEOTIDE-BINDING DOMAIN; SENSITIVE POTASSIUM CHANNELS; P-GLYCOPROTEIN; ADENYLATE KINASE; HYPOXIA-REOXYGENATION; PHYSICAL ASSOCIATION; DISTINCT FUNCTIONS; INSULIN-SECRETION; SUR1	ATP-sensitive K+ (K-ATP) channels are unique metabolic sensors formed by association of Kir6.2, an inwardly rectifying K+ channel, and the sulfonylurea receptor SUR, an ATP binding cassette protein. We identified an ATPase activity in immunoprecipitates of cardiac K-ATP channels and in purified fusion proteins containing nucleotide binding domains NBD1 and NBD2 of the cardiac SUR2A isoform. NBD2 hydrolyzed ATP with a twofold higher rate compared to NBD1, The ATPase required Mg2+ and was insensitive to ouabain, oligomycin, thapsigargin, or levamisole, K1348A and D1469N mutations in NBD2 reduced ATPase activity and produced channels with increased sensitivity to ATP. K-ATP channel openers, which bind to SUR, promoted ATPase activity in purified sarcolemma. At higher concentrations, openers reduced ATPase activity, possibly through stabilization of MgADP at the channel site, K1348A and D1469N mutations attenuated the effect of openers on K-ATP channel activity. Opener-induced channel activation was also inhibited by the creatine kinase/creatine phosphate system that removes ADP from the channel complex, Thus, the K-ATP channel complex functions not only as a K+ conductance, but also as an enzyme regulating nucleotide-dependent channel gating through an intrinsic ATPase activity of the SUR subuniT. Modulation of the channel ATPase activity and/or scavenging the product of the ATPase reaction provide novel means to regulate cellular functions associated with K-ATP channel opening.	Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, Div Cardiovasc Dis, Rochester, MN 55905 USA; CEA, DBMS, Lab Biophys Mol Cellulaire, F-38054 Grenoble, France	Mayo Clinic; Mayo Clinic; CEA	Terzic, A (corresponding author), Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, Guggenheim 7,200 1st St SW, Rochester, MN 55905 USA.		MOREAU, Christophe/AAC-7912-2020; Vivaudou, Michel/C-5338-2008; MOREAU, Christophe J/D-3736-2009; Alekseev, Alexey/I-5346-2013	MOREAU, Christophe/0000-0002-5463-9593; Vivaudou, Michel/0000-0002-9777-3127; MOREAU, Christophe J/0000-0002-5463-9593; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064822] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM019567] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07111, HL64822] Funding Source: Medline; NIGMS NIH HHS [GM19567] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham MR, 1999, FASEB J, V13, P1901; ABRAHAM MR, 1999, PHYSIOLOGIST, V42, pA5; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Alekseev AE, 1998, J GEN PHYSIOL, V111, P381, DOI 10.1085/jgp.111.2.381; Alekseev AE, 1997, J MEMBRANE BIOL, V159, P161, DOI 10.1007/s002329900279; Aparicio G, 1996, FEMS MICROBIOL LETT, V141, P157, DOI 10.1111/j.1574-6968.1996.tb08378.x; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bryan J, 1999, BBA-BIOMEMBRANES, V1461, P285, DOI 10.1016/S0005-2736(99)00164-9; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; D'Hahan N, 1999, MOL PHARMACOL, V56, P308, DOI 10.1124/mol.56.2.308; D'hahan N, 1999, P NATL ACAD SCI USA, V96, P12162, DOI 10.1073/pnas.96.21.12162; Dzeja PP, 1999, CIRC RES, V84, P1137, DOI 10.1161/01.RES.84.10.1137; Dzeja PP, 1999, MOL CELL BIOCHEM, V201, P33, DOI 10.1023/A:1007016703229; Dzeja PP, 1998, FASEB J, V12, P523, DOI 10.1096/fasebj.12.7.523; DZEJA PP, 1999, PHYSIOLOGIST, V42, pA3; ElvirMairena JR, 1996, J BIOL CHEM, V271, P31903, DOI 10.1074/jbc.271.50.31903; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; Gribble FM, 1998, P NATL ACAD SCI USA, V95, P7185, DOI 10.1073/pnas.95.12.7185; Gross GJ, 1999, CIRC RES, V84, P973, DOI 10.1161/01.RES.84.9.973; Hambrock A, 1999, MOL PHARMACOL, V55, P832; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hille B, 1999, NAT MED, V5, P1105, DOI 10.1038/13415; Hiromura M, 1998, J BIOL CHEM, V273, P5435, DOI 10.1074/jbc.273.10.5435; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Jovanovic A, 1998, LAB INVEST, V78, P1101; Jovanovic A, 1998, CIRCULATION, V98, P1548, DOI 10.1161/01.CIR.98.15.1548; Jovanovic N, 1999, FASEB J, V13, P923, DOI 10.1096/fasebj.13.8.923; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Loffler-Walz C, 1998, BRIT J PHARMACOL, V123, P1395, DOI 10.1038/sj.bjp.0701756; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; Lorenz E, 1998, MOL CELL BIOL, V18, P1652, DOI 10.1128/MCB.18.3.1652; Lorenz E, 1999, J MOL CELL CARDIOL, V31, P425, DOI 10.1006/jmcc.1998.0876; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; MILLER C, 1992, SCIENCE, V258, P240, DOI 10.1126/science.1384128; NICHOLS CG, 1990, J PHYSIOL-LONDON, V423, P91, DOI 10.1113/jphysiol.1990.sp018013; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Randak C, 1997, FEBS LETT, V410, P180, DOI 10.1016/S0014-5793(97)00574-7; Schultz BD, 1996, J MEMBRANE BIOL, V151, P63, DOI 10.1007/s002329900058; Schwanstecher M, 1998, EMBO J, V17, P5529, DOI 10.1093/emboj/17.19.5529; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; SHARMA S, 1995, J BIOL CHEM, V270, P14085, DOI 10.1074/jbc.270.23.14085; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; SNABES MC, 1981, J BIOL CHEM, V256, P6291; TERZIC A, 1994, NEURON, V12, P1049, DOI 10.1016/0896-6273(94)90313-1; TERZIC A, 1994, J PHARMACOL EXP THER, V268, P818; Terzic A, 1999, CLIN PHARMACOL THER, V66, P105, DOI 10.1053/cp.1999.v66.99991; TERZIC A, 1994, CARDIOVASC RES, V28, P746, DOI 10.1093/cvr/28.6.746; TERZIC A, 1995, AM J PHYSIOL, V38, pC525; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Ueda K, 1999, BBA-BIOMEMBRANES, V1461, P305, DOI 10.1016/S0005-2736(99)00157-1; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; Uhde I, 1999, J BIOL CHEM, V274, P28079, DOI 10.1074/jbc.274.40.28079; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; VENKATESH N, 1992, CIRC RES, V71, P1324, DOI 10.1161/01.RES.71.6.1324; Wang C, 1999, BIOCHEM J, V338, P77, DOI 10.1042/0264-6021:3380077; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	66	122	123	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					1943	1952		10.1096/fj.00-0027com	http://dx.doi.org/10.1096/fj.00-0027com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023978				2022-12-25	WOS:000089634400013
J	Palmieri, L; Agrimi, G; Runswick, MJ; Fearnley, IM; Palmieri, F; Walker, JE				Palmieri, L; Agrimi, G; Runswick, MJ; Fearnley, IM; Palmieri, F; Walker, JE			Identification in Saccharomyces cerevisiae of two isoforms of a novel mitochondrial transporter for 2-oxoadipate and 2-oxoglutarate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; BACTERIAL EXPRESSION; FUNCTIONAL RECONSTITUTION; OXOGLUTARATE CARRIER; ALPHA-AMINOADIPATE; GENE-EXPRESSION; YEAST; PROTEINS; PURIFICATION; SEQUENCE	The nuclear genome of Saccharomyces cerevisiae encodes 35 members of a family of membrane proteins, Known members transport substrates and products across the inner membranes of mitochondria. We have localized two hitherto unidentified family members, Odc1p and Odc2p, to the inner membranes of mitochondria. They are isoforms with 61% sequence identity, and we have shown in reconstituted liposomes that they transport the oxodicarboxylates 2-oxoadipate and 2-oxoglutarate by a strict counter exchange mechanism. Intraliposomal adipate and glutarate and to a lesser extent malate and citrate supported [C-14]oxoglutarate uptake. The expression of Odc1p, the more abundant isoform, made in the presence of nonfermentable carbon sources, is repressed by glucose. The main physiological roles of Odc1p and Odc2p are probably to supply 2-oxoadipate and a-oxoglutarate from the mitochondrial matrix to the cytosol where they are used in the biosynthesis of lysine and glutamate, respectively, and in lysine catabolism.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2, England; Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, I-70125 Bari, Italy	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; Universita degli Studi di Bari Aldo Moro	Walker, JE (corresponding author), MRC, Dunn Human Nutr Unit, HIlls Rd, Cambridge CB2 2, England.	walker@mrc-dunn.cam.ac.uk	Agrimi, Gennaro/D-4001-2018; agrimi, gennaro/C-6020-2009	Agrimi, Gennaro/0000-0002-5219-4412; Walker, John/0000-0001-7929-2162				BHATTACHARJEE JK, 1985, CRC CR REV MICROBIOL, V12, P131, DOI 10.3109/10408418509104427; BISACCIA F, 1985, BIOCHIM BIOPHYS ACTA, V810, P362, DOI 10.1016/0005-2728(85)90222-1; CROMPTON M, 1974, BIOCHEM J, V142, P127, DOI 10.1042/bj1420127; DAUM G, 1982, J BIOL CHEM, V257, P3075; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; Fiermonte G, 1998, J BIOL CHEM, V273, P24754, DOI 10.1074/jbc.273.38.24754; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; GOODMAN SI, 1995, METABOLIC MOL BASIS, V1, P1451; HIGASHINO K, 1971, ARCH BIOCHEM BIOPHYS, V142, P606, DOI 10.1016/0003-9861(71)90525-X; HOLLENBERG CP, 1970, BIOCHIM BIOPHYS ACTA, V201, P13, DOI 10.1016/0304-4165(70)90004-8; KLINGENBERG M, 1975, EUR J BIOCHEM, V52, P351, DOI 10.1111/j.1432-1033.1975.tb04003.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MITCHELL AP, 1983, J BIOL CHEM, V258, P119; NIHIZUKA Y, 1970, METHOD ENZYMOL, V17, P463; Palmieri F, 1995, METHOD ENZYMOL, V260, P349, DOI 10.1016/0076-6879(95)60150-3; PALMIERI F, 1972, EUR J BIOCHEM, V26, P587, DOI 10.1111/j.1432-1033.1972.tb01801.x; PALMIERI F, 1972, EUR J BIOCHEM, V29, P408, DOI 10.1111/j.1432-1033.1972.tb02003.x; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Palmieri Ferdinando, 1999, P489; Palmieri L, 1999, FEBS LETT, V462, P472, DOI 10.1016/S0014-5793(99)01555-0; Palmieri L, 1999, J BIOL CHEM, V274, P22184, DOI 10.1074/jbc.274.32.22184; Palmieri L, 2000, J BIOENERG BIOMEMBR, V32, P67, DOI 10.1023/A:1005564429242; Palmieri L, 1997, FEBS LETT, V417, P114, DOI 10.1016/S0014-5793(97)01269-6; Palmieri L, 1996, FEBS LETT, V399, P299, DOI 10.1016/S0014-5793(96)01350-6; PERKINS M, 1973, BIOCHEM J, V134, P923, DOI 10.1042/bj1340923; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Valenzuela L, 1998, J BACTERIOL, V180, P3533, DOI 10.1128/JB.180.14.3533-3540.1998; Walker J.E., 1992, CURR OPIN STRUC BIOL, V2, P519, DOI DOI 10.1016/0959-440X(92)90081-H; Zhao WN, 1996, BIOCHEMISTRY-US, V35, P7873, DOI 10.1021/bi9605189	31	87	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1916	1922		10.1074/jbc.M004332200	http://dx.doi.org/10.1074/jbc.M004332200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11013234	hybrid			2022-12-25	WOS:000166528000038
J	Armstrong, JL; Bonavaud, SM; Toole, BJ; Yeaman, SJ				Armstrong, JL; Bonavaud, SM; Toole, BJ; Yeaman, SJ			Regulation of glycogen synthesis by amino acids in cultured human muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; ACTIVATED PROTEIN-KINASE; RABBIT SKELETAL-MUSCLE; SYNTHASE KINASE-3; IN-VITRO; MAMMALIAN TARGET; PHOSPHOINOSITIDE 3-KINASE; INTACT-CELLS; INSULIN; PHOSPHORYLATION	Insulin and a number of metabolic factors stimulate glycogen synthesis and the enzyme glycogen synthase. Using human muscle cells we find that glycogen synthesis is stimulated by treatment of the cells with lithium ions, which inhibit glycogen synthase kinase 3. Insulin further stimulates glycogen synthesis in the presence of lithium ions, an effect abolished by wortmannin and rapamycin. We report also that amino acids stimulate glycogen synthesis and glycogen synthase, these effects also being blocked by rapamycin and wortmannin. Amino acids stimulate p70(s6k) and transiently inhibit glycogen synthase kinase 3 without effects on the activity of protein kinase B or the mitogen-activated protein kinase pathway. Thus, the work reported here demonstrates that amino acid availability can regulate glycogen synthesis. Furthermore, it demonstrates that glycogen synthase kinase 3 can be inactivated within cells independent of activation of protein kinase B and p90(rsk).	Univ Newcastle Upon Tyne, Sch Med, Sch Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Yeaman, SJ (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Sch Biochem & Genet, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Armstrong, Jane/0000-0002-5822-0597				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Campbell LE, 1999, BIOCHEM J, V344, P433, DOI 10.1042/0264-6021:3440433; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COHEN P, 1993, BIOCHEM SOC T, V21, P555, DOI 10.1042/bst0210555; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; EldarFinkelman H, 1996, P NATL ACAD SCI USA, V93, P10228, DOI 10.1073/pnas.93.19.10228; GUINOVART JJ, 1979, FEBS LETT, V106, P284, DOI 10.1016/0014-5793(79)80515-3; Halse R, 1999, J BIOL CHEM, V274, P776, DOI 10.1074/jbc.274.2.776; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hurel SJ, 1996, BIOCHEM J, V320, P871, DOI 10.1042/bj3200871; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Markuns JF, 1999, J BIOL CHEM, V274, P24896, DOI 10.1074/jbc.274.35.24896; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Peyrollier K, 2000, BIOCHEM J, V350, P361, DOI 10.1042/0264-6021:3500361; PRICE TB, 1994, J APPL PHYSIOL, V76, P104, DOI 10.1063/1.357116; Ryves WJ, 1998, ANAL BIOCHEM, V264, P124, DOI 10.1006/abio.1998.2832; Sanchez-Margalet V, 2000, J CELL PHYSIOL, V182, P182, DOI 10.1002/(SICI)1097-4652(200002)182:2<182::AID-JCP6>3.0.CO;2-X; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SKURAT AV, 1994, J BIOL CHEM, V269, P25534; SKURAT AV, 1995, J BIOL CHEM, V270, P12491, DOI 10.1074/jbc.270.21.12491; Skurat AV, 2000, DIABETES, V49, P1096, DOI 10.2337/diabetes.49.7.1096; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Sung CK, 1998, J RECEPT SIGNAL TR R, V18, P243, DOI 10.3109/10799899809047746; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; Welsh GI, 1997, ANAL BIOCHEM, V244, P16, DOI 10.1006/abio.1996.9838; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Withers DJ, 1997, BIOCHEM BIOPH RES CO, V241, P704, DOI 10.1006/bbrc.1997.7878	43	95	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					952	956		10.1074/jbc.M004812200	http://dx.doi.org/10.1074/jbc.M004812200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11013237	hybrid, Green Accepted			2022-12-25	WOS:000166430900014
J	Croniger, CM; Millward, C; Yang, JQ; Kawai, Y; Arinze, IJ; Liu, S; Harada-Shiba, M; Chakravarty, K; Friedman, JE; Poli, V; Hanson, RW				Croniger, CM; Millward, C; Yang, JQ; Kawai, Y; Arinze, IJ; Liu, S; Harada-Shiba, M; Chakravarty, K; Friedman, JE; Poli, V; Hanson, RW			Mice with a deletion in the gene for CCAAT/enhancer-binding protein beta have an attenuated response to cAMP and impaired carbohydrate metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; KINASE SUBUNITS; RAT; EXPRESSION; TRANSCRIPTION; LIVER; IDENTIFICATION; HYPOGLYCEMIA; SENSITIVITY	Fifty percent of the mice homozygous for a deletion in the gene for CCAAT/enhancer-binding protein beta (C/ EBP beta-/- mice; B phenotype) die within 1 to 2 h after birth of hypoglycemia. They do not mobilize their hepatic glycogen or induce the cytosolic form of phosphoenolpyruvate carboxykinase (PEPCK). Administration of cAMP resulted in mobilization of glycogen, induction of PEPCK mRNA, and a normal blood glucose; these mice survived beyond 2 h postpartum. Adult C/EBP beta-/- mice (A phenotype) also had difficulty in maintaining blood glucose levels during starvation. Fasting these mice for 16 or 30 h resulted in lower levels of hepatic PEPCK mRNA, blood glucose, beta -hydroxybutyrate, blood urea nitrogen, and gluconeogenesis when compared with control mice. The concentration of hepatic cAMP in these mice was 50% of controls, but injection of theophylline, together with glucagon, resulted in a normal cAMP levels. Agonists (glucagon, epinephrine, and isoproterenol) and other effecters of activation of adenylyl cyclase were the same in liver membranes isolated from C/EBP beta-/- mice and littermates, The hepatic activity of cAMP-dependent protein kinase was 80% of wild type mice. There was a 79% increase in the concentration of RI alpha and 27% increase in RII alpha in the particulate fraction of the livers of C/EBP beta-/- mice relative to wild type mice, with no change in the catalytic subunit (C alpha). Thus, a 45% increase in hepatic cAMP (relative to the wild type) would be required in C/EBP beta-/- mice to activate protein kinase A by 50%. In addition, the total activity of phosphodiesterase in the livers of C/EBP beta-/- mice, as well as the concentration of mRNA for phosphodiesterase 3A (PDE3A) and PDE3B was approximately 25% higher than in control animals, suggesting accelerated degradation of cAMP. C/EBP beta influences the regulation of carbohydrate metabolism by altering the level of hepatic cAMP and the activity of protein kinase A.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH 44106 USA; Meharry Med Coll, Dept Biochem, Nashville, TN 37208 USA; Univ Dundee, Dept Mol Biol, Dundee DD1 4HN, Scotland	Case Western Reserve University; Case Western Reserve University; Meharry Medical College; University of Dundee	Croniger, CM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.	cmc6@po.cwru.edu	Poli, Valeria/A-9215-2012	Poli, Valeria/0000-0002-3739-3966	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK050272, R01DK025541] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-25541, DK-50272, DK-07319] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad F, 1999, J IMMUNOL, V162, P4864; Arizmendi C, 1999, J BIOL CHEM, V274, P13033, DOI 10.1074/jbc.274.19.13033; BALLARD FJ, 1967, BIOCHEM J, V104, P866, DOI 10.1042/bj1040866; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; CADD GG, 1990, J BIOL CHEM, V265, P19502; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; EKANGER R, 1989, J BIOL CHEM, V264, P4374; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; HETENYI G, 1974, FED PROC, V33, P1841; HOUGE G, 1990, MOL ENDOCRINOL, V4, P481, DOI 10.1210/mend-4-3-481; KAWAI Y, 1993, MOL CELL ENDOCRINOL, V90, P203, DOI 10.1016/0303-7207(93)90153-B; KAWAI Y, 1981, JBC, V26, P853; KEMP BE, 1988, METHOD ENZYMOL, V159, P173; Kimura T, 1998, J BIOL CHEM, V273, P27505, DOI 10.1074/jbc.273.42.27505; Kun E, 1974, METHOD ENZYMAT AN, P1801; LIU JS, 1991, J BIOL CHEM, V266, P19095; Liu S, 1999, J CLIN INVEST, V103, P207, DOI 10.1172/JCI4243; LO S, 1970, J APPL PHYSIOL, V28, P234, DOI 10.1152/jappl.1970.28.2.234; LOOSE DS, 1986, P NATL ACAD SCI USA, V83, P5184, DOI 10.1073/pnas.83.14.5184; Lopez HW, 1998, J NUTR, V128, P1487, DOI 10.1093/jn/128.9.1487; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Massillon D, 1998, J BIOL CHEM, V273, P228, DOI 10.1074/jbc.273.1.228; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; O'Brien LJ, 1998, J NUTR, V128, P927, DOI 10.1093/jn/128.6.927; Owen O.E., 1976, GLUCONEOGENESIS ITS, P533; Park EA, 1999, J BIOL CHEM, V274, P211, DOI 10.1074/jbc.274.1.211; PARK EA, 1993, J BIOL CHEM, V268, P613; PARRILLA R, 1978, PFLUG ARCH EUR J PHY, V374, P9, DOI 10.1007/BF00585691; PARRILLA R, 1978, PFLUG ARCH EUR J PHY, V374, P3, DOI 10.1007/BF00585690; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Shahid M, 1995, Methods Mol Biol, V41, P129; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; TAKIGUCHI M, 1991, J BIOL CHEM, V266, P9186; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; Wang LQ, 2000, J BIOL CHEM, V275, P14173, DOI 10.1074/jbc.M000764200; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880; YOOWARREN H, 1981, J BIOL CHEM, V256, P224	46	66	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					629	638		10.1074/jbc.M007576200	http://dx.doi.org/10.1074/jbc.M007576200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024029	hybrid			2022-12-25	WOS:000166280700085
J	Nagata, D; Suzuki, E; Nishimatsu, H; Satonaka, H; Goto, A; Omata, M; Hirata, Y				Nagata, D; Suzuki, E; Nishimatsu, H; Satonaka, H; Goto, A; Omata, M; Hirata, Y			Transcriptional activation of the cyclin D1 gene is mediated by multiple cis-elements, including SP1 sites and a cAMP-responsive element in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; SIGNAL-REGULATED KINASE; RIBOSOMAL S6 KINASE; GROWTH-FACTOR GENE; DOWN-REGULATION; DNA-BINDING; PROMOTER; PROTEIN; EXPRESSION; INDUCTION	In an attempt to examine the mechanisms by which transcriptional activity of the cyclin D1 promoter is regulated in vascular endothelial cells (EC), we examined the cis-elements in the human cyclin D1 promoter, which are required for transcriptional activation of the gene. The results of luciferase assays showed that transcriptional activity of the cyclin D1 promoter was largely mediated by SP1 sites and a cARIP-responsive element (CRE), DNA binding activity at the SP1 sites, which was analyzed by electrophoretic mobility shift assays, was significantly increased in the early to mid G(1) phase, whereas DNA binding activity at CRE did not change significantly. Furthermore, Induction of the cyclin D1 promoter activity in the early to mid G(1) phase depended largely on the promoter fragment containing the SP1 sites, whereas the proximal fragment containing CRE but not the SP1 sites was constitutively active. Finally, the increase in DNA binding and promoter activities via the SP1 sites was mediated by the Ras-dependent pathway. The results suggested that the activation of the cyclin D1 gene in vascular ECs was regulated by a dual system; one was inducible in the G(1) phase, and the other was constitutively active.	Univ Tokyo, Fac Med, Dept Internal Med 2, Bunkyo Ku, Tokyo 1338655, Japan; Univ Tokyo, Fac Med, Dept Urol, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo; University of Tokyo	Suzuki, E (corresponding author), Univ Tokyo, Fac Med, Dept Internal Med 2, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1338655, Japan.	suzuki-2im@h.u-tokyo.ac.jp						Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hinz M, 1999, MOL CELL BIOL, V19, P2690; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kanno T, 1996, J IMMUNOL, V157, P5277; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; MERCHANT JL, 1995, J BIOL CHEM, V270, P6314, DOI 10.1074/jbc.270.11.6314; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Noe V, 1998, ONCOGENE, V16, P1931, DOI 10.1038/sj.onc.1201718; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SUZUKI E, 1995, MOL CELL BIOL, V15, P3415; Suzuki E, 1999, CIRC RES, V84, P611, DOI 10.1161/01.RES.84.5.611; Suzuki E, 2000, J BIOL CHEM, V275, P3637, DOI 10.1074/jbc.275.5.3637; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; VIGNE P, 1990, BIOCHEM J, V266, P415, DOI 10.1042/bj2660415; Wang ZY, 1999, BLOOD, V93, P4208, DOI 10.1182/blood.V93.12.4208.412k17_4208_4221; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yan GZ, 1997, J NEUROSCI, V17, P6122; Ye JP, 1996, MOL CELL BIOL, V16, P6178	45	81	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					662	669		10.1074/jbc.M005522200	http://dx.doi.org/10.1074/jbc.M005522200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024050	hybrid			2022-12-25	WOS:000166280700089
J	Rusche, KM; Marletta, MA				Rusche, KM; Marletta, MA			Reconstitution of pterin-free inducible nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXY-L-ARGININE; MACROPHAGE NO SYNTHASE; TETRAHYDROBIOPTERIN-BINDING; ESCHERICHIA-COLI; DIMERIC ENZYME; HEME; BRAIN; PURIFICATION; SUBSTRATE; CATALYSIS	Inducible nitric-oxide synthase (NOS) was expressed and purified in the absence of 6(R)-tetrahydro-L-biopterin (H4B). Pterin-free NOS exhibits a Soret band (416-420 nm) characteristic of predominantly low spin heme and does not catalyze the formation of nitric oxide (. NO) (Rusche, K. M., Spiering, M. M., and Marletta, M. A. (1998) Biochemistry 37, 15503-15512). Reconstitution of pterin-free NOS with H4B was monitored by a shift in the Soret band to 396-400 nm, the recovery of . NO-forming activity, and the measurement of H4B bound to the enzyme. As assessed by these properties, H4B binding was not rapid and required the presence of a reduced thiol. Spectral changes and recovery of activity were incomplete in the absence of reduced thiol. Full reconstitution of holoenzyme activity and stoichiometric H4B binding was achieved in the presence of 5 mM glutathione (GSH). Preincubation with GSH before the addition of H4B decreased, whereas lower concentrations of GSH extended, the time required for reconstitution. Six protected cysteine residues in pterin-free NOS were identified by labeling of NOS with cysteine-directed reagents before and after reduction with GSH. Heme and metal content of pterin-free and H4B-reconstituted NOS were also measured and were found to be independent of H4B content. Additionally, pterin-free NOS was reconstituted with 6-methylpterin analogs, including redox-stable deazapterins. Reconstitution with the redox-stable pterin analogs was neither time- nor thiol-dependent, Apparent binding constants were determined for the 6-methyl- (50 muM) and 6-ethoxymethyl (200 muM) deazapterins. The redox-stable pterin analogs appear to bind to NOS in a different manner than H4B.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Div Med Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Marletta, MA (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.				PHS HHS [50414] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Brandish PE, 1998, BIOCHEMISTRY-US, V37, P16898, DOI 10.1021/bi9814989; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BRENNEMAN AR, 1965, J BIOL CHEM, V240, P3617; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; Clague MJ, 1997, BIOCHEMISTRY-US, V36, P14465, DOI 10.1021/bi971024u; Crane BR, 2000, BIOCHEMISTRY-US, V39, P4608, DOI 10.1021/bi992409a; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; Ghosh S, 1999, J BIOL CHEM, V274, P24100, DOI 10.1074/jbc.274.34.24100; Gorren ACF, 1997, BIOCHEMISTRY-US, V36, P4360, DOI 10.1021/bi962381s; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HOFMANN H, 1995, BIOCHEMISTRY-US, V34, P13443, DOI 10.1021/bi00041a023; HOWELLS DW, 1986, J CHROMATOGR, V381, P285, DOI 10.1016/S0378-4347(00)83594-X; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; Mayer B, 1997, BIOCHEMISTRY-US, V36, P8422, DOI 10.1021/bi970144z; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MOAD G, 1979, J AM CHEM SOC, V101, P6068, DOI 10.1021/ja00514a033; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Pfeiffer S, 1997, BIOCHEM J, V328, P349, DOI 10.1042/bj3280349; PFLEIDERER W, 1985, FOLATES PTERINS, V2, P43; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; PUFAHL RA, 1993, BIOCHEM BIOPH RES CO, V193, P963, DOI 10.1006/bbrc.1993.1719; PUFAHL RA, 1992, BIOCHEMISTRY-US, V31, P6822, DOI 10.1021/bi00144a024; PUFAHL RA, 1995, BIOCHEMISTRY-US, V34, P1930, DOI 10.1021/bi00006a014; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Rodriguez-Crespo I, 1999, J BIOL CHEM, V274, P21617, DOI 10.1074/jbc.274.31.21617; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; RUSCHE KM, 1995, FASEB J, V1381, pA1495; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SCHMIDT HHW, 1991, BIOCHEM BIOPH RES CO, V181, P1372, DOI 10.1016/0006-291X(91)92090-7; Sono M, 1999, BIOCHEMISTRY-US, V38, P15853, DOI 10.1021/bi991580j; STEVENSTRUSS R, 1995, BIOCHEMISTRY-US, V34, P15638, DOI 10.1021/bi00048a006; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WHITE KA, 1994, THESIS U MICHIGAN AN	52	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					421	427		10.1074/jbc.M006860200	http://dx.doi.org/10.1074/jbc.M006860200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11022039	hybrid			2022-12-25	WOS:000166280700057
J	Wu, F; Lee, AS				Wu, F; Lee, AS			YY1 as a regulator of replication-dependent hamster histone H3.2 promoter and an interactive partner of AP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR YY1; GROWTH-REGULATION; GENE-EXPRESSION; BINDING; ELEMENT; PROTEIN; IDENTIFICATION; SEQUENCES; DOMAIN; ACTIN	In analyzing cia-regulatory elements important for cell cycle control of the replication-dependent hamster histone H3.2 gene, we discovered a binding site for the transcription factor YY1 embedded within GC-rich sequences between the two tandem CCAAT repeats proximal to the TATA element. Base mutations that specifically eliminated YY1 binding resulted in suppression of the S phase induction of the H3.2 promoter. In addition, we discovered that YY1 is an interactive partner of AP-2, which also binds the H3.2 promoter and regulates its cell cycle-dependent expression. The critical domains for YY1 and AP-2A interaction are mapped, revealing that the N-terminal portion of YY1 (amino acids 1500) and the DNA-binding/dimerization region of AP-2A are required. Our results suggest that YY1, acting as a transcription factor binding to its site on the promoter, or through protein-protein interaction with AP-2, may be part of a regulatory network including key cell cycle regulators such as c-Myc and Rb in controlling growth- and differentiation-regulated gene expression.	Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Lee, AS (corresponding author), Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA.			Lee, Amy/0000-0002-0378-5443	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031138] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31138] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ARTISHEVSKY A, 1987, NATURE, V328, P823, DOI 10.1038/328823a0; Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Eliassen KA, 1998, MOL CELL BIOL, V18, P7106, DOI 10.1128/MCB.18.12.7106; FARNHAM PJ, 1990, MOL CELL BIOL, V10, P1390, DOI 10.1128/MCB.10.4.1390; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FLANAGAN JR, 1995, CELL GROWTH DIFFER, V6, P185; Foti DM, 1999, J BIOL CHEM, V274, P30402, DOI 10.1074/jbc.274.43.30402; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Kaludov NK, 1996, P NATL ACAD SCI USA, V93, P4465, DOI 10.1073/pnas.93.9.4465; Kim EC, 1997, CELL GROWTH DIFFER, V8, P1329; Last TJ, 1999, J CELL BIOCHEM, V72, P507, DOI 10.1002/(SICI)1097-4644(19990315)72:4<507::AID-JCB6>3.0.CO;2-5; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE TC, 1994, ONCOGENE, V9, P1047; Lee TC, 1998, NUCLEIC ACIDS RES, V26, P3215, DOI 10.1093/nar/26.13.3215; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; NAEVE GS, 1995, NUCLEIC ACIDS RES, V23, P475, DOI 10.1093/nar/23.3.475; RESENDEZ E, 1985, MOL CELL BIOL, V5, P1212, DOI 10.1128/MCB.5.6.1212; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; vanGinkel PR, 1997, J BIOL CHEM, V272, P18367, DOI 10.1074/jbc.272.29.18367; Wu F, 1998, NUCLEIC ACIDS RES, V26, P4837, DOI 10.1093/nar/26.21.4837; YANT SR, 1995, NUCLEIC ACIDS RES, V23, P4353, DOI 10.1093/nar/23.21.4353; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	30	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					28	34		10.1074/jbc.M006074200	http://dx.doi.org/10.1074/jbc.M006074200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11018030	hybrid			2022-12-25	WOS:000166280700005
J	Zucker, WR; Kerentseva, TA; Lawson, CL; Barbour, AG				Zucker, WR; Kerentseva, TA; Lawson, CL; Barbour, AG			Structural conservation of neurotropism-associated VspA within the variable Borrelia Vsp-OspC lipoprotein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYME-DISEASE SPIROCHETE; MEMBRANE PROTEIN P66; SURFACE PROTEIN; RELAPSING FEVER; ANTIGENIC VARIATION; TRYPANOSOMA-BRUCEI; MOUSE MODEL; BURGDORFERI; HERMSII; TURICATAE	Vsp surface lipoproteins are serotype-defining antigens of relapsing fever spirochetes that undergo multiphasic antigenic variation to avoid the immune response. One of these proteins, VspA of Borrelia turicatae, is also associated with neurotropism in infected mice. Vsp proteins are highly polymorphic in sequence, which may relate to their specific antibody reactivities and host cell interactions. To determine whether sequence variations affect protein structure, we compared B. turicatae VspA with three related proteins: VspB of B. turicatae, Vsp26 of the relapsing fever agent Borrelia hermsii, and OspC of the Lyme disease spirochete Borrelia burgdorferi. Recombinant mon-lipidated proteins were purified by affinity or ion exchange chromatography. Circular dichroism spectra revealed similar, highly alpha -helical secondary structures for all four proteins. In vitro assays demonstrated protease-resistant, thermostable Vsp cores starting at, a conserved serine at position 34 (Ser(34)). All proteins aggregate as dimers in solution. In situ trypsin treatment and surface protein cross-linking showed that the native lipoproteins also form protease-resistant dimers. These findings indicate that Vsp proteins have a common compact fold and that their established functions are based on localized polymorphisms. Two forms of VspA crystals suitable for structure determination by x-ray diffraction methods have been obtained.	Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Med, Irvine, CA 92697 USA; Rutgers State Univ, Dept Chem, Piscataway, NJ 08854 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; Rutgers State University New Brunswick	Zucker, WR (corresponding author), Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.		Barbour, Alan/B-3160-2009	Barbour, Alan/0000-0002-0719-5248; Lawson, Catherine/0000-0002-3261-7035	NIAID NIH HHS [AI24424] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024424, R01AI024424] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Antoniou AN, 2000, IMMUNITY, V12, P391, DOI 10.1016/S1074-7613(00)80191-0; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARBOUR AG, 1982, J EXP MED, V156, P1312, DOI 10.1084/jem.156.5.1312; Barbour AG, 2000, EMERG INFECT DIS, V6, P449, DOI 10.3201/eid0605.000502; BARBOUR AG, 1984, YALE J BIOL MED, V57, P521; BARBOUR AG, 1984, INFECT IMMUN, V45, P94, DOI 10.1128/IAI.45.1.94-100.1984; BARBOUR AG, 1986, MICROBIOL REV, V50, P381, DOI 10.1128/MMBR.50.4.381-400.1986; BARBOUR AG, 1990, ANNU REV MICROBIOL, V44, P155, DOI 10.1146/annurev.mi.44.100190.001103; Beermann C, 2000, BIOCHEM BIOPH RES CO, V267, P897, DOI 10.1006/bbrc.1999.2057; BRANDT ME, 1990, INFECT IMMUN, V58, P983, DOI 10.1128/IAI.58.4.983-991.1990; Bunikis J, 1999, INFECT IMMUN, V67, P2874, DOI 10.1128/IAI.67.6.2874-2883.1999; Bunikis J, 1998, J BACTERIOL, V180, P1618, DOI 10.1128/JB.180.7.1618-1623.1998; CADAVID D, 1994, J EXP MED, V179, P631, DOI 10.1084/jem.179.2.631; Cadavid D, 1997, INFECT IMMUN, V65, P3352, DOI 10.1128/IAI.65.8.3352-3360.1997; CADAVID D, 1993, J INFECT DIS, V168, P143, DOI 10.1093/infdis/168.1.143; Carrington M, 1998, MOL BIOCHEM PARASIT, V91, P153, DOI 10.1016/S0166-6851(97)00190-4; Casjens S, 2000, MOL MICROBIOL, V35, P490, DOI 10.1046/j.1365-2958.2000.01698.x; Coleman JL, 1999, INFECT IMMUN, V67, P3929, DOI 10.1128/IAI.67.8.3929-3936.1999; Coleman JL, 1997, CELL, V89, P1111, DOI 10.1016/S0092-8674(00)80298-6; Deitsch KW, 1997, MICROBIOL MOL BIOL R, V61, P281, DOI 10.1128/.61.3.281-293.1997; DELBECQ F, 1993, LANGMUIR, V9, P197, DOI 10.1021/la00025a039; DIMENT S, 1990, J IMMUNOL, V145, P417; Ding W, 2000, J MOL BIOL, V302, P1153, DOI 10.1006/jmbi.2000.4119; DONELSON JE, 1995, J BIOL CHEM, V270, P7783, DOI 10.1074/jbc.270.14.7783; Dunn J J, 1990, Protein Expr Purif, V1, P159, DOI 10.1016/1046-5928(90)90011-M; ERDILE LF, 1993, INFECT IMMUN, V61, P81, DOI 10.1128/IAI.61.1.81-90.1993; Fairlie DP, 2000, J MED CHEM, V43, P1271, DOI 10.1021/jm990315t; Fehr T, 1997, J EXP MED, V185, P1785, DOI 10.1084/jem.185.10.1785; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; FREYMANN D, 1990, J MOL BIOL, V216, P141, DOI 10.1016/S0022-2836(05)80066-X; FUNG BP, 1994, INFECT IMMUN, V62, P3213, DOI 10.1128/IAI.62.8.3213-3221.1994; Gebbia JA, 1999, J CLIN INVEST, V103, P81, DOI 10.1172/JCI5171; Guo BP, 1998, MOL MICROBIOL, V30, P711, DOI 10.1046/j.1365-2958.1998.01103.x; Hendrickson WA, 1997, METHOD ENZYMOL, V276, P494, DOI 10.1016/S0076-6879(97)76074-9; Hinnebusch BJ, 1998, INFECT IMMUN, V66, P432, DOI 10.1128/IAI.66.2.432-440.1998; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HOWE TR, 1985, SCIENCE, V227, P645, DOI 10.1126/science.3969554; Huang XL, 1999, J BIOMOL NMR, V14, P283, DOI 10.1023/A:1008398527355; JAURISHEIPKE S, 1993, MED MICROBIOL IMMUN, V182, P37; KERLIN RL, 1992, MED VET ENTOMOL, V6, P121, DOI 10.1111/j.1365-2915.1992.tb00587.x; Li H, 1995, J STRUCT BIOL, V115, P335, DOI 10.1006/jsbi.1995.1058; Li H, 1997, P NATL ACAD SCI USA, V94, P3584, DOI 10.1073/pnas.94.8.3584; LIVEY I, 1995, MOL MICROBIOL, V18, P257, DOI 10.1111/j.1365-2958.1995.mmi_18020257.x; Magoun L, 2000, MOL MICROBIOL, V36, P886, DOI 10.1046/j.1365-2958.2000.01906.x; McKisic MD, 2000, INFECT IMMUN, V68, P5190, DOI 10.1128/IAI.68.9.5190-5197.2000; Mendiola J, 1996, EXP PARASITOL, V82, P27, DOI 10.1006/expr.1996.0004; NEWMAN K, 1984, INFECT IMMUN, V45, P572, DOI 10.1128/IAI.45.3.572-576.1984; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pennington PM, 1999, MOL MICROBIOL, V34, P1120, DOI 10.1046/j.1365-2958.1999.01675.x; Pennington PM, 1997, INFECT IMMUN, V65, P285, DOI 10.1128/IAI.65.1.285-292.1997; Pennington PM, 1999, INFECT IMMUN, V67, P4637, DOI 10.1128/IAI.67.9.4637-4645.1999; Probert WS, 1998, MOL MICROBIOL, V30, P1003, DOI 10.1046/j.1365-2958.1998.01127.x; Ras NM, 2000, RES MICROBIOL, V151, P5, DOI 10.1016/S0923-2508(00)00133-9; RESTREPO BI, 1992, MOL MICROBIOL, V6, P3299, DOI 10.1111/j.1365-2958.1992.tb02198.x; RESTREPO BI, 1994, CELL, V78, P867, DOI 10.1016/S0092-8674(94)90642-4; Riese RJ, 2000, CURR OPIN IMMUNOL, V12, P107, DOI 10.1016/S0952-7915(99)00058-8; SADZIENE A, 1993, INFECT IMMUN, V61, P2192, DOI 10.1128/IAI.61.5.2192-2195.1993; Sambrook J., 2002, MOL CLONING LAB MANU; SELA M, 1972, P NATL ACAD SCI USA, V69, P2696, DOI 10.1073/pnas.69.9.2696; Shamaei-Tousi A, 1999, J INFECT DIS, V180, P1929, DOI 10.1086/315118; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; STULTZ CM, 1997, PROTEIN STRUCTURAL B, V22; THOMAS DD, 1994, J INFECT DIS, V169, P445, DOI 10.1093/infdis/169.2.445; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VATSN, 2000, ARCH ORAL BIOL, V45, P305; Vidal V, 1998, NAT MED, V4, P1416, DOI 10.1038/4007; Wang IN, 1999, GENETICS, V151, P15; Zinkernagel RM, 1997, BIOL CHEM, V378, P725; Zuckert WR, 1999, INFECT IMMUN, V67, P3257; 1999, EUR J BIOCH, V264, P610	71	39	42	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					457	463		10.1074/jbc.M008449200	http://dx.doi.org/10.1074/jbc.M008449200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11018048	hybrid			2022-12-25	WOS:000166280700062
J	Pucar, D; Janssen, E; Dzeja, PP; Juranic, N; Macura, S; Wieringa, B; Terzic, A				Pucar, D; Janssen, E; Dzeja, PP; Juranic, N; Macura, S; Wieringa, B; Terzic, A			Compromised energetics in the adenylate kinase AK1 gene knockout heart under metabolic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE K+ CHANNELS; ACTIVATED PROTEIN-KINASE; CREATINE-KINASE; CATALYZED PHOSPHOTRANSFER; PHOSPHORYL TRANSFER; SKELETAL-MUSCLE; ATP; ENERGY; MITOCHONDRIAL; ADENOSINE	Rapid exchange of high energy carrying molecules between intracellular compartments is essential in sustaining cellular energetic homeostasis, Adenylate kinase (AK)-catalyzed transfer of adenine nucleotide beta- and gamma -phosphoryls has been implicated in intracellular energy communication and nucleotide metabolism. To demonstrate the significance of this reaction in cardiac energetics, phosphotransfer dynamics were determined by [O-18]phosphoryl oxygen analysis using P-31 NMR and mass spectrometry. In hearts with a null mutation of the AK1 gene, which encodes the major AK isoform, total AX activity and beta -phosphoryl transfer was reduced by 94% and 36%, respectively. This was associated with up-regulation of phosphoryl flux through remaining minor AK isoforms and the glycolytic phosphotransfer enzyme, S-phosphoglycerate kinase, In the absence of metabolic stress, deletion of AK1 did not translate into gross abnormalities in nucleotide levels, gamma -ATP turnover rate or creatine kinase-catalyzed phosphotransfer. However, under hypoxia AK1-deficient hearts, compared with the wild type, had a blunted AK-catalyzed phosphotransfer response, lowered intracellular ATP levels, increased P-i/ATP ratio, and suppressed generation of adenosine, Thus, although lack of AK1 phosphotransfer can be compensated in the absence of metabolic challenge, under hypoxia AK1-knockout hearts display compromised energetics and impaired cardioprotective signaling, This study, therefore, provides first direct evidence that AK1 is essential in maintaining myocardial energetic homeostasis, in particular under metabolic stress.	Mayo Clin, Div Cardiovasc Dis, Dept Med, Rochester, MN 55905 USA; Mayo Clin, Div Cardiovasc Dis, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Clin, Div Cardiovasc Dis, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Univ Nijmegen, Dept Cell Biol, Med Ctr, NL-6525 Nijmegen, Netherlands	Mayo Clinic; Mayo Clinic; Mayo Clinic; Radboud University Nijmegen	Terzic, A (corresponding author), Mayo Clin, Div Cardiovasc Dis, Dept Med, Guggenheim 7, Rochester, MN 55905 USA.		Wieringa, Berend/A-5346-2011	Wieringa, Berend/0000-0001-9192-8020	NHLBI NIH HHS [HL64822, HL07111] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064822] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; Bienengraeber M, 2000, FASEB J, V14, P1943, DOI 10.1096/fj.00-0027com; Boyer P.D, 1973, ENZYMES, P279; COHN M, 1978, P NATL ACAD SCI USA, V75, P200, DOI 10.1073/pnas.75.1.200; Colowick SP, 1943, J BIOL CHEM, V148, P117; Dougherty C, 1998, FASEB J, V12, P1785, DOI 10.1096/fasebj.12.15.1785; Dzeja P P, 2000, Curr Cardiol Rep, V2, P212, DOI 10.1007/s11886-000-0071-9; Dzeja PP, 1996, J BIOL CHEM, V271, P12847, DOI 10.1074/jbc.271.22.12847; Dzeja PP, 1999, CIRC RES, V84, P1137, DOI 10.1161/01.RES.84.10.1137; Dzeja PP, 1999, MOL CELL BIOCHEM, V201, P33, DOI 10.1023/A:1007016703229; Dzeja PP, 1998, MOL CELL BIOCHEM, V184, P169, DOI 10.1023/A:1006859632730; Dzeja PP, 1998, FASEB J, V12, P523, DOI 10.1096/fasebj.12.7.523; ElvirMairena JR, 1996, J BIOL CHEM, V271, P31903, DOI 10.1074/jbc.271.50.31903; Gross GJ, 1999, CIRC RES, V84, P973, DOI 10.1161/01.RES.84.9.973; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; HIMORI N, 1993, PSYCHOPHARMACOLOGY, V111, P153, DOI 10.1007/BF02245517; Ingwall J S, 1980, Methods Cell Biol, V21A, P167, DOI 10.1016/S0091-679X(08)60765-7; JANSSEN E, 2000, IN PRESS EMBO J, V19; Jovanovic A, 1998, ANN THORAC SURG, V65, P586, DOI 10.1016/S0003-4975(97)01240-X; Jovanovic A, 1998, CIRCULATION, V98, P1548, DOI 10.1161/01.CIR.98.15.1548; Jovanovic N, 1999, FASEB J, V13, P923, DOI 10.1096/fasebj.13.8.923; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Kitakaze M, 1999, JPN CIRC J, V63, P231, DOI 10.1253/jcj.63.231; KLETHI J, 1968, NATURE, V218, P467, DOI 10.1038/218467a0; Kloner RA, 1998, CIRCULATION, V97, P1848, DOI 10.1161/01.CIR.97.18.1848; KONRAD M, 1993, J BIOL CHEM, V268, P11326; KROLL K, 1993, CIRC RES, V73, P846, DOI 10.1161/01.RES.73.5.846; KUBO S, 1974, EUR J BIOCHEM, V48, P325, DOI 10.1111/j.1432-1033.1974.tb03772.x; Laterveer FD, 1997, MOL CELL BIOCHEM, V174, P43, DOI 10.1023/A:1006899621926; Loh E, 1999, CIRCULATION, V99, P1422, DOI 10.1161/01.CIR.99.11.1422; Nascimben L, 1996, CIRCULATION, V94, P1894, DOI 10.1161/01.CIR.94.8.1894; Neubauer S, 1997, CIRCULATION, V96, P2190; Olson LK, 1996, J BIOL CHEM, V271, P16544, DOI 10.1074/jbc.271.28.16544; OROURKE JF, 1996, J PHARM, V24, P403; Saks VA, 1996, MOL CELL BIOCHEM, V161, P195, DOI 10.1007/BF00240050; Saupe KW, 1998, CIRC RES, V82, P898; SCHULZ GE, 1987, COLD SPRING HARB SYM, V52, P429, DOI 10.1101/SQB.1987.052.01.050; Shen WQ, 1999, CIRCULATION, V100, P2113, DOI 10.1161/01.CIR.100.20.2113; Steeghs K, 1998, MOL CELL BIOCHEM, V184, P183, DOI 10.1023/A:1006811717709; Steeghs K, 1997, CELL, V89, P93, DOI 10.1016/S0092-8674(00)80186-5; TANABE T, 1993, J BIOCHEM-TOKYO, V113, P200, DOI 10.1093/oxfordjournals.jbchem.a124026; Terzic A, 1999, CLIN PHARMACOL THER, V66, P105, DOI 10.1053/cp.1999.v66.99991; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; Ventura-Clapier R, 1998, MOL CELL BIOCHEM, V184, P231, DOI 10.1023/A:1006840508139; Williams JP, 1996, BBA-BIOENERGETICS, V1276, P71, DOI 10.1016/0005-2728(96)00036-9; ZELEZNIKAR RJ, 1990, J BIOL CHEM, V265, P300; ZELEZNIKAR RJ, 1995, J BIOL CHEM, V270, P7311, DOI 10.1074/jbc.270.13.7311	48	72	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41424	41429		10.1074/jbc.M007903200	http://dx.doi.org/10.1074/jbc.M007903200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11006295	hybrid, Green Published			2022-12-25	WOS:000166114600100
J	Wu, WH; Lee, WL; Wu, YY; Chen, D; Liu, TJ; Jang, A; Sharma, PM; Wang, PH				Wu, WH; Lee, WL; Wu, YY; Chen, D; Liu, TJ; Jang, A; Sharma, PM; Wang, PH			Expression of constitutively active phosphatidylinositol 3-kinase inhibits activation of caspase 3 and apoptosis of cardiac muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; PROTEIN-KINASE PATHWAYS; HEART-FAILURE; CARDIOMYOCYTE APOPTOSIS; AKT PHOSPHORYLATION; SIGNALING PATHWAYS; CYTOCHROME-C; INSULIN; DEATH; TRANSDUCTION	Apoptosis of cardiac muscle cells contributes to the development of cardiomyopathy. Recent studies showed that insulin-like growth factor I (IGF-I) inhibits apoptosis of cardiac muscle cells and improves myocardial function in experimental heart failure. This study was carried out to elucidate the role of phosphatidylinositol 3-kinase (PI 3-kinase) in the anti-apoptotic actions of IGF-I in cardiomyocytes and to explore whether expression of constitutively active PI 3-kinase can inhibit apoptosis in cardiomyocytes. Apoptosis of primary cardiomyocytes was induced by doxorubicin treatment and serum withdrawal. Transduction of cardiomyocytes with constitutively active PI 3-kinase specifically lead to serine phosphorylation of Akt, whereas phosphorylation of IGF-I receptor, IRS1/2 and p44/42 mitogen-activated protein kinase were not increased. In the cardiomyocytes transduced with constitutively active PI 3-kinase, activation of the pro-apoptotic caspase 3 was attenuated and fragmentation of DNA was reduced. Preincubating cells with PI 3-kinase inhibitor LY294002 was associated with loss of anti-apoptotic actions of IGF-I and PI S-kinase. Neither IGF-I nor constitutively active PI 3-kinase lead to serine phosphorylation of Bad, suggesting that the anti-apoptotic effects of PI 3-kinase are not mediated through Bad phosphorylation in cardiac muscle cells. To determine whether activation of caspase 3 is sufficient to induce apoptosis in cardiomyocytes, an engineered TAT-caspase 3 protein was introduced to cardiomyocytes. Significant reduction of cell viability occurred in the cardiomyocytes transduced with active caspase 3, indicating that activation of caspase 3 is sufficient to cause cardiomyocyte death. These findings indicate the existence of an IGF-I receptor-PI 3-kinase-caspase 3 pathway in cardiomyocytes that plays an important role in the anti-apoptotic actions of IGF-I in heart. Moreover, these data suggest that modulation of PI 3-kinase activities may represent a potential therapeutic strategy to counteract the occurrence of apoptosis in cardiomyopathy.	Univ Calif Irvine, Dept Med, Div Hematol & Oncol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Med & Biol Chem, Div Endocrinol Diabet & Metab, Irvine, CA 92697 USA; Univ Calif San Diego, Dept Med, Div Endocrinol, San Diego, CA 92162 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California San Diego	Wang, PH (corresponding author), Univ Calif Irvine, Dept Med, Div Hematol & Oncol, C240, Irvine, CA 92697 USA.							Bialik S, 1999, CIRC RES, V85, P403, DOI 10.1161/01.RES.85.5.403; BUERKE M, 1995, P NATL ACAD SCI USA, V92, P8031, DOI 10.1073/pnas.92.17.8031; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; Colussi PA, 1999, IMMUNOL CELL BIOL, V77, P58, DOI 10.1046/j.1440-1711.1999.00788.x; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DECLERCK LS, 1994, J IMMUNOL METHODS, V172, P115, DOI 10.1016/0022-1759(94)90384-0; Delpy E, 1999, CARDIOVASC RES, V43, P398, DOI 10.1016/S0008-6363(99)00142-X; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FLINK IL, 1992, J BIOL CHEM, V267, P9917; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; James TN, 1999, AM J MED, V107, P606, DOI 10.1016/S0002-9343(99)00308-3; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Koglin J, 1999, CIRCULATION, V99, P836, DOI 10.1161/01.CIR.99.6.836; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Lee WL, 1999, ENDOCRINOLOGY, V140, P4831, DOI 10.1210/en.140.10.4831; Li Q, 1997, J CLIN INVEST, V100, P1991, DOI 10.1172/JCI119730; MacLellan WR, 1997, CIRC RES, V81, P137, DOI 10.1161/01.RES.81.2.137; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; Matsuzaki H, 1999, J NEUROCHEM, V73, P2037; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Narula J, 1999, P NATL ACAD SCI USA, V96, P8144, DOI 10.1073/pnas.96.14.8144; OLSON RD, 1990, FASEB J, V4, P3076, DOI 10.1096/fasebj.4.13.2210154; Parrizas M, 1997, J BIOL CHEM, V272, P154; Rosen A, 1997, J CELL BIOCHEM, V64, P50, DOI 10.1002/(SICI)1097-4644(199701)64:1<50::AID-JCB8>3.0.CO;2-Z; Ryu BR, 1999, J NEUROBIOL, V39, P536, DOI 10.1002/(SICI)1097-4695(19990615)39:4<536::AID-NEU7>3.0.CO;2-J; Saraste A, 1999, EUR J CLIN INVEST, V29, P380; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Wang L, 1998, CIRC RES, V83, P516, DOI 10.1161/01.RES.83.5.516; Wang L, 1998, ENDOCRINOLOGY, V139, P1354, DOI 10.1210/en.139.3.1354; Williams RS, 1999, NEW ENGL J MED, V341, P759, DOI 10.1056/NEJM199909023411012; Yue TL, 1998, J MOL CELL CARDIOL, V30, P495, DOI 10.1006/jmcc.1997.0614; Zhu WD, 1999, CIRCULATION, V100, P2100, DOI 10.1161/01.CIR.100.20.2100	40	112	117	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40113	40119		10.1074/jbc.M004108200	http://dx.doi.org/10.1074/jbc.M004108200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007772	hybrid			2022-12-25	WOS:000166039500044
J	Ki, SW; Ishigami, K; Kitahara, T; Kasahara, K; Yoshida, M; Horinouchi, S				Ki, SW; Ishigami, K; Kitahara, T; Kasahara, K; Yoshida, M; Horinouchi, S			Radicicol binds and inhibits mammalian ATP citrate lyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHASE; SELECTIVE DEPLETION; EXPRESSION; TRANSFORMATION; KINASE; HSP90; COMPLEX; AGENT; RAS; DIFFERENTIATION	Six different biotinylated radicicol derivatives were synthesized as affinity probes for identification of cellular radicicol-binding proteins. Derivatives biotinylated at the C-17 (BR-1) and C-11 (BR-6) positions retained the activity of morphological reversion in v-src-transformed 3Y1 fibroblasts. Two radicicol-binding proteins, 120 and 90-kDa in size, were detected in HeLa cell extracts by employing BR-1 and BR-6, respectively. The 90-kDa protein bound to BR-6 was identified to be Hsp90 by immunoblotting. The 120-kDa protein bound to BR-1 was purified from rabbit reticulocyte lysate, and its internal amino acid sequence was identical to that of human and rat ATP citrate lyase. The identity of the 120-kDa protein as ATP citrate lyase was confirmed by immunoblotting. Interaction between BR-1 and ATP citrate lyase was blocked by radicicol but not by herbimycin A that interacts with Hsp90. These results suggest that radicicol binds the two proteins through different molecular portions of its structure. BR-1-bound ATP citrate lyase isolated from rabbit reticulocyte lysate showed no enzymatic activity. The activity of rat liver ATP citrate lyase was inhibited by radicicol and BR-1 but not by BR-6. Kinetic analysis demonstrated that radicicol was a noncompetitive inhibitor of ATP citrate lyase with K-i values for citrate and ATP of 13 and 7 muM, respectively.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo; University of Tokyo	Yoshida, M (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1138657, Japan.		Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674; Ishigami, Ken/0000-0002-6917-1532				BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CHANMUGAM P, 1995, J BIOL CHEM, V270, P5418, DOI 10.1074/jbc.270.10.5418; CREWS CM, 1994, J BIOL CHEM, V269, P15411; DELMOTTE P, 1953, NATURE, V171, P344, DOI 10.1038/171344a0; ELSHOURBAGY NA, 1990, J BIOL CHEM, V265, P1430; Gribble AD, 1996, J MED CHEM, V39, P3569, DOI 10.1021/jm960167w; Ki SW, 1998, J ANTIBIOT, V51, P936, DOI 10.7164/antibiotics.51.936; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; KWON HJ, 1995, J BIOCHEM-TOKYO, V118, P221, DOI 10.1093/oxfordjournals.jbchem.a124882; KWON HJ, 1992, CANCER RES, V52, P6926; Kwon HJ, 1997, ONCOGENE, V15, P2625, DOI 10.1038/sj.onc.1201443; KWON HJ, 1992, BIOSCI BIOTECH BIOCH, V56, P538; McCAPRA FRANK, 1964, TETRAHEDRON LETT, V15/16, P869; OIKAWA T, 1993, EUR J PHARMACOL, V241, P221, DOI 10.1016/0014-2999(93)90206-W; Pizer ES, 1998, CANCER-AM CANCER SOC, V83, P528, DOI 10.1002/(SICI)1097-0142(19980801)83:3<528::AID-CNCR22>3.0.CO;2-X; Pizer ES, 2000, CANCER RES, V60, P213; Rashid A, 1997, AM J PATHOL, V150, P201; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Schulte TW, 1998, CELL STRESS CHAPERON, V3, P100, DOI 10.1379/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2; Sharma SV, 1998, ONCOGENE, V16, P2639, DOI 10.1038/sj.onc.1201790; SHIMADA Y, 1995, J ANTIBIOT, V48, P824, DOI 10.7164/antibiotics.48.824; Soga S, 1999, CANCER RES, V59, P2931; Soga S, 1998, J BIOL CHEM, V273, P822, DOI 10.1074/jbc.273.2.822; Takeda Y., 1969, METHOD ENZYMOL, V13, P153, DOI [DOI 10.1016/0076-6879(69)13032-3, 10.1016/0076-6879(69)13032-3]; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; ZHAO JF, 1995, ONCOGENE, V11, P161	29	53	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39231	39236		10.1074/jbc.M006192200	http://dx.doi.org/10.1074/jbc.M006192200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11007781	hybrid			2022-12-25	WOS:000165953100040
J	Kusch, A; Tkachuk, S; Haller, H; Dietz, R; Gulba, DC; Lipp, M; Dumler, I				Kusch, A; Tkachuk, S; Haller, H; Dietz, R; Gulba, DC; Lipp, M; Dumler, I			Urokinase stimulates human vascular smooth muscle cell migration via a phosphatidylinositol 3-kinase-Tyk2 interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PLASMINOGEN-ACTIVATOR; SIGNAL-TRANSDUCTION; PHOSPHOINOSITIDE 3-KINASES; RECOMBINANT ADENOVIRUS; ENDOTHELIAL-CELLS; HUMAN-NEUTROPHILS; MAMMALIAN-CELLS; RECEPTOR; CHEMOTAXIS	Janus kinases Jak1 and Tyk2 play an important role in urokinase-type plasminogen activator (uPA)-dependent signaling. We have recently demonstrated that both kinases are associated with the uPA receptor (uPAR) and mediate uPA-induced activation of signal transducers and activators of transcription (Stat1, Stat2, and Stat4) in human vascular smooth muscle cells (VSMC). Janus kinases are not only required for Stat activation but may also interfere with other intracellular signaling pathways. Here we report that in VSMC, Tyk2 interacts with a downstream signaling cascade involving phosphatidylinositol S-kinase (PI3-K). me demonstrate that uPA induces PI3-K activation, which is abolished in VSMC expressing the dominant negative form of Tyk2. The regulatory subunit p85 of PI3-K. co-immunoprecipitates with Tyk2 but not with Jak1, Jak2, or Jak3, and uPA stimulation increases the PI3-K activity in Tyk2 immunoprecipitates. Tyk2 directly binds to either of the two Src homology 2(SH2)p85 domains in a uPA-dependent fashion. me provide evidence that the Tyk2-mediated PI3-K activation in response to uPA is required for VSMC migration. Thus, two unrelated structurally distinct specific inhibitors of PI3-K, wortmannin and LY294002, prevent VSMC migration induced by uPA. No migratory effect of uPA was observed in VSMC expressing the dominant negative form of Tyk2. Our results underscore the versatile function of Tyk2 in uPA-related intracellular signaling and indicate that PI3-K plays a selective role in the regulation of VSMC migration.	Humboldt Univ, Charite Franz Volhard Clin, D-13125 Berlin, Germany; Humboldt Univ, Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Hannover Med Sch, D-30625 Hannover, Germany	Humboldt University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; Hannover Medical School	Dumler, I (corresponding author), Humboldt Univ, Charite Franz Volhard Clin, Wiltberg Str 50, D-13125 Berlin, Germany.		Lipp, Martin/G-2235-2010	Lipp, Martin/0000-0002-0087-2672				Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Al-Shami A, 1999, J BIOL CHEM, V274, P5333, DOI 10.1074/jbc.274.9.5333; Bao HF, 1999, BLOOD, V93, P3757, DOI 10.1182/blood.V93.11.3757.411a34_3757_3773; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; Blasi F, 1999, APMIS, V107, P96, DOI 10.1111/j.1699-0463.1999.tb01531.x; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; Carmeliet P, 1998, THROMB RES, V91, P255, DOI 10.1016/S0049-3848(98)00122-4; Carmeliet P, 1997, J CLIN INVEST, V99, P200, DOI 10.1172/JCI119148; Carriero MV, 1999, CANCER RES, V59, P5307; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Chatterjee-Kishore M, 2000, TRENDS CELL BIOL, V10, P106, DOI 10.1016/S0962-8924(99)01709-2; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chiaradonna F, 1999, EMBO J, V18, P3013, DOI 10.1093/emboj/18.11.3013; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dear AE, 1998, EUR J BIOCHEM, V252, P185, DOI 10.1046/j.1432-1327.1998.2520185.x; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; DELROSSO M, 1993, BIOCHEM BIOPH RES CO, V190, P347, DOI 10.1006/bbrc.1993.1054; Dumler I, 1999, ARTERIOSCL THROM VAS, V19, P290, DOI 10.1161/01.ATV.19.2.290; DUMLER I, 1994, FEBS LETT, V343, P103, DOI 10.1016/0014-5793(94)80298-X; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; Dumler I, 1999, J BIOL CHEM, V274, P24059, DOI 10.1074/jbc.274.34.24059; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; FIBBI G, 1988, EXP CELL RES, V179, P385, DOI 10.1016/0014-4827(88)90277-7; GUDEWICZ PW, 1987, BIOCHEM BIOPH RES CO, V147, P1176, DOI 10.1016/S0006-291X(87)80193-6; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; ODEKON LE, 1992, J CELL PHYSIOL, V150, P258, DOI 10.1002/jcp.1041500206; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Santos SCR, 2000, ONCOGENE, V19, P1164, DOI 10.1038/sj.onc.1203418; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; SHARFE N, 1995, BLOOD, V86, P2077, DOI 10.1182/blood.V86.6.2077.bloodjournal8662077; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Vicente-Manzanares M, 1999, J IMMUNOL, V163, P4001; Ward AC, 2000, BLOOD, V95, P19; Webb DJ, 2000, J CELL SCI, V113, P123; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	55	69	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39466	39473		10.1074/jbc.M003626200	http://dx.doi.org/10.1074/jbc.M003626200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995743	hybrid			2022-12-25	WOS:000165953100072
J	Forster, C; Kane, PM				Forster, C; Kane, PM			Cytosolic Ca2+ homeostasis is a constitutive function of the V-ATPase in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; YEAST-CELLS; ADENOSINE-TRIPHOSPHATASES; CALCIUM; CALCINEURIN; GENE; DISRUPTION; MUTANTS; HOMOLOG	The vacuole is the major site of intracellular Ca2+ storage in yeast and functions to maintain cytosolic Ca2+ levels within a narrow physiological range via a Ca2+ pump (Pmc1p) and a H+/Ca2+ antiporter (Vcx1p) driven by the vacuolar H+-ATPase (V-ATPase). We examined the function of the V-ATPase in cytosolic Ca2+ homeostasis by comparing responses to a brief Ca2+ challenge of a V-ATPase mutant (vma2 Delta) and wild-type cells treated with the V-ATPase inhibitor concanamycin A. The kinetics of the Ca2+ response were determined using transgenic aequorin as an in vivo cytosolic Ca2+ reporter system. In wild-type cells, the V-ATPase-driven Vcx1p was chiefly responsible for restoring cytosolic Ca2+ concentrations after a brief pulse. In cells lacking V-ATPase activity, brief exposure to elevated Ca2+ compromised viability, even when there was little change in the final cytosolic Ca2+ concentration. vma2 Delta cells were more efficient at restoring cytosolic [Ca2+] after a pulse than concanamycin-treated wild-type cells, suggesting long term loss of V-ATPase triggers compensatory mechanisms. This compensation was dependent on calcineurin, and was mediated primarily by Pmc1p.	SUNY Syracuse, Dept Biochem & Mol Biol, Upstate Med Univ, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Kane, PM (corresponding author), SUNY Syracuse, Dept Biochem & Mol Biol, Upstate Med Univ, 750 E Adams St, Syracuse, NY 13210 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM050322, R01GM50322] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN DG, 1976, SCIENCE, V195, P966; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; Batiza AF, 1996, J BIOL CHEM, V271, P23357, DOI 10.1074/jbc.271.38.23357; Bowman EJ, 2000, J BIOL CHEM, V275, P167, DOI 10.1074/jbc.275.1.167; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Conboy IM, 1999, P NATL ACAD SCI USA, V96, P6324, DOI 10.1073/pnas.96.11.6324; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; DAVIS TN, 1995, ADV SEC MESS PHOSPH, V30, P339; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; DUNN T, 1994, J BIOL CHEM, V269, P7273; Forgac M, 1999, J BIOENERG BIOMEMBR, V31, P57, DOI 10.1023/A:1005496530380; Forster C, 1999, J BIOL CHEM, V274, P9442, DOI 10.1074/jbc.274.14.9442; Fu LW, 2000, J BIOL CHEM, V275, P5431, DOI 10.1074/jbc.275.8.5431; GARRETTENGELE P, 1995, MOL CELL BIOL, V15, P4103; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Graham LA, 1999, J BIOENERG BIOMEMBR, V31, P39, DOI 10.1023/A:1005492429471; HALACHMI D, 1993, FEBS LETT, V316, P73, DOI 10.1016/0014-5793(93)81739-M; IIDA H, 1990, J BIOL CHEM, V265, P13391; Kane PM, 1999, J BIOENERG BIOMEMBR, V31, P49, DOI 10.1023/A:1005444513542; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Miseta A, 1999, J BIOL CHEM, V274, P5939, DOI 10.1074/jbc.274.9.5939; Miseta A, 1999, FEBS LETT, V451, P132, DOI 10.1016/S0014-5793(99)00519-0; NAKAJIMASHIMADA J, 1991, P NATL ACAD SCI USA, V88, P6878, DOI 10.1073/pnas.88.15.6878; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OHYA Y, 1991, J BIOL CHEM, V266, P13971; Paidhungat M, 1997, MOL CELL BIOL, V17, P6339, DOI 10.1128/MCB.17.11.6339; Plant PJ, 1999, J BIOL CHEM, V274, P37270, DOI 10.1074/jbc.274.52.37270; Pozos TC, 1996, MOL CELL BIOL, V16, P3730; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Schiavo G, 1998, ESSAYS BIOCHEM, V33, P29, DOI 10.1042/bse0330029; SHERMAN F, 1982, METHODS YEAST GENETI, P177; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; TANIDA I, 1995, J BIOL CHEM, V270, P10113, DOI 10.1074/jbc.270.17.10113; van Leeuwen JEM, 1999, CURR OPIN IMMUNOL, V11, P242, DOI 10.1016/S0952-7915(99)80040-5; WILLIAMS RJP, 1990, ADV EXP MED BIOL, V269, P7; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZHANG JW, 1998, J BIOL CHEM, V26, P99763	42	64	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38245	38253		10.1074/jbc.M006650200	http://dx.doi.org/10.1074/jbc.M006650200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10991947	hybrid			2022-12-25	WOS:000165739800017
J	Williams, DM; Wang, DX; Cole, PA				Williams, DM; Wang, DX; Cole, PA			Chemical rescue of a mutant protein-tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC MECHANISM; ESCHERICHIA-COLI; GUANIDINE DERIVATIVES; TRANSITION-STATE; CSK; ACTIVATION; SPECIFICITY; INSIGHTS; CELLS; BASE	Protein-tyrosine kinases contain a catalytic loop Arg residue located either two or four positions downstream of a highly conserved Asp residue, In this study, the role of this Arg (Arg-318) in the protein-tyrosine kinase C-terminal Src kinase (Csk) was investigated, The observed k(cat) for phosphorylation of the random copolymer poly(Glu,Tyr) substrate by Csk R318A is similar to 3000-fold smaller compared with that of wild type Csk, whereas the K-m values for ATP and poly(Glu,Tyr) are only mildly affected. The k(cat) value for poly(Glu,Tyr) phosphorylation by the Csk double mutant A316R,R318A is 100-fold greater than the k(cat) value for the single R318A mutant, suggesting that an Arg positioned at the alternative location fulfills a similar function as in wild type, Csk R318A kinase activity can also be partially recovered by several exogenous small molecules including guanidinium and imidazole, These molecules contain key features whose roles in catalysis can be rationalized from a known x-ray structure of the insulin receptor tyrosine kinase, Imidazole is the best of these activators, enhancing phosphorylation rates by Csk R318A up to 100-fold for poly(Glu,Tyr) and significantly stimulating Csk R318A phosphorylation of the physiologic substrate Src. This chemical rescue of mutant protein kinase activity might find applications in cell signal transduction experiments.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Johns Hopkins University	Cole, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Rm 316,Hunterian Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL CANCER INSTITUTE [R01CA074305, R29CA074305, T32CA009243] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA09243, CA74305-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Admiraal SJ, 1999, BIOCHEMISTRY-US, V38, P4701, DOI 10.1021/bi9827565; Boehlein SK, 1997, J BIOL CHEM, V272, P12384, DOI 10.1074/jbc.272.19.12384; BOUGERET C, 1993, ONCOGENE, V8, P1241; CARTER P, 1987, SCIENCE, V237, P394, DOI 10.1126/science.3299704; COLE PA, 1995, J BIOL CHEM, V270, P22105, DOI 10.1074/jbc.270.38.22105; COLE PA, 1994, J BIOL CHEM, V269, P30880; Curley K, 1998, J AM CHEM SOC, V120, P8573, DOI 10.1021/ja981786s; DHALLA AM, 1994, PROTEIN SCI, V3, P476; EHRIG T, 1991, BIOCHEMISTRY-US, V30, P1062, DOI 10.1021/bi00218a026; Grace MR, 1997, BIOCHEMISTRY-US, V36, P1874, DOI 10.1021/bi962138t; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jiang WJ, 2000, BIOCHEMISTRY-US, V39, P7990, DOI 10.1021/bi000630d; Kim K, 1997, J AM CHEM SOC, V119, P11096, DOI 10.1021/ja972110k; Kim K, 1998, J AM CHEM SOC, V120, P6851, DOI 10.1021/ja9808393; Lee CL, 1999, NAT BIOTECHNOL, V17, P759, DOI 10.1038/11691; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; Muir TW, 1998, P NATL ACAD SCI USA, V95, P6705, DOI 10.1073/pnas.95.12.6705; Nagai Y, 2000, NAT BIOTECHNOL, V18, P313, DOI 10.1038/73767; Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; PERONA JJ, 1994, BIOCHEMISTRY-US, V33, P3252, DOI 10.1021/bi00177a016; PHILLIPS MA, 1992, PROTEIN SCI, V1, P517; Rynkiewicz MJ, 1996, BIOCHEMISTRY-US, V35, P16174, DOI 10.1021/bi961311i; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SEKIMOTO T, 1993, J BIOL CHEM, V268, P27039; Shah K, 1997, P NATL ACAD SCI USA, V94, P3565, DOI 10.1073/pnas.94.8.3565; SHOKAT KM, 1995, CHEM BIOL, V2, P509, DOI 10.1016/1074-5521(95)90183-3; Sober H. A., 1970, CRC HDB BIOCH SELECT; Sondhi D, 1999, BIOCHEMISTRY-US, V38, P11147, DOI 10.1021/bi990827+; Sondhi D, 1998, BIOCHEMISTRY-US, V37, P165, DOI 10.1021/bi9722960; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; TU CK, 1989, BIOCHEMISTRY-US, V28, P7913, DOI 10.1021/bi00445a054	35	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38127	38130		10.1074/jbc.C000606200	http://dx.doi.org/10.1074/jbc.C000606200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11006267	hybrid			2022-12-25	WOS:000165739800001
J	Stitt, AW; Burke, GA; Chen, F; McMullen, CBT; Vlassara, H				Stitt, AW; Burke, GA; Chen, F; McMullen, CBT; Vlassara, H			Advanced glycation end-product receptor interactions on microvascular cells occur within caveolin-rich membrane domains	FASEB JOURNAL			English	Article									Queens Univ Belfast, Dept Ophthalmol, Belfast BT7 1NN, Antrim, North Ireland; Mt Sinai Med Ctr, Dept Geriatr, New York, NY 10029 USA	Queens University Belfast; Icahn School of Medicine at Mount Sinai	Stitt, AW (corresponding author), Queens Univ Belfast, Royal Victoria Hosp, Dept Ophthalmol, Belfast BT12 6BA, Antrim, North Ireland.		Stitt, Alan/A-9842-2009	Stitt, Alan/0000-0002-8647-9918; Moore, Tara/0000-0002-7659-9326					0	45	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2390	2392						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11024005				2022-12-25	WOS:000165723400007
J	Vos, MD; Ellis, CA; Bell, A; Birrer, MJ; Clark, GJ				Vos, MD; Ellis, CA; Bell, A; Birrer, MJ; Clark, GJ			Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENIC RAS; INCREASING COMPLEXITY; EPITHELIAL-CELLS; HUMAN CANCER; PROTEIN; GROWTH; TRANSFORMATION; KINASE; DIFFERENTIATION; REQUIREMENT	Although activated Ras proteins are usually associated with driving growth and transformation, they may also induce senescence, apoptosis, and terminal differentiation. The subversion of these anti-neoplastic effects during Ras-dependent tumor development may be as important as the acquisition of the pro-neoplastic effects. None of the currently identified potential Ras effector proteins can satisfactorily explain the apoptotic action of Ras. Consequently, we have sought to identify novel Ras effecters that may be responsible for apoptosis induction. By examining the EST data base, we identified a potential. Ras association domain in the tumor suppressor RASSF1. We now show that RASSF1 binds Ras in a GTP-dependent manner, both in vivo and directly in vitro. Moreover, activated Ras enhances and dominant negative Ras inhibits the cell death induced by transient transfection of RASSF1 into 293-T cells. This cell death appears to be apoptotic in nature, as RASSF1-transfected 293-T cells exhibit membrane blebbing and can be rescued by the addition of a caspase inhibitor. Thus, the RASSF1 tumor suppressor may serve as a novel Ras effector that mediates the apoptotic effects of oncogenic Ras.	NCI, Dept Cell & Canc Biol, NIH, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Clark, GJ (corresponding author), NCI, Dept Cell & Canc Biol, NIH, 9610 Med Ctr Dr, Rockville, MD 20850 USA.				DIVISION OF CLINICAL SCIENCES - NCI [Z01SC010359] Funding Source: NIH RePORTER	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOS JL, 1989, CANCER RES, V49, P4682; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHEN CY, 1995, ONCOGENE, V11, P1487; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Ellis CA, 2000, CELL SIGNAL, V12, P425, DOI 10.1016/S0898-6568(00)00084-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fullwood P, 1999, CANCER RES, V59, P4662; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; HUBER BE, 1988, ONCOGENE, V3, P245; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; OCHIENG J, 1991, INVAS METAST, V11, P38; PATERSON H, 1987, CELL, V51, P803, DOI 10.1016/0092-8674(87)90103-6; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Stennicke HR, 2000, BBA-PROTEIN STRUCT M, V1477, P299, DOI 10.1016/S0167-4838(99)00281-2; TAKIGUCHI Y, 1992, CLIN EXP METASTAS, V10, P351, DOI 10.1007/BF00058175; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; Wyllie AH, 1997, EUR J CELL BIOL, V73, P189; YUSPA SH, 1985, NATURE, V314, P459, DOI 10.1038/314459a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	52	238	259	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35669	35672		10.1074/jbc.C000463200	http://dx.doi.org/10.1074/jbc.C000463200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10998413	hybrid			2022-12-25	WOS:000165382000004
J	Andoh, T; Lee, SY; Chiueh, CC				Andoh, T; Lee, SY; Chiueh, CC			Preconditioning regulation of bcl-2 and p66(shc) by human NOS1 enhances tolerance to oxidative stress	FASEB JOURNAL			English	Article									NIMH, Ctr Clin, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Institute of Mental Health (NIMH)	Chiueh, CC (corresponding author), NIMH, Ctr Clin, NIH, NIH Bldg 10,Room 3D-41, Bethesda, MD 20892 USA.			Lee, Sang/0000-0003-3911-8316	NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002648] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))			0	71	71	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2144	2146						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11023998				2022-12-25	WOS:000165190800006
J	Gardiner, EM; Baldock, PA; Thomas, GP; Sims, NA; Henderson, NK; Hollis, B; White, CP; Sunn, KL; Morrison, NA; Walsh, WR; Eisman, JA				Gardiner, EM; Baldock, PA; Thomas, GP; Sims, NA; Henderson, NK; Hollis, B; White, CP; Sunn, KL; Morrison, NA; Walsh, WR; Eisman, JA			Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage	FASEB JOURNAL			English	Article						osteoclast; osteocyte; periosteum; uncoupling; turnover	OSTEOCALCIN GENE-EXPRESSION; POSTMENOPAUSAL OSTEOPOROSIS; OSTEOCLAST DIFFERENTIATION; MOUSE; 1,25-DIHYDROXYVITAMIN-D; CALCITRIOL; MATRIX; RAT; RADIOIMMUNOASSAY; RESPONSIVENESS	The microarchitecture of bone is regulated by complex interactions between the bone-forming and resorbing cells, and several compounds regulate both actions. For example, vitamin D, which is required for bone mineralization, also stimulates bone resorption. Transgenic mice overexpressing the vitamin D receptor solely in mature cells of the osteoblastic bone-forming lineage were generated to test the potential therapeutic value of shifting the balance of vitamin D activity in favor of bone formation. Cortical bone was 5% wider and 15% stronger in these mice due to a doubling of periosteal mineral apposition rate without altered body weight or calcium homeostatic hormone levels. A 20% increase in trabecular bone volume in transgenic vertebrae was also observed, unexpectedly associated with a 30% reduction in resorption surface rather than greater bone formation. These findings indicate anabolic vitamin D activity in bone and identify a previously unknown pathway from mature osteoblastic cells to inhibit osteoclastic bone resorption, counterbalancing the known stimulatory action through immature osteoblastic cells. A therapeutic approach that both stimulates cortical anabolic and inhibits trabecular resorptive pathways would be ideal for treatment of osteoporosis and other osteopenic disorders.	Garvan Inst Med Res, Bone & Mineral Res Program, Sydney, NSW 2010, Australia; Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; Prince Wales Hosp, Dept Orthopaed, Sydney, NSW, Australia	Garvan Institute of Medical Research; Medical University of South Carolina	Gardiner, EM (corresponding author), Garvan Inst Med Res, Bone & Mineral Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	e.gardiner@ganan.unsw.edu.au	White, Christopher/K-8262-2019; Eisman, John A/C-2886-2014; Thomas, Gethin P/A-3624-2011; Baldock, Paul/B-3840-2012; Morrison, Nigel A/F-4082-2012; Sims, Natalie Ann/A-7192-2012	White, Christopher/0000-0002-7732-2206; Morrison, Nigel A/0000-0003-4774-3808; Sims, Natalie Ann/0000-0003-1421-8468; Briffa, Kathy/0000-0002-0731-4112; Walsh, William/0000-0002-5023-6148; Thomas, Gethin/0000-0001-9081-3686	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043421] Funding Source: NIH RePORTER; NIAMS NIH HHS [1RO1AR43421] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAK B, 1992, BONE, V13, P289, DOI 10.1016/8756-3282(92)90073-6; Candeliere GA, 1996, MOL CELL BIOL, V16, P584; Corral DA, 1998, P NATL ACAD SCI USA, V95, P13835, DOI 10.1073/pnas.95.23.13835; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; GALLAGHER JC, 1990, ANN INTERN MED, V113, P649, DOI 10.7326/0003-4819-113-9-649; Gerstenfeld LC, 1999, J BONE MINER RES, V14, P850, DOI 10.1359/jbmr.1999.14.6.850; GUNDBERG CM, 1992, ENDOCRINOLOGY, V130, P1909, DOI 10.1210/en.130.4.1909; Hollis BW, 1996, CLIN CHEM, V42, P586; Horwood NJ, 1998, ENDOCRINOLOGY, V139, P4743, DOI 10.1210/en.139.11.4743; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V217, P264, DOI 10.1006/bbrc.1995.2773; ISHIDA H, 1993, ENDOCRINOLOGY, V132, P61, DOI 10.1210/en.132.1.61; Kartsogiannis V, 1999, J BONE MINER RES, V14, pS361; Lian JB, 1997, ENDOCRINOLOGY, V138, P2117, DOI 10.1210/en.138.5.2117; Lips P, 1996, ANN INTERN MED, V124, P400, DOI 10.7326/0003-4819-124-4-199602150-00003; MAJESKA RJ, 1982, CALCIFIED TISSUE INT, V34, P59, DOI 10.1007/BF02411210; MARIE PJ, 1985, METABOLISM, V34, P777, DOI 10.1016/0026-0495(85)90030-7; MARTIN TJ, 1994, J CELL BIOCHEM, V56, P357, DOI 10.1002/jcb.240560312; McClung MR, 1996, BONE, V19, pS195, DOI 10.1016/S8756-3282(96)90165-9; MCDONNELL DP, 1989, MOL ENDOCRINOL, V3, P635, DOI 10.1210/mend-3-4-635; Murakami T, 1998, BIOCHEM BIOPH RES CO, V252, P747, DOI 10.1006/bbrc.1998.9723; Nijweide P. J., 1996, P115; OTT SM, 1989, ANN INTERN MED, V110, P267, DOI 10.7326/0003-4819-110-4-267; OWEN TA, 1991, ENDOCRINOLOGY, V128, P1496, DOI 10.1210/endo-128-3-1496; PAGE KM, 1977, THEORY PRACTICE HIST, P223; PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096; PARFITT AM, 1995, J BONE MINER RES, V10, P466; PIERCE EA, 1987, J BIOL CHEM, V262, P17092; PRICE PA, 1982, P NATL ACAD SCI-BIOL, V79, P7734, DOI 10.1073/pnas.79.24.7734; REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939; Rico H, 1997, CALCIFIED TISSUE INT, V61, P431, DOI 10.1007/s002239900361; Sims NA, 1997, MOL ENDOCRINOL, V11, P1695, DOI 10.1210/me.11.11.1695; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Terai K, 1999, J BONE MINER RES, V14, P839, DOI 10.1359/jbmr.1999.14.6.839; Thomsen JS, 1996, BONE, V19, P505, DOI 10.1016/S8756-3282(96)00231-1; TILYARD MW, 1992, NEW ENGL J MED, V326, P357, DOI 10.1056/NEJM199202063260601; TUOHIMAA P, 1992, J STEROID BIOCHEM, V43, P649, DOI 10.1016/0960-0760(92)90290-Y; UhlandSmith A, 1996, J BONE MINER RES, V11, P1921; Vedi S, 1996, BONE, V19, P535, DOI 10.1016/S8756-3282(96)00227-X; Westerlind KC, 1997, P NATL ACAD SCI USA, V94, P4199, DOI 10.1073/pnas.94.8.4199; Yasuda H, 1999, BONE, V25, P109, DOI 10.1016/S8756-3282(99)00121-0; Zhang R, 1997, J BIOL CHEM, V272, P110, DOI 10.1074/jbc.272.1.110; Zhou H, 1999, J BONE MINER RES, V14, pS361; Zhou H, 1999, J BONE MINER RES, V14, pS198	43	121	128	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2000	14	13					1908	1916		10.1096/fj.99-1075com	http://dx.doi.org/10.1096/fj.99-1075com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023975				2022-12-25	WOS:000089634400010
J	Kasof, GM; Gomes, BC				Kasof, GM; Gomes, BC			Livin, a novel inhibitor of apoptosis protein family member	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CELL-DEATH; BACULOVIRAL-INHIBITOR; SURVIVIN; IAP; CASPASES; GENE; CANCER; XIAP; EXPRESSION	A novel human inhibitor of apoptosis protein (IAP) family member termed Livin was identified, containing a single baculoviral IAP repeat (BIR) domain and a COOH-terminal RING finger domain. The mRNA for livin was not detectable by Northern blot in most normal adult tissues with the exception of the placenta, but was present in developmental tissues and in several cancer cell lines. Highest levels were observed in two melanoma-derived cell lines, G361 and SK-Me129, Transfection of livin in HeLa cells resulted in protection from apoptosis induced by expression of FADD, Bax, RIP, RIP3, and DR6. Similar to other IAP family members, the anti-apoptotic activity of Livin was dependent on the BIR domain, Livin was also capable of inhibiting DEVD-like caspase activity triggered by tumor necrosis factor-cy, In vitro binding studies demonstrated a direct interaction between Livin and the active form of the downstream caspases, caspase-3 and -7, that was dependent on the BIR domain of Livin, In addition, the unprocessed and cleaved forms of caspase-9 co-immuno-precipitated with Livin in vivo, and recombinant Livin could inhibit the activation of caspase-9 induced by Apaf-1, cytochrome c, and dATP, The subcellular distribution of the transfected Livin was analyzed by immunofluorescence. Both Livin and Survivin were expressed in the nucleus and in a filamentous pattern throughout the cytoplasm. In contrast to the apoptotic activity, the COOH-terminal RING domain mediated its subcellular localization patterning. Further studies found that transfection of an antisense construct against livin could trigger apoptosis specifically in cell lines expressing livin mRNA, This was associated with an increase in DNA fragmentation and in DEVD-like caspase activity. Thus, disruption of Livin may provide a strategy to induce apoptosis in certain cancer cells.	AstraZeneca Pharmaceut, Enabling Sci & Technol, Wilmington, DE 19803 USA	AstraZeneca	Gomes, BC (corresponding author), AstraZeneca Pharmaceut, Enabling Sci & Technol, CRDL 145,1800 Concord Pike, Wilmington, DE 19803 USA.							Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Barks JH, 1997, GENE CHROMOSOME CANC, V19, P278, DOI 10.1002/(SICI)1098-2264(199708)19:4<278::AID-GCC11>3.3.CO;2-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Grossman D, 1999, LAB INVEST, V79, P1121; Hauser HP, 1998, J CELL BIOL, V141, P1415, DOI 10.1083/jcb.141.6.1415; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hinds MG, 1999, NAT STRUCT BIOL, V6, P648; Kasof GM, 2000, FEBS LETT, V473, P285, DOI 10.1016/S0014-5793(00)01473-3; Kawasaki H, 1998, CANCER RES, V58, P5071; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Lu CD, 1998, CANCER RES, V58, P1808; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Olie RA, 2000, CANCER RES, V60, P2805; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pan GH, 1998, FEBS LETT, V431, P351, DOI 10.1016/S0014-5793(98)00791-1; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Saitoh Y, 1999, INT J ONCOL, V15, P137; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Sun XQ, 1999, J BIOL CHEM, V274, P16871, DOI 10.1074/jbc.274.24.16871; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tamm I, 1998, CANCER RES, V58, P5315; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Xu DG, 1997, NAT MED, V3, P997, DOI 10.1038/nm0997-997; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yu PW, 1999, CURR BIOL, V9, P539, DOI 10.1016/S0960-9822(99)80239-5	47	375	539	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3238	3246		10.1074/jbc.M003670200	http://dx.doi.org/10.1074/jbc.M003670200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11024045	hybrid			2022-12-25	WOS:000166784900035
J	Chen, CH; Tsai, WY; Chen, HR; Wang, CH; Cheng, SC				Chen, CH; Tsai, WY; Chen, HR; Wang, CH; Cheng, SC			Identification and characterization of two novel components of the prp19p-associated complex, Ntc30p and Ntc20p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNWINDS RNA DUPLEXES; SMALL NUCLEAR-RNA; SACCHAROMYCES-CEREVISIAE; PREMESSENGER RNA; IN-VITRO; PROTEIN; YEAST; SPLICEOSOME; PRP19; U4	The yeast Saccharomyces cerevisiae Prp19p protein is an essential splicing factor and a spliceosomal component. It is not tightly associated with small nuclear RNAs (snRNAs) but is associated with a protein complex consisting of at least eight proteins. We have identified two novel components of the Prp19p-associated complex, Ntc30p and Ntc20p, Like other identified components of the complex, both Ntc30p and Ntc20p are associated with the spliceosome in the same manner as Prp19p immediately after or concurrently with dissociation of U4, indicating that the entire complex may bind to the spliceosome as an intact form. Neither Ntc30p nor Ntc20p directly interacts with Prp19p, but both interact with another component of the complex, Ntc85p. Immunoprecipitation analysis revealed an ordered interactions of these components in formation of the Prp19-passociated complex. Although null mutants of NTC30 or NTC20 showed no obvious growth phenotype, deletion of both genes impaired yeast growth resulting in accumulation of precursor mRNA Extracts prepared from such a strain were defective in pre-mRNA splicing in vitro, but the splicing activity could be restored upon addition of the purified Prp19p-associated complex. These results indicate that Ntc30p and Ntc20p are auxiliary splicing factors the functions of which may be modulating the function of the Prp19p-associated complex.	Natl Yang Ming Univ, Inst Microbiol & Immunol, Shih Pai 112, Taiwan; Acad Sinica, Inst Mol Biol, Nankang 115, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Cheng, SC (corresponding author), Natl Yang Ming Univ, Inst Microbiol & Immunol, Shih Pai 112, Taiwan.		Chen, Chun-Hong/E-3990-2010	CHEN, CHUN-HONG/0000-0002-3028-5508				BEGGS JD, 1993, MOL BIOL REP, V18, P99, DOI 10.1007/BF00986763; Chen HR, 1999, P NATL ACAD SCI USA, V96, P5406, DOI 10.1073/pnas.96.10.5406; Chen HR, 1998, MOL CELL BIOL, V18, P2196, DOI 10.1128/MCB.18.4.2196; Dix I, 1999, RNA, V5, P360, DOI 10.1017/S1355838299981396; Fabrizio P, 1997, EMBO J, V16, P4092, DOI 10.1093/emboj/16.13.4092; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; Laggerbauer B, 1998, P NATL ACAD SCI USA, V95, P4188, DOI 10.1073/pnas.95.8.4188; LIN RJ, 1985, J BIOL CHEM, V260, P4780; MELNICK L, 1993, J MOL BIOL, V233, P372, DOI 10.1006/jmbi.1993.1518; Moore M., 1993, RNA WORLD, P303; RYMOND BC, 1992, MOL CELLULAR BIOL YE, P143; Schwer B, 1998, EMBO J, V17, P2086, DOI 10.1093/emboj/17.7.2086; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; TARN WY, 1993, P NATL ACAD SCI USA, V90, P10821, DOI 10.1073/pnas.90.22.10821; TARN WY, 1993, MOL CELL BIOL, V13, P1883, DOI 10.1128/MCB.13.3.1883; TARN WY, 1994, EMBO J, V13, P2421, DOI 10.1002/j.1460-2075.1994.tb06527.x; Tsai WY, 1999, J BIOL CHEM, V274, P9455, DOI 10.1074/jbc.274.14.9455; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; Wagner JDO, 1998, EMBO J, V17, P2926, DOI 10.1093/emboj/17.10.2926; Wang Y, 1998, CURR BIOL, V8, P441, DOI 10.1016/S0960-9822(98)70178-2; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; XU Y, 1990, MOL CELL BIOL, V10, P1217, DOI 10.1128/MCB.10.3.1217	23	35	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					488	494		10.1074/jbc.M006958200	http://dx.doi.org/10.1074/jbc.M006958200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11018040	hybrid			2022-12-25	WOS:000166280700066
J	Katsel, PL; Greenstein, RJ				Katsel, PL; Greenstein, RJ			Identification of overlapping AP-2/NF-kappa B-responsive elements on the rat cholecystokinin gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MESSENGER-RNA EXPRESSION; CARCINOMA CELL-LINE; PROTEIN-KINASE C; TRANSCRIPTION FACTOR; DIFFERENTIAL EXPRESSION; GLUCOCORTICOID RECEPTOR; IMMUNOREACTIVE CCK; BRAIN; SITE	In this study we evaluate both proximal and more distal transcriptional regulation of the 5' flanking region of the rat cholecystokinin gene in transfected GH3 (rat pituitary tumor) cells. Transcriptional activity was measured on the intact (-400 to +73) 5' flanking region of cholecystokinin (CCK), as well as with DNA constructs, which were deleted in both the conventional 5' to 3', as well as an unconventional 3' to 5' direction. Our in vivo studies indicate complex phorbol ester and forskolin interactions in the 10-base pair region between - 130 and -140. We conclude, there are at least two transcriptional factors involved in regulation of the rat CCK transcription in this region. In vitro studies utilizing heterologous nuclear (HeLa) extract, as well as purified transcription factors AP-2 and NF-KB, identify overlapped AP-2- and NF-KB-responsive elements within the 17-base pair sequence between -149 and -134 of the distal 5' flanking region. In this region complex transcriptional regulation occurs, which indicates inhibition of AP-2 CCK promoter complexing by NF-KB. Six-point mutations introduced into this sequence prevent AP-2 and NF-KB binding to CCK promoter, as well as its transcriptional activation by phorbol ester and forskolin in GH3 cells.	VAMC, Bronx, NY 10468 USA; CUNY Mt Sinai Sch Med, Dept Anesthesiol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Katsel, PL (corresponding author), VAMC, 151,Res Bldg,Rm 2F-30,130 W Kingsbridge Rd, Bronx, NY 10468 USA.							AGNATI LF, 1985, ANN NY ACAD SCI, V448, P315, DOI 10.1111/j.1749-6632.1985.tb29927.x; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BEINFELD MC, 1992, NEUROPEPTIDES, V22, P213, DOI 10.1016/0143-4179(92)90048-2; BEINFELD MC, 1992, PEPTIDES, V13, P545, DOI 10.1016/0196-9781(92)90087-J; BRUNVAND MW, 1993, NUCLEIC ACIDS RES, V21, P4824, DOI 10.1093/nar/21.20.4824; Ciaccio PJ, 1996, BIOCHEM BIOPH RES CO, V228, P524, DOI 10.1006/bbrc.1996.1693; DESCHENES RJ, 1984, P NATL ACAD SCI-BIOL, V81, P726, DOI 10.1073/pnas.81.3.726; DOCKRAY GJ, 1976, NATURE, V264, P568, DOI 10.1038/264568a0; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; FONG CLW, 1995, BIOCHEM BIOPH RES CO, V212, P879, DOI 10.1006/bbrc.1995.2051; FRIEDMAN J, 1985, P NATL ACAD SCI USA, V82, P5593, DOI 10.1073/pnas.82.17.5593; GREENSTEIN RJ, 1992, J SURG RES, V53, P12, DOI 10.1016/0022-4804(92)90005-K; Hansen TV, 1999, MOL ENDOCRINOL, V13, P466, DOI 10.1210/me.13.3.466; HAUN RS, 1990, J BIOL CHEM, V265, P15455; ICHIHARA K, 1983, BIOCHEM BIOPH RES CO, V112, P891, DOI 10.1016/0006-291X(83)91701-1; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Ivy AC, 1928, AM J PHYSIOL, V86, P599, DOI 10.1152/ajplegacy.1928.86.3.599; JUNCOSAGINESTA M, 1994, BIOTECHNIQUES, V16, P820; Katsel PL, 1997, DNA CELL BIOL, V16, P1013, DOI 10.1089/dna.1997.16.1013; KONINGS PNM, 1993, NEUROPEPTIDES, V25, P19, DOI 10.1016/0143-4179(93)90064-H; Li JJ, 1997, CANCER RES, V57, P3569; Liden J, 1997, J BIOL CHEM, V272, P21467, DOI 10.1074/jbc.272.34.21467; MONSTEIN HJ, 1993, NEUROREPORT, V4, P195, DOI 10.1097/00001756-199302000-00020; MONSTEIN HJ, 1991, FEBS LETT, V293, P145, DOI 10.1016/0014-5793(91)81172-5; MONSTEIN HJ, 1993, NEUROREPORT, V4, P1167; MULLER JE, 1977, P NATL ACAD SCI USA, V74, P3035, DOI 10.1073/pnas.74.7.3035; Nielsen FC, 1996, DNA CELL BIOL, V15, P53, DOI 10.1089/dna.1996.15.53; ODUM L, 1995, NEUROPEPTIDES, V29, P45, DOI 10.1016/0143-4179(95)90055-1; Ratineau C, 1996, J ENDOCRINOL, V151, P137, DOI 10.1677/joe.0.1510137; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SIMERLY RB, 1987, P NATL ACAD SCI USA, V84, P2087, DOI 10.1073/pnas.84.7.2087; TAKAHASHI Y, 1986, GENE, V50, P353; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; VANDERHAEGHEN JJ, 1975, NATURE, V257, P604, DOI 10.1038/257604a0; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VITALE M, 1991, NUCLEIC ACIDS RES, V19, P169, DOI 10.1093/nar/19.1.169; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Wissink S, 1997, J BIOL CHEM, V272, P22278, DOI 10.1074/jbc.272.35.22278; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	42	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					752	758		10.1074/jbc.M007553200	http://dx.doi.org/10.1074/jbc.M007553200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11022044	hybrid			2022-12-25	WOS:000166280700101
J	Tokita, K; Hocart, SJ; Katsuno, T; Mantey, SA; Coy, DH; Jensen, RT				Tokita, K; Hocart, SJ; Katsuno, T; Mantey, SA; Coy, DH; Jensen, RT			Tyrosine 220 in the 5th transmembrane domain of the neuromedin B receptor is critical for the high selectivity of the peptoid antagonist PD168368	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIN-RELEASING PEPTIDE; SITE-DIRECTED MUTAGENESIS; PROTEIN-COUPLED RECEPTORS; MAMMALIAN BOMBESIN RECEPTORS; HUMAN NEUROKININ-1 RECEPTOR; CATION-PI INTERACTIONS; HIGH-AFFINITY; BINDING-SITES; AGONIST-BINDING; ORBITAL ELECTRONEGATIVITY	Peptoid antagonists are increasingly being described for G; protein-coupled receptors; however, little is known about the molecular basis of their binding, Recently, the peptoid PD168368 was found to be a potent selective neuromedin B receptor (MMBR) antagonist. To investigate the molecular basis for its selectivity for the NMBR over the closely related receptor for gastrin-releasing peptide (GRPR), we used a chimeric receptor approach and a site-directed mutagenesis approach. Mutated receptors were transiently expressed in Balb 3T3. The extracellular domains of the NMBR were not important for the selectivity of PD168368, However, substitution of the 5th upper transmembrane domain (uTM5) of the NMBR by the comparable GRPR domains decreased the affinity Is-fold. When the reverse study was performed by substituting the uTM5 of NMBR into the GRPR, a 9-fold increase in affinity occurred. Each of the 4 amino acids that differed between NMBR and GRPR in the uTM5 region were exchanged, but only the substitution of Phe(220) for Tyr in the NMBR caused a decrease in affinity, When the reverse study was performed to attempt to demonstrate a gain of affinity in the GRPR, the substitution of Tyr(219) for phe caused an increase in affinity. These results suggest that the hydroxyl group of Tyr(220) in uTM5 of NMBR plays a critical role for high selectivity of PD168368 for NMBR over GRPR. Receptor and ligand modeling suggests that the hydroxyl of the Tyr(220) interacts with nitrophenyl group of PD168368 likely primarily by hydrogen bonding; This result shows the selectivity of the peptoid PD168368, similar to that reported for numerous non-peptide analogues with other G protein-coupled receptors, is primarily dependent on interaction with transmembrane amino acids.	NIDDK, Digest Dis Branch, NIH, Bethesda, MD 20892 USA; Tulane Univ, Hlth Sci Ctr, Dept Med, Peptide Res Labs, New Orleans, LA 70112 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Tulane University	Jensen, RT (corresponding author), NIDDK, Digest Dis Branch, NIH, Bldg 10,Rm 9C-103,10 Ctr Dr,MSC 1804, Bethesda, MD 20892 USA.	robertj@bdg10.niddk.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK053100, ZIADK053100] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERS HE, 1991, J NEUROSCI, V11, P846; Ashwood V, 1998, BIOORG MED CHEM LETT, V8, P2589, DOI 10.1016/S0960-894X(98)00462-4; Bastian S, 2000, J BIOL CHEM, V275, P6107, DOI 10.1074/jbc.275.9.6107; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BENYA RV, 1994, MOL PHARMACOL, V46, P235; Boden P, 1996, J MED CHEM, V39, P1664, DOI 10.1021/jm950892r; BODEN PR, 1993, J MED CHEM, V36, P552, DOI 10.1021/jm00057a005; Boyle S, 1994, Bioorg Med Chem, V2, P101, DOI 10.1016/S0968-0896(00)82006-4; BREU V, 1995, EUR J BIOCHEM, V231, P266, DOI 10.1111/j.1432-1033.1995.0266f.x; BROWN MR, 1988, ANN NY ACAD SCI, V547, P174, DOI 10.1111/j.1749-6632.1988.tb23885.x; CASCIERI MA, 1995, MOL PHARMACOL, V47, P660; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; CRIDLAND RA, 1992, BRAIN RES, V584, P163, DOI 10.1016/0006-8993(92)90890-L; DELAFUENTE M, 1993, J NEUROIMMUNOL, V48, P143, DOI 10.1016/0165-5728(93)90186-3; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Du P, 1997, PROTEIN ENG, V10, P109, DOI 10.1093/protein/10.2.109; Eden JM, 1996, BIOORG MED CHEM LETT, V6, P2617, DOI 10.1016/0960-894X(96)00481-7; ENDO T, 1991, J ENDOCRINOL, V131, P313, DOI 10.1677/joe.0.1310313; FATHI Z, 1993, J BIOL CHEM, V268, P14622; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1577, DOI 10.1021/bi00405a027; FONG TM, 1992, J BIOL CHEM, V267, P25664; FUNK CD, 1993, MOL PHARMACOL, V44, P934; GASTEIGER J, 1978, TETRAHEDRON LETT, P3181; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GHATEI MA, 1982, J CLIN ENDOCR METAB, V54, P980, DOI 10.1210/jcem-54-5-980; Gigoux V, 1999, J BIOL CHEM, V274, P20457, DOI 10.1074/jbc.274.29.20457; Gouldson PR, 1997, J MED CHEM, V40, P3871, DOI 10.1021/jm960647n; Hammerland LG, 1999, MOL PHARMACOL, V55, P642; HILL DJ, 1992, ENDOCRINOLOGY, V130, P2811, DOI 10.1210/en.130.5.2811; Horwell D C, 1994, Drug Des Discov, V12, P63; HORWELL DC, 1995, TRENDS BIOTECHNOL, V13, P132; HUNYADY L, 1995, J BIOL CHEM, V270, P9702, DOI 10.1074/jbc.270.17.9702; Jensen RT, 1997, CURRENT CLINICAL TOPICS IN GASTROINTESTINAL PHARMACOLOGY, P144; JENSEN RT, 1988, ANN NY ACAD SCI, V547, P138, DOI 10.1111/j.1749-6632.1988.tb23882.x; JENSEN RT, 1991, TRENDS PHARMACOL SCI, V12, P13, DOI 10.1016/0165-6147(91)90483-9; JI H, 1994, J BIOL CHEM, V269, P16533; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Kobayashi T, 1997, J BIOL CHEM, V272, P15154, DOI 10.1074/jbc.272.24.15154; KOPIN AS, 1995, J BIOL CHEM, V270, P5019, DOI 10.1074/jbc.270.10.5019; KROOG GS, 1995, MED RES REV, V15, P389, DOI 10.1002/med.2610150502; KRYSTEK SR, 1994, J BIOL CHEM, V269, P12383; LEE JA, 1994, BIOCHEMISTRY-US, V33, P14543, DOI 10.1021/bi00252a022; Liaw CW, 1997, MOL ENDOCRINOL, V11, P2048, DOI 10.1210/me.11.13.2048; LIN JT, 1995, J PHARMACOL EXP THER, V275, P285; MAGGI CA, 1993, EUR J PHARMACOL, V234, P83, DOI 10.1016/0014-2999(93)90709-Q; MALATYNSKA E, 1995, NEUROREPORT, V6, P1325, DOI 10.1097/00001756-199506090-00024; Mantey SA, 1997, J BIOL CHEM, V272, P26062, DOI 10.1074/jbc.272.41.26062; MARSILI M, 1980, CROAT CHEM ACTA, V53, P601; MCCOY JG, 1990, PEPTIDES, V11, P595, DOI 10.1016/0196-9781(90)90064-C; Mecozzi S, 1996, P NATL ACAD SCI USA, V93, P10566, DOI 10.1073/pnas.93.20.10566; MOODY TW, 1992, J PHARMACOL EXP THER, V263, P311; Moody TW., 1996, GROWTH FACTORS, P491; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4417, DOI 10.1073/pnas.91.10.4417; NOVOTNY EA, 1994, BIOCHEM BIOPH RES CO, V201, P523, DOI 10.1006/bbrc.1994.1733; PEARLMAN RS, 2000, CONCORD VERSION 4 02; Pearlman RS, 1987, CHEM DES AUTOM NEWS, V2, P1; PERLMAN JH, 1994, J BIOL CHEM, V269, P1610; PINNOCK RD, 1994, BRAIN RES, V653, P119, DOI 10.1016/0006-8993(94)90379-4; RETTORI V, 1989, P NATL ACAD SCI USA, V86, P4789, DOI 10.1073/pnas.86.12.4789; Rodriguez R, 1998, BIOINFORMATICS, V14, P523, DOI 10.1093/bioinformatics/14.6.523; ROUISSI N, 1991, BRIT J PHARMACOL, V103, P1141, DOI 10.1111/j.1476-5381.1991.tb12314.x; RUFFOLO RR, 1993, ANNU REV PHARMACOL, V33, P243, DOI 10.1146/annurev.pharmtox.33.1.243; Ryan FR, 1999, J PHARMACOL EXP THER, V290, P1202; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; Silvente-Poirot S, 1998, MOL PHARMACOL, V54, P364, DOI 10.1124/mol.54.2.364; SINGH L, 1995, EUR J PHARMACOL, V286, P185, DOI 10.1016/0014-2999(95)00445-Q; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; SUNDAY ME, 1993, ANAT REC, V236, P25, DOI 10.1002/ar.1092360107; TACHE Y, 1988, ANN NY ACAD SCI, V547, P183, DOI 10.1111/j.1749-6632.1988.tb23886.x; Tran TA, 1998, J MED CHEM, V41, P2679, DOI 10.1021/jm970393l; Trivedi BK, 1998, J MED CHEM, V41, P38, DOI 10.1021/jm970065l; VARGA G, 1995, EUR J PHARMACOL, V286, P109, DOI 10.1016/0014-2999(95)00567-5; VIGNE P, 1997, EUR J BIOCHEM, V272, pR433; Vogel WK, 1997, MOL PHARMACOL, V52, P1087, DOI 10.1124/mol.52.6.1087; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang WW, 1995, P NATL ACAD SCI USA, V92, P12436, DOI 10.1073/pnas.92.26.12436; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; WESS J, 1993, LIFE SCI, V53, P1447, DOI 10.1016/0024-3205(93)90618-D	80	28	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					495	504		10.1074/jbc.M006059200	http://dx.doi.org/10.1074/jbc.M006059200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11013243	hybrid			2022-12-25	WOS:000166280700067
J	Zamostiano, R; Pinhasov, A; Gelber, E; Steingart, RA; Seroussi, E; Giladi, E; Bassan, M; Wollman, Y; Eyre, HJ; Mulley, JC; Brenneman, DE; Gozes, I				Zamostiano, R; Pinhasov, A; Gelber, E; Steingart, RA; Seroussi, E; Giladi, E; Bassan, M; Wollman, Y; Eyre, HJ; Mulley, JC; Brenneman, DE; Gozes, I			Cloning and characterization of the human activity-dependent neuroprotective protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; COMPARATIVE GENOMIC HYBRIDIZATION; BREAST-CANCER; IN-VITRO; RECEPTOR; LOCALIZATION; GROWTH; VIP; IDENTIFICATION; HOMEODOMAIN	We have recently cloned the mouse activity-dependent neuroprotective protein (ADNP). Here, we disclose the cloning of human ADNP (hADNP) from a fetal brain cDNA library. Comparative sequence analysis of these two ADNP orthologs indicated 90% identity at the mRNA level. Several single nucleotide polymorphic sites were noticed. The deduced protein structure contained nine zinc fingers, a proline-rich region, a nuclear bipartite localization signal, and a homeobox domain profile, suggesting a transcription factor function. Further comparative analysis identified an ADNP paralog (33% identity and 46% similarity), indicating that these genes belong to a novel protein family with a nine-zinc finger motif followed by a homeobox domain. The hADNP gene structure spans similar to 40 kilobases and includes five exons and four introns with alternative splicing of an untranslated second exon. The hADNP gene was mapped to chromosome 20q12-13.2, a region associated with aggressive tumor growth, frequently amplified in many neoplasias, including breast, bladder, ovarian, pancreatic, and colon cancers, hADNP mRNA is abundantly expressed in distinct normal tissues, and high expression levels were encountered in malignant cells. Down-regulation of ADNP by antisense oligodeoxynucleotides up-regulated the tumor suppressor p53 and reduced the viability of intestinal cancer cells by 90%. Thus, ADNP is implicated in maintaining cell survival, perhaps through modulation of p53.	Tel Aviv Univ, Sackler Fac Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel; Agr Res Org, Volcani Ctr, Inst Anim Sci, IL-50250 Bet Dagan, Israel; Tel Aviv Med Ctr & Sch Med, Dept Nephrol, IL-64239 Tel Aviv, Israel; Univ Adelaide, Dept Genet, Adelaide, SA 5006, Australia; NICHD, Dev Neurobiol Lab, Sect Dev & Mol Pharmacol, NIH, Bethesda, MD 20892 USA	Tel Aviv University; Sackler Faculty of Medicine; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; Tel Aviv University; Sackler Faculty of Medicine; University of Adelaide; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Gozes, I (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel.	igozes@post.tau.ac.il	Pinhasov, Albert/X-5304-2019	Pinhasov, Albert/0000-0001-8116-4565	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000047] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Amson R, 2000, P NATL ACAD SCI USA, V97, P5346, DOI 10.1073/pnas.97.10.5346; Ashur-Fabian O, 1997, J MOL NEUROSCI, V9, P211, DOI 10.1007/BF02800503; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; Bassan M, 1999, J NEUROCHEM, V72, P1283, DOI 10.1046/j.1471-4159.1999.0721283.x; BRENNEMAN DE, 1990, J NEUROSCI RES, V25, P386, DOI 10.1002/jnr.490250316; Buniatian G, 1999, BIOL CELL, V91, P675, DOI 10.1016/S0248-4900(00)88531-7; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; DILLOM PJ, 1990, SCIENCE, V248, P1650; El-Rifai W, 1998, CANCER RES, V58, P34; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Gozes I, 1999, CURR MED CHEM, V6, P1019; GOZES I, 1991, J PHARMACOL EXP THER, V257, P959; GOZES I, 2000, IN PRESS ANN N Y ACA; GRESSENS P, 1993, NATURE, V362, P155, DOI 10.1038/362155a0; Hill JM, 1999, NEUROSCIENCE, V93, P783, DOI 10.1016/S0306-4522(99)00155-4; Hoyle J, 1997, HUM GENET, V99, P285, DOI 10.1007/s004390050356; ISOLA JJ, 1995, AM J PATHOL, V147, P905; Jeong J, 2000, DNA CELL BIOL, V19, P291, DOI 10.1089/10445490050021203; JOHNSON GP, 1991, VIROLOGY, V181, P378, DOI 10.1016/0042-6822(91)90508-9; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Lange D, 1999, HISTOL HISTOPATHOL, V14, P821, DOI 10.14670/HH-14.821; Lee TJF, 2000, J BIOMED SCI, V7, P16; LILLING G, 1994, J MOL NEUROSCI, V5, P231, DOI 10.1007/BF02736724; Maizel A, 1999, DEVELOPMENT, V126, P3183; Maruno K, 1998, P NATL ACAD SCI USA, V95, P14373, DOI 10.1073/pnas.95.24.14373; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; Palmedo G, 1997, LAB INVEST, V77, P633; Reichwald K, 2000, MAMM GENOME, V11, P182, DOI 10.1007/s003350010035; Reubi JC, 1996, ANN NY ACAD SCI, V805, P753; SAID SI, 1972, EUR J BIOCHEM, V28, P199, DOI 10.1111/j.1432-1033.1972.tb01903.x; Sonoda G, 1997, GENE CHROMOSOME CANC, V20, P320; Taguchi E, 1998, J BIOCHEM, V124, P1220, DOI 10.1093/oxfordjournals.jbchem.a022241; Tew KD, 1998, CHEM-BIOL INTERACT, V112, P199, DOI 10.1016/S0009-2797(97)00162-2; Virgolini I, 1997, EUR J CLIN INVEST, V27, P793, DOI 10.1046/j.1365-2362.1997.1990742.x; Williams SC, 1997, GENE EXPRESSION, V6, P371; Zabarovsky ER, 2000, NUCLEIC ACIDS RES, V28, P1635, DOI 10.1093/nar/28.7.1635; Zia H, 1996, CANCER RES, V56, P3486; Zupan V, 1998, J NEUROCHEM, V70, P2165	41	179	190	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					708	714		10.1074/jbc.M007416200	http://dx.doi.org/10.1074/jbc.M007416200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11013255	hybrid			2022-12-25	WOS:000166280700095
J	Jui, HY; Tseng, RJ; Wen, X; Fang, HI; Huang, LM; Chen, KY; Kung, HJ; Ann, DK; Shih, HM				Jui, HY; Tseng, RJ; Wen, X; Fang, HI; Huang, LM; Chen, KY; Kung, HJ; Ann, DK; Shih, HM			Protein-tyrosine phosphatase D1, a potential regulator and effector for Tec family kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; PLECKSTRIN HOMOLOGY DOMAINS; RI CROSS-LINKING; BRUTON TYROSINE; SIGNALING PATHWAY; SRC FAMILY; PH DOMAIN; CYTOSKELETAL PROTEIN-4.1; CONSTITUTIVE ACTIVATION; INTERLEUKIN-6 FAMILY	Etk, also named Bmx, is a member of the Tec tyrosine kinase family, which is characterized by a multimodular structure including a pleckstrin homology (PH) domain, an SH3 domain, an SH2 domain, and a catalytic domain. The signaling mechanisms regulating Etk kinase activity remain largely unknown. To identify factor(s) regulating Etk activity, we used the PH domain and a linker region of Etk as a bait for a yeast two-hybrid screen. Three independent clones encoding protein-tyrosine phosphatase D1 (PTPD1) fragments were isolated. The binding of PTPD1 to Etk is specific since PTPD1 cannot associate with either the Akt PH domain or lamin. In vitro and in vivo binding studies demonstrated that PTPD1 can interact with Etk and that residues 726-848 of PTPD1 are essential for this interaction. Deletion analysis of Etk indicated that the PH domain is essential for PTPD1 interaction. Furthermore, the Etk-PTPD1 interaction stimulated the kinase activity of Etk, resulting in an increased phosphotyrosine content in both factors. The Etk-PTPD1 interaction also increased Stat3 activation. The-effect of PTPD1 on Etk activation is specific since PTPD1 cannot potentiate Jak2 activity upon Stat3 activation In addition, Tec (but not Btk) kinase can also be activated by PTPD1. Taken together, these findings indicate that PTPD1 can selectively associate with and stimulate Tec family kinases and modulate Stat3 activation.	Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 11529, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei 11529, Taiwan; Univ So Calif, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA	National Health Research Institutes - Taiwan; National Defense Medical Center; University of Southern California; University of California System; University of California Davis	Shih, HM (corresponding author), Natl Hlth Res Inst, Div Mol & Genom Med, 128 Sect 2,Yen Chiu Yuan Rd, Taipei 11529, Taiwan.		Shih, Hsiu-Ming/S-7023-2018; Kung, Hsing-Jien/C-7651-2013		NATIONAL CANCER INSTITUTE [R37CA039207, R01CA039207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010742] Funding Source: NIH RePORTER; NCI NIH HHS [CA39207] Funding Source: Medline; NIDCR NIH HHS [R01DE10742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P4204, DOI 10.1073/pnas.91.10.4204; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Bhandari V, 1998, J BIOL CHEM, V273, P8691, DOI 10.1074/jbc.273.15.8691; Cao XM, 1996, MOL CELL BIOL, V16, P1595; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; Dorner C, 1998, J BIOL CHEM, V273, P20267, DOI 10.1074/jbc.273.32.20267; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Gibson S, 1996, J IMMUNOL, V156, P2716; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; HIGASHITSUJI H, 1995, ONCOGENE, V10, P407; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3556; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Ma YC, 1998, P NATL ACAD SCI USA, V95, P12197, DOI 10.1073/pnas.95.21.12197; MACHIDE M, 1995, ONCOGENE, V11, P619; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MANO H, 1995, BLOOD, V85, P343; MANO H, 1994, ONCOGENE, V9, P3205; Mano H, 1999, CYTOKINE GROWTH F R, V10, P267, DOI 10.1016/S1359-6101(99)00019-2; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; Miyazato A, 1996, CELL GROWTH DIFFER, V7, P1135; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Novina CD, 1999, MOL CELL BIOL, V19, P5014; Okoh MP, 1999, BIOCHEM BIOPH RES CO, V265, P151, DOI 10.1006/bbrc.1999.1407; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Saharinen P, 1997, BLOOD, V90, P4341; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Sartor CI, 1997, CANCER RES, V57, P978; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SAWADA M, 1994, BIOCHEM BIOPH RES CO, V203, P479, DOI 10.1006/bbrc.1994.2207; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SMITH AL, 1995, BIOCHEM BIOPH RES CO, V209, P959, DOI 10.1006/bbrc.1995.1591; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; Tomlinson MG, 1999, J BIOL CHEM, V274, P13577, DOI 10.1074/jbc.274.19.13577; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; VIHINEN M, 1995, BIOCHEMISTRY-US, V34, P1475, DOI 10.1021/bi00005a002; Vihinen M, 1996, IMMUNOL TODAY, V17, P502, DOI 10.1016/0167-5699(96)30058-3; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; WeberNordt RM, 1996, BLOOD, V88, P809; Weil D, 1997, BLOOD, V90, P4332, DOI 10.1182/blood.V90.11.4332.4332_4332_4340; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; Yamashita Y, 1997, EXP HEMATOL, V25, P211; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yao LB, 1999, J BIOL CHEM, V274, P19752, DOI 10.1074/jbc.274.28.19752; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	74	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41124	41132		10.1074/jbc.M007772200	http://dx.doi.org/10.1074/jbc.M007772200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11013262	hybrid			2022-12-25	WOS:000166114600063
J	Spittaels, K; Van den Haute, C; Van Dorpe, J; Geerts, H; Mercken, M; Bruynseels, K; Lasrado, R; Vandezande, K; Laenen, I; Boon, T; Van Lint, J; Vandenheede, J; Moechars, D; Loos, R; Van Leuven, F				Spittaels, K; Van den Haute, C; Van Dorpe, J; Geerts, H; Mercken, M; Bruynseels, K; Lasrado, R; Vandezande, K; Laenen, I; Boon, T; Van Lint, J; Vandenheede, J; Moechars, D; Loos, R; Van Leuven, F			Glycogen synthase kinase-3 beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; AMYLOID PRECURSOR PROTEIN; DISEASE-LIKE PHOSPHORYLATION; ALZHEIMER-LIKE STATE; HUMAN BRAIN TAU; INTACT-CELLS; KINASE-I; MICROTUBULE-BINDING; NEUROFIBRILLARY TANGLES; MONOCLONAL-ANTIBODIES	Protein tau filaments in brain of patients suffering from Alzheimer's disease, frontotemporal dementia, and other tauopathies consist of protein tau that is hyperphosphorylated.,The responsible kinases operating in vivo in neurons still need to be identified. Here we demonstrate that glycogen synthase kinase-3 beta (GSK-3 beta) is an effective kinase for protein tau in cerebral neurons in vivo in adult GSK-3 beta and GSK-3 beta x human tau40 transgenic mice; Phosphorylated protein tau migrates slower during electrophoretic separation and is revealed by phosphorylation-dependent anti-tau antibodies in Western blot analysis. In addition, its capacity to bind to re-assembled paclitaxel (Taxol(R))-stabilized microtubules is reduced, compared with protein tau isolated from mice not overexpressing GSK-3 beta. Co-expression of GSK-3 beta reduces the number of axonal dilations and alleviates the motoric impairment that was typical for single htau40 transgenic animals (Spittaels, K., Van den Haute, C., Van Dorpe, J., Bruynseels, K., Vandezande, K., Laenen, I., Geerts, H., Mercken, M., Sciot, R., Van Lommel, A., Loos, R., and Van Leuven, F. (1999) Am. J. Pathol. 155, 2153-2165). Although more hyperphosphorylated protein tau is available, neither an increase in insoluble protein tau aggregates nor the presence of paired helical filaments or tangles was observed. These findings could have therapeutic implications in the field of neurodegeneration, as discussed.	Katholieke Univ Leuven VIB, Ctr Human Genet, Expt Genet Grp, B-3000 Leuven, Belgium; Janssen Res Fdn, B-2340 Beerse, Belgium; Katholieke Univ Leuven, Fac Med, Dept Biochem, B-3000 Leuven, Belgium; Katholieke Univ Leuven, Dept Genet Epidemiol, B-3000 Leuven, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; Johnson & Johnson; KU Leuven; KU Leuven	Van Leuven, F (corresponding author), Katholieke Univ Leuven VIB, Ctr Human Genet, Expt Genet Grp, Campus Gasthuisberg O&N 06, B-3000 Leuven, Belgium.	fredvl@med.kuleuven.ac.be	Loos, Ruth J F/Q-2862-2016; Loos, Ruth/GON-5877-2022; Van Lint, Johan/P-9073-2019	Loos, Ruth J F/0000-0002-8532-5087; Van Lint, Johan/0000-0002-0275-571X				ANDERTON BH, 1995, NEUROBIOL AGING, V16, P389, DOI 10.1016/0197-4580(94)00160-3; Arawaka S, 1999, NEUROREPORT, V10, P993, DOI 10.1097/00001756-199904060-00018; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; Billingsley ML, 1997, BIOCHEM J, V323, P577, DOI 10.1042/bj3230577; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; Brion JP, 1999, AM J PATHOL, V154, P255, DOI 10.1016/S0002-9440(10)65272-8; Brownlees J, 1997, NEUROREPORT, V8, P3251, DOI 10.1097/00001756-199710200-00013; BueeScherrer V, 1996, MOL BRAIN RES, V39, P79, DOI 10.1016/0169-328X(96)00003-4; Dayanandan R, 1999, FEBS LETT, V446, P228, DOI 10.1016/S0014-5793(99)00222-7; DREWES G, 1997, CELL, V89, P397; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; FEIGUIN F, 1994, J CELL BIOL, V127, P1021, DOI 10.1083/jcb.127.4.1021; Gartner U, 1998, NEUROBIOL AGING, V19, P535, DOI 10.1016/S0197-4580(98)00094-3; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOTZ J, 1995, EMBO J, V14, P1304, DOI 10.1002/j.1460-2075.1995.tb07116.x; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; Hall GF, 2000, J CELL SCI, V113, P1373; Hall GF, 1997, P NATL ACAD SCI USA, V94, P4733, DOI 10.1073/pnas.94.9.4733; Hanger DP, 1998, J NEUROCHEM, V71, P2465; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Hartigan JA, 1999, J BIOL CHEM, V274, P21395, DOI 10.1074/jbc.274.30.21395; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Hasegawa M, 1999, FEBS LETT, V443, P93, DOI 10.1016/S0014-5793(98)01696-2; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; Hong M, 1997, J BIOL CHEM, V272, P19547, DOI 10.1074/jbc.272.31.19547; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; ISHIGURO K, 1992, NEUROSCI LETT, V148, P202, DOI 10.1016/0304-3940(92)90839-Y; ISHIGURO K, 1993, FEBS LETT, V325, P167, DOI 10.1016/0014-5793(93)81066-9; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; Ishihara T, 1999, NEURON, V24, P751, DOI 10.1016/S0896-6273(00)81127-7; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; LAMBERTY Y, 1991, PHYSIOL BEHAV, V51, P81; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Lovestone S, 1996, NEUROSCIENCE, V73, P1145, DOI 10.1016/0306-4522(96)00126-1; Lovestone S, 1997, NEUROSCIENCE, V78, P309; MANDELKOW EM, 1995, NEUROBIOL AGING, V16, P355, DOI 10.1016/0197-4580(95)00025-A; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MASUROVSKY EB, 1983, NEUROSCIENCE, V10, P491, DOI 10.1016/0306-4522(83)90148-3; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; MERCKEN M, 1992, ACTA NEUROPATHOL, V84, P265, DOI 10.1007/BF00227819; Michel G, 1998, BBA-GEN SUBJECTS, V1380, P177, DOI 10.1016/S0304-4165(97)00139-6; Moechars D, 1996, EMBO J, V15, P1265, DOI 10.1002/j.1460-2075.1996.tb00468.x; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; MunozMontano JR, 1997, FEBS LETT, V411, P183, DOI 10.1016/S0014-5793(97)00688-1; Nonaka S, 1998, P NATL ACAD SCI USA, V95, P2642, DOI 10.1073/pnas.95.5.2642; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Pei JJ, 1999, J NEUROPATH EXP NEUR, V58, P1010, DOI 10.1097/00005072-199909000-00011; Preuss U, 1997, J CELL SCI, V110, P789; Probst A, 2000, ACTA NEUROPATHOL, V99, P469, DOI 10.1007/s004010051148; SatoHarada R, 1996, CELL STRUCT FUNCT, V21, P283, DOI 10.1247/csf.21.283; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; Sengupta A, 1998, ARCH BIOCHEM BIOPHYS, V357, P299, DOI 10.1006/abbi.1998.0813; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; Shiurba RA, 1996, BRAIN RES, V737, P119, DOI 10.1016/0006-8993(96)00717-2; SPERBER BR, 1995, NEUROSCI LETT, V197, P149, DOI 10.1016/0304-3940(95)11902-9; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Spittaels K, 1999, AM J PATHOL, V155, P2153, DOI 10.1016/S0002-9440(10)65533-2; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; TAKEMURA R, 1992, J CELL SCI, V103, P953; Tatebayashi Y, 1999, J NEUROSCI, V19, P5245; Tesseur I, 2000, AM J PATHOL, V156, P951, DOI 10.1016/S0002-9440(10)64963-2; Torroja L, 1999, CURR BIOL, V9, P489, DOI 10.1016/S0960-9822(99)80215-2; Trinczek B, 1999, J CELL SCI, V112, P2355; Utton MA, 1997, BIOCHEM J, V323, P741, DOI 10.1042/bj3230741; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; Van Dorpe J, 2000, AM J PATHOL, V157, P1283, DOI 10.1016/S0002-9440(10)64644-5; VANLINT J, 1993, ANAL BIOCHEM, V208, P132, DOI 10.1006/abio.1993.1018; Wagner U, 1996, J CELL SCI, V109, P1537; WEBB BC, 1980, BIOCHEMISTRY-US, V19, P1993, DOI 10.1021/bi00550a041; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Yabe JT, 1999, J CELL SCI, V112, P3799; Yamaguchi H, 1996, ACTA NEUROPATHOL, V92, P232, DOI 10.1007/s004010050513	81	257	271	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41340	41349		10.1074/jbc.M006219200	http://dx.doi.org/10.1074/jbc.M006219200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007782	hybrid			2022-12-25	WOS:000166114600090
J	Vishnivetskiy, SA; Schubert, C; Climaco, GC; Gurevich, YV; Velez, MG; Gurevich, VV				Vishnivetskiy, SA; Schubert, C; Climaco, GC; Gurevich, YV; Velez, MG; Gurevich, VV			An additional phosphate-binding element in arrestin molecule - Implications for the mechanism of arrestin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; VISUAL ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; PHOSPHORYLATION-RECOGNITION; CRYSTAL-STRUCTURE; 48-KDA PROTEIN; RHODOPSIN; DEPHOSPHORYLATION; SELECTIVITY; PHOSPHORHODOPSIN	Arrestins quench the signaling of a wide variety of G protein-coupled receptors by virtue of high-affinity binding to phosphorylated activated receptors, The high selectivity of arrestins for this particular functional form of receptor ensures their timely binding and dissociation. In a continuing effort to elucidate the molecular mechanisms responsible for arrestin's selectivity, we used the visual arrestin model to probe the functions of its N-terminal beta -strand I comprising the highly conserved hydrophobic element Val-Ile-Phe (residues 11-13) and the adjacent positively charged Lys(14) and Lys(15). Charge elimination and reversal in positions 14 and 15 dramatically reduce arrestin binding to phosphorylated light-activated rhodopsin (P-Rh*). The same mutations in the context of various constitutively active arrestin mutants (which bind to P-Rh*, dark phosphorylated rhodopsin (P-Rh), and unphosphorylated light-activated rhodopsin (Rh*)) have minimum impact on P-Rh* and Rh* binding and virtually eliminate P-Rh binding. These results suggest that the two lysines "guide" receptor-attached phosphates toward the phosphorylation-sensitive trigger Arg(175) and participate in phosphate binding in the active state of arrestin, The elimination of the hydrophobic side chains of residues 11-13 (triple mutation V11A, I12A, and F13A) moderately enhances arrestin binding to P-Rh and Rh*, The effects of triple mutation V11A, I12A, and F13A in the context of phosphorylation-independent mutants suggest that residues 11-13 play a dual role. They stabilize arrestin's basal conformation via interaction with hydrophobic elements in arrestin's C-tail and alpha -helix I as well as its active state by interactions with alternative partners. In the context of the recently solved crystal structure of arrestin's basal state, these findings allow us to propose a model of initial phosphate-driven structural rearrangements in arrestin that ultimately result in its transition into the active receptor-binding state.	Sun Hlth Res Inst, Ralph & Muriel Roberts Lab Vis Sci, Sun City, AZ 85372 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06511 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06511 USA	Banner Research; Banner Health; Banner Sun Health Research Institute; Howard Hughes Medical Institute; Yale University; Yale University	Gurevich, VV (corresponding author), Sun Hlth Res Inst, Ralph & Muriel Roberts Lab Vis Sci, 10515 W Santa Fe Dr, Sun City, AZ 85372 USA.		Vishnivetskiy, Sergey/AAJ-8661-2020; Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NEI NIH HHS [EY11500] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GrayKeller MP, 1997, BIOCHEMISTRY-US, V36, P7058, DOI 10.1021/bi963110k; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 2000, METHOD ENZYMOL, V315, P422; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; Gurevich VV, 1996, METHOD ENZYMOL, V275, P382; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LI TS, 1995, P NATL ACAD SCI USA, V92, P3551, DOI 10.1073/pnas.92.8.3551; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; McDowell J. H., 1993, PHOTORECEPTOR CELLS, V15, P123; Mendez A, 2000, NEURON, V28, P153, DOI 10.1016/S0896-6273(00)00093-3; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; OHGURO H, 1994, PROTEIN SCI, V3, P2428, DOI 10.1002/pro.5560031226; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P15334; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P319; Pulvermuller A, 2000, J BIOL CHEM, V275, P37679, DOI 10.1074/jbc.M006776200; Pulvermuller A, 1997, BIOCHEMISTRY-US, V36, P9253, DOI 10.1021/bi970772g; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451	35	137	140	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41049	41057		10.1074/jbc.M007159200	http://dx.doi.org/10.1074/jbc.M007159200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024026	hybrid			2022-12-25	WOS:000166114600053
J	Attur, MG; Dave, M; Cipolletta, C; Kang, P; Goldring, MB; Patel, IR; Abramson, SB; Amin, AR				Attur, MG; Dave, M; Cipolletta, C; Kang, P; Goldring, MB; Patel, IR; Abramson, SB; Amin, AR			Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type IIIL-1 decoy receptor - Potential for pharmacological intervention	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; ARTICULAR CHONDROCYTES; ALGINATE BEADS; II RECEPTOR; IN-VIVO; RHEUMATOID-ARTHRITIS; SIGNAL-TRANSDUCTION; AFFECTED CARTILAGE; MESSENGER-RNA; EXPRESSION	Interleukin 1 (IL-1), produced by both synovial cells and chondrocytes, plays a pivotal role in the pathogenesis of cartilage destruction in osteoarthritis (OA). We examined the specific expression and function of IL-1 receptor family-related genes in human joint tissues. Gene array analysis of human normal and OA-affected cartilage showed mRNA expression of IL-1 receptor accessory protein (IL-1RAcp) and IL-1 type I receptor (IL-1RI), but not IL-1 antagonist (IL-1ra) and IL-1 type II decoy receptor (IL-1RII). Similarly, human synovial and epithelial cells showed an absence of IL-1RII mRNA. Functional genomic analyses showed that soluble (s) IL-1RII, at picomolar concentrations, but not soluble TNF receptor:Fc, significantly inhibited LL-1 beta -induced nitric oxide (NO) and/or prostaglandin E-2 production in chondrocytes, synovial and epithelial cells. In OA-affected cartilage, the IC50 for inhibition of NO production by sIL-1RII was 2 log orders lower than that for sIL-1RI. Human chondrocytes that overexpressed IL-1RII were resistant to IL-l-induced IL-1 beta mRNA accumulation and inhibition of proteoglycan synthesis. In osteoarthritis, deficient expression by chondrocytes of innate regulators or antagonists of IL-1 such as IL-1ra and IL-1RII (soluble or membrane form) may allow the catabolic effects of IL-1 to proceed unopposed. The sensitivity of IL-1 action to inhibition by sIL-1RII has therapeutic implications that could be directed toward correcting this unfavorable tissue(s) dependent imbalance.	Hosp Joint Dis & Med Ctr, Dept Rheumatol, New York, NY 10003 USA; NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Dept Med, New York, NY 10016 USA; CNRS, UMR 7561, Pharmacol Lab, F-54505 Vandoeuvre Les Nancy, France; NYU, Kaplan Canc Ctr, New York, NY 10016 USA; Beth Israel Deaconess Med Ctr, Div Rheumatol, Boston, MA 02115 USA; Harvard Univ, New England Baptist Bone & Joint Inst, Inst Med, Boston, MA 02115 USA	NYU Langone Medical Center; Hospital for Joint Disease NYULMC; New York University; New York University; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; New York University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; New England Baptist Hospital	Amin, AR (corresponding author), Hosp Joint Dis & Med Ctr, Dept Rheumatol, 301 E 17th St,Rm 1600, New York, NY 10003 USA.	amina01@popmail.med.nyu.edu		Abramson, Steven/0000-0002-0668-6344				ADAMS ME, 1992, ANAL BIOCHEM, V202, P89, DOI 10.1016/0003-2697(92)90211-O; Amin AR, 1997, J CLIN INVEST, V99, P1231, DOI 10.1172/JCI119280; Amin AR, 1996, J INFLAMM, V47, P190; Amin Ashok R., 1998, Current Opinion in Rheumatology, V10, P263, DOI 10.1097/00002281-199805000-00018; AREND WP, 1994, J IMMUNOL, V153, P4766; Attur MG, 1998, OSTEOARTHR CARTILAGE, V6, P269, DOI 10.1053/joca.1998.0120; Attur MG, 2000, J IMMUNOL, V164, P2684, DOI 10.4049/jimmunol.164.5.2684; Attur MG, 1998, P ASSOC AM PHYSICIAN, V110, P65; Auron PE, 1998, CYTOKINE GROWTH F R, V9, P221, DOI 10.1016/S1359-6101(98)00018-5; Bendele A, 1999, ARTHRITIS RHEUM, V42, P498, DOI 10.1002/1529-0131(199904)42:3<498::AID-ANR15>3.0.CO;2-A; BURGER D, 1995, J CLIN INVEST, V96, P38, DOI 10.1172/JCI118045; Clancy RM, 1997, J CELL PHYSIOL, V172, P183, DOI 10.1002/(SICI)1097-4652(199708)172:2<183::AID-JCP5>3.0.CO;2-K; COLOTTA F, 1994, IMMUNOL TODAY, V15, P562, DOI 10.1016/0167-5699(94)90217-8; Coulter KR, 1999, AM J RESP CELL MOL, V20, P964, DOI 10.1165/ajrcmb.20.5.3458; Crofford LJ, 1997, J RHEUMATOL, V24, P15; Daun JM, 1999, J LEUKOCYTE BIOL, V65, P863, DOI 10.1002/jlb.65.6.863; Dawson J, 1999, RHEUMATOLOGY, V38, P401, DOI 10.1093/rheumatology/38.5.401; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; Ghivizzani SC, 1997, J IMMUNOL, V159, P3604; GOLDRING MB, 1986, J BIOL CHEM, V261, P9049; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; GOLDRING MB, 1988, J CLIN INVEST, V82, P2026, DOI 10.1172/JCI113823; GUO JF, 1989, CONNECT TISSUE RES, V19, P277, DOI 10.3109/03008208909043901; HAUSELMANN HJ, 1994, J CELL SCI, V107, P17; HAUSELMANN HJ, 1992, MATRIX, V12, P116; Heaney ML, 1998, J LEUKOCYTE BIOL, V64, P135, DOI 10.1002/jlb.64.2.135; Homandberg Gene A., 1999, Frontiers in Bioscience, V4, pd713, DOI 10.2741/Homandberg; Horai R, 2000, J EXP MED, V191, P313, DOI 10.1084/jem.191.2.313; Jouvenne P, 1998, ARTHRITIS RHEUM, V41, P1083, DOI 10.1002/1529-0131(199806)41:6<1083::AID-ART15>3.0.CO;2-9; LEFEBVRE V, 1991, BIOCHIM BIOPHYS ACTA, V1094, P8, DOI 10.1016/0167-4889(91)90020-X; Ma YH, 1998, ARTHRITIS RHEUM, V41, P1798, DOI 10.1002/1529-0131(199810)41:10<1798::AID-ART11>3.3.CO;2-C; Malinowsky D, 1998, FEBS LETT, V429, P299, DOI 10.1016/S0014-5793(98)00467-0; Martel-Pelletier Johanne, 1999, Frontiers in Bioscience, V4, pd694, DOI 10.2741/Martel; Melchiorri C, 1998, ARTHRITIS RHEUM-US, V41, P2165, DOI 10.1002/1529-0131(199812)41:12<2165::AID-ART11>3.3.CO;2-F; Moos V, 1999, J RHEUMATOL, V26, P870; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; PELLETIER JP, 1995, J RHEUMATOL, V22, P109; Pelletier JP, 1998, ARTHRITIS RHEUM-US, V41, P1275, DOI 10.1002/1529-0131(199807)41:7<1275::AID-ART19>3.0.CO;2-T; PENTON RG, 1997, EUR CYTOKINE NETW, V8, P265; Rauschmayr T, 1997, P NATL ACAD SCI USA, V94, P5814, DOI 10.1073/pnas.94.11.5814; RE F, 1994, J EXP MED, V179, P739, DOI 10.1084/jem.179.2.739; SYMONS JA, 1995, P NATL ACAD SCI USA, V92, P1714, DOI 10.1073/pnas.92.5.1714; Towle CA, 1997, OSTEOARTHR CARTILAGE, V5, P293, DOI 10.1016/S1063-4584(97)80008-8; van den Berg WB, 1999, Z RHEUMATOL, V58, P136, DOI 10.1007/s003930050163; Webb GR, 1998, OSTEOARTHR CARTILAGE, V6, P167, DOI 10.1053/joca.1998.0109; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	48	94	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40307	40315		10.1074/jbc.M002721200	http://dx.doi.org/10.1074/jbc.M002721200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007768	hybrid			2022-12-25	WOS:000166039500070
J	Jensen, TC; Crosson, SM; Kartha, PM; Brady, MJ				Jensen, TC; Crosson, SM; Kartha, PM; Brady, MJ			Specific desensitization of glycogen synthase activation by insulin in 3T3-L1 adipocytes - Connection between enzymatic activation and subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GLUCOSE-TRANSPORT; SKELETAL-MUSCLE; HORMONAL-STIMULATION; RAT ADIPOCYTES; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; RESISTANCE	A protocol was developed in 3T3-L1 adipocytes that resulted in the specific desensitization of glycogen synthase activation by insulin. Cells were pretreated for 15 min with 100 nM insulin, and then recovered for 1.5 h in the absence of hormone. Subsequent basal and insulin-induced phosphorylation of the insulin receptor, IRS-1, MAPK, Akt kinase, and GSK-3 were similar in control and pretreated cells. Additionally, enhanced glucose transport and incorporation into lipid in response to insulin were unaffected. However, pretreatment reduced insulin-stimulated glycogen synthesis by over 50%, due to a nearly complete inhibition of glycogen synthase activation. Removal of extracellular glucose during the recovery period blocked the increase in glycogen levels, and restored insulin-induced glycogen synthase activation. Furthermore, incubation of pretreated 3T3-L1 adipocytes with glycogenolytic agents reversed the desensitization event. Separation of cellular lysates on sucrose gradients revealed that glycogen synthase was primarily located in the dense pellet fraction, with lesser amounts in the lighter fractions. Insulin induced glycogen synthase translocation from the lighter to the denser glycogen-containing fractions. Interestingly, insulin preferentially activated translocated enzyme while having little effect on the majority of glycogen synthase activity in the pellet fraction. In insulin-pretreated cells, glycogen synthase did not return to the lighter fractions during recovery, and thus did not move in response to the second insulin exposure. These results suggest that, in 3T3-L1 adipocytes, the translocation of glycogen synthase may be an important step in the regulation of glycogen synthesis by insulin. Furthermore, intracellular glycogen levels can regulate glycogen synthase activation, potentially through modulation of enzymatic localization.	Pfizer Global Res & Dev, Dept Cell Biol, Ann Arbor, MI 48105 USA; Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA	Pfizer; University of Michigan System; University of Michigan	Brady, MJ (corresponding author), Pfizer Global Res & Dev, Dept Cell Biol, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.							ALURENT D, 2000, AM J PHYSIOL, V278, pE663; Azpiazu I, 2000, AM J PHYSIOL-ENDOC M, V278, pE234, DOI 10.1152/ajpendo.2000.278.2.E234; Brady MJ, 1999, J BIOL CHEM, V274, P27497, DOI 10.1074/jbc.274.39.27497; Brady MJ, 1999, TRENDS ENDOCRIN MET, V10, P408, DOI 10.1016/S1043-2760(99)00201-5; Brady MJ, 1997, J BIOL CHEM, V272, P29698, DOI 10.1074/jbc.272.47.29698; Brady MJ, 1998, J BIOL CHEM, V273, P14063, DOI 10.1074/jbc.273.23.14063; Brau L, 1997, BIOCHEM J, V322, P303; BURANT CF, 1984, AM J PHYSIOL, V247, pE657, DOI 10.1152/ajpendo.1984.247.5.E657; Cadefau J, 1997, BIOCHEM J, V322, P745, DOI 10.1042/bj3220745; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; CONSIDINE RV, 1993, J CELL BIOCHEM, V52, P8, DOI 10.1002/jcb.240520103; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; De Luca JP, 1999, AM J PHYSIOL-HEART C, V276, pH1520, DOI 10.1152/ajpheart.1999.276.5.H1520; DELPRATO S, 1994, DIABETOLOGIA, V37, P1025, DOI 10.1007/BF00400466; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; Derave W, 1999, AM J PHYSIOL-ENDOC M, V277, pE1103, DOI 10.1152/ajpendo.1999.277.6.E1103; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V288, P497, DOI 10.1042/bj2880497; FLORESRIVEROS JR, 1993, P NATL ACAD SCI USA, V90, P512, DOI 10.1073/pnas.90.2.512; Franch J, 1999, BIOCHEM J, V344, P231, DOI 10.1042/0264-6021:3440231; GARETTO LP, 1984, AM J PHYSIOL, V246, pE471, DOI 10.1152/ajpendo.1984.246.6.E471; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Henry RR, 1996, DIABETES, V45, P400, DOI 10.2337/diabetes.45.4.400; HEYDRICK SJ, 1991, DIABETES, V40, P1707, DOI 10.2337/diabetes.40.12.1707; Holloszy John O., 1998, Frontiers in Bioscience, V3, pD1011; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; Kawanaka K, 1999, AM J PHYSIOL-ENDOC M, V276, pE907, DOI 10.1152/ajpendo.1999.276.5.E907; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; LAWRENCE JC, 1978, J BIOL CHEM, V253, P2104; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LAWRENCE JC, 1984, J BIOL CHEM, V259, P7975; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; Montell E, 1999, AM J PHYSIOL-REG I, V276, pR1489, DOI 10.1152/ajpregu.1999.276.5.R1489; MOULE SK, 1995, BIOCHEM J, V311, P595, DOI 10.1042/bj3110595; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; Orena SJ, 2000, J BIOL CHEM, V275, P15765, DOI 10.1074/jbc.M910002199; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Ragolia L, 1998, MOL CELL BIOCHEM, V182, P49, DOI 10.1023/A:1006827227162; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; RICORT JM, 1995, DIABETOLOGIA, V38, P1148, DOI 10.1007/s001250050406; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SMITH RL, 1988, J BIOL CHEM, V263, P658; SMITH RL, 1984, J BIOL CHEM, V259, P2201; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; Summers SA, 1999, J BIOL CHEM, V274, P23858, DOI 10.1074/jbc.274.34.23858; TANTI JF, 1993, AM J PHYSIOL, V264, pE868, DOI 10.1152/ajpendo.1993.264.6.E868; Thomson MJ, 1997, J BIOL CHEM, V272, P7759, DOI 10.1074/jbc.272.12.7759; VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078; VILLARPALASI C, 1995, BBA-GEN SUBJECTS, V1244, P203, DOI 10.1016/0304-4165(95)00006-W; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442	54	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40148	40154		10.1074/jbc.M004902200	http://dx.doi.org/10.1074/jbc.M004902200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11013239	hybrid			2022-12-25	WOS:000166039500049
J	Okajima, T; Nakamura, Y; Uchikawa, M; Haslam, DB; Numata, S; Furukawa, K; Urano, T; Furukawa, K				Okajima, T; Nakamura, Y; Uchikawa, M; Haslam, DB; Numata, S; Furukawa, K; Urano, T; Furukawa, K			Expression cloning of human globoside synthase cDNAs - Identification of beta 3Gal-T3 as UDP-N-acetylgalactosamine: Globotriaosylceramide beta 1,3-N-acetylgalactosaminyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; BINDING-SPECIFICITY; GENE; GALACTOSE; BETA-1,3-GALACTOSYLTRANSFERASE; FAMILY; CELLS; PK; BIOSYNTHESIS; GLYCOLIPIDS	By using a eukaryocytic cell expression cloning system, we have isolated cDNAs of the globoside synthase (beta1,3-N-acetylgalactosaminyltransferase) gene. Mouse fibroblast L cells transfected with SV40 large T antigen and previously cloned Gb3/CD77 synthase cDNAs were co-transfected with a cDNA library prepared from mRNA from human kidney together with Forssman synthase cDNA, and Forssman antigen-positive cells were panned using an anti-Forssman monoclonal antibody. The isolated cDNAs contained a single open reading frame predicting a type II membrane protein with 351 amino acids. Surprisingly, the cDNA clones turned out to be identical with previously reported beta 3Gal-T3, which had been cloned by sequence homology with other galactosyltransferases. Substrate specificity analysis with extracts from cDNA-transfected L cells confirmed that the gene product was actually pl,3-N-acetylgalactosaminyltransferase that specifically catalyzes the transfer of N-acetylgalactosamine onto globotriaosylceramide. Results of TLC immunostaining of neutral glycolipids from the cDNA-transfected cells also supported the identity of the newly synthesized component as globoside. The results show that glycosyltransferases apparently belonging to a single glycosyltransferase family do not necessarily catalyze reactions utilizing the same acceptor or even the same sugar donor. The globoside synthase gene was expressed in many tissues, such as heart, brain, testis, etc. We propose the designation beta 3GalNAc-T1 for the cloned globoside synthase gene.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Japanese Red Cross Cent Blood Ctr, Shibuya Ku, Tokyo 150, Japan; Washington Univ, Sch Med, Dept Pediat, Child Hlth Res Ctr Excellence Dev Biol, St Louis, MO 63110 USA	Nagoya University; Japanese Red Cross Medical Center; Washington University (WUSTL)	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.	koichi@med.nagoya-u.ac.jp	Okajima, Tetsuya/I-7332-2014; Haslam, David/G-3825-2012	Okajima, Tetsuya/0000-0002-3677-648X; Urano, Takeshi/0000-0003-3383-3554	NIAID NIH HHS [R29 AI042817] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI042817] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; Bennett EP, 1999, FEBS LETT, V460, P226, DOI 10.1016/S0014-5793(99)01268-5; BOYD B, 1993, J EXP MED, V177, P1745, DOI 10.1084/jem.177.6.1745; CHIEN JL, 1973, J BIOL CHEM, V248, P1778; DEGRANDIS S, 1989, J BIOL CHEM, V264, P12520; FELLOUS M, 1974, VOX SANG, V26, P518, DOI 10.1111/j.1423-0410.1974.tb02729.x; FURUKAWA K, 1985, BIOCHEMISTRY-US, V24, P7820, DOI 10.1021/bi00347a047; HAKOMORI SI, 1986, CHEM PHYS LIPIDS, V42, P209, DOI 10.1016/0009-3084(86)90054-X; Haslam DB, 1996, P NATL ACAD SCI USA, V93, P10697, DOI 10.1073/pnas.93.20.10697; HILDEBRAND J, 1969, J BIOL CHEM, V244, P5170; ISHIBASHI T, 1974, BIOCHIM BIOPHYS ACTA, V337, P92; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; Keusch JJ, 2000, J BIOL CHEM, V275, P25315, DOI 10.1074/jbc.M002630200; KIJIMOTOOCHIAI S, 1977, P NATL ACAD SCI USA, V74, P5407, DOI 10.1073/pnas.74.12.5407; Kojima Y, 2000, J BIOL CHEM, V275, P15152, DOI 10.1074/jbc.M909620199; Kolbinger F, 1998, J BIOL CHEM, V273, P433, DOI 10.1074/jbc.273.1.433; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUND B, 1985, J BACTERIOL, V162, P1293, DOI 10.1128/JB.162.3.1293-1301.1985; MARCUS DM, 1976, P NATL ACAD SCI USA, V73, P3263, DOI 10.1073/pnas.73.9.3263; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NAIKI M, 1975, BIOCHEMISTRY-US, V14, P4837, DOI 10.1021/bi00693a010; NAIKI M, 1975, BIOCHEMISTRY-US, V14, P4831, DOI 10.1021/bi00693a009; Okajima T, 1999, J BIOL CHEM, V274, P11479, DOI 10.1074/jbc.274.17.11479; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; Song Y, 1998, J BIOL CHEM, V273, P2517, DOI 10.1074/jbc.273.5.2517; Steffensen R, 2000, J BIOL CHEM, V275, P16723, DOI 10.1074/jbc.M000728200; SUZUKI A, 1980, J LIPID RES, V21, P473; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P455; TAKI T, 1994, ANAL BIOCHEM, V221, P312, DOI 10.1006/abio.1994.1418; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; TYRRELL GJ, 1992, P NATL ACAD SCI USA, V89, P524, DOI 10.1073/pnas.89.2.524; WIELS J, 1981, P NATL ACAD SCI-BIOL, V78, P6485, DOI 10.1073/pnas.78.10.6485; Xu HJ, 1999, J BIOL CHEM, V274, P29390, DOI 10.1074/jbc.274.41.29390; YAMAKAWA T, 1952, J BIOCHEM-TOKYO, V39, P393, DOI 10.1093/oxfordjournals.jbchem.a126309; YAMASHIRO S, 1995, J BIOL CHEM, V270, P6149, DOI 10.1074/jbc.270.11.6149; Zhou DP, 1999, EUR J BIOCHEM, V263, P571, DOI 10.1046/j.1432-1327.1999.00541.x; Zhou DP, 2000, J BIOL CHEM, V275, P22631, DOI 10.1074/jbc.C000263200; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	43	55	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40498	40503		10.1074/jbc.M006902200	http://dx.doi.org/10.1074/jbc.M006902200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10993897	hybrid			2022-12-25	WOS:000166039500094
J	Perzov, N; Nelson, H; Nelson, N				Perzov, N; Nelson, H; Nelson, N			Altered distribution of the yeast plasma membrane H+-ATPase as a feature of vacuolar H+-ATPase null mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; SACCHAROMYCES-CEREVISIAE; PHOSPHORYLATION DOMAIN; ENDOPLASMIC-RETICULUM; DIRECTED MUTAGENESIS; SECRETORY PATHWAY; PROTEIN; ACIDIFICATION; TRANSPORT; GOLGI	The effect of vacuolar H+-ATPase (V-ATPase) null mutations on the targeting of the plasma membrane HC ATPase (Pma1p) through the secretory pathway was analyzed. Gas1p, which is another plasma membrane component, was used as a control for the experiments with Pma1p. Contrary to Gas1p, which is not affected by the deletion of the V-ATPase complex in the V-ATPase null mutants, the amount of Pma1p in the plasma membrane is markedly reduced, and there is a large accumulation of the protein in the endoplasmic reticulum. Kex2p and Gef1p, which are considered to reside in the post-Golgi vesicles, were suggested as required for the V-ATPase function; hence, their null mutant phenotype should have been similar to the V-ATPase null mutants. We show that, in addition to the known differences between those yeast phenotypes, deletions of KEX2 or GEF1 in yeast do not affect the distribution of Pma1p as the V-ATPase null mutant does. The possible location of the vital site of acidification by V-ATPase along the secretory pathway is discussed.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel	Tel Aviv University	Nelson, N (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel.	nelson@post.tau.ac.il						Ambesi A, 2000, J EXP BIOL, V203, P155; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; BLANPAIN JP, 1992, J BIOL CHEM, V267, P3735; BRADA D, 1988, J BACTERIOL, V170, P2775, DOI 10.1128/jb.170.6.2775-2783.1988; Catty P, 1997, FEBS LETT, V409, P325, DOI 10.1016/S0014-5793(97)00446-8; CHANG A, 1995, J CELL BIOL, V128, P39, DOI 10.1083/jcb.128.1.39; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; Cohen A, 1999, J BIOL CHEM, V274, P26885, DOI 10.1074/jbc.274.38.26885; Cohen A, 2000, J BIOL CHEM, V275, P33388, DOI 10.1074/jbc.M004611200; DeWitt ND, 1998, J BIOL CHEM, V273, P21744, DOI 10.1074/jbc.273.34.21744; dExaerde AD, 1996, YEAST, V12, P907; Doering TL, 1996, EMBO J, V15, P182, DOI 10.1002/j.1460-2075.1996.tb00346.x; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; FANKHAUSER C, 1991, EUR J BIOCHEM, V195, P439, DOI 10.1111/j.1432-1033.1991.tb15723.x; Forgac M, 1998, FEBS LETT, V440, P258, DOI 10.1016/S0014-5793(98)01425-2; Gaxiola RA, 1998, P NATL ACAD SCI USA, V95, P4046, DOI 10.1073/pnas.95.7.4046; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KLIONSKY DJ, 1992, J BIOL CHEM, V267, P3416; KOLAND JG, 1986, J BIOL CHEM, V261, P5936; Linstedt AD, 1997, MOL BIOL CELL, V8, P1073, DOI 10.1091/mbc.8.6.1073; Luo WJ, 1997, J CELL BIOL, V138, P731, DOI 10.1083/jcb.138.4.731; Luo WJ, 2000, MOL BIOL CELL, V11, P579, DOI 10.1091/mbc.11.2.579; Lupashin VV, 1997, MOL BIOL CELL, V8, P2659, DOI 10.1091/mbc.8.12.2659; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MELLMAN I, 1992, J EXP BIOL, V172, P39; MORANO KA, 1994, J CELL SCI, V107, P2813; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; Nakamoto RK, 1998, J BIOL CHEM, V273, P7338, DOI 10.1074/jbc.273.13.7338; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1983, METHOD ENZYMOL, V97, P510; Nelson N, 1996, EXPERIENTIA, V52, P1101, DOI 10.1007/BF01952108; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; Oluwatosin YE, 1998, MOL CELL BIOL, V18, P1534, DOI 10.1128/MCB.18.3.1534; Palokangas H, 1998, MOL BIOL CELL, V9, P3561, DOI 10.1091/mbc.9.12.3561; PERLIN DS, 1992, ACTA PHYSIOL SCAND, V146, P183; Perzov N, 1998, ACTA PHYSIOL SCAND, V163, P185; PETROV VV, 1995, J BIOL CHEM, V270, P28535, DOI 10.1074/jbc.270.48.28535; RAO R, 1993, J BIOL CHEM, V268, P6708; Roberg KJ, 1999, J CELL BIOL, V145, P659, DOI 10.1083/jcb.145.4.659; Roberg KJ, 1997, J CELL BIOL, V137, P1469, DOI 10.1083/jcb.137.7.1469; Schwappach B, 1998, J BIOL CHEM, V273, P15110, DOI 10.1074/jbc.273.24.15110; SERRANO R, 1993, FEBS LETT, V325, P108, DOI 10.1016/0014-5793(93)81424-X; SetoYoung D, 1997, BBA-BIOMEMBRANES, V1326, P249, DOI 10.1016/S0005-2736(97)00028-X; SLAYMAN CL, 1987, J BIOENERG BIOMEMBR, V19, P1; Sorin A, 1997, J BIOL CHEM, V272, P9895; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; Wang GF, 1996, J BIOL CHEM, V271, P25438, DOI 10.1074/jbc.271.41.25438; Wang QQ, 1999, EMBO J, V18, P5972, DOI 10.1093/emboj/18.21.5972; Wendland B, 1998, CURR OPIN CELL BIOL, V10, P513, DOI 10.1016/S0955-0674(98)80067-7; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; YAVER DS, 1993, J BIOL CHEM, V268, P10564	59	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40088	40095		10.1074/jbc.M007011200	http://dx.doi.org/10.1074/jbc.M007011200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007788	hybrid, Green Submitted			2022-12-25	WOS:000166039500041
J	Brin, E; Yi, JZ; Skalka, AM; Leis, J				Brin, E; Yi, JZ; Skalka, AM; Leis, J			Modeling the late steps in HIV-1 retroviral integrase-catalyzed DNA integration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; IN-VITRO; VIRAL-DNA; SUBSTRATE-SPECIFICITY; PROTEIN; REQUIREMENT; DOMAIN; ENDS; ENDONUCLEASE; SEQUENCES	Model oligodeoxyribonucleotide substrates representing viral DNA integration intermediates with a gap and a two-nucleotide 5 ' overhang were used to examine late steps in human immunodeficiency virus, type 1 (HIV-1) retroviral integrase (IN)-cataIyzed DNA integration in vitro. HIV-1 or avian myeloblastosis virus reverse transcriptase (RT) were capable of quantitatively filling in the gap to create a nicked substrate but did not remove the 5 ' overhang. HIV-1 IN also failed to remove the 5 ' overhang with the gapped substrate. However, with a nicked substrate formed by RT, HIV-1 IN removed the overhang and covalently closed the nick in a disintegration-like reaction. The efficiency of this closure reaction was very low, Such closure was not stimulated by the addition of HMG-(I/Y), suggesting that this protein only acts during the early processing and joining reactions. Addition of Flap endonuclease-1, a nuclease known to remove 5 ' overhangs, abolished the closure reaction catalyzed by IN, A series of base pair inversions, introduced into the HIV-1 U5 long terminal repeat sequence adjacent to and/or including the conserved CA dinucleotide, produced no or only a small. decrease in the HIV-1 IN-dependent strand closure reaction. These same mutations caused a significant decrease in the efficiency of concerted DNA integration by a modified donor DNA in vitro, suggesting that recognition of the ends of the long terminal repeat sequence is required only in the early steps of DNA integration, Finally, a combination of HIV-1 RT,Flap endonuclease-1, and DNA ligase is capable of quantitatively forming covalently closed DNA with these model substrates, These results support the hypothesis that cellular enzyme(s) may catalyze the late steps of retroviral DNA integration.	Northwestern Univ, Sch Med, Dept Microbiol & Immunol, Chicago, IL 60611 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Northwestern University; Fox Chase Cancer Center	Leis, J (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol & Immunol, 303 E Chicago Ave, Chicago, IL 60611 USA.				NCI NIH HHS [CA38046, CA49042, CA06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049042, R01CA038046, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aiyar A, 1996, J VIROL, V70, P3571, DOI 10.1128/JVI.70.6.3571-3580.1996; Balakrishnan M, 1997, J VIROL, V71, P1025, DOI 10.1128/JVI.71.2.1025-1035.1997; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; Carteau S, 1999, J VIROL, V73, P6670, DOI 10.1128/JVI.73.8.6670-6679.1999; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; COLLETT MS, 1978, J VIROL, V26, P498, DOI 10.1128/JVI.26.2.498-509.1978; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hindmarsh P, 1999, J VIROL, V73, P2994, DOI 10.1128/JVI.73.4.2994-3003.1999; Hindmarsh P, 1999, MICROBIOL MOL BIOL R, V63, P836, DOI 10.1128/MMBR.63.4.836-843.1999; HOTTIGER M, 1994, J BIOL CHEM, V269, P986; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KUKOLJ G, 1995, GENE DEV, V9, P2556, DOI 10.1101/gad.9.20.2556; KULKOSKY J, 1995, VIROLOGY, V206, P448, DOI 10.1016/S0042-6822(95)80060-3; MARUSYK R, 1980, ANAL BIOCHEM, V105, P403, DOI 10.1016/0003-2697(80)90477-7; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; MURANTE RS, 1994, J BIOL CHEM, V270, P30377; NISSEN MS, 1995, J BIOL CHEM, V270, P4355, DOI 10.1074/jbc.270.9.4355; ROBINS P, 1994, J BIOL CHEM, V269, P28535; SHERMAN PA, 1992, J VIROL, V66, P3593, DOI 10.1128/JVI.66.6.3593-3601.1992; VANDENENT FMI, 1994, J VIROL, V68, P7825, DOI 10.1128/JVI.68.12.7825-7832.1994; VINCENT KA, 1990, NUCLEIC ACIDS RES, V18, P6045, DOI 10.1093/nar/18.20.6045; VINK C, 1990, J VIROL, V64, P5626, DOI 10.1128/JVI.64.11.5626-5627.1990; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036	32	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39287	39295		10.1074/jbc.M006929200	http://dx.doi.org/10.1074/jbc.M006929200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11006285	hybrid			2022-12-25	WOS:000165953100048
J	Chimploy, K; Tassotto, ML; Mathews, CK				Chimploy, K; Tassotto, ML; Mathews, CK			Ribonucleotide reductase, a possible agent in deoxyribonucleotide pool asymmetries induced by hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-SYNTHESIS; RECOMBINANT MOUSE; MECHANISM; SUBUNIT; CELLS; PURIFICATION; REPLICATION; OXYGEN; ASSAY; R2	While investigating the basis for marked natural asymmetries in deoxyribonucleoside triphosphate (dNTP) pools in mammalian cells, we observed that culturing V79 hamster lung cells in a 2% oxygen atmosphere causes 2-3-fold expansions of the dATP, dGTP, and dTTP pools, whereas dCTP declines by a comparable amount. Others have made similar observations and have proposed that, because O-2 is required for formation of the catalytically essential oxygen-bridged iron center in ribonucleotide reductase, dCTP depletion at low oxygen tension results from direct or indirect effects upon ribonucleotide reductase, We have tested the hypothesis that oxygen limitation affects ribonucleotide specificity using recombinant mouse ribonucleotide reductase and an assay that permits simultaneous monitoring of the reduction of all four nucleotide substrates, Preincubation and assay of the enzyme in an anaerobic chamber caused only partial activity loss. Accordingly, me treated the enzyme with hydroxyurea, followed by removal of the hydroxyurea and exposure to atmospheres of varying oxygen content. The activity was totally depleted by hydroxyurea treatment and nearly fully regained by exposure to air. By the criterion of activities regained at different oxygen tensions, we found CDP reduction not to be specifically sensitive to oxygen depletion; however, GDP reduction was specifically sensitive, The basis for the differential response to reactivation by O-2 is not known, but it evidently does not involve varying rates of reactivation of different allosteric forms of the enzyme or altered response to allosteric effecters at reduced oxygen tension.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Mathews, CK (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055134] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 55134] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARECCO A, 1988, MUTAT RES, V200, P165, DOI 10.1016/0027-5107(88)90079-6; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; Brischwein K, 1997, EUR J BIOCHEM, V244, P286, DOI 10.1111/j.1432-1033.1997.00286.x; DAVIS R, 1994, J BIOL CHEM, V269, P23171; Hendricks SP, 1998, J BIOL CHEM, V273, P29512, DOI 10.1074/jbc.273.45.29512; Hendricks SP, 1997, J BIOL CHEM, V272, P2861, DOI 10.1074/jbc.272.5.2861; LEEDS JM, 1987, MOL CELL BIOL, V7, P532, DOI 10.1128/MCB.7.1.532; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MATHERLY LH, 1989, ANAL BIOCHEM, V182, P338, DOI 10.1016/0003-2697(89)90605-2; MATHEWS CK, 1992, BIOESSAYS, V14, P295, DOI 10.1002/bies.950140502; Mole ML, 1998, ANAL BIOCHEM, V259, P245, DOI 10.1006/abio.1998.2647; NORTH TW, 1980, J BIOL CHEM, V255, P6640; OCHIAI EI, 1990, J BIOL CHEM, V265, P15758; Probst G, 1999, BIOL CHEM, V380, P1371, DOI 10.1515/BC.1999.177; PROBST H, 1988, CANCER RES, V48, P2053; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Schmidt PP, 1998, J BIOL CHEM, V273, P21463, DOI 10.1074/jbc.273.34.21463; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Sjoberg BM, 1997, STRUCT BOND, V88, P139; SLABAUGH MB, 1984, J VIROL, V52, P501, DOI 10.1128/JVI.52.2.501-506.1984; THELANDER L, 1983, BIOCHEM BIOPH RES CO, V110, P859, DOI 10.1016/0006-291X(83)91040-9; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361	23	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39267	39271		10.1074/jbc.M006233200	http://dx.doi.org/10.1074/jbc.M006233200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11006282	hybrid			2022-12-25	WOS:000165953100045
J	Gesbert, F; Sellers, WR; Signoretti, S; Loda, M; Griffin, JD				Gesbert, F; Sellers, WR; Signoretti, S; Loda, M; Griffin, JD			BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27(Kip1) through the phosphatidylinositol 3-kinase/AKT pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL ONCOGENE; HEMATOPOIETIC-CELLS; TYROSINE KINASE; C-ABL; SIGNAL TRANSDUCERS; PROGENITOR CELLS; POSITIVE CELLS; CDK INHIBITORS	Deregulation of cell cycle checkpoints is an almost universal abnormality in human cancers and is most often due to loss-of-function mutations of tumor suppressor genes such as Rb, p53, or p16(INK4a). In this study, we demonstrate that BCR/ABL inhibits the expression of a key cell cycle inhibitor, p27(Kip1), by signaling through a pathway involving phosphatidylinositol 3-kinase (PI3K). p27(Kip1) is a widely expressed inhibitor of cdk2, an essential cell cycle kinase regulating entry into S phase. We demonstrate that the decrease of p27(Kip1) is directly due to BCR/ABL in hematopoietic cells by two different approaches. First, induction of BCR/ABL by a tetracycline-regulated promoter is associated with a reversible down-regulation of p27(Kip1). Second, inhibition of BCR/ABL kinase activity with the Abl tyrosine kinase inhibitor STI571 rapidly increases p27(Kip1) levels. The PI3K inhibitor LY-294002 blocks the ability of BCR/ABL to induce p27(Kip1) down-regulation and inhibits BCR/ ABL-induced entry into S phase. The serine/threonine kinase AKT/protein kinase B is a known downstream target of PI3K. Transient expression of an activated mutant of AKT was found to decrease expression of p27(Kip1), even when PI3K was inhibited by LY-294002. The mechanism of p27(Kip1) regulation is primarily related to protein stability, since inhibition of proteasome activity increased p27(Kip1) levels in BCR/ABL-transformed cells, whereas very little change in p27 transcription was found. Overall, these data are consistent with a model in which BCR/ABL suppresses p27(Kip1) protein levels through PI3K/AKT, leading to accelerated entry into S phase. This activity is likely to explain in part previous studies showing that activation of PI3K was required for optimum transformation of hematopoietic cells by BCR/ABL in vitro and in vivo.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Griffin, JD (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.			Gesbert, Franck/0000-0002-5800-8385				AFAR DEH, 1995, P NATL ACAD SCI USA, V92, P9540, DOI 10.1073/pnas.92.21.9540; AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; BEDI A, 1994, BLOOD, V83, P2038; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; DellaRagione F, 1997, BIOCHEM BIOPH RES CO, V231, P73, DOI 10.1006/bbrc.1997.5938; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; EAVES AC, 1986, P NATL ACAD SCI USA, V83, P5306, DOI 10.1073/pnas.83.14.5306; Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; GORDON MY, 1989, CURR TOP MICROBIOL, V149, P151; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; Kramer A, 1999, P NATL ACAD SCI USA, V96, P2087, DOI 10.1073/pnas.96.5.2087; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; LI Y, 1994, ONCOGENE, V9, P2261; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MANDANAS RA, 1992, LEUKEMIA, V6, P796; MANDANAS RA, 1993, BLOOD, V82, P1838; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Melo JV, 1996, LEUKEMIA, V10, P751; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; ODA T, 1994, J BIOL CHEM, V269, P22925; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PELICCI G, 1995, ONCOGENE, V11, P899; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Quackenbush RC, 2000, BLOOD, V95, P2913, DOI 10.1182/blood.V95.9.2913.009k32_2913_2921; Salgia R, 1996, EXP HEMATOL, V24, P310; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; Sattler M, 1996, ONCOGENE, V12, P839; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Shuai K, 1996, ONCOGENE, V13, P247; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334	65	188	194	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39223	39230		10.1074/jbc.M007291200	http://dx.doi.org/10.1074/jbc.M007291200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11010972	hybrid			2022-12-25	WOS:000165953100039
J	Lin, FLM; Majumdar, A; Klotz, LC; Reszka, AP; Neidle, S; Seidman, MM				Lin, FLM; Majumdar, A; Klotz, LC; Reszka, AP; Neidle, S; Seidman, MM			Stability of DNA triplexes on shuttle vector plasmids in the replication pool in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM-MEDIATED INHIBITION; POTENTIAL ANTICANCER AGENTS; KI-RAS PROMOTER; HELIX FORMATION; 3RD STRAND; FORMING OLIGONUCLEOTIDES; INTRACELLULAR STABILITY; KINETIC-ANALYSIS; BINDING PROTEIN; IN-VITRO	Triple helix-forming oligonucleotides may be useful as gene-targeting reagents in vivo, for applications such as gene knockout. One important property of these complexes is their often remarkable stability, as demonstrated in solution and in cells following transfection, Although encouraging, these measurements do not necessarily report tripler stability in cellular compartments that support DNA functions such as replication and mutagenesis. We have devised a shuttle vector plasmid assay that reports the stability of triplexes on DNA that undergoes replication and mutagenesis. The assay is based on plasmids with novel variant supF tRNA genes containing embedded sequences for tripler formation and psoralen cross-linking. Triple helix-forming oligonucleotides were linked to psoralen and used to form triplexes on the plasmids, At various times after introduction into cells, the psoralen was activated by exposure to long wave ultraviolet light (WA). After time for replication and mutagenesis, progeny plasmids were recovered and the frequency of plasmids with mutations in the supF gene determined. Site-specific mutagenesis by psoralen cross-links was dependent on precise placement of the psoralen by the triple helix-forming oligonucleotide at the time of WA treatment. The results indicated that both pyrimidine and purine motif triplexes were much less stable on replicated DNA than on DNA in vitro or in total transfected DNA. Incubation of cells with amidoanthraquinone-based tripler stabilizing compounds enhanced the stability of the pyrimidine triplex.	NIA, Mol Genet Lab, NIH, Baltimore, MD 21224 USA; LCK Associates, Gloucester, MA 01930 USA; Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Seidman, MM (corresponding author), NIA, Mol Genet Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	seidmanm@grc.nia.nih.gov			NATIONAL INSTITUTE ON AGING [Z01AG000738, ZIAAG000738] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGBANDJE M, 1992, J MED CHEM, V35, P1418, DOI 10.1021/jm00086a010; Agrawal S, 1997, P NATL ACAD SCI USA, V94, P2620, DOI 10.1073/pnas.94.6.2620; AlunniFabbroni M, 1996, BIOCHEMISTRY-US, V35, P16361, DOI 10.1021/bi961750h; AlunniFabbroni M, 1996, EUR J BIOCHEM, V238, P143, DOI 10.1111/j.1432-1033.1996.0143q.x; Barre FX, 2000, P NATL ACAD SCI USA, V97, P3084, DOI 10.1073/pnas.050368997; Belousov ES, 1998, NUCLEIC ACIDS RES, V26, P1324, DOI 10.1093/nar/26.5.1324; Blommers MJJ, 1998, BIOCHEMISTRY-US, V37, P17714, DOI 10.1021/bi9816352; Blume SW, 1999, NUCLEIC ACIDS RES, V27, P695, DOI 10.1093/nar/27.2.695; BREDBERG A, 1986, P NATL ACAD SCI USA, V83, P8273, DOI 10.1073/pnas.83.21.8273; Chan PP, 1997, J MOL MED, V75, P267, DOI 10.1007/s001090050112; Cheng AJ, 1998, ANTISENSE NUCLEIC A, V8, P215, DOI 10.1089/oli.1.1998.8.215; CHUBB JM, 1992, TRENDS BIOTECHNOL, V10, P132, DOI 10.1016/0167-7799(92)90195-2; Coonrod A, 1997, GENE THER, V4, P1313, DOI 10.1038/sj.gt.3300536; Dagle JM, 1996, NUCLEIC ACIDS RES, V24, P2143, DOI 10.1093/nar/24.11.2143; Debin A, 1997, NUCLEIC ACIDS RES, V25, P1965, DOI 10.1093/nar/25.10.1965; Escude C, 1996, P NATL ACAD SCI USA, V93, P4365, DOI 10.1073/pnas.93.9.4365; Faruqi AF, 1997, NUCLEIC ACIDS RES, V25, P633, DOI 10.1093/nar/25.3.633; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FOSSELLA JA, 1993, NUCLEIC ACIDS RES, V21, P4511, DOI 10.1093/nar/21.19.4511; FOX KR, 1995, P NATL ACAD SCI USA, V92, P7887, DOI 10.1073/pnas.92.17.7887; Giovannangeli C, 1996, J MOL BIOL, V261, P386, DOI 10.1006/jmbi.1996.0471; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Guieysse AL, 1997, J MOL BIOL, V267, P289, DOI 10.1006/jmbi.1997.0884; Keppler M, 1999, FEBS LETT, V447, P223, DOI 10.1016/S0014-5793(99)00284-7; Keppler MD, 1999, EUR J BIOCHEM, V263, P817, DOI 10.1046/j.1432-1327.1999.00566.x; KIYAMA R, 1991, P NATL ACAD SCI USA, V88, P10450, DOI 10.1073/pnas.88.23.10450; KLEINA LG, 1990, J MOL BIOL, V213, P705, DOI 10.1016/S0022-2836(05)80257-8; Kopel V, 1996, NUCLEIC ACIDS RES, V24, P330, DOI 10.1093/nar/24.2.330; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LATIMER LJP, 1995, BIOCHEM CELL BIOL, V73, P11, DOI 10.1139/o95-002; LEE JS, 1984, NUCLEIC ACIDS RES, V12, P6603, DOI 10.1093/nar/12.16.6603; LEE JS, 1993, BIOCHEMISTRY-US, V32, P5591, DOI 10.1021/bi00072a014; Levy DD, 1996, J MOL BIOL, V255, P435, DOI 10.1006/jmbi.1996.0036; Luo D, 2000, NAT BIOTECHNOL, V18, P33, DOI 10.1038/71889; MAHER LJ, 1990, BIOCHEMISTRY-US, V29, P8820, DOI 10.1021/bi00489a045; Maher LJ, 1996, CANCER INVEST, V14, P66, DOI 10.3109/07357909609018437; Majumdar A, 1998, NAT GENET, V20, P212, DOI 10.1038/2530; Marchand C, 1996, BIOCHEMISTRY-US, V35, P5022, DOI 10.1021/bi952908l; MERGNY JL, 1991, BIOCHEMISTRY-US, V30, P9791, DOI 10.1021/bi00104a031; MoraruAllen AA, 1997, NUCLEIC ACIDS RES, V25, P1890, DOI 10.1093/nar/25.10.1890; Musso M, 1998, BIOCHEMISTRY-US, V37, P3086, DOI 10.1021/bi9717486; Neidle S, 1997, ANTI-CANCER DRUG DES, V12, P433; NOONBERG SB, 1995, NUCLEIC ACIDS RES, V23, P1956, DOI 10.1093/nar/23.11.1956; OLIVAS WM, 1995, BIOCHEMISTRY-US, V34, P278, DOI 10.1021/bi00001a034; PARRIS CN, 1992, GENE, V117, P1, DOI 10.1016/0378-1119(92)90482-5; PEDEN KWC, 1980, SCIENCE, V209, P1392, DOI 10.1126/science.6251547; PLUM GE, 1995, ANNU REV BIOPH BIOM, V24, P319; Poon J, 1997, BIOPHYS J, V73, P3257, DOI 10.1016/S0006-3495(97)78350-4; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; Raha M, 1998, PHOTOCHEM PHOTOBIOL, V67, P289, DOI 10.1111/j.1751-1097.1998.tb05201.x; Ren JS, 1999, BIOCHEMISTRY-US, V38, P16067, DOI 10.1021/bi992070s; ROBERTS RW, 1991, P NATL ACAD SCI USA, V88, P9397, DOI 10.1073/pnas.88.21.9397; ROUGEE M, 1992, BIOCHEMISTRY-US, V31, P9269, DOI 10.1021/bi00153a021; Sedelnikova OA, 1999, NUCLEIC ACIDS RES, V27, P3844, DOI 10.1093/nar/27.19.3844; SEIDMAN MM, 1985, GENE, V38, P233, DOI 10.1016/0378-1119(85)90222-7; SHIMIZU M, 1992, FEBS LETT, V302, P155, DOI 10.1016/0014-5793(92)80428-J; SKOOG JU, 1993, NUCLEIC ACIDS RES, V21, P4055, DOI 10.1093/nar/21.17.4055; SMITH JD, 1970, J MOL BIOL, V54, P1, DOI 10.1016/0022-2836(70)90442-0; Spink CH, 1999, BIOCHEMISTRY-US, V38, P496, DOI 10.1021/bi9820154; STROBEL SA, 1992, METHOD ENZYMOL, V216, P309; SVINARCHUK F, 1995, J BIOL CHEM, V270, P14068, DOI 10.1074/jbc.270.23.14068; SVINARCHUK F, 1995, NUCLEIC ACIDS RES, V23, P3831, DOI 10.1093/nar/23.19.3831; Svinarchuk F, 1996, NUCLEIC ACIDS RES, V24, P3858, DOI 10.1093/nar/24.19.3858; Svinarchuk F, 1996, NUCLEIC ACIDS RES, V24, P295, DOI 10.1093/nar/24.2.295; SVINARCHUK F, 1994, NUCLEIC ACIDS RES, V22, P3742, DOI 10.1093/nar/22.18.3742; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; Vasquez KM, 1999, NUCLEIC ACIDS RES, V27, P1176, DOI 10.1093/nar/27.4.1176; Vasquez KM, 1998, TRENDS BIOCHEM SCI, V23, P4, DOI 10.1016/S0968-0004(97)01158-4; Venitt S, 1998, J MED CHEM, V41, P3748, DOI 10.1021/jm980167r; WANG G, 1995, MOL CELL BIOL, V15, P1759; Wang G, 1996, SCIENCE, V271, P802, DOI 10.1126/science.271.5250.802; WEAVER JC, 1993, J CELL BIOCHEM, V51, P426, DOI 10.1002/jcb.2400510407; XODO LE, 1995, EUR J BIOCHEM, V228, P918, DOI 10.1111/j.1432-1033.1995.tb20340.x; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	74	13	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39117	39124		10.1074/jbc.M005404200	http://dx.doi.org/10.1074/jbc.M005404200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993885	hybrid			2022-12-25	WOS:000165953100025
J	Cook, BC; Rudolph, AE; Kurumbail, RG; Porche-Sorbet, R; Miletich, JP				Cook, BC; Rudolph, AE; Kurumbail, RG; Porche-Sorbet, R; Miletich, JP			Directed glycosylation of human coagulation factor X at residue 333 - Insight into factor Va-dependent prothrombin catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RUSSELLS VIPER VENOM; BINDING-SITE; AUTOLYSIS LOOP; PROTEASE; PROTEOLYSIS; INHIBITOR; THROMBIN	Based on homology, amino acids 326-336 (143-154 in chymotrypsin numbering) of factor X (fX) comprise a flexible surface loop, which is susceptible to self-proteolysis and influences substrate catalysis, To investigate the role of this autolysis loop in fg function, a recombinant variant with a new site for asparagine-linked glycosylation has been produced by changing glutamine 333 to asparagine. Q333N fX is activated normally by factor Wa and tissue factor, factors IXa and VIIIa, and Russell's viper venom. Proteolysis of the loop is prevented by the mutation. Reactivity of the free enzyme toward substrates and inhibitors is attenuated 4-20-fold; relative to wild type fXa, Spectrozyme Xa(TM) hydrolysis is 25%, inhibition by antithrombin III and the tissue factor pathway inhibitor is similar to 20%, and prothrombin activation in the absence of the cofactor Va is only 5%. Surprisingly, activities of the variant and wild type enzymes are equivalent when part of the prothrombinase complex. N-Glycanase cleaves the new oligosaccharide from Q333N Ma leaving aspartic acid. Q333D Ma is similar to1.6-fold more reactive with Spectrozyme Xa(TM), antithrombin III and tissue factor pathway inhibitor, and prothrombin than its glycosylated counterpart, Q333N Ma, but still quite abnormal relative to wild type Ma. Like Q333N Ma, Q333D fXa is fully functional as part of the prothrombinase complex. me conclude that Gln-333 is geographically close to a site of proteolytic degradation but not to activator, cofactor, or membrane binding sites. Mutation of Gln-333 impairs catalytic function, but given normal prothrombin activation by the complexed enzyme, the importance of Gln-333 for catalysis is not manifest in the prothrombinase assembly, suggesting a conformational change in complexed fXa.	Washington Univ, Sch Med, Dept Pathol, Div Lab Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Pharmacia Corp, Div Biochem & Mol Biol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Pfizer	Cook, BC (corresponding author), Marquette Univ, Clin Lab Sci, POB 1881, Milwaukee, WI 53201 USA.				NHLBI NIH HHS [HL60567, HL14147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R15HL060567] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; BROZE GJ, 1984, J CLIN INVEST, V73, P933, DOI 10.1172/JCI111317; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; FASS DN, 1982, BLOOD, V59, P594; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Inui Y, 1998, BIOSCI BIOTECH BIOCH, V62, P1612, DOI 10.1271/bbb.62.1612; KATAKURA S, 1993, BIOCHEM BIOPH RES CO, V197, P965, DOI 10.1006/bbrc.1993.2573; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; Mathur A, 1997, J BIOL CHEM, V272, P23418, DOI 10.1074/jbc.272.37.23418; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; ROVELLI G, 1992, BIOCHEMISTRY-US, V31, P3542, DOI 10.1021/bi00128a031; RUDOLPH A, 1996, J BIOL CHEM, V272, P28601; Rudolph AE, 1997, PROTEIN EXPRES PURIF, V10, P373, DOI 10.1006/prep.1997.0752; Sabharwal AK, 1997, J BIOL CHEM, V272, P22037, DOI 10.1074/jbc.272.35.22037; STONE SR, 1987, ARCH BIOCHEM BIOPHYS, V252, P237, DOI 10.1016/0003-9861(87)90028-2; Tams JW, 1999, BBA-PROTEIN STRUCT M, V1432, P214, DOI 10.1016/S0167-4838(99)00103-X; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; Ueda T, 1996, J BIOCHEM-TOKYO, V119, P157	22	8	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38774	38779		10.1074/jbc.M004573200	http://dx.doi.org/10.1074/jbc.M004573200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10995746	hybrid			2022-12-25	WOS:000165739800087
J	Yu, R; Heaney, AP; Lu, WG; Chen, JD; Melmed, S				Yu, R; Heaney, AP; Lu, WG; Chen, JD; Melmed, S			Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYC-INDUCED APOPTOSIS; CELL-CYCLE ARREST; P53; PTTG; EXPRESSION; PROLIFERATION; ACTIVATION	The pituitary tumor transforming gene, PTTG, is abundantly expressed in several neoplasms. We recently showed that PTTG overexpression is associated with apoptosis and therefore have now studied the role of p53 in this process. In MCF-7 breast cancer cells that express wild type p53, PTTG overexpression caused apoptosis. p53 was translocated to the nuclei in cells expressing PTTG. Overexpression of p53, along with PTTG, augmented apoptosis, whereas expression of the human papillomavirus E6 protein inhibited PTTG-induced apoptosis. In MG-63 osteosarcoma cells that are deficient in p53, PTTG caused cell cycle arrest and subsequent apoptosis that was inhibited by caspase inhibitors. A proteasome inhibitor augmented PTTG expression in stable PTTG transfectants, suggesting that down-regulated PTTG expression is required for cell survival. Finally, MG-63 cells expressing PTTG showed signs of aneuploidy including the presence of micronuclei and multiple nuclei. These results indicate that PTTG overexpression causes p53-dependent and p53-independent apoptosis. In the absence of p58, PTTG causes aneuploidy. These results may provide a mechanism for PTTG-induced tumorigenesis whereby PTTG mediates aneuploidy and subsequent cell transformation.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Los Angeles, CA 90048 USA; H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; H Lee Moffitt Cancer Center & Research Institute	Melmed, S (corresponding author), Cedars Sinai Med Ctr, 8700 Beverly Blvd, Los Angeles, CA 90048 USA.	melmed@csmc.edu			NATIONAL CANCER INSTITUTE [R01CA075979] Funding Source: NIH RePORTER; NCI NIH HHS [CA75979] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; ELSTNER E, 1995, CANCER RES, V55, P2822; Heaney AP, 1999, NAT MED, V5, P1317, DOI 10.1038/15275; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; Kakar SS, 1999, CYTOGENET CELL GENET, V84, P211, DOI 10.1159/000015261; Lu WG, 2000, ONCOGENE, V19, P232, DOI 10.1038/sj.onc.1203262; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Panvichian R, 1998, CANCER RES, V58, P4667; Sakamuro D, 1995, ONCOGENE, V11, P2411; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shostak LD, 1999, EXP CELL RES, V251, P156, DOI 10.1006/excr.1999.4568; Suganuma M, 1999, CANCER RES, V59, P5887; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Trudel M, 1997, J EXP MED, V186, P1873, DOI 10.1084/jem.186.11.1873; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wang ZY, 2000, J BIOL CHEM, V275, P7459, DOI 10.1074/jbc.275.11.7459; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Yu R, 2000, MOL ENDOCRINOL, V14, P1137, DOI 10.1210/me.14.8.1137; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	26	95	116	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36502	36505		10.1074/jbc.C000546200	http://dx.doi.org/10.1074/jbc.C000546200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	11013229	hybrid			2022-12-25	WOS:000165577700007
J	Hayashi, H; Ichihara, M; Iwashita, T; Murakami, H; Shimono, Y; Kawai, K; Kurokawa, K; Murakumo, Y; Imai, T; Funahashi, H; Nakao, A; Takahashi, M				Hayashi, H; Ichihara, M; Iwashita, T; Murakami, H; Shimono, Y; Kawai, K; Kurokawa, K; Murakumo, Y; Imai, T; Funahashi, H; Nakao, A; Takahashi, M			Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor	ONCOGENE			English	Article						RET; GDNF; SHC; CREB; NF-kappa B	MICE LACKING GDNF; ENTERIC NERVOUS-SYSTEM; DOCKING SITE; INDEPENDENT MECHANISMS; TRANSDUCTION PATHWAYS; SYMPATHETIC NEURONS; RECEPTOR COMPLEX; KINASE; NEURTURIN; SURVIVAL	Glial cell line derived neurotrophic factor (GDNF) signals through a multicomponent receptor complex consisting of RET receptor tyrosine kinase and a member of GDNF family receptor alpha (GPR alpha). Recently, it was shown that tyrosine 1062 in RET represents a binding site for SHC adaptor proteins and is crucial for both RAS/mitogen activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathways. In the present study, we characterized how these two pathways diverge from tyrosine 1062, using human neuroblastoma and primitive neuroectodermal tumor cell lines expressing RET at high levels. In response to GDNF stimulation, SHC bound to GAB1 and GRB2 adaptor proteins as well as RET, and SHC and GAB1 were highly phosphorylated on tyrosine. The complex formation consisting of SHC, GAB1 and GRB2 was almost abolished by replacement of tyrosine 1062 in RET with phenylalanine. Tyrosine-phosphorylated GAB1 was also associated with p85 subunit of PI3-K, resulting in PI3-K and AKT activation, whereas SHC-GRB2-SOS complex was responsible for the RAS/ERK signaling pathway. These results suggested that the RAS and PI3K pathways activated by GDNF bifurcate mainly through SHC bound to tyrosine 1062 in RET. Furthermore, using luciferase reporter-gene assays, we found that the RAS/ERK and PI3-K signaling pathways are important for activation of CREB and NF-kappa B in GDNF-treated cells, respectively.	Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Surg, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University	Takahashi, M (corresponding author), Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		TAKAHASHI, Masahide/I-7244-2014; Kumi, Kawai/I-6275-2014; Takahashi, Masahide/AAN-4770-2020	Kumi, Kawai/0000-0002-7772-2605; Takahashi, Masahide/0000-0002-2803-2683; Shimono, Yohei/0000-0002-6256-4704				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Cacalano G, 1998, NEURON, V21, P53, DOI 10.1016/S0896-6273(00)80514-0; Chiariello M, 1998, ONCOGENE, V16, P2435, DOI 10.1038/sj.onc.1201778; Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; Eketjall S, 1999, EMBO J, V18, P5901, DOI 10.1093/emboj/18.21.5901; Enomoto H, 1998, NEURON, V21, P317, DOI 10.1016/S0896-6273(00)80541-3; Feng L, 1999, NEUROSCIENCE, V93, P265, DOI 10.1016/S0306-4522(99)00129-3; Geneste O, 1999, HUM MOL GENET, V8, P1989, DOI 10.1093/hmg/8.11.1989; Heuckeroth RO, 1999, NEURON, V22, P253, DOI 10.1016/S0896-6273(00)81087-9; Ishiguro Y, 1999, ENDOCRINOLOGY, V140, P3992, DOI 10.1210/en.140.9.3992; Iwashita T, 1999, ONCOGENE, V18, P3919, DOI 10.1038/sj.onc.1202742; Iwashita T, 2000, BIOCHEM BIOPH RES CO, V268, P804, DOI 10.1006/bbrc.2000.2227; Jing SQ, 1997, J BIOL CHEM, V272, P33111, DOI 10.1074/jbc.272.52.33111; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Melillo RM, 1999, CANCER RES, V59, P1120; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Murakami H, 1999, ONCOGENE, V18, P1975, DOI 10.1038/sj.onc.1202514; Murakami H, 1999, BIOCHEM BIOPH RES CO, V262, P68, DOI 10.1006/bbrc.1999.1186; Nishino J, 1999, NEURON, V23, P725, DOI 10.1016/S0896-6273(01)80031-3; Nozaki C, 1998, ONCOGENE, V16, P293, DOI 10.1038/sj.onc.1201548; Ohiwa M, 1997, BIOCHEM BIOPH RES CO, V237, P747, DOI 10.1006/bbrc.1997.7225; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rossi J, 1999, NEURON, V22, P243, DOI 10.1016/S0896-6273(00)81086-7; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Soler RM, 1999, J NEUROSCI, V19, P9160; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing S, 1998, J BIOL CHEM, V273, P4909, DOI 10.1074/jbc.273.9.4909	48	182	188	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4469	4475		10.1038/sj.onc.1203799	http://dx.doi.org/10.1038/sj.onc.1203799			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002419				2022-12-25	WOS:000089236800003
J	Heldermon, C; DeAngelis, PL; Weigel, PH				Heldermon, C; DeAngelis, PL; Weigel, PH			Topological organization of the hyaluronan synthase from Streptococcus pyogenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; INTEGRAL MEMBRANE-PROTEINS; LAC CARRIER PROTEIN; AMINO-ACID-RESIDUES; ESCHERICHIA-COLI; MOLECULAR-CLONING; SYNTHESIZE HYALURONAN; SECONDARY-STRUCTURE; GLOBULAR PROTEINS; GENE FUSIONS	Since we first reported (DeAngelis, P, L,, Papaconstantinou, J,, and Weigel, P, H. (1993) J, Biol. Chem. 268, 19181-19184) the cloning of the hyaluronan (HA) synthase from Streptococcus pyogenes (spHAS), numerous membrane-bound HA synthases have been discovered in both prokaryotes and eukaryotes. The HASs are unique among enzymes studied to date because they mediate 6-7 discrete functions in order to assemble a polysaccharide containing hetero-disaccharide units and simultaneously effect translocation of the growing HA chain through the plasma membrane. To understand how the relatively small spHAS performs these various functions, we investigated the topological organization of the protein utilizing fusion analysis with two reporter enzymes, alkaline phosphatase and beta -galactosidase, as well as several other approaches. From these studies, we conclude that the NH2 terminus and the COOH terminus, as well as the major portion of a large central domain are localized intracellularly, The first two predicted membrane domains were confirmed to be transmembrane domains and give rise to a very small extracellular loop that is inaccessible to proteases, Several regions of the large internal central domain appear to be associated with, but do not traverse, the membrane. Following the central domain, there are two additional transmembrane domains connected by a second small extracellular loop that also is inaccessible to proteases, The COOH-terminal similar to 25% of spHAS also contains a membrane domain that does not traverse the membrane and may contain extensive re-entrant loops or amphipathic helices, Numerous membrane associations of this latter COOH-terminal region and the central domain may be required to create a pore-like structure through which a growing HA chain can be extruded to the cell exterior. Based on the high degree of similarity among Class I HAS family members, these enzymes may have a similar topological organization for their spHAS-related domains.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.	paul-weigel@OUHSC.edu		Heldermon, Coy/0000-0002-2148-2868	NIGMS NIH HHS [GM35978, GM56497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978, R01GM056497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOTFIELD MC, 1992, J BIOL CHEM, V267, P1818; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DeAngelis PL, 1999, CELL MOL LIFE SCI, V56, P670, DOI 10.1007/s000180050461; DeAngelis PL, 1998, J BIOL CHEM, V273, P8454, DOI 10.1074/jbc.273.14.8454; DeAngelis PL, 1997, SCIENCE, V278, P1800, DOI 10.1126/science.278.5344.1800; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; EVERED D, 1989, CIBA F SYMP, V143, P1; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; FISCHBARG J, 1994, MOL CELL BIOCHEM, V140, P147, DOI 10.1007/BF00926753; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Geller D, 1996, J BIOL CHEM, V271, P13746, DOI 10.1074/jbc.271.23.13746; GOLDKORN T, 1983, P NATL ACAD SCI-BIOL, V80, P3322, DOI 10.1073/pnas.80.11.3322; Haardt M, 1996, J BACTERIOL, V178, P5370, DOI 10.1128/jb.178.18.5370-5381.1996; HERZLINGER D, 1984, BIOCHEMISTRY-US, V23, P3688, DOI 10.1021/bi00311a018; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Huber F, 1996, EUR J BIOCHEM, V239, P810, DOI 10.1111/j.1432-1033.1996.0810u.x; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; Itano N, 1996, BIOCHEM BIOPH RES CO, V222, P816, DOI 10.1006/bbrc.1996.0827; Jung H, 1998, J BIOL CHEM, V273, P26400, DOI 10.1074/jbc.273.41.26400; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Kumari K, 1997, J BIOL CHEM, V272, P32539, DOI 10.1074/jbc.272.51.32539; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT TC, 1967, ACTA OTOLARYNGOL, V442, P7; LEVENGOOD SK, 1991, P NATL ACAD SCI USA, V88, P5939, DOI 10.1073/pnas.88.14.5939; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; Meyer K, 1934, J BIOL CHEM, V107, P629; Meyer MF, 1996, P NATL ACAD SCI USA, V93, P4543, DOI 10.1073/pnas.93.10.4543; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; Miller J. H ., 1971, EXPT MOL GENETICS; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; PAGE MGP, 1988, J BIOL CHEM, V263, P15906; Rockey DC, 1998, HEPATOLOGY, V27, P86, DOI 10.1002/hep.510270115; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; ROSE GD, 1978, NATURE, V272, P586, DOI 10.1038/272586a0; Rothman A, 1996, J BIOL CHEM, V271, P32288, DOI 10.1074/jbc.271.50.32288; Saaf A, 1998, J BIOL CHEM, V273, P30415, DOI 10.1074/jbc.273.46.30415; SAIER MH, 1989, MICROBIOL REV, V53, P333, DOI 10.1128/MMBR.53.3.333-366.1989; Semino CE, 1996, P NATL ACAD SCI USA, V93, P4548, DOI 10.1073/pnas.93.10.4548; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Spicer AP, 1996, J BIOL CHEM, V271, P23400, DOI 10.1074/jbc.271.38.23400; STOOLMILLER AC, 1969, J BIOL CHEM, V244, P236; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4246, DOI 10.1074/jbc.274.7.4246; Tlapak-Simmons VL, 1998, J BIOL CHEM, V273, P26100, DOI 10.1074/jbc.273.40.26100; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4239, DOI 10.1074/jbc.274.7.4239; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; TRAXLER B, 1993, J MEMBRANE BIOL, V132, P1; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; vanGeest M, 1996, J BIOL CHEM, V271, P25582, DOI 10.1074/jbc.271.41.25582; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317; WESSELS MR, 1994, INFECT IMMUN, V62, P433, DOI 10.1128/IAI.62.2.433-441.1994; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; WHITNACK E, 1981, INFECT IMMUN, V31, P985, DOI 10.1128/IAI.31.3.985-991.1981; Yoshida M, 2000, J BIOL CHEM, V275, P497, DOI 10.1074/jbc.275.1.497; YUN CH, 1991, J BIOL CHEM, V266, P10967	72	69	79	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2037	2046		10.1074/jbc.M002276200	http://dx.doi.org/10.1074/jbc.M002276200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11024012	hybrid			2022-12-25	WOS:000166528000054
J	Hill-Kapturczak, N; Truong, L; Thamilselvan, V; Visner, GA; Nick, HS; Agarwal, A				Hill-Kapturczak, N; Truong, L; Thamilselvan, V; Visner, GA; Nick, HS; Agarwal, A			Smad7-dependent regulation of heme oxygenase-1 by transforming growth factor-beta in human renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; CARBON-MONOXIDE PRODUCTION; NF-KAPPA-B; TGF-BETA; ENDOTHELIAL-CELLS; GENE-EXPRESSION; TUMOR-SUPPRESSOR; MESSENGER-RNA; OXIDATIVE STRESS; PROTEIN	Heme oxygenase-l (HO-1), a 32-kDa microsomal enzyme, is induced as a beneficial and adaptive response in cells/tissues exposed to oxidative stress. Transforming growth factor-beta1 (TGF-beta1) is a regulatory cytokine that has been implicated in a variety of renal diseases where it promotes extracellular matrix deposition and proinflammatory events. We hypothesize that the release of TGF-beta1 via autocrine and/or paracrine pathways may induce HO-1 and serve as a protective response lin renal injury. To understand the molecular mechanism of HO-1 induction by TGF-beta1, we exposed confluent human renal proximal tubule cells to TGF-beta1 and observed a significant induction of HO-1 mRNA at 4 h with a maximal induction at 8 h. This induction was accompanied by increased expression of HO-1 protein. TGF-beta1 treatment in conjunction with actinomycin D or cycloheximide demonstrated that induction of HO-1 mRNA requires de novo transcription and, in part, protein synthesis. Exposure to TGF-beta1 resulted in marked induction of Smad7 mRNA with no effect on Smad6 expression. Overexpression of Smad7, but not Smad6, inhibited TGF-beta1-mediated induction of endogenous HO-1 gene expression. We speculate that the induction of HO-1 in the kidney is an adaptive response to the inflammatory effects of TGF-beta1 and manipulations of the Smad pathway to alter HO-1 expression may serve as a potential therapeutic target.	Univ Florida, Div Nephrol Hypertens & Transplantat, JHMHC, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Div Nephrol Hypertens & Transplantat, Dept Pediat, Gainesville, FL 32610 USA; Univ Florida, Div Nephrol Hypertens & Transplantat, Dept Neurosci, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Agarwal, A (corresponding author), Univ Florida, Div Nephrol Hypertens & Transplantat, JHMHC, Dept Med, Box 100224,1600 SW Archer Rd, Gainesville, FL 32610 USA.	agarwal@nersp.nerdc.ufl.edu	Hill-Kapturczak, Nathalie/A-4106-2009		NHLBI NIH HHS [HL39593] Funding Source: Medline; NIDDK NIH HHS [R03DK56279, K08DK02446] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK056279, K08DK002446] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Agarwal A, 1998, J AM SOC NEPHROL, V9, P1990; Agarwal A, 1996, AM J PHYSIOL-RENAL, V271, pF814, DOI 10.1152/ajprenal.1996.271.4.F814; ALAM J, 1995, J BIOL CHEM, V270, P11977, DOI 10.1074/jbc.270.20.11977; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; BALLA G, 1991, LAB INVEST, V64, P648; BALLA G, 1992, J BIOL CHEM, V267, P18148; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; Bitzer M, 2000, GENE DEV, V14, P187; Candia AF, 1997, DEVELOPMENT, V124, P4467; Chatani Y, 1995, J BIOL CHEM, V270, P30686, DOI 10.1074/jbc.270.51.30686; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; Chin BY, 1999, J BIOL CHEM, V274, P11362, DOI 10.1074/jbc.274.16.11362; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dechend R, 1999, CIRCULATION, V100, P1369, DOI 10.1161/01.CIR.100.13.1369; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Durante W, 1999, ARTERIOSCL THROM VAS, V19, P2666, DOI 10.1161/01.ATV.19.11.2666; Durante W, 1997, CIRC RES, V80, P557, DOI 10.1161/01.RES.80.4.557; Engel ME, 1998, J CELL BIOCHEM, P111; Fogg S, 1999, AM J RESP CELL MOL, V20, P797, DOI 10.1165/ajrcmb.20.4.3477; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Han DC, 1999, J AM SOC NEPHROL, V10, P1891; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Kays S E, 1996, J Biochem Toxicol, V11, P79; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KUTTY RK, 1994, J CELL PHYSIOL, V159, P371; LAVROVSKY Y, 1994, P NATL ACAD SCI USA, V91, P5987, DOI 10.1073/pnas.91.13.5987; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; LLESUY SF, 1994, BBA-MOL CELL RES, V1223, P9, DOI 10.1016/0167-4889(94)90067-1; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1999, J CLIN INVEST, V104, P5, DOI 10.1172/JCI6094; Nath KA, 1998, KIDNEY INT, V53, P100, DOI 10.1046/j.1523-1755.1998.00731.x; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Pellacani A, 1998, CIRC RES, V83, P396, DOI 10.1161/01.RES.83.4.396; PHILLIPS AO, 1995, AM J PATHOL, V147, P362; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; RIZZARDINI M, 1993, BIOCHEM J, V290, P343, DOI 10.1042/bj2900343; Sharma VK, 1996, KIDNEY INT, V49, P1297, DOI 10.1038/ki.1996.185; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; STOCKER R, 1990, FREE RADICAL RES COM, V9, P101, DOI 10.3109/10715769009148577; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Terry CM, 1999, AM J PHYSIOL-HEART C, V276, pH1493, DOI 10.1152/ajpheart.1999.276.5.H1493; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Wagner CT, 1997, J CLIN INVEST, V100, P589, DOI 10.1172/JCI119569; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamamoto T, 1996, KIDNEY INT, V49, P461, DOI 10.1038/ki.1996.65; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3; Zhu HJ, 1999, J BIOL CHEM, V274, P32258, DOI 10.1074/jbc.274.45.32258	68	82	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40904	40909		10.1074/jbc.M006621200	http://dx.doi.org/10.1074/jbc.M006621200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018038	hybrid			2022-12-25	WOS:000166114600033
J	Jacques, SL; LeMasurier, M; Sheridan, PJ; Seeley, SK; Kuliopulos, A				Jacques, SL; LeMasurier, M; Sheridan, PJ; Seeley, SK; Kuliopulos, A			Substrate-assisted catalysis of the PAR1 thrombin receptor - Enhancement of macromolecular association and cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLATELET; ACTIVATION; HIRUDIN; SPECIFICITY; MECHANISM; BINDING; SITE; IDENTIFICATION; ANTITHROMBIN; PREVENTION	Platelet activation and aggregation are mediated by thrombin cleavage of the exodomain of the PAR1 receptor. The specificity of thrombin for PAR1 is enhanced by binding to a hirudin-like region (Hir) located in the receptor exodomain, Here, we examine the mechanism of thrombin-PAR1 recognition and cleavage by steady-state kinetic measurements using soluble PAR1 N-terminal exodomains. We determined that the primary role of the PAR1 Hir sequence is to reduce the kinetic barriers to formation of the docked thrombin-PAR1 complex rather than to form high affinity ground-state interactions. In addition, the exosite I-bound Hir motif facilitates the productive interaction of the PARI (LDPR)-L-38/SFL44 sequence with the active site of thrombin, This locking process is the most energetically unfavorable step of the overall reaction. The subsequent irreversible steps of peptide bond cleavage are rapid and allosterically enhanced by the presence of the docked Hir sequence. Furthermore, the C-terminal exodomain product of thrombin cleavage, corresponding to the activated receptor, binds tightly to thrombin, This would suggest that an additional role of the Hir sequence in the thrombin-activated receptor is to sequester thrombin to the platelet surface and modulate cleavage of other platelet receptors such as the PAR4 thrombin receptor, which lacks a functional Hir sequence.	Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Tufts Univ, Sch Med, New England Med Ctr, Mol Cardiol Res Inst,Div Hematol Oncol, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts Medical Center; Tufts University	Kuliopulos, A (corresponding author), Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA.				NHLBI NIH HHS [R01HL57905] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057905] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn HS, 1997, MOL PHARMACOL, V51, P350, DOI 10.1124/mol.51.2.350; AYALA YM, 1995, J MOL BIOL, V253, P787, DOI 10.1006/jmbi.1995.0591; BAHOU WF, 1994, BLOOD, V84, P4195, DOI 10.1182/blood.V84.12.4195.bloodjournal84124195; BONNIEC BFL, 1996, BIOCHEMISTRY-US, V35, P7114; BRASS LF, 1992, J BIOL CHEM, V267, P13795; CHEN J, 1994, J BIOL CHEM, V269, P16041; CLELAND WW, 1986, INVESTIGATION RATE 1, P791; Covic L, 2000, BIOCHEMISTRY-US, V39, P5458, DOI 10.1021/bi9927078; Doolittle RF, 1994, MOL BASIS BLOOD DIS, P701; FERSHT A, 1985, ENZYME STRUCTURE MEC, P121; Hayes KL, 1999, J BIOL CHEM, V274, P972, DOI 10.1074/jbc.274.2.972; ISHII K, 1995, J BIOL CHEM, V270, P16435, DOI 10.1074/jbc.270.27.16435; JACKMAN MP, 1992, J BIOL CHEM, V267, P15375; Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; KULIOPULOS A, 1990, BIOCHEMISTRY-US, V29, P10271, DOI 10.1021/bi00496a017; KULIOPULOS A, 1994, J AM CHEM SOC, V116, P4599, DOI 10.1021/ja00090a008; KULIOPULOS A, 1989, BIOCHEMISTRY-US, V28, P149, DOI 10.1021/bi00427a022; Kuliopulos A, 1999, BIOCHEMISTRY-US, V38, P4572, DOI 10.1021/bi9824792; LATALLO ZS, 1986, THROMB RES, V43, P507, DOI 10.1016/0049-3848(86)90071-X; LIU LW, 1991, J BIOL CHEM, V266, P16977; MATTEWS II, 1994, BIOCHEMISTRY-US, V33, P3266; Miyata S, 2000, J BIOL CHEM, V275, P4592, DOI 10.1074/jbc.275.7.4592; MOLINO M, 1995, J BIOL CHEM, V270, P11168, DOI 10.1074/jbc.270.19.11168; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; NANEVICZ T, 1995, J BIOL CHEM, V270, P21619, DOI 10.1074/jbc.270.37.21619; Parry MAA, 1996, BIOCHEM J, V320, P335, DOI 10.1042/bj3200335; PARRY MAA, 1994, BIOCHEMISTRY-US, V33, P14807, DOI 10.1021/bi00253a020; PICOZZI M, 1993, BIOCHEM J, V294, P563, DOI 10.1042/bj2940563; Rand MD, 1996, BLOOD, V88, P3432, DOI 10.1182/blood.V88.9.3432.bloodjournal8893432; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; STONE SR, 1995, BIOCHEMISTRY-US, V34, P5164, DOI 10.1021/bi00015a030; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WASIEWSKI W, 1976, THROMB RES, V8, P881, DOI 10.1016/0049-3848(76)90017-7; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	36	65	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40671	40678		10.1074/jbc.M004544200	http://dx.doi.org/10.1074/jbc.M004544200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11005807	hybrid			2022-12-25	WOS:000166114600004
J	Rybin, VO; Xu, XH; Lisanti, MP; Steinberg, SF				Rybin, VO; Xu, XH; Lisanti, MP; Steinberg, SF			Differential targeting of beta-adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae - A mechanism to functionally regulate the cAMP signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; PROTEIN-KINASE; PLASMA-MEMBRANE; BETA-2-ADRENERGIC RECEPTORS; BETA-1-ADRENERGIC RECEPTOR; VENTRICULAR MYOCYTES; CELLS; TRANSDUCTION; CHOLESTEROL; EXPRESSION	Differential modes for beta (1)- and beta (2)-adrenergic receptor (AR) regulation of adenylyl cyclase in cardiomyocytes is most consistent with spatial regulation in microdomains of the plasma membrane. This study examines whether caveolae represent specialized subdomains that concentrate and organize these moieties in cardiomyocytes. Caveolae from quiescent rat ventricular cardiomyocytes are highly enriched in beta (2)-ARs, G alpha (i), protein kinase A RII alpha subunits, caveolin-3, and flotillins (caveolin functional homologues); beta (1)-ARs, m(2)-muscarinic cholinergic receptors, G alpha (s), and cardiac types V/VI adenylyl cyclase distribute between caveolae and other cell fractions, whereas protein kinase A RI alpha subunits, G protein-coupled receptor kinase-a, and clathrin are largely excluded from caveolae, Cell surface beta (2)-ARs localize to caveolae in cardiomyocytes and cardiac fibroblasts (with markedly different beta (2)-AR expression levels), indicating that the fidelity of beta (2)-AR targeting to caveolae is maintained over a physiologic range of beta (2)-AR expression. In cardiomyocytes, agonist stimulation leads to a marked decline in the abundance of beta (2)-ARs (but not beta (1)-ARs) in caveolae. Other studies show co-immunoprecipitation of cardiomyocytes adenylyl cyclase V/VI and caveolin-3, suggesting their in vivo association. However, caveolin is not required for adenylyl cyclase targeting to low density membranes, since adenylyl cyclase targets to low buoyant density membrane fractions of HEK cells that lack prototypical caveolins, Nevertheless, cholesterol depletion with cyclodextrin augments agonist-stimulated cAMP accumulation, indicating that caveolae function as negative regulators of cAMP accumulation. The inhibitory interaction between caveolae and the cAMP signaling pathway as well as domain-specific differences in the stoichiometry of individual elements in the beta -AR signaling cascade represent important modifiers of cAMP dependent signaling in the heart.	Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Columbia University; Columbia University; Yeshiva University; Albert Einstein College of Medicine	Steinberg, SF (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pharmacol, 630 W 168th St, New York, NY 10032 USA.	sfs1@columbia.edu	Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028958] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007328] Funding Source: NIH RePORTER; NCI NIH HHS [CA80251] Funding Source: Medline; NHLBI NIH HHS [HL28958] Funding Source: Medline; NIDDK NIH HHS [2T32DK07328-18] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aprigliano O, 1997, AM J PHYSIOL-HEART C, V272, pH2726, DOI 10.1152/ajpheart.1997.272.6.H2726; BARNETT JV, 1989, J BIOL CHEM, V264, P10779; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BRISTOW MR, 1989, MOL PHARMACOL, V35, P295; BUXTON ILO, 1983, J BIOL CHEM, V258, P233; Carman CV, 1999, J BIOL CHEM, V274, P8858, DOI 10.1074/jbc.274.13.8858; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FAGAN KA, 2000, J BIOL CHEM, V275; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GADBUT AP, 1994, J BIOL CHEM, V269, P30707; GREEN SA, 1994, J BIOL CHEM, V269, P26215; GREEN SA, 1992, MOL PHARMACOL, V41, P889; Hare JM, 2000, CIRC RES, V86, P1085, DOI 10.1161/01.RES.86.10.1085; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HOHL CM, 1991, CIRC RES, V69, P1369, DOI 10.1161/01.RES.69.5.1369; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Ishikawa Y, 1997, CIRC RES, V80, P297, DOI 10.1161/01.RES.80.3.297; Kohout TA, 1996, CIRC RES, V78, P971, DOI 10.1161/01.RES.78.6.971; LEVY FO, 1993, P NATL ACAD SCI USA, V90, P10798, DOI 10.1073/pnas.90.22.10798; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lin FB, 2000, J BIOL CHEM, V275, P19025, DOI 10.1074/jbc.275.25.19025; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ostrom RS, 2000, MOL PHARMACOL, V57, P1075; Puceat M, 1998, FEBS LETT, V431, P189, DOI 10.1016/S0014-5793(98)00747-9; RAPOSO G, 1987, BIOL CELL, V60, P117, DOI 10.1111/j.1768-322X.1987.tb00551.x; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Rohrer DK, 1996, P NATL ACAD SCI USA, V93, P7375, DOI 10.1073/pnas.93.14.7375; RYBIN VO, 1994, CIRC RES, V74, P299, DOI 10.1161/01.RES.74.2.299; Rybin VO, 1999, CIRC RES, V84, P980, DOI 10.1161/01.RES.84.9.980; Sabri A, 2000, CIRC RES, V86, P1054, DOI 10.1161/01.RES.86.10.1054; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Schwencke C, 1999, J CELL BIOCHEM, V75, P64, DOI 10.1002/(SICI)1097-4644(19991001)75:1<64::AID-JCB7>3.0.CO;2-L; Schwencke C, 1999, MOL ENDOCRINOL, V13, P1061, DOI 10.1210/me.13.7.1061; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Steinberg SF, 1999, CIRC RES, V85, P1101; Stulnig TM, 1997, J BIOL CHEM, V272, P19242, DOI 10.1074/jbc.272.31.19242; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Toya Y, 1998, ENDOCRINOLOGY, V139, P2025, DOI 10.1210/en.139.4.2025; Volonte D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702; Yamamoto M, 1999, LIFE SCI, V64, P1349, DOI 10.1016/S0024-3205(99)00070-3	52	443	449	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41447	41457		10.1074/jbc.M006951200	http://dx.doi.org/10.1074/jbc.M006951200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11006286	hybrid			2022-12-25	WOS:000166114600103
J	Roper, JM; Raux, E; Brindley, AA; Schubert, HL; Gharbia, SE; Shah, HN; Warren, MJ				Roper, JM; Raux, E; Brindley, AA; Schubert, HL; Gharbia, SE; Shah, HN; Warren, MJ			The enigma of cobalamin (vitamin B-12) biosynthesis in Porphyromonas gingivalis - Identification and characterization of a functional corrin pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; PROTEIN; GENES; BACTERIA	The ability of Porphyromonas gingivalis to biosynthesize tetrapyrroles de novo has been investigated. Extracts of the bacterium do not possess activity for 5-aminolevulinic-acid dehydratase or porphobilinogen deaminase, two key enzymes involved in the synthesis of uroporphyrinogen III. Similarly, it was not possible to detect any genetic evidence for these early enzymes with the use of degenerate polymerase chain reaction. However, the bacterium does appear to harbor some of the enzymes for cobalamin biosynthesis since cobyric acid, a pathway intermediate, was converted into cobinamide. Furthermore, degenerate polymerase chain reaction with primers to cbiP, which encodes cobyric-acid synthase, produced a fragment with a high degree of identity to Salmonella typhimurium cbiP. Indeed, the recently released genome sequence data confirmed the presence of cbiP together with 14 other genes of the cobalamin pathway. A number of these genes were cloned and functionally characterized. Although P. gingivalis harbors all the genes necessary to convert precorrin-2 into cobalamin, it is missing the genes for the synthesis of precorrin-2. Either the organism has a novel pathway for the synthesis of precorrin-2, or more likely, it has lost this early part of the pathway. The remainder of the pathway may be being maintained to act as a salvage route for corrin synthesis.	Univ London Queen Mary Coll, Sch Biol Sci, London E1 4NS, England; Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA; Univ E London, Dept Life Sci, London E15 4LZ, England; Cent Publ Hlth Lab, Publ Hlth Lab Serv, London NW9 5HT, England	University of London; Queen Mary University London; Utah System of Higher Education; University of Utah; University of East London; Public Health England	Warren, MJ (corresponding author), Univ London Queen Mary Coll, Sch Biol Sci, Mile End Rd, London E1 4NS, England.			Warren, Martin/0000-0002-6028-6456				AduseOpoku J, 1997, J BACTERIOL, V179, P4778, DOI 10.1128/jb.179.15.4778-4788.1997; BLANCHE F, 1993, ANGEW CHEM INT EDIT, V32, P1651, DOI 10.1002/anie.199316511; BLANCHE F, 1995, ANGEW CHEM INT EDIT, V34, P383, DOI 10.1002/anie.199503831; BONNETT R, 1969, J CHEM SOC C, P1163, DOI 10.1039/j39690001163; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Dashper SG, 2000, J BACTERIOL, V182, P6456, DOI 10.1128/JB.182.22.6456-6462.2000; Finegold S M, 1995, Clin Infect Dis, V20 Suppl 2, P205; GRIFFITHS L, 1987, ARCH MICROBIOL, V147, P364, DOI 10.1007/BF00406134; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; HENDTLASS A, 2001, IN PRESS ORAL MICROB; HENDTLASS AJ, 1997, Patent No. 9700212; Ishida T, 1998, P NATL ACAD SCI USA, V95, P4853, DOI 10.1073/pnas.95.9.4853; Jackson CA, 1995, GENE, V167, P127, DOI 10.1016/0378-1119(95)00682-6; JORDAN PM, 1988, BIOCHEM J, V254, P427, DOI 10.1042/bj2540427; LAWRENCE JG, 1995, J BACTERIOL, V177, P6371, DOI 10.1128/jb.177.22.6371-6380.1995; Lawrence JG, 1996, GENETICS, V142, P11; Lecerof D, 2000, J MOL BIOL, V297, P221, DOI 10.1006/jmbi.2000.3569; LOEB MR, 1995, J BACTERIOL, V177, P3613, DOI 10.1128/jb.177.12.3613-3615.1995; Maggio-Hall LA, 1999, P NATL ACAD SCI USA, V96, P11798, DOI 10.1073/pnas.96.21.11798; Marsh ENG, 1999, ESSAYS BIOCHEM, V34, P139; Milner P, 1996, FEMS MICROBIOL LETT, V140, P125, DOI 10.1016/0378-1097(96)00159-0; Raux E, 1997, J BACTERIOL, V179, P3202, DOI 10.1128/jb.179.10.3202-3212.1997; Raux E, 1998, BIOCHEM J, V335, P159, DOI 10.1042/bj3350159; Raux E, 1999, BIOCHEM J, V338, P701, DOI 10.1042/0264-6021:3380701; Raux E, 1999, BIOORG CHEM, V27, P100, DOI 10.1006/bioo.1998.1125; Raux E, 1996, J BACTERIOL, V178, P753, DOI 10.1128/jb.178.3.753-767.1996; RAUX E, 1999, THESIS U LONDON; Rose TM, 1998, NUCLEIC ACIDS RES, V26, P1628, DOI 10.1093/nar/26.7.1628; ROSS B, 1998, Patent No. 980123; ROTH JR, 1993, J BACTERIOL, V175, P3303, DOI 10.1128/jb.175.11.3303-3316.1993; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; Sambrook J., 2002, MOL CLONING LAB MANU; Santander PJ, 1997, CHEM BIOL, V4, P659, DOI 10.1016/S1074-5521(97)90221-0; Scannapleco FA, 1999, J PERIODONTAL RES, V34, P340, DOI 10.1111/j.1600-0765.1999.tb02263.x; Schubert HL, 1999, BIOCHEMISTRY-US, V38, P10660, DOI 10.1021/bi9906773; Schubert HL, 1998, NAT STRUCT BIOL, V5, P585, DOI 10.1038/846; Senior NM, 1996, BIOCHEM J, V320, P401; SHAH H, 1981, THESIS U LONDON; Shah HN, 1996, TRENDS MICROBIOL, V4, P372, DOI 10.1016/0966-842X(96)30026-7; Spencer P, 1998, BIOCHEMISTRY-US, V37, P14917, DOI 10.1021/bi981366f; Thomas MG, 2000, J BACTERIOL, V182, P4227, DOI 10.1128/JB.182.15.4227-4233.2000; WARREN MJ, 1990, TRENDS BIOCHEM SCI, V15, P486, DOI 10.1016/0968-0004(90)90304-T	42	52	55	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40316	40323		10.1074/jbc.M007146200	http://dx.doi.org/10.1074/jbc.M007146200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007789	hybrid			2022-12-25	WOS:000166039500071
J	Ogilvie, M; Yu, XB; Nicolas-Metral, V; Pulido, SM; Liu, C; Ruegg, UT; Noguchi, CT				Ogilvie, M; Yu, XB; Nicolas-Metral, V; Pulido, SM; Liu, C; Ruegg, UT; Noguchi, CT			Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIC MOUSE MUSCLE; HELIX-LOOP-HELIX; STEM-CELL-FACTOR; ENDOTHELIAL-CELLS; SIGNAL-TRANSDUCTION; ERYTHROID-CELLS; CYTOKINE RECEPTORS; PROLACTIN RECEPTOR; CALCIUM CHANNELS; SKELETAL-MUSCLE	Erythropoietin (Epo) is required for the production of mature red blood cells. The requirement for Epo and its receptor (EpoR) for normal heart development and the response of vascular endothelium and cells of neural origin to Epo provide evidence that the function of Epo as a growth factor or cytokine to protect cells from apoptosis extends beyond the hematopoietic lineage. me now report that the EpoR is expressed on myoblasts and can mediate a biological response of these cells to treatment with Epo. Primary murine satellite cells and myoblast C2C12 cells, both of which express endogenous EpoR, exhibit a proliferative response to Epo and a marked decrease in terminal differentiation to form myotubes. me also observed that Epo stimulation activates Jak2/Stat5 signal transduction and increases cytoplasmic calcium, which is dependent on tyrosine phosphorylation. In erythroid progenitor cells, Epo stimulates induction of transcription factor GATA-1 and EpoR; in C2C12 cells, GATA-3 and EpoR expression are induced. The decrease in differentiation of C2C12 cells is concomitant with an increase in Myf-5 and MyoD expression and inhibition of myogenin induction during differentiation, altering the pattern of expression of the MyoD family of transcription factors during muscle differentiation. These data suggest that, rather than acting in an instructive or specific mode for differentiation, Epo can stimulate proliferation of myoblasts to expand the progenitor population during differentiation and may have a potential role in muscle development or repair.	NIDDK, Biol Chem Lab, NIH, Bethesda, MD 20892 USA; Univ Lausanne, Sch Pharm, Pharmacol Grp, CH-1015 Lausanne, Switzerland	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Lausanne	Noguchi, CT (corresponding author), NIDDK, Biol Chem Lab, NIH, Bethesda, MD 20892 USA.	cnoguchi@helix.nih.gov		RUEGG, Urs/0000-0001-6078-8280	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK025061, Z01DK025061] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANAGNOSTOU A, 1990, P NATL ACAD SCI USA, V87, P5978, DOI 10.1073/pnas.87.15.5978; ANAGNOSTOU A, 1994, P NATL ACAD SCI USA, V91, P3974, DOI 10.1073/pnas.91.9.3974; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Blaveri K, 1999, DEV DYNAM, V216, P244, DOI 10.1002/(SICI)1097-0177(199911)216:3<244::AID-DVDY3>3.0.CO;2-9; BROUDY VC, 1991, BLOOD, V77, P2583, DOI 10.1182/blood.V77.12.2583.2583; Cheung JY, 1997, BLOOD, V89, P92, DOI 10.1182/blood.V89.1.92.92_92_100; CHIN K, 1995, NUCLEIC ACIDS RES, V23, P3041, DOI 10.1093/nar/23.15.3041; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; FIBACH E, 1994, BRIT J HAEMATOL, V88, P39, DOI 10.1111/j.1365-2141.1994.tb04974.x; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Jacobs-Helber SM, 1998, MOL CELL BIOL, V18, P3699, DOI 10.1128/MCB.18.7.3699; KIMATA H, 1991, CLIN EXP IMMUNOL, V85, P151; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liu C, 1997, J BIOL CHEM, V272, P32395, DOI 10.1074/jbc.272.51.32395; LIU ZY, 1994, DEV BIOL, V166, P159, DOI 10.1006/dbio.1994.1304; Marrero MB, 1998, KIDNEY INT, V53, P1259, DOI 10.1046/j.1523-1755.1998.00887.x; MASUDA S, 1993, J BIOL CHEM, V268, P11208; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; MILLER BA, 1989, BLOOD, V73, P1188; Miller BA, 1999, J BIOL CHEM, V274, P20465, DOI 10.1074/jbc.274.29.20465; MILLER BA, 1994, P SOC EXP BIOL MED, V206, P263; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Morakkabati N, 1996, EXP HEMATOL, V24, P392; MUTA K, 1994, J CLIN INVEST, V94, P34, DOI 10.1172/JCI117327; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; NOGUCHI CT, 1991, BLOOD, V78, P2548; OHNEDA O, 1993, EXP CELL RES, V208, P327, DOI 10.1006/excr.1993.1253; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1991, MOL CELL BIOCHEM, V104, P7; ORLIC D, 1995, P NATL ACAD SCI USA, V92, P4601, DOI 10.1073/pnas.92.10.4601; PAPAYANNOPOULOU T, 1988, BLOOD, V72, P1029; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; Ribatti D, 1999, BLOOD, V93, P2627, DOI 10.1182/blood.V93.8.2627.408k21_2627_2636; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Sawyer ST, 1996, J BIOL CHEM, V271, P32430, DOI 10.1074/jbc.271.50.32430; Socolovsky M, 1998, P NATL ACAD SCI USA, V95, P6573, DOI 10.1073/pnas.95.12.6573; Socolovsky M, 1998, BLOOD, V92, P1491, DOI 10.1182/blood.V92.5.1491.417k40_1491_1496; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; STOCKDALE FE, 1992, DEV BIOL, V154, P284, DOI 10.1016/0012-1606(92)90068-R; Vogel V, 1997, AM J HYPERTENS, V10, P289, DOI 10.1016/S0895-7061(96)00410-4; Wald MR, 1996, J CELL PHYSIOL, V167, P461, DOI 10.1002/(SICI)1097-4652(199606)167:3<461::AID-JCP10>3.3.CO;2-N; Watowich SS, 1999, J BIOL CHEM, V274, P5415, DOI 10.1074/jbc.274.9.5415; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Wu H, 1999, DEVELOPMENT, V126, P3597; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yasuda Y, 1998, J BIOL CHEM, V273, P25381, DOI 10.1074/jbc.273.39.25381; Zaman K, 1999, J NEUROSCI, V19, P9821	60	213	223	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39754	39761		10.1074/jbc.M004999200	http://dx.doi.org/10.1074/jbc.M004999200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995753	hybrid			2022-12-25	WOS:000165953100106
J	Gilbert, SL; Pehrson, JR; Sharp, PA				Gilbert, SL; Pehrson, JR; Sharp, PA			XIST RNA associates with specific regions of the inactive X chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOSAGE COMPENSATION; CHROMOSOME INACTIVATION; FEMALE MAMMALS; DROSOPHILA; GENES; ACETYLATION; H4; EXPRESSION; NUCLEUS; DOMAINS	Microscopy studies have shown that XIST RNA colocalizes with the inactive X chromosome (Xi). However, the molecular basis for this colocalization is unknown, Here we provide two lines of evidence from chromatin immunoprecipitation experiments that XTST RNA physically associates with the Xi chromatin. First, XTST RNA can be co-precipitated by antiserum against macroH2A, a histone H2A variant enriched in the Xi. Second, XIST RNA can be co-precipitated by antisera that recognize unacetylated, but not acetylated, isoforms of histones H3 and H4. The specificity of XIST RNA association with hypoacetylated chromatin, together with the previous finding that hypoacetylated histone H4 is enriched at promoters of X-inactivated genes, raises the possibility that XIST RNA may contribute to the hypoacetylation of specific regions of the Xi so as to alter the expression of X-linked genes.	MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA; Univ Penn, Sch Vet Med, Dept Biol Anim, Philadelphia, PA 19104 USA	Massachusetts Institute of Technology (MIT); University of Pennsylvania	Sharp, PA (corresponding author), MIT, Ctr Canc Res, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.				NCI NIH HHS [P30-CA14051] Funding Source: Medline; NIGMS NIH HHS [R37-GM34277] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034277] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Belyaev ND, 1996, HUM GENET, V97, P573; Boggs BA, 1996, CHROMOSOMA, V105, P303, DOI 10.1007/BF02524648; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; Brown CJ, 1997, AM J HUM GENET, V60, P1333, DOI 10.1086/515488; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; Costanzi C, 2000, DEVELOPMENT, V127, P2283; Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275; Csankovszki G, 1999, NAT GENET, V22, P323, DOI 10.1038/11887; Gilbert SL, 1999, P NATL ACAD SCI USA, V96, P13825, DOI 10.1073/pnas.96.24.13825; Gu WG, 1998, DEV GENET, V22, P56, DOI 10.1002/(SICI)1520-6408(1998)22:1<56::AID-DVG6>3.0.CO;2-6; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; Kelley RL, 1999, CELL, V98, P513, DOI 10.1016/S0092-8674(00)81979-0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; Meller VH, 2000, CURR BIOL, V10, P136, DOI 10.1016/S0960-9822(00)00311-0; Mermoud JE, 1999, J CELL BIOL, V147, P1399, DOI 10.1083/jcb.147.7.1399; Pehrson JR, 1998, NUCLEIC ACIDS RES, V26, P2837, DOI 10.1093/nar/26.12.2837; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B	26	57	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36491	36494		10.1074/jbc.C000409200	http://dx.doi.org/10.1074/jbc.C000409200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	11006266	hybrid			2022-12-25	WOS:000165577700004
J	Mehrani, T; Wu, KC; Morasso, MI; Bryan, JT; Marekov, LN; Parry, DAD; Steinert, PM				Mehrani, T; Wu, KC; Morasso, MI; Bryan, JT; Marekov, LN; Parry, DAD; Steinert, PM			Residues in the 1A rod domain segment and the linker L2 are required for stabilizing the A(11) molecular alignment mode in keratin intermediate filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED-COIL; CROSS-LINKING; II KERATINS; EXPRESSION; DISEASE; HETERODIMER; MECHANISM; DISTINCT; PROTEINS; INVITRO	Both analyses of x-ray diffraction patterns of well oriented specimens of trichocyte keratin intermediate filaments (IF) and in vitro cross-linking experiments on several types of IF have documented that there are three modes of alignment of pairs of antiparallel molecules in all IF: A(11), A(22), and A(12), based on which parts of the major rod domain segments are overlapped. Here we have examined which residues may be important for stabilizing the A(11) mode. Using the K5/R14 system, we have made point mutations of charged residues along the chains and examined the propensities of equimolar mixtures of wild type and mutant chains to reassemble using as criteria: the formation (or not) of IF in vitro or in vivo; and stabilities of one- and two-molecule assemblies. We identified that the conserved residue Arg(10) of the 1A rod domain, and the conserved residues Glu(4) and Glu(6) of the linker L2, were essential for stability. Additionally, conserved residues Lys(31) of 1A and Asp(1) of 2A and non-conserved residues Asp/Asn(9) of 1A, Asp/Asn(3) of 2A, and Asp(7) of L2 are important for stability. Notably, these groups of residues lie close to each other when two antiparallel molecules are aligned in the A(11) mode, and are located toward the ends of the overlap region. Although other sets of residues might theoretically also contribute, we conclude that these residues in particular engage in favorable intermolecular ionic and/or H-bonding interactions and thereby may play a role in stabilizing the A(11) mode of alignment in keratin IF.	NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA; Massey Univ, Inst Fundamental Sci, Palmerston North, New Zealand	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Massey University	Steinert, PM (corresponding author), NIAMS, Skin Biol Lab, NIH, Bldg 6,Rm 425, Bethesda, MD 20892 USA.			Bryan, Janine/0000-0002-4923-6247	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041084] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; Candi E, 1998, P NATL ACAD SCI USA, V95, P2067, DOI 10.1073/pnas.95.5.2067; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; Fradette J, 1998, J BIOL CHEM, V273, P35176, DOI 10.1074/jbc.273.52.35176; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; HATZFELD M, 1990, J CELL BIOL, V110, P1199, DOI 10.1083/jcb.110.4.1199; Herrmann H, 1999, J MOL BIOL, V286, P1403, DOI 10.1006/jmbi.1999.2528; Herrmann H, 1998, CURR OPIN STRUC BIOL, V8, P177, DOI 10.1016/S0959-440X(98)80035-3; Irvine AD, 1999, BRIT J DERMATOL, V140, P815, DOI 10.1046/j.1365-2133.1999.02810.x; KONIGSBERG WH, 1983, METHOD ENZYMOL, V91, P254; Parry DAD, 1999, Q REV BIOPHYS, V32, P99, DOI 10.1017/S0033583500003516; PARRY DAD, 1995, INTERMEDIATE FILAMEM; STEINERT PM, 1976, J MOL BIOL, V108, P547, DOI 10.1016/S0022-2836(76)80136-2; STEINERT PM, 1993, BIOCHEMISTRY-US, V32, P10046, DOI 10.1021/bi00089a021; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; Steinert PM, 1999, J BIOL CHEM, V274, P1657, DOI 10.1074/jbc.274.3.1657; STEINERT PM, 1993, J MOL BIOL, V230, P436, DOI 10.1006/jmbi.1993.1161; STEINERT PM, 1991, J STRUCT BIOL, V107, P157, DOI 10.1016/1047-8477(91)90019-S; STEINERT PM, 1998, MOL BIOL CELL, V11, P3539; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; Wang H, 1999, J INVEST DERMATOL, V112, P619; Wawersik M, 1997, J BIOL CHEM, V272, P32557, DOI 10.1074/jbc.272.51.32557; Windoffer R, 1999, J CELL SCI, V112, P4521	23	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2088	2097		10.1074/jbc.M007260200	http://dx.doi.org/10.1074/jbc.M007260200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11022041	hybrid			2022-12-25	WOS:000166528000061
J	Remy, JJ; Nespoulous, C; Grosclaude, J; Grebert, D; Couture, L; Pajot, E; Salesse, R				Remy, JJ; Nespoulous, C; Grosclaude, J; Grebert, D; Couture, L; Pajot, E; Salesse, R			Purification and structural analysis of a soluble human chorionogonadotropin hormone-receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; HIGH-LEVEL EXPRESSION; LEUCINE-RICH REPEATS; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; LH RECEPTOR; PROTEIN; BINDING; CHORIOGONADOTROPIN; CELLS	Receptors for the luteotropin/human chorionogonadotropin hormone belong to the G-protein-coupled receptor family by their membrane-anchoring domains. They also possess a large extracellular domain (ECD) responsible for most of the hormone-receptor interactions. Structure-function studies identified several contacts between hormone and receptor ECD, but the precise topology of the complex is still unknown because of the lack of suitable heterologous expression means. Receptor ECDs exhibit leucine repeats and have been modelized on the basis of the three-dimensional structure of the porcine ribonuclease inhibitor, the first structurally known leucine-rich repeats protein. Here we report overexpression (up to 20 mg per liter) and purification to homogeneity of a soluble human chorionogonadotropin-ECD receptor complex secreted by stably cotransfected Chinese hamster ovary cells. Biochemical analysis and surface plasmon resonance data were in favor of a unique dimer with a 1:1 ligand-receptor stoichiometry. Immunopurified complex was submitted to circular dichroism characterization; CD spectra deconvolution indicated more than 25% alpha helices contributed by the receptor, in agreement with the porcine ribonuclease inhibitor-based modelization.	INRA, F-78352 Jouy En Josas, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay	Remy, JJ (corresponding author), INRA, F-78352 Jouy En Josas, France.	remy@biotec.jouy.inra.fr						Aritomi M, 1999, NATURE, V401, P713, DOI 10.1038/44394; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BIDART JM, 1987, J BIOL CHEM, V262, P15483; BOZON V, 1995, J MOL ENDOCRINOL, V14, P277, DOI 10.1677/jme.0.0140277; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; COCKETT MI, 1990, BIO-TECHNOL, V8, P662, DOI 10.1038/nbt0790-662; Couture L, 1996, J MOL ENDOCRINOL, V16, P15, DOI 10.1677/jme.0.0160015; Da Costa CR, 1998, J BIOL CHEM, V273, P11874, DOI 10.1074/jbc.273.19.11874; ElTayar N, 1996, MOL CELL ENDOCRINOL, V125, P65; Emsley P, 1996, NATURE, V381, P90, DOI 10.1038/381090a0; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Helman D, 1998, J BIOL CHEM, V273, P16067, DOI 10.1074/jbc.273.26.16067; Hong SH, 1999, MOL ENDOCRINOL, V13, P1285, DOI 10.1210/me.13.8.1285; HUET JC, 1992, PHYTOCHEMISTRY, V31, P1471, DOI 10.1016/0031-9422(92)83089-H; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; Osuga Y, 1997, J BIOL CHEM, V272, P25006, DOI 10.1074/jbc.272.40.25006; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PAJOTAUGY E, 1995, J MOL ENDOCRINOL, V14, P51, DOI 10.1677/jme.0.0140051; PANTEL J, 1993, BIOCHEM BIOPH RES CO, V195, P588, DOI 10.1006/bbrc.1993.2086; Puett D, 1996, MOL CELL ENDOCRINOL, V125, P55, DOI 10.1016/S0303-7207(96)03954-8; REMY JJ, 1993, BIOCHEM BIOPH RES CO, V193, P1023, DOI 10.1006/bbrc.1993.1727; ROBERT P, 1994, MOL CELL ENDOCRINOL, V101, P11, DOI 10.1016/0303-7207(94)90214-3; ROCHE PC, 1992, ENDOCRINOLOGY, V131, P268, DOI 10.1210/en.131.1.268; Simoni M, 1998, STEROIDS, V63, P288, DOI 10.1016/S0039-128X(98)00008-7; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; VUHAILUUTHI MT, 1990, ENDOCRINOLOGY, V127, P2090, DOI 10.1210/endo-127-5-2090; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; XIE YB, 1990, J BIOL CHEM, V265, P21411; YANG JT, 1986, METHOD ENZYMOL, V130, P208	38	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1681	1687		10.1074/jbc.M005206200	http://dx.doi.org/10.1074/jbc.M005206200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11018026	Green Published, hybrid			2022-12-25	WOS:000166528000005
J	D'Souza, S; Xin, H; Walter, S; Choubey, D				D'Souza, S; Xin, H; Walter, S; Choubey, D			The gene encoding p202, an interferon-inducible negative regulator of the p53 turner suppressor, is a target of p53-mediated transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TATA-BINDING PROTEIN; DNA-BINDING; CELL-PROLIFERATION; FUNCTIONAL DOMAIN; INHIBITION; EXPRESSION; APOPTOSIS; ACTIVATORS; GROWTH	The p53 tumor suppressor protein regulates the transcription of regulatory genes involved in cell cycle arrest and apoptosis. We reported previously that overexpression of p202, an interferon-inducible negative regulator of cell growth, negatively regulates the transcriptional activity of p53. Now we identify the gene encoding p202 as one whose mRNA and protein expression decrease in cells following the expression of wildtype, but not mutant, p53. Furthermore, the levels of p202 also decrease after exposure of cells to ultra violet light, which correlate with increase in the levels of p53. We report that the sequence-specific DNA binding of p53 to the 5'-regulatory region of the 202 gene contributes to the transcriptional repression of the 202 gene. Interestingly, overexpression of p202 in cells induced to undergo p53-dependent apoptosis significantly delays this process, indicating that the negative regulation of the 202 gene by wild-type p53 is important to potentiate apoptosis.	Loyola Univ, Med Ctr, Dept Radiat Oncol, Stritch Sch Med, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Program Mol Biol, Stritch Sch Med, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago	Choubey, D (corresponding author), Loyola Univ, Med Ctr, Dept Radiat Oncol, Stritch Sch Med, 2160 S 1st Ave,Bldg 1, Maywood, IL 60153 USA.		Choubey, Divaker/A-4771-2008		PHS HHS [C69031] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; Basu A, 1998, MOL HUM REPROD, V4, P1099, DOI 10.1093/molehr/4.12.1099; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; CHOUBEY D, 1993, J INTERFERON RES, V13, P43, DOI 10.1089/jir.1993.13.43; Choubey D, 2000, J BIOL REG HOMEOS AG, V14, P187; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; GRIBAUDO G, 1987, J BIOL CHEM, V262, P11878; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; Koul D, 1998, BIOCHEM BIOPH RES CO, V247, P379, DOI 10.1006/bbrc.1998.8804; Lee KC, 1999, MOL CELL BIOL, V19, P1279; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Martinez JD, 1998, ONCOGENE, V16, P453, DOI 10.1038/sj.onc.1201565; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Pitkanen K, 1998, ONCOGENE, V16, P459, DOI 10.1038/sj.onc.1201528; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SAMANTA H, 1986, J BIOL CHEM, V261, P1849; Sandri MI, 1996, NUCLEIC ACIDS RES, V24, P4464, DOI 10.1093/nar/24.22.4464; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang H, 2000, J BIOL CHEM, V275, P27377; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Zhao RB, 2000, GENE DEV, V14, P981; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	50	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					298	305		10.1074/jbc.M007155200	http://dx.doi.org/10.1074/jbc.M007155200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11013253	hybrid			2022-12-25	WOS:000166280700041
J	Galli, A; Pinaire, J; Fischer, M; Dorris, R; Crabb, DW				Galli, A; Pinaire, J; Fischer, M; Dorris, R; Crabb, DW			The transcriptional and DNA binding activity of peroxisome proliferator-activated receptor alpha is inhibited by ethanol metabolism - A novel mechanism for the development of ethanol-induced fatty liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC ALCOHOL-CONSUMPTION; RAT HEPATOCYTE COUPLETS; BETA-OXIDATION; LIPID-PEROXIDATION; NUCLEAR RECEPTORS; MAMMALIAN-CELLS; PROTEIN ADDUCTS; ACYL-COENZYME; ACETALDEHYDE; GENE	Fatty acids are ligands for the peroxisome proliferator-activated receptor a (PPAR alpha). Fatty acid levels are increased in liver during the metabolism of ethanol and might be expected to activate PPAR alpha. However, ethanol inhibited PPAR alpha activation of a reporter gene in H4IIEC3 hepatoma cells expressing alcohol-metabolizing enzymes but not in CV-1 cells, which lack these enzymes. Ethanol also reduced the ability of the PPAR alpha ligand WY14,643 to activate reporter constructs in the hepatoma cells or cultured rat hepatocytes, This effect of ethanol was abolished by the alcohol dehydrogenase inhibitor 4-methylpyrazole and augmented by the aldehyde dehydrogenase inhibitor cyanamide, indicating that acetaldehyde was responsible for the action of ethanol. PPAR alpha /retinoid X receptor extracted from hepatoma cells exposed to ethanol or acetaldehyde bound poorly to an oligonucleotide containing peroxisome proliferator response elements. This effect was also blocked by 4-methylpyrazole and augmented by cyanamide. Furthermore, in vitro translated PPAR alpha exposed to acetaldehyde failed to bind DNA. Thus, ethanol metabolism blocks transcriptional activation by PPARa, in part due to impairment of its ability to bind DNA. This effect of ethanol may promote the development of alcoholic fatty liver and other hepatic consequences of alcohol abuse.	Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Univ Florence, Dept Clin Pathophysiol, Florence, Italy	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; University of Florence	Crabb, DW (corresponding author), Emerson Hall 312,545 Barnhill Dr, Indianapolis, IN 46202 USA.	dcrabb@iupui.edu	Galli, Andrea/AAC-1623-2019	Galli, Andrea/0000-0001-5416-6290	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007462, P50AA007611, R37AA006434, R01AA006434] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA06434, P50 AA07611, T32 AA07462] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BEHRENS UJ, 1988, BIOCHEM BIOPH RES CO, V154, P584, DOI 10.1016/0006-291X(88)90180-5; Berson A, 1998, GASTROENTEROLOGY, V114, P764, DOI 10.1016/S0016-5085(98)70590-6; BOCOS C, 1995, J STEROID BIOCHEM, V53, P1; CARTER ME, 1994, MOL CELL BIOL, V14, P4360, DOI 10.1128/MCB.14.7.4360; CASINI A, 1993, J HEPATOL, V19, P385, DOI 10.1016/S0168-8278(05)80547-1; CRABB DW, 1987, ANAL BIOCHEM, V163, P88, DOI 10.1016/0003-2697(87)90096-0; Crabb DW, 1995, ALCOHOL CLIN EXP RES, V19, P1414, DOI 10.1111/j.1530-0277.1995.tb01000.x; DeCraemer D, 1996, ALCOHOL CLIN EXP RES, V20, P908; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Everett LM, 1999, J STEROID BIOCHEM, V70, P197, DOI 10.1016/S0960-0760(99)00109-0; Fan CY, 1996, J BIOL CHEM, V271, P24698, DOI 10.1074/jbc.271.40.24698; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FROMENTY B, 1995, PHARMACOL THERAPEUT, V67, P101, DOI 10.1016/0163-7258(95)00012-6; Galli A, 2000, HEPATOLOGY, V31, P101, DOI 10.1002/hep.510310117; Galli A, 1998, ARCH BIOCHEM BIOPHYS, V354, P288, DOI 10.1006/abbi.1997.0701; GAUTAM A, 1987, HEPATOLOGY, V7, P216, DOI 10.1002/hep.1840070203; GEARING KL, 1994, J NUTR, V124, pS1284, DOI 10.1093/jn/124.suppl_8.1284S; GINOT F, 1989, EUR J BIOCHEM, V180, P289, DOI 10.1111/j.1432-1033.1989.tb14646.x; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAF J, 1984, P NATL ACAD SCI-BIOL, V81, P6516, DOI 10.1073/pnas.81.20.6516; GRUNNET N, 1986, ALCOHOL CLIN EXP RES, V10, pS64, DOI 10.1111/j.1530-0277.1986.tb05182.x; Grunnet N, 1987, Alcohol Alcohol Suppl, V1, P257; JENNETT RB, 1987, ARCH BIOCHEM BIOPHYS, V256, P10, DOI 10.1016/0003-9861(87)90420-6; Johnson EF, 1996, FASEB J, V10, P1241, DOI 10.1096/fasebj.10.11.8836037; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; Li CJ, 1997, HEPATOLOGY, V26, P650, DOI 10.1002/hep.510260317; LIEBER CS, 1965, J CLIN INVEST, V44, P1009, DOI 10.1172/JCI105200; LIN RC, 1988, J CLIN INVEST, V81, P615, DOI 10.1172/JCI113362; MA XL, 1993, HEPATOLOGY, V18, P1247; Masuda N, 1998, GENE, V221, P225, DOI 10.1016/S0378-1119(98)00461-2; Nakshatri H, 1998, NUCLEIC ACIDS RES, V26, P2491, DOI 10.1093/nar/26.10.2491; NOMURA F, 1981, BIOCHEM BIOPH RES CO, V100, P131, DOI 10.1016/S0006-291X(81)80073-3; NUUTINEN HU, 1984, EUR J CLIN INVEST, V14, P306, DOI 10.1111/j.1365-2362.1984.tb01186.x; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; PANCHENKO LF, 1987, EXPERIENTIA, V43, P580, DOI 10.1007/BF02143593; PIGNON JP, 1987, HEPATOLOGY, V7, P865, DOI 10.1002/hep.1840070512; Polavarapu R, 1998, HEPATOLOGY, V27, P1317, DOI 10.1002/hep.510270518; RABINOWITZ JL, 1991, ALCOHOL, V8, P241, DOI 10.1016/0741-8329(91)90289-9; Rakic V, 1998, ATHEROSCLEROSIS, V137, P243, DOI 10.1016/S0021-9150(97)00269-4; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; SALASPURO MP, 1981, HEPATOLOGY, V1, P33, DOI 10.1002/hep.1840010106; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; SMITH SL, 1989, J CLIN INVEST, V84, P337, DOI 10.1172/JCI114159; Stewart MJ, 1998, BBA-GENE STRUCT EXPR, V1399, P181, DOI 10.1016/S0167-4781(98)00115-8; Tsukamoto H, 1996, AM J PHYSIOL-GASTR L, V270, pG581, DOI 10.1152/ajpgi.1996.270.4.G581; Tuma DJ, 1996, HEPATOLOGY, V23, P872, DOI 10.1002/hep.510230431; WAN YJY, 1994, LIFE SCI, V56, P307, DOI 10.1016/0024-3205(94)00953-8; WOLFLA CE, 1988, ARCH BIOCHEM BIOPHYS, V263, P69, DOI 10.1016/0003-9861(88)90614-5; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	55	155	167	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					68	75		10.1074/jbc.M008791200	http://dx.doi.org/10.1074/jbc.M008791200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11022051	hybrid			2022-12-25	WOS:000166280700011
J	Nakazawa, T; Komai, S; Tezuka, T; Hisatsune, C; Umemori, H; Semba, K; Mishina, M; Manabe, T; Yamamoto, T				Nakazawa, T; Komai, S; Tezuka, T; Hisatsune, C; Umemori, H; Semba, K; Mishina, M; Manabe, T; Yamamoto, T			Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR epsilon 2 (NR2B) subunit of the N-methyl-D-aspartate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; DEPENDENT PROTEIN-KINASE; POSTSYNAPTIC DENSITY FRACTION; EXCITATORY AMINO-ACIDS; CENTRAL-NERVOUS-SYSTEM; NMDA-RECEPTOR; SYNAPTIC TRANSMISSION; GLUTAMATE RECEPTORS; MUTANT MICE; 2B SUBUNIT	The N-methyl-D-aspartate (NMDA) receptors play critical roles in synaptic plasticity, neuronal development, and excitotoxicity, Tyrosine phosphorylation of NMDA receptors by Src-family tyrosine kinases such as Fyn is implicated in synaptic plasticity. To precisely address the roles of NMDA receptor tyrosine phosphorylation, we identified Fyn-mediated phosphorylation sites on the GluR epsilon2 (NR2B) subunit of NMDA receptors, Seven out of 25 tyrosine residues in the C-terminal cytoplasmic region of GluR epsilon2 were phosphorylated by Fyn in vitro. Of these 7 residues, Tyr-1252, Tyr-1336, and Tyr-1472 in GluR epsilon2 were phosphorylated in human embryonic kidney fibroblasts when co-expressed with active Fyn, and Tyr-1472 was the major phosphorylation site in this system. We then generated rabbit polyclonal antibodies specific to Tyr-1472-phosphorylated GluR epsilon2 and showed that Tyr-1472 of GluR epsilon2 was indeed phosphorylated in murine brain using the antibodies. Importantly Tyr-1472 phosphorylation was greatly reduced in fyn mutant mice. Moreover, Tyr-1472 phosphorylation became evident when hippocampal long term potentiation started to be observed, and its magnitude became larger in murine brain. Finally, Tyr-1472 phosphorylation was significantly enhanced after induction of long term potentiation in the hippocampal CA1 region. These data suggest that Tyr-1472 phosphorylation of GluR epsilon2 is important for synaptic plasticity.	Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Dept Cellular & Mol Biol, Minato Ku, Tokyo 1088639, Japan; Kobe Univ, Sch Med, Dept Physiol, Kobe, Hyogo 6500017, Japan; Univ Tokyo, Sch Med, Dept Mol Neurobiol & Pharmacol, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo; Kobe University; University of Tokyo	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tyamamot@ims.u-tokyo.ac.jp	Nakazawa, Takanobu/E-1012-2014; Hisatsune, Chihiro/C-6661-2017; Komai, Shoji/L-9273-2018	Nakazawa, Takanobu/0000-0002-5049-9140; Hisatsune, Chihiro/0000-0001-7811-7784; Komai, Shoji/0000-0002-8474-7800; NAKAZAWA, Takanobu/0000-0003-4863-1277; Umemori, Hisashi/0000-0001-7198-2062				Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BOLSHAKOV VY, 1995, SCIENCE, V269, P1730, DOI 10.1126/science.7569903; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; COLLINGRIDGE GL, 1995, TRENDS NEUROSCI, V18, P54, DOI 10.1016/0166-2236(95)93868-X; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; Dunah AW, 1998, J NEUROCHEM, V71, P1926; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Gurd JW, 1997, J NEUROCHEM, V69, P623; Hisatsune C, 1999, GENES CELLS, V4, P657, DOI 10.1046/j.1365-2443.1999.00287.x; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kutsuwada T, 1996, NEURON, V16, P333, DOI 10.1016/S0896-6273(00)80051-3; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; Leonard AS, 1997, J BIOL CHEM, V272, P12107, DOI 10.1074/jbc.272.18.12107; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; Liao DZ, 1996, LEARN MEMORY, V3, P138, DOI 10.1101/lm.3.2-3.138; Lin SY, 1999, MOL BRAIN RES, V70, P18, DOI 10.1016/S0169-328X(99)00122-9; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; Lu YM, 1998, SCIENCE, V279, P1363, DOI 10.1126/science.279.5355.1363; Manabe T, 2000, J NEUROSCI, V20, P2504; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; Mori H, 1998, NEURON, V21, P571, DOI 10.1016/S0896-6273(00)80567-X; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; Okabe S, 1998, J NEUROSCI, V18, P4177; Omkumar RV, 1996, J BIOL CHEM, V271, P31670, DOI 10.1074/jbc.271.49.31670; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Rosenblum K, 1996, P NATL ACAD SCI USA, V93, P10457, DOI 10.1073/pnas.93.19.10457; Rosenblum K, 1997, J NEUROSCI, V17, P5129; Rostas JAP, 1996, P NATL ACAD SCI USA, V93, P10452, DOI 10.1073/pnas.93.19.10452; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; Sans N, 2000, J NEUROSCI, V20, P1260, DOI 10.1523/JNEUROSCI.20-03-01260.2000; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; SUZUKI T, 1995, BIOCHEM BIOPH RES CO, V216, P582, DOI 10.1006/bbrc.1995.2662; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Wechsler A, 1998, EMBO J, V17, P3931, DOI 10.1093/emboj/17.14.3931; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zhao WQ, 2000, P NATL ACAD SCI USA, V97, P8098, DOI 10.1073/pnas.97.14.8098	56	377	393	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					693	699		10.1074/jbc.M008085200	http://dx.doi.org/10.1074/jbc.M008085200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024032	hybrid			2022-12-25	WOS:000166280700093
J	Pariyarath, R; Wang, HX; Aitchison, JD; Ginsberg, HN; Welch, WJ; Johnson, AE; Fisher, EA				Pariyarath, R; Wang, HX; Aitchison, JD; Ginsberg, HN; Welch, WJ; Johnson, AE; Fisher, EA			Co-translational interactions of apoprotein B with the ribosome and translocon during lipoprotein assembly or targeting to the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; LOW-DENSITY LIPOPROTEINS; APOLIPOPROTEIN-B; ENDOPLASMIC-RETICULUM; INTRACELLULAR DEGRADATION; SECRETORY PROTEINS; NASCENT POLYPEPTIDES; MOLECULAR CHAPERONES; MEMBRANE-PROTEIN; PAUSE TRANSFER	Hepatic lipoprotein assembly and secretion can be regulated by proteasomal degradation of newly synthesized apoB, especially if lipid synthesis or lipid transfer is low. Our previous studies in HepG2 cells showed that, under these conditions, newly synthesized apoB remains stably associated with the endoplasmic reticulum (ER) membrane (Mitchell, D. M., Zhou, M., Pariyarath, R., Wang, H., Aitchison, J. D., Ginsberg, T-I. N., and Fisher, E. A (1998) Proc. Natl. Acad. Sci. U.S.A. 95, 14733-14738). We now show that independent of lipid synthesis, apoB chains that appear full-length are, in fact, incompletely translated polypeptides still engaged by the ribosome and associated with the ER translocon. In the presence of active lipid synthesis and transfer, translation and lipoprotein assembly are completed, and the complexes exit the ER. Upon omitting fatty acids from, or adding a microsomal triglyceride transfer protein inhibitor to, culture media to reduce lipid synthesis or transfer, respectively, apoB was degraded while it remained associated with the ER and complexed with cytosolic hsp70 and proteasomes. Thus, unlike other ER substrates of the proteasome, such as major histocompatibility complex class I molecules, apoB does not fully retrotranslocate to the cytosol before entering the ubiquitin-proteasome pathway. Although, upon immunofluorescence, apoB in proteasome-inhibited cells accumulated in punctate structures similar in appearance to aggresomes (cytosolic structures containing molecules irreversibly lost from the secretory pathway), these apoB molecules could be secreted when lipid synthesis was stimulated. The results suggest a model in which 1) apoB translation does not complete until lipoprotein assembly terminates, and 2) assembly with lipids or entry into the ubiquitin-proteasome pathway occurs while apoB polypeptides remain associated with the translocon and attached to the ribosome.	CUNY Mt Sinai Sch Med, Cardiovasc Inst, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Cell Biol & Anat, New York, NY 10029 USA; Univ Alberta, Dept Anat & Cell Biol, Edmonton, AB T6G 2H7, Canada; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Texas A&M Univ, Dept Med Biochem, College Stn, TX 77843 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Alberta; Columbia University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Texas A&M University System; Texas A&M University College Station	Fisher, EA (corresponding author), CUNY Mt Sinai Sch Med, Cardiovasc Inst, 1 Gustave Levy Pl,POB 1269, New York, NY 10029 USA.	edmd-phd.fisher@mssm.edu	Adiels, Martin/C-9278-2011; Johnson, Arthur E/G-3457-2012	Fisher, Edward/0000-0001-9802-143X	NHLBI NIH HHS [HL 58541, HL 55683] Funding Source: Medline; NIGMS NIH HHS [GM 26494] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026494] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anton LC, 1999, J CELL BIOL, V146, P113, DOI 10.1083/jcb.146.1.113; Benoist F, 1996, EUR J BIOCHEM, V240, P713, DOI 10.1111/j.1432-1033.1996.0713h.x; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; Brooks P, 2000, BIOCHEM J, V346, P155, DOI 10.1042/0264-6021:3460155; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; Eggers DK, 1997, MOL BIOL CELL, V8, P1559, DOI 10.1091/mbc.8.8.1559; Eleuteri AM, 1997, J BIOL CHEM, V272, P11824, DOI 10.1074/jbc.272.18.11824; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HALL MN, 1982, ANN INST PASTEUR MIC, VA133, P123; Hegde RS, 1998, CELL, V92, P621, DOI 10.1016/S0092-8674(00)81130-7; Huang XF, 1999, J LIPID RES, V40, P2212; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; Johnson CH, 1999, YEAST, V15, P799, DOI 10.1002/(SICI)1097-0061(19990630)15:9&lt;799::AID-YEA419&gt;3.0.CO;2-N; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kivlen MH, 1997, J LIPID RES, V38, P1149; Kuehn DL, 1999, MOL BIOL CELL, V10, p213A; Laird V, 1997, J BIOL CHEM, V272, P1983, DOI 10.1074/jbc.272.3.1983; Leiper JM, 1996, J LIPID RES, V37, P2215; Liang JS, 1998, J BIOL CHEM, V273, P35216, DOI 10.1074/jbc.273.52.35216; Liang JS, 2000, J BIOL CHEM, V275, P32003, DOI 10.1074/jbc.M004646200; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Olofsson SO, 1999, CURR OPIN LIPIDOL, V10, P341, DOI 10.1097/00041433-199908000-00008; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; Pilon M, 1999, CELL, V97, P679, DOI 10.1016/S0092-8674(00)80780-1; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; SPARKS JD, 1992, J CLIN INVEST, V89, P1418, DOI 10.1172/JCI115731; Stillemark P, 2000, J BIOL CHEM, V275, P10506, DOI 10.1074/jbc.275.14.10506; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; WETTERAU JR, 1992, SCIENCE, V258, P999; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wigley WC, 1999, J CELL BIOL, V145, P481; Wilkinson CRM, 1998, EMBO J, V17, P6465, DOI 10.1093/emboj/17.22.6465; Yao ZM, 1997, J LIPID RES, V38, P1937; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Zhou MY, 1999, MOL CELL, V4, P925, DOI 10.1016/S1097-2765(00)80222-1; ZHOU MY, 1995, J BIOL CHEM, V270, P25220, DOI 10.1074/jbc.270.42.25220; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	56	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					541	550		10.1074/jbc.M007944200	http://dx.doi.org/10.1074/jbc.M007944200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11022045	hybrid			2022-12-25	WOS:000166280700073
J	Zhang, CL; McKinsey, TA; Lu, JR; Olson, EN				Zhang, CL; McKinsey, TA; Lu, JR; Olson, EN			Association of COOH-terminal-binding protein (CtBP) and MEF2-interacting transcription repressor (MITR) contributes to transcriptional repression of the MEF2 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE; CELLULAR PHOSPHOPROTEIN; NEGATIVE MODULATION; INTERACTS; IDENTIFICATION; EXPRESSION; CLONING; DOMAIN; COREPRESSORS; FAMILY	The class II histone deacetylases (HDACs) 4, 5, and 7 share a common structural organization, with a carboxyl-terminal catalytic domain and an amino-terminal extension that mediates interactions with members of the myocyte enhancer factor-2 (MEF2) family of transcription factors. Association of these HDACs with MEF2 factors represses transcription of MEF2 target genes. MEF2-interacting transcription repressor (MITR) shares homology with the amino-terminal extensions of class II HDACs and also acts as a transcriptional repressor, but lacks a histone deacetylase catalytic domain. This suggests that MITR represses transcription by recruiting other corepressors. We show that the amino-terminal regions of MITR and class II HDACs interact with the transcriptional corepressor, COOH-terminal-binding protein (CtBP), through a CtBP-binding motif (P-X-D-L-R) conserved in MITR and HDACs 4, 5, and 7. Mutation of this sequence in MITR abolishes interaction with CtBP and impairs, but does not eliminate, the ability of MITR to inhibit MEF2-dependent transcription. The residual repressive activity of MITR mutants that fail to bind CtBP can be attributed to association with other HDAC family members. These findings reveal CtBP-dependent and -independent mechanisms for transcriptional repression by MITR and show that MITR represses MEF2 activity through recruitment of multi-component corepressor complexes that include CtBP and HDACs.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA.	eolson@hamon.swmed.edu	Lu, Jianrong/F-5240-2013	Lu, Jianrong/0000-0002-4969-6040				Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Dangond F, 1998, BIOCHEM BIOPH RES CO, V242, P648, DOI 10.1006/bbrc.1997.8033; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Huang EY, 2000, GENE DEV, V14, P45; Kao HY, 2000, GENE DEV, V14, P55; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; van Vliet J, 2000, NUCLEIC ACIDS RES, V28, P1955; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P1056, DOI 10.1073/pnas.97.3.1056	35	158	165	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					35	39		10.1074/jbc.M007364200	http://dx.doi.org/10.1074/jbc.M007364200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11022042	hybrid			2022-12-25	WOS:000166280700006
J	Bandyopadhyay, G; Sajan, MP; Kanoh, Y; Standaert, ML; Burke, TR; Quon, MJ; Reed, BC; Dikic, I; Noel, LE; Newgard, CB; Farese, R				Bandyopadhyay, G; Sajan, MP; Kanoh, Y; Standaert, ML; Burke, TR; Quon, MJ; Reed, BC; Dikic, I; Noel, LE; Newgard, CB; Farese, R			Glucose activates mitogen-activated protein kinase (extracellular signal-regulated kinase) through proline-rich tyrosine kinase-2 and the glut1 glucose transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-STIMULATED TRANSLOCATION; RAT ADIPOSE CELL; C-ZETA; MAP KINASE; INCREASES DIACYLGLYCEROL; ADIPOCYTES; RECEPTOR; BETA; SECRETION; ALPHA	Glucose serves as both a nutrient and regulator of physiological and pathological processes. Presently, we found that glucose and certain sugars rapidly activated extracellular signal-regulated kinase (ERK) by a mechanism that was: (a) independent of glucose uptake/metabolism and protein kinase C but nevertheless cytochalasin B-inhibitable; (b) dependent upon proline-rich tyrosine kinase-2 (PYK2), GRBB, SOS, RAS, RAF, and MEK1; and (c) amplified by overexpression of the Glut1, but not Glut2, Gluts, or Glut4, glucose transporter. This amplifying effect was independent of glucose uptake but dependent on residues 463-468, IASGFR, in the Glut1 C terminus. Accordingly, glucose effects on ERK were amplified by expression of Glut 4/Glut1 or Glut2/Glut1 chimeras containing IASGFR but not by Glut1/Glut4 or Glut1/Grlut4 chimeras lacking these residues. Also, deletion of Glut1 residues 469-492 was without effect, but mutations involving serine 465 or arginine 468 yielded dominant-negative forms that inhibited glucose-dependent ERK activation. Glucose stimulated the phosphorylation of tyrosine residues 402 and 881 in PYK2 and binding of PYK2 to Myc-Glut1. Our findings suggest that: (a) glucose activates the GRB2/SOS/RAS/RAF/ MEK1/ERK pathway by a mechanism that requires PYK2 and residues 463-468, LASGFR, in the Glut1 C terminus and (b) Glutl serves as a sensor, transducer, and amplifier for glucose signaling to PYK2 and ERK.	James A Haley Vet Hosp, Res Serv VAR 151, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Internal Med, Tampa, FL 33612 USA; NHLBI, Hypertens Endocrine Branch, NIH, Bethesda, MD 20892 USA; NCI, NIH, Bethesda, MD 20892 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Gifford Labs Diabet Res, Dallas, TX 75235 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Ludwig Institute for Cancer Research; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Farese, R (corresponding author), James A Haley Vet Hosp, Res Serv VAR 151, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	rfarese@com1.med.usf.edu	Quon, Michael/B-1970-2008; Burke, Terrence R/N-2601-2014; Dikic, Ivan/O-4650-2015	Dikic, Ivan/0000-0001-8156-9511; QUON, MICHAEL/0000-0002-5289-3707; Quon, Michael/0000-0002-9601-9915; Burke, Terrence/0000-0001-9925-8586	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL003608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038079] Funding Source: NIH RePORTER; NIDDK NIH HHS [2R01DK38079-09A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1999, BIOCHEM J, V337, P461, DOI 10.1042/0264-6021:3370461; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Benes C, 1998, J BIOL CHEM, V273, P15507, DOI 10.1074/jbc.273.25.15507; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; BOYD AE, 1992, J CELL BIOCHEM, V48, P234, DOI 10.1002/jcb.240480303; CHIN JE, 1993, J BIOL CHEM, V268, P6338; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DERUBERTIS FR, 1994, DIABETES, V43, P1, DOI 10.2337/diabetes.43.1.1; DRAZNIN B, 1987, DIABETES, V36, P174, DOI 10.2337/diabetes.36.2.174; DRAZNIN B, 1988, BIOCHEM BIOPH RES CO, V156, P570, DOI 10.1016/S0006-291X(88)80880-5; FARESE RV, 1987, SCIENCE, V236, P586, DOI 10.1126/science.3107122; FARESE RV, 1994, J CLIN INVEST, V93, P1894, DOI 10.1172/JCI117180; FARESE RV, 1988, BIOCHEM J, V256, P175, DOI 10.1042/bj2560175; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; Haneda M, 1995, J DIABETES COMPLICAT, V9, P246, DOI 10.1016/1056-8727(95)80013-5; HARING H, 1986, J BIOL CHEM, V261, P3869; HOFFMAN JM, 1991, ENDOCRINOLOGY, V128, P2937, DOI 10.1210/endo-128-6-2937; ISHIZUKA T, 1989, FEBS LETT, V249, P234, DOI 10.1016/0014-5793(89)80630-1; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; LEE TS, 1989, P NATL ACAD SCI USA, V86, P5141, DOI 10.1073/pnas.86.13.5141; LONGO EA, 1991, J BIOL CHEM, V266, P9314; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; MULLER HK, 1991, DIABETES, V40, P1440, DOI 10.2337/diabetes.40.11.1440; MURAOKA A, 1995, BIOCHEM J, V311, P699, DOI 10.1042/bj3110699; Noel LE, 1997, BIOCHEMISTRY-US, V36, P5465, DOI 10.1021/bi9630624; PETERSEN OH, 1987, PHYSIOL REV, V67, P1054, DOI 10.1152/physrev.1987.67.3.1054; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; WEBER TM, 1988, RECEPTOR BIOCH MET B, V12, P171; WOLLHEIM CB, 1986, ANN NY ACAD SCI, V488, P317; YANG YC, 1993, FEBS LETT, V333, P287, DOI 10.1016/0014-5793(93)80672-H; Yao ZJ, 1999, J MED CHEM, V42, P25, DOI 10.1021/jm980388x	40	58	60	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40817	40826		10.1074/jbc.M007920200	http://dx.doi.org/10.1074/jbc.M007920200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007796	hybrid			2022-12-25	WOS:000166114600023
J	Korneeva, NL; Lamphear, BJ; Hennigan, FLC; Rhoads, RE				Korneeva, NL; Lamphear, BJ; Hennigan, FLC; Rhoads, RE			Mutually cooperative binding of eukaryotic translation initiation factor (eIF) 3 and eIF4A to human eIF4G-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 4G EIF4G; CAP-DEPENDENT TRANSLATION; PROTEIN-SYNTHESIS; MESSENGER-RNA; WHEAT-GERM; POLY(A)-BINDING PROTEIN; FUNCTIONAL DOMAINS; RIBOSOMAL-SUBUNIT; CROSS-LINKING; FACTOR EIF-3	Eukaryotic translation initiation factor 4G-1 (eIF4G) plays a critical role in the recruitment of mRNA to the 43 S preinitiation complex. The central region of eIF4G binds the ATP-dependent RNA helicase eIF4A, the 40 S binding factor eIF3, and RNA. In the present work, we have further characterized the binding properties of the central region of human eIF4G, Both titration and competition experiments were consistent with a 1:1 stoichiometry for eIF3 binding. Surface plasmon resonance studies showed that three recombinant eIF4G fragments corresponding to amino acids 642-1560, 613-1078, and 975-1078 bound eIF3 with similar kinetics. A dissociation equilibrium constant of similar to 42 nM was derived from an association rate constant of 3.9 x 10(4) M-1 s(-1) and dissociation rate constant of 1.5 x 10(-3) s(-1). Thus, the eIF3-binding region is included within amino acid residues 975-1078. This region does not overlap with the RNA-binding site, which suggests that eIF3 binds eIF4G directly and not through an RNA bridge, or the central eIF4A-binding site. Surprisingly, the binding of eIF3 and eIF4A to the central region was mutually cooperative; eIF3 binding to eIF4G: increased 4-fold in the presence of eIF4A, and conversely, eIF4A binding to the central (but not COOH-terminal) region of eIF4G increased 2.4-fold in the presence of eIF3.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Rhoads, RE (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.	rrhoad@lsuhsc.edu			NIGMS NIH HHS [GM20818] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Bandyopadhyay A, 1999, NUCLEIC ACIDS RES, V27, P1331, DOI 10.1093/nar/27.5.1331; BENNE R, 1978, J BIOL CHEM, V253, P3078; Block KL, 1998, J BIOL CHEM, V273, P31901, DOI 10.1074/jbc.273.48.31901; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNLUEDI ML, 1982, BIOCHEMISTRY-US, V21, P4202, DOI 10.1021/bi00261a002; CARBERRY SE, 1991, BIOCHEMISTRY-US, V30, P6977, DOI 10.1021/bi00242a024; Chaudhuri J, 1999, J BIOL CHEM, V274, P17975, DOI 10.1074/jbc.274.25.17975; De Gregorio E, 1999, EMBO J, V18, P4865, DOI 10.1093/emboj/18.17.4865; Dominguez D, 1999, J BIOL CHEM, V274, P26720, DOI 10.1074/jbc.274.38.26720; Fletcher CM, 1999, EMBO J, V18, P2631, DOI 10.1093/emboj/18.9.2631; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; Hershey J, 1996, BIOCHIMIE, V78, P903, DOI 10.1016/S0300-9084(97)86711-9; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Keiper BD, 1999, INT J BIOCHEM CELL B, V31, P37, DOI 10.1016/S1357-2725(98)00130-7; Kolupaeva VG, 1998, J BIOL CHEM, V273, P18599, DOI 10.1074/jbc.273.29.18599; KORNEEVA NL, 2001, IN PRESS J BIOL CHEM, V276; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamphear BJ, 1996, BIOCHEMISTRY-US, V35, P15726, DOI 10.1021/bi961864t; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LAX S, 1985, P NATL ACAD SCI USA, V82, P330, DOI 10.1073/pnas.82.2.330; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; LIEBIG HD, 1993, BIOCHEMISTRY-US, V32, P7581, DOI 10.1021/bi00080a033; MADER S, 1995, MOL CELL BIOL, V15, P4990; Merrick WC., 1996, TRANSLATION CONTROL, P31; Methot N, 1996, MOL CELL BIOL, V16, P5328; Metz AM, 1996, J BIOL CHEM, V271, P31033, DOI 10.1074/jbc.271.49.31033; Morino S, 2000, MOL CELL BIOL, V20, P468, DOI 10.1128/MCB.20.2.468-477.2000; Neff CL, 1999, MOL CELL BIOL, V19, P5557; NYGARD O, 1982, NUCLEIC ACIDS RES, V10, P1327, DOI 10.1093/nar/10.4.1327; Odreman-Macchioli FE, 2000, NUCLEIC ACIDS RES, V28, P875, DOI 10.1093/nar/28.4.875; Pestova TV, 2000, NATURE, V403, P332, DOI 10.1038/35002118; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEAL SN, 1986, ARCH BIOCHEM BIOPHYS, V246, P710, DOI 10.1016/0003-9861(86)90327-9; SETYONO B, 1984, BIOCHIM BIOPHYS ACTA, V782, P242, DOI 10.1016/0167-4781(84)90058-7; Sizova DV, 1998, J VIROL, V72, P4775, DOI 10.1128/JVI.72.6.4775-4782.1998; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TOLAN DR, 1983, BIOCHIMIE, V65, P427, DOI 10.1016/S0300-9084(83)80062-5; TRACHSEL H, 1979, BIOCHIM BIOPHYS ACTA, V565, P305, DOI 10.1016/0005-2787(79)90207-7; Vornlocher HP, 1999, J BIOL CHEM, V274, P16802, DOI 10.1074/jbc.274.24.16802; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; WESTERMANN P, 1984, NUCLEIC ACIDS RES, V12, P8887, DOI 10.1093/nar/12.23.8887; WESTERMANN P, 1986, FEBS LETT, V205, P171, DOI 10.1016/0014-5793(86)80891-2; YODERHILL J, 1993, J BIOL CHEM, V268, P5566	53	89	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41369	41376		10.1074/jbc.M007525200	http://dx.doi.org/10.1074/jbc.M007525200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11022043	hybrid			2022-12-25	WOS:000166114600094
J	Mo, YY; Wang, CY; Beck, WT				Mo, YY; Wang, CY; Beck, WT			A novel nuclear localization signal in human DNA topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL DOMAIN; POINT MUTATION; HEAT-SHOCK; II-ALPHA; IDENTIFICATION; PROTEINS; SITE; EXPRESSION; CLONING; CELLS	DNA topoisomerase (topo) I is a nuclear enzyme that plays an important role in DNA metabolism. Based on conserved nuclear targeting sequences, four classic nuclear localization signals (NLSs) have been proposed at the N terminus of human topo I, but studies with yeast have suggested that only one of them (amino acids (aa) 150-156) is sufficient to direct the enzyme to the nucleus. In this study, we expressed human topo I fused to enhanced green fluorescent protein (EGFP) in mammalian cells and demonstrated that whereas aa 150-156 are sufficient for nuclear localization, the nucleolar localization requires as 157-199. More importantly, we identified a novel NLS within aa 117-146. In contrast to the classic MLSs that are rich in basic amino acids, the novel NLS identified in this study is rich in acidic amino acids, Furthermore, this novel NLS alone is sufficient to direct not only EGFP into the nucleus but also topo I; and the EGFP topo I fusion driven by the novel NLS is as active in vivo as the wild-type topo I in response to the topo I inhibitor topotecan. Together, our results suggest that human topo I carries two independent NLSs that have opposite amino acid compositions.	Univ Illinois, Div Mol Pharmacol, Dept Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Dept Pharmaceut & Pharmacodynam, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Beck, WT (corresponding author), Univ Illinois, Div Mol Pharmacol, Dept Mol Genet, MC 669,900 S Ashland Ave, Chicago, IL 60607 USA.	wtbeck@uic.edu	Mo, Yin-Yuan/B-6141-2011; Mo, Yin-Yuan/R-8255-2019		NCI NIH HHS [CA27469, CA30103, CA40570] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040570, R01CA030103, U10CA027469] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALSNER J, 1992, J BIOL CHEM, V267, P12408; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BAKER SD, 1995, CYTOMETRY, V19, P134, DOI 10.1002/cyto.990190208; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; Castano IB, 1996, GENE DEV, V10, P2564, DOI 10.1101/gad.10.20.2564; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; Cowell IG, 1998, EXP CELL RES, V243, P232, DOI 10.1006/excr.1998.4150; DARPA P, 1990, CANCER RES, V50, P6919; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FLEISCHMANN G, 1984, P NATL ACAD SCI-BIOL, V81, P6958, DOI 10.1073/pnas.81.22.6958; Ginisty H, 1999, J CELL SCI, V112, P761; Gobert C, 1999, P NATL ACAD SCI USA, V96, P10355, DOI 10.1073/pnas.96.18.10355; Haluska P, 1998, NUCLEIC ACIDS RES, V26, P1841, DOI 10.1093/nar/26.7.1841; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; Hann C, 1998, J BIOL CHEM, V273, P8425, DOI 10.1074/jbc.273.14.8425; HASHIMOTO S, 1995, ONCOL RES, V7, P21; HIRANO T, 1989, J CELL BIOL, V108, P243, DOI 10.1083/jcb.108.2.243; Jakel S, 1999, EMBO J, V18, P2411, DOI 10.1093/emboj/18.9.2411; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KOIWAI O, 1993, GENE, V125, P211, DOI 10.1016/0378-1119(93)90331-V; Mirski SEL, 1999, EXP CELL RES, V251, P329, DOI 10.1006/excr.1999.4587; Mo YY, 1998, BIOTECHNIQUES, V25, P1052, DOI 10.2144/98256cr04; Mo YY, 1999, EXP CELL RES, V252, P50, DOI 10.1006/excr.1999.4616; Mo YY, 2000, EXP CELL RES, V256, P480, DOI 10.1006/excr.2000.4864; Morcillo G, 1997, EXP CELL RES, V236, P361, DOI 10.1006/excr.1997.3726; MULLER MT, 1985, EMBO J, V4, P1237, DOI 10.1002/j.1460-2075.1985.tb03766.x; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nitiss JL, 1998, CONT CANC RES, P517; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; Rossi F, 1998, NUCLEIC ACIDS RES, V26, P2963, DOI 10.1093/nar/26.12.2963; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; SCHEER U, 1994, CURR OPIN CELL BIOL, V6, P354, DOI 10.1016/0955-0674(94)90026-4; Sekiguchi J, 1997, MOL CELL, V1, P89, DOI 10.1016/S1097-2765(00)80010-6; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; SUGIMOTO Y, 1990, CANCER RES, V50, P6925; TANIZAWA A, 1993, J BIOL CHEM, V268, P25463; Trowbridge PW, 1999, MOL CELL BIOL, V19, P1686; Ueki N, 1998, BIOCHEM BIOPH RES CO, V252, P97, DOI 10.1006/bbrc.1998.9606; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; VINCENT M, 1979, NATURE, V281, P501, DOI 10.1038/281501a0; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223	45	42	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41107	41113		10.1074/jbc.M003135200	http://dx.doi.org/10.1074/jbc.M003135200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11016921	hybrid			2022-12-25	WOS:000166114600061
J	Natochin, M; Lester, B; Peterson, YK; Bernard, ML; Lanier, SM; Artemyev, NO				Natochin, M; Lester, B; Peterson, YK; Bernard, ML; Lanier, SM; Artemyev, NO			AGS3 inhibits GDP dissociation from G alpha subunits of the G(i) family and rhodopsin-dependent activation of transducin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE BINDING; G-PROTEINS; EXCHANGE FACTOR; RGS; CHROMATOGRAPHY; PURIFICATION; G-ALPHA(O); GTP	A number of recently discovered proteins that interact with the alpha subunits of G(i)-like G proteins contain homologous repeated sequences named G protein regulatory (GPR) motifs, Activator of G: protein signaling 3 (AGS3), identified as an activator of the yeast pheromone pathway in the absence of the pheromone receptor, has a domain with four such repeats. To elucidate the potential mechanisms of regulation of G protein signaling by proteins containing GPR motifs, we examined the effects of the AGS3 GPR domain on the kinetics of guanine nucleotide exchange and GTP hydrolysis by G(i)alpha (1) and transducin-alpha (G(t)alpha). The AGS3 GPR domain markedly inhibited the rates of spontaneous guanosine 5'-O-(3-thiotriphosphate) (GTP gammaS) binding to G(i)alpha and rhodopsin-stimulated GTP gammaS binding to G(i)alpha The full-length AGS3 GPR domain, AGS3-(463-650), was similar to 30-fold more potent than AGS3-(572-629), containing two AGS3 GPR motifs, The IC50 values for the AGS3-(463-650) inhibitory effects on G(i)alpha and transducin were 0.12 and 0.15 muM, respectively. Furthermore, AGS3-(463-650) and AGS3-(572-629) effectively blocked the GDP release from G(i)alpha and rhodopsin-induced dissociation of GDP from G(i)alpha The potencies of AGS3-(572-629) and AGS3(463-650) to suppress the GDP dissociation rates correlated with their ability to inhibit the rates of GTP gammaS binding. Consistent with the inhibition of nucleotide exchange, the AGS3 GPR domain slowed the rate of steady-state GTP hydrolysis by G(i)alpha The catalytic rate of G(i)alpha GTP hydrolysis, measured under single turnover conditions, remained unchanged with the addition of AGS3-(463-650). Altogether, our results suggest that proteins containing GPR motifs, in addition to their potential role as G protein-coupled receptor-independent activators of G beta gamma signaling pathways, act as GDP dissociation inhibitors and negatively regulate the activation of a G protein by a G protein-coupled receptor.	Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29403 USA	University of Iowa; Medical University of South Carolina	Artemyev, NO (corresponding author), Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA.		Bernard, Michael/AAW-3944-2021	Artemyev, Nikolai/0000-0002-5266-6854; Lanier, Stephen/0000-0002-2740-7607	NATIONAL EYE INSTITUTE [R01EY012682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NEI NIH HHS [R01EY12682] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTY DJ, 1990, J BIOL CHEM, V265, P6268; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Granderath S, 1999, DEVELOPMENT, V126, P1781; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; KLEUSS C, 1987, J CHROMATOGR, V407, P281, DOI 10.1016/S0021-9673(01)92625-1; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; LINDER ME, 1990, J BIOL CHEM, V265, P8243; Luo Y, 1999, J BIOL CHEM, V274, P10685, DOI 10.1074/jbc.274.16.10685; Mochizuki N, 1996, GENE, V181, P39, DOI 10.1016/S0378-1119(96)00456-8; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Natochin M, 1997, J BIOL CHEM, V272, P17444, DOI 10.1074/jbc.272.28.17444; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YAMAZAKI A, 1988, METHOD ENZYMOL, V159, P702	24	90	91	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40981	40985		10.1074/jbc.M006478200	http://dx.doi.org/10.1074/jbc.M006478200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024022	hybrid			2022-12-25	WOS:000166114600044
J	Scherer, A; Graff, JM				Scherer, A; Graff, JM			Calmodulin differentially modulates Smad1 and Smad2 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA SUPERFAMILY; FAMILY MEDIATOR SMAD1; MAD-RELATED PROTEIN; TUMOR-SUPPRESSOR; GROWTH-FACTOR; TRANSDUCTION PATHWAY; MESODERM INDUCTION; IN-VIVO; XENOPUS; RECEPTOR	The members of the Smad protein family are intracellular mediators of transforming growth factor beta (TGF-beta) signaling. Smad1 transduces bone morphogenetic protein signals, inducing formation of ventral mesoderm in Xenopus embryos, whereas Smad2 transduces activin/TGF-beta signals, generating dorsal mesoderm. Calmodulin directly binds to-many Smads and was shown to downregulate Smad2 activity in a cell culture system (Zimmerman, C. M., Kariapper, M. S. T., and Mathews, L. S. (1997) J. Biol. Chen. 273, 677-680). Here, we extend those data and demonstrate that calmodulin alters Smad signaling in living embryos, increasing Smad1 activity while inhibiting Smad2 function. To characterize this regulation, we undertook a structure-function analysis and found that calmodulin binds to two distinct and conserved;regions in both Smad1 and Smad2. Receptor tyrosine kinase signaling also modifies Smad activity (Kretzschmar, M., Doody, J., and Massague, J. (1997) Nature 389, 618-622; Kretzschmar, M Doody, J., Timokhina, I., and Massague, J. (1999) Genes Dev. 13, 804-816; de Caestecker, M. P., Parks, W. T., Frank, C. J., Castagnino, P., Bottaro, D. P., Roberts, A. B., and Lechleider, R. J. (1998) Genes Dev. 12, 1587-1592). We show that calmodulin binding to Smads inhibits subsequent Erk2-dependent phosphorylation of Smads and vice versa. These observations suggest the presence of a cross-talk between three major signaling cascades as follows: Ca2+/calmodulin, receptor tyrosine kinase, and TGF-beta pathways.	Univ Texas, SW Med Ctr, Ctr Dev Biol, Dept Mol Biol & Oncol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Graff, JM (corresponding author), Univ Texas, SW Med Ctr, Ctr Dev Biol, Dept Mol Biol & Oncol, 5323 Harry Hines Blvd,NB 5-118A, Dallas, TX 75390 USA.		Scherer, Andreas/ABD-8660-2020	Scherer, Andreas/0000-0002-4254-7122	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036001] Funding Source: NIH RePORTER; NICHD NIH HHS [R01HD3600101A1] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; Ault KT, 1996, DEVELOPMENT, V122, P2033; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BUSA WB, 1989, DEV BIOL, V132, P315, DOI 10.1016/0012-1606(89)90228-5; Casellas R, 1998, DEV BIOL, V198, P1; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Clements D, 1999, DEVELOPMENT, V126, P4903; COOKE J, 1989, DEVELOPMENT, V105, P549; Creton R, 2000, DEV BIOL, V217, P375, DOI 10.1006/dbio.1999.9542; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Dick A, 2000, GENE, V246, P69, DOI 10.1016/S0378-1119(00)00056-1; Eisaki A, 2000, BIOCHEM BIOPH RES CO, V271, P151, DOI 10.1006/bbrc.2000.2545; Ferguson EL, 1996, CURR OPIN GENET DEV, V6, P424, DOI 10.1016/S0959-437X(96)80063-3; Fritz JL, 2000, DEVELOPMENT, V127, P1991; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hedgepeth CM, 1999, MOL CELL BIOL, V19, P7147; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HINRICHSEN RD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P277, DOI 10.1016/0304-419X(93)90010-A; Holley SA, 1997, BIOESSAYS, V19, P281, DOI 10.1002/bies.950190404; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Howell M, 1999, DEV BIOL, V214, P354, DOI 10.1006/dbio.1999.9430; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; Lebman DA, 1999, MICROBES INFECT, V1, P1297, DOI 10.1016/S1286-4579(99)00254-3; LeSuer JA, 1999, DEVELOPMENT, V126, P137; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MASLANSKI JA, 1992, SCIENCE, V256, P243, DOI 10.1126/science.1314424; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Masuyama N, 1999, J BIOL CHEM, V274, P12163, DOI 10.1074/jbc.274.17.12163; Miyanaga Y, 1999, DEV GENES EVOL, V209, P69, DOI 10.1007/s004270050229; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Muller F, 1999, MECH DEVELOP, V88, P73, DOI 10.1016/S0925-4773(99)00173-2; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nishimatsu S, 1998, MECH DEVELOP, V74, P75, DOI 10.1016/S0925-4773(98)00070-7; Onions J, 2000, BIOCHEMISTRY-US, V39, P4366, DOI 10.1021/bi992533u; Osada SI, 1999, DEVELOPMENT, V126, P3229; Patterson GI, 2000, TRENDS GENET, V16, P27, DOI 10.1016/S0168-9525(99)01916-2; Pouliot F, 1999, INT J CANCER, V81, P98, DOI 10.1002/(SICI)1097-0215(19990331)81:1<98::AID-IJC17>3.0.CO;2-9; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Riggins GJ, 1997, CANCER RES, V57, P2578; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; Schutte M, 1996, CANCER RES, V56, P2527; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; SWANLJUNGCOLLINS H, 1991, J BIOL CHEM, V266, P1312; Tada M, 2000, DEVELOPMENT, V127, P2227; Watanabe M, 1999, CELL MOL BIOL, V45, P537; Watanabe M, 1999, DEVELOPMENT, V126, P5621; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; Xu RH, 1999, BIOCHEM BIOPH RES CO, V258, P366, DOI 10.1006/bbrc.1999.0598; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4; Zimmerman CM, 1998, J BIOL CHEM, V273, P677, DOI 10.1074/jbc.273.2.677	78	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41430	41438		10.1074/jbc.M005727200	http://dx.doi.org/10.1074/jbc.M005727200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007779	hybrid			2022-12-25	WOS:000166114600101
J	Huttunen, HJ; Kuja-Panula, J; Sorci, G; Agneletti, AL; Donato, R; Rauvala, H				Huttunen, HJ; Kuja-Panula, J; Sorci, G; Agneletti, AL; Donato, R; Rauvala, H			Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DEVELOPING NERVOUS-SYSTEM; CALCIUM-BINDING PROTEINS; HIPPOCAMPAL-NEURONS; ALZHEIMERS-DISEASE; S-100 PROTEINS; OXIDANT STRESS; GROWTH-FACTOR; CYTOCHROME-C; BRAIN	Amphoterin is a protein enhancing process extension and migration in embryonic neurons and in tumor cells through binding to receptor for advanced glycation end products (RAGE), a multiligand transmembrane receptor. S100 proteins, especially S100B, are abundantly expressed in the nervous system and are suggested to function as cytokines with both neurotrophic and neurotoxic effects. However, the cell surface receptor for the cytokine function of S100B has not been identified. Here we show that two S100 family proteins, S100B and S100A1, activate RAGE in concert with amphoterin inducing neurite outgrowth and activation of transcription factor NF-kappaB. Furthermore, activation of RAGE by amphoterin and S100B promotes cell survival through increased expression of the anti-apoptotic protein Bcl-2. However, whereas nanomolar concentrations of S100B induce trophic effects in RAGE-expressing cells, micromolar concentrations of S100B induce apoptosis in an oxidant-dependent manner. Both trophic and toxic effects are specific for cells expressing full-length RAGE since cells expressing a cytoplasmic domain deletion mutant of RAGE are unresponsive to these stimuli. These findings suggest that activation of RAGE by multiple ligands is able to promote trophic effects whereas hyperactivation of RAGE signaling pathways promotes apoptosis, We suggest that RAGE is a signal-transducing receptor for both trophic and toxic effects of S100B.	Univ Helsinki, Inst Biotechnol, Program Mol Neurobiol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Biosci, FIN-00014 Helsinki, Finland; Univ Perugia, Dept Expt Med & Biochem Sci, Sect Anat, I-06122 Perugia, Italy	University of Helsinki; University of Helsinki; University of Perugia	Huttunen, HJ (corresponding author), Univ Helsinki, Inst Biotechnol, Program Mol Neurobiol, POB 56,Viikinkaari 5, FIN-00014 Helsinki, Finland.		Donato, Rosario/I-3943-2019	Huttunen, Henri/0000-0002-9867-4438; Sorci, Guglielmo/0000-0002-1973-9679; Rauvala, Heikki/0000-0001-7809-9811				Alexanian AR, 1999, FASEB J, V13, P1611, DOI 10.1096/fasebj.13.12.1611; ALLORE R, 1988, SCIENCE, V239, P1311, DOI 10.1126/science.2964086; AZMITIA EC, 1990, BRAIN RES, V516, P354, DOI 10.1016/0006-8993(90)90942-5; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; BHATTACHARYYA A, 1992, J NEUROBIOL, V23, P451, DOI 10.1002/neu.480230410; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; DONATO R, 1988, J BIOL CHEM, V263, P106; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Garbuglia M, 1999, BIOCHEM BIOPH RES CO, V254, P36, DOI 10.1006/bbrc.1998.9881; Goncalves DS, 2000, NEUROREPORT, V11, P807, DOI 10.1097/00001756-200003200-00030; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Holm K, 1999, TRENDS NEUROSCI, V22, P269, DOI 10.1016/S0166-2236(98)01352-6; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Hu JG, 1996, J BIOL CHEM, V271, P2543, DOI 10.1074/jbc.271.5.2543; Hu JR, 1997, J NEUROCHEM, V69, P2294; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; IVANENKOV VV, 1995, J BIOL CHEM, V270, P14651, DOI 10.1074/jbc.270.24.14651; Iwasaki Y, 1997, J NEUROL SCI, V151, P7, DOI 10.1016/S0022-510X(97)00073-7; Kaltschmidt B, 1999, P NATL ACAD SCI USA, V96, P9409, DOI 10.1073/pnas.96.16.9409; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; KUBE E, 1992, J BIOL CHEM, V267, P14175; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; LIU JP, 1992, J NEUROSCI RES, V33, P248, DOI 10.1002/jnr.490330208; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MARIGGIO MA, 1994, NEUROSCIENCE, V60, P29, DOI 10.1016/0306-4522(94)90201-1; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Milev P, 1998, J BIOL CHEM, V273, P6998, DOI 10.1074/jbc.273.12.6998; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Nair SM, 1997, J NEUROCHEM, V68, P1286; Osterloh D, 1998, CELL CALCIUM, V24, P137, DOI 10.1016/S0143-4160(98)90081-1; PANDE SV, 1994, ANAL BIOCHEM, V220, P424, DOI 10.1006/abio.1994.1361; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; Petrova TV, 2000, BRAIN RES, V853, P74, DOI 10.1016/S0006-8993(99)02251-9; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Rauvala H, 2000, MATRIX BIOL, V19, P377, DOI 10.1016/S0945-053X(00)00084-6; RAUVALA H, 1988, J CELL BIOL, V107, P2293, DOI 10.1083/jcb.107.6.2293; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; Rety S, 2000, STRUCTURE, V8, P175, DOI 10.1016/S0969-2126(00)00093-9; Rety S, 1999, NAT STRUCT BIOL, V6, P89; SALMIVIRTA M, 1992, EXP CELL RES, V200, P444, DOI 10.1016/0014-4827(92)90194-D; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VANELDIK LJ, 1987, BRAIN RES, V436, P367, DOI 10.1016/0006-8993(87)91681-7; VANELDIK LJ, 1991, BRAIN RES, V542, P280, DOI 10.1016/0006-8993(91)91579-P; Wang S, 1999, MOL BRAIN RES, V70, P167, DOI 10.1016/S0169-328X(99)00145-X; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Zhang KZ, 1996, P NATL ACAD SCI USA, V93, P4504, DOI 10.1073/pnas.93.9.4504; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	63	483	508	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40096	40105		10.1074/jbc.M006993200	http://dx.doi.org/10.1074/jbc.M006993200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007787	hybrid			2022-12-25	WOS:000166039500042
J	Widen, C; Zilliacus, J; Gustafsson, JA; Wikstrom, AC				Widen, C; Zilliacus, J; Gustafsson, JA; Wikstrom, AC			Glucocorticoid receptor interaction with 14-3-3 and Raf-1, a proposed mechanism for cross-talk of two signal transduction pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK; ACTIVATION; PROTEIN; BINDING; 14-3-3-PROTEINS; HSP90	The glucocorticoid receptor (GR) functions as a ligand-dependant transcription factor. In the present study we describe a specific immunoaffinity chromatography purification of GR from liver cytosol from adrenalectomized rats that may be used to identify hitherto unknown cytosolic GR interacting proteins. me have identified the ubiquitously expressed 14-3-3 as well as Raf-1, a downstream effector of Ras, as GR co-purifying proteins. In our semi-quantitative analysis liganded/activated GR showed the strongest interaction with 14-3-3 and Raf-l, but 14-3-3 was also found to co-purify with GR in a nonliganded/nonactivated state. By extensive salt washes we were also able to demonstrate that the glucocorticoid induced interaction between GR, 14-3-3, and Raf-1, respectively, is remarkably stable and withstood 2.4 M salt. The interaction between GR and 14-3-3 was also verified by 14-3-3 co-immunoprecipitation studies. Our observations that GR and Raf-1 are found within the same protein complex ("receptosome") in the cytoplasm of rat liver cells could provide a mechanistic explanation for glucocorticoid effects on the Raf-1-Ras signaling pathway.	Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden	Karolinska Institutet	Wikstrom, AC (corresponding author), Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden.	lotta.wikstrom@mednut.ki.se						AKNER G, 1992, EUR J CELL BIOL, V58, P356; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cenni B, 1999, TRENDS ENDOCRIN MET, V10, P41, DOI 10.1016/S1043-2760(98)00121-0; Croxtall JD, 2000, BRIT J PHARMACOL, V130, P289, DOI 10.1038/sj.bjp.0703272; Evans-Storms RB, 2000, ENDOCRINOLOGY, V141, P1854, DOI 10.1210/en.141.5.1854; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; King KL, 1998, ANNU REV PHYSIOL, V60, P601, DOI 10.1146/annurev.physiol.60.1.601; LEACH KL, 1979, J BIOL CHEM, V254, P1884; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; MCEWAN IJ, 1994, J BIOL CHEM, V269, P25629; MERRY WH, 1994, SURGERY, V116, P1095; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NEMOTO T, 1990, BIOCHEMISTRY-US, V29, P1880, DOI 10.1021/bi00459a031; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; OKRET S, 1984, P NATL ACAD SCI-BIOL, V81, P1609, DOI 10.1073/pnas.81.6.1609; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; SUEN KL, 1995, ONCOGENE, V11, P825; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607	31	49	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39296	39301		10.1074/jbc.M006943200	http://dx.doi.org/10.1074/jbc.M006943200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11005817	hybrid			2022-12-25	WOS:000165953100049
J	Bastie, C; Luquet, S; Holst, D; Jehl-Pietri, C; Grimaldi, PA				Bastie, C; Luquet, S; Holst, D; Jehl-Pietri, C; Grimaldi, PA			Alterations of peroxisome proliferator-activated receptor delta activity affect fatty acid-controlled adipose differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREADIPOCYTE CLONAL LINE; AP2 GENE-EXPRESSION; CELL-DIFFERENTIATION; BINDING DOMAIN; PPAR-GAMMA; LIGAND; ADIPOGENESIS; FIBROBLASTS; INDUCTION; AF-2	Fatty acids have been postulated to regulate adaptation of adipose mass to nutritional changes by controlling expression of genes implicated in lipid metabolism via activation of nuclear receptors. Ectopic expression of the nuclear receptors PPAR gamma or PPAR delta promotes adipogenesis in fibroblastic cells exposed to thiazolidinediones or long-chain fatty acids. To investigate the role of PPAR delta in fatty acid regulation of gene expression and adipogenesis in a preadipose cellular context, we studied the effects of overexpressing the native receptor or the dominant-negative PPAR delta mutant in Ob1771 and 3T3-F442A cells. Overexpression of PPAR delta enhanced fatty acid induction of the adipose-related genes for fatty acid translocase, adipocyte lipid binding protein, and PPAR gamma and fatty acid effects on terminal differentiation. A transactivation deficient form of PPAR delta mutated in the AF2 domain severely reduced these effects. Findings are similar in Ob1771 or 3T3-F442A preadipose cells. These data demonstrate that PPAR delta plays a central role in fatty acid-controlled differentiation of preadipose cells. Furthermore, they suggest that modulation of PPAR delta expression or activity could affect adaptive responses of white adipose tissue to nutritional changes.	Univ Nice, Fac Sci, Ctr Biochim, INSERM U470,Inst Rech Signalisat Biol Dev & Canc, F-06108 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Grimaldi, PA (corresponding author), Univ Nice, Fac Sci, Ctr Biochim, INSERM U470,Inst Rech Signalisat Biol Dev & Canc, Parc Valrose, F-06108 Nice 2, France.		Luquet, serge/AAT-1809-2021	Luquet, serge/0000-0001-8668-6645; Bastie, Claire/0000-0001-8178-4748				AMRI EZ, 1994, J LIPID RES, V35, P930; AMRI EZ, 1991, J LIPID RES, V32, P1449; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; AMRI EZ, 1986, BIOCHEM J, V238, P115, DOI 10.1042/bj2380115; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; Bastie C, 1999, J BIOL CHEM, V274, P21920, DOI 10.1074/jbc.274.31.21920; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FAUST IM, 1978, AM J PHYSIOL, V235, pE279, DOI 10.1152/ajpendo.1978.235.3.E279; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FRITSCH M, 1992, BIOCHEMISTRY-US, V31, P5303, DOI 10.1021/bi00138a009; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GRIMALDI PA, 1992, P NATL ACAD SCI USA, V89, P10930, DOI 10.1073/pnas.89.22.10930; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KLYDE JB, 1979, J LIPID RES, V20, P705; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LOWRY OH, 1951, J BIOL CHEM, V193, P173; NEGREL R, 1978, P NATL ACAD SCI USA, V75, P6054, DOI 10.1073/pnas.75.12.6054; NEGREL R, 1981, BIOCHEM BIOPH RES CO, V98, P768, DOI 10.1016/0006-291X(81)91178-5; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; SHILLABEER G, 1994, J LIPID RES, V35, P592; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; TATE BF, 1995, J BIOL CHEM, V270, P20258, DOI 10.1074/jbc.270.35.20258; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VIVILLE S, 1995, METHOD MOL BIOL, V31, P57; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0	31	90	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38768	38773		10.1074/jbc.M006450200	http://dx.doi.org/10.1074/jbc.M006450200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10991946	hybrid			2022-12-25	WOS:000165739800086
J	Hahn, JS; Oh, SY; Chater, KF; Cho, YH; Roe, JH				Hahn, JS; Oh, SY; Chater, KF; Cho, YH; Roe, JH			H2O2-sensitive fur-like repressor CatR regulating the major catalase gene in Streptomyces coelicolor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTAINING SUPEROXIDE-DISMUTASE; ESCHERICHIA-COLI; OXIDATIVE STRESS; BACILLUS-SUBTILIS; SALMONELLA-TYPHIMURIUM; HYDROGEN-PEROXIDE; SIGMA-FACTOR; PROTEIN; MULLER; A3(2)	Streptomyces coelicolor produces three distinct catalases to cope with oxidative and osmotic stresses and allow proper growth and differentiation. The major vegetative catalase A (CatA) is induced by H2O2 and is required for efficient aerobic growth. In order to investigate the H2O2-dependent regulatory mechanism, an H2O2-resistant mutant (HR40) overproducing CatA was isolated from S. coelicolor A3(2). Based on the genetic map location of the mutated locus in HR40, the wild type catR gene was isolated from the ordered cosmid library of S. coelicolor by screening for its ability to suppress the HR40 phenotype. catR encodes a protein of 138 amino acids (15319 Da), with sequence homology to ferric uptake regulator (Fur)-like proteins. Disruption of catR caused CatA overproduction as observed in the HR40 mutant, confirming the role of CatR as a negative regulator of catA expression. The levels of catA and catR transcripts were higher in HR40 than in the wild type, implying that CatR represses transcription of these genes. Transcripts from the catA and catR genes were induced within 10 min of H2O2 treatment, suggesting that the repressor activity of CatR may be directly modulated by H2O2. A putative CatR-binding site containing an inverted repeat of 23 base pairs was localized upstream of the catA and catR gene, on the basis of sequence comparison and deletion analysis, CatR protein purified in the presence of dithiothreitol bound to this region, whereas oxidized CatR, treated with H2O2 or diamide, did not. The redox shift of CatR involved thiol-disulfide exchange as judged by modification of free thiols with 4-acetamido-4'-maleimidylstilbene-2,2'-disulfonate. From these results we propose that CatR regulates its downstream target genes as a repressor whose DNA binding ability is directly modulated by redox changes in the cell.	Seoul Natl Univ, Mol Microbiol Lab, Sch Biol Sci, Seoul 151742, South Korea; Seoul Natl Univ, Inst Microbiol, Seoul 151742, South Korea; John Innes Ctr Plant Sci Res, Dept Genet, Norwich NR4 7UH, Norfolk, England	Seoul National University (SNU); Seoul National University (SNU); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Roe, JH (corresponding author), Seoul Natl Univ, Mol Microbiol Lab, Sch Biol Sci, Seoul 151742, South Korea.		Rho, Hyunji/R-6242-2016; Cho, You-Hee/AAF-8582-2020	Rho, Hyunji/0000-0001-7650-8933; Cho, You-Hee/0000-0001-7942-5893				BIERMAN M, 1992, GENE, V116, P43, DOI 10.1016/0378-1119(92)90627-2; Bsat N, 1998, MOL MICROBIOL, V29, P189, DOI 10.1046/j.1365-2958.1998.00921.x; Bsat N, 1999, J BACTERIOL, V181, P4299, DOI 10.1128/JB.181.14.4299-4307.1999; CHEN L, 1995, P NATL ACAD SCI USA, V92, P8190, DOI 10.1073/pnas.92.18.8190; Cho YH, 1997, J BACTERIOL, V179, P4049, DOI 10.1128/jb.179.12.4049-4052.1997; Cho YH, 2000, MOL MICROBIOL, V35, P150, DOI 10.1046/j.1365-2958.2000.01685.x; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; CHUNG HJ, 1993, KOREAN J MICROBIOL, V31, P166; COY M, 1994, BIOMETALS, V7, P292; de Peredo AG, 1999, BIOCHEMISTRY-US, V38, P8582, DOI 10.1021/bi9902283; Deretic V, 1997, TRENDS MICROBIOL, V5, P367, DOI 10.1016/S0966-842X(97)01112-8; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; Facey SJ, 1996, MICROBIOL-UK, V142, P657, DOI 10.1099/13500872-142-3-657; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; Gaballa A, 1998, J BACTERIOL, V180, P5815, DOI 10.1128/JB.180.22.5815-5821.1998; Hahn JS, 2000, J BACTERIOL, V182, P3767, DOI 10.1128/JB.182.13.3767-3774.2000; Hahn JS, 2000, J MICROBIOL, V38, P18; HAHN JS, 1999, THESIS SEOUL NAT U S; Hidalgo E, 1997, CELL, V88, P121, DOI 10.1016/S0092-8674(00)81864-4; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Hopwood D. A., 1985, GENETIC MANIPULATION; INGRAM C, 1989, J BACTERIOL, V171, P6617, DOI 10.1128/jb.171.12.6617-6624.1989; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Kang JG, 1999, EMBO J, V18, P4292, DOI 10.1093/emboj/18.15.4292; KELEMEN GH, 1995, MOL MICROBIOL, V17, P221, DOI 10.1111/j.1365-2958.1995.mmi_17020221.x; Kim EJ, 1998, MOL MICROBIOL, V27, P187, DOI 10.1046/j.1365-2958.1998.00674.x; Kim EJ, 1998, J BACTERIOL, V180, P2014, DOI 10.1128/JB.180.8.2014-2020.1998; Koh YS, 1996, MOL GEN GENET, V251, P591, DOI 10.1007/s004380050206; MACNEIL DJ, 1992, GENE, V111, P61, DOI 10.1016/0378-1119(92)90603-M; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; MAZODIER P, 1989, J BACTERIOL, V171, P3583, DOI 10.1128/jb.171.6.3583-3585.1989; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; Oh SH, 1997, J BACTERIOL, V179, P122, DOI 10.1128/jb.179.1.122-127.1997; Pagan-Ramos E, 1998, J BACTERIOL, V180, P4856; Paget MSB, 1998, EMBO J, V17, P5776, DOI 10.1093/emboj/17.19.5776; Redenbach M, 1996, MOL MICROBIOL, V21, P77, DOI 10.1046/j.1365-2958.1996.6191336.x; SMITH CP, 1991, ESSENTIAL MOL BIOL P, P237; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; van Vliet AHM, 1999, J BACTERIOL, V181, P6371, DOI 10.1128/JB.181.20.6371-6376.1999; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; Zou PJ, 1999, MICROBIOL-SGM, V145, P549, DOI 10.1099/13500872-145-3-549	41	62	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38254	38260		10.1074/jbc.M006079200	http://dx.doi.org/10.1074/jbc.M006079200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10991944	hybrid			2022-12-25	WOS:000165739800018
J	Machaca, K; Haun, S				Machaca, K; Haun, S			Store-operated calcium entry inactivates at the germinal vesicle breakdown stage of Xenopus meiosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; ADRENAL CHROMAFFIN CELLS; MEIOTIC MATURATION; DOWN-REGULATION; LAEVIS OOCYTES; T-LYMPHOCYTES; CL CURRENTS; DEPLETION; INFLUX; CHANNELS	Store-operated calcium entry (SOCE) is the predominant Ca2+ influx pathway in non-excitable cells and is activated in response to depletion of intracellular Ca2+ stores. We have studied SOCE regulation during Xenopus oocyte meiosis. SOCE can be measured readily in stage VI Xenopus oocytes arrested at the G(2)-M transition of the cell cycle, either by Ca2+ imaging or by recording the SOCE current. However, following meiotic maturation, SOCE can no longer be activated by store depletion. We have characterized the time course of SOCE inactivation during oocyte maturation, and show that SOCE inactivates almost completely, in a very short time period, at the germinal vesicle breakdown stage of meiosis. This acute inactivation offers an opportunity to better understand SOCE regulation.	Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Machaca, K (corresponding author), Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA.		Machaca, Khaled/AAF-3579-2019	Machaca, Khaled/0000-0001-6215-2411	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061829] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM061829-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; COOMBS JL, 1992, DEV BIOL, V153, P272, DOI 10.1016/0012-1606(92)90112-T; Csutora P, 1999, P NATL ACAD SCI USA, V96, P121, DOI 10.1073/pnas.96.1.121; DAY ML, 1993, NATURE, V365, P560, DOI 10.1038/365560a0; DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; Fomina AF, 1999, J NEUROSCI, V19, P3711; GILON P, 1995, J BIOL CHEM, V270, P8050, DOI 10.1074/jbc.270.14.8050; GREY RD, 1982, DEV BIOL, V89, P475, DOI 10.1016/0012-1606(82)90335-9; GREY RD, 1974, DEV BIOL, V36, P44, DOI 10.1016/0012-1606(74)90189-4; Hartzell HC, 1996, J GEN PHYSIOL, V108, P157, DOI 10.1085/jgp.108.3.157; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Machaca K, 1999, J GEN PHYSIOL, V113, P249, DOI 10.1085/jgp.113.2.249; MIYAZAKI S, 1995, CIBA F SYMP, V188, P235; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; Pardo LA, 1998, J CELL BIOL, V143, P767, DOI 10.1083/jcb.143.3.767; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PRESTON SF, 1991, CELL REGUL, V2, P915, DOI 10.1091/mbc.2.11.915; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RICHTER HP, 1984, J MEMBRANE BIOL, V79, P203, DOI 10.1007/BF01871059; Rosado JA, 2000, J BIOL CHEM, V275, P7527, DOI 10.1074/jbc.275.11.7527; SCHMALZING G, 1990, AM J PHYSIOL, V258, pC179, DOI 10.1152/ajpcell.1990.258.1.C179; SERAFINI AT, 1995, IMMUNITY, V3, P239, DOI 10.1016/1074-7613(95)90093-4; SMITH LD, 1989, DEVELOPMENT, V107, P685; SOMASUNDARAM B, 1995, BIOCHEM J, V309, P725, DOI 10.1042/bj3090725; Stricker SA, 1999, DEV BIOL, V211, P157, DOI 10.1006/dbio.1999.9340; Takahashi A, 1996, AM J PHYSIOL-CELL PH, V271, pC1887, DOI 10.1152/ajpcell.1996.271.6.C1887; VASILETS LA, 1990, J MEMBRANE BIOL, V118, P131, DOI 10.1007/BF01868470; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WASSERMAN WJ, 1975, EXP CELL RES, V91, P381, DOI 10.1016/0014-4827(75)90118-4; Yao Y, 1997, J GEN PHYSIOL, V109, P703, DOI 10.1085/jgp.109.6.703	32	62	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38710	38715		10.1074/jbc.M007887200	http://dx.doi.org/10.1074/jbc.M007887200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10991950	Green Accepted, hybrid			2022-12-25	WOS:000165739800079
J	Qing, J; Zhang, Y; Derynck, R				Qing, J; Zhang, Y; Derynck, R			Structural and functional characterization of the transforming growth factor-beta-induced Smad3/c-Jun transcriptional cooperativity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEINS; ACTIVATOR INHIBITOR-1 GENE; DNA-BINDING PROTEIN; SMAD PROTEINS; TUMOR-SUPPRESSOR; CRYSTAL-STRUCTURE; AP-1 COMPLEX; PROMOTER; JUN; ACTIVIN	Smads are intracellular proteins that act as central effecters for transforming growth factor-beta (TGF-beta) and related proteins from the activated receptor into the nucleus, where they regulate Ligand-induced gene expression. AP-1 binding sites have been functionally linked to the transcriptional activation of various genes in response to TGF-beta. Accordingly, we have previously shown that the heteromeric complex of Smad3 and Smad4 synergizes with c-Jun/c-Fos at the AP-1 binding site of the collagenase I promoter to induce transcriptional activation in response to TGF-beta. Using the collagenase I promoter as model system, we have now investigated the role of the c-Jun and Smad3 interactions with the promoter DNA and have further characterized the physical basis of the c-Jun/Smad3 interaction in the transcriptional response. Mutational analyses of the c-Jun protein and the AP-1 binding site in the promoter revealed that the interaction of c-Jun with DNA is necessary for transcriptional activation by TGF-beta and Smads. Similar analyses of Smad3 and the Smad binding sites revealed that binding of Smad3 to DNA is also required, but that its DNA sequence-specific recognition is not essential. We also found that the basic leucine zipper domain of c-Jun and a short sequence close to the N terminus of Smad3 mediate their physical interaction, and that these regions are critical for their DNA-binding function. Our studies provide a basis for understanding the functional cooperativity of Smads with the diversity of transcription factors, which underlies the Smad-induced transcriptional activation in response to TGF-beta and related factors.	Univ Calif San Francisco, Dept Growth & Dev, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Cell Biol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Program Dev Biol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Derynck, R (corresponding author), Univ Calif San Francisco, Dept Growth & Dev, San Francisco, CA 94143 USA.		Zhang, Ying E/G-3657-2015	Zhang, Ying E/0000-0003-2753-7601	NATIONAL CANCER INSTITUTE [ZIABC010419, Z01BC010419] Funding Source: NIH RePORTER; NCI NIH HHS [CA63301] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Attisano L, 1996, MOL CELL BIOL, V16, P1066; Brass AL, 1999, EMBO J, V18, P977, DOI 10.1093/emboj/18.4.977; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen Y, 1996, J BIOL CHEM, V271, P31602, DOI 10.1074/jbc.271.49.31602; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Derynck Rik, 1998, P593; Eresh S, 1997, EMBO J, V16, P2014, DOI 10.1093/emboj/16.8.2014; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jin G, 1997, J BIOL CHEM, V272, P26620, DOI 10.1074/jbc.272.42.26620; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liu B, 1999, MOL CELL BIOL, V19, P424; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCKNIGHT SL, 1992, COLD SPRINGER HARBOR, V22; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; ROBERTS A, 1990, PEPTIDE GROWTH FACTO, V1; Roberts AB, 1999, MICROBES INFECT, V1, P1265, DOI 10.1016/S1286-4579(99)00258-0; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Tan S, 1998, NATURE, V391, P660, DOI 10.1038/35563; Tang WL, 1998, J BIOL CHEM, V273, P5506, DOI 10.1074/jbc.273.10.5506; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yeo CY, 1999, J BIOL CHEM, V274, P26584, DOI 10.1074/jbc.274.37.26584; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	58	89	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38802	38812		10.1074/jbc.M004731200	http://dx.doi.org/10.1074/jbc.M004731200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10995748	hybrid			2022-12-25	WOS:000165739800091
J	Xia, GQ; Evers, MR; Kang, HG; Schachner, M; Baenziger, JU				Xia, GQ; Evers, MR; Kang, HG; Schachner, M; Baenziger, JU			Molecular cloning and expression of the pituitary glycoprotein hormone N-acetylgalactosamine-4-O-sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; BETA 1,4GLCNAC BETA; N-ACETYLGALACTOSAMINE; SULFATED OLIGOSACCHARIDES; SIALYLATED OLIGOSACCHARIDES; HNK-1 SULFOTRANSFERASE; L2/HNK-1 CARBOHYDRATE; GALNAC-TRANSFERASE; CRYSTAL-STRUCTURE; MONOCLONAL IGM	N-Linked oligosaccharides terminating with the sequence SO4-4-GalNAc beta1,4GlcNAc beta1,2Man alpha are present on the pituitary hormones lutropin (LH), thyrotropin, and pro-opiomelanocortin. The sulfated structures on LII are essential for expression of its biologic function in vivo. We have cloned the N-acetglgalactosamine-4-sulfo-transferase (GalNac-4-ST1, GenBank(TM) accession number AF300612), which mediates sulfate addition to the N-linked oligosaccharides on LH and other pituitary glycoproteins with terminal (beta1,4-linked GalNAc based on its homology to HNK-1 sulfotransferase (HNK-1 ST). GalNAc-4-ST1 displays 23% identity to HNK-1 ST and 28% to chondroitin 4-sulfotransferase I (C4ST-1) and 26% to chondroitin 4-sulfotransferase 2 (C4ST-2), The cDNA predicts a type II transmembrane protein of 424 amino acids with four potential N-linked glycosylation sites and a single membrane-spanning domain. GalNAc-4-ST1 has putative 5'-phosphosulfonate and S'-phosphate binding sites, Three more carboxyl-terminal regions of unknown function also show a high degree of identity with HNK-1 ST, C4ST-1, and C4ST-2. The membrane-bound form of GalNAc-4-ST1 transfers sulfate to GalNAc beta1,4GlcNAc beta -R but not to chondroitin, whereas truncated forms of GalNAc-4-ST1 that are released into the medium transfer sulfate to both GalNAc beta1, 4GlcNAc beta -R and chondroitin, The first 118 amino acids of GalNAc-4-ST1 appear to contribute to both its activity and specificity for terminal beta1,4-linked GalNAc. GalNAc-4-ST1 also efficiently transfers sulfate to N-linked oligosaccharides on native LH and other glycoproteins terminating with beta1,4-linked GalNAc. A single transcript of 2.4 kilobases is most highly expressed in the pituitary and other regions of the central nervous system. The GalNAc-4-ST1 gene is located on human chromosome 19q13.1.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ Hamburg, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany	Washington University (WUSTL); University of Hamburg; University Medical Center Hamburg-Eppendorf	Baenziger, JU (corresponding author), Washington Univ, Sch Med, Dept Pathol, 660 S Euclid Ave, St Louis, MO 63110 USA.	baenziger@pathology.wustl.edu	Xia, Guoqing/C-2365-2015; Baenziger, Jacques U/E-9430-2012	Xia, Guoqing/0000-0003-4492-9156; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK41738] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; Baenziger JU, 1996, ENDOCRINOLOGY, V137, P1520, DOI 10.1210/en.137.5.1520; BAENZIGER JU, 1994, FASEB J, V8, P1019, DOI 10.1096/fasebj.8.13.7926366; BAENZIGER JU, 1991, BIOL CARBOHYDRATES, V3; Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; BERGWERFF AA, 1995, EUR J BIOCHEM, V228, P1009; CHAN A L, 1991, Glycobiology, V1, P173, DOI 10.1093/glycob/1.2.173; CHOU KH, 1985, BIOCHEM BIOPH RES CO, V128, P383, DOI 10.1016/0006-291X(85)91690-0; CODDEVILLE B, 1992, CARBOHYD RES, V236, P145, DOI 10.1016/0008-6215(92)85013-P; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; DHARMESH SM, 1993, P NATL ACAD SCI USA, V90, P11127, DOI 10.1073/pnas.90.23.11127; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; Fiete D, 1997, J BIOL CHEM, V272, P14629, DOI 10.1074/jbc.272.23.14629; Fiete D, 1997, P NATL ACAD SCI USA, V94, P11256, DOI 10.1073/pnas.94.21.11256; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; Fiete DJ, 1998, P NATL ACAD SCI USA, V95, P2089, DOI 10.1073/pnas.95.5.2089; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; HARTREE AS, 1992, BIOCHEM J, V287, P665, DOI 10.1042/bj2870665; Hiraoka N, 2000, J BIOL CHEM, V275, P20188, DOI 10.1074/jbc.M002443200; Hooper LV, 1996, FASEB J, V10, P1137, DOI 10.1096/fasebj.10.10.8751716; HOOPER LV, 1995, J BIOL CHEM, V270, P5985, DOI 10.1074/jbc.270.11.5985; HOOPER LV, 1995, J BIOL CHEM, V270, P16327, DOI 10.1074/jbc.270.27.16327; JUNGALWALA FB, 1994, NEUROCHEM RES, V19, P945, DOI 10.1007/BF00968704; Kakuta Y, 1999, J BIOL CHEM, V274, P10673, DOI 10.1074/jbc.274.16.10673; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LITJENS T, 1991, BIOCHEM INT, V24, P209; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; MANZELLA SM, 1995, J BIOL CHEM, V270, P21665, DOI 10.1074/jbc.270.37.21665; Manzella SM, 1997, J BIOL CHEM, V272, P4775, DOI 10.1074/jbc.272.8.4775; MARTINI R, 1994, J NEUROSCI, V14, P7180; MENGELING BJ, 1995, P NATL ACAD SCI USA, V92, P502, DOI 10.1073/pnas.92.2.502; MOHAN PS, 1990, J NEUROCHEM, V54, P2024, DOI 10.1111/j.1471-4159.1990.tb04907.x; Mukherjee S, 1999, P NATL ACAD SCI USA, V96, P493, DOI 10.1073/pnas.96.2.493; NAKATA N, 1993, BIOCHEMISTRY-US, V32, P4369, DOI 10.1021/bi00067a029; Ong E, 1999, J BIOL CHEM, V274, P25608, DOI 10.1074/jbc.274.36.25608; PFEIFFER G, 1992, GLYCOBIOLOGY, V2, P411, DOI 10.1093/glycob/2.5.411; Roseman DS, 2000, P NATL ACAD SCI USA, V97, P9949, DOI 10.1073/pnas.170184597; Saghatelyan AK, 2000, EUR J NEUROSCI, V12, P3331, DOI 10.1046/j.1460-9568.2000.00216.x; Salamov AA, 2000, GENOME RES, V10, P516, DOI 10.1101/gr.10.4.516; SATO T, 1995, J BIOCHEM-TOKYO, V117, P147, DOI 10.1093/oxfordjournals.jbchem.a124702; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SCHMITZ B, 1994, GLYCOCONJUGATE J, V11, P345, DOI 10.1007/BF00731208; SICILIANO RA, 1993, GLYCOBIOLOGY, V3, P225, DOI 10.1093/glycob/3.3.225; SICILIANO RA, 1994, J BIOL CHEM, V269, P910; SKELTON TP, 1991, J BIOL CHEM, V266, P17142; SKELTON TP, 1992, J BIOL CHEM, V267, P12998; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1992, J BIOL CHEM, V267, P19140; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SMITH PL, 1990, P NATL ACAD SCI USA, V87, P7275, DOI 10.1073/pnas.87.18.7275; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; STECK AJ, 1983, NEUROLOGY, V33, P19, DOI 10.1212/WNL.33.1.19; Van Rooijen JJM, 1998, EUR J BIOCHEM, V256, P471, DOI 10.1046/j.1432-1327.1998.2560471.x; Yamauchi S, 1999, J BIOL CHEM, V274, P2456, DOI 10.1074/jbc.274.4.2456; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975; YAN SB, 1993, GLYCOBIOLOGY, V3, P597, DOI 10.1093/glycob/3.6.597	64	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38402	38409		10.1074/jbc.M007821200	http://dx.doi.org/10.1074/jbc.M007821200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10988300	hybrid, Green Published			2022-12-25	WOS:000165739800037
J	Yu, JC; Koenig, RJ				Yu, JC; Koenig, RJ			Regulation of hepatocyte thyroxine 5 '-deiodinase by T3 and nuclear receptor coactivators as a model of the sick euthyroid syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; SERUM RESPONSE ELEMENT; CREB-BINDING-PROTEIN; NONTHYROIDAL ILLNESS; MEDIATED TRANSACTIVATIONS; CBP; 3,5,3'-TRIIODOTHYRONINE; TRIIODOTHYRONINE; INTERLEUKIN-6; TRANSCRIPTION	The syndrome of nonthyroidal illness, also known as the sick euthyroid syndrome, is characterized by a low plasma T3 and an "inappropriately normal" plasma thyrotropin in the absence of intrinsic disease of the hypothalamic-pituitary-thyroid axis, The syndrome is due in part to decreased activity of type I iodothyronine 5'-deiodinase (5' D-I), the hepatic enzyme that converts thyroxine to T3 and that is induced at the transcriptional level by T3, The hypothesis tested is that cytokines decrease T3 induction of 5' D-I, resulting in decreased T3 production and hence a further decrease in 5' D-I. The proposed mechanism is competition for limiting amounts of nuclear receptor coactivators between the 5' D-I promoter and the promoters of cytokine-induced genes, Using primary cultures of rat hepatocytes, we demonstrate that interleukins 1 and 6 inhibit the T3 induction of 5' D-I RNA and enzyme activity. This effect is at the level of transcription and can be partially overcome by exogenous steroid receptor coactivator-1 (SRC-1). The physical. mass of endogenous SRC-1 is not affected by cytokine exposure, and exogenous SRC-1 does not affect 5' D-I in the absence of cytokines. The data support the hypothesis that cytokine-induced competition for limiting amounts of coactivators decreases hepatic 5' D-I expression, contributing to the etiology of the sick euthyroid syndrome.	Univ Michigan, Med Ctr, Div Endocrinol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Koenig, RJ (corresponding author), Univ Michigan, Med Ctr, Div Endocrinol, 5560 MSRB 2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044155] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44155] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACCI V, 1982, J CLIN ENDOCR METAB, V54, P1229, DOI 10.1210/jcem-54-6-1229; Bartalena L, 1998, EUR J ENDOCRINOL, V138, P603, DOI 10.1530/eje.0.1380603; BECKER RA, 1982, CRIT CARE MED, V10, P870, DOI 10.1097/00003246-198212000-00014; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Boelen A, 1996, ENDOCRINOLOGY, V137, P5250, DOI 10.1210/en.137.12.5250; BOELEN A, 1995, J ENDOCRINOL, V146, P475, DOI 10.1677/joe.0.1460475; BOELEN A, 1993, J CLIN ENDOCR METAB, V77, P1695, DOI 10.1210/jc.77.6.1695; BRENT GA, 1986, J CLIN ENDOCR METAB, V63, P1; Brown SB, 1997, J BIOL CHEM, V272, P2163, DOI 10.1074/jbc.272.4.2163; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chopra IJ, 1997, J CLIN ENDOCR METAB, V82, P329, DOI 10.1210/jc.82.2.329; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; De Groot LJ, 1999, J CLIN ENDOCR METAB, V84, P151, DOI 10.1210/jc.84.1.151; DOZIN B, 1985, BIOCHEMISTRY-US, V24, P5581, DOI 10.1021/bi00341a044; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Ikeda M, 1999, MOL CELL ENDOCRINOL, V147, P103, DOI 10.1016/S0303-7207(98)00211-1; JUMP DB, 1989, J BIOL CHEM, V264, P4698; Kahl S, 2000, DOMEST ANIM ENDOCRIN, V18, P133, DOI 10.1016/S0739-7240(99)00069-7; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kaptein EM, 1986, THYROID HORMONE META, P297; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; Koenig RJ, 1998, THYROID, V8, P703, DOI 10.1089/thy.1998.8.703; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; MALDONADO LS, 1992, THYROID, V2, P119, DOI 10.1089/thy.1992.2.119; McIver B, 1997, THYROID, V7, P125, DOI 10.1089/thy.1997.7.125; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; NICOLOFF JT, 1996, WERNER INGBARS THYRO, P286; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Oate SA, 1995, SCIENCE, V270, P1354, DOI DOI 10.1126/SCIENCE.270.5240.1354.PUBMED:7481822; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Ramadori G, 1999, SEMIN LIVER DIS, V19, P141, DOI 10.1055/s-2007-1007106; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; SARNE DH, 1985, J CLIN ENDOCR METAB, V61, P1046, DOI 10.1210/jcem-61-6-1046; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Stylianou E, 1998, INT J BIOCHEM CELL B, V30, P1075, DOI 10.1016/S1357-2725(98)00081-8; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torpy DJ, 1998, METABOLISM, V47, P1289, DOI 10.1016/S0026-0495(98)90338-9; TOYODA N, 1995, MOL CELL BIOL, V15, P5100; TOYODA N, 1994, J BIOL CHEM, V269, P20329; Weiss RE, 1999, EMBO J, V18, P1900, DOI 10.1093/emboj/18.7.1900; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	49	74	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38296	38301		10.1074/jbc.M004866200	http://dx.doi.org/10.1074/jbc.M004866200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10995750	hybrid			2022-12-25	WOS:000165739800024
J	Patel, S; Churchill, GC; Sharp, T; Galione, A				Patel, S; Churchill, GC; Sharp, T; Galione, A			Widespread distribution of binding sites for the novel Ca2+-mobilizing messenger, nicotinic acid adenine dinucleotide phosphate, in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; SENSITIVE CA2+ RELEASE; INOSITOL TRISPHOSPHATE; CALCIUM-RELEASE; NAADP; CHANNELS; INACTIVATION; MICROSOMES; RECEPTORS; AGONIST	Nicotinic acid adenine dinucleotide phosphate (NAADP) is a potent Ca2+-mobilizing agent in invertebrate eggs that has recently been shown to be active in certain mammalian and plant systems, Little, however, is known concerning the properties of putative NAADP receptors. Here, for the first time, we report binding sites for NAADP in brain. In contrast to sea urchin egg homogenates, [P-32]NAADP bound reversibly to multiple sites in brain membranes. The rank order of potency of NAADP, 2',3'-cyclic NAADP and 3'-NAADP in displacing [P-32]NAADP was, however, the same in the two systems and in agreement with their ability to mobilize Ca2+ from homogenates, These data indicate that [P-32]NAADP likely binds to receptors mediating Ca2+ mobilization. Autoradiography revealed striking heterogeneity in the distribution of [P-32]NAADP binding sites throughout the brain. Our data strongly support a role for NAADP-induced Ca2+ signaling in the brain.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	University of Oxford	Patel, S (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.		Galione, Antony/E-5884-2011; Patel, Sandip/O-9591-2015	Sharp, Trevor/0000-0001-7434-9713; Patel, Sandip/0000-0001-7247-2013; Galione, Antony/0000-0002-4132-7646				Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; Bak J, 1999, CURR BIOL, V9, P751, DOI 10.1016/S0960-9822(99)80335-2; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Berridge MJ, 1997, J EXP BIOL, V200, P315; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; Chini EN, 1996, BIOCHEM J, V316, P709, DOI 10.1042/bj3160709; CHINI EN, 1995, BIOCHEM BIOPH RES CO, V209, P167, DOI 10.1006/bbrc.1995.1485; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; GALIONE A, 1994, MOL CELL ENDOCRINOL, V98, P125, DOI 10.1016/0303-7207(94)90130-9; Genazzani AA, 1996, BIOCHEM J, V315, P721, DOI 10.1042/bj3150721; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 1997, J BIOL CHEM, V272, P20378, DOI 10.1074/jbc.272.33.20378; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; MILLER RJ, 1991, PROG NEUROBIOL, V37, P255, DOI 10.1016/0301-0082(91)90028-Y; Navazio L, 2000, P NATL ACAD SCI USA, V97, P8693, DOI 10.1073/pnas.140217897; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SHARP AH, 1993, J NEUROSCI, V13, P3051; Sorrentino V, 1995, Adv Pharmacol, V33, P67, DOI 10.1016/S1054-3589(08)60666-3; Taylor CW, 1998, BBA-MOL CELL BIOL L, V1436, P19, DOI 10.1016/S0005-2760(98)00122-2; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296	25	52	53	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36495	36497		10.1074/jbc.C000458200	http://dx.doi.org/10.1074/jbc.C000458200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	11010959	hybrid			2022-12-25	WOS:000165577700005
J	Deng, L; Lin-Lee, YC; Claret, FX; Kuo, MT				Deng, L; Lin-Lee, YC; Claret, FX; Kuo, MT			2-acetylaminofluorene up-regulates rat mdr1b expression through generating reactive oxygen species that activate NF-kappa B pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MULTIDRUG RESISTANCE-1 GENE; P-GLYCOPROTEIN; CELL-PROLIFERATION; TRANSCRIPTIONAL ACTIVITY; HEPATOCYTE CULTURES; OXIDATIVE STRESS; BINDING-SITE; INDUCTION; LIVER	Overexpression of multidrug resistance genes and their encoded P-glycoproteins is a major mechanism for the development of multidrug resistance in cancer cells, The hepatocarcinogen 2-acetylaminofluorene (2-AAF) efficiently activates rat mdr1b expression. However, the underlying mechanisms are largely unknown. In this study, we demonstrated that a NF-kappaB site on the mdr1b promoter was required for this induction. Overexpression of antisense p65 and I kappaB alpha partially abolished the induction. We then delineated the pathway through which 2-AAF activates NF-kappaB. 2-AAF treatment led to the increase of intracellular reactive oxygen species (ROS) which causes activation of IKK kinases, degradation of I kappaB beta (but not I kappaB alpha), and increase in NF-kappaB DNA binding activity. Consistent with the idea that ROS may participate in mdr1b regulation, antioxidant N-acetylcysteine inhibited the induction of mdr1b by 2-AAF. Overproduction of a physiological antioxidant glutathione (GSH) blocked the activation of IKK kinase complex and NF-kappaB DNA binding. Based on these results, we conclude that 2-AAF up-regulates mdr1b through the generation of ROS, activation of IKK kinase, degradation of I kappaB beta, and subsequent activation of NF-kappaB. This is the first report that reveals the specific cis-elements and signaling pathway responsible for the induction of mdr1b by the chemical carcinogen 2-AAF.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kuo, MT (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA.		Claret, Francois X/R-2104-2016	Claret, Francois X/0000-0003-4629-6495	NATIONAL CANCER INSTITUTE [R01CA079085, R01CA072404, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 79085, CA 72404, CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balansky R, 1996, CANCER RES, V56, P1642; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Chen F, 1999, J BIOL CHEM, V274, P20307, DOI 10.1074/jbc.274.29.20307; Christman JW, 1998, INTENS CARE MED, V24, P1131, DOI 10.1007/s001340050735; Christman JW, 2000, BRAIN PATHOL, V10, P153; COGSWELL JP, 1994, J IMMUNOL, V153, P712; Egan LJ, 1999, J BIOL CHEM, V274, P26448, DOI 10.1074/jbc.274.37.26448; Fenwick C, 2000, SCIENCE, V287, P869, DOI 10.1126/science.287.5454.869; GANT TW, 1991, MOL CARCINOGEN, V4, P499, DOI 10.1002/mc.2940040614; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; Hirsch-Ernst KI, 1998, J CELL PHYSIOL, V176, P506, DOI 10.1002/(SICI)1097-4652(199809)176:3<506::AID-JCP7>3.0.CO;2-S; Huang RP, 1999, CARCINOGENESIS, V20, P485, DOI 10.1093/carcin/20.3.485; Janssen-Heininger YMW, 1999, AM J RESP CELL MOL, V20, P942, DOI 10.1165/ajrcmb.20.5.3452; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; Klaunig JE, 1998, ENVIRON HEALTH PERSP, V106, P289, DOI 10.2307/3433929; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Lin Jen-Kun, 1999, Proceedings of the National Science Council Republic of China Part B Life Sciences, V23, P99; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; MEHTA R, 1995, CANCER LETT, V93, P85, DOI 10.1016/0304-3835(95)03790-4; MIYAZAKI M, 1992, BIOCHEM BIOPH RES CO, V187, P677, DOI 10.1016/0006-291X(92)91248-O; Ng IOL, 2000, AM J CLIN PATHOL, V113, P355, DOI 10.1309/AC1M-4TY4-U0TN-EN7T; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; POIRIER MC, 1991, CARCINOGENESIS, V12, P895, DOI 10.1093/carcin/12.5.895; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; SILVERMAN JA, 1995, MOL CARCINOGEN, V13, P50, DOI 10.1002/mc.2940130109; Soini Y, 1996, J CLIN PATHOL, V49, P470, DOI 10.1136/jcp.49.6.470; TEETER LD, 1993, MOL CARCINOGEN, V8, P67, DOI 10.1002/mc.2940080202; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; UMEMURA T, 1993, CANCER LETT, V73, P1, DOI 10.1016/0304-3835(93)90181-8; Utsunomiya Y, 1997, LEUKEMIA, V11, P894, DOI 10.1038/sj.leu.2400663; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Verna L, 1996, PHARMACOL THERAPEUT, V71, P83, DOI 10.1016/0163-7258(96)00063-0; VOLM M, 1990, CARCINOGENESIS, V11, P169, DOI 10.1093/carcin/11.1.169; Yamane Y, 1998, J BIOL CHEM, V273, P31075, DOI 10.1074/jbc.273.47.31075; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhou G, 1998, J BIOL CHEM, V273, P15387, DOI 10.1074/jbc.273.25.15387; Zhou G, 1996, CELL GROWTH DIFFER, V7, P1369	43	92	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					413	420		10.1074/jbc.M004551200	http://dx.doi.org/10.1074/jbc.M004551200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11020383	hybrid			2022-12-25	WOS:000166280700056
J	Prufer, K; Racz, A; Lin, GC; Barsony, J				Prufer, K; Racz, A; Lin, GC; Barsony, J			Dimerization with retinoid X receptors promotes nuclear localization and subnuclear targeting of vitamin D receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENT PROTEIN CHIMERA; LIVING CELLS; PROGESTERONE-RECEPTOR; 1,25-DIHYDROXYVITAMIN D-3; ACID RECEPTORS; DNA-BINDING; IN-VIVO; EXPRESSION; VISUALIZATION; TRANSCRIPTION	The vitamin D receptor (VDR) acts as heterodimer with the retinoid X receptor alpha (RXR) to control transcriptional activity of target genes. To explore the influence of heterodimerization on the subcellular distribution of these receptors in living cells, we developed a series of fluorescent-protein chimeras. The steady-state distribution of the yellow fluorescent protein-RXR was more nuclear than the unliganded green fluorescent protein (GFP)-VDR. Coexpression of RXR-blue fluorescent protein (BFP) promoted nuclear accumulation of GFP-VDR by influencing both nuclear import and retention. Fluorescence resonance energy transfer microscopy (FRET) demonstrated that the unliganded GFP-VDR and RXR-BFP form heterodimers. The increase in nuclear heterodimer content correlated with an increase in basal transcriptional activity. FRET also revealed that calcitriol induces formation of multiple nuclear foci of heterodimers. Mutational analysis showed a correlation; between hormone-dependent nuclear VDR foci formation and DNA binding. RXR-BFP also promoted hormone-dependent nuclear accumulation and intranuclear foci formation of a nuclear localization signal mutant receptor (nlsGFP-VDR) and rescued its transcriptional activity. Heterodimerization mutant RXR failed to alter GFP-VDR and nlsGFP-VDR distribution or activity. These experiments suggest that RXR has a profound effect on VDR distribution. This effect of RXR to promote nuclear accumulation and intranuclear targeting contributes to the regulation of VDR activity and probably the activity of other heterodimerization partners.	NIDDK, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Barsony, J (corresponding author), NIDDK, Lab Cell Biochem & Biol, NIH, Bldg 8,Rm 422,8 Ctr Dr, Bethesda, MD 20892 USA.	jul@helix.nih.gov	Stone, Kirsten/AAB-3804-2019	Stone, Kirsten/0000-0001-5511-1638	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060051, Z01DK060050] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barsony J, 1997, J BIOL CHEM, V272, P5774, DOI 10.1074/jbc.272.9.5774; BARSONY J, 1999, 81 ANN M END SOC JUN, P415; BARSONY J, 1997, MICROSC MICROANAL S2, V3, P131; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; Carlberg C, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 1, APRIL 1996, V1, P82; Castillo AI, 1999, MOL ENDOCRINOL, V13, P1141, DOI 10.1210/me.13.7.1141; Chauchereau A, 2000, J BIOL CHEM, V275, P8540, DOI 10.1074/jbc.275.12.8540; Chen SC, 1999, J BIOL CHEM, V274, P11260, DOI 10.1074/jbc.274.16.11260; Dabrowski M, 1998, MOL CELL ENDOCRINOL, V142, P131, DOI 10.1016/S0303-7207(98)00111-7; Day RN, 1998, MOL ENDOCRINOL, V12, P1410, DOI 10.1210/me.12.9.1410; Ellenberg J, 1998, BIOTECHNIQUES, V25, P838, DOI 10.2144/98255bt01; Feng X, 1997, GENE DEV, V11, P59, DOI 10.1101/gad.11.1.59; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; GUIOCHONMANTEL A, 1992, J STEROID BIOCHEM, V41, P209; GUIOCHONMANTEL A, 1994, BIOCHEM PHARMACOL, V47, P21, DOI 10.1016/0006-2952(94)90433-2; Harnish DC, 1996, J BIOL CHEM, V271, P13621, DOI 10.1074/jbc.271.23.13621; HOLLEY SJ, 1995, MOL BIOL CELL, V6, P1833, DOI 10.1091/mbc.6.12.1833; Hopper AK, 1999, CURR BIOL, V9, pR803, DOI 10.1016/S0960-9822(99)80494-1; Hsieh JC, 1998, J CELL BIOCHEM, V70, P94, DOI 10.1002/(SICI)1097-4644(19980701)70:1<94::AID-JCB10>3.3.CO;2-Q; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Janssen JJM, 1999, CURR EYE RES, V19, P338, DOI 10.1076/ceyr.19.4.338.5307; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Kahlen JP, 1997, NUCLEIC ACIDS RES, V25, P4307, DOI 10.1093/nar/25.21.4307; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Kephart DD, 1996, MOL ENDOCRINOL, V10, P408, DOI 10.1210/me.10.4.408; KimmelJehan C, 1997, ARCH BIOCHEM BIOPHYS, V341, P75, DOI 10.1006/abbi.1997.9952; Kohler M, 1999, EXP NEPHROL, V7, P290; Lemon BD, 1996, MOL CELL BIOL, V16, P1006; Li C, 1997, P NATL ACAD SCI USA, V94, P2278, DOI 10.1073/pnas.94.6.2278; Lim CS, 1999, MOL ENDOCRINOL, V13, P366, DOI 10.1210/me.13.3.366; LUO ZJ, 1994, EUR J BIOCHEM, V223, P381, DOI 10.1111/j.1432-1033.1994.tb19004.x; Michigami T, 1999, J BIOL CHEM, V274, P33531, DOI 10.1074/jbc.274.47.33531; Periasamy A, 1999, METHOD CELL BIOL, V58, P293; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; Prufer K, 1999, J CHEM NEUROANAT, V16, P135, DOI 10.1016/S0891-0618(99)00002-2; Racz A, 1999, J BIOL CHEM, V274, P19352, DOI 10.1074/jbc.274.27.19352; Reichrath J, 1997, HISTOCHEM J, V29, P127, DOI 10.1023/A:1026481205135; Sanno N, 1997, NEUROENDOCRINOLOGY, V65, P299, DOI 10.1159/000127188; Schulman IG, 1997, GENE DEV, V11, P299, DOI 10.1101/gad.11.3.299; SONE T, 1990, MOL ENDOCRINOL, V4, P623, DOI 10.1210/mend-4-4-623; SONE T, 1991, J BIOL CHEM, V266, P23296; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Sugawara A, 1997, ENDOCRINOLOGY, V138, P3175, DOI 10.1210/en.138.8.3175; Tagami T, 1998, BIOCHEM BIOPH RES CO, V253, P358, DOI 10.1006/bbrc.1998.9799; Thompson PD, 1998, J BIOL CHEM, V273, P8483, DOI 10.1074/jbc.273.14.8483; WHITFIELD GK, 1995, MOL ENDOCRINOL, V9, P1166, DOI 10.1210/me.9.9.1166; Zhu XG, 1998, J BIOL CHEM, V273, P27058, DOI 10.1074/jbc.273.42.27058	48	111	115	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41114	41123		10.1074/jbc.M003791200	http://dx.doi.org/10.1074/jbc.M003791200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11001945	hybrid			2022-12-25	WOS:000166114600062
J	Shen, AL; Kasper, CB				Shen, AL; Kasper, CB			Differential contributions of NADPH-cytochrome P450 oxidoreductase FAD binding site residues to flavin binding and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-450 REDUCTASE; NADPH-CYTOCHROME-P-450 REDUCTASE; DIRECTED MUTAGENESIS; CODING NUCLEOTIDE; DOMAINS; FMN; ACID; IDENTIFICATION; PROTOTYPE; SEQUENCE	Transfer of reducing equivalents from NADPH to the cytochromes P450 is mediated by NADPH-cytochrome P450 oxidoreductase, which contains stoichiometric amounts of tightly bound FMN and FAD. Hydrogen bonding and van der Waals interactions between FAD and amino acid residues in the FAD binding site of the reductase serve to regulate both flavin binding and reactivity. The precise orientation of key residues (Arg(454), Tyr(456), Cys(472), Gly(488), Thr(491), and Trp(677)) has been defined by x-ray crystallography (Wang, M., Roberts, D. L., Paschke, R., Shea, T. M., Masters, B. S., Kim, J.-J. P. (1997) Proc. Natl. Acad Sci. U.S. A. 94, 8411-8416). The current study examines the relative contributions of these residues to FAD binding and catalysis by site-directed mutagenesis and kinetic analysis. Mutation of either Tyr(456), which makes van der Waals contact with the FAD isoalloxazine ring and also hydrogen-bonds to the ribityl 4'-hydroxyl, or Arg(454), which bonds to the FAD pyrophosphate, decreases the affinity for FAD 8000- and 25,000-fold, respectively, with corresponding decreases in cytochrome c reductase activity. In contrast, substitution of Thr(491), which also interacts with the pyrophosphate grouping, had a relatively modest effect on both FAD binding (100-fold decrease) and catalytic activity (2-fold decrease), while the G488L mutant exhibited, respectively, 800- and 50-fold decreases in FAD binding and catalytic activity. Enzymic activity of each of these mutants could be restored by addition of FAD. Kinetic properties and the FMN content of these mutants were not affected by these substitutions, with the exception of a 3-fold increase in Y456S K-m(cyt c) and a 70% decrease in R454E FMN content, suggesting that the FMN- and FAD-binding domains are largely, but not completely, independent, Even though Trp(677) iS stacked against the re-face of FAD, suggesting an important role in FAD binding, deletion of both Trp(677) and the carboxyl-terminal Ser(678) decreased catalytic activity 50-fold without affecting FAD content.	Univ Wisconsin, Mcardle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Shen, AL (corresponding author), Univ Wisconsin, Mcardle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.				NATIONAL CANCER INSTITUTE [P01CA022484, K04CA000920] Funding Source: NIH RePORTER; NCI NIH HHS [CA22484, CA0920] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barsukov I, 1997, J BIOMOL NMR, V10, P63, DOI 10.1023/A:1018313830207; BLACK SD, 1982, J BIOL CHEM, V257, P5929; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CALCATERRA NB, 1995, BIOCHEMISTRY-US, V34, P12842, DOI 10.1021/bi00039a045; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; Dwyer TM, 1999, BIOCHEMISTRY-US, V38, P9735, DOI 10.1021/bi9903906; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; GUEX N, 1997, PROTEIN DATA BANK Q, V77, P7; Hodgson AV, 1996, ARCH BIOCHEM BIOPHYS, V325, P99, DOI 10.1006/abbi.1996.0012; HUBBARD PA, 1999, FLAVINS FLAVOPROTEIN, P159; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KURZBAN GP, 1986, J BIOL CHEM, V261, P7824; KURZBAN GP, 1990, J BIOL CHEM, V265, P12272; Leclerc D, 1998, P NATL ACAD SCI USA, V95, P3059, DOI 10.1073/pnas.95.6.3059; NARAYANASAMI R, 1995, ARCH BIOCHEM BIOPHYS, V316, P267, DOI 10.1006/abbi.1995.1037; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; PORTER TD, 1985, P NATL ACAD SCI USA, V82, P973, DOI 10.1073/pnas.82.4.973; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; SEM DS, 1993, BIOCHEMISTRY-US, V32, P11548, DOI 10.1021/bi00094a011; SEM DS, 1994, BIOCHEMISTRY-US, V33, P12012, DOI 10.1021/bi00206a002; SHEN AL, 1989, J BIOL CHEM, V264, P7584; SHEN AL, 1995, J BIOL CHEM, V270, P27475, DOI 10.1074/jbc.270.46.27475; SHEN AL, 1993, HDB EXPT PHARM, V105, P35; SMITH GCM, 1994, P NATL ACAD SCI USA, V91, P8710, DOI 10.1073/pnas.91.18.8710; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411	29	38	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41087	41091		10.1074/jbc.M008380200	http://dx.doi.org/10.1074/jbc.M008380200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11022049	hybrid			2022-12-25	WOS:000166114600058
J	Alonso, G; Ambrosino, C; Jones, M; Nebreda, AR				Alonso, G; Ambrosino, C; Jones, M; Nebreda, AR			Differential activation of p38 mitogen-activated protein kinase isoforms depending on signal strength	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING SITE; MAP KINASE; CELLULAR STRESSES; SELECTIVE ACTIVATION; MAMMALIAN-CELLS; SAP KINASES; CASCADE; PHOSPHORYLATION; MKK6; TRANSDUCTION	We have investigated the ability of the mitogen-activated protein kinase (MAPK) kinase MKK6 to activate different members of the p38 subfamily of MAPKs and found that some MKK6 mutants can efficiently activate p38 alpha but not p38 gamma. In contrast, a constitutively active MKK6 mutant activated both p38 MAPK isoforms to similar extents. The same results were obtained upon coexpression in Xenopus oocytes and in vitro using either MKK6 immunoprecipitates from transfected cells or bacterially produced recombinant proteins. We also found that the preferential activation of p38 alpha by MKK6 correlated with more efficient binding of MKK6 to p38 alpha than to p38 gamma. Furthermore, increasing concentrations of constitutively active MKK6 differentially activated either p38 alpha alone (low MKK6 activity) or both p38 alpha and p38 gamma (high MKK6 activity), both in vitro and in injected oocytes. The determinants for selectivity are located at the carboxyl-terminal lobe of p38 MAPKs but do not correspond to the activation loop or common docking sequences. We also showed that different stimuli can induce different levels of endogenous MKK6 activity that correlate with differential activation of p38 MAPKs. Our results suggest that the level of MKK6 activity triggered by a given stimulus may determine the pattern of downstream p38 MAPK activation in the particular response.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Nebreda, AR (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Nebreda, Angel Rodriguez/R-9594-2019; ambrosino, concetta/AAB-3452-2019					Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; BRILL JA, 1994, MOL BIOL CELL, V5, P297, DOI 10.1091/mbc.5.3.297; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOZA YN, 1995, FEBS LETT, V364, P223, DOI 10.1016/0014-5793(95)00346-B; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; Hale KK, 1999, J IMMUNOL, V162, P4246; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Howell M, 1997, EMBO J, V16, P7411, DOI 10.1093/emboj/16.24.7411; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531	49	78	85	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40641	40648		10.1074/jbc.M007835200	http://dx.doi.org/10.1074/jbc.M007835200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11010976	hybrid			2022-12-25	WOS:000166039500113
J	Fujimori, K; Kanaoka, T; Sakaguchi, Y; Urade, Y				Fujimori, K; Kanaoka, T; Sakaguchi, Y; Urade, Y			Transcriptional activation of the human hematopoietic prostaglandin D synthase gene in megakaryoblastic cells - Roles of the Oct-1 element in the 5 '-flanking region and the AP-2 element in the untranslated exon 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; D SYNTHETASE; PHORBOL ESTER; D-2 SYNTHASE; PPAR-GAMMA; MAST-CELLS; EXPRESSION; PROMOTER; DIFFERENTIATION; LOCALIZATION	The human hematopoietic prostaglandin D synthase (H-PGDS) gene is highly expressed in human megakaryoblastic cells, in which phorbol ester induces its expression. We characterized the promoter activity of the 5'-flanking region and the untranslated exon 1 (-1044 to +290) of the human H-PGDS gene in human megakaryoblastic Dami cells, Transient expression analysis using the luciferase reporter gene revealed that the 5'-flanking region and the untranslated exon 1 were sufficient for efficient expression of the H-PGDS gene in Dami cells, but not in monocytic U937 cells. Deletion and site-directed mutagenesis of the Oct-1 element in the 5'-flanking region decreased the promoter activity by similar to 30% compared with that of the entire region from -1044 to +290. An electrophoretic mobility shift assay demonstrated that Oct-1 specifically bound to the promoter region. Interestingly, even only untranslated exon 1 (+1 to +290) showed similar to 60% of the promoter activity of the entire region from -1044 to +290. Site-directed mutagenesis of the AP-2 element within the untranslated exon 1 abolished the basal promoter activity as well as its phorbol ester-mediated up-regulation. In AP-2-deficient HepG2 cells, the H-PGDS promoter activity was enhanced by coexpression with AP-2 alpha. These findings indicate that the Oct-1 element in the 5'-flanking region acts as a positive cis-acting element and that the AP-2 element in the untranslated exon 1 is crucial for both basal and phorbol ester-mediated up-regulation of human H-PGDS gene expression in megakaryoblastic Dami cells.	Japan Sci & Technol Corp, Osaka Biosci Inst, Dept Mol Behav Biol, Osaka 5650874, Japan; Japan Sci & Technol Corp, Osaka Biosci Inst, Core Res Evolut Sci & Technol, Osaka 5650874, Japan; Harvard Univ, Sch Med, Dept Med,Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; ALOKA Co Ltd, Tokyo 1818622, Japan	Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Harvard University; Brigham & Women's Hospital; Harvard Medical School	Urade, Y (corresponding author), Japan Sci & Technol Corp, Osaka Biosci Inst, Dept Mol Behav Biol, 6-2-4 Furuedai, Osaka 5650874, Japan.		Fujimori, Ko/AAD-5428-2021	Fujimori, Ko/0000-0002-2506-0769				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTHAZELHOF E, 1979, BIOCHIM BIOPHYS ACTA, V572, P43, DOI 10.1016/0005-2760(79)90198-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FONG CLW, 1995, J INTERF CYTOK RES, V15, P887, DOI 10.1089/jir.1995.15.887; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GILES H, 1988, PROSTAGLANDINS, V35, P277, DOI 10.1016/0090-6980(88)90093-7; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Kanaoka Y, 2000, EUR J BIOCHEM, V267, P3315, DOI 10.1046/j.1432-1327.2000.01362.x; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KOMATSU N, 1989, BLOOD, V74, P42; Lee KD, 1996, BIOCHEM J, V319, P783, DOI 10.1042/bj3190783; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; Mahmud I, 1997, J BIOL CHEM, V272, P28263, DOI 10.1074/jbc.272.45.28263; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; MEDCALF RL, 1990, J BIOL CHEM, V265, P14618; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; PARK K, 1993, J BIOL CHEM, V268, P17811; Pinzar E, 2000, J BIOL CHEM, V275, P31239, DOI 10.1074/jbc.M000750200; SATO T, 1989, BRIT J HAEMATOL, V72, P184, DOI 10.1111/j.1365-2141.1989.tb07681.x; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Suzuki T, 1997, BIOCHEM BIOPH RES CO, V241, P288, DOI 10.1006/bbrc.1997.7803; Tanaka K, 2000, J IMMUNOL, V164, P2277, DOI 10.4049/jimmunol.164.5.2277; Thomson AM, 1998, BIOCHEM J, V333, P317, DOI 10.1042/bj3330317; Urade Y, 2000, VITAM HORM, V58, P89, DOI 10.1016/S0083-6729(00)58022-4; URADE Y, 1989, J IMMUNOL, V143, P2982; URADE Y, 1987, J BIOL CHEM, V262, P3820; URADE Y, 1990, J BIOL CHEM, V265, P371; VOSS J, 1997, GENE DEV, V5, P1309; WANG LH, 1993, BIOCHEM BIOPH RES CO, V190, P406, DOI 10.1006/bbrc.1993.1062; Warren G, 1996, GENOMICS, V31, P234, DOI 10.1006/geno.1996.0037; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WIDEN SG, 1988, J BIOL CHEM, V263, P16992; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Williamson JA, 1996, GENOMICS, V35, P262, DOI 10.1006/geno.1996.0351	38	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40511	40516		10.1074/jbc.M007688200	http://dx.doi.org/10.1074/jbc.M007688200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10998423	hybrid			2022-12-25	WOS:000166039500096
J	Lerin, C; Montell, E; Berman, HK; Newgard, CB; Gomez-Foix, AM				Lerin, C; Montell, E; Berman, HK; Newgard, CB; Gomez-Foix, AM			Overexpression of protein targeting to glycogen in cultured human muscle cells stimulates glycogen synthesis independent of glycogen and glucose 6-phosphate levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PHOSPHATASE 1; PHOSPHORYLASE; EXPRESSION; PTG; SUBUNITS; SYNTHASE; IDENTIFICATION; ACTIVATION; INCREASES	There is growing evidence that glycogen targeting subunits of protein phosphatase-l play a critical role in regulation of glycogen metabolism. In the current study, we have investigated the effects of adenovirus-mediated overexpression of a specific glycogen targeting subunit known as protein targeting to glycogen (PTG) in cultured human muscle cells. PTG; was overexpressed both in muscle cells cultured at high glucose (glycogen replete) or in cells incubated for 18 h in the absence of glucose and then incubated in high glucose (glycogen re-synthesizing). In both glycogen replete and glycogen resynthesizing cells, PTG overexpression caused glycogen to be synthesized at a linear rate 1-5 days after viral treatment, while in cells treated with a virus lacking a cDNA insert (control virus), glycogen content reached a plateau at day 1 with no further increase, In the glycogen replete PTG overexpressing cells, glycogen content was 20 times that in controls at day 5, Furthermore, in cells undergoing glycogen resynthesis, PTG overexpression caused a doubling of the initial rate of glycogen synthesis over the first 24 h relative to cells treated with control virus. In both sets of experiments, the effects of PTG; on glycogen synthesis were correlated with a 2-3-fold increase in glycogen synthase activity state, with no changes in glycogen phosphorylase activity. The alterations in glycogen synthase activity were not accompanied by changes in the intracellular concentration of glucose 6-phosphate, We conclude that PTG; overexpression activates glycogen synthesis in a glucose 6-phosphate-independent manner in human muscle cells while overriding glycogen-mediated inhibition. Our findings suggest that modulation of PTG expression in muscle may be a mechanism for enhancing muscle glucose disposal and improving glucose tolerance in diabetes.	Univ Barcelona, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dallas, TX 75235 USA	University of Barcelona; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gomez-Foix, AM (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Marti Franques 1, E-08028 Barcelona, Spain.	anamaria@sun.bq.ub.es	Lerin, Carles/AAP-9916-2020	Lerin, Carles/0000-0003-0950-4363	NIDDK NIH HHS [P01DK58398] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK058398] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Armstrong CG, 1997, FEBS LETT, V418, P210, DOI 10.1016/S0014-5793(97)01385-9; Armstrong CG, 1998, BIOCHEM J, V336, P699, DOI 10.1042/bj3360699; Askanas V, 1992, HDB CLIN NEUROL, P85; BAK JF, 1990, AM J PHYSIOL, V258, pE957, DOI 10.1152/ajpendo.1990.258.6.E957; Baque S, 1998, DIABETES, V47, P1185, DOI 10.2337/diabetes.47.8.1185; Baque S, 1998, DIABETES, V47, P1392, DOI 10.2337/diabetes.47.9.1392; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Berman HK, 1998, J BIOL CHEM, V273, P26421, DOI 10.1074/jbc.273.41.26421; Brady MJ, 1997, J BIOL CHEM, V272, P20198, DOI 10.1074/jbc.272.32.20198; Brau L, 1997, BIOCHEM J, V322, P303; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; Gasa R, 2000, J BIOL CHEM, V275, P26396, DOI 10.1074/jbc.M002427200; GILBOE DP, 1972, ANAL BIOCHEM, V47, P20, DOI 10.1016/0003-2697(72)90274-6; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; JIMENEZCHILLARO.JC, 1999, FASEB J, V13, P2513; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; Laurent D, 2000, AM J PHYSIOL-ENDOC M, V278, pE663, DOI 10.1152/ajpendo.2000.278.4.E663; MELLGREN RL, 1983, BIOCHEM BIOPH RES CO, V114, P148, DOI 10.1016/0006-291X(83)91606-6; Montell E, 1999, AM J PHYSIOL-REG I, V276, pR1489, DOI 10.1152/ajpregu.1999.276.5.R1489; MUNGER R, 1993, METABOLISM, V42, P36, DOI 10.1016/0026-0495(93)90169-O; O'Doherty RM, 2000, J CLIN INVEST, V105, P479, DOI 10.1172/JCI8673; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; SHULMAN RG, 1995, P NATL ACAD SCI USA, V92, P8535, DOI 10.1073/pnas.92.19.8535; TANG PM, 1991, J BIOL CHEM, V266, P15782; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078; VILLARPALASI C, 1991, BIOCHIM BIOPHYS ACTA, V1095, P261, DOI 10.1016/0167-4889(91)90109-B	29	31	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39991	39995		10.1074/jbc.M006251200	http://dx.doi.org/10.1074/jbc.M006251200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10998419	hybrid			2022-12-25	WOS:000166039500028
J	Rekdal, C; Sjottem, E; Johansen, T				Rekdal, C; Sjottem, E; Johansen, T			The nuclear factor SPBP contains different functional domains and stimulates the activity of various transcriptional activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; PROTEIN; ENHANCER; GENE; DROSOPHILA; FAMILY; SIGNAL; RECOGNITION; EXPRESSION; INDUCTION	SPBP (stromelysin-1 platelet-derived growth factor-responsive element binding protein) was originally cloned from a cDNA expression library by virtue of its ability to bind to a platelet-derived growth factor-responsive element in the human stromelysin-1 promoter. A 937-amino acid-long protein was deduced from a 3995-nucleotide murine cDNA sequence. By analyses of both human and murine cDNAs, we now show that SPBP is twice as large as originally found. The human SPBP gene contains six exons and is located on chromosome 22q13.1-13.3. Two isoforms differing in their C termini are expressed due to alternative splicing. PCR analyses of multitissue cDNA panels showed that SPBP is expressed in most tissues except for ovary and prostate. Functional mapping revealed that SPBP is a nuclear, multidomain protein containing an N-terminal region with transactivating ability, a novel type of DNA-binding domain containing an AT hook motif, and a bipartite nuclear localization signal as well as a C-terminal zinc finger domain. This type of zinc finger domain is also found in the trithorax family of chromatin-based transcriptional regulator proteins. Using cotransfection experiments, we find that SPBP enhances the transcriptional activity of various transcription factors such as c-Sun, Ets1, Spl, and Pax6. Hence, SPBP seems to act as a transcriptional coactivator.	Univ Tromso, Inst Med Biol, Dept Biochem, N-9037 Tromso, Norway	UiT The Arctic University of Tromso	Johansen, T (corresponding author), Univ Tromso, Inst Med Biol, Dept Biochem, POB 977, N-9037 Tromso, Norway.	terjej@fagmed.uit.no	Johansen, Terje/AAY-1753-2021; Johansen, Terje/N-2971-2015	Johansen, Terje/0000-0003-1451-9578; Johansen, Terje/0000-0003-1451-9578; Sjottem, Eva/0000-0003-2668-1708				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FUNAHASHI J, 1993, DEVELOPMENT, V119, P433; Girard F, 1998, EMBO J, V17, P2079, DOI 10.1093/emboj/17.7.2079; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; IMAI Y, 1995, MOL BRAIN RES, V31, P1, DOI 10.1016/0169-328X(95)00020-S; JOHANSEN T, 1993, NUCLEIC ACIDS RES, V21, P475, DOI 10.1093/nar/21.3.475; Kahari VM, 1999, ANN MED, V31, P34, DOI 10.3109/07853899909019260; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kirstein M, 1996, J BIOL CHEM, V271, P18231, DOI 10.1074/jbc.271.30.18231; Lemon BD, 1999, CURR OPIN GENET DEV, V9, P499, DOI 10.1016/S0959-437X(99)00010-6; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Matrisian LM, 1999, CURR BIOL, V9, pR776, DOI 10.1016/S0960-9822(00)80011-1; Mikkola I, 1999, J BIOL CHEM, V274, P15115, DOI 10.1074/jbc.274.21.15115; Nornes S, 1998, MECH DEVELOP, V77, P185, DOI 10.1016/S0925-4773(98)00156-7; Ohara O, 1997, DNA Res, V4, P53, DOI 10.1093/dnares/4.1.53; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Prasad R, 1997, ONCOGENE, V15, P549, DOI 10.1038/sj.onc.1201211; Rajadhyaksha A, 1998, CYTOGENET CELL GENET, V81, P176, DOI 10.1159/000015021; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; REEVES R, 1990, J BIOL CHEM, V265, P8573; SANZ L, 1994, J BIOL CHEM, V269, P10044; SANZ L, 1995, MOL CELL BIOL, V15, P3164; SETH A, 1992, J BIOL CHEM, V267, P24796; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Sjottem E, 1996, J VIROL, V70, P188; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Watanabe G, 1997, J BIOL CHEM, V272, P20063, DOI 10.1074/jbc.272.32.20063; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	41	40	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40288	40300		10.1074/jbc.M006978200	http://dx.doi.org/10.1074/jbc.M006978200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10995766	hybrid			2022-12-25	WOS:000166039500068
J	Serna-Rico, A; Illana, B; Salas, M; Meijer, WJJ				Serna-Rico, A; Illana, B; Salas, M; Meijer, WJJ			The putative coiled coil domain of the phi 29 terminal protein is a major determinant involved in recognition of the origin of replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC MODEL PROTEINS; PRIMED DNA-REPLICATION; BACILLUS-SUBTILIS; PHAGE-PHI-29 DNA; INITIATION; POLYMERASE; TEMPLATE; BACTERIOPHAGE-PHI-29; STABILITY; SEQUENCE	The linear double-stranded genome of phage phi 29 contains a terminal protein (TP) covalently linked at each 5' DNA end, called parental TP. Initiation of phi 29 DNA replication starts with the recognition of the origins of replication, constituted by the parental TP-containing DNA ends, by a heterodimer containing phi 29 DNA polymerase and primer TP. It has been argued that origin recognition involves protein-protein interactions between parental and primer TP. Analysis of the TP sequence revealed that the region between amino acids 84 and 118 has a high probability to form an amphipatic alpha -helix that could be involved in the interaction between parental and primer TP. Therefore, this TP region may be important for origin recognition. To test this hypothesis we introduced various mutations in the predicted amphipatic alpha -helix and analyzed the functionality of the corresponding purified TP mutants. The results obtained show that the identified putative amphipatic alpha -helix of TP is an important determinant involved in origin recognition.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Salas, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Salas, Margarita/J-9873-2014	Salas, Margarita/0000-0001-5939-3441; Meijer, Wilfried/0000-0003-1842-0049	NIGMS NIH HHS [2R01GM27242-20] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANCO L, 1987, J VIROL, V61, P3983, DOI 10.1128/JVI.61.12.3983-3991.1987; BLANCO L, 1984, P NATL ACAD SCI-BIOL, V81, P5325, DOI 10.1073/pnas.81.17.5325; BLANCO L, 1992, J BIOL CHEM, V267, P1225; BLANCO L, 1994, P NATL ACAD SCI USA, V91, P12198, DOI 10.1073/pnas.91.25.12198; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; GARCIA JA, 1984, P NATL ACAD SCI-BIOL, V81, P80, DOI 10.1073/pnas.81.1.80; GARMENDIA C, 1988, NUCLEIC ACIDS RES, V16, P5727, DOI 10.1093/nar/16.13.5727; Gonzalez-Huici V, 2000, J BIOL CHEM, V275, P14678, DOI 10.1074/jbc.M910058199; GUTIERREZ C, 1991, J MOL BIOL, V222, P983, DOI 10.1016/0022-2836(91)90589-X; GUTIERREZ J, 1986, VIROLOGY, V155, P474, DOI 10.1016/0042-6822(86)90209-6; GUTIERREZ J, 1986, GENE, V43, P1, DOI 10.1016/0378-1119(86)90002-8; HERMOSO JM, 1985, NUCLEIC ACIDS RES, V13, P7715, DOI 10.1093/nar/13.21.7715; HODGES R S, 1992, Current Biology, V2, P122, DOI 10.1016/0960-9822(92)90241-2; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; Illana B, 1999, J BIOL CHEM, V274, P15073, DOI 10.1074/jbc.274.21.15073; Illana B, 1998, VIROLOGY, V248, P12, DOI 10.1006/viro.1998.9276; INCIARTE MR, 1980, J VIROL, V34, P187, DOI 10.1128/JVI.34.1.187-199.1980; Innis MA, 1990, PCR PROTOCOLS GUIDE; KOHN WD, 1995, J BIOL CHEM, V270, P25495, DOI 10.1074/jbc.270.43.25495; Kornberg A., 1992, DNA REPLICATION; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Mendez J, 1997, EMBO J, V16, P2519, DOI 10.1093/emboj/16.9.2519; MENDEZ J, 1992, P NATL ACAD SCI USA, V89, P9579, DOI 10.1073/pnas.89.20.9579; ORTIN J, 1971, NATURE-NEW BIOL, V234, P275, DOI 10.1038/newbio234275a0; Pecenkova T, 1999, J MOL EVOL, V48, P197, DOI 10.1007/PL00006458; PENALVA MA, 1982, P NATL ACAD SCI-BIOL, V79, P5522, DOI 10.1073/pnas.79.18.5522; SALAS M, 1978, J MOL BIOL, V119, P269, DOI 10.1016/0022-2836(78)90438-2; SALAS M, 1996, DNA REPLICATION EUKA, P131; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHON U, 1994, GENE, V147, P91, DOI 10.1016/0378-1119(94)90044-2; SERRANO M, 1993, TRENDS BIOCHEM SCI, V18, P202, DOI 10.1016/0968-0004(93)90187-R; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZABALLOS A, 1989, NUCLEIC ACIDS RES, V17, P10353, DOI 10.1093/nar/17.24.10353; ZHOU NE, 1992, J BIOL CHEM, V267, P2664; ZHOU NE, 1992, BIOCHEMISTRY-US, V31, P5739, DOI 10.1021/bi00140a008	38	23	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40529	40538		10.1074/jbc.M007855200	http://dx.doi.org/10.1074/jbc.M007855200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11005822	hybrid			2022-12-25	WOS:000166039500098
J	Wang, ZF; Morris, JC; Drew, ME; Englund, PT				Wang, ZF; Morris, JC; Drew, ME; Englund, PT			Inhibition of Trypanosoma brucei gene expression by RNA interference using an integratable vector with opposing T7 promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; CRITHIDIA-FASCICULATA; C-ELEGANS; NEUROSPORA; POLYMERASE; PROTEIN; REPLICATION; HELICASE; CLONING; DSRNA	RNA interference is a powerful method for inhibition of gene expression in Trypanosoma brucei (Ngo, H., Tschudi, C,, Gull, K,, and Ullu, E. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 14687-14692), Here we describe a vector (pZJM) for in vivo tetracycline-inducible synthesis of double-stranded RNA (dsRNA) in stably transformed cells. The dsRNA is synthesized from opposing T7 promoters. We tested the vector with genes involved in processes such as kinetoplast DNA replication, mitochondrial mRNA synthesis, glycosyl phosphatidylinositol biosynthesis, glycosome biogenesis, and polyamine biosynthesis, In most cases the induction of dsRNA caused specific and dramatic loss of the appropriate mRNA and in many cases there was growth inhibition or cell death. One striking phenotype was the loss of kinetoplast DNA after interference with expression of a topoisomerase II. The gene being analyzed by this procedure need not even be fully sequenced. In fact, many of the genes we tested were derived from partial sequences in the T. brucei genome data base that were identified by homology with known proteins. It takes as little as 3 weeks from identification of a gene sequence in the data base to the appearance of a phenotype.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Englund, PT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.			Morris, James/0000-0003-2515-5714	NIAID NIH HHS [AI21334] Funding Source: Medline; NIGMS NIH HHS [GM27608] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027608, R37GM027608] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarado AS, 1999, P NATL ACAD SCI USA, V96, P5049, DOI 10.1073/pnas.96.9.5049; Bass BL, 2000, CELL, V101, P235, DOI 10.1016/S0092-8674(02)71133-1; Bastin P, 2000, J CELL SCI, V113, P3321; CAMPBELL AG, 1993, P NATL ACAD SCI USA, V90, P9350, DOI 10.1073/pnas.90.20.9350; Cogoni C, 1999, SCIENCE, V286, P2342, DOI 10.1126/science.286.5448.2342; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; DALTON S, 1995, P NATL ACAD SCI USA, V92, P2514, DOI 10.1073/pnas.92.7.2514; Engel ML, 1998, NUCLEIC ACIDS RES, V26, P4733, DOI 10.1093/nar/26.20.4733; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grishok A, 2000, SCIENCE, V287, P2494, DOI 10.1126/science.287.5462.2494; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Li F, 1996, MOL BIOCHEM PARASIT, V78, P227, DOI 10.1016/S0166-6851(96)02630-8; Li YX, 2000, DEV BIOL, V217, P394, DOI 10.1006/dbio.1999.9540; Lorenz P, 1998, EMBO J, V17, P3542, DOI 10.1093/emboj/17.13.3542; Nagamune K, 2000, P NATL ACAD SCI USA, V97, P10336, DOI 10.1073/pnas.180230697; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; PHILLIPS MA, 1987, J BIOL CHEM, V262, P8721; Schrader M, 1998, J BIOL CHEM, V273, P29607, DOI 10.1074/jbc.273.45.29607; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; STRAUSS PR, 1990, MOL BIOCHEM PARASIT, V38, P141, DOI 10.1016/0166-6851(90)90214-7; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; TORRI AF, 1995, J BIOL CHEM, V270, P3495, DOI 10.1074/jbc.270.8.3495; TZFATI Y, 1992, P NATL ACAD SCI USA, V89, P6891, DOI 10.1073/pnas.89.15.6891; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; Wianny F, 2000, NAT CELL BIOL, V2, P70, DOI 10.1038/35000016; Wirtz E, 1998, NUCLEIC ACIDS RES, V26, P4626, DOI 10.1093/nar/26.20.4626; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zhang J, 1997, MOL BIOCHEM PARASIT, V87, P145, DOI 10.1016/S0166-6851(97)00060-1	33	437	455	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40174	40179		10.1074/jbc.M008405200	http://dx.doi.org/10.1074/jbc.M008405200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11013266	hybrid			2022-12-25	WOS:000166039500053
J	Farsetta, DL; Chandran, K; Nibert, ML				Farsetta, DL; Chandran, K; Nibert, ML			Transcriptional activities of reovirus RNA polymerase in recoated cores - Initiation and elongation are regulated by separate mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; SUBVIRAL PARTICLES; NUCLEOTIDE-SEQUENCES; MAMMALIAN REOVIRUSES; LAMBDA-2 PROTEIN; ACTIVE-SITE; RICH RNA; OLIGONUCLEOTIDES; VIRUS; PHOSPHORYLATION	The particle-associated reovirus polymerase synthesizes mRNA within only certain viral particle types. Reovirus cores, subviral particles lacking outer capsid proteins mu1, sigma3, and sigma1, produce mRNA and abortive transcripts. Reovirus virions, which contain complete outer capsids, cannot produce mRNA and produce few abortive transcripts. Recoated cores are virion-like particles generated by the addition of recombinant outer capsid proteins to cores, We used-recoated cores to analyze transcriptional regulation by reovirus outer capsid proteins. Partially recoated particles, containing less than virion amounts of mu1 and sigma3, synthesized mRNA at levels inversely proportional to outer capsid protein levels, Fully recoated cores exhibited undetectable mRNA synthesis levels, as did virions. However, recoated cores produced high levels of abortive transcripts. Recoated core abortive transcripts remained particle-associated and appeared to inhibit further abortive transcript production, Proteolysis of recoated cores removing mu1 and sigma3 released accumulated abortive transcripts and relieved inhibition of mRNA and abortive transcript synthesis. These results suggest transcriptional elongation, but not initiation, is blocked by virion-like amounts of mu1 and sigma3, Particle-associated abortive transcripts may down-regulate transcriptional initiation. Minor outer capsid protein sigma1 had no demonstrable effect on transcriptional activities, Transcriptional regulation may ensure progeny virions do not compete with transcribing particles for ribonucleoside triphosphates.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Inst Mol Virol, Madison, WI 53706 USA; Univ Wisconsin, Cell & Mol Biol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Nibert, ML (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 220 Longwood Ave, Boston, MA 02115 USA.	mnibert@hms.harvard.edu	Chandran, Kartik/I-2232-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI039533] Funding Source: NIH RePORTER; NIAID NIH HHS [AI39533] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arnold JJ, 1999, J BIOL CHEM, V274, P37060, DOI 10.1074/jbc.274.52.37060; BABLANIAN R, 1986, P NATL ACAD SCI USA, V83, P1290, DOI 10.1073/pnas.83.5.1290; BANERJEE AK, 1970, J VIROL, V6, P1; BELLAMY AR, 1972, NATURE-NEW BIOL, V238, P49, DOI 10.1038/newbio238049a0; BELLAMY AR, 1967, P NATL ACAD SCI USA, V58, P1389, DOI 10.1073/pnas.58.4.1389; BELLAMY AR, 1970, VIROLOGY, V40, P808, DOI 10.1016/0042-6822(70)90126-1; BELLAMY AR, 1970, VIROLOGY, V42, P415, DOI 10.1016/0042-6822(70)90284-9; BORSA J, 1968, BIOCHEM BIOPH RES CO, V33, P895, DOI 10.1016/0006-291X(68)90396-3; BORSA J, 1981, VIROLOGY, V111, P191, DOI 10.1016/0042-6822(81)90664-4; Broering TJ, 2000, J VIROL, V74, P5516, DOI 10.1128/JVI.74.12.5516-5524.2000; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CARTER C, 1974, J VIROL, V13, P1331, DOI 10.1128/JVI.13.6.1331-1337.1974; Chandran K, 1999, J VIROL, V73, P3941, DOI 10.1128/JVI.73.5.3941-3950.1999; Chen DY, 1999, VIROLOGY, V265, P120, DOI 10.1006/viro.1999.0029; CLEVELAND DR, 1986, J VIROL, V60, P307, DOI 10.1128/JVI.60.1.307-311.1986; Coombs KM, 1998, VIROLOGY, V243, P218, DOI 10.1006/viro.1998.9061; DRAYNA D, 1982, J VIROL, V41, P110, DOI 10.1128/JVI.41.1.110-118.1982; Dryden KA, 1998, VIROLOGY, V245, P33, DOI 10.1006/viro.1998.9146; DRYDEN KA, 1993, J CELL BIOL, V122, P1023, DOI 10.1083/jcb.122.5.1023; Dupuy LC, 1999, J VIROL, V73, P8384, DOI 10.1128/JVI.73.10.8384-8392.1999; FARRELL JA, 1974, VIROLOGY, V62, P145, DOI 10.1016/0042-6822(74)90310-9; FAUSNAUGH J, 1990, J BIOL CHEM, V265, P7669; FURLONG DB, 1988, J VIROL, V62, P246, DOI 10.1128/JVI.62.1.246-256.1988; FURUICHI Y, 1975, P NATL ACAD SCI USA, V72, P362, DOI 10.1073/pnas.72.1.362; GOMATOS PJ, 1963, BIOCHIM BIOPHYS ACTA, V72, P651; Gralla JD, 1996, METHOD ENZYMOL, V273, P99; GROSS L, 1992, J MOL BIOL, V228, P488, DOI 10.1016/0022-2836(92)90837-A; ITO Y, 1972, VIROLOGY, V50, P189, DOI 10.1016/0042-6822(72)90359-5; Johnston D. E., 1976, RNA POLYMERASE, P413; JOKLIK WK, 1972, VIROLOGY, V49, P700, DOI 10.1016/0042-6822(72)90527-2; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; KOONIN EV, 1993, J GEN VIROL, V74, P733, DOI 10.1099/0022-1317-74-4-733; Lawton JA, 1999, P NATL ACAD SCI USA, V96, P5428, DOI 10.1073/pnas.96.10.5428; Lawton JA, 1997, NAT STRUCT BIOL, V4, P118, DOI 10.1038/nsb0297-118; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEVIN DH, 1970, P NATL ACAD SCI USA, V66, P890, DOI 10.1073/pnas.66.3.890; Lu CX, 1996, P NATL ACAD SCI USA, V93, P2037, DOI 10.1073/pnas.93.5.2037; Luongo CL, 1998, J BIOL CHEM, V273, P23773, DOI 10.1074/jbc.273.37.23773; Luongo CL, 1997, J VIROL, V71, P8035, DOI 10.1128/JVI.71.10.8035-8040.1997; Luongo CL, 2000, J BIOL CHEM, V275, P2804, DOI 10.1074/jbc.275.4.2804; MAO ZX, 1991, VIROLOGY, V185, P377, DOI 10.1016/0042-6822(91)90785-A; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Millward S, 1983, REOVIRIDAE, P107; MORGAN EM, 1975, VIROLOGY, V68, P455, DOI 10.1016/0042-6822(75)90286-X; MULLER DK, 1988, BIOCHEMISTRY-US, V27, P5763, DOI 10.1021/bi00415a055; NAGAMINE Y, 1978, BIOCHIM BIOPHYS ACTA, V519, P440, DOI 10.1016/0005-2787(78)90097-7; Nagy PD, 1997, P NATL ACAD SCI USA, V94, P1113, DOI 10.1073/pnas.94.4.1113; Nibert ML, 1998, CURR TOP MICROBIOL, V233, P1; NIBERT ML, 1992, J VIROL, V66, P6408, DOI 10.1128/JVI.66.11.6408-6418.1992; NIBERT ML, 1996, FIELDS VIROLOGY, P1557; NICHOLS JL, 1972, VIROLOGY, V49, P562, DOI 10.1016/0042-6822(72)90507-7; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; RECORD J, 1996, ESCHERICHIA COLI SAL, P792; Reinisch KM, 2000, NATURE, V404, P960, DOI 10.1038/35010041; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SELIGER LS, 1987, J BIOL CHEM, V262, P16289; SHATKIN AJ, 1974, P NATL ACAD SCI USA, V71, P3204, DOI 10.1073/pnas.71.8.3204; SHATKIN AJ, 1968, P NATL ACAD SCI USA, V61, P1462, DOI 10.1073/pnas.61.4.1462; SHATKIN AJ, 1968, P NATL ACAD SCI USA, V59, P246, DOI 10.1073/pnas.59.1.246; SHATKIN AJ, 1972, J VIROL, V10, P698, DOI 10.1128/JVI.10.4.698-706.1972; SKEHEL JJ, 1969, VIROLOGY, V39, P822, DOI 10.1016/0042-6822(69)90019-1; SMITH RE, 1969, VIROLOGY, V39, P791, DOI 10.1016/0042-6822(69)90017-8; Sun JH, 1996, VIROLOGY, V226, P1, DOI 10.1006/viro.1996.0622; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; YAMAKAWA M, 1981, J BIOL CHEM, V256, P6507; YAMAKAWA M, 1982, VIROLOGY, V118, P157, DOI 10.1016/0042-6822(82)90329-4; ZWEERINK HJ, 1976, VIROLOGY, V73, P442, DOI 10.1016/0042-6822(76)90405-0; ZWEERINK HJ, 1970, VIROLOGY, V41, P501, DOI 10.1016/0042-6822(70)90171-6	72	34	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39693	39701		10.1074/jbc.M004562200	http://dx.doi.org/10.1074/jbc.M004562200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11007773	hybrid			2022-12-25	WOS:000165953100098
J	Jang, BC; Sanchez, T; Schaefers, HJ; Trifan, OC; Liu, CH; Creminon, C; Huang, CK; Hla, T				Jang, BC; Sanchez, T; Schaefers, HJ; Trifan, OC; Liu, CH; Creminon, C; Huang, CK; Hla, T			Serum withdrawal-induced post-transcriptional stabilization of cyclooxygenase-2 mRNA in MDA-MB-231 mammary carcinoma cells requires the activity of the p38 stress-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; MESSENGER-RNA STABILITY; RENAL MESANGIAL CELLS; POSTTRANSCRIPTIONAL REGULATION; PROSTAGLANDIN; EXPRESSION; GENE; DEXAMETHASONE; FIBROBLASTS; SYNTHASE-2	Overexpression of the cyclooxygenase-2 (COX-2) gene is observed in several neoplastic diseases. However, molecular mechanisms involved in the regulation of expression of COX-2 are not well understood. In this report, we describe a unique post-transcriptional regulatory mechanism of COX-2 mRNA stabilization in MDA-MB-231 cells, a highly metastatic cell line derived from a human mammary tumor. High levels of COX-2 mRNA, protein, and enzyme activity were induced by serum withdrawal, which were potently inhibited by the addition of serum or >100-kDa serum factor. Nuclear run-on analysis and actinomycin D chase experiments indicate that regulation is primarily at the level of post-transcriptional mRNA stability. Interestingly, SB203580, an inhibitor of the p38 stress-activated protein kinase (SAPK), and overexpression of the dominant-negative p38 alpha construct potently inhibited the serum withdrawal-induced COX-2 mRNA levels. Indeed, the half-life of COX-2 mRNA decreased from 9 to 4.5 h after SB203580 treatment, suggesting that signal transduction by the p38 SAPK pathway is required for COX-2 mRNA stability.	Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Dept Physiol, Farmington, CT 06030 USA; CEA, Serv Physiol & Pharmacol, F-91191 Gif Sur Yvette, France; Univ Connecticut, Ctr Hlth, Dept Pathol, Farmington, CT 06030 USA; CEA Saclay, Serv Physiol & Pharmacol, F-91191 Gif Sur Yvette, France	University of Connecticut; CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Connecticut; CEA; UDICE-French Research Universities; Universite Paris Saclay	Hla, T (corresponding author), Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Dept Physiol, 263 Farmington Ave, Farmington, CT 06030 USA.		Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065; Jang, Byeong-Churl/0000-0002-2691-5503	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049094, P01HL054710] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54710, HL49094] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; BAILEY JM, 1985, J LIPID RES, V26, P54; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CELANO P, 1989, BIOTECHNIQUES, V7, P942; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P341, DOI 10.1016/0005-2760(94)00197-7; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; CUENDA A, 1995, FEBS LETT, V364, P3985; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DELATORRE M, 1993, ANTICANCER RES, V13, P1425; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; HANNIGAN M, 1998, BIOCH CELL BIOL COMM, V46, P55; Herschman HR, 1997, ADV EXP MED BIOL, V407, P61; HLA T, 1993, ANN NY ACAD SCI, V696, P197; Hla T, 1999, INT J BIOCHEM CELL B, V31, P551, DOI 10.1016/S1357-2725(98)00152-6; KYRIAKIS JM, 1994, NATURE, V369, P150; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Liu XH, 1996, CANCER RES, V56, P5125; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; Miller WE, 1999, TRENDS MICROBIOL, V7, P453, DOI 10.1016/S0966-842X(99)01605-4; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Montero L, 1999, CANCER RES, V59, P5286; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; ROLLAND PH, 1980, JNCI-J NATL CANCER I, V64, P1061; SANO H, 1995, CANCER RES, V55, P3785; SCHREY MP, 1995, BRIT J CANCER, V72, P1412, DOI 10.1038/bjc.1995.523; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; SRIVASTAVA SK, 1994, AM J PHYSIOL, V267, pF504, DOI 10.1152/ajprenal.1994.267.3.F504; Subbaramaiah K, 1996, CANCER RES, V56, P4424; TAN WC, 1974, CANCER RES, V34, P3229; Trifan OC, 1999, J BIOL CHEM, V274, P34141, DOI 10.1074/jbc.274.48.34141; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97	44	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39507	39515		10.1074/jbc.M003224200	http://dx.doi.org/10.1074/jbc.M003224200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993880	hybrid			2022-12-25	WOS:000165953100077
J	Kitazume, T; Takaya, N; Nakayama, N; Shoun, H				Kitazume, T; Takaya, N; Nakayama, N; Shoun, H			Fusarium oxysporum fatty-acid subterminal hydroxylase (CYP505) is a membrane-bound eukaryotic: Counterpart of Bacillus megaterium cytochrome P450BM3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE REDUCTASE; CRYSTAL-STRUCTURE; AMINO-ACID; MYCOBACTERIUM-TUBERCULOSIS; OMEGA-HYDROXYLASE; CODING NUCLEOTIDE; SEQUENCES; PROTEINS; GENE; IDENTIFICATION	The gene of a fatty-acid hydroxylase of the fungus Fusarium oxtysporum (P450foxy) was cloned and expressed in yeast. The putative primary structure reveal ed the close relationship of P450foxy to the bacterial cytochrome P450BM3, a fused protein of cytochrome P450 and its reductase from Bacillus megaterium. The amino acid sequence identities of the P450 and P450 reductase domains of P450foxy were highest (40.6 and 35.3%, respectively) to the corresponding domains of P450BM3. Recombinant P450foxy expressed in yeast was catalytically and spectrally indistinguishable from the native protein, except most of the recombinant P450foxy was recovered in the soluble fraction of the yeast cells, in marked contrast to native P450foxy, which was exclusively recovered in the membrane fraction of the fungal cells. This difference implies that a post (or co)-translational mechanism functions in the fungal cells to target and bind the protein to the membrane. These results provide conclusive evidence that P450foxy is the eukaryotic counterpart of bacterial P450BM3, which evokes interest in the evolutionary aspects concerning the P450 superfamily along with its reducing systems. P450foxy was classified in the new family, CYP505.	Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba	Shoun, H (corresponding author), Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan.							AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; Aoyama Y, 1998, J BIOCHEM-TOKYO, V124, P694; BALLANCE DJ, 1986, YEAST, V2, P229, DOI 10.1002/yea.320020404; Bellamine A, 1999, P NATL ACAD SCI USA, V96, P8937, DOI 10.1073/pnas.96.16.8937; Benveniste I, 1998, BIOCHEM BIOPH RES CO, V243, P688, DOI 10.1006/bbrc.1998.8156; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOTOH O, 1992, J BIOL CHEM, V267, P83; Gotoh O., 1993, CYTOCHROME P450, P255; GrahamLorence S, 1996, FASEB J, V10, P206, DOI 10.1096/fasebj.10.2.8641554; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KIMURA S, 1989, DNA-J MOLEC CELL BIO, V8, P503, DOI 10.1089/dna.1.1989.8.503; KIZAWA H, 1991, J BIOL CHEM, V266, P10632; KLEIN ML, 1994, BBA-GEN SUBJECTS, V1201, P245; KUSUNOSE M, 1964, J BIOL CHEM, V239, P1374; LIANG QW, 1995, J BIOL CHEM, V270, P4438, DOI 10.1074/jbc.270.9.4438; Makita K, 1996, FASEB J, V10, P1456, DOI 10.1096/fasebj.10.13.8940291; MCKENNA EJ, 1970, J BIOL CHEM, V245, P3882; MORRISON JFJ, 1995, PCR2 PRACTICAL APPRO, P181; NAKAHARA K, 1993, J BIOL CHEM, V268, P8350; Nakayama N, 1996, J BIOCHEM-TOKYO, V119, P435; NARHI LO, 1986, J BIOL CHEM, V261, P7160; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; NELSON DR, 1987, MOL BIOL EVOL, V4, P572; NELSON DR, 1989, BIOCHEMISTRY-US, V28, P656, DOI 10.1021/bi00428a036; OHKUMA M, 1995, DNA CELL BIOL, V14, P163, DOI 10.1089/dna.1995.14.163; Omura T, 1999, BIOCHEM BIOPH RES CO, V266, P690, DOI 10.1006/bbrc.1999.1887; OMURA T, 1964, J BIOL CHEM, V239, P2379; Park SY, 1997, NAT STRUCT BIOL, V4, P827, DOI 10.1038/nsb1097-827; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; Salaun Jean-Pierre, 1995, Drug Metabolism and Drug Interactions, V12, P261; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; TOMURA D, 1994, J BIOCHEM-TOKYO, V116, P88, DOI 10.1093/oxfordjournals.jbchem.a124508; Urban P, 1997, J BIOL CHEM, V272, P19176, DOI 10.1074/jbc.272.31.19176; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Williams PA, 2000, MOL CELL, V5, P121, DOI 10.1016/S1097-2765(00)80408-6; YOSHIDA Y, 1993, CYTOCHROME P 450, P1	44	64	68	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39734	39740		10.1074/jbc.M005617200	http://dx.doi.org/10.1074/jbc.M005617200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995755	hybrid			2022-12-25	WOS:000165953100103
J	Ohashi, E; Bebenek, K; Matsuda, T; Feaver, WJ; Gerlach, VL; Friedberg, EC; Ohmori, H; Kunkel, TA				Ohashi, E; Bebenek, K; Matsuda, T; Feaver, WJ; Gerlach, VL; Friedberg, EC; Ohmori, H; Kunkel, TA			Fidelity and processivity of DNA synthesis by DNA polymerase kappa, the product of the human DINB1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; ESCHERICHIA-COLI; NUCLEOTIDE INCORPORATION; BASE SUBSTITUTION; MOUSE HOMOLOGS; MUTAGENESIS; REPLICATION; BETA; ENCODES; PROTEIN	Mammalian DNA polymerase kappa (pol kappa), a member of the UmuC/DinB nucleotidyl transferase superfamily, has been implicated in spontaneous mutagenesis. Here we show that human pol kappa copies undamaged DNA with average single-base substitution and deletion error rates of 7 x 10(-3) and 2 x 10(-3), respectively. These error rates are high when compared to those of most other DNA polymerases. pol kappa also has unusual error specificity, producing a high proportion of T.CMP mispairs and deleting and adding non-reiterated nucleotides at extraordinary rates. Unlike other members of the UmuC/DinB family, pol kappa can processively synthesize chains of 25 or more nucleotides. This moderate processivity may reflect a contribution of C-terminal residues, which include two zinc clusters. The very low fidelity and moderate processivity of pol kappa is novel in comparison to any previously studied DNA polymerase, and is consistent with a role in spontaneous mutagenesis.	NIEHS, Struct Biol Lab, Res Triangle Pk, NC 27709 USA; NIEHS, Mol Genet Lab, Res Triangle Pk, NC 27709 USA; Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75390 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Kyoto University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kunkel, TA (corresponding author), NIEHS, Struct Biol Lab, POB 12233,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	kunkel@niehs.nih.gov	Ohashi, Eiji/AAO-5794-2021; Kunkel, Thomas A./D-5088-2019	Ohashi, Eiji/0000-0002-1771-5585; Kunkel, Thomas A./0000-0002-9900-1788	NATIONAL CANCER INSTITUTE [R01CA069029, F32CA075733] Funding Source: NIH RePORTER; NCI NIH HHS [CA-69029, CA-75733] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Beard WA, 1998, J BIOL CHEM, V273, P30435, DOI 10.1074/jbc.273.46.30435; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345; BROTCORNELANNOYE A, 1986, P NATL ACAD SCI USA, V83, P3904, DOI 10.1073/pnas.83.11.3904; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Efrati E, 1997, J BIOL CHEM, V272, P2559; Friedberg EC, 1999, CELL, V98, P413, DOI 10.1016/S0092-8674(00)81970-4; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; GERLACH VL, 2000, IN PRESS J BIOL CHEM; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Kelman Z, 1998, STRUCTURE, V6, P121, DOI 10.1016/S0969-2126(98)00014-8; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kim SR, 1997, P NATL ACAD SCI USA, V94, P13792, DOI 10.1073/pnas.94.25.13792; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; Ogi T, 1999, GENES CELLS, V4, P607, DOI 10.1046/j.1365-2443.1999.00289.x; Ohashi E, 2000, GENE DEV, V14, P1589; Osheroff WP, 1999, J BIOL CHEM, V274, P20749, DOI 10.1074/jbc.274.30.20749; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; Osheroff WP, 2000, J BIOL CHEM, V275, P28033; Roberts J.D., 1996, DNA REPLICATION EUKA, P217; Sharief FS, 1999, GENOMICS, V59, P90, DOI 10.1006/geno.1999.5843; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; Vaisman A, 2000, BIOCHEMISTRY-US, V39, P4575, DOI 10.1021/bi000130k; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7	45	214	220	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39678	39684		10.1074/jbc.M005309200	http://dx.doi.org/10.1074/jbc.M005309200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11006276	hybrid			2022-12-25	WOS:000165953100096
J	Sawai, H; Okamoto, Y; Luberto, C; Mao, CG; Bielawska, A; Domae, N; Hannun, YA				Sawai, H; Okamoto, Y; Luberto, C; Mao, CG; Bielawska, A; Domae, N; Hannun, YA			Identification of ISC1 (YER019w) as inositol phosphosphingolipid phospholipase C in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOMYELINASE ACTIVITY; NEUTRAL SPHINGOMYELINASE; ACID SPHINGOMYELINASE; YEAST SPHINGOLIPIDS; CERAMIDE; GENE; STRESS; PHOSPHORYLCERAMIDE; PURIFICATION; RESPONSES	Sphingolipids have emerged as novel bioactive mediators in eukaryotic cells including yeast. It has been proposed that sphingomyelin (SM) hydrolysis and the concomitant generation of ceramide are involved in various stress responses in mammalian cells, The yeast Saccharomyces cerevisiae has inositol phosphosphingolipids (IPS) instead of SM and glycolipids, and synthesis of IFS is indispensable to its growth. Although the genes responsible for the synthesis of IFS have been identified, the gene(s) for the degradation of IFS has not been reported, Here we show that ISC1 (YER019w), which has homology to bacterial neutral sphingomyelinase (SMase), encodes IFS phospholipase C (IPS-PLC). First, we observed that overexpression of ISC1 greatly increased neutral SMase activity, and this activity was dependent on the presence of phosphatidylserine. Cells deleted in ISC1 demonstrated negligible neutral SMase activity. Because yeast cells have IFS instead of SM, we investigated whether IFS are the physiologic substrates of this enzyme. Lysates of ISC1-overexpressing cells demonstrated very high PLC activities on IFS. Deletion of ISC1 eliminated endogenous IPS-PLC activities, Labeling yeast cells with [H-3]dihydrosphingosine showed that IFS were increased in the deletion mutant cells, This study identifies the first enzyme involved in catabolism of complex sphingolipids in S. cerevisiae.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Ralph H Johnson Vet Adm Hosp, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Osaka Dent Univ, Dept Med, Hirakata, Osaka 573, Japan	Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.		OKAMOTO, Yasuo/J-8438-2015		NIGMS NIH HHS [GM43825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beeler TJ, 1997, MOL GEN GENET, V255, P570, DOI 10.1007/s004380050530; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; Dickson RC, 1997, J BIOL CHEM, V272, P29620, DOI 10.1074/jbc.272.47.29620; Dickson RC, 1999, BBA-GEN SUBJECTS, V1426, P347, DOI 10.1016/S0304-4165(98)00135-4; DUAN RD, 1995, BBA-LIPID LIPID MET, V1259, P49, DOI 10.1016/0005-2760(95)00137-2; Ella KM, 1997, ARCH BIOCHEM BIOPHYS, V340, P101, DOI 10.1006/abbi.1997.9897; Fensome AC, 2000, J BIOL CHEM, V275, P1128, DOI 10.1074/jbc.275.2.1128; FOLCH J, 1957, J BIOL CHEM, V226, P497; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANSON BA, 1980, J LIPID RES, V21, P309; Liu B, 1998, J BIOL CHEM, V273, P34472, DOI 10.1074/jbc.273.51.34472; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; PATTON JL, 1991, J BACTERIOL, V173, P3101, DOI 10.1128/JB.173.10.3101-3108.1991; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; QUINTERN LE, 1989, EMBO J, V8, P2469, DOI 10.1002/j.1460-2075.1989.tb08382.x; Sawai H, 1999, J BIOL CHEM, V274, P38131, DOI 10.1074/jbc.274.53.38131; Sawai H, 1997, J BIOL CHEM, V272, P2452; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SMITH SW, 1974, J BIOL CHEM, V249, P3395; STEINER S, 1969, P NATL ACAD SCI USA, V64, P1042, DOI 10.1073/pnas.64.3.1042; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wells GB, 1998, J BIOL CHEM, V273, P7235, DOI 10.1074/jbc.273.13.7235	29	125	134	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39793	39798		10.1074/jbc.M007721200	http://dx.doi.org/10.1074/jbc.M007721200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11006294	hybrid			2022-12-25	WOS:000165953100112
J	Chi, NW; Lodish, HF				Chi, NW; Lodish, HF			Tankyrase is a Golgi-associated mitogen-activated protein kinase substrate that interacts with IRAP in GLUT4 vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUCOSE-TRANSPORT; 3T3-L1 ADIPOCYTES; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; INSULIN; DOMAIN; RAT; TRANSLOCATION; LOCALIZATION; ANKYRIN	The poly(ADP-ribose) polymerase tankyrase was originally described as a telomeric protein whose catalytic activity was proposed to regulate telomere function. Subsequent studies revealed that most tankyrase is actually extranuclear, but a discordant pattern of cytoplasmic targeting was reported, Here we used fractionation and immunofluorescence to show in 3T3-L1 fibroblasts that tankyrase is a peripheral membrane protein associated with the Golgi. We further colocalized tankyrase with GLUT4 storage vesicles in the juxtanuclear region of adipocytes. Consistent with this colocalization, we found that tankyrase binds specifically to a resident protein of GLUT4 vesicles, IRAP (insulin-responsive amino peptidase). The binding of tankyrase to IRAP involves the ankyrin repeats of tankyrase and a defined sequence ((96)RQSPDG(101)) in the IRAP cytosolic domain (IRAP(1-109)). Tankyrase is a novel signaling target of mitogen-activated protein kinase (MAPK); it is stoichiometrically phosphorylated upon insulin stimulation. Phosphorylation enhances the poly(ADP-ribose) polymerase activity of tankyrase but apparently does not mediate the acute effect of insulin on GLUT4 targeting. Taken together, tankyrase is a novel target of MAPK. signaling in the Golgis, where it is tethered to GLUT4 vesicles by binding to IRAP. We speculate that tankyrase may be involved in the long term effect of the MAPK cascade on the metabolism of GLUT4 vesicles.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Med Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047618, K08DK002540] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37DK47618, DK02540] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Batrukova MA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P395; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FINGAR DC, 1994, J BIOL CHEM, V269, P10127; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gao YS, 1998, J BIOL CHEM, V273, P33825, DOI 10.1074/jbc.273.50.33825; GARZA LA, 1997, J BIOL CHEM, V272, pE600; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21391; Herbst JJ, 1997, AM J PHYSIOL-ENDOC M, V272, pE600, DOI 10.1152/ajpendo.1997.272.4.E600; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lee W, 1997, J BIOL CHEM, V272, P21427, DOI 10.1074/jbc.272.34.21427; Lippincott-Schwartz J, 1998, CURR OPIN CELL BIOL, V10, P52, DOI 10.1016/S0955-0674(98)80086-0; MARSH BJ, 1995, J CELL BIOL, V130, P1081, DOI 10.1083/jcb.130.5.1081; Martinez-Arca S, 2000, J CELL SCI, V113, P1705; Michaely P, 1995, J BIOL CHEM, V270, P31298, DOI 10.1074/jbc.270.52.31298; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SCHIEMANN WP, 1995, P NATL ACAD SCI USA, V92, P5361, DOI 10.1073/pnas.92.12.5361; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Smith S, 1999, J CELL SCI, V112, P3649; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Spanfo S, 1999, J BIOL CHEM, V274, P17705, DOI 10.1074/jbc.274.25.17705; STECK TL, 1974, J CELL BIOL, V62, P1, DOI 10.1083/jcb.62.1.1; Subtil A, 2000, J BIOL CHEM, V275, P4787, DOI 10.1074/jbc.275.7.4787; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; Waters SB, 1997, J BIOL CHEM, V272, P23323, DOI 10.1074/jbc.272.37.23323; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Yamamoto Y, 2000, DIABETES, V49, P332, DOI 10.2337/diabetes.49.3.332; Zhang ZS, 1998, J BIOL CHEM, V273, P18681, DOI 10.1074/jbc.273.30.18681	41	236	258	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38437	38444		10.1074/jbc.M007635200	http://dx.doi.org/10.1074/jbc.M007635200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10988299	hybrid			2022-12-25	WOS:000165739800041
J	Goumon, Y; Lugardon, K; Gadroy, P; Strub, JM; Welters, ID; Stefano, GB; Aunis, D; Metz-Boutigue, MH				Goumon, Y; Lugardon, K; Gadroy, P; Strub, JM; Welters, ID; Stefano, GB; Aunis, D; Metz-Boutigue, MH			Processing of proenkephalin-A in bovine chromaffin cells - Identification of natural derived fragments by N-terminal sequencing and matrix-assisted laser desorption ionization-time of flight mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROHORMONE THIOL PROTEASE; ADRENAL-MEDULLA; ANTIBACTERIAL ACTIVITY; SECRETORY VESICLES; MONONUCLEAR-CELLS; CHROMOGRANIN-A; GROWTH-FACTOR; GRANULES; ENKEPHALIN; ENZYME	A large variety of proenkephalin-A-derived peptides (PEAPs) are present in bovine adrenal medulla secretory granules that are cosecreted with catecholamines upon stimulation of chromaffin cells. In the present paper, after reverse phase high performance liquid chromatography of intragranular soluble material, PEAPs were immunodetected with antisera raised against specific proenkephalin-A (PEA) sequences (PEA63-70 and PEA224-237) and analyzed by matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry, Thirty PEAPs were characterized in addition to enkephalins and whole PEA, indicating that preferential proteolytic attacks occurred at both N- and C-terminal regions. A similar approach was used to characterize PEA-derived fragments exocytotically released into the extracellular space that showed five additional minor PEAPs. Among all these naturally generated peptides, enkelytin, the antibacterial bisphosphorylated C-terminal peptide (PEA209-237), was predominantly generated, as shown by MALDI-TOF mass spectrometry analysis, which constituted an efficient method for its identification. Finally, the data on PEA intragranular and extracellular processing in adrenal medulla are discussed in regard to the known enzymatic processing mechanisms. We note the high conservation of the cleavage points in evolutionarily diverse organisms, highlighting an important biological function for the released PEAPs.	INSERM, U338, F-67084 Strasbourg, France; Univ Giessen, Dept Anaesthesiol & Intens Care Med, D-35385 Giessen, Germany; SUNY Coll Old Westbury, Neurosci Res Inst, Old Westbury, NY 11568 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Justus Liebig University Giessen; State University of New York (SUNY) System; SUNY Old Westbury	Metz-Boutigue, MH (corresponding author), INSERM, U338, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.	metz@neurochem.u-strasbg.fr	Dominique, Aunis/W-1419-2019; Stefano, George Bogdan/ABD-9152-2021	Stefano, George Bogdan/0000-0002-8146-0740; Welters, Ingeborg/0000-0002-3408-8798; Strub, Jean-Marc/0000-0001-6224-3428				AUNIS D, 1977, J NEUROCHEM, V29, P439, DOI 10.1111/j.1471-4159.1977.tb10692.x; Aunis D, 1998, INT REV CYTOL, V181, P213, DOI 10.1016/S0074-7696(08)60419-2; AZARYAN AV, 1992, BIOCHEM BIOPH RES CO, V185, P398, DOI 10.1016/S0006-291X(05)80999-4; AZARYAN AV, 1994, FEBS LETT, V341, P197, DOI 10.1016/0014-5793(94)80456-7; AZARYAN AV, 1995, J NEUROCHEM, V65, P1771; AZARYAN AV, 1995, BIOCHEMISTRY-US, V34, P7988; BANKS P, 1965, BIOCHEM J, V97, pC40, DOI 10.1042/bj0970040C; BASTIAENSEN E, 1989, FEBS LETT, V244, P477, DOI 10.1016/0014-5793(89)80587-3; Bongiorno L, 1999, GERONTOLOGY, V45, P10, DOI 10.1159/000022049; Brar BK, 1999, J ENDOCRINOL, V161, P475, DOI 10.1677/joe.0.1610475; Danielson PB, 1999, GEN COMP ENDOCR, V113, P169, DOI 10.1006/gcen.1998.7206; DILLEN L, 1993, NEUROCHEM INT, V22, P315, DOI 10.1016/0197-0186(93)90016-X; EVANGELISTA R, 1982, BIOCHEM BIOPH RES CO, V106, P895, DOI 10.1016/0006-291X(82)91795-8; FERRO ES, 1995, J CELL BIOCHEM, V57, P311, DOI 10.1002/jcb.240570215; FRICKER LD, 1986, NATURE, V323, P461, DOI 10.1038/323461a0; Goumon Y, 1996, EUR J BIOCHEM, V235, P516, DOI 10.1111/j.1432-1033.1996.t01-1-00516.x; Goumon Y, 1998, J BIOL CHEM, V273, P29847, DOI 10.1074/jbc.273.45.29847; HOLLT V, 1982, EUR J PHARMACOL, V85, P355, DOI 10.1016/0014-2999(82)90226-6; Hook VYH, 1999, J BIOL CHEM, V274, P3165, DOI 10.1074/jbc.274.5.3165; HOOK VYH, 1982, NATURE, V295, P341, DOI 10.1038/295341a0; HOOK VYH, 1984, FEBS LETT, V172, P212, DOI 10.1016/0014-5793(84)81128-X; Hook VYH, 1999, ENDOCRINOLOGY, V140, P3744, DOI 10.1210/en.140.8.3744; HOOK VYH, 1994, FASEB J, V8, P1269, DOI 10.1096/fasebj.8.15.8001739; Hook VYH, 1996, ARCH BIOCHEM BIOPHYS, V328, P107, DOI 10.1006/abbi.1996.0149; INTURRISI CE, 1980, P NATL ACAD SCI-BIOL, V77, P5512, DOI 10.1073/pnas.77.9.5512; Johanning K, 1998, J BIOL CHEM, V273, P22672, DOI 10.1074/jbc.273.35.22672; KOJIMA K, 1982, ARCH BIOCHEM BIOPHYS, V215, P638, DOI 10.1016/0003-9861(82)90125-4; KRIEGER TJ, 1991, J BIOL CHEM, V266, P8376; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG I, 1982, LIFE SCI, V31, P1713, DOI 10.1016/0024-3205(82)90192-8; LISTON D, 1984, SCIENCE, V225, P734, DOI 10.1126/science.6547780; Liu F, 1996, J NEUROCHEM, V67, P1457; Loewe H, 1999, ARZNEIMITTEL-FORSCH, V49, P297; Lugardon K, 2000, J BIOL CHEM, V275, P10745, DOI 10.1074/jbc.275.15.10745; Mains RE, 1996, ANN NY ACAD SCI, V805, P10; Marx R, 1999, J NEUROSCI, V19, P8300; MATHIS JP, 1992, ENDOCRINOLOGY, V131, P2287, DOI 10.1210/en.131.5.2287; METTERS KM, 1988, J BIOL CHEM, V263, P12543; Metz-Boutigue MH, 1998, CELL MOL NEUROBIOL, V18, P249, DOI 10.1023/A:1022573004910; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; MIZUNO K, 1985, BIOCHEM BIOPH RES CO, V128, P884, DOI 10.1016/0006-291X(85)90129-9; NODA M, 1982, NATURE, V295, P202, DOI 10.1038/295202a0; PADROS MR, 1995, J NEUROIMMUNOL, V61, P79, DOI 10.1016/0165-5728(95)00077-F; PAYNE CM, 1989, ARCH HISTOL CYTOL, V52, P277, DOI 10.1679/aohc.52.Suppl_277; Plotnikoff NP, 1997, CLIN IMMUNOL IMMUNOP, V82, P93, DOI 10.1006/clin.1996.4287; ROBERTS SF, 1992, J NEUROCHEM, V58, P593, DOI 10.1111/j.1471-4159.1992.tb09760.x; ROSTOVTSEV AP, 1994, MOL CELL ENDOCRINOL, V101, P277, DOI 10.1016/0303-7207(94)90244-5; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; SARAVIA F, 1993, ENDOCRINOLOGY, V132, P1431, DOI 10.1210/en.132.4.1431; Saravia F, 1998, NEUROPEPTIDES, V32, P351, DOI 10.1016/S0143-4179(98)90058-0; SCHNEIDER FH, 1967, BRIT J PHARM CHEMOTH, V31, P94, DOI 10.1111/j.1476-5381.1967.tb01980.x; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHEN FS, 1989, J BIOL CHEM, V264, P15600; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMITH AD, 1967, BIOCHEM J, V103, P480, DOI 10.1042/bj1030480; Stefano GB, 1999, INT REV CYTOL, V187, P261, DOI 10.1016/S0074-7696(08)62420-1; Stefano GB, 1998, IMMUNOL TODAY, V19, P265, DOI 10.1016/S0167-5699(98)01268-7; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; STEINER DF, 1992, J BIOL CHEM, V267, P23435; Strub JM, 1996, FEBS LETT, V379, P273, DOI 10.1016/0014-5793(95)01529-9; Strub JM, 1996, J BIOL CHEM, V271, P28533, DOI 10.1074/jbc.271.45.28533; STRUB JM, 1995, EUR J BIOCHEM, V229, P356, DOI 10.1111/j.1432-1033.1995.0356k.x; Tasiemski A, 2000, MOL BRAIN RES, V76, P237, DOI 10.1016/S0169-328X(00)00005-X; TEZAPSIDIS N, 1994, BIOCHEM J, V301, P607, DOI 10.1042/bj3010607; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UDENFRIEND S, 1984, PEPTIDES, V6, P25; VIDA MIR, 1994, DEV BRAIN RES, V77, P151; Vindrola O, 1998, ENDOCRINE, V8, P231, DOI 10.1385/ENDO:8:3:231; VINDROLA O, 1990, J CLIN INVEST, V86, P531, DOI 10.1172/JCI114740; VORM O, 1994, J AM SOC MASS SPECTR, V5, P955, DOI 10.1016/1044-0305(94)80013-8; Yasothornsrikul S, 1999, BIOCHEMISTRY-US, V38, P7421, DOI 10.1021/bi990239w; Zagon IS, 1999, BRAIN RES, V839, P313, DOI 10.1016/S0006-8993(99)01753-9	74	27	27	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38355	38362		10.1074/jbc.M007557200	http://dx.doi.org/10.1074/jbc.M007557200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10988298	hybrid			2022-12-25	WOS:000165739800031
J	Stochaj, U; Rassadi, R; Chiu, J				Stochaj, U; Rassadi, R; Chiu, J			Stress-mediated inhibition of the classical nuclear protein import pathway and nuclear accumulation of the small GTPase Gsp1p	FASEB JOURNAL			English	Article									McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada	McGill University	Stochaj, U (corresponding author), McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada.	stochaj@med.mcgill.ca	stochaj, ursula/AAC-1865-2021						0	67	68	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2000	14	14					2130	2132		10.1096/fj.99-0751fje	http://dx.doi.org/10.1096/fj.99-0751fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11024003				2022-12-25	WOS:000165190800001
J	D'Amico, M; Di Filippo, C; La, M; Solito, E; McLean, PG; Flower, RJ; Oliani, SM; Perretti, M				D'Amico, M; Di Filippo, C; La, M; Solito, E; McLean, PG; Flower, RJ; Oliani, SM; Perretti, M			Lipocortin 1 reduces myocardial ischemia-reperfusion injury by affecting local leukocyte recruitment	FASEB JOURNAL			English	Article									William Harvey Res Inst, Dept Biochem Pharmacol, London EC1M 6BQ, England; Univ Naples 2, Inst Pharmacol & Toxicol, I-80138 Naples, Italy; Inst Cochin Genet Mol, INSERM, U332, F-75014 Paris, France; UNESP, IBILCE, Dept Biol, Sao Paulo, Brazil	University of London; Queen Mary University London; Universita della Campania Vanvitelli; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universidade Estadual Paulista	Perretti, M (corresponding author), William Harvey Res Inst, Dept Biochem Pharmacol, Charterhouse Sq, London EC1M 6BQ, England.		Oliani, Sonia Maria/E-3476-2012	Oliani, Sonia Maria/0000-0003-0918-2130; d'amico, michele/0000-0002-6899-0595; Solito, Egle/0000-0001-5279-0049					0	79	80	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					1867	1869						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023969				2022-12-25	WOS:000089634400004
J	Giehl, K; Seidel, B; Gierschik, P; Adler, G; Menke, A				Giehl, K; Seidel, B; Gierschik, P; Adler, G; Menke, A			TGF beta(1) represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation	ONCOGENE			English	Article						TGF beta; EGF; ERK2; proliferation control	GROWTH-FACTOR-BETA; RAS-BINDING DOMAIN; TGF-BETA; PROTEIN-KINASE; EPITHELIAL-CELLS; CANCER-CELLS; MAP KINASE; I RECEPTOR; NUCLEAR TRANSLOCATION; SIGNALING PATHWAYS	Transforming growth factor beta (TGF beta) is a tumor suppressor acting as inhibitor of cell cycle progression of epithelial cells. We show that treatment of the pancreatic carcinoma cell lines PANC-1 and BxPC-3 with TGF beta(1) inhibits both growth factor-induced activation of the extracellular signal-regulated kinase 2 (ERK2) and translocation of the kinase to the nucleus. TGF beta(1) causes a concentration-dependent reduction of cell proliferation in both cell lines, By measuring ERK activation, we can show that TGF beta(1) is able to repress ERK activation induced by mitogenic stimuli such as EGF, This inhibitory effect of TGF beta(1) is not mediated by suppression of Ras or c-Raf-1 activation, but mediated by TGF beta(1)-induced activation of a serine-threonine phosphatase, as demonstrated by inhibition of phosphatases by treatment with okadaic acid. Results obtained in the Smad4-deficient pancreatic carcinoma cell line BxPC-3, demonstrate that TGF beta(1)-induced growth inhibition is mediated by a Smad4-independent prevention of ERK2 activation. In contrast to the effects of TGF beta(1) on epithelial cells, mesenchymal NIH3T3 fibroblasts exhibit elevated ERK2 activation and increased cell proliferation in response to TGF beta(1) treatment, Smad4-independent phosphatase-mediated inhibition of mitogen-activated ERK2 represents a novel effector pathway contributing to suppression of epithelial pancreatic carcinoma cell proliferation by TGF beta(1), in addition to the well-known Smad-induced tumor suppressor activity of TGF beta.	Univ Ulm, Dept Internal Med 1, D-89070 Ulm, Germany; Univ Ulm, Dept Pharmacol & Toxicol, D-89070 Ulm, Germany	Ulm University; Ulm University	Menke, A (corresponding author), Univ Ulm, Dept Internal Med 1, D-89070 Ulm, Germany.							ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Axmann A, 1998, BIOCHEM BIOPH RES CO, V249, P456, DOI 10.1006/bbrc.1998.9188; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Dixon M, 1999, HEPATOLOGY, V29, P1418, DOI 10.1002/hep.510290516; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; Giehl K, 2000, ONCOGENE, V19, P2930, DOI 10.1038/sj.onc.1203612; Griswold-Prenner I, 1998, MOL CELL BIOL, V18, P6595, DOI 10.1128/MCB.18.11.6595; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Heldin Carl-Henrik, 1996, Cytokine and Growth Factor Reviews, V7, P3, DOI 10.1016/1359-6101(96)00002-0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Liu JH, 1999, ONCOGENE, V18, P269, DOI 10.1038/sj.onc.1202263; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Menke A, 1999, BBA-MOL CELL RES, V1449, P178, DOI 10.1016/S0167-4889(99)00011-7; Menke A, 1997, GASTROENTEROLOGY, V113, P295, DOI 10.1016/S0016-5085(97)70107-0; MULDER KM, 1992, J BIOL CHEM, V267, P5029; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; Reimann T, 1997, FEBS LETT, V403, P57, DOI 10.1016/S0014-5793(97)00024-0; Roberts AB, 1990, GROWTH FACTORS, V2, P135, DOI 10.3109/08977199009071500; Rodeck U, 1999, CANCER RES, V59, P547; Schutte M, 1996, CANCER RES, V56, P2527; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; ZHENG CF, 1994, J BIOL CHEM, V269, P19947	50	70	73	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4531	4541		10.1038/sj.onc.1203806	http://dx.doi.org/10.1038/sj.onc.1203806			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002426				2022-12-25	WOS:000089236800010
J	Susse, S; Janz, C; Janus, F; Deppert, W; Wiesmuller, L				Susse, S; Janz, C; Janus, F; Deppert, W; Wiesmuller, L			Role of heteroduplex joints in the functional interactions between human Rad51 and wild-type p53	ONCOGENE			English	Article						exonuclease; fidelity control; homologous recombination; mismatch correction; strand exchange	DOUBLE-STRAND BREAKS; INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; NUCLEOTIDE EXCISION-REPAIR; MOUSE L-CELLS; DNA-BINDING; SACCHAROMYCES-CEREVISIAE; MUTANT P53; GENETIC-RECOMBINATION; TRANSACTIVATION ACTIVITY; REPLICATION FIDELITY	Our previous work (Dudenhoffer et al., 1999) unveiled a link between the capacity of p53 to regulate homologous recombination processes and to specifically bind to heteroduplex junction DNAs. Here, we show that p53 participates in ternary complex formation after preassembly of nucleoproteins, consisting of the human recombinase hRad51 and junction DNA, The cancer-related mutant p53(273H), which is defective in inhibiting recombination processes, displays a reduced capacity to associate with hRad51-DNA complexes, even under conditions which support DNA-binding, This suggests that hRad51-p53 contacts play a role in targeting p53 to heteroduplex joints and indicates an involvement in recombination immediately following hRad51-mediated strand transfer. To study the initial phase of strand exchange, when heteroduplex joints arise, we applied oligonucleotide based strand transfer assays. We observed that hRad51 stimulates exonucleolytic DNA degradation by p53, when it generates strand transfer intermediates. In agreement with this observation, artificial 3-stranded junction DNAs, designed to mimic nascent recombination intermediates, were found to represent preferred exonuclease substrates, especially when comprising a mismatch within the heteroduplex part. From our data, we propose a model according to which, p53-dependent correction of DNA exchange events is triggered by high-affinity binding to joint molecules and by stabilizing contacts with hRad51 oligomers.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Wiesmuller, L (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							Albor A, 1998, CANCER RES, V58, P2091; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Baumann P, 1997, EMBO J, V16, P5198, DOI 10.1093/emboj/16.17.5198; Baumann P, 1999, J MOL BIOL, V291, P363, DOI 10.1006/jmbi.1999.2954; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BELMAAZA A, 1994, MUTAT RES, V314, P199, DOI 10.1016/0921-8777(94)90065-5; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; Bernstein C., 1991, AGING SEX DNA REPAIR; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BRAIN R, 1994, ONCOGENE, V9, P1775; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cleaver JE, 1999, CANCER RES, V59, P1102; Cox MM, 1997, P NATL ACAD SCI USA, V94, P11764, DOI 10.1073/pnas.94.22.11764; De Zutter SK, 1999, J MOL BIOL, V293, P769, DOI 10.1006/jmbi.1999.3200; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; GAME JC, 1974, MUTAT RES, V24, P281, DOI 10.1016/0027-5107(74)90176-6; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; Grosse Frank, 1993, V16, P95; Gupta RC, 1999, MOL CELL, V4, P705, DOI 10.1016/S1097-2765(00)80381-0; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; Gupta RC, 1999, J BIOL CHEM, V274, P1248, DOI 10.1074/jbc.274.3.1248; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; HACHIYA M, 1994, ANTICANCER RES, V14, P1853; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; Janus F, 1999, MOL CELL BIOL, V19, P2155; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; Jean D, 1997, NUCLEIC ACIDS RES, V25, P4004, DOI 10.1093/nar/25.20.4004; Kanaar R, 1998, NATURE, V391, P335, DOI 10.1038/34790; Kawamura M, 1996, ONCOGENE, V12, P2361; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KUCHERLAPATI R, 1988, GENETIC RECOMBINATIO; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Lim DS, 1996, MOL CELL BIOL, V16, P7133; LIN FL, 1984, MOL CELL BIOL, V4, P1020, DOI 10.1128/MCB.4.6.1020; LIN FLM, 1990, MOL CELL BIOL, V10, P103, DOI 10.1128/MCB.10.1.103; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Namsaraev E, 1997, MOL CELL BIOL, V17, P5359, DOI 10.1128/MCB.17.9.5359; Namsaraev EA, 2000, J BIOL CHEM, V275, P3970, DOI 10.1074/jbc.275.6.3970; Namsaraev EA, 1998, BIOCHEMISTRY-US, V37, P11932, DOI 10.1021/bi9810297; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Palecek E, 1999, ONCOGENE, V18, P3617, DOI 10.1038/sj.onc.1202710; Paques F, 1997, MOL CELL BIOL, V17, P6765, DOI 10.1128/MCB.17.11.6765; PARK DJ, 1994, ONCOGENE, V9, P1899; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Prasad KAN, 1997, BIOCHEM BIOPH RES CO, V232, P14, DOI 10.1006/bbrc.1997.6212; RADDING CM, 1991, J BIOL CHEM, V266, P5355; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schneider E, 1998, ONCOGENE, V17, P2733, DOI 10.1038/sj.onc.1202504; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMITH ML, 1995, ONCOGENE, V10, P1053; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Tang W, 1999, CANCER RES, V59, P2562; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Van Dyck E, 1999, NATURE, V398, P728, DOI 10.1038/43942; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG Y, 1993, GENE DEV, V7, P2476; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; Wiesmuller L, 1996, J VIROL, V70, P737; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Xia SJJ, 1997, MOL CELL BIOL, V17, P7151, DOI 10.1128/MCB.17.12.7151; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	96	54	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2000	19	39					4500	4512		10.1038/sj.onc.1203809	http://dx.doi.org/10.1038/sj.onc.1203809			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002423				2022-12-25	WOS:000089236800007
J	Gentzsch, M; Riordan, JR				Gentzsch, M; Riordan, JR			Localization of sequences within the C-terminal domain of the cystic fibrosis transmembrane conductance regulator which impact maturation and stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-F508 CFTR; PDZ DOMAINS; CONFORMATIONAL MATURATION; CHLORIDE CHANNEL; P-GLYCOPROTEIN; PROTEIN; GENE; DEGRADATION; PROTEASOME; REQUIRES	Some disease-associated truncations within the 100-residue domain C-terminal of the second nucleotide-binding domain destabilize the mature protein (Haardt, M,, Benharouga, M,, Lechardeur, D,, Kartner, N,, and Lukacs, G;. L, (1999) J, Biol. Chem, 274, 21873-21877), We now have identified three short oligopeptide regions in the C-terminal domain which impact cystic fibrosis transmembrane conductance regulator (CFTR) maturation and stability in different ways, A highly conserved hydrophobic patch (region I) formed by residues 1413-1416 (FLVI) was found to be crucial for the stability of the mature protein. Nascent chain stability was severely decreased by shortening the protein by 81 amino acids (1400X). This accelerated degradation was sensitive to proteasome inhibitors but not influenced by brefeldin A, indicating that it occurred at the endoplasmic reticulum. The five residues at positions 1400 to 1404 (region II) normally maintain nascent CFTR stability in a positional rather than a sequence-specific manner. A third modulating region (III) constituted by residues 1390 to 1394 destabilizes the protein. Hence the nascent form regains stability on further truncation back to residues 1390 or 1380, permitting some degree of maturation and a low level of cyclic AMP-stimulated chloride channel activity at the cell surface. Thus while not absolutely essential, the C-terminal domain strongly modulates the biogenesis and maturation of CFTR.	Mayo Clin Scottsdale, SC Johnson Med Res Ctr, Mayo Fdn, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son	Riordan, JR (corresponding author), Mayo Clin Scottsdale, SC Johnson Med Res Ctr, Mayo Fdn, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.		Gentzsch, Martina/AAY-1815-2021	Lechardeur, Delphine/0000-0002-5331-4607	NIDDK NIH HHS [DK54076] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054076] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akabas MH, 2000, J BIOL CHEM, V275, P3729, DOI 10.1074/jbc.275.6.3729; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Chang XB, 1999, MOL CELL, V4, P137, DOI 10.1016/S1097-2765(00)80196-3; Chen EYJ, 2000, BIOCHEMISTRY-US, V39, P3797, DOI 10.1021/bi992620m; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Gadsby David C., 1999, Physiological Reviews, V79, pS77; Haardt M, 1999, J BIOL CHEM, V274, P21873, DOI 10.1074/jbc.274.31.21873; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Harlow E., 1988, ANTIBODIES LAB MANUA; Huang P, 2000, AM J PHYSIOL-CELL PH, V278, pC417, DOI 10.1152/ajpcell.2000.278.2.C417; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Luo JX, 1998, AM J PHYSIOL-CELL PH, V274, pC1397, DOI 10.1152/ajpcell.1998.274.5.C1397; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; Mickle JE, 1998, HUM MOL GENET, V7, P729, DOI 10.1093/hmg/7.4.729; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Naren AP, 1999, SCIENCE, V286, P544, DOI 10.1126/science.286.5439.544; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; Reddy MM, 1999, NATURE, V402, P301, DOI 10.1038/46297; RICH DP, 1993, RECEPTOR CHANNEL, V1, P221; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Seibert FS, 1997, J BIOENERG BIOMEMBR, V29, P429, DOI 10.1023/A:1022478822214; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stutts MJ, 1997, J BIOL CHEM, V272, P14037, DOI 10.1074/jbc.272.22.14037; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weixel KM, 2000, J BIOL CHEM, V275, P3655, DOI 10.1074/jbc.275.5.3655; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180; Zhang L, 1998, P NATL ACAD SCI USA, V95, P10158, DOI 10.1073/pnas.95.17.10158	43	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1291	1298		10.1074/jbc.M003672200	http://dx.doi.org/10.1074/jbc.M003672200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11022033	hybrid			2022-12-25	WOS:000166430900059
J	Vonakis, BM; Haleem-Smith, H; Benjamin, P; Metzger, H				Vonakis, BM; Haleem-Smith, H; Benjamin, P; Metzger, H			Interaction between the unphosphorylated receptor with high affinity for IgE and Lyn kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; DETERGENT-RESISTANT MEMBRANES; BASOPHILIC LEUKEMIA-CELLS; IMMUNOGLOBULIN-E RECEPTOR; PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION; T-CELL; BETA-SUBUNIT; MAST-CELLS; ACTIVATION	Chinese hamster ovary fibroblasts previously transfected with the high affinity receptor for IgE (Fc epsilon RI) were further transfected with the cu subunit of the receptor for interleukin 2 (Tac) or with chimeric constructs in which the cytoplasmic domain of Tac was replaced with the C-terminal cytoplasmic domain of either the beta subunit or the gamma subunit of Fc epsilon RI. Whereas native Tac failed to affect the aggregation-induced phosphorylation of Fc epsilon RI, both chimeric constructs substantially inhibited this reaction. Alternatively, the Fc epsilon RI-bearing fibroblasts were transfected with two chimeric constructs in which the cytoplasmic domain of Tac was replaced with a modified short form of Lyn kinase. The Lyn in both of the chimeric constructs had been mutated to remove the sites that are normally myristoylated and palmitoylated, respectively; one of the constructs had in addition been altered to be catalytically inactive. The catalytically active construct enhanced, and the inactive construct inhibited, aggregation-induced phosphorylation of the receptors. All of the chimeric constructs were largely distributed outside the detergent resistant microdomains, and whereas aggregation caused them to move to the domains in part, their aggregation was neither necessary nor enhanced their effects. These results and others indicate that the receptor and Lyn interact through protein-protein interactions that neither are dependent upon either the posttranslational modification of the kinase with lipid moieties nor result exclusively from their co-localization in specialized membrane domains.	NIAMS, Sect Chem Immunol, Arthrit & Rheumatism Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Metzger, H (corresponding author), NIAMS, Sect Chem Immunol, Arthrit & Rheumatism Branch, NIH, Bldg 10,Rm 9N-228,10 Ctr Dr,MSC-1820, Bethesda, MD 20892 USA.	metzgerh@exchange.nih.gov		Vonakis, Becky/0000-0003-4174-6514				ALBER G, 1992, J IMMUNOL, V149, P2428; Baird B, 1999, BIOPHYS CHEM, V82, P109, DOI 10.1016/S0301-4622(99)00110-6; BARCLAY AN, 1993, LEUKOCYTE ANTIGEN FA; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CHENG HC, 1991, J BIOL CHEM, V266, P17919; EISEMAN E, 1992, J BIOL CHEM, V267, P21027; EISEMAN E, 1992, NATURE, V355, P78; Field KA, 1999, J BIOL CHEM, V274, P1753, DOI 10.1074/jbc.274.3.1753; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Junghans RP, 1999, IMMUNOL TODAY, V20, P401, DOI 10.1016/S0167-5699(97)01178-X; KOVAROVA L, COMMUNICATION; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; MATTHYSSENS GE, 1975, MOL CELL BIOCHEM, V7, P119, DOI 10.1007/BF01792078; Metzger H, 1999, IMMUNOL LETT, V68, P53, DOI 10.1016/S0165-2478(99)00030-9; MINOGUCHI K, 1994, MOL IMMUNOL, V31, P519; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; Pribluda VS, 1997, J BIOL CHEM, V272, P11185; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RIVNAY B, 1982, BIOCHEMISTRY-US, V21, P6922, DOI 10.1021/bi00269a047; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; SIRAGANIAN RP, 1998, SIGNAL TRANSDUCTION, P115; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Stauffer TP, 1997, J CELL BIOL, V139, P1447, DOI 10.1083/jcb.139.6.1447; Torigoe C, 1997, P NATL ACAD SCI USA, V94, P1372, DOI 10.1073/pnas.94.4.1372; van't Hof W, 1999, J CELL BIOL, V145, P377, DOI 10.1083/jcb.145.2.377; Vonakis BM, 1997, J BIOL CHEM, V272, P24072, DOI 10.1074/jbc.272.38.24072; WILSON BS, 1995, J BIOL CHEM, V270, P4013, DOI 10.1074/jbc.270.8.4013; Wofsy C, 1999, P NATL ACAD SCI USA, V96, P8615, DOI 10.1073/pnas.96.15.8615; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251; YAMASHITA T, UNPUB	38	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1041	1050		10.1074/jbc.M003397200	http://dx.doi.org/10.1074/jbc.M003397200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11010962	hybrid			2022-12-25	WOS:000166430900026
J	Hauck, CR; Hsia, DA; Schlaepfer, DD				Hauck, CR; Hsia, DA; Schlaepfer, DD			Focal adhesion kinase facilitates platelet-derived growth factor-BB-stimulated ERK2 activation required for chemotaxis migration of vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE SHP-2; C-TERMINAL DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; NEOINTIMA FORMATION; PROTEIN-KINASE; INTEGRIN; FAK; SRC; PHOSPHORYLATION; INHIBITION	The focal adhesion (FAK) non-receptor protein-tyrosine kinase (PTR) links both extracellular matrix/integrin and growth factor stimulation to intracellular signals promoting cell migration. Here we show that both transient and stable overexpression of the FAR C-terminal domain termed FRNK (FAK-related non-kinase) inhibits serum and platelet-derived growth factor (PDGF)HE-induced vascular smooth muscle cell (SMC) migration in wound healing and in vitro Boyden Chamber chemotaxis assays, respectively. Expression of FRNK, but not a point mutant of FRNK (FRNK L1034S), disrupted the formation of a complex containing both FAK and the activated PDGF-beta receptor and resulted in reduced tyrosine phosphorylation of endogenous FAK at the Tyr-397 binding site for Src family PTKs. As demonstrated using:FAK-deficient and FAR-reconstituted fibroblasts, FAK positively contributed to PDGF-BB-stimulated ERK2/MAP kinase activity, and in SMCs, ERR2/MAP kinase activity was required for PDGF-BB-stimulated chemotaxis, Stable expression of FRNK but not FRNK L1034S expression in SMCs lowered the extent and duration of stimulated ERK2/MAP kinase activation at low but not at high PDGF-BB concentrations. Importantly, stable expression of FRNK in SMCs did not affect SMC morphology or proliferation in culture. Because the increased migration of vascular SMCs in response to extracellular matrix proteins and growth factors contributes to neointima formation, our results show that FAR inhibition by FRNK expression may provide a novel approach to regulate abnormal vascular SMC migration in vivo.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Schlaepfer, DD (corresponding author), Scripps Res Inst, Dept Immunol, IMM-26,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [CA75240] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075240, R29CA075240] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andres V, 1998, INT J MOL MED, V2, P81; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cospedal R, 1999, CARDIOVASC RES, V41, P708, DOI 10.1016/S0008-6363(98)00232-6; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Gotwals PJ, 1996, J CLIN INVEST, V97, P2469, DOI 10.1172/JCI118693; Graf BM, 1997, J CARDIOVASC PHARM, V29, P1, DOI 10.1097/00005344-199701000-00001; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; HANKE H, 1990, CIRC RES, V67, P651, DOI 10.1161/01.RES.67.3.651; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Lai JF, 2000, J BIOL CHEM, V275, P7474, DOI 10.1074/jbc.275.11.7474; Manes S, 1999, MOL CELL BIOL, V19, P3125; MATSUNO H, 1994, CIRCULATION, V90, P2203, DOI 10.1161/01.CIR.90.5.2203; Nolan K, 1999, MOL CELL BIOL, V19, P6120; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Qi JH, 1999, J BIOL CHEM, V274, P14455, DOI 10.1074/jbc.274.20.14455; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Rutherford C, 1997, ATHEROSCLEROSIS, V130, P45, DOI 10.1016/S0021-9150(96)06042-X; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Waltenberger J, 1999, CIRC RES, V85, P12; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; Zheng DQ, 1999, CANCER RES, V59, P1655	43	98	107	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41092	41099		10.1074/jbc.M005450200	http://dx.doi.org/10.1074/jbc.M005450200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10998418	hybrid, Green Published			2022-12-25	WOS:000166114600059
J	Jayaraman, L; Massague, J				Jayaraman, L; Massague, J			Distinct oligomeric states of SMAD proteins in the transforming growth factor-beta pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVATION; SMAD4/DPC4; GENE; PROMOTER; DNA; COACTIVATORS; ONCOPROTEIN; CBP/P300; RECEPTOR	Protein interactions are critical for the function of SMADs as mediators of transforming growth factor-beta (TGF-beta) signals. TGF-beta receptor phosphorylation of SMAD2 or SMAD3 causes their association with SMAD4 and accumulation in the nucleus where the SMAD complex binds cofactors that determine the choice of target genes. We provide evidence that in the basal state, SMADs 2, 3, and 4 form separate, strikingly different complexes. SMAD2 is found mostly as monomer, whereas the closely related SMAD3 exists in multiple oligomeric states. This difference is due to a unique structural element in the MH1 domain of SMAD2 that inhibits protein-protein interactions in the basal state. In contrast to SMAD2 and SMAD3, SMAD4 in the basal state is found mostly as a homo-oligomer, most likely a trimer. Upon cell stimulation with TGF-beta, SMAD proteins become engaged in a multitude of complexes ranging in size from SMAD2-SMAD4 heterodimers to assemblies of >650 kDa, The latter display the highest DNA binding affinity for the TGF-beta -response elements of JUNB and collagen 7. These observations, all validated with endogenous SMAD proteins, modify previous models regarding the assembly and activity of SMAD complexes in the TGF-beta pathway.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave,Box 116, New York, NY 10021 USA.			Massague, Joan/0000-0001-9324-8408				Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Germain S, 2000, GENE DEV, V14, P435; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Takenoshita S, 1998, GENOMICS, V48, P1, DOI 10.1006/geno.1997.5149; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	33	95	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40710	40717		10.1074/jbc.M005799200	http://dx.doi.org/10.1074/jbc.M005799200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018029	hybrid			2022-12-25	WOS:000166114600009
J	Yamakura, T; Borghese, C; Harris, RA				Yamakura, T; Borghese, C; Harris, RA			A transmembrane site determines sensitivity of neuronal nicotinic acetylcholine receptors to general anesthetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; GLYCINE RECEPTORS; XENOPUS OOCYTES; BETA-SUBUNIT; M2 SEGMENT; IDENTIFICATION; CONTRIBUTE; ISOFLURANE; DIVERSITY; REGIONS	Neuronal nicotinic acetylcholine receptors (nAChRs) are potential targets for a wide variety of general anesthetics. We recently showed that alpha (4)beta (2) nAChRS are more sensitive than alpha (4)beta (4) receptors to the gaseous anesthetics nitrous oxide and xenon. The present study examines chimeric and point mutant rat nAChRs expressed in Xenopus oocytes and identifies a single amino acid residue (beta (2)-Val(253) or beta (4)-Phe(255)) near the middle of the second transmembrane segment (TM2) that determines gaseous anesthetic sensitivity. Mutations of this residue in beta subunits and the homologous residue of alpha (4) subunits (alpha (4)-Val(254)) showed that this position also determines sensitivities of nAChRs to acetylcholine, isoflurane, pentobarbital, and hexanol, In contrast, these mutations did not affect actions of ketamine, The positively charged sulfhydryl-specific reagent methanethiosulfonate ethylammonium reacted with a cysteine introduced at alpha (4)-Val(254) or beta (2)-Val(258), and irreversibly reduced anesthetic sensitivities of nAChRs, Propyl methanethiosulfonate is an anesthetic analog that covalently binds to a TM2 site of gamma -aminobutyric acid, and glycine receptors and irreversibly enhances receptor function. However, propyl methanethiosulfonate reversibly inhibited cysteine-substitution mutants at alpha (4)-Val(254) or beta (2)-Val(253) of nAChRs, and did not affect anesthetic sensitivity. Thus, residues alpha (4)-Val(254) and beta (2)-Val(253) alter channel gating and determine anesthetic sensitivity of nAChRs, but are not likely to be anesthetic-binding sites.	Univ Texas, Inst Cellular & Mol Biol, Austin, TX 78712 USA; Univ Texas, Waggoner Ctr Alcohol & Addict Res, Austin, TX 78712 USA; Niigata Univ, Sch Med, Dept Anesthesiol, Niigata 9518510, Japan	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Niigata University	Harris, RA (corresponding author), Univ Texas, Inst Cellular & Mol Biol, 2500 Speedway,MBB 1-124, Austin, TX 78712 USA.			Borghese, Cecilia/0000-0002-1028-8277	NIAAA NIH HHS [AA06399] Funding Source: Medline; NIGMS NIH HHS [GM47818] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA006399, R01AA006399] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; ALIFIMOFF JK, 1989, BRIT J PHARMACOL, V96, P9, DOI 10.1111/j.1476-5381.1989.tb11777.x; Cardoso RA, 1999, ANESTHESIOLOGY, V91, P1370, DOI 10.1097/00000542-199911000-00029; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; DENERIS ES, 1988, NEURON, V1, P45, DOI 10.1016/0896-6273(88)90208-5; DildyMayfield JE, 1996, J PHARMACOL EXP THER, V276, P1058; DUVOISIN RM, 1989, NEURON, V3, P487, DOI 10.1016/0896-6273(89)90207-9; FIGL A, 1992, FEBS LETT, V308, P245, DOI 10.1016/0014-5793(92)81284-S; FIRESTONE LL, 1986, MOL CELLULAR MECH AN, P455; Flood P, 1997, ANESTHESIOLOGY, V86, P859, DOI 10.1097/00000542-199704000-00016; Forman SA, 1997, BIOPHYS J, V72, P2170, DOI 10.1016/S0006-3495(97)78860-X; FORMAN SA, 1995, MOL PHARMACOL, V48, P574; Francis MM, 2000, MOL PHARMACOL, V58, P109, DOI 10.1124/mol.58.1.109; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; GALZI JL, 1995, NEUROPHARMACOLOGY, V34, P563, DOI 10.1016/0028-3908(95)00034-4; GOLDMAN D, 1987, CELL, V48, P965, DOI 10.1016/0092-8674(87)90705-7; Gotti C, 1997, PROG NEUROBIOL, V53, P199, DOI 10.1016/S0301-0082(97)00034-8; Husain SS, 1999, J MED CHEM, V42, P3300, DOI 10.1021/jm9806300; Koltchine VV, 1999, MOL PHARMACOL, V56, P1087, DOI 10.1124/mol.56.5.1087; Krasowski MD, 1999, CELL MOL LIFE SCI, V55, P1278, DOI 10.1007/s000180050371; Mascia MP, 2000, P NATL ACAD SCI USA, V97, P9305, DOI 10.1073/pnas.160128797; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Pratt MB, 2000, J BIOL CHEM, V275, P29441, DOI 10.1074/jbc.M004710200; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; Stafford GA, 1998, J PHARMACOL EXP THER, V286, P619; Violet JM, 1997, ANESTHESIOLOGY, V86, P866, DOI 10.1097/00000542-199704000-00017; Yamakura T, 2000, ANESTHESIOLOGY, V92, P1144, DOI 10.1097/00000542-200004000-00033; Yamakura T, 1999, J BIOL CHEM, V274, P23006, DOI 10.1074/jbc.274.33.23006; Yamakura T, 2000, ANESTHESIOLOGY, V93, P1095, DOI 10.1097/00000542-200010000-00034; Zhang H, 1998, BIOCHEMISTRY-US, V37, P7952, DOI 10.1021/bi980143m; Zhang L, 1997, BRIT J PHARMACOL, V120, P353, DOI 10.1038/sj.bjp.0700934; Zoli M, 1998, J NEUROSCI, V18, P4461	33	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40879	40886		10.1074/jbc.M005771200	http://dx.doi.org/10.1074/jbc.M005771200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11020384	hybrid			2022-12-25	WOS:000166114600030
J	Leinweber, B; Parissenti, AM; Gallant, C; Gangopadhyay, SS; Kirwan-Rhude, A; Leavis, PC; Morgan, KG				Leinweber, B; Parissenti, AM; Gallant, C; Gangopadhyay, SS; Kirwan-Rhude, A; Leavis, PC; Morgan, KG			Regulation of protein kinase C by the cytoskeletal protein calponin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALPONIN; ACTIN-BINDING; SELECTIVE BINDING; MOLECULAR-CLONING; ACTIVATION; EPSILON; DOMAIN; IDENTIFICATION; PHOSPHOLIPIDS; REQUIREMENTS	Previous studies from this laboratory have shown that, upon agonist activation, calponin co-immunoprecipitates and co-localizes with protein kinase CE (PKC epsilon) in vascular smooth muscle cells. In the present study we demonstrate that calponin binds directly to the regulatory domain of PKC both in overlay assays and, under native conditions, by sedimentation with lipid vesicles. Calponin was found to bind to the Ca region of both PKC epsilon and PKC alpha with possible involvement of C1B. The C2 region of PKC epsilon binds to the calponin repeats with a requirement for the region between amino acids 160 and 182. We have also found that calponin can directly activate PKC autophosphorylation. By using anti-phospho-antibodies to residue Ser-660 of PKC beta II, we found that calponin, in a lipid-independent manner, increased auto-phosphorylation of PKCa, -epsilon, and -beta II severalfold compared with control conditions. Similarly, calponin was found to increase the amount of P-32-labeled phosphate incorporated into PKC from [gamma-P-32]ATP. We also observed that calponin addition strongly increased the incorporation of radiolabeled phosphate into an exogenous PKC peptide substrate, suggesting an activation of enzyme activity. Thus, these results raise the possibility that calponin may function in smooth muscle to regulate PKC activity by facilitating the phosphorylation of PRC.	Boston Biomed Res Inst, Watertown, MA 02472 USA; Northeastern Ontario Reg Canc Ctr, Sudbury, ON P3E 5J1, Canada; Tufts Univ, Grad Sch Biomed Sci, Dept Physiol, Boston, MA 02111 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Boston Biomedical Research Institute; Tufts University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Morgan, KG (corresponding author), Boston Biomed Res Inst, 64 Grove St, Watertown, MA 02472 USA.	morgan@bbri.org		Morgan, Kathleen/0000-0003-3300-3630	NHLBI NIH HHS [HL42293, HL31704, HL10026] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042293, R01HL031704] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE M, 1990, J BIOCHEM-TOKYO, V108, P835, DOI 10.1093/oxfordjournals.jbchem.a123289; Andrea JE, 1998, FEBS LETT, V429, P73, DOI 10.1016/S0014-5793(98)00567-5; Banuelos S, 1998, STRUCTURE, V6, P1419, DOI 10.1016/S0969-2126(98)00141-5; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BOGATCHEVA NV, 1995, FEBS LETT, V371, P123, DOI 10.1016/0014-5793(95)00868-A; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; Dessy C, 1998, AM J PHYSIOL-CELL PH, V275, pC1081, DOI 10.1152/ajpcell.1998.275.4.C1081; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; FUJII T, 1995, J BIOCHEM-TOKYO, V117, P999, DOI 10.1093/oxfordjournals.jbchem.a124833; Gimona M, 1998, J CELL SCI, V111, P1813; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; Horowitz A, 1996, PHYSIOL REV, V76, P967, DOI 10.1152/physrev.1996.76.4.967; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Le YH, 1999, J PHYSIOL-LONDON, V517, P709, DOI 10.1111/j.1469-7793.1999.0709s.x; Leinweber BD, 1999, BIOCHEM J, V344, P117, DOI 10.1042/0264-6021:3440117; LEVENTHAL PS, 1993, J BIOL CHEM, V268, P13906; Masuda H, 1996, J BIOCHEM-TOKYO, V120, P415; Menice CB, 1997, J BIOL CHEM, V272, P25157, DOI 10.1074/jbc.272.40.25157; MEZGUELDI M, 1992, J BIOL CHEM, V267, P15943; Mino T, 1998, EUR J BIOCHEM, V251, P262, DOI 10.1046/j.1432-1327.1998.2510262.x; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; ORR JW, 1994, J BIOL CHEM, V269, P27715; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Parissenti AM, 1998, J BIOL CHEM, V273, P8940, DOI 10.1074/jbc.273.15.8940; Parissenti AM, 1996, J CELL PHYSIOL, V166, P609, DOI 10.1002/(SICI)1097-4652(199603)166:3<609::AID-JCP16>3.0.CO;2-1; PARKER CA, 1994, AM J PHYSIOL-CELL PH, V267, pC1262, DOI 10.1152/ajpcell.1994.267.5.C1262; Parker CA, 1998, J PHYSIOL-LONDON, V508, P187, DOI 10.1111/j.1469-7793.1998.187br.x; Prekeris R, 1998, J BIOL CHEM, V273, P26790, DOI 10.1074/jbc.273.41.26790; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; STAFFORD WF, 1995, J BIOL CHEM, V270, P10576, DOI 10.1074/jbc.270.18.10576; TAKAHASHI K, 1991, J BIOL CHEM, V266, P13284; WILLS FL, 1993, BIOCHEMISTRY-US, V32, P2321, DOI 10.1021/bi00060a025; WINDER SJ, 1993, CELL SIGNAL, V5, P677, DOI 10.1016/0898-6568(93)90029-L; Winder SJ, 1998, ACTA PHYSIOL SCAND, V164, P415, DOI 10.1111/j.1365-201X.1998.tb10697.x	42	55	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40329	40336		10.1074/jbc.M008257200	http://dx.doi.org/10.1074/jbc.M008257200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11006297	hybrid			2022-12-25	WOS:000166039500073
J	Prakobphol, A; Xu, F; Hoang, VM; Larsson, T; Bergstrom, J; Johansson, I; Frangsmyr, L; Holmskov, U; Leffler, H; Nilsson, C; Boren, T; Wright, JR; Stromberg, N; Fisher, SJ				Prakobphol, A; Xu, F; Hoang, VM; Larsson, T; Bergstrom, J; Johansson, I; Frangsmyr, L; Holmskov, U; Leffler, H; Nilsson, C; Boren, T; Wright, JR; Stromberg, N; Fisher, SJ			Salivary agglutinin, which binds Streptococcus mutans and Helicobacter pylori, is the lung scavenger receptor cysteine-rich protein gp-340	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP ANTIGENS; MEDIATED ADHERENCE; ORAL STREPTOCOCCI; MONOCLONAL-ANTIBODIES; ARTIFICIAL SALIVAS; PROMOTES ADHESION; HUMAN-ENAMEL; MUCIN; GLYCOPROTEIN; HYDROXYAPATITE	Salivary agglutinin is a high molecular mass component of human saliva that binds Streptococcus mutans, an oral bacterium implicated in dental caries. To study its protein sequence, we isolated the agglutinin from human parotid saliva. After trypsin digestion, a portion was analyzed by matrix-assisted laser/desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS), which gave the molecular mass of 14 unique peptides. The remainder of the digest was subjected to high performance liquid chromatography, and the separated peptides were analyzed by MALDI-TOF/post-source decay; the spectra gave the sequences of five peptides. The molecular mass and peptide sequence information showed that salivary agglutinin peptides were identical to sequences in lung (lavage) gp-340, a member of the scavenger receptor cysteine-rich protein family. Immunoblotting with antibodies that specifically recognized either lung gp-340 or the agglutinin confirmed that the salivary agglutinin was gp-340. Immunoblotting with an antibody specific to the sialyl Le(X) carbohydrate epitope detected expression on the salivary but not the lung glycoprotein, possible evidence of different glycoforms. The salivary agglutinin also interacted with Helicobacter pylori, implicated in gastritis and peptic ulcer disease, Streptococcus agalactiae, implicated in neonatal meningitis, and several oral commensal streptococci. These results identify the salivary agglutinin as gp-340 and suggest it binds bacteria that are important determinants of either the oral ecology or systemic diseases.	Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA; Umea Univ, Dept Odontol Cardiol & Oral Microbiol, SE-90187 Umea, Sweden; Odense Univ, Med Biol Inst, Dept Med Microbiol, DK-5000 Odense C, Denmark; Univ Gothenburg, Dept Biochem Med, SE-41390 Gothenburg, Sweden; Lund Univ, Dept Mol Med, SE-22100 Lund, Sweden; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Umea University; University of Southern Denmark; University of Gothenburg; Lund University; Duke University	Fisher, SJ (corresponding author), Univ Calif San Francisco, Dept Stomatol, HSW 604, San Francisco, CA 94143 USA.	sfisher@cgl.ucsf.edu	Holmskov, Uffe/AAA-3056-2022; Abrams, William R/A-5782-2008; Leffler, Hakon/A-2416-2019	Holmskov, Uffe/0000-0002-2391-9445; Leffler, Hakon/0000-0003-4482-8945	NCRR NIH HHS [RR01614] Funding Source: Medline; NHLBI NIH HHS [HL51134] Funding Source: Medline; NIDCR NIH HHS [DE07244] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE007244, R37DE007244] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aguirre A, 1989, Dysphagia, V4, P95, DOI 10.1007/BF02407152; ALHASHIMI I, 1989, ARCH ORAL BIOL, V34, P289, DOI 10.1016/0003-9969(89)90070-8; AZEN EA, 1988, ADV HUM GENET, V17, P141; BENNICK A, 1983, ARCH ORAL BIOL, V28, P19, DOI 10.1016/0003-9969(83)90022-5; Blaser MJ, 1997, J CLIN INVEST, V100, P759, DOI 10.1172/JCI119588; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; BRADY LJ, 1992, INFECT IMMUN, V60, P1008, DOI 10.1128/IAI.60.3.1008-1017.1992; Bratt P, 1999, J DENT RES, V78, P1238, DOI 10.1177/00220345990780060701; Carlen A, 1996, ARCH ORAL BIOL, V41, P1133, DOI 10.1016/S0003-9969(96)00094-5; CARLEN A, 1995, J DENT RES, V74, P1040, DOI 10.1177/00220345950740040301; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Dunn BE, 1997, CLIN MICROBIOL REV, V10, P720, DOI 10.1128/CMR.10.4.720; EMILSON CG, 1989, ARCH ORAL BIOL, V34, P335, DOI 10.1016/0003-9969(89)90106-4; ERICSON T, 1983, EUR J BIOCHEM, V133, P255, DOI 10.1111/j.1432-1033.1983.tb07456.x; FISHER SJ, 1987, ARCH ORAL BIOL, V32, P509, DOI 10.1016/S0003-9969(87)80013-4; GANS RF, 1990, ARCH ORAL BIOL, V35, P487, DOI 10.1016/0003-9969(90)90077-N; GILLECECASTRO BL, 1991, J BIOL CHEM, V266, P17358; Groenink J, 1996, ANTON LEEUW INT J G, V70, P79, DOI 10.1007/BF00393572; HATTON MN, 1985, BIOCHEM J, V230, P817, DOI 10.1042/bj2300817; Holmskov U, 1999, P NATL ACAD SCI USA, V96, P10794, DOI 10.1073/pnas.96.19.10794; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; KISHIMOTO E, 1989, INFECT IMMUN, V57, P3702, DOI 10.1128/IAI.57.12.3702-3707.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMONT RJ, 1991, INFECT IMMUN, V59, P3446, DOI 10.1128/IAI.59.10.3446-3450.1991; LENANDERLUMIKARI M, 1992, CARIES RES, V26, P371, DOI 10.1159/000261471; LEVINE MJ, 1993, CRIT REV ORAL BIOL M, V4, P279, DOI 10.1177/10454411930040030401; LEVINE MJ, 1987, J DENT RES, V66, P693, DOI 10.1177/00220345870660S215; MAGNUSSON I, 1976, CARIES RES, V10, P113, DOI 10.1159/000260195; MANDEL ID, 1987, J DENT RES, V66, P623, DOI 10.1177/00220345870660S203; MARSHALL BJ, 1984, LANCET, V1, P1311; MELLERSH A, 1979, BRIT J VENER DIS, V55, P20; Miyabayashi H, 2000, HELICOBACTER, V5, P30, DOI 10.1046/j.1523-5378.2000.00004.x; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; MURRAY PA, 1992, INFECT IMMUN, V60, P31, DOI 10.1128/IAI.60.1.31-38.1992; Nagashunmugam T, 1998, J INFECT DIS, V178, P1635, DOI 10.1086/314511; OBENAUF SD, 1986, INFECT IMMUN, V51, P440, DOI 10.1128/IAI.51.2.440-444.1986; Oho T, 1998, INFECT IMMUN, V66, P115, DOI 10.1128/IAI.66.1.115-121.1998; Prakobphol A, 1998, BIOCHEMISTRY-US, V37, P4916, DOI 10.1021/bi972612a; Prakobphol A, 1999, BIOCHEMISTRY-US, V38, P6817, DOI 10.1021/bi990145m; PRAKOBPHOL A, 1993, CRIT REV ORAL BIOL M, V4, P325, DOI 10.1177/10454411930040031001; SCANNAPIECO FA, 1995, J DENT RES, V74, P1360, DOI 10.1177/00220345950740070701; Spahr H, 2000, J BIOL CHEM, V275, P1351, DOI 10.1074/jbc.275.2.1351; STENUDD CD, 1999, THESIS UMEA U UMEA S; Takano K., 1992, Okajimas Folia Anatomica Japonica, V69, P225; Tenovuo J, 1992, J Biol Buccale, V20, P85; Tino MJ, 1999, AM J RESP CELL MOL, V20, P759, DOI 10.1165/ajrcmb.20.4.3439; VANDERSPEK JC, 1989, AM J HUM GENET, V45, P381	48	186	191	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39860	39866		10.1074/jbc.M006928200	http://dx.doi.org/10.1074/jbc.M006928200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007786	hybrid			2022-12-25	WOS:000166039500012
J	Foryst-Ludwig, A; Naumann, M				Foryst-Ludwig, A; Naumann, M			p21-activated kinase 1 activates the nuclear factor kappa B (NF-kappa B)-inducing kinase-I kappa B kinases NF-kappa B pathway and proinflammatory cytokines in Helicobacter pylori infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC EPITHELIAL-CELLS; PATHOGENICITY ISLAND; CAGA PROTEIN; IKK-GAMMA; INDUCTION; ALPHA; PAK; PHOSPHORYLATION; COSTIMULATION; TRANSLOCATION	Helicobacter pylori, the causative agent of several human gastric diseases, induces activation of the immediate early response transcription factor nuclear factor kappaB (NF-kappaB), which subsequently triggers release of proinflammatory cytokines in colonized epithelial cells. Here we report that in H. pylori infection p21-activated kinase 1 (PAK1) activates NF-kappaB. Activated PAK1 associates with NF-kappaB-inducing kinase, which upon activation directs the activity of I kappaB kinases to I kappaB alpha. Our results indicate that in epithelial cells PAK1 participates in a unique pathway that links H. pylori dependent effector molecules to the activation of NF-kappaB and the induction of the innate immune response.	Max Planck Inst Infektionsbiol, Mol Biol Abt, D-10117 Berlin, Germany	Max Planck Society	Naumann, M (corresponding author), Max Planck Inst Infektionsbiol, Mol Biol Abt, Schumannstr 21-22, D-10117 Berlin, Germany.	naumann@mpiib-berlin.mpg.de	Naumann, Michael/B-5285-2011	Naumann, Michael/0000-0002-8060-2313				Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; BLASER MJ, 1987, GASTROENTEROLOGY, V93, P371, DOI 10.1016/0016-5085(87)91028-6; Bodger K, 1998, BRIT MED BULL, V54, P139; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Fackler OT, 2000, MOL CELL BIOL, V20, P2619, DOI 10.1128/MCB.20.7.2619-2627.2000; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Garceau N, 2000, J EXP MED, V191, P381, DOI 10.1084/jem.191.2.381; Glocker E, 1998, INFECT IMMUN, V66, P2346, DOI 10.1128/IAI.66.5.2346-2348.1998; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Naumann M, 1999, J BIOL CHEM, V274, P31655, DOI 10.1074/jbc.274.44.31655; Naumann M, 2000, BIOCHEM PHARMACOL, V60, P1109, DOI 10.1016/S0006-2952(00)00390-7; Naumann M, 1997, J EXP MED, V186, P247, DOI 10.1084/jem.186.2.247; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Tuazon PT, 1997, BIOCHEMISTRY-US, V36, P16059, DOI 10.1021/bi9717845; Wessler S, 2000, J BIOL CHEM, V275, P3629, DOI 10.1074/jbc.275.5.3629; Wu CL, 1996, J BIOL CHEM, V271, P31787, DOI 10.1074/jbc.271.50.31787; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	50	90	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39779	39785		10.1074/jbc.M007617200	http://dx.doi.org/10.1074/jbc.M007617200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11016939	hybrid			2022-12-25	WOS:000165953100110
J	Lancaster, CRD; Bibikova, MV; Sabatino, P; Oesterhelt, D; Michel, H				Lancaster, CRD; Bibikova, MV; Sabatino, P; Oesterhelt, D; Michel, H			Structural basis of the drastically increased initial electron transfer rate in the reaction center from a Rhodopseudomonas viridis mutant described at 2.00-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION-CENTER; MEMBRANE-PROTEIN COMPLEX; CRYSTAL-STRUCTURES; CHARGE SEPARATION; PURPLE BACTERIA; MODEL; SPECTROSCOPY; MOLSCRIPT; REFINEMENT; QUINONE	It has previously been shown that replacement of the residue His L168 with Phe (HL168F) in the Rhodopseudomonas viridis reaction center (RC) leads to an unprecedented drastic acceleration of the initial electron transfer rate. Here we describe the determination of the x-ray crystal structure at 2.00-Angstrom resolution of the HL168F RC. The electron density maps confirm that a hydrogen bond from the protein to the special pair is removed by this mutation. Compared with the wild-type RC, the acceptor of this hydrogen bond, the ring I acetyl group of the "special pair" bacteriochlorophyll, D-L, is rotated, and its acetyl oxygen is found 1.1 Angstrom closer to the bacteriochlorophyll-Mg2+ Of the other special pair bacteriochlorophyll, D-M. The rotation of this acetyl group and the increased interaction between the D-L ring I acetyl oxygen and the D-M-Mg2+ provide the structural basis for the previously observed 80-mV decrease in the D+/D redox potential and the drastically increased rate of initial electron transfer to the accessory bacteriochlorophyll, B-A The high quality of the electron density maps also allowed a reliable discussion of the mode of binding of the triazine herbicide terbutryn at the binding site of the secondary quinone, Q(B).	Max Planck Inst Biophys, Abt Mol Membranbiol, D-60528 Frankfurt, Germany; Max Planck Inst Biochem, Abt Membranbiochem, D-82152 Martinsried, Germany	Max Planck Society; Max Planck Society	Lancaster, CRD (corresponding author), Max Planck Inst Biophys, Abt Mol Membranbiol, Heinrich Hoffmann Str 7, D-60528 Frankfurt, Germany.	Roy.Lancaster@mpibp-frankfurt.mpg.de	Lancaster, C. Roy/E-4313-2010	Lancaster, C. Roy D./0000-0002-2814-0051				Arlt T, 1996, J PHYS CHEM-US, V100, P12060, DOI 10.1021/jp960699o; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BIXON M, 1991, BIOCHIM BIOPHYS ACTA, V1056, P301, DOI 10.1016/S0005-2728(05)80062-3; BLANKENSHIP RE, 1995, ANOXYGENIC PHOTOSYNT; Bowyer J. R., 1991, Herbicides., P27; Breton J, 1998, PHOTOSYNTH RES, V55, P117; BRETON J, 1986, P NATL ACAD SCI USA, V83, P5121, DOI 10.1073/pnas.83.14.5121; BRUNGER AT, 1991, ANNU REV PHYS CHEM, V42, P197, DOI 10.1146/annurev.pc.42.100191.001213; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V726, P149, DOI 10.1016/0304-4173(83)90004-6; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x; DEISENHOFER J, 1995, J MOL BIOL, V246, P429, DOI 10.1006/jmbi.1994.0097; DEISENHOFER J, 1984, J MOL BIOL, V180, P385, DOI 10.1016/S0022-2836(84)80011-X; DRESSLER K, 1991, CHEM PHYS LETT, V183, P270, DOI 10.1016/0009-2614(91)80062-3; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; HEARST JE, 1986, PHOTOSYNTHESIS, V3, P382; Hiraishi A, 1997, INT J SYST BACTERIOL, V47, P217, DOI 10.1099/00207713-47-1-217; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; Hoff AJ, 1997, PHYS REP, V287, P1, DOI 10.1016/S0370-1573(97)00004-5; JEFFREY GA, 1991, HYDROGEN BONDING BIO, P372; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KNAFF DB, 1993, PHOTOSYNTH RES, V35, P117, DOI 10.1007/BF00014743; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lancaster C. R. D., 1995, ANOXYGENIC PHOTOSYNT, P503; Lancaster CRD, 1999, J MOL BIOL, V286, P883, DOI 10.1006/jmbi.1998.2532; Lancaster CRD, 1997, STRUCTURE, V5, P1339, DOI 10.1016/S0969-2126(97)00285-2; Lancaster CRD, 1996, BIOPHYS J, V70, P2469, DOI 10.1016/S0006-3495(96)79820-X; Lancaster CRD, 1998, BBA-BIOENERGETICS, V1365, P143; MCPHERSON PH, 1990, BIOCHIM BIOPHYS ACTA, V1016, P289, DOI 10.1016/0005-2728(90)90071-B; MEYER E, 1992, PROTEIN SCI, V1, P1543, DOI 10.1002/pro.5560011203; Meyer TE, 1995, ANOXYGENIC PHOTOSYNT, P725; MICHEL H, 1985, EMBO J, V4, P1667, DOI 10.1002/j.1460-2075.1985.tb03835.x; MICHEL H, 1982, J MOL BIOL, V158, P567, DOI 10.1016/0022-2836(82)90216-9; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MICHEL H, 1986, ENCY PLANT PHYSL PHO, V19, P371; Michel-Beyerle M. E., 1996, REACTION CTR PHOTOSY; MITCHELL P, 1979, SCIENCE, V206, P1148, DOI 10.1126/science.388618; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parson William W., 1996, P125; Percival M. P., 1991, Herbicides., P1; SINNING I, 1989, BIOCHEMISTRY-US, V28, P5544, DOI 10.1021/bi00439a031; Sinning I, 1990, REACTION CTR PHOTOSY, P199; THORNBER JP, 1980, BIOCHIM BIOPHYS ACTA, V593, P60, DOI 10.1016/0005-2728(80)90008-0; TREBST A, 1986, Z NATURFORSCH C, V41, P240; TREBST A, 1987, Z NATURFORSCH C, V42, P742; WILLIAMS JC, 1992, BIOCHEMISTRY-US, V31, P11029, DOI 10.1021/bi00160a012; Woodbury NW, 1995, ANOXYGENIC PHOTOSYNT, P527, DOI [DOI 10.1007/0-306-47954-0_24, 10.1007/0-306-47954-0_24]; WRAIGHT CA, 1982, FUNCTIONS QUINONES E, P181; Zinth W, 1998, PHILOS T R SOC A, V356, P465, DOI 10.1098/rsta.1998.0176	55	59	64	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39364	39368		10.1074/jbc.M008225200	http://dx.doi.org/10.1074/jbc.M008225200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11005826	hybrid			2022-12-25	WOS:000165953100059
J	Marron, MB; Hughes, DP; Edge, MD; Forder, CL; Brindle, NPJ				Marron, MB; Hughes, DP; Edge, MD; Forder, CL; Brindle, NPJ			Evidence for heterotypic interaction between the receptor tyrosine kinases TIE-1 and TIE-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; VASCULAR ENDOTHELIAL-CELLS; MOLECULAR-CLONING; SURFACE-RECEPTOR; SOLUBLE TIE; PROTEIN; EXPRESSION; ANGIOPOIETIN-1; ANGIOGENESIS; SURVIVAL	The orphan receptor tyrosine kinase Tie-1 is expressed in endothelial cells and is essential for vascular development, Nothing is known about the signaling pathways utilized by this receptor. In this study we have used chimeric receptors composed of the TrkA ectodomain fused to the transmembrane and intracellular domains of Tie-1, or the related receptor Tie-2, to examine Tie-1 signaling capacity. In contrast to TrkA/Tie-2, the Tie-1 chimera was unable to phosphorylate cellular proteins or undergo autophosphorylation, Consistent with this Tie-1 exhibited negligible kinase activity, Co-immunoprecipitation analysis revealed Tie-1 was present in endothelial cells bound to Tie-2, Full-length Tie-1 and truncated receptor, formed by regulated endoproteolytic cleavage, were found to complex with Tie-2. Association was mediated by the intracellular domains of the receptors and did not require Tie-1 to be membrane-localized, Tie-1 bound to Tie-2 was not tyrosine-phosphorylated under basal conditions or following Tie-2 stimulation. This study provides the first evidence for the existence of a pre-formed complex of Tie-1 and Tie-2 in endothelial cells. The data suggest Tie-1 does not signal via ligand-induced kinase activation involving homo-oligomerization. The physical association between Tie-1 and Tie-2 is consistent with Tie-1 having a role in modulating Tie-2 signaling.	Univ Leicester, RKCSB, Dept Surg, Leicester LE2 7LX, Leics, England; AstraZeneca, Canc & Infect Biosci Dept, Macclesfield SK10 4TG, Cheshire, England	University of Leicester; AstraZeneca	Brindle, NPJ (corresponding author), Univ Leicester, RKCSB, Dept Surg, POB 65, Leicester LE2 7LX, Leics, England.	npjb1@leicester.ac.uk		Brindle, Nicholas/0000-0002-4221-677X				BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1993, ONCOGENE, V8, P1293; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; DUMONT DJ, 1992, ONCOGENE, V7, P71; Glazebrook H, 1998, J VASC RES, V35, P143, DOI 10.1159/000025577; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HACK N, 1993, J BIOL CHEM, V268, P26441; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hayes AJ, 1999, MICROVASC RES, V58, P224, DOI 10.1006/mvre.1999.2179; HERBST R, 1991, J BIOL CHEM, V266, P19908; HUANG LW, 1995, ONCOGENE, V11, P2097; Huttelmaier S, 1999, FEBS LETT, V451, P68, DOI 10.1016/S0014-5793(99)00546-3; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; Katso RM, 1999, MOL CELL BIOL, V19, P6427; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kim I, 1999, FEBS LETT, V443, P353, DOI 10.1016/S0014-5793(99)00008-3; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MATTHEWS JA, 1985, ANAL BIOCHEM, V151, P205, DOI 10.1016/0003-2697(85)90073-9; McCarthy MJ, 1999, LAB INVEST, V79, P889; Mezquita J, 1999, BIOCHEM BIOPH RES CO, V260, P492, DOI 10.1006/bbrc.1999.0934; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Papapetropoulos A, 1999, LAB INVEST, V79, P213; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; Patan S, 1998, MICROVASC RES, V56, P1, DOI 10.1006/mvre.1998.2081; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; RUNTING AS, 1993, GROWTH FACTORS, V9, P99; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Sierke SL, 1997, BIOCHEM J, V322, P757, DOI 10.1042/bj3220757; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; Tallquist MD, 1999, ONCOGENE, V18, P7917, DOI 10.1038/sj.onc.1203216; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Yabkowitz R, 1999, BLOOD, V93, P1969, DOI 10.1182/blood.V93.6.1969.406k14_1969_1979; Yabkowitz R, 1997, BLOOD, V90, P706, DOI 10.1182/blood.V90.2.706.706_706_715; ZIEGLER SF, 1993, ONCOGENE, V8, P663	55	63	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39741	39746		10.1074/jbc.M007189200	http://dx.doi.org/10.1074/jbc.M007189200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995770	hybrid			2022-12-25	WOS:000165953100104
J	Nyborg, AC; Johnson, JL; Gunn, A; Watt, GD				Nyborg, AC; Johnson, JL; Gunn, A; Watt, GD			Evidence for a two-electron transfer using the all-ferrous Fe protein during nitrogenase catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII NITROGENASE; IRON PROTEIN; KLEBSIELLA-PNEUMONIAE; FE4S4 CLUSTER; COMPONENT; MOLYBDENUM; COMPLEX; STATE; HYDROLYSIS; MECHANISM	The nitrogenase catalyzed H-2 evolution and acetylene-reduction reactions using Ti(III) and dithionite (DT) as reductants were examined and compared under a variety of conditions. Ti(III) is known to make the all-ferrous Fe protein ([Fe4S4](0)) and lowers the amount of ATP hydrolyzed during nitrogenase catalysis by approximately a-fold. Here we further investigate this behavior and present results consistent with the Pe protein in the [Fe4S4](0) redox state transferring two electrons ([Fe4S4](2+)/[Fe4S4](0)) per MoFe protein interaction using Ti(III) but transferring only one electron ([Fe4S4](2+)/[Fe4S4](1+)) using DT, MoFe protein specific activity was measured as a function of Fe:MoFe protein ratio for both a one- and a two-electron transfer reaction, and nearly identical curves were obtained. However, Fe protein specific activity curves as a function of MoFe:Pe protein ratio showed two distinct reactivity patterns. With DT as reductant, typical MoFe inhibition curves were obtained for operation of the [Fe4S4](2+)/ [Fe4S4](1+) redox couple, but with Ti(III) as reductant the [Fe4S4](2+)/[Fe4S4](0) redox couple was functional and MoFe inhibition was not observed at high MoFe:Fe protein ratios. With Ti(III) as reductant, nitrogenase catalysis produced hyperbolic curves, yielding a V-max for the Fe protein specific activity of about 3200 nmol of H-2 min(-1) mg(-1) Fe protein, significantly higher than for reactions conducted with DT as reductant, Lag phase experiments (Hageman, R. V., and Burris, R. H. (1978) Proc. Natl. Acad. Sci. U. S. A. 75, 2699-2702) were carried out at MoFe:Fe protein ratios of 100 and 300 using both DT and Ti(III). A lag phase was observed for DT but, with Ti(III) product formation, began immediately and remained linear for over 30 min. Activity measurements using Av-Cp heterologous crosses were examined using both DT and Ti(III) as reductants to compare the reactivity of the [Fe4S4](2+)/[Fe4S4](1+) and [Fe4S4](2+)/ [Fe4S4](0) redox couples and both were inactive. The results are discussed in terms of the Fe protein transferring two electrons per MoFe protein encounter using the [Fe4S4,](2+)/[Fe4S4](0) redox couple with Ti(III) as reductant.	Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84604 USA; Brigham Young Univ, Undergrad Res Program, Provo, UT 84604 USA	Brigham Young University; Brigham Young University	Watt, GD (corresponding author), Brigham Young Univ, Dept Chem & Biochem, C-100 BNSN Bldg, Provo, UT 84604 USA.			Gunn, Alexander/0000-0002-1018-454X				Angove HC, 1998, J BIOL CHEM, V273, P26330, DOI 10.1074/jbc.273.41.26330; Angove HC, 1997, J AM CHEM SOC, V119, P8730, DOI 10.1021/ja9712837; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; DAESCH G, 1968, J BACTERIOL, V96, P346, DOI 10.1128/JB.96.2.346-351.1968; DALTON H, 1969, J GEN MICROBIOL, V56, P307, DOI 10.1099/00221287-56-3-307; DETROY RW, 1968, P NATL ACAD SCI USA, V61, P537, DOI 10.1073/pnas.61.2.537; EMERICH DW, 1976, P NATL ACAD SCI USA, V73, P4369, DOI 10.1073/pnas.73.12.4369; Erickson JA, 1999, BIOCHEMISTRY-US, V38, P14279, DOI 10.1021/bi991389+; Fiske CH, 1925, J BIOL CHEM, V66, P375; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HAGEMAN RV, 1980, BIOCHEMISTRY-US, V19, P2333, DOI 10.1021/bi00552a009; HAGEMAN RV, 1979, J BIOL CHEM, V254, P1189; Johnson JL, 2000, BBA-PROTEIN STRUCT M, V1543, P24, DOI 10.1016/S0167-4838(00)00195-3; Johnson JL, 2000, BBA-PROTEIN STRUCT M, V1543, P36, DOI 10.1016/S0167-4838(00)00196-5; Johnson JL, 1996, BIOCHEMISTRY-US, V35, P11336, DOI 10.1021/bi952581o; KIM J, 1994, BIOCHEMISTRY-US, V33, P389, DOI 10.1021/bi00168a001; Lanzilotta WN, 1996, BIOCHEMISTRY-US, V35, P7188, DOI 10.1021/bi9603985; MORTENSON LE, 1976, P 1 INT S NITR FIX, V1, P117; NYBORG AC, 2000, J INORG BIOCH; Orme-Johnson W. H., 1977, Recent developments in nitrogen fixation., P131; ORMEJOHNSON WH, 1977, IRON SULFUR PROTEINS, V3, P15; POSTGATE JR, 1971, CHEM BIOCH NITROGEN; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; SILVERST.R, 1970, BIOCHEMISTRY-US, V9, P3809, DOI 10.1021/bi00821a021; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; SORGER GJ, 1971, BIOCHEM J, V122, P305, DOI 10.1042/bj1220305; Thorneley R. N. F., 1985, MOLYBDENUM ENZYMES, P221; THORNELEY RNF, 1975, BIOCHIM BIOPHYS ACTA, V403, P269, DOI 10.1016/0005-2744(75)90057-1; THORNELEY RNF, 1984, BIOCHEM J, V224, P903, DOI 10.1042/bj2240903; WATT GD, 1994, J INORG BIOCHEM, V53, P281, DOI 10.1016/0162-0134(94)85115-8; WATT GD, 1986, BIOCHEMISTRY-US, V25, P8156, DOI 10.1021/bi00373a005; ZUMFT WG, 1975, BIOCHIM BIOPHYS ACTA, V416, P1, DOI 10.1016/0304-4173(75)90012-9	33	20	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39307	39312		10.1074/jbc.M007069200	http://dx.doi.org/10.1074/jbc.M007069200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11005818	hybrid			2022-12-25	WOS:000165953100051
J	Previs, SF; Withers, DJ; Ren, JM; White, MF; Shulman, GI				Previs, SF; Withers, DJ; Ren, JM; White, MF; Shulman, GI			Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR SUBSTRATE FAMILY; INSULIN-RESISTANCE; PHOSPHOTYROSINE PROTEIN; SIGNALING SYSTEM; MICE; MEMBER; GROWTH	To examine the impact of homozygous genetic disruption of insulin receptor substrate (IRS)-1 (IRS-1(-/-)) or IRS-S (IRS-2(-/-)) on basal and insulin-stimulated carbohydrate and lipid metabolism in vivo, we infused 18-h fasted mice (wild-type (WT), IRS-1(-/-), and IRS-2(-/-)) with [3-H-3]glucose and [H-2(5)]glycerol and assessed rates of glucose and glycerol turnover under basal (0-90 min) and hyperinsulinemic-euglycemic clamp (90-210 min; 5 mM glucose, and 5 milliunits of insulin kg(-1).min(-1)) conditions. Both IRS-1(-/-) and IRS-2(-/-) mice were insulin-resistant as reflected by markedly impaired insulin-stimulated whole-body glucose utilization compared with WT mice. Insulin resistance in the IRS-1(-/-) mice could be ascribed mainly to decreased insulin-stimulated peripheral glucose metabolism. In contrast, IRS-2(-/-) mice displayed multiple defects in insulin-mediated carbohydrate metabolism as reflected by (i) decreased peripheral glucose utilization, (ii) decreased suppression of endogenous glucose production, and (iii) decreased hepatic glycogen synthesis. Additionally, IRS-2(-/-) mice also showed marked insulin resistance in adipose tissue as reflected by reduced suppression of plasma free fatty acid concentrations and glycerol turnover during the hyperinsulinemic-euglycemic clamp. These data suggest important tissue-specific roles for IRS-1 and IRS-2 in mediating the effect of insulin on carbohydrate and Lipid metabolism in vivo in mice. IRS-1 appears to have its major role in muscle, whereas IRS-2 appears to impact on liver, muscle, and adipose tissue.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06536 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06536 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Joslin Diabet Ctr,Dept Biochem, Boston, MA 02215 USA	Howard Hughes Medical Institute; Yale University; Yale University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute	Shulman, GI (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, 295 C Ave,POB 9812, New Haven, CT 06536 USA.		Withers, Dominic J/D-7671-2014; Shulman, Gerald I./P-7176-2019	Withers, Dominic J/0000-0002-8009-7521; Shulman, Gerald I./0000-0003-1529-5668	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK045735, R01DK040936] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK040936, R01 DK-40936, P30 DK-45735] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Bergman RN, 1997, RECENT PROG HORM RES, V52, P359; DeFronzo RA, 1997, DIABETES REV, V5, P177; Fantin VR, 2000, AM J PHYSIOL-ENDOC M, V278, pE127, DOI 10.1152/ajpendo.2000.278.1.E127; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Higaki Y, 1999, J BIOL CHEM, V274, P20791, DOI 10.1074/jbc.274.30.20791; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kim JK, 2000, J BIOL CHEM, V275, P8456, DOI 10.1074/jbc.275.12.8456; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Liu SCH, 1999, J BIOL CHEM, V274, P18093, DOI 10.1074/jbc.274.25.18093; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; Shen HQ, 1999, METABOLISM, V48, P965, DOI 10.1016/S0026-0495(99)90191-9; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; WALAAS O, 1950, J BIOL CHEM, V187, P769; WHITE MF, 1994, J BIOL CHEM, V269, P1; White MF, 1998, CURR TOP MICROBIOL, V228, P179; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074	24	215	227	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					38990	38994		10.1074/jbc.M006490200	http://dx.doi.org/10.1074/jbc.M006490200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995761	hybrid			2022-12-25	WOS:000165953100008
J	Zhang, W; Ou, JW; Inagaki, Y; Greenwel, P; Ramirez, F				Zhang, W; Ou, JW; Inagaki, Y; Greenwel, P; Ramirez, F			Synergistic cooperation between Sp1 and Smad3/Smad4 mediates transforming growth factor beta 1 stimulation of alpha 2(I)-collagen (COL1A2) transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR-1 PROMOTER; TGF-BETA; GENE-EXPRESSION; COLLAGEN GENE; SMAD PROTEINS; INDUCIBLE ELEMENTS; RESPONSIVE ELEMENT; DIRECT BINDING; C/EBP-BETA; RECEPTOR	Transforming growth factor-beta1 (TGF beta) is a strong activator of extracellular matrix accumulation. TG;FP stimulates the gene coding for human alpha2(I)-collagen (COL1A2) by inducing binding of an Sp1-containing complex to an upstream promoter element (TGF beta responsive element or TbRE) that contains a CAGA box. Here we report that the CAGA box of the TbRE is the binding site of the Smad3/Smad4 complex, and that the binding of the complex is required for TGF beta -induced COL1A2 up-regulation. Recombinant Smad3 and Smad4 bind in vitro to the CAGA box of COL1A2; TGF beta treatment of cultured fibroblasts induces Smad3/Smad4 binding to the TbRE; transient overexpression of Smad3 and Smad4 in fibroblasts transactivates TbRE-driven transcription; and COL1A2 gene up-regulation by TGF beta is abolished in cells stably transfected with plasmids that express dominant negative forms of Smad3 or Smad4. In Sp1-deficient Drosophila Schneider cells, there was cooperative synergy between Smad3/Smad4 and Sp1 at the TbRE site. The analysis also emphasized the requirement of both Sp1- and Smad-binding sites for optimal promoter transactivation. In cells stably transfected with a plasmid expressing a dominant negative form of Sp1, the synergy was shown to be promoter-specific and dependent on the binding of Sp1 to the TbRE. Interestingly, overexpression of dominant negative Sp1 was found to block the antagonistic signal of tumor necrosis factor-alpha on COL1A2 transcription, as well. These results provide the first linkage between the Smad3 and Smad4 proteins and TGF beta stimulation of type I collagen biosynthesis.	NYU, Mt Sinai Sch Med, Dept Biochem & Mol Biol, Brookdale Ctr, New York, NY 10029 USA; Natl Kanazawa Hosp, Dept Internal Med, Kanazawa, Ishikawa 9208650, Japan; Natl Kanazawa Hosp, Clin Res Inst, Kanazawa, Ishikawa 9208650, Japan	Icahn School of Medicine at Mount Sinai; New York University	Ramirez, F (corresponding author), NYU, Mt Sinai Sch Med, Dept Biochem & Mol Biol, Brookdale Ctr, 1 Gustave L Levy Pl, New York, NY 10029 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012196] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA12196] Funding Source: Medline; NIAMS NIH HHS [AR-386481] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Bitzer M, 2000, GENE DEV, V14, P187; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DIEGELMANN RF, 1988, COLLAGEN BIOCH BIOME, V2, P113; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; GREENWEL P, 1995, MOL CELL BIOL, V15, P6813; Greenwel P, 2000, MOL CELL BIOL, V20, P912, DOI 10.1128/MCB.20.3.912-918.2000; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hay E.D., 1991, CELL BIOL EXTRACELLU, P419; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; Johnson K, 1999, J BIOL CHEM, V274, P20709, DOI 10.1074/jbc.274.29.20709; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, GENE DEV, V14, P627; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; NEHLS MC, 1992, DNA CELL BIOL, V11, P443, DOI 10.1089/dna.1992.11.443; NIEDERREITHER K, 1992, J CELL BIOL, V119, P1361, DOI 10.1083/jcb.119.5.1361; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Raftery LA, 1999, DEV BIOL, V210, P251, DOI 10.1006/dbio.1999.9282; Sambrook J., 1983, MOL CLONING LAB MANU; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; VANDERREST M, 1991, FASEB J, V5, P1814; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; Yanagi Y, 1999, J BIOL CHEM, V274, P12971, DOI 10.1074/jbc.274.19.12971; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	47	195	201	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39237	39245		10.1074/jbc.M003339200	http://dx.doi.org/10.1074/jbc.M003339200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11007770	hybrid			2022-12-25	WOS:000165953100041
J	Salter, JP; Lim, KC; Hansell, E; Hsieh, I; McKerrow, JH				Salter, JP; Lim, KC; Hansell, E; Hsieh, I; McKerrow, JH			Schistosome invasion of human skin and degradation of dermal elastin are mediated by a single serine protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANSONI; CERCARIAE; PROTEINASE; PENETRATION; PARASITE; ENZYMES; TISSUE; LARVAE	Aquatic larvae (cercariae) of the trematode parasite Schistosoma mansoni rapidly penetrate human skin by degrading host proteins including elastin, Two serine proteases, one chymotrypsin-like and the second trypsin-like, have been proposed to be involved. To evaluate the relative roles of these two proteases in larval invasion, both were purified, identified by sequence, and then biochemically characterized. The trypsin-like activity was resolved into two distinct serine proteases 76% similar in predicted amino acid sequence, Southern blot analysis, genomic polymerase chain reaction, and immunolocalization demonstrated that the trypsin-like proteases are in fact not from the schistosome, but are released with larvae from the snail host Biomphalaria glabrata, Invasion inhibition assays using selective inhibitors confirmed that the chymotrypsin-like protease is the enzyme involved in skin penetration. Its ability to degrade skin elastin was confirmed, and the three sites of cleavage within elastin help define a new family of elastases.	Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Biomed Sci Grad Program, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	McKerrow, JH (corresponding author), Univ Calif San Francisco, Dept Pathol, 4150 Clement St,113-B, San Francisco, CA 94121 USA.	jmck@cgl.ucsf.edu						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; COHEN FE, 1991, BIOCHEMISTRY-US, V30, P11221, DOI 10.1021/bi00111a005; COHEN LM, 1980, J PARASITOL, V66, P362, DOI 10.2307/3280843; Dalton JP, 1997, PARASITOLOGY, V114, P105, DOI 10.1017/S003118209600830X; DRESDEN MH, 1972, BIOCHIM BIOPHYS ACTA, V289, P378, DOI 10.1016/0005-2744(72)90089-7; Fukuyama K, 1983, Curr Probl Dermatol, V11, P185; GAZZINEL.A, 1964, J PARASITOL, V50, P591, DOI 10.2307/3275632; GORDON RM, 1951, ANN TROP MED PARASIT, V45, P227, DOI 10.1080/00034983.1951.11685493; Haas W, 1997, J PARASITOL, V83, P1079, DOI 10.2307/3284366; LEWERT RM, 1956, J INFECT DIS, V99, P1, DOI 10.1093/infdis/99.1.1; Lim KC, 1999, AM J TROP MED HYG, V60, P487, DOI 10.4269/ajtmh.1999.60.487; MCKERROW JH, 1985, BIOCHEM J, V231, P47, DOI 10.1042/bj2310047; MCKERROW JH, 1985, J BIOL CHEM, V260, P3703; Mecham RP, 1997, J BIOL CHEM, V272, P18071, DOI 10.1074/jbc.272.29.18071; MISHKIN EM, 1986, J PARASITOL, V72, P885, DOI 10.2307/3281840; NEWPORT GR, 1988, J BIOL CHEM, V263, P13179; RAJU K, 1987, J BIOL CHEM, V262, P5755; RING CS, 1993, P NATL ACAD SCI USA, V90, P3583, DOI 10.1073/pnas.90.8.3583; Stirewalt M.A., 1974, Advances Parasit, V12, P115, DOI 10.1016/S0065-308X(08)60388-7; STIREWALT MA, 1974, EXP PARASITOL, V35, P1, DOI 10.1016/0014-4894(74)90002-2; STIREWALT MA, 1973, J PARASITOL, V59, P741, DOI 10.2307/3278879; STIREWALT MA, 1956, J PARASITOL, V42, P565, DOI 10.2307/3274873; TZENG S, 1983, J PARASITOL, V69, P992, DOI 10.2307/3281072	23	83	86	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38667	38673		10.1074/jbc.M006997200	http://dx.doi.org/10.1074/jbc.M006997200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10993899	hybrid			2022-12-25	WOS:000165739800072
J	Menshikova, EV; Cheong, EJ; Salama, G				Menshikova, EV; Cheong, EJ; Salama, G			Low N-ethylmaleimide concentrations activate ryanodine receptors by a reversible interaction, not an alkylation of critical thiols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; CARDIAC SARCOPLASMIC-RETICULUM; NITRIC-OXIDE PROTECTS; TRIGGER CA-2+ RELEASE; SKELETAL-MUSCLE; SINGLE-CHANNEL; INHIBITION; ATPASE; AG+	Previous studies proposed that N-ethylmaleimide (NEM) alkylates 3 classes of thiols on skeletal muscle ryanodine receptors (RyRs) producing 3 phases of channel modification, as function of time and concentration. NEM (5 mM) decreased, increased, and then decreased the open probability (P-o) of the channel by thiol alkylation, a reaction not reversed by reducing agents. We now show that low NEM concentrations (20-200 muM) elicit Ca2+ release from sarcoplasmic reticulum (SR) vesicles, but contrary to expectations, the effect was fully reversed by reducing agents or by washing SR vesicles, In bilayers, NEM (0.2 mM) increased P-o of RyRs within seconds when added to the cis (not trans) side, and dithiothreitol (DTT; 1 mM) decreased P-o in seconds. High (5 mM) NEM concentrations elicited SR Ca2+ release that was not reversed by DTT, as expected for an alkylation reaction. A non-sulfhydryl reagent structurally related to NEM, N-ethylsuccinimide (0.1-0.5 mM), also elicited SR Ca2+ release that was not reversed by DTT (1 mM). Other alkylating agents elicited SR Ca2+ release, which was fully (N-methylmaleimide) or partially (iodoacetic acid) reversed by DTT and inhibited by ruthenium red. Nitric oxide (NO) donors at concentrations that did not activate RyRs inhibited NEM-induced Ca2+ release, most likely by an interaction of NO with NEM rather than an inactivation of RyRs by NO. Thus, at low concentrations, NEM does not act as a selective thiol reagent and activates RyRs without alkylating critical thiols indicating that the multiple phases of ryanodine binding are unrelated to RyR activity or to NEM alkylation of RyRs,	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Salama, G (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Rm S314,Biomed Sci Tower,3500 Terrace St, Pittsburgh, PA 15261 USA.				NHLBI NIH HHS [R01 HL57929, HL59614] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059614, R01HL057929] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMSON JJ, 1995, J BIOL CHEM, V270, P29644; Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; Aghdasi B, 1997, J BIOL CHEM, V272, P25462, DOI 10.1074/jbc.272.41.25462; BROCKLEHURST K, 1979, INT J BIOCHEM, V10, P259, DOI 10.1016/0020-711X(79)90088-0; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; Gorbunov NV, 1998, BIOCHEM BIOPH RES CO, V244, P647, DOI 10.1006/bbrc.1997.7951; Hart JDE, 2000, J MEMBRANE BIOL, V173, P227, DOI 10.1007/s002320001022; HASSELBACH W, 1972, MOL BIOENERGETICS MA, P149; HILKERT R, 1992, ARCH BIOCHEM BIOPHYS, V292, P1, DOI 10.1016/0003-9861(92)90043-V; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; Marengo JJ, 1998, BIOPHYS J, V74, P1263, DOI 10.1016/S0006-3495(98)77840-3; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; Menshikova EV, 1999, ANN NY ACAD SCI, V874, P371, DOI 10.1111/j.1749-6632.1999.tb09252.x; Meszaros LG, 1996, FEBS LETT, V380, P49, DOI 10.1016/0014-5793(96)00003-8; MOUTIN MJ, 1989, BIOCHIM BIOPHYS ACTA, V984, P289, DOI 10.1016/0005-2736(89)90295-2; MURPHY AJ, 1976, BIOCHEMISTRY-US, V15, P4492, DOI 10.1021/bi00665a025; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; PRABHU SD, 1990, ARCH BIOCHEM BIOPHYS, V277, P47, DOI 10.1016/0003-9861(90)90548-D; ROUSSEAU E, 1986, BIOPHYS J, V50, P1009, DOI 10.1016/S0006-3495(86)83543-3; SALAMA G, 1984, J BIOL CHEM, V259, P3363; SALAMA G, 1980, J BIOL CHEM, V255, P6525; Salama G, 2000, ANTIOXID REDOX SIGN, V2, P5, DOI 10.1089/ars.2000.2.1-5; Stoyanovsky D, 1997, CELL CALCIUM, V21, P19, DOI 10.1016/S0143-4160(97)90093-2; STOYANOVSKY DA, 1994, ARCH BIOCHEM BIOPHYS, V308, P214, DOI 10.1006/abbi.1994.1030; Suko J, 1999, BBA-MOL CELL RES, V1451, P271, DOI 10.1016/S0167-4889(99)00098-1; TRIMM JL, 1986, J BIOL CHEM, V261, P6092; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Zahradnikova A, 1997, CELL CALCIUM, V22, P447, DOI 10.1016/S0143-4160(97)90072-5; ZAIDI NF, 1989, J BIOL CHEM, V264, P21725; Zucchi R, 1997, PHARMACOL REV, V49, P1	30	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36775	36780		10.1074/jbc.C000367200	http://dx.doi.org/10.1074/jbc.C000367200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10998412	hybrid			2022-12-25	WOS:000165577700048
J	Blander, G; Zalle, N; Leal, JFM; Bar-Or, RL; Yu, CE; Oren, M				Blander, G; Zalle, N; Leal, JFM; Bar-Or, RL; Yu, CE; Oren, M			The Warner syndrome protein contributes to induction of p53 by DNA damage	FASEB JOURNAL			English	Article									Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Vet Affairs Med Ctr, Seattle, WA 98108 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	Weizmann Institute of Science; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Leal, Juan F Martinez/N-6328-2013	Leal, Juan F Martinez/0000-0002-7538-0875; Oren, Moshe/0000-0003-4311-7172					0	32	34	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2138	2140						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11023999				2022-12-25	WOS:000165190800004
J	Azam, N; Vairapandi, M; Zhang, W; Hoffman, B; Liebermann, DA				Azam, N; Vairapandi, M; Zhang, W; Hoffman, B; Liebermann, DA			Interaction of CR6 (GADD45 gamma) with proliferating cell nuclear antigen impedes negative growth control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; RESPONSE GENE MYD118; DNA-REPLICATION; TERMINAL KINASE; PCNA; PROTEIN; DIFFERENTIATION; ACTIVATION; APOPTOSIS; TRANSCRIPTION	GADD45, MyDII8, and CR6 (also termed GADD45 alpha, beta, and gamma) comprise a family of genes that encode for related proteins playing important roles in negative growth control, including growth suppression. Data accumulated suggest that MyD118/GADD45/CR6 serve similar but not identical functions along different apoptotic and growth suppressive pathways. It is also apparent that individual members of the MyD118/GADD45/CR6 family are differentially induced by a variety of genetic and environmental stress agents. The MyD118, CR6, and GADD45 proteins were shown to predominantly localize within the cell nucleus. Recently, we have shown that both MyD118 and GADD45 interact with proliferating cell nuclear antigen (PCNA), a protein that plays a central role in DNA replication, DNA repair, and cell cycle progression, as well as with the universal cyclin-dependent kinase inhibitor p21, In this work we show that also CR6 interacts with PCNA and p21, Moreover, it is shown that CR6 interacts with PCNA via a domain that also mediates interaction of both GADD45 and MyD118 with PCNA. Importantly, evidence has been obtained that interaction of CR6 with PCNA impedes the function of this protein in negative growth control, similar to observations reported for MyD118 and GADD45 (1).	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Hoffman, B (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	lieberma@unix.temple.edu			NCI NIH HHS [1RO1CA43618] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043618] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; Fan W, 1999, ONCOGENE, V18, P6573, DOI 10.1038/sj.onc.1203054; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GRANA X, 1995, ONCOGENE, V11, P211; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HALL PA, 1995, ONCOGENE, V10, P2427; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; Muschel RJ, 1998, ONCOGENE, V17, P3359, DOI 10.1038/sj.onc.1202580; Nakayama K, 1999, J BIOL CHEM, V274, P24766, DOI 10.1074/jbc.274.35.24766; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Vairapandi M, 1996, ONCOGENE, V12, P2579; Vairapandi M, 2000, J BIOL CHEM, V275, P16810, DOI 10.1074/jbc.275.22.16810; Wang XT, 1999, J BIOL CHEM, V274, P29599, DOI 10.1074/jbc.274.42.29599; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang P, 1998, J BIOL CHEM, V273, P713, DOI 10.1074/jbc.273.2.713; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885	54	75	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2766	2774		10.1074/jbc.M005626200	http://dx.doi.org/10.1074/jbc.M005626200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11022036	hybrid			2022-12-25	WOS:000166784800064
J	Sweeney, HL; Chen, LQ; Trybus, KM				Sweeney, HL; Chen, LQ; Trybus, KM			Regulation of asymmetric smooth muscle myosin II molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION-DEPENDENT REGULATION; LIGHT CHAIN PHOSPHORYLATION; 2 HEADS; ADP RELEASE; CONFORMATIONAL STATES; SKELETAL-MUSCLE; CROSS-LINKING; HEAVY-CHAIN; ACTIN; BINDING	The emerging view of smooth/nonmuscle myosin regulation suggests that the attainment of the completely inhibited state requires numerous weak interactions between components of the two heads and the myosin rod. To further examine the nature of the structural requirements for regulation, we engineered smooth muscle heavy meromyosin molecules that contained one complete head and truncations of the second head. These truncations eliminated the motor domain but retained two, one, or no light chains. All constructs contained 37 heptads of rod sequence. None of the truncated constructs displayed complete regulation of both ATPase and motility, reinforcing the idea that interactions between motor domains are necessary for complete regulation. Surprisingly, the rate of ADP release was slowed by regulatory light chain dephosphorylation of the truncated construct that contained all four light chains and one motor domain, These data suggest that there is a second step (ADP release) in the smooth muscle myosin-actin-activated ATPase cycle that is modulated by regulatory light chain phosphorylation. This may be part of the mechanism underlying "latch" in smooth muscle.	Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Univ Vermont, Dept Physiol & Biophys, Burlington, VT 05405 USA	University of Pennsylvania; University of Vermont	Sweeney, HL (corresponding author), Univ Penn, Sch Med, Dept Physiol, 3700 Hamilton Walk, Philadelphia, PA 19104 USA.		Sweeney, H Lee/F-1862-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038113, R29HL038113, P01HL015835] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38113, HL15835] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; BURNS CG, 1995, P NATL ACAD SCI USA, V92, P8244, DOI 10.1073/pnas.92.18.8244; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P3309, DOI 10.1021/bi00465a023; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; Ellison PA, 2000, J BIOL CHEM, V275, P15142, DOI 10.1074/jbc.275.20.15142; Gollub J, 1996, NAT STRUCT BIOL, V3, P796, DOI 10.1038/nsb0996-796; Hai C.M., 1988, AM J PHYSIOL, V254, P99; HARADA Y, 1987, NATURE, V326, P805, DOI 10.1038/326805a0; Ito K, 1999, BIOPHYS J, V76, P985, DOI 10.1016/S0006-3495(99)77262-0; KATOH T, 1995, EUR J BIOCHEM, V233, P123, DOI 10.1111/j.1432-1033.1995.123_1.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XD, 2000, BIOCHEMISTRY-US, V39, P2254, DOI 10.1021/bi9924617; Malmqvist U, 1997, P NATL ACAD SCI USA, V94, P7655, DOI 10.1073/pnas.94.14.7655; NISHIYE E, 1993, J PHYSIOL-LONDON, V460, P247, DOI 10.1113/jphysiol.1993.sp019470; PERRIE WT, 1973, BIOCHEM J, V135, P151, DOI 10.1042/bj1350151; POLLARD TD, 1982, METHOD ENZYMOL, V85, P698; Rosenfeld SS, 1998, J BIOL CHEM, V273, P28682, DOI 10.1074/jbc.273.44.28682; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; TRYBUS KM, 1989, J CELL BIOL, V109, P2879, DOI 10.1083/jcb.109.6.2879; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; Trybus KM, 1998, J BIOL CHEM, V273, P18423, DOI 10.1074/jbc.273.29.18423; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; Tyska MJ, 1999, P NATL ACAD SCI USA, V96, P4402, DOI 10.1073/pnas.96.8.4402; VYAS TB, 1992, AM J PHYSIOL, V263, pC210, DOI 10.1152/ajpcell.1992.263.1.C210; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; Wendt T, 1999, J CELL BIOL, V147, P1385, DOI 10.1083/jcb.147.7.1385; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0	33	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41273	41277		10.1074/jbc.M008310200	http://dx.doi.org/10.1074/jbc.M008310200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018047	hybrid			2022-12-25	WOS:000166114600082
J	Alkhalil, A; Achur, RN; Valiyaveettil, M; Ockenhouse, CF; Gowda, DC				Alkhalil, A; Achur, RN; Valiyaveettil, M; Ockenhouse, CF; Gowda, DC			Structural requirements for the adherence of Plasmodium falciparum-infected erythrocytes to chondroitin sulfate proteoglycans of human placenta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG OLIGOSACCHARIDE SEGMENT; HERPES-SIMPLEX-VIRUS; ANTIGENIC VARIATION; HEPARAN-SULFATE; ALCIAN BLUE; GROWTH-FACTOR; ADHESION; MALARIA; RECEPTOR; BINDING	Plasmodium falciparum infection during pregnancy results in the accumulation of infected red blood cells (IRBCs) in the placenta, leading to poor pregnancy outcome. In the preceding paper (Achur, R.N., Valiyaveettil, M., Alkhalil, A., Ockenhouse, C. F., and Gowda, D.C. (2000) J. Biol. Chem. 275, 40344-40356), we reported that unusually low sulfated chondroitin sulfate proteoglycans (CSPGs) in the intervillous spaces of the placenta mediate the IRBC adherence. In this study, we report the structural requirements for the adherence and the minimum chondroitin 4-sulfate (C4S) structural motif that supports IRBC adherence. Partially sulfated C4Ss with varying sulfate contents were prepared by solvolytic desulfation of a fully sulfated C4S. These and other nonmodified C4Ss, with different proportions of 4-, 6-, and nonsulfated disaccharide repeats, were analyzed for inhibition of IRBC adherence to the placental CSPG. C4Ss containing 30-50% 4-sulfated and 50-70% nonsulfated disaccharide repeats efficiently inhibited IRBC adherence; C6S had no inhibitory activity. Oligosaccharides of varying sizes were prepared by the partial depolymerization of C4Ss containing varying levels of 4-sulfation, and their ability to inhibit the IRBC adherence was studied. Oligosaccharides with six or more disaccharide repeats inhibited IRBC adherence to the same level as that of the intact C4Ss, indicating that a dodecasaccharide is the minimum structural motif required for optimal IRBC adherence. Of the C4S dodecasaccharides, only those with two or three sulfate groups per molecule showed maximum IRBC inhibition. These data define the structural requirements for the IRBC adherence to placental CSPGs with implications for the development of therapeutics for maternal malaria.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Walter Reed Army Inst Res, Dept Immunol, Silver Spring, MD 20910 USA	Georgetown University; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Gowda, DC (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	gowda@bc.georgetown.edu		Achur, Rajeshwara/0000-0001-9867-8917; Gowda, Channe/0000-0002-6860-5108	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045086, R21AI045086] Funding Source: NIH RePORTER; NIAID NIH HHS [AI45086] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Achur RN, 2000, J BIOL CHEM, V275, P40344, DOI 10.1074/jbc.M006398200; BANFIELD BW, 1995, J VIROL, V69, P3290, DOI 10.1128/JVI.69.6.3290-3298.1995; Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; Beeson JG, 1998, INFECT IMMUN, V66, P3397, DOI 10.1128/IAI.66.7.3397-3402.1998; BHAVANANDAN VP, 1992, GLYCOCONJUGATES COMP, P167; BIGGS BA, 1991, P NATL ACAD SCI USA, V88, P9171, DOI 10.1073/pnas.88.20.9171; BIGGS BA, 1992, J IMMUNOL, V149, P2047; BORST P, 1995, CELL, V82, P1, DOI 10.1016/0092-8674(95)90044-6; BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005; BRISSON JR, 1992, BIOCHEMISTRY-US, V31, P4996, DOI 10.1021/bi00136a012; Buffet PA, 1999, P NATL ACAD SCI USA, V96, P12743, DOI 10.1073/pnas.96.22.12743; Chaiyaroj SC, 1996, AM J TROP MED HYG, V55, P76, DOI 10.4269/ajtmh.1996.55.76; Chen JCR, 1996, J BIOL CHEM, V271, P11134, DOI 10.1074/jbc.271.19.11134; Cooke BM, 1996, BLOOD, V88, P4040, DOI 10.1182/blood.V88.10.4040.bloodjournal88104040; COWMAN MK, 1984, BIOCHEM J, V221, P707, DOI 10.1042/bj2210707; DISCHE Z, 1947, J BIOL CHEM, V167, P189; FINNE J, 1985, J BIOL CHEM, V260, P1265; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; Fried M, 1998, J MOL MED-JMM, V76, P162, DOI 10.1007/s001090050205; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Fried M, 1998, GLYCOBIOLOGY, V8, P1121; Gardner JP, 1996, P NATL ACAD SCI USA, V93, P3503, DOI 10.1073/pnas.93.8.3503; Gowda DC, 1999, BIOSCIENCE REP, V19, P261, DOI 10.1023/A:1020542206916; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Gysin J, 1997, MOL BIOCHEM PARASIT, V88, P267, DOI 10.1016/S0166-6851(97)00082-0; HATAE Y, 1975, ANAL BIOCHEM, V64, P30, DOI 10.1016/0003-2697(75)90400-5; HAYRINEN J, 1989, MOL IMMUNOL, V26, P523, DOI 10.1016/0161-5890(89)90003-5; HEROLD BC, 1995, VIROLOGY, V206, P1108, DOI 10.1006/viro.1995.1034; HOVINGH P, 1974, CARBOHYD RES, V37, P181, DOI 10.1016/S0008-6215(00)87073-1; JENSEN JB, 1978, AM J TROP MED HYG, V27, P1274, DOI 10.4269/ajtmh.1978.27.1274; Kishibe J, 2000, J BIOL CHEM, V275, P15321, DOI 10.1074/jbc.275.20.15321; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOLIAKOS GG, 1989, J BIOL CHEM, V264, P2313; KRUEGER RC, 1987, ANAL BIOCHEM, V167, P295, DOI 10.1016/0003-2697(87)90167-9; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MAGOWAN C, 1988, J EXP MED, V168, P1307, DOI 10.1084/jem.168.4.1307; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MATSUO M, 1993, CARBOHYD RES, V241, P209, DOI 10.1016/0008-6215(93)80107-P; MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0; NAGASAWA K, 1979, J BIOCHEM-TOKYO, V86, P1323, DOI 10.1093/oxfordjournals.jbchem.a132648; Najjam S, 1998, GLYCOBIOLOGY, V8, P509, DOI 10.1093/glycob/8.5.509; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; OCKENHOUSE CF, 1991, J INFECT DIS, V164, P163, DOI 10.1093/infdis/164.1.163; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; POOLE AR, 1986, BIOCHEM J, V236, P1; Pouvelle B, 1998, INFECT IMMUN, V66, P4950, DOI 10.1128/IAI.66.10.4950-4956.1998; Pouvelle B, 1997, MOL MED, V3, P508, DOI 10.1007/BF03401697; Reeder JC, 1999, P NATL ACAD SCI USA, V96, P5198, DOI 10.1073/pnas.96.9.5198; Robert C, 1995, RES IMMUNOL, V146, P383, DOI 10.1016/0923-2494(96)81042-X; Rogerson SJ, 1997, PARASITOL TODAY, V13, P70, DOI 10.1016/S0169-4758(96)10081-8; ROGERSON SJ, 1995, J EXP MED, V182, P15, DOI 10.1084/jem.182.1.15; Rostand KS, 1997, INFECT IMMUN, V65, P1; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; Steketee RW, 1996, AM J TROP MED HYG, V55, P2, DOI 10.4269/ajtmh.1996.55.2; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; VLODAVSKY I, 1993, BASEMENT MEMBRANES C, P327; Wadstrom T, 1999, J MED MICROBIOL, V48, P223, DOI 10.1099/00222615-48-3-223; WALL RS, 1988, ANAL BIOCHEM, V175, P298, DOI 10.1016/0003-2697(88)90392-2; WESSELS MR, 1989, J EXP MED, V169, P2121, DOI 10.1084/jem.169.6.2121	68	95	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40357	40364		10.1074/jbc.M006399200	http://dx.doi.org/10.1074/jbc.M006399200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11005815				2022-12-25	WOS:000166039500076
J	Christoffels, VM; Habets, PEMH; Das, AT; Clout, DEW; van Roon, MA; Moorman, AFM; Lamers, WH				Christoffels, VM; Habets, PEMH; Das, AT; Clout, DEW; van Roon, MA; Moorman, AFM; Lamers, WH			A single regulatory module of the carbamoylphosphate synthetase I gene executes its hepatic program of expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; ELEMENT-BINDING PROTEIN; RAT-LIVER ONTOGENESIS; TRANSGENIC MICE; GLUCOCORTICOID RECEPTOR; ORNITHINE CYCLE; MESSENGER-RNA; TRANSCRIPTION FACTORS; MULTIHORMONAL CONTROL	A 469-base pair (bp) upstream regulatory fragment (URF) and the proximal promoter of the carbamoylphosphate synthetase I (CPS) gene were analyzed for their role in the regulation of spatial, developmental, and hormone-induced expression in vivo. The URF is essential and sufficient for hepatocyte-specific expression, periportal localization, perinatal activation and induction by glucocorticoids, and cAMP in transgenic mice. Before birth, the transgene is silent but can be induced by cAMP and glucocorticoids, indicating that these compounds are responsible for the activation of expression at birth. A 102-bp glucocorticoid response unit within the URF, containing binding sites for HNF3, C/EBP, and the glucocorticoid receptor, is the main determinant of the hepatocyte-specific and hormone-controlled activity. Additional sequences are required for a productive interaction between this minimal response unit and the core CPS promoter. These results show that the 469-bp URF, and probably only the 102-bp glucocorticoid response unit, functions as a regulatory module, in that it autonomously executes a correct spatial, developmental and hormonal program of CPS expression in the liver.	Univ Amsterdam, Acad Med Ctr, Dept Anat & Embryol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Genetically Modofied Mice Facil, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Lamers, WH (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Anat & Embryol, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.		Lamers, Wouter H./D-2965-2012					ALBERTS B, 1994, MOL BIOL CELL, P756; Arnone MI, 1997, DEVELOPMENT, V124, P1851; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Christoffels VM, 1996, J BIOL CHEM, V271, P31243, DOI 10.1074/jbc.271.49.31243; CHRISTOFFELS VM, 1995, J BIOL CHEM, V270, P24932, DOI 10.1074/jbc.270.42.24932; Christoffels VM, 1998, MOL CELL BIOL, V18, P6305, DOI 10.1128/MCB.18.11.6305; Christoffels VM, 1999, HEPATOLOGY, V29, P1180, DOI 10.1002/hep.510290413; Chung JH, 1997, P NATL ACAD SCI USA, V94, P575, DOI 10.1073/pnas.94.2.575; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; Dingemanse MA, 1996, HEPATOLOGY, V24, P407; ESPINAS ML, 1995, MOL CELL BIOL, V15, P5346; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Franco D, 1997, DEV BIOL, V188, P17, DOI 10.1006/dbio.1997.8622; GEBHARDT R, 1992, PHARMACOL THERAPEUT, V53, P275, DOI 10.1016/0163-7258(92)90055-5; GOPING IS, 1994, J BIOL CHEM, V269, P3891; GOPING IS, 1995, NUCLEIC ACIDS RES, V23, P1717, DOI 10.1093/nar/23.10.1717; GOPING IS, 1992, GENE, V118, P283, DOI 10.1016/0378-1119(92)90201-Y; HOGAN B, 1994, MANIPULATING MOUSE E, P217; IMAI E, 1993, J BIOL CHEM, V268, P5353; Jungermann K, 1996, ANNU REV NUTR, V16, P179, DOI 10.1146/annurev.nu.16.070196.001143; JUNGERMANN K, 1995, HISTOCHEM CELL BIOL, V103, P81, DOI 10.1007/BF01454004; JUNGERMANN K, 1989, PHYSIOL REV, V69, P708, DOI 10.1152/physrev.1989.69.3.708; Kadonaga JT, 1999, CURR OPIN GENET DEV, V9, P129, DOI 10.1016/S0959-437X(99)80019-7; Kirchhamer CV, 1996, P NATL ACAD SCI USA, V93, P9322, DOI 10.1073/pnas.93.18.9322; KUO CF, 1990, DEVELOPMENT, V109, P473; LAGACE M, 1992, GENE, V118, P231, DOI 10.1016/0378-1119(92)90193-S; LAMERS WH, 1981, MECH AGEING DEV, V15, P93, DOI 10.1016/0047-6374(81)90010-5; LAMERS WH, 1981, MECH AGEING DEV, V15, P77, DOI 10.1016/0047-6374(81)90009-9; LAMERS WH, 1984, DEV BIOL, V105, P500, DOI 10.1016/0012-1606(84)90307-5; Legraverend C, 1996, MOL ENDOCRINOL, V10, P1507, DOI 10.1210/me.10.12.1507; LIEVENEMA H, 1995, J BIOL CHEM, V270, P28251; MCGRANE MM, 1992, TRENDS BIOCHEM SCI, V17, P40, DOI 10.1016/0968-0004(92)90426-A; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MEIJER AJ, 1990, PHYSIOL REV, V70, P701, DOI 10.1152/physrev.1990.70.3.701; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; MONTOLIU L, 1995, P NATL ACAD SCI USA, V92, P4244, DOI 10.1073/pnas.92.10.4244; MOORMAN AFM, 1993, HISTOCHEM J, V25, P251, DOI 10.1007/BF00159117; MOORMAN AFM, 1991, FEBS LETT, V288, P133, DOI 10.1016/0014-5793(91)81019-5; MOORMAN AFM, 1990, FEBS LETT, V276, P9, DOI 10.1016/0014-5793(90)80494-4; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; MORRIS SM, 1987, ARCH BIOCHEM BIOPHYS, V256, P343, DOI 10.1016/0003-9861(87)90455-3; MOYER ML, 1993, J BIOL CHEM, V268, P22933; NAGY P, 1994, J CELL BIOL, V126, P223, DOI 10.1083/jcb.126.1.223; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; PARK EA, 1993, J BIOL CHEM, V268, P613; RAMESH TM, 1995, MOL CELL BIOL, V15, P4947; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; ROBERTSON G, 1995, P NATL ACAD SCI USA, V92, P5371, DOI 10.1073/pnas.92.12.5371; Sambrook J., 2002, MOL CLONING LAB MANU; Sassi H, 1998, P NATL ACAD SCI USA, V95, P5621, DOI 10.1073/pnas.95.10.5621; SEITZ HJ, 1976, ENDOCRINOLOGY, V99, P1313, DOI 10.1210/endo-99-5-1313; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; Takiguchi M, 1995, BIOCHEM J, V312, P649, DOI 10.1042/bj3120649; VANDENHOFF MJB, 1993, NUCLEIC ACIDS RES, V21, P4987, DOI 10.1093/nar/21.21.4987; VANDENHOFF MJB, 1995, EUR J BIOCHEM, V228, P351; Wang YL, 1997, NAT BIOTECHNOL, V15, P239, DOI 10.1038/nbt0397-239; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yuh CH, 1998, SCIENCE, V279, P1896, DOI 10.1126/science.279.5358.1896; ZHANG HY, 1993, P NATL ACAD SCI USA, V90, P3880, DOI 10.1073/pnas.90.9.3880	60	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40020	40027		10.1074/jbc.M007001200	http://dx.doi.org/10.1074/jbc.M007001200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11006287	hybrid			2022-12-25	WOS:000166039500032
J	Raya, A; Revert-Ros, F; Martinez-Martinez, P; Navarro, S; Rosello, E; Vieitas, B; Granero, F; Forteza, J; Saus, J				Raya, A; Revert-Ros, F; Martinez-Martinez, P; Navarro, S; Rosello, E; Vieitas, B; Granero, F; Forteza, J; Saus, J			Goodpasture antigen-binding protein, the kinase that phosphorylates the goodpasture antigen, is an alternatively spliced variant implicated in autoimmune pathogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; KERATINOCYTE APOPTOSIS; AUTOANTIGENS; GENE; EXPRESSION; MECHANISM; REGION	The non-collagenous C-terminal domain of the ag chain of collagen IV is the autoantigen in Goodpasture disease, an autoimmune disorder described only in humans. Specific N-terminal phosphorylation is a biological feature unique to the human domain when compared with other homologous domains lacking immunopathogenic potential. We have recently cloned from a HeLa-derived cDNA library a novel serine/threonine kinase (Goodpasture antigen-binding protein (GPBP)) that phosphorylates the N-terminal region of the human domain (Raya, A. Revert, F, Navarro, S. and Saus J, (1999) J. Biol. Chem. 274, 12642-12649). We show here that the pre-mRNA of GPBP is alternatively spliced in human tissues and that the most common transcript found encodes GPBP Delta 26, a molecular isoform devoid of a 26-residue serine-rich motif, Recombinantly expressed GPBP Delta 26 exhibits lower activity than GPBP, due at least in part to a reduced ability of GPBP Delta 26 to interact and to form very active high molecular weight aggregates. In human tissues, GPBP shows a more limited expression than GPBP Delta 26 but displays a remarkable preference for the small vessels and for histological structures targeted by natural autoimmune responses including alveolar and glomerular basement membranes, the two main targets in Goodpasture disease. GPBP expression is, in turn, up-regulated in the striated muscle of a Goodpasture patient and in other autoimmune conditions including cutaneous lupus erythematosus, pemphigoid, and lichen planus.	Inst Invest Citol, Fdn Valenciana Invest Biomed, Valencia 46010, Spain; Univ Valencia, Fac Med, Dept Patol, Valencia 46010, Spain; Hosp Peset Aleixandre, Serv Anat Patol, Valencia 46017, Spain; Hosp Clin Univ, Serv Anat Patol, Santiago De Compostela 15706, Spain	University of Valencia; Complexo Hospitalario Universitario de Santiago de Compostela	Saus, J (corresponding author), Inst Invest Citol, Fdn Valenciana Invest Biomed, C Amadeo Saboya 4, Valencia 46010, Spain.		Revert-Ros, Francisco/AAB-7055-2019; Raya, Angel/E-6205-2010	Raya, Angel/0000-0003-2189-9775; Martinez Martinez, Pilar/0000-0002-5990-3373; Saus, Juan/0000-0003-2082-1597; Revert-Ros, Francisco/0000-0002-6162-3370				Bayer KU, 1996, MOL CELL BIOL, V16, P29; BERNAL D, 1993, J BIOL CHEM, V268, P12090; Bolivar J, 1998, J BIOL CHEM, V273, P17122, DOI 10.1074/jbc.273.27.17122; CasciolaRosen L, 1997, LUPUS, V6, P175, DOI 10.1177/096120339700600213; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Casiano CA, 1996, J EXP MED, V184, P765, DOI 10.1084/jem.184.2.765; GOLAN TD, 1992, J CLIN INVEST, V90, P1067, DOI 10.1172/JCI115922; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Maruoka Y, 1997, BIOCHEM BIOPH RES CO, V238, P886, DOI 10.1006/bbrc.1997.7405; Naito Y, 1997, J BIOL CHEM, V272, P32704, DOI 10.1074/jbc.272.51.32704; Pablos JL, 1999, J PATHOL, V188, P63; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; PENADES JR, 1995, EUR J BIOCHEM, V229, P754, DOI 10.1111/j.1432-1033.1995.tb20524.x; POLAKOWSKA RR, 1994, DEV DYNAM, V199, P176, DOI 10.1002/aja.1001990303; QUINONES S, 1992, J BIOL CHEM, V267, P19780; Raya A, 1999, J BIOL CHEM, V274, P12642, DOI 10.1074/jbc.274.18.12642; REVERT F, 1995, J BIOL CHEM, V270, P13254, DOI 10.1074/jbc.270.22.13254; SAUS J, 1998, GOODPASTURES SYNDROM, V2, P1005; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; Utz PJ, 1998, ARTHRITIS RHEUM, V41, P1152, DOI 10.1002/1529-0131(199807)41:7<1152::AID-ART3>3.0.CO;2-L; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	24	63	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40392	40399		10.1074/jbc.M002769200	http://dx.doi.org/10.1074/jbc.M002769200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007769	hybrid			2022-12-25	WOS:000166039500081
J	Harris, D; Engelman, A				Harris, D; Engelman, A			Both the structure and DNA binding function of the barrier-to-autointegration factor contribute to reconstitution of HIV type 1 integration in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS PREINTEGRATION COMPLEXES; RETROVIRAL DNA; CELLULAR FACTOR; IN-VITRO; PROTEIN; DOMAIN; PURIFICATION	Retroviral integration is mediated by viral preintegration complexes (PICs), and human immunodeficiency virus type 1 (HIV-1) PICs treated with high salt lose their in vitro integration activity. Barrier-to-autointegration factor (EAF) is a host protein that efficiently restores PIC activity, but the mechanism(s) by which BAF participates in HIV-1 integration remains largely unknown. Here we developed a gel shift assay to study BAF DNA binding, and analyzed 14 mutant proteins containing substitutions of conserved residues for binding and PIC reconstitution activities, Although wild-type BAF efficiently bound double-stranded DNA, binding to single-stranded DNA, RNA, or an RNA/DNA hybrid was not detected, suggesting that BAF associates with retroviral cDNA relatively late during reverse transcription. Although some of the BAF mutant proteins efficiently bound DNA, others were defective for binding. Mutants that bound DNA efficiently reconstituted HIV-1 integration, even though in one case binding was just 0.2% of wild-type BAF, Although misfolded mutants did not reconstitute integration, a structurally intact DNA binding-defective mutant displayed partial activity at high BAF concentration. We therefore conclude that both BAF protein structure and its DNA binding activity play roles in reconstituting HIV-1 integration in vitro.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Engelman, A (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.				NIAID NIH HHS [AI39394] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI039394, R01AI039394] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brown P. O., 1997, P161; Cai M, 1998, NAT STRUCT BIOL, V5, P903, DOI 10.1038/2345; Chen HM, 1998, P NATL ACAD SCI USA, V95, P15270, DOI 10.1073/pnas.95.26.15270; Chen HM, 1999, J BIOL CHEM, V274, P17358, DOI 10.1074/jbc.274.24.17358; Craigie R., 1995, HIV, V2, P53; ENGELMAN A, 1995, J VIROL, V69, P5908, DOI 10.1128/JVI.69.9.5908-5911.1995; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Furukawa K, 1999, J CELL SCI, V112, P2485; HICKMAN AB, 1994, J BIOL CHEM, V269, P29279; LEE MS, 1994, P NATL ACAD SCI USA, V91, P9823, DOI 10.1073/pnas.91.21.9823; Lee MS, 1998, P NATL ACAD SCI USA, V95, P1528, DOI 10.1073/pnas.95.4.1528; Li L, 1998, J VIROL, V72, P2125, DOI 10.1128/JVI.72.3.2125-2131.1998; SMITH JS, 1993, J VIROL, V67, P4037, DOI 10.1128/JVI.67.7.4037-4049.1993; Telesnitsky A., 1997, P121; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R; Wei SQ, 1998, P NATL ACAD SCI USA, V95, P10535, DOI 10.1073/pnas.95.18.10535; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; Wilson KL, 2000, TRENDS CELL BIOL, V10, P125, DOI 10.1016/S0962-8924(99)01708-0; YANG JT, 1986, METHOD ENZYMOL, V130, P208	19	56	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39671	39677		10.1074/jbc.M002626200	http://dx.doi.org/10.1074/jbc.M002626200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11005805	Green Published, hybrid			2022-12-25	WOS:000165953100095
J	Melhuish, TA; Wotton, D				Melhuish, TA; Wotton, D			The interaction of the carboxyl terminus-binding protein with the Smad corepressor TGIF is disrupted by a holoprosencephaly mutation in TGIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; TRANSCRIPTIONAL REPRESSOR; CELLULAR PHOSPHOPROTEIN; NEGATIVE MODULATION; BETA; HOX; HOMEODOMAIN; COMPLEXES; DOMAIN; PBX	The homeodomain protein TGIF represses transcription in part by recruiting histone deacetylases. TGIF binds directly to DNA to repress transcription or interacts with TGF-beta -activated Smads, thereby repressing genes normally activated by TGF-beta. Loss of function mutations in TGIF result in holoprosencephaly (HPE) in humans. One HPE mutation in TGIF results in a single amino acid substitution in a conserved PLDLS motif within the amino-terminal repression domain. We demonstrate that TGIF interacts with the corepressor carboxyl terminus-binding protein (CtBP) via this motif. CtBP, which was first identified by its ability to bind the adenovirus E1A protein, interacts both with gene-specific transcriptional repressors and with a subset of polycomb proteins, Efficient repression of TGF-beta -activated gene responses by TGIF is dependent on interaction with CtBP, and we show that TGIF is able to recruit CtBP to a TGF-beta -activated Smad complex. Disruption of the PLDLS motif in TGIF abolishes the interaction of CtBP with TGIF and compromises the ability of TGIF to repress transcription. Thus, at least one HPE mutation in TGIF appears to prevent CtBP-dependent transcriptional repression by TGIF, suggesting an important developmental role for the recruitment of CtBP by TGIF.	Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Wotton, D (corresponding author), Univ Virginia, Hosp West, Ctr Cell Signaling, HSC, Box 800577, Charlottesville, VA 22908 USA.	dw2p@virginia.edu		Wotton, David/0000-0002-4652-5350				Alkema MJ, 1997, J MOL BIOL, V273, P993, DOI 10.1006/jmbi.1997.1372; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Asahara H, 1999, MOL CELL BIOL, V19, P8219; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Bertolino E, 1995, J BIOL CHEM, V270, P31178, DOI 10.1074/jbc.270.52.31178; Bertolino E, 1996, DEV DYNAM, V205, P410, DOI 10.1002/(SICI)1097-0177(199604)205:4<410::AID-AJA5>3.0.CO;2-L; BIENZ L, 1995, BIOESSAYS, V17, P775, DOI 10.1002/bies.950170907; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P517; Gripp KW, 2000, NAT GENET, V25, P205, DOI 10.1038/76074; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Li C, 1998, MOL CELL BIOL, V18, P3771, DOI 10.1128/MCB.18.7.3771; Liu B, 1999, MOL CELL BIOL, V19, P424; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Ming JE, 1998, CLIN GENET, V53, P155; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Newberry EP, 1997, BIOCHEMISTRY-US, V36, P10451, DOI 10.1021/bi971008x; ORLANDO V, 1995, CURR OPIN GENET DEV, V5, P174, DOI 10.1016/0959-437X(95)80005-0; OVERHAUSER J, 1995, AM J HUM GENET, V57, P1080; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; RYAN AK, 1995, NUCLEIC ACIDS RES, V23, P3252, DOI 10.1093/nar/23.16.3252; Saurin AJ, 1998, J CELL BIOL, V142, P887, DOI 10.1083/jcb.142.4.887; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Shanmugam K, 1999, MOL CELL BIOL, V19, P7577; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wotton D, 1999, J BIOL CHEM, V274, P37105, DOI 10.1074/jbc.274.52.37105; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yang Y, 2000, J BIOL CHEM, V275, P20734, DOI 10.1074/jbc.M908382199; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	56	90	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39762	39766		10.1074/jbc.C000416200	http://dx.doi.org/10.1074/jbc.C000416200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10995736	hybrid			2022-12-25	WOS:000165953100107
J	Otsuka, F; Yao, ZX; Lee, TH; Yamamoto, S; Erickson, GF; Shimasaki, S				Otsuka, F; Yao, ZX; Lee, TH; Yamamoto, S; Erickson, GF; Shimasaki, S			Bone morphogenetic protein-15 - Identification of target cells and biological functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT GRANULOSA-CELLS; FOLLICLE-STIMULATING-HORMONE; GROWTH FACTOR-BETA; INDUCED DIFFERENTIATION; AROMATASE-ACTIVITY; HOMOLOG GDF-9B; BOVINE ACTIVIN; ESTROUS-CYCLE; TGF-BETA; FOLLICULOGENESIS	In developing ovarian follicles, the regulation of cell proliferation and differentiation is tightly coordinated, Precisely how this coordination is achieved is unknown, but recent observations have suggested that molecules emitted by the oocyte are involved in the process. The newly discovered oocyte-specific growth factor, bone morphogenetic protein-15 (BMP-15), is one such molecule,At present, nothing is known about the target cells and biological functions of BMP-15. To fill this gap in our knowledge, recombinant BMP-15 and its antibody were produced and used to determine BMP-15 expression and bioactivity, BMP-15 mRNA and protein were shown to be co-expressed in oocytes throughout folliculogenesis, supporting the idea that BMP-15 is a physiological regulator of follicle cell proliferation and/or differentiation. To test this, we used primary cultures of rat granulosa cells (GCs), We found that BMP-15 is a potent stimulator of GC proliferation and importantly, the mitogenic effect was follicle-stimulating hormone (FSH)-independent. By contrast, BMP-15 alone had no effect on steroidogenesis. However, it produced a marked decrease in FSH-induced progesterone production, but had no effect on FSH stimulated estradiol production. This result indicates that BMP-15 is a selective modulator of FSH action. In summary, this study identifies GCs as the first target cells for BMP-15. Moreover, it identifies the stimulation of GC proliferation and the differential regulation of two crucial steroid hormones as the first biological functions of BMP-15, Significantly, BMP-15 is the first growth factor that can coordinate GC proliferation and differentiation in a way that reflects normal physiology.	Univ Calif San Diego, Sch Med, Dept Reprod Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Shimasaki, S (corresponding author), Univ Calif San Diego, Sch Med, Dept Reprod Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NICHD NIH HHS [U54HD12303] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD012303] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aaltonen J, 1999, J CLIN ENDOCR METAB, V84, P2744, DOI 10.1210/jc.84.8.2744; ADASHI EY, 1989, MOL CELL ENDOCRINOL, V61, P247, DOI 10.1016/0303-7207(89)90136-6; Carabatsos MJ, 1998, DEV BIOL, V204, P373, DOI 10.1006/dbio.1998.9087; Channing C P, 1970, Recent Prog Horm Res, V26, P589; DODSON WC, 1987, ENDOCRINOLOGY, V120, P512, DOI 10.1210/endo-120-2-512; Dong JW, 1996, NATURE, V383, P531, DOI 10.1038/383531a0; Dube JL, 1998, MOL ENDOCRINOL, V12, P1809, DOI 10.1210/me.12.12.1809; Elvin JA, 2000, MOL CELL ENDOCRINOL, V159, P1, DOI 10.1016/S0303-7207(99)00185-9; Eppig John J., 1997, Human Reproduction (Oxford), V12, P127; Erickson GF, 2000, TRENDS ENDOCRIN MET, V11, P193, DOI 10.1016/S1043-2760(00)00249-6; ERICKSON GF, 1978, ENDOCRINOLOGY, V102, P1275, DOI 10.1210/endo-102-4-1275; Galloway SM, 2000, NAT GENET, V25, P279, DOI 10.1038/77033; HUTCHINSON LA, 1987, BIOCHEM BIOPH RES CO, V146, P1405, DOI 10.1016/0006-291X(87)90806-0; INOUYE S, 1991, ENDOCRINOLOGY, V129, P815, DOI 10.1210/endo-129-2-815; Jaatinen R, 1999, MOL CELL ENDOCRINOL, V156, P189, DOI 10.1016/S0303-7207(99)00100-8; KNECHT M, 1987, ENDOCRINOLOGY, V120, P1243, DOI 10.1210/endo-120-4-1243; Laitinen M, 1998, MECH DEVELOP, V78, P135, DOI 10.1016/S0925-4773(98)00161-0; MIRO F, 1991, ENDOCRINOLOGY, V129, P3388, DOI 10.1210/endo-129-6-3388; NAKATANI A, 1991, ENDOCRINOLOGY, V129, P1521, DOI 10.1210/endo-129-3-1521; NAKATANI A, 1991, ENDOCRINOLOGY, V129, P603, DOI 10.1210/endo-129-2-603; NALBANDOV AV, 1970, S OOGENESIS, P513; Shimasaki S, 1999, P NATL ACAD SCI USA, V96, P7282, DOI 10.1073/pnas.96.13.7282; SMITH MS, 1975, ENDOCRINOLOGY, V96, P219, DOI 10.1210/endo-96-1-219; SUGINO H, 1988, BIOCHEM BIOPH RES CO, V153, P281, DOI 10.1016/S0006-291X(88)81219-1; Vitt UA, 2000, BIOL REPROD, V62, P370, DOI 10.1095/biolreprod62.2.370; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; XIAO S, 1990, MOL CELL ENDOCRINOL, V69, P1, DOI 10.1016/0303-7207(90)90082-J; YING SY, 1986, BIOCHEM BIOPH RES CO, V136, P969, DOI 10.1016/0006-291X(86)90427-4	28	325	356	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39523	39528		10.1074/jbc.M007428200	http://dx.doi.org/10.1074/jbc.M007428200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10998422	hybrid			2022-12-25	WOS:000165953100079
J	Suter, M; Reme, C; Grimm, C; Wenzel, A; Jaattela, M; Esser, P; Kociok, N; Leist, M; Richter, C				Suter, M; Reme, C; Grimm, C; Wenzel, A; Jaattela, M; Esser, P; Kociok, N; Leist, M; Richter, C			Age-related macular degeneration - The lipofuscin component N-retinyl-N-retinylidene ethanolamine detaches proapoptotic proteins from mitochondria and induces apoptosis in mammalian retinal pigment epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BEAVER DAM EYE; NEURONAL APOPTOSIS; AUTOCRINE EXCITOTOXICITY; CYTOCHROME-C; CARDIOLIPINS; DISEASE; RELEASE; FLUOROPHORES; PATHOGENESIS; INHIBITION	10-20% of individuals over the age of 65 suffer hom age-related macular degeneration (ARID), the leading cause of severe visual impairment in humans living in developed countries, The pathogenesis of this complex disease is poorly understood, and no efficient therapy or prevention exists to date. A precondition for ARID appears to be the accumulation of the age pigment lipofuscin in lysosomes of retinal pigment epithelial (RPE) cells. In AMD, these cells seem to die by apoptosis with subsequent death of photoreceptor cells, and light may accelerate the disease process. Intracellular factors leading to cell death are not known. Here we show that the lipophilic cation N-retinyl-N-retinylidene ethanolamine (A2E), a lipofuscin component, induces apoptosis in RPE and other cells at concentrations found in human retina. Apoptosis is accompanied by the appearance of the proapoptotic proteins cytochrome c and apoptosis-inducing factor in the cytoplasm and the nucleus. Biochemical examinations show that A2E specifically targets cytochrome oxidase (COX). With both isolated mitochondria and purified COX, A2E inhibits oxygen consumption synergistically with light. Inhibition is reversed by the addition of cytochrome c or cardiolipin, a negatively charged phospholipid that facilitates the binding of cytochrome c to membranes, Succinate dehydrogenase activity is not altered by A2E, We suggest that A2E can act as a proapoptotic molecule via a mitochondria-related mechanism, possibly through site-specific targeting of this cation to COX Loss of RPE cell viability through inhibition of mitochondrial function might constitute a pivotal step toward the progressive degeneration of the central retina.	Swiss Fed Inst Technol, Inst Biochem, CH-8092 Zurich, Switzerland; Univ Zurich Hosp, Dept Ophthalmol, Lab Retinal Cell Biol, CH-8091 Zurich, Switzerland; Danish Canc Soc, Apoptosis Lab, DK-2100 Copenhagen, Denmark; Univ Cologne, Eye Clin, D-50931 Cologne, Germany; Univ Constance, Fac Biol, Dept Mol Toxicol, D-78457 Constance, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University Zurich Hospital; Danish Cancer Society; University of Cologne; University of Konstanz	Richter, C (corresponding author), Swiss Fed Inst Technol, Inst Biochem, Univ Str 16, CH-8092 Zurich, Switzerland.	richter@bc.biol.ethz.ch	Jäättelä, Marja/AAT-7932-2021; Leist, Marcel/D-2133-2010	Jäättelä, Marja/0000-0001-5950-7111; Leist, Marcel/0000-0002-3778-8693; Grimm, Christian/0000-0001-9318-4352				ALDEZ IZ, 1977, J BIOENERG BIOMEMBR, V9, P237; Allikmets R, 1999, EUR J OPHTHALMOL, V9, P255, DOI 10.1177/112067219900900401; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Carmody RJ, 2000, CELL DEATH DIFFER, V7, P282, DOI 10.1038/sj.cdd.4400646; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cellbio.4.1.155; CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042; Cubeddu R, 1999, PHOTOCHEM PHOTOBIOL, V70, P172, DOI 10.1562/0031-8655(1999)070<0172:PSOAEP>2.3.CO;2; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Eldred GE, 1995, GERONTOLOGY, V41, P15; ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; Esser P, 1997, INVEST OPHTH VIS SCI, V38, P2852; FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583; Gorin MB, 1999, MOL VIS, V5, pU31; Hoch FL, 1998, J BIOENERG BIOMEMBR, V30, P511, DOI 10.1023/A:1020576315771; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737; Holz FG, 1999, OPHTHALMOLOGE, V96, P781, DOI 10.1007/s003470050496; ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KLEIN R, 1992, OPHTHALMOLOGY, V99, P933; Koshkin V, 2000, BIOCHEM J, V347, P687, DOI 10.1042/0264-6021:3470687; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Latta M, 2000, J EXP MED, V191, P1975, DOI 10.1084/jem.191.11.1975; LEIBOWITZ HM, 1989, SURF OPHTHALMOL S, V24, P335; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Leist M, 1997, EUR J NEUROSCI, V9, P1488, DOI 10.1111/j.1460-9568.1997.tb01503.x; Leist M, 1999, EXP CELL RES, V249, P396, DOI 10.1006/excr.1999.4514; Leist M, 1998, MOL PHARMACOL, V54, P789, DOI 10.1124/mol.54.5.789; MAFTAH A, 1994, MECH AGEING DEV, V77, P83, DOI 10.1016/0047-6374(94)90017-5; Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609; Reinboth JJ, 1997, EXP EYE RES, V65, P639, DOI 10.1006/exer.1997.0367; Richter C, 1996, FEBS LETT, V378, P107, DOI 10.1016/0014-5793(95)01431-4; Salamon Z, 1996, BIOPHYS J, V71, P858, DOI 10.1016/S0006-3495(96)79287-1; SCHLEGEL J, 1992, BIOCHEM J, V285, P65, DOI 10.1042/bj2850065; Schousboe A., 1989, DISSECTION TISSUE CU, P203; Silvestri G, 1997, MOL MED TODAY, V3, P84, DOI 10.1016/S1357-4310(96)10057-5; Single B, 1998, CELL DEATH DIFFER, V5, P1001, DOI 10.1038/sj.cdd.4400462; SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448; Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988; Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Volbracht C, 1999, MOL MED, V5, P477; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Xu G Z, 1996, Trans Am Ophthalmol Soc, V94, P411; YOUNG RW, 1976, INVEST OPHTH VISUAL, V15, P700; YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392; Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401	56	240	252	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39625	39630		10.1074/jbc.M007049200	http://dx.doi.org/10.1074/jbc.M007049200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11006290	hybrid, Green Submitted			2022-12-25	WOS:000165953100089
J	Townson, JR; Graham, GJ; Landau, NR; Rasala, B; Nibbs, RJB				Townson, JR; Graham, GJ; Landau, NR; Rasala, B; Nibbs, RJB			Aminooxypentane addition to the chemokine macrophage inflammatory Protein-1 alpha P increases receptor affinities and HIV inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; GENETIC RESTRICTION; BETA-CHEMOKINES; RANTES; CCR5; POTENT; ANTAGONISTS; IDENTIFICATION; INDIVIDUALS; MIP-1-ALPHA	To enter its target cells, human immunodeficiency virus (HIV) must interact with CD4 and one of a family of chemokine receptors. CCR5 is widely used by the virus in this context, and its ligands can prevent HIV entry. Amino-terminal modified chemokine variants, in particular AOP-RANTES (aminooxypentane-linked regulated on activation normal T cell expressed and secreted), exhibit enhanced HIV entry inhibition. We have previously demonstrated that a non-allelic isoform of macrophage inflammatory protein (MIP)-l alpha termed MIP-1 alphaP, is the most active naturally occurring inhibitor of HIV entry known. Here we report the properties of a variant of MIP-l alphaP with an AOP group on the amino terminus. We show that, like RANTES, the addition of AOP to MIP-1 alphaP enhances its interactions with CCR1 and CCR5, allows more effective internalization of CCR5, and increases the ligand's potency as an inhibitor of HIV entry through CCR5. Importantly, AOP-MIP-l alphaP is about 10-fold more active than AOP-RANTES at inhibiting HIV entry, malting it the most effective chemokine-based inhibitor of HIV entry through CCR5 described to date. Surprisingly, the enhanced receptor interactions of AOP-MIP-1 alphaP do not translate into increased chemotaxis or coupling to calcium ion fluxes, suggesting that this protein should be viewed as a partial, rather than a full, agonist for CCR1 and CCR5.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Salk Inst Biol Studies, Infect Dis Lab, La Jolla, CA 92037 USA	Beatson Institute; Salk Institute	Nibbs, RJB (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	r.nibbs@beatson.gla.ac.uk	Graham, Gerard/D-1240-2009	Graham, Gerard/0000-0002-7801-204X; Nibbs, Robert/0000-0002-8150-0044	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043252] Funding Source: NIH RePORTER; NCI NIH HHS [CA7214] Funding Source: Medline; NIAID NIH HHS [AI43252] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Alkhatib G, 1997, VIROLOGY, V234, P340, DOI 10.1006/viro.1997.8673; ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Cairns JS, 1998, NAT MED, V4, P563, DOI 10.1038/nm0598-563; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; Furci L, 1997, J EXP MED, V186, P455, DOI 10.1084/jem.186.3.455; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; Gong JH, 1997, J EXP MED, V186, P131, DOI 10.1084/jem.186.1.131; Gosling J, 1997, P NATL ACAD SCI USA, V94, P5061, DOI 10.1073/pnas.94.10.5061; Graham GJ, 1992, GROWTH FACTORS, V7, P151, DOI 10.3109/08977199209046404; GRAHAM GJ, 1994, J BIOL CHEM, V269, P4974; GRAHAM GJ, 1993, CELL GROWTH DIFFER, V4, P137; Grone HJ, 1999, FASEB J, V13, P1371, DOI 10.1096/fasebj.13.11.1371; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; Jones SA, 1997, J BIOL CHEM, V272, P16166, DOI 10.1074/jbc.272.26.16166; Lalani AS, 1999, SCIENCE, V286, P1968, DOI 10.1126/science.286.5446.1968; Liu HL, 1999, P NATL ACAD SCI USA, V96, P4581, DOI 10.1073/pnas.96.8.4581; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; Martin MP, 1998, SCIENCE, V282, P1907, DOI 10.1126/science.282.5395.1907; MOSER B, 1993, J BIOL CHEM, V268, P7125; Nibbs RJB, 1999, J BIOL CHEM, V274, P17478, DOI 10.1074/jbc.274.25.17478; Nibbs RJB, 2000, J IMMUNOL, V164, P1488, DOI 10.4049/jimmunol.164.3.1488; Nibbs RJB, 1997, J BIOL CHEM, V272, P32078, DOI 10.1074/jbc.272.51.32078; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Panzer U, 1999, KIDNEY INT, V56, P2107, DOI 10.1046/j.1523-1755.1999.00767.x; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Price DA, 1998, CURR BIOL, V8, P355, DOI 10.1016/S0960-9822(98)70138-1; Proost P, 1998, J IMMUNOL, V160, P4034; Proost P, 1998, J BIOL CHEM, V273, P7222, DOI 10.1074/jbc.273.13.7222; Proudfoot AEI, 1999, J BIOL CHEM, V274, P32478, DOI 10.1074/jbc.274.45.32478; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259; Signoret N, 1998, J CELL SCI, V111, P2819; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Teixeira MM, 1997, J CLIN INVEST, V100, P1657, DOI 10.1172/JCI119690; Torre VS, 2000, J VIROL, V74, P4868, DOI 10.1128/JVI.74.10.4868-4876.2000; Vila-Coro AJ, 1999, J IMMUNOL, V163, P3037; Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129; Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yang OO, 1999, J VIROL, V73, P4582, DOI 10.1128/JVI.73.6.4582-4589.1999; Zagury D, 1998, P NATL ACAD SCI USA, V95, P3857, DOI 10.1073/pnas.95.7.3857; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	54	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39254	39261		10.1074/jbc.M006768200	http://dx.doi.org/10.1074/jbc.M006768200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11005816	hybrid			2022-12-25	WOS:000165953100043
J	Wang, XT; Martindale, JL; Holbrook, NJ				Wang, XT; Martindale, JL; Holbrook, NJ			Requirement for ERK activation in cisplatin-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SIGNAL-REGULATED KINASE; PROGRAMMED CELL-DEATH; PROTEIN-KINASE; CYTOCHROME-C; OXIDATIVE STRESS; CANCER CELLS; INDUCED CYTOTOXICITY; MAMMALIAN-CELLS; FACTOR RECEPTOR	Cisplatin activates multiple signal transduction pathways involved in coordinating cellular responses to stress, Here we demonstrate a requirement for extracellular signal-regulated protein kinase (ERK), a member of the mitogen-activated protein kinase family in mediating cisplatin-induced apoptosis of human cervical carcinoma HeLa cells. Cisplatin treatment resulted in dose- and time- dependent activation of ERK, That elevated ERK activity contributed to cell death by cisplatin was supported by several observations: 1) PD98059 and U0126, chemical inhibitors of the MEK/ERK signaling pathway, prevented apoptosis; 2) pretreatment of cells with TPA, an activator of the ERK pathway, enhanced their sensitivity to cisplatin; 3) suramin, a growth factor receptor antagonist that greatly suppressed ERK activation, likewise inhibited cisplatin-induced apoptosis; and, finally, 4) HeLa cell variants selected for cisplatin resistance showed reduced activation of ERK following cisplatin treatment. Cisplatin-induced apoptosis was associated with cytochrome c release and subsequent caspase-3 activation, both of which could be prevented by treatment with the MEK inhibitors. However, the caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone protected HeLa cells against apoptosis without affecting ERK activation. Taken together, our findings suggest that ERK activation plays an active role in mediating cisplatin-induced apoptosis of HeLa cells and functions upstream of caspase activation to initiate the apoptotic signal.	NIA, Cell Stress & Aging Sect, Biol Chem Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Holbrook, NJ (corresponding author), NIA, Cell Stress & Aging Sect, Biol Chem Lab, NIH, Box 12,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Martindale, Jennifer Luethy/AAD-1963-2022	Martindale, Jennifer Luethy/0000-0002-3234-6861				Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; CHU G, 1990, P NATL ACAD SCI USA, V87, P3324, DOI 10.1073/pnas.87.9.3324; CHU G, 1994, J BIOL CHEM, V269, P787; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Dixit M, 1997, J NATL CANCER I, V89, P365, DOI 10.1093/jnci/89.5.365; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fokstuen T, 1997, ANTICANCER RES, V17, P2347; Fulda S, 1997, CANCER RES, V57, P3823; Gao XS, 1995, ANTICANCER RES, V15, P1911; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hayakawa J, 1999, J BIOL CHEM, V274, P31648, DOI 10.1074/jbc.274.44.31648; HE H, 1997, CELL GROWTH DIFFER, V10, P307; Hocker M, 1998, J BIOL CHEM, V273, P23046, DOI 10.1074/jbc.273.36.23046; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; Kaneki M, 1999, MOL CELL BIOL, V19, P461; KRONING R, 1995, BRIT J CANCER, V72, P615, DOI 10.1038/bjc.1995.382; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Miyajima A, 1997, BRIT J CANCER, V76, P206, DOI 10.1038/bjc.1997.363; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Perez RP, 1998, EUR J CANCER, V34, P1535, DOI 10.1016/S0959-8049(98)00227-5; Persons DL, 1999, CLIN CANCER RES, V5, P1007; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Rao GN, 1996, ONCOGENE, V13, P713; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; Sasada T, 1996, J CLIN INVEST, V97, P2268, DOI 10.1172/JCI118668; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sutherland CL, 1996, J IMMUNOL, V157, P3381; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TIMMERBOSSCHA H, 1992, BRIT J CANCER, V66, P227, DOI 10.1038/bjc.1992.249; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zanella CL, 1996, CANCER RES, V56, P5334; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhou H, 2000, J BIOL CHEM, V275, P22868, DOI 10.1074/jbc.M909273199; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	54	586	599	2	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39435	39443		10.1074/jbc.M004583200	http://dx.doi.org/10.1074/jbc.M004583200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993883	hybrid			2022-12-25	WOS:000165953100068
J	Berg, BJV; Beard, WA; Wilson, SH				Berg, BJV; Beard, WA; Wilson, SH			DNA structure and aspartate 276 influence nucleotide binding to human DNA polymerase beta - Implication for the identity of the rate-limiting conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; BASE-EXCISION-REPAIR; DEPENDENT RNA-POLYMERASE; HEPATITIS-C VIRUS; CRYSTAL-STRUCTURE; KLENOW FRAGMENT; GAPPED DNA; REPLICATION FIDELITY; SECONDARY STRUCTURE; TERNARY COMPLEXES	Structures of DNA polymerase (pol) beta bound to single-nucleotide gapped DNA had revealed that the lyase and pol domains form a "doughnut-shaped" structure altering the dNTP binding pocket in a fashion that is not observed when bound to non-gapped DNA, We have investigated dNTP binding to pol beta -DNA complexes employing steady-state and pre-steady-state kinetics. Although po beta has a kinetic scheme similar to other DNA polymerases, polymerization by pol beta is limited by at least two partially rate-limiting steps: a conformational change after dNTP ground-state binding and product release. The equilibrium binding constant, K-d(dNTP) decreased and the insertion efficiency increased with a one-nucleotide gapped DNA substrate, as compared with non-gapped DNA. Valine substitution for Asp(276), which interacts with the base of the incoming nucleotide, increased the binding affinity for the incoming nucleotide indicating that the negative charge contributed by Asp(276) weakens binding and that an interaction between residue 276 with the incoming nucleotide occurs during ground-state binding. Since the interaction between Asp276 and the nascent base pair is observed only in the "closed" conformation of pol beta, the increased free energy in ground-state binding for the mutant suggests that the subsequent rate-limiting conformational change is not the "open" to "closed" structural transition, but instead is triggered in the closed pol conformation.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wilson, SH (corresponding author), NIEHS, Struct Biol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293				Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; Ahn JW, 1998, BIOCHEM J, V331, P79, DOI 10.1042/bj3310079; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; BEARD WA, 1994, J BIOL CHEM, V269, P28091; Beard WA, 1995, METHOD ENZYMOL, V262, P98; Beard WA, 1998, CHEM BIOL, V5, pR7, DOI 10.1016/S1074-5521(98)90081-3; Beard WA, 2000, MUTAT RES-DNA REPAIR, V460, P231, DOI 10.1016/S0921-8777(00)00029-X; BEARD WA, 1995, PRACTICAL APPROACH, V2, P15; BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CASASFINET JR, 1991, J BIOL CHEM, V266, P19618; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; DONLIN MJ, 1994, BIOCHEMISTRY-US, V33, P14908, DOI 10.1021/bi00253a030; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039; Feng JY, 1999, BIOCHEMISTRY-US, V38, P9440, DOI 10.1021/bi990709m; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; FREY MW, 1995, BIOCHEMISTRY-US, V34, P9185, DOI 10.1021/bi00028a031; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4; Hopfner KP, 1999, P NATL ACAD SCI USA, V96, P3600, DOI 10.1073/pnas.96.7.3600; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JAJU M, 1995, J BIOL CHEM, V270, P9740, DOI 10.1074/jbc.270.17.9740; KATI WM, 1992, J BIOL CHEM, V267, P25988; KOHISTAEDT LA, 1992, SCIENCE, V256, P1783; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUMAR A, 1990, J BIOL CHEM, V265, P2124; Lavrik OI, 1996, J BIOL CHEM, V271, P21891, DOI 10.1074/jbc.271.36.21891; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Lewis DA, 1999, J BIOL CHEM, V274, P32924, DOI 10.1074/jbc.274.46.32924; Li Y, 1998, PROTEIN SCI, V7, P1116, DOI 10.1002/pro.5560070505; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oliveros M, 1997, J BIOL CHEM, V272, P30899, DOI 10.1074/jbc.272.49.30899; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; PRASAD R, 1994, J BIOL CHEM, V269, P18096; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; SARAFIANOS SG, 1995, J BIOL CHEM, V270, P19729, DOI 10.1074/jbc.270.34.19729; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; Suo ZC, 1998, J BIOL CHEM, V273, P27259, DOI 10.1074/jbc.273.42.27259; TANABE K, 1979, BIOCHEMISTRY-US, V18, P3401, DOI 10.1021/bi00582a029; Wade RC, 1998, P NATL ACAD SCI USA, V95, P5942, DOI 10.1073/pnas.95.11.5942; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; WHARTON CW, 1981, MOL ENZYMOLOGY, P204; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0; Zhong XJ, 1997, BIOCHEMISTRY-US, V36, P11891, DOI 10.1021/bi963181j; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381; ZINNEN S, 1994, J BIOL CHEM, V269, P24195	62	139	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3408	3416		10.1074/jbc.M002884200	http://dx.doi.org/10.1074/jbc.M002884200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11024043	hybrid			2022-12-25	WOS:000166784900056
J	Heaton, JH; Dlakic, WM; Dlakic, M; Gelehrter, TD				Heaton, JH; Dlakic, WM; Dlakic, M; Gelehrter, TD			Identification and cDNA cloning of a novel RNA-binding protein that interacts with the cyclic nucleotide-responsive sequence in the type-1 plasminogen activator inhibitor mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOMA-CELLS; A+U-RICH ELEMENTS; MESSENGER-RNA; 3'-UNTRANSLATED REGION; GENE-EXPRESSION; POSTTRANSCRIPTIONAL REGULATION; STABILITY COMPLEX; AUF1; DESTABILIZATION; INCREASES	Incubation of HTC rat hepatoma cells with 8-bromo-cAMP results in a 3-fold increase in the rate of degradation of type-1 plasminogen activator inhibitor (PAI-1) mRNA. We have reported previously that the 3'-most 134 nt of the PAI-1 mRNA is able to confer cyclic nucleotide regulation of message stability onto a heterologous transcript. R-EMSA and UV cross-linking experiments have shown that this 134 nt cyclic nucleotide-responsive sequence (CRS) binds HTC cell cytoplasmic proteins ranging in size from 38 to 76 kDa. Mutations in the A-rich region of the CRS both eliminate cyclic nucleotide regulation of mRNA decay and abolish RN-protein complex formation, suggesting that these RNA-binding proteins may be important regulators of mRNA stability. By sequential R-EMSA and SOS-PAGE we have purified a protein from HTC cell polysomes that binds to the PAI-1 CRS. N-terminal sequence analysis and a search of protein data bases revealed identity with two human sequences of unknown function. We have expressed one of these sequences in E. coli and confirmed that the recombinant protein interacts specifically with the PAI-1 CRS, Mutation of the A-rich portion of the PAI-1 CRS reduces binding by the recombinant PAI-1 RNA-binding protein. The amino acid sequence of this protein includes an RGG box and two arginine-rich regions, but does not include other recognizable RNA binding motifs, Detailed analyses of nucleic acid and protein data bases demonstrate that blocks of this sequence are highly conserved in a number of metazoans, including Arabidopsis, Drosophila, birds, and mammals. Thus, we have described a novel RNA-binding protein that identifies a family of proteins with a previously undefined sequence motif. Our results suggest that this protein, PAI-RBP1, may play a role in regulation of mRNA stability.	Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Heaton, JH (corresponding author), Univ Michigan, Sch Med, Dept Human Genet, 4909 Buhl Bldg,Box 0618,1241 E Catherine, Ann Arbor, MI 48109 USA.	heatonj@umich.edu	Dlakic, Mensur/S-2702-2019	Dlakic, Mensur/0000-0003-4315-1514	NATIONAL CANCER INSTITUTE [R01CA022729, R37CA022729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER; NCI NIH HHS [CA22729] Funding Source: Medline; NIDDK NIH HHS [5 P60 DK-20572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Buzby JS, 1999, J BIOL CHEM, V274, P33973, DOI 10.1074/jbc.274.48.33973; Chkheidze AN, 1999, MOL CELL BIOL, V19, P4572; Cusack Stephen, 1999, Current Opinion in Structural Biology, V9, P66; DeMaria CT, 1997, J BIOL CHEM, V272, P27635, DOI 10.1074/jbc.272.44.27635; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Dieci G, 2000, PROTEIN EXPRES PURIF, V18, P346, DOI 10.1006/prep.2000.1203; Dodson RE, 1997, J BIOL CHEM, V272, P12249, DOI 10.1074/jbc.272.19.12249; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; HARGROVE JL, 1991, BIOESSAYS, V13, P667, DOI 10.1002/bies.950131209; HEATON JH, 1990, MOL ENDOCRINOL, V4, P171, DOI 10.1210/mend-4-1-171; HEATON JH, 1989, MOL ENDOCRINOL, V3, P349, DOI 10.1210/mend-3-2-349; HEATON JH, 1992, MOL ENDOCRINOL, V6, P53, DOI 10.1210/me.6.1.53; Heaton JH, 1998, J BIOL CHEM, V273, P14261, DOI 10.1074/jbc.273.23.14261; Henikoff JG, 2000, NUCLEIC ACIDS RES, V28, P228, DOI 10.1093/nar/28.1.228; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; KILEDJIAN M, 1995, EMBO J, V14, P4357, DOI 10.1002/j.1460-2075.1995.tb00110.x; KRUITHOF EKO, 1988, ENZYME, V40, P113, DOI 10.1159/000469153; Lai CH, 2000, GENOME RES, V10, P703, DOI 10.1101/gr.10.5.703; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Makeyev AV, 1999, J BIOL CHEM, V274, P24849, DOI 10.1074/jbc.274.35.24849; Nelson LD, 2000, J BIOL CHEM, V275, P5573, DOI 10.1074/jbc.275.8.5573; Neuwald AF, 1997, NUCLEIC ACIDS RES, V25, P1665, DOI 10.1093/nar/25.9.1665; Paulding WR, 1999, J BIOL CHEM, V274, P2532, DOI 10.1074/jbc.274.4.2532; Rajagopalan LE, 1997, PROG NUCLEIC ACID RE, V56, P257, DOI 10.1016/S0079-6603(08)61007-7; Ramos A, 1997, CURR OPIN STRUC BIOL, V7, P317, DOI 10.1016/S0959-440X(97)80046-2; RANISH JA, 1991, J BIOL CHEM, V266, P19320; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; Siomi H, 1997, CURR OPIN GENET DEV, V7, P345, DOI 10.1016/S0959-437X(97)80148-7; SYKES DE, 1992, DIFFERENTIATION, V50, P41, DOI 10.1111/j.1432-0436.1992.tb00484.x; Tillmann-Bogush M, 1999, J BIOL CHEM, V274, P1172, DOI 10.1074/jbc.274.2.1172; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; ZEHEB R, 1988, GENE, V73, P459, DOI 10.1016/0378-1119(88)90510-0; Zhang MC, 1999, MOL CELL BIOL, V19, P7314; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	46	94	100	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3341	3347		10.1074/jbc.M006538200	http://dx.doi.org/10.1074/jbc.M006538200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11001948	hybrid			2022-12-25	WOS:000166784900048
J	Oosterom, J; Garner, KM; den Dekker, WK; Nijenhuiss, WAJ; Gispen, WH; Burbach, JPH; Barsh, GS; Adan, RAH				Oosterom, J; Garner, KM; den Dekker, WK; Nijenhuiss, WAJ; Gispen, WH; Burbach, JPH; Barsh, GS; Adan, RAH			Common requirements for melanocortin-4 receptor selectivity of structurally unrelated melanocortin agonist and endogenous antagonist, Agouti protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; HYPOTHALAMUS; BINDING; MC4; EXPRESSION; PEPTIDES; OBESITY; CLONING; MICE; FORM	The activity of melanocortin receptors (MCR) is regulated by melanocortin peptide agonists and by the endogenous antagonists, Agouti protein and AgRP (Agouti-related protein). To understand how the selectivity for these structurally unrelated agonists and antagonist is achieved, chimeric and mutants MC3R and MC4R were expressed in cell lines and pharmacologically analyzed. A region containing the third extracellular loop, EC3, of MC4R was essential for selective Agouti protein antagonism. In addition, this part of MC4R, when introduced in MC3R, conferred Agouti protein antagonism. Further mutational analysis of this region of MC4R demonstrated that Tyr(268) was required for the selective interaction with Agouti protein, because a profound loss of the ability of Agouti protein to inhibit I-125-labeled [Nle(4),D-Phe(7)] alpha -melanocyte-stimulating hormone (MSH) binding was observed by the single mutation of Tyr(268) to Ile, This same residue conferred selectivity for the MC4R selective agonist, [D-Tyr(4)]MT-II, whereas it inhibited interaction with the MC3R-selective agonist, [Nle(4)]Lys-gamma (2)-MSH. Conversely, mutation of Ile(265) in MC3 (the corresponding residue of Tyr(268)) to Tyr displayed a gain of affinity for [D-Tyr(4)]MT-II, but not for Agouti protein, and a loss of affinity for [Me-4]Lys-gamma (2)-MSH as compared with wild-type MC3R. This single amino acid mutation thus confers the selectivity of MC3R toward a pharmacological profile like that observed for MC4R agonists but not for the antagonist, Agouti protein. Thus, selectivity for structurally unrelated ligands with opposite activities is achieved in a similar manner for MC4R but not for MC3R.	Univ Utrecht, Ctr Med, Dept Med Pharmacol, Rudolf Magnus Inst Neurosci, NL-3508 AB Utrecht, Netherlands; Stanford Univ, Sch Med, Howard Hughes Med Inst, Beckman Ctr B271A, Stanford, CA 94305 USA	Utrecht University; Utrecht University Medical Center; Howard Hughes Medical Institute; Stanford University	Adan, RAH (corresponding author), Univ Utrecht, Ctr Med, Dept Med Pharmacol, Rudolf Magnus Inst Neurosci, POB 85060, NL-3508 AB Utrecht, Netherlands.	r.a.h.adan@med.uu.nl						Bray GA, 2000, NATURE, V404, P672, DOI 10.1038/35007544; Broberger C, 1998, J COMP NEUROL, V402, P460; Broberger C, 1998, P NATL ACAD SCI USA, V95, P15043, DOI 10.1073/pnas.95.25.15043; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; Elias CF, 1998, J COMP NEUROL, V402, P442, DOI 10.1002/(SICI)1096-9861(19981228)402:4<442::AID-CNE2>3.0.CO;2-R; GANTZ I, 1993, J BIOL CHEM, V268, P15174; Haskell-Luevano C, 1999, ENDOCRINOLOGY, V140, P1408, DOI 10.1210/en.140.3.1408; Huang QH, 1999, AM J PHYSIOL-REG I, V276, pR864, DOI 10.1152/ajpregu.1999.276.3.R864; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Kiefer LL, 1998, BIOCHEMISTRY-US, V37, P991, DOI 10.1021/bi971913h; Kiefer LL, 1997, BIOCHEMISTRY-US, V36, P2084, DOI 10.1021/bi962647v; Kistler-Heer V, 1998, J NEUROENDOCRINOL, V10, P133; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; Miltenberger RJ, 1997, J NUTR, V127, pS1902, DOI 10.1093/jn/127.9.1902S; Mountjoy KG, 1999, ENDOCRINOLOGY, V140, P2167, DOI 10.1210/en.140.5.2167; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Oosterom J, 1999, J BIOL CHEM, V274, P16853, DOI 10.1074/jbc.274.24.16853; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schaaper WMM, 1998, LETT PEPT SCI, V5, P205, DOI 10.1023/A:1008877507882; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; Vergoni AV, 1999, EUR J PHARMACOL, V369, P11, DOI 10.1016/S0014-2999(99)00045-X; WOLFF GL, 1986, J HERED, V77, P151, DOI 10.1093/oxfordjournals.jhered.a110206; Yang YK, 1997, MOL ENDOCRINOL, V11, P274, DOI 10.1210/me.11.3.274; Yang YK, 1999, MOL ENDOCRINOL, V13, P148, DOI 10.1210/me.13.1.148	27	33	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					931	936		10.1074/jbc.M007261200	http://dx.doi.org/10.1074/jbc.M007261200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11024027	hybrid			2022-12-25	WOS:000166430900011
J	Sheng, SH; Li, JQ; McNulty, KA; Kieber-Emmons, T; Kleyman, TR				Sheng, SH; Li, JQ; McNulty, KA; Kieber-Emmons, T; Kleyman, TR			Epithelial sodium channel pore region - Structure and role in gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NA+ CHANNEL; CAENORHABDITIS-ELEGANS; CYSTEINE MUTAGENESIS; POTASSIUM CHANNEL; K+-CHANNEL; MEMBRANE TOPOLOGY; MOLECULAR-BASIS; ION PERMEATION; ALPHA-SUBUNIT; SELECTIVITY	Epithelial sodium channels (ENaC) have a crucial role in the regulation of extracellular fluid volume and blood pressure. To study the structure of the pore region of ENaC, the susceptibility of introduced cysteine residues to sulfhydryl-reactive methanethiosulfonate derivatives ((a-aminoethyl)methanethiosulfonate hydrobromide (MTSEA) and [(2-(trimethylammonium)ethyl]methanethiosulfonate bromide (MTSET)) and to Cd2+ was determined. Selected mutants within the amino-terminal portion (alpha Val(569)-alpha Trp(582)) of the pore region responded to MTSEA, MTSET, or Cd2+ with stimulation or inhibition of whole cell Na+ current. The reactive residues were not contiguous but were separated by 23 residues where substituted cysteine residues did not respond to the reagents and line one face of an cu-helix. The activation of (alpha S580C beta gamma mENaC by MTSET was associated with a large increase in channel open probability. Within the carboxyl-terminal portion (alpha Ser(583)-alpha Ser(592)) of the pore region, only one mutation (alpha S583C) conferred a rapid, nearly complete block by MTSEA, MTSET, and Cd2+, whereas several other mutant channels were partially blocked by MTSEA or Cd2+ but not by MTSET. Our data suggest that the outer pore of ENaC is formed by an cr-helix, followed by an extended region that forms a selectivity filter. Furthermore, our data suggest that the pore region participates in ENaC gating.	Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19104 USA; Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	Kleyman, TR (corresponding author), Div Renal, A919 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15213 USA.	kleyman@pitt.edu	Sheng, Shaohu/G-7052-2016	Sheng, Shaohu/0000-0002-7198-1702	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054354, P01DK050268] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK50268, DK54354] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams CM, 1998, J BIOL CHEM, V273, P30204, DOI 10.1074/jbc.273.46.30204; Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; Becchetti A, 2000, PFLUG ARCH EUR J PHY, V440, P556, DOI 10.1007/s004240050006; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Chiamvimonvat N, 1996, NEURON, V16, P1037, DOI 10.1016/S0896-6273(00)80127-0; Dart C, 1998, J PHYSIOL-LONDON, V511, P25, DOI 10.1111/j.1469-7793.1998.025bi.x; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; Eskandari S, 1999, J BIOL CHEM, V274, P27281, DOI 10.1074/jbc.274.38.27281; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Fyfe GK, 1999, J BIOL CHEM, V274, P36415, DOI 10.1074/jbc.274.51.36415; GARCIAANOVEROS J, 1995, CURR BIOL, V5, P441, DOI 10.1016/S0960-9822(95)00085-6; Grunder S, 1999, PFLUG ARCH EUR J PHY, V438, P709, DOI 10.1007/s004240051097; HILLE B, 1992, IONIC CHANNELS EXCIT, P276; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; Kellenberger S, 1999, J GEN PHYSIOL, V114, P13, DOI 10.1085/jgp.114.1.13; Khakh BS, 1999, NEURON, V23, P653, DOI 10.1016/S0896-6273(01)80025-8; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Kubo Y, 1998, FEBS LETT, V435, P69, DOI 10.1016/S0014-5793(98)01038-2; Liu Y, 1996, NEURON, V16, P859, DOI 10.1016/S0896-6273(00)80106-3; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; Melander O, 1998, HYPERTENSION, V31, P1118, DOI 10.1161/01.HYP.31.5.1118; PALMER LG, 1990, RENAL PHYSIOL BIOCH, V13, P51; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; RENARD S, 1994, J BIOL CHEM, V269, P12981; Roux B, 1999, SCIENCE, V285, P100, DOI 10.1126/science.285.5424.100; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; Schneggenburger R, 1997, NEURON, V18, P167, DOI 10.1016/S0896-6273(01)80055-6; Sheng SH, 2000, J BIOL CHEM, V275, P8572, DOI 10.1074/jbc.275.12.8572; Snyder PM, 1999, J BIOL CHEM, V274, P28484, DOI 10.1074/jbc.274.40.28484; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Sun ZP, 1996, NEURON, V16, P141, DOI 10.1016/S0896-6273(00)80031-8; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; TOMASELLI GF, 1995, BIOPHYS J, V68, P1814, DOI 10.1016/S0006-3495(95)80358-9; Tsushima RG, 1997, J GEN PHYSIOL, V110, P59, DOI 10.1085/jgp.110.1.59; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; Yamagishi T, 1997, BIOPHYS J, V73, P195, DOI 10.1016/S0006-3495(97)78060-3	45	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1326	1334		10.1074/jbc.M008117200	http://dx.doi.org/10.1074/jbc.M008117200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11022046	hybrid			2022-12-25	WOS:000166430900064
J	Bertrand, C; Chatonnet, A; Takke, C; Yan, YL; Postlethwait, J; Toutant, JP; Cousin, X				Bertrand, C; Chatonnet, A; Takke, C; Yan, YL; Postlethwait, J; Toutant, JP; Cousin, X			Zebrafish acetylcholinesterase is encoded by a single gene localized on linkage group 7 - Gene structure and polymorphism; Molecular forms and expression pattern during development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEBRATE GENOME EVOLUTION; C-TERMINAL DOMAINS; TRANSPOSABLE ELEMENTS; EMBRYONIC ZEBRAFISH; BUNGARUS-FASCIATUS; MESSENGER-RNA; MUSCLE; BUTYRYLCHOLINESTERASE; PROMOTER; BRAIN	We cloned and sequenced the acetylcholinesterase gene and cDNA of zebrafish, Danio rerio. We found a single gene (ache) located on linkage group LG7. The relative organization of ache, eng2, and shh genes is conserved between zebrafish and mammals and defines a synteny. Restriction fragment length polymorphism analysis was allowed to identify several allelic variations. We also identified two transposable elements in non-coding regions of the gene. Compared with other vertebrate acetylcholinesterase genes, ache gene contains no alternative splicing at 5' or 3' ends where only a T exon is present. The translated sequence is 60-80% identical to acetylcholinesterases of the vertebrates and exhibits an extra loop specific to teleosts. Analysis of molecular forms showed a transition, at the time of hatching, from the globular G4 form to asymmetric A12 form that becomes prominent in adults. In situ hybridization and enzymatic activity detection on whole embryos confirmed early expression of the acetylcholinesterase gene in nervous and muscular tissues. We found no butyrylcholinesterase gene or activity in Danio. These findings make zebrafish a promising model to study function of acetylcholinesterase during development and regulation of molecular forms assembly in vivo.	INRA, F-34060 Montpellier, France; Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA	INRAE; University of Oregon	Cousin, X (corresponding author), INRA, 2 Pl Viala, F-34060 Montpellier, France.	cousin@ensam.inra.fr	Yan, Yi/GSO-3046-2022; BERTRAND-GADAY, Christelle/ABA-8619-2021; Cousin, Xavier/E-2542-2013; Chatonnet, Arnaud/AAM-5569-2021; Chatonnet, Arnaud/E-2190-2017	BERTRAND-GADAY, Christelle/0000-0003-0461-2402; Cousin, Xavier/0000-0002-8520-3610; Chatonnet, Arnaud/0000-0002-4057-3896	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD022486] Funding Source: NIH RePORTER; NICHD NIH HHS [P01HD22486] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amores A, 1998, SCIENCE, V282, P1711, DOI 10.1126/science.282.5394.1711; Atanasova E, 1999, J BIOL CHEM, V274, P21078, DOI 10.1074/jbc.274.30.21078; BIGBEE JW, 2000, PHARMACOL THERAPEUT, V86, P29; Brimijoin S, 1999, ENVIRON HEALTH PERSP, V107, P59, DOI 10.2307/3434472; Chan RYY, 1999, P NATL ACAD SCI USA, V96, P4627, DOI 10.1073/pnas.96.8.4627; CHATONNET A, 1991, CELL MOL NEUROBIOL, V11, P119, DOI 10.1007/BF00712804; Cousin X, 1996, J BIOL CHEM, V271, P15099, DOI 10.1074/jbc.271.25.15099; Cousin X, 1998, J BIOL CHEM, V273, P9812, DOI 10.1074/jbc.273.16.9812; Durbin L, 2000, DEVELOPMENT, V127, P1703; Durliat M, 2000, EUR J BIOCHEM, V267, P549, DOI 10.1046/j.1432-1327.2000.01033.x; EKKER M, 1992, DEVELOPMENT, V116, P1001; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Feng GP, 1999, J CELL BIOL, V144, P1349, DOI 10.1083/jcb.144.6.1349; Grauso M, 1998, FEBS LETT, V424, P279, DOI 10.1016/S0014-5793(98)00191-4; GREENSPAN RJ, 1980, J COMP NEUROL, V189, P741, DOI 10.1002/cne.901890409; Hallbook F, 1999, CURR OPIN NEUROBIOL, V9, P616, DOI 10.1016/S0959-4388(99)00011-2; HANNEMAN E, 1989, J COMP NEUROL, V284, P350, DOI 10.1002/cne.902840303; HANNEMAN E, 1988, DEVELOPMENT, V103, P49; HANNEMAN EH, 1992, J EXP ZOOL, V263, P41, DOI 10.1002/jez.1402630106; HEIERHORST J, 1992, P NATL ACAD SCI USA, V89, P6798, DOI 10.1073/pnas.89.15.6798; Ivics Z, 1996, P NATL ACAD SCI USA, V93, P5008, DOI 10.1073/pnas.93.10.5008; Izsvak Z, 1996, P NATL ACAD SCI USA, V93, P1077, DOI 10.1073/pnas.93.3.1077; Izsvak Z, 1999, J MOL EVOL, V48, P13, DOI 10.1007/PL00006440; JBILO O, 1994, J BIOL CHEM, V269, P20829; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; KIMMEL CB, 1991, DEVELOPMENT, P47; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; Krejci E, 1999, J NEUROSCI, V19, P10672, DOI 10.1523/JNEUROSCI.19-24-10672.1999; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; LAYER PG, 1988, DEVELOPMENT, V102, P387; LAYER PG, 1990, BIOESSAYS, V12, P415, DOI 10.1002/bies.950120904; LEIBEL WS, 1988, J EXP ZOOL, V247, P209, DOI 10.1002/jez.1402470304; LIU DWC, 1992, J NEUROSCI, V12, P1859; Luo ZD, 1998, J BIOL CHEM, V273, P28486, DOI 10.1074/jbc.273.43.28486; Massoulie J, 1998, J PHYSIOLOGY-PARIS, V92, P183, DOI 10.1016/S0928-4257(98)80007-7; MAULET Y, 1990, NEURON, V4, P289, DOI 10.1016/0896-6273(90)90103-M; MURATANI K, 1991, P NATL ACAD SCI USA, V88, P11315, DOI 10.1073/pnas.88.24.11315; MUSSET F, 1987, BIOCHIMIE, V69, P147, DOI 10.1016/0300-9084(87)90247-1; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; Nornes S, 1998, MECH DEVELOP, V77, P185, DOI 10.1016/S0925-4773(98)00156-7; Pezzementi L, 1998, STRUCTURE AND FUNCTION OF CHOLINESTERASES AND RELATED PROTEINS, P105; Plasterk RHA, 1999, TRENDS GENET, V15, P326, DOI 10.1016/S0168-9525(99)01777-1; Postlethwait JH, 1998, NAT GENET, V18, P345, DOI 10.1038/ng0498-345; RANDALL WR, 1994, BBA-GENE STRUCT EXPR, V1218, P453, DOI 10.1016/0167-4781(94)90204-6; REINHARD E, 1994, DEVELOPMENT, V120, P1767; ROSS LS, 1992, J NEUROSCI, V12, P467; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sawada A, 2000, DEVELOPMENT, V127, P1691; Shimoda N, 1999, GENOMICS, V58, P219, DOI 10.1006/geno.1999.5824; Simon S, 1997, J BIOL CHEM, V272, P33045, DOI 10.1074/jbc.272.52.33045; Simon S, 1998, EMBO J, V17, P6178, DOI 10.1093/emboj/17.21.6178; STIEGER S, 1989, EUR J BIOCHEM, V181, P633, DOI 10.1111/j.1432-1033.1989.tb14770.x; TOUTANT JP, 1985, J NEUROCHEM, V44, P580, DOI 10.1111/j.1471-4159.1985.tb05452.x; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; Venters SJ, 1999, DEV DYNAM, V216, P219, DOI 10.1002/(SICI)1097-0177(199911)216:3<219::AID-DVDY1>3.0.CO;2-J; WESTERFIELD M, 1995, ZEBRAFISH BOOK; WILSON SW, 1990, DEVELOPMENT, V108, P121; Xie WH, 2000, J PHARMACOL EXP THER, V293, P896	60	78	82	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					464	474		10.1074/jbc.M006308200	http://dx.doi.org/10.1074/jbc.M006308200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11016933	hybrid, Green Published			2022-12-25	WOS:000166280700063
J	Dixon, TM; Daniel, KW; Farmer, SR; Collins, S				Dixon, TM; Daniel, KW; Farmer, SR; Collins, S			CCAAT/enhancer-binding protein alpha is required for transcription of the beta(3)-adrenergic receptor gene during adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIET-INDUCED OBESITY; PPAR-GAMMA; ADIPOSE-TISSUE; C/EBP-ALPHA; ADIPOCYTE DIFFERENTIATION; ADRENERGIC-RECEPTOR; ECTOPIC EXPRESSION; BROWN ADIPOCYTES; MESSENGER-RNA; BETA	The beta (3)-adrenergic receptor (beta (3)AR) is expressed predominantly in adipocytes, and it plays a major role in regulating lipolysis and adaptive thermogenesis, Its expression in a variety of adipocyte cell models is preceded by the appearance of CCAAT/enhancer-binding protein alpha (C/EBP alpha), which has been shown to regulate a number of other adipocyte-specific genes. Importantly, it has been demonstrated that several adipocyte cell lines that fail to express C/EBP alpha exhibit reduced insulin sensitivity, despite an apparent adipogenic phenotype, Here we show that transcription and function of the beta (3)AR correlates with C/EBP alpha expression in these adipocyte models. A 5.13-kilobase pair fragment of the mouse beta (3)AR promoter was isolated and sequenced. This fragment conferred a 50-fold increase in luciferase reporter gene expression in adipocytes, Two putative C/EBP binding sites exist at -3306 to -3298 and at -1462 to -1454, but only the more distal site is functional. Oligo nucleotides corresponding to both the wild-type and mutated -3306 element were inserted upstream of a thymidine kinase luciferase construct. When cotransfected in fibroblasts with a C/EBP alpha expression vector, reporter gene expression increased 3-fold only in the wild-type constructs, The same mutation, when placed into the intact 5.13-kilobase pair promoter, reduced promoter activity in adipocytes from 50-fold to <10-fold. Electrophoretic mobility shift analysis demonstrated that the site at -3306 generated a specific protein-oligonucleotide complex that was supershifted by C/EBP<alpha> antibody, while a probe corresponding to a putative site at -1462 did not. These results define C/EBP alpha as a key transcriptional regulator of the mouse beta (3)AR gene during adipogenesis.	Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Duke University; Duke University; Boston University	Collins, S (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol, Box 3557, Durham, NC 27710 USA.	colli008@mc.duke.edu		Farmer, Stephen/0000-0003-2483-2795	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053092] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK46793, R01DK53092] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCH JRS, 1984, NATURE, V309, P163, DOI 10.1038/309163a0; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; Cannon B, 1996, BIOCHEM SOC T, V24, P407, DOI 10.1042/bst0240407; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Collins S., 2000, Adipocyte biology and hormone signaling., P51; COLLINS S, 1988, J BIOL CHEM, V263, P9067; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; Collins S, 1996, J BIOL CHEM, V271, P9437, DOI 10.1074/jbc.271.16.9437; Collins S, 1997, ENDOCRINOLOGY, V138, P405, DOI 10.1210/en.138.1.405; Collins S, 1999, INT J OBESITY, V23, P669, DOI 10.1038/sj.ijo.0800894; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; Elberg G, 2000, J BIOL CHEM, V275, P27815; FEVE B, 1991, J BIOL CHEM, V266, P20329; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GETTYS TW, 1991, J BIOL CHEM, V266, P15949; GORMAN CM, 1984, PHILOS T ROY SOC B, V307, P343, DOI 10.1098/rstb.1984.0137; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HIMMSHAGEN J, 1994, AM J PHYSIOL, V266, pR1371, DOI 10.1152/ajpregu.1994.266.4.R1371; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; LARGIS EE, 1994, DRUG DEVELOP RES, V32, P69, DOI 10.1002/ddr.430320203; LAUDAT MH, 1975, EUR J BIOCHEM, V56, P583, DOI 10.1111/j.1432-1033.1975.tb02265.x; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; ROHLFS EM, 1995, J BIOL CHEM, V270, P10723, DOI 10.1074/jbc.270.18.10723; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Sasaki N, 1998, J VET MED SCI, V60, P465, DOI 10.1292/jvms.60.465; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; SHEPHERD RE, 1977, J BIOL CHEM, V252, P7243; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VANSPRONSEN A, 1993, EUR J BIOCHEM, V213, P1117, DOI 10.1111/j.1432-1033.1993.tb17861.x; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	47	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					722	728		10.1074/jbc.M008440200	http://dx.doi.org/10.1074/jbc.M008440200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024036	hybrid			2022-12-25	WOS:000166280700097
J	Sumi, T; Matsumoto, K; Nakamura, T				Sumi, T; Matsumoto, K; Nakamura, T			Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROCK, a rho-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN CYTOSKELETON; CLEAVAGE FURROW; ZINC-FINGER; GENOMIC ORGANIZATION; FOCAL ADHESIONS; CELL LOCOMOTION; CDNA CLONING; IN-VIVO; BINDING; CYTOKINESIS	LIM-kinase 1 (LIMK1) and LIM-kinase 2 (LIMK2) regulate actin cytoskeletal reorganization via cofilin phosphorylation downstream of distinct Rho family GTPases, We report our findings that ROCK, a downstream protein kinase of Rho, specifically activates LIMK2 but not LIMK1 downstream of RhoA LIMK1 and LIMH2 activities toward cofilin phosphorylation were stimulated by co-expression with the active form of ROCK (ROCKL-Delta3), whereas full-length ROCK selectively activates LIMH2 but not LIMK1. Activation of LIMX2 by RhoA was inhibited by Y-27632, a specific inhibitor of ROCK, but Rad-mediated activation of LIMK1 was not. ROCK directly phosphorylated the threonine 505 residue within the activation segment of LIMK2 and markedly stimulated LIMK2 activity. A LIMK2 mutant with replacement of threonine 505 by valine abolished LIMK2 activities for cofilin phosphorylation and actin cytoskeletal changes, whereas replacement by glutamate enhanced the protein kinase activity and stress fiber formation by LIMK2. These results indicate that ROCK directly phosphorylates threonine 505 and activates LIMK2 downstream of RhoA and that this phosphorylation is essential for LIMK2 to induce actin cytoskeletal reorganization. Together with the finding that LIMK1 is regulated by Pak1, LIMK1 and LIMK2 are regulated by different protein kinases downstream of distinct Rho family GTPases.	Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Oncol,Div Biochem, Suita, Osaka 5650871, Japan	Osaka University	Nakamura, T (corresponding author), Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Oncol,Div Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	nakamura@onbich.med.osaka-u.ac.jp	MATSUMOTO, Kunio/D-8441-2015	MATSUMOTO, Kunio/0000-0002-6532-4482				AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Ayscough KR, 1998, CURR OPIN CELL BIOL, V10, P102, DOI 10.1016/S0955-0674(98)80092-6; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bamburg JR, 1999, TRENDS CELL BIOL, V9, P364, DOI 10.1016/S0962-8924(99)01619-0; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Edwards DC, 1999, J BIOL CHEM, V274, P11352, DOI 10.1074/jbc.274.16.11352; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Ikebe C, 1997, GENOMICS, V46, P504, DOI 10.1006/geno.1997.5060; Inada H, 1999, J BIOL CHEM, V274, P34932, DOI 10.1074/jbc.274.49.34932; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kosako H, 1999, ONCOGENE, V18, P2783, DOI 10.1038/sj.onc.1202633; Kosako H, 1997, J BIOL CHEM, V272, P10333; Koshimizu U, 1997, BIOCHEM BIOPH RES CO, V241, P243, DOI 10.1006/bbrc.1997.7795; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MIZUNO K, 1994, ONCOGENE, V9, P1605; Mori T, 1997, MOL BRAIN RES, V45, P247, DOI 10.1016/S0169-328X(96)00257-4; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; NUNOUE K, 1995, ONCOGENE, V11, P701; OHASHI K, 1994, J BIOCHEM, V116, P636, DOI 10.1093/oxfordjournals.jbchem.a124573; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; SATO N, 1991, J CELL BIOL, V113, P321, DOI 10.1083/jcb.113.2.321; Schafer DA, 1995, ANNU REV CELL DEV BI, V11, P497, DOI 10.1146/annurev.cellbio.11.1.497; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Takahashi H, 1998, BIOCHEM BIOPH RES CO, V249, P138, DOI 10.1006/bbrc.1998.9094; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	47	238	245	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					670	676		10.1074/jbc.M007074200	http://dx.doi.org/10.1074/jbc.M007074200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11018042	hybrid			2022-12-25	WOS:000166280700090
J	Bengtsson, E; Aspberg, A; Heinegard, D; Sommarin, Y; Spillmann, D				Bengtsson, E; Aspberg, A; Heinegard, D; Sommarin, Y; Spillmann, D			The amino-terminal part of PRELP binds to heparin and heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; COLLAGEN FIBRILLOGENESIS; PROTEOGLYCAN DECORIN; PROTEIN; CARTILAGE; GLYCOSAMINOGLYCAN; FIBROMODULIN; FAMILY; DIVERSITY; HOMOLOGY	PRELP (proline, arginine-rich end leucine-rich repeat protein) is an extracellular matrix leucine-rich repeat protein. The amino-terminal region of PRELP differs from that of other leucine-rich repeat proteins in containing a high number of proline and arginine residues. The clustered proline and basic residues are conserved in rat, bovine, and human PRELP, Although the function of PRELP is not yet known, the clustered arginine residues suggest a heparan sulfate/heparin-binding capacity, We show here that PRELP indeed binds heparin and heparan sulfate. Truncated PRELP without the amino-terminal region does not bind heparin. The dissociation constant for the interaction of PRELP with heparin was determined by an in solution binding assay and by surface plasmon resonance analysis to be in the range of 10-30 nM A 6-mer heparin oligosaccharide was the smallest size showing binding to PRELP, The binding increased with increasing length up to an 18-mer and depended on the degree of sulfation of heparin as well as heparan sulfate, Sulfate groups at all positions were shown to be of importance for the binding. Fibroblasts bind PRELP, and this interaction is inhibited with heparin, suggesting a function for PRELP as a linker between the matrix and cell surface proteoglycans.	Univ Lund, Dept Cell & Mol Biol, Sect Connect Tissue Biol, SE-22100 Lund, Sweden; Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden	Lund University; Uppsala University	Heinegard, D (corresponding author), Univ Lund, Dept Cell & Mol Biol, Sect Connect Tissue Biol, POB 94, SE-22100 Lund, Sweden.		Bengtsson, Eva/AAA-1968-2019	Aspberg, Anders/0000-0002-6588-6944; Bengtsson, Eva/0000-0001-7075-1772				ADAMS ME, 1992, ANAL BIOCHEM, V202, P89, DOI 10.1016/0003-2697(92)90211-O; ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; BENGTSSON E, 1995, J BIOL CHEM, V270, P25639, DOI 10.1074/jbc.270.43.25639; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Feyzi E, 1997, J BIOL CHEM, V272, P24850, DOI 10.1074/jbc.272.40.24850; FISHER LW, 1989, J BIOL CHEM, V264, P4571; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HEINEGARD D, 1986, J BIOL CHEM, V261, P3866; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Kohfeldt E, 1996, EUR J BIOCHEM, V238, P333, DOI 10.1111/j.1432-1033.1996.0333z.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Moses J, 1997, EUR J BIOCHEM, V248, P767, DOI 10.1111/j.1432-1033.1997.t01-1-00767.x; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; Petersen F, 1999, J BIOL CHEM, V274, P12376, DOI 10.1074/jbc.274.18.12376; POSCHL E, 1994, EMBO J, V13, P3741, DOI 10.1002/j.1460-2075.1994.tb06683.x; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; Roden L., 1972, METHODS ENZYMOLOGY, V28, P73; Schmid F. Z., 1997, PROTEIN STRUCTURE PR, P261; SHINOMURA T, 1992, J BIOL CHEM, V267, P1265; SOMMARIN Y, 1989, EXP CELL RES, V184, P181, DOI 10.1016/0014-4827(89)90376-5; Sommarin Y, 1998, J BIOL CHEM, V273, P16723, DOI 10.1074/jbc.273.27.16723; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	45	53	61	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40695	40702		10.1074/jbc.M007917200	http://dx.doi.org/10.1074/jbc.M007917200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007795	hybrid			2022-12-25	WOS:000166114600007
J	Cruz, JC; Chang, TY				Cruz, JC; Chang, TY			Fate of endogenously synthesized cholesterol in Niemann-Pick type C1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; SPHINGOLIPID-STORAGE DISEASES; COENZYME-A REDUCTASE; HAMSTER OVARY CELLS; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; N-BUTYLDEOXYNOJIRIMYCIN; INTRACELLULAR-TRANSPORT; FIBROBLASTS; PROTEIN	Mammalian cells obtain cholesterol via two pathways: endogenous synthesis in the endoplasmic reticulum and exogenous sources mainly through the low density lipoprotein (LDL) receptor pathway. We performed pulse-chase experiments to monitor the fate of endogenously synthesized cholesterol and showed that, after reaching the plasma membrane from the endoplasmic reticulum, the newly synthesized cholesterol eventually accumulates in an internal compartment in Niemann-Pick type C1 (NPC1) cells. Thus, the ultimate fate of endogenously synthesized cholesterol in NPC1 cells is the same as LDL-derived cholesterol. However, the time required for endogenous cholesterol to accumulate internally is much slower than LDL-derived cholesterol. Different pathways thus govern the post-plasma membrane trafficking of endogenous cholesterol and LDL-derived cholesterol to the internal compartment, Results using the inhibitor N-butyldeoxynojirimycin, which depletes cellular complex glycosphingolipids, demonstrates that the cholesterol trafficking defect in NPC1 cells is not caused by ganglioside accumulation. The ultimate cause of death in NPC disease is progressive neurological deterioration in the central nervous system, where the major source of cholesterol is derived from endogenous synthesis. Our current study provides a plausible link between defects in intracellular trafficking of endogenous cholesterol and the etiology of Niemann-Pick type C disease.	Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Chang, TY (corresponding author), Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA.			Chang, Ta-Yuan/0000-0002-3249-0468	NHLBI NIH HHS [HL36709] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036709, R37HL036709] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BYERS DM, 1992, BIOCHIM BIOPHYS ACTA, V1138, P20, DOI 10.1016/0925-4439(92)90146-E; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CHANG CCY, 1986, BIOCHEMISTRY-US, V25, P1693, DOI 10.1021/bi00355a038; Chang CCY, 1998, J BIOL CHEM, V273, P35132, DOI 10.1074/jbc.273.52.35132; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; CHANG TY, 1980, J BIOL CHEM, V255, P7787; Chen CS, 1999, LANCET, V354, P901, DOI 10.1016/S0140-6736(98)10034-X; CHIN J, 1981, J BIOL CHEM, V256, P6304; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; Gu JZ, 1997, P NATL ACAD SCI USA, V94, P7378, DOI 10.1073/pnas.94.14.7378; Heino S, 2000, P NATL ACAD SCI USA, V97, P8375, DOI 10.1073/pnas.140218797; Henderson LP, 2000, J BIOL CHEM, V275, P20179, DOI 10.1074/jbc.M001793200; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; LANGE Y, 1994, J BIOL CHEM, V269, P3411; Lange Y, 1998, J BIOL CHEM, V273, P18915, DOI 10.1074/jbc.273.30.18915; LIMANEK JS, 1978, P NATL ACAD SCI USA, V75, P5452, DOI 10.1073/pnas.75.11.5452; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; Liu YJ, 2000, HUM MOL GENET, V9, P1087, DOI 10.1093/hmg/9.7.1087; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; Millard EE, 2000, J BIOL CHEM, V275, P38445, DOI 10.1074/jbc.M003180200; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Pentchev P. G., 1995, METABOLIC MOL BASIS; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Platt FM, 1997, SCIENCE, V276, P428, DOI 10.1126/science.276.5311.428; PLATT FM, 1994, J BIOL CHEM, V269, P8362; Platt FM, 1997, J BIOL CHEM, V272, P19365, DOI 10.1074/jbc.272.31.19365; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; SPILLANE DM, 1995, BBA-LIPID LIPID MET, V1254, P283, DOI 10.1016/0005-2760(94)00190-A; Turley SD, 1998, AM J PHYSIOL-ENDOC M, V274, pE1099, DOI 10.1152/ajpendo.1998.274.6.E1099; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; URBANI L, 1990, J BIOL CHEM, V265, P1919; Xie CL, 2000, J LIPID RES, V41, P1278; Yano T, 1996, P JPN ACAD B-PHYS, V72, P214, DOI 10.2183/pjab.72.214	42	79	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41309	41316		10.1074/jbc.M008272200	http://dx.doi.org/10.1074/jbc.M008272200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11013265	hybrid			2022-12-25	WOS:000166114600086
J	Lechner, T; Carrozza, MJ; Yu, YX; Grant, PA; Eberharter, A; Vannier, D; Brosch, G; Stillman, DJ; Shore, D; Workman, JL				Lechner, T; Carrozza, MJ; Yu, YX; Grant, PA; Eberharter, A; Vannier, D; Brosch, G; Stillman, DJ; Shore, D; Workman, JL			Sds3 (suppressor of defective silencing 3) is an integral component of the yeast Sin3 center dot Rpd3 histone deacetylase complex and is required for histone deacetylase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSION; ACETYLTRANSFERASE COMPLEXES; SACCHAROMYCES-CEREVISIAE; NUCLEOSOMAL ARRAYS; GENE ACTIVATION; MAIZE EMBRYOS; ADA-COMPLEX; N-COR; RPD3; ACETYLATION	SDS3 (suppressor of defective silencing 3) was originally identified in a screen for mutations that cause increased silencing of a crippled HMR silencer in a rap1 mutant background, In addition, sds3 mutants have phenotypes very similar to those seen in sind and rpd3 mutants, suggesting that it functions in the same genetic pathway. In this manuscript we demonstrate that Sds3p is an integral subunit of a previously identified high molecular weight Rpd3p.Sin3p containing yeast histone deacetylase complex. By analyzing an sds3 Delta strain we show that, in the absence of Sds3p, Sin3p can be chromatographically separated from Rpd3p, indicating that Sds3p promotes the integrity of the complex. Moreover, the remaining Rpd3p complex in the sds3 Delta strain had little or no histone deacetylase activity. Thus, Sds3p plays important roles in the integrity and catalytic activity of the Rpd3p.Sin3p complex.	Penn State Univ, Dept Biochem & Mol Biol, Howard Hughes Med Inst, University Pk, PA 16802 USA; Univ Utah, Hlth Sci Ctr, Dept Oncol Sci, Div Mol Biol & Genet, Salt Lake City, UT 84132 USA; Columbia Univ, Dept Microbiol, New York, NY 10032 USA; Univ Innsbruck, Sch Med, Dept Microbiol, A-6020 Innsbruck, Austria; Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland	Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Utah System of Higher Education; University of Utah; Columbia University; University of Innsbruck; University of Geneva	Workman, JL (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Howard Hughes Med Inst, University Pk, PA 16802 USA.	jlw10@psu.edu	Shore, David/F-6240-2015	Shore, David/0000-0002-9859-143X; VANNIER, DAVID/0000-0002-8753-2418; Stillman, David/0000-0002-5268-2416				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Brosch G, 1996, FEBS LETT, V393, P287, DOI 10.1016/0014-5793(96)00909-X; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Carmen AA, 1999, P NATL ACAD SCI USA, V96, P12356, DOI 10.1073/pnas.96.22.12356; Dorland S, 2000, GENETICS, V154, P573; Eberharter A, 1999, MOL CELL BIOL, V19, P6621; Eberharter A, 1998, METHODS, V15, P315, DOI 10.1006/meth.1998.0635; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Ikeda K, 1999, MOL CELL BIOL, V19, P855; John S, 2000, GENE DEV, V14, P1196; Johnson CA, 1999, SEMIN CELL DEV BIOL, V10, P179, DOI 10.1006/scdb.1999.0299; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KASTEN MM, 1997, MOL CELL BIOL, V17, P4215; Kolle D, 1998, METHODS, V15, P323, DOI 10.1006/meth.1998.0636; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; Lechner T, 2000, BIOCHEMISTRY-US, V39, P1683, DOI 10.1021/bi9918184; LOIDL P, 1994, CHROMOSOMA, V103, P441; Lusser A, 1997, SCIENCE, V277, P88, DOI 10.1126/science.277.5322.88; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Rossi V, 1998, MOL GEN GENET, V258, P288, DOI 10.1007/s004380050733; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Sendra R, 2000, J BIOL CHEM, V275, P24928, DOI 10.1074/jbc.M003783200; Steger DJ, 1998, P NATL ACAD SCI USA, V95, P12924, DOI 10.1073/pnas.95.22.12924; STILLMAN DJ, 1994, GENETICS, V136, P781; SUSSEL L, 1995, GENETICS, V141, P873; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Vannier D, 1996, GENETICS, V144, P1343; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; Vignali M, 2000, EMBO J, V19, P2629, DOI 10.1093/emboj/19.11.2629; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	40	75	77	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40961	40966		10.1074/jbc.M005730200	http://dx.doi.org/10.1074/jbc.M005730200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024051	Green Published			2022-12-25	WOS:000166114600041
J	So, SP; Li, DW; Ruan, KH				So, SP; Li, DW; Ruan, KH			Identification of the substrate interaction site in the N-terminal membrane anchor segment of thromboxane A(2) synthase by determination of its substrate analog conformational changes using high resolution NMR technique	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; COHERENCE TRANSFER; SMOOTH-MUSCLE; SPECTROSCOPY; PROSTACYCLIN; TOPOLOGY; BIOSYNTHESIS; ASSIGNMENT; METABOLISM; PROTEINS	The present studies describe an investigation for the interaction of N-terminal membrane anchor domain of thromboxane A(2) synthase (TXAS) with its substrate analog in a membrane-bound environment using the two-dimensional NMR technique. TXAS and prostaglandin I-2 synthase (PGIS), respectively, convert the same substrate, prostaglandin H-2 (PGH(2)), to thromboxane A, and prostaglandin I-2, which have opposite biological functions. Our topology studies have indicated that the N-terminal region of TXAS has a longer N-terminal endoplasmic reticulum (ER) membrane anchor region compared with the same segment proposed for PGIS, The differences in their interaction with the ER membrane may have an important impact to facilitate their common substrate, PGH(2), across the membrane into their active sites from the luminal to the cytoplasmic side of the ER. To test this hypothesis, we first investigated the interaction of the TXAS N-terminal membrane anchor domain with its substrate analog. A synthetic peptide corresponding to the N-terminal membrane anchor domain (residues 135) of TXAS, which adopted a stable helical structure and exhibited a membrane anchor function in the membrane-bound environment, was used to interact with a stable PGH, analog, U44069, High resolution two-dimensional NMR experiments, NOESY and TOCSY, were performed to solve the solution structures of U44069 in a membrane-mimicking environment using dodecylphosphocholine micelles, Different U44069 conformations were clearly observed in the presence and absence of the TXAS N-terminal membrane anchor domain, Through combination of the two-dimensional NMR experiments, completed H-1 NMR assignments of U44069 were obtained, and the data were used to construct three-dimensional structures of U44069 in H2O and dodecylphosphocholine micelles, showing the detailed conformation change upon the interaction with the membrane anchor domain, The observation supported the presence of a substrate interaction site in the N-terminal region. The combination of the structural information of U44069 and U46619 was able to simulate a solution structure of the unstable TXAS and PGIS substrate, PGH(2).	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Vasc Biol Res Ctr, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Ruan, KH (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, 6431 Fannin St, Houston, TX 77030 USA.	kruan@imed2010.med.uth.tmc.edu			NHLBI NIH HHS [HL56712] Funding Source: Medline; NINDS NIH HHS [NS23327] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056712, R29HL056712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BASUS VJ, 1989, METHOD ENZYMOL, V177, P132; BAX A, 1985, J MAGN RESON, V61, P306, DOI 10.1016/0022-2364(85)90085-X; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BUNTING S, 1976, PROSTAG OTH LIPID M, V12, P897, DOI 10.1016/0090-6980(76)90125-8; CHAZIN WJ, 1988, J MOL BIOL, V202, P603, DOI 10.1016/0022-2836(88)90290-2; ENGLANDER SW, 1987, BIOCHEMISTRY-US, V26, P5953, DOI 10.1021/bi00393a001; GRANSTROM E, 1982, PROSTAGLANDINS CARDI, P15; HECKER M, 1989, J BIOL CHEM, V264, P141; INGERMANWOJENSKI C, 1981, J CLIN INVEST, V67, P1292, DOI 10.1172/JCI110157; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Lin YZ, 1998, ARCH BIOCHEM BIOPHYS, V352, P78, DOI 10.1006/abbi.1998.0599; MAJERUS PW, 1983, J CLIN INVEST, V72, P1521, DOI 10.1172/JCI111110; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V22, P1970; MILLER DK, 1985, J BIOL CHEM, V260, P1006; MONCADA S, 1977, THROMB RES, V11, P323, DOI 10.1016/0049-3848(77)90185-2; MOORE WT, 1991, TECHNIQUES PROTEIN C, V2, P511; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; OTTO JC, 1994, J BIOL CHEM, V269, P19868; Peterson Julian A., 1995, P151; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; REN Y, 1995, ARCH BIOCHEM BIOPHYS, V323, P205, DOI 10.1006/abbi.1995.0027; RUAN KH, 1993, J BIOL CHEM, V268, P19483; Ruan KH, 1998, BIOCHEMISTRY-US, V37, P822, DOI 10.1021/bi971881y; RUAN KH, 1994, J BIOL CHEM, V269, P20938; RUAN KH, 1991, BIOCHEM J, V274, P849, DOI 10.1042/bj2740849; SMITH WL, 1986, ANNU REV PHYSIOL, V48, P251; SMITH WL, 1983, J BIOL CHEM, V258, P5922; Wang LH, 1996, J BIOL CHEM, V271, P19970, DOI 10.1074/jbc.271.33.19970; WEKSLER BB, 1978, J CLIN INVEST, V62, P923, DOI 10.1172/JCI109220; WUTHRICH K, 1986, NMR PROTEINS NUCL AC, P44	32	11	11	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40679	40685		10.1074/jbc.M005752200	http://dx.doi.org/10.1074/jbc.M005752200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11006279	hybrid			2022-12-25	WOS:000166114600005
J	Bettati, S; Benci, S; Campanini, B; Raboni, S; Chirico, G; Beretta, S; Schnackerz, KD; Hazlett, TL; Gratton, E; Mozzarelli, A				Bettati, S; Benci, S; Campanini, B; Raboni, S; Chirico, G; Beretta, S; Schnackerz, KD; Hazlett, TL; Gratton, E; Mozzarelli, A			Role of pyridoxal 5 '-phosphate in the structural stabilization of O-acetylserine sulfhydrylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM LT-2; TIME-RESOLVED FLUORESCENCE; ESCHERICHIA-COLI; ASPARTATE-AMINOTRANSFERASE; TRYPTOPHAN SYNTHASE; MULTIENZYME COMPLEX; GUANIDINE-HYDROCHLORIDE; 3-DIMENSIONAL STRUCTURE; CONFORMATIONAL-CHANGE; CYSTEINE SYNTHETASE	Proteins belonging to the superfamily of pyridoxal 5'-phosphate-dependent enzymes are currently classified into three functional groups and five distinct structural fold types. The variation within this enzyme group creates an ideal system to investigate the relationships among amino acid sequences, folding pathways, and enzymatic functions. The number of known three-dimensional structures of pyridoxal 5'-phosphate-dependent enzymes is rapidly increasing, but only for relatively few have the folding mechanisms been characterized in detail. The dimeric O-acetylserine sulfhydrylase from Salmonella typhimurium belongs to the beta -family and fold type II group. Here we report the guanidine hydrochloride-induced unfolding of the apo- and holoprotein, investigated using a variety of spectroscopic techniques. Data from absorption, fluorescence, circular dichroism, P-31 nuclear magnetic resonance, time-resolved fluorescence anisotropy, and photon correlation spectroscopy indicate that the O-acetylserine sulfhydrylase undergoes extensive disruption of native secondary and tertiary structure before monomerization. Also, we have observed that the holo-O-acetylserine sulfhydrylase exhibits a greater conformational stability than the apoenzyme form. The data are discussed in light of the fact that the role of the coenzyme in structural stabilization varies among the pyridoxal 5'-phosphate-dependent enzymes and does not seem to be linked to the particular enzyme fold type.	Univ Parma, Inst Biochem Sci, I-43100 Parma, Italy; Univ Parma, Inst Phys Sci, I-43100 Parma, Italy; Univ Parma, Natl Inst Phys Matter, I-43100 Parma, Italy; Univ Milan, Dept Phys, I-20133 Milan, Italy; Univ Birmingham, Sch Chem, Birmingham B15 2TT, W Midlands, England; Univ Illinois, Fluorescence Dynam Lab, Urbana, IL 61801 USA	University of Parma; University of Parma; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Parma; University of Milan; University of Birmingham; University of Illinois System; University of Illinois Urbana-Champaign	Mozzarelli, A (corresponding author), Univ Parma, Inst Biochem Sci, I-43100 Parma, Italy.	biochim@unipr.it	Bettati, Stefano/V-9975-2018; Campanini, Barbara/L-9723-2017; Mozzarelli, Andrea/C-3615-2014; RABONI, Samanta/P-7823-2018	Bettati, Stefano/0000-0001-6787-0594; Campanini, Barbara/0000-0003-0359-0627; Mozzarelli, Andrea/0000-0003-3762-0062; RABONI, Samanta/0000-0003-3068-3714; CHIRICO, Giuseppe/0000-0001-6578-6460	NCRR NIH HHS [RR03155] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; ARTIGUES A, 1994, J BIOL CHEM, V269, P21990; BALK H, 1981, BIOCHEMISTRY-US, V20, P6391, DOI 10.1021/bi00525a017; BECKER MA, 1969, J BIOL CHEM, V244, P2418; Beechem J. M., 1988, SPIE, V909, P70; Benci S, 1999, BBA-PROTEIN STRUCT M, V1429, P317, DOI 10.1016/S0167-4838(98)00229-5; Benci S, 1997, BIOCHEMISTRY-US, V36, P15419, DOI 10.1021/bi970464i; Benci S, 1999, J PHOTOCH PHOTOBIO B, V48, P17, DOI 10.1016/S1011-1344(99)00003-2; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burkhard P, 1999, J MOL BIOL, V291, P941, DOI 10.1006/jmbi.1999.3002; Burkhard P, 1998, J MOL BIOL, V283, P121, DOI 10.1006/jmbi.1998.2037; CAI K, 1995, J BIOL CHEM, V270, P19294, DOI 10.1074/jbc.270.33.19294; Chen CH, 1998, ARCH BIOCHEM BIOPHYS, V349, P175, DOI 10.1006/abbi.1997.0457; Chirico G, 1999, APPL OPTICS, V38, P2059, DOI 10.1364/AO.38.002059; Christen P, 1985, TRANSAMINASES; COOK PF, 1978, J BIOL CHEM, V253, P7874; COOK PF, 1977, ARCH BIOCHEM BIOPHYS, V178, P293, DOI 10.1016/0003-9861(77)90194-1; Cunningham EL, 1999, P NATL ACAD SCI USA, V96, P11008, DOI 10.1073/pnas.96.20.11008; DOMINICI P, 1993, BIOCHEM J, V295, P493, DOI 10.1042/bj2950493; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; HARA S, 1990, PROTEIN EXPRES PURIF, V1, P79; HAZLETT TL, 1993, BIOCHEMISTRY-US, V32, P13575, DOI 10.1021/bi00212a025; HEROLD M, 1992, FEBS LETT, V308, P26, DOI 10.1016/0014-5793(92)81042-K; HEROLD M, 1990, BIOCHEMISTRY-US, V29, P1907, DOI 10.1021/bi00459a035; Hindson VJ, 2000, J BIOL CHEM, V275, P461, DOI 10.1074/jbc.275.1.461; HYDE CC, 1988, J BIOL CHEM, V263, P17857; IVANOV VI, 1973, EUR J BIOCHEM, V40, P519, DOI 10.1111/j.1432-1033.1973.tb03222.x; JAENICKE R, 1991, EUR J BIOCHEM, V202, P715, DOI 10.1111/j.1432-1033.1991.tb16426.x; JAMESON RM, 1991, BIOPHYSICAL BIOCH AS, P105; KALLEN RG, 1985, TRANSAMINASES, P37; KAWAHARA K, 1966, J BIOL CHEM, V241, P3228; KREDICH NM, 1969, J BIOL CHEM, V244, P2428; KREDICH NM, 1966, J BIOL CHEM, V241, P4955; LAKOWICZ JR, 1983, TOPICS FLUORESCENCE, P241; LEISTLER B, 1992, EUR J BIOCHEM, V205, P603, DOI 10.1111/j.1432-1033.1992.tb16818.x; MCCLURE GD, 1994, BIOCHEMISTRY-US, V33, P1674, DOI 10.1021/bi00173a009; MEI G, 1992, BIOCHEMISTRY-US, V31, P7224, DOI 10.1021/bi00147a003; MIZOBATA T, 1995, J BIOCHEM, V117, P384, DOI 10.1093/jb/117.2.384; Mozzarelli A, 1998, J MOL BIOL, V283, P135, DOI 10.1006/jmbi.1998.2038; MUNRO I, 1979, P NATL ACAD SCI USA, V76, P56, DOI 10.1073/pnas.76.1.56; NEET KE, 1994, PROTEIN SCI, V3, P2167, DOI 10.1002/pro.5560031202; Nozaki Y, 1972, Methods Enzymol, V26, P43; Pace C N, 1986, Methods Enzymol, V131, P266; RAIBAUD O, 1973, J BIOL CHEM, V248, P3451; Rege VD, 1996, BIOCHEMISTRY-US, V35, P13485, DOI 10.1021/bi961517j; RELIMPIO A, 1981, J BIOL CHEM, V256, P4478; REMETA DP, 1995, PURE APPL CHEM, V67, P1859, DOI 10.1351/pac199567111859; REYES AM, 1993, J BIOL CHEM, V268, P22281; Schnackerz KD, 1995, ARCH BIOCHEM BIOPHYS, V324, P71, DOI 10.1006/abbi.1995.9927; SCHNACKERZ KD, 1995, BIOCHEMISTRY-US, V34, P12152, DOI 10.1021/bi00038a008; Schneider G, 2000, STRUCT FOLD DES, V8, pR1, DOI 10.1016/S0969-2126(00)00085-X; SEIFERT T, 1985, BIOCHEMISTRY-US, V24, P339, DOI 10.1021/bi00323a016; SKRZYNIA C, 1974, J BIOL CHEM, V249, P2325; Sohl JL, 1998, NATURE, V395, P817, DOI 10.1038/27470; Steiner R. F., 1991, TOPICS FLUORESCENCE, V2, P1, DOI DOI 10.1007/0-306-47058-6_; Strambini GB, 1996, BIOCHEMISTRY-US, V35, P8392, DOI 10.1021/bi952919e; TAI CH, 1993, BIOCHEMISTRY-US, V32, P6433, DOI 10.1021/bi00076a017; Tanford C., 1961, PHYS CHEM MACROMOLEC; TOYAMA H, 1991, J BIOCHEM-TOKYO, V110, P279, DOI 10.1093/oxfordjournals.jbchem.a123571; Venkatesha B, 1998, BBA-PROTEIN STRUCT M, V1384, P141, DOI 10.1016/S0167-4838(98)00013-2; WEBER G, 1977, J CHEM PHYS, V66, P4081, DOI 10.1063/1.434481; WEBER G, 1960, BIOCHEM J, V75, P335, DOI 10.1042/bj0750335; ZETINA CR, 1980, J BIOL CHEM, V255, P4381	65	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40244	40251		10.1074/jbc.M007015200	http://dx.doi.org/10.1074/jbc.M007015200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10995767	Green Published, hybrid			2022-12-25	WOS:000166039500062
J	Dhakshinamoorthy, S; Jaiswal, AK				Dhakshinamoorthy, S; Jaiswal, AK			Small Maf (MafG and MafK) proteins negatively regulate antioxidant response element-mediated expression and antioxidant induction of the NAD(P)H : quinone oxidoreductase1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; YA-SUBUNIT GENE; CONTROLLING INDUCIBLE EXPRESSION; TRANSCRIPTION FACTOR NRF2; OXIDATIVE STRESS; PHENOLIC ANTIOXIDANTS; DETOXIFYING ENZYMES; HEME OXYGENASE-1; C-FOS; FAMILY	The antioxidant response element (ARE) is known to regulate expression and induction of NQO1, GST Ya, and other detoxifying enzyme genes in response to antioxidants and xenobiotics. The nuclear transcription factor Nrf2 and Nrf1 bind to the ARE and positively regulate expression and induction of the NQO1 and GST Ya genes. In this study, we demonstrate that overexpression of small Maf (MafG and MafK) proteins negatively regulate ARE-mediated expression and tert-butyl hydroquinone induction of the NQO1 and GST Ya genes in transfected Hep-G2 cells. In similar experiments, overexpression of small Maf proteins also repressed Nrf2-mediated up-regulation of ARE-mediated NQO1 and GST Ya genes expression in Hep-G2 cells co-transfected with Nrf2 and small Maf proteins. Band and supershift assays with the NQO1 gene ARE and nuclear proteins demonstrate that small MafG and MafK bind to the ARE as Maf-Maf homodimers and Maf-Nrf2 heterodimers. Therefore, Maf-Maf homodimers and possibly Maf-Nrf2 heterodimers play a role in negative regulation of ARE-mediated transcription and antioxidant induction of NQO1 and other detoxifying enzyme genes. In contrast to Maf-Nrf2, the Maf-Nrf1 heterodimers failed to bind with the NQO1 gene ARE and did not demonstrate the repressive effect in transfection assays.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.	ajaiswal@bcm.tmc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047466, R01GM047466] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; CRESTEIL T, 1991, BIOCHEM PHARMACOL, V42, P1021, DOI 10.1016/0006-2952(91)90284-C; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; JAISWAL AK, 1994, J BIOL CHEM, V269, P14502; Jaiswal AK, 1999, INT CONGR SER, V1172, P103; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; Kwong M, 1999, J BIOL CHEM, V274, P37491, DOI 10.1074/jbc.274.52.37491; LI Y, 1992, J BIOL CHEM, V267, P15097; Liu SX, 1996, BIOCHEMISTRY-US, V35, P11517, DOI 10.1021/bi960572p; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; MONINOVA H, 1999, BIOCHEM BIOPH RES CO, V261, P661; Montano MM, 1998, J BIOL CHEM, V273, P25443, DOI 10.1074/jbc.273.39.25443; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; OESCH F, 1991, NATO ADV SCI I A-LIF, V202, P447; OKUDA A, 1990, EMBO J, V9, P1131, DOI 10.1002/j.1460-2075.1990.tb08219.x; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; Radjendirane Venugopal, 1997, P441; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SCHLAGER JJ, 1990, INT J CANCER, V45, P403, DOI 10.1002/ijc.2910450304; Talalay P, 1995, TOXICOL LETT, V82-3, P173, DOI 10.1016/0378-4274(95)03553-2; TEPHLY TR, 1990, TRENDS PHARMACOL SCI, V11, P276, DOI 10.1016/0165-6147(90)90008-V; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; VASLIOU V, 1995, BIOCHEM PHARMACOL, V12, P2057; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wilkinson J, 1998, BIOCHEM BIOPH RES CO, V253, P855, DOI 10.1006/bbrc.1998.9804; XIE T, 1995, J BIOL CHEM, V270, P6894, DOI 10.1074/jbc.270.12.6894; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972	46	174	180	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40134	40141		10.1074/jbc.M003531200	http://dx.doi.org/10.1074/jbc.M003531200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11013233	hybrid			2022-12-25	WOS:000166039500047
J	Jung, K; Veen, M; Altendorf, K				Jung, K; Veen, M; Altendorf, K			K+ and ionic strength directly influence the autophosphorylation activity of the putative turgor sensor KdpD of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-VESICLES; KINASE KDPD; OPERON EXPRESSION; OSMOTIC-STRESS; ATP CHANNELS; TRANSPORT; SYSTEM; POTASSIUM; RECONSTITUTION; OSMOSENSOR	The membrane-bound histidine kinase KdpD is a putative turgor sensor that regulates, together with the response regulator KdpE, the expression of the Kdp-FABC operon coding for the high affinity K+-uptake system KdpFABC of Escherichia coli. To elucidate the nature of the primary stimulus for KdpD, we developed an in vitro assay based on right-side-out membrane vesicles. Conditions were varied inside and outside of the vesicles, and KdpD autophosphorylation activity was tested. It was shown that an increase of the ionic strength inside the vesicles was accompanied by an increase of the autophosphorylation activity of KdpD with ATP. However, K+ at concentrations higher than 1 mM inhibited KdpD autophosphorylation activity. This KC specific effect was not observed with KdpD-Arg-511 --> Gln, a KdpD derivative, which causes K+-independent kdpFABC expression. When the osmolality outside the vesicles was increased, autophosphorylation activity of KdpD was stimulated, whereby salts were more effective than sugars. Treatment of the vesicles with amphipathic compounds did not affect KdpD autophosphorylation activity. Based on these results it is proposed that changes of intracellular parameters elicited by K+ limitation or osmotic upshock directly influence KdpD autophosphorylation activity, whereby K+ has an inhibitory and ionic strength a stimulatory effect.	Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany; Tech Univ Berlin, Inst Biotechnol, Fachgebiet Mikrobiol & Genet, D-13355 Berlin, Germany	University Osnabruck; Technical University of Berlin	Jung, K (corresponding author), Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany.	jung_k@biologie.uni-osnabrueck.de						ALTENDORF K, 1996, BIOMEMBR, V5, P403; ASHA H, 1993, J BACTERIOL, V175, P4528, DOI 10.1128/JB.175.14.4528-4537.1993; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; Frymier JS, 1997, J BACTERIOL, V179, P3061, DOI 10.1128/jb.179.9.3061-3063.1997; Heermann R, 2000, J BIOL CHEM, V275, P17080, DOI 10.1074/jbc.M000093200; HUGENHOLTZ J, 1981, P NATL ACAD SCI-BIOL, V78, P3446, DOI 10.1073/pnas.78.6.3446; Jung K, 1997, J BIOL CHEM, V272, P10847; Jung K, 1998, J BIOL CHEM, V273, P26415, DOI 10.1074/jbc.273.41.26415; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KOLLMANN R, 1993, BIOCHIM BIOPHYS ACTA, V1143, P62, DOI 10.1016/0005-2728(93)90216-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIMINS LA, 1981, P NATL ACAD SCI-BIOL, V78, P464, DOI 10.1073/pnas.78.1.464; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; Malli R, 1998, J BACTERIOL, V180, P5102, DOI 10.1128/JB.180.19.5102-5108.1998; MILNER JL, 1988, J BIOL CHEM, V263, P14900; NAKASHIMA K, 1993, J BIOCHEM-TOKYO, V114, P615, DOI 10.1093/oxfordjournals.jbchem.a124226; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POLAREK JW, 1992, J BACTERIOL, V174, P2145, DOI 10.1128/JB.174.7.2145-2151.1992; RAMOS S, 1976, P NATL ACAD SCI USA, V73, P1892, DOI 10.1073/pnas.73.6.1892; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P143, DOI 10.1016/S0968-0004(98)01196-7; Roe AJ, 2000, MOL MICROBIOL, V35, P1235, DOI 10.1046/j.1365-2958.2000.01793.x; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Stallkamp I, 1999, ARCH MICROBIOL, V172, P295, DOI 10.1007/s002030050783; SUGIURA A, 1992, MOL MICROBIOL, V6, P1769, DOI 10.1111/j.1365-2958.1992.tb01349.x; SUGIURA A, 1994, MOL MICROBIOL, V14, P929, DOI 10.1111/j.1365-2958.1994.tb01328.x; SUTHERLAND L, 1986, J BACTERIOL, V168, P805, DOI 10.1128/jb.168.2.805-814.1986; Tjaden J, 1998, J BIOL CHEM, V273, P9630, DOI 10.1074/jbc.273.16.9630; VOELKNER P, 1993, EUR J BIOCHEM, V217, P1019, DOI 10.1111/j.1432-1033.1993.tb18333.x; WALDERHAUG MO, 1992, J BACTERIOL, V174, P2152, DOI 10.1128/JB.174.7.2152-2159.1992; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZIMMANN P, 1995, J BIOL CHEM, V270, P28282	33	58	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40142	40147		10.1074/jbc.M008917200	http://dx.doi.org/10.1074/jbc.M008917200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11016946	hybrid			2022-12-25	WOS:000166039500048
J	Okuda, T; Mita, S; Yamauchi, S; Fukuta, N; Nakano, H; Sawada, T; Habuchi, O				Okuda, T; Mita, S; Yamauchi, S; Fukuta, N; Nakano, H; Sawada, T; Habuchi, O			Molecular cloning and characterization of GalNAc (4-sulfotransferase expressed in human pituitary gland	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; FIBROBLAST GROWTH-FACTOR; L-SELECTIN LIGAND; CHONDROITIN 6-SULFOTRANSFERASE; HEPARAN-SULFATE; GLYCOPROTEIN HORMONES; CARBONIC-ANHYDRASE; SIALYLATED OLIGOSACCHARIDES; STRUCTURAL ELUCIDATION	We have previously cloned chondroitin-4-sulfotransferase (C4ST) cDNA from mouse brain. In this paper, we report cloning and characterization of GalNAc 4-sulfotransferase (GalNAc4ST), which transfers sulfate to position 4 of the nonreducing terminal GalNAc residue. The obtained cDNA contains a single open reading frame that predicts a type II transmembrane protein composed of 424 amino acid residues. Identity of the amino acid sequence between GalNAc4ST and human C4ST was 30%. When the cDNA was transfected in COS-7 cells, sulfotransferase activity toward carbonic anhydrase VI was overexpressed but no sulfotransferase activity toward chondroitin or desulfated dermatan sulfate was increased over the control. Sulfation of carbonic anhydrase VI by the recombinant GalNAc4ST occurred at position 4 of the GalNAc residue of N-linked oligosaccharides. The recombinant GalNAc4ST transferred sulfate to position 4 of GalNAc residue of p-nitrophenyl GalNAc, indicating that this sulfotransferase transfers sulfate to position 4 at the nonreducing terminal GalNAc residue. Dot blot analysis showed that the message of GalNAc4ST was expressed strongly in the human pituitary, suggesting that the cloned GalNAc4ST may be involved in the synthesis of the nonreducing terminal GalNAc 4-sulfate residues found in the N-linked oligosaccharides of pituitary glycoprotein hormones.	Aichi Univ Educ, Dept Life Sci, Kariya, Aichi 4488542, Japan; Aichi Univ Educ, Dept Chem, Kariya, Aichi 4488542, Japan	Aichi University Education; Aichi University Education	Habuchi, O (corresponding author), Aichi Univ Educ, Dept Life Sci, Kariya, Aichi 4488542, Japan.		Nakano, Hirofumi/N-4588-2019; Okuda, Tetsuya/K-5305-2018	Nakano, Hirofumi/0000-0002-7632-8630; Okuda, Tetsuya/0000-0002-5262-8057				ARUFFO A, 1991, CURRENT PROTOCOL S43, V3; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brockhausen I, 1997, TRENDS GLYCOSCI GLYC, V9, P379, DOI 10.4052/tigg.9.379; DELFERT DM, 1985, ANAL BIOCHEM, V148, P303, DOI 10.1016/0003-2697(85)90233-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERNLEY RT, 1988, BIOCHEM J, V249, P201, DOI 10.1042/bj2490201; Fiete D, 1997, J BIOL CHEM, V272, P14629, DOI 10.1074/jbc.272.23.14629; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; Galustian C, 1997, BIOCHEM BIOPH RES CO, V240, P748, DOI 10.1006/bbrc.1997.7737; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; Habuchi O, 1996, GLYCOBIOLOGY, V6, P51, DOI 10.1093/glycob/6.1.51; HABUCHI O, 1980, BIOCHIM BIOPHYS ACTA, V616, P208, DOI 10.1016/0005-2744(80)90139-4; Habuchi O, 2000, BBA-GEN SUBJECTS, V1474, P115, DOI 10.1016/S0304-4165(00)00016-7; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; Habuchi O, 1997, GLYCOBIOLOGY, V7, P405, DOI 10.1093/glycob/7.3.405; HABUCHI O, 1995, J BIOL CHEM, V260, P13102; Hiraoka N, 2000, J BIOL CHEM, V275, P20188, DOI 10.1074/jbc.M002443200; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; HOOPER LV, 1995, J BIOL CHEM, V270, P5985, DOI 10.1074/jbc.270.11.5985; HOOPER LV, 1995, J BIOL CHEM, V270, P16327, DOI 10.1074/jbc.270.27.16327; IMAI Y, 1993, NATURE, V361, P555; Kimura N, 1999, P NATL ACAD SCI USA, V96, P4530, DOI 10.1073/pnas.96.8.4530; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; Malet C, 1997, CARBOHYD RES, V303, P51, DOI 10.1016/S0008-6215(97)00142-0; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; NAGASAWA K, 1979, J BIOCHEM-TOKYO, V86, P1323, DOI 10.1093/oxfordjournals.jbchem.a132648; Nair SM, 1997, J NEUROCHEM, V68, P1286; Okuda T, 2000, J BIOCHEM, V128, P763, DOI 10.1093/oxfordjournals.jbchem.a022813; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; SKELTON TP, 1991, J BIOL CHEM, V266, P17142; SKELTON TP, 1992, J BIOL CHEM, V267, P12998; SUNDARAM V, 1986, AM J HUM GENET, V38, P125; Torii T, 2000, GLYCOBIOLOGY, V10, P203, DOI 10.1093/glycob/10.2.203; Tsuboi S, 1996, J BIOL CHEM, V271, P27213, DOI 10.1074/jbc.271.44.27213; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; Yamauchi S, 1999, J BIOL CHEM, V274, P2456, DOI 10.1074/jbc.274.4.2456; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975	51	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40605	40613		10.1074/jbc.M007983200	http://dx.doi.org/10.1074/jbc.M007983200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11001942	hybrid			2022-12-25	WOS:000166039500108
J	Robino, G; Parola, M; Marra, F; Caligiuri, A; De Franco, RMS; Zamara, E; Bellomo, G; Gentilini, P; Pinzani, M; Dianzani, MU				Robino, G; Parola, M; Marra, F; Caligiuri, A; De Franco, RMS; Zamara, E; Bellomo, G; Gentilini, P; Pinzani, M; Dianzani, MU			Interaction between 4-hydroxy-2,3-alkenals and the platelet-derived growth factor-beta receptor - Reduced tyrosine phosphorylation and downstream signaling in hepatic stellate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAT-STORING CELLS; NF-KAPPA-B; MONOCYTE CHEMOTACTIC PROTEIN-1; LIPID-PEROXIDATION; HUMAN LIVER; PHOSPHATIDYLINOSITOL 3-KINASE; FIBROBLAST PROLIFERATION; OXIDATIVE MODIFICATION; TRANSCRIPTION FACTOR; BINDING-ACTIVITY	Hepatic stellate cells (HSC) undergo activation toward myofibroblast-like cells during early stages of liver injury associated with fibrogenesis. Platelet-derived growth factor (PDGF), particularly its BE isoform, has been identified as the most potent mitogen for HSC. 4-Hydroxy-2,3-nonenal and related 4-hydroxy-2,3-alkenals (HAKs) have been suggested to modulate the process of HSC activation. In this study we investigated the relationship between HAKs and PDGF receptor activation in human HSC. By employing noncytotoxic concentrations (10(-6) M) of HAKs, we observed a significant inhibition of PDGF-BB-dependent DNA synthesis. HAKs inhibited relevant pathways of PDGF-BB-dependent mitogenic signaling, including autophosphorylation of PDGF receptor (PDGF-R) beta subunits and activation of phosphatidylinositol 3-kinase and extracellular regulated kinases 1/2. Inhibition of DNA synthesis was reversible, and recovery of PDGF-mediated mitogenic signaling occurred within 24-48 h and was associated with HAKs-induced up-regulation of PDGF-R beta gene expression. 4-Hydroxy-2,3-nonena1, used as a model HAK, inhibited the intrinsic tyrosine kinase activity associated with the PDGF-R beta subunit, whereas binding of PDGF to its receptor was unaffected. This study identifies a novel regulatory mechanism of reactive aldehydes on PDGF receptor signaling and biologic actions, which may be relevant in several pathophysiological conditions, including liver fibrosis.	Univ Turin, Dipartimento Med & Oncol Sperimentale, I-10125 Turin, Italy; Univ Florence, Dipartimento Med Interna, I-50134 Florence, Italy; Univ A Avogadro, Dipartimento Sci Med, I-28100 Novara, Italy	University of Turin; University of Florence; University of Eastern Piedmont Amedeo Avogadro	Parola, M (corresponding author), Univ Turin, Dipartimento Med & Oncol Sperimentale, Corso Raffaello 30, I-10125 Turin, Italy.	parola@medfarm.unito.it	Marra, Fabio/K-7263-2016	Marra, Fabio/0000-0001-8629-0878; Parola, Maurizio/0000-0001-7720-5141				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Baroni GS, 1998, HEPATOLOGY, V27, P720; Blanc EM, 1997, J NEUROCHEM, V69, P570; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; CASINI A, 1993, GASTROENTEROLOGY, V105, P245, DOI 10.1016/0016-5085(93)90033-9; Casini A, 1997, HEPATOLOGY, V25, P361; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CRAWFORD D, 1988, ONCOGENE, V3, P27; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dianzani MU, 1998, FREE RADICAL RES, V28, P553, DOI 10.3109/10715769809065811; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; GAY S, 1989, J INVEST DERMATOL, V92, P301, DOI 10.1111/1523-1747.ep12276895; GESUALDO L, 1994, J CLIN INVEST, V94, P50, DOI 10.1172/JCI117348; GESUALDO L, 1991, LAB INVEST, V65, P160; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KS, 1995, J CLIN INVEST, V96, P2461, DOI 10.1172/JCI118304; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; MARRA F, 1993, J CLIN INVEST, V92, P1674, DOI 10.1172/JCI116753; Marra F, 1999, J INVEST MED, V47, P66; MARRA F, 1995, FEBS LETT, V376, P141, DOI 10.1016/0014-5793(95)01261-0; Marra F, 1997, GASTROENTEROLOGY, V112, P1297, DOI 10.1016/S0016-5085(97)70144-6; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; NAGAOKA I, 1990, J CLIN INVEST, V85, P2023, DOI 10.1172/JCI114669; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PARADISI L, 1985, CHEM-BIOL INTERACT, V53, P209, DOI 10.1016/S0009-2797(85)80097-1; PAROLA M, 1993, BIOCHEM BIOPH RES CO, V194, P1044, DOI 10.1006/bbrc.1993.1927; Parola M, 1998, J CLIN INVEST, V102, P1942, DOI 10.1172/JCI1413; Parola M, 1999, ANTIOXID REDOX SIGN, V1, P255, DOI 10.1089/ars.1999.1.3-255; PINZANI M, 1995, HEPATOLOGY, V21, P232, DOI 10.1002/hep.1840210136; PINZANI M, 1989, J CLIN INVEST, V84, P1786, DOI 10.1172/JCI114363; Pinzani M, 1998, LIVER, V18, P2; Pinzani M, 1996, AM J PATHOL, V148, P785; Poli G, 1997, FREE RADICAL BIO MED, V22, P287, DOI 10.1016/S0891-5849(96)00327-9; REUTERDAHL C, 1991, LAB INVEST, V64, P321; Rigacci S, 1997, BIOCHEM J, V324, P791, DOI 10.1042/bj3240791; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSSI MA, 1991, BIOCHEM PHARMACOL, V39, P1715; Sandirasegarane L, 2000, AM J PHYSIOL-CELL PH, V279, pC225, DOI 10.1152/ajpcell.2000.279.1.C225; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHIBANUMA M, 1988, ONCOGENE, V3, P17; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SILVER BJ, 1989, P NATL ACAD SCI USA, V86, P1056, DOI 10.1073/pnas.86.3.1056; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; UCHIDA K, 1994, BIOCHEMISTRY-US, V33, P12487, DOI 10.1021/bi00207a016; UCHIDA K, 1994, METHOD ENZYMOL, V233, P371; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Whalen R, 1999, HEPATOLOGY, V30, P927, DOI 10.1002/hep.510300404; Wilmer WA, 1997, J BIOL CHEM, V272, P10877	61	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40561	40567		10.1074/jbc.M007694200	http://dx.doi.org/10.1074/jbc.M007694200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007794	hybrid			2022-12-25	WOS:000166039500102
J	Sinal, CJ; Miyata, M; Tohkin, M; Nagata, K; Bend, JR; Gonzalez, FJ				Sinal, CJ; Miyata, M; Tohkin, M; Nagata, K; Bend, JR; Gonzalez, FJ			Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID EPOXYGENASE; NA-K-ATPASE; EPOXYEICOSATRIENOIC ACIDS; HYPERTENSIVE RATS; LIVER; METABOLITES; EICOSANOIDS; MICE; BIOSYNTHESIS; INHIBITORS	Renal microsomal cytochrome P-450 monooxygenase-dependent metabolism of arachidonic acid generates a series of regioisomeric epoxyeicosatrienoic acids that can be further metabolized by soluble epoxide hydrolase to the corresponding dihydroxyeicosatrienoic acids. Evidence exists that these metabolites affect renal function and, in particular, blood pressure regulation. To examine this possibility, blood pressure and renal arachidonic acid metabolism were examined in mice with a targeted disruption of the soluble epoxide hydrolase gene. Systolic blood pressure of male soluble epoxide hydrolase-null mice was lower compared with wild-type mice in both the absence and presence of dietary salt loading. Both female soluble epoxide hydrolase-null and wild-type female mice also had significantly lower systolic blood pressure than male wild-type mice. Renal formation of epoxyeicosatrienoic and dihydroxyeicosatrienoic acids was markedly lower for soluble epoxide hydrolase-null versus wild-type mice of both sexes. Although disruption of soluble epoxide hydrolase in female mice had minimal effects on blood pressure, deletion of this gene feminized male mice by lowering systolic blood pressure and altering arachidonic acid metabolism. These data provide the first direct evidence for a role for soluble epoxide hydrolase in blood pressure regulation and identify this enzyme as a novel and attractive target for therapeutic intervention in hypertension.	NCI, Lab Metab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON N6A 5C1, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Western University (University of Western Ontario)	Gonzalez, FJ (corresponding author), NCI, Lab Metab, Div Basic Sci, NIH, Bldg 37,Rm 3E24, Bethesda, MD 20892 USA.			Sinal, Christopher/0000-0001-8301-3349	NATIONAL CANCER INSTITUTE [Z01BC005562, ZIABC005562] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Argiriadi MA, 1999, P NATL ACAD SCI USA, V96, P10637, DOI 10.1073/pnas.96.19.10637; BORHAN B, 1995, ANAL BIOCHEM, V231, P188, DOI 10.1006/abio.1995.1520; Campbell WB, 2000, TRENDS PHARMACOL SCI, V21, P125, DOI 10.1016/S0165-6147(00)01472-3; Capdevila JH, 2000, J LIPID RES, V41, P163; CAPDEVILA JH, 1992, J BIOL CHEM, V267, P21720; CARROLL MA, 1993, J BIOL CHEM, V268, P12260; Carroll MA, 1997, ADV EXP MED BIOL, V407, P255; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; GILL SS, 1979, BIOCHEM BIOPH RES CO, V89, P965, DOI 10.1016/0006-291X(79)91872-2; Grant DF, 1996, BIOCHEM PHARMACOL, V51, P503, DOI 10.1016/0006-2952(95)02227-9; GRANT DF, 1993, J BIOL CHEM, V268, P17628; HASEGAWA LS, 1982, BIOCHEM PHARMACOL, V31, P1979, DOI 10.1016/0006-2952(82)90408-7; HIRT DL, 1989, J CLIN INVEST, V84, P1805, DOI 10.1172/JCI114365; HU SL, 1993, EUR J PHARMACOL, V230, P215, DOI 10.1016/0014-2999(93)90805-R; Imig JD, 1996, J AM SOC NEPHROL, V7, P2364; Imig JD, 1999, METH MOL B, V120, P173; INOUE N, 1995, BIOL PHARM BULL, V18, P536; KATOH T, 1991, AM J PHYSIOL, V261, pF578, DOI 10.1152/ajprenal.1991.261.4.F578; KNICKLE LC, 1994, MOL PHARMACOL, V45, P1273; LOURY DN, 1985, BIOCHEM PHARMACOL, V34, P1827, DOI 10.1016/0006-2952(85)90656-2; MA YH, 1994, AM J PHYSIOL, V267, pR579, DOI 10.1152/ajpregu.1994.267.2.R579; MAKITA K, 1994, J CLIN INVEST, V94, P2414, DOI 10.1172/JCI117608; Messer-Letienne I, 1999, AM J HYPERTENS, V12, P398; Miyata M, 1999, J BIOL CHEM, V274, P23963, DOI 10.1074/jbc.274.34.23963; Morisseau C, 1999, P NATL ACAD SCI USA, V96, P8849, DOI 10.1073/pnas.96.16.8849; O'Banion MK, 1999, CRIT REV NEUROBIOL, V13, P45, DOI 10.1615/CritRevNeurobiol.v13.i1.30; Ominato M, 1996, J MEMBRANE BIOL, V152, P235, DOI 10.1007/s002329900101; PINOT F, 1995, BIOCHEM PHARMACOL, V50, P501, DOI 10.1016/0006-2952(95)00167-X; RAPP JP, 1982, HYPERTENSION, V4, P753, DOI 10.1161/01.HYP.4.6.753; ROMERO MF, 1991, ADV PROSTAG THROMB L, V21, P205; ROMERO MF, 1991, RENAL PHYSIOL BIOCH, V14, P199; SAKAIRI Y, 1995, AM J PHYSIOL-RENAL, V268, pF931, DOI 10.1152/ajprenal.1995.268.5.F931; SATOH T, 1993, J CLIN INVEST, V91, P409, DOI 10.1172/JCI116215; SCHLADT L, 1987, BIOCHEM PHARMACOL, V36, P345, DOI 10.1016/0006-2952(87)90292-9; SCHLONDORFF D, 1987, AM J PHYSIOL, V253, pF464, DOI 10.1152/ajprenal.1987.253.3.F464; Seeds MC, 1999, CLIN REV ALLERG IMMU, V17, P5, DOI 10.1007/BF02737594; Seidegard J, 1997, ENVIRON HEALTH PERSP, V105, P791, DOI 10.2307/3433285; Spokas EG, 1999, METH MOL B, V120, P213; Stec DE, 1996, HYPERTENSION, V27, P1329, DOI 10.1161/01.HYP.27.6.1329; Yu ZG, 2000, MOL PHARMACOL, V57, P1011; Zeldin DC, 1996, ARCH BIOCHEM BIOPHYS, V330, P87, DOI 10.1006/abbi.1996.0229; ZELDIN DC, 1993, J BIOL CHEM, V268, P6402	42	285	303	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40504	40510		10.1074/jbc.M008106200	http://dx.doi.org/10.1074/jbc.M008106200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11001943	hybrid			2022-12-25	WOS:000166039500095
J	Withers, DA; Hakomori, S				Withers, DA; Hakomori, S			Human alpha(1,3)-fucosyltransferase IV (FUTIV) gene expression is regulated by Elk-1 in the U937 cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; SIALYL-LEWIS-X; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; DOMAIN TRANSCRIPTION FACTORS; MESSENGER-RNA EXPRESSION; FUCOSYL-TRANSFERASE GENE; HUMAN COLORECTAL-CANCER; TERNARY COMPLEX FACTORS; MOLECULAR-CLONING; E-SELECTIN	The alpha1,3-fucosyltransferase IV (FucTIV) encoded by its gene (FUTIV) is responsible for synthesis of Le(x) (Gal beta4[Fuc alpha3]GlcNAc beta 3Gal beta1,R), which causes compaction in the morula stage of the preimplantation mouse embryo, as well as alpha1,3-fucosylation at multiple internal GlcNAc of unbranched poly-N-acetyllactosamine, termed "myeloglycan," the physiological epitope of E-selectin. Since myeloglycan-type structure is also expressed in various types of human cancer and may mediate E-selectin-dependent metastasis, expression of FUTIV is oncodevelopmentally regulated. The mechanisms controlling FUTIV expression remain to be clarified. In this report, we further characterize FUTIV gene structure and define a non-TATA box-dependent transcriptional start region just upstream from the translational start. FUTIV promoter/reporter fusion constructs defined a "full-length" promoter and highly active fragments in the macrophage-derived U937 and myeloid HL60 cell lines. One highly active fragment contains a consensus binding site for the Ets-l transcription factor (Withers, D. A. and Hakomori, S. (1997) Glycoconj. J. 14, 764). Gel shift analysis shows specific binding to this site in nuclear extracts from U937 cells. Mutation of the Ets consensus site significantly reduces FUTIV promoter activity in both cell lines. Gel supershift and dominant negative cotransfection experiments identified the Ets family member Elk-l as one component binding and regulating the FUTIV promoter in U937 cells. The significance of FUTIV regulation by Elk-l is discussed.	Pacific NW Res Inst, Div Biomembrane Res, Seattle, WA 98122 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Withers, DA (corresponding author), Pacific NW Res Inst, Div Biomembrane Res, 720 Broadway, Seattle, WA 98122 USA.				NATIONAL CANCER INSTITUTE [R35CA042505] Funding Source: NIH RePORTER; NCI NIH HHS [CA42505] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akamatsu S, 1996, GLYCOCONJUGATE J, V13, P1021, DOI 10.1007/BF01053198; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BIRD JM, 1984, DEV BIOL, V104, P449, DOI 10.1016/0012-1606(84)90101-5; Boubelik M, 1998, GLYCOBIOLOGY, V8, P139, DOI 10.1093/glycob/8.2.139; Boubelik M, 1996, BIOCHEM BIOPH RES CO, V224, P283, DOI 10.1006/bbrc.1996.1022; Buckhaults P, 1997, J BIOL CHEM, V272, P19575, DOI 10.1074/jbc.272.31.19575; CAMERON HS, 1995, J BIOL CHEM, V270, P20112, DOI 10.1074/jbc.270.34.20112; Charron M, 1999, MOL CELL BIOL, V19, P5823; CHILDS RA, 1983, BIOCHEM J, V215, P491, DOI 10.1042/bj2150491; Clarke JL, 1996, J BIOL CHEM, V271, P10317, DOI 10.1074/jbc.271.17.10317; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Cullen P, 1997, ARTERIOSCL THROM VAS, V17, P1591, DOI 10.1161/01.ATV.17.8.1591; DENT CL, 1993, TRANSCRIPTION FACTOR, P1; DRABER P, 1987, P NATL ACAD SCI USA, V84, P5798, DOI 10.1073/pnas.84.16.5798; EGGENS I, 1989, J BIOL CHEM, V264, P9476; EGGENS I, 1989, BIOCHEM BIOPH RES CO, V158, P913, DOI 10.1016/0006-291X(89)92809-X; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; FUKUSHI Y, 1984, J BIOL CHEM, V259, P511; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; Grabenhorst E, 1998, J BIOL CHEM, V273, P30985, DOI 10.1074/jbc.273.47.30985; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Hakomori S, 1996, CANCER RES, V56, P5309; Handa K, 1997, BIOCHEMISTRY-US, V36, P12412, DOI 10.1021/bi971181t; Handa K, 1998, BIOCHEM BIOPH RES CO, V243, P199, DOI 10.1006/bbrc.1998.8080; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOLMES EH, 1995, J BIOL CHEM, V270, P8145, DOI 10.1074/jbc.270.14.8145; Ito H, 1997, INT J CANCER, V71, P556, DOI 10.1002/(SICI)1097-0215(19970516)71:4<556::AID-IJC9>3.3.CO;2-J; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Kaneko M, 1999, FEBS LETT, V452, P237, DOI 10.1016/S0014-5793(99)00640-7; Kang R, 1996, J BIOL CHEM, V271, P26706, DOI 10.1074/jbc.271.43.26706; Ko JH, 1999, J BIOL CHEM, V274, P22941, DOI 10.1074/jbc.274.33.22941; KOJIMA N, 1994, GLYCOCONJUGATE J, V11, P238, DOI 10.1007/BF00731224; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; Kudo T, 1998, LAB INVEST, V78, P797; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; LeMarer N, 1997, GLYCOBIOLOGY, V7, P357; Lo SK, 1997, BLOOD, V89, P307, DOI 10.1182/blood.V89.1.307.307_307_314; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MCCURLEY RS, 1995, GENOMICS, V26, P142, DOI 10.1016/0888-7543(95)80094-3; MIYAKE M, 1988, CANCER RES, V48, P7150; MOLLICONE R, 1992, CARBOHYD RES, V228, P265, DOI 10.1016/S0008-6215(00)90564-0; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; Niemela R, 1998, J BIOL CHEM, V273, P4021, DOI 10.1074/jbc.273.7.4021; Ogawa J, 1996, CANCER RES, V56, P325; Ozawa M, 1996, J BIOCHEM-TOKYO, V119, P302; Petretti T, 1999, BBA-GEN SUBJECTS, V1428, P209, DOI 10.1016/S0304-4165(99)00080-X; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; ROBINSON NE, 1994, GLYCOBIOLOGY, V4, P317, DOI 10.1093/glycob/4.3.317; Sambrook J., 2002, MOL CLONING LAB MANU; SASAKI K, 1994, J BIOL CHEM, V269, P14730; Schug J., 1997, CBILTR19971001V00 U; Shore P, 1996, MOL CELL BIOL, V16, P3338; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P770, DOI 10.1021/bi952461g; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; TURNER H, 1997, J EXP MED, V185, P45; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; Weissensteiner T, 1996, BIOTECHNIQUES, V21, P1102; WERNERT N, 1994, CANCER RES, V54, P5683; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Withers D. A., 1997, Glycoconjugate Journal, V14, P764; YAGO K, 1993, CANCER RES, V53, P5559; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Zhang W, 2000, BIOCHEM J, V347, P511, DOI 10.1042/0264-6021:3470511	79	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40588	40593		10.1074/jbc.M007262200	http://dx.doi.org/10.1074/jbc.M007262200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11006292	hybrid			2022-12-25	WOS:000166039500105
J	Cohen, H; Azriel, A; Cohen, T; Meraro, D; Hashmueli, S; Bech-Otschir, D; Kraft, R; Dubiel, W; Levi, BZ				Cohen, H; Azriel, A; Cohen, T; Meraro, D; Hashmueli, S; Bech-Otschir, D; Kraft, R; Dubiel, W; Levi, BZ			Interaction between interferon consensus sequence-binding protein and COP9/signalosome subunit CSN2 (Trip15) - A possible link between interferon regulatory factor signaling and the COP9/signalosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; GP91(PHOX) EXPRESSION; POSITIVE FEEDBACK; HORMONE-RECEPTOR; COP9 SIGNALOSOME; MAMMALIAN-CELLS; FACTOR FAMILY; DNA-BINDING; FACTOR-I; COMPLEX	Interferon consensus sequence-binding protein (ICSBP) is a member of the interferon regulatory factors (IRF) that has a pivotal role in mediating resistance to pathogenic infections in mice and in promoting the differentiation of myeloid cells. ICSBP exerts some of its transcriptional activities via association with other factors that enable its binding to a variety of promoters containing DNA composite elements. These interactions are mediated through a specific COOH-terminal domain termed IAD (IRF association domain). To gain a broader insight of the capacity of ICSBP to interact with other factors, yeast two-hybrid screens were performed using ICSBP-IAD as a bait against a B-cell cDNA library. Trip15 was identified as a specific interacting factor with ICSBP in yeast cells, which was also confirmed by in vitro glutathione S-transferase pull-down assays and by coimmunoprecipitation studies in COS7 cells. Trip15 was recently identified as a component of the COP9/signalosome (CSN) complex composed of eight evolutionary conserved subunits and thus termed CSN2. This complex has a role in cell-signaling processes, which is manifested by its associated novel kinase activity and by the involvement of its subunits in regulating multiple cell-signaling pathways and cell-cycle progression. We show that in vitro association of ICSBP with the CSN leads to phosphorylation of ICSBP at a unique serine residue within its IAD. The phosphorylated residue is essential for efficient association with IRF-1 and thus for the repressor activity of ICSBP exerted on IRF-1. This suggests that the CSN has a role in integrating incoming signals that affect the transcriptional activity of ICSBP.	Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel; Humboldt Univ, Med Fac Charit 233, Inst Biochem, D-10117 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Technion Israel Institute of Technology; Humboldt University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Levi, BZ (corresponding author), Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel.	fobenzi@techunix.technion.ac.il		Dubiel, Wolfgang/0000-0002-3393-0701				Bartel P. L., 1993, CELLULAR INTERACTION, P153; BOVOLENTA C, 1994, P NATL ACAD SCI USA, V91, P5046, DOI 10.1073/pnas.91.11.5046; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Dressel U, 1999, MOL CELL BIOL, V19, P3383; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Fehr T, 1997, J EXP MED, V185, P921, DOI 10.1084/jem.185.5.921; Giese NA, 1997, J EXP MED, V186, P1535, DOI 10.1084/jem.186.9.1535; Goubeaud A, 1996, MECH DEVELOP, V57, P59, DOI 10.1016/0925-4773(96)00532-1; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; Hein J, 2000, INFECT IMMUN, V68, P1408, DOI 10.1128/IAI.68.3.1408-1417.2000; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Kantakamalakul W, 1999, J IMMUNOL, V162, P7417; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Mahalingam S, 1998, P NATL ACAD SCI USA, V95, P3419, DOI 10.1073/pnas.95.7.3419; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Meraro D, 1999, J IMMUNOL, V163, P6468; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Nagulapalli S, 1998, MOL CELL BIOL, V18, P4639, DOI 10.1128/MCB.18.8.4639; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Ortiz MA, 1999, P NATL ACAD SCI USA, V96, P2740, DOI 10.1073/pnas.96.6.2740; Osterlund MT, 1999, TRENDS CELL BIOL, V9, P113, DOI 10.1016/S0962-8924(99)01499-3; Perkel JM, 1998, J IMMUNOL, V160, P241; POLITIS AD, 1994, J IMMUNOL, V152, P2270; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Schaefer L, 1999, GENOMICS, V56, P310, DOI 10.1006/geno.1998.5728; SchartonKersten T, 1997, J EXP MED, V186, P1523, DOI 10.1084/jem.186.9.1523; Schmidt M, 1998, BLOOD, V91, P22, DOI 10.1182/blood.V91.1.22.22_22_29; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; SHARF R, 1995, J BIOL CHEM, V270, P13063, DOI 10.1074/jbc.270.22.13063; Sharf R, 1997, J BIOL CHEM, V272, P9785; Spain BH, 1996, MOL CELL BIOL, V16, P6698; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; Wei N, 1998, PHOTOCHEM PHOTOBIOL, V68, P237; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; WEISZ A, 1992, J BIOL CHEM, V267, P25589; WEISZ A, 1994, INT IMMUNOL, V6, P1125; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	51	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39081	39089		10.1074/jbc.M004900200	http://dx.doi.org/10.1074/jbc.M004900200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10991940	hybrid			2022-12-25	WOS:000165953100020
J	Carroll, JS; Prall, OWJ; Musgrove, EA; Sutherland, RL				Carroll, JS; Prall, OWJ; Musgrove, EA; Sutherland, RL			A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITORS; MAMMARY-CARCINOMA CELLS; CDK INHIBITORS; D1 EXPRESSION; GROWTH-FACTOR; S-PHASE; ANTIESTROGEN; PHOSPHORYLATION; PROGRESSION; ACTIVATION	Estrogen antagonists inhibit cell cycle progression in estrogen-responsive cells, but the molecular mechanisms are not fully defined. Antiestrogen-mediated G(0)/G(1) arrest is associated with decreased cyclin D1 gene expression, inactivation of cyclin D1-cyclin dependent kinase (Cdk) 4 complexes, and decreased phosphorylation of the retinoblastoma protein (pRb). We now show that treatment of MCF-7 breast cancer cells with the pure estrogen antagonist ICI 182780 results in inhibition of cyclin E-Cdk2 activity prior to a decrease in the G(1) to S phase transition. This decrease was dependent on p21(WAF1/Cip1) since treatment with antisense oligonucleotides to p21 attenuated the effect, Recruitment of p21 to cyclin E-Cdk2 complexes was in turn dependent on decreased cyclin D1 expression since it was apparent following treatment with antisense cyclin D1 oligonucleotides, To define where within the G(0) to S phase continuum antiestrogen-treated cells arrested, we assessed the relative abundance and phosphorylation state of pocket protein-E2F complexes. While both pRb and p107 levels were significantly decreased, p130 was increased 4-fold and was accompanied by the formation of p130.E2F4 complexes and the accumulation of hyperphophorylated E2F4, putative markers of cellular quiescence. Thus, ICI 182780 inhibits both cyclin D1-Cdk4 and cyclin E-Cdk2 activity, resulting in the arrest of MCF-7 cells in a state with characteristics of quiescence (G(0)), as opposed to G(1) arrest.	St Vincents Hosp, Canc Res Program, Garvan Inst Med Res, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney	Sutherland, RL (corresponding author), St Vincents Hosp, Canc Res Program, Garvan Inst Med Res, 384 Victoria St, Sydney, NSW 2010, Australia.		Sutherland, Robert L/A-8378-2008	Carroll, Jason/0000-0003-3643-0080				Altucci L, 1996, ONCOGENE, V12, P2315; Barboule N, 1997, ONCOGENE, V15, P2867, DOI 10.1038/sj.onc.1201469; Baserga R, 1985, BIOL CELL REPROD; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Clarke M, 1998, LANCET, V351, P1451; DEFRIEND DJ, 1994, CANCER RES, V54, P408; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harlow E., 1988, ANTIBODIES LAB MANUA; Harper JW, 1998, GENE DEV, V12, P285, DOI 10.1101/gad.12.3.285; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; KATZENELLENBOGEN BS, 1991, J NATL CANCER I, V83, P1434, DOI 10.1093/jnci/83.20.1434; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; Liu JB, 2000, ONCOGENE, V19, P661, DOI 10.1038/sj.onc.1203373; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MacGregor JI, 1998, PHARMACOL REV, V50, P151; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mayol X, 1997, Prog Cell Cycle Res, V3, P157; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Mori A, 1999, ONCOGENE, V18, P6209, DOI 10.1038/sj.onc.1203044; MUSGROVE EA, 1989, CANCER RES, V49, P2398; MUSGROVE EA, 1993, EUR J CANCER, V29A, P2273, DOI 10.1016/0959-8049(93)90221-Z; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Musgrove EA, 1998, MOL CELL BIOL, V18, P1812, DOI 10.1128/MCB.18.4.1812; MUSGROVE EA, 1995, INT J CANCER, V63, P584, DOI 10.1002/ijc.2910630420; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; OSBORNE CK, 1995, J NATL CANCER I, V87, P746, DOI 10.1093/jnci/87.10.746; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; STEIN RC, 1995, OXFORD TXB ONCOL, P629; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; SUTHERLAND RL, 1983, CANCER RES, V43, P3998; Swarbrick A, 2000, MOL CELL BIOL, V20, P2581, DOI 10.1128/MCB.20.7.2581-2591.2000; TAYLOR IW, 1983, CANCER RES, V43, P4007; Thomas NSB, 1998, J BIOL CHEM, V273, P23659, DOI 10.1074/jbc.273.37.23659; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; van der Sman J, 1999, J BIOL CHEM, V274, P12009, DOI 10.1074/jbc.274.17.12009; WAKELING AE, 1991, CANCER RES, V51, P3867; WAKELING AE, 1989, J MOL ENDOCRINOL, V2, P225, DOI 10.1677/jme.0.0020225; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804	56	121	126	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38221	38229		10.1074/jbc.M004424200	http://dx.doi.org/10.1074/jbc.M004424200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10991938	hybrid			2022-12-25	WOS:000165739800014
J	Wang, CZ; Yano, H; Nagashima, K; Seino, S				Wang, CZ; Yano, H; Nagashima, K; Seino, S			The Na+-driven Cl-/HCO3- exchanger - Cloning, tissue distribution, and functional characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH; CYTOPLASMIC PH; GLUCOSE; TRANSPORT; EXPRESSION; CELLS; CL	The Na+-driven Cl-/HCO3- exchanger is an important regulator of intracellular pH in various cells, but its molecular basis has not been determined. We show here the primary structure, tissue distribution, and functional characterization of (N) under bara(+)-driven (c) under bar hloride/(b) under bar icarbonate exchanger (designated NCBE) cloned from the insulin-secreting cell line MING cDNA library. The NCBE protein consists of 1088 amino acids having 74, 72, and 55% amino acid identity to the human skeletal muscle, rat smooth muscle, and human kidney sodium bicarbonate cotransporter, respectively. The protein has 10 putative membrane-spanning regions. NCBE mRNA is expressed at high levels in the brain and the mouse insulinoma cell line MIN6 and at low levels in the pituitary, testis, kidney, and ileum. Functional analyses of the NCBE protein expressed in Xenopus laevis oocytes and HEK293 cells demonstrate that it transports extracellular Na+ and HCO3- into cells in exchange for intracellular Cl- and H+, thus raising the intracellular pH. Thus, we conclude that NCBE is a Na+-driven Cl-/HCO3- exchanger that regulates intracellular pH in native cells.	Chiba Univ, Grad Sch Med, Dept Mol Med, Chuo Ku, Chiba 2608670, Japan	Chiba University	Yano, H (corresponding author), Chiba Univ, Grad Sch Med, Dept Mol Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	hyano@molmed.m.chiba-u.ac.jp						ALPER SL, 1991, ANNU REV PHYSIOL, V53, P549, DOI 10.1146/annurev.physiol.53.1.549; ARKHAMMAR P, 1986, BIOSCIENCE REP, V6, P355, DOI 10.1007/BF01116422; BEST L, 1988, J MOL ENDOCRINOL, V1, P33, DOI 10.1677/jme.0.0010033; Boron WF, 1997, J EXP BIOL, V200, P263; Burnham CE, 1997, J BIOL CHEM, V272, P19111, DOI 10.1074/jbc.272.31.19111; BUSA WB, 1986, CURR TOP MEMBR TRANS, V26, P291; BUSA WB, 1984, AM J PHYSIOL, V246, pR409, DOI 10.1152/ajpregu.1984.246.4.R409; CHOL I, 2000, NATURE, V405, P571; DELEERS M, 1985, HORM METAB RES, V17, P391, DOI 10.1055/s-2007-1013555; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; INAGAKI N, 1994, P NATL ACAD SCI USA, V91, P2679, DOI 10.1073/pnas.91.7.2679; ISHIBASHI K, 1993, AM J PHYSIOL, V264, pF251, DOI 10.1152/ajprenal.1993.264.2.F251; Ishibashi K, 1998, BIOCHEM BIOPH RES CO, V246, P535, DOI 10.1006/bbrc.1998.8658; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; LINDSTROM P, 1984, BIOCHEM J, V218, P887, DOI 10.1042/bj2180887; PACE CS, 1983, J MEMBRANE BIOL, V73, P39, DOI 10.1007/BF01870339; Pushkin A, 1999, J BIOL CHEM, V274, P16569, DOI 10.1074/jbc.274.23.16569; Romero MF, 1999, ANNU REV PHYSIOL, V61, P699, DOI 10.1146/annurev.physiol.61.1.699; Romero MF, 2000, J BIOL CHEM, V275, P24552, DOI 10.1074/jbc.M003476200; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; RUSSELL JM, 1976, NATURE, V264, P73, DOI 10.1038/264073a0; SCHWIENING CJ, 1994, J PHYSIOL-LONDON, V475, P59, DOI 10.1113/jphysiol.1994.sp020049; SHEPHERD RM, 1995, J BIOL CHEM, V270, P7915, DOI 10.1074/jbc.270.14.7915; SHRODE LD, 1994, GLIA, V12, P196, DOI 10.1002/glia.440120305; Strazzabosco M, 1997, HEPATOLOGY, V25, P976, DOI 10.1002/hep.510250431; Sun B, 1999, AM J PHYSIOL-HEART C, V277, pH28, DOI 10.1152/ajpheart.1999.277.1.H28; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TOBEY NA, 1993, GASTROENTEROLOGY, V104, P185, DOI 10.1016/0016-5085(93)90851-3; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wang CZ, 1996, BIOCHEM BIOPH RES CO, V220, P196, DOI 10.1006/bbrc.1996.0380; Zeng Y, 1996, DEV BIOL, V173, P510, DOI 10.1006/dbio.1996.0044	33	118	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35486	35490		10.1074/jbc.C000456200	http://dx.doi.org/10.1074/jbc.C000456200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10993873	hybrid			2022-12-25	WOS:000165422800086
J	Vassileva, G; Huwyler, L; Poirier, K; Agellon, LB; Toth, MJ				Vassileva, G; Huwyler, L; Poirier, K; Agellon, LB; Toth, MJ			The intestinal fatty acid binding protein is not essential for dietary fat absorption in mice	FASEB JOURNAL			English	Article						intestine; gene targeting; mouse; I-FABP	INSULIN-RESISTANCE; ESCHERICHIA-COLI; GENE; EXPRESSION; POLYMORPHISM; REFINEMENT; ADIPOCYTE; MEMBRANES; PALMITATE; CODON-54	The intestinal fatty acid binding protein (I-FABP) belongs to a family of 15 kDa clamshell-like proteins that are found in many different tissues. So far, nine types have been identified. Their primary structures are highly conserved between species but somewhat less so among the different types. The function of these proteins, many of which are highly expressed, is not web understood. Their ability to bind lipid ligands suggests a role in lipid metabolism, but direct evidence for this idea is still lacking. We tested the hypothesis that I-FABP serves an essential role in the assimilation of dietary fatty acids by disrupting its gene (Fabpi) in the mouse. We discovered that Fabpi(-/-) mice are viable, but they display alterations in body weight and are hyperinsulinemic. Male Fabpi(-/-) mice had elevated plasma triacylglycerols and weighed more regardless of the dietary fat content. In contrast, female Fabpi(-/-) mice gained less weight in response to a high-fat diet. The results clearly demonstrate that I-FABP is not essential for dietary fat absorption. We propose that I-FABP functions as a lipid-sensing component of energy homeostasis that alters body weight gain in a gender-specific fashion.	Novartis Inst Biomed Res, Summit, NJ 07901 USA; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada	Novartis; University of Alberta	Toth, MJ (corresponding author), Novartis Inst Biomed Res, 130-2265,556 Morris Ave, Summit, NJ 07901 USA.		Vassileva, Galya/A-6807-2009					Agren JJ, 1998, ARTERIOSCL THROM VAS, V18, P1606, DOI 10.1161/01.ATV.18.10.1606; BAIER LJ, 1995, J CLIN INVEST, V95, P1281, DOI 10.1172/JCI117778; Bernlohr DA, 1997, ANNU REV NUTR, V17, P277, DOI 10.1146/annurev.nutr.17.1.277; Binas B, 1999, FASEB J, V13, P805, DOI 10.1096/fasebj.13.8.805; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Coe NR, 1999, J LIPID RES, V40, P967; Corsico B, 1998, P NATL ACAD SCI USA, V95, P12174, DOI 10.1073/pnas.95.21.12174; Darimont C, 2000, J LIPID RES, V41, P84; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; GREEN RP, 1992, DNA CELL BIOL, V11, P31, DOI 10.1089/dna.1992.11.31; Hodsdon ME, 1996, J MOL BIOL, V264, P585, DOI 10.1006/jmbi.1996.0663; Hogan B., 1994, MANIPULATING MOUSE E, P296; Hohoff C, 1998, FETT-LIPID, V100, P252; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Hsu KT, 1996, J BIOL CHEM, V271, P13317, DOI 10.1074/jbc.271.23.13317; KNOWLER WC, 1990, DIABETES METAB REV, V6, P1, DOI 10.1002/dmr.5610060101; LOWE JB, 1987, J BIOL CHEM, V262, P5931; Pihlajamaki J, 1997, ARTERIOSCL THROM VAS, V17, P1039, DOI 10.1161/01.ATV.17.6.1039; Richieri GV, 1996, J BIOL CHEM, V271, P11291, DOI 10.1074/jbc.271.19.11291; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SCAPIN G, 1992, J BIOL CHEM, V267, P4253; SWEETSER DA, 1987, ANNU REV NUTR, V7, P337, DOI 10.1146/annurev.nu.07.070187.002005; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060	24	134	139	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					2040	2046		10.1096/fj.99-0959com	http://dx.doi.org/10.1096/fj.99-0959com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023988				2022-12-25	WOS:000089634400023
J	Chaudhary, PM; Eby, MT; Jasmin, A; Kumar, A; Liu, L; Hood, L				Chaudhary, PM; Eby, MT; Jasmin, A; Kumar, A; Liu, L; Hood, L			Activation of the NF-kappa B pathway by Caspase 8 and its homologs	ONCOGENE			English	Article						NF-kappa B; caspase; FADD; death effector domain; MRIT; cFLIP	DOMAIN-CONTAINING PROTEIN; NECROSIS-FACTOR RECEPTOR; INDUCED CELL-DEATH; INDUCED APOPTOSIS; CD95 FAS/APO-1; KINASE-ALPHA; TNF; FADD; INTERACTS; INDUCTION	Caspase 8 is the most proximal caspase in the caspase cascade and has been known for its role in the mediation of cell death by various death receptors belonging to the TNFR family. We have discovered that Caspase 8 can activate the NF-kappa B pathway independent of its activity as a pro-apoptotic protease, This property is localized to its N-terminal prodomain, which contains two homologous death effector domains (DEDs). Caspase 10 and MRIT, two DEDs-containing homologs of Caspase 8, can similarly activate the NF-kappa B pathway. Dominantnegative mutants of the Caspase 8 prodomain can block NF-kappa B induced by Caspase 8, FADD and several death receptors belonging to the TNFR family. Caspase 8 can interact with multiple proteins known to be involved in the activation of the NF-kappa B pathway, including the serine-threonine kinases RIP, NIK, IKK1 and IKK2, Thus, DEDs-containing caspases and caspase homolog(s) may have functions beyond their known role in the mediation of cell death.	UT, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Washington; University of Washington Seattle	Chaudhary, PM (corresponding author), UT, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Kumar, Arvind/B-6094-2009; Chaudhary, Preet/E-1970-2018					Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baker SJ, 1996, ONCOGENE, V12, P1; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chaudhary PM, 1999, J BIOL CHEM, V274, P19211, DOI 10.1074/jbc.274.27.19211; Chinnaiyan A M, 1997, Semin Immunol, V9, P69, DOI 10.1006/smim.1996.0055; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lin KI, 1998, J CELL BIOL, V141, P1479, DOI 10.1083/jcb.141.7.1479; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	45	188	200	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4451	4460		10.1038/sj.onc.1203812	http://dx.doi.org/10.1038/sj.onc.1203812			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002417				2022-12-25	WOS:000089236800001
J	Kim, I; Kim, JH; Moon, SO; Kwak, HJ; Kim, NG; Koh, GY				Kim, I; Kim, JH; Moon, SO; Kwak, HJ; Kim, NG; Koh, GY			Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3 '-kinase/Akt signal transduction pathway	ONCOGENE			English	Article						angiopoietin-2; endothelial cells; apoptosis; PI 3 '-kinase; Akt	TIE2 RECEPTOR; ANGIOGENESIS; EXPRESSION; GROWTH; PHOSPHORYLATION; MECHANISMS; LIGANDS; CLONING; HYPOXIA; VEGF	The angiopoietin-Tie2 system in endothelial cells is an important regulator of vasculogenesis and vascular integrity, High levels of angiopoietin-2 (Ang2) mRNA are observed in vascular activation during tumorigenesis. Although Ang2 is known to be a naturally occurring antagonist of angiopoietin-1 (Ang1) in vivo, the exact function of Ang2 itself is not known. Here, we found that a high concentration of Ang2 (800 ng/ml) acts as an apoptosis survival factor for endothelial cells during serum deprivation apoptosis, The survival effect of high concentration Ang2 was blocked by pre-treatment with soluble Tie2 receptor and the PI 3'-kinase-specific inhibitors, wortmannin and LY294002. Accordingly, 800 ng/ml of Ang2 induced phosphorylation of Tie2, the p85 subunit of phosphatidylinositol 3'-kinase (PI 3'-kinase), and serine-threonine kinase Akt at Ser473 in the human umbilical vein endothelial cells; lower concentrations of Ang2 (50-400 ng/ml) did not produce notable effects. These findings indicate that at high concentrations, Ang2, like Ang1, can be an apoptosis survival factor for endothelial cells through the activation of the Tie2 receptor, PI 3'-kinase and Akt, and thus may be a positive regulator of tumor angiogenesis.	Chonbuk Univ, Sch Med, Natl Creat Res Initiat Ctr Cardiac Regenerat, Chonju 560180, South Korea; Chonbuk Univ, Sch Med, Cardiovasc Res Inst, Chonju 560180, South Korea; Chonbuk Univ, Sch Med, Dept Biomed Engn, Chonju 560180, South Korea	Jeonbuk National University; Jeonbuk National University; Jeonbuk National University	Koh, GY (corresponding author), Chonbuk Univ, Sch Med, Natl Creat Res Initiat Ctr Cardiac Regenerat, San 2-20, Chonju 560180, South Korea.		Koh, Gou Young/C-1615-2011; Kim, Injune/C-1710-2011	Kim, Injune/0000-0001-9244-815X				Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dunk C, 2000, AM J PATHOL, V156, P2185, DOI 10.1016/S0002-9440(10)65089-4; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Kim I, 2000, J BIOL CHEM, V275, P18550, DOI 10.1074/jbc.M910084199; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kim I, 1999, J BIOL CHEM, V274, P26523, DOI 10.1074/jbc.274.37.26523; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Mandriota SJ, 1998, CIRC RES, V83, P852, DOI 10.1161/01.RES.83.8.852; Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Papapetropoulos A, 1999, LAB INVEST, V79, P213; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Shyu KG, 1998, CIRCULATION, V98, P2081, DOI 10.1161/01.CIR.98.19.2081; Stratmann A, 1998, AM J PATHOL, V153, P1459, DOI 10.1016/S0002-9440(10)65733-1; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Tanaka S, 1999, J CLIN INVEST, V103, P341, DOI 10.1172/JCI4891; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514	28	255	270	0	12	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4549	4552		10.1038/sj.onc.1203800	http://dx.doi.org/10.1038/sj.onc.1203800			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002428				2022-12-25	WOS:000089236800012
J	Ferrington, DA; Sun, HY; Murray, KK; Costa, J; Williams, TD; Bigelow, DJ; Squier, TC				Ferrington, DA; Sun, HY; Murray, KK; Costa, J; Williams, TD; Bigelow, DJ; Squier, TC			Selective degradation of oxidized calmodulin by the 20 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; MEMBRANE CA-ATPASE; SEQUENCE-INDEPENDENT RECOGNITION; SECONDARY STRUCTURE; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; METHIONINE OXIDATION; ANTIGEN PRESENTATION; MODIFIED HEMOGLOBIN; 26S PROTEASOME	We have investigated the mechanisms that target oxidized calmodulin for degradation by the proteasome, After methionine oxidation within calmodulin, rates of degradation by the 20 S proteasome are substantially enhanced. Mass spectrometry was used to identify the time course of the proteolytic fragments released from the proteasome. Oxidized calmodulin is initially degraded into large proteolytic fragments that are released from the proteasome and subsequently degraded into small peptides that vary in size from 6 to 12 amino acids. To investigate the molecular determinants that result in the selective degradation of oxidized calmodulin, we used circular dichroism and fluorescence spectroscopy to assess oxidant-induced structural changes. There is a linear correlation between decreases in secondary structure and the rate of degradation. Calcium binding or the repair of oxidized calmodulin by methionine sulfoxide reductase induces comparable changes in alpha -helical content and rates of degradation. In contrast, alterations in the surface hydrophobicity of oxidized calmodulin do not alter the rate of degradation by the proteasome, indicating that changes in surface hydrophobicity do not necessarily lead to enhanced proteolytic susceptibility. These results suggest that decreases in secondary structure expose proteolytically sensitive sites in oxidized calmodulin that are cleaved by the proteasome in a nonprocessive manner.	Univ Minnesota, Dept Ophthalmol, Minneapolis, MN 55455 USA; Univ Kansas, Mass Spectrometry Lab, Lawrence, KS 66045 USA; Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA; Univ Kansas, Mass Spectrometry Lab, Lawrence, KS 66045 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Kansas; University of Kansas; University of Kansas	Ferrington, DA (corresponding author), Univ Minnesota, Dept Ophthalmol, Minneapolis, MN 55455 USA.	ferri013@tc.umn.edu		Ferrington, Deborah/0000-0003-2561-7464	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR006294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG012993, R01AG017996] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR0 6294] Funding Source: Medline; NIA NIH HHS [AG17996, AG12993] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; Conconi M, 1996, ARCH BIOCHEM BIOPHYS, V331, P232, DOI 10.1006/abbi.1996.0303; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DADO GP, 1993, J AM CHEM SOC, V115, P12609, DOI 10.1021/ja00079a060; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; Ferrington DA, 1997, BIOCHEM BIOPH RES CO, V237, P163, DOI 10.1006/bbrc.1997.7105; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; Gao J, 1998, BIOPHYS J, V74, P1115, DOI 10.1016/S0006-3495(98)77830-0; Gao J, 1998, BIOCHEMISTRY-US, V37, P9536, DOI 10.1021/bi9803877; GarciaEcheverria C, 1996, BIOORG MED CHEM LETT, V6, P229, DOI 10.1016/0960-894X(96)00009-1; GELLMAN SH, 1991, BIOCHEMISTRY-US, V30, P6633, DOI 10.1021/bi00241a001; GIULIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329, DOI 10.1006/abbi.1994.1245; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; Grune T, 1997, BIOFACTORS, V6, P165, DOI 10.1002/biof.5520060210; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Holzhutter HG, 1999, J MOL BIOL, V286, P1251, DOI 10.1006/jmbi.1998.2530; Huhmer AFR, 1996, CHEM RES TOXICOL, V9, P484, DOI 10.1021/tx950152l; JENNISSEN HP, 1995, EUR J BIOCHEM, V231, P1; Kisselev AF, 1998, J BIOL CHEM, V273, P1982, DOI 10.1074/jbc.273.4.1982; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laub M, 1998, EUR J BIOCHEM, V255, P422, DOI 10.1046/j.1432-1327.1998.2550422.x; LEVINE RL, 1981, P NATL ACAD SCI-BIOL, V78, P2120, DOI 10.1073/pnas.78.4.2120; Majetschak M, 1998, EUR J BIOCHEM, V255, P482, DOI 10.1046/j.1432-1327.1998.2550482.x; Michaelis ML, 1996, LIFE SCI, V59, P405, DOI 10.1016/0024-3205(96)00319-0; Moskovitz J, 1996, P NATL ACAD SCI USA, V93, P2095, DOI 10.1073/pnas.93.5.2095; MYKLES DL, 1991, ARCH BIOCHEM BIOPHYS, V288, P543, DOI 10.1016/0003-9861(91)90233-9; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; Niedermann G, 1996, P NATL ACAD SCI USA, V93, P8572, DOI 10.1073/pnas.93.16.8572; Nussbaum AK, 1998, P NATL ACAD SCI USA, V95, P12504, DOI 10.1073/pnas.95.21.12504; ONEIL KT, 1989, J BIOL CHEM, V264, P14571; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; POTTER SM, 1993, PROTEIN SCI, V2, P1648, DOI 10.1002/pro.5560021011; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; RIVETT AJ, 1994, METHOD ENZYMOL, V244, P331; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; Schenck HL, 1996, J AM CHEM SOC, V118, P12487, DOI 10.1021/ja962026p; Sharov VS, 1999, FEBS LETT, V455, P247, DOI 10.1016/S0014-5793(99)00888-1; Squier TC, 2000, FRONT BIOSCI-LANDMRK, V5, pD504, DOI 10.2741/Squier; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STRASBURG GM, 1988, J BIOL CHEM, V263, P542; Sun HY, 1999, BIOCHEMISTRY-US, V38, P105, DOI 10.1021/bi981295k; Szymanska G, 1998, J BIOL CHEM, V273, P28516, DOI 10.1074/jbc.273.43.28516; Tarcsa E, 2000, J BIOL CHEM, V275, P20295, DOI 10.1074/jbc.M001555200; TAYLOR JE, 1994, BIOCHEM SOC T, V22, P949, DOI 10.1042/bst0220949; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wang R, 1999, BIOCHEMISTRY-US, V38, P14573, DOI 10.1021/bi990826h; Yao YH, 1996, BIOCHEMISTRY-US, V35, P2767, DOI 10.1021/bi951712i; Yin D, 2000, CHEM RES TOXICOL, V13, P103, DOI 10.1021/tx990142a; YU B, 1991, J BIOL CHEM, V266, P17396	61	101	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					937	943		10.1074/jbc.M005356200	http://dx.doi.org/10.1074/jbc.M005356200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11010965	hybrid			2022-12-25	WOS:000166430900012
J	Landrieu, I; Odaert, B; Wieruszeski, JM; Drobecq, H; Rousselot-Pailley, P; Inze, D; Lippens, G				Landrieu, I; Odaert, B; Wieruszeski, JM; Drobecq, H; Rousselot-Pailley, P; Inze, D; Lippens, G			p13(SUC1) and the WW domain of PIN1 bind to the same phosphothreonine-proline epitope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL-PROLYL ISOMERASE; XENOPUS SUC1/CKS PROTEIN; CYCLE-REGULATORY PROTEIN; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; PHOSPHORYLATION; RECOGNITION; SUBSTRATE; INTERACTS; COMPLEX	The WW domain of the human PIN1 and p13SUC1, a subunit of the cyclin-dependent kinase complex, were previously shown to be involved in the regulation of the cyclin-dependent kinase complex activity at the entry into mitosis, by an unresolved molecular mechanism. We report here experimental evidence for the direct interaction of p13(SUC1) With a model CDC25 peptide, dependent on the phosphorylation state of its threonine, Chemical shift perturbation of backbone H-1(N), N-15, and C-13 alpha, resonances during MMR titration experiments allows accurate identification of the binding site, primarily localized around the anion-binding site, occupied in the crystal structure of the homologous p9(CKSHs2) by a sulfate molecule. The epitope recognized by p13(SUC1) includes the proline at position +1 of the phosphothreonine, as was shown by the decrease in affinity for a mutated CDC25 phosphopeptide, containing an alanine/ proline substitution. No direct interaction between the PIN1 WW domain or its catalytic proline cis/transisomerase domain and p13(SUC1) was detected, but our study showed that in vitro the WW domain of the human PIN1 antagonizes the binding of the p13(SUC1) to the CDC25 phosphopeptide, by binding to the same phosphoepitope. We thus propose that the full cyclin-dependent kinase complex stimulates the phosphorylation of CDC25 through binding of its p13(SUC1) module to the phosphoepitope of the substrate and that the reported WW antagonism of p13(SUC1)-stimulated CDC25 phosphorylation is caused by competitive binding of both protein modules to the same phosphoepitope.	Inst Pasteur, Inst Biol Lille, CNRS UMR 8525, F-59019 Lille, France; Fac Univ Sci Agron Gembloux, Unite Microbiol, B-5030 Gembloux, Belgium; State Univ Ghent VIB, Dept Plant Genet, Genet Lab, B-9000 Ghent, Belgium	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; University of Liege; Flanders Institute for Biotechnology (VIB); Ghent University	Landrieu, I (corresponding author), Inst Pasteur, Inst Biol Lille, CNRS UMR 8525, F-59019 Lille, France.	isabelle.landrieu@pasteur-lille.fr; guy.lippens@pasteur-lille.fr	Rousselot-Pailley, Pierre/E-4151-2015; Inzé, Dirk/AAW-6381-2021; Landrieu, Isabelle/AAF-8495-2019	Inzé, Dirk/0000-0002-3217-8407; Landrieu, Isabelle/0000-0002-4883-2637; Lippens, Guy/0000-0002-8236-0901; Drobecq, Herve/0000-0002-4081-1575				ARVAI AS, 1995, J MOL BIOL, V249, P835, DOI 10.1006/jmbi.1995.0341; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; Egan EA, 1998, MOL CELL BIOL, V18, P3659, DOI 10.1128/MCB.18.7.3659; ENDICOTT JA, 1995, EMBO J, V14, P1004, DOI 10.1002/j.1460-2075.1995.tb07081.x; Landrieu I, 2000, J BIOL CHEM, V275, P10577, DOI 10.1074/jbc.275.14.10577; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Morris MC, 1998, BIOCHEMISTRY-US, V37, P14257, DOI 10.1021/bi980913u; Morris MC, 2000, J BIOL CHEM, V275, P28849, DOI 10.1074/jbc.M002942200; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; PARGE HE, 1993, SCIENCE, V262, P387, DOI 10.1126/science.8211159; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; Patra D, 1999, J BIOL CHEM, V274, P36839, DOI 10.1074/jbc.274.52.36839; Patra D, 1998, GENE DEV, V12, P2549, DOI 10.1101/gad.12.16.2549; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Rippmann JF, 2000, CELL GROWTH DIFFER, V11, P409; Rousseau F, 1998, J MOL BIOL, V284, P503, DOI 10.1006/jmbi.1998.2173; Sambrook J., 1989, MOL CLONING LAB MANU; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Sudakin V, 1997, J BIOL CHEM, V272, P18051, DOI 10.1074/jbc.272.29.18051; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Watson MH, 1996, J MOL BIOL, V261, P646, DOI 10.1006/jmbi.1996.0490; Winkler KE, 2000, SCIENCE, V287, P1644, DOI 10.1126/science.287.5458.1644; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Zarrinpar A, 2000, NAT STRUCT BIOL, V7, P611, DOI 10.1038/77891	34	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1434	1438		10.1074/jbc.M006420200	http://dx.doi.org/10.1074/jbc.M006420200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11013245	hybrid			2022-12-25	WOS:000166430900077
J	Okamoto, T; Toyooka, K; Minamikawa, T				Okamoto, T; Toyooka, K; Minamikawa, T			Identification of a membrane-associated cysteine protease with possible dual roles in the endoplasmic reticulum and protein storage vacuole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEPTIDASE SH-EP; VIGNA-MUNGO SEEDS; HUMAN PROCATHEPSIN-L; HUMAN CATHEPSIN-L; ASPARAGINYL ENDOPEPTIDASE; SULFHYDRYL-ENDOPEPTIDASE; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; PAPAIN PRECURSOR; THIOL PROTEASES	SH-EP is a vacuolar cysteine proteinase from germinated seeds of Vigna mungo, The enzyme has a C-terminal propeptide of 1 kDa that contains an endoplasmic reticulum (ER) retention signal, KDEL, The KDEL-tail has been suggested to function to store SH-EP as a transient zymogen in the lumen of the ER, and the C-terminal propeptide was thought to be removed within the ER or immediately after exit from the ER, In the present study, a protease that may be involved in the post-translational processing of the C-terminal propeptide of SH-EP was isolated from the microsomes of cotyledons of V. muno seedlings. cDNA sequence for the protease indicated that the enzyme is a member of the papain superfamily, Immunocytochemistry and subcellular fractionation of cotyledon cells suggested that the protease was localized in both the ER and protein storage vacuoles as enzymatically active mature form. In addition, protein fractionations of the cotyledonary microsome and Sf9 cells expressing the recombinant protease indicated that the enzyme associates with the microsomal membrane on the luminal side. The protease was named membrane-associated cysteine protease, MCP, The possibility that a papain-type enzyme, MCP, exists as mature enzyme in both ER and protein storage vacuoles will be discussed.	Tokyo Metropolitan Univ, Dept Sci Biol, Hachioji, Tokyo 1920397, Japan	Tokyo Metropolitan University	Okamoto, T (corresponding author), Tokyo Metropolitan Univ, Dept Sci Biol, Minami Osawa 1-1, Hachioji, Tokyo 1920397, Japan.	okamoto-takashi@c.metro-u.ac.jp	Toyooka, Kiminori/B-5027-2011					AKASOFU H, 1989, NUCLEIC ACIDS RES, V17, P6733, DOI 10.1093/nar/17.16.6733; BECKER C, 1995, EUR J BIOCHEM, V228, P456, DOI 10.1111/j.1432-1033.1995.tb20284.x; Carmona E, 1996, BIOCHEMISTRY-US, V35, P8149, DOI 10.1021/bi952736s; Cercos M, 1999, PLANT PHYSIOL, V119, P1341, DOI 10.1104/pp.119.4.1341; CHRISPEELS MJ, 1992, CELL, V68, P613, DOI 10.1016/0092-8674(92)90134-X; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; DENECKE J, 1992, EMBO J, V11, P2345, DOI 10.1002/j.1460-2075.1992.tb05294.x; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Galili G, 1998, PLANT MOL BIOL, V38, P1, DOI 10.1023/A:1006011919671; Guerrero C, 1998, PLANT MOL BIOL, V36, P565, DOI 10.1023/A:1005952005739; Hara-Nishimura I, 1998, PLANT CELL, V10, P825, DOI 10.1105/tpc.10.5.825; HERMAN EM, 1990, PLANTA, V182, P305, DOI 10.1007/BF00197126; HERMAN EM, 1990, PLANT PHYSIOL, V94, P341, DOI 10.1104/pp.94.1.341; HIRANO H, 1992, J BIOCHEM-TOKYO, V111, P754, DOI 10.1093/oxfordjournals.jbchem.a123831; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; Jerala R, 1998, J BIOL CHEM, V273, P11498, DOI 10.1074/jbc.273.19.11498; KALINSKI A, 1992, J BIOL CHEM, V267, P12068; KALINSKI A, 1990, J BIOL CHEM, V265, P13843; KALINSKI A, 1995, PLANTA, V195, P611, DOI 10.1007/BF00195722; LEE HI, 1993, P NATL ACAD SCI USA, V90, P11433, DOI 10.1073/pnas.90.23.11433; MACH L, 1994, J BIOL CHEM, V269, P13030; MCINTYRE GF, 1994, J BIOL CHEM, V269, P567; MCINTYRE GF, 1993, P NATL ACAD SCI USA, V90, P10588, DOI 10.1073/pnas.90.22.10588; MITSUHASHI W, 1986, PLANT PHYSIOL, V80, P628, DOI 10.1104/pp.80.3.628; MITSUHASHI W, 1989, PLANT PHYSIOL, V89, P274, DOI 10.1104/pp.89.1.274; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAPIER RM, 1992, J CELL SCI, V102, P261; Nomura T, 1997, BIOCHEM BIOPH RES CO, V230, P143, DOI 10.1006/bbrc.1996.5905; OKAMOTO T, 1994, FEBS LETT, V351, P31, DOI 10.1016/0014-5793(94)00809-4; Okamoto T, 1999, EUR J BIOCHEM, V264, P223, DOI 10.1046/j.1432-1327.1999.00618.x; Okamoto T, 1999, PLANT MOL BIOL, V39, P63, DOI 10.1023/A:1006170518002; Okita TW, 1996, ANNU REV PLANT PHYS, V47, P327, DOI 10.1146/annurev.arplant.47.1.327; Okomoto T, 1999, J BIOL CHEM, V274, P11390, DOI 10.1074/jbc.274.16.11390; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schmid M, 1998, PLANTA, V206, P466, DOI 10.1007/s004250050423; SMITH SM, 1989, J BIOL CHEM, V264, P20487; SUZUKI Y, 1985, PLANT PHYSIOL, V79, P327, DOI 10.1104/pp.79.2.327; TANAKA T, 1991, PLANT MOL BIOL, V16, P1083, DOI 10.1007/BF00016081; TOMURA H, 1981, PLANT PHYSIOL, V79, P935; Toyooka K, 2000, J CELL BIOL, V148, P453, DOI 10.1083/jcb.148.3.453; VALPUESTA V, 1995, PLANT MOL BIOL, V28, P575, DOI 10.1007/BF00020403; VERNET T, 1991, J BIOL CHEM, V266, P21451; VERNET T, 1995, J BIOL CHEM, V270, P10838, DOI 10.1074/jbc.270.18.10838; Vitale A, 1999, PLANT CELL, V11, P615, DOI 10.1105/tpc.11.4.615; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; YU WJ, 1994, J EXP BOT, V45, P261, DOI 10.1093/jxb/45.2.261; YU WJ, 1996, PLANT PHYSL PGR, V112, P862	48	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					742	751		10.1074/jbc.M003078200	http://dx.doi.org/10.1074/jbc.M003078200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11022031	hybrid			2022-12-25	WOS:000166280700100
J	Sakthivel, R; Zhang, JC; Strickland, DK; Gafvels, M; McCrae, KR				Sakthivel, R; Zhang, JC; Strickland, DK; Gafvels, M; McCrae, KR			Regulation of the ligand binding activity of the human very low density lipoprotein receptor by protein kinase C-dependent phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; APOLIPOPROTEIN-E RECEPTOR; TISSUE-SPECIFIC EXPRESSION; PROMOTING PHORBOL ESTERS; IN-SITU HYBRIDIZATION; MESSENGER-RNA LEVELS; VLDL RECEPTOR; ENDOTHELIAL-CELLS; LDL RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR	The very low density lipoprotein receptor (VLDL-R) binds and internalizes several ligands, including very low density lipoprotein (VLDL), urokinase-type plasminogen activator:plasminogen activator inhibitor type 1 complexes, lipoprotein lipase, and the 39-kDa receptor-associated protein that copurifies with the low density lipoprotein receptor-related protein/alpha (2)-macraglobulin receptor. Although several agonists regulate VLDL-R mRNA and/or protein expression, post-transcriptional regulation of receptor activity has not been described. Here, we report that the ligand binding activity of the VLDL-R in THP-1 monocytic cells, endothelial cells, smooth muscle cells, and VLDL-R transfected HEK 293 cells is diminished after treatment with phorbol 12-myristate 13-acetate. This response was blacked by inhibitors of protein kinase C (PK-C), including a specific inhibitor of the PK-C PII isoform, and was associated with phosphorylation of serine residues in the cytoplasmic domain of the receptor. Culture of endothelial cells in the presence of high glucose concentrations, which stimulate diacylglycerol synthesis and PK-C PII activation, also induced a PK-C-dependent loss of VLDL-R ligand binding activity. Taken together, these studies demonstrate that the ligand binding activity of the VLDL-R is regulated by PK-C-dependent phosphorylation and that hyperglycemia may diminish VLDL-R activity.	Case Western Reserve Univ, Sch Med, Dept Med, Div Hematol Oncol, Cleveland, OH 44106 USA; Amer Red Cross, Holland Labs, Rockville, MD 20855 USA; Huddinge Univ Hosp, Karolinska Inst, Ctr Nutr & Toxicol, S-14186 Huddinge, Sweden	Case Western Reserve University; American Red Cross; Karolinska Institutet	McCrae, KR (corresponding author), Case Western Reserve Univ, Sch Med, Dept Med, Div Hematol Oncol, BRB 329,10900 Euclid Ave, Cleveland, OH 44106 USA.				NHLBI NIH HHS [HL50787, HL50827] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050827] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ando M, 1997, KIDNEY INT, V51, P785, DOI 10.1038/ki.1997.110; Argraves KM, 1997, J CLIN INVEST, V100, P2170, DOI 10.1172/JCI119753; ARGRAVES KM, 1995, J BIOL CHEM, V270, P26550, DOI 10.1074/jbc.270.44.26550; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; BINGHAM EW, 1976, BIOCHIM BIOPHYS ACTA, V429, P448, DOI 10.1016/0005-2744(76)90293-X; Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; BROWN KD, 1984, BIOCHEM BIOPH RES CO, V123, P377, DOI 10.1016/0006-291X(84)90424-8; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; Bu GJ, 1998, J BIOL CHEM, V273, P13359, DOI 10.1074/jbc.273.21.13359; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHRIST G, 1993, BLOOD, V81, P1277; DEISHER TA, 1993, FEBS LETT, V331, P285, DOI 10.1016/0014-5793(93)80354-W; FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453; GAFVELS ME, 1994, ENDOCRINOLOGY, V135, P387, DOI 10.1210/en.135.1.387; GAFVELS ME, 1993, SOMAT CELL MOLEC GEN, V19, P557, DOI 10.1007/BF01233382; GRUNBERGER G, 1982, AM J PHYSIOL, V246, pE319; HEEGAARD CW, 1995, J BIOL CHEM, V270, P20855, DOI 10.1074/jbc.270.35.20855; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1994, FUNCTIONS LDL RECEPT, P14; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; ISHIBASHI T, 1994, ARTERIOSCLER THROMB, V14, P1534, DOI 10.1161/01.ATV.14.10.1534; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; IWASHITA S, 1984, J BIOL CHEM, V259, P2559; JACOBS S, 1983, P NATL ACAD SCI-BIOL, V80, P6211, DOI 10.1073/pnas.80.20.6211; Jingami Hisato, 1995, Current Opinion in Lipidology, V6, P104, DOI 10.1097/00041433-199504000-00008; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; Kibbey RG, 1998, J CELL BIOL, V142, P59, DOI 10.1083/jcb.142.1.59; King GL, 1996, DIABETS, V45, P105; KISHIMOTO A, 1987, J BIOL CHEM, V262, P9367; KISHIMOTO A, 1987, J BIOL CHEM, V262, P1344; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Kobayashi K, 1996, J BIOL CHEM, V271, P6852, DOI 10.1074/jbc.271.12.6852; Kohno M, 1997, ATHEROSCLEROSIS, V133, P45, DOI 10.1016/S0021-9150(97)00112-3; Kozarsky KF, 1996, NAT GENET, V13, P54, DOI 10.1038/ng0596-54; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE LS, 1978, SCIENCE, V202, P313, DOI 10.1126/science.308698; LEE TS, 1989, P NATL ACAD SCI USA, V86, P5141, DOI 10.1073/pnas.86.13.5141; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; MAGNUSON DK, 1989, SURGERY, V106, P216; Magrane J, 1998, J LIPID RES, V39, P2172; Martensen PM, 1997, EUR J BIOCHEM, V248, P583, DOI 10.1111/j.1432-1033.1997.00583.x; MASUZAKI H, 1994, FEBS LETT, V347, P211, DOI 10.1016/0014-5793(94)00546-X; MCCAFFREY PG, 1984, J BIOL CHEM, V259, P2502; MCCRAE KR, 1991, BRIT J HAEMATOL, V79, P595, DOI 10.1111/j.1365-2141.1991.tb08087.x; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MEHTA K, 1986, CANCER RES, V46, P1388; Multhaupt HAB, 1996, AM J PATHOL, V148, P1985; Nakamura J, 1999, DIABETES, V48, P2090, DOI 10.2337/diabetes.48.10.2090; Nakazato K, 1996, AM J PATHOL, V149, P1831; Niemeier A, 1996, J LIPID RES, V37, P1733; Nimpf J, 1998, ATHEROSCLEROSIS, V141, P191, DOI 10.1016/S0021-9150(98)00172-5; OKA K, 1994, EUR J BIOCHEM, V224, P975, DOI 10.1111/j.1432-1033.1994.00975.x; OKA K, 1994, GENOMICS, V20, P298, DOI 10.1006/geno.1994.1171; Park JY, 2000, DIABETES, V49, P1239, DOI 10.2337/diabetes.49.7.1239; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; RUDLING M, 1992, J LIPID RES, V33, P493; RUSSELL DW, 1983, P NATL ACAD SCI-BIOL, V80, P7501, DOI 10.1073/pnas.80.24.7501; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SAKTHIVEL R, 1998, VASCULAR BIOL 9 0415, P32; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; SIMONSEN ACW, 1994, FEBS LETT, V354, P279, DOI 10.1016/0014-5793(94)01138-9; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; SUZUKI J, 1995, BIOCHEM BIOPH RES CO, V206, P835, DOI 10.1006/bbrc.1995.1119; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; Takahashi S, 1996, FEBS LETT, V386, P197, DOI 10.1016/0014-5793(96)00439-5; TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747, DOI 10.1074/jbc.270.26.15747; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320; Warshawsky I, 1996, J BIOL CHEM, V271, P25873, DOI 10.1074/jbc.271.42.25873; Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412; WEBB JC, 1994, HUM MOL GENET, V3, P531, DOI 10.1093/hmg/3.4.531; WHITELEY B, 1986, J CELL BIOL, V103, P1355, DOI 10.1083/jcb.103.4.1355; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Willnow TE, 1999, J MOL MED-JMM, V77, P306, DOI 10.1007/s001090050356; WITTMAACK FM, 1995, ENDOCRINOLOGY, V136, P340, DOI 10.1210/en.136.1.340; WRANN M, 1980, SCIENCE, V210, P1363, DOI 10.1126/science.6254158; Wyne KL, 1996, ARTERIOSCL THROM VAS, V16, P407, DOI 10.1161/01.ATV.16.3.407; XIA P, 1994, DIABETES, V43, P1122, DOI 10.2337/diabetes.43.9.1122; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; YAMAMOTO T, 1993, TRENDS CARDIOVAS MED, V3, P144, DOI 10.1016/1050-1738(93)90015-X; Yan SF, 2000, J BIOL CHEM, V275, P11921, DOI 10.1074/jbc.275.16.11921; Yanase K, 1997, J CLIN INVEST, V100, P25, DOI 10.1172/JCI119517	93	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					555	562		10.1074/jbc.M003953200	http://dx.doi.org/10.1074/jbc.M003953200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11010963	hybrid			2022-12-25	WOS:000166280700075
J	Carlotti, F; Dower, SK; Qwarnstrom, EE				Carlotti, F; Dower, SK; Qwarnstrom, EE			Dynamic shuttling of nuclear factor kappa B between the nucleus and cytoplasm as a consequence of inhibitor dissociation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; DNA-BINDING; FACTOR-ALPHA; ACTIVATION; PHOSPHORYLATION; INTERLEUKIN-1; DEGRADATION; PROTEINS; ASSOCIATION	Activation of the nuclear factor kappaB (NF kappaB) transcription factor is intimately associated with its translocation from the cytoplasm to the nucleus. Using the nuclear export inhibitor leptomycin B, we demonstrate shuttling of the RELA subunit of NF kappaB and the inhibitory subunit I kappaB alpha between these two compartments in unstimulated cells. Determination of the kinetics of nuclear entry shows marked differences for the two components; the entry of I kappaB alpha occurs more rapidly than RELA. The shuttling is suggested to be a consequence of the cytoplasmic dissociation of the NF kappaB.I kappaB complex rather than its direct nuclear import or degradation and resynthesis of I kappaB alpha. Using previously published kinetic data, this proposition is born out by the deduction that 17% of NF kappaB is not complexed to I kappaB alpha in a resting cell. A numerical model is presented to validate the proposed regulation of NF kappaB subcellular localization consequent in part on the:nuclear export function and in part on the cytoplasmic retention function of I kappaB alpha. We suggest that the non-saturated interaction of NF kappaB with the inhibitor may enhance the specificity of action of I kappaB proteins on different NF kappaB dimers and allow additional modes of regulation of I kappaB function.	Univ Sheffield, Royal Hallamshire Hosp, Div Mol & Genet Med, Funct Genom Grp, Sheffield S10 2JF, S Yorkshire, England; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	University of Sheffield; University of Washington; University of Washington Seattle	Qwarnstrom, EE (corresponding author), Univ Sheffield, Royal Hallamshire Hosp, Div Mol & Genet Med, Funct Genom Grp, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.			Qwarnstrom, Eva/0000-0003-4417-8663; dower, steve/0000-0002-4675-4225				BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Carlotti F, 1999, J BIOL CHEM, V274, P37941, DOI 10.1074/jbc.274.53.37941; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang DM, 1998, LINEAR ALGEBRA APPL, V273, P1; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	27	123	126	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41028	41034		10.1074/jbc.M006179200	http://dx.doi.org/10.1074/jbc.M006179200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024020	hybrid			2022-12-25	WOS:000166114600051
J	Hahn-Dantona, EA; Aimes, RT; Quigley, JP				Hahn-Dantona, EA; Aimes, RT; Quigley, JP			The isolation, characterization, and molecular cloning of a 75-kDa gelatinase B-like enzyme, a member of the matrix metalloproteinase (MMP) family - An avian enzyme that is MMP-9-like in its cell expression pattern but diverges from mammalian gelatinase B in sequence and biochemical properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEPWISE ACTIVATION MECHANISMS; HUMAN FIBROBLAST COLLAGENASE; CHICKEN-EMBRYO FIBROBLASTS; C-TERMINAL DOMAIN; TISSUE INHIBITOR; IV COLLAGENASE; PROGELATINASE-A; 4-AMINOPHENYLMERCURIC ACETATE; POLYACRYLAMIDE GELS; 72-KDA GELATINASE	We have isolated a novel 75-kDa gelatinase from a chicken macrophage cell line, HD11. Biochemical and immunological characterization of the purified enzyme demonstrated that it is distinct from the chicken 72-kDa gelatinase A (MMP-2). The enzyme is capable of specific gelatin binding and rapid gelatin cleavage. Incubation with an organomercurial compound (p-aminophenylmercuric acetate) induces proteolytic processing and activation of this enzyme, and the resultant gelatinolytic activity is sensitive to both zinc chelators and tissue inhibitors of metalloproteinases. A full-length cDNA for the enzyme has been cloned, and sequence analysis demonstrated that the enzyme possesses the characteristic multidomain structure of an MMP gelatinase including a cysteine switch prodomain, three fibronectin type II repeats, a catalytic zinc binding region, and a hemopexin-like domain, The 75-kDa gelatinase is produced by phorbol ester-treated chicken bone marrow cells, monocytes, and polymorphonuclear leukocytes, cell types that characteristically produce the 92-kDa mammalian gelatinase B (MMP-9). The absence of a 90-110-kDa gelatinase in these cell types indicates that the 75-kDa gelatinase is likely the avian counterpart of gelatinase B, However, the protein is only 59% identical to human gelatinase B, whereas all previously cloned chicken MMP homologues are 75-90% identical to their human counterparts. In addition, the new 75-kDa chicken gelatinase lacks the type V collagen domain that is found in all mammalian gelatinase Bs, Furthermore, the secreted enzyme appears structurally distinct from known gelatinase Bs and the activated enzyme can cleave fibronectin, which is not a substrate for mammalian gelatinase B, Thus the results of this study indicate that a second MMP gelatinase exists in chickens, and although it is MIMP-9/gelatinase B-like in its overall domain structure and expression pattern, it appears to be biochemically divergent from mammalian gelatinase B.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA	Scripps Research Institute; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Quigley, JP (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines RD,VB1, La Jolla, CA 92037 USA.	jquigley@scripps.edu			NCI NIH HHS [CA55852] Funding Source: Medline; PHS HHS [H60769S] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055852] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams DO., 1992, INFLAMMATION BASIC P, P637; Aimes RT, 1998, J CELL PHYSIOL, V174, P342, DOI 10.1002/(SICI)1097-4652(199803)174:3<342::AID-JCP8>3.3.CO;2-K; AMES RT, 1994, BIOCHEM J, V300, P729, DOI 10.1042/bj3000729; Andreasen CB, 1999, AVIAN DIS, V43, P656, DOI 10.2307/1592734; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; BEBBINGTON CR, 1992, BIO-TECHNOL, V10, P169, DOI 10.1038/nbt0292-169; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BROWN PD, 1993, KIDNEY INT, V43, P163, DOI 10.1038/ki.1993.27; CHEN JM, 1991, J BIOL CHEM, V266, P5113; FRIDMAN R, 1995, CANCER RES, V55, P2548; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Hahn-Dantona E, 1999, ANN NY ACAD SCI, V878, P372, DOI 10.1111/j.1749-6632.1999.tb07696.x; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; Hua J, 1996, CANCER RES, V56, P5279; HUARTE J, 1987, GENE DEV, V1, P1201, DOI 10.1101/gad.1.10.1201; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; Lei HQ, 1999, BIOL REPROD, V60, P183, DOI 10.1095/biolreprod60.1.183; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Mazo IB, 1999, J LEUKOCYTE BIOL, V66, P25, DOI 10.1002/jlb.66.1.25; Miyazaki K, 1996, P NATL ACAD SCI USA, V93, P6819, DOI 10.1073/pnas.93.13.6819; MOLL UM, 1990, CANCER RES, V50, P6162; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; MURPHY G, 1994, J BIOL CHEM, V269, P6632; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1992, J BIOL CHEM, V267, P9612; Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945-053X(97)90025-1; Nagase H, 1992, Matrix Suppl, V1, P237; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NAGASE H, 1991, BIOMED BIOCHIM ACTA, V50, P749; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OGATA Y, 1995, J BIOL CHEM, V270, P18506, DOI 10.1074/jbc.270.31.18506; Owen CA, 1999, J LEUKOCYTE BIOL, V65, P137, DOI 10.1002/jlb.65.2.137; Park HI, 2000, J BIOL CHEM, V275, P20540, DOI 10.1074/jbc.M002349200; POURMOTABBED T, 1994, ANN NY ACAD SCI, V732, P372, DOI 10.1111/j.1749-6632.1994.tb24757.x; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; Sato T, 1999, ANN NY ACAD SCI, V878, P713, DOI 10.1111/j.1749-6632.1999.tb07770.x; Solari F, 1996, J CELL SCI, V109, P1203; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; Steffensen B, 1998, J BIOL CHEM, V273, P20622, DOI 10.1074/jbc.273.32.20622; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Suzuki K, 1998, BIOL CHEM, V379, P185, DOI 10.1515/bchm.1998.379.2.185; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANFURTH R, 1992, INFLAMMATION BASIC P, P325; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOESSNER JF, 1994, ANN NY ACAD SCI, V732, P11; Yang MZ, 1996, J BIOL CHEM, V271, P25548, DOI 10.1074/jbc.271.41.25548	58	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40827	40838		10.1074/jbc.M006234200	http://dx.doi.org/10.1074/jbc.M006234200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11010969	hybrid			2022-12-25	WOS:000166114600024
J	Nyitrai, M; Hild, G; Hartvig, N; Belagyi, J; Somogyi, B				Nyitrai, M; Hild, G; Hartvig, N; Belagyi, J; Somogyi, B			Conformational and dynamic differences between actin filaments polymerized from ATP- or ADP-actin monomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE ENERGY-TRANSFER; NUCLEOTIDE-BINDING-SITES; RABBIT SKELETAL-MUSCLE; F-ACTIN; TRANSFER SPECTROSCOPY; RADIAL COORDINATE; DIVALENT-CATIONS; PHALLOIDIN; FLEXIBILITY; MYOSIN	Conformational and dynamic properties of actin filaments polymerized from ATP- or ADP-actin monomers were compared by using fluorescence spectroscopic methods. The fluorescence intensity of LAEDANS attached to the Cys(374) residue of actin was smaller in filaments from ADP-actin than in filaments from ATP-actin monomers, which reflected a nucleotide-induced conformational difference in subdomain 1 of the monomer. Radial coordinate calculations revealed that this conformational difference did not modify the distance of Cys(374) from the longitudinal filament axis. Temperature-dependent fluorescence resonance energy transfer measurements between donor and acceptor molecules on Cys(374) Of neighboring actin protomers revealed that the inter-monomer flexibility of filaments assembled from ADP-actin monomers were substantially greater than the one of filaments from ATP-actin monomers, Flexibility was reduced by phalloidin in both types of filaments.	Univ Pecs, Res Grp Fluorescence Spect, Off Acad Res Grp Attached Univ & Other Inst, H-7601 Pecs, Hungary; Univ Pecs, Dept Biophys, Fac Med, H-7601 Pecs, Hungary; Univ Pecs, Cent Res Lab, Fac Med, H-7601 Pecs, Hungary	University of Pecs; University of Pecs; University of Pecs	Somogyi, B (corresponding author), Univ Pecs, Res Grp Fluorescence Spect, Off Acad Res Grp Attached Univ & Other Inst, POB 99, H-7601 Pecs, Hungary.			Nyitrai, Miklos/0000-0002-6229-4337				BARDEN JA, 1987, EUR J BIOCHEM, V162, P583, DOI 10.1111/j.1432-1033.1987.tb10679.x; BAY Z, 1963, P NATL ACAD SCI USA, V50, P1071, DOI 10.1073/pnas.50.6.1071; BURLACU S, 1992, AM J PHYSIOL, V262, P569; Carlier M F, 1990, Adv Biophys, V26, P51, DOI 10.1016/0065-227X(90)90007-G; Carlier MF, 1991, CURR OPIN CELL BIOL, V3, P12, DOI 10.1016/0955-0674(91)90160-Z; CARLIER MF, 1987, BIOCHEM BIOPH RES CO, V143, P1069, DOI 10.1016/0006-291X(87)90361-5; CARLIER MF, 1988, J BIOL CHEM, V263, P817; CARLIER MF, 1991, J BIOL CHEM, V266, P1; CARLIER MF, 1986, BIOCHEMISTRY-US, V25, P7789, DOI 10.1021/bi00372a001; DANCKER P, 1975, BIOCHIM BIOPHYS ACTA, V400, P407, DOI 10.1016/0005-2795(75)90196-8; DREWES G, 1991, J BIOL CHEM, V266, P5508; ELZINGA M, 1973, P NATL ACAD SCI USA, V70, P2687, DOI 10.1073/pnas.70.9.2687; FAULSTICH H, 1988, J MUSCLE RES CELL M, V9, P370, DOI 10.1007/BF01774064; FAULSTICH H, 1993, FEBS LETT, V318, P218, DOI 10.1016/0014-5793(93)80515-V; Feuer G., 1948, HUNGARICA ACTA PHYSIOL, V1, P150; FRIEDEN C, 1980, J BIOL CHEM, V255, P8991; Gaszner B, 1999, BIOCHEMISTRY-US, V38, P12885, DOI 10.1021/bi990748y; GENNIS RB, 1972, BIOCHEMISTRY-US, V11, P2509, DOI 10.1021/bi00763a020; Hild G, 1998, BIOPHYS J, V75, P3015, DOI 10.1016/S0006-3495(98)77742-2; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; HUDSON EN, 1973, BIOCHEMISTRY-US, V12, P4154, DOI 10.1021/bi00745a019; ISAMBERT H, 1995, J BIOL CHEM, V270, P11437, DOI 10.1074/jbc.270.19.11437; Ishiwata S, 1997, BIOPHYS J, V73, P895, DOI 10.1016/S0006-3495(97)78122-0; JANMEY PA, 1990, NATURE, V347, P95, DOI 10.1038/347095a0; KASPRZAK AA, 1988, BIOCHEMISTRY-US, V27, P4512, DOI 10.1021/bi00412a044; KAWAMURA M, 1972, J BIOCHEM-TOKYO, V72, P179, DOI 10.1093/oxfordjournals.jbchem.a129884; KOUYAMA T, 1985, BIOPHYS J, V47, P43, DOI 10.1016/S0006-3495(85)83875-3; MIKI M, 1986, BIOCHIM BIOPHYS ACTA, V871, P137, DOI 10.1016/0167-4838(86)90166-4; MIKI M, 1986, BIOCHEM INT, V12, P725; MIKI M, 1986, BIOCHIM BIOPHYS ACTA, V872, P76, DOI 10.1016/0167-4838(86)90149-4; MIKI M, 1987, EUR J BIOCHEM, V165, P125, DOI 10.1111/j.1432-1033.1987.tb11202.x; MIKI M, 1987, EUR J BIOCHEM, V168, P339, DOI 10.1111/j.1432-1033.1987.tb13425.x; Moens PDJ, 1997, BIOCHEMISTRY-US, V36, P7353, DOI 10.1021/bi962588l; MOENS PDJ, 1994, BIOCHEMISTRY-US, V33, P13102, DOI 10.1021/bi00248a020; NEWMAN J, 1993, BIOPHYS J, V64, P1559, DOI 10.1016/S0006-3495(93)81525-X; NUNNALLY MH, 1981, J BIOL CHEM, V256, P2083; Nyitrai M, 1999, J BIOL CHEM, V274, P12996, DOI 10.1074/jbc.274.19.12996; ORLOVA A, 1995, J MOL BIOL, V245, P582, DOI 10.1006/jmbi.1994.0048; ORLOVA A, 1993, J MOL BIOL, V232, P334, DOI 10.1006/jmbi.1993.1393; ORLOVA A, 1992, J MOL BIOL, V227, P1043, DOI 10.1016/0022-2836(92)90520-T; POLLARD TD, 1992, J BIOL CHEM, V267, P20339; POLLARD TD, 1984, FEBS LETT, V170, P94, DOI 10.1016/0014-5793(84)81376-9; Rebello CA, 1998, BIOCHEMISTRY-US, V37, P14529, DOI 10.1021/bi981240i; RICKARD JE, 1988, J MOL BIOL, V201, P675, DOI 10.1016/0022-2836(88)90466-4; SELVE N, 1986, J MOL BIOL, V187, P627, DOI 10.1016/0022-2836(86)90341-4; SOMOGYI B, 1984, BIOCHEMISTRY-US, V23, P3403, DOI 10.1021/bi00310a004; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Steinmetz MO, 1997, J CELL BIOL, V138, P559, DOI 10.1083/jcb.138.3.559; STRZELECKAGOLASZEWSKA H, 1993, EUR J BIOCHEM, V211, P731, DOI 10.1111/j.1432-1033.1993.tb17603.x; TAKASHI R, 1979, BIOCHEMISTRY-US, V18, P5164, DOI 10.1021/bi00590a021; TAYLOR DL, 1981, J CELL BIOL, V89, P362, DOI 10.1083/jcb.89.2.362; WEGNER A, 1970, J MOL BIOL, V109, P139; YIN HL, 1980, J BIOL CHEM, V255, P9494	53	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41143	41149		10.1074/jbc.M004146200	http://dx.doi.org/10.1074/jbc.M004146200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11005806	hybrid			2022-12-25	WOS:000166114600066
J	Borsu, L; Presse, F; Nahon, JL				Borsu, L; Presse, F; Nahon, JL			The AROM gene, spliced mRNAs encoding new DNA/RNA-binding proteins are transcribed from the opposite strand of the melanin-concentrating hormone gene in mammals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; TISSUE-SPECIFIC EXPRESSION; FIBROBLAST GROWTH-FACTOR; RNA-RECOGNITION; ANTISENSE RNA; RAT-BRAIN; SEQUENCE; DNA; PEPTIDE; CELLS	Melanin-concentrating hormone (MCH) mRNA expression is induced by nerve growth factor and lithium in PC12 cells, whereas three large MCH RNA species are found in untreated cells. In this study, we investigated the structures, regulations of expression, and putative functions of these transcripts. Northern blot, rapid amplification of cDNA ends-polymerase chain reaction, reverse transcriptase-polymerase chain reaction, and sequencing experiments demonstrated that they are antisense RNAs complementary to the MCH gene. Two classes of antisense RNAs could be discriminated as follows: 1) non-coding unspliced RNAs that overlap mainly the coding part of the MCH gene; 2) spliced variant mRNAs complementary to the 3'-flanking end of the MCH gene and that encode putative proteins containing DNA/RNA binding domains. We named this new transcriptional unit AROM for antisense-RNA-overlapping-MCH gene. Spliced variant AROM mRNAs are expressed in a broad range of rat organs. Western blot and immunohistochemistry experiments revealed several proteins with cytoplasmic but also nuclear localization in PC12 cells. Time course studies during nerve growth factor and lithium treatment of PC12 cells indicated a reciprocal regulation of the MCH and AROM gene transcripts, reflected also at the level of AROM proteins. The major translational product is a 64-kDa protein (AROM-p64). Recombinant AROM-p64 displayed high binding to single-stranded DNA and poly(A) homopolymers suggesting that this protein could play a role in mRNA maturation/metabolism.	Inst Pharmacol Mol & Cellulaire, CNRS UPR 411, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Nahon, JL (corresponding author), Inst Pharmacol Mol & Cellulaire, CNRS UPR 411, 660 Route Lucioles Sophia Antipolis, F-06560 Valbonne, France.		PRESSE, Francoise/O-8508-2016; NAHON, Jean-Louis/O-7977-2016	NAHON, Jean-Louis/0000-0001-9572-7779				ARMSTRONG BC, 1992, CELL GROWTH DIFFER, V3, P385; BAKER BI, 1994, TRENDS ENDOCRIN MET, V5, P120, DOI 10.1016/1043-2760(94)90093-0; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; BRESSON JL, 1989, NEUROSCI LETT, V102, P39, DOI 10.1016/0304-3940(89)90304-2; BRETON C, 1993, MOL BRAIN RES, V18, P297, DOI 10.1016/0169-328X(93)90093-5; BRETON C, 1993, MOL CELL NEUROSCI, V4, P271, DOI 10.1006/mcne.1993.1035; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; Ellis NA, 1997, CURR OPIN GENET DEV, V7, P354, DOI 10.1016/S0959-437X(97)80149-9; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; HENIKOFF S, 1986, CELL, V44, P33, DOI 10.1016/0092-8674(86)90482-4; HERVIEU G, 1995, NEUROENDOCRINOLOGY, V61, P348, DOI 10.1159/000126857; KADONAGA JT, 1991, METHOD ENZYMOL, V208, P10; KAWAUCHI H, 1983, NATURE, V305, P321, DOI 10.1038/305321a0; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; Knee R, 1997, P NATL ACAD SCI USA, V94, P4943, DOI 10.1073/pnas.94.10.4943; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Krystal G. W., 1992, Gene regulation: biology of antisense RNA and DNA., P11; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Miller CL, 1998, BRAIN RES, V803, P86, DOI 10.1016/S0006-8993(98)00626-X; MUNROE SH, 1991, J BIOL CHEM, V266, P22083; NAHON JL, 1989, ENDOCRINOLOGY, V125, P2056, DOI 10.1210/endo-125-4-2056; NAHON JL, 1994, CRIT REV NEUROBIOL, V8, P221; Presse F, 1997, MOL BRAIN RES, V52, P270, DOI 10.1016/S0169-328X(97)00273-8; Presse F, 1996, NEUROSCIENCE, V71, P735, DOI 10.1016/0306-4522(95)00481-5; PRESSE F, 1991, HORIZONS ENDOCRINOLO, V2, P241; PRESSE F, 1997, MCH SEIZURES NEUROMO, P31; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Rossi M, 1997, ENDOCRINOLOGY, V138, P351, DOI 10.1210/en.138.1.351; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; SKOFITSCH G, 1985, BRAIN RES BULL, V15, P635, DOI 10.1016/0361-9230(85)90213-8; Soret J, 1998, MOL CELL BIOL, V18, P4924, DOI 10.1128/MCB.18.8.4924; THOMPSON RC, 1990, DNA CELL BIOL, V9, P637, DOI 10.1089/dna.1990.9.637; Tommasi S, 1999, J BIOL CHEM, V274, P27829, DOI 10.1074/jbc.274.39.27829; Toumaniantz G, 1996, ENDOCRINOLOGY, V137, P4518, DOI 10.1210/en.137.10.4518; VAUGHAN JM, 1989, ENDOCRINOLOGY, V125, P1660, DOI 10.1210/endo-125-3-1660; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; Viale A, 1998, MOL BIOL EVOL, V15, P196, DOI 10.1093/oxfordjournals.molbev.a025915; Zhang G, 1998, J BACTERIOL, V180, P377, DOI 10.1128/JB.180.2.377-387.1998	47	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40576	40587		10.1074/jbc.M006524200	http://dx.doi.org/10.1074/jbc.M006524200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11006283	hybrid			2022-12-25	WOS:000166039500104
J	Iglesias, T; Cabrera-Poch, N; Mitchell, MP; Naven, TJP; Rozengurt, E; Schiavo, G				Iglesias, T; Cabrera-Poch, N; Mitchell, MP; Naven, TJP; Rozengurt, E; Schiavo, G			Identification and cloning of Kidins220, a novel neuronal substrate of protein kinase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; C-MU; PHORBOL ESTER; D PKD; CELLS; ACTIVATION; DIACYLGLYCEROL; COMPLEX; ASSOCIATION; CORTACTIN	Protein kinase D (PKD) is a serine/threonine kinase regulated by diacylglycerol signaling pathways with unique domain composition and enzymatic properties, still awaiting identification of its specific substrate(s). Here we have isolated, cloned, and characterized a novel protein from PC12 cells, termed Kidins220 (kinase D-interacting substrate of 220 kDa), as the first identified PKD physiological substrate. Kidins220 contains 11 ankyrin repeats and four transmembrane domains within the N-terminal region. We have shown that Kidins220 is an integral membrane protein selectively expressed in brain and neuroendocrine cells, where it concentrates at the tip of neurites. In PC12 cells, PKD coimmunoprecipitates and phosphorylates endogenous Kidins220. This phosphorylation is increased after stimulating PKD activity in vivo by phorbol-12,13-dibutyrate treatment. A constitutively active PKD mutant (PKD-S744E/S748E) phosphorylates recombinant Kidins220-VSVG in vitro in the absence of phorbol-12,13-dibutyrate. Conversely, Kidins220-VSVG phosphorylation is abolished when a dominant negative mutant of PHD (PKD-D733A) is used. Moreover, a peptide within the Kidins220 sequence, containing serine 919 in a consensus motif for PHD-specific phosphorylation, behaved as the best peptide substrate to date. Substitution of serine 919 to alanine abrogated peptide phosphorylation. Furthermore, by generating an antibody recognizing Kidins220 phosphorylated on serine 919, we show that phorbol ester treatment causes the specific phosphorylation of this residue in PC12 cells in vivo. Our results provide the first physiological substrate for PKD and indicate that Kidins220 is phosphorylated by PKD at serine 919 in vivo.	Imperial Canc Res Fund, Mol Neuropathobiol Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Cell Biol Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Computat Genome Anal Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Prot Sequencing Lab, London WC2A 3PX, England; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Cancer Research UK; Cancer Research UK; Cancer Research UK; The Genome Analysis Centre (TGAC); Cancer Research UK; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Iglesias, T (corresponding author), Imperial Canc Res Fund, Mol Neuropathobiol Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	tiglesias@iib.uam.es	Vacas, Teresa Iglesias/ABF-8663-2020	Vacas, Teresa Iglesias/0000-0002-4326-9005; Schiavo, Giampietro/0000-0002-4319-8745				Abedi H, 1998, FEBS LETT, V427, P209, DOI 10.1016/S0014-5793(98)00427-X; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Burgoyne RD, 1998, BIOESSAYS, V20, P328, DOI 10.1002/(SICI)1521-1878(199804)20:4<328::AID-BIES9>3.0.CO;2-L; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; EXTON JH, 1990, J BIOL CHEM, V265, P1; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, FEBS LETT, V437, P19, DOI 10.1016/S0014-5793(98)01189-2; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Johannes FJ, 1999, FEBS LETT, V461, P68, DOI 10.1016/S0014-5793(99)01424-6; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Nagase T, 1999, DNA Res, V6, P337, DOI 10.1093/dnares/6.5.337; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Paolucci L, 1999, CANCER RES, V59, P572; Rozengurt E, 1995, MUTAT RES-FUND MOL M, V333, P153, DOI 10.1016/0027-5107(95)00141-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 1999, ELECTROPHORESIS, V20, P382, DOI 10.1002/(SICI)1522-2683(19990201)20:2<382::AID-ELPS382>3.0.CO;2-N; Wooten MW, 1997, J NEUROSCI RES, V49, P393, DOI 10.1002/(SICI)1097-4547(19970815)49:4<393::AID-JNR1>3.0.CO;2-3; Yaffe MB, 1999, NATURE, V402, P30; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	44	125	130	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40048	40056		10.1074/jbc.M005261200	http://dx.doi.org/10.1074/jbc.M005261200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10998417	hybrid			2022-12-25	WOS:000166039500036
J	Lin, M; Napoli, JL				Lin, M; Napoli, JL			cDNA cloning and expression of a human aldehyde dehydrogenase (ALDH) active with 9-cis-retinal and identification of a rat ortholog, ALDH12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-BINDING-PROTEINS; ESCHERICHIA-COLI; ACID RECEPTORS; RETINALDEHYDE; BIOSYNTHESIS; OXIDATION; 9-CIS; RECOGNITION; MECHANISMS; METABOLISM	This report describes the isolation of a heretofore uncharacterized aldehyde dehydrogenase (ALDH) with retinal dehydrogenase activity from rat kidney and the cloning and expression of a cDNA that encodes its human ortholog, the previously unknown ALDH12. The human ALDH12 cDNA predicts a 487-residue protein with the 23 invariant amino acids, four conserved regions, cofactor binding motif (G(209)XGX(3)G), and active site cysteine residue (Cys(287)) that typify members of the ALDH superfamily. ALDH12 seems at least as efficient (V-m/K-m) in converting 9-cis-retinal into the retinoid X receptor ligand 9-cis-retinoic acid as two previously identified ALDHs with 9-cis-retinal dehydrogenase activity, rat retinal dehydrogenase (RALDH) 1 and RALDH2. ALDH12, however, has similar to 40-fold higher activity with 9-cis- retinal than with all-trans-retinal, whereas RALDH1 and RALDH2 have equivalent and similar to4-fold less efficiencies for 9-cis-retinal versus all-trans-retinal, respectively. Therefore, ALDH12 is the first known ALDH to show a preference for 9-cis-retinal relative to all-trans-retinal. Evidence consistent with the possibility that ALDH12 could function in a pathway of 9-cis-retinoic acid biosynthesis in vivo includes biosynthesis of 9-cis-retinoic acid from 9-cis-retinol in cells co-transfected with cDNAs encoding ALDH12 and the 9-cis-retinoUandrogen dehydrogenase, cis-retinoid/androgen dehydrogenase type 1. Intense ALDH12 mRNA expression in adult and fetal liver and kidney, two organs that reportedly have relatively high concentrations of 9-cis-retinol, reinforces this notion.	Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Napoli, JL (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, 119 Morgan Hall,MC 3104, Berkeley, CA 94720 USA.	jna@uclink4.berkeley.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013566] Funding Source: NIH RePORTER; NIA NIH HHS [AG13566] Funding Source: Medline; NIDDK NIH HHS [DK47839] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABEDINIA M, 1990, EXP EYE RES, V51, P419, DOI 10.1016/0014-4835(90)90154-M; Bhat PV, 1995, GENE, V166, P303, DOI 10.1016/0378-1119(96)81752-5; Chai XY, 1997, J BIOL CHEM, V272, P33125, DOI 10.1074/jbc.272.52.33125; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHANDLER LA, 1987, J FOOD SCI, V52, P669, DOI 10.1111/j.1365-2621.1987.tb06700.x; DOCKHAM PA, 1992, BIOCHEM PHARMACOL, V43, P2453, DOI 10.1016/0006-2952(92)90326-E; ELAKAWI Z, 1994, BIOCHEMISTRY-US, V33, P1938, DOI 10.1021/bi00173a042; Glass CK, 1997, BIOCHEM SOC T, V25, P602, DOI 10.1042/bst0250602; Graham C, 1996, J BIOL CHEM, V271, P15623, DOI 10.1074/jbc.271.26.15623; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; LABRECQUE J, 1995, BIOCHEM J, V305, P681, DOI 10.1042/bj3050681; Lamb AL, 1999, BIOCHEMISTRY-US, V38, P6003, DOI 10.1021/bi9900471; Lamb AL, 1998, ACTA CRYSTALLOGR D, V54, P639, DOI 10.1107/S0907444997014121; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Maden M, 1998, SUB CELL BIOCHEM, V30, P81; Morriss-Kay GM, 1999, INT REV CYTOL, V188, P73; NAGAO A, 1994, FASEB J, V8, P968, DOI 10.1096/fasebj.8.12.8088462; Napoli JL, 1997, SEMIN CELL DEV BIOL, V8, P403, DOI 10.1006/scdb.1997.0164; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; NAPOLI JL, 2000, IN PRESS MOL CELL EN; Paik J, 2000, BIOCHEMISTRY-US, V39, P8073, DOI 10.1021/bi992152g; Penzes P, 1997, GENE, V191, P167, DOI 10.1016/S0378-1119(97)00054-1; Penzes P, 1997, BBA-PROTEIN STRUCT M, V1342, P175, DOI 10.1016/S0167-4838(97)00102-7; PEREIRA F, 1991, BIOCHEM BIOPH RES CO, V175, P831, DOI 10.1016/0006-291X(91)91640-X; POSCH KC, 1992, J BIOL CHEM, V267, P19676; Vasiliou V, 1999, PHARMACOGENETICS, V9, P421, DOI 10.1097/00008571-199910000-00004; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; YOSHIDA A, 1993, ADV EXP MED BIOL, V328, P37; Yoshida A, 1998, EUR J BIOCHEM, V251, P549, DOI 10.1046/j.1432-1327.1998.2510549.x; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x	31	45	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40106	40112		10.1074/jbc.M008027200	http://dx.doi.org/10.1074/jbc.M008027200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11007799	hybrid			2022-12-25	WOS:000166039500043
J	Ali, S; Ali, S				Ali, S; Ali, S			Recruitment of the protein-tyrosine phosphatase SHP-2 to the C-terminal tyrosine of the prolactin receptor and to the adaptor protein Gab2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; GRB2 BINDING-SITE; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; DOCKING PROTEIN; ACTIVATION; KINASE; PHOSPHORYLATION; ASSOCIATION	The protein-tyrosine phosphatase SHP-2 modulates signaling events through receptor tyrosine kinases and cytokine receptors including the receptor for prolactin (PRLR). Here we investigated mechanisms of SHP-2 recruitment within the PRLR signaling complex. Using SHP-2 and PRLR immunoprecipitation studies in 293 cells and in the mouse mammary epithelial cell line HC11, we found that SHP-2 co-immunoprecipitates with the PRLR and that the C-terminal tyrosine of the PRLR plays a regulatory role in both the tyrosine phosphorylation and the recruitment of SHP-2. Our results further indicate that SHP-2 association to the PRLR occurs via the C-terminal SH2 domain of the phosphatase. In addition, we determined that the newly identified adaptor protein Gab2, but not Gab1, is specifically tyrosine phosphorylated and is able to recruit SHP-2 and phosphatidyinositol 3-kinase in response to PRLR activation. Together, these studies suggest the presence of dual recruitment sites for SHP-2; the first is to the C-terminal tyrosine of the PRLR and the second is to the adaptor protein Gab2.	McGill Univ, Royal Victoria Hosp, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Dept Med, Div Hematol, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital	Ali, S (corresponding author), McGill Univ, Royal Victoria Hosp, Mol Oncol Grp, H5-81,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	Suhad.Ali@muhc.mcgill.ca						ALI S, 1992, MOL ENDOCRINOL, V6, P1242, DOI 10.1210/me.6.8.1242; Ali S, 1998, J BIOL CHEM, V273, P7709, DOI 10.1074/jbc.273.13.7709; Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Bazenet CE, 1996, MOL CELL BIOL, V16, P6926; Berchtold S, 1998, MOL ENDOCRINOL, V12, P556, DOI 10.1210/me.12.4.556; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Gadina M, 1998, J IMMUNOL, V160, P4657; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Ingham RJ, 1998, J BIOL CHEM, V273, P30630, DOI 10.1074/jbc.273.46.30630; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kim H, 1999, MOL CELL BIOL, V19, P5326; LEBRUN JJ, 1995, P NATL ACAD SCI USA, V92, P4031, DOI 10.1073/pnas.92.9.4031; LEBRUN JJ, 1995, J BIOL CHEM, V270, P10664, DOI 10.1074/jbc.270.18.10664; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Liu L, 1997, J BIOL CHEM, V272, P10998; Maegawa H, 1999, J BIOL CHEM, V274, P30236, DOI 10.1074/jbc.274.42.30236; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; Merlo GR, 1996, EUR J CELL BIOL, V70, P97; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Okuda K, 1997, BLOOD, V90, P4759, DOI 10.1182/blood.V90.12.4759.4759_4759_4766; Pezet A, 1997, J BIOL CHEM, V272, P25043, DOI 10.1074/jbc.272.40.25043; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Rocchi S, 1998, MOL ENDOCRINOL, V12, P914, DOI 10.1210/me.12.7.914; Ronnstrand L, 1999, ONCOGENE, V18, P3696, DOI 10.1038/sj.onc.1202705; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Sorensen P, 1997, BIOCHEM BIOPH RES CO, V241, P710, DOI 10.1006/bbrc.1997.7879; Stofega MR, 1998, J BIOL CHEM, V273, P7112, DOI 10.1074/jbc.273.12.7112; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	31	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39073	39080		10.1074/jbc.M007478200	http://dx.doi.org/10.1074/jbc.M007478200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10991949	hybrid			2022-12-25	WOS:000165953100019
J	Baron, V; Schwartz, M				Baron, V; Schwartz, M			Cell adhesion regulates ubiquitin-mediated degradation of the platelet-derived growth factor receptor beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION; TRANSFORMED PHENOTYPE; C-CBL; FIBRONECTIN; PDGF; PHOSPHORYLATION; PROTEASOME; ATTACHMENT; ACTIVATION	Cross-talk between integrin-mediated adhesion and growth factors has been described in many recent studies; however, the underlying mechanisms remain incompletely understood. We report here that detachment of cells from the extracellular matrix induced a decrease in both the autophosphorylation and protein levels of the platelet-derived growth factor receptor beta (PDGF-R beta), which was completely reversed upon replating cells on fibronectin. The effect occurred in all cells examined but to a greater extent in primary fibroblasts compared with established cell lines. Decreased PDGF-R levels in suspended cells correlated with ubiquitination of the PDGF-R and was blocked by treatment with inhibitors of the proteasome pathway. Unlike PDGF-induced down-regulation, detachment-induced degradation did not require receptor autophosphorylation, internalization, or tyrosine kinase activity. me conclude that cell detachment results in cellular desensitization to PDGF that is mediated by degradation of the PDGF-R via a novel ubiquitin-dependent pathway.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schwartz, M (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			schwartz, martin/0000-0002-2071-1243	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL48728] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; ClaessonWelsh L, 1996, INT J BIOCHEM CELL B, V28, P373, DOI 10.1016/1357-2725(95)00156-5; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; HELDIN CH, 1982, J BIOL CHEM, V257, P4216; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hirsch C, 2000, TRENDS CELL BIOL, V10, P268, DOI 10.1016/S0962-8924(00)01768-2; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; Leng J, 1999, J BIOL CHEM, V274, P37855, DOI 10.1074/jbc.274.53.37855; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lin TH, 1997, J BIOL CHEM, V272, P8849; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; SYMINGTON BE, 1990, CELL REGUL, V1, P637, DOI 10.1091/mbc.1.9.637; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707	38	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39318	39323		10.1074/jbc.M003618200	http://dx.doi.org/10.1074/jbc.M003618200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11007771	hybrid			2022-12-25	WOS:000165953100053
J	Fanayan, S; Firth, SM; Butt, AJ; Baxter, RC				Fanayan, S; Firth, SM; Butt, AJ; Baxter, RC			Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-beta (TGF-beta) and the type II TGF-beta receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SKIN FIBROBLASTS; EPITHELIAL-CELLS; CELLULAR GROWTH; CARCINOMA CELLS; RETINOIC ACID; SMAD PROTEINS; MAD PROTEINS; MCF-7 CELLS; EXPRESSION; RESISTANCE	This study explores the relationship between anti-proliferative signaling by transforming growth factor-p (TGF-beta) and insulin-like growth factor-binding protein-3 (IGFBP-3) in human breast cancer cells. In MCF-7 cells, the expression of recombinant IGFBP-3 inhibited proliferation and sensitized the cells to further inhibition by TGF-beta1. To investigate the mechanism, we used T47D cells that lack type II TGF-P receptor (TGF-beta RII) and are insensitive to TGF-beta1. After introducing the TGF-beta RII by transfection, the basal proliferation rate was significantly decreased. Exogenous TGF-beta1 caused no further growth inhibition, but immunoneutralization of endogenous TGF-PI restored the proliferation rate almost to the control level. The addition of IGFBP-3 did not inhibit the proliferation of control cells but caused dose-dependent inhibition in TGF-beta RII-expressing cells when exogenous TGF-beta1 was also present. Similarly, receptor-expressing cells showed dose-dependent sensitivity to exogenous TGF-beta 1only in the presence of exogenous IGFBP-3. This indicates that in these cells, antiproliferative signaling by exogenous IGFBP-3 requires both the TGF-beta RII and exogenous TGF-beta1. To investigate this synergism, the phosphorylation of TGF-beta signaling intermediates, Smad2 and Smad3, was measured. Phosphorylation of each Smad was stimulated by TGF-beta1 and, independently, by IGFBP-3 with the two agents together showing a cumulative effect. These data suggest that IGFBP-3 inhibitory signaling requires an active TGF-beta signaling pathway and implicate Smad2 and Smad3 in IGFBP-3 signal transduction.	Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Baxter, RC (corresponding author), Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia.	robaxter@med.usyd.edu.au	Baxter, Robert C/F-3927-2012; Fanayan, Susan/H-1137-2011	Baxter, Robert C/0000-0001-5061-2142; Fanayan, Susan/0000-0003-4369-6987; Butt, Alison/0000-0002-6216-5105				ARTEAGA CL, 1988, CANCER RES, V48, P3898; ATTISAN L, 1990, ANN REV CELL BIOL, V6, P597; Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BAXTER RC, 1994, HORM RES, V42, P140, DOI 10.1159/000184186; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1988, J BIOL CHEM, V263, P17225; CHEN JC, 1994, J CELL PHYSIOL, V158, P69, DOI 10.1002/jcp.1041580110; Chen Y, 1996, P NATL ACAD SCI USA, V93, P12992, DOI 10.1073/pnas.93.23.12992; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; Colston KW, 1998, J MOL ENDOCRINOL, V20, P157, DOI 10.1677/jme.0.0200157; DALY RJ, 1990, J CELL BIOCHEM, V43, P199, DOI 10.1002/jcb.240430302; deJonge RR, 1997, ONCOL RES, V9, P89; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; Firth SM, 1998, BIOCHEM BIOPH RES CO, V246, P325, DOI 10.1006/bbrc.1998.8615; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; Grimes RW, 1996, BREAST CANCER RES TR, V39, P187, DOI 10.1007/BF01806185; Gucev ZS, 1996, CANCER RES, V56, P1545; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HODGKINSON S, 1995, J ENDOCRINOL, V145, pR1, DOI 10.1677/joe.0.145R001; Huynh H, 1996, J BIOL CHEM, V271, P1016, DOI 10.1074/jbc.271.2.1016; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Jakowlew SB, 1997, ANTICANCER RES, V17, P1849; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Kim IY, 1996, CANCER RES, V56, P44; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; Ko Y, 1998, J CELL PHYSIOL, V176, P424, DOI 10.1002/(SICI)1097-4652(199808)176:2<424::AID-JCP21>3.3.CO;2-N; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; Leal SM, 1999, J BIOL CHEM, V274, P6711, DOI 10.1074/jbc.274.10.6711; Martin JL, 1999, J BIOL CHEM, V274, P16407, DOI 10.1074/jbc.274.23.16407; MARTIN JL, 1990, ENDOCRINOLOGY, V127, P781, DOI 10.1210/endo-127-2-781; MARTIN JL, 1986, J BIOL CHEM, V261, P8754; MARTIN JL, 1995, ENDOCRINOLOGY, V136, P1219, DOI 10.1210/en.136.3.1219; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MURPHY LC, 1989, MOL ENDOCRINOL, V3, P611, DOI 10.1210/mend-3-4-611; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; OH Y, 1993, J BIOL CHEM, V268, P26045; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; OH YM, 1993, J BIOL CHEM, V268, P14964; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PIRCHER R, 1986, BIOCHEM BIOPH RES CO, V136, P30, DOI 10.1016/0006-291X(86)90872-7; PIRCHER R, 1984, CANCER RES, V44, P5538; Pouliot F, 1999, INT J CANCER, V81, P98, DOI 10.1002/(SICI)1097-0215(19990331)81:1<98::AID-IJC17>3.0.CO;2-9; PRATT SE, 1993, CANCER RES, V53, P5193; PRATT SE, 1994, BIOCHEM BIOPH RES CO, V198, P292, DOI 10.1006/bbrc.1994.1041; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; ROBERTS AB, 1988, RECENT PROG HORM RES, V44, P157; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; Salahifar H, 2000, ENDOCRINOLOGY, V141, P3104, DOI 10.1210/en.141.9.3104; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TUCKER RF, 1984, P NATL ACAD SCI-BIOL, V81, P6757, DOI 10.1073/pnas.81.21.6757; VALVERIUS EM, 1989, CANCER RES, V49, P6269; Wakefield L M, 1992, Cancer Treat Res, V61, P97; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WOOD WI, 1988, MOL ENDOCRINOL, V2, P1176, DOI 10.1210/mend-2-12-1176; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521	65	108	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39146	39151		10.1074/jbc.M006964200	http://dx.doi.org/10.1074/jbc.M006964200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993898	hybrid			2022-12-25	WOS:000165953100029
J	Ogier-Denis, E; Pattingre, S; El Benna, J; Codogno, P				Ogier-Denis, E; Pattingre, S; El Benna, J; Codogno, P			Erk1/2-dependent phosphorylation of G alpha-interacting protein stimulates its GTPase accelerating activity and autophagy in human colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; RGS PROTEINS; ACTIVATING PROTEINS; KINASE ACTIVATION; HT-29 CELLS; GAIP; FAMILY; SUBUNITS; SEQUESTRATION; PROTEOLYSIS	G alpha -interacting protein (GAIP) is a regulator of G protein signaling (RGS) that accelerates the rate of GTP hydrolysis by the alpha -subunit of the trimeric G(i3) protein. Both proteins are part of a signaling pathway that controls lysosomal-autophagic catabolism in human colon cancer HT-29 cells. Here we show that GAIP is phosphorylated by an extracellular signal-regulated (Erk1/2) MAP kinase-dependent pathway sensitive to amino acids, MEK1/2 (PD098059), and protein kinase C (GF109203X) inhibitors. An in vitro phosphorylation assay demonstrates that Erk2-dependent phosphorylation of GAIP stimulates its GTPase-activating protein activity toward the G alpha (i3) protein (k = 0.187 +/- 0.001 s(-1), EC50 = 1.12 +/- 0.10 muM) when compared with unphosphorylated recombinant GAIP (k = 0.145 +/- 0.003 s(-1), EC50 = 3.16 +/- 0.12 muM) or to GAIP phosphorylated by other Ser/Thr protein kinases (protein kinase C, casein kinase II). This stimulation and the phosphorylation of GAIP by Erk2 were abrogated when serine at position 151 in the RGS domain was substituted by an alanine residue using site-directed mutagenesis. Furthermore, the lysosomal-autophagic pathway was not stimulated in S151A-GAIP mutant-expressing cells when compared with wild-type GAIP-expressing cells. These results demonstrate that the GTPase-activating protein activity of GAIP is stimulated by Erk2 phosphorylation. They also suggested that Erk1/2 and GAIP are engaged in the signaling control of a major catabolic pathway in intestinal derived cells.	INSERM, U504, F-94807 Villejuif, France; Fac Med Xavier Bichat, INSERM, U479, F-75018 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Codogno, P (corresponding author), INSERM, U504, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.		Codogno, Patrice/G-1384-2013; Ogier-Denis, Eric/E-5030-2016	Codogno, Patrice/0000-0002-5492-3180; Ogier-Denis, Eric/0000-0002-0057-7593; Pattingre, Sophie/0000-0001-6284-6050				Andre F, 1999, GASTROENTEROLOGY, V116, P64, DOI 10.1016/S0016-5085(99)70230-1; Arshavsky VY, 1998, NEURON, V20, P11, DOI 10.1016/S0896-6273(00)80430-4; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BIOMMAART EFC, 1995, J BIOL CHEM, V270, P2320; Blommaart EFC, 1997, HISTOCHEM J, V29, P365, DOI 10.1023/A:1026486801018; BOYLE DM, 1988, J STEROID BIOCHEM, V30, P239, DOI 10.1016/0022-4731(88)90099-4; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; de Alba E, 1999, J MOL BIOL, V291, P927, DOI 10.1006/jmbi.1999.2989; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; De Vries L, 1998, MOL BIOL CELL, V9, P1123, DOI 10.1091/mbc.9.5.1123; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Fischer T, 2000, P NATL ACAD SCI USA, V97, P4040, DOI 10.1073/pnas.97.8.4040; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; Haussinger D, 1999, GASTROENTEROLOGY, V116, P921, DOI 10.1016/S0016-5085(99)70076-4; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; Kreegipuu A, 1998, FEBS LETT, V430, P45, DOI 10.1016/S0014-5793(98)00503-1; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; Mortimore G E, 1996, Subcell Biochem, V27, P93; OgierDenis E, 1997, J BIOL CHEM, V272, P24599, DOI 10.1074/jbc.272.39.24599; OgierDenis E, 1996, J BIOL CHEM, V271, P28593, DOI 10.1074/jbc.271.45.28593; OGIERDENIS E, 1995, J BIOL CHEM, V270, P13, DOI 10.1074/jbc.270.1.13; Petiot A, 1999, BIOCHEM J, V337, P289, DOI 10.1042/0264-6021:3370289; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wylie F, 1999, AM J PHYSIOL-CELL PH, V276, pC497, DOI 10.1152/ajpcell.1999.276.2.C497; Zheng B, 1999, TRENDS BIOCHEM SCI, V24, P411, DOI 10.1016/S0968-0004(99)01474-7	38	246	253	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39090	39095		10.1074/jbc.M006198200	http://dx.doi.org/10.1074/jbc.M006198200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10993892	hybrid			2022-12-25	WOS:000165953100021
J	Gu, XJ; Kozarsky, K; Krieger, M				Gu, XJ; Kozarsky, K; Krieger, M			Scavenger receptor class B, type I-mediated [H-3]cholesterol efflux to high and low density lipoproteins is dependent on lipoprotein binding to the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SR-BI; CELLULAR CHOLESTEROL; TANGIER-DISEASE; SURFACE-RECEPTOR; SELECTIVE UPTAKE; HDL; IDENTIFICATION; EXPRESSION; REMOVAL; PATHWAY	The murine scavenger receptor class B, type I (mSR-BI) is a receptor for high density lipoprotein (HDL), low density lipoprotein (LDL), and acetylated LDL (AcLDL). It mediates selective uptake of lipoprotein lipid and stimulates efflux of [H-3]cholesterol to lipoproteins. SR-BI-mediated [H-3]cholesterol efflux was proposed to be independent of ligand binding. In this study, using anti-mSR-BI antibody KKB-1 and two mSR-BI mutants with altered ligand binding properties, we demonstrated that SR-BI-mediated [H-3]cholesterol efflux to lipoproteins was correlated with ligand binding and lipid uptake activities of the receptor. The KKB-1 antibody, which blocked lipoprotein binding without substantially altering the cholesterol oxidase-accessible cellular [H-3]cholesterol, also blocked [H-3]cholesterol efflux to HDL and LDL. One of the SR-BI mutants, which has a double substitution of arginines for glutamines at positions 402 and 418 (Q402R/Q418R), exhibited a high level of LDL binding and lipid uptake from LDL, but lost most of the corresponding HDL receptor activity. This mutant could mediate efficient [H-3]cholesterol efflux to LDL, but not to HDL. Another mutant, M158R, with an arginine in place of methionine at position 158, exhibited reduced HDL and LDL receptor activities, but apparently normal AcLDL receptor activity. This mutant could mediate efficient [H-3]cholesterol efflux to AcLDL, but not to HDL or LDL. These results suggest that SR-BI-stimulated [H-3]cholesterol efflux to lipoproteins critically depends on ligand binding to this receptor and raise the possibility that the mechanisms of selective lipid uptake and [H-3]cholesterol efflux may be intimately related.	MIT, Dept Biol, Cambridge, MA 02139 USA; Smith Kline Beecham Pharmaceut, Dept Cardiovasc Pharmacol, King Of Prussia, PA 19406 USA	Massachusetts Institute of Technology (MIT)	Krieger, M (corresponding author), MIT, Dept Biol, Rm 68-483,77 Mass Ave, Cambridge, MA 02139 USA.		Krieger, Marco/AAE-8611-2020		NHLBI NIH HHS [HL41484, HL52212] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052212, P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Calvo D, 1997, ARTERIOSCL THROM VAS, V17, P2341, DOI 10.1161/01.ATV.17.11.2341; Chernomordik LV, 1999, MOL MEMBR BIOL, V16, P33; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; Gillotte KL, 1998, J LIPID RES, V39, P1918; GLOMSET JA, 1968, J LIPID RES, V9, P155; Gu XJ, 2000, J BIOL CHEM, V275, P9120, DOI 10.1074/jbc.275.13.9120; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Hauser H, 1998, BIOCHEMISTRY-US, V37, P17843, DOI 10.1021/bi982404y; Hirano K, 1999, CIRC RES, V85, P108; Huszar D, 2000, ARTERIOSCL THROM VAS, V20, P1068, DOI 10.1161/01.ATV.20.4.1068; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Kellner-Weibel G, 2000, BIOCHEMISTRY-US, V39, P221, DOI 10.1021/bi991666c; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Monck JR, 1996, CURR OPIN CELL BIOL, V8, P524, DOI 10.1016/S0955-0674(96)80031-7; Oram J F, 1986, Methods Enzymol, V129, P645; Oram JF, 1996, J LIPID RES, V37, P2473; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rigotti A, 1997, CURR OPIN LIPIDOL, V8, P181, DOI 10.1097/00041433-199706000-00009; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; Rothblat G H, 1986, Methods Enzymol, V129, P628; Rothblat GH, 1999, J LIPID RES, V40, P781; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SCHOUTEN D, 1990, ARTERIOSCLEROSIS, V10, P1127, DOI 10.1161/01.ATV.10.6.1127; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; Stangl H, 1998, J BIOL CHEM, V273, P31002, DOI 10.1074/jbc.273.47.31002; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; von Eckardstein A, 1998, ATHEROSCLEROSIS, V137, pS7, DOI 10.1016/S0021-9150(97)00311-0; Williams DL, 1999, CURR OPIN LIPIDOL, V10, P329, DOI 10.1097/00041433-199908000-00007	45	166	171	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					29993	30001		10.1074/jbc.275.39.29993	http://dx.doi.org/10.1074/jbc.275.39.29993			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	11001950	hybrid			2022-12-25	WOS:000089577900012
J	Baouz, S; Jacquet, E; Accorsi, K; Hountondji, C; Balestrin, M; Zippel, R; Sturani, E; Parmeggiani, A				Baouz, S; Jacquet, E; Accorsi, K; Hountondji, C; Balestrin, M; Zippel, R; Sturani, E; Parmeggiani, A			Sites of phosphorylation by protein kinase a in CDC25Mm/GRF1, a guanine nucleotide exchange factor for Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM-MEMORY; DEPENDENT ACTIVATION; SIGNALING PATHWAY; CATALYTIC DOMAIN; STRUCTURAL BASIS; FACTOR CDC25(MM); CALCIUM; GRF; SOS; MODULATION	Activation of the neuronal Ras GDP/GTP exchange factor (GEF) CDC25Mm/GRF1 is known to be associated with phosphorylation of serine/threonine. To increase our knowledge of the mechanism involved, we have analyzed the ability of several serine/threonine kinases to phosphorylate CDC25Mm in vivo and in vitro. We could demonstrate the involvement of cAMP-dependent protein kinase (PKA) in the phosphorylation of CDC25Mm in fibroblasts overexpressing this RasGEF as well as in mouse brain synaptosomal membranes. In vitro, PKA was found to phosphorylate multiple sites on purified CDC25Mm, in contrast to protein kinase C, calmodulin kinase II, and casein kinase II, which were virtually inactive. Eight phosphorylated serines and one threonine were identified by mass spectrometry and Edman degradation. Most of them were clustered around the Ras exchanger motif/PEST motifs situated in the C-terminal moiety (residues 631-978) preceding the catalytic domain. Ser(745) and Ser(822) were the most heavily phosphorylated residues and the only ones coinciding with PKA consensus sequences. Substitutions S745D and S822D showed that the latter mutation strongly inhibited the exchange activity of CDC25Mm on Ha-Ras. The multiple PKA-dependent phosphorylation sites on CDC25Mm suggest a complex regulatory picture of this RasGEF. The results are discussed in the light of structural and/or functional similarities with other members of this RasGEF family.	Ecole Polytech, Grp Biophys, Equipe 2, F-91128 Palaiseau, France; Ecole Polytech, CNRS, UMR 7654, Biochim Lab, F-91128 Palaiseau, France; Univ Milan, Dipartimento Fisiol & Biochim Gen, I-20133 Milan, Italy	Institut Polytechnique de Paris; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut Polytechnique de Paris; University of Milan	Parmeggiani, A (corresponding author), Ecole Polytech, Grp Biophys, Equipe 2, F-91128 Palaiseau, France.			JACQUET, Eric/0000-0001-6366-8436; Hountondji, Codjo/0000-0003-0683-4439				Ambrosini A, 2000, MOL BRAIN RES, V75, P54, DOI 10.1016/S0169-328X(99)00294-6; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; Baouz S, 1997, J BIOL CHEM, V272, P6671, DOI 10.1074/jbc.272.10.6671; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; Carrera V, 1998, FEBS LETT, V440, P291, DOI 10.1016/S0014-5793(98)01481-1; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; Crechet JB, 1996, J BIOL CHEM, V271, P17234, DOI 10.1074/jbc.271.29.17234; de Hoog CL, 2000, MOL CELL BIOL, V20, P2727, DOI 10.1128/MCB.20.8.2727-2733.2000; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; Fan WT, 1998, CURR BIOL, V8, P935, DOI 10.1016/S0960-9822(07)00376-4; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Fenwick C, 2000, SCIENCE, V287, P869, DOI 10.1126/science.287.5454.869; FERRARI C, 1994, EXP CELL RES, V210, P353, DOI 10.1006/excr.1994.1048; Innocenti M, 1999, FEBS LETT, V460, P357, DOI 10.1016/S0014-5793(99)01374-5; Itier JM, 1998, NATURE, V393, P125, DOI 10.1038/30120; JACQUET E, 1995, BIOCHEMISTRY-US, V34, P12347, DOI 10.1021/bi00038a031; KAPLON T, 1995, J BIOL CHEM, V270, P20742, DOI 10.1074/jbc.270.35.20742; Kiyono M, 2000, J BIOL CHEM, V275, P5441, DOI 10.1074/jbc.275.8.5441; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; Mattingly RR, 1999, J BIOL CHEM, V274, P37379, DOI 10.1074/jbc.274.52.37379; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Orban PC, 1999, TRENDS NEUROSCI, V22, P38, DOI 10.1016/S0166-2236(98)01306-X; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Schlessinger J, 1993, Harvey Lect, V89, P105; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Sturani E, 1997, EXP CELL RES, V235, P117, DOI 10.1006/excr.1997.3660; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; Zippel R, 1996, ONCOGENE, V12, P2697; Zippel R, 2000, EXP CELL RES, V258, P403, DOI 10.1006/excr.2000.4937	36	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1742	1749		10.1074/jbc.M005770200	http://dx.doi.org/10.1074/jbc.M005770200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11018028	hybrid			2022-12-25	WOS:000166528000014
J	Barry, R; Moore, S; Alonso, A; Ausio, J; Buckley, JT				Barry, R; Moore, S; Alonso, A; Ausio, J; Buckley, JT			The channel-forming protein proaerolysin remains a dimer at low concentrations in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIN AEROLYSIN; RECEPTOR-BINDING; MEMBRANE-CHANNEL	Proaerolysin, the preform of the channel-forming protein aerolysin, is secreted as a dimer by Aeromonas sp, The protein also exists as a dimer in the crystal, as well as in solution, at least at concentrations in the region of 500 mug/ml. Recently it has been argued that proaerolysin becomes monomeric at concentrations below 100 mug/ml and that only the monomeric form of the protoxin can bind to cell surface receptors (Fivaz, M,, Velluz, DI,-C,, and van der Goot, F. G. (1999) J. Biol. Chem. 274, 37705-37708), Here we show, using non-denaturing polyacrylamide electrophoresis, chemical cross-linking, and analytical ultracentrifugation, that proaerolysin remains dimeric at the lowest concentrations of the protein that we measured (less than 5 mug/ml) and that the dimeric protoxin is quite capable of receptor binding.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada	University of Victoria	Buckley, JT (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055, Victoria, BC V8W 3P6, Canada.		Alonso, Alicia/E-5310-2012	Alonso, Alicia/0000-0002-2730-7470				BUCKLEY JT, 1990, BIOCHEM CELL BIOL, V68, P221, DOI 10.1139/o90-029; BUCKLEY JT, 1999, COMPREHENSIVE SOURCE, P362; Diep DB, 1998, J BIOL CHEM, V273, P2355, DOI 10.1074/jbc.273.4.2355; Fivaz M, 1999, J BIOL CHEM, V274, P37705, DOI 10.1074/jbc.274.53.37705; GARLAND WJ, 1988, INFECT IMMUN, V56, P1249, DOI 10.1128/IAI.56.5.1249-1253.1988; HARDIE KR, 1995, MOL MICROBIOL, V14, P1093; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacKenzie CR, 1999, J BIOL CHEM, V274, P22604, DOI 10.1074/jbc.274.32.22604; McRorie D. K., 1993, SELF ASSOCIATING SYS; Moniatte M, 1996, FEBS LETT, V384, P269, DOI 10.1016/0014-5793(96)00328-6; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; Rossjohn J, 1997, EMBO J, V16, P3426, DOI 10.1093/emboj/16.12.3426; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; VANDERGOOT FG, 1993, J BIOL CHEM, V268, P18272; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; WILMSEN HU, 1992, EMBO J, V11, P2457, DOI 10.1002/j.1460-2075.1992.tb05310.x	18	15	18	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					551	554		10.1074/jbc.M008097200	http://dx.doi.org/10.1074/jbc.M008097200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11016941	hybrid			2022-12-25	WOS:000166280700074
J	Gerlach, VL; Feaver, WJ; Fischhaber, PL; Friedberg, EC				Gerlach, VL; Feaver, WJ; Fischhaber, PL; Friedberg, EC			Purification and characterization of pol kappa, a DNA polymerase encoded by the human DINB1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; ESCHERICHIA-COLI; MUTAGENESIS; PROTEIN; DELTA; IV; REQUIREMENT	The Escherichia coli dinB gene encodes DNA polymerase (pol) IV, a protein involved in increasing spontaneous mutations in vivo. The protein-coding region of DINB1, the human ortholog of DNA pol IV was fused to glutathione S-transferase and expressed in insect cells. The purified fusion protein was shown to be a template-directed DNA polymerase that we propose to designate pol kappa, Human pol kappa lacks detectable 3' --> 5' proofreading exonuclease activity and is not stimulated by recombinant human proliferating cell nuclear antigen in vitro, Between pH 6.5 and 8.5, human pol kappa possesses optimal activity at 37 degreesC over the pH range 6.5-7.5, and is insensitive to inhibition by aphidicolin, dideoxynucleotides, or NaCl up to 50 mM. Either Mg2+ or Mn2+ can satisfy a metal cofactor requirement for pol kappa activity, with Mg2+ being preferred, Human pol kappa is unable to bypass a cisplatin adduct in the template. However, pol kappa shows limited bypass of an 2-acetylaminofluorene lesion and can incorporate dCTP or dTTP across from this lesion, suggesting that the bypass is potentially mutagenic. These results are consistent with a model in which pol kappa acts as a specialized DNA polymerase whose possible role is to facilitate the replication of templates containing abnormal bases, or possessing structurally aberrant replication forks that inhibit normal DNA synthesis.	Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Friedberg, EC (corresponding author), Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75390 USA.	friedberg.errol@pathology.swmed.edu			NCI NIH HHS [CA83314, CA69029, CA75733] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA083314, F32CA075733, R01CA069029] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biggerstaff M, 1999, METH MOL B, V113, P357; BROTCORNELANNOYE A, 1986, P NATL ACAD SCI USA, V83, P3904, DOI 10.1073/pnas.83.11.3904; BRUHN SL, 1990, PROG INORG CHEM, V38, P477; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; CLARK JM, 1987, J MOL BIOL, V198, P123, DOI 10.1016/0022-2836(87)90462-1; Fischhaber PL, 1997, NUCLEOS NUCLEOT, V16, P365, DOI 10.1080/07328319708001356; Friedberg EC, 2000, P NATL ACAD SCI USA, V97, P5681, DOI 10.1073/pnas.120152397; Friedberg EC, 1999, CELL, V98, P413, DOI 10.1016/S0092-8674(00)81970-4; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; Hatahet Z, 1998, CONT CANC RES, P229; Hindges R, 1997, BIOL CHEM, V378, P345; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Johnson RE, 1999, J BIOL CHEM, V274, P15975, DOI 10.1074/jbc.274.23.15975; KENYON CJ, 1980, P NATL ACAD SCI-BIOL, V77, P2819, DOI 10.1073/pnas.77.5.2819; Kim SR, 1997, P NATL ACAD SCI USA, V94, P13792, DOI 10.1073/pnas.94.25.13792; KRIEK E, 1971, CHEM-BIOL INTERACT, V3, P397, DOI 10.1016/0009-2797(71)90019-6; KRIEK E, 1969, Chemico-Biological Interactions, V1, P3, DOI 10.1016/0009-2797(69)90015-5; KRIEK E, 1967, BIOCHEMISTRY-US, V6, P177, DOI 10.1021/bi00853a029; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; McConnell M, 1996, BIOCHEMISTRY-US, V35, P8268, DOI 10.1021/bi9530649; Mozzherin DJ, 1997, P NATL ACAD SCI USA, V94, P6126, DOI 10.1073/pnas.94.12.6126; Ogi T, 1999, GENES CELLS, V4, P607, DOI 10.1046/j.1365-2443.1999.00289.x; OHASHI E, 2000, IN PRESS J BIOL CHEM, V275; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Schumacher SB, 2000, NUCLEIC ACIDS RES, V28, P620, DOI 10.1093/nar/28.2.620; Sharief FS, 1999, GENOMICS, V59, P90, DOI 10.1006/geno.1999.5843; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; Wang TSF, 1999, PRACT APPROACH SER, V199, P67; WEISSBACH A, 1975, SCIENCE, V190, P401, DOI 10.1126/science.1179222	31	112	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					92	98		10.1074/jbc.M004413200	http://dx.doi.org/10.1074/jbc.M004413200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024016	hybrid			2022-12-25	WOS:000166280700014
J	Podust, LM; Krezel, AM; Kim, Y				Podust, LM; Krezel, AM; Kim, Y			Crystal structure of the CCAAT box/enhancer-binding protein beta activating transcription factor-4 basic leucine zipper heterodimer in the absence of DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR FAMILY; NMR-SPECTRA; JUN; COMPLEX; C/EBP; CREB; GCN4; FOS; EXPRESSION; SPECTROSCOPY	dThe crystal structure of the heterodimer formed by the basic leucine zipper (bZIP) domains of activating transcription factor-4 (ATF4) and CCAAT box/enhancer-binding protein beta (C/EBP beta), from two different bZIP transcription factor families, has been determined and refined to 2.6 A. The structure shows that the heterodimer forms an asymmetric coiled-coil. Even in the absence of DNA, the basic region of ATF4 forms a continuous a-helix, but the basic region of C/EBP beta is disordered. Proteolysis, electrophoretic mobility shift assay, circular dichroism, and NMR analyses indicated that (i) the bZIP domain of ATF4 is a disordered monomer and forms a homodimer upon binding to the DNA target; (ii) the bZIP domain of ATF4 forms a heterodimer with the bZIP domain of C/EBP beta that binds the cAMP response element, but not CCAAT box DNA, with high affinity; and (iii) the basic region of ATF4 has a higher alpha -helical propensity than that of C/EBP beta. These results suggest that the degree of ordering of the basic region and the fork and the dimerization properties of the leucine zipper combine to distinguish the structurally similar bZIP domains of ATF I: and C/EBP beta with respect to DNA target sequence. This study provides insight into the mechanism by which dimeric bZIP transcription factors discriminate between closely related but distinct DNA targets.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Kim, Y (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.		Podust, Larissa/ABB-7940-2020	Podust, Larissa/0000-0002-8537-8760; Kim, Youngchang/0000-0002-1610-4889	NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485] Funding Source: Medline; NIDDK NIH HHS [P60 DK20593, DK20593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRISANI OM, 1988, MOL CELL BIOL, V8, P1947, DOI 10.1128/MCB.8.5.1947; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BENBROOK DM, 1990, ONCOGENE, V5, P295; Bracken C, 1999, J MOL BIOL, V285, P2133, DOI 10.1006/jmbi.1998.2429; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHATTON B, 1994, ONCOGENE, V9, P375; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ESTES SD, 1995, EXP CELL RES, V220, P47, DOI 10.1006/excr.1995.1290; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; JASANOFF A, 1994, BIOCHEMISTRY-US, V33, P2129, DOI 10.1021/bi00174a020; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELLER W, 1995, J MOL BIOL, V254, P657, DOI 10.1006/jmbi.1995.0645; KIM J, 1995, NUCLEIC ACIDS RES, V23, P2531, DOI 10.1093/nar/23.13.2531; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KONRADI C, 1993, P NATL ACAD SCI USA, V90, P7005, DOI 10.1073/pnas.90.15.7005; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; Osada S, 1996, J BIOL CHEM, V271, P3891; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P59; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; SANTIAGORIVERA ZI, 1993, PROTEIN SCI, V2, P1461, DOI 10.1002/pro.5560020910; SCHOLTZ JM, 1991, BIOPOLYMERS, V31, P1463, DOI 10.1002/bip.360311304; SHAKA AJ, 1983, J MAGN RESON, V51, P169, DOI 10.1016/0022-2364(83)90117-8; Shuman JD, 1997, J BIOL CHEM, V272, P12793, DOI 10.1074/jbc.272.19.12793; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8020, DOI 10.1021/bi00487a004; Woody R. W., 1992, ADV BIOPHYS CHEM, V2, P37; Wuthrich K, 1986, NMR PROTEINS NUCL AC	42	63	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					505	513		10.1074/jbc.M005594200	http://dx.doi.org/10.1074/jbc.M005594200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11018027	hybrid			2022-12-25	WOS:000166280700068
J	Atkins, A; Wyborn, NR; Wallace, AJ; Stillman, TJ; Black, LK; Fielding, AB; Hisakado, M; Artymiuk, PJ; Green, J				Atkins, A; Wyborn, NR; Wallace, AJ; Stillman, TJ; Black, LK; Fielding, AB; Hisakado, M; Artymiuk, PJ; Green, J			Structure-function relationships of a novel bacterial toxin, hemolysin E - The role of alpha(G)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FUSION PROTEINS; PORE; EXPRESSION; MEMBRANE; BINDING; SLYA; CLYA	The novel pore-forming toxin hemolysin E (HlyE, ClyA,or SheA) consists of a long four-helix bundle with a subdomain (beta tongue) that interacts with target membranes at one pole and an additional helix (alpha (G)) that, with the four long helices, forms a five-helix bundle (tail domain) at the other pole. Random amino acid substitutions that-impair hemolytic activity were clustered mostly, but clot exclusively, within the tail domain, specifically-amino acids within, adjacent to, or interacting with cud. Deletion of amino acids downstream of alpha (G) did not affect activity, but deletions encompassing alpha (G) yielded insoluble and inactive proteins. In the periplasm Cys-285 (alpha (G)) is linked to Cys-87 (alpha (B)) of the four-helix bundle via an intramolecular disulfide, Oxidized HlyE did not form spontaneously in vitro but could be generated by addition of Cu(II) or mimicked by treatment with Hg(II) salts to yield inactive proteins, Such treatments did not affect binding to target membranes:nor assembly into non-covalently linked octameric complexes once associated with a membrane. However, gel filtration analyses suggested that immobilizing alpha (G) inhibits oligomerization in solution. Thus once associated with a membrane, immobilizing alpha (G) inhibits HlyE activity at a late stage of pore formation, whereas in solution it prevents aggregation and consequent inactivation.	Univ Sheffield, Krebs Inst, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Green, J (corresponding author), Univ Sheffield, Krebs Inst, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England.			Fielding, Andrew/0000-0002-3170-9966				Duche D, 1999, J MOL BIOL, V285, P1965, DOI 10.1006/jmbi.1998.2423; EBERSPACHER B, 1989, INFECT IMMUN, V57, P983; Green J, 1997, MICROBIOL-SGM, V143, P3785, DOI 10.1099/00221287-143-12-3785; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Kerr ID, 1996, PROTEIN ENG, V9, P161, DOI 10.1093/protein/9.2.161; Ludwig A, 1995, MOL GEN GENET, V249, P474, DOI 10.1007/BF00290573; Ludwig A, 1999, MOL MICROBIOL, V31, P557, DOI 10.1046/j.1365-2958.1999.01196.x; MARSH P, 1986, NUCLEIC ACIDS RES, V14, P3603, DOI 10.1093/nar/14.8.3603; Oscarsson J, 1999, MOL MICROBIOL, V32, P1226, DOI 10.1046/j.1365-2958.1999.01435.x; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; Ralph ET, 1998, P NATL ACAD SCI USA, V95, P10449, DOI 10.1073/pnas.95.18.10449; ROWE GE, 1994, METHOD ENZYMOL, V235, P657; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Wallace AJ, 2000, CELL, V100, P265, DOI 10.1016/S0092-8674(00)81564-0; Zitzer A, 1999, J BIOL CHEM, V274, P1375, DOI 10.1074/jbc.274.3.1375; Zitzer A, 1997, EUR J BIOCHEM, V247, P209, DOI 10.1111/j.1432-1033.1997.00209.x	16	40	55	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41150	41155		10.1074/jbc.M005420200	http://dx.doi.org/10.1074/jbc.M005420200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11006277	hybrid			2022-12-25	WOS:000166114600067
J	Bond, M; Murphy, G; Bennett, MR; Amour, A; Knauper, V; Newby, AC; Baker, AH				Bond, M; Murphy, G; Bennett, MR; Amour, A; Knauper, V; Newby, AC; Baker, AH			Localization of the death domain of tissue inhibitor of metalloproteinase-3 to the N terminus - Metalloproteinase inhibition is associated with proapoptotic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-POTENTIATING ACTIVITY; SMOOTH-MUSCLE-CELLS; SORSBYS-FUNDUS-DYSTROPHY; 72 KDA PROGELATINASE; MELANOMA-CELLS; IV COLLAGENASE; GELATINASE-A; IN-VITRO; TIMP-3; EXPRESSION	The tissue inhibitors of metalloproteinases (TIMPs) are a family of four secreted inhibitors of matrix metalloproteinases (MIMPs). Recently, additional functions have been attributed to the TIMPs, including cell growth and inhibition of angiogenesis. In particular, we demonstrated that TIMP-3 overexpression using gene transfer induces apoptosis in a variety of cell types and can inhibit vascular neointima formation in vivo. However, little is know about the mechanisms underlying TIMP-3-mediated apoptosis. Here, using both purified recombinant proteins and novel adenoviral vectors we demonstrate that the prodeath domain of TIMP-3 is located within the N-terminal three loops of TIMP-3. Although both wild type and N-terminal TIMP-3 proteins promoted apoptosis, a T-2/T-3 chimera, in which the N-terminal three loops of TIMP-3 are replaced by those of TIMP-2, failed to induce cell death. Furthermore, a point mutation at residue 1 of TIMP-3 totally abolished MMP-inhibitory activity of TIMP-3 and also failed to promote apoptosis. This study demonstrates, using multiple apoptosis assays, that the predeath function of TIMP-3 is located within the N-terminal three loops and the presence of functional metalloproteinase-inhibitory activity is associated with the induction of apoptosis.	Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol BS2 8HW, Avon, England; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; Univ Glasgow, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland	Bristol Royal Infirmary; University of Bristol; University of East Anglia; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Glasgow	Bond, M (corresponding author), Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Level 7, Bristol BS2 8HW, Avon, England.	Mark.bond@bris.ac.uk	Baker, Andy/AAO-5250-2021; Bond, Mark/AAG-9293-2019	Baker, Andy/0000-0003-1441-5576; Bennett, Martin/0000-0002-2565-1825; Knauper, Vera/0000-0002-3965-9924; Bond, Mark/0000-0003-2788-278X				Ahonen M, 1998, CANCER RES, V58, P2310; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; Baker AH, 1996, MATRIX BIOL, V15, P383, DOI 10.1016/S0945-053X(96)90158-4; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Bendeck MP, 1996, CIRC RES, V78, P38, DOI 10.1161/01.RES.78.1.38; BENNETT MR, 1994, J CLIN INVEST, V93, P820, DOI 10.1172/JCI117036; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; Butler GS, 1999, J BIOL CHEM, V274, P10846, DOI 10.1074/jbc.274.16.10846; Caterina NCM, 1997, J BIOL CHEM, V272, P32141, DOI 10.1074/jbc.272.51.32141; CHESLER L, 1995, BLOOD, V86, P4506, DOI 10.1182/blood.V86.12.4506.bloodjournal86124506; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; Fabunmi RP, 1996, BIOCHEM J, V315, P335, DOI 10.1042/bj3150335; GALIS ZS, 1994, CIRC RES, V75, P181, DOI 10.1161/01.RES.75.1.181; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; George SJ, 2000, CIRCULATION, V101, P296, DOI 10.1161/01.CIR.101.3.296; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778; LECO KJ, 1994, J BIOL CHEM, V269, P9352; NGUYEN Q, 1994, BIOCHEMISTRY-US, V33, P2089, DOI 10.1021/bi00174a015; NICKLIN S, 1999, VASCULAR DIS MOL BIO, V1, P271; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; SOUTHGATE KM, 1992, BIOCHEM J, V288, P93, DOI 10.1042/bj2880093; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; Valente P, 1998, INT J CANCER, V75, P246, DOI 10.1002/(SICI)1097-0215(19980119)75:2<246::AID-IJC13>3.0.CO;2-B; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; YANG TT, 1992, P NATL ACAD SCI USA, V89, P10676, DOI 10.1073/pnas.89.22.10676; YU W, 2000, IN PRESS J BIOL CHEM	41	98	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41358	41363		10.1074/jbc.M007929200	http://dx.doi.org/10.1074/jbc.M007929200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11007798	hybrid			2022-12-25	WOS:000166114600092
J	Long, XM; Griffith, LC				Long, XM; Griffith, LC			Identification and characterization of a SUMO-1 conjugation system that modifies neuronal calcium/calmodulin-dependent protein kinase II in Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; GTPASE-ACTIVATING PROTEIN; NUCLEAR-PORE COMPLEX; COVALENT MODIFICATION; HUMAN HOMOLOG; CENTROMERE PROTEIN; ESCHERICHIA-COLI; ENZYME; GENE; YEAST	Drosophila Uba2 and Ubc9 SUMO-1 conjugation enzyme homologs (DmUba2 and DmUbc9) were isolated as calcium/calmodulin-dependent kinase II (CaMKII) interacting proteins by yeast two-hybrid screening of an adult head cDNA library. We found that at least one isoform of Drosophila neuronal CaMXII is conjugated to DmSUMO-1 in vivo. The interactions observed in the two-hybrid screen may therefore reflect catalytic events. To understand the role of SUMO conjugation in the brain, we undertook a characterization of the system. The other required components of the system, Drosophila Aos1 and SUMO-1 (DmAos1 and DmSUMO-1), were identified in expressed sequence tag data base searches. Purified recombinant DmUbaB/DmAos1 dimer can activate DmSUMO-1 in vitro and transfer DmSUMO-1 to recombinant DmUbc9. DmSUMO-1 conjugation occurs in all developmental stages of Drosophila and in the adult central nervous system. Overexpression of a putative dominant negative DmUba2(C175S) mutant protein in the Drosophila central nervous system resulted in an increase in overall DmSUMO-1 conjugates and a base-sensitive p120 species, which is likely to be DmUba2(C175S) linked to endogenous DmSUMO-1 through an oxygen ester bond. Overexpression of DmUba2(wt) protein in vivo also led to increased levels of DmSUMO-1 conjugates. High level overexpression of either DmUba2(wt) or DmUba2(C175S) in the Drosophila central nervous system caused pupal and earlier stage lethality. Expression in the developing eye led to a rough eye phenotype with retinal degeneration. These results suggest that normal SUMO conjugation is essential in the differentiated nervous system and reveal a potential novel mechanism that regulates neuronal calcium/calmodulin-dependent protein kinase II function.	Brandeis Univ, Dept Biol, Biochem Grad Program, Waltham, MA 02254 USA; Brandeis Univ, Volen Ctr Complex Syst, Waltham, MA 02254 USA	Brandeis University; Brandeis University	Griffith, LC (corresponding author), Brandeis Univ, Dept Biol, Biochem Grad Program, MS008,415 South St, Waltham, MA 02254 USA.		Long, Samuel/AAR-8118-2021	Long, Samuel/0000-0001-7559-3232; Griffith, Leslie/0000-0003-3164-9876	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054408] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM054408, GM54408] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhaskar V, 2000, J BIOL CHEM, V275, P4033, DOI 10.1074/jbc.275.6.4033; Boddy MN, 1996, ONCOGENE, V13, P971; BRAND AH, 1993, DEVELOPMENT, V118, P401; Choudhury BK, 1997, BIOCHEM BIOPH RES CO, V234, P788, DOI 10.1006/bbrc.1997.6709; delOlmo M, 1997, MOL GEN GENET, V255, P209, DOI 10.1007/s004380050491; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; DEV IK, 1988, P NATL ACAD SCI USA, V85, P1472, DOI 10.1073/pnas.85.5.1472; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; Epps JL, 1998, CURR BIOL, V8, P1277, DOI 10.1016/S0960-9822(07)00538-6; GRIFFITH LC, 1993, J NEUROCHEM, V61, P1534, DOI 10.1111/j.1471-4159.1993.tb13650.x; Griffith Leslie C., 1997, Invertebrate Neuroscience, V3, P93, DOI 10.1007/BF02480364; Haas AL, 1997, FASEB J, V11, P1053, DOI 10.1096/fasebj.11.13.9367340; Haas AL, 1997, FASEB J, V11, P1257; Hay BA, 1997, P NATL ACAD SCI USA, V94, P5195, DOI 10.1073/pnas.94.10.5195; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Joanisse DR, 1998, BIOCHEM BIOPH RES CO, V244, P102, DOI 10.1006/bbrc.1998.8214; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kevil CG, 1997, BIOCHEM BIOPH RES CO, V238, P277, DOI 10.1006/bbrc.1997.7284; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Lapenta V, 1997, GENOMICS, V40, P362, DOI 10.1006/geno.1996.4556; Lee GW, 1998, J BIOL CHEM, V273, P6503, DOI 10.1074/jbc.273.11.6503; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mannen H, 1996, BIOCHEM BIOPH RES CO, V222, P178, DOI 10.1006/bbrc.1996.0717; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Merrill C, 1999, SCIENCE, V283, P1742, DOI 10.1126/science.283.5408.1742; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; OGILVIE JW, 1964, BIOCHEMISTRY-US, V3, P754, DOI 10.1021/bi00894a003; Okura T, 1996, J IMMUNOL, V157, P4277; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Sambrook J., 2002, MOL CLONING LAB MANU; Schopperle WM, 1998, NEURON, V20, P565, DOI 10.1016/S0896-6273(00)80995-2; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Takahashi Y, 1999, BIOCHEM BIOPH RES CO, V259, P582, DOI 10.1006/bbrc.1999.0821; Yasugi T, 1996, NUCLEIC ACIDS RES, V24, P2005, DOI 10.1093/nar/24.11.2005	50	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40765	40776		10.1074/jbc.M003949200	http://dx.doi.org/10.1074/jbc.M003949200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10995744	hybrid			2022-12-25	WOS:000166114600016
J	Zakhary, DR; Fink, MA; Ruehr, ML; Bond, M				Zakhary, DR; Fink, MA; Ruehr, ML; Bond, M			Selectivity and regulation of A-kinase anchoring proteins in the heart - The role of autophosphorylation of the type II regulatory subunit of cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPONIN-I; MOLECULAR CHARACTERIZATION; SARCOPLASMIC-RETICULUM; CALCIUM CHANNELS; PHOSPHORYLATION; BINDING; MODULATION; MEMBRANE; BETA; RII	Downstream regulation of the cAMP-dependent protein kinase (PKA) pathway is mediated by anchoring proteins (AKAPs) that sequester PKA to specific subcellular locations through binding to PKA regulatory subunits (RI or RII). The RII-binding domain of all AKAPs forms an amphipathic alpha -helix with similar secondary structure. However, the importance of sequence differences in the RII-binding domains of different AKAPs is unknown, and mechanisms that regulate AKAP-PKA affinity are not clearly defined. Using surface plasmon resonance (SPR) spectroscopy, we measured real-time kinetics of RII interaction with various AKAPs, Baseline equilibrium binding constants (K-d) for RII binding to Ht31, mAKAP, and AKAP15/18 were 10 nM, 119 nM, and 6.6 muM, respectively, PKA stimulation of intact Chinese hamster ovary cells increased RII alpha binding to AKAP100/mAKAP and AKAP15/18 by similar to7- and 82-fold, respectively. These results suggest that differences in primary sequence of the RII-binding domain may be responsible for the selective affinity of RII for different AKAPs. Furthermore, RII autophosphorylation may provide additional localized regulation of kinase anchoring. In cardiac myocytes, disruption of RII-AKAP interaction decreased PKA phosphorylation of the PKA substrate, myosin-binding protein C. Thus, these mechanisms may be involved in adding additional specificity in intracellular signaling in diverse cell types and under conditions of cAMP/PKA activation.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University	Bond, M (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, NB50, Cleveland, OH 44195 USA.			Russell, Mary A/0000-0001-5677-8194; Zakhary, Daniel/0000-0002-5328-6757	NHLBI NIH HHS [HL56256, F32HL10236] Funding Source: Medline; NIA NIH HHS [AG16613] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010236, R01HL056256] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016613] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Angelo R, 1998, J BIOL CHEM, V273, P14633, DOI 10.1074/jbc.273.23.14633; Angelo RG, 2000, J BIOL CHEM, V275, P4351, DOI 10.1074/jbc.275.6.4351; Bodor GS, 1997, CIRCULATION, V96, P1495, DOI 10.1161/01.CIR.96.5.1495; Burton KA, 1997, P NATL ACAD SCI USA, V94, P11067, DOI 10.1073/pnas.94.20.11067; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; Davare MA, 1999, J BIOL CHEM, V274, P30280, DOI 10.1074/jbc.274.42.30280; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Dong F, 1998, J BIOL CHEM, V273, P6533, DOI 10.1074/jbc.273.11.6533; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; Fraser IDC, 1999, NEURON, V23, P423, DOI 10.1016/S0896-6273(00)80795-3; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; GARVEY JL, 1988, BIOCHEM J, V249, P709, DOI 10.1042/bj2490709; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; Hausken ZE, 1996, J BIOL CHEM, V271, P29016, DOI 10.1074/jbc.271.46.29016; Herberg FW, 2000, J MOL BIOL, V298, P329, DOI 10.1006/jmbi.2000.3662; HITT M, 1995, METH MOL G, V7, P13; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; JIN JP, 1995, J BIOL CHEM, V270, P6908; Kapiloff MS, 1999, J CELL SCI, V112, P2725; Lester LB, 1997, P NATL ACAD SCI USA, V94, P14942, DOI 10.1073/pnas.94.26.14942; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; MCCARTNEY S, 1995, J BIOL CHEM, V270, P9327, DOI 10.1074/jbc.270.16.9327; McConnell BK, 1997, AM J PHYSIOL-HEART C, V273, pH1440, DOI 10.1152/ajpheart.1997.273.3.H1440; Miki E, 1998, J BIOL CHEM, V273, P34384, DOI 10.1074/jbc.273.51.34384; Miki K, 1999, J BIOL CHEM, V274, P29057, DOI 10.1074/jbc.274.41.29057; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; Purcell IF, 2000, BIOPHYS J, V78, p226A; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; Ruehr ML, 1999, J BIOL CHEM, V274, P33092, DOI 10.1074/jbc.274.46.33092; Russell MA, 2000, BIOPHYS J, V78, p432A; Scott JD, 1997, SOC GEN PHY, V52, P227; SOLARO RJ, 1976, NATURE, V262, P615, DOI 10.1038/262615a0; TADA M, 1983, J MOL CELL CARDIOL, V15, P335, DOI 10.1016/0022-2828(83)91345-7; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TSIEN RW, 1986, J MOL CELL CARDIOL, V18, P691, DOI 10.1016/S0022-2828(86)80941-5; Yang JC, 1998, J CELL BIOL, V142, P511, DOI 10.1083/jcb.142.2.511; YOSHIDA A, 1992, J BIOCHEM-TOKYO, V111, P186, DOI 10.1093/oxfordjournals.jbchem.a123735; Zakhary DR, 2000, CIRCULATION, V101, P1459, DOI 10.1161/01.CIR.101.12.1459; Zakhary DR, 1999, CIRCULATION, V99, P505, DOI 10.1161/01.CIR.99.4.505	43	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41389	41395		10.1074/jbc.M004212200	http://dx.doi.org/10.1074/jbc.M004212200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10993882	hybrid			2022-12-25	WOS:000166114600096
J	Yan, BX; Smith, JW				Yan, BX; Smith, JW			A redox site involved in integrin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; GLYCOPROTEIN IIB-IIIA; NITRIC-OXIDE; PLATELET-AGGREGATION; BETA(3) SUBUNIT; NITROSATIVE STRESS; FIBRINOGEN BINDING; RELAXING FACTOR; SERUM-ALBUMIN; GPIIB-IIIA	Integrin adhesion receptors contain an on/off switch that regulates ligand binding affinity and cell adhesion. The switch from "off" to "on" is commonly referred to as integrin activation. The objective of this study was to gain insight into the nature of the on/off switch in platelet integrin alpha (IIb)beta (3). Here, we show that a select group of the cysteines, located within the extracellular cysteine-rich domain of the beta subunit, remain unpaired. These unpaired cysteine residues exhibit the properties of a redox site involved in integrin activation. Alterations to the redox site prevent the inter-conversion between resting and active integrin. Altogether, the study establishes integrin as a direct target for redox modulation, revealing an unappreciated link between cell adhesion and redox biology.	Burnham Inst, Ctr Canc Res, Program Cell Adhes, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Smith, JW (corresponding author), Burnham Inst, Ctr Canc Res, Program Cell Adhes, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jsmith@burnham.org			NATIONAL CANCER INSTITUTE [R01CA069306, P30CA030199] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058925] Funding Source: NIH RePORTER; NCI NIH HHS [CA69306, CA30199] Funding Source: Medline; NHLBI NIH HHS [HL58925] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEER J, 1989, J BIOL CHEM, V264, P17564; BEER JH, 1992, BLOOD, V79, P117; Burgess JK, 2000, J BIOL CHEM, V275, P9758, DOI 10.1074/jbc.275.13.9758; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CHEN YP, 1994, J BIOL CHEM, V269, P18307; COLLER BS, 1995, THROMB HAEMOSTASIS, V74, P302; COTTRELL JS, 1994, PEPTIDE RES, V7, P115; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Edwards BS, 1998, J LEUKOCYTE BIOL, V63, P190, DOI 10.1002/jlb.63.2.190; EDWARDS BS, 1995, BLOOD, V86, P2288, DOI 10.1182/blood.V86.6.2288.bloodjournal8662288; Essex DW, 1999, BRIT J HAEMATOL, V104, P448, DOI 10.1046/j.1365-2141.1999.01197.x; ESSEX DW, 1995, BLOOD, V86, P2168, DOI 10.1182/blood.V86.6.2168.bloodjournal8662168; FITZGERALD LA, 1985, ANAL BIOCHEM, V151, P169, DOI 10.1016/0003-2697(85)90067-3; Fox-Robichaud A, 1998, J CLIN INVEST, V101, P2497, DOI 10.1172/JCI2736; Freedman JE, 1998, CIRCULATION, V98, P1481, DOI 10.1161/01.CIR.98.15.1481; Freedman JE, 1999, CIRC RES, V84, P1416; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; JANG YS, 1994, J AM COLL CARDIOL, V24, P1591, DOI 10.1016/0735-1097(94)90162-7; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Kashiwagi H, 1999, BLOOD, V93, P2559, DOI 10.1182/blood.V93.8.2559.408k12_2559_2568; KEANEY JF, 1993, J CLIN INVEST, V91, P1582, DOI 10.1172/JCI116364; Kim WK, 1999, NEURON, V24, P461, DOI 10.1016/S0896-6273(00)80859-4; KOUNS WC, 1992, J BIOL CHEM, V267, P18844; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Landry F, 2000, ANAL BIOCHEM, V279, P1, DOI 10.1006/abio.1999.4468; Loftus JC, 1997, J CLIN INVEST, V100, pS77; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; Martin-Bermudo MD, 1998, J CELL BIOL, V141, P1073, DOI 10.1083/jcb.141.4.1073; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MENDELSOHN ME, 1990, J BIOL CHEM, V265, P19028; Ni HY, 1998, J BIOL CHEM, V273, P7981, DOI 10.1074/jbc.273.14.7981; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Pappin D J, 1997, Methods Mol Biol, V64, P165; PEERSCHKE EI, 1995, THROMB HAEMOSTASIS, V73, P862; PELLETIER AJ, 1995, J BIOL CHEM, V270, P18133, DOI 10.1074/jbc.270.30.18133; Pelletier AJ, 1996, J BIOL CHEM, V271, P1364, DOI 10.1074/jbc.271.3.1364; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; Shattil SJ, 1997, J CLIN INVEST, V100, pS91; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; SIMON DI, 1993, ARTERIOSCLER THROMB, V13, P791, DOI 10.1161/01.ATV.13.6.791; SMITH JW, 1990, J BIOL CHEM, V265, P11008; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; *SYNPH INV, 2000, LANCET, V355, P337; TIMMONS S, 1989, METHOD ENZYMOL, V169, P11; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; WIPPLER J, 1994, J BIOL CHEM, V269, P8754; Yan B, 2000, J BIOL CHEM, V275, P7249, DOI 10.1074/jbc.275.10.7249; YAN B, 1992, CHIN BIOCH J, V8, P755; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; ZUCKER MB, 1984, THROMB HAEMOSTASIS, V51, P119	62	135	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39964	39972		10.1074/jbc.M007041200	http://dx.doi.org/10.1074/jbc.M007041200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10993900	hybrid			2022-12-25	WOS:000166039500025
J	Lenk, U; Sommer, T				Lenk, U; Sommer, T			Ubiquitin-mediated proteolysis of a short lived regulatory protein depends on its cellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME PATHWAY; ENDOPLASMIC-RETICULUM; NUCLEAR TRANSPORT; DEGRADATION; YEAST; EXPORT; REPRESSOR; LOCATION; SIGNAL; IDENTIFICATION	In this study we demonstrate that the Deg1 degradation signal of the transcriptional repressor Mat alpha2 confers compartment-specific turnover to a reporter protein. Rapid degradation of a Deg1-containing fusion protein is observed only when the reporter is efficiently imported into the nucleus, In contrast, a reporter that is constantly exported from the nucleus exhibits an extended half-life. Furthermore, nuclear import functions are crucial for both Deg1-induced degradation as well as for the turnover of the endogenous Mat alpha2 protein. The conjugation of ubiquitin to a Deg1 containing reporter protein is abrogated in mutants affected in nuclear import. Obviously, the Deg1 signal initiates rapid proteolysis within the nucleoplasm, whereas in the cytosol it mediates turnover via a slower pathway. In both pathways the ubiquitin-conjugating enzymes Ubc6p/Ubc7p play a pivotal role. These observations imply that both the cellular targeting of a substrate and the compartment-specific activity of components of the ubiquitin-proteasome system define the half-life of naturally short-lived proteins.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Sommer, T (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.							Ausubel F.M, 1989, CURRENT PROTOCALS MO; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Cormack BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303; Davarinos NA, 1999, J BIOL CHEM, V274, P28708, DOI 10.1074/jbc.274.40.28708; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Enenkel C, 1998, EMBO J, V17, P6144, DOI 10.1093/emboj/17.21.6144; Gorner M, 1999, BIOL CHEM, V380, P147; HALL MN, 1990, P NATL ACAD SCI USA, V87, P6954, DOI 10.1073/pnas.87.18.6954; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; Johnson PR, 1998, CELL, V94, P217, DOI 10.1016/S0092-8674(00)81421-X; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; NEHRBASS U, 1993, EUR J CELL BIOL, V62, P1; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	33	44	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39403	39410		10.1074/jbc.M006949200	http://dx.doi.org/10.1074/jbc.M006949200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10991948	hybrid			2022-12-25	WOS:000165953100064
J	Rodriguez, JA; Henderson, BR				Rodriguez, JA; Henderson, BR			Identification of a functional nuclear export sequence in BRCA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN-CANCER CELLS; SUBCELLULAR-LOCALIZATION; BREAST-CANCER; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; IMPORTIN-BETA; IN-VIVO; SIGNAL; PROTEIN; CRM1	Germ-line mutations in the tumor suppressor gene Brca1 confer increased susceptibility to breast and ovarian cancers. BRCA1 is a 1863-amino acid protein with roles in transcriptional regulation and the cellular responses to DNA damage. Given its function in these nuclear processes, the subcellular localization of BRCA1 is an important issue and has been the object of recent controversy. BRCA1 contains two nuclear localization signals and is most frequently detected in the cell nucleus by immunofluorescence microscopy. In this study, we show that BRCA1 is a nuclear-cytoplasmic shuttling protein, capable of both entering and exiting the nucleus. We identified a functional Rev-type nuclear export sequence ((81)QLVEELLKIICAFQLDTGL) near the amino terminus of BRCA1 that facilitates export via the CRM1/exportin pathway. Mutational inactivation of this nuclear export sequence, or treatment of cells with the CRM1-specific export inhibitor leptomycin B, induced nuclear accumulation of ectopic full-length BRCA1. Moreover, overexpression of the CRM1 export receptor resulted in decreased nuclear localization of endogenous BRCA1. The unexpected ability of BRCA1 to shuttle between nucleus and cytoplasm may have implications for the regulation and function of this tumor suppressor.	Univ Sydney, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia	University of Sydney; Westmead Institute for Medical Research	Henderson, BR (corresponding author), Univ Sydney, Westmead Millennium Inst, Westmead Inst Canc Res, POB 412,Darcy Rd, Westmead, NSW 2145, Australia.		Rodriguez, Jose Antonio/AAA-1125-2019	Rodriguez, Jose Antonio/0000-0002-2823-3733				Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen YM, 1996, SCIENCE, V272, P125, DOI 10.1126/science.272.5258.125; Chen YM, 1996, CANCER RES, V56, P3168; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; FISHER U, 1995, CELL, V82, P475; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Taylor J, 1998, INT J CANCER, V79, P334, DOI 10.1002/(SICI)1097-0215(19980821)79:4<334::AID-IJC5>3.0.CO;2-W; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wilson CA, 1996, NAT GENET, V13, P264, DOI 10.1038/ng0796-264; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	40	124	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38589	38596		10.1074/jbc.M003851200	http://dx.doi.org/10.1074/jbc.M003851200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10991937	hybrid			2022-12-25	WOS:000165739800061
J	Viedt, C; Hansch, GM; Brandes, RP; Kubler, W; Kreuzer, J				Viedt, C; Hansch, GM; Brandes, RP; Kubler, W; Kreuzer, J			The terminal complement complex C5b-9 stimulates interleukin-6 production in human smooth muscle cells through activation of transcription factors NF-kappa B and AP-1	FASEB JOURNAL			English	Article									Univ Heidelberg, Inst Immunol, D-69115 Heidelberg, Germany; Univ Frankfurt, Inst Kardiovaskulare Physiol, D-6000 Frankfurt, Germany	Ruprecht Karls University Heidelberg; Goethe University Frankfurt	Kreuzer, J (corresponding author), Univ Heidelberg, Inst Immunol, Bergheimer Str 58, D-69115 Heidelberg, Germany.		Brandes, Ralf P/L-3058-2017	Brandes, Ralf P/0000-0002-8035-0048					0	76	84	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2370	2372						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11024008				2022-12-25	WOS:000165723400001
J	Janosch, P; Kieser, A; Eulitz, M; Lovric, J; Sauer, G; Reichert, M; Gounari, F; Buscher, D; Baccarini, M; Mischak, H; Kolch, W				Janosch, P; Kieser, A; Eulitz, M; Lovric, J; Sauer, G; Reichert, M; Gounari, F; Buscher, D; Baccarini, M; Mischak, H; Kolch, W			The Raf-1 kinase associates with vimentin kinases and regulates the structure of vimentin filaments	FASEB JOURNAL			English	Article						Raf; phosphorylation; cytoskeleton; casein kinase 2	DEPENDENT PROTEIN-KINASE; NIH 3T3 CELLS; INTERMEDIATE FILAMENTS; SIGNAL-TRANSDUCTION; IN-VITRO; V-RAF; PLASMA-MEMBRANE; PHOSPHORYLATION; ACTIVATION; DIFFERENTIATION	Using immobilized GST-Raf-1 as bait, we have isolated the intermediate filament protein vimentin as a Raf-1-associated protein. Vimentin coimmunoprecipitated and colocalized with Raf-1 in fibroblasts, Vimentin was not a Raf-1 substrate, but was phosphorylated by Raf-1-associated vimentin kinases, We provide evidence for at least two Raf-1-associated vimentin kinases and identified one as casein kinase 2. They are regulated by Raf-1, since the activation status of Raf-1 correlated with the phosphorylation of vimentin. Vimentin phosphorylation by Raf-1 preparations interfered with its polymerization in vitro. A subset of tryptic vimentin phosphopeptides induced by Raf-1. in vitro matched the vimentin phosphopeptides isolated from v-raf-transfected cells labeled with orthophosphoric acid, indicating that Raf-1 also induces vimentin phosphorylation in intact cells. In NIH 3T3 fibroblasts, the selective activation of an estrogen-regulated Raf-1 mutant induced a rearrangement and depolymerization of the reticular vimentin scaffold similar to the changes elicited by serum treatment. The rearrangement of the vimentin network occurred independently of the MEK/ERK pathway. These data identify a new branch point in Raf-1 signaling, which links Raf-1 to changes in the cytoskeletal architecture.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; GSF Forschungszentrum Umwelt & Gesundheit, Inst Klin Mol Biol & Tumorgenet, D-81377 Munich, Germany; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland; Dana Farber Canc Inst, Boston, MA 02115 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA; Vienna Bioctr, Inst Microbiol & Genet, A-1030 Vienna, Austria; Hannover Med Sch, Dept Nephrol, D-30625 Hannover, Germany	Beatson Institute; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Lausanne; Harvard University; Dana-Farber Cancer Institute; Salk Institute; Vienna Biocenter (VBC); Hannover Medical School	Janosch, P (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	pjanosch@beatson.gla.ac.uk	Admin, SBI/HGB-2738-2022; Baccarini, Manuela/B-6481-2014; Mischak, Harald/E-8685-2011; Kieser, Arnd/M-4616-2014; Kolch, Walter/ABF-2102-2021	Baccarini, Manuela/0000-0002-3033-391X; Kieser, Arnd/0000-0003-0783-1950; Kolch, Walter/0000-0001-5777-5016; Mischak, Harald/0000-0003-0323-0306; Lovric, Josip/0000-0002-0338-6581				ANDO S, 1989, BIOCHEMISTRY-US, V28, P2974, DOI 10.1021/bi00433a035; ANDO S, 1991, BIOCHEM BIOPH RES CO, V175, P955, DOI 10.1016/0006-291X(91)91658-Y; ANDO S, 1993, BIOCHEM BIOPH RES CO, V195, P837, DOI 10.1006/bbrc.1993.2121; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BAI WL, 1993, ONCOGENE, V8, P2207; BERTRAND F, 1994, AM J PHYSIOL, V266, pC611, DOI 10.1152/ajpcell.1994.266.3.C611; CAPETANAKI Y, 1989, J CELL BIOL, V109, P1653, DOI 10.1083/jcb.109.4.1653; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; CHOU YH, 1991, J BIOL CHEM, V266, P7325; CHOU YH, 1989, P NATL ACAD SCI USA, V86, P1885, DOI 10.1073/pnas.86.6.1885; CHOU YH, 1989, P NATL ACAD SCI USA, V86, P3214; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1995, MOL CELL BIOL, V15, P4125; EIDEN MV, 1991, MOL CELL BIOL, V11, P5321, DOI 10.1128/MCB.11.10.5321; ERIKSSON J E, 1992, Current Opinion in Cell Biology, V4, P99, DOI 10.1016/0955-0674(92)90065-K; ESCRIBANO J, 1988, J CELL PHYSIOL, V137, P223, DOI 10.1002/jcp.1041370204; Evans RM, 1998, BIOESSAYS, V20, P79, DOI 10.1002/(SICI)1521-1878(199801)20:1<79::AID-BIES11>3.3.CO;2-I; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GARD DL, 1982, MOL CELL BIOL, V2, P1104, DOI 10.1128/MCB.2.9.1104; GEISLER N, 1989, EUR J BIOCHEM, V183, P441, DOI 10.1111/j.1432-1033.1989.tb14947.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEINS S, 1994, CURR OPIN CELL BIOL, V6, P25, DOI 10.1016/0955-0674(94)90112-0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KLYMKOWSKY MW, 1995, CURR OPIN CELL BIOL, V7, P46, DOI 10.1016/0955-0674(95)80044-1; Kolch W, 1996, ONCOGENE, V13, P1305; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KONDOH SK, 1993, FEBS LETT, V336, P255; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KOUKLIS PD, 1993, J CELL SCI, V106, P919; KVRIAKIS JM, 1992, NATURE, V358, P417; LAMB NJC, 1989, J CELL BIOL, V108, P2409, DOI 10.1083/jcb.108.6.2409; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lovric J, 1998, J BIOL CHEM, V273, P22848; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MISCHAK H, 1990, ONCOGENE, V5, P1377; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NGAI J, 1984, J CELL BIOL, V99, P306, DOI 10.1083/jcb.99.1.306; OCONNOR CM, 1981, CELL, V23, P135, DOI 10.1016/0092-8674(81)90278-6; PAPAMARCAKI T, 1991, J BIOL CHEM, V266, P21247; PORRAS A, 1994, J BIOL CHEM, V269, P12741; Porras A, 1996, INT J OBESITY, V20, pS43; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SATOH Y, 1994, MUTAT RES, V316, P25, DOI 10.1016/0921-8734(94)90005-1; SHEA TB, 1993, J NEUROSCI RES, V36, P66, DOI 10.1002/jnr.490360108; SINGLETARY K, 1989, In Vivo (Attiki), V3, P173; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Takai Y, 1996, J CELL BIOL, V133, P141, DOI 10.1083/jcb.133.1.141; TRAUB P, 1994, INT REV CYTOL, V154, P1, DOI 10.1016/S0074-7696(08)62198-1; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; WYATT TA, 1991, J BIOL CHEM, V266, P21274; YEUNG K, 2000, IN PRESS MOL CELL BI; ZEH AK, 1997, NATURE, V385, P544	71	55	56	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2000	14	13					2008	2021		10.1096/fj.99-0883com	http://dx.doi.org/10.1096/fj.99-0883com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023985				2022-12-25	WOS:000089634400020
J	Miranda, SRP; He, XX; Simonaro, CM; Gatt, S; Dagan, A; Desnick, RJ; Schuchman, EH				Miranda, SRP; He, XX; Simonaro, CM; Gatt, S; Dagan, A; Desnick, RJ; Schuchman, EH			Infusion of recombinant human acid sphingomyelinase into Niemann-Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology	FASEB JOURNAL			English	Article						lysosomal storage disease; enzyme therapy; animal models	INHERITED ENZYME DEFICIENCY; HAMSTER OVARY CELLS; MACROPHAGE-TARGETED GLUCOCEREBROSIDASE; REPLACEMENT THERAPY; NUCLEOTIDE-SEQUENCE; GAUCHERS-DISEASE; MAMMALIAN-CELLS; GENE; MUCOPOLYSACCHARIDOSIS; TRANSPLANTATION	An inherited deficiency of acid sphingomyelinase (ASM) activity results in the Type A and B forms of Niemann-Pick disease (NPD). Using the ASM-deficient mouse model (ASMKO) of NPD, we evaluated the efficacy of enzyme replacement therapy (ERT) for the treatment of this disorder. Recombinant human ASM (rhASM) was purified from the media of overexpressing Chinese Hamster ovary cells and i.v. injected into 16 five-month-old ASMKO mice at doses of 0.3, 1, 3, or 10 mg/kg every other day for 14 days (7 injections). On day 16, the animals were killed and the tissues were analyzed for their sphingomyelin (SPM) content. Notably, the SPM levels were markedly reduced in the hearts, livers, and spleens of these animals, and to a lesser degree in the lungs. Little or no substrate depletion was found in the kidneys or brains. Based on these results, three additional 5-month-old ASMKO animals were injected every other day with 5 mg/kg for 8 days (4 injections) and killed on day 10 for histological analysis. Consistent with the biochemical results, marked histological improvements were observed in the livers, spleens, and lungs, indicating a reversal of the disease pathology. A group of 10 ASMKO mice were then i.v. injected once a week with 1 mg/kg rhASM for 15 wk, starting at 3 wk of age. Although anti-rhASM antibodies were produced in these mice, the antibodies were not neutralizing and no adverse effects were observed from this treatment. Weight gain and rota-rod performance were slightly improved in the treated animals as compared with ASMKO control animals, but significant neurological deficits were still observed and their life span was not extended by ERT. In contrast with these CNS results, striking histological and biochemical improvements were found in the reticuloendothelial system organs (livers, spleens, and lungs). These studies indicate that ERT should be an effective therapeutic approach for Type B NPD, but is unlikely to prevent the severe neurodegeneration associated with Type A NPD.	Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Mt Sinai Sch Med, Inst Gene Therapy & Mol Med, New York, NY 10029 USA; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-92710 Jerusalem, Israel	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Hebrew University of Jerusalem	Schuchman, EH (corresponding author), Mt Sinai Sch Med, Dept Human Genet, 1425 Madison Ave,14-20A, New York, NY 10029 USA.				NCRR NIH HHS [RR0071] Funding Source: Medline; NICHD NIH HHS [HD28607, HD32654] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD028607] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028607, P01HD032654] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BEUTLER E, 1995, BLOOD CELL MOL DIS, V21, P86, DOI 10.1006/bcmd.1995.0012; Bielicki J, 1999, J BIOL CHEM, V274, P36335, DOI 10.1074/jbc.274.51.36335; BRADY RO, 1974, NEW ENGL J MED, V291, P989, DOI 10.1056/NEJM197411072911901; BRADY RO, 1966, P NATL ACAD SCI USA, V55, P366, DOI 10.1073/pnas.55.2.366; BRADY RO, 1973, NEW ENGL J MED, V289, P9, DOI 10.1056/NEJM197307052890103; DEAN MF, 1973, NATURE-NEW BIOL, V243, P143, DOI 10.1038/newbio243143a0; DESNICK RJ, 1976, PHYSIOL REV, V56, P57, DOI 10.1152/physrev.1976.56.1.57; DESNICK RJ, 1979, P NATL ACAD SCI USA, V76, P5326, DOI 10.1073/pnas.76.10.5326; DIFERRANTE N, 1971, P NATL ACAD SCI USA, V68, P303; DINUR T, 1992, HUM GENE THER, V3, P633, DOI 10.1089/hum.1992.3.6-633; DUNHAM NM, 1957, J AM PHARM ASS, V46; He XX, 1999, BBA-PROTEIN STRUCT M, V1432, P251, DOI 10.1016/S0167-4838(99)00069-2; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; IOANNOU YA, 1992, J CELL BIOL, V119, P1137, DOI 10.1083/jcb.119.5.1137; JONES BJ, 1968, J PHARM PHARMACOL, V20, P302, DOI 10.1111/j.2042-7158.1968.tb09743.x; Kakkis ED, 1996, BIOCHEM MOL MED, V58, P156, DOI 10.1006/bmme.1996.0044; KAKKIS ED, 1994, PROTEIN EXPRES PURIF, V5, P225, DOI 10.1006/prep.1994.1035; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P537, DOI 10.1016/0076-6879(90)85044-O; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; Kikuchi T, 1998, J CLIN INVEST, V101, P827, DOI 10.1172/JCI1722; Matsuura F, 1998, GLYCOBIOLOGY, V8, P329, DOI 10.1093/glycob/8.4.329; Miranda SRP, 1998, TRANSPLANTATION, V65, P884, DOI 10.1097/00007890-199804150-00005; Miranda SRP, 1997, BLOOD, V90, P444; Neufeld E F, 1980, Birth Defects Orig Artic Ser, V16, P77; NEUFELD EF, 1975, ANNU REV BIOCHEM, V44, P357, DOI 10.1146/annurev.bi.44.070175.002041; O'Connor LH, 1998, J CLIN INVEST, V101, P1394, DOI 10.1172/JCI1773; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; QUINTERN LE, 1989, EMBO J, V8, P2469, DOI 10.1002/j.1460-2075.1989.tb08382.x; ROSENTHAL DI, 1995, PEDIATRICS, V96, P629; ROUSSEAU A, 1986, ARCH BIOCHEM BIOPHYS, V244, P838, DOI 10.1016/0003-9861(86)90653-3; Schissel SL, 1998, J BIOL CHEM, V273, P18250, DOI 10.1074/jbc.273.29.18250; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SCHNEIDER PB, 1967, J LIPID RES, V8, P202; SCHUCHMAN EH, 1992, GENOMICS, V12, P197, DOI 10.1016/0888-7543(92)90366-Z; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; Schuchman EHDR, 1995, METABOLIC MOL BASIS, V7th, P2601; STEIN S, 1973, ARCH BIOCHEM BIOPHYS, V155, P202, DOI 10.1016/S0003-9861(73)80022-0; Verderese C L, 1993, J Neurosci Nurs, V25, P296	39	96	111	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					1988	1995		10.1096/fj.00-0014com	http://dx.doi.org/10.1096/fj.00-0014com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023983	Green Submitted			2022-12-25	WOS:000089634400018
J	Partanen, TA; Arola, J; Saaristo, A; Jussila, L; Ora, A; Miettinen, M; Stacker, SA; Achen, MG; Alitalo, K				Partanen, TA; Arola, J; Saaristo, A; Jussila, L; Ora, A; Miettinen, M; Stacker, SA; Achen, MG; Alitalo, K			VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues	FASEB JOURNAL			English	Article						growth substance; receptor tyrosine kinase; vascular endothelium	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; LYMPHATIC ENDOTHELIUM; TYROSINE KINASES; FACTOR FAMILY; IN-VITRO; TUMORS; ANGIOGENESIS; PATTERN; BINDING	Recently, vascular endothelial growth factor receptor 3 (VEGFR-3) has been shown to provide a specific marker for lymphatic endothelia in certain human tissues. In this study, we have investigated the expression of VEGFR-3 and its ligands VEGF-C and VEGF-D in fetal and adult tissues. VEGFR-3 was consistently detected in the endothelium of lymphatic vessels such as the thoracic duct, but fenestrated capillaries of several organs including the bone marrow, splenic and hepatic sinusoids, kidney glomeruli and endocrine glands also expressed this receptor. VEGF-C and VEGF-D, which bind both VEGFR-2 and VEGFR-3 were expressed in vascular smooth muscle cells. In addition, intense cytoplasmic staining for VEGF-C was observed in neuroendocrine cells such as the alpha cells of the islets of Langerhans, prolactin secreting cells of the anterior pituitary, adrenal medullary cells, and dispersed neuroendocrine cells of the gastrointestinal tract. VEGF-D was observed in the innermost zone of the adrenal cortex and in certain dispersed neuroendocrine cells. These results suggest that VEGF-C and VEGF-D have a paracrine function and perhaps a role in peptide release from secretory granules of certain neuroendocrine cells to surrounding capillaries.	Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Armed Forces Inst Pathol, Dept Soft Tissue Pathol, Washington, DC 20306 USA; Royal Melbourne Hosp, Melbourne Tumour Biol Branch, Ludwig Inst Canc Res, Angiogenesis Lab, Parkville, Vic 3050, Australia	University of Helsinki; University of Helsinki; United States Department of Defense; Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Alitalo, K (corresponding author), Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, Haartmaninkatu 3, FIN-00014 Helsinki, Finland.	Kari.Alitalo@Helsinki.fi	ora, ari/P-5180-2015; Alitalo, Kari K/J-5013-2014; Broth, Taina/M-2397-2019	Alitalo, Kari K/0000-0002-7331-0902; Achen, Marc/0000-0002-3791-803X; Stacker, Steven/0000-0003-4096-9273				Achen MG, 2000, EUR J BIOCHEM, V267, P2505, DOI 10.1046/j.1432-1327.2000.01257.x; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Avantaggiato V, 1998, MECH DEVELOP, V73, P221, DOI 10.1016/S0925-4773(98)00049-5; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; Breiteneder-Geleff S, 1999, AM J PATHOL, V154, P385, DOI 10.1016/S0002-9440(10)65285-6; BreitenederGeleff S, 1997, AM J PATHOL, V151, P1141; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; CHRISTY AA, 1995, VIB SPECTROSC, V9, P1, DOI 10.1016/0924-2031(95)90021-7; Damsky CH, 1998, CURR OPIN CELL BIOL, V10, P660, DOI 10.1016/S0955-0674(98)80043-4; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947; Farnebo F, 1999, BIOCHEM BIOPH RES CO, V257, P891, DOI 10.1006/bbrc.1999.0562; FERRARA N, 1991, METHOD ENZYMOL, V198, P391; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Guy L, 1998, BRIT J UROL, V82, P738; Jabbour HN, 1997, MOL CELL ENDOCRINOL, V134, P91, DOI 10.1016/S0303-7207(97)00158-5; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1998, J BIOL CHEM, V273, P6599, DOI 10.1074/jbc.273.12.6599; Joukov V, 1996, EMBO J, V15, P290; Jussila L, 1998, CANCER RES, V58, P1599; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kukk E, 1996, DEVELOPMENT, V122, P3829; KURODA M, 1995, J CLIN ENDOCR METAB, V80, P3196, DOI 10.1210/jc.80.11.3196; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Lymboussaki A, 1998, AM J PATHOL, V153, P395, DOI 10.1016/S0002-9440(10)65583-6; Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; Partanen TA, 1999, CANCER-AM CANCER SOC, V86, P2406, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2406::AID-CNCR31>3.3.CO;2-5; PLATE KH, 1994, BRAIN PATHOL, V4, P207, DOI 10.1111/j.1750-3639.1994.tb00835.x; Ross MH., 1995, HISTOLOGY TEXT ATLAS, V3; Sabin FR, 1902, AM J ANAT, V1, P367, DOI 10.1002/aja.1000010310; Salven P, 1998, AM J PATHOL, V153, P103, DOI 10.1016/S0002-9440(10)65550-2; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Simon M, 1998, J AM SOC NEPHROL, V9, P1032; Terris B, 1998, HISTOPATHOLOGY, V32, P133; Tsurusaki T, 1999, BRIT J CANCER, V80, P309, DOI 10.1038/sj.bjc.6690356; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Vuorela P, 1997, BIOL REPROD, V56, P489, DOI 10.1095/biolreprod56.2.489; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Wilting J, 1997, CELL TISSUE RES, V288, P207, DOI 10.1007/s004410050807; Witzenbichler B, 1998, AM J PATHOL, V153, P381, DOI 10.1016/S0002-9440(10)65582-4; Yamada Y, 1997, GENOMICS, V42, P483, DOI 10.1006/geno.1997.4774	44	263	292	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2000	14	13					2087	2096		10.1096/fj.99-1049com	http://dx.doi.org/10.1096/fj.99-1049com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023993				2022-12-25	WOS:000089634400028
